<SEC-DOCUMENT>0001821586-24-000008.txt : 20240229
<SEC-HEADER>0001821586-24-000008.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229080529
ACCESSION NUMBER:		0001821586-24-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MoonLake Immunotherapeutics
		CENTRAL INDEX KEY:			0001821586
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39630
		FILM NUMBER:		24698977

	BUSINESS ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300
		BUSINESS PHONE:		41 41 510 8022

	MAIL ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Helix Acquisition Corp
		DATE OF NAME CHANGE:	20200818
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mnlk-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:mnlk="http://moonlaketx.com/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mnlk-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-33">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0001821586</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-52">135</ix:nonNumeric><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-53">135</ix:nonNumeric><ix:nonNumeric contextRef="c-104" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-428">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" id="f-439">http://fasb.org/us-gaap/2023#OtherNonoperatingIncome</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mnlk-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.KristianReichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.KristianReichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.KristianReichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.JorgeSantosDaSilvaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.JorgeSantosDaSilvaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.JorgeSantosDaSilvaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chfPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mnlk:ClassVVotingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:PIPEInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:PIPEInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mnlk:CommonClassAPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mnlk:CommonClassARedeemableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>mnlk:lease</xbrli:measure></xbrli:unit><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:OfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:OfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:OfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:PortoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-09</xbrli:startDate><xbrli:endDate>2023-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:PortoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-09</xbrli:startDate><xbrli:endDate>2023-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>mnlk:period</xbrli:measure></xbrli:unit><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:CambridgeOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-13</xbrli:startDate><xbrli:endDate>2023-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:CambridgeOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanLiquidityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanLiquidityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanInfrastructureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanInfrastructureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>mnlk:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlk:ATMSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:May2023SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlk:ATMSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:May2023SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:August2023SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlk:ATMSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-27</xbrli:startDate><xbrli:endDate>2023-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MoonLakeImmunotherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-09</xbrli:startDate><xbrli:endDate>2023-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MoonLakeImmunotherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-09</xbrli:startDate><xbrli:endDate>2023-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MLPartiesOtherThanBVFShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MLPartiesOtherThanBVFShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MLPartiesOtherThanBVFShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="co-founder"><xbrli:measure>mnlk:co-founder</xbrli:measure></xbrli:unit><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-28</xbrli:startDate><xbrli:endDate>2021-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mnlk:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mnlk:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>mnlk:installment</xbrli:measure></xbrli:unit><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mnlk:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mnlk:OperatingLossCarryforwardExpirationAxis">mnlk:ExpirationIn2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mnlk:OperatingLossCarryforwardExpirationAxis">mnlk:ExpirationIn2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mnlk:PrepaidExpensesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:SonelokimabProgramSLKProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:OfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:August2023SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_1"></div><div style="min-height:28.8pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNITED STATES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(MARK ONE)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from                      to                    </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39630</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">MOONLAKE IMMUNOTHERAPEUTICS</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-8">Cayman Islands</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">98-1711963</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">Dorfstrasse 29</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">6300</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Zug</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-13">Switzerland</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">N/A</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Address of principal executive offices) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(ZIP Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">41</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">415108022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:31.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Title of each class</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Trading Symbol(s)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Class A ordinary share, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:3pt;padding-right:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">MLTX</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">None</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">   <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#9746;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">   <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#9746;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> &#9746;   No &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> &#9746;   No &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric> &#160;&#160;&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="f-28">&#9744;</ix:nonNumeric>     No &#9746;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the ordinary shares on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) on June 30, 2023, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-7" name="dei:EntityPublicFloat" scale="9" id="f-29">1.12</ix:nonFraction> billion. Ordinary shares held by each officer and director and by each person who is known to own 10% or more of the outstanding ordinary shares have been excluded in that such persons may be deemed to be affiliates of the Registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">As of February&#160;29, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">62,874,637</ix:nonFraction> Class A Ordinary Shares, $0.0001 par value (the "Class A Ordinary Shares"), and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">1,012,120</ix:nonFraction> Class C Ordinary Shares, $0.0001 par value (the "Class C Ordinary Shares"), issued and outstanding.</span></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:28.8pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Portions of the registrant&#8217;s definitive proxy statement relating to its 2024 Annual Meeting of Shareholders, to be held on or about June 5, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</span></div></ix:nonNumeric><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_7"></div><hr style="page-break-after:always"/><div style="min-height:93.6pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEARLY ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></div></div><div style="margin-bottom:0.05pt;padding-left:0.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:17.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">PART I</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_16">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_16">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_19">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_19">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_46">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_46">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_46">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline">Item 1C.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline">Cybersecurity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_46">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_49">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_49">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_49">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_52">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_52">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_52">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_55">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_55">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_55">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">PART II</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_61">Item 5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_61">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_61">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_64">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_64">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_64">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_67">Item 7.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_67">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_67">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_109">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_109">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_112">Item 8.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_112">Financial Statements and Supplementary Data</a> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_112">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_115">Item 9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_115">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_115">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_118">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_118">Controls and Procedures </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_118">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_121">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_121">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_121">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_124">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_124">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_124">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">PART III</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_130">Item 10.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_130">Directors Executive Officers and Corporate Governance </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_130">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_133">Item 11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_133">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_133">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_136">Item 12.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_136">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_136">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_139">Item 13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_139">Certain Relationships and Related Transactions and Director Independence </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_139">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_142">Item 14.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_142">Principal Accountant Fees and Services </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_142">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">PART IV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_148">Item 15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_148">Exhibits Financial Statements Schedules </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_148">81</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_151">Item 16.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_151">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_151">84</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify;text-indent:-5.77pt"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_154">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_10"></div><hr style="page-break-after:always"/><div style="min-height:93.6pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEARLY ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note on Forward-Looking Statements</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including without limitation, statements regarding the following, are forward-looking statements: our future results of operations and financial position, our expectations regarding industry trends, the sufficiency of our cash and cash equivalents, anticipated sources and uses of cash, the anticipated investments in our business, our business strategy, the plans and objectives of management for future operations and capital expenditures, and other information referred to in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;might,&#8221; &#8220;possible,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report on Form 10&#8209;K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report contain forward-looking statements that reflect our plans and strategy for our business and related financing. Our actual results and the timing of events could differ materially from those anticipated in the forward-looking statements.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of important risks, uncertainties and other factors that could cause actual results to differ materially from those in the forward-looking statements expressed or implied in this Annual Report on Form 10-K. Such risks, uncertainties and other factors include, among others, the risks, uncertainties and factors set forth in &#8220;Risk Factors,&#8221; and the following risks, uncertainties and factors:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in retaining or recruiting, or changes required in, our officers, key employees or directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors relating to our business, operations and financial performance, including, but not limited to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are substantially dependent on the success of our novel tri-specific Nanobody&#174;, Sonelokimab (&#8220;SLK,&#8221; also known as M1095/ALX 0761), which we license from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (&#8220;MHKDG&#8221;);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approval for our products, and any related restrictions or limitations of any approved products;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition and competitive pressures from other global companies in the industries in which we operate; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage our growth effectively;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of adverse business and economic conditions including inflationary pressures, general economic slowdown or a recession, increasing interest rates, and changes in monetary policy, banking institution instability and the prospect of a shutdown of the U.S. federal government;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">while we have initiated and completed clinical trials, we have no products approved for commercial sale;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we require substantial additional capital to finance our operations, and if we are unable to raise such capital when needed or on acceptable terms, we may be forced to delay, reduce, and/or eliminate one or more of our development programs or future commercialization efforts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to renew existing contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our limited operating history;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to respond to general economic conditions; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation and the ability to adequately protect our intellectual property rights.</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:93.6pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEARLY ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New risk factors emerge from time to time and it is not possible to predict all such risks, nor can we assess the impact of all such risks on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be other factors that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; You should read this Annual Report on Form 10-K and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_13"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this Annual Report on Form 10-K, unless the context otherwise requires or where otherwise indicated, references to &#8220;MoonLake,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our Company,&#8221; &#8220;the Company&#8221; and &#8220;our business&#8221; refer to MoonLake Immunotherapeutics and its consolidated subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SLK is a proprietary Nanobody that was discovered by Ablynx N.V., Belgium, a Sanofi company (&#8220;Ablynx&#8221;), and previously studied by MHKDG and Avillion LLP (&#8220;Avillion&#8221;) under a 2017 co-development agreement. The terms &#8220;Nanobody&#8221; and &#8220;Nanobodies&#8221; used herewith are registered trademarks of Ablynx. Nanobodies are able to bind selectively to a specific antigen with high affinity. Nanobodies have a fraction of the molecular weight compared to traditional antibodies. They offer a number of potential advantages over traditional monoclonal antibodies, including the potential to create multivalent molecules with enhanced ability to penetrate inflamed tissue, especially when containing an additional albumin binding domain such as SLK, an easier manufacturing process and a higher thermostability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently develop SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. This group of diseases comprises our initial target diseases, hidradenitis suppurativa (&#8220;HS&#8221;) and psoriatic arthritis (&#8220;PsA&#8221;), and several other inflammatory conditions (including axial spondyloarthritis ("axSpA") and psoriasis (&#8220;PsO&#8221;). Our initial target diseases affect millions of people worldwide, and we believe there is a need for improved treatment options. We believe that SLK has a differentiated mechanism of action and that its purposefully designed molecular characteristics, including its small size and its albumin binding site, facilitate deep tissue penetration in the skin and joints. We envision SLK as a key therapeutic alternative in our initial target indications and potentially in multiple other IL-17 driven inflammatory conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, we initiated a Phase 2b trial of SLK in patients with moderate-to-severe HS (the MIRA trial (M1095-HS-201)), and in June 2023, we announced positive top-line results from this trial, which met its primary endpoint of Hidradenitis Suppurativa Clinical Response (&#8220;HiSCR&#8221;) 75. In October 2023, we announced positive 24-week top-line results showing that the maintenance treatment with SLK led to further improvements in HiSCR75 response rates and other clinically relevant outcomes in patients with moderate-to-severe HS. In February 2024, we announced the successful outcome of our end-of-Phase 2 interactions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), as well as positive feedback from our interactions with the E.U. European Medicines Agency (&#8220;EMA&#8221;), with both regulatory bodies unanimously supporting our proposed approach for advancing our Phase 3 program of SLK in HS. In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)), and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology (&#8220;ACR&#8221;) 50. We expect to announce 24-week top-line results of the ARGO trial in the first quarter of 2024. SLK was also studied in a Phase 2b trial in PsO patients where it showed a significant improvement in the primary end point as compared with placebo and for which results were presented in peer-reviewed scientific publications and conferences.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All three Phase 2b trials were conducted with active reference arms. In the HS and PsA trials, patients randomized to the active reference arm were treated with adalimumab (also known as Humira), and in PsO, with  secukinumab (also known as Cosentyx), both drugs being considered the current standard of care in the respective indications. In all three trials, patients on the active reference arm achieved outcomes consistent with those achieved in previous studies for those molecules, demonstrating the validity of our own trial results. In addition, SLK numerically outperformed the active reference arms, highlighting SLK&#8217;s promise as a treatment for inflammatory diseases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the three Phase 2b trials, Phase 1 single ascending and multiple ascending dosing trials were previously completed, bringing the total number of patients in SLK-related trials to more than 700.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on the robust clinical data generated to date, we intend to further pursue the clinical development of SLK. We expect to commence Phase 3 clinical trials in HS in the first half of 2024, and in PsA in the second half of 2024. We also expect to commence clinical trials of SLK in other indications to be announced in 2024.</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Vision and Our Strategy</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vision is to elevate treatment goals for inflammatory skin and joint diseases. Our strategy is centered on developing SLK as, to our knowledge, the first ever Nanobody in clinical development for our selected indications. We seek to accomplish this strategy by:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Completing the development of SLK in our initial focus indications, HS and PsA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212; We began the Phase 2b MIRA trial for HS and the Phase 2b ARGO trial for PsA in May 2022 and December 2022, respectively. We announced positive top-line results for the MIRA trial and the ARGO trial in October 2023 and November 2023, respectively.  The clinical trials employ established therapeutic endpoints, such as response criteria defined by HiSCR and ACR, that reflect real-world improvement in patient outcomes. In February 2024, we announced the successful outcome of our end-of-Phase 2 interactions with the FDA, as well as positive feedback from our interactions with the EMA, with both regulatory bodies unanimously supporting our proposed approach for advancing our Phase 3 program of SLK in HS. We expect to commence Phase 3 clinical trials in HS in the first half of 2024, and in PsA in the second half of 2024, and expect primary endpoint data in mid 2025 and early 2026, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Broadening our portfolio of indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; We believe that there are other indications beyond HS and PsA where SLK has the potential to represent a differentiated therapeutic alternative. We expect to announce details on which indications we intend to pursue during 2024, and intend to initiate one or more trials of SLK in such indications in 2024.</span></div><div style="margin-bottom:0.12pt;padding-left:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Strengthening the differentiation elements for future SLK patients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In parallel to our clinical trials, we conduct basic research to continue refining our understanding of SLK and Nanobody biology. This research will inform our clinical efforts and includes the study of SLK&#8217;s pharmacokinetics and pharmacodynamics in a variety of cellular, deep-tissue, and disease models (in vitro and in vivo), including exploration of tissue penetration and targeting of SLK in disease models. We expect these studies to provide a more complete picture of IL-17A and IL17-F regulation. We expect this work to more clearly differentiate SLK, a Nanobody, from monoclonal antibody-based treatment options, including other IL-17 A and F inhibitors. We also expect this work to contribute to the furthering of our intellectual property.</span></div><div style="margin-bottom:0.12pt;padding-left:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Building our manufacturing and commercial capabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; We intend to continue investing in our manufacturing capabilities. Technology transfers for drug substance and drug product to commercial scale contract manufacturing organizations (&#8220;CMOs&#8221;) were executed in 2022, and we have reserved manufacturing capacity to build supply for first commercial launches which we expect to be as early as the end of 2026. We intend to continue investments in continual improvements in manufacturing capabilities to drive efficiency, to maintain high standards of quality control, and to ensure that investigators, physicians, and patients have adequate access to our product candidates at all points during studies and upon approval. We also plan to further invest in our commercial capabilities. In 2024, we started hiring dedicated personnel to our marketing, access and pricing functions and intend to continue building out this team to prepare for commercial launches of SLK in our target indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Deepening our intellectual property portfolio to support our Nanobody technology and product candidates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; We intend to continue extending our global intellectual property portfolio consisting of patents and patent applications, trade secrets, trademarks, and know-how to protect SLK and its applications.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Licensing/broadening our portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; To further enhance our overall potential and provide increased optionality, we may in-license or acquire other product candidates, in addition to SLK, for clinical development. We believe that our management team is well-positioned to identify assets that have attractive risk/reward profiles and that can be rapidly advanced to market approval, supplemented by our expertise and capabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Focus: Inflammatory Diseases Involving IL-17A and IL-17F</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SLK is an inhibitor of IL-17A and IL-17F that modulates cytokine activity in a fashion that is founded in current understanding of the importance of IL-17 biology in inflammatory disease. IL-17 cytokines can potently promote inflammation and also play a role in protection against some infectious agents. The inflammatory effects of IL-17 can be targeted directly by blocking the cytokine or its receptor, or indirectly by blocking cytokines upstream of IL-17-producing cells. IL-17 contributes to various lesions that are produced by Th17 cells, one subset of helper T cells, by gamma delta (&#947;&#948;) T cells, and by innate lymphoid cells. In healthy tissue, IL-17A is largely absent, but is significantly upregulated in inflamed lesions in our focus indications. While IL-17F is present in healthy and non-lesional tissue at detectably higher concentrations than IL-17A, it is also significantly upregulated in inflamed tissue in our focus indications. The current view is that IL-17F contributes to inflammatory conditions such as HS and PsA, which is why IL-17A and F inhibition could well exert an increased anti-inflammatory therapeutic potential compared to just IL-17A inhibition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Millions of people worldwide suffer from diseases in which overexpression of IL-17A and IL17-F are potentially implicated in the pathophysiology and we believe there are limited treatment options. Well-known diseases include HS, PsA, PsO, and axSpA among others. HS has an estimated worldwide prevalence of up to 2.1%, though we believe it is currently underdiagnosed and undertreated with limited effective treatment options available. PsA has an estimated worldwide prevalence of up to 0.5%. Furthermore, up to 40% of patients with PsA have axial disease. These diseases exhibit notable overlap with approximately 30% of PsO patients exhibiting PsA and up to 40% of PsA patients exhibiting axSpA. In the United States alone, HS, PsA, and axSpA together affect between 3.0 and 3.5 million diagnosed patients. Finally, PsO has an estimated worldwide prevalence of approximately 3% and affects an estimated 6 million diagnosed patients in the United States alone. Other diseases, where IL17-A and IL17-F play a role, will represent additional pools of diagnosed patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a portfolio of therapeutic indications for SLK (Figure 1).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="mnlk-20231231_g1.jpg" alt="SLK Pipeline.jpg" style="height:170px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 1 &#8212; Overview of development pipeline for SLK</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Development of SLK</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2b Clinical Trial in HS: The MIRA Trial</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of SLK, administered subcutaneously, in the treatment of adult patients with active moderate-to-severe HS. The trial recruited 234 patients, with the aim to evaluate two different doses of SLK (120mg and 240mg) with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving HiSCR75, defined as a &#8805;75% reduction in total abscess and inflammatory nodule (&#8220;AN&#8221;) count with no increase in abscess or draining tunnel count relative to baseline. The trial also evaluated a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (&#8220;IHS4&#8221;), the proportion of patients achieving a Dermatology Life Quality Index total score of &#8804;5, and the proportion of patients achieving at least 30% reduction from baseline in Numerical Rating Scale in the Patient&#8217;s Global Assessment of Skin Pain. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the MIRA set a landmark milestone as the first placebo-controlled randomized trial in HS to use HiSCR75 as the primary endpoint which it met with a significantly greater proportion of patients treated with both SLK 120mg and 240mg achieving HiSCR75 compared to those on placebo at week 12. The primary analysis was based on a very stringent type of analysis for such trials, intent-to-treat non-responder imputation ("ITT-NRI"). Both doses performed similarly, with the 120mg dose providing the highest delta on HiSCR75 and HiSCR50. The 120mg dose achieved a 29 percentage points ("ppt") delta to placebo on HiSCR75 (p=0.0002) and a 38 ppt delta to placebo on HiSCR50 (p&lt;0.0001). The results suggest that, as early as week 12, SLK, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly stringent pivotal-like trials (Figure 2).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="mnlk-20231231_g2.jpg" alt="HS data.jpg" style="height:336px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 2 &#8212; Comparison of HiSCR75 and HiSCR50 deltas to placebo between the MIRA trial and other pivotal-like trials</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, 24-week results were presented, showing that ongoing treatment with SLK 120mg and 240mg dosed Q4W further increased HiSCR75 response rates compared to week 12. 57% of patients continuously treated with 120mg achieved a HiSCR75 response (more than 10 ppt improvement from week 12) and 38% achieved HiSCR90 (more than 14 ppt improvement versus week 12). The IHS4 score, which encompasses changes in all active HS lesions (nodules, abscesses, draining tunnels), decreased by 65% in patients treated with the 120mg maintenance dose.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rates of complete resolution of inflammatory nodules and abscesses (AN 100) together with complete resolution of draining tunnels (DT 100) also increased between week 12 and 24 (31% and 49% of patients achieving this high level of response at week 24 with 120mg respectively, an increase of up to 15 ppt). Complete inflammatory remission (IHS4-100) was achieved in 1 in 4 patients (24%) treated with 120mg at week 24. Clinical responses translated to profound improvements in patient-reported outcomes at 24 weeks including quality of life, pain, and patient global impression of severity. 43% of patients reached self-reported absent or minimal disease activity on the PGI-S scale.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results obtained with placebo patients re-randomized to SLK 120mg or 240mg in Part B, after the primary analysis, replicated the dose responses observed in Part A. Difficult-to-treat subgroup analysis (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Hurley stage III patients or those previously exposed to biologics) confirms the advantage of the 120mg dose. Similarly, PK analysis support the use of the monthly maintenance 120mg dose. For patients who were inadequate responders to adalimumab at week 12 switching to SLK resulted in HiSCR75 response rates similar to responses in those randomized to SLK at baseline. SLK provided better durability of response compared to that observed with adalimumab in other studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety profile of SLK was consistent with that observed in previous studies. Overall, SLK continues to show a favorable safety profile, in line with the known profile of IL-17 inhibitors. Based on the efficacy and safety results, Q4W maintenance dosing of SLK 120mg has been confirmed in our view as the optimal dose, in terms of speed and depth of response, and overall benefit-risk profile, for progression into Phase 3 development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2b Clinical Trial in PsA: the ARGO Trial</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ARGO trial (M1095-PSA-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of SLK, administered subcutaneously, in the treatment of adult patients with active PsA. The trial was designed to evaluate different doses of SLK, with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving &#8805;50% improvement in signs and symptoms of disease from baseline, compared to placebo, as measured by ACR50 response. The trial also evaluates a number of secondary endpoints, including improvement compared to placebo in ACR20, complete skin clearance as measured by at least a 100% improvement in PASI (PASI100), physical function as measured by the Health Assessment Questionnaire-Disability Index, enthesitis as measured by the Leeds Enthesitis Index and pain as measured by the Patients Assessment of Arthritis Pain. Important composite scores, such as ACR50+PASI100, measuring both joint and skin improvement in the same patients were also studied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the ARGO trial, which enrolled 207 patients, met its primary endpoint with a statistically significant greater proportion of patients treated with either SLK 60mg or 120mg (with induction) achieving an ACR50 response compared to those on placebo at week 12. Specifically, for the 60mg and 120mg doses with induction, respectively, 46% and 47% of patients treated with SLK achieved ACR50 (p&lt;0.01 versus placebo); 78% and 72% of patients achieved ACR20; and 29% and 26% achieved ACR70. The primary analyses were based on a very stringent type of analysis for such trials, ITT-NRI. As expected, the 60mg dose without induction did not reach statistical significance, confirming the 60mg and 120mg with induction as the potential dose regimens to carry forward into Phase 3. All key secondary endpoints were met for the 60mg and 120mg doses with induction. The key secondary endpoint PASI90 was met for all doses with induction. 77% of patients achieved a PASI90 response at week 12 to the 60mg dose (ITT-NRI, p&lt;0.001 versus placebo). For this dose, 58% of patients achieved complete skin clearance (PASI100) at week 12. PASI responses across dose arms were consistent with the previously reported Phase 2b data of SLK in moderate-to-severe plaque-type PsO, with the 120mg dose achieving the highest responses for PASI100 (close to 60% of patients at week 12, ITT-NRI) in patients with more severe skin lesions (PASI score &#8805; 10 at baseline).  Up to 33% of patients achieved both ACR50 and PASI100 at week 12 (Figure 3). Other clinically relevant secondary endpoints, such as Minimal Disease Activity (MDA), the modified Nail Psoriasis Severity Index (mNAPSI), the Leeds Enthesitis Index (LEI) and the patient self-reported Psoriatic Arthritis Impact of Disease (PsAID-12), each show promising levels of response at week 12. Adalimumab was used as an active reference to validate responses across arms (not powered for statistical comparisons to active treatment). SLK 60mg and 120mg (with induction) numerically outperformed adalimumab on the primary endpoint and all key secondary endpoints, with the observed deltas further supporting the potential for SLK as a future leading therapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><img src="mnlk-20231231_g3.jpg" alt="PsA data.jpg" style="height:325px;margin-bottom:5pt;vertical-align:text-bottom;width:576px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 3 &#8212; Patients reaching both ACR50 and PASI100 in the ARGO trial at week 12.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety profile of SLK in ARGO was consistent with previously reported studies with no new safety signals. Overall, SLK continued to show a favorable safety profile. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results suggest that, as early as week 12, SLK reaches levels of clinical response at or above those seen with other therapies tested in similarly stringent trials. 24 weeks data of the ARGO trial is expected to be presented in March 2024. The high performance of SLK and its favorable safety profile continue to support the plan for progression into Phase 3 development in 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2b Clinical Trial in Psoriasis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, data for the Phase 2b trial of SLK in PsO was published. This trial was conducted by Avillion under a 2017 co-development agreement with MHKDG. The randomized, double-blind, placebo-controlled, multi-center trial was designed to assess efficacy, safety and tolerability of SLK in patients with moderate-to-severe chronic plaque-type PsO, over a total period of 52 weeks (inclusive of a 40-week follow-up assessment). In all cases, patients were administered SLK via subcutaneous injection.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of the trial was to evaluate the efficacy of four dose regimens of SLK compared to placebo on achievement of an Investigator&#8217;s Global Assessment (&#8220;IGA&#8221;) score of 0 or 1 after 12 weeks of treatment in patients with moderate to severe chronic plaque-type PsO. The secondary objectives were to evaluate the efficacy of four dose regimens of SLK compared to placebo during a 12-week treatment period on secondary endpoints: PASI 75, PASI 90, PASI 100, change in mean PASI and shift in IGA, to assess the dose-regimen efficacy relationship for SLK after 12, 24, 36, and 48 weeks of treatment, to evaluate the longer-term efficacy of SLK at week 24 and at weeks 36 and 48, and to assess the safety and tolerability of SLK. Other exploratory objectives were also considered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary and secondary end-points, associated with the described objectives were achieved. Doses up to 120 mg showed rapid and significant differences in PASI 100 compared with placebo (Figure 2). In the highest dosage group, nearly six out of ten patients (57%) achieved total skin clearance (PASI 100 response) after 24 weeks. Rapid response was demonstrated with one of three patients already achieving nearly clear skin (PASI 90 response) by week four. Analysis of an individualized dosing scheme including off-drug periods in controlled patients revealed durable responses over one year. SLK was generally well </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tolerated, with a safety profile similar to the active control, secukinumab, and an overall Candida infection rate of 2.9% from week 0 to week 12 and 6.4% in the period from week 12 to week 52 across all doses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing and Planned Clinical Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to present 24 weeks data of the ARGO trial in the first quarter of 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to commence Phase 3 clinical trials in HS in the first half of 2024, and in PsA in the second half of 2024, with primary endpoint data expected in mid 2025 and early 2026, respectively. In February 2024, we announced the successful outcome of our end-of-Phase 2 interactions with the FDA, as well as positive feedback from our interactions with the EMA, with both regulatory bodies unanimously supporting our proposed approach for advancing our Phase 3 program of SLK in HS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there are other indications beyond HS and PsA where SLK has the potential to represent a differentiated therapeutic alternative. We expect to announce details on which indications we intend to pursue during 2024, and intend to initiate one or more trials of SLK in such indications in 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities and currently have no plans to establish any. We partner with third-party CMOs for both drug substance and finished drug product, through established contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current drug substance supplier is Richter-Helm Biologics GmbH &amp; Co. KG (&#8220;RHB&#8221;) based in Bovenau, Germany. Effective July 1, 2021, we entered into a contract manufacturing agreement with RHB with respect to the manufacture of SLK. We may terminate the contract manufacturing agreement for convenience in accordance with the terms of the agreement. Either party may also terminate the contract manufacturing agreement with respect to an uncured breach by the other party in accordance with the terms of the agreement. The agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MHKDG produced the drug product supply for our Phase 2 clinical trials, the MIRA trial and the ARGO trial. In 2022, we successfully transferred the drug product process to Vetter Pharma International GmbH as part of our strategy to ensure sufficient supply for potential commercialization following all regulatory and related requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we entered into a collaboration agreement with SHL Medical to develop an autoinjector for clinical and potential subsequent commercial supply of SLK.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we have the exclusive license to a patent family directed to Il-17 Nanobodies, including SLK, and methods of making and using the same derived from International Patent Application PCT/EP2012/058313, published as WO 2012/156219, entitled &#8220;Amino Acid Sequences Directed Against IL-17A, IL-17F and/or IL17-A/F and Polypeptides Comprising the Same.&#8221; Applications in this family have been filed in the United States, the European Patent Office (EPO), the Eurasian Patent Organization (EAPO), Australia, Brazil, Canada, Chile, China, Hong Kong, India, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Philippines, Singapore, and South Africa. To date, 24 patents have issued and several applications are pending. Three patents have been issued in the United States in this family thus far (U.S. Patent Nos. 10,017,568, 10,829,552 and 11,773,159), all three providing protection until May 2032, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity and other governmental fees. There are several non-U.S. patents that have been granted or are pending in this family, all of which are expected to have similar expiration dates, absent any extensions that may be available through supplementary protection certificates or similar mechanisms. Additional data exclusivity rights may be applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Merck Healthcare KGaA (Darmstadt, Germany) License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2021, we entered into a license agreement with MHKDG (the &#8220;License Agreement&#8221;). The License Agreement is a sublicense of a license agreement between MHKDG and Ablynx, dated September 3, 2008 (the &#8220;Initial License Agreement&#8221;), pursuant to which MHKDG developed SLK, and subsequently acquired exclusive right and title to SLK, including the right to further develop and commercialize (and grant sublicenses to further develop and commercialize) SLK. Pursuant to the License Agreement, we acquired (i) a royalty- and milestone-bearing exclusive (even as to MHKDG), sublicensable right and license under MHKDG&#8217;s controlled patents, materials, and exclusive know-how to develop, manufacture, use, sell, offer for sale, export and import and otherwise commercialize SLK on a world-wide basis, (ii) a royalty- and milestone-bearing non-exclusive, sublicensable, right and sublicense under Ablynx&#8217;s and certain others&#8217; controlled patents, materials, and know-how to develop, manufacture, use, sell, offer for sale, export and import and otherwise commercialize SLK on a world-wide basis, in each case subject to certain restrictions and compliance with the terms and conditions of the Initial License Agreement; and (iii) a royalty- and milestone-bearing non-exclusive, sublicensable right and sublicense under Research Cooperation Technologies (&#8220;RCT&#8221;) patents and know-how related to the manufacturing process using the underlying yeast strain Pichia pastoris, to develop, manufacture, use, sell, offer for sale, export and import and otherwise commercialize SLK on a world-wide basis, in each case subject to certain restrictions and compliance with the terms and conditions of the underlying license granted to MHKDG from RCT. Under the terms of the License Agreement, we have the first right to file, prosecute and maintain the licensed patents as well as the first right to attempt to resolve any third party infringement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement includes a development plan, subject to specified periodic updates, which describes the plan for developing the licensed products in the initial target indications of HS and PsA, including the plan for conducting clinical trials to obtain regulatory approval in the major European markets, Japan, and the United States (the &#8220;Major Markets&#8221;). In accordance with the foregoing, we, among other requirements, are obligated to use commercially reasonable efforts to develop one licensed product in at least two indications, including initiating certain Phase 2 trials for the licensed product within a specified period following conclusion of the License Agreement, and launching and commercializing the same in each of the Major Markets a certain period following receipt of regulatory approval in such respective markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate purchase price in respect of the License Agreement was $29.9 million and consisted of an upfront cash payment by us to MHKDG and an issuance of equity by us to MHKDG, representing a 9.9% ownership stake in our subsidiary, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#8220;MoonLake AG&#8221;), following such issuance. Subject to the terms of the License Agreement, milestone cash payments of up to EUR 307.1 million ($339.5 million using a December 31, 2023 exchange rate) are potentially payable, of which EUR 7.5 million ($8.0 million using the then applicable exchange rate) has been recognized as R&amp;D expense to date. Future milestones will become payable upon regulatory filing acceptances in the US, in the European Union (&#8220;EU&#8221;) and Japan, first commercial sales in these geographies, and meeting certain annual thresholds in global net sales. In addition, the License Agreement requires us to pay royalties within the range of low to mid-teen percent of net sales. Our obligation to pay royalties are on a licensed product-by-licensed product and country-by-country basis and continue from the date of first commercial sale of a licensed product in a country until the later of (i) ten years from such first commercial sale of such licensed product in such country or (ii) the expiration or invalidation of the last remaining valid claim of a licensed patent covering such licensed product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless sooner terminated, the term of the License Agreement continues until the expiration of the last-to-expire royalty term. Either party may terminate the License Agreement due to a material breach by the other party (subject to a cure period). We may terminate the License Agreement (i) at our convenience upon 90 days&#8217; prior written notice to MHKDG following receipt by MHKDG of the required upfront payment or (ii) upon 90 days&#8217; prior written notice to MHKDG if we have reasonable belief that the medical risk/benefit of SLK is unfavorable in light of the welfare of patients and not suitable for further development or commercialization. Obligations accrued prior to termination, such as milestone payments, will persist.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the License Agreement, on April 29, 2021, we also executed a Side Letter to the License Agreement with MHKDG, which provides that upon the termination of the Initial License Agreement, under the terms of the Initial License Agreement, for any reason, the License Agreement will be automatically assigned to Ablynx. Upon assignment to Ablynx, any intellectual property licensed to us by MHKDG, and the obligations and liability associated therewith, under the License </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement, shall continue, provided that the continuing obligations and liability of MHKDG under the License Agreement shall be limited to only that intellectual property owned or held by MHKDG following termination of the Initial License Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2023, we entered into an agreement with RCT and MHKDG, effective as of June 1, 2023, pursuant to which we were granted a royalty-bearing, nonexclusive, sublicensable right and license under RCT&#8217;s patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces our sublicense for similar rights under the License Agreement with MHKDG.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Biologics Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), and the Public Health Service Act (the &#8220;PHSA&#8221;), and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequence compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;) application, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical site before the trial is commenced;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation of and submission to the FDA of a Biologics License Application (&#8220;BLA&#8221;) after completion of all pivotal clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical and Clinical Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an IND product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA Submission and Review</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after for the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited Development and Review Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the FDA established a new regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation as part of its implementation of the 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Century Cures Act (the &#8220;Cures Act&#8221;). The RMAT designation program is intended to fulfill the Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (i) the drug qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii) the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides all the benefits of breakthrough therapy designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through: the submission of clinical evidence, preclinical studies, clinical trials, patient registries or other sources of real world evidence such as electronic health records; the collection of larger confirmatory datasets; or post-approval monitoring of all patients treated with the therapy prior to approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation, breakthrough therapy designation, priority review and RMAT designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Diagnostic Tests</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates may require use of a diagnostic to identify appropriate patient populations for our product candidates. These diagnostics, often referred to as companion diagnostics, are medical devices, often in vitro devices, which provide information that is essential for the safe and effective use of a corresponding drug. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (&#8220;PMA&#8221;). We expect that any companion diagnostic developed for our drug candidates will utilize the PMA pathway.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. FDA review of an initial PMA may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;In Vitro Companion Diagnostic Devices.&#8221; According to the guidance, for novel drugs such as our drug candidates, a companion diagnostic device and its corresponding drug should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (&#8220;IDE&#8221;) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and Reference Product Exclusivity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act (&#8220;ACA&#8221;) includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute, the federal False Claims Act, the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value, including stock options. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent. For example, the federal False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Several pharmaceutical and other healthcare </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, the government may assert that a claim resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act (&#8220;IRA&#8221;), enacted August 16, 2022, aims to control prescription drug prices in the upcoming years. The IRA will allow the CMS to cap out-of-pocket costs in 2025 and to negotiate prescription drug prices in 2026 for the first time. Additionally, the IRA provides a new &#8220;inflation rebate&#8221; covering Medicare patients to take effect in 2023 to prevent rapid and arbitrary price increases in prescription drugs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data Privacy &amp; Security</span></div><div style="text-align:justify;text-indent:0.35pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) and the EU General Data Protection Regulation (&#8220;GDPR&#8221;), govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, our use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of data from Iceland, Norway and Liechtenstein (the &#8220;European Economic Area&#8221; or &#8220;EEA&#8221;) to the UK, on June 28, 2021, the European Commission (the &#8220;EC&#8221;) adopted two adequacy decisions for the United Kingdom (the &#8220;UK&#8221;) &#8211; one under the GDPR and the other for the Law Enforcement Directive (2016/680). Personal data may now freely flow from the EU to the UK since the UK is deemed to have an adequate data protection level for the purposes of the EU regime. Additionally, following Brexit, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR, which is based on the EU GDPR), the latter regime having the ability to impose fines up to the greater of &#163;17.5 million or 4% of global turnover. Furthermore, transfers from the UK to other countries, including to the EEA, are subject to specific transfer rules under the UK regime; personal data may freely flow from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the EU GDPR rules. The adequacy decisions include a &#8220;sunset clause&#8221; which entails that the decisions will automatically expire four years after their entry into force, unless renewed. On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the European Commission&#8217;s standard contractual clauses for international data transfers (&#8220;Addendum&#8221;) and a document setting out transitional provisions. The IDTA and Addendum came into force on March 21, 2022 and replaced the old EU SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September 21, 2022 on the basis of any old EU SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March 21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of data from the UK to the United States, the UK government has adopted an adequacy decision for the United States, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as offering an adequate level of data protection where the transfer is to a United States company participating in the EU-US Data Privacy Framework and the UK Extension.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the Tax Act was enacted, which, among other things, removes penalties for not complying with ACA&#8217;s requirement to carry health insurance, known as the &#8220;individual mandate,&#8221; effective January 1, 2019. Since the enactment of the Tax Act, there have been additional amendments to certain provisions of the ACA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2030, unless additional action is taken by Congress.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives beginning January 1, 2021. In addition, in August 2022, Congress passed the IRA, which for the first time authorized CMS to negotiate Medicare reimbursement rates for certain prescription drug products, which may put limits on prices paid for drugs by government health programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress and the Biden administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Government Regulation Outside of the United States</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application, much like the IND prior to the commencement of human clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation in the European Union</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug and Biologic Development Process</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are studies intended to discover or verify the effects of one or more investigational medicines. The regulation of clinical trials aims to ensure that the rights, safety and well-being of trial participants are protected and the results of clinical trials are credible. Regardless of where they are conducted, all clinical trials included in applications for marketing authorization for human medicines in the EU and in the EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international GCP and the Declaration of Helsinki.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conduct of clinical trials in the EU is governed by the EU Clinical Trials Regulation (EU) No. 536/2014 (the &#8220;Clinical Trials Regulation&#8221; or &#8220;CTR&#8221;), which entered into force on January 31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (Clinical Trials Directive) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the former regime, which will expire after a transition period of one or three years, respectively, as outlined below in more detail, before a clinical trial can be initiated, it must be approved in each EU Member State where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (the &#8220;NCA&#8221;), and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU Member State before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU Member State where they occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A more unified procedure will apply under the new Clinical Trials Regulation. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU Member State proposed by the applicant) will take the lead in validating and evaluating the application and will consult and coordinate with the other concerned Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned Member States. However, a concerned EU Member State may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such Member State. The Clinical Trials Regulation also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year transition period. Member states will work in the Clinical Trials Information System (&#8220;CTIS&#8221;) immediately after the system has gone </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">live. Since January 31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both the former regime and the new Clinical Trials Regulation, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on BCP and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;), on the recommendation of the Scientific Advice Working Party, or SAWP. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs and is not legally binding with regard to any future Marketing Authorization Application, (&#8220;MA Application&#8221;), of the product concerned.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Marketing Authorization</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MA Application through, amongst others, a centralized or decentralized procedure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA, that is valid for all EU Member States as well as in the three additional EEA Member States. The centralized procedure is compulsory for specific medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products, or ATMP, and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP, established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MA Application by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MA Application. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization (mutual recognition procedure). </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, known as the reference EU Member State, is appointed to review the application and provide an assessment report. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference EU Member State and concerned EU Member States. The reference EU Member State prepares a draft assessment report and drafts of the related materials within 120 days after receipt of a valid application. Subsequently each concerned EU Member State must decide whether to approve the assessment report and related materials. If an EU Member State cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All new marketing authorization applications must include a Risk Management Plan (&#8220;RMP&#8221;), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. We need to submit an updated RMP: (i) at the request of EMA or a national competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20, 2023, all RMPs for centrally authorized products are published by the EMA subject to only limited redactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing Authorizations have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules apply in part for ATMPs. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. The manufacturing and control information that should be submitted in a MA Application; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the mandatory RMP, the holder of a marketing authorization for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data and Market Exclusivity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing exclusivity.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant pre-clinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial chance was authorized).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to include an NCE. Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full marketing authorization application with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Designation and Exclusivity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United States. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (prevalence criterion). In addition, Orphan Drug Designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a marketing authorization; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a marketing authorization, orphan drug designation provides up to ten years of market exclusivity in the orphan indication.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for marketing authorization, accept an application to extend an </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;) addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation (i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products). When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a marketing authorization may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP, together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MA Application for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRIME Designation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines (&#8220;PRIME&#8221;), scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the EU Member </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of marketing authorization, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holder of a marketing authorization for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;), in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase IV safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the marketing authorization holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products in the European Union is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for GMP. These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union. Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Regulations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC, as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited in the European Union. Violations of the rules governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption Legislation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Markets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The UK formally left the EU on January 31, 2020 and the EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework agreed by the UK and EU on February 27, 2023.  Amongst other things, the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. From January 1, 2025, medicines will need to be approved and licensed on a UK-wide basis by the UK&#8217;s Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;), with medicines using the same packaging and labelling across the UK. The EMA will have no role in approving or licensing new drugs for provision in Northern Ireland. The Windsor Framework has not, up to this point, been extended to the regulation of medical devices. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union and the United Kingdom have agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK government has adopted the Medicines and Medical Devices Act 2021 (&#8220;MMDA&#8221;) which seeks to address this regulatory gap through introducing regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The purpose of the MMDA is to enable the existing regulatory frameworks to be updated following the UK&#8217;s departure from the EU</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MMDA supplements the UK Medical Devices Regulations 2002 (the &#8220;Regulations&#8221;), which are based on the EU Medical Devices Directive as amended to reflect the United Kingdom&#8217;s post-Brexit regulatory regime. Notably, the Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which has gained full application in all EU Member States since May 26, 2021 but is not applicable in the UK as &#8220;retained law&#8221;. Additionally, the MHRA launched a comprehensive consultation in 2021 with proposals to amend the regulatory framework for medical devices in the United Kingdom. The stated objectives of the proposals include expansion of the scope </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Regulations (for example, by expanding the in vitro diagnostic medical device definition to include software and other products, including products without an intended medical purpose but with similar functioning and risk profiles) and potentially through use of internationally recognized definitions (for example, by excluding products that contain viable biological substances and excluding food), remove trade barriers, further the availability of medical devices and improve the favorability of the UK market. The consultation period closed on November 25, 2021 and on June 26, 2022, the MHRA published a response to its consultation, which sets out the proposed new UK regulatory framework for medical devices and in vitro diagnostic medical devices. The proposals are intended to improve patient safety and public health through appropriate regulatory oversight, improve the traceability of medical devices, improve the regulation of the rules governing software and AI as medical devices and introduce alternative routes to market to ensure the UK aligns with any superior international best practices. Core aspects of the new framework are expected to apply from July 1, 2025 with appropriate transitional measures and the introduction of secondary legislation (although the strengthened post-market surveillance regime for medical devices is expected to come into effect in mid-2024). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medical Devices (Amendment) (Great Britain) Regulations 2023, CE marked European medical devices will continue to be accepted for sale in the UK until 2028 or 2030, depending on the type of device.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Employees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown to a team of approximately 50 employees as of December 31, 2023. Our employees are based in the following countries: Switzerland, the United Kingdom, Portugal and Belgium. Our highly qualified and experienced team includes scientists, physicians and professionals across clinical development, regulatory affairs, manufacturing, medical affairs, commercialization, finance and other important functions that are critical to our success. We also leverage certain external experts in drug development and corporate functions to provide flexibility for our business needs. </span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to hire additional employees in 2024 and beyond to expand our expertise and bandwidth across all functions. We continue to evaluate our business needs and opportunities.</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Culture</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the success of our human capital management investments is evidenced by our low employee turnover, a metric which is regularly reviewed by our board of directors (the &#8220;Board&#8221;) as part of its oversight of our human capital strategy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Engagement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Development &amp; Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries, bonuses, and opportunities for equity ownership.</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee and Visitor Safety Protocols</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow applicable health and safety guidelines to protect the well-being of our employees and visitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity &amp; Inclusion</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were originally incorporated on August 13, 2020 in the Cayman Islands as a special purpose acquisition company under the name Helix Acquisition Corp., and our subsidiary, MoonLake AG, was incorporated in Switzerland in 2021. In connection with the consummation of the Business Combination (as defined below), we changed our name from Helix Acquisition Corp. to MoonLake Immunotherapeutics. Our principal executive office is located in Dorfstrasse 29, 6300, Zug, Switzerland.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is www.moonlaketx.com. The contents of, or information accessible through, our website are not part of this Annual Report on Form 10-K. We make our filings with the SEC, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports, available free of charge on our website as soon as reasonably practicable after we file such reports with, or furnish such reports to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on or available through our website, and you should not consider such information to be a part of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_19"></div><div style="margin-bottom:0.12pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks described below, as well as general economic and business risks and the other information in this Annual Report on Form 10-K. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also harm our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves significant risks. You should carefully consider the risks described below before making a decision to invest in our common stock. If we are unable to successfully address these risks and challenges, our business, financial condition, results of operations, or prospects could be materially adversely affected. In such case, the trading price of our common stock would likely decline, and you may lose all or part of your investment. Below is a summary of some of the risks we face.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of SLK, and our ongoing and anticipated clinical trials of SLK may not be successful.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business relies on certain licensing rights from MHKDG and RCT that can be terminated in certain circumstances. If we breach those agreements, or if we are unable to satisfy our diligence obligations under which we license rights to SLK from MHKDG, we could lose the ability to develop and commercialize SLK.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from SLK and may never generate revenue or become profitable.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history and have no products approved for commercial sale.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never successfully completed the regulatory approval process for any of our product candidates and we may be unable to do so for any product candidates we acquire or develop.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of preclinical testing and early clinical trials may not be predictive of the success of our later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authorities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preliminary, interim data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may find it difficult to enroll patients in our clinical trials. If we experience delays or difficulties in the enrollment of patients in clinical trials, our successful completion of clinical trials or receipt of marketing approvals could be delayed or prevented.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing, licensing or commercializing products before or more successfully than we do.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SLK may have a safety profile that could prevent regulatory approval, marketing approval or market acceptance, or limit its commercial potential.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our development programs or future commercialization efforts, which would have a negative impact on our business, prospects, operating results, and financial condition.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently rely on third parties to produce and process SLK. Our business could be adversely affected if the third-party manufacturers fail to provide us with sufficient quantities of SLK or fail to do so at acceptable quality levels or prices.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_22"></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Business, Financial Condition, and Results of Operations</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history and have no products approved for commercial sale.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage company with limited operating history. To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including establishing our business model and key third-party relationships with payers, completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing, selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and, since our inception, we have been incurring significant operating losses, and expect to incur significant losses in the foreseeable future. As with any clinical development, we cannot be certain that our planned clinical trials will begin or be completed on time or at all. In addition, we have not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully complete our ongoing and planned preclinical and clinical studies for SLK;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely file and gain acceptance of IND applications for our programs in order to commence planned clinical trials or future clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully enroll subjects in, and complete, our ongoing and planned clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain data related to SLK and generated prior to the License Agreement, but not transferred from MHKDG, which may delay our development and commercialization;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate and successfully complete all safety and efficacy studies required to obtain U.S. and foreign regulatory approval for our product candidates, and additional clinical trials or other studies beyond those planned to support the approval and commercialization of SLK;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully demonstrate to the satisfaction of the FDA, EMA, or similar foreign regulatory authorities the safety and efficacy and acceptable risk to benefit profile of SLK or any future SLK product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully manage the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, if any;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain the timely receipt of necessary marketing approvals from the FDA, EMA and similar foreign regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical supply and commercial manufacturing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain acceptance of the products, if and when approved, by patients, the medical community and third-party payers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">position our product conducts to effectively compete with other therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain healthcare coverage and adequate reimbursement for our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforce and defend intellectual property rights and claims; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain a continued acceptable safety profile of SLK following approval.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent of any further losses or if or when we might achieve profitability. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. We may never succeed in these activities and, even if we succeed in commercializing SLK, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable could decrease the value of our shares and impair our ability to raise capital, maintain our research and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development efforts, expand our business or continue our operations. Further, we may encounter unexpected expenses, challenges and complications from known and unknown factors.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from SLK and may never generate revenue or become profitable.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is a highly speculative undertaking and entails substantial upfront capital expenditures and risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale, we have not generated any revenue from product sales to date, and we continue to incur research and development and other expenses related to our ongoing operations. We do not expect to generate product revenue unless or until we successfully complete clinical development and obtain regulatory approval from the FDA, EMA and similar foreign regulatory authorities of, and then successfully commercialize, SLK in one or more indications. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If we are unable to generate sufficient revenue through the sale of SLK, we may be unable to continue operations without additional funding.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses in each period since we commenced operations on March 10, 2021. Our net losses were $44.1 million for the year ended December&#160;31, 2023. We expect to continue to incur significant losses for the foreseeable future. Our failure to become profitable would decrease the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our Company could also cause you to lose all or part of your investment.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our development programs or future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing biopharmaceutical products is a very long, time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval from the FDA, EMA, and similar foreign regulatory authorities for, SLK. Even if SLK is approved for commercial sale, we anticipate incurring costs associated with sales, marketing, manufacturing and distribution activities to launch SLK. Our expenses could increase beyond expectations if we are required by the FDA, EMA, or other regulatory agencies to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of funding that will be necessary to successfully complete the development and commercialization of SLK. Our future capital requirements depend on many factors, including factors that are not within our control. Based on our current operating plan, we believe our existing cash, cash equivalents and short-term marketable securities, will be sufficient to fund our operations to the end of 2026. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external sources of funds and adequate additional financing may not be available to us on acceptable terms, or at all. We may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. Such financing may dilute our shareholders or the failure to obtain such financing may restrict our operating activities. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect your rights as a shareholder. Debt financing may result in the imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to future collaborations with third parties, we may have to relinquish valuable rights to SLK, or grant licenses on terms that are not favorable to us. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide. If our costs, in particular costs related to clinical development, manufacture and supply, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financial condition. Our failure to raise capital as and when needed or on acceptable terms has in the past had, and in the future may have, a negative impact on our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial condition and our ability to pursue our business strategy, and we have in the past had to, and in the future may have to, delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our own required quarterly assessments, we may conclude that there is substantial doubt about our ability to continue as a going concern, and future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business relies on certain licensing rights from MHKDG and RCT that can be terminated in certain circumstances. If we breach those agreements, or if we are unable to satisfy our diligence obligations under which we license rights to SLK from MHKDG, we could lose the ability to develop and commercialize SLK.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to develop and commercialize SLK is dependent on the use of certain intellectual property that is licensed to us by MHKDG and RCT. These licenses are granted pursuant to agreements setting forth certain terms and condition for maintaining such licenses. In the event that the terms and conditions are not met, the licenses are at risk of being revoked and the granting process may be terminated. Our primary license agreement is the License Agreement. See &#8220;Business &#8212; The Merck Healthcare KGaA (Darmstadt, Germany) License Agreement&#8221;.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2021, we entered into the License Agreement, a worldwide exclusive license agreement with MHKDG, for certain intellectual property covering SLK and to sublicense certain rights licensed to MHKDG to (i) develop and commercialize products containing SLK; and (ii) manufacture SLK using the underlying yeast strain Pichia pastoris. If there is any dispute between us and MHKDG regarding our rights under the License Agreement, including if we disagree with MHKDG&#8217;s comments to our development plan for SLK or if we are unable to make our milestone obligations, our ability to develop and commercialize SLK may be adversely affected. Any uncured, material breach by us under the License Agreement could result in our loss of exclusive rights to SLK and may lead to a complete termination of our product development efforts for SLK.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have diligence obligations under the License Agreement, including: (a) developing one licensed product in at least two indications; (b) launching and commercializing one product in seven major markets, including with pricing approval if required for commercialization, within 12 months of receiving regulatory approval in the respective market; (c) securing within six months of the effective date of the exclusive license a contract research facility; and (d) initiating two Phase 2 clinical trials for a product within 12 months of the effective date of the exclusive license, taking into account any regulatory requirements from the FDA, EMA or other regulatory authorities, of which we satisfied upon the initiation of our MIRA and ARGO trials. We have not yet demonstrated our ability to  obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Due to the uncertainties and risks associated with these activities, we may not be successful in meeting these diligence obligations within the required timeframes, and may lose the ability to develop and commercialize SLK.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2023, we entered into an agreement with RCT and MHKDG, effective as of June 1, 2023, pursuant to which we were granted a royalty-bearing, nonexclusive, sublicensable right and license under RCT&#8217;s patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces our sublicense for similar rights under the License Agreement with MHKDG.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the significant resources required for the development of SLK, we must prioritize the pursuit of treatments for certain indications. We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing therapies for patients with inflammatory skin and joint diseases with unmet needs. In particular, we are developing a portfolio of therapeutic indications for SLK, and are initially focused on the development of SLK in inflammatory diseases including HS and PSA. In May 2022, we initiated our MIRA trial, and in December 2022, we initiated </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our ARGO trial. In October 2023, we announced full 24-week data from the global Phase 2 MIRA clinical trial. In November 2023, we announced top-line 12-week data from the global Phase 2 ARGO trial. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular indications may not lead to the development of any viable commercial product and may divert resources away from opportunities for other indications that later prove to have greater commercial potential or a greater likelihood of success. The primary endpoints for the Phase 2 trials for the therapeutic indications of HS and PsA were the therapeutic scores of the HiSCR and ACR, respectively. The primary endpoints of such trials were met and SLK demonstrated meaningful increases in such therapeutic scores. However, there is no guarantee that the results will be replicated in Phase 3 studies, nor that they will lead to market acceptance or commercial success of SLK, if approved. Even if SLK receives marketing approval, it may not achieve commercial success. If we do not accurately evaluate the commercial potential or target market for SLK, we may relinquish valuable rights to SLK through future collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. We may make incorrect determinations regarding the viability or market potential of SLK or misread trends in our industry.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to later write-down or write-off assets, restructure our operations, or incur impairment or other charges that could result in losses. Even though these charges may be non-cash items and not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to negative market perceptions about us or our securities. In addition, charges of this nature may cause us to violate net worth or other covenants to which we may be subject. Accordingly, any shareholders could suffer a reduction in the value of their shares. Such shareholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The only principal assets of our Company are cash and our interest in MoonLake AG, and accordingly we will depend on distributions from MoonLake AG to pay taxes and expenses.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company and have no material assets other than cash and our ownership of Class V shares in MoonLake AG and common shares in MoonLake AG (&#8220;MoonLake AG Common Shares&#8221;). As such, we have no independent means of generating revenue or cash flow, and our ability to pay taxes and operating expenses or declare and pay dividends in the future, if any, will be dependent upon the financial results and cash flows of MoonLake AG and its subsidiaries, and distributions we receive from MoonLake AG. There can be no assurance that MoonLake AG and its subsidiaries will generate sufficient profits and/or cash flow to distribute funds to us, or that applicable laws and contractual restrictions, including negative covenants in any debt agreements of MoonLake AG or its subsidiaries, will permit such distributions.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributions by MoonLake AG to the Company are subject to a Swiss federal dividend withholding tax at the statutory rate of 35%, unless and to the extent that such distributions constitute a repayment of duly reported capital contributions. Under the current structure, we are not entitled to any relief from Swiss federal dividend withholding tax, such that MoonLake AG will be required to deduct the Swiss federal dividend withholding tax at the statutory rate of 35% and that such tax deduction will result in a final tax burden for the Company. If our place of management is relocated to Switzerland such withholding tax on distributions from MoonLake AG to us may be eliminated (although such relocation would result in Swiss withholding taxes applying on distributions from us to our shareholders; depending on the specific shareholder, such shareholder may be entitled to a full or partial relief or credit for such Swiss withholding tax). There can be no assurances that our place of management will be relocated or that such withholding tax will be reduced or eliminated.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_25"></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never successfully completed the regulatory approval process for any of our product candidates and we may be unable to do so for any product candidates we acquire or develop.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet demonstrated our ability to successfully obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. If we are required to conduct additional preclinical studies or clinical trials of SLK beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of SLK or other testing, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining regulatory approval from the FDA, EMA or other regulatory authorities for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain regulatory approval at all and lose our right and ability under our license from MHKDG to further develop and commercialize SLK;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to be subject to post-marketing testing requirements from the FDA, EMA or other regulatory authorities; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience having the product removed from the market after obtaining regulatory approval.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of SLK, and our ongoing and anticipated clinical trials of SLK may not be successful.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is substantially dependent on our ability to successfully develop SLK for future marketing approval, and then successful commercialization. We are investing a majority of our efforts and financial resources into the research and development of SLK. In October 2023, we announced full 24-week data from the global Phase 2 MIRA clinical trial. In November 2023, we announced top-line 12-week data from the global Phase 2 ARGO trial.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SLK will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote SLK before we receive marketing approval from the FDA, EMA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of SLK will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any third parties with whom we choose to collaborate in the future. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of SLK, even if approved. If we are not successful in commercializing SLK, or are significantly delayed in doing so, our business will be materially harmed.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll patients in our clinical trials. If we experience delays or difficulties in the enrollment of patients in clinical trials, our successful completion of clinical trials or receipt of marketing approvals could be delayed or prevented.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for SLK if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. Patient enrollment may be affected by various factors, including if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as SLK, and patients instead enroll in such clinical trials. Our inability to enroll a sufficient number of patients would result in significant delays in completing clinical trials or receipt of marketing approvals and increased development costs or may require us to abandon one or more clinical trials altogether.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of preclinical testing and early clinical trials may not be predictive of the success of our later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authorities.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to demonstrate with substantial evidence through well-controlled clinical trials that SLK is safe and efficacious before we can seek marketing approvals for commercial sale. Demonstrations of efficacy or an acceptable safety profile in prior preclinical studies of SLK does not mean that future clinical trials will yield the same results. For instance, we do not know whether SLK will perform in future clinical trials as SLK has performed in preclinical studies and prior clinical trials conducted by us, MHKDG, Avillion or Ablynx. SLK may fail to demonstrate in later-stage clinical trials sufficient </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety and efficacy to the satisfaction of the FDA, EMA, and other comparable foreign regulatory authorities despite having progressed through preclinical studies and earlier stage clinical trials. Regulatory authorities may also limit the scope of later-stage trials until we have demonstrated satisfactory safety or efficacy results in preclinical studies or earlier-stage trials, which could prevent us from conducting the clinical trials we currently anticipate. There is no guarantee that the FDA, EMA, and other comparable foreign regulatory authorities will consider the data obtained from prior SLK trials sufficient to allow us to initiate our planned clinical trials within the timelines we anticipate, or at all. Even if we are able to initiate our planned clinical trials on schedule, there is no guarantee that we will be able to complete such trials on the timelines we anticipate or that such trials will produce positive results. Any limitation on our ability to conduct clinical trials could delay or prevent regulatory approval or limit the size of the patient population that can be treated by SLK, if approved.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for commercialization of SLK, we must complete clinical trials to demonstrate the safety and efficacy of SLK in humans and in selected diseases. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and a failure of one or more clinical trials can occur at any stage. The outcome of preclinical studies and prior clinical trials may not be predictive of the success of later clinical trials, and the outcome of preclinical studies and prior clinical trials for a product candidate for a particular indication may not be predictive of the success of preclinical studies and clinical trials for the same product candidate for a different indication. In particular, in October 2023, we announced full 24-week data from the global Phase 2 MIRA clinical trial and, in November 2023, we announced top-line 12-week data from the global Phase 2 ARGO trial. We expect to commence Phase 3 clinical trials in HS and PsA in 2024. Although data from the Phase 2 MIRA and ARGO clinical trials for SLK in patients established SLK as a highly promising and differentiated therapeutic solution in HS and PsA, respectively, Phase 3 trials of the efficacy of SLK in patients with HS and PsA may not yield similar results. If a Phase 3 study is initially conducted for SLK in patients with PsA and HS, or PSO, the outcome may be different than those observed in the respective Phase 2 trials. Unexpectedly favorable results of comparator arms in any trial could lead to unfavorable comparisons to SLK. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. We also cannot be sure that submission of an IND or similar application will result in the FDA, EMA, or other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of SLK for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s GCPs or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to larger-scale facilities operated by a CMO and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to us. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from SLK, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of SLK beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of SLK, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary, interim data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We might also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of SLK and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary, or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, SLK may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing, licensing or commercializing products before or more successfully than we do.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face substantial competition from major pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, pharmaceutical companies that develop and/or market products for the indications we are pursuing, including HS and PsA, are likely to represent substantial competition. These include companies developing and/or marketing IL-17A and IL-17AA inhibitors (such as Novartis AG, Eli Lilly and Co, Amgen, Acelyrin, Zura Bio Ltd and LEO Pharma), IL-23 inhibitors (such as AbbVie, Janssen, Sun Pharmaceutical and Almirall), IL-12/23 inhibitors (including Janssen), TNF alpha inhibitors (such as AbbVie, Pfizer, Janssen and UCB), TYK2 inhibitors (such as Bristol Myers Squibb), JAK inhibitors (such as AbbVie, Incyte and Pfizer), IL1a/IL1b inhibitors (including Abbvie), OX40L inhibitors (such as Sanofi), and IRAK4 degraders (such as Kymera Therapeutics Inc). It also includes UCB as the development and commercializing company for bimekizumab, the only other IL-17A and F inhibitor beyond SLK that has received approval or is in late-stage clinical development of which we are aware. While SLK represents a novel mechanism of action, all of the above mechanisms are also of potential therapeutic use in one or more other indications that we are or may be pursuing. If SLK does not offer sustainable advantages over competing products, we may otherwise not be able to successfully compete against current and future competitors.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize SLK. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than SLK and these competitors may also be more successful than us in manufacturing and marketing their products.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we also face competition more broadly across the market for existing cost-effective and reimbursable inflammatory skin and joint disease treatments. SLK, if approved, may compete with these existing drug and other therapies but may not be competitive with them in price. We expect that if SLK is approved, it will be priced at a significant premium over generic, including branded generic, or biosimilar products. In particular, the availability of biosimilar products of adalimumab and in the future secukinumab may intensify competition. As a result, obtaining market acceptance of, and gaining significant share of the market for, SLK will pose challenges.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLK may have a safety profile that could prevent regulatory approval, marketing approval or market acceptance, or limit its commercial potential.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in previous SLK trials have experienced adverse events, including oral Candida. If SLK is associated with undesirable side effects or has unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or INDs, we may need to interrupt, delay or abandon SLK&#8217;s development or limit development to more narrow uses or subpopulations in which such potential undesirable side effects or other characteristics may be less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of SLK and may adversely affect our business, financial condition and prospects significantly. For details of the current understanding of the SLK safety profile, see the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, after SLK may receive marketing approval, we or others may later identify undesirable side effects or adverse events caused by SLK. In such cases, regulatory authorities may suspend, limit or withdraw approvals of SLK or seek an injunction against its manufacture or distribution, require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, require press releases or other communications containing warnings or other safety information about SLK, require us to change the way SLK is administered or conduct additional clinical trials or post-approval studies, require us to create a REMS which could include a medication guide outlining the risks of such side effects for distribution to patients, impose fines, injunctions or criminal penalties. We could also be sued and held liable for harm caused to patients, and our reputation may suffer. Any of these events could prevent us from achieving or maintaining market acceptance of SLK, if approved, and could seriously harm our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises such as pandemics or similar outbreaks could seriously and adversely affect our preclinical studies and ongoing and anticipated clinical trials, business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of pandemics and related &#8220;shelter in place&#8221; orders and other public health guidance measures, we may in the future experience disruptions that could seriously harm our business. Potential disruptions include but are not limited to: delays or difficulties in enrolling patients in, initiating or expanding our clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff; increased rates of patients withdrawing from our clinical trials following enrollment as a result of certain health conditions or being forced to quarantine; interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed; recommendations by federal, state or local governments, employers and others or interruptions of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical trial endpoints; diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at CROs and vendors; interruption or delays in the operations of the FDA, EMA, and comparable foreign regulatory authorities including delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; interruption of, or delays in receiving, supplies of SLK from our CMOs due to staffing shortages, raw materials shortages, production slowdowns or stoppages and disruptions in delivery systems; and limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and preclinical work, including because of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future pandemics may also affect the ability of the FDA, EMA, and other regulatory authorities to perform routine functions. If global health concerns prevent the FDA, EMA, or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA, EMA, or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_28"></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Process and Other Legal Compliance Matters</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA, EMA, and other comparable foreign regulatory authorities are complex, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for SLK, we may not be able to commercialize, or may be delayed in commercializing, SLK, and our ability to generate revenue will be materially impaired.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals in the United States, the EU, and other jurisdictions is complex, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot commercialize SLK in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize SLK outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of SLK, we must demonstrate through complex and expensive preclinical studies and clinical trials that SLK is both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authorities. Further, SLK may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval. The FDA, EMA, and comparable foreign regulatory authorities have discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. SLK could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to demonstrate to the satisfaction of the FDA, EMA, or comparable foreign regulatory authorities that SLK is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA, or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to SLK; we may be unable to demonstrate that SLK&#8217;s clinical and other benefits outweigh its safety risks; the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of SLK may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; the FDA, EMA, or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of SLK; the FDA, EMA, or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA, EMA, or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. Thus, the approval requirements for SLK are likely to vary by jurisdiction such that success in one jurisdiction is not necessarily predicative of success elsewhere.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of drugs in development, only a small percentage successfully complete the FDA, EMA, or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market SLK, which would significantly harm our business, results of operations and prospects.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to obtain approval, regulatory authorities may approve SLK for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve SLK with a label that does not include the labeling claims necessary </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or desirable for the successful commercialization of SLK. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for SLK, we may not be able to commercialize, or may be delayed in commercializing, SLK and our ability to generate revenue could be materially impaired.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with SLK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for SLK will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of SLK, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. In addition, if the FDA, EMA, or comparable foreign regulatory authorities approve SLK, SLK and the activities associated with its development and commercialization, including its design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA in the EU and comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA, EMA, and other regulatory authorities for compliance with cGMPs.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or a regulatory authority discover previously unknown problems with SLK, such as adverse events of unanticipated severity or frequency, or problems with the facilities where SLK is manufactured, a regulatory authority may impose restrictions on SLK, the manufacturing facility or us, including requiring recall or withdrawal of SLK from the market or suspension of manufacturing, restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize SLK and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s, EMA&#8217;s and other regulatory comparable authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit, delay, increase the cost or risks of obtaining regulatory approval of our product candidates, including if as a result new or more costly or difficult to achieve clinical trial or manufacturing quality requirements are imposed. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer SLK at competitive prices which would seriously harm our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize SLK also will depend in part on the extent to which reimbursement for SLK and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with the laws and regulations prohibiting the promotion of off-label uses can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, EMA, and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If SLK is approved and we are found to have improperly promoted off-label uses of SLK, we may become subject to significant liability. See the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business &#8212; Government Regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. If we cannot successfully manage the promotion of SLK, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted a code of conduct to more closely reflect our operations, but it is not always possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute SLK, if approved.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our future arrangements with third-party payers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain regulatory approval. See the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business &#8212; Government Regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for a more detailed description of the laws that may affect our ability to operate.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payers, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the ACA was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to amend or challenge the ACA, will impact our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At a federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#8217;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#8217;s implementing regulations. The FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, the HHS&#8217;s CMS stated that drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further, on November 20, 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation (the &#8220;MFN&#8221;) Model under which Medicare Part B reimbursement rates would have been calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) countries with a similar gross domestic product per capita. However, the MFN rule was immediately challenged in federal courts and on August 6, 2021 CMS announced a proposed rule to rescind it. On November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. In response to litigation, the Biden administration agreed to delay the effective date of the rule until January 1, 2023. On November 15, 2021, Public Law 117-58 went into effect. Section 90006 prohibits the Secretary of Health and Human Services from implementing the provisions of the final rule prior to January 1, 2026, extending the moratorium by an additional three years. Further, implementation of these changes and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that it will continue to seek new legislative measures to control drug costs. The effect of these legislative and executive activities on our business model and operations is currently unclear.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our external partners are subject to complex environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes, and the rehabilitation of contaminated sites. Our operations, including those performed by our external partners, may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we and/or our external partners may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations related to privacy, data protection, information security and consumer protection across different markets where we conduct our business. Our actual or perceived failure to comply with such obligations could harm our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations related to, among other things, privacy, data protection, information security and consumer protection across different markets where we conduct our business. Such laws and regulations are constantly evolving and changing and are likely to remain uncertain for the foreseeable future. Our actual or perceived failure to comply with such obligations could have an adverse effect on our business, operating results and financial operations. Complying with these numerous, complex, and often changing regulations is expensive and difficult, and failure to comply with any data protection, privacy laws or data security laws or any security incident or breach involving the potential or actual misappropriation, loss or other unauthorized processing, use or disclosure of sensitive or confidential patient, consumer or other personal information, whether by us, one of our collaborators or another third party, could adversely affect our business, financial condition, and results of operations, including but not limited to investigation costs, material fines and penalties, compensatory, special, punitive, and statutory damages, litigation, consent orders regarding our privacy and security practices, requirements that we provide notices, credit monitoring services, and/or credit restoration services or other relevant services to impacted individuals, adverse actions against our licenses to do business, reputational damage and injunctive relief.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the GDPR, which became applicable in May 2018, and related data protection laws in individual EU Member States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR imposes a number of strict obligations and restrictions on the ability to process (processing includes collecting, analyzing and transferring) personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the EEA that are not considered by the EC to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the EC's standard contractual clauses (&#8220;SCCs&#8221;). In this respect, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EEA. For example, following the Schrems II decision of the Court of Justice of the EU on July 16, 2020, in which the Court invalidated the Privacy Shield under which personal data could be transferred from the EEA to United States entities who had self-certified under the Privacy Shield scheme, there is uncertainty as to the general permissibility of international data transfers under the GDPR. The Court did not invalidate the then-current SCCs, but ruled that data exporters relying on these SCCs are required to verify, on a case-by-case basis, if the law of the third country ensures a level of data protection that is essentially equivalent to that guaranteed in the EEA. In light of the implications of this decision, we may face difficulties regarding the transfer of personal data from the EEA to third countries. In 2021 the EC issued a new set of SCCs. Since December 27, 2022, the previous set of SCCs can no longer be used. When relying on SCCs, the data exporters are also required to conduct a transfer risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the SCCs in the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to bring the level of protection of the data transferred to the EU standard of essential equivalence. Where no supplementary measure is suitable, the data exporter should avoid, suspend or terminate the transfer. On June 18, 2021, the European Data Protection Board adopted recommendations to assist data exporters with such assessment and their duty to identify and implement supplementary measures where they are needed to ensure compliance with the EU level of protection to the personal data they transfer to third countries. With regard to the transfer of personal data from the EEA to the United States, on July 10, 2023, the European Commission adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to United States companies participating in the framework.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a personal data breach, the GDPR also requires us, as a controller, to notify the competent supervisory authorities and/or the affected data subjects. Such notification must be issued without undue delay, and where feasible not later than 72 hours after having become aware of the data breach. The notification obligation exists regardless of whether the processing is carried out on our or our vendors&#8217; systems. The only exception where such notification may be omitted is if the personal data breach is unlikely to result in a risk to the rights and freedoms of natural persons. In addition to the disruptions to our business and impact to our reputation that any such breach of security could cause, we may be subject to regulatory fines, class actions, or other costly measures if there is a personal data breach on our or our vendors&#8217; systems. Furthermore, under the GDPR, when we act as a processor, we must notify the relevant controller without undue delay after become aware of a personal data breach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global turnover of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU CTR, EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection regulation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of data from the EU to the United Kingdom, on June 28, 2021 the EC adopted two adequacy decisions for the UK &#8211; one under the GDPR and the other for the Law Enforcement Directive. Personal data may now freely flow from the EU to the UK since the UK is deemed to have an adequate data protection level for purposes of the EU regime. However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after their entry into force, unless renewed. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, known as Brexit, companies also have to comply with the UK&#8217;s data protection laws (including the GDPR, as incorporated into UK national law), the latter regime having the ability to impose fines up to the greater of &#163;17.5 million or 4% of global turnover. Furthermore, transfers from the UK to other countries, including the EEA, are subject to specific transfer rules under the UK regime; personal data may freely flow from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the EU GDPR rules. With regard to the transfer of personal data from the UK to the United States, from 12 October 2023, businesses in the UK can start to transfer personal data to US organizations certified to the &#8220;UK Extension to the EU-US Data Privacy Framework&#8221; (UK Extension) under the UK GDPR, without the need for further safeguards. On March 21, 2022, the international data transfer agreement (IDTA) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (Addendum), and a document setting out transitional provisions came into force and replaced the old EU SCCs for purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before 21 September 2022 on the basis of any old EU SCCs continue to provide appropriate safeguards for the purpose of the UK regime until 21 March 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and appropriate safeguards can be ensured.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, processing of personal data in Switzerland is governed by restrictive regulations, in particular with respect to health and medical data. The collection, storage, use, revision, disclosure, archiving or destruction of personal data in Switzerland is subject to the Federal Act on Data Protection (the &#8220;FDAP&#8221;); as well as various other federal and cantonal acts governing medical research and professional secrecy. This regulatory regime is going to be strongly adjusted by the revision of the FDAP, which is coming into force on the September 1, 2023. The FDAP is wide-ranging in scope and imposes </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data and taking certain measures when engaging third-party processors. Compliance with the FDAP will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to sanctions. Breaches of or non-compliance with applicable data protection regulations and professional secrecy obligations could result in fines, or, under certain circumstances, imprisonment of the individuals responsible for the breach or non-compliance. The sanctions regime relating to data protection obligations will be more comprehensive under the revised FDAP.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that our third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217; and employees&#8217; personally identifiable and other sensitive or confidential information will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations, and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, use, storage, and transmission of such information. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Cayman Islands Economic Substance Act may affect our operations.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cayman Islands has recently enacted the International Tax Co-operation (Economic Substance) Act (As Revised) (the &#8220;Cayman Economic Substance Act&#8221;). The Cayman Economic Substance Act generally requires legal entities domiciled or registered in the Cayman Islands and carrying out specific &#8220;relevant activities&#8221; to have demonstrable substance in the Cayman Islands. The Cayman Economic Substance Act was introduced by the Cayman Islands to ensure that it meets its commitments to the EU, as well as its obligations under the OECD&#8217;s global Base Erosion and Profit Shifting initiatives. We are required to comply with the Cayman Economic Substance Act. As we are a Cayman Islands company, compliance obligations include filing annual notifications for the Company, which need to state whether the Company is carrying out any relevant activities and, if so, whether we have satisfied economic substance tests to the extent required under the Cayman Economic Substance Act. As it is a relatively new regime, it is anticipated that the Cayman Economic Substance Act will evolve and be subject to further clarification and amendments. We may need to allocate additional resources to keep updated with these developments, and may have to make changes to our operations in order to comply with all requirements under the Cayman Economic Substance Act. Failure to satisfy these requirements may subject us to penalties under the Cayman Economic Substance Act. The Cayman Islands Tax Information Authority shall impose a penalty of CI$10,000 (or US$12,500) on a relevant entity for failing to satisfy the economic substance test or CI$100,000 (or US$125,000) if it is not satisfied in the subsequent financial year after the initial notice of failure. Following failure after two consecutive years the Grand Court of the Cayman Islands may make an order requiring the relevant entity to take specified action to satisfy the economic substance test or ordering it that it is defunct or be struck off.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us, and any collaborators, to obtain marketing approval of and commercialize our drug candidates and affect the prices we, or they, may obtain. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed drug products has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. We expect that additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare therapies, which could result in reduced demand for our drug candidate, if approved for commercial use, or additional pricing pressures. Most recently, on August 16, 2022, President Biden signed into law the IRA, which, among other provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. We cannot be sure whether additional legislation or rulemaking related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain qualified managerial, scientific and medical personnel. We are dependent on our managerial, scientific and medical personnel, including our Chief Executive Officer, our Chief Scientific Officer, and our Chief Financial Officer. If we do not succeed in attracting and retaining qualified personnel, it could materially adversely affect our business, financial condition and results of operations. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention efforts. Furthermore, we are dependent on our ability to attract, hire, relocate and retain qualified managerial, scientific and medical personnel from jurisdictions other than Switzerland, the United Kingdom and Portugal. Therefore, Swiss, British and Portuguese immigration requirements have a significant influence on our human resources planning. Immigration applications can take several months or more to be finalized. If we are unable to complete the requisite visa applications, either as a result of changing requirements or otherwise, our ability to successfully implement our business strategy could suffer, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, regulatory affairs and, potentially, others. To manage our anticipated future growth, we must continue to implement and develop our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure in our information technology and storage systems or those of third parties upon whom we rely could significantly disrupt the operation of our business and adversely impact our financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute our business plan and maintain operations depends on the continued and uninterrupted performance of our information technology (&#8220;IT&#8221;) systems or those of third parties upon whom we rely. IT systems are vulnerable to risks and damages from a variety of sources, including telecommunications or network failures, malicious human acts, and natural disasters (such as a tornado, an earthquake, or a fire). Moreover, despite network security and back-up measures, some of our and our vendors&#8217; servers are potentially vulnerable to physical or electronic break-ins, including cyber-attacks, computer viruses, and similar disruptive problems. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently, and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. If the IT systems are </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compromised, we could be subject to fines, damages, litigation, and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business. Despite precautionary measures designed to prevent unanticipated problems that could affect the IT systems, sustained or repeated system failures that interrupt our ability to generate and maintain data could adversely affect our ability to operate our business. In addition, the failure of our systems, maintenance problems, upgrading or transitioning to new platforms, or a breach in security could result in delays and reduce efficiency in our operations. Remediation of such problems could result in significant, unplanned capital investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, parties in our supply chain may be operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems and those of our third-party CROs, other contractors (including sites performing our clinical trials) and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. In addition, techniques used to obtain unauthorized access to networks in which data is stored or through which data is transmitted change frequently and generally are not recognized until launched against a target. As a result, we may be unable to anticipate these techniques or implement adequate preventative measures to prevent such an event. To the extent that any disruption or security breach were to result in a loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of SLK could be delayed. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored. The successful assertion of one or more large claims against us that exceeds our available insurance coverage or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that any existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third-party service providers to comply with our data privacy, security, protection, or confidentiality, or to respond to any data security incidents, breaches or other unauthorized access, acquisition, or disclosure of sensitive information (including, without limitation personal information), may result in additional cost and/or liability to us, including costs from governmental investigations, enforcement actions, regulatory fines, litigation, costs of doing business, or damage to our reputation. Any of these events could cause harm to our reputation, business, financial condition, or operational results.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_34"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize SLK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs and strategic partners, to conduct and support our preclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations, even if responsibilities have been outlined in agreements with external partners, such as CROs. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to SLK. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize SLK.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely on third parties to produce and process SLK. Our business could be adversely affected if the third-party manufacturers fail to provide us with sufficient quantities of SLK or fail to do so at acceptable quality levels or prices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate any facility that may be used to produce SLK (including any drug substance or finished drug product) and must currently rely on CMOs to produce them for us. We have not yet caused SLK to be manufactured in a commercially validated and registered process and may not be able to do so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of SLK. Beyond periodic audits, we have no control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA, or a comparable foreign regulatory authority does not approve these facilities for the manufacture of SLK or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and materially and adversely affect our ability to develop, obtain regulatory approval for or market SLK, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of SLK, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of SLK and harm our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if any CMOs on which we will rely fail to manufacture quantities of SLK at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. Our business could be similarly affected by business disruptions to our third-party providers with potential impacts on our future revenue and financial condition and our costs and expenses. Each of these risks could delay or prevent the completion of our clinical trials or the approval of SLK by the FDA, result in higher costs or adversely impact commercialization of SLK.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we have not yet completed the development of the autoinjector device for SLK and may not be able to do.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, form or seek strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to SLK and/or our Company more broadly. Any of these relationships may require us to increase our near and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_37"></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to SLK and our technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market. Our success depends in large part on our ability to obtain and maintain patent protection for SLK and its uses, components, formulations, methods of manufacturing and methods of treatment, as well as our ability to operate without infringing on or violating the proprietary rights of others. We own and have licensed rights to patent applications and pending patent applications, and expect to continue to file patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drug candidates or which effectively prevent others from commercializing competitive technologies and drug candidates. The patent examination process may require us or our licensors to narrow the scope of the claims of our or our licensors&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent application from being issued as a patent.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to protect our intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on SLK worldwide would be prohibitively expensive and our intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States. We have licensed patents in the most relevant countries but may not be able to obtain patents in all jurisdictions even if we apply for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications. Our pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of SLK or its intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates. Further, even if these patents are granted, they may be difficult to enforce.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Many countries also limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business and financial condition may be adversely affected.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the United States Patent and Trademark Office (&#8220;USPTO&#8221;) and foreign patent agencies over the lifetime of a patent. In addition, the USPTO and other foreign patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such non-compliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, and non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our drug candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our drug candidates in any indication for which they are approved.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering one or more of our drug candidates could be found invalid or unenforceable.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any issued patents that we may license or own covering SLK could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO. Also, patent terms, including any extensions or adjustments that may or may not be available to us, may be inadequate to protect our competitive position with respect to SLK for an adequate amount of time, and we may be subject to claims challenging the inventorship, validity, enforceability of our patents and/or other intellectual property. Finally, changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect SLK. Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market SLK under patent protection would be reduced. Thus, the patents that we own and license may not afford us any meaningful competitive advantage.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we or our licensors may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or SLK and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize SLK. In addition to seeking patents for some of our technology and SLK, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. As our organization grows, so does the risk of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors and those affiliated with or controlled by state actors. In addition, while we undertake efforts to protect our trade secrets and other </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals and engage the services of consultants who previously worked for other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that our consultants have used or disclosed trade secrets or other proprietary information of their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Class A Ordinary Shares. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to absorb the costs of such litigation or proceedings more effectively than we can. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position with respect to SLK for an adequate amount of time.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering SLK are obtained, once the patent life has expired, we may be subject to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for SLK, our business may be materially harmed.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in the EU and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when SLK receives FDA approval, we expect to apply for patent term extensions on patents covering SLK, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we will not succeed in obtaining patent term extension under the Hatch-Waxman Act for a U.S. patent covering SLK that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO, a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we may be unable to obtain patents covering SLK that contain one or more claims that satisfy the requirements for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If SLK is approved and a patent covering SLK is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of SLK.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect SLK.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to challenge the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Also, under the Leahy-Smith Act, the United States transitioned from a first-to-invent to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. Foreign counterparts to this law are also not uniform, and there is no worldwide policy governing the subject matter and scope of claims granted in a pharmaceutical or biotechnology patent. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and altered the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future legislation by the U.S. Congress, decisions by the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. Similarly, changes in the patent laws of other jurisdictions could adversely affect our ability to obtain and effectively enforce our patent rights, which would have a material adverse effect on our business and financial condition.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market SLK.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of SLK in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market SLK.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering SLK or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing SLK or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing SLK.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and is interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on or violating third party rights. If a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon SLK and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g. patent infringement or trade secret theft) brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors may be able to absorb the costs of complex intellectual property litigation more effectively than we can. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise funds and on the market price of our Class A Ordinary Shares.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may be required to protect our patents through procedures created to challenge the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if SLK is found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain a license for SLK.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license patent rights from third-party owners and thus our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to certain licenses, including with our licensor with MHKDG, that provide us rights to intellectual property that are necessary or useful for SLK and its respective components, formulations, methods of manufacturing and methods of treatment. These license agreements require us to satisfy certain obligations and, if these agreements are terminated (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as a result of our failure to satisfy such obligations), our technology and our business could be adversely affected. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also enter into additional licenses to third-party intellectual property in the future; however, we may not be able to obtain such licenses on economically feasible terms or other reasonable terms and conditions, or at all. Additionally, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In those instances, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our licensors, are not able to obtain and maintain patent protection for any products that we develop and for our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or substantially identical to ours, which could adversely affect our competitive business position and harm our business prospects. Even if patents are issued in respect of these patent applications, we or our licensors may determine not to pursue litigation against other companies that are infringing these patents, or may not be able to pursue such litigation at a reasonable cost or in a timely manner. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our license from MHKDG may be subject to retained rights.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MHKDG retains certain rights under its license agreement with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether MHKDG limits its use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to effectively secure first-tier technologies when competing against other companies or investors.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success may require that we acquire patent rights and know-how to new or complimentary technologies. However, we compete with a substantial number of other companies that may also compete for technologies we desire. In addition, many venture capital firms and other institutional investors, as well as other biotechnology companies, invest in companies seeking to commercialize various types of emerging technologies. Many of these companies have greater financial, scientific and commercial resources than us. Therefore, we may not be able to secure the technologies we desire. Furthermore, should any commercial undertaking by us prove to be successful, there can be no assurance competitors with greater financial resources will not offer competitive products and/or technologies.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The factors that may limit any potential competitive advantage provided by our intellectual property rights include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications that we own or license may not lead to issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents, should they issue, that we own or license, may not provide us with any competitive advantages, or may be challenged and held invalid or unenforceable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology but that is not covered by the claims of any of our owned or in-licensed patents, should any such patents issue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we (or our licensors) might not have been the first to make the inventions covered by a pending patent application that we own or license;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we (or our licensors) might not have been the first to file patent applications covering a particular invention;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may develop patents that could expire prior to or shortly after commencing commercialization of a product; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or in-license additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business and results of operation.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If approved, our product candidates that are regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;), was enacted as part of the ACA to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as their BLA does not reply on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty, and any new policies or processes adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that SLK approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The approval of a biosimilar of our product candidates could have a material adverse impact on our business due to increased competition and pricing pressure.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_40"></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Class A Ordinary Shares</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our shares may be volatile, and you could lose all or part of your investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Class A Ordinary Shares is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including the factors discussed in this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section and elsewhere in this Annual Report on Form 10-K. The realization of any of these factors could have an adverse impact on the market price of our Class A Ordinary Shares.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for biotechnology companies in particular, have experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In addition, broad market and industry factors may negatively affect the market price of our Class A Ordinary Shares, regardless of our actual operating performance. The market price for our Class A Ordinary Shares may be influenced by many factors, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advancement of our preclinical programs into clinical testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of our product candidates or those of our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our programs and product candidates or preclinical and clinical development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our share price is volatile, we may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would materially adversely affect our business, financial condition and results of operation.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our Class A Ordinary Shares, or the perception that such sales may occur, may cause the market price of the Class A Ordinary Shares to decline significantly, even if our business is doing well.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our Class A Ordinary Shares. As restrictions on resale end and registration statements (filed to provide for the resale of such shares from time to time) are available for use, the sale or possibility of sale of these shares could have the effect of increasing the volatility in our share price or the market price of the Class A Ordinary Shares could decline if the holders of currently restricted shares sell them or are perceived by the market as intending to sell them.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal shareholders and management own a significant percentage of our stock and are able to exert significant influence over matters subject to shareholder approval.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially own a significant portion of our outstanding voting common stock. These shareholders, acting together, may be able to impact matters requiring shareholder approval. They may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our capital stock that you may feel are in your best interest as one of our shareholders. The interests of this group of shareholders may not always coincide with your interests or the interests of other shareholders and they may act in a manner that advances their best interests and not necessarily those of other shareholders, including seeking a premium value for their shares, and might affect the prevailing market price for our Class A Ordinary Shares.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our organizational documents could delay or prevent a change of control.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our Memorandum and Articles of Association (the "MAA") and Cayman Islands Law may have an anti-takeover effect and may delay, defer or prevent a merger, acquisition, tender offer, takeover attempt or other change of control transaction that a shareholder might consider in its best interest, including those attempts that might result in a premium over the market price for the shares held by our members.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions provide for, among other things:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing a classified Board;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allowing the Board to issue one or more series of preference shares;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing advance notice for nominations of directors by members and for members to include matters to be considered at general meetings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminating the ability of members to fill vacancies on the Board;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing advance notice requirements for nominations for election to the Board or for proposing matters that can be acted upon by at our annual general meetings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permitting the Board to establish the number of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminating the ability of members to call general meetings or act by written consent;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring a special resolution to amend the MAA; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the jurisdictions in which certain shareholder litigation may be brought.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These anti-takeover provisions could make it more difficult for a third party to acquire our Company, even if the third party&#8217;s offer may be considered beneficial by many of our shareholders. As a result, our shareholders may be limited in their ability to obtain a premium for their shares. These provisions could also discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and to cause us to take other corporate actions you desire. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indemnification obligations to our officers and directors may result in a significant cost to us and hurt the interests of our shareholders.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, actual fraud or the consequences of committing a crime. The MAA provides for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such, except through their own actual fraud, willful default or willful neglect. We purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. We have entered into indemnification agreements with each of our directors and executive officers that obligate us to indemnify, hold harmless, exonerate, and to advance expenses as incurred, to the fullest extent permitted under applicable law, from damage arising from the fact that such person is or was an officer or director of our Company or its subsidiaries.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indemnification obligations may discourage shareholders from bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on its capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our Class A Ordinary Shares will be your sole source of gain for the foreseeable future.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future issuances of debt securities and equity securities may adversely affect our Company, including the market price of our Class A Ordinary Shares and may be dilutive to existing shareholders.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will not incur debt or issue equity ranking senior to the Class A Ordinary Shares. Those securities will generally have priority upon liquidation. Such securities also may be governed by an indenture or other instrument containing covenants restricting its operating flexibility. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of Class A Ordinary Shares. Separately, additional financing may not be available on favorable terms, or at all. Because our decision to issue debt or equity in the future will depend on market conditions and other factors beyond our control, it cannot predict or estimate the amount, timing, nature or success of our future capital raising efforts. As a result, future capital raising efforts may reduce the market price of Class A Ordinary Shares and be dilutive to existing shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_43"></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we would be exempt from certain provisions applicable to U.S. domestic public companies.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become a &#8220;foreign private issuer&#8221; as defined in Rule 36-4 promulgated under the Exchange Act. If we do become a foreign private issuer, we would be exempt from certain rules and regulations in the United States that are applicable to U.S. domestic issuers, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q or current report on Form 8-K;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the section of the Exchange Act regulating the solicitation of proxies, consents or authorizations respect of a security registered under the Exchange Act;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the section of the Exchange Act requiring directors, officers and 10% holders to file public reporting of their stock ownership and trading activities and imposing liability on insiders who profit from trades made in a short period of time; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the selective disclosure rules under Regulation FD restricting issuers from selectively disclosing material nonpublic information.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the information we would be required to file with or furnish to the SEC as a foreign private issuer is less extensive and less frequent as compared to the information required to be filed with the SEC by U.S. domestic issuers.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we become a foreign private issuer whose securities are listed on Nasdaq, we would permitted to, and may elect to, follow certain home country corporate governance practices in lieu of the requirements of the Nasdaq Rules pursuant to Nasdaq Rule 5615(a)(3). Certain corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq corporate governance listing standards applicable to U.S. domestic issuers and may afford our shareholders less protection than they otherwise would enjoy under the Nasdaq corporate governance listing standards applicable to U.S. domestic issuers. We would be required to disclose any significant ways in which our corporate governance practices differ from those followed by U.S. domestic issuers under Nasdaq corporate governance listing standards in an annual report on Form 20-F filed with the SEC or on our website.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_46"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_549755814997"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, use, store, and transmit digitally large amounts of confidential, sensitive, proprietary, personal, and health-related information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by a dedicated information technology team, which is led by our Director of IT, and include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data and maintain a stable information technology environment. For example, we perform daily vulnerability scans on our endpoints; we have a dedicated security operations center (&#8220;SOC&#8221;), which is run by a third-party; and we conduct data recovery testing, security audits, and ongoing risk assessments, including due diligence on our key vendors, CROs, and other contractors and suppliers. We also conduct regular employee trainings on cyber and information security, among other topics. In addition, we consult with outside advisors and experts, including our SOC, on a regular basis to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the Company&#8217;s risk environment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Director of IT, who reports directly to the Chief Financial Officer and has over 10 years of experience managing information technology and cybersecurity matters and holds various EC-Council certifications including &#8220;Certified Chief Information Security Officer&#8221;, &#8220;Certified Ethical Hacker&#8221; and &#8220;Computer Hacking Forensic Investigator&#8221;, together with our senior leadership team, is responsible for assessing and managing cybersecurity risks. We consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework. In the last fiscal year, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks threats that, if realized, are reasonably likely to materially affect us.  Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the headings &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure in our information technology and storage systems or those of third parties upon whom we rely could significantly disrupt the operation of our business and adversely impact our financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEARLY ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our Chief Financial Officer, as well as our Director of IT. The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Zug, Switzerland, where we occupy approximately 4,000 square feet of office space under two open-ended office lease agreements. We use this facility for administrative purposes. In addition, we have facilities in Cambridge, UK where we occupy approximately 6,000 square feet of office space under a 3-year term agreement set to expire in October 2026, and in Porto, Portugal where we occupy approximately 3,900 square feet of office space under a 3-year initial term agreement set to expire in October 2026, with two extendable periods of 3 years each. The office in Cambridge, UK serves as working space primarily for our research and development teams. The office in Porto, Portugal serves as working space for our general and administrative teams. We believe that our facilities are sufficient to meet our current needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently subject to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_58"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_61"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160; Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securitie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class A Ordinary Shares are currently listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;MLTX&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 23, 2024, there were 9 holders of record of our Class A Ordinary Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid any cash dividends on our ordinary shares to date and do not intend to pay any cash dividends for the foreseeable future. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends is within the discretion of our board of directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_67"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. This discussion and analysis contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated as a result of various factors, including those set forth under the section titled &#8220;Risk Factors&#8221; and included elsewhere in this Annual Report on Form 10-K. You should carefully read the sections titled &#8220;Note on Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from the results described below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of Sonelokimab (&#8220;SLK&#8221;), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from Merck Healthcare KGaA, Darmstadt, Germany (&#8220;MHKDG&#8221;) and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SLK is a proprietary Nanobody that was discovered by Ablynx N.V., Belgium, a Sanofi company (&#8220;Ablynx&#8221;), and previously studied by MHKDG and Avillion LLP ("Avillion") under a 2017 co-development agreement. The terms &#8220;Nanobody&#8221; and &#8220;Nanobodies&#8221; used herewith are registered trademarks of Ablynx. Nanobodies are able to bind selectively to a specific antigen with high affinity. Nanobodies have a fraction of the molecular weight compared to traditional antibodies. They offer a number of potential advantages over traditional monoclonal antibodies, including the potential to create multivalent molecules with enhanced ability to penetrate inflamed tissue, especially when containing an additional albumin binding domain such as SLK, an easier manufacturing process and a higher thermostability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently develop SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. This group of diseases comprises our initial target diseases, hidradenitis suppurativa (&#8220;HS&#8221;) and psoriatic arthritis (&#8220;PsA&#8221;), and several other inflammatory conditions (including axial spondyloarthritis ("axSpA") and psoriasis (&#8220;PsO&#8221;). Our initial target diseases affect millions of people worldwide, and we believe there is a need for improved treatment options. We believe that SLK has a differentiated mechanism of action and that its purposefully designed molecular characteristics, including its small size and its albumin binding site, facilitate deep tissue penetration in the skin and joints. We envision SLK as a key therapeutic alternative in our initial target indications and potentially in multiple other IL-17 driven inflammatory conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, we initiated a Phase 2b trial of SLK in patients with moderate-to-severe HS (the MIRA trial (M1095-HS-201)), and in June 2023, we announced positive top-line results from this trial, which met its primary endpoint of Hidradenitis Suppurativa Clinical Response (&#8220;HiSCR&#8221;) 75. In October 2023, we announced positive 24-week top-line results showing that the maintenance treatment with SLK led to further improvements in HiSCR75 response rates and other clinically relevant outcomes in patients with moderate-to-severe HS. In February 2024, we announced the successful outcome of our end-of-Phase 2 interactions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), as well as positive feedback from our interactions with the E.U. European Medicines Agency (&#8220;EMA&#8221;), with both regulatory bodies unanimously supporting our proposed approach for advancing our Phase 3 program of SLK in HS. In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)), and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology (&#8220;ACR&#8221;) 50. We expect to announce 24-week top-line results of the ARGO trial in the first quarter of 2024. SLK was also studied in a Phase 2b trial in PsO patients where it showed a significant improvement in the primary end point as compared with placebo and for which results were presented in peer-reviewed scientific publications and conferences. In addition to the three Phase 2b trials, Phase 1 single ascending and multiple ascending dosing trials were previously completed, bringing the total number of patients in SLK-related trials to more than 700.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on the robust clinical data generated to date, we intend to further pursue the clinical development of SLK. We expect to commence Phase 3 clinical trials in HS and PsA in 2024. We also expect to commence clinical trials of SLK in other indications to be announced in 2024.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any product candidates approved for commercial sale, and we have not generated any revenue from product sales. Our ability to generate revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of SLK in one or more indications, which we expect to take a number of years. We expect to continue to incur significant expenses and operating losses for at least the next three years as we continue the development of SLK and prepare for commercial launches. It is expected that operating losses will fluctuate significantly from year to year depending on the timing of our planned clinical development programs and efforts to achieve regulatory approval.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $451.2 million of cash and cash equivalents. Based on our current operating plans, we believe that our existing cash, cash equivalents and short-term marketable securities, together amounting to $511.0 million, will be sufficient to fund our operating expenses and capital expenditure requirements until the end of 2026.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2023, MNLK Immunotherapeutics, Unipessoal Lda, our wholly-owned subsidiary, was incorporated as a private limited company under the laws of Portugal to conduct administrative and business support services, and research and development activities in biotechnology and immunotherapy.</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we announced the successful outcome of our end-of-Phase 2 interactions with the FDA, as well as positive feedback from our interactions with the EMA, with both regulatory bodies unanimously supporting our proposed approach for advancing our Phase 3 program of SLK in HS. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, we completed the Business Combination (as defined below) which raised $134.7 million net of transaction related expenses. In May 2023, June 2023, and December 2023 we completed equity offerings which raised an additional gross proceeds of $15.2 million, $460.0 million, and $31.7 million respectively. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-Market Offering</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;11, 2023, we entered into a Sales Agreement (the &#8220;May 2023 Sales Agreement&#8221;) with Leerink Partners LLC (formerly known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), through which we could issue and sell up to $200,000,000 of our Class A Ordinary Shares (the &#8220;May 2023 ATM Shares&#8221;), through Leerink Partners as sales agent. The May 2023 ATM Shares to be sold under the May 2023 Sales Agreement, if any, would be issued and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-271546), which was declared effective by the SEC on May 9, 2023, and a prospectus supplement thereto filed with the SEC on May 11, 2023.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2023, in connection with the Offering (as defined below), we reduced the maximum aggregate offering amount of our Class A Ordinary Shares that could be issued and sold under the May 2023 Sales Agreement to $0 and no longer intend to sell Class A Ordinary Shares under the May 2023 Sales Agreement unless we file a further prospectus supplement indicating an amount of shares proposed to be sold. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2023, we entered into a Sales Agreement with Leerink Partners (the &#8220;August 2023 Sales Agreement&#8221;), through which we could issue and sell up to $350,000,000 of our Class A Ordinary Shares (the &#8220;August 2023 ATM Shares&#8221; and together with the May 2023 Sales Agreement, the &#8220;Sales Agreements&#8221;), through Leerink Partners as sales agent. The August 2023 ATM Shares to be sold under the August 2023 Sales Agreement, if any, would be issued and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-274286), which was declared effective by the SEC on September 11, 2023, and a prospectus supplement thereto filed with the SEC on August 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, the Company sold 1,070,818 Class A Ordinary Shares through the Sales Agreements for gross proceeds of $46.9 million.</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023 and through to February 9, 2024 we sold a further 914,828 Class A Ordinary shares through the August 2023 Sales Agreement for gross proceeds of $53.3 million, bringing total gross proceeds under the August 2023 Sales Agreement to $85.0 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public Offering of Class A Ordinary Shares </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2023, we entered into an underwriting agreement with Leerink Partners LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein to issue and sell 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per share (the &#8220;Offering&#8221;). In addition, we granted the underwriters an option for a period of 30 days to purchase up to an additional 1,200,000 Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions (the &#8220;Option&#8221;), and such Option was exercised in full by the underwriters.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Offering closed on June 30, 2023, and net proceeds from the Offering, including proceeds from the exercise in full by the underwriters of the Option, were $436.7 million, after deducting the underwriting discounts and commissions and the offering expenses in the amount of $23.3 million.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of the Offering, we opted to direct a substantial portion of the net proceeds to MoonLake AG. This was executed as a two-step process: (1) we acquired the remaining 22,756 shares of MoonLake AG common stock held in treasury through a share purchase and assignment agreement formally executed on July 09, 2023 ($38.9 million) and (2) additional funds were contributed to MoonLake AG&#8217;s capital reserves through a cash contribution agreement formally executed on July 10, 2023 ($275 million).</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combination</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, we consummated the previously announced business combination pursuant to that certain Business Combination Agreement, dated October 4, 2021 (the &#8220;Business Combination Agreement&#8221;), by and among Helix Acquisition Corp. (&#8220;Helix&#8221;), MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#8220;MoonLake AG&#8221;), the existing equityholders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equityholders of MoonLake AG that executed joinders to the Business Combination Agreement (collectively, the &#8220;ML Parties&#8221;), Helix Holdings LLC, a Cayman Islands limited liability company and the sponsor of Helix, and the representative of the ML Parties (such transactions contemplated by the Business Combination Agreement, collectively, the &#8220;Business Combination&#8221;). Pursuant to the Business Combination Agreement, MoonLake AG merged with and into Helix, with MoonLake AG as the surviving company in the Business Combination and, after giving effect to such Business Combination, MoonLake AG became our subsidiary. The ML Parties received the right to transfer their MoonLake AG Common Shares to the Company in exchange for 33.638698 MoonLake Immunotherapeutics Class A Ordinary Shares (the &#8220;Exchange Ratio&#8221;). In connection with the consummation of the Business Combination, we changed our name from Helix Acquisition Corp. to MoonLake Immunotherapeutics. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business Combination was accounted for as a reverse recapitalization. Under this method of accounting, Helix was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of MoonLake AG issuing shares for the net assets of Helix, accompanied by a recapitalization, whereby no goodwill or other intangible assets was recorded. Operations prior to the Business Combination are those of MoonLake AG. </span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_76"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales. If our development efforts for SLK are successful and result in regulatory approval, or new license agreements with third parties, we may generate revenue in the future from product sales or milestone payments. However, there can be no assurance as to when we will generate such revenue, if at all.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_82"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including third-party license fees and efforts relating to the development of SLK. We expense research and development costs as incurred, which include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, bonuses, benefits, share-based compensation, and other related costs for those employees involved in research and development efforts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses incurred under agreements with Clinical Research Organizations (&#8220;CROs&#8221;) as well as consultants that conduct our research program and development services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred under collaboration agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to manufacturing material for our research program and clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, utilities and insurance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate research and clinical trial expenses based on the services performed pursuant to contracts with research institutions, CROs, and Clinical Manufacturing Organizations (&#8220;CMOs&#8221;), that conduct and manage research studies and clinical trials on our behalf based on actual time and expenses incurred by them or probable achievement of milestone events that are associated with contractually agreed milestone payments.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received rather than when the payment is made.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate employee costs, facilities costs, including depreciation, or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily for managing our research program, clinical development, and manufacturing activities.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of SLK is highly uncertain. We expect to incur significant research and development expenses for the foreseeable future as we continue the development and manufacturing partnerships for SLK, conduct research activities and potentially expand our pipeline by pursuing additional indications for SLK or including new product candidates in our portfolio. We cannot determine with certainty the timing of initiation, the duration, or the completion costs of current or future research studies and clinical trials of SLK due to the inherently unpredictable nature of research activities and clinical development. Clinical development timelines, the probability of success and the development costs can differ materially from expectations. We anticipate that we will make determinations as to which indications to pursue and how much funding to direct to each indication on an ongoing basis in response to the results of ongoing and future research studies and clinical trials, regulatory developments, and our ongoing assessments as to each indication&#8217;s commercial potential. Our clinical development costs are expected to increase significantly when we progress into Phase 3 clinical trials.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any changes in the outcome of any of these variables with respect to the development of SLK could mean a significant change in the costs and timing associated with its development. We may never succeed in achieving regulatory approval </span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for SLK. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials or focus on other product candidates. For example, if the FDA, the EMA, or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of SLK&#8217;s clinical development.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense (&#8220;G&amp;A&#8221;) consists primarily of employee related costs, including salaries, bonuses, benefits, share-based compensation and other related costs for our executive and administrative functions. G&amp;A expense also includes professional services, including legal, accounting and audit services and other consulting fees, as well as facility costs not otherwise included in research and development expenses, insurance and other general administrative expenses.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our strategy, there are a number of factors that we expect will impact the level of research and development expenses, G&amp;A expenses, and capital expenditures incurred by the business. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Building the leading efficacy and safety profile of SLK for patients &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant research and development expenses, and G&amp;A expenses as we: (i) conduct and initiate further clinical trials for SLK including Phase 3 clinical trials in HS and PsA and one or more clinical trials in other indications; (ii)&#160;seek regulatory approvals for SLK; (iii)&#160;make milestone and commercial payments under the In-License Agreement, dated April 29, 2021, by and between MoonLake AG and MHKDG (the "In-License Agreement")  (based on regulatory filing acceptances, first commercial sales, and aggregate annual net sales); (iv)&#160;establish a sales, marketing and distribution infrastructure to commercialize SLK; (v)&#160;attract, hire and retain additional clinical, scientific, quality control, and administrative personnel; and (vi)&#160;add clinical, operational, financial and management information systems and personnel.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Strengthening the differentiation elements for future SLK patients </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In parallel with our clinical trials, we expect to incur additional research expenditures as we conduct non-clinical research to continue refining our understanding of SLK/nanobody biology and the potential impact in our selected therapeutic indications.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Building our manufacturing and commercialization capabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; We do not own or operate manufacturing facilities, and currently have no plans to establish any. We partner with third-party CMOs for both drug substance and finished drug product. We obtain our supplies from these manufacturers based on purchase orders. Therefore, we expect to incur research and development costs for the purchase of our supplies on an as needed basis to conduct our clinical trials. Technology transfers for drug substance and drug product to commercial scale CMOs have already been executed in 2022, but we may pursue additional technology transfers and process improvements. This is designed to allow us to scale-up while SLK is in clinical development and advance potential commercial requirements. The improvement of our manufacturing capabilities will be important in driving efficiency, maintaining high standards of quality control, and ensuring that investigators, physicians, and patients have adequate access to our product candidates, if approved. We also plan to further invest in our commercial capabilities. In 2024, we started hiring dedicated personnel to our marketing, access and pricing functions and intend to continue building out this team to prepare for commercial launches of SLK in our target indications.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Deepening our intellectual property portfolio to support our nanobody technology and product candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;We expect to continue to incur additional research and development expenditures as we continue extending our global intellectual property portfolio consisting of patents and patent applications, trade secrets, trademarks, and know-how to protect the product candidates developed from our nanobody technology. We plan to expand our intellectual property portfolio as we continue to advance and develop existing product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Licensing/broadening our portfolio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; We may supplement our current strategy with the in-licensing or acquisition of additional product candidates for clinical development (beyond SLK), rather than discovering </span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such candidates ourselves, which would lead to additional research and development expenses, G&amp;A expenses, and capital expenditures.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Granting share-based compensation awards and vesting of existing plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; We expect to continue to grant awards to selected employees, directors and non-employees pursuant to the MoonLake AG&#8217;s Employee Stock Option Plan (&#8220;ESOP&#8221;), MoonLake AG&#8217;s Employee Share Participation Plan (&#8220;ESPP&#8221;), and MoonLake Immunotherapeutics 2022 Equity Incentive Plan. Further, we expect to continue to incur share-based compensation charges in connection with the above-mentioned plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to incur additional legal, accounting, investor relations and other expenses associated with operating as a public company and as we continue to grow our business. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our existing cash and cash equivalents to be sufficient to advance the development of SLK in multiple indications, including Phase 3 clinical trials in HS and PsA, and to submit a Biologics License Application (&#8220;BLA&#8221;) for SLK. Clinical development involves a lengthy and expensive process with uncertain outcomes and is subject to risks described under the heading &#8220;Risk Factors&#8221; in Item 1A, including that our preclinical studies or clinical trials may not be conducted as planned or completed on schedule and may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authorities. If we are required to conduct additional preclinical studies or clinical trials of SLK beyond those that we currently contemplate, if we are delayed or unable to successfully complete clinical trials of SLK or other testing, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may require additional funding. Moreover, we will require additional capital to commercialize SLK and to discover, develop, obtain regulatory approval and commercialize any future product candidates, as applicable. We do not have any committed external source of funds. We expect to finance future cash needs through public or private equity or debt offerings or product collaborations. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all. The current market environment for small biotechnology companies, like us, and broader macroeconomic factors, including recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, may preclude us from successfully raising additional capital.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not raise additional capital, we may not be able to expand our operations or otherwise capitalize on our business opportunities, our business and financial condition will be negatively impacted and we may need to: significantly delay, scale back or discontinue research and discovery efforts and the development or commercialization of SLK or any other product candidates or cease operations altogether; seek strategic alliances for research and development programs when we otherwise would not, or at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available; or relinquish, or license on unfavorable terms, our rights to technologies or SLK or any other product candidates that we otherwise would seek to develop or commercialize ourselves.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our functional currency is the U.S.&#160;dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective transaction date.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain or losses from foreign currency translation are included "other income, net" in the audited consolidated statement of operations. We recognized foreign currency transaction gain of $151,493 for the year ended December&#160;31, 2023. We recognized foreign currency transaction gain of $325,317 for the year ended December 31, 2022.</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_88"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the years ended December&#160;31, 2023 and 2022</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.657%"><tr><td style="width:1.0%"/><td style="width:30.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Change %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(31,801,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(42,048,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,247,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(22,321,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(23,012,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">691,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(54,123,096)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(65,061,417)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">10,938,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(16.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(54,123,096)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(65,061,417)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">10,938,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(16.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,138,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">591,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,546,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,613.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Loss before income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(43,984,729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(64,469,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">20,484,956</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(94,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(36,366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(58,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">159.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(44,079,117)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(64,506,051)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">20,426,934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(31.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net unrealized gain on marketable securities and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,330,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">390,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,939,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">496.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial income (loss) on employee benefit plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(336,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">269,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(606,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(224.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,993,522</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">660,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,332,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">201.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(42,085,595)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(63,845,405)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">21,759,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(34.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $31.8 million for the year ended December&#160;31, 2023, compared to $42.0 million for the year ended December 31, 2022. The decrease of $10.2 million primarily related to a decrease of $10.2 million for milestone expenses and research and development services incurred under the In-License Agreements, and a decrease of $4.0 million in CRO expenses for the Phase 2 clinical trials in HS and PsA. The decreases were partially offset by an increase of $2.2 million in personnel-related expenses to support the research and development effort as we move to Phase 3 clinical trials, and an increase of $1.8 million related to contracted non-clinical research expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $22.3&#160;million for the year ended December&#160;31, 2023, compared to $23.0 million for the year ended December 31, 2022. The decrease of $0.7 million was primarily due to a decrease of $3.1 million in share-based compensation due to the restricted founder shares becoming fully vested in April 2023 and a decrease of $1.6 million of professional, legal and other fees as a result of the Business Combination in 2022. The decreases were partially offset by increases of $1.8 million in personnel-related costs and $2.2 million in other general and administrative expenses to support organizational growth and operating as a public company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, we recognized $10.1 million in other income, compared to an income of $0.6 million for the year ended December 31, 2022. The increase of $9.5 million is primarily due to an increase of $10.0 million in interest income on cash held in bank and investments in short-term marketable debt securities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, and for the year ended December&#160;31, 2022, we recognized an income tax expense of $94,388 and $36,366 respectively, which was related to corporate income tax of our U.K. and Portugal subsidiaries in 2023 and of our U.K subsidiary in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, we recognized $2.0 million in other comprehensive income, compared to other comprehensive income of $0.7 million for the year ended December&#160;31, 2022. The increase of $1.3 million was primarily due to net unrealized gain in short-term marketable debt securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale, have not generated any revenue from product sales, and cannot guarantee when or if we will generate any revenue from product sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses and capital requirements to remain consistent with our current spending levels as we continue to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract with third parties to support clinical trials related to SLK;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct our research and development activities related to SLK;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract, hire and retain additional management, scientific and administrative personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, protect and expand our intellectual property portfolio, including patents, trade secrets and know how;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement operational, financial and management information systems; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate as a public company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate a significant future increase in our expenses and capital requirements when proceeding to Phase 3 clinical trials in 2024, and when building up our commercialization capabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, we incurred a loss of $44.1 million, which includes non-cash items such as share-based compensation expense of $7.1 million, and cash outflow from operations of $42.8 million. As of December&#160;31, 2023, we had a total of $511.0 million in cash, cash equivalents and short-term marketable debt securities. Based on our current operating plans, we believe our available cash, cash equivalents and short-term marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements until the end of 2026. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and operating losses for at least the next three years, assuming we continue the clinical development of, and seek regulatory approval for, our product candidate under an in-licensing agreement. It is expected that operating losses will fluctuate significantly from year to year due to the timing of clinical development programs, efforts to achieve regulatory approval, and sales and marketing efforts. We will require substantial additional funding to bring our product candidate to market and support our continuing operations. Until such time that we can generate significant revenue from product sales or other sources, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which may include income from collaborations, strategic partnerships, or marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to fund our operating expense requirements. Refer to &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors &#8212; Risks Related to Our Limited Operating History, Business, </span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition, and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this Annual Report on Form 10-K for further details related to the risk of raising additional capital to fund our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_94"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(42,778,167)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(55,893,900)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(25,184,324)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(32,340,593)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">479,701,508</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">119,692,735</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Effect of movements in exchange rates on cash held</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(75,307)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,540</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">411,663,710</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">31,466,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not generate any cash inflows from our operating activities. Our cash flows from operating activities are significantly influenced by our use of cash for operating expenses and working capital requirements, and we have historically experienced negative cash flows from operating activities as we invested in clinical research and related development and infrastructure efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $42.8 million and $55.9 million for the year ended December&#160;31, 2023, and December 31, 2022, respectively. The reduction of net cash used in operating activities was primarily driven by the reduction in operating loss related to clinical research and development expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, net cash used in investing activities primarily comprised of $175.7 million related to the purchase of short-term marketable debt securities, partially offset by $150.8 million in proceeds received from maturities of short-term marketable debt securities with original maturities longer than three months, and changes in unrealized interests pertaining to short-term marketable debt securities with original maturities less than three months. During the period ended December 31, 2022, net cash used in investing activities of $32.3 primarily related to purchases of short-term marketable debt securities in the amount of $42.2 million, partially offset by $9.9 million of cash proceeds from principal payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, net cash provided by financing activities was $479.7&#160;million consisting primarily of the net proceeds from the shares sold under the Sales Agreements and the Offering. During the period December 31, 2022, net cash provided by financing activities was $119.7 million consisting of $134.7 million of net proceeds from the Business Combination offset by the $15.0 million loan repayment to the Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_97"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our significant contractual obligations and other obligations as of December&#160;31, 2023, which we generally expect to satisfy with cash on hand:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:27.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.044%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.044%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.044%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.044%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.387%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Less than 1 <br/>year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">1 to 5 <br/>Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">More than <br/>5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Purchase obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">44,226,489&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">24,250,498&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,975,991&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lease commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,372,202</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,476,232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,830,047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">65,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total contractual obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">48,598,691</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">25,726,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">22,806,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">65,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:24pt;text-align:justify;text-indent:-24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">____________</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;Purchase obligations refer to an agreement to purchase goods or services that is enforceable and legally binding on the Company that specifies all significant terms. The figures presented primarily relate to contractual commitments towards contract manufacturing and contract research organizations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;We have committed ourselves to three leases, with terms that commenced on November 1, 2021, October 9, 2023, and October 13, 2023, and one lease that commenced on January 15, 2024. We have accounted for the office lease arrangements as operating leases under the guidance ASU 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Leases Topic 842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> through the consolidated statement of operations for the year ended December&#160;31, 2023. The future lease commitments relate to the office leases for our headquarters in Zug, Switzerland, Cambridge, United Kingdom, and Porto, Portugal, and reflect minimum payments due.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires us to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. We continually evaluate these judgments, estimates and assumptions based on the most recently available information, our own historical experience and various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from our expectations as a result of changes in estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An accounting policy is considered critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time such an estimate is made, and if different accounting estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact the financial statements. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. The In-License Agreement for the SLK program has been accounted for as an asset purchase on the basis that there were no tangible assets acquired or liabilities assumed by us under the In-License Agreement and substantially all of the fair value of the gross assets acquired related to the in-process research and development expenditure (&#8220;IPR&amp;D&#8221;) of SLK.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents incomplete technologies we acquire, which at the time of acquisition, are still under development and have no alternative future use. Our management&#8217;s judgement was required to determine whether the IPR&amp;D had any alternative future use. Our management determined that at the time of acquisition, and without significant additional research, there was no alternative future use other than the development of SLK for the treatment of immunological diseases. Therefore, in accordance with our policy, the aggregate consideration for the IPR&amp;D was recorded as research and development expenses during the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Share-based Transaction</span></div><div><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure all share-based awards granted to employees, directors and non-employees based on the fair value on the date of grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. We grant share options and restricted share awards that are subject to either service or performance-based vesting conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify share-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determination of Fair Value &#8211; Common Shares and Class A Ordinary Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the completion of the Business Combination, given that there had been no public market for MoonLake AG's common shares, the estimated fair value of MoonLake AG&#8217;s common shares was determined by reference to separate market-based transactions involving the sale of its shares to two third-party investors that were not considered related parties to us or MHKDG. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our share-based compensation arrangements contain service and performance conditions that, depending on the relevant equity plan, are settled with shares of MoonLake or MoonLake AG, as applicable and meet the definition of a share-based compensation arrangements. All awards granted under our various share-based compensation plans were classified as equity-settled share-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent to the closing of the Business Combination, the fair value of each MoonLake AG Common Share granted is determined based on the closing price of MoonLake Class A Ordinary Shares as reported by Nasdaq on the date of grant and multiplied by the Exchange Ratio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determination of Fair Value &#8211; Share Option Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the award, the risk-free interest rate and expected dividends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We estimate our expected share price volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded share price. The expected term of options granted has been determined based on the expected period that share-based awards are expected to be outstanding. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends on Common Shares and do not expect to pay any cash dividends in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoverability of Deferred Tax Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the recoverability of our deferred tax assets, we considered whether it was more likely than not that some or all of our deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We considered the scheduled reversal of deferred tax liabilities, the seven-year expiry of tax losses carried forward under Swiss tax legislation, projected future taxable income (including the risks associated with the completion of the development and obtaining regulatory approvals to commercialize the product), and tax planning strategies in making this assessment. Based on the weight of all evidence, we determined that it is not more likely than not that the net deferred tax assets will be realized. A valuation allowance has been recorded against the full amount of the deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors, including research laboratories, in connection with preclinical development activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CROs and investigative sites in connection with preclinical studies and clinical trials; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 3 &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Basis of Presentation and Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements included in Part IV, Item 15 of this Form 10-K for more information about recent accounting pronouncements, the timing of their adoption, and our assessment to the extent it has been made, of their potential impact on our financial condition and our results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_106"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to December 31, 2023, we were an &#8220;emerging growth company&#8221;, as defined in the Jumpstart Our Business Startups Act of 2012, and a &#8220;smaller reporting company&#8221;, as defined under the Exchange Act. As such, we were eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 and reduced disclosure obligations regarding executive compensation. As of December 31, 2023, we are no longer an emerging growth company or smaller reporting company. In accordance with SEC rules, we are availing ourselves of the exemptions from disclosure requirements, including certain of the reduced and scaled disclosure obligations, that are available to smaller reporting companies. However, beginning with our Quarterly Report on Form 10-Q for the quarter ending March 31, 2024, we will no longer be permitted to take advantage of the reduced reporting requirements applicable to smaller reporting companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_109"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As we recently transitioned out of smaller reporting company status, and in accordance with SEC rules, we are not required to provide the information under this item.</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2a9ec06b35fd41f2b71136a5c42fce99_148">Item 15</a>, Exhibits and Financial Statement Schedules, of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_115"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_118"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures designed to ensure that information required to be disclosed by us in our reports filed under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December&#160;31, 2023. Based on management's evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&#160;31, 2023. </span></div><div style="text-align:justify;text-indent:0.35pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of any system of internal control over financial reporting is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Lastly, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="text-align:justify;text-indent:0.35pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal </span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Control - Integrated Framework (2013 Framework). Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></div><div style="text-align:justify;text-indent:0.35pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, Baker Tilly US, LLP, has audited the effectiveness of our internal control over financial reporting as of December 31, 2023, as stated in its report which is included in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Exhibits and Financial Statement Schedules, of this Annual Report on Form 10-K. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three month period ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_121"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Plans</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-5" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-37" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrAdoptionDate" id="f-38">October 16, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndName" id="f-39">Dr. Kristian Reich</ix:nonNumeric>, the <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndTitle" id="f-40">Chief Scientific Officer</ix:nonNumeric> of the Company, <ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-41">adopted</ix:nonNumeric> a trading plan intended to satisfy Rule 10b5-1(c). Dr. Reich&#8217;s plan provides for the sale, subject to certain conditions, of up to <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-42">200,000</ix:nonFraction> Class A Ordinary Shares held directly and indirectly by Dr. Reich. The plan terminated on February 28, 2024.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-8" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-43" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On <ix:nonNumeric contextRef="c-9" name="ecd:TrdArrAdoptionDate" id="f-44">October 17, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="c-9" name="ecd:TrdArrIndName" id="f-45">Dr. Jorge Santos da Silva</ix:nonNumeric>, the <ix:nonNumeric contextRef="c-9" name="ecd:TrdArrIndTitle" id="f-46">Chief Executive Officer</ix:nonNumeric> and a director of the Company, <ix:nonNumeric contextRef="c-9" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-47">adopted</ix:nonNumeric> a trading plan intended to satisfy Rule 10b5-1(c). Dr. Santos da Silva&#8217;s plan provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-48">200,000</ix:nonFraction> Class A Ordinary Shares, subject to certain conditions. The plan terminated on February 29, 2024.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2023, no other director or Section 16 officer of the Company <ix:nonNumeric contextRef="c-11" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-49">adopted</ix:nonNumeric> or <ix:nonNumeric contextRef="c-11" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-50"><ix:nonNumeric contextRef="c-11" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-51">terminated</ix:nonNumeric></ix:nonNumeric> any &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_124"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_127"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></div></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_130"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item 10 is incorporated herein by reference to information in our proxy statement for our 2024 Annual Meeting of Stockholders (the &#8220;2024 Proxy Statement&#8221;), which we expect to be filed with the SEC within 120 days of the end of our fiscal year ended December 31, 2023, including under the headings &#8220;Corporate Governance,&#8221; &#8220;Executive Officers&#8221; and, as applicable, &#8220;Delinquent Section 16(a) Reports&#8221; per Item 405 of Regulation S-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have adopted a Code of Ethics that applies to all of our directors, officers and employees, including our principal executive, principal financial and principal accounting officers, or persons performing similar functions. Our Code of Ethics is posted on our website located at https://ir.moonlaketx.com/, under &#8220;Corporate Governance&#8221;. We intend to disclose future amendments to certain provisions of the Code of Ethics, and waivers of the Code of Ethics granted to executive officers and directors, on the website within four business days following the date of the amendment or waiver.</span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_133"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 11 is incorporated herein by reference to information in the 2024 Proxy Statement, including under the heading &#8220;Executive Compensation&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_136"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 12 is incorporated herein by reference to information in the 2024 Proxy Statement, including under the heading &#8220;Certain Information About Our Ordinary Shares&#8212;Security Ownership of Certain Beneficial Owners and Management&#8221;.</span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_139"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item 13 is incorporated herein by reference to information in the 2024 Proxy Statement, including under the headings &#8220;Corporate Governance&#8221; and &#8220;Certain Relationships and Related Party Transactions&#8221;.</span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 14 is incorporated herein by reference to information in the 2024 Proxy Statement, including under the heading &#8220;Proposal 2: Ratification of Independent Auditor Selection&#8221;.</span></div><div><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_145"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%">s</span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_148"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 15. Exhibits and Financial Statement Schedules</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following documents are filed as part of this report:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a) Financial Statements:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:17.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.353%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_160">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:none" href="#i2a9ec06b35fd41f2b71136a5c42fce99_160">2</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_163">Consolidated Balance Sheets as of December 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:none" href="#i2a9ec06b35fd41f2b71136a5c42fce99_163">4</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_166">Consolidated Statements of Operations and Comprehensive Loss for the Year Ended </a></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">December 31, 2023 and</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_166"> </a></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:none" href="#i2a9ec06b35fd41f2b71136a5c42fce99_166">5</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_169">Consolidated Statements of Changes in Equity (Deficit) for the Year Ended December 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:none" href="#i2a9ec06b35fd41f2b71136a5c42fce99_169">6</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_172">Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:none" href="#i2a9ec06b35fd41f2b71136a5c42fce99_172">8</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_175">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:none" href="#i2a9ec06b35fd41f2b71136a5c42fce99_175">9</a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b) Financial Statement Schedules:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c) Exhibits.</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K.</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.1&#8224;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872ex2-1_helixacq.htm">Business Combination Agreement, dated as of October 4, 2021, by and among Helix Acquisition Corp., MoonLake Immunotherapeutics AG, the existing shareholders and option rights holders of MoonLake Immunotherapeutics AG, Helix Holdings LLC, and Matthias Bodenstedt (incorporated by reference to Exhibit 2.1 of the Company&#8217;s Form 8-K, filed with the SEC on October 4, 2021).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227ex3-1_moonlake.htm">Memorandum and Articles of Association of MoonLake Immunotherapeutics (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 11, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227ex3-1_moonlake.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227ex3-1_moonlake.htm">.</a></span></div><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="mltx-exhibit41.htm">Description of Securities.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227ex10-2_moonlake.htm">Amended and Restated Shareholders&#8217; Agreement, dated as of April 5, 2022, by and among MoonLake Immunotherapeutics, MoonLake Immunotherapeutics AG and the investors signatory thereto (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 8-K, filed with the SEC on April 11, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227ex10-5_moonlake.htm">Amended and Restated Registration Rights Agreement, dated as of April 5, 2022, by and among MoonLake Immunotherapeutics, Helix Holdings LLC and the holders signatory thereto (incorporated by reference to Exhibit 10.5 of the Company&#8217;s Form 8-K, filed with the SEC on April 11, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872ex10-3_helixacq.htm">Form of Subscription Agreement (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Form 8-K, filed with the SEC on October 4, 2021).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227ex10-7_moonlake.htm">Form of Subscription Agreement (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Form 8-K, filed with the SEC on April 11, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022023173/fs12022a3ex10-8_moonlakeim.htm">Form of Subscription Agreement (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Form S-1/A filed with the SEC on May 2, 2022).</a></span></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227ex10-8_moonlake.htm">MoonLake Immunotherapeutics 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 of the Company&#8217;s Form 8-K, filed with the SEC on April 11, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.7&#8224;#</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022023173/fs12022a3ex10-12_moonlakeim.htm">Clinical and Commercial Manufacturing Agreement, dated April 11, 2022, effective July 1, 2021, by and between MoonLake Immunotherapeutics AG and Richter-Helm Biologics GmbH &amp; Co. KG (incorporated by reference to Exhibit 10.12 of the Company&#8217;s Form S-1/A, filed with the SEC on May 2, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.8&#8224;#</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000121390022012161/ea156790ex10-9_helixacq.htm">License Agreement, dated April 29, 2021, by and between MoonLake Immunotherapeutics AG and MERCK Healthcare KGaA (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Form S-1/A, filed with the SEC on March 14, 2022)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000121390022012161/ea156790ex10-10_helixacq.htm">Side Letter to License Agreement, dated April 29, 2021, by and between MoonLake Immunotherapeutics AG and MERCK Healthcare KGaA. (incorporated by reference to Exhibit 10.10 of the Company&#8217;s Form S-1/A, filed with the SEC on March 14, 2022)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-28_helixacqu.htm">Loan Agreement, dated October 15, 2021, by and among MoonLake Immunotherapeutics AG and the Lenders named therein (incorporated by reference to Exhibit 10.28 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-29_helixacqu.htm">Amendment to the Loan Amendment, dated January 18, 2022, by and among MoonLake Immunotherapeutics AG and the Lenders named therein (incorporated by reference to Exhibit 10.29 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-30_helixacqu.htm">Second Amendment to the Loan Agreement, dated February 15, 2022, by and among MoonLake Immunotherapeutics AG and the Lenders named therein (incorporated by reference to Exhibit 10.30 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022009481/ea156204ex10-1_helixacq.htm">Convertible Loan Agreement, dated as of February 20, 2022, by and among Cormorant Private Healthcare Fund IV. L.P., MoonLake Immunotherapeutics AG, Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. and Helix Acquisition Corp. (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K, filed with the SEC on February 25, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.14&#8224;#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000182158623000015/novationandarlimiteduselic.htm">Novation, Amended and Restatement of License Agreement, dated June 1, 2023, between MoonLake Immunotherapeutics AG, Research Corporation Technologies, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000162828023031149/exhibit12-sx308312023.htm">Sales Agreement, by and between the Company and Leerink Partners, dated August 31, 2023 (incorporate</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000162828023031149/exhibit12-sx308312023.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000162828023031149/exhibit12-sx308312023.htm"> by reference to Exhibit 1.2 to the Company&#8217;s Registration Statement on Form S-3 filed with the SEC on August 31, 2023). </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-14_helixacqu.htm">Employment Agreement, dated April 30, 2021, by and between MoonLake Immunotherapeutics AG and Dr. Jorge Santos da Silva (incorporated by reference to Exhibit 10.14 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-15_helixacqu.htm">Amendment to Employment Agreement, dated September 9, 2021, by and between MoonLake Immunotherapeutics AG and Dr. Jorge Santos da Silva (incorporated by reference to Exhibit 10.15 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-16_helixacqu.htm">Employment Agreement, dated April 30, 2021, by and between MoonLake Immunotherapeutics AG and Prof. Dr. Kristian Reich (incorporated by reference to Exhibit 10.16 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-17_helixacqu.htm">Amendment to Employment Agreement, dated November 8, 2021, by and between MoonLake Immunotherapeutics AG and Prof. Dr. Kristian Reich (incorporated by reference to Exhibit 10.17 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-18_helixacqu.htm">Employment Agreement, dated May 10, 2021, by and between MoonLake Immunotherapeutics AG and Matthias Bodenstedt (incorporated by reference to Exhibit 10.18 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-19_helixacqu.htm">Amendment to Employment Agreement, dated June 22, 2021, by and between MoonLake Immunotherapeutics AG and Matthias Bodenstedt (incorporated by reference to Exhibit 10.19 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22&#8224;+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-23_helixacqu.htm">Board Member Agreement, dated September 25, 2021, by and between MoonLake Immunotherapeutics AG and Simon Sturge (incorporated by reference to Exhibit 10.23 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.23+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-32_helixacqu.htm">Form of Indemnification Agreement for directors and executive officers (incorporated by reference to Exhibit 10.32 of the Company&#8217;s Form S-1/A, filed with the SEC on March 8, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.24+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227ex10-33_moonlake.htm">Form of Non-Employee Director Stock Option Agreement (incorporated by reference to Exhibit 10.33 of the Company&#8217;s Form 8-K, filed with the SEC on April 11, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.25+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000121390022060668/ea166557ex10-4_moonlake.htm">Employee Stock Option Plan of MoonLake Immunotherapeutics AG, dated June 22, 2022 (incorporated by reference to Exhibit 10.4 of the Company's Form S-8, filed with the SEC on September 30, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.26+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000121390022060668/ea166557ex10-7_moonlake.htm">Employee Share Participation Plan of MoonLake Immunotherapeutics AG, dated June 22, 2022 (incorporated by reference to Exhibit 10.7 of the Company's Form S-8, filed with the SEC on September 30, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.27+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000182158623000007/mltx_ex1025forformxformofs.htm">Form of Nonqualified Stock Option Agreement (incorporated by reference to Exhibit 10.25 of the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 20, 2023).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.28+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000182158623000015/a2023-06x15employeestockop.htm">Amended and Restated Employee Stock Option Plan of MoonLake Immunotherapeutics AG, dated June 15, 2023 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.29+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1821586/000182158623000015/a2023-06x15employeesharepa.htm">Amended and Restated Employee Share Participation Plan of MoonLake Immunotherapeutics AG, dated June 15, 2023 (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21.1*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_ex211subsidiarieslist.htm">Subsidiaries of MoonLake Immunotherapeutics</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_ex211subsidiarieslist.htm">.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_ex231consentofindepen.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Power of Attorney (included on the signature page to this Annual Report on Form 10-K).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">31.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_2023q4xex311dasilva.htm">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">31.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_2023q4xex312bodenstedt.htm">Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32.1**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_2023q4xex321dasilva.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32.2**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_2023q4xex322bodenstedt.htm">Certification of Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">97.1*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_ex971-clawbackpolicy.htm">Incentive Compensation Clawback Policy</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="mltx_ex971-clawbackpolicy.htm">.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.INS*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Instance Document.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.SCH*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.CAL*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.DEF*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.LAB*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.PRE*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">104*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></div></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished.</span></div><div style="padding-left:36pt;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5).</span></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">#&#160;&#160;&#160;&#160;Portions of the Exhibit have been omitted because they are both (i) customarily and actually treated as private and confidential  and (ii) not material.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_154"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:5.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">MOONLAKE IMMUNOTHERAPEUTICS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Dr. Jorge Santos da Silva</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Name:</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dr. Jorge Santos da Silva</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Matthias Bodenstedt</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Name:</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Matthias Bodenstedt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">POWER OF ATTORNEY</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Jorge Santos da Silva and Matthias Bodenstedt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and each of them, the true and lawful attorneys-in-fact and agents of the undersigned, with full power of substitution and resubstitution, for and in the name, place and stead of the undersigned, to sign in any and all capacities (including, without limitation, the capacities listed below), this Annual Report on Form 10-K, any and all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every </span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">act and anything necessary to be done to enable the registrant to comply with the provisions of the Securities Exchange Act and all the requirements of the Securities and Exchange Commission, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute, or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:482.25pt"><tr><td style="width:1.0pt"/><td style="width:178.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:9.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:158.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:10.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:115.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Name</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Title</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Date</span></div></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Dr. Jorge Santos da Silva</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Executive Officer; Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 29, 2024</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Jorge Santos da Silva</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Matthias Bodenstedt</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td></tr><tr style="height:26pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Matthias Bodenstedt</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Simon Sturge</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chairperson; Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Simon Sturge</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Dr. Kara Lassen</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Kara Lassen</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Spike Loy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Spike Loy</span></div><div style="margin-bottom:0.08pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Catherine Moukheibir</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Catherine Moukheibir</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Dr. Andrew Phillips</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Andrew Phillips</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Dr. Ramnik Xavier</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">February 29, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Ramnik Xavier</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_157"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INDEX TO FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:17.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Page</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_160">Report of Independent Registered Public Accounting Firm (</a>Baker Tilly US, LLP<a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_160"> </a>- PCAOB Firm ID No. <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-54">23</ix:nonNumeric><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_160">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_160">2</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_163">Consolidated Balance Sheets </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_163">4</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_166">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_166">5</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_169">Consolidated Statements of Changes in Equity (Deficit)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_169">6</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_172">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_172">8</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:6pt;text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_175">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i2a9ec06b35fd41f2b71136a5c42fce99_175">9</a></span></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_160"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To the Shareholders and the Board of Directors of MoonLake Immunotherapeutics</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have audited the accompanying consolidated balance sheets of MoonLake Immunotherapeutics (the "Company") as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, changes in equity (deficit) and cash flows, for the years ended December 31, 2023 and December 31, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Internal Control &#8211; Integrated Framework: (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years ended December 31, 2023 and December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Internal Control &#8211; Integrated Framework: (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> issued by COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Basis for Opinions</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control Over Financial Reporting in Item 9A of this Annual Report on Form 10-K. Our responsibility is to express an opinion on the Company's consolidated financial statements and an opinion on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud and whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Critical Audit Matter</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Accrued Research and Development Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As discussed in Notes 3 and 9 to the consolidated financial statements, the Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs and makes significant judgments and estimates in determining the accrued balances at the end of any reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We identified the accrual of research and development costs as a critical audit matter. The Company&#8217;s estimates are based on a number of factors, including the Company&#8217;s knowledge of the status of each of the research and development project milestones, and contract terms together with related executed change orders. Higher degree of auditor judgment was required in evaluating the results of our audit procedures regarding the Company&#8217;s estimates, because of the subjectivity and estimation uncertainty in the significant assumptions used in the calculation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">How the Critical Audit Matter was Addressed in Our Audit</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our audit procedures related to management&#8217;s estimates used in the accrued research and development costs included the following, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We obtained an understanding of the Company&#8217;s process for estimating the amount of accrued research and development costs incurred by the contract research organizations and contract manufacturing organizations (the &#8220;R&amp;D service providers&#8221;).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We inquired with the Company&#8217;s personnel outside of the finance function responsible for overseeing the research and development activities about the progress of the activities completed as of year-end for selected R&amp;D service providers.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We obtained external confirmations for select R&amp;D service providers as to the completion status for billed and unbilled services and compared responses to management&#8217;s accrual estimates.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We performed an analysis of the accuracy and completeness of the calculation of estimated accrual and R&amp;D expenses by comparing totals at year end to the actual amounts that were invoiced by the third-party R&amp;D service providers and paid by the Company for selected R&amp;D service providers.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We compared the Company&#8217;s estimate of the research and development costs incurred as of year-end to a selection of cash disbursements and third-party invoices received after year-end but prior to the issuance of the Company&#8217;s consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-55">Baker Tilly US, LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-56">Mountain View, CA</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;29, 2024</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-3</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_163"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Amounts in USD, except share data)</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:61.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.67pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-57">451,169,337</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-58">39,505,627</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">59,838,900</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-60">32,609,108</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-61">1,056,862</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-62">217,129</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Prepaid expenses - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-63">2,102,203</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-64">4,179,468</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total current assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-65">514,167,302</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-66">76,511,332</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-67">3,628,480</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-68">282,580</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-69">320,865</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-70">49,389</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Prepaid expenses - non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-71">8,423,468</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:fixed-zero" scale="0" id="f-72">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-73">12,372,813</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-74">331,969</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-75">526,540,115</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-76">76,843,301</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Trade and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:TradeAndOtherPayablesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-77">1,837,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:TradeAndOtherPayablesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-78">254,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Short-term portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-79">1,197,876</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-80">153,629</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-81">6,930,120</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-82">7,256,845</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-83">9,965,680</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-84">7,665,446</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Long-term portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-85">2,499,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-86">128,951</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Pension liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-87">583,426</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-88">282,206</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-89">3,083,416</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-90">411,157</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-91">13,049,096</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-92">8,076,603</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-12" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-93"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-13" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-94"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:11.72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Class A Ordinary Shares: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-95"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-96">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-97"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-98">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-100">60,466,453</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-102">38,977,600</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-103">6,047</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-104">3,898</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:11.72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Class C Ordinary Shares: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-105"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-106">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-108">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-110">2,505,476</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-112">13,723,511</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" name="us-gaap:CommonStockValue" scale="0" id="f-113">251</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-114">1,373</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-115">609,969,236</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-116">129,192,291</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-117">116,657,472</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-118">80,650,212</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-119">2,357,621</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-120">350,946</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:0.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total shareholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-121">495,675,683</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-122">48,898,296</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="f-123">17,815,336</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="f-124">19,868,402</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-125">513,491,019</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-126">68,766,698</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:9.85pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-127">526,540,115</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-128">76,843,301</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><br/><br/>The accompanying Notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_166"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Amounts in USD, except share and per share data)</span></div></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.082%"><tr><td style="width:1.0%"/><td style="width:62.168%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.903%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 3.77pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-129">31,801,880</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-130">42,048,954</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-131">22,321,216</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-132">23,012,463</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-133">54,123,096</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-134">65,061,417</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Operating loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-135">54,123,096</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-136">65,061,417</ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:3.25pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherNonoperatingIncome" format="ixt:num-dot-decimal" scale="0" id="f-137">10,138,367</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OtherNonoperatingIncome" format="ixt:num-dot-decimal" scale="0" id="f-138">591,732</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Loss before income tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-139">43,984,729</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-140">64,469,685</ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:6.4pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-141">94,388</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-142">36,366</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-143">44,079,117</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-144">64,506,051</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">Of which: net loss attributable to controlling interests shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-145">36,007,260</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-146">49,973,249</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">Of which: net loss attributable to noncontrolling interests shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-147">8,071,857</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-148">14,532,802</ix:nonFraction>)</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:3.25pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net unrealized gain on marketable securities and short-term investments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-149">2,330,101</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-150">390,753</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Actuarial income (loss) on employee benefit plans</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-151">336,579</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-152">269,893</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Other comprehensive income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-153">1,993,522</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-154">660,646</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-155">42,085,595</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-156">63,845,405</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">Comprehensive loss attributable to controlling interests shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-157">34,511,723</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-158">49,437,461</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">Comprehensive loss attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-159">7,573,872</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-160">14,407,944</ix:nonFraction>)</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:3.25pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Weighted-average number of Class A Ordinary Shares, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-161"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-162">49,122,534</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-163"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-164">29,361,353</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Basic and diluted net loss per share attributable to controlling interests shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-165"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-166">0.73</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-167"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-168">1.70</ix:nonFraction></ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">The accompanying Notes are an integral part of these Consolidated Financial Statements.&#160;&#160;&#160;&#160;</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_169"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Amounts in USD, except share data)</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:80%">The accompanying Notes are an integral part of these Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.877%"><tr><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.317%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.317%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.807%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:3.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.290%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">MoonLake AG Series A Preferred Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">MoonLake AG Common Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">MoonLake AG Common Shares Held In Treasury</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Class A Ordinary Shares</span></td><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Class C Ordinary Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Additional Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Accumulated Other Comprehensive Income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Total Shareholders' Equity (Deficit)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Noncontrolling Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Total Equity (Deficit)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Balance at December 31, 2021 (As previously reported)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-169">680,196</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-170">72,466</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-171">361,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-172">38,537</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-173">57,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-174">6,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-175">42,061,984</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-176">53,643,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-177">168,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-178">11,645,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-179">11,645,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Retroactive application of the recapitalization due to the Business Combination (Note 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-180">22,200,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-181">11,799,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-31" decimals="0" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-182">1,885,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Balance at December 31, 2021, effect of Business Combination (Note 2)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">22,880,908</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-184">72,466</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-185">12,161,331</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-186">38,537</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-34" decimals="0" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-187">1,942,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-188">6,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-189">42,061,984</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-190">53,643,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-191">168,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-192">11,645,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-193">11,645,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Noncontrolling interests recognized on historical net assets of MoonLake AG in connection with the Business Combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-194">23,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="0" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-195">12,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" sign="-" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" scale="0" id="f-196">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-197">14,551,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" sign="-" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-198">22,966,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-199">32,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" sign="-" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-200">8,346,506</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-201">8,346,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization" format="ixt:fixed-zero" scale="0" id="f-202">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Conversion of MoonLake AG shares into Class A Ordinary Shares and issuance of Class C Ordinary Shares following the Business Combination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-203">22,880,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-204">48,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-49" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-205">12,161,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-206">25,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-207">765,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-208">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-209">18,501,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-210">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-211">15,775,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-212">1,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-213">70,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-214">1,578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-215">1,578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Issuance of Class A Ordinary Shares upon Business Combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-216">18,424,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-217">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-218">90,782,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-219">90,783,936</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-220">43,869,268</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-221">134,653,204</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-222">2,051,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-223">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-224">2,051,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-225">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-226">3,520,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-227">15,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-228">3,536,045</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-229">3,536,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="f-230">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Emission fees and capital tax payments on share issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" sign="-" name="mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" format="ixt:num-dot-decimal" scale="0" id="f-231">40,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" sign="-" name="mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" format="ixt:num-dot-decimal" scale="0" id="f-232">40,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" sign="-" name="mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" format="ixt:num-dot-decimal" scale="0" id="f-233">16,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" format="ixt:num-dot-decimal" scale="0" id="f-234">56,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Share-based compensation granted under the equity incentive plan ESPP, ESOP, reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-235">1,177,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-236">3,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-237">7,348,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-238">7,352,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-239">2,305,791</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-240">9,658,568</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Net loss for the year ended December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-241">49,973,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-242">49,973,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-243">14,532,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-244">64,506,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-245">535,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-246">535,788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-247">124,858</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-248">660,646</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-249">38,977,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-250">3,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-251">13,723,511</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-252">1,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-253">129,192,291</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-254">80,650,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-255">350,946</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-256">48,898,296</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-257">19,868,402</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-258">68,766,698</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">The accompanying Notes are an integral part of these Consolidated Financial Statements.</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Amounts in USD, except share data)</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">The accompanying Notes are an integral part of these Consolidated Financial Statements.</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.196%"><tr><td style="width:1.0%"/><td style="width:11.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.334%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:4.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Class A Ordinary Shares</span></td><td colspan="3" style="display:none"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Class C Ordinary Shares</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Additional Paid-In Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Accumulated Other Comprehensive Income</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Total Shareholders' Equity (Deficit)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Noncontrolling Interests</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Total Equity (Deficit)</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-259">38,977,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-260">3,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-261">13,723,511</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-262">1,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-263">129,192,291</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-264">80,650,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-265">350,946</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-266">48,898,296</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-267">19,868,402</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-268">68,766,698</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-269">10,270,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-270">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-271">482,453,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-272">482,454,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-273">482,454,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Capital injection from MoonLake to MoonLake AG (Note 12)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" sign="-" name="mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" format="ixt:num-dot-decimal" scale="0" id="f-274">60,061,761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" format="ixt:num-dot-decimal" scale="0" id="f-275">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" sign="-" name="mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" format="ixt:num-dot-decimal" scale="0" id="f-276">60,060,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" format="ixt:num-dot-decimal" scale="0" id="f-277">57,310,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" format="ixt:num-dot-decimal" scale="0" id="f-278">2,750,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-279">11,218,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-280">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-76" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-281">11,218,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-282">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-283">52,479,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-284">510,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-285">52,989,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-286">52,989,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="f-287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Share-based compensation under the equity incentive plan ESPP, ESOP, 2022 MoonLake Immunotherapeutics Equity Incentive Plan and reverse vesting of Restricted Founder Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-288">5,907,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-289">5,907,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-290">1,198,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-291">7,106,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Refund of stamp duty fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" sign="-" name="mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees" format="ixt:num-dot-decimal" scale="0" id="f-292">1,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" sign="-" name="mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees" format="ixt:num-dot-decimal" scale="0" id="f-293">1,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees" format="ixt:num-dot-decimal" scale="0" id="f-294">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees" format="ixt:fixed-zero" scale="0" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Net loss for the year ended December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-296">36,007,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-297">36,007,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-298">8,071,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-299">44,079,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:125%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-300">1,495,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-301">1,495,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-302">497,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-303">1,993,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-304">60,466,453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-305">6,047</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-306">2,505,476</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="f-307">251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-308">609,969,236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-309">116,657,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-310">2,357,621</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-311">495,675,683</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-312">17,815,336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-313">513,491,019</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">The accompanying Notes are an integral part of these Consolidated Financial Statements.</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-7</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_172"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Amounts in USD, except share and per share data)</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:59.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-314">44,079,117</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="f-315">64,506,051</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-316">13,158</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-317">12,358</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-318">7,106,005</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-319">9,654,778</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net periodic pension benefit cost for the qualified pension plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:PensionExpenseReversalOfExpenseNoncash" format="ixt:num-dot-decimal" scale="0" id="f-320">85,254</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:PensionExpenseReversalOfExpenseNoncash" format="ixt:num-dot-decimal" scale="0" id="f-321">304,031</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Other non-cash items</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-322">484,762</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-323">220,880</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.87pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.92pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="0" id="f-324">839,733</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="0" id="f-325">68,355</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="mnlk:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-326">65,513</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="mnlk:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="0" id="f-327">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.92pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="0" id="f-328">6,346,203</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="0" id="f-329">2,730,373</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.92pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Trade and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-330">1,582,712</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-331">1,314,318</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.92pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Operating leases liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-332">222,259</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1.27pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-333">152,425</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.92pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-334">326,725</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-335">2,685,576</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Net cash flow used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-336">42,778,167</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-337">55,893,900</ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Cash flow from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Purchase of short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="f-338">175,732,711</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="f-339">42,226,021</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Proceeds from maturities of short-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-340">150,833,021</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-341">9,901,437</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-342">284,634</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-343">16,009</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Net cash flow used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-344">25,184,324</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-345">32,340,593</ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Cash flow from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="0" id="f-346">482,454,426</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="0" id="f-347">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Stamp duty on capital injection from MoonLake to MoonLake AG (Note 12)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="mnlk:PaymentsOfStampDuty" format="ixt:num-dot-decimal" scale="0" id="f-348">2,752,918</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="mnlk:PaymentsOfStampDuty" format="ixt:fixed-zero" scale="0" id="f-349">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Proceeds from Business Combination</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="mnlk:ProceedsFromReverseRecapitalization" format="ixt:fixed-zero" scale="0" id="f-350">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="mnlk:ProceedsFromReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-351">134,646,009</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Contribution for par value of Class V Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="mnlk:ProceedsFromContributionFromParValueOfCommonStock" format="ixt:fixed-zero" scale="0" id="f-352">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="mnlk:ProceedsFromContributionFromParValueOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-353">42,935</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Repayment of loan liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="0" id="f-354">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-355">15,000,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Grants of additional shares under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:fixed-zero" scale="0" id="f-356">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="0" id="f-357">3,791</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Net cash flow provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-358">479,701,508</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-359">119,692,735</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Effect of movements in exchange rates on cash held</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="f-360">75,307</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="f-361">8,540</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-362">411,663,710</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-363">31,466,782</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-364">39,505,627</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-365">8,038,845</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-366">451,169,337</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-367">39,505,627</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:125%">Supplementary disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-368">41,713</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-369">4,312</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Non-cash operating lease assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-370">3,637,545</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-371">435,005</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="f-372">422,519</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="f-373">155,552</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">The accompanying Notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-8</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_175"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div style="margin-bottom:0.12pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_178"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;1 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-374" continuedAt="f-374-1" escape="true">Overview of the Company</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-374-1" continuedAt="f-374-2"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Information</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. MoonLake Immunotherapeutics is currently a single asset company focused on the development of Sonelokimab (&#8220;SLK&#8221;), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.</span></div></ix:continuation><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><ix:continuation id="f-374-2" continuedAt="f-374-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, &#8220;MoonLake&#8221;, and the &#8220;Company&#8221; refer to the combined company following the Business Combination (as defined in Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combination Agreement with Helix and Recapitalization</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-374-3">), together with its subsidiaries.</ix:continuation> </span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_181"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="c-1" name="mnlk:ReverseRecapitalizationDisclosureTextBlock" id="f-375" continuedAt="f-375-1" escape="true">Business Combination Agreement with Helix and Recapitalization</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-375-1" continuedAt="f-375-2"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022 (the &#8220;Closing Date&#8221;), MoonLake Immunotherapeutics, a Cayman Islands exempted company (formerly known as Helix Acquisition Corp.) (prior to the Closing Date, &#8220;Helix&#8221; and after the Closing Date, &#8220;MoonLake&#8221; or the &#8220;Company&#8221;) consummated the previously announced business combination (the &#8220;Closing&#8221;) pursuant to that certain Business Combination Agreement dated October 4, 2021 (the &#8220;Business Combination Agreement&#8221;), by and among Helix, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#8220;MoonLake AG&#8221;), the existing equityholders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equityholders of MoonLake AG that executed joinders to the Business Combination Agreement (collectively, the &#8220;ML Parties&#8221;), Helix Holdings LLC, a Cayman Islands limited liability company and the sponsor of Helix (the &#8220;Sponsor&#8221;), and the representative of the ML Parties (such transactions contemplated by the Business Combination Agreement collectively, the &#8220;Business Combination&#8221;). Net proceeds from the Business Combination totaled $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="mnlk:ReverseRecapitalizationNet" scale="6" id="f-376">134.7</ix:nonFraction> million, which included funds held in Helix&#8217;s trust account and the completion of a concurrent PIPE investment.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Business Combination Agreement, approved by the boards of directors of each of MoonLake AG and Helix, (i) the Company changed its name from Helix Acquisition Corp. to MoonLake Immunotherapeutics, and (ii) MoonLake AG merged with and into MoonLake, with MoonLake AG as the surviving company in the Business Combination and, after giving effect to such Business Combination, MoonLake AG as a subsidiary of MoonLake. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business Combination Agreement provided for, among other things, the following transactions:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.37pt">Two business days prior to the Closing Date, the ML Parties and MoonLake AG effectuated a restructuring of MoonLake AG&#8217;s share capital to, among other things, (x) convert the Series A preferred shares of MoonLake AG, par value of CHF <ix:nonFraction unitRef="chfPerShare" contextRef="c-86" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-377">0.10</ix:nonFraction> per share, into an equal number of MoonLake AG Common Shares such that the ML Parties held a single class of capital share of MoonLake AG immediately prior to the Closing and (y) approve a capital increase for the issuance of <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-378">4,006,736</ix:nonFraction> Class V Voting Shares of MoonLake AG, par value CHF <ix:nonFraction unitRef="chfPerShare" contextRef="c-87" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-379">0.01</ix:nonFraction> per share, to Helix, each Class V Voting Share due to its lower par value having <ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="mnlk:CommonStockVotesMultiplier" format="ixt-sec:numwordsen" id="f-380">ten</ix:nonFraction> times the voting power of a MoonLake AG Common Share (the &#8220;Restructuring&#8221;).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.6pt">At the Closing, <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-381">2,875,000</ix:nonFraction> Class B ordinary shares of Helix, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-382">0.0001</ix:nonFraction> per share (the &#8220;Class B Ordinary Shares&#8221;), constituting all of the then-outstanding Class B Ordinary Shares, were automatically converted into Class A Ordinary Shares on a <ix:nonFraction unitRef="number" contextRef="c-89" decimals="INF" name="mnlk:CommonStockConversionRatio" format="ixt-sec:numwordsen" id="f-383">one</ix:nonFraction>-for-one basis.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.83pt">At the Closing, Helix amended and restated its existing memorandum and articles of association to, among other things, establish a share structure consisting of the Class A Ordinary Shares, which carry economic and voting rights, and Class C Ordinary Shares, which carry voting rights but no economic rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.37pt">On the Closing Date, Helix paid all unpaid transaction expenses and contributed $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="mnlk:ReverseRecapitalizationNet" scale="6" id="f-384">134.7</ix:nonFraction> million to MoonLake AG, including $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="f-385">15.0</ix:nonFraction> million loan repayment pursuant to a convertible loan agreement dated March 20, 2022, </span></div></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-375-2" continuedAt="f-375-3"><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by and between MoonLake AG and Cormorant Asset Management LP (&#8220;Cormorant&#8221;), and assigned by Cormorant to Helix on March 31, 2022.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.14pt">On the Closing Date, following the Restructuring, Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P. (collectively, the &#8220;BVF Shareholders&#8221;) assigned all of their MoonLake AG Common Shares to Helix and Helix issued to the BVF Shareholders <ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-386">18,501,284</ix:nonFraction> Class A Ordinary Shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.37pt">On the Closing Date, following the Restructuring, Helix issued <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="mnlk:StockConvertedReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-387">15,775,472</ix:nonFraction> Class C Ordinary Shares to the ML Parties (other than the BVF Shareholders). Please refer to Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholders&#8217; Equity (Deficit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on the exchange mechanism adopted. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on the Closing Date, Helix issued to the PIPE Investors (as defined below in the section entitled &#8220;PIPE Financing&#8221;) an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-388">11,700,000</ix:nonFraction> Class A Ordinary Shares.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the open of trading on April 6, 2022, the Class A Ordinary Shares, formerly those of Helix, began trading on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the trading symbol &#8220;MLTX&#8221;.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PIPE Financing</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2021, concurrently with the execution of the Business Combination Agreement, and subsequently on March 31, 2022 and April 4, 2022, Helix entered into subscription agreements with certain investors (collectively, the &#8220;PIPE Investors&#8221;, which includes affiliates of the Sponsor and certain existing equityholders of MoonLake AG) pursuant to which, and on the terms and subject to the conditions of which, the PIPE Investors have collectively subscribed for <ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-389">11,700,000</ix:nonFraction> Class A Ordinary Shares, <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-390">11,600,000</ix:nonFraction> shares of which were issued at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-391">10.00</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-392">116.0</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-393">100,000</ix:nonFraction> shares of which were issued to placement agents of the PIPE in satisfaction of an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="mnlk:SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" scale="6" id="f-394">1.0</ix:nonFraction> million of fees owed by Helix to such placement agents.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Net Proceeds</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="mnlk:ScheduleOfReverseRecapitalizationTableTextBlock" id="f-395" continuedAt="f-395-1" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the elements of the net proceeds from the Business Combination:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:83.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">in thousands</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investments held in Trust Account</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="mnlk:InvestmentsAcquiredThroughReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-396">115,051</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix  prior to the Closing Date</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-397">80,842</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plus PIPE investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-398">116,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less Helix transaction expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="mnlk:ReverseRecapitalizationTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-399">15,520</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="mnlk:ReverseRecapitalizationAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-400">5,798</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which deferred IPO underwriting fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="mnlk:ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" format="ixt:num-dot-decimal" scale="3" id="f-401">4,025</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which other transaction expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="mnlk:ReverseRecapitalizationOtherTransactionExpenses" format="ixt:num-dot-decimal" scale="3" id="f-402">5,697</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Available Closing Date Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="mnlk:ReverseRecapitalizationNet" format="ixt:num-dot-decimal" scale="3" id="f-403">134,689</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Ordinary Shares Issued</span></div><ix:continuation id="f-395-1" continuedAt="f-395-2"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the number of Ordinary Shares outstanding immediately following the consummation of the Business Combination:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:83.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Helix Acquisition Corp. Ordinary Shares prior to the Business Combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-404">14,805,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class A Ordinary Shares (Helix management - IPO private placement shares)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-405">430,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class A Ordinary Shares redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-406">11,500,000</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-375-3"><ix:continuation id="f-395-2"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:83.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class B Ordinary Shares (Helix management - sponsor promote)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-407">2,875,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-408">8,080,645</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus issuance of Helix Class A Ordinary Shares to PIPE Investors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-409">11,700,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plus issuance of Helix Class A Ordinary Shares to BVF Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-410">18,501,284</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total MoonLake Class A Ordinary Shares Outstanding at Closing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="mnlk:StockIssuedDuringPeriodSharesReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-411">36,925,639</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus issuance of Helix Class C Ordinary Shares to ML Parties (other than the BVF Shareholders)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="mnlk:StockConvertedReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-412">15,775,472</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total MoonLake Class A and Class C Ordinary Shares Outstanding at Closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-413">52,701,111</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information about the Business Combination can be found on Form S-1/A filed with the SEC on July 26, 2022, declared effective on August 2, 2022 and to the exhibits included therein, available at www.sec.gov.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_184"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-414" continuedAt="f-414-1" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-414-1" continuedAt="f-414-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-415" continuedAt="f-415-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#8220;MoonLake AG&#8221;), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board ("FASB").</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to ASC 805, for financial accounting and reporting purposes, MoonLake AG was deemed the accounting acquirer and Helix was treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Accordingly, the Business Combination was treated as the equivalent of MoonLake AG issuing shares for the net assets of Helix, accompanied by a recapitalization. The net assets of Helix were stated at historical costs, with no goodwill or other intangible assets recorded, and are consolidated with MoonLake AG&#8217;s financial statements on the Closing Date. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Business Combination Agreement, the ML Parties received <ix:nonFraction unitRef="number" contextRef="c-101" decimals="INF" name="mnlk:RecapitalizationExchangeRatio" scale="0" id="f-416">33.638698</ix:nonFraction> Ordinary Shares in the Company for every MoonLake AG Common Share or Series A Preferred Share (the &#8220;Exchange Ratio&#8221;). The BVF Shareholders received <ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-417">18,501,284</ix:nonFraction> Class A Ordinary Shares whereas the rest of the ML Parties (excluding the BVF Shareholders) received <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-418">15,775,472</ix:nonFraction> Class C Ordinary Shares which can be converted into Class A Ordinary Shares at the discretion of the shareholder (refer to Note&#160;12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; Shareholders&#8217; Equity (Deficit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on the classes of ordinary shares). The number of shares, and the number of shares within the net income (loss) per share held by the ML Parties in MoonLake AG prior to the Business Combination have been adjusted by the Exchange Ratio to reflect the equivalent number of ordinary shares in the Company (identified as &#8220;the equivalent of&#8221; throughout these consolidated financial statements).</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain MoonLake AG shareholders (ML Parties other than the BVF Shareholders), did not exchange their shares in MoonLake AG for Class A Ordinary Shares in the Company and therefore continued to hold an economic interest in MoonLake AG and Class C Ordinary Shares in the Company. The Company recognized a noncontrolling interest equal to the ML Parties&#8217; (other than the BVF Shareholders) proportionate interest in the net assets of MoonLake AG.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-414-2" continuedAt="f-414-3"><ix:continuation id="f-415-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are presented in U.S. Dollar (&#8220;$&#8221;), unless otherwise indicated. The term &#8220;Swiss franc&#8221; and &#8220;CHF&#8221; refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and &#8220;&#8364;&#8221; refers to euros.</span></div></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-419" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining whether the in-process research and development expenditure (&#8220;IPR&amp;D&#8221;) has an alternative future use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining assumptions used in estimating the fair value of share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the amount of accruals in connection with the completion of clinical trial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company&#8217;s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future results of operation may be affected.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-420" escape="true">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value.</ix:nonNumeric> As of December&#160;31, 2023, the Company considers $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-421">129.4</ix:nonFraction> million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. As of December&#160;31, 2022, the Company considered $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-422">19.9</ix:nonFraction> million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities and short-term investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-423" continuedAt="f-423-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in &#8220;Interest and dividend income&#8221;. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the &#8220;Accumulated other comprehensive income (loss)&#8221; component of shareholders&#8217; equity (deficit) until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-414-3" continuedAt="f-414-4"><ix:continuation id="f-423-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified as either &#8220;Cash and cash equivalents&#8221; or &#8220;Short&#8209;term marketable debt securities&#8221; according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statement of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-424" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the &#8364;100,000 Fundo de Garantia de Dep&#243;sitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-425" continuedAt="f-425-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the guidance included in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three levels of inputs to fair value measurements:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1, meaning the use of quoted prices for identical instruments in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3, meaning the use of unobservable inputs. Observable market data is used when available.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-425-1">Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred.</ix:continuation> </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-426" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a stand-alone basis for the purposes of allocating resources, and assessing financial performance.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-427" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of <span style="-sec-ix-hidden:f-428">three</span> to <ix:nonNumeric contextRef="c-105" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-429">five years</ix:nonNumeric>. As of December&#160;31, 2023, property and equipment, net relates to information technology, office equipment, and leasehold improvements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-414-4" continuedAt="f-414-5"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Contract Costs and Accruals</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-430" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Transaction</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-431" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goods or services received in a share-based payment transaction are measured using a fair value-based measure.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#8217;s common stock on the date of the grant.</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companies&#8217; volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The fair value of the common stock granted under the ESPP (as defined below) has historically been estimated by management with reference to the market-based transaction with the other Series A Preferred Shares Investors, as there was no public market for the common stock. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-432" continuedAt="f-432-1" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in </span></div></ix:nonNumeric></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-414-5" continuedAt="f-414-6"><ix:continuation id="f-432-1" continuedAt="f-432-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.</span></div></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-432-2">Gains or losses from foreign currency translation are included in the consolidated statement of operations in "other income, net".</ix:continuation> The Company recognized foreign currency transaction gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" format="ixt:num-dot-decimal" scale="0" id="f-433">151,493</ix:nonFraction> for the year ended December&#160;31, 2023 and a foreign currency transaction gain of $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" format="ixt:num-dot-decimal" scale="0" id="f-434">325,317</ix:nonFraction> for the year ended December 31, 2022.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-435" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Class A Ordinary Shares</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-436" continuedAt="f-436-1" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-436-1">In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive.</ix:continuation> </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-437" continuedAt="f-437-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the &#8220;In-License Agreement&#8221;) with Merck Healthcare KGaA, Darmstadt, Germany (&#8220;MHKDG&#8221;) to acquire the Sonelokimab program (the &#8220;SLK Program&#8221;) and determined that substantially all of the fair value of the gross assets acquired related to IPR&amp;D of SLK. Therefore, this transaction was accounted for as an asset acquisition.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. </span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-414-6" continuedAt="f-414-7"><ix:continuation id="f-437-1"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&amp;D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized.</span></div></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension Accounting</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy" id="f-438" continuedAt="f-438-1" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for pension assets and liabilities in accordance with ASC 715, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Retirement Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the recognition of the funded status of pension plans in the Company&#8217;s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of December&#160;31, 2023 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statement of operations separately from the service cost component, in &#8220;<span style="-sec-ix-hidden:f-439">other income (expenses), net</span>.&#8221; Plan assets are recorded at their fair value. </span></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-438-1">Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income (loss).</ix:continuation> </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-440" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake does not have any finance leases. As of December&#160;31, 2023, the Company has <ix:nonFraction unitRef="lease" contextRef="c-1" decimals="INF" name="mnlk:NumberOfOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="f-441">three</ix:nonFraction> operating leases related to the office spaces which are located in (i) Dorfstrasse 29, 6300, Zug, Switzerland, (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. The operating leases are recognized over a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-Use (&#8220;RoU&#8221;) assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less and that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-442" continuedAt="f-442-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-414-7"><ix:continuation id="f-442-1" continuedAt="f-442-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. The FASB also issued subsequent amendments to the initial guidance, ASU 2019-04, ASU 2019-05, ASU 2019-11, and ASU 2020-03 (collectively, &#8220;Topic 326&#8221;). The Current Expected Credit Losses model requires a company to estimate credit losses expected over the life of the financial assets based on historical experience, current conditions and reasonable and supportable forecasts. The Company adopted this new guidance as of December 31, 2023 upon the loss of its &#8220;emerging growth company&#8221; status. The adoption did not have a material impact on the balances reported in the Company&#8217;s consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment reporting &#8212; Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends guidance on reportable segment disclosure requirements. It is effective for fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact. The early adoption option will not be exercised. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="f-442-2" continuedAt="f-442-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income taxes - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Taxes Disclosure,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-442-3"> which amends guidance on to enhance the transparency and decision usefulness of income tax disclosures. It is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact. The early adoption option will not be exercised.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large Accelerated Filer Status</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company is considered a &#8220;large accelerated filer&#8221; and no longer qualifies as an emerging growth company or smaller reporting company. The Company is required, pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, to include in its Annual Report on Form 10-K for the year ended December 31, 2023 an attestation report as to the effectiveness of the Company's internal control over financial reporting that is issued by its independent registered public accounting firm. In addition, beginning with the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2024, it will no longer be permitted to take advantage of the reduced reporting requirements applicable to smaller reporting companies.</span></div></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_187"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="mnlk:RiskAndLiquidityDisclosureTextBlock" id="f-443" continuedAt="f-443-1" escape="true">Risks and Liquidity</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-443-1" continuedAt="f-443-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern, Liquidity and Capital Resources&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-444">44.1</ix:nonFraction> million for the year ended December&#160;31, 2023. As of December&#160;31, 2023, the Company&#8217;s current assets exceeded its current liabilities by $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="mnlk:CurrentAssetsInExcessOfCurrentLiabilities" scale="6" id="f-445">504.2</ix:nonFraction> million. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-443-2">As of December&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Cash" scale="6" id="f-446">451.2</ix:nonFraction> million of cash and cash equivalents. Based on the Company's current operating plan, management believes that the Company has sufficient capital to fund its operations and capital expenditures until the end of 2026.</ix:continuation> </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_190"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-447" continuedAt="f-447-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-448" continuedAt="f-448-1" escape="true"><ix:continuation id="f-447-1" continuedAt="f-447-2"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:</span></div></ix:continuation></ix:nonNumeric><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-447-2"><ix:continuation id="f-448-1"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                               </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:21.761%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:18.184%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:18.184%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.184%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Level 2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-449">109,608,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-450">109,608,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-451">42,552,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-452">42,552,608</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certificates of deposit</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-453">79,626,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-454">79,626,727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-455">9,937,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-456">9,937,899</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-457">189,235,642</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-458">189,235,642</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-459">52,490,507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-460">52,490,507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, accounts payable and accrued liabilities approximate their fair values as of December&#160;31, 2023 and December 31, 2022, due to their short-term nature. Pension plan assets fair value is determined based on Level 2 inputs.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_193"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-461" continuedAt="f-461-1" escape="true">Investments</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-461-1" continuedAt="f-461-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-462" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of December&#160;31, 2023 and December&#160;31, 2022 are as follows:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"/><td style="width:21.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-463">107,624,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-464">1,984,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-466">109,608,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Certificates of Deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-467">78,890,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-468">736,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-470">79,626,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-471">186,514,788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-472">2,720,854</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-473">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-474">189,235,642</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-475">128,197,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-476">1,199,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-478">129,396,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within short-term marketable debt securities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-479">58,317,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-480">1,521,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-482">59,838,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"/><td style="width:21.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-483">42,265,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-484">287,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-486">42,552,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Certificates of Deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-487">9,834,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-488">103,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-490">9,937,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-491">52,099,754</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-492">390,753</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-493">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-494">52,490,507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-495">19,775,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-496">106,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-498">19,881,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-499">32,324,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-500">284,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-502">32,609,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock" id="f-503" continuedAt="f-503-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair values of the Company&#8217;s short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:78.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-461-2"><ix:continuation id="f-503-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:78.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning balance, January 1, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-504">390,753</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-505">8,751,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-506">6,421,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ending balance, December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-507">2,720,854</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company&#8217;s marketable debt securities maturities are all due within one year.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_196"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;7 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentAssetsTextBlock" id="f-508" continuedAt="f-508-1" escape="true">Prepaid Expenses</ix:nonNumeric></span></div><div style="margin-bottom:0.12pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-508-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-509" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:58.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prepaid expenses - current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Insurances</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="f-510">1,077,478</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="f-511">1,416,597</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Non-clinical research and clinical development services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:PrepaidResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-512">842,729</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:PrepaidResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-513">2,443,863</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other consulting and advisory services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:OtherPrepaidConsultingAndAdvisoryFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-514">70,018</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:OtherPrepaidConsultingAndAdvisoryFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-515">105,651</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other prepayments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-516">111,978</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-517">213,357</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-518">2,102,203</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-519">4,179,468</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:58.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prepaid expenses - non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing services</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:SupplyAndManufacturingExpenseNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-520">8,423,468</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:SupplyAndManufacturingExpenseNoncurrent" format="ixt:fixed-zero" scale="0" id="f-521">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-522">8,423,468</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:fixed-zero" scale="0" id="f-523">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses - non-current relate to advance payments made to a contract manufacturing organization pursuant to a manufacturing run reservation agreement for the commercial-scale manufacturing of Sonelokimab in 2025.</span></div></ix:continuation><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_199"></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:0.12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note&#160;8 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-524" continuedAt="f-524-1" escape="true">Trade and Other Payables</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="mnlk:TradeAndOtherPayablesCurrentTableTextBlock" id="f-525" escape="true"><ix:continuation id="f-524-1" continuedAt="f-524-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development services</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:AccruedResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-526">911,454</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:AccruedResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-527">31,687</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing fees payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:SupplyAndManufacturingFeesPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-528">553,459</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:SupplyAndManufacturingFeesPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-529">65,979</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rent / leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AccruedRentCurrent" format="ixt:num-dot-decimal" scale="0" id="f-530">108,249</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AccruedRentCurrent" format="ixt:fixed-zero" scale="0" id="f-531">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AccountsPayableOtherCurrent" format="ixt:num-dot-decimal" scale="0" id="f-532">264,522</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AccountsPayableOtherCurrent" format="ixt:num-dot-decimal" scale="0" id="f-533">157,306</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:TradeAndOtherPayablesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-534">1,837,684</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:TradeAndOtherPayablesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-535">254,972</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:12pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_202"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note&#160;9 &#8212; <ix:continuation id="f-524-2" continuedAt="f-524-3">Accrued Expenses and Other Current Liabilities</ix:continuation></span></div><div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-536" escape="true"><ix:continuation id="f-524-3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bonuses and related employees compensation expenses</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-537">2,780,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-538">1,109,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:AccruedSupplyAndManufacturingFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-539">1,603,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:AccruedSupplyAndManufacturingFeesCurrent" format="ixt:fixed-zero" scale="0" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development services and license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-541">1,226,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-542">5,803,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Consultant and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:AccruedConsultingAndOtherFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-543">853,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:AccruedConsultingAndOtherFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-544">218,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-545">367,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-546">109,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Legal fees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-547">98,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-548">15,832</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-549">6,930,120</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-550">7,256,845</ix:nonFraction></span></td></tr></table></ix:continuation></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:0.12pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-19</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_205"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;10 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-551" continuedAt="f-551-1" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-551-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an open-ended office lease agreement, effective November 1, 2021, to lease approximately <ix:nonFraction unitRef="sqft" contextRef="c-119" decimals="0" name="mnlk:OperatingLeaseAreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="f-552">2,300</ix:nonFraction> square feet of space on the last two floors of the building located at Dorfstrasse 29, 6300 Zug, Switzerland (the &#8220;Office Lease"). The Company estimated the effective duration of the Office Lease at inception and determined a period of <ix:nonNumeric contextRef="c-120" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-553">3</ix:nonNumeric> years, with expected expiration in November 2024. In December, 2023, the contract was extended, leading to a new estimated effective duration of the lease period of <ix:nonNumeric contextRef="c-121" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-554">3</ix:nonNumeric> years, with expected expiration in January 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2023, the Company entered into an office lease agreement, effective as of October 9, 2023, to lease approximately <ix:nonFraction unitRef="sqft" contextRef="c-122" decimals="-2" name="mnlk:OperatingLeaseAreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="f-555">3,900</ix:nonFraction> square feet of office space on the fifth floor of  the building located at Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. This lease has a <ix:nonNumeric contextRef="c-123" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-556">3-year</ix:nonNumeric> initial term, with <ix:nonFraction unitRef="period" contextRef="c-124" decimals="INF" name="mnlk:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="f-557">two</ix:nonFraction> extendable periods of <ix:nonNumeric contextRef="c-123" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="f-558">3</ix:nonNumeric> years each. It is expected to be extended once until October 2029. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2023, the Company entered into an office lease agreement, effective as of October 16, 2023, to lease approximately <ix:nonFraction unitRef="sqft" contextRef="c-125" decimals="0" name="mnlk:OperatingLeaseAreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="f-559">6,000</ix:nonFraction> square feet of office space on the first floor of the building located at 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom. This lease has a <ix:nonNumeric contextRef="c-126" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-560">3-year</ix:nonNumeric> term agreement and is set to expire in October 2026. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-561" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average discount rate for the operating leases as of December&#160;31, 2023 and December 31, 2022 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average remaining lease term (in months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-12" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durmonth" id="f-562">39</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-13" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durmonth" id="f-563">22</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-564">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-565">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-566" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum annual lease payments under these operating leases as of December&#160;31, 2023 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:70.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-567">1,343,255</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-568">1,343,255</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-569">1,029,249</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="f-570">95,794</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="f-571">95,794</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="f-572">65,923</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-573">3,973,270</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-574">275,404</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-575">3,697,866</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less current portion of lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-576">1,197,876</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term portion operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-577">2,499,990</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded lease expense related to its operating leases of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="f-578">399,882</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="f-579">155,552</ix:nonFraction> for the years ended December&#160;31, 2023 and December 31, 2022, respectively.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:0.12pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-20</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_208"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;11 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-580" continuedAt="f-580-1" escape="true">Employee Benefit Plans </ix:nonNumeric></span></div><div style="margin-bottom:0.12pt"><span><br/></span></div><ix:continuation id="f-580-1" continuedAt="f-580-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates a defined benefit pension plan in Switzerland (&#8220;the Plan&#8221;) and a defined contribution pension plan in the United Kingdom and Portugal, in accordance with local regulations and practices. As of December&#160;31, 2023 the Plan covers the Company&#8217;s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="f-581" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in projected benefit obligations (&#8220;PBO&#8221;) and plan assets is presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:57.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Beginning PBO </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="0" id="f-582">1,321,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="0" id="f-583">1,322,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Service cost </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="0" id="f-584">122,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="0" id="f-585">451,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:num-dot-decimal" scale="0" id="f-586">30,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:num-dot-decimal" scale="0" id="f-587">5,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by plan participants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:num-dot-decimal" scale="0" id="f-588">200,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:num-dot-decimal" scale="0" id="f-589">138,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / losses </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-590">487,991</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-591">374,317</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="mnlk:DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-592">229,902</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="mnlk:DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-593">204,695</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign currency exchange rates changes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:num-dot-decimal" scale="0" id="f-594">208,608</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:num-dot-decimal" scale="0" id="f-595">16,267</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plan amendment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:num-dot-decimal" scale="0" id="f-596">107,750</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="0" id="f-597">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Ending PBO</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="0" id="f-598">2,494,481</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="0" id="f-599">1,321,969</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:57.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Beginning fair value of plan assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="0" id="f-600">1,039,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="0" id="f-601">1,083,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="0" id="f-602">36,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="0" id="f-603">15,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Return on plan assets above expected return</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="mnlk:DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" format="ixt:num-dot-decimal" scale="0" id="f-604">48,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="mnlk:DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" format="ixt:num-dot-decimal" scale="0" id="f-605">115,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by the employer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="0" id="f-606">200,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="0" id="f-607">138,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by plan participants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:num-dot-decimal" scale="0" id="f-608">200,424</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:num-dot-decimal" scale="0" id="f-609">138,243</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Benefits paid </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="mnlk:DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-610">229,902</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="mnlk:DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-611">204,695</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign currency exchange rates changes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-612">155,082</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-613">14,687</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Ending fair value of plan assets</span></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="0" id="f-614">1,911,056</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="0" id="f-615">1,039,763</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="f-616" continuedAt="f-616-1" escape="true">Amounts recorded on the consolidated balance sheets:</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:continuation id="f-616-1"><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:57.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fair value of plan assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-617">1,911,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-618">1,039,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Present value of projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-619">2,494,481</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-620">1,321,969</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Funded status</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="0" id="f-621">583,425</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="0" id="f-622">282,206</ix:nonFraction>)</span></td></tr></table></div></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="f-623" continuedAt="f-623-1" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded in accumulated other comprehensive (income) / loss:</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-580-2"><ix:continuation id="f-623-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:57.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / loss - beginning of year</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-624">101,716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-625">168,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / loss of current year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-626">444,329</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-627">268,076</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-628">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-629">1,817</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prior service (cost) / credit recognized in current year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-630">107,750</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="0" id="f-631">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-632">234,863</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-633">101,716</ix:nonFraction>)</span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="f-634" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to calculate the ASC 715 liabilities are summarized in the table below:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.657%"><tr><td style="width:1.0%"/><td style="width:57.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-635">1.35</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-636">2.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" scale="-2" id="f-637">3.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" scale="-2" id="f-638">3.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Inflation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" scale="-2" id="f-639">1.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" scale="-2" id="f-640">1.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term expected rate of salary increase</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-641">2.30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-642">2.30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service cost of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="0" id="f-643">122,698</ix:nonFraction> was recognized in the net periodic benefit cost for the year ended December&#160;31, 2023. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DefinedBenefitPlanPlanAssetsAllocationTableTextBlock" id="f-644" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of plan assets is presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:57.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Equities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-645">34.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-646">34.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-647">32.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-648">28.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mortgages</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-649">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-650">3.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liquidity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-133" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-651">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-652">2.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Real estate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-653">26.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-654">27.17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Alternative investments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-655">3.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-138" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-656">3.40</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Infrastructure</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-139" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" format="ixt:fixed-zero" scale="-2" id="f-657">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-658">0.16</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of plan assets is determined based on Level 2 inputs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As all members of the Plan are active, no future expected benefit payments are currently in payment and foreseen to occur within the next ten years.</span></div></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-22</span></div></div></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_211"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;12 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-659" continuedAt="f-659-1" escape="true">Shareholders&#8217; Equity (Deficit)</ix:nonNumeric></span></div><div style="margin-bottom:0.12pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-659-1" continuedAt="f-659-2"><ix:nonNumeric contextRef="c-1" name="mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" id="f-660" continuedAt="f-660-1" escape="true"><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:17.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class C Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued and Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Balance - January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-661">500,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-662">38,977,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-663">100,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-664">13,723,511</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="mnlk:SharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-665">600,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-666">52,701,111</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Issuance of Class A Ordinary Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-667">10,270,818</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-668">10,270,818</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Conversion of Class C Ordinary Shares into Class A Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-669">11,218,035</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-143" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-670">11,218,035</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Balance - December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-671">500,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-672">60,466,453</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-673">100,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-674">2,505,476</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="mnlk:SharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-675">600,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-676">62,971,929</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="padding-left:36pt;text-align:justify;text-indent:-18.01pt"><ix:continuation id="f-660-1" continuedAt="f-660-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="f-660-2">Fully paid-in registered shares with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-677"><ix:nonFraction unitRef="usdPerShare" contextRef="c-79" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-678">0.0001</ix:nonFraction></ix:nonFraction></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, the Company had the following classes of shares:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class A Ordinary Shares</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company's Class A Ordinary Shares began trading on The Nasdaq Capital Market ("Nasdaq") under the symbol &#8220;MLTX&#8221;. As of December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-679"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-680">60,466,453</ix:nonFraction></ix:nonFraction> Class A Ordinary Shares issued and outstanding. The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-681">500,000,000</ix:nonFraction> Class A Ordinary Shares, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-682">0.0001</ix:nonFraction> per share. Holders of Class A Ordinary Shares are entitled to <ix:nonFraction unitRef="vote" contextRef="c-78" decimals="0" name="mnlk:CommonStockVotesAttachedToShares" format="ixt-sec:numwordsen" scale="0" id="f-683">one</ix:nonFraction> vote for each share. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class C Ordinary Shares</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-684"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-685">2,505,476</ix:nonFraction></ix:nonFraction> Class C Ordinary Shares issued and outstanding. The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-686">100,000,000</ix:nonFraction> Class C Ordinary Shares, with a par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-79" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-687">0.0001</ix:nonFraction> per share. Each Class C Ordinary Share entitles the holders thereof to <ix:nonFraction unitRef="vote" contextRef="c-79" decimals="0" name="mnlk:CommonStockVotesAttachedToShares" format="ixt-sec:numwordsen" scale="0" id="f-688">one</ix:nonFraction> vote per share, but carries no economic rights.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Business Combination (the "Closing"), MoonLake, MoonLake AG and each ML Party entered into a Restated and Amended Shareholders' Agreement (the &#8220;A&amp;R Shareholders' Agreement&#8221;). With the intent to approximate the rights, obligations and restrictions that an ML Party would enjoy if it were a holder of Class A Ordinary Shares, the A&amp;R Shareholders&#8217; Agreement (i) imposes certain transfer and other restrictions on the ML Parties, (ii) provides for the waiver of certain statutory rights and (iii) establishes certain mechanics whereby MoonLake and each of the ML Parties are able to effect the conversion of MoonLake AG Common Shares and Class C Ordinary Shares into a number of Class A Ordinary Shares equal to the Exchange Ratio. In 2022, pursuant to the A&amp;R Shareholders&#8217; Agreement, a ML Party submitted an exchange notice to the Company, pursuant to which the ML Party effected the conversion of <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-689">61,000</ix:nonFraction> MoonLake AG Common Shares and <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-690">2,051,961</ix:nonFraction> Class C Ordinary Shares into <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-691">2,051,961</ix:nonFraction> Class A Ordinary Shares using the Exchange Ratio. In 2023, pursuant to the A&amp;R Shareholders&#8217; Agreement, certain ML Parties submitted exchange notices to the Company, pursuant to which such ML Parties effected, in the aggregate, the conversion of <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-692">333,486</ix:nonFraction> MoonLake AG Common Shares and <ix:nonFraction unitRef="shares" contextRef="c-76" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-693">11,218,035</ix:nonFraction> Class C Ordinary Shares into <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-694">11,218,035</ix:nonFraction> Class A Ordinary Shares using the Exchange Ratio. The foregoing description of the A&amp;R Shareholders&#8217; Agreement is not complete and is qualified in its entirety by reference to, and should be read in connection with, the full text of the A&amp;R Shareholders&#8217; Agreement filed as an exhibit on the Company's Current Report on Form 8-K filed with the SEC on April 11, 2022.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-695">10,270,818</ix:nonFraction> Class A Ordinary Shares under the following: </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-Market Offering</span></div></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-659-2"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2023, the Company entered into a Sales Agreement (the &#8220;May 2023 Sales Agreement&#8221;) with Leerink Partners LLC (formerly known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), through which the Company could issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="INF" name="mnlk:SaleOfStockAuthorizedAmount" format="ixt:num-dot-decimal" scale="0" id="f-696">200,000,000</ix:nonFraction> of its Class A Ordinary Shares (the &#8220;May 2023 ATM Shares&#8221;), through Leerink Partners  as its sales agent. The May 2023 ATM Shares to be sold under the May 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-271546), which was declared effective by the SEC on May 9, 2023, and a prospectus supplement thereto filed with the SEC on May 11, 2023.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 27, 2023, the Company reduced the maximum aggregate offering amount of its Class A Ordinary Shares that could be issued and sold under the May 2023 Sales Agreement to $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="INF" name="mnlk:SaleOfStockRemainingAuthorizedRepurchaseAmount" scale="0" id="f-697">0</ix:nonFraction> and no longer intends to sell Class A Ordinary Shares under the May 2023 Sales Agreement unless the Company files a further prospectus supplement indicating an amount of shares proposed to be sold.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2023, the Company entered into a Sales Agreement with Leerink Partners (the &#8220;August 2023 Sales Agreement&#8221; and together with the May 2023 Sales Agreement, the &#8220;Sales Agreements&#8221;), through which the Company could issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="INF" name="mnlk:SaleOfStockAuthorizedAmount" format="ixt:num-dot-decimal" scale="0" id="f-698">350,000,000</ix:nonFraction> of its Class A Ordinary Shares (the &#8220;August 2023 ATM Shares&#8221;), through Leerink Partners as its sales agent. The August 2023 ATM Shares to be sold under the August 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-274286), which was declared effective by the SEC on September 11, 2023, and a prospectus supplement thereto filed with the SEC on August 31, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-699">544,894</ix:nonFraction> Class A Ordinary Shares for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-700">15.2</ix:nonFraction> million. In December 2023, the Company sold a further <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-701">525,924</ix:nonFraction> Class A Ordinary Shares for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-702">31.7</ix:nonFraction> million. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public Offering of Class A Ordinary Shares </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2023, the Company entered into an underwriting agreement with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein, to issue and sell <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-703">8,000,000</ix:nonFraction> Class A Ordinary Shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="0" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-704">50.00</ix:nonFraction> per share (the &#8220;Offering&#8221;). In addition, the Company granted the underwriters an option for a period of <ix:nonNumeric contextRef="c-152" name="mnlk:SaleOfStockOptionToPurchaseTerm" format="ixt-sec:durday" id="f-705">30</ix:nonNumeric> days to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-706">1,200,000</ix:nonFraction> Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions (the &#8220;Option&#8221;), and such Option was exercised in full by the underwriters.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Offering closed on June 30, 2023, and net proceeds from the Offering, including proceeds from the exercise in full by the underwriters of the Option, were $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-707">436.7</ix:nonFraction> million, after deducting the underwriting discounts and commissions and the offering expenses in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-708">23.3</ix:nonFraction> million.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of the Offering, the Company opted to direct a substantial portion of the net proceeds to MoonLake AG. This was executed as a two-step process: (1) the Company acquired the remaining <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-709">22,756</ix:nonFraction> shares of MoonLake AG common stock held in treasury through a share purchase and assignment agreement formally executed on July 09, 2023 ($<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-710">38.9</ix:nonFraction> million) and (2) the Company contributed additional funds to MoonLake AG&#8217;s capital reserves through a cash contribution agreement formally executed on July 10, 2023 ($<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:ProceedsFromContributionsFromParent" scale="6" id="f-711">275</ix:nonFraction> million). A stamp duty tax of $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" sign="-" name="mnlk:SaleOfStockStampDutyTax" scale="6" id="f-712">2.8</ix:nonFraction> million was levied on the aforementioned capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_214"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;13 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-714" continuedAt="f-714-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-713" continuedAt="f-713-1" escape="true">Net Loss per Share</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-714-1" continuedAt="f-714-2"><ix:continuation id="f-713-1" continuedAt="f-713-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Business Combination, the Company has retroactively restated the weighted average number of outstanding prior to April 5, 2022 to give effect to the Exchange Ratio.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-716" continuedAt="f-716-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-715" continuedAt="f-715-1" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the loss per share calculations for the year ended December&#160;31, 2023 compared to the year ended December 31, 2022:</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:continuation id="f-714-2"><ix:continuation id="f-713-2"><ix:continuation id="f-716-1"><ix:continuation id="f-715-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:56.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss attributable to controlling interests shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-717">36,007,260</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-718">49,973,249</ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total weighted average number of outstanding shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-719"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-720"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-721"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-722">49,122,534</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-723"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-724"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-725"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-726">29,361,353</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net loss per share &#8211; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-727"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-728"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-729"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-730">0.73</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-731"><ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-732"><ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-733"><ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-734">1.70</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of shares used to calculate the net loss per share &#8211; basic for the year ended December&#160;31, 2023 excludes <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-735"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-736">2,505,476</ix:nonFraction></ix:nonFraction> Class C Ordinary Shares as they do not carry economic rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that ML Parties (other than Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.) elected to convert their <ix:nonFraction unitRef="shares" contextRef="c-157" decimals="0" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-737">74,482</ix:nonFraction> MoonLake AG Common Shares into <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="0" name="mnlk:StockConvertedReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-738">2,505,476</ix:nonFraction> Class A Ordinary Shares, the weighted average number of shares outstanding would have been <ix:nonFraction unitRef="shares" contextRef="c-159" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-739"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-740">57,679,106</ix:nonFraction></ix:nonFraction> for the year ended December&#160;31, 2023, resulting in a net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-741"><ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-742">0.76</ix:nonFraction></ix:nonFraction>. Upon conversion, <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="mnlk:StockForfeitedReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-743">2,505,476</ix:nonFraction> Class C Ordinary Shares would be forfeited and there would no longer be any non-controlling interests.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the Company's number of Class A Ordinary Shares outstanding would be <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-744">63,886,757</ix:nonFraction> as of February&#160;29, 2024, the date the consolidated financial statements were issued.</span></div></ix:continuation></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_217"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-745" continuedAt="f-745-1" escape="true">Share-based Compensation </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-745-1" continuedAt="f-745-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 the Company had the following share-based compensation arrangements:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Restricted Founder Shares (as defined below) &#8211; created in April 2021 by MoonLake AG (no longer active and fully vested as of April 2023);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Employee Share Participation Plan (&#8220;ESPP&#8221;) &#8211; created in July 2021 by MoonLake AG;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The Employee Stock Option Plan (&#8220;ESOP&#8221;) &#8211; created in July 2021 by MoonLake AG;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">MoonLake Immunotherapeutics 2022 Equity Incentive Plan &#8211; created in April 2022 by MoonLake Immunotherapeutics. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the arrangements is to attract and retain the best available personnel and to provide participants with additional incentive to increase their efforts on behalf and in the best interest of the Company and its subsidiaries.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake AG's compensation plans are settled with Common Shares, and with a number of Class C Ordinary Shares determined by multiplying the number of Common Shares by the Exchange Ratio. The reference to &#8220;Common Shares&#8221; in this Note 14 refers to common shares in MoonLake AG. As a result of the Business Combination, the Company has adjusted the share numbers related to the Restricted Founder Shares and Common Shares (under the ESPP and ESOP) prior to the Business Combination by the Exchange Ratio. The owners of Common Shares have the right to exchange their Common Shares for a number of Class A Ordinary Shares derived using the Exchange Ratio. In the event MoonLake AG shareholders elect to exchange their Common Shares, such MoonLake AG shareholder forfeits a number of Class C Ordinary Shares equal to the number of Class A Ordinary Shares issued (refer to Note&#160;12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; Shareholders&#8217; Equity (Deficit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class C Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-745-2" continuedAt="f-745-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, the Company has recognized an increase in equity in the consolidated balance sheet, and share-based compensation expense in the consolidated statement of operations of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-746">7.1</ix:nonFraction> million. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-747" continuedAt="f-747-1" escape="true">The share-based compensation expense was driven by the following share-based compensation plans and programs:</ix:nonNumeric></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:continuation id="f-747-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:50.688%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Compensation Plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MoonLake AG Restricted Founder Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-748">1,574,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-749">4,840,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ESPP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-750">3,352,885</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-751">3,910,076</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ESOP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-752">973,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-753">539,713</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MoonLake Immunotherapeutics 2022 Equity Incentive Plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-754">1,204,952</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-755">364,381</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-756">7,106,005</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-757">9,654,778</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which: included in research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-758">1,524,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-759">954,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which: included in general and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-760">5,581,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-761">8,700,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-762">11,079</ix:nonFraction> Common Shares (the equivalent of <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-763">372,683</ix:nonFraction> Class C Ordinary Shares) issuable from the authorized conditional capital shares remain available for future grants under the ESPP and the ESOP by MoonLake AG.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MoonLake AG - Restricted Founder Shares  </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2021, the shareholders&#8217; agreement between the co-founders, the Series A investors and MoonLake AG imposed a reverse vesting condition on <ix:nonFraction unitRef="number" contextRef="c-175" decimals="2" name="mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" scale="-2" id="f-764">90</ix:nonFraction>% of the total <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-765">110,000</ix:nonFraction> Common Shares (the equivalent of <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-766">3,700,257</ix:nonFraction> Class C Ordinary Shares) held by each of the <ix:nonFraction unitRef="co-founder" contextRef="c-12" decimals="INF" name="mnlk:NumberOfCoFounders" format="ixt-sec:numwordsen" scale="0" id="f-767">three</ix:nonFraction> co-founders. Therefore, <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-768">99,000</ix:nonFraction> Common Shares (the equivalent of <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-769">3,330,231</ix:nonFraction>  Class C Ordinary Shares) held by each of the co-founders were subject to these restrictions and considered unvested (the &#8220;Restricted Founder Shares&#8221;). The Restricted Founder Shares vested on the 28th of each month at a rate of <ix:nonFraction unitRef="number" contextRef="c-179" decimals="5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-770">4.166</ix:nonFraction>% over a period of <ix:nonNumeric contextRef="c-179" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-771">two years</ix:nonNumeric> until April 28, 2023. In the event of a termination of the contractual relationship of the relevant co-founder before the end of the vesting period, MoonLake AG in first priority, or any third party designated by it, and the other shareholders in second priority pro rata to their shareholdings, had an option to purchase all or a pro rata portion of the leaver shares that remained unvested on the effective day of the termination at nominal value of CHF <ix:nonFraction unitRef="chfPerShare" contextRef="c-177" decimals="2" name="mnlk:SharePriceNominalValue" scale="0" id="f-772">0.10</ix:nonFraction> (equivalent of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-773">0.0001</ix:nonFraction>) per share.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="mnlk:ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" id="f-774" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the valuation of the Restricted Founder Shares awarded are summarized below:</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:71.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4/28/2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value of Restricted Founder Shares on the grant date (USD)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-181" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="f-775">49</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders (USD) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-181" decimals="2" name="mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" format="ixt:num-dot-decimal" id="f-776">336.39</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Purchase price (CHF)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="chfPerShare" contextRef="c-182" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" format="ixt:num-dot-decimal" id="f-777">0.10</ix:nonFraction></span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Restricted Founder Shares with reference to the market-based transaction with the other Series A Preferred Shares Investors (refer to Note 9 of MoonLake AG's audited consolidated financial statements for the year ended December 31, 2021, as filed by Helix Acquisition Corp. together with its revised definitive proxy soliciting materials with the SEC on March 4, 2022).</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Restricted Founder Shares at co-founder&#8217;s resignation date by dividing the Company Enterprise Value ($<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="0" name="mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" format="ixt:num-dot-decimal" scale="0" id="f-778">360,000,000</ix:nonFraction>) as defined by the Business Combination Agreement by the Company&#8217;s fully diluted shares (<ix:nonFraction unitRef="shares" contextRef="c-183" decimals="0" name="mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" format="ixt:num-dot-decimal" scale="0" id="f-779">1,070,196</ix:nonFraction>).</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-745-3" continuedAt="f-745-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-780" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:71.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Restricted Founder Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-781">4,440,309</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards vested for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-163" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-782">3,330,231</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-783">1,110,078</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards vested for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-162" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-784">1,110,078</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="f-785">0</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Share Participation Plan (ESPP) 2021-2025 - MoonLake AG</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP grants will vest <ix:nonFraction unitRef="number" contextRef="c-186" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-786"><ix:nonFraction unitRef="number" contextRef="c-187" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-787"><ix:nonFraction unitRef="number" contextRef="c-188" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-788"><ix:nonFraction unitRef="number" contextRef="c-189" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-789">25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, the awards can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#8220;Change of Control&#8221;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="f-791" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="f-790" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:71.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESPP 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">01/18/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value per share of Common Shares on the grant date ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-165" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" id="f-792">336.39</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Purchase price (CHF)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="chfPerShare" contextRef="c-190" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" format="ixt:num-dot-decimal" id="f-793">0.10</ix:nonFraction></span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value (USD <ix:nonFraction unitRef="usd" contextRef="c-183" decimals="0" name="mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" format="ixt:num-dot-decimal" scale="0" id="f-794">360,000,000</ix:nonFraction>) as defined by the Business Combination Agreement by the Company&#8217;s fully diluted shares (<ix:nonFraction unitRef="shares" contextRef="c-183" decimals="0" name="mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" format="ixt:num-dot-decimal" scale="0" id="f-795">1,070,196</ix:nonFraction>). </span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESPP</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-796">1,060,561</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-165" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-797">1,177,354</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of January 1. 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-798">2,237,915</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which vested as of January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-165" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-799">307,794</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-800">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-801">2,237,915</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which vested as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-802">1,607,425</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, MoonLake AG had $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-803">6.2</ix:nonFraction> million of total unrecognized compensation expense related to the ESPP that will be recognized over the weighted average period of <ix:nonNumeric contextRef="c-164" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-804">2.05</ix:nonNumeric> years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Option Plan (ESOP) 2021-2025 - MoonLake AG</span></div></ix:continuation><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-745-4" continuedAt="f-745-5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESOP grants will vest <ix:nonFraction unitRef="number" contextRef="c-193" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-805"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-806"><ix:nonFraction unitRef="number" contextRef="c-195" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-807"><ix:nonFraction unitRef="number" contextRef="c-196" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-808">25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% on each anniversary of the grant date. In the event of a termination of the contractual relationship between the Company and the entitled employee, options can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#8220;Change of Control&#8221;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.  </span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-809" continuedAt="f-809-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:71.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">ESOP 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">5/1/2022, 6/22/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-810">4.21</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price (USD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-811">3.64</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonNumeric contextRef="c-197" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-812">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-813">75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-814">3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-815">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#8217;s industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:72.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.650%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">01/01/2023, 04/24/2023, 07/03/2023, 07/17/2023, 08/01/2023, 08/07/2023, 08/21/2023, 08/29/2023, 09/01/2023, 09/11/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-816">25.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price (USD)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-817">37.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-199" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-818">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-819">75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-820">4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-821">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#8217;s industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-822" continuedAt="f-822-1" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESOP</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-823">224,033</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-824">242,736</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-198" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-825">466,769</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-826">133,446</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards forfeited for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="c-199" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-827">15,137</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-828">585,078</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-829">219,223</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, MoonLake AG had $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-830">4.2</ix:nonFraction> million of total unrecognized compensation expense related to the ESOP that will be recognized over the weighted average period of <ix:nonNumeric contextRef="c-203" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-831">2.45</ix:nonNumeric> years. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-745-5" continuedAt="f-745-6"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MoonLake Immunotherapeutics 2022 Equity Incentive Plan</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022 (the &#8220;Effective Date&#8221;) the Company created the &#8220;MoonLake Immunotherapeutics 2022 Equity Incentive Plan&#8221; (the &#8220;Equity Incentive Plan&#8221;) to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the <ix:nonNumeric contextRef="c-204" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-832">10</ix:nonNumeric>th anniversary of the Effective Date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Awards made under the Equity Incentive Plan to a person who is initially elected or appointed to the Board, and who is a non-employee director at the time of such initial election or appointment, vests and becomes exercisable in <ix:nonFraction unitRef="installment" contextRef="c-205" decimals="INF" name="mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" scale="0" id="f-833">3</ix:nonFraction> equal yearly installments occurring over the <ix:nonNumeric contextRef="c-205" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-834">three year</ix:nonNumeric> period following the date of grant, subject to the non-employee director continuing in service on the Board through each such vesting date. Each subsequent award vests and becomes exercisable on the earlier of (i) the <ix:nonNumeric contextRef="c-206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-835">12-month</ix:nonNumeric> anniversary of the date of grant, and (ii) the next annual meeting of the Company&#8217;s stockholders following the date of grant, subject to the non-employee director continuing in service on the Board through such vesting date. Awards made to employees, officers and other service providers of the Company under the Equity Incentive Plan vest <ix:nonFraction unitRef="number" contextRef="c-207" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-836"><ix:nonFraction unitRef="number" contextRef="c-208" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-837"><ix:nonFraction unitRef="number" contextRef="c-209" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-838"><ix:nonFraction unitRef="number" contextRef="c-210" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-839">25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% on each anniversary date. In the event of a termination of the contractual relationship between the Company and the beneficiary, options can be deemed forfeited by the Company if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#8220;Change of Control&#8221;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.</span></div></ix:continuation><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-745-6" continuedAt="f-745-7"><ix:continuation id="f-809-1"><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:71.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.806%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:106%">Weighted average assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">4/6/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-840">8.25</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price ($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-211" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-841">12.25</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonNumeric contextRef="c-169" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-842">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-843">75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-844">3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-845">-</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. </span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:72.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.028%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">06/08/2023, 10/11/2023, 10/25/2023, 11/01/2023, 11/06/2023, 11/15/2023, 11/16/2023, 11/20/2023, 11/27/2023, 12/01/2023, 12/04/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-846">25.58</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price ($)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-212" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-847">37.22</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-168" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-848">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="0" id="f-849">0.75</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-850">4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="f-851">0</ix:nonFraction></span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. </span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><ix:continuation id="f-822-1"><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"/><td style="width:35.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">MoonLake Immunotherapeutics 2022 Equity Incentive Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-213" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-852">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-853">180,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-211" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-854">180,000</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-211" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:fixed-zero" scale="0" id="f-855">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-856">132,400</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-212" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-857">312,400</ix:nonFraction></span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards exercisable as of December 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="c-212" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-858">60,000</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-745-7">As of December&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-859">3.3</ix:nonFraction> million of total unrecognized compensation expense related to the Equity Incentive Plan that will be recognized over the weighted average period of <ix:nonNumeric contextRef="c-168" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-860">1.75</ix:nonNumeric> years.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_223"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;15 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-861" continuedAt="f-861-1" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:0.12pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-861-1" continuedAt="f-861-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate (&#8220;ETR&#8221;) was -<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-862">0.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-863">0.1</ix:nonFraction>% for the year ended December&#160;31, 2023, and for the year ended December 31, 2022, respectively. The Company is not aware of any items that would cause the quarterly or period-to-date ETR to be significantly different from the Company's annual ETR. The difference between the income tax provision that would be derived by applying the statutory rate to the Company's loss before income taxes and the </span></div></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-861-2" continuedAt="f-861-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income tax provision recorded was primarily attributable to non-deductible expense which includes the Swiss entity's recognition of taxable income associated with the sale of treasury shares from MoonLake AG to MoonLake Immunotherapeutics.. The Company continues to incur losses for the Cayman Island and Swiss entity and its ability to utilize the deferred tax asset related to the tax losses is not considered more likely than not.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's main operating affiliate, MoonLake AG, is subject to taxation in the Canton of Zug, Switzerland. For the years ended December&#160;31, 2023 and 2022, the Company did not incur any significant income tax expense or benefit, as the Company incurred tax losses and provided a full valuation allowance.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-864" escape="true"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income or loss before income tax were as follows:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:41.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="0" id="f-865">43,469,946</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="0" id="f-866">62,115,251</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="0" id="f-867">514,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="0" id="f-868">2,354,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-869">43,984,729</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-870">64,469,685</ix:nonFraction>)</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-871" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount computed by applying the statutory income tax rate to loss before income taxes as follows:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:41.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Statutory income tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-872">11.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-873">11.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Effect of income taxed at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-874">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="f-875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in prior year estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="f-876">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="f-877">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Utilization of unrecognized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="mnlk:EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" scale="-2" id="f-878">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="mnlk:EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" format="ixt:fixed-zero" scale="-2" id="f-879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-880">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-881">10.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Non-deductible expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-882">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-883">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" format="ixt:fixed-zero" scale="-2" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="f-885">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-886">0.3</ix:nonFraction>)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-887">0.1</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-888" escape="true"><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets (liabilities) were:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:41.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-889">4,493,559</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-890">4,492,435</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Defined benefit plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" format="ixt:num-dot-decimal" scale="0" id="f-891">69,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" format="ixt:num-dot-decimal" scale="0" id="f-892">33,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:DeferredTaxAssetsLeaseLiabililties" format="ixt:num-dot-decimal" scale="0" id="f-893">56,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:DeferredTaxAssetsLeaseLiabililties" format="ixt:fixed-zero" scale="0" id="f-894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net operating loss carry forward</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-895">6,715,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-896">7,210,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-897">11,334,793</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-898">11,736,269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="f-899">55,862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:fixed-zero" scale="0" id="f-900">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-901">55,862</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="0" id="f-902">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax assets (net)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="mnlk:DeferredTaxAssetsNetIncludingValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-903">11,278,931</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="mnlk:DeferredTaxAssetsNetIncludingValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-904">11,736,269</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-905">11,278,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-906">11,736,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax (net)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="0" id="f-907">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt;text-indent:1.44pt"/><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="0" id="f-908">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company&#8217;s net deferred tax assets before valuation allowance were $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-909">11.3</ix:nonFraction> million. In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of its deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent </span></div></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><ix:continuation id="f-861-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on the weight of all evidence, the Company has determined that it is not more likely than not that the net deferred tax assets will be realized. A valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-910">11.3</ix:nonFraction> million has been recorded against the deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, MoonLake AG had net operating losses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-911">56.6</ix:nonFraction> million of which $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="0" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-912">12.6</ix:nonFraction> million will expire in 2028 and $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="0" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-913">44.0</ix:nonFraction> million will expire in 2029.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net operating losses will not be subject to any limitation due to change in ownership according to Swiss Income Tax Law.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no unrecognized tax benefits and does not expect that uncertain tax benefits will change significantly in the next twelve months.</span></div></ix:continuation><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_226"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;16 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-914" continuedAt="f-914-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-914-1" continuedAt="f-914-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements as of December&#160;31, 2023 primarily in regards to the clinical and non-clinical development services with contract research organizations ("CROs"), as well as supply and logistics services with contract manufacturing organizations ("CMOs"), for the advancement of SLK. As of December&#160;31, 2023, the total committed expense under these agreements amounted to $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="mnlk:UnrecognizedCommitmentsAndContingencies" scale="6" id="f-915">44.2</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="mnlk:UnrecognizedCommitmentsAndContingencies" format="ixt:num-dot-decimal" scale="6" id="f-916">8.4</ix:nonFraction>&#160;million are recognized under Prepaid expenses - non-current and the rest remain unrecognized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's In-License Agreement with MHKDG includes contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company is obligated to make research and development and regulatory milestone payments upon the occurrence of certain events. Subject to the terms of the license, additional milestone payments of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-5" name="mnlk:RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" scale="6" id="f-917">299.6</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="mnlk:RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" scale="6" id="f-918">331.3</ix:nonFraction> million using a December&#160;31, 2023 exchange rate) are potentially payable upon satisfying specific milestones related to regulatory filing acceptance, first commercial sales, and aggregate annual net sales. The milestone payments are payable in cash. Milestone payments due prior to obtaining regulatory approval will be recorded as research and development expense upon determination that a milestone payment is probable to occur. Milestone payments due after obtaining regulatory approval will be capitalized when and if incurred. The Company will use commercially reasonable efforts to cause the milestones to occur. However, if the Company reasonably determines that a technical failure or commercial failure has occurred with respect to all or a part of the SLK Program, the Company, at its sole discretion, can terminate all or part of the SLK Program. As of December&#160;31, 2023, the Company made a total of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-5" name="mnlk:RevenueRemainingPerformanceObligationVariableConsiderationAmount" scale="6" id="f-919">7.5</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="mnlk:RevenueRemainingPerformanceObligationVariableConsiderationAmount" scale="6" id="f-920">8.1</ix:nonFraction> million using the then applicable exchange rate) in additional milestone payments.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on May 12, 2023, MoonLake AG entered into an agreement with Research Cooperation Technologies, Inc. (&#8220;RCT&#8221;) and MHKDG, effective as of June 1, 2023, pursuant to which the Company was granted a royalty-bearing, nonexclusive, sublicensable right and license under RCT&#8217;s patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces the Company&#8217;s sublicense for similar rights under the In-License Agreement. In the aggregate, the Company is required to pay royalties within the range of low to mid-teen percent of net sales under the aforementioned agreements with MHKDG and RCT. Royalties will be recognized in the consolidated statement of operations when net sales are recognized.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Lease </span></div></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2023 AND 2022</span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </span></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><ix:continuation id="f-914-2"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2023, the Company committed to an open-ended lease agreement with an effective start date of January 15, 2024, for additional office space at its corporate headquarters at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the effective duration of the Office Lease at inception and determined a <ix:nonNumeric contextRef="c-218" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-921">3-year</ix:nonNumeric> term, commencing at the effective start date of January 15, 2024.</span></div></ix:continuation><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_12094627906675"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;17 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-922" continuedAt="f-922-1" escape="true">Segment Information and Geographic Data</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="f-923" escape="true"><ix:continuation id="f-922-1"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, net of consisting of property and equipment, and operating lease right-of-use assets by geographical area as of December&#160;31, 2023  are as follows:</span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"/><td style="width:41.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Country</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="0" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-924">507,392</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="0" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-925">331,969</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="0" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-926">2,704,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="0" name="us-gaap:NoncurrentAssets" format="ixt:fixed-zero" scale="-2" id="f-927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="0" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-928">737,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="0" name="us-gaap:NoncurrentAssets" format="ixt:fixed-zero" scale="-2" id="f-929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-930">3,949,345</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-931">331,969</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div id="i2a9ec06b35fd41f2b71136a5c42fce99_232"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;18 &#8212; <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-932" continuedAt="f-932-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-932-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partial Share Conversion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2024, pursuant to the A&amp;R Shareholders&#8217; Agreement, a ML Party submitted an exchange notice to the Company, pursuant to which such ML Party effected the conversion of <ix:nonFraction unitRef="shares" contextRef="c-225" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-933">44,394</ix:nonFraction> MoonLake AG Common Shares and <ix:nonFraction unitRef="shares" contextRef="c-226" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-934">1,493,356</ix:nonFraction> Class C Ordinary Shares into <ix:nonFraction unitRef="shares" contextRef="c-227" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-935">1,493,356</ix:nonFraction> Class A Ordinary Shares using the Exchange Ratio. Please refer to Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholders&#8217; Equity (Deficit) &#8212; Class C Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information regarding the conversion mechanics.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market offering</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January and February 2024, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-228" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-936">914,828</ix:nonFraction> Class A Ordinary shares through the August 2023 Sales Agreement for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-937">53.3</ix:nonFraction> million, bringing total gross proceeds under the August 2023 Sales Agreement to $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-938">85.0</ix:nonFraction> million.</span></div></ix:continuation><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-33</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>mltx-exhibit41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie43939adde54445e97399f5e0efeb548_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 4.1</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a brief description of the material provisions of the share capital of MoonLake Immunotherapeutics (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221;). As of December 31, 2023, our Class A ordinary share is the only class of our securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The following description of our share capital does not purport to be complete and is subject to and qualified in its entirety by our Memorandum and Articles of Association (the &#8220;MAA&#8221;), which is filed as an exhibit to the Annual Report on Form 10-K, of which this exhibit is a part, and the applicable provisions of the Companies Act of the Cayman Islands, as amended (the &#8220;Companies Act&#8221;). We encourage you to read the MAA and the applicable provisions of the Companies Act for more information. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Authorized and Outstanding Shares</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The MAA authorizes the issuance of up to 655,000,000 ordinary shares, consisting of&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8pt">500,000,000 Class A Ordinary Shares, par value US$0.0001 per share (&#8220;Class A Ordinary Shares&#8221;)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8pt">50,000,000 Class B Ordinary Shares, par value US$0.0001 per share (&#8220;Class B Ordinary Shares&#8221;)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.67pt">100,000,000 Class C Ordinary Shares, par value US$0.0001 per share (&#8220;Class C Ordinary Shares&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8pt">5,000,000 preference shares, par value US$0.0001 per share (&#8220;preference shares&#8221;).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Class Rights</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event of a winding up or dissolution of the Company, whether voluntary or involuntary or for the purposes of a reorganization or otherwise or upon any repayment or distribution of capital, the entitlement of the holders of Class C Ordinary Shares is determined in accordance with the MAA. Class C Ordinary Shares confer no other right to participate in the profits or assets of the Company (including, for the avoidance of doubt, any right to receive a dividend or other distribution).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Class A Ordinary Shares carry the right to receive notice of and to attend, to speak at and to vote at any general meeting of the Company, rights in a winding up or repayment or distribution of capital and the right to participate in the profits or assets of the Company, in each case, in accordance with the MAA.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Except as otherwise provided by the rights attached to any ordinary shares in the MAA, rights attaching to the Class A Ordinary Shares and the Class C Ordinary Shares rank pari passu in all respects, and the Class A Ordinary Shares and Class C Ordinary Shares vote together as a single class on all matters.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The MAA authorizes 5,000,000 preference shares and provides that preference shares may be issued from time to time in one or more series. Our board of directors (the &#8220;Board&#8221;) is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Board is able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the ordinary shares and could have anti-takeover effects. The ability of the Board to issue preference shares without shareholder approval could have the effect of delaying, deferring or preventing a change of control of us or the removal of existing management. We have no preference shares issued and outstanding at the date hereof. Although we do not currently intend to issue any preference shares, we cannot assure you that we will not do so in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are no Class B Ordinary Shares issued or outstanding.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Register of Members</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As required under Cayman Islands law, we keep a register of members that states&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the names and addresses of the members, a statement of the shares held by each member and the amount paid or agreed to be considered as paid on the shares of each member and the voting rights of the shares of each member&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">whether voting rights are attached to the share in issue&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the date on which the name of any person was entered on the register as a member&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the date on which any person ceased to be a member.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under Cayman Islands law, the register of members of our Company is prima facie evidence of the matters set out therein (i.e., the register of members raises a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members is deemed as a matter of Cayman Islands law to have legal title to the shares as set against its name in the register of members. However, there are certain limited circumstances where an application may be made to a Cayman Islands court for a determination on whether the register of members reflects the correct legal position. Further, the Cayman Islands court has the power to order that the register of members maintained by a company should be rectified where it considers that the register of members does not reflect the correct legal position. If an application for an order for rectification of the register of members were made in respect of our ordinary shares, then the validity of such shares may be subject to re-examination by a Cayman Islands court.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Certain Differences in Corporate Law</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cayman Islands companies are governed by the Companies Act. The Companies Act is modeled on English Law but does not follow recent English Law statutory enactments, and differs from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of the material differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the United States and their shareholders.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mergers and Similar Arrangements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In certain circumstances, the Companies Act permits mergers or consolidations between two Cayman Islands companies, or between a Cayman Islands exempted company and a company incorporated in another jurisdiction (provided that is permitted or not prohibited by the constitutional documents of the company incorporated in another jurisdiction and facilitated by the laws of that other jurisdiction).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Where the merger or consolidation is between two Cayman Islands companies, the directors of each company must approve a written plan of merger or consolidation containing certain prescribed information. That plan of merger or consolidation must then be authorized by (a) a special resolution (usually a majority of shareholders holding at least two-thirds of the voting shares voted at a general meeting) of the shareholders of each company&#59; and (b) such other authorization, if any, as may be specified in such constituent company&#8217;s articles of association. No shareholder resolution is required for a merger between a parent company (i.e., a company that holds issued shares that together represent 90% of the votes at a general meeting of the subsidiary company) and its subsidiary company, if a copy of the plan of merger is given to every member of each subsidiary company to be merged, unless that member agrees otherwise. The consent of each holder of a fixed or floating security interest of a constituent company must be obtained, unless the Cayman Islands court waives such requirement or makes such order as the Cayman Islands court otherwise considers reasonable. The directors of each company are required to provide a declaration of the assets and liabilities of the company made up to the latest practicable date before the making of the declaration, and are further required to make a declaration to the effect that&#58; (i) the company is able to pay its debts as they fall due and that the merger or consolidation is bona fide and not intended to defraud unsecured creditors of the company&#59; (ii) no petition or other similar proceeding has been filed and remains outstanding and that no order has been made or resolution adopted to wind up the company in any jurisdiction&#59; (iii) no receiver, trustee, administrator or other similar person has been appointed in any jurisdiction and is acting in respect of the company, its affairs or its property or any part thereof&#59; (iv) no scheme, order, compromise or other similar arrangement has been entered into or made in any jurisdiction whereby the rights of creditors of the company are and continue to be suspended or restricted&#59; (v) in the case of a constituent company that is not a surviving company, the constituent company has retired from any fiduciary office held or will do so immediately prior to the merger or consolidation&#59; and (vi) where relevant, the company has complied with any applicable requirements under Cayman Islands regulatory laws. If the Cayman Islands Registrar of Companies is satisfied that the requirements of the Companies Act (which includes certain other formalities) have been complied with, the Registrar of Companies will register the plan of merger or consolidation.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Where the merger or consolidation involves a foreign company and the surviving company is the Cayman Islands exempted company, the procedure is similar, save that where the surviving or consolidated company is the Cayman Islands exempted company, the Cayman Islands Registrar of Companies is required to be satisfied in respect of any constituent overseas company that&#58; (i) the merger or consolidation is permitted or not prohibited by the constitutional documents of the foreign company and by the laws of the jurisdiction in which the foreign company is incorporated, and that those laws and any requirements of those constitutional documents have been or will be complied with&#59; (ii) no petition or other similar proceeding has been filed and remains outstanding or order made or resolution adopted to wind up or liquidate the foreign company in the jurisdiction in which the foreign company is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">existing&#59; (iii) no receiver, trustee, administrator or other similar person has been appointed in any jurisdiction and is acting in respect of the foreign company, its affairs or its property or any part thereof&#59; (iv) no scheme, order, compromise or other similar arrangement has been entered into or made in any jurisdiction whereby the rights of creditors of the foreign company are and continue to be suspended or restricted&#59; (v) the foreign company is able to pay its debts as they fall due and that the merger or consolidation is bona fide and not intended to defraud unsecured creditors of the foreign company&#59; (vi) in respect of the transfer of any security interest granted by the foreign company to the surviving or consolidated company (a) consent or approval to the transfer has been obtained, released or waived&#59; (b) the transfer is permitted by and has been approved in accordance with the constitutional documents of the foreign company&#59; and (c) the laws of the jurisdiction of the foreign company with respect to the transfer have been or will be complied with&#59; (vii) the foreign company will, upon the merger or consolidation becoming effective, cease to be incorporated, registered or exist under the laws of the relevant foreign jurisdiction&#59; and (viii) there is no other reason why it would be against the public interest to permit the merger or consolidation. The requirements set out in sections (i) to (vii) above shall be met by a director of the Cayman Islands exempted company making a declaration to the effect that, having made due enquiry, they are of the opinion that such requirements have been met, such declaration to include a statement of the assets and liabilities of the foreign company made up to the latest practicable date before making the declaration.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Where the above procedures are adopted, the Companies Act provides for a right of dissenting shareholders to be paid a payment of the fair value of their shares upon their dissenting to the merger or consolidation if they follow a prescribed procedure. In essence, that procedure is as follows&#58; (a) the shareholder must give their written objection to the merger or consolidation to the constituent company before the vote on the merger or consolidation, including a statement that the shareholder proposes to demand payment for their shares if the merger or consolidation is authorized by the vote&#59; (b) within 20 days following the date on which the merger or consolidation is approved by the shareholders, the constituent company must give written notice to each shareholder who made a written objection&#59; (c) a shareholder must within 20 days following receipt of such notice from the constituent company, give the constituent company a written notice of their intention to dissent including, among other details, a demand for payment of the fair value of their shares&#59; (d) within seven days following the date of the expiration of the period set out in paragraph (c) above or within seven days following the date on which the plan of merger or consolidation is filed, whichever is later, the constituent company, the surviving company or the consolidated company must make a written offer to each dissenting shareholder to purchase their shares at a price that the company determines is the fair value and if the company and the shareholder agree to the price within 30 days following the date on which the offer was made, the company must pay the shareholder such amount&#59; and (e) if the company and the shareholder fail to agree to a price within such 30 day period, within 20 days following the date on which such 30 day period expires, the company shall (and any dissenting shareholder may) file a petition with the Cayman Islands Grand Court to determine the fair value and such petition must be accompanied by a list of the names and addresses of the dissenting shareholders with whom agreements as to the fair value of their shares have not been reached by the company. At the hearing of that petition, the Cayman Islands court has the power to determine the fair value of the shares together with a fair rate of interest, if any, to be paid by the company upon the amount determined to be the fair value. Any dissenting shareholder whose name appears on the list filed by the company may participate fully in all proceedings until the determination of fair value is reached. These rights of a dissenting shareholder are not available in certain circumstances, for example, to dissenters holding shares of any class in respect of which an open market exists on a recognized stock exchange or recognized interdealer quotation system at the relevant date or where the consideration for such shares to be contributed are shares of any company listed on a national securities exchange or shares of the surviving or consolidated company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, Cayman Islands law has separate statutory provisions that facilitate the reconstruction or amalgamation of companies in certain circumstances, which will generally be more suited for complex mergers or other transactions involving widely held companies, commonly referred to in the Cayman Islands as a &#8220;scheme of arrangement&#8221; which may be tantamount to a merger. In the event that a merger was sought pursuant to a scheme of arrangement (the procedures for which are more rigorous and take longer to complete than the procedures typically required to consummate a merger in the United States), the arrangement in question must be approved by (i) in respect a scheme of arrangement proposed between a company and its shareholders (or any class of shareholder), 75% in value of the shareholders (or each class of shareholder) who attend and vote, either in person or by proxy, at a meeting (or meetings) convened for that purpose&#59; or (ii) a scheme of arrangement proposed between a company and its creditors (or any class of creditors), a majority in number representing 75% in value of the creditors (or each class of creditors) who attend and vote, either in person or by proxy, at a meeting (or meetings) convened for that purpose. The convening of the meetings and subsequently the terms of the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder would have the right to express to the Cayman </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Islands court the view that the scheme of arrangement should not be sanctioned, the Cayman Islands court may be expected to sanction the scheme of arrangement if it satisfies itself that&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the company is not proposing to act illegally or beyond the scope of its corporate authority and the statutory provisions as to dual majority vote have been complied with&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the shareholders have been fairly represented at the meeting in question&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the arrangement is such as a businessman would reasonably approve&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act or that would amount to a &#8220;fraud on the minority.&#8221;</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a scheme of arrangement is sanctioned by the Cayman Islands court, the scheme of arrangement will be binding on all of the shareholders (or each class of shareholder) or creditors (or each class of creditor).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a scheme of arrangement or takeover offer (as described below) is sanctioned by the Cayman Islands court, any dissenting shareholder would have no rights comparable to appraisal rights (providing rights to receive payment in cash for the judicially determined value of the shares), which would otherwise ordinarily be available to dissenting shareholders of United States corporations.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Squeeze-out Provisions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When a takeover offer is made and accepted by holders of 90% of the shares to whom the offer relates within four months, the offeror may, within a two-month period following the expiration of the initial four month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands, but this is unlikely to succeed unless there is evidence of fraud, bad faith, collusion or inequitable treatment of the shareholders.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">No Appraisal Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our shareholders have no rights comparable to appraisal rights, which might otherwise ordinarily be available to dissenting shareholders of United States corporations and allow such dissenting shareholders to receive payment in cash for the judicially determined value of the shares. However, appraisal rights would also not be available to shareholders of a Delaware target in a business combination transaction if the shares of the target were listed on a national securities exchange and target shareholders receive only shares of a corporation which shares are also listed on a national securities exchange.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, transactions similar to a merger, reconstruction and&#47;or an amalgamation may in some circumstances be achieved through means other than these statutory provisions, such as a share capital exchange, asset acquisition or control, or through contractual arrangements of an operating business.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Shareholders&#8217; Suits. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Walkers (Cayman) LLP, our Cayman Islands counsel, is not aware of any reported class action having been brought in a Cayman Islands court. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. In most cases, we will be the proper plaintiff in any claim based on a breach of duty owed to us, and a claim against (for example) our officers or directors usually may not be brought by a shareholder. However, based both on Cayman Islands authorities and on English authorities, which would in all likelihood be of persuasive authority and be applied by a court in the Cayman Islands, exceptions to the foregoing principle apply in circumstances in which&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">a company is acting, or proposing to act, illegally or beyond the scope of its authority&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained&#59; or</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">those who control the company are perpetrating a &#8220;fraud on the minority.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A shareholder may have a direct right of action against us where the individual rights of that shareholder have been infringed or are about to be infringed.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Enforcement of Civil Liabilities. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Cayman Islands has a different body of securities laws as compared to the United States and provides less protection to investors. Additionally, Cayman Islands companies may not have standing to sue before the Federal courts of the United States.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have been advised by Walkers (Cayman) LLP, our Cayman Islands legal counsel, that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state in the United States&#59; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state in the United States, so far as the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Special Considerations for Exempted Companies. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. &#8220;Limited liability&#8221; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Certain Anti-takeover Provisions of the MAA</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The MAA provides that the Board be classified into three classes of directors, each to be elected for a three year term.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our authorized but unissued ordinary shares and preference shares are available for future issuances without shareholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved ordinary shares and preference shares could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transfer Agent</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Transfer Agent and Registrar for the Class A Ordinary Shares and Class C Ordinary Shares is Continental Stock Transfer &#38; Trust Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>mltx_ex211subsidiarieslist.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id0fbf82a75aa4b44bd1046fa68016a89_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:96%">Exhibit 21.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:96%">Subsidiaries of MoonLake Immunotherapeutics</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%">MoonLake Immunotherapeutics AG, a Swiss stock corporation (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:96%">Aktiengesellschaft</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%">)</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%">MoonLake Immunotherapeutics Ltd, a private limited company incorporated in the United Kingdom</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%">MNLK Immunotherapeutics, Unipessoal Lda, a private limited company incorporated in Portugal<br></font><font style="color:#6d6d6d;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:96%">______________________________________________________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>mltx_ex231consentofindepen.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i81f38351fca64de2bd8e579d9c14249d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-267673) and on Form S-3 (No. 333-274286, and 333-262643) of MoonLake Immunotherapeutics of our report dated February 29, 2024, relating to the consolidated financial statements and the effectiveness of internal control over financial reporting of MoonLake Immunotherapeutics, appearing in this Annual Report on Form 10-K of MoonLake Immunotherapeutics for the year ended December 31, 2023.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.769%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#47;s&#47; BAKER TILLY US, LLP</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Mountain View, CA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">February 29, 2024</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>mltx_2023q4xex311dasilva.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i96177eb963294b02822f597a6fde2a74_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:145%">Exhibit 31.1</font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">Certification Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">of the Sarbanes-Oxl</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">ey Act of 2002</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:4pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">I, Jorge Santos Da Silva, certif</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">y that&#58;</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">I have reviewed this Annual Report on Form 10-K of MoonLake Immunotherapeutics&#59;</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:2pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Dated&#58; February&#160;29, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline">&#47;s&#47; Jorge Santos Da Silva</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Name&#58; Jorge Santos Da Silva</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Title&#58;    Chief Executive Officer</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">            (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:145%">principal executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>mltx_2023q4xex312bodenstedt.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3b4696aea73547a4a373474fc22ead51_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:145%">Exhibit 31.2</font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">Certification Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">of the Sarbanes-Oxl</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">ey Act of 2002</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:4pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">I, Matthias Bodenstedt, certif</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">y that&#58;</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">I have reviewed this Annual Report on Form 10-K of MoonLake Immunotherapeutics&#59;</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:4pt;padding-left:13.7pt;text-align:justify;text-indent:-13.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:6.2pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:4pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Dated&#58; February&#160;29, 2024</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline">&#47;s&#47; Matthias Bodenstedt</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Name&#58; Matthias Bodenstedt</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Title&#58;    Chief Financial Officer</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">             (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:145%">principal financial and accounting officer) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>mltx_2023q4xex321dasilva.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7237ae39a9f64d43b0c5da22445cb3fc_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:145%">Exhibit 32.1</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:145%">Certification Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">I, Jorge Santos Da Silva, to the best of my knowledge certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of MoonLake Immunotherapeutics (the &#8220;Company&#8221;) for the period ended December 31, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Dated&#58; February&#160;29, 2024</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:145%;text-decoration:underline">&#47;s&#47; Jorge Santos Da Silva</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Name&#58; Jorge Santos Da Silva</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Title&#58;    Chief Executive Officer</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:145%">principal executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">)</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Note&#58; A signed original of this written statement required by Section 906 has been provided to MoonLake Immunotherapeutics and will be retained by MoonLake Immunotherapeutics and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>mltx_2023q4xex322bodenstedt.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8789056b65df439097a38a87e95bfb2e_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:145%">Exhibit 32.2</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:145%">Certification Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">I, Matthias Bodenstedt, to the best of my knowledge certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of MoonLake Immunotherapeutics (the &#8220;Company&#8221;) for the period ended December 31, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Dated&#58; February&#160;29, 2024</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:145%;text-decoration:underline">&#47;s&#47; Matthias Bodenstedt</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Name&#58; Matthias Bodenstedt</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Title&#58;    Chief Financial Officer</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">&#160;&#160;&#160;&#160;(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:145%">principal financial and accounting officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">)</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Note&#58; A signed original of this written statement required by Section 906 has been provided to MoonLake Immunotherapeutics and will be retained by MoonLake Immunotherapeutics and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>mltx_ex971-clawbackpolicy.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="idab2427ccd99451184655fe26c6ff241_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="image.jpg" src="image.jpg" style="height:105px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INCENTIVE COMPENSATION CLAWBACK POLICY</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Recoupment of Incentive-Based Compensation</font></div><div style="text-align:justify;text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is the policy of MoonLake Immunotherapeutics (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) that, in the event the Company is required to prepare an accounting restatement of the Company&#8217;s financial statements due to material non-compliance with any financial reporting requirement under the federal securities laws (including any such correction that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period), the Company will recover on a reasonably prompt basis the amount of any Incentive-Based Compensation Received by a Covered Executive during the Recovery Period that exceeds the amount that otherwise would have been Received had it been determined based on the restated financial statements (each as defined below). This Incentive Compensation Clawback Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) has been adopted by the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) effective October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;). The Board may amend or change the terms of this Policy at any time for any reason, including as required to comply with any laws, rules, regulations and listing standards that may be applicable to the Company.</font></div><div style="text-align:justify;text-indent:41pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Policy Administration and Definitions</font></div><div style="text-align:justify;text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Policy is administered by the Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) of the Board, subject to ratification by the Board with respect to application of this Policy to the Company&#8217;s Chief Executive Officer, and is intended to comply with, and as applicable to be administered and interpreted consistent with, and subject to the exceptions set forth in, Listing Rule 5608 adopted by the Nasdaq Stock Market (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Nasdaq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) to implement Rule 10D-1 under the Securities Exchange Act of 1934, as amended (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Rule 10D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify;text-indent:41pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For purposes of this Policy&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any &#8220;executive officer&#8221; of the Company as defined under Rule 10D-1.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Reporting Measure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements and any measure derived wholly or in part from such a measure, and (ii) any measure based in whole or in part on the Company&#8217;s stock price or total shareholder return.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any compensation granted, earned or vested based in whole or in part on the Company&#8217;s attainment of a Financial Reporting Measure that was Received by a person (i) on or after the Effective Date and after the person began service as a Covered Executive, and (ii) who served as a Covered Executive at any time during the performance period for the Incentive-Based Compensation.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Incentive-Based Compensation is deemed to be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; in the fiscal period during which the relevant Financial Reporting Measure is attained, regardless of when the compensation is actually paid or awarded.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Recovery Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting restatement described in this Policy and any transition period of less than nine months that is within or immediately following such three fiscal years, all as determined pursuant to Rule 10D-1.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Determination by the Committee</font></div><div style="text-align:justify;text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the Committee determines the amount of Incentive-Based Compensation Received by a Covered Executive during a Recovery Period exceeds the amount that would have been Received if determined or calculated based on the Company&#8217;s restated financial results, such excess amount of Incentive-Based Compensation shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subject to recoupment by the Company pursuant to this Policy. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the Committee will determine the amount based on a reasonable estimate of the effect of the accounting restatement on the relevant stock price or total shareholder return. In all cases, the calculation of the excess amount of Incentive-Based Compensation to be recovered will be determined on a pre-tax basis (i.e., without regard to any taxes paid with respect to such compensation). The Company will maintain and will provide to Nasdaq documentation of all determinations and actions taken in complying with this Policy. Any determinations made by the Committee under this Policy shall be final and binding on all affected individuals.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Methods of Clawback</font></div><div style="text-align:justify;text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company may effect any recovery pursuant to this Policy in any manner consistent with applicable law, including by requiring payment of such amount(s) to the Company, by set- off, by reducing future compensation, or by such other means or combination of means as the Committee determines to be appropriate. The Company need not recover the excess amount of Incentive-Based Compensation if and to the extent that the Committee determines that such recovery is impracticable, subject to and in accordance with any applicable exceptions under the Nasdaq listing rules and not required under Rule 10D-1, including if the Committee determines that the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered after making a reasonable attempt to recover such amounts. The Company is authorized to take appropriate steps to implement this Policy with respect to Incentive-Based Compensation arrangements with Covered Executives.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Not Exclusive Remedy</font></div><div style="text-align:justify;text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any right of recoupment or recovery pursuant to this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any other policy, any employment agreement or plan or award terms, and any other legal remedies available to the Company (including, but not limited to, Section 304 of the Sarbanes-Oxley Act of 2002)&#59; provided that the Company shall not recoup amounts pursuant to such other policy, terms or remedies to the extent it is recovered pursuant to this Policy. The Company shall not indemnify any Covered Executive against the loss of any Incentive-Based Compensation pursuant to this Policy, nor will the Company pay or agree to pay any insurance premium to cover any such loss.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Certification</font></div><div style="text-align:justify;text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Covered Executives subject to this Policy will be required to certify their understanding of and intent to comply with this Policy periodically.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idab2427ccd99451184655fe26c6ff241_42"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:128.64pt"><font><br></font></div><div style="text-indent:128.64pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ACKNOWLEDGMENT AND CERTIFICATION</font></div><div style="text-indent:128.64pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By signing below, the undersigned covered executive (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Covered Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) acknowledges and confirms that the Covered Executive has received and reviewed a copy of the MoonLake Immunotherapeutics (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) Incentive Compensation Clawback Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), and in addition, the Covered Executive acknowledges and agrees that, for good and valid consideration, including continuing participation in the Company&#8217;s incentive compensation programs, the receipt and sufficiency of which the Covered Executive hereby acknowledges, the Covered Executive will be bound by and abide by the Policy as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:98%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%;padding-left:9.67pt">the Covered Executive is and will continue to be subject to the Policy and the Policy will apply both during and after the Covered Executive&#8217;s employment with the Company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%;padding-left:10.5pt">to the extent necessary to comply with the Policy, the Company hereby amends any employment agreement, equity award agreement or similar agreement that the Covered Executive is a party to with the Company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%;padding-left:11.07pt">the Covered Executive shall abide by the terms of the Policy, including, without limitation, by returning any compensation to the Company to the extent required by, and in a manner permitted by, the Policy, and understands and agrees that the Company is not permitted to, and will not, indemnify the Covered Executive for the loss of any compensation that is subject to recovery by the Company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%;padding-left:10.5pt">any amounts payable to the Covered Executive shall be subject to the Policy as may be in effect and interpreted or modified from time to time in the sole discretion of the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%">&#8221;) or as required by applicable law or the requirements of any securities exchange on which the Company&#8217;s securities are listed, and that such interpretation or modification will be covered by this acknowledgment&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%;padding-left:11.07pt">the Company may recover compensation paid to the Covered Executive through any method of recovery the Committee or its delegate deems appropriate, including without limitation by reducing any amount that is or may become payable to the Covered Executive, and the Covered Executive agrees to comply with any request or demand for repayment by the Company in order to comply with the Policy&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:98%;padding-left:12.17pt">the Company is not responsible for and shall not make the Covered Executive whole for any effect under any tax law or regulation of the recovery of any compensation pursuant to the Policy, or for any taxes paid by the Covered Executive on compensation that is subject to recovery or is recovered pursuant to the Policy.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:279pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________________________________<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature</font></div><div style="padding-left:279pt"><font><br></font></div><div style="padding-left:279pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________________________________<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Print Name </font></div><div style="padding-left:279pt"><font><br></font></div><div style="padding-left:279pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________________________________<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date</font></div><div style="padding-left:279pt"><font><br></font></div><div style="padding-left:279pt"><font><br></font></div><div style="padding-left:279pt"><font><br></font></div><div style="padding-left:279pt;text-align:right;text-indent:88.4pt"><font><br></font></div><div style="text-align:right;text-indent:88.4pt"><font><br></font></div><div style="text-align:right;text-indent:88.4pt"><font><br></font></div><div style="text-align:center;text-indent:88.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;ACKNOWLEDGMENT AND CERTIFICATION&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>mnlk-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:25f78456-bf3c-4d7d-8669-3aa27460a960,g:c66f622e-48e1-41cd-88e8-9a7e0d2c3eaf-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mnlk="http://moonlaketx.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://moonlaketx.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlk-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlk-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlk-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlk-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://moonlaketx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://moonlaketx.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" roleURI="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OverviewoftheCompany" roleURI="http://moonlaketx.com/role/OverviewoftheCompany">
        <link:definition>0000008 - Disclosure - Overview of the Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationAgreementwithHelixandRecapitalization" roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalization">
        <link:definition>0000009 - Disclosure - Business Combination Agreement with Helix and Recapitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandLiquidity" roleURI="http://moonlaketx.com/role/RisksandLiquidity">
        <link:definition>0000011 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://moonlaketx.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://moonlaketx.com/role/Investments">
        <link:definition>0000013 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpenses" roleURI="http://moonlaketx.com/role/PrepaidExpenses">
        <link:definition>0000014 - Disclosure - Prepaid Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandOtherPayables" roleURI="http://moonlaketx.com/role/TradeandOtherPayables">
        <link:definition>0000015 - Disclosure - Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000016 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://moonlaketx.com/role/Leases">
        <link:definition>0000017 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://moonlaketx.com/role/EmployeeBenefitPlans">
        <link:definition>0000018 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDeficit" roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficit">
        <link:definition>0000019 - Disclosure - Shareholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://moonlaketx.com/role/NetLossperShare">
        <link:definition>0000020 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://moonlaketx.com/role/SharebasedCompensation">
        <link:definition>0000021 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://moonlaketx.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://moonlaketx.com/role/CommitmentandContingencies">
        <link:definition>0000023 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationandGeographicData" roleURI="http://moonlaketx.com/role/SegmentInformationandGeographicData">
        <link:definition>0000024 - Disclosure - Segment Information and Geographic Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://moonlaketx.com/role/SubsequentEvents">
        <link:definition>0000025 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationAgreementwithHelixandRecapitalizationTables" roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationTables">
        <link:definition>9954472 - Disclosure - Business Combination Agreement with Helix and Recapitalization (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://moonlaketx.com/role/FairValueMeasurementsTables">
        <link:definition>9954473 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://moonlaketx.com/role/InvestmentsTables">
        <link:definition>9954474 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesTables" roleURI="http://moonlaketx.com/role/PrepaidExpensesTables">
        <link:definition>9954475 - Disclosure - Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandOtherPayablesTables" roleURI="http://moonlaketx.com/role/TradeandOtherPayablesTables">
        <link:definition>9954476 - Disclosure - Trade and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9954477 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://moonlaketx.com/role/LeasesTables">
        <link:definition>9954478 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTables" roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansTables">
        <link:definition>9954479 - Disclosure - Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDeficitTables" roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficitTables">
        <link:definition>9954480 - Disclosure - Shareholders&#8217; Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://moonlaketx.com/role/NetLossperShareTables">
        <link:definition>9954481 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://moonlaketx.com/role/SharebasedCompensationTables">
        <link:definition>9954482 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://moonlaketx.com/role/IncomeTaxesTables">
        <link:definition>9954483 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationandGeographicDataTables" roleURI="http://moonlaketx.com/role/SegmentInformationandGeographicDataTables">
        <link:definition>9954484 - Disclosure - Segment Information and Geographic Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails" roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails">
        <link:definition>9954485 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails" roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails">
        <link:definition>9954486 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Summary of Net Proceeds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails" roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails">
        <link:definition>9954487 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Ordinary Shares Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesDetails" roleURI="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails">
        <link:definition>9954488 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandLiquidityDetails" roleURI="http://moonlaketx.com/role/RisksandLiquidityDetails">
        <link:definition>9954489 - Disclosure - Risks and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://moonlaketx.com/role/FairValueMeasurementsDetails">
        <link:definition>9954490 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails" roleURI="http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails">
        <link:definition>9954491 - Disclosure - Investments - Schedule of Fair Value and Amortized Cost of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFVchangesDetails" roleURI="http://moonlaketx.com/role/InvestmentsFVchangesDetails">
        <link:definition>9954492 - Disclosure - Investments - FV changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesDetails" roleURI="http://moonlaketx.com/role/PrepaidExpensesDetails">
        <link:definition>9954493 - Disclosure - Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeandOtherPayablesDetails" roleURI="http://moonlaketx.com/role/TradeandOtherPayablesDetails">
        <link:definition>9954494 - Disclosure - Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9954495 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://moonlaketx.com/role/LeasesNarrativeDetails">
        <link:definition>9954496 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails" roleURI="http://moonlaketx.com/role/LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails">
        <link:definition>9954497 - Disclosure - Leases - Schedule of Weighted Average Lease Term And Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureLeasePaymentsDetails" roleURI="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails">
        <link:definition>9954498 - Disclosure - Leases - Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureLeasePaymentsDetails_1" roleURI="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1">
        <link:definition>9954498 - Disclosure - Leases - Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansNarrativeDetails" roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails">
        <link:definition>9954499 - Disclosure - Employee Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails" roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails">
        <link:definition>9954500 - Disclosure - Employee Benefit Plans - Changes in Summary of PBO And Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails" roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails">
        <link:definition>9954501 - Disclosure - Employee Benefit Plans - Amounts Recorded on the Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansChangesinPreTaxAOCIDetails" roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails">
        <link:definition>9954502 - Disclosure - Employee Benefit Plans - Changes in Pre-Tax AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails" roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails">
        <link:definition>9954503 - Disclosure - Employee Benefit Plans - Assumptions used to calculate liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAllocationPercentageDetails" roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails">
        <link:definition>9954504 - Disclosure - Employee Benefit Plans - Allocation Percentage (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails" roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails">
        <link:definition>9954505 - Disclosure - Shareholders&#8217; Equity (Deficit) - Schedule of Stock Authorized and Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDeficitNarrativeDetails" roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails">
        <link:definition>9954506 - Disclosure - Shareholders&#8217; Equity (Deficit) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareCalculationofNetLossperShareDetails" roleURI="http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails">
        <link:definition>9954507 - Disclosure - Net Loss per Share - Calculation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareNarrativeDetails" roleURI="http://moonlaketx.com/role/NetLossperShareNarrativeDetails">
        <link:definition>9954508 - Disclosure - Net Loss per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>9954509 - Disclosure - Share-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationSharebasedCompensationExpenseByPlanDetails" roleURI="http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails">
        <link:definition>9954510 - Disclosure - Share-based Compensation - Share-based Compensation Expense By Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationAssumptionsDetails" roleURI="http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails">
        <link:definition>9954511 - Disclosure - Share-based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationAwardedandGrantedDetails" roleURI="http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails">
        <link:definition>9954512 - Disclosure - Share-based Compensation - Awarded and Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://moonlaketx.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954513 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofNetIncomeDetails" roleURI="http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails">
        <link:definition>9954514 - Disclosure - Income Taxes - Summary of Net Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesStatutoryTaxPercentDetails" roleURI="http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails">
        <link:definition>9954515 - Disclosure - Income Taxes - Statutory Tax Percent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofDeferredTaxDetails" roleURI="http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails">
        <link:definition>9954516 - Disclosure - Income Taxes - Summary of Deferred Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://moonlaketx.com/role/CommitmentandContingenciesDetails">
        <link:definition>9954517 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationandGeographicDataDetails" roleURI="http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails">
        <link:definition>9954518 - Disclosure - Segment Information and Geographic Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://moonlaketx.com/role/SubsequentEventsDetails">
        <link:definition>9954519 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanLiquidityMember" abstract="true" name="DefinedBenefitPlanLiquidityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_TradeAndOtherPayablesCurrent" abstract="false" name="TradeAndOtherPayablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_UnderwritingAgreementMember" abstract="true" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanAOCIRollforwardRollForward" abstract="true" name="DefinedBenefitPlanAOCIRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_NumberOfOperatingLeases" abstract="false" name="NumberOfOperatingLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlk_ConversionFollowingBusinessCombinationMember" abstract="true" name="ConversionFollowingBusinessCombinationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent" abstract="false" name="OtherPrepaidConsultingAndAdvisoryFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_SonelokimabProgramSLKProgramMember" abstract="true" name="SonelokimabProgramSLKProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_MoonLakeImmunotherapeuticsMember" abstract="true" name="MoonLakeImmunotherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization" abstract="false" name="NoncontrollingInterestDecreaseFromReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_EquityIncentivePlanMember" abstract="true" name="EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_InvestmentsAcquiredThroughReverseRecapitalization" abstract="false" name="InvestmentsAcquiredThroughReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_Dr.KristianReichMember" abstract="true" name="Dr.KristianReichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_PaymentsOfStampDuty" abstract="false" name="PaymentsOfStampDuty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_AccruedConsultingAndOtherFeesCurrent" abstract="false" name="AccruedConsultingAndOtherFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_MLPartiesOtherThanBVFShareholdersMember" abstract="true" name="MLPartiesOtherThanBVFShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mnlk_SupplyAndManufacturingExpenseNoncurrent" abstract="false" name="SupplyAndManufacturingExpenseNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_OperatingLeaseAreaOfLeasedSpace" abstract="false" name="OperatingLeaseAreaOfLeasedSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="mnlk_ClassVVotingStockMember" abstract="true" name="ClassVVotingStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_TradeAndOtherPayablesCurrentTableTextBlock" abstract="false" name="TradeAndOtherPayablesCurrentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mnlk_ProceedsFromContributionFromParValueOfCommonStock" abstract="false" name="ProceedsFromContributionFromParValueOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_SaleOfStockStampDutyTax" abstract="false" name="SaleOfStockStampDutyTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalStampDutyFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_ReverseRecapitalizationAccruedExpenses" abstract="false" name="ReverseRecapitalizationAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_RecapitalizationExchangeRatio" abstract="false" name="RecapitalizationExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlk_HelixAcquisitionCorpMember" abstract="true" name="HelixAcquisitionCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_RiskAndLiquidityDisclosureTextBlock" abstract="false" name="RiskAndLiquidityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mnlk_PIPEInvestorsMember" abstract="true" name="PIPEInvestorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_ExpirationIn2028Member" abstract="true" name="ExpirationIn2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanInfrastructureMember" abstract="true" name="DefinedBenefitPlanInfrastructureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_CurrentAssetsInExcessOfCurrentLiabilities" abstract="false" name="CurrentAssetsInExcessOfCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_AccruedSupplyAndManufacturingFeesCurrent" abstract="false" name="AccruedSupplyAndManufacturingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_ReverseRecapitalizationNet" abstract="false" name="ReverseRecapitalizationNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_ATMSharesMember" abstract="true" name="ATMSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_OfficeLeaseMember" abstract="true" name="OfficeLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_ReverseRecapitalizationTransactionCosts" abstract="false" name="ReverseRecapitalizationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_August2023SalesAgreementMember" abstract="true" name="August2023SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_UnrecognizedCommitmentsAndContingencies" abstract="false" name="UnrecognizedCommitmentsAndContingencies" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_CommonClassARedeemableMember" abstract="true" name="CommonClassARedeemableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_AccruedResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlk_EmployeeStockOptionPlanESOPMember" abstract="true" name="EmployeeStockOptionPlanESOPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mnlk_ReverseRecapitalizationDisclosureTextBlock" abstract="false" name="ReverseRecapitalizationDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mnlk_StockForfeitedReverseRecapitalization" abstract="false" name="StockForfeitedReverseRecapitalization" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mnlk_CommonStockConversionRatio" abstract="false" name="CommonStockConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanBondMember" abstract="true" name="DefinedBenefitPlanBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_PrepaidResearchAndDevelopmentExpense" abstract="false" name="PrepaidResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_ScheduleOfReverseRecapitalizationLineItems" abstract="true" name="ScheduleOfReverseRecapitalizationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_CommonClassAPrivatePlacementMember" abstract="true" name="CommonClassAPrivatePlacementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_DeferredTaxAssetsNetIncludingValuationAllowance" abstract="false" name="DeferredTaxAssetsNetIncludingValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount" abstract="false" name="SaleOfStockRemainingAuthorizedRepurchaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" abstract="false" name="ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" abstract="false" name="ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlk_ReverseRecapitalizationOtherTransactionExpenses" abstract="false" name="ReverseRecapitalizationOtherTransactionExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_ExpirationIn2029Member" abstract="true" name="ExpirationIn2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_Dr.JorgeSantosDaSilvaMember" abstract="true" name="Dr.JorgeSantosDaSilvaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_ShareBasedPaymentArrangementTrancheFourMember" abstract="true" name="ShareBasedPaymentArrangementTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_CommonStockVotesAttachedToShares" abstract="false" name="CommonStockVotesAttachedToShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" abstract="false" name="DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mnlk_ScheduleOfReverseRecapitalizationTable" abstract="true" name="ScheduleOfReverseRecapitalizationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_SupplyAndManufacturingFeesPayableCurrent" abstract="false" name="SupplyAndManufacturingFeesPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_NumberOfCoFounders" abstract="false" name="NumberOfCoFounders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlk_SharePriceNominalValue" abstract="false" name="SharePriceNominalValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" abstract="false" name="DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_SaleOfStockOptionToPurchaseTerm" abstract="false" name="SaleOfStockOptionToPurchaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mnlk_DeferredTaxAssetsLeaseLiabililties" abstract="false" name="DeferredTaxAssetsLeaseLiabililties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_CommonStockVotesMultiplier" abstract="false" name="CommonStockVotesMultiplier" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="mnlk_ConversionOfClassCIntoClassAMember" abstract="true" name="ConversionOfClassCIntoClassAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_CommonStockRollForward" abstract="true" name="CommonStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_PortoOfficeMember" abstract="true" name="PortoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_OperatingLossCarryforwardExpirationDomain" abstract="true" name="OperatingLossCarryforwardExpirationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_May2023SalesAgreementMember" abstract="true" name="May2023SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_OperatingLossCarryforwardExpirationAxis" abstract="true" name="OperatingLossCarryforwardExpirationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_ConversionOfClassCIntoClassASharesMember" abstract="true" name="ConversionOfClassCIntoClassASharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_StockConvertedReverseRecapitalization" abstract="false" name="StockConvertedReverseRecapitalization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" abstract="false" name="NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_MoonLakeAGMember" abstract="true" name="MoonLakeAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mnlk_ReverseRecapitalizationAbstract" abstract="true" name="ReverseRecapitalizationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward" abstract="true" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_ProceedsFromReverseRecapitalization" abstract="false" name="ProceedsFromReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_ScheduleOfReverseRecapitalizationTableTextBlock" abstract="false" name="ScheduleOfReverseRecapitalizationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" abstract="false" name="AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_CambridgeOfficeMember" abstract="true" name="CambridgeOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlk_PrepaidExpensesNoncurrentMember" abstract="true" name="PrepaidExpensesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" abstract="false" name="DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlk_TotalSharesRollForward" abstract="true" name="TotalSharesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlk_SharesAuthorized" abstract="false" name="SharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>mnlk-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:25f78456-bf3c-4d7d-8669-3aa27460a960,g:c66f622e-48e1-41cd-88e8-9a7e0d2c3eaf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fa62cc4e-0ee7-423e-bc10-c5d71775a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2cb94188-ac03-4caf-8303-ab32656dec79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa62cc4e-0ee7-423e-bc10-c5d71775a02b" xlink:to="loc_us-gaap_LiabilitiesCurrent_2cb94188-ac03-4caf-8303-ab32656dec79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_d7dcf724-19ac-4512-853e-a5c9e10bcab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa62cc4e-0ee7-423e-bc10-c5d71775a02b" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_d7dcf724-19ac-4512-853e-a5c9e10bcab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e0feeefc-4d98-4ef1-bbdc-1e788ebb831e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3d859039-7fce-4e71-b385-08a9335f0190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e0feeefc-4d98-4ef1-bbdc-1e788ebb831e" xlink:to="loc_us-gaap_Liabilities_3d859039-7fce-4e71-b385-08a9335f0190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f78c362c-5c08-499d-9570-0d014b2c7a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e0feeefc-4d98-4ef1-bbdc-1e788ebb831e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f78c362c-5c08-499d-9570-0d014b2c7a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9646e091-2231-4779-85cf-8a653829a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e0feeefc-4d98-4ef1-bbdc-1e788ebb831e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9646e091-2231-4779-85cf-8a653829a74d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d68c641a-a625-4c1b-a151-ee2a22ba8b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26211844-4037-4ad0-a0d6-b9998a3b1d92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d68c641a-a625-4c1b-a151-ee2a22ba8b58" xlink:to="loc_us-gaap_StockholdersEquity_26211844-4037-4ad0-a0d6-b9998a3b1d92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2c0faaa5-7bb8-4ebb-b8b1-f645702d35a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d68c641a-a625-4c1b-a151-ee2a22ba8b58" xlink:to="loc_us-gaap_MinorityInterest_2c0faaa5-7bb8-4ebb-b8b1-f645702d35a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_629a119a-0de4-4e97-bdef-287e67f66b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_4e96c8f1-199c-46ba-9127-fd2888bdaa11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_629a119a-0de4-4e97-bdef-287e67f66b15" xlink:to="loc_us-gaap_AssetsNoncurrent_4e96c8f1-199c-46ba-9127-fd2888bdaa11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f3605e61-920c-4d04-8adb-9b03c9960d46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_629a119a-0de4-4e97-bdef-287e67f66b15" xlink:to="loc_us-gaap_AssetsCurrent_f3605e61-920c-4d04-8adb-9b03c9960d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fde6b4cd-3e9f-4aa1-861e-5fe238c40cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_67450a43-6786-420e-a0f6-b784276fc6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_fde6b4cd-3e9f-4aa1-861e-5fe238c40cdb" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_67450a43-6786-420e-a0f6-b784276fc6c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d3cfcb2-6426-4565-abf4-04f048d7be20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_fde6b4cd-3e9f-4aa1-861e-5fe238c40cdb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d3cfcb2-6426-4565-abf4-04f048d7be20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_a14407f9-e54d-4122-b76e-f327edb31ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_af6c8885-95ed-436b-bb00-201e87b9c5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a14407f9-e54d-4122-b76e-f327edb31ac4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_af6c8885-95ed-436b-bb00-201e87b9c5fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2e47cfdc-7d0d-47b4-bfe0-f5eba61441e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a14407f9-e54d-4122-b76e-f327edb31ac4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2e47cfdc-7d0d-47b4-bfe0-f5eba61441e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_a2983750-6324-4b59-ab42-3ad3cc904d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a14407f9-e54d-4122-b76e-f327edb31ac4" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_a2983750-6324-4b59-ab42-3ad3cc904d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c34667b-8ffe-44cc-971d-41a441d275b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_94b1dedb-8f0b-47f0-9d13-64ce5dcbf8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c34667b-8ffe-44cc-971d-41a441d275b9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_94b1dedb-8f0b-47f0-9d13-64ce5dcbf8c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_fa1c976f-b09d-45a3-8718-479e9b4e4514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c34667b-8ffe-44cc-971d-41a441d275b9" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_fa1c976f-b09d-45a3-8718-479e9b4e4514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_bf075408-3847-4622-ae03-e3ff64ecf151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c34667b-8ffe-44cc-971d-41a441d275b9" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_bf075408-3847-4622-ae03-e3ff64ecf151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d6733227-4089-4657-ae5e-da76503294f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c34667b-8ffe-44cc-971d-41a441d275b9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d6733227-4089-4657-ae5e-da76503294f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d26992b5-ecc9-48ff-b014-c00f55483e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fee6e08a-46ba-4be9-a6e9-7c8cd1f33cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d26992b5-ecc9-48ff-b014-c00f55483e7a" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fee6e08a-46ba-4be9-a6e9-7c8cd1f33cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TradeAndOtherPayablesCurrent_cb7279e9-daa6-45f9-9dea-8833ce67ce70" xlink:href="mnlk-20231231.xsd#mnlk_TradeAndOtherPayablesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d26992b5-ecc9-48ff-b014-c00f55483e7a" xlink:to="loc_mnlk_TradeAndOtherPayablesCurrent_cb7279e9-daa6-45f9-9dea-8833ce67ce70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f6079853-44e2-4987-bcad-5b324b383524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d26992b5-ecc9-48ff-b014-c00f55483e7a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f6079853-44e2-4987-bcad-5b324b383524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_289b3603-d0ef-41b3-9e14-bc0320f6fa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_957a1d18-a995-4bba-bb7d-3ed4e7572438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_289b3603-d0ef-41b3-9e14-bc0320f6fa4c" xlink:to="loc_us-gaap_CommonStockValue_957a1d18-a995-4bba-bb7d-3ed4e7572438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3678be68-ecbb-43ad-ae24-753948670a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_289b3603-d0ef-41b3-9e14-bc0320f6fa4c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3678be68-ecbb-43ad-ae24-753948670a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d3420021-8f38-45b5-bfb6-e4aae91fd249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_289b3603-d0ef-41b3-9e14-bc0320f6fa4c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d3420021-8f38-45b5-bfb6-e4aae91fd249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_35ed8e90-93e5-479a-8996-7bb39ab3ce78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_289b3603-d0ef-41b3-9e14-bc0320f6fa4c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_35ed8e90-93e5-479a-8996-7bb39ab3ce78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23dec476-0bf9-456b-9a93-6a0c699f8778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c2038579-31d7-410f-bd80-508362629134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23dec476-0bf9-456b-9a93-6a0c699f8778" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c2038579-31d7-410f-bd80-508362629134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_c46ffe64-7eb1-40d1-82c5-8322a51ff750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23dec476-0bf9-456b-9a93-6a0c699f8778" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_c46ffe64-7eb1-40d1-82c5-8322a51ff750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c283c6de-5224-4ffa-906d-514a1afcdd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f4f33265-3c5b-4242-9ef5-22f8b2aecefa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c283c6de-5224-4ffa-906d-514a1afcdd6a" xlink:to="loc_us-gaap_ProfitLoss_f4f33265-3c5b-4242-9ef5-22f8b2aecefa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5d8f105a-5bf6-4af0-ad85-49748435a95c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c283c6de-5224-4ffa-906d-514a1afcdd6a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5d8f105a-5bf6-4af0-ad85-49748435a95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_d6163f7a-316e-406e-a8eb-98295c0a5ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_48355392-d07d-4aed-a90d-82fcb1ee17b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_d6163f7a-316e-406e-a8eb-98295c0a5ef3" xlink:to="loc_us-gaap_OtherNonoperatingIncome_48355392-d07d-4aed-a90d-82fcb1ee17b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_71bc22b5-7085-4db7-ab2a-677a64251835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_d6163f7a-316e-406e-a8eb-98295c0a5ef3" xlink:to="loc_us-gaap_OperatingIncomeLoss_71bc22b5-7085-4db7-ab2a-677a64251835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f5f6b2f2-dc73-41fe-9d67-994b691d688c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c91565a1-e27b-4b99-b20f-67ac6e6fad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f5f6b2f2-dc73-41fe-9d67-994b691d688c" xlink:to="loc_us-gaap_OperatingExpenses_c91565a1-e27b-4b99-b20f-67ac6e6fad7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec89db99-2cfa-443f-b7e4-93b2e0df3c02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e2f2a54-f56d-49ab-8183-9615a46a2e12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec89db99-2cfa-443f-b7e4-93b2e0df3c02" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e2f2a54-f56d-49ab-8183-9615a46a2e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_997177ce-9d1a-4d3f-828e-7236fd681335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec89db99-2cfa-443f-b7e4-93b2e0df3c02" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_997177ce-9d1a-4d3f-828e-7236fd681335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2510992c-2d9a-4ed1-9aab-044887f43a98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_db429962-a3cb-44c4-acb3-f6803ebea32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2510992c-2d9a-4ed1-9aab-044887f43a98" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_db429962-a3cb-44c4-acb3-f6803ebea32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7544a313-dbfe-4e7a-abd4-0eac73f723a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2510992c-2d9a-4ed1-9aab-044887f43a98" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7544a313-dbfe-4e7a-abd4-0eac73f723a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bd5861ce-e786-4e90-8e67-c771849e8a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f7e4b47c-b500-4a6f-9514-d962504c6207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bd5861ce-e786-4e90-8e67-c771849e8a72" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f7e4b47c-b500-4a6f-9514-d962504c6207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bbb16536-5c97-4ac2-8df6-4778eec3bfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bd5861ce-e786-4e90-8e67-c771849e8a72" xlink:to="loc_us-gaap_ProfitLoss_bbb16536-5c97-4ac2-8df6-4778eec3bfdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_83145c7f-0646-4bd8-aa39-43ca0855961b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b738cc3e-c242-4402-8804-751fa6ddc7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_83145c7f-0646-4bd8-aa39-43ca0855961b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b738cc3e-c242-4402-8804-751fa6ddc7bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_a9cff3fd-8afe-436e-9f86-9832ca576407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_83145c7f-0646-4bd8-aa39-43ca0855961b" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_a9cff3fd-8afe-436e-9f86-9832ca576407" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_842f0d2d-026d-47ac-8893-36be34b23584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54df382c-afca-4773-b8a6-8038f7832678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_842f0d2d-026d-47ac-8893-36be34b23584" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54df382c-afca-4773-b8a6-8038f7832678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2099e726-ec0b-4b39-bed6-0ddc2336f1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_842f0d2d-026d-47ac-8893-36be34b23584" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2099e726-ec0b-4b39-bed6-0ddc2336f1cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_168c2264-35b3-473a-baf0-35a4d5c28286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_842f0d2d-026d-47ac-8893-36be34b23584" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_168c2264-35b3-473a-baf0-35a4d5c28286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b98d8239-bf27-4e02-8544-f659efbb08f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_842f0d2d-026d-47ac-8893-36be34b23584" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b98d8239-bf27-4e02-8544-f659efbb08f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f051ef56-07b2-483d-b9ec-1ea5db44bd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_Depreciation_f051ef56-07b2-483d-b9ec-1ea5db44bd9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d9044876-40a4-4c77-a09f-ab038f6a4eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d9044876-40a4-4c77-a09f-ab038f6a4eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_99d590e9-9b31-4af6-be51-395e831fcda2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_99d590e9-9b31-4af6-be51-395e831fcda2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpenseReversalOfExpenseNoncash_d3f9bb31-7407-4857-b62d-ef47e2d4ad47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpenseReversalOfExpenseNoncash"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_PensionExpenseReversalOfExpenseNoncash_d3f9bb31-7407-4857-b62d-ef47e2d4ad47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c6c985f6-620f-410f-9554-bf74f32cfae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_ShareBasedCompensation_c6c985f6-620f-410f-9554-bf74f32cfae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_007a9e20-54c4-4b41-b1f9-1d6b3297b577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_ProfitLoss_007a9e20-54c4-4b41-b1f9-1d6b3297b577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7265e624-54be-4336-a4f5-d519101dc4be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7265e624-54be-4336-a4f5-d519101dc4be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_bd77fbd2-e6c8-4a6b-88b5-df2f120f5e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_bd77fbd2-e6c8-4a6b-88b5-df2f120f5e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e2f0eb31-c039-49b6-9fac-d4851f9bc528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e2f0eb31-c039-49b6-9fac-d4851f9bc528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_4add7bfe-01a8-4e26-816e-b2ee25c38dfd" xlink:href="mnlk-20231231.xsd#mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_4add7bfe-01a8-4e26-816e-b2ee25c38dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fdd43679-253d-4e1b-8e75-331c8bc9a0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d964d83-fdab-4076-aeb3-064d571e7081" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fdd43679-253d-4e1b-8e75-331c8bc9a0ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7aca59cc-d3cc-4b9d-9629-d1c344910cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ProceedsFromContributionFromParValueOfCommonStock_aca3c754-da30-4ac3-925a-42e89d74c8a5" xlink:href="mnlk-20231231.xsd#mnlk_ProceedsFromContributionFromParValueOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7aca59cc-d3cc-4b9d-9629-d1c344910cbb" xlink:to="loc_mnlk_ProceedsFromContributionFromParValueOfCommonStock_aca3c754-da30-4ac3-925a-42e89d74c8a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_c36ca59b-7f91-48e1-afa7-6c9f6dbcb1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7aca59cc-d3cc-4b9d-9629-d1c344910cbb" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_c36ca59b-7f91-48e1-afa7-6c9f6dbcb1d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ProceedsFromReverseRecapitalization_0aadf228-d652-4554-84d5-954d24ef52a8" xlink:href="mnlk-20231231.xsd#mnlk_ProceedsFromReverseRecapitalization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7aca59cc-d3cc-4b9d-9629-d1c344910cbb" xlink:to="loc_mnlk_ProceedsFromReverseRecapitalization_0aadf228-d652-4554-84d5-954d24ef52a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a2349d5b-88c0-4712-a4e9-8140c6ea3219" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7aca59cc-d3cc-4b9d-9629-d1c344910cbb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a2349d5b-88c0-4712-a4e9-8140c6ea3219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PaymentsOfStampDuty_516387ec-1bdf-4bf3-a9cf-4446bd8adeec" xlink:href="mnlk-20231231.xsd#mnlk_PaymentsOfStampDuty"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7aca59cc-d3cc-4b9d-9629-d1c344910cbb" xlink:to="loc_mnlk_PaymentsOfStampDuty_516387ec-1bdf-4bf3-a9cf-4446bd8adeec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_49a785d0-ec77-40fe-917c-2011c0ac4111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7aca59cc-d3cc-4b9d-9629-d1c344910cbb" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_49a785d0-ec77-40fe-917c-2011c0ac4111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17f8aaab-423c-4db3-b6d0-4a07881c3c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_12ec7135-8794-4f64-afe4-8ad2b14c8f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17f8aaab-423c-4db3-b6d0-4a07881c3c0d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_12ec7135-8794-4f64-afe4-8ad2b14c8f96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7a1bed2c-f7fc-424c-b003-d09d56623de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17f8aaab-423c-4db3-b6d0-4a07881c3c0d" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7a1bed2c-f7fc-424c-b003-d09d56623de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4852b187-747c-4a74-a2ab-8f0667541f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17f8aaab-423c-4db3-b6d0-4a07881c3c0d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4852b187-747c-4a74-a2ab-8f0667541f24" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationNet_6da398f6-660e-47a9-8cef-13ba3bae7202" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_7c360035-01e6-4d81-9c62-4681bf5cbfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_ReverseRecapitalizationNet_6da398f6-660e-47a9-8cef-13ba3bae7202" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_7c360035-01e6-4d81-9c62-4681bf5cbfbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_64e4571d-03e9-480e-adc8-bbc4bef81abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_ReverseRecapitalizationNet_6da398f6-660e-47a9-8cef-13ba3bae7202" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_64e4571d-03e9-480e-adc8-bbc4bef81abf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_InvestmentsAcquiredThroughReverseRecapitalization_3687f715-01e7-4d6e-aa0b-1e48617a91b4" xlink:href="mnlk-20231231.xsd#mnlk_InvestmentsAcquiredThroughReverseRecapitalization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_ReverseRecapitalizationNet_6da398f6-660e-47a9-8cef-13ba3bae7202" xlink:to="loc_mnlk_InvestmentsAcquiredThroughReverseRecapitalization_3687f715-01e7-4d6e-aa0b-1e48617a91b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationTransactionCosts_b8883e67-d62c-4a2b-8ed4-aa0548cf5713" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationTransactionCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_ReverseRecapitalizationNet_6da398f6-660e-47a9-8cef-13ba3bae7202" xlink:to="loc_mnlk_ReverseRecapitalizationTransactionCosts_b8883e67-d62c-4a2b-8ed4-aa0548cf5713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationTransactionCosts_5608e160-d237-4585-bc13-91f39a29afe3" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationOtherTransactionExpenses_b9d116f6-1f62-4fd6-8538-30499433c214" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationOtherTransactionExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_ReverseRecapitalizationTransactionCosts_5608e160-d237-4585-bc13-91f39a29afe3" xlink:to="loc_mnlk_ReverseRecapitalizationOtherTransactionExpenses_b9d116f6-1f62-4fd6-8538-30499433c214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees_e5b9dc72-0446-4231-b2b1-43dd80ed5b05" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_ReverseRecapitalizationTransactionCosts_5608e160-d237-4585-bc13-91f39a29afe3" xlink:to="loc_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees_e5b9dc72-0446-4231-b2b1-43dd80ed5b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAccruedExpenses_45c0c20d-4527-4ae6-846f-92a2bbdc412d" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAccruedExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_ReverseRecapitalizationTransactionCosts_5608e160-d237-4585-bc13-91f39a29afe3" xlink:to="loc_mnlk_ReverseRecapitalizationAccruedExpenses_45c0c20d-4527-4ae6-846f-92a2bbdc412d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c02a4373-4e2a-4726-bb3e-9aad18b62fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bfcc7e3b-02f9-46d7-a722-c216216640eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c02a4373-4e2a-4726-bb3e-9aad18b62fb0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bfcc7e3b-02f9-46d7-a722-c216216640eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3b78cb8-4179-4dc3-bc3b-058493c5f0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c02a4373-4e2a-4726-bb3e-9aad18b62fb0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3b78cb8-4179-4dc3-bc3b-058493c5f0b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_52c977ac-a398-4bc9-b4a3-d5fb9bc2ecc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c02a4373-4e2a-4726-bb3e-9aad18b62fb0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_52c977ac-a398-4bc9-b4a3-d5fb9bc2ecc4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/PrepaidExpensesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#PrepaidExpensesDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/PrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_73d8ce1f-1a4f-4308-a31b-7d9582f80b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SupplyAndManufacturingExpenseNoncurrent_7ff556f0-a829-4077-8149-292dc7106c5d" xlink:href="mnlk-20231231.xsd#mnlk_SupplyAndManufacturingExpenseNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_73d8ce1f-1a4f-4308-a31b-7d9582f80b99" xlink:to="loc_mnlk_SupplyAndManufacturingExpenseNoncurrent_7ff556f0-a829-4077-8149-292dc7106c5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_05a45a06-365b-4ad8-a8ca-5f2415737f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_0f987008-7d79-4bcb-90da-fd39277615df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_05a45a06-365b-4ad8-a8ca-5f2415737f39" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_0f987008-7d79-4bcb-90da-fd39277615df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PrepaidResearchAndDevelopmentExpense_2754d0c4-36f4-4e23-96b6-05fef4b77e22" xlink:href="mnlk-20231231.xsd#mnlk_PrepaidResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_05a45a06-365b-4ad8-a8ca-5f2415737f39" xlink:to="loc_mnlk_PrepaidResearchAndDevelopmentExpense_2754d0c4-36f4-4e23-96b6-05fef4b77e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_364218db-feee-4d2a-bcc9-2ec85fae07f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_05a45a06-365b-4ad8-a8ca-5f2415737f39" xlink:to="loc_us-gaap_PrepaidInsurance_364218db-feee-4d2a-bcc9-2ec85fae07f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent_5c8e9526-f81a-4265-98c7-a319957270ee" xlink:href="mnlk-20231231.xsd#mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_05a45a06-365b-4ad8-a8ca-5f2415737f39" xlink:to="loc_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent_5c8e9526-f81a-4265-98c7-a319957270ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/TradeandOtherPayablesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#TradeandOtherPayablesDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/TradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TradeAndOtherPayablesCurrent_dfca23e4-a094-422a-b54c-12a4cec75f35" xlink:href="mnlk-20231231.xsd#mnlk_TradeAndOtherPayablesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedResearchAndDevelopmentExpensesCurrent_b8610c3d-4632-4619-a612-f72d5767a36a" xlink:href="mnlk-20231231.xsd#mnlk_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_TradeAndOtherPayablesCurrent_dfca23e4-a094-422a-b54c-12a4cec75f35" xlink:to="loc_mnlk_AccruedResearchAndDevelopmentExpensesCurrent_b8610c3d-4632-4619-a612-f72d5767a36a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_2255fb81-94eb-41ad-ae98-c5920567a1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_TradeAndOtherPayablesCurrent_dfca23e4-a094-422a-b54c-12a4cec75f35" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_2255fb81-94eb-41ad-ae98-c5920567a1a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent_e384258f-e781-4307-9364-11cfd42b4ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_TradeAndOtherPayablesCurrent_dfca23e4-a094-422a-b54c-12a4cec75f35" xlink:to="loc_us-gaap_AccruedRentCurrent_e384258f-e781-4307-9364-11cfd42b4ae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SupplyAndManufacturingFeesPayableCurrent_0bf9e081-5167-41cf-934d-aff2332b6386" xlink:href="mnlk-20231231.xsd#mnlk_SupplyAndManufacturingFeesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_TradeAndOtherPayablesCurrent_dfca23e4-a094-422a-b54c-12a4cec75f35" xlink:to="loc_mnlk_SupplyAndManufacturingFeesPayableCurrent_0bf9e081-5167-41cf-934d-aff2332b6386" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_58a6fb55-3daa-43f9-920c-bdf3bdbe5b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17e64931-876a-4e88-9208-d96785f0c75a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_58a6fb55-3daa-43f9-920c-bdf3bdbe5b9b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17e64931-876a-4e88-9208-d96785f0c75a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedConsultingAndOtherFeesCurrent_6ec86dd7-23e9-4029-aede-3ab02323aeed" xlink:href="mnlk-20231231.xsd#mnlk_AccruedConsultingAndOtherFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_58a6fb55-3daa-43f9-920c-bdf3bdbe5b9b" xlink:to="loc_mnlk_AccruedConsultingAndOtherFeesCurrent_6ec86dd7-23e9-4029-aede-3ab02323aeed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent_fa619de8-5494-4766-a81c-236cae4e73d7" xlink:href="mnlk-20231231.xsd#mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_58a6fb55-3daa-43f9-920c-bdf3bdbe5b9b" xlink:to="loc_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent_fa619de8-5494-4766-a81c-236cae4e73d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedSupplyAndManufacturingFeesCurrent_4c9ea98d-0318-4959-9842-416814836ce5" xlink:href="mnlk-20231231.xsd#mnlk_AccruedSupplyAndManufacturingFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_58a6fb55-3daa-43f9-920c-bdf3bdbe5b9b" xlink:to="loc_mnlk_AccruedSupplyAndManufacturingFeesCurrent_4c9ea98d-0318-4959-9842-416814836ce5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_da971933-cdf7-409e-807f-d3c17d1fb469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_58a6fb55-3daa-43f9-920c-bdf3bdbe5b9b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_da971933-cdf7-409e-807f-d3c17d1fb469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_8717a309-f223-4a73-9b48-e56631460d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_58a6fb55-3daa-43f9-920c-bdf3bdbe5b9b" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_8717a309-f223-4a73-9b48-e56631460d27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#LeasesFutureLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31386497-93f9-4d2d-9673-56bb3ea3e824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_56a8211a-fad2-4305-9f94-81ff9d9d5390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31386497-93f9-4d2d-9673-56bb3ea3e824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_56a8211a-fad2-4305-9f94-81ff9d9d5390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_002765f3-dfea-4f23-9e38-b171fb7d3ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31386497-93f9-4d2d-9673-56bb3ea3e824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_002765f3-dfea-4f23-9e38-b171fb7d3ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3bbcedae-6db6-45f5-8140-5729e8e84247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31386497-93f9-4d2d-9673-56bb3ea3e824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3bbcedae-6db6-45f5-8140-5729e8e84247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2cf982e3-fb82-4511-91a6-9ce6efc7a37d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31386497-93f9-4d2d-9673-56bb3ea3e824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2cf982e3-fb82-4511-91a6-9ce6efc7a37d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_35383517-055e-46ef-b168-a43627b3eda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31386497-93f9-4d2d-9673-56bb3ea3e824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_35383517-055e-46ef-b168-a43627b3eda5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_aec4183e-86a6-4411-ad9a-036bdc302ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31386497-93f9-4d2d-9673-56bb3ea3e824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_aec4183e-86a6-4411-ad9a-036bdc302ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3671ab06-4536-4fd7-a0b0-bb18e12bfb50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_36b9b424-b65e-485f-bab6-ee50ef3305b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3671ab06-4536-4fd7-a0b0-bb18e12bfb50" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_36b9b424-b65e-485f-bab6-ee50ef3305b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3f53cbbc-820c-46e0-84d8-20557643a10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3671ab06-4536-4fd7-a0b0-bb18e12bfb50" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3f53cbbc-820c-46e0-84d8-20557643a10c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mnlk-20231231.xsd#LeasesFutureLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c6c51c69-e2e3-41a5-a990-aa9e42b4a1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f2f09fa9-38ed-470f-a28e-2e439a6e3459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c6c51c69-e2e3-41a5-a990-aa9e42b4a1a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f2f09fa9-38ed-470f-a28e-2e439a6e3459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_971d7607-10d4-4b16-903d-0e0e4db7a527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c6c51c69-e2e3-41a5-a990-aa9e42b4a1a6" xlink:to="loc_us-gaap_OperatingLeaseLiability_971d7607-10d4-4b16-903d-0e0e4db7a527" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_63aad789-53c3-44d6-8848-b8660e5872c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_08e0c3e4-acef-4268-bb1e-bca032984521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_63aad789-53c3-44d6-8848-b8660e5872c2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_08e0c3e4-acef-4268-bb1e-bca032984521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_bca14d0f-5ab1-421d-a3fd-bd30bd900d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_63aad789-53c3-44d6-8848-b8660e5872c2" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_bca14d0f-5ab1-421d-a3fd-bd30bd900d4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesSummaryofNetIncomeDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac49ff01-461a-4ab5-b07b-ed5c8aa64840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0a9b796b-884a-48ec-955b-8091f70f7217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac49ff01-461a-4ab5-b07b-ed5c8aa64840" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0a9b796b-884a-48ec-955b-8091f70f7217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e1231503-ab17-4d8b-8826-f4fcdcef8d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac49ff01-461a-4ab5-b07b-ed5c8aa64840" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e1231503-ab17-4d8b-8826-f4fcdcef8d4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesStatutoryTaxPercentDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_28412588-209d-4d44-938f-3f7d498e6aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7298ace6-05bf-4ba4-a5b2-8e9bef49c5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_28412588-209d-4d44-938f-3f7d498e6aa0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7298ace6-05bf-4ba4-a5b2-8e9bef49c5f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_c2194536-ccdc-4142-993b-68dc0aabca80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_28412588-209d-4d44-938f-3f7d498e6aa0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_c2194536-ccdc-4142-993b-68dc0aabca80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d1406392-22c5-4501-ac14-30455e44ee47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_28412588-209d-4d44-938f-3f7d498e6aa0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d1406392-22c5-4501-ac14-30455e44ee47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d6bdc512-fbb8-4ad0-847c-de4657f14eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_28412588-209d-4d44-938f-3f7d498e6aa0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d6bdc512-fbb8-4ad0-847c-de4657f14eb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent_e2e85140-40af-4910-b037-75c1629f0704" xlink:href="mnlk-20231231.xsd#mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_28412588-209d-4d44-938f-3f7d498e6aa0" xlink:to="loc_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent_e2e85140-40af-4910-b037-75c1629f0704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_50c27829-67e1-494e-a8d4-3b311b8ef963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_28412588-209d-4d44-938f-3f7d498e6aa0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_50c27829-67e1-494e-a8d4-3b311b8ef963" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ef398647-3aed-4470-81d1-6e6b25e945da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_28412588-209d-4d44-938f-3f7d498e6aa0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ef398647-3aed-4470-81d1-6e6b25e945da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesSummaryofDeferredTaxDetails"/>
  <link:calculationLink xlink:role="http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_b689ae31-7c72-4d9a-b229-40a94484a232" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxAssetsNetIncludingValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_db2d9c1c-bc77-4d91-853b-03e7de388574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_b689ae31-7c72-4d9a-b229-40a94484a232" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_db2d9c1c-bc77-4d91-853b-03e7de388574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3e1ef38d-3003-47e3-8c6b-a399c0b2bdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_b689ae31-7c72-4d9a-b229-40a94484a232" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3e1ef38d-3003-47e3-8c6b-a399c0b2bdf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5827d89d-6878-4504-a1cb-57b4aff79005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_8c8a72dc-fdcd-4642-ba3e-bceb7ba17ce8" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5827d89d-6878-4504-a1cb-57b4aff79005" xlink:to="loc_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_8c8a72dc-fdcd-4642-ba3e-bceb7ba17ce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b1b15418-01f2-4edf-ac93-5fcca44def27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxAssetsLeaseLiabililties_8bd50aeb-9d46-417a-b538-5575e872f7d5" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxAssetsLeaseLiabililties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1b15418-01f2-4edf-ac93-5fcca44def27" xlink:to="loc_mnlk_DeferredTaxAssetsLeaseLiabililties_8bd50aeb-9d46-417a-b538-5575e872f7d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a3681ed8-1d73-43a8-b664-00d41d628e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1b15418-01f2-4edf-ac93-5fcca44def27" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a3681ed8-1d73-43a8-b664-00d41d628e8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_47b41c1c-0aaf-4df7-9703-583d410bfbce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1b15418-01f2-4edf-ac93-5fcca44def27" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_47b41c1c-0aaf-4df7-9703-583d410bfbce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4d644e4d-cb57-4d3f-90cc-74d29ac4e481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1b15418-01f2-4edf-ac93-5fcca44def27" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4d644e4d-cb57-4d3f-90cc-74d29ac4e481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_34cee9c5-948d-4f76-9688-9be4c0495a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_e94c2f1c-d9e0-4df0-80bf-5ff18692a4d9" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxAssetsNetIncludingValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_34cee9c5-948d-4f76-9688-9be4c0495a2f" xlink:to="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_e94c2f1c-d9e0-4df0-80bf-5ff18692a4d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ae727458-9bb5-4fb8-b0b6-5f10fb9a02b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_34cee9c5-948d-4f76-9688-9be4c0495a2f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ae727458-9bb5-4fb8-b0b6-5f10fb9a02b3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>mnlk-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:25f78456-bf3c-4d7d-8669-3aa27460a960,g:c66f622e-48e1-41cd-88e8-9a7e0d2c3eaf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://moonlaketx.com/role/Cover" xlink:type="simple" xlink:href="mnlk-20231231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_ece3c852-c446-4dbf-8cdf-3302a863f0bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentInformationTable_ece3c852-c446-4dbf-8cdf-3302a863f0bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_ece3c852-c446-4dbf-8cdf-3302a863f0bf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26" xlink:to="loc_us-gaap_ClassOfStockDomain_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_615b5f9a-0543-4f9e-a6b1-5be590453fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26" xlink:to="loc_us-gaap_ClassOfStockDomain_615b5f9a-0543-4f9e-a6b1-5be590453fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d4959eb2-c7e7-43e0-a20a-09be3e23d030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_615b5f9a-0543-4f9e-a6b1-5be590453fcd" xlink:to="loc_us-gaap_CommonClassAMember_d4959eb2-c7e7-43e0-a20a-09be3e23d030" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_722129b9-b61c-42c3-81cd-9ef0f354c0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_615b5f9a-0543-4f9e-a6b1-5be590453fcd" xlink:to="loc_us-gaap_CommonClassCMember_722129b9-b61c-42c3-81cd-9ef0f354c0d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_320fa574-868c-4ced-a06e-1fe12a526639" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentType_320fa574-868c-4ced-a06e-1fe12a526639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c9551395-db61-486a-8dda-e33f20fcf66b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentAnnualReport_c9551395-db61-486a-8dda-e33f20fcf66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a9127f05-d2c2-4a9f-9876-230f1cf0fea0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_CurrentFiscalYearEndDate_a9127f05-d2c2-4a9f-9876-230f1cf0fea0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8880d6e5-cff9-4130-999f-ceda4dbda2e0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentPeriodEndDate_8880d6e5-cff9-4130-999f-ceda4dbda2e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e39fda42-aa69-4597-af6f-51d034e0d634" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentTransitionReport_e39fda42-aa69-4597-af6f-51d034e0d634" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ab39ede9-e679-46c0-81ef-8d528817300f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityFileNumber_ab39ede9-e679-46c0-81ef-8d528817300f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a7bb7e37-84c6-4e37-9e70-54c3faba9af5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityRegistrantName_a7bb7e37-84c6-4e37-9e70-54c3faba9af5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2049e05a-5cb0-4c37-9f7d-091a1c76c6ee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2049e05a-5cb0-4c37-9f7d-091a1c76c6ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_24fa03da-42e3-47bd-91e5-7f5e762a7aa6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityTaxIdentificationNumber_24fa03da-42e3-47bd-91e5-7f5e762a7aa6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_eab299ad-51d2-4347-b3b7-da1abfceac62" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityAddressAddressLine1_eab299ad-51d2-4347-b3b7-da1abfceac62" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_45490885-f8ef-4e48-a470-8cc1be1424c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityAddressPostalZipCode_45490885-f8ef-4e48-a470-8cc1be1424c2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e009f59b-497f-4cae-8578-2cb3605b3a35" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityAddressCityOrTown_e009f59b-497f-4cae-8578-2cb3605b3a35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_fe68fd5f-35dd-4245-97c2-4b32ff2b31e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityAddressCountry_fe68fd5f-35dd-4245-97c2-4b32ff2b31e3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_de198459-ab97-4b7b-8adb-11cb77657bba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_CityAreaCode_de198459-ab97-4b7b-8adb-11cb77657bba" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2c7bc242-3ea8-4c14-a330-74f4b5e1a015" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_LocalPhoneNumber_2c7bc242-3ea8-4c14-a330-74f4b5e1a015" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6bc23b49-e7fc-4a63-a455-d275fc0bf1a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_Security12bTitle_6bc23b49-e7fc-4a63-a455-d275fc0bf1a8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c9d908f2-2846-4500-9ae0-1b4e5ef2b300" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_TradingSymbol_c9d908f2-2846-4500-9ae0-1b4e5ef2b300" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_edb57af5-1f90-4ab5-bb62-43feb8b27144" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_SecurityExchangeName_edb57af5-1f90-4ab5-bb62-43feb8b27144" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_20fc2a01-93a3-4f61-8152-689fc553eecb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_20fc2a01-93a3-4f61-8152-689fc553eecb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_9ff8b107-bce2-47cc-b870-45f0859176bc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityVoluntaryFilers_9ff8b107-bce2-47cc-b870-45f0859176bc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c15200a6-8e5e-42a7-9dbe-d72db7e618ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityCurrentReportingStatus_c15200a6-8e5e-42a7-9dbe-d72db7e618ed" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2b43ad70-5790-45ab-81ed-d952a63ec569" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityInteractiveDataCurrent_2b43ad70-5790-45ab-81ed-d952a63ec569" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a6d9df3d-d2c7-44ff-9521-115a2f3eb546" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityFilerCategory_a6d9df3d-d2c7-44ff-9521-115a2f3eb546" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_02c040ab-0ab8-446a-b892-c072efa1d9d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntitySmallBusiness_02c040ab-0ab8-446a-b892-c072efa1d9d6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eff582af-8407-4f58-9f97-3dce47c3387d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityEmergingGrowthCompany_eff582af-8407-4f58-9f97-3dce47c3387d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_ddcd5cdd-a27c-4c45-80e6-41381ee48e8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_IcfrAuditorAttestationFlag_ddcd5cdd-a27c-4c45-80e6-41381ee48e8a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_6d672cfb-2783-493d-b0b2-47f082413686" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_6d672cfb-2783-493d-b0b2-47f082413686" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_331e2177-d267-447a-80bb-45afbfa06cc7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityShellCompany_331e2177-d267-447a-80bb-45afbfa06cc7" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_102412b2-9f18-4cd3-96a3-fcc64b518faa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityPublicFloat_102412b2-9f18-4cd3-96a3-fcc64b518faa" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_937910bc-f845-41c7-94b7-68ec0db84200" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_937910bc-f845-41c7-94b7-68ec0db84200" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f7b6ef71-34e0-48ae-bda2-bf7c79d7a756" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f7b6ef71-34e0-48ae-bda2-bf7c79d7a756" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_27705019-beb0-4c90-80e1-a7df44b77e7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_AmendmentFlag_27705019-beb0-4c90-80e1-a7df44b77e7e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4009eea6-5449-4d9e-9fcb-7ff8fa61916f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentFiscalYearFocus_4009eea6-5449-4d9e-9fcb-7ff8fa61916f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f7e18eed-7c3c-4ddb-8e6b-14ff15759204" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f7e18eed-7c3c-4ddb-8e6b-14ff15759204" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_64a11978-0bc8-4dab-b8f0-64beb9aa92f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityCentralIndexKey_64a11978-0bc8-4dab-b8f0-64beb9aa92f4" xlink:type="arc" order="34"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ae0f316-3299-45d2-a9c9-923dcc1e5221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_StatementTable_4ae0f316-3299-45d2-a9c9-923dcc1e5221" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a079ac24-479f-4004-bcde-ed2fc5231d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4ae0f316-3299-45d2-a9c9-923dcc1e5221" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a079ac24-479f-4004-bcde-ed2fc5231d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a079ac24-479f-4004-bcde-ed2fc5231d8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a079ac24-479f-4004-bcde-ed2fc5231d8c" xlink:to="loc_us-gaap_ClassOfStockDomain_a079ac24-479f-4004-bcde-ed2fc5231d8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_85d49b86-1297-4f41-b1e8-80b7878cc055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a079ac24-479f-4004-bcde-ed2fc5231d8c" xlink:to="loc_us-gaap_ClassOfStockDomain_85d49b86-1297-4f41-b1e8-80b7878cc055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9507ed40-98f1-4d7b-874f-1b09c1214d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_85d49b86-1297-4f41-b1e8-80b7878cc055" xlink:to="loc_us-gaap_CommonClassAMember_9507ed40-98f1-4d7b-874f-1b09c1214d2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_e2b7c6b4-75fd-46d6-9d6c-0d3a79096630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_85d49b86-1297-4f41-b1e8-80b7878cc055" xlink:to="loc_us-gaap_CommonClassCMember_e2b7c6b4-75fd-46d6-9d6c-0d3a79096630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ba997bf-1f07-4bd8-9edd-1a0e3834baa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ba997bf-1f07-4bd8-9edd-1a0e3834baa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_af46f2b6-c0e6-4d8f-af0f-28ff365890c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_af46f2b6-c0e6-4d8f-af0f-28ff365890c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ef7d3cb3-3784-4805-af72-40670843838d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ef7d3cb3-3784-4805-af72-40670843838d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_97775efe-b959-40d2-b350-eda0c5a7dac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_97775efe-b959-40d2-b350-eda0c5a7dac1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a8bbdfbc-4f58-45ab-881c-d28a1758452c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_AssetsCurrent_a8bbdfbc-4f58-45ab-881c-d28a1758452c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e4d4c41-097f-414b-87f7-8f9063c2e99f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e4d4c41-097f-414b-87f7-8f9063c2e99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_27829250-196b-451c-98c0-bdf937b72c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_27829250-196b-451c-98c0-bdf937b72c19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_24a13e45-e37b-4f16-9dc0-0ac397a78d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_24a13e45-e37b-4f16-9dc0-0ac397a78d5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_f0166e5e-f693-4d4b-84c9-dce3e9a896c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:to="loc_us-gaap_AssetsNoncurrent_f0166e5e-f693-4d4b-84c9-dce3e9a896c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4efcc909-8201-462a-929b-c48bd7984ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_Assets_4efcc909-8201-462a-929b-c48bd7984ae6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TradeAndOtherPayablesCurrent_c5b7d97a-55c3-49f3-b002-be6801fdaca0" xlink:href="mnlk-20231231.xsd#mnlk_TradeAndOtherPayablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:to="loc_mnlk_TradeAndOtherPayablesCurrent_c5b7d97a-55c3-49f3-b002-be6801fdaca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f5b169c-9480-47dd-9249-522d501f706f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f5b169c-9480-47dd-9249-522d501f706f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4fd80066-a4d6-4d70-aa4f-4ec87c905c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4fd80066-a4d6-4d70-aa4f-4ec87c905c0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_34b7cff0-1000-4eed-a725-1799a9f391bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:to="loc_us-gaap_LiabilitiesCurrent_34b7cff0-1000-4eed-a725-1799a9f391bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da349f2e-2a25-4356-8a12-8c9b441567e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da349f2e-2a25-4356-8a12-8c9b441567e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0bc609bf-a390-41a0-85e7-7cf69cc7ff1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0bc609bf-a390-41a0-85e7-7cf69cc7ff1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fcd0510d-0dfb-43d0-9c2c-96a235d307e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_fcd0510d-0dfb-43d0-9c2c-96a235d307e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0953124b-3cff-487a-8296-1074c0ac3121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_Liabilities_0953124b-3cff-487a-8296-1074c0ac3121" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4b23d642-0cc0-4061-abca-a09a11794858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4b23d642-0cc0-4061-abca-a09a11794858" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a9b5e073-9c76-4ff2-ac4b-0226422892f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_CommonStockValue_a9b5e073-9c76-4ff2-ac4b-0226422892f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_07d311b1-1093-4ba6-8031-a8c90cd636be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_AdditionalPaidInCapital_07d311b1-1093-4ba6-8031-a8c90cd636be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e91fb5ff-33a3-4ba2-9cc9-8b59f44bd7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e91fb5ff-33a3-4ba2-9cc9-8b59f44bd7d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_074ce07d-9344-4abd-897a-03ba1e1afaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_074ce07d-9344-4abd-897a-03ba1e1afaa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_985d35d8-63d9-486f-88d6-cffc6c1275c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_StockholdersEquity_985d35d8-63d9-486f-88d6-cffc6c1275c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ecd4c4ad-b966-48f8-af53-5c3671b3dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_MinorityInterest_ecd4c4ad-b966-48f8-af53-5c3671b3dacf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_79773ee4-768d-4c9b-afb7-625b1a36ce28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_79773ee4-768d-4c9b-afb7-625b1a36ce28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c7289a9-01b4-4f93-8e95-6af69f3db30b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c7289a9-01b4-4f93-8e95-6af69f3db30b" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_396abef4-a1de-4684-bf79-6822cb09399f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_StatementTable_396abef4-a1de-4684-bf79-6822cb09399f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_870972b5-c978-415e-9ffa-31b307e520dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_396abef4-a1de-4684-bf79-6822cb09399f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_870972b5-c978-415e-9ffa-31b307e520dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_870972b5-c978-415e-9ffa-31b307e520dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_870972b5-c978-415e-9ffa-31b307e520dd" xlink:to="loc_us-gaap_ClassOfStockDomain_870972b5-c978-415e-9ffa-31b307e520dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b0581b7a-2668-418b-aa61-06aa0c33aa97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_870972b5-c978-415e-9ffa-31b307e520dd" xlink:to="loc_us-gaap_ClassOfStockDomain_b0581b7a-2668-418b-aa61-06aa0c33aa97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9a9d90ea-22ef-4ddc-b8c3-3f432f897af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b0581b7a-2668-418b-aa61-06aa0c33aa97" xlink:to="loc_us-gaap_CommonClassAMember_9a9d90ea-22ef-4ddc-b8c3-3f432f897af0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_c4e71266-fc3d-4d3e-ac58-8e219802ca28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b0581b7a-2668-418b-aa61-06aa0c33aa97" xlink:to="loc_us-gaap_CommonClassCMember_c4e71266-fc3d-4d3e-ac58-8e219802ca28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9bbb3524-60ac-410d-a0cb-8f8d7c2a2842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9bbb3524-60ac-410d-a0cb-8f8d7c2a2842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_865e9642-801b-4128-b52c-a2693b1c3aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_865e9642-801b-4128-b52c-a2693b1c3aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2fb5d100-a7d3-4437-a499-d2bf35b7f689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_CommonStockSharesIssued_2fb5d100-a7d3-4437-a499-d2bf35b7f689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b55575e4-3331-42a1-b8f9-10d1329bf4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b55575e4-3331-42a1-b8f9-10d1329bf4c9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_803df6fe-8cc2-43cd-baec-34ac3ce90f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_StatementTable_803df6fe-8cc2-43cd-baec-34ac3ce90f86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3800b995-c0cb-4e71-bf8f-32eb9e3144a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_803df6fe-8cc2-43cd-baec-34ac3ce90f86" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3800b995-c0cb-4e71-bf8f-32eb9e3144a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3800b995-c0cb-4e71-bf8f-32eb9e3144a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3800b995-c0cb-4e71-bf8f-32eb9e3144a8" xlink:to="loc_us-gaap_ClassOfStockDomain_3800b995-c0cb-4e71-bf8f-32eb9e3144a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ad03ee0-442a-477b-b182-0758f8a7e2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3800b995-c0cb-4e71-bf8f-32eb9e3144a8" xlink:to="loc_us-gaap_ClassOfStockDomain_9ad03ee0-442a-477b-b182-0758f8a7e2a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_fc49a007-287f-4f1e-b0ca-71615ba1dea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9ad03ee0-442a-477b-b182-0758f8a7e2a3" xlink:to="loc_us-gaap_CommonClassAMember_fc49a007-287f-4f1e-b0ca-71615ba1dea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e8727a89-946a-4e39-a4da-4a2c075df93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e8727a89-946a-4e39-a4da-4a2c075df93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_19f6c031-d085-41ff-b07b-9939296f7004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_19f6c031-d085-41ff-b07b-9939296f7004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_14cb8d46-2893-45ca-9762-a0c23b2791b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:to="loc_us-gaap_OperatingExpenses_14cb8d46-2893-45ca-9762-a0c23b2791b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_452edb57-7815-4587-91af-bff5a722eae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OperatingIncomeLoss_452edb57-7815-4587-91af-bff5a722eae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_34d6347f-7fff-49aa-abe5-e15a94493f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OtherNonoperatingIncome_34d6347f-7fff-49aa-abe5-e15a94493f31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_551f78c5-0fd9-4714-98a8-1e9a443f8634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_551f78c5-0fd9-4714-98a8-1e9a443f8634" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_032fe4a1-fe09-48f9-b5b2-71a2ba3fc345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_032fe4a1-fe09-48f9-b5b2-71a2ba3fc345" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c8d52fe2-646a-4c53-ae50-537d93be2c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_ProfitLoss_c8d52fe2-646a-4c53-ae50-537d93be2c87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1837b9ae-7f09-4f0f-ab9e-29dff9f92457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_NetIncomeLoss_1837b9ae-7f09-4f0f-ab9e-29dff9f92457" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5840eb5a-62e4-4475-9e85-09d74cb7f335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5840eb5a-62e4-4475-9e85-09d74cb7f335" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8b112ad7-b4c6-42e2-8102-7bda574aa634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8b112ad7-b4c6-42e2-8102-7bda574aa634" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_28a31212-f5b1-483f-bbe1-34ab017b7838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_28a31212-f5b1-483f-bbe1-34ab017b7838" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_75a83482-2a10-4f4a-99a2-2b4692417d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_75a83482-2a10-4f4a-99a2-2b4692417d50" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2879eae8-b1b5-4fcf-8189-663860ef7998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2879eae8-b1b5-4fcf-8189-663860ef7998" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_97c2135e-f2c2-4cae-b74b-402d1a3682c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_97c2135e-f2c2-4cae-b74b-402d1a3682c0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a8565ef2-7103-4f1b-9cd6-cc3bd96bb8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a8565ef2-7103-4f1b-9cd6-cc3bd96bb8e1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_841a5df3-5a81-4b79-9d86-ec55a870c838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_841a5df3-5a81-4b79-9d86-ec55a870c838" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2b7940b9-f773-46f3-8334-2becd8bd45c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2b7940b9-f773-46f3-8334-2becd8bd45c9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8fbd8944-3916-4074-9554-14b900d22f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8fbd8944-3916-4074-9554-14b900d22f02" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e563a96-ece1-4c1c-b63e-99a411481eef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e563a96-ece1-4c1c-b63e-99a411481eef" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b39f5b37-56a3-4f05-aa56-cbe0411e5057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b39f5b37-56a3-4f05-aa56-cbe0411e5057" xlink:to="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3ee37c72-b7da-4f70-8e5b-a690d3006331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3ee37c72-b7da-4f70-8e5b-a690d3006331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3ee37c72-b7da-4f70-8e5b-a690d3006331_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3ee37c72-b7da-4f70-8e5b-a690d3006331" xlink:to="loc_us-gaap_EquityComponentDomain_3ee37c72-b7da-4f70-8e5b-a690d3006331_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f1c64c4f-f232-4f5f-8057-1e4fa0099f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3ee37c72-b7da-4f70-8e5b-a690d3006331" xlink:to="loc_us-gaap_EquityComponentDomain_f1c64c4f-f232-4f5f-8057-1e4fa0099f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1c64c4f-f232-4f5f-8057-1e4fa0099f1d" xlink:to="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ee8c0046-531d-4761-992b-58f74a6f3475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_PreferredStockMember_ee8c0046-531d-4761-992b-58f74a6f3475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dfe43770-a964-4d21-a756-a4977000a98e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_CommonStockMember_dfe43770-a964-4d21-a756-a4977000a98e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_aa48c652-0a89-4a1e-9b24-1005c30a7fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_TreasuryStockCommonMember_aa48c652-0a89-4a1e-9b24-1005c30a7fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ca780546-3781-422a-a2ed-0d68730e3fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ca780546-3781-422a-a2ed-0d68730e3fc4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ea1164e3-cd74-45d4-9b01-a0b529756f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_RetainedEarningsMember_ea1164e3-cd74-45d4-9b01-a0b529756f8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcf1acd6-7463-4169-86cd-e5ffacd949ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcf1acd6-7463-4169-86cd-e5ffacd949ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_25c57b20-ef74-46d8-af70-3f49c95752b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1c64c4f-f232-4f5f-8057-1e4fa0099f1d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_25c57b20-ef74-46d8-af70-3f49c95752b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_a0f85242-01b1-4db0-bd90-c629b7f81da9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_srt_RestatementAxis_a0f85242-01b1-4db0-bd90-c629b7f81da9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_a0f85242-01b1-4db0-bd90-c629b7f81da9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_a0f85242-01b1-4db0-bd90-c629b7f81da9" xlink:to="loc_srt_RestatementDomain_a0f85242-01b1-4db0-bd90-c629b7f81da9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5b9cb120-4df6-4bc1-9861-bb62b47e5338" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_a0f85242-01b1-4db0-bd90-c629b7f81da9" xlink:to="loc_srt_RestatementDomain_5b9cb120-4df6-4bc1-9861-bb62b47e5338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_557326b1-bafd-4623-acf8-14f97a2410db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5b9cb120-4df6-4bc1-9861-bb62b47e5338" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_557326b1-bafd-4623-acf8-14f97a2410db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_42f7637f-47ca-4671-ac0b-0ef6e8543cc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5b9cb120-4df6-4bc1-9861-bb62b47e5338" xlink:to="loc_srt_RestatementAdjustmentMember_42f7637f-47ca-4671-ac0b-0ef6e8543cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c" xlink:to="loc_us-gaap_ClassOfStockDomain_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_899cc692-48b8-4268-a411-62bd14b2f629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c" xlink:to="loc_us-gaap_ClassOfStockDomain_899cc692-48b8-4268-a411-62bd14b2f629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_32dd9614-f82a-4f08-b4f5-a18e77242d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_899cc692-48b8-4268-a411-62bd14b2f629" xlink:to="loc_us-gaap_CommonClassAMember_32dd9614-f82a-4f08-b4f5-a18e77242d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_f3dca9cf-6376-4d77-a078-b80a6e73a1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_899cc692-48b8-4268-a411-62bd14b2f629" xlink:to="loc_us-gaap_CommonClassCMember_f3dca9cf-6376-4d77-a078-b80a6e73a1c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_28532529-8b7e-4c32-80d5-0ec5b348fbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_28532529-8b7e-4c32-80d5-0ec5b348fbbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_28532529-8b7e-4c32-80d5-0ec5b348fbbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_28532529-8b7e-4c32-80d5-0ec5b348fbbc" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_28532529-8b7e-4c32-80d5-0ec5b348fbbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_3afe17a0-ea65-4182-a5ce-d02cbd26314d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_28532529-8b7e-4c32-80d5-0ec5b348fbbc" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_3afe17a0-ea65-4182-a5ce-d02cbd26314d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionFollowingBusinessCombinationMember_7caa61cd-5d1a-42ea-ad10-886098b80e6f" xlink:href="mnlk-20231231.xsd#mnlk_ConversionFollowingBusinessCombinationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_3afe17a0-ea65-4182-a5ce-d02cbd26314d" xlink:to="loc_mnlk_ConversionFollowingBusinessCombinationMember_7caa61cd-5d1a-42ea-ad10-886098b80e6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionOfClassCIntoClassASharesMember_76c52911-5999-4c6e-b1fe-4847c53ae27f" xlink:href="mnlk-20231231.xsd#mnlk_ConversionOfClassCIntoClassASharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_3afe17a0-ea65-4182-a5ce-d02cbd26314d" xlink:to="loc_mnlk_ConversionOfClassCIntoClassASharesMember_76c52911-5999-4c6e-b1fe-4847c53ae27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b39f5b37-56a3-4f05-aa56-cbe0411e5057" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_aad830ed-8746-46d8-842b-709cd2806f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_aad830ed-8746-46d8-842b-709cd2806f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f11b4ed9-9b8a-4bad-aa0f-47805ab1572c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f11b4ed9-9b8a-4bad-aa0f-47805ab1572c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_199fab9e-68fa-4ada-9c32-23b17aacfc98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_199fab9e-68fa-4ada-9c32-23b17aacfc98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_06aeef25-4e30-4880-a890-595b213f8bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_06aeef25-4e30-4880-a890-595b213f8bf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization_e0f412de-354c-47da-90e3-92c3cf1ee2e0" xlink:href="mnlk-20231231.xsd#mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization_e0f412de-354c-47da-90e3-92c3cf1ee2e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8ac99893-73be-42d8-97df-1c9ccb8a31de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8ac99893-73be-42d8-97df-1c9ccb8a31de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_cbfce7ea-e7c4-4c4b-b45b-0fe2869eae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_cbfce7ea-e7c4-4c4b-b45b-0fe2869eae3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9659319a-1707-4f48-97ee-7edadad07a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9659319a-1707-4f48-97ee-7edadad07a37" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a821bb3b-553b-46f8-9440-d14101672282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a821bb3b-553b-46f8-9440-d14101672282" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement_4cf7e36b-a3b1-4276-8bae-f93c5e945be9" xlink:href="mnlk-20231231.xsd#mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement_4cf7e36b-a3b1-4276-8bae-f93c5e945be9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6609c863-f6a5-46c9-8fe2-bda90e2c4340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6609c863-f6a5-46c9-8fe2-bda90e2c4340" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_de9756e3-6086-48bd-b6cb-5a2a6dd0d789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_de9756e3-6086-48bd-b6cb-5a2a6dd0d789" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b6b1246-9f77-4b41-bb9c-75db893369c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_ProfitLoss_4b6b1246-9f77-4b41-bb9c-75db893369c0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_61fdd95a-af1f-4ae9-9c58-bbfc32f77ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_61fdd95a-af1f-4ae9-9c58-bbfc32f77ffc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a6f23566-84d8-481f-a7b1-b62b56d616f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a6f23566-84d8-481f-a7b1-b62b56d616f5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1e69d123-49e1-4034-a51a-1660827412fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1e69d123-49e1-4034-a51a-1660827412fe" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary_4110f4ee-70b6-41f3-a119-7a7bc75af419" xlink:href="mnlk-20231231.xsd#mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary_4110f4ee-70b6-41f3-a119-7a7bc75af419" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees_e3f42594-b4f2-45e0-878b-f9f32f07e2e2" xlink:href="mnlk-20231231.xsd#mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees_e3f42594-b4f2-45e0-878b-f9f32f07e2e2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3b5df86e-f354-4d54-a0e0-36efced6674b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ead4206e-1f02-4b3a-b9e5-156588d54c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4f8aae9b-2f74-413a-950b-7d406e3c4f43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_67b9ef25-b700-4674-8d1e-80dc8876a441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e4efb4b2-e5aa-45af-8bb0-edf0b0823681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e4efb4b2-e5aa-45af-8bb0-edf0b0823681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e4efb4b2-e5aa-45af-8bb0-edf0b0823681_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e4efb4b2-e5aa-45af-8bb0-edf0b0823681" xlink:to="loc_us-gaap_ClassOfStockDomain_e4efb4b2-e5aa-45af-8bb0-edf0b0823681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e4efb4b2-e5aa-45af-8bb0-edf0b0823681" xlink:to="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1daf355c-eeb8-4f59-b7c9-bb930b75ad12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1daf355c-eeb8-4f59-b7c9-bb930b75ad12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ClassVVotingStockMember_3d783152-cbe5-4917-909e-25bd23e2f21c" xlink:href="mnlk-20231231.xsd#mnlk_ClassVVotingStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_mnlk_ClassVVotingStockMember_3d783152-cbe5-4917-909e-25bd23e2f21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_49525f3c-c69f-476d-af32-4a332fae1d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_us-gaap_CommonClassBMember_49525f3c-c69f-476d-af32-4a332fae1d24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_433c4d98-0160-4de2-ab42-1fbfe2126926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_us-gaap_CommonClassAMember_433c4d98-0160-4de2-ab42-1fbfe2126926" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_7c2d4399-8145-47cc-b717-3b9418cd08d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_us-gaap_CommonClassCMember_7c2d4399-8145-47cc-b717-3b9418cd08d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1003dad3-ebea-423e-ae72-4dee9d28b482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1003dad3-ebea-423e-ae72-4dee9d28b482" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1003dad3-ebea-423e-ae72-4dee9d28b482_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1003dad3-ebea-423e-ae72-4dee9d28b482" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1003dad3-ebea-423e-ae72-4dee9d28b482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f15a5d2-3ef2-4ad3-93a4-ec2a41628898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1003dad3-ebea-423e-ae72-4dee9d28b482" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f15a5d2-3ef2-4ad3-93a4-ec2a41628898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PIPEInvestorsMember_16a40a7f-f14d-4bde-be39-ea1a5986cb2c" xlink:href="mnlk-20231231.xsd#mnlk_PIPEInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f15a5d2-3ef2-4ad3-93a4-ec2a41628898" xlink:to="loc_mnlk_PIPEInvestorsMember_16a40a7f-f14d-4bde-be39-ea1a5986cb2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_6f7f5716-26a1-488a-b0fa-fc5cab969913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f15a5d2-3ef2-4ad3-93a4-ec2a41628898" xlink:to="loc_us-gaap_PrivatePlacementMember_6f7f5716-26a1-488a-b0fa-fc5cab969913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ed1bc80b-16b1-42b9-906f-e566d8800368" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:to="loc_srt_CounterpartyNameAxis_ed1bc80b-16b1-42b9-906f-e566d8800368" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1bc80b-16b1-42b9-906f-e566d8800368_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ed1bc80b-16b1-42b9-906f-e566d8800368" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed1bc80b-16b1-42b9-906f-e566d8800368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4591a-9ab9-410a-8c31-f7d5e5decffa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ed1bc80b-16b1-42b9-906f-e566d8800368" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4591a-9ab9-410a-8c31-f7d5e5decffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PIPEInvestorsMember_28f7a1d8-ee16-464a-ab4d-d4bb7612b0d6" xlink:href="mnlk-20231231.xsd#mnlk_PIPEInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4591a-9ab9-410a-8c31-f7d5e5decffa" xlink:to="loc_mnlk_PIPEInvestorsMember_28f7a1d8-ee16-464a-ab4d-d4bb7612b0d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationNet_cc353640-b003-4ed8-9b87-6da8d9875922" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_ReverseRecapitalizationNet_cc353640-b003-4ed8-9b87-6da8d9875922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_896d650f-3471-4010-9a77-ff7a73f03fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_896d650f-3471-4010-9a77-ff7a73f03fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e825e39f-2e76-43ea-be9a-13aee7751b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e825e39f-2e76-43ea-be9a-13aee7751b5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_721936b4-723d-4e61-8498-f6fc0ecee1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_721936b4-723d-4e61-8498-f6fc0ecee1f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockVotesMultiplier_aa260f56-e69c-4d32-a24c-003806e7fb33" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockVotesMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_CommonStockVotesMultiplier_aa260f56-e69c-4d32-a24c-003806e7fb33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_8ea1f268-1ca0-46ea-afc8-f336200f358a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_8ea1f268-1ca0-46ea-afc8-f336200f358a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockConversionRatio_ccc54969-be04-4524-b1f4-38dd9bef18c4" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_CommonStockConversionRatio_ccc54969-be04-4524-b1f4-38dd9bef18c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_0fd851a3-15ef-457c-9c00-0baeb1059ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_0fd851a3-15ef-457c-9c00-0baeb1059ff3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1e12558b-d68a-4a6d-99fe-2b3b15090aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1e12558b-d68a-4a6d-99fe-2b3b15090aab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockConvertedReverseRecapitalization_2e9a6e5e-f4e2-4638-bc90-1c248c55da68" xlink:href="mnlk-20231231.xsd#mnlk_StockConvertedReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_StockConvertedReverseRecapitalization_2e9a6e5e-f4e2-4638-bc90-1c248c55da68" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_663627ea-752e-4eac-8541-7d595106fdce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_663627ea-752e-4eac-8541-7d595106fdce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_aa837057-ea9f-485a-9b55-0650f02c41a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_aa837057-ea9f-485a-9b55-0650f02c41a2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f2f1c35-1478-4bed-b67e-841e6de8a938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f2f1c35-1478-4bed-b67e-841e6de8a938" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_692f6336-966e-4145-8f6e-b19b9d8ed11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_692f6336-966e-4145-8f6e-b19b9d8ed11f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed_1ac44499-4a1f-4d83-b29f-ac143d66ff49" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed_1ac44499-4a1f-4d83-b29f-ac143d66ff49" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:to="loc_dei_LegalEntityAxis_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a" xlink:to="loc_dei_EntityDomain_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f4c9b682-6796-4bbd-9a32-9acae844a6b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a" xlink:to="loc_dei_EntityDomain_f4c9b682-6796-4bbd-9a32-9acae844a6b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_HelixAcquisitionCorpMember_c9eeae02-2e77-4390-a055-27d9b16f88c9" xlink:href="mnlk-20231231.xsd#mnlk_HelixAcquisitionCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f4c9b682-6796-4bbd-9a32-9acae844a6b6" xlink:to="loc_mnlk_HelixAcquisitionCorpMember_c9eeae02-2e77-4390-a055-27d9b16f88c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b88621b5-2e03-40da-a423-36487a956416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b88621b5-2e03-40da-a423-36487a956416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b88621b5-2e03-40da-a423-36487a956416_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b88621b5-2e03-40da-a423-36487a956416" xlink:to="loc_us-gaap_ClassOfStockDomain_b88621b5-2e03-40da-a423-36487a956416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b88621b5-2e03-40da-a423-36487a956416" xlink:to="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_a589dd91-72ab-4988-9188-63ceeccb7edb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:to="loc_us-gaap_PrivatePlacementMember_a589dd91-72ab-4988-9188-63ceeccb7edb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_164ba37d-d542-4e68-9d16-3b01020d03ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:to="loc_us-gaap_CommonClassAMember_164ba37d-d542-4e68-9d16-3b01020d03ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonClassAPrivatePlacementMember_2affab67-6a3e-454a-8beb-24703a8cf5d8" xlink:href="mnlk-20231231.xsd#mnlk_CommonClassAPrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonClassAMember_164ba37d-d542-4e68-9d16-3b01020d03ae" xlink:to="loc_mnlk_CommonClassAPrivatePlacementMember_2affab67-6a3e-454a-8beb-24703a8cf5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonClassARedeemableMember_cb09a1b0-3c38-4623-a296-7e427c377130" xlink:href="mnlk-20231231.xsd#mnlk_CommonClassARedeemableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonClassAMember_164ba37d-d542-4e68-9d16-3b01020d03ae" xlink:to="loc_mnlk_CommonClassARedeemableMember_cb09a1b0-3c38-4623-a296-7e427c377130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_851fb1fe-6437-42af-84f7-66705294a574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:to="loc_us-gaap_CommonClassBMember_851fb1fe-6437-42af-84f7-66705294a574" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_0a1b4b1f-abe5-464c-8565-e075a41fdaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:to="loc_us-gaap_CommonClassCMember_0a1b4b1f-abe5-464c-8565-e075a41fdaf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2ef11ec6-bc66-4803-9d1c-64b7f9339ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2ef11ec6-bc66-4803-9d1c-64b7f9339ebe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ed8835fc-eaec-4dfc-b781-cabfd54a7ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ed8835fc-eaec-4dfc-b781-cabfd54a7ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a1ea807c-20b8-47c6-b33a-b1ce22ee33c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a1ea807c-20b8-47c6-b33a-b1ce22ee33c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_825a35d4-41ee-4ee8-aa1c-daa67dbae659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_825a35d4-41ee-4ee8-aa1c-daa67dbae659" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization_69129f80-a0ab-4898-935b-b0a277ab4776" xlink:href="mnlk-20231231.xsd#mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization_69129f80-a0ab-4898-935b-b0a277ab4776" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockConvertedReverseRecapitalization_037d9a7b-2de4-4c6a-844b-c75fe5aa1441" xlink:href="mnlk-20231231.xsd#mnlk_StockConvertedReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_mnlk_StockConvertedReverseRecapitalization_037d9a7b-2de4-4c6a-844b-c75fe5aa1441" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BasisofPresentationandSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a5c025a2-14a9-4127-96a6-30f920d5794d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a5c025a2-14a9-4127-96a6-30f920d5794d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a5c025a2-14a9-4127-96a6-30f920d5794d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a5c025a2-14a9-4127-96a6-30f920d5794d" xlink:to="loc_us-gaap_ClassOfStockDomain_a5c025a2-14a9-4127-96a6-30f920d5794d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_770d97b5-7a6b-4de2-b114-2ca24dac016c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a5c025a2-14a9-4127-96a6-30f920d5794d" xlink:to="loc_us-gaap_ClassOfStockDomain_770d97b5-7a6b-4de2-b114-2ca24dac016c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_30d00f00-2c7b-4a88-9651-66c27525a1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_770d97b5-7a6b-4de2-b114-2ca24dac016c" xlink:to="loc_us-gaap_CommonClassAMember_30d00f00-2c7b-4a88-9651-66c27525a1ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_eb0c7bb4-88d9-4efd-aa13-8d235d7c7458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_770d97b5-7a6b-4de2-b114-2ca24dac016c" xlink:to="loc_us-gaap_CommonClassCMember_eb0c7bb4-88d9-4efd-aa13-8d235d7c7458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_114ae073-c485-4b1b-9275-399c05a8af9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:to="loc_srt_RangeAxis_114ae073-c485-4b1b-9275-399c05a8af9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_114ae073-c485-4b1b-9275-399c05a8af9c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_114ae073-c485-4b1b-9275-399c05a8af9c" xlink:to="loc_srt_RangeMember_114ae073-c485-4b1b-9275-399c05a8af9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6426416-89bd-44fd-afa5-9360ae5b1b92" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_114ae073-c485-4b1b-9275-399c05a8af9c" xlink:to="loc_srt_RangeMember_a6426416-89bd-44fd-afa5-9360ae5b1b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ef41746-e7ee-4c96-a4e5-dce0df312516" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6426416-89bd-44fd-afa5-9360ae5b1b92" xlink:to="loc_srt_MinimumMember_8ef41746-e7ee-4c96-a4e5-dce0df312516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab9cd08f-cb24-4574-bc2f-aefe7a12921b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6426416-89bd-44fd-afa5-9360ae5b1b92" xlink:to="loc_srt_MaximumMember_ab9cd08f-cb24-4574-bc2f-aefe7a12921b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_694f0572-bd9b-4df2-a0d7-ff3ce6411498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_694f0572-bd9b-4df2-a0d7-ff3ce6411498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_694f0572-bd9b-4df2-a0d7-ff3ce6411498_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_694f0572-bd9b-4df2-a0d7-ff3ce6411498" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_694f0572-bd9b-4df2-a0d7-ff3ce6411498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94b5337e-7c3b-4d31-9c36-746e3ccb491e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_694f0572-bd9b-4df2-a0d7-ff3ce6411498" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94b5337e-7c3b-4d31-9c36-746e3ccb491e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_25482f2b-1a1f-4858-956d-def88f75c4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94b5337e-7c3b-4d31-9c36-746e3ccb491e" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_25482f2b-1a1f-4858-956d-def88f75c4bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RecapitalizationExchangeRatio_00a7dcc9-9ce7-4cf6-8d1e-8acb8a96fadd" xlink:href="mnlk-20231231.xsd#mnlk_RecapitalizationExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_mnlk_RecapitalizationExchangeRatio_00a7dcc9-9ce7-4cf6-8d1e-8acb8a96fadd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_501e8f9f-4016-4039-b6b9-bba15caae740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_501e8f9f-4016-4039-b6b9-bba15caae740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8efb3974-6547-4f4c-8d55-822489d094e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8efb3974-6547-4f4c-8d55-822489d094e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_de7e2cdd-b270-4ac9-8c84-407734d2e387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_de7e2cdd-b270-4ac9-8c84-407734d2e387" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_63a0b148-8a77-47ae-bc8a-5f39e50c5332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_63a0b148-8a77-47ae-bc8a-5f39e50c5332" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_8b136c04-f156-4154-a010-fa0e8b8ecb75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_8b136c04-f156-4154-a010-fa0e8b8ecb75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NumberOfOperatingLeases_c4dd9b82-da29-4726-8411-e99147c87ddf" xlink:href="mnlk-20231231.xsd#mnlk_NumberOfOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_mnlk_NumberOfOperatingLeases_c4dd9b82-da29-4726-8411-e99147c87ddf" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_949bec74-8f5b-4588-87d1-90fb0ac3d0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_949bec74-8f5b-4588-87d1-90fb0ac3d0e7" xlink:to="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ef95151-a6dd-475e-93d1-ca7f59a1f396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ef95151-a6dd-475e-93d1-ca7f59a1f396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ef95151-a6dd-475e-93d1-ca7f59a1f396_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ef95151-a6dd-475e-93d1-ca7f59a1f396" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ef95151-a6dd-475e-93d1-ca7f59a1f396_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ef77a36-98f6-40bd-8964-4ebec32ec40b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ef95151-a6dd-475e-93d1-ca7f59a1f396" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ef77a36-98f6-40bd-8964-4ebec32ec40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e9a7fdde-31df-4e7b-822f-1f2f4ca4c524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ef77a36-98f6-40bd-8964-4ebec32ec40b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e9a7fdde-31df-4e7b-822f-1f2f4ca4c524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_107c4a38-7970-49a3-9f7f-7fbcdfee55c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:to="loc_us-gaap_FinancialInstrumentAxis_107c4a38-7970-49a3-9f7f-7fbcdfee55c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_107c4a38-7970-49a3-9f7f-7fbcdfee55c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_107c4a38-7970-49a3-9f7f-7fbcdfee55c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_107c4a38-7970-49a3-9f7f-7fbcdfee55c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75865f12-e52c-4412-bc1b-e4f0274f3a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_107c4a38-7970-49a3-9f7f-7fbcdfee55c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75865f12-e52c-4412-bc1b-e4f0274f3a59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a1667d92-a48c-4102-9051-2f1cf4719899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75865f12-e52c-4412-bc1b-e4f0274f3a59" xlink:to="loc_us-gaap_CommercialPaperMember_a1667d92-a48c-4102-9051-2f1cf4719899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ad4207ac-23ad-4d6c-ac71-e34f5609a9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75865f12-e52c-4412-bc1b-e4f0274f3a59" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ad4207ac-23ad-4d6c-ac71-e34f5609a9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b0be0ed4-b616-45ca-b37e-401796ad0ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_949bec74-8f5b-4588-87d1-90fb0ac3d0e7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b0be0ed4-b616-45ca-b37e-401796ad0ad1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b11d98a5-ea61-4223-9a34-82bac2c94b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_949bec74-8f5b-4588-87d1-90fb0ac3d0e7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b11d98a5-ea61-4223-9a34-82bac2c94b62" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_97e0faca-f349-4049-96f7-7a34b3f06ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:to="loc_us-gaap_FinancialInstrumentAxis_97e0faca-f349-4049-96f7-7a34b3f06ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97e0faca-f349-4049-96f7-7a34b3f06ecb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97e0faca-f349-4049-96f7-7a34b3f06ecb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97e0faca-f349-4049-96f7-7a34b3f06ecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9ac6536-6afa-4aab-8f0d-217af1d2d697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97e0faca-f349-4049-96f7-7a34b3f06ecb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9ac6536-6afa-4aab-8f0d-217af1d2d697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5be71cc9-9ccf-4d36-95bb-6c045ade8074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9ac6536-6afa-4aab-8f0d-217af1d2d697" xlink:to="loc_us-gaap_CommercialPaperMember_5be71cc9-9ccf-4d36-95bb-6c045ade8074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f44fac7b-c5eb-4e44-8964-03cb087eb53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9ac6536-6afa-4aab-8f0d-217af1d2d697" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f44fac7b-c5eb-4e44-8964-03cb087eb53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_219ce96a-2674-4c63-b784-c808b8937298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_219ce96a-2674-4c63-b784-c808b8937298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_219ce96a-2674-4c63-b784-c808b8937298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_219ce96a-2674-4c63-b784-c808b8937298" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_219ce96a-2674-4c63-b784-c808b8937298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d5d90521-eeb3-47ee-a36d-1ffa03e062f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_219ce96a-2674-4c63-b784-c808b8937298" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d5d90521-eeb3-47ee-a36d-1ffa03e062f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6c9f3f79-71a4-4adc-a156-c916d45b696e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d5d90521-eeb3-47ee-a36d-1ffa03e062f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6c9f3f79-71a4-4adc-a156-c916d45b696e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_095e43c0-e7cb-4c4e-93bc-e263ae18117f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d5d90521-eeb3-47ee-a36d-1ffa03e062f7" xlink:to="loc_us-gaap_DebtSecuritiesMember_095e43c0-e7cb-4c4e-93bc-e263ae18117f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b5997064-68dc-4d1b-b95d-517073a3aa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b5997064-68dc-4d1b-b95d-517073a3aa5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f44bf770-380c-45e5-95a6-4946a5cc0f58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f44bf770-380c-45e5-95a6-4946a5cc0f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dda2891b-47d8-4a25-8fa7-0c2ecd2400ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dda2891b-47d8-4a25-8fa7-0c2ecd2400ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_195b53f8-7682-4098-a513-f9a172395a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_195b53f8-7682-4098-a513-f9a172395a8a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/InvestmentsFVchangesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#InvestmentsFVchangesDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/InvestmentsFVchangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e81f1ebc-ad46-4646-b0c9-60644c8fe162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_74910250-dcaf-43d1-a81c-999c4a4495df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e81f1ebc-ad46-4646-b0c9-60644c8fe162" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_74910250-dcaf-43d1-a81c-999c4a4495df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbb4e0d2-4838-4732-98ed-d22806a91825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_74910250-dcaf-43d1-a81c-999c4a4495df" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbb4e0d2-4838-4732-98ed-d22806a91825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbb4e0d2-4838-4732-98ed-d22806a91825_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbb4e0d2-4838-4732-98ed-d22806a91825" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbb4e0d2-4838-4732-98ed-d22806a91825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6da9d64d-60cc-441a-a8c8-aa667a6cd80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbb4e0d2-4838-4732-98ed-d22806a91825" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6da9d64d-60cc-441a-a8c8-aa667a6cd80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fddd3401-eca4-4a67-b99c-84c958ec3e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6da9d64d-60cc-441a-a8c8-aa667a6cd80b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fddd3401-eca4-4a67-b99c-84c958ec3e3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:href="mnlk-20231231.xsd#mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e81f1ebc-ad46-4646-b0c9-60644c8fe162" xlink:to="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_5b10973e-6546-442e-af34-080f90739fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_5b10973e-6546-442e-af34-080f90739fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5effdcff-765b-4c4c-a289-3bb99cd56925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5effdcff-765b-4c4c-a289-3bb99cd56925" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax_311272bd-3be4-418d-9795-fe95775ba8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax_311272bd-3be4-418d-9795-fe95775ba8cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_dd1e1647-c639-4d1e-a1f6-18f7362a69b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ab88f92f-bddb-49fb-9b44-b542c47ae4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ab88f92f-bddb-49fb-9b44-b542c47ae4eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e531f9ee-a769-4ff1-909a-a540732e7a99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ab88f92f-bddb-49fb-9b44-b542c47ae4eb" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e531f9ee-a769-4ff1-909a-a540732e7a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_e531f9ee-a769-4ff1-909a-a540732e7a99_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e531f9ee-a769-4ff1-909a-a540732e7a99" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_e531f9ee-a769-4ff1-909a-a540732e7a99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e531f9ee-a769-4ff1-909a-a540732e7a99" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OfficeLeaseMember_b2b58652-f0e4-4ff2-926b-719c75c9249f" xlink:href="mnlk-20231231.xsd#mnlk_OfficeLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:to="loc_mnlk_OfficeLeaseMember_b2b58652-f0e4-4ff2-926b-719c75c9249f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PortoOfficeMember_efdd5cf9-ffbc-4ad0-ba2d-eacfc7ce5eb9" xlink:href="mnlk-20231231.xsd#mnlk_PortoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:to="loc_mnlk_PortoOfficeMember_efdd5cf9-ffbc-4ad0-ba2d-eacfc7ce5eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CambridgeOfficeMember_88ae4eb8-ef54-48dc-a087-110b2cc12dec" xlink:href="mnlk-20231231.xsd#mnlk_CambridgeOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:to="loc_mnlk_CambridgeOfficeMember_88ae4eb8-ef54-48dc-a087-110b2cc12dec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLeaseAreaOfLeasedSpace_09037f67-28b6-4512-843f-c9b002e69c29" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLeaseAreaOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_mnlk_OperatingLeaseAreaOfLeasedSpace_09037f67-28b6-4512-843f-c9b002e69c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_92074990-0e0a-430d-9db0-6703d6f130d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_92074990-0e0a-430d-9db0-6703d6f130d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions_af3266a4-593d-416a-ac8c-53961497bb73" xlink:href="mnlk-20231231.xsd#mnlk_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions_af3266a4-593d-416a-ac8c-53961497bb73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6af0acd0-c0eb-4b59-9d17-3f7eb476bc24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6af0acd0-c0eb-4b59-9d17-3f7eb476bc24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_ae46a244-03b2-4e75-b2f4-a781cf64c0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_us-gaap_OperatingLeaseExpense_ae46a244-03b2-4e75-b2f4-a781cf64c0f7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansAllocationPercentageDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems_578f13fc-a668-4e30-8b86-95def08c0a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_2c00f7ff-1442-4df6-ab07-542311600675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems_578f13fc-a668-4e30-8b86-95def08c0a2e" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_2c00f7ff-1442-4df6-ab07-542311600675" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5d1c0273-9bca-4e32-999a-5685d6921141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_2c00f7ff-1442-4df6-ab07-542311600675" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5d1c0273-9bca-4e32-999a-5685d6921141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_5d1c0273-9bca-4e32-999a-5685d6921141_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5d1c0273-9bca-4e32-999a-5685d6921141" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_5d1c0273-9bca-4e32-999a-5685d6921141_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5d1c0273-9bca-4e32-999a-5685d6921141" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_dc590775-bbfc-48c7-b4d5-27d657c40af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_dc590775-bbfc-48c7-b4d5-27d657c40af7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanBondMember_4a5f7cd8-4a7d-4445-a4f8-b35a50c82722" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_mnlk_DefinedBenefitPlanBondMember_4a5f7cd8-4a7d-4445-a4f8-b35a50c82722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_f2889209-d54a-4669-a0e6-6a5a362251ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_f2889209-d54a-4669-a0e6-6a5a362251ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanLiquidityMember_10b16523-b46a-4037-a139-797bced42c38" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanLiquidityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_mnlk_DefinedBenefitPlanLiquidityMember_10b16523-b46a-4037-a139-797bced42c38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_6019d01c-b788-4b82-a1a2-f262aa834f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_6019d01c-b788-4b82-a1a2-f262aa834f6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_4ac4eae3-e2ad-47f4-ab8c-8ee76b13cf53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_us-gaap_OtherInvestmentsMember_4ac4eae3-e2ad-47f4-ab8c-8ee76b13cf53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanInfrastructureMember_9921a914-58a8-49d1-9213-5e8e3ae0c6c3" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanInfrastructureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_mnlk_DefinedBenefitPlanInfrastructureMember_9921a914-58a8-49d1-9213-5e8e3ae0c6c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_8612671c-3435-461b-83f0-5e142ad0b39c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems_578f13fc-a668-4e30-8b86-95def08c0a2e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_8612671c-3435-461b-83f0-5e142ad0b39c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_00cb033e-61d2-4a4a-960d-c6e4c0332b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_00cb033e-61d2-4a4a-960d-c6e4c0332b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_00cb033e-61d2-4a4a-960d-c6e4c0332b46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_00cb033e-61d2-4a4a-960d-c6e4c0332b46" xlink:to="loc_us-gaap_EquityComponentDomain_00cb033e-61d2-4a4a-960d-c6e4c0332b46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1ab5deee-9d93-46d4-a644-f5e0569a904b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_00cb033e-61d2-4a4a-960d-c6e4c0332b46" xlink:to="loc_us-gaap_EquityComponentDomain_1ab5deee-9d93-46d4-a644-f5e0569a904b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_53ff95d7-730a-40da-8663-407c5234a810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ab5deee-9d93-46d4-a644-f5e0569a904b" xlink:to="loc_us-gaap_CommonStockMember_53ff95d7-730a-40da-8663-407c5234a810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ac6749d8-201e-48cb-9691-459eb25e3066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ac6749d8-201e-48cb-9691-459eb25e3066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac6749d8-201e-48cb-9691-459eb25e3066_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ac6749d8-201e-48cb-9691-459eb25e3066" xlink:to="loc_us-gaap_ClassOfStockDomain_ac6749d8-201e-48cb-9691-459eb25e3066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_99628cc1-45bb-4dec-aed9-bf0d764d28f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ac6749d8-201e-48cb-9691-459eb25e3066" xlink:to="loc_us-gaap_ClassOfStockDomain_99628cc1-45bb-4dec-aed9-bf0d764d28f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e0611f1b-4d83-496f-8290-cfe66a5c026f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_99628cc1-45bb-4dec-aed9-bf0d764d28f0" xlink:to="loc_us-gaap_CommonClassAMember_e0611f1b-4d83-496f-8290-cfe66a5c026f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_cb85daf3-d928-46cf-ab7e-a4f70559d3df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_99628cc1-45bb-4dec-aed9-bf0d764d28f0" xlink:to="loc_us-gaap_CommonClassCMember_cb85daf3-d928-46cf-ab7e-a4f70559d3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_655d181f-f8c3-4395-aa3e-577a5cb4717c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_655d181f-f8c3-4395-aa3e-577a5cb4717c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_655d181f-f8c3-4395-aa3e-577a5cb4717c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_655d181f-f8c3-4395-aa3e-577a5cb4717c" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_655d181f-f8c3-4395-aa3e-577a5cb4717c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_9b28a0cc-fad0-4f86-ab59-d334d5407234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_655d181f-f8c3-4395-aa3e-577a5cb4717c" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_9b28a0cc-fad0-4f86-ab59-d334d5407234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionOfClassCIntoClassAMember_0aa829c5-57bf-4913-ace5-a56eadb55524" xlink:href="mnlk-20231231.xsd#mnlk_ConversionOfClassCIntoClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_9b28a0cc-fad0-4f86-ab59-d334d5407234" xlink:to="loc_mnlk_ConversionOfClassCIntoClassAMember_0aa829c5-57bf-4913-ace5-a56eadb55524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:to="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a83db472-16ec-4f44-84c5-749e2fcf8410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a83db472-16ec-4f44-84c5-749e2fcf8410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5820b3f3-59b6-4970-ab4d-be0cddcb7b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_CommonStockSharesIssued_5820b3f3-59b6-4970-ab4d-be0cddcb7b9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa1e9119-14f3-48f8-bda1-13d94f2db2db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa1e9119-14f3-48f8-bda1-13d94f2db2db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0aba1d45-a1ad-4ed3-b847-fc56cf688207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0aba1d45-a1ad-4ed3-b847-fc56cf688207" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8ba59655-f2ab-4885-9020-d9f6f4745b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_91871083-2106-49a3-a6b5-c943304d536d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:href="mnlk-20231231.xsd#mnlk_TotalSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:to="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SharesAuthorized_765699bf-669d-402c-a9b7-3e845377922a" xlink:href="mnlk-20231231.xsd#mnlk_SharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:to="loc_mnlk_SharesAuthorized_765699bf-669d-402c-a9b7-3e845377922a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8a330f50-7419-4081-85b3-8dbc3fc07a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:to="loc_us-gaap_SharesIssued_8a330f50-7419-4081-85b3-8dbc3fc07a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_00b98874-d9a8-46d9-90c1-8d1ad7fd7e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SharesAuthorized_9a9af908-63ca-4da1-bd58-fb4c0ce4f457" xlink:href="mnlk-20231231.xsd#mnlk_SharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_00f0b61e-85d0-4070-9c5c-a50153601a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_df4c96c9-9156-4cd2-84de-7eb24044c951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_df4c96c9-9156-4cd2-84de-7eb24044c951" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#ShareholdersEquityDeficitNarrativeDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2" xlink:to="loc_us-gaap_ClassOfStockDomain_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_201b24b7-50c5-4cc3-a7b0-b8434a044330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2" xlink:to="loc_us-gaap_ClassOfStockDomain_201b24b7-50c5-4cc3-a7b0-b8434a044330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_be0f387c-4c5a-4b8e-8e5b-9beefb69c672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201b24b7-50c5-4cc3-a7b0-b8434a044330" xlink:to="loc_us-gaap_CommonClassAMember_be0f387c-4c5a-4b8e-8e5b-9beefb69c672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_ada1b22c-3994-4289-9eef-dc0af0769399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201b24b7-50c5-4cc3-a7b0-b8434a044330" xlink:to="loc_us-gaap_CommonClassCMember_ada1b22c-3994-4289-9eef-dc0af0769399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5e4f13ec-fa2a-441b-9863-4732d7b67944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5e4f13ec-fa2a-441b-9863-4732d7b67944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e4f13ec-fa2a-441b-9863-4732d7b67944_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e4f13ec-fa2a-441b-9863-4732d7b67944" xlink:to="loc_us-gaap_EquityComponentDomain_5e4f13ec-fa2a-441b-9863-4732d7b67944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4f1056df-b059-4d92-9481-8759070c2034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e4f13ec-fa2a-441b-9863-4732d7b67944" xlink:to="loc_us-gaap_EquityComponentDomain_4f1056df-b059-4d92-9481-8759070c2034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b2303cba-9538-4957-acc9-49bd913bc2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4f1056df-b059-4d92-9481-8759070c2034" xlink:to="loc_us-gaap_CommonStockMember_b2303cba-9538-4957-acc9-49bd913bc2c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b189b683-330d-443c-8b46-f1201dd2a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_AwardTypeAxis_b189b683-330d-443c-8b46-f1201dd2a7b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b189b683-330d-443c-8b46-f1201dd2a7b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b189b683-330d-443c-8b46-f1201dd2a7b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b189b683-330d-443c-8b46-f1201dd2a7b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e45ee91-f09b-44d5-a22d-6059f82a81e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b189b683-330d-443c-8b46-f1201dd2a7b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e45ee91-f09b-44d5-a22d-6059f82a81e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ATMSharesMember_7854d71d-5767-447c-ac84-1413cd9bd7c0" xlink:href="mnlk-20231231.xsd#mnlk_ATMSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e45ee91-f09b-44d5-a22d-6059f82a81e3" xlink:to="loc_mnlk_ATMSharesMember_7854d71d-5767-447c-ac84-1413cd9bd7c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_94612f9d-feda-4b12-aa3b-7473b5735482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_PlanNameAxis_94612f9d-feda-4b12-aa3b-7473b5735482" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_94612f9d-feda-4b12-aa3b-7473b5735482_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_94612f9d-feda-4b12-aa3b-7473b5735482" xlink:to="loc_us-gaap_PlanNameDomain_94612f9d-feda-4b12-aa3b-7473b5735482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be32170c-a08d-489a-ad82-e8ef882f7bff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_94612f9d-feda-4b12-aa3b-7473b5735482" xlink:to="loc_us-gaap_PlanNameDomain_be32170c-a08d-489a-ad82-e8ef882f7bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_May2023SalesAgreementMember_2dd1c5f4-af13-4012-97d6-2a7ee385662e" xlink:href="mnlk-20231231.xsd#mnlk_May2023SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_be32170c-a08d-489a-ad82-e8ef882f7bff" xlink:to="loc_mnlk_May2023SalesAgreementMember_2dd1c5f4-af13-4012-97d6-2a7ee385662e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_August2023SalesAgreementMember_c3c27beb-2e77-46c7-8cbe-ddefb1ddff6f" xlink:href="mnlk-20231231.xsd#mnlk_August2023SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_be32170c-a08d-489a-ad82-e8ef882f7bff" xlink:to="loc_mnlk_August2023SalesAgreementMember_c3c27beb-2e77-46c7-8cbe-ddefb1ddff6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9f27694c-7858-43d9-8258-b1a1caafaea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9f27694c-7858-43d9-8258-b1a1caafaea7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9f27694c-7858-43d9-8258-b1a1caafaea7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9f27694c-7858-43d9-8258-b1a1caafaea7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9f27694c-7858-43d9-8258-b1a1caafaea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9f27694c-7858-43d9-8258-b1a1caafaea7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_UnderwritingAgreementMember_4a36ce20-a385-4b9c-bffe-ad6ed3c5871a" xlink:href="mnlk-20231231.xsd#mnlk_UnderwritingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:to="loc_mnlk_UnderwritingAgreementMember_4a36ce20-a385-4b9c-bffe-ad6ed3c5871a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a21dcb2f-17a3-4b77-9237-a26355305db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a21dcb2f-17a3-4b77-9237-a26355305db0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_May2023SalesAgreementMember_fdeb7b5b-27d2-4ac0-8abc-f7d2bc28012b" xlink:href="mnlk-20231231.xsd#mnlk_May2023SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:to="loc_mnlk_May2023SalesAgreementMember_fdeb7b5b-27d2-4ac0-8abc-f7d2bc28012b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad15a2e2-6604-4d1a-a1bd-076f79e96902" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_srt_CounterpartyNameAxis_ad15a2e2-6604-4d1a-a1bd-076f79e96902" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad15a2e2-6604-4d1a-a1bd-076f79e96902_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ad15a2e2-6604-4d1a-a1bd-076f79e96902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad15a2e2-6604-4d1a-a1bd-076f79e96902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d8829a2-78e5-436a-b829-587714995a3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ad15a2e2-6604-4d1a-a1bd-076f79e96902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d8829a2-78e5-436a-b829-587714995a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MoonLakeImmunotherapeuticsMember_e5a79015-37b0-4a02-8d7a-7f8f9ac664da" xlink:href="mnlk-20231231.xsd#mnlk_MoonLakeImmunotherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d8829a2-78e5-436a-b829-587714995a3c" xlink:to="loc_mnlk_MoonLakeImmunotherapeuticsMember_e5a79015-37b0-4a02-8d7a-7f8f9ac664da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_059f9d35-be4b-413c-9f7b-001a1e8e7275" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_dei_LegalEntityAxis_059f9d35-be4b-413c-9f7b-001a1e8e7275" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_059f9d35-be4b-413c-9f7b-001a1e8e7275_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_059f9d35-be4b-413c-9f7b-001a1e8e7275" xlink:to="loc_dei_EntityDomain_059f9d35-be4b-413c-9f7b-001a1e8e7275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b86c8f10-918d-498a-9930-368511c66382" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_059f9d35-be4b-413c-9f7b-001a1e8e7275" xlink:to="loc_dei_EntityDomain_b86c8f10-918d-498a-9930-368511c66382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MoonLakeAGMember_00b91a65-edf0-4a82-9c2d-3f09e00c9766" xlink:href="mnlk-20231231.xsd#mnlk_MoonLakeAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b86c8f10-918d-498a-9930-368511c66382" xlink:to="loc_mnlk_MoonLakeAGMember_00b91a65-edf0-4a82-9c2d-3f09e00c9766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1dd43b01-06d0-4519-ac9d-ed6b5faf5a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_CommonStockSharesIssued_1dd43b01-06d0-4519-ac9d-ed6b5faf5a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_161db033-b254-4b94-b8ac-39b0e60a1b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_161db033-b254-4b94-b8ac-39b0e60a1b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0203c917-5115-406d-8e9c-eccf8a03d8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0203c917-5115-406d-8e9c-eccf8a03d8a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2620aa87-7104-457e-bf06-c7a4f9dbff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2620aa87-7104-457e-bf06-c7a4f9dbff1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockVotesAttachedToShares_6f6c452e-9414-44e3-b51e-43756816d7a0" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockVotesAttachedToShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_CommonStockVotesAttachedToShares_6f6c452e-9414-44e3-b51e-43756816d7a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8cef48f0-c2e6-4c25-88be-9d307b71510a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8cef48f0-c2e6-4c25-88be-9d307b71510a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_430b3341-3ca6-47a5-8b6b-c523750bd412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_430b3341-3ca6-47a5-8b6b-c523750bd412" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockAuthorizedAmount_b763a899-7faa-4e49-a008-2dfa0f932236" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_SaleOfStockAuthorizedAmount_b763a899-7faa-4e49-a008-2dfa0f932236" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount_94125efe-b744-4c11-8b7b-18b750468d09" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount_94125efe-b744-4c11-8b7b-18b750468d09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4404799d-ee32-4e72-a925-fea6213ff191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4404799d-ee32-4e72-a925-fea6213ff191" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e8d0872c-1767-41e0-88ad-17038ea4cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e8d0872c-1767-41e0-88ad-17038ea4cdf7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf60f799-798a-4e79-a8be-af5c6f39b808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf60f799-798a-4e79-a8be-af5c6f39b808" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockOptionToPurchaseTerm_8532c3fc-5cb9-41bc-97ac-d1d95cbb0167" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockOptionToPurchaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_SaleOfStockOptionToPurchaseTerm_8532c3fc-5cb9-41bc-97ac-d1d95cbb0167" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_92c4ba80-0325-43b1-b43c-70b08d9d4ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_92c4ba80-0325-43b1-b43c-70b08d9d4ffb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockStampDutyTax_5543d782-ee11-40bb-bddc-a170556b0bb3" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockStampDutyTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_SaleOfStockStampDutyTax_5543d782-ee11-40bb-bddc-a170556b0bb3" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/NetLossperShareNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#NetLossperShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/NetLossperShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_52da509c-072d-41be-996d-5a632badb515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_us-gaap_StatementClassOfStockAxis_52da509c-072d-41be-996d-5a632badb515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_52da509c-072d-41be-996d-5a632badb515_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_52da509c-072d-41be-996d-5a632badb515" xlink:to="loc_us-gaap_ClassOfStockDomain_52da509c-072d-41be-996d-5a632badb515_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ead7c7d-2a78-48de-a5eb-593fded5de16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_52da509c-072d-41be-996d-5a632badb515" xlink:to="loc_us-gaap_ClassOfStockDomain_9ead7c7d-2a78-48de-a5eb-593fded5de16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_a18c3743-4658-4f31-97f7-ecdfc30fb109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9ead7c7d-2a78-48de-a5eb-593fded5de16" xlink:to="loc_us-gaap_CommonClassCMember_a18c3743-4658-4f31-97f7-ecdfc30fb109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1761d347-ff04-4081-a744-03217fcc07be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9ead7c7d-2a78-48de-a5eb-593fded5de16" xlink:to="loc_us-gaap_CommonClassAMember_1761d347-ff04-4081-a744-03217fcc07be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ea58bf33-948a-49b2-864d-82c780602422" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_srt_CounterpartyNameAxis_ea58bf33-948a-49b2-864d-82c780602422" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea58bf33-948a-49b2-864d-82c780602422_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ea58bf33-948a-49b2-864d-82c780602422" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea58bf33-948a-49b2-864d-82c780602422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9c85d2c-d602-4a7b-b165-75f167f5e171" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ea58bf33-948a-49b2-864d-82c780602422" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9c85d2c-d602-4a7b-b165-75f167f5e171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MLPartiesOtherThanBVFShareholdersMember_41250b1d-b91f-46e8-98c3-5ab14ed1cb65" xlink:href="mnlk-20231231.xsd#mnlk_MLPartiesOtherThanBVFShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9c85d2c-d602-4a7b-b165-75f167f5e171" xlink:to="loc_mnlk_MLPartiesOtherThanBVFShareholdersMember_41250b1d-b91f-46e8-98c3-5ab14ed1cb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_acf0af5b-0818-4e42-9a6b-0847708da76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_acf0af5b-0818-4e42-9a6b-0847708da76a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_acf0af5b-0818-4e42-9a6b-0847708da76a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_acf0af5b-0818-4e42-9a6b-0847708da76a" xlink:to="loc_us-gaap_EquityComponentDomain_acf0af5b-0818-4e42-9a6b-0847708da76a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_46e7dfdc-c0f3-46af-bb2f-07b4e381aacb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_acf0af5b-0818-4e42-9a6b-0847708da76a" xlink:to="loc_us-gaap_EquityComponentDomain_46e7dfdc-c0f3-46af-bb2f-07b4e381aacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ee1b4794-52d5-4942-bcc4-c406fb1c82c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_46e7dfdc-c0f3-46af-bb2f-07b4e381aacb" xlink:to="loc_us-gaap_CommonStockMember_ee1b4794-52d5-4942-bcc4-c406fb1c82c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_srt_StatementScenarioAxis_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a3db1bf9-6d53-490b-a689-9915976d2d92" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a3db1bf9-6d53-490b-a689-9915976d2d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_9e6288df-1cca-45a6-b6e8-428602f68a66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a3db1bf9-6d53-490b-a689-9915976d2d92" xlink:to="loc_srt_ProFormaMember_9e6288df-1cca-45a6-b6e8-428602f68a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_92031988-cd6b-4323-9bb1-e067a67a9505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_92031988-cd6b-4323-9bb1-e067a67a9505" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_92031988-cd6b-4323-9bb1-e067a67a9505_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_92031988-cd6b-4323-9bb1-e067a67a9505" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_92031988-cd6b-4323-9bb1-e067a67a9505_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cb4f7b8a-64dd-48f3-9e9b-78dfe35070cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_92031988-cd6b-4323-9bb1-e067a67a9505" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cb4f7b8a-64dd-48f3-9e9b-78dfe35070cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6fd06dfd-0c51-438e-9524-7a1414880975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cb4f7b8a-64dd-48f3-9e9b-78dfe35070cd" xlink:to="loc_us-gaap_SubsequentEventMember_6fd06dfd-0c51-438e-9524-7a1414880975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_19402576-b577-4434-8dee-3812cfb6c024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_CommonStockSharesIssued_19402576-b577-4434-8dee-3812cfb6c024" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_ef3b4995-359d-44cd-994c-ad5138651498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_ef3b4995-359d-44cd-994c-ad5138651498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockConvertedReverseRecapitalization_8890830d-8edf-475c-b5cd-eaa8f37b02b7" xlink:href="mnlk-20231231.xsd#mnlk_StockConvertedReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_mnlk_StockConvertedReverseRecapitalization_8890830d-8edf-475c-b5cd-eaa8f37b02b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b1384fc-8e5c-4e3b-a0c6-e97acf014e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b1384fc-8e5c-4e3b-a0c6-e97acf014e9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d0ba618-6b1a-486d-8f86-56a11a98a9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d0ba618-6b1a-486d-8f86-56a11a98a9e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_319a960a-61d9-4d00-9df4-15c81bafbde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_EarningsPerShareBasic_319a960a-61d9-4d00-9df4-15c81bafbde0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_02d58422-2d0c-4bf5-8c6d-d0a1b0abd96f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_EarningsPerShareDiluted_02d58422-2d0c-4bf5-8c6d-d0a1b0abd96f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockForfeitedReverseRecapitalization_98357419-ab2a-4853-9769-753c9f71bcca" xlink:href="mnlk-20231231.xsd#mnlk_StockForfeitedReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_mnlk_StockForfeitedReverseRecapitalization_98357419-ab2a-4853-9769-753c9f71bcca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6ac3baba-f9c1-48d2-aedc-b82495272ead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6ac3baba-f9c1-48d2-aedc-b82495272ead" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a" xlink:to="loc_us-gaap_EquityComponentDomain_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42b91af7-147a-4132-b2a3-333a10515575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a" xlink:to="loc_us-gaap_EquityComponentDomain_42b91af7-147a-4132-b2a3-333a10515575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_da5d59a3-8301-45af-937e-f4b1dc370f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42b91af7-147a-4132-b2a3-333a10515575" xlink:to="loc_us-gaap_CommonStockMember_da5d59a3-8301-45af-937e-f4b1dc370f16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6a350649-65b9-446c-a5d4-665832848c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6a350649-65b9-446c-a5d4-665832848c7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6a350649-65b9-446c-a5d4-665832848c7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6a350649-65b9-446c-a5d4-665832848c7f" xlink:to="loc_us-gaap_ClassOfStockDomain_6a350649-65b9-446c-a5d4-665832848c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_24503c92-1333-4047-b21f-b2da5cda49dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6a350649-65b9-446c-a5d4-665832848c7f" xlink:to="loc_us-gaap_ClassOfStockDomain_24503c92-1333-4047-b21f-b2da5cda49dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_6546c57c-f061-4e6f-8d46-3242eec969db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_24503c92-1333-4047-b21f-b2da5cda49dd" xlink:to="loc_us-gaap_CommonClassCMember_6546c57c-f061-4e6f-8d46-3242eec969db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ca5589e0-33cb-4735-b16e-eb53d6a9abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_24503c92-1333-4047-b21f-b2da5cda49dd" xlink:to="loc_us-gaap_CommonClassAMember_ca5589e0-33cb-4735-b16e-eb53d6a9abc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6428f820-ff89-48cf-b9b9-a8ffb79de539" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_dei_LegalEntityAxis_6428f820-ff89-48cf-b9b9-a8ffb79de539" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6428f820-ff89-48cf-b9b9-a8ffb79de539_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6428f820-ff89-48cf-b9b9-a8ffb79de539" xlink:to="loc_dei_EntityDomain_6428f820-ff89-48cf-b9b9-a8ffb79de539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e9208cf9-d4a8-4a2f-8ab3-4a549355350e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6428f820-ff89-48cf-b9b9-a8ffb79de539" xlink:to="loc_dei_EntityDomain_e9208cf9-d4a8-4a2f-8ab3-4a549355350e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MoonLakeAGMember_028f1a08-7d23-4342-abf1-447c8b93fef0" xlink:href="mnlk-20231231.xsd#mnlk_MoonLakeAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e9208cf9-d4a8-4a2f-8ab3-4a549355350e" xlink:to="loc_mnlk_MoonLakeAGMember_028f1a08-7d23-4342-abf1-447c8b93fef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_765a2bac-4eb4-43ec-b955-046ab2ee3d09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_AwardTypeAxis_765a2bac-4eb4-43ec-b955-046ab2ee3d09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765a2bac-4eb4-43ec-b955-046ab2ee3d09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_765a2bac-4eb4-43ec-b955-046ab2ee3d09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765a2bac-4eb4-43ec-b955-046ab2ee3d09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_765a2bac-4eb4-43ec-b955-046ab2ee3d09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_78d08e87-0174-498f-9c17-13902157fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:to="loc_us-gaap_RestrictedStockMember_78d08e87-0174-498f-9c17-13902157fd5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0d2883c8-98a9-4fc5-a23d-f7aa1fa44f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:to="loc_us-gaap_EmployeeStockMember_0d2883c8-98a9-4fc5-a23d-f7aa1fa44f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ef65029b-f1d8-4316-b085-dee1b54f57a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ef65029b-f1d8-4316-b085-dee1b54f57a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9bf9b688-9c43-4355-aad0-9be296d1f977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_VestingAxis_9bf9b688-9c43-4355-aad0-9be296d1f977" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9bf9b688-9c43-4355-aad0-9be296d1f977_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_9bf9b688-9c43-4355-aad0-9be296d1f977" xlink:to="loc_us-gaap_VestingDomain_9bf9b688-9c43-4355-aad0-9be296d1f977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_9bf9b688-9c43-4355-aad0-9be296d1f977" xlink:to="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_baf88241-4985-4102-a55b-98dcf69cb4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_baf88241-4985-4102-a55b-98dcf69cb4c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedPaymentArrangementTrancheFourMember_886e30e9-6d8a-47a8-b172-758ffec82f57" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:to="loc_mnlk_ShareBasedPaymentArrangementTrancheFourMember_886e30e9-6d8a-47a8-b172-758ffec82f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a6e7e01f-d1a9-4173-ad17-b01534eee247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a6e7e01f-d1a9-4173-ad17-b01534eee247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1ede1c64-035b-4737-ba84-4ee8c9b85ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1ede1c64-035b-4737-ba84-4ee8c9b85ae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5e3357ca-5912-468d-8b99-ee7c2f1979d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_PlanNameAxis_5e3357ca-5912-468d-8b99-ee7c2f1979d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5e3357ca-5912-468d-8b99-ee7c2f1979d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5e3357ca-5912-468d-8b99-ee7c2f1979d7" xlink:to="loc_us-gaap_PlanNameDomain_5e3357ca-5912-468d-8b99-ee7c2f1979d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fae26e7a-1db6-4559-8903-3ab3b1e757e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5e3357ca-5912-468d-8b99-ee7c2f1979d7" xlink:to="loc_us-gaap_PlanNameDomain_fae26e7a-1db6-4559-8903-3ab3b1e757e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EmployeeStockOptionPlanESOPMember_ae7e0577-4fae-4e3e-b4c6-2929505910c3" xlink:href="mnlk-20231231.xsd#mnlk_EmployeeStockOptionPlanESOPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fae26e7a-1db6-4559-8903-3ab3b1e757e1" xlink:to="loc_mnlk_EmployeeStockOptionPlanESOPMember_ae7e0577-4fae-4e3e-b4c6-2929505910c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember_72762b9d-bdf0-4b41-b11c-2aaedfd67752" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fae26e7a-1db6-4559-8903-3ab3b1e757e1" xlink:to="loc_mnlk_EquityIncentivePlanMember_72762b9d-bdf0-4b41-b11c-2aaedfd67752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_f9cc8951-5442-4895-a26f-6efabbeccd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_GranteeStatusAxis_f9cc8951-5442-4895-a26f-6efabbeccd7d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_f9cc8951-5442-4895-a26f-6efabbeccd7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_f9cc8951-5442-4895-a26f-6efabbeccd7d" xlink:to="loc_us-gaap_GranteeStatusDomain_f9cc8951-5442-4895-a26f-6efabbeccd7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_df2418a0-7b62-42b0-90f6-177ab2bf7fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_f9cc8951-5442-4895-a26f-6efabbeccd7d" xlink:to="loc_us-gaap_GranteeStatusDomain_df2418a0-7b62-42b0-90f6-177ab2bf7fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6dbefe6d-bd55-4c4e-9e1c-ef6a4f242165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_df2418a0-7b62-42b0-90f6-177ab2bf7fdb" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6dbefe6d-bd55-4c4e-9e1c-ef6a4f242165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_687a4b3b-7d72-4bb9-93c1-e4acf4e8fd95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_df2418a0-7b62-42b0-90f6-177ab2bf7fdb" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_687a4b3b-7d72-4bb9-93c1-e4acf4e8fd95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0979181e-a19e-4652-891f-12a80310427b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0979181e-a19e-4652-891f-12a80310427b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_278b32a2-1896-4502-bae5-bbcea0a0705d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_278b32a2-1896-4502-bae5-bbcea0a0705d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage_36a587a9-f96f-4391-9e66-562fa75597c9" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage_36a587a9-f96f-4391-9e66-562fa75597c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2a44fe0b-e4ad-4932-bcc4-4675a7b51020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2a44fe0b-e4ad-4932-bcc4-4675a7b51020" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NumberOfCoFounders_1e305b67-813b-4b53-8dce-3bc266be49ba" xlink:href="mnlk-20231231.xsd#mnlk_NumberOfCoFounders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_mnlk_NumberOfCoFounders_1e305b67-813b-4b53-8dce-3bc266be49ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_84939cac-1d20-424b-8ecb-18819755a34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_84939cac-1d20-424b-8ecb-18819755a34c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_420e8181-6b89-462d-a4c7-528dfb8e503b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_420e8181-6b89-462d-a4c7-528dfb8e503b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SharePriceNominalValue_1c9b9ac8-05cb-4fad-bf79-cb17f390005f" xlink:href="mnlk-20231231.xsd#mnlk_SharePriceNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_mnlk_SharePriceNominalValue_1c9b9ac8-05cb-4fad-bf79-cb17f390005f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_006e6bc5-c28d-4ccc-a018-1d4b5cf61693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_006e6bc5-c28d-4ccc-a018-1d4b5cf61693" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c99851d9-1419-4095-90ed-15a0b5a939eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c99851d9-1419-4095-90ed-15a0b5a939eb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4cfe723b-c3e1-4a0d-a455-f2f460f38539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4cfe723b-c3e1-4a0d-a455-f2f460f38539" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13ab32e0-38e9-4af1-9997-1a29b44ba85e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13ab32e0-38e9-4af1-9997-1a29b44ba85e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ad150fff-0435-4e3a-a69e-d0bc4b148ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ad150fff-0435-4e3a-a69e-d0bc4b148ef7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_d7c74d81-09d8-4acb-8fed-8c52b2dea183" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_d7c74d81-09d8-4acb-8fed-8c52b2dea183" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6e6d4cb2-a394-402f-87ea-fa221ce791eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6e6d4cb2-a394-402f-87ea-fa221ce791eb" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6bcc00cf-fc39-4524-bbfe-2deada58da59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6bcc00cf-fc39-4524-bbfe-2deada58da59" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e79a683-e3ef-4919-aa23-09fef024f85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:to="loc_us-gaap_AwardTypeAxis_0e79a683-e3ef-4919-aa23-09fef024f85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e79a683-e3ef-4919-aa23-09fef024f85b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0e79a683-e3ef-4919-aa23-09fef024f85b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e79a683-e3ef-4919-aa23-09fef024f85b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0e79a683-e3ef-4919-aa23-09fef024f85b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e9b7c550-1818-4b31-a9a8-c02b2ab14ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:to="loc_us-gaap_RestrictedStockMember_e9b7c550-1818-4b31-a9a8-c02b2ab14ea3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_38008e83-49c1-4e7c-adbf-1383a39e612d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:to="loc_us-gaap_EmployeeStockMember_38008e83-49c1-4e7c-adbf-1383a39e612d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_992e6e3d-a89e-4bcd-9bb0-3d45ab0fbbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:to="loc_us-gaap_EmployeeStockOptionMember_992e6e3d-a89e-4bcd-9bb0-3d45ab0fbbc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6e59b8c6-af78-4d2a-99f1-791b2f744bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:to="loc_us-gaap_PlanNameAxis_6e59b8c6-af78-4d2a-99f1-791b2f744bab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6e59b8c6-af78-4d2a-99f1-791b2f744bab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6e59b8c6-af78-4d2a-99f1-791b2f744bab" xlink:to="loc_us-gaap_PlanNameDomain_6e59b8c6-af78-4d2a-99f1-791b2f744bab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2c813c9f-f693-4c2c-b72c-269e1a090829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6e59b8c6-af78-4d2a-99f1-791b2f744bab" xlink:to="loc_us-gaap_PlanNameDomain_2c813c9f-f693-4c2c-b72c-269e1a090829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember_a02212ee-b096-4725-8f8b-c556dba6321b" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2c813c9f-f693-4c2c-b72c-269e1a090829" xlink:to="loc_mnlk_EquityIncentivePlanMember_a02212ee-b096-4725-8f8b-c556dba6321b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_288f4a4d-4f54-4a68-85e6-3b41edd9ca22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_288f4a4d-4f54-4a68-85e6-3b41edd9ca22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_288f4a4d-4f54-4a68-85e6-3b41edd9ca22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_288f4a4d-4f54-4a68-85e6-3b41edd9ca22" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_288f4a4d-4f54-4a68-85e6-3b41edd9ca22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d10f95e-8ca4-46fa-b899-a334b09c1556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_288f4a4d-4f54-4a68-85e6-3b41edd9ca22" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d10f95e-8ca4-46fa-b899-a334b09c1556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f7c67a8-6d5b-4537-ae91-31d467d4c246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d10f95e-8ca4-46fa-b899-a334b09c1556" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f7c67a8-6d5b-4537-ae91-31d467d4c246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da715845-4cb9-4eb0-ad61-94bbce80e749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d10f95e-8ca4-46fa-b899-a334b09c1556" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da715845-4cb9-4eb0-ad61-94bbce80e749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0921601e-07e7-4d5f-a37a-d61c9b81be7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6bcc00cf-fc39-4524-bbfe-2deada58da59" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0921601e-07e7-4d5f-a37a-d61c9b81be7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:to="loc_us-gaap_AwardTypeAxis_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_343ce9c0-e751-4695-a280-b1326b1d9579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:to="loc_us-gaap_RestrictedStockMember_343ce9c0-e751-4695-a280-b1326b1d9579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_aa4fceaf-4b08-4ac3-b7ed-7b56661b7bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:to="loc_us-gaap_EmployeeStockMember_aa4fceaf-4b08-4ac3-b7ed-7b56661b7bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e8125bee-d198-4816-a682-6ca006e61db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e8125bee-d198-4816-a682-6ca006e61db4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8699dd4f-8ce1-4e24-a9d7-d857027032f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:to="loc_us-gaap_PlanNameAxis_8699dd4f-8ce1-4e24-a9d7-d857027032f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8699dd4f-8ce1-4e24-a9d7-d857027032f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8699dd4f-8ce1-4e24-a9d7-d857027032f0" xlink:to="loc_us-gaap_PlanNameDomain_8699dd4f-8ce1-4e24-a9d7-d857027032f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e6325db5-a3f8-49bd-9863-575fe596a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8699dd4f-8ce1-4e24-a9d7-d857027032f0" xlink:to="loc_us-gaap_PlanNameDomain_e6325db5-a3f8-49bd-9863-575fe596a2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EmployeeStockOptionPlanESOPMember_b1ac8d9e-56ef-4c83-9edf-1ca2c32019e4" xlink:href="mnlk-20231231.xsd#mnlk_EmployeeStockOptionPlanESOPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e6325db5-a3f8-49bd-9863-575fe596a2a7" xlink:to="loc_mnlk_EmployeeStockOptionPlanESOPMember_b1ac8d9e-56ef-4c83-9edf-1ca2c32019e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember_c666f7fb-50bc-4af0-a50d-cceab663d1ec" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e6325db5-a3f8-49bd-9863-575fe596a2a7" xlink:to="loc_mnlk_EquityIncentivePlanMember_c666f7fb-50bc-4af0-a50d-cceab663d1ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc65e792-75ef-4521-9786-67caf209070d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc65e792-75ef-4521-9786-67caf209070d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue_686b260e-9620-4404-bcdd-64860b28ec09" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue_686b260e-9620-4404-bcdd-64860b28ec09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_b288fb0a-5c25-4925-ab9b-eff77109c6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_b288fb0a-5c25-4925-ab9b-eff77109c6ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise_74be5528-6455-4895-a238-0f370d63a314" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise_74be5528-6455-4895-a238-0f370d63a314" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares_66821004-c798-4bd8-877b-f45c28cd4a47" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares_66821004-c798-4bd8-877b-f45c28cd4a47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fef0167a-e25b-4461-894a-2dffc891f56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fef0167a-e25b-4461-894a-2dffc891f56c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b856e60b-6d5e-4d33-b11d-7ab51bea97c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b856e60b-6d5e-4d33-b11d-7ab51bea97c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eea1278e-15f3-43e2-bf89-72d05ea43889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eea1278e-15f3-43e2-bf89-72d05ea43889" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_eb3a72f5-f983-4e54-9096-a28d30776ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_eb3a72f5-f983-4e54-9096-a28d30776ceb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d4a50d6-9160-4c20-b4ad-ddfc67640129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d4a50d6-9160-4c20-b4ad-ddfc67640129" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a91c7eab-050e-4d3c-bd25-98200f79bc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a91c7eab-050e-4d3c-bd25-98200f79bc6b" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationAwardedandGrantedDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f63f05af-e686-4234-a09b-17040e934a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:to="loc_us-gaap_AwardTypeAxis_f63f05af-e686-4234-a09b-17040e934a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f63f05af-e686-4234-a09b-17040e934a3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f63f05af-e686-4234-a09b-17040e934a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f63f05af-e686-4234-a09b-17040e934a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f63f05af-e686-4234-a09b-17040e934a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b5bb51e4-8b92-42a1-879f-e0437400ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:to="loc_us-gaap_RestrictedStockMember_b5bb51e4-8b92-42a1-879f-e0437400ddba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_af3a422c-5454-41dc-86e9-57d946da3d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:to="loc_us-gaap_EmployeeStockMember_af3a422c-5454-41dc-86e9-57d946da3d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_33bcc47f-5993-4185-9c9a-62ff39010461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_33bcc47f-5993-4185-9c9a-62ff39010461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0540e7c9-1557-4482-b711-f2440c6c4664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:to="loc_us-gaap_PlanNameAxis_0540e7c9-1557-4482-b711-f2440c6c4664" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0540e7c9-1557-4482-b711-f2440c6c4664_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0540e7c9-1557-4482-b711-f2440c6c4664" xlink:to="loc_us-gaap_PlanNameDomain_0540e7c9-1557-4482-b711-f2440c6c4664_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b884b592-34f4-4905-90d8-a24b65cf801b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0540e7c9-1557-4482-b711-f2440c6c4664" xlink:to="loc_us-gaap_PlanNameDomain_b884b592-34f4-4905-90d8-a24b65cf801b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EmployeeStockOptionPlanESOPMember_d0bb91e4-5557-47da-b5ba-136da4561186" xlink:href="mnlk-20231231.xsd#mnlk_EmployeeStockOptionPlanESOPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b884b592-34f4-4905-90d8-a24b65cf801b" xlink:to="loc_mnlk_EmployeeStockOptionPlanESOPMember_d0bb91e4-5557-47da-b5ba-136da4561186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember_90bb176f-fb1f-4253-9bef-e41ffc5c7569" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b884b592-34f4-4905-90d8-a24b65cf801b" xlink:to="loc_mnlk_EquityIncentivePlanMember_90bb176f-fb1f-4253-9bef-e41ffc5c7569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_501fd52c-1b97-4342-a076-e5d17a670ece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_501fd52c-1b97-4342-a076-e5d17a670ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd37a34b-1fb7-4ad6-8036-8f952e80c622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd37a34b-1fb7-4ad6-8036-8f952e80c622" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00aaf339-c27f-4085-b548-0510f2af9645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00aaf339-c27f-4085-b548-0510f2af9645" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4bf5f749-40b7-4c36-9e08-cfe521a0c0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b96e562a-70a6-4ef3-a711-7efa4768ce0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b96e562a-70a6-4ef3-a711-7efa4768ce0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38740505-4759-4c29-b798-672d24001d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38740505-4759-4c29-b798-672d24001d89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b09052e6-89a0-404f-b2dd-e5c59f6f7852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b09052e6-89a0-404f-b2dd-e5c59f6f7852" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_62ae3dd4-a699-4454-b8b7-b6a11442ad99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1f56cf45-694a-4fed-a447-b69c6588caf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1f56cf45-694a-4fed-a447-b69c6588caf1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_734447ed-ac45-460a-9440-6148f0893b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_734447ed-ac45-460a-9440-6148f0893b45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLossCarryforwardExpirationAxis_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLossCarryforwardExpirationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_734447ed-ac45-460a-9440-6148f0893b45" xlink:to="loc_mnlk_OperatingLossCarryforwardExpirationAxis_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLossCarryforwardExpirationDomain_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4_default" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLossCarryforwardExpirationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationAxis_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4" xlink:to="loc_mnlk_OperatingLossCarryforwardExpirationDomain_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLossCarryforwardExpirationDomain_e6055893-d505-4800-a08c-cb17c47d3985" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLossCarryforwardExpirationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationAxis_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4" xlink:to="loc_mnlk_OperatingLossCarryforwardExpirationDomain_e6055893-d505-4800-a08c-cb17c47d3985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ExpirationIn2028Member_d7012986-7c19-42fc-aa74-0cdb4cac41f0" xlink:href="mnlk-20231231.xsd#mnlk_ExpirationIn2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationDomain_e6055893-d505-4800-a08c-cb17c47d3985" xlink:to="loc_mnlk_ExpirationIn2028Member_d7012986-7c19-42fc-aa74-0cdb4cac41f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ExpirationIn2029Member_1dadd828-f48a-4779-b8af-63d2c786f46d" xlink:href="mnlk-20231231.xsd#mnlk_ExpirationIn2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationDomain_e6055893-d505-4800-a08c-cb17c47d3985" xlink:to="loc_mnlk_ExpirationIn2029Member_1dadd828-f48a-4779-b8af-63d2c786f46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97a42d7-6cf6-4130-9404-926d5285129f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97a42d7-6cf6-4130-9404-926d5285129f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b056a260-44cd-4c3d-bc93-0886414a6d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b056a260-44cd-4c3d-bc93-0886414a6d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_637c6b24-62a2-4452-8bb6-c5ac81128a04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_637c6b24-62a2-4452-8bb6-c5ac81128a04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_62c49856-4abc-4ccc-9cf4-b26248539bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_OperatingLossCarryforwards_62c49856-4abc-4ccc-9cf4-b26248539bb5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dc5729ce-6114-488e-99b5-1d6350d9ef96" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_srt_ProductOrServiceAxis_dc5729ce-6114-488e-99b5-1d6350d9ef96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc5729ce-6114-488e-99b5-1d6350d9ef96_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dc5729ce-6114-488e-99b5-1d6350d9ef96" xlink:to="loc_srt_ProductsAndServicesDomain_dc5729ce-6114-488e-99b5-1d6350d9ef96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_301c6959-09b5-4940-aba7-89bde62ca45b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dc5729ce-6114-488e-99b5-1d6350d9ef96" xlink:to="loc_srt_ProductsAndServicesDomain_301c6959-09b5-4940-aba7-89bde62ca45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a402dd31-4f3e-4cc7-bae4-2937d594329e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_301c6959-09b5-4940-aba7-89bde62ca45b" xlink:to="loc_us-gaap_LicenseMember_a402dd31-4f3e-4cc7-bae4-2937d594329e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c1d2f105-22ac-45c1-87f2-2ab8ff97e733" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_srt_CounterpartyNameAxis_c1d2f105-22ac-45c1-87f2-2ab8ff97e733" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c1d2f105-22ac-45c1-87f2-2ab8ff97e733_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c1d2f105-22ac-45c1-87f2-2ab8ff97e733" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c1d2f105-22ac-45c1-87f2-2ab8ff97e733_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b15a622-e9e3-4660-b452-8796e871d281" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c1d2f105-22ac-45c1-87f2-2ab8ff97e733" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b15a622-e9e3-4660-b452-8796e871d281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SonelokimabProgramSLKProgramMember_e10a3e9d-8005-461b-82aa-1abe1c8a8e79" xlink:href="mnlk-20231231.xsd#mnlk_SonelokimabProgramSLKProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b15a622-e9e3-4660-b452-8796e871d281" xlink:to="loc_mnlk_SonelokimabProgramSLKProgramMember_e10a3e9d-8005-461b-82aa-1abe1c8a8e79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8a00de47-3be0-4dac-aaab-824f32d8f1ff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8a00de47-3be0-4dac-aaab-824f32d8f1ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OfficeLeaseMember_dc8216b3-a47f-42e9-bcf1-76f7126f202c" xlink:href="mnlk-20231231.xsd#mnlk_OfficeLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8a00de47-3be0-4dac-aaab-824f32d8f1ff" xlink:to="loc_mnlk_OfficeLeaseMember_dc8216b3-a47f-42e9-bcf1-76f7126f202c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3d12874f-5ee3-424e-a554-9bdf22a4902c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3d12874f-5ee3-424e-a554-9bdf22a4902c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3d12874f-5ee3-424e-a554-9bdf22a4902c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3d12874f-5ee3-424e-a554-9bdf22a4902c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3d12874f-5ee3-424e-a554-9bdf22a4902c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf8dc3c7-c1eb-494c-ad06-d5a68fee6472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3d12874f-5ee3-424e-a554-9bdf22a4902c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf8dc3c7-c1eb-494c-ad06-d5a68fee6472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PrepaidExpensesNoncurrentMember_3d2c179f-ac23-442d-9cd1-8e9ae4d119ac" xlink:href="mnlk-20231231.xsd#mnlk_PrepaidExpensesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf8dc3c7-c1eb-494c-ad06-d5a68fee6472" xlink:to="loc_mnlk_PrepaidExpensesNoncurrentMember_3d2c179f-ac23-442d-9cd1-8e9ae4d119ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_UnrecognizedCommitmentsAndContingencies_26e255fb-9d44-4c49-afaf-c9fb8b881ad3" xlink:href="mnlk-20231231.xsd#mnlk_UnrecognizedCommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_mnlk_UnrecognizedCommitmentsAndContingencies_26e255fb-9d44-4c49-afaf-c9fb8b881ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount_45cac5b8-0d60-48a8-9693-f7af391551c0" xlink:href="mnlk-20231231.xsd#mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount_45cac5b8-0d60-48a8-9693-f7af391551c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_60bb47a1-c313-47d5-90a4-676babfed25c" xlink:href="mnlk-20231231.xsd#mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_60bb47a1-c313-47d5-90a4-676babfed25c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dceed4d1-63cf-4f3f-8ba2-4b483ba05488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dceed4d1-63cf-4f3f-8ba2-4b483ba05488" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SegmentInformationandGeographicDataDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_508c0e46-5623-4dcc-a41b-581f470a4680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_39cb7cd5-d08f-4c5d-91ee-06ac803ebb01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_508c0e46-5623-4dcc-a41b-581f470a4680" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_39cb7cd5-d08f-4c5d-91ee-06ac803ebb01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_37c4af07-6e9a-4426-8327-5ca95415cc1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_39cb7cd5-d08f-4c5d-91ee-06ac803ebb01" xlink:to="loc_srt_StatementGeographicalAxis_37c4af07-6e9a-4426-8327-5ca95415cc1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_37c4af07-6e9a-4426-8327-5ca95415cc1c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_37c4af07-6e9a-4426-8327-5ca95415cc1c" xlink:to="loc_srt_SegmentGeographicalDomain_37c4af07-6e9a-4426-8327-5ca95415cc1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_37c4af07-6e9a-4426-8327-5ca95415cc1c" xlink:to="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_a499f8f8-abdc-4980-a94e-98a4569a4534" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:to="loc_country_CH_a499f8f8-abdc-4980-a94e-98a4569a4534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_1f28d33c-1bde-4427-b0b2-42fa7278beb6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:to="loc_country_GB_1f28d33c-1bde-4427-b0b2-42fa7278beb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PT_35a9c95c-f99b-4384-a1a6-b121dcf817db" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_PT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:to="loc_country_PT_35a9c95c-f99b-4384-a1a6-b121dcf817db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_0fb82d43-b287-4d2f-bde0-e8872380dbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_508c0e46-5623-4dcc-a41b-581f470a4680" xlink:to="loc_us-gaap_NoncurrentAssets_0fb82d43-b287-4d2f-bde0-e8872380dbe4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://moonlaketx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bb736c4d-2f8b-44c2-b918-d0bdee2a9927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bb736c4d-2f8b-44c2-b918-d0bdee2a9927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bb736c4d-2f8b-44c2-b918-d0bdee2a9927_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb736c4d-2f8b-44c2-b918-d0bdee2a9927" xlink:to="loc_us-gaap_EquityComponentDomain_bb736c4d-2f8b-44c2-b918-d0bdee2a9927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27b82232-ef1d-4457-989b-d31154c2af45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb736c4d-2f8b-44c2-b918-d0bdee2a9927" xlink:to="loc_us-gaap_EquityComponentDomain_27b82232-ef1d-4457-989b-d31154c2af45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5948555a-1e1a-43b9-b1a1-4c0cd75d2648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27b82232-ef1d-4457-989b-d31154c2af45" xlink:to="loc_us-gaap_CommonStockMember_5948555a-1e1a-43b9-b1a1-4c0cd75d2648" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a79ab89e-5b0d-400d-b277-fe7a3ecb0229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a79ab89e-5b0d-400d-b277-fe7a3ecb0229" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a79ab89e-5b0d-400d-b277-fe7a3ecb0229_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a79ab89e-5b0d-400d-b277-fe7a3ecb0229" xlink:to="loc_us-gaap_ClassOfStockDomain_a79ab89e-5b0d-400d-b277-fe7a3ecb0229_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_360484ac-b74f-4175-938d-2c59c80e218b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a79ab89e-5b0d-400d-b277-fe7a3ecb0229" xlink:to="loc_us-gaap_ClassOfStockDomain_360484ac-b74f-4175-938d-2c59c80e218b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_852de4c1-a3d8-4695-aa12-e1ff666336c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_360484ac-b74f-4175-938d-2c59c80e218b" xlink:to="loc_us-gaap_CommonClassCMember_852de4c1-a3d8-4695-aa12-e1ff666336c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3060fadc-7d1b-4dc8-9be7-9fad412ad3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_360484ac-b74f-4175-938d-2c59c80e218b" xlink:to="loc_us-gaap_CommonClassAMember_3060fadc-7d1b-4dc8-9be7-9fad412ad3f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7ce0bd63-2b3e-4438-a827-c740c3e2f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7ce0bd63-2b3e-4438-a827-c740c3e2f09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ab42b5b8-e4e4-4226-b16f-ce54cab28090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7ce0bd63-2b3e-4438-a827-c740c3e2f09d" xlink:to="loc_us-gaap_SubsequentEventMember_ab42b5b8-e4e4-4226-b16f-ce54cab28090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3c9fa3f5-58a7-4053-81ac-3e50bff4315f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3c9fa3f5-58a7-4053-81ac-3e50bff4315f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c9fa3f5-58a7-4053-81ac-3e50bff4315f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c9fa3f5-58a7-4053-81ac-3e50bff4315f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c9fa3f5-58a7-4053-81ac-3e50bff4315f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ccb3e6e-c2a9-4783-af6a-ac3994605ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c9fa3f5-58a7-4053-81ac-3e50bff4315f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ccb3e6e-c2a9-4783-af6a-ac3994605ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_August2023SalesAgreementMember_c954589b-df6a-406e-ba58-abff1b623e25" xlink:href="mnlk-20231231.xsd#mnlk_August2023SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ccb3e6e-c2a9-4783-af6a-ac3994605ad2" xlink:to="loc_mnlk_August2023SalesAgreementMember_c954589b-df6a-406e-ba58-abff1b623e25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_78e8daea-4b6c-49e5-a89d-17a77d5516f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_78e8daea-4b6c-49e5-a89d-17a77d5516f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5a2de872-5777-4d2b-86af-a44d1af93a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5a2de872-5777-4d2b-86af-a44d1af93a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f9b76823-71bf-4f7f-a6e5-de49981a00d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f9b76823-71bf-4f7f-a6e5-de49981a00d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_847fd11e-66e7-47ef-8b35-fc57f4c01a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_847fd11e-66e7-47ef-8b35-fc57f4c01a62" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ATMSharesMember_57496a67-e537-4104-9cd7-a8c6c03129a1" xlink:href="mnlk-20231231.xsd#mnlk_ATMSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_mnlk_ATMSharesMember_57496a67-e537-4104-9cd7-a8c6c03129a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_Dr.KristianReichMember_2317da8f-774b-406b-b126-2d43b76bba49" xlink:href="mnlk-20231231.xsd#mnlk_Dr.KristianReichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mnlk_Dr.KristianReichMember_2317da8f-774b-406b-b126-2d43b76bba49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_Dr.JorgeSantosDaSilvaMember_5d6d9e18-c27b-4a11-84fa-02ee1563517f" xlink:href="mnlk-20231231.xsd#mnlk_Dr.JorgeSantosDaSilvaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mnlk_Dr.JorgeSantosDaSilvaMember_5d6d9e18-c27b-4a11-84fa-02ee1563517f" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>mnlk-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:25f78456-bf3c-4d7d-8669-3aa27460a960,g:c66f622e-48e1-41cd-88e8-9a7e0d2c3eaf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation_83017ed0-ff06-4273-b6fa-781e730f36d5_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflation</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Inflation</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Inflation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" xlink:to="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_4e370ddf-b82d-442e-ae56-557f8afdc9e7_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_245d93dd-f3b3-4497-947f-02581b1a4c12_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Of which: net loss attributable to noncontrolling interests shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_118d20a2-ea05-4ead-867f-8aabad06e8da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_23980ee6-7f92-494d-adca-bdcbed961d74_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d6791104-7a7b-4414-8cf2-ced5ba63dca9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c3f3e873-5aef-4e85-8a9e-dc2cdd802944_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_73bfabec-af33-4cac-9973-91815beea0df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f80c37b5-7df7-46cf-ae52-1f87c1653f5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c5f188b8-46dd-4967-aeeb-0971b96d0719_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd69e7cc-ef42-4f95-bcb7-be3c76cd1fb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e410dcb-a885-4521-a5c6-a15b0d5b5c13_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dac87bcf-6d2b-4442-b6e3-7a2cd1a770de_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_f70d90a9-cadb-4334-a6eb-92ec6fedf8ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of loan liability</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_89ee3ca6-9e3d-4152-a680-61f121d47307_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of loan liability</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage_a1f199a2-57f2-451c-9bc2-82aadcfed310_terseLabel_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse vesting percentage</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage_label_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage_documentation_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" xlink:to="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e4baf40b-2aff-489c-93c2-ea299bd868e5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Contract Costs and Accruals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ReverseRecapitalizationDisclosureTextBlock_f6146db0-253a-4f13-9425-2cac19371b9f_terseLabel_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Agreement with Helix and Recapitalization</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationDisclosureTextBlock_label_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization Disclosure [Text Block]</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationDisclosureTextBlock_documentation_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationDisclosureTextBlock" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ReverseRecapitalizationDisclosureTextBlock" xlink:to="lab_mnlk_ReverseRecapitalizationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_8acaccb0-33a7-495f-84c8-565a90b49816_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value changes of marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:to="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_CommonStockConversionRatio_29e14068-1eb4-4b37-b138-fd241c7e3369_terseLabel_en-US" xlink:label="lab_mnlk_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, conversion ratio (in shares)</link:label>
    <link:label id="lab_mnlk_CommonStockConversionRatio_label_en-US" xlink:label="lab_mnlk_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Conversion Ratio</link:label>
    <link:label id="lab_mnlk_CommonStockConversionRatio_documentation_en-US" xlink:label="lab_mnlk_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockConversionRatio" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_CommonStockConversionRatio" xlink:to="lab_mnlk_CommonStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_1cf3339e-6a6c-492c-96f4-21823eb7e5d6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:to="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c74f47ef-f7df-425f-a7c7-36cf4223a2fb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2efef1ee-8509-4c81-a16e-75ba1c7419ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_7de5ba5e-2dc1-4c5f-8329-f747bbacb246_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_203036fe-018a-455f-a55b-84754332a4e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b8fd40e6-ab74-49ce-9a54-9114cfbe2b4e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_e8462ef1-badc-4914-b5a8-8c7508999fef_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_641f94ed-95ca-4763-a887-a34014d5061f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a19c9d89-40dc-4ae1-b326-9ebbf0cdf947_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f573c043-da5c-472d-8f27-26e7fe6d03cc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c916c2cc-45c1-4960-83e0-1520056a10d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_93e0b7e7-5b22-4fdb-8d7d-c6d31e6c43fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_26a927bb-0068-44f1-b964-f685d536f064_negatedTerseLabel_en-US" xlink:label="lab_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lab_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_50d76a33-cd26-4873-a5a8-3303da0f0921_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SharesAuthorized_d26b5f4c-7223-49c1-914f-b1c12b0b0272_periodStartLabel_en-US" xlink:label="lab_mnlk_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized, beginning balance (in shares)</link:label>
    <link:label id="lab_mnlk_SharesAuthorized_8d1a008b-f97b-452b-b37d-32f094a99f56_periodEndLabel_en-US" xlink:label="lab_mnlk_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized, ending balance (in shares)</link:label>
    <link:label id="lab_mnlk_SharesAuthorized_label_en-US" xlink:label="lab_mnlk_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Authorized</link:label>
    <link:label id="lab_mnlk_SharesAuthorized_documentation_en-US" xlink:label="lab_mnlk_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SharesAuthorized" xlink:href="mnlk-20231231.xsd#mnlk_SharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SharesAuthorized" xlink:to="lab_mnlk_SharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions_d0b08d92-02be-4b62-9a08-3bfaf4866823_terseLabel_en-US" xlink:label="lab_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, lease term extension</link:label>
    <link:label id="lab_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="mnlk-20231231.xsd#mnlk_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_201b9687-2290-4d43-8775-1f9c262fb72f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a3cf7c87-c1df-4baa-9666-3120a37b7cf6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_34218351-551b-45ca-927d-b0b82e63d165_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (CHF per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ExpirationIn2028Member_e201d10f-474b-4a0d-b0c6-25c4f43128a9_terseLabel_en-US" xlink:label="lab_mnlk_ExpirationIn2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 2028</link:label>
    <link:label id="lab_mnlk_ExpirationIn2028Member_label_en-US" xlink:label="lab_mnlk_ExpirationIn2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 2028 [Member]</link:label>
    <link:label id="lab_mnlk_ExpirationIn2028Member_documentation_en-US" xlink:label="lab_mnlk_ExpirationIn2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ExpirationIn2028Member" xlink:href="mnlk-20231231.xsd#mnlk_ExpirationIn2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ExpirationIn2028Member" xlink:to="lab_mnlk_ExpirationIn2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f55a78eb-659e-4e3b-a373-c78aed19e51a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_NumberOfOperatingLeases_0889b6f2-d063-4a4d-b507-1dbb17adea60_terseLabel_en-US" xlink:label="lab_mnlk_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating leases</link:label>
    <link:label id="lab_mnlk_NumberOfOperatingLeases_label_en-US" xlink:label="lab_mnlk_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:label id="lab_mnlk_NumberOfOperatingLeases_documentation_en-US" xlink:label="lab_mnlk_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NumberOfOperatingLeases" xlink:href="mnlk-20231231.xsd#mnlk_NumberOfOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_NumberOfOperatingLeases" xlink:to="lab_mnlk_NumberOfOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_be2a4c54-95b4-4c9e-a304-e62655aad00c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share attributable to controlling interest shareholders (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_63dd0684-d55a-4936-9df2-2da415024602_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a2de0d4f-602b-4ed3-930c-ae8cb5ccecb6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_e038e477-1265-4873-a98b-404b4def2b81_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term expected rate of salary increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_b4c44d4d-b706-4344-92aa-c678040e0584_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held in Treasury, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_7a289165-2d3b-428f-93c0-06f2bfb76d00_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held in Treasury, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_62c7973a-2bd8-42a4-ab52-dffa754fb33a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_436995c1-f168-4818-9840-1c8c50b32978_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_2f39fffb-9b15-46d7-9d44-91d423eab249_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9572fd3e-74a8-4ab7-b2ab-8904cb79a5b6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60dc809f-79f8-4f79-b235-4010d583eb1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of the option on the grant date using Black-Scholes model (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_2550b15f-1937-47da-965d-a9aab2b8105c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Of which classified within short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_aa963f62-409c-45c3-8e06-ab82c0bf7f0c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Of which: net loss attributable to controlling interests shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3b266c61-48a2-4efe-90eb-58e09dda970c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to controlling interests shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ad6fd889-bf68-4644-b39a-1aef5af84cce_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_59f1096e-2372-48c8-9c33-c4dd705e06ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_0bbf073d-1dbf-45b2-b6f7-4a87feb38318_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ac4978a2-6193-4021-82cd-db899714aa0d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_InvestmentsAcquiredThroughReverseRecapitalization_78da3539-c2e5-4fa1-8462-10ade32ad4cb_terseLabel_en-US" xlink:label="lab_mnlk_InvestmentsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments held in Trust Account</link:label>
    <link:label id="lab_mnlk_InvestmentsAcquiredThroughReverseRecapitalization_label_en-US" xlink:label="lab_mnlk_InvestmentsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Acquired Through Reverse Recapitalization</link:label>
    <link:label id="lab_mnlk_InvestmentsAcquiredThroughReverseRecapitalization_documentation_en-US" xlink:label="lab_mnlk_InvestmentsAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Acquired Through Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_InvestmentsAcquiredThroughReverseRecapitalization" xlink:href="mnlk-20231231.xsd#mnlk_InvestmentsAcquiredThroughReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_InvestmentsAcquiredThroughReverseRecapitalization" xlink:to="lab_mnlk_InvestmentsAcquiredThroughReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_eaf49c72-b372-4e37-8658-7b8b8ce33a12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount_f1c52d95-3b16-40e5-8c56-6b5d73bb2d5f_terseLabel_en-US" xlink:label="lab_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue remaining performance obligation additional variable consideration amount</link:label>
    <link:label id="lab_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount_label_en-US" xlink:label="lab_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Additional Variable Consideration Amount</link:label>
    <link:label id="lab_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Additional Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" xlink:href="mnlk-20231231.xsd#mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" xlink:to="lab_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments_a34f0eb9-7353-4db3-9292-c007b4102b2d_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid, Net Of Adjustments</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid, Net Of Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" xlink:to="lab_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationTable_063fb3fc-3d07-40bb-b70e-1c354a4f57e1_terseLabel_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reverse Recapitalization [Table]</link:label>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationTable_label_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reverse Recapitalization [Table]</link:label>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationTable_documentation_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reverse Recapitalization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationTable" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable" xlink:to="lab_mnlk_ScheduleOfReverseRecapitalizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_fc92d3ee-79c7-45bd-b8cf-74a04814d12c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_45401016-3c6b-4489-bdd5-1db86ebcf5e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_a91538b3-fa67-40af-95ff-9138b8f8b6bb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_aa3f4610-4ea3-4924-998c-01abc3762964_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rates changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1e690752-70cd-40cb-8bf0-fdc64e2ca6a8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_98b5f7f3-2612-4c56-87a5-c460b9a47ac0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of income taxed at different rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_OfficeLeaseMember_3ec0fcc5-d7cd-480e-84f0-7d533dc62144_terseLabel_en-US" xlink:label="lab_mnlk_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Lease</link:label>
    <link:label id="lab_mnlk_OfficeLeaseMember_label_en-US" xlink:label="lab_mnlk_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Lease [Member]</link:label>
    <link:label id="lab_mnlk_OfficeLeaseMember_documentation_en-US" xlink:label="lab_mnlk_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OfficeLeaseMember" xlink:href="mnlk-20231231.xsd#mnlk_OfficeLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_OfficeLeaseMember" xlink:to="lab_mnlk_OfficeLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2d0c53c3-f931-4377-9174-808424efb6e3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_HelixAcquisitionCorpMember_18883cab-2157-463a-b89e-0e6a1ceba1da_terseLabel_en-US" xlink:label="lab_mnlk_HelixAcquisitionCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Helix Acquisition Corp.</link:label>
    <link:label id="lab_mnlk_HelixAcquisitionCorpMember_label_en-US" xlink:label="lab_mnlk_HelixAcquisitionCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Helix Acquisition Corp. [Member]</link:label>
    <link:label id="lab_mnlk_HelixAcquisitionCorpMember_documentation_en-US" xlink:label="lab_mnlk_HelixAcquisitionCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Helix Acquisition Corp.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_HelixAcquisitionCorpMember" xlink:href="mnlk-20231231.xsd#mnlk_HelixAcquisitionCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_HelixAcquisitionCorpMember" xlink:to="lab_mnlk_HelixAcquisitionCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ded41e08-f3ce-4ad1-8a62-cc29185415d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7a6f13d3-a763-4c85-adce-4b18712e8a1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of earnings per share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_f49cd7fe-a9e1-4c56-9ab8-13ce88b27867_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34f0c654-1e88-4a96-807c-7602108e0770_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c2082aa6-74e6-4733-971b-4d2b4e2f3f81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_405c9b15-6a5b-4882-b28b-8fc68f973e0c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4ce59441-a539-480b-9656-64b0bc444907_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of movements in exchange rates on cash held</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2de2fb6e-dbcb-4695-ad89-6f33b406e541_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_3b323823-8eca-4aa4-abcf-2edf07164d01_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_554a7839-07fc-4ce0-a08a-e528abcfdf60_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax (net)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_PrepaidResearchAndDevelopmentExpense_800abb8f-603f-4ba4-a98d-e0689b853033_terseLabel_en-US" xlink:label="lab_mnlk_PrepaidResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-clinical research and clinical development services</link:label>
    <link:label id="lab_mnlk_PrepaidResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_mnlk_PrepaidResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Expense</link:label>
    <link:label id="lab_mnlk_PrepaidResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_mnlk_PrepaidResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PrepaidResearchAndDevelopmentExpense" xlink:href="mnlk-20231231.xsd#mnlk_PrepaidResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_PrepaidResearchAndDevelopmentExpense" xlink:to="lab_mnlk_PrepaidResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_OperatingLossCarryforwardExpirationDomain_f8ccda01-95c1-43fc-94e5-654128232625_terseLabel_en-US" xlink:label="lab_mnlk_OperatingLossCarryforwardExpirationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward Expiration [Domain]</link:label>
    <link:label id="lab_mnlk_OperatingLossCarryforwardExpirationDomain_label_en-US" xlink:label="lab_mnlk_OperatingLossCarryforwardExpirationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward Expiration [Domain]</link:label>
    <link:label id="lab_mnlk_OperatingLossCarryforwardExpirationDomain_documentation_en-US" xlink:label="lab_mnlk_OperatingLossCarryforwardExpirationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward Expiration [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLossCarryforwardExpirationDomain" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLossCarryforwardExpirationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationDomain" xlink:to="lab_mnlk_OperatingLossCarryforwardExpirationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed_5b6cb9a0-330b-4a8c-b60c-da21e03c1334_terseLabel_en-US" xlink:label="lab_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fees</link:label>
    <link:label id="lab_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed_label_en-US" xlink:label="lab_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Satisfaction Of Fees Owed</link:label>
    <link:label id="lab_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed_documentation_en-US" xlink:label="lab_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Satisfaction Of Fees Owed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" xlink:to="lab_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c649a379-2235-4eea-98ed-c6b895fd9791_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c3b817a-83ec-441f-918f-94d3e839fdea_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionExpenseReversalOfExpenseNoncash_ff0e763c-9b61-4165-9a1c-f044aa837f59_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic pension benefit cost for the qualified pension plan</link:label>
    <link:label id="lab_us-gaap_PensionExpenseReversalOfExpenseNoncash_label_en-US" xlink:label="lab_us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Expense (Reversal of Expense), Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpenseReversalOfExpenseNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:to="lab_us-gaap_PensionExpenseReversalOfExpenseNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_59ecdc1a-c721-4782-9102-97360254805e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_09d05483-b257-4b30-8f8a-0cddce561686_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock_a1ada1c5-fd14-47ee-98d5-139b1dccfebe_terseLabel_en-US" xlink:label="lab_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Authorized and Issued</link:label>
    <link:label id="lab_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock_label_en-US" xlink:label="lab_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock Authorized And Issued Roll Forward [Table Text Block]</link:label>
    <link:label id="lab_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock_documentation_en-US" xlink:label="lab_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock Authorized And Issued Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" xlink:to="lab_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_230a611d-f7a6-4471-9a27-335b9a2b9bf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a39c1a30-84ba-4eda-aa44-8abb3bf1949c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock_e0d6858e-9668-4117-bdb7-cb8841feda74_terseLabel_en-US" xlink:label="lab_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions</link:label>
    <link:label id="lab_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" xlink:to="lab_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_EquityIncentivePlanMember_03b5dd98-3d55-4c7f-bc5e-f72aa9ebd34e_terseLabel_en-US" xlink:label="lab_mnlk_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:label id="lab_mnlk_EquityIncentivePlanMember_label_en-US" xlink:label="lab_mnlk_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_mnlk_EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_mnlk_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_EquityIncentivePlanMember" xlink:to="lab_mnlk_EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b59ab045-12bb-46f0-9095-96563ceb61c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0f5daaaa-9499-4bbd-b3aa-bb098fd039d3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b1131330-f710-4c40-a822-0143203d6339_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_54af91cd-2902-4806-988f-7b61a8ef0f2b_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, AOCI Rollforward [Roll Forward]</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, AOCI Rollforward [Roll Forward]</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, AOCI Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanAOCIRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward" xlink:to="lab_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c85032dd-fe96-4541-946f-851e4a3f0193_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_7854f7e3-875a-4cbb-aa9c-434fecdb2bf5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_89e85b4e-cf19-4092-a5ea-de7d833b0565_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_ecbc9c85-378f-452e-a473-876dad35157e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e5bf8699-2590-45c8-8d86-e22d99efd10b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a1dc31cc-06fe-4b60-af1c-7d2df9112261_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ShareBasedPaymentArrangementTrancheFourMember_617c34ed-6269-4327-aec1-4d7b59502d9a_terseLabel_en-US" xlink:label="lab_mnlk_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Four</link:label>
    <link:label id="lab_mnlk_ShareBasedPaymentArrangementTrancheFourMember_label_en-US" xlink:label="lab_mnlk_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Four [Member]</link:label>
    <link:label id="lab_mnlk_ShareBasedPaymentArrangementTrancheFourMember_documentation_en-US" xlink:label="lab_mnlk_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedPaymentArrangementTrancheFourMember" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ShareBasedPaymentArrangementTrancheFourMember" xlink:to="lab_mnlk_ShareBasedPaymentArrangementTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_EmployeeStockOptionPlanESOPMember_646dd49c-0ba9-4b48-a3a2-fbaf0848b323_terseLabel_en-US" xlink:label="lab_mnlk_EmployeeStockOptionPlanESOPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option Plan (ESOP)</link:label>
    <link:label id="lab_mnlk_EmployeeStockOptionPlanESOPMember_label_en-US" xlink:label="lab_mnlk_EmployeeStockOptionPlanESOPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option Plan (ESOP) [Member]</link:label>
    <link:label id="lab_mnlk_EmployeeStockOptionPlanESOPMember_documentation_en-US" xlink:label="lab_mnlk_EmployeeStockOptionPlanESOPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option Plan (ESOP)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EmployeeStockOptionPlanESOPMember" xlink:href="mnlk-20231231.xsd#mnlk_EmployeeStockOptionPlanESOPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_EmployeeStockOptionPlanESOPMember" xlink:to="lab_mnlk_EmployeeStockOptionPlanESOPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8b4f7797-9a90-4f13-89e3-72abd1e040dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_bad931b2-1a56-4558-8026-ea2bfe545cd0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses - non-current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_b241fb76-4a30-4bb4-989e-ef380469f0d8_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_18d4c0c0-e6f8-44a9-bf9b-11111d3a274d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DeferredTaxAssetsLeaseLiabililties_1e609f7d-8b1e-4f87-8824-0031c29f40c7_terseLabel_en-US" xlink:label="lab_mnlk_DeferredTaxAssetsLeaseLiabililties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mnlk_DeferredTaxAssetsLeaseLiabililties_label_en-US" xlink:label="lab_mnlk_DeferredTaxAssetsLeaseLiabililties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabililties</link:label>
    <link:label id="lab_mnlk_DeferredTaxAssetsLeaseLiabililties_documentation_en-US" xlink:label="lab_mnlk_DeferredTaxAssetsLeaseLiabililties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabililties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxAssetsLeaseLiabililties" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxAssetsLeaseLiabililties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DeferredTaxAssetsLeaseLiabililties" xlink:to="lab_mnlk_DeferredTaxAssetsLeaseLiabililties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_60a0a6b8-593d-4c64-9f93-cc691927e81f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fb84a23c-73f4-41ff-9845-e78ceca8a0b7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_9ef58c44-500e-419c-a5a3-1abbe13399e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_b62a4977-7114-40f8-81f6-03d9127be6fb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems_0cc2b55c-87cd-4672-9f4f-3d221f9a09c0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Allocation [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Allocation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5baa6b15-bc51-4505-8906-06146ee9cb4b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_78318acc-82b1-4908-a6a8-4f04bddc5ac8_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_31b97c05-c5d3-4da7-961f-5265ea4c1098_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization_101e6435-774e-4f7a-883e-89ee2eb744ee_verboseLabel_en-US" xlink:label="lab_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total MoonLake class A ordinary Shares outstanding at closing (in shares)</link:label>
    <link:label id="lab_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization_label_en-US" xlink:label="lab_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:label id="lab_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization_documentation_en-US" xlink:label="lab_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:href="mnlk-20231231.xsd#mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:to="lab_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d03d22c6-9a7d-46aa-9bbc-6bd35d0c5475_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_PIPEInvestorsMember_0e954033-6713-4ac9-9ff8-3afd58cd3e16_terseLabel_en-US" xlink:label="lab_mnlk_PIPEInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIPE Investors</link:label>
    <link:label id="lab_mnlk_PIPEInvestorsMember_label_en-US" xlink:label="lab_mnlk_PIPEInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIPE Investors [Member]</link:label>
    <link:label id="lab_mnlk_PIPEInvestorsMember_documentation_en-US" xlink:label="lab_mnlk_PIPEInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIPE Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PIPEInvestorsMember" xlink:href="mnlk-20231231.xsd#mnlk_PIPEInvestorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_PIPEInvestorsMember" xlink:to="lab_mnlk_PIPEInvestorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_ce3cf985-b6a4-45fd-99d1-d9d7cf923e8a_totalLabel_en-US" xlink:label="lab_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets (net)</link:label>
    <link:label id="lab_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_label_en-US" xlink:label="lab_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Including Valuation Allowance</link:label>
    <link:label id="lab_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_documentation_en-US" xlink:label="lab_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Including Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxAssetsNetIncludingValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance" xlink:to="lab_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b0816ce9-0b12-42c2-8952-f6008fc6af76_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DefinedBenefitPlanLiquidityMember_55e53ba1-182d-4cc9-8823-85cf1921296f_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanLiquidityMember_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Liquidity [Member]</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanLiquidityMember_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanLiquidityMember" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanLiquidityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanLiquidityMember" xlink:to="lab_mnlk_DefinedBenefitPlanLiquidityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_87ebf4e6-58ee-4116-9320-5692317964a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1f671967-35f8-482f-9fd6-f7a18d6297df_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ConversionOfClassCIntoClassASharesMember_dc3ef460-b1e0-454e-bcb9-95d91d8f2147_terseLabel_en-US" xlink:label="lab_mnlk_ConversionOfClassCIntoClassASharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Class C Into Class A Shares</link:label>
    <link:label id="lab_mnlk_ConversionOfClassCIntoClassASharesMember_label_en-US" xlink:label="lab_mnlk_ConversionOfClassCIntoClassASharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Class C Into Class A Shares [Member]</link:label>
    <link:label id="lab_mnlk_ConversionOfClassCIntoClassASharesMember_documentation_en-US" xlink:label="lab_mnlk_ConversionOfClassCIntoClassASharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Class C Into Class A Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionOfClassCIntoClassASharesMember" xlink:href="mnlk-20231231.xsd#mnlk_ConversionOfClassCIntoClassASharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ConversionOfClassCIntoClassASharesMember" xlink:to="lab_mnlk_ConversionOfClassCIntoClassASharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_506ef6c6-d523-4583-b9f8-b3ea59337083_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense, non-option awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78376017-c0b2-4c1a-b969-0fbfae9e58e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_cc1b5f79-cc99-4971-bc92-d788d55b28d3_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_441da1d3-c9e8-4488-adca-055814a20444_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747e074b-211a-40ed-8257-e5f68427e523_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8e172fe7-ea7f-495f-b47f-07af2e5cbc5a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ae076109-6752-48d1-8a5e-4de2dda5424f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_9655abeb-283f-4fd3-a694-b0daa2f5bc95_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by the employer</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a3eb5165-9e35-4c38-bf00-a0cda91808a9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_67ff7cf6-5f05-4c33-afa3-7356b9d42c8a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_da3aeec7-047e-478b-9a2d-bc7cc82c1faf_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_384d5d48-476d-42b8-913c-a3252edb6b29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_1a8695dd-dfe6-4c76-a424-662d8205529e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a3d184c2-16d1-4ef1-87da-b29d818ad8cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9ea5c59f-8a6a-4707-ba58-c24434861bca_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_41c5764f-c203-401b-9397-cb0e125be3ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_25037d67-02ed-448c-b51e-8cb421849bdb_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses - current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_f8deba04-9617-4b2e-907c-de196c6c6e7d_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_bbd4d57a-eb98-490c-bcbd-9c9989d423c3_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_76c21bc2-cd5e-433a-9820-3f8646b4d070_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0f54ce02-18a1-4864-96de-32e237f4c98c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f508f51c-00e6-4f29-8aa4-980ffd11b4f5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_fe62787e-415b-45ec-8a68-769a6094e91e_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4f1487d3-2069-45b9-8047-97608574cb55_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_622c841c-754b-44c2-ba2c-f897d79f3cad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_36931e0f-7307-4dff-8562-027edba14524_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e9d47858-695d-4585-a20c-6b3a2116ee6c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8552ec0f-de3e-4cc4-b858-724e7fafaa3f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares_eba8f102-a6f9-4eb1-8658-a05d3fa330c7_terseLabel_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fully diluted shares (in shares)</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares_label_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Denominator, Fully Diluted Shares</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares_documentation_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Denominator, Fully Diluted Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" xlink:to="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a51829be-662b-4495-86c2-31f17b382d14_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_ad644102-e7be-4310-abd8-cb10ffa71eef_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, plan assets, actual allocation, percentage</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b1914e99-b0bd-4b37-a5e1-1ce72ed5ece5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_TradeAndOtherPayablesCurrentTableTextBlock_32853610-76ce-4aca-bb46-346f250441b5_terseLabel_en-US" xlink:label="lab_mnlk_TradeAndOtherPayablesCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of trade and other payables, current</link:label>
    <link:label id="lab_mnlk_TradeAndOtherPayablesCurrentTableTextBlock_label_en-US" xlink:label="lab_mnlk_TradeAndOtherPayablesCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade And Other Payables, Current [Table Text Block]</link:label>
    <link:label id="lab_mnlk_TradeAndOtherPayablesCurrentTableTextBlock_documentation_en-US" xlink:label="lab_mnlk_TradeAndOtherPayablesCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade And Other Payables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TradeAndOtherPayablesCurrentTableTextBlock" xlink:href="mnlk-20231231.xsd#mnlk_TradeAndOtherPayablesCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_TradeAndOtherPayablesCurrentTableTextBlock" xlink:to="lab_mnlk_TradeAndOtherPayablesCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8af34c69-b3e1-4c83-96ab-2186bc73d395_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance price per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_f1413b0c-221b-4004-97ff-9e1bf00d3d35_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Private Placement Shares</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_303f68f9-b308-4d2f-a4ab-0ec04ee4c9cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_01b3704a-dcd3-4acd-8cdb-05c621226068_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e02db7a3-87d7-4f07-a5e8-43a47cbd0ade_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5c264d51-eab4-42c1-b810-fbba3a559c3f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_107b1702-9d99-4d7e-9b65-76db97ffaa03_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6e3bbac1-6d24-4e53-a95b-fe3acc8df68c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_cb34315b-a680-4407-a1d1-4ced61a41c32_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) / loss - beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_4188feaf-bc8f-4e44-888c-fa483d6219bd_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ProceedsFromContributionFromParValueOfCommonStock_5b051ff2-e6ee-407c-9cc2-8a99aa95a4ee_terseLabel_en-US" xlink:label="lab_mnlk_ProceedsFromContributionFromParValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution for par value of Class V Shares</link:label>
    <link:label id="lab_mnlk_ProceedsFromContributionFromParValueOfCommonStock_label_en-US" xlink:label="lab_mnlk_ProceedsFromContributionFromParValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Contribution From Par Value Of Common Stock</link:label>
    <link:label id="lab_mnlk_ProceedsFromContributionFromParValueOfCommonStock_documentation_en-US" xlink:label="lab_mnlk_ProceedsFromContributionFromParValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Contribution From Par Value Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ProceedsFromContributionFromParValueOfCommonStock" xlink:href="mnlk-20231231.xsd#mnlk_ProceedsFromContributionFromParValueOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ProceedsFromContributionFromParValueOfCommonStock" xlink:to="lab_mnlk_ProceedsFromContributionFromParValueOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets_0cfdeced-e7b5-4547-a91a-903b56054df9_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Expected return on plan assets</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Expected return on plan assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" xlink:to="lab_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_68adbf66-95b0-46f5-ac59-1e65df5d29a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2a2989a6-095e-440b-85cf-77acbf551acc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4b39fe8c-3bb6-458b-8c8f-6d539db43a6b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_e0fcabf7-3efa-436b-886d-f000be20ce32_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Accounting</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9b4458a6-8979-40c5-bfac-357396da1cb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Transaction</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees_7b94b06d-9df5-47f2-ac9e-3727a8b57345_negatedTerseLabel_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">of which deferred IPO underwriting fee</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees_label_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Deferred Initial Public Offering Underwriting Fees</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees_documentation_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Deferred Initial Public Offering Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" xlink:to="lab_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3ac4ce56-7964-4e66-96ef-de459a79c352_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ae68f36b-b075-4f96-b596-8a7a786551dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_AccruedConsultingAndOtherFeesCurrent_0db2a69a-4317-4121-b6a2-2285c8cfe0df_terseLabel_en-US" xlink:label="lab_mnlk_AccruedConsultingAndOtherFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultant and other fees</link:label>
    <link:label id="lab_mnlk_AccruedConsultingAndOtherFeesCurrent_label_en-US" xlink:label="lab_mnlk_AccruedConsultingAndOtherFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Consulting And Other Fees, Current</link:label>
    <link:label id="lab_mnlk_AccruedConsultingAndOtherFeesCurrent_documentation_en-US" xlink:label="lab_mnlk_AccruedConsultingAndOtherFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Consulting And Other Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedConsultingAndOtherFeesCurrent" xlink:href="mnlk-20231231.xsd#mnlk_AccruedConsultingAndOtherFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_AccruedConsultingAndOtherFeesCurrent" xlink:to="lab_mnlk_AccruedConsultingAndOtherFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7c927786-b404-474c-a937-207acc7e8dd4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_44bf3cea-977d-4a1b-af06-3ab60231b8a5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESOP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization_4e4b9f39-5179-4939-b63b-f420919fcc26_negatedTerseLabel_en-US" xlink:label="lab_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests recognized on historical net assets of MoonLake AG in connection with the Business Combination</link:label>
    <link:label id="lab_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization_label_en-US" xlink:label="lab_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Reverse Recapitalization</link:label>
    <link:label id="lab_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization_documentation_en-US" xlink:label="lab_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization" xlink:href="mnlk-20231231.xsd#mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization" xlink:to="lab_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_89f517d8-661d-4e1e-b423-423aa1961c22_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cf6a2c77-28e9-4eaf-b96f-3a216abad03f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_b6782c56-6b7b-4bbd-9f59-03726a0979bc_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_36e16956-767d-4712-9f1b-d4d2ddc1507c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3e11fad9-284d-42c4-a8f6-36679688e171_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to controlling interests shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8184251a-0690-44bd-b083-43de71fd516c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_94702c80-0e8f-4048-88e4-408d8ab2910e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ReverseRecapitalizationOtherTransactionExpenses_a33362a4-240a-4c39-aadf-ca9a5253a61b_negatedTerseLabel_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationOtherTransactionExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">of which other transaction expenses</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationOtherTransactionExpenses_label_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationOtherTransactionExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Other Transaction Expenses</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationOtherTransactionExpenses_documentation_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationOtherTransactionExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Other Transaction Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationOtherTransactionExpenses" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationOtherTransactionExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ReverseRecapitalizationOtherTransactionExpenses" xlink:to="lab_mnlk_ReverseRecapitalizationOtherTransactionExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a09fc8ba-9fcb-4021-97c6-c55e06dfae55_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Ordinary Shares upon Business Combination</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5f2d125a-6972-47e7-b5a1-242b1a4f837c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_23f390c1-4361-4442-ab76-37fc55a9c44a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f59bc56c-0a42-4e52-a64b-092d50283c14_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3b02569e-f658-484a-be55-ee886c876e11_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_24438205-b1f1-4d79-b1ce-fd7d218beb6e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a28b2796-0290-47c6-a108-d28de2d5d890_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_2f5142d7-52f5-4177-958b-6e0f08c25caf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_564d285b-6fa9-4d8f-a26b-cd444e43cec5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_35b70c02-a515-4c22-baae-28e19fce7278_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_50e7fbe2-e9ee-43c4-98f3-8614c9d2470e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_05bd7e4b-2dfc-4db5-95c8-8faa69689036_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Ordinary Shares, net of transaction costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0a5857c8-b94c-40c9-bd84-961f230e1ef0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Shares purchased by a director following his appointment as chairman of the board of directors (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e2f4acb6-85d4-46fd-8b03-d75389e5ff7c_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares under the ATM facility (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b5b5f30a-32c5-4125-9b6a-3999de9b6820_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_edce5e08-b232-4f8e-8675-e147fee6b3a0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_37cd6115-e39e-4fe0-b8fd-aa4524e4212c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_15bf7750-02b9-465d-93e6-eee3d507cec2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) / losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_NumberOfCoFounders_3aeb149f-47c0-4694-8af5-f82be059ad11_terseLabel_en-US" xlink:label="lab_mnlk_NumberOfCoFounders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of co-founders</link:label>
    <link:label id="lab_mnlk_NumberOfCoFounders_label_en-US" xlink:label="lab_mnlk_NumberOfCoFounders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Co-Founders</link:label>
    <link:label id="lab_mnlk_NumberOfCoFounders_documentation_en-US" xlink:label="lab_mnlk_NumberOfCoFounders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Co-Founders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NumberOfCoFounders" xlink:href="mnlk-20231231.xsd#mnlk_NumberOfCoFounders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_NumberOfCoFounders" xlink:to="lab_mnlk_NumberOfCoFounders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_92d1464d-c46c-4b6b-92dd-50487f02d15c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_50b4dd47-857d-4b93-930d-b26c2876fb5e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_206de8e7-2e9e-407e-9ecc-e1726c3524c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service (cost) / credit recognized in current year</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dc486ee1-ce90-4146-80ae-1eca39e49cca_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_PrepaidExpensesNoncurrentMember_1dba1ba8-adec-4af2-b5a2-9e21b2a77439_terseLabel_en-US" xlink:label="lab_mnlk_PrepaidExpensesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses, Noncurrent</link:label>
    <link:label id="lab_mnlk_PrepaidExpensesNoncurrentMember_label_en-US" xlink:label="lab_mnlk_PrepaidExpensesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses, Noncurrent [Member]</link:label>
    <link:label id="lab_mnlk_PrepaidExpensesNoncurrentMember_documentation_en-US" xlink:label="lab_mnlk_PrepaidExpensesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PrepaidExpensesNoncurrentMember" xlink:href="mnlk-20231231.xsd#mnlk_PrepaidExpensesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_PrepaidExpensesNoncurrentMember" xlink:to="lab_mnlk_PrepaidExpensesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fbbcdf51-14a0-4a83-951a-148a70d42bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus PIPE investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7a31a6c9-0937-4438-a30c-94f62ecf6fd9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ConversionFollowingBusinessCombinationMember_bc33adca-f765-4e04-9791-8de6c21972f0_terseLabel_en-US" xlink:label="lab_mnlk_ConversionFollowingBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Following Business Combination</link:label>
    <link:label id="lab_mnlk_ConversionFollowingBusinessCombinationMember_label_en-US" xlink:label="lab_mnlk_ConversionFollowingBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Following Business Combination [Member]</link:label>
    <link:label id="lab_mnlk_ConversionFollowingBusinessCombinationMember_documentation_en-US" xlink:label="lab_mnlk_ConversionFollowingBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Following Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionFollowingBusinessCombinationMember" xlink:href="mnlk-20231231.xsd#mnlk_ConversionFollowingBusinessCombinationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ConversionFollowingBusinessCombinationMember" xlink:to="lab_mnlk_ConversionFollowingBusinessCombinationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_2323f1ad-fd14-458a-9130-2c64301ad124_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1889c6bc-684c-45e6-8450-ed1d6e5a4404_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_14f32439-0e46-400a-9c9c-efcab3ec054b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f8ceafe5-9719-49a2-be94-ed7d8319b128_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_CommonStockVotesAttachedToShares_700acd77-9ba1-4ad0-a535-8f1945bb10d1_terseLabel_en-US" xlink:label="lab_mnlk_CommonStockVotesAttachedToShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, votes per share</link:label>
    <link:label id="lab_mnlk_CommonStockVotesAttachedToShares_label_en-US" xlink:label="lab_mnlk_CommonStockVotesAttachedToShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Votes Attached To Shares</link:label>
    <link:label id="lab_mnlk_CommonStockVotesAttachedToShares_documentation_en-US" xlink:label="lab_mnlk_CommonStockVotesAttachedToShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Votes Attached To Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockVotesAttachedToShares" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockVotesAttachedToShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_CommonStockVotesAttachedToShares" xlink:to="lab_mnlk_CommonStockVotesAttachedToShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_f11a5d30-a11e-4414-a928-078e02bb00a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dc67593f-f524-4f17-a6eb-99472d83bc67_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_9c97bb0a-9b35-4cfe-bbaf-cf8851754028_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ExpirationIn2029Member_64f423c8-b930-4797-b05d-9d2d6b4b0260_terseLabel_en-US" xlink:label="lab_mnlk_ExpirationIn2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 2029</link:label>
    <link:label id="lab_mnlk_ExpirationIn2029Member_label_en-US" xlink:label="lab_mnlk_ExpirationIn2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 2029 [Member]</link:label>
    <link:label id="lab_mnlk_ExpirationIn2029Member_documentation_en-US" xlink:label="lab_mnlk_ExpirationIn2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ExpirationIn2029Member" xlink:href="mnlk-20231231.xsd#mnlk_ExpirationIn2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ExpirationIn2029Member" xlink:to="lab_mnlk_ExpirationIn2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1c1afd3c-97e1-4145-a0bd-58ab155acb42_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProFormaMember_c34abde2-e8b6-4d24-ad68-e8781a32745c_terseLabel_en-US" xlink:label="lab_srt_ProFormaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma</link:label>
    <link:label id="lab_srt_ProFormaMember_label_en-US" xlink:label="lab_srt_ProFormaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProFormaMember" xlink:to="lab_srt_ProFormaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_1efa1b25-039b-4f4d-8d76-6041f202918e_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_99419895-5fe4-429e-8171-20300429008b_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue_e9cac5b2-5eab-41fc-b76e-8ec58ab1aa67_terseLabel_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders of MoonLake AG (in dollars per share)</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue_label_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Founder Resignation Date Fair Value</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue_documentation_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Founder Resignation Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" xlink:to="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8be8ff5c-608c-459e-88c2-bcee7b4ce7c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4cc9a011-7122-4ee1-afb2-212777dd7d4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_699856e2-413f-4f5b-85b2-3d96856ede3f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_70191d30-6f6a-4611-9145-065d022a3b1f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bae119b9-2839-4795-9a46-244a52db82ad_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_1495b347-6339-425d-9ae9-b46613c8c7cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_489a154c-3c73-4a61-99dc-f5cc7dedb9ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c126f5ec-4de5-47ed-b063-559c2860fc82_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_15086ff9-2272-4aef-8312-52db302745b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ReverseRecapitalizationNet_fd9322fe-8885-4af2-b1a5-2f8ee8296b4e_terseLabel_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse recapitalization, net</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationNet_575f3312-8938-4f6f-8a31-fe9f99268784_totalLabel_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available Closing Date Cash</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationNet_label_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Net</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationNet_documentation_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationNet" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ReverseRecapitalizationNet" xlink:to="lab_mnlk_ReverseRecapitalizationNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52e620d3-e04a-461b-aec3-12cad830e7a8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ebf53b5f-93a4-4bf5-8504-29e089420771_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e17db8ce-9311-4ed9-a859-353751a1abd4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on marketable securities and short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a9de6f4-c1de-4f36-bdd8-61fc9de5e7e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_af9b2a18-110e-4120-8fe9-2a87d4a5c5b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_67774045-6a43-496b-a507-c9ebb796b850_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0b6b4b5b-f44c-4eec-a1cd-f2d822383b50_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4828e1d5-abbe-48cc-a3ea-561ed55a784b_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_86001763-e22b-4af7-b519-74ae84ae67ce_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_03d33de0-964b-42d4-a192-0afe1e73d8e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_cdf9a3de-0f6c-4833-8710-9cfeca54cf7e_terseLabel_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of vesting installments</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_label_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Vesting Installments</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_documentation_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Vesting Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:to="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_8a7c6a1b-1682-4b06-80dc-c2120f41f15d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_e161e812-cee9-44c4-86b8-25eb83014362_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_e57f9e9e-218e-4329-81f4-9e7cb75fb390_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fbce07bf-0b4f-4694-a6d8-0bfac6d24199_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_bfb72342-5655-4b74-8ba4-1082583bac64_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise_c550c325-0ea6-4e6a-87b9-14cb29257ac9_terseLabel_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enterprise value</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise_label_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Numerator, Enterprise</link:label>
    <link:label id="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise_documentation_en-US" xlink:label="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Numerator, Enterprise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" xlink:to="lab_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_0e5e7ade-a84a-4a52-beb4-2149ac8c3aaf_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5f77dbc8-b12a-4fc0-bd11-fce21864a0ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_90433e57-68f1-4c29-b733-eabe8b1bdb59_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (CHF/USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d599f2f5-ee7c-4fef-a77a-2cf32a348e95_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_Dr.KristianReichMember_label_en-US" xlink:label="lab_mnlk_Dr.KristianReichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Kristian Reich [Member]</link:label>
    <link:label id="lab_mnlk_Dr.KristianReichMember_documentation_en-US" xlink:label="lab_mnlk_Dr.KristianReichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Kristian Reich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_Dr.KristianReichMember" xlink:href="mnlk-20231231.xsd#mnlk_Dr.KristianReichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_Dr.KristianReichMember" xlink:to="lab_mnlk_Dr.KristianReichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_31166032-b081-4ad4-8f83-5d9a87804cf6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c4c57c72-cb0d-44b9-8e2f-12e20be21912_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_52176a07-0a61-4e18-9023-dba58658210a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent_95d9041e-3fe9-4729-bdf6-c3012fc84fb8_terseLabel_en-US" xlink:label="lab_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utilization of unrecognized losses</link:label>
    <link:label id="lab_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent_label_en-US" xlink:label="lab_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Utilization Of Unrealized Loss Not Recognized In Prior Year, Percent</link:label>
    <link:label id="lab_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent_documentation_en-US" xlink:label="lab_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Utilization Of Unrealized Loss Not Recognized In Prior Year, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" xlink:href="mnlk-20231231.xsd#mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" xlink:to="lab_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_May2023SalesAgreementMember_8b4927b2-68c8-4f9f-a11d-0aa8ef14b560_terseLabel_en-US" xlink:label="lab_mnlk_May2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2023 Sales Agreement</link:label>
    <link:label id="lab_mnlk_May2023SalesAgreementMember_label_en-US" xlink:label="lab_mnlk_May2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2023 Sales Agreement [Member]</link:label>
    <link:label id="lab_mnlk_May2023SalesAgreementMember_documentation_en-US" xlink:label="lab_mnlk_May2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2023 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_May2023SalesAgreementMember" xlink:href="mnlk-20231231.xsd#mnlk_May2023SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_May2023SalesAgreementMember" xlink:to="lab_mnlk_May2023SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_7d711c34-fc6c-4481-9f3c-0c944945859a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b655fe3a-322c-410f-9073-7d407bcd0d2d_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8a2ad26-67b7-4562-92b6-c11e57d2fc6c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_753771e9-6892-43f2-b64e-b5a28a0a6759_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_736f2fa6-cbcf-4733-8576-233d55feca51_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SharePriceNominalValue_b98063da-dfd5-4edb-b9bc-5a45827ee037_terseLabel_en-US" xlink:label="lab_mnlk_SharePriceNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nominal value (CHF per share)</link:label>
    <link:label id="lab_mnlk_SharePriceNominalValue_label_en-US" xlink:label="lab_mnlk_SharePriceNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price, Nominal Value</link:label>
    <link:label id="lab_mnlk_SharePriceNominalValue_documentation_en-US" xlink:label="lab_mnlk_SharePriceNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price, Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SharePriceNominalValue" xlink:href="mnlk-20231231.xsd#mnlk_SharePriceNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SharePriceNominalValue" xlink:to="lab_mnlk_SharePriceNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_3cc8aa38-82f6-4ff4-a3ae-69c24b81ebb9_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares converted</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_75f71490-7c13-46bf-95d6-82797679ef5c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8e45c763-1c54-4d0b-b8e2-ad05cce21a21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility of the share price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_48616f98-0a79-41ec-b308-a81ef4570111_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:to="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fb4f3961-bfc3-4b4d-9abd-639ee781a723_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview of the Company</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_46b7732f-39bd-46d2-8e4f-30604eb0f9f8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_636fdc8f-e612-462f-a4eb-fd4c99227c27_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_PaymentsOfStampDuty_d365e511-3974-4da0-ba92-50596ce2da04_negatedTerseLabel_en-US" xlink:label="lab_mnlk_PaymentsOfStampDuty" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stamp duty on capital injection from MoonLake to MoonLake AG (Note 12)</link:label>
    <link:label id="lab_mnlk_PaymentsOfStampDuty_label_en-US" xlink:label="lab_mnlk_PaymentsOfStampDuty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Stamp Duty</link:label>
    <link:label id="lab_mnlk_PaymentsOfStampDuty_documentation_en-US" xlink:label="lab_mnlk_PaymentsOfStampDuty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Stamp Duty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PaymentsOfStampDuty" xlink:href="mnlk-20231231.xsd#mnlk_PaymentsOfStampDuty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_PaymentsOfStampDuty" xlink:to="lab_mnlk_PaymentsOfStampDuty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_c3a4139f-1aaf-46ee-be94-3e2f89bb8f0c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_CommonClassARedeemableMember_45486421-fbe2-43f0-b35c-75fa5e23db0c_terseLabel_en-US" xlink:label="lab_mnlk_CommonClassARedeemableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common class A, redeemable</link:label>
    <link:label id="lab_mnlk_CommonClassARedeemableMember_label_en-US" xlink:label="lab_mnlk_CommonClassARedeemableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A, Redeemable [Member]</link:label>
    <link:label id="lab_mnlk_CommonClassARedeemableMember_documentation_en-US" xlink:label="lab_mnlk_CommonClassARedeemableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A, Redeemable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonClassARedeemableMember" xlink:href="mnlk-20231231.xsd#mnlk_CommonClassARedeemableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_CommonClassARedeemableMember" xlink:to="lab_mnlk_CommonClassARedeemableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2984c618-1c8d-4cfd-baf5-dc0d6cfc9f3d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6ec40636-310f-48a1-a589-b241aec599ec_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and Other Payables</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_99164333-c9a7-481f-88de-ab74ddbc3a35_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_4448ba8f-3587-48dc-a34d-6ff638abea02_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_PortoOfficeMember_85f18553-074d-4af8-a4d9-e5a1a1b13356_terseLabel_en-US" xlink:label="lab_mnlk_PortoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Porto Office</link:label>
    <link:label id="lab_mnlk_PortoOfficeMember_label_en-US" xlink:label="lab_mnlk_PortoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Porto Office [Member]</link:label>
    <link:label id="lab_mnlk_PortoOfficeMember_documentation_en-US" xlink:label="lab_mnlk_PortoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Porto Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PortoOfficeMember" xlink:href="mnlk-20231231.xsd#mnlk_PortoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_PortoOfficeMember" xlink:to="lab_mnlk_PortoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_7d87da5b-1f0c-4695-a6d7-ce0feed8e9cd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CH_6779d131-1a5b-49fe-be27-e442f4ad14ce_terseLabel_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_country_CH_label_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_7400ba0e-28ca-413c-9a8e-b16a5ce3c41a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities and short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2d873549-7885-4677-bcaf-73b6f0f6234b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3ae13844-8392-41aa-9cb1-5d197f5f561d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_5d221d22-a9d4-4a10-a9f7-577cd2a16c35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_819b3523-2ee8-49f2-acb7-5e41a27734de_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c005a423-e03e-4bdb-8178-3f1dbeadd47f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_ab1efe71-626b-4f0c-9f23-8bc24014fd8d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9e6e5bc4-cb91-40a9-b5b1-ac1436f8a58c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_fcb115e7-6619-4868-88e6-933968bf1680_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operating activities</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8c17bde4-97d9-46d8-a968-5fdf2bb0c465_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cee723af-6275-462a-b6b3-615cec1de5a2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_60f304e7-f510-47c4-853e-6c117d08c9da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_MoonLakeImmunotherapeuticsMember_bef5bd07-1e9d-4634-a909-f1f4d52ca621_terseLabel_en-US" xlink:label="lab_mnlk_MoonLakeImmunotherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MoonLake Immunotherapeutics</link:label>
    <link:label id="lab_mnlk_MoonLakeImmunotherapeuticsMember_label_en-US" xlink:label="lab_mnlk_MoonLakeImmunotherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MoonLake Immunotherapeutics [Member]</link:label>
    <link:label id="lab_mnlk_MoonLakeImmunotherapeuticsMember_documentation_en-US" xlink:label="lab_mnlk_MoonLakeImmunotherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MoonLake Immunotherapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MoonLakeImmunotherapeuticsMember" xlink:href="mnlk-20231231.xsd#mnlk_MoonLakeImmunotherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_MoonLakeImmunotherapeuticsMember" xlink:to="lab_mnlk_MoonLakeImmunotherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8d90459e-54b0-4b6f-a820-9fefc9ee6b2d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_88228215-26a5-4a88-bbbe-c28ddc94c10f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Class A Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_dc5d7a75-5a7f-47f8-9142-9bc752dfe4a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less redemptions of class A ordinary shares of the class A ordinary shares issued by Helix prior to the closing date (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_477f58b1-16d3-4df9-8e3b-9f360bde0672_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d9877a2-b4ed-422e-8abe-9b4e57fe577d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value per share of Restricted Founder Shares on the grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_AccruedResearchAndDevelopmentExpensesCurrent_352f9659-cef2-4c78-bf47-b731b13a0388_terseLabel_en-US" xlink:label="lab_mnlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_mnlk_AccruedResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_mnlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:label id="lab_mnlk_AccruedResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_mnlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:href="mnlk-20231231.xsd#mnlk_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="lab_mnlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_462d12ae-ca44-4e5e-a0c4-83224ab9dde6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurances</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_68d7c847-b70b-4f61-8f7a-46a08dc83865_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_992fa1d8-f0b8-4ba4-bc33-056aabf649f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_35ce13ce-2aab-49f8-8aa3-0ea8310780cd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f1469cf-7f7c-40e7-9b55-6afa3153298c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_fa8a811e-af1f-4685-bed9-fe15b3b0f665_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_6d37d56d-7c54-4307-952f-9016f8a8f1b4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Allocation [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Allocation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1f8e1438-e2f1-4fda-aa1e-a3b94e5938c5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_OperatingLossCarryforwardExpirationAxis_22165791-139a-432e-9853-bcc5c199745a_terseLabel_en-US" xlink:label="lab_mnlk_OperatingLossCarryforwardExpirationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward Expiration [Axis]</link:label>
    <link:label id="lab_mnlk_OperatingLossCarryforwardExpirationAxis_label_en-US" xlink:label="lab_mnlk_OperatingLossCarryforwardExpirationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward Expiration [Axis]</link:label>
    <link:label id="lab_mnlk_OperatingLossCarryforwardExpirationAxis_documentation_en-US" xlink:label="lab_mnlk_OperatingLossCarryforwardExpirationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLossCarryforwardExpirationAxis" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLossCarryforwardExpirationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationAxis" xlink:to="lab_mnlk_OperatingLossCarryforwardExpirationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_59002c0d-7b50-4a48-9836-b988fa481038_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) / loss of current year</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ConversionOfClassCIntoClassAMember_fc15bc4e-b4bb-44e0-9d18-e883f525ba15_terseLabel_en-US" xlink:label="lab_mnlk_ConversionOfClassCIntoClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Class C into Class A</link:label>
    <link:label id="lab_mnlk_ConversionOfClassCIntoClassAMember_label_en-US" xlink:label="lab_mnlk_ConversionOfClassCIntoClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Class C into Class A [Member]</link:label>
    <link:label id="lab_mnlk_ConversionOfClassCIntoClassAMember_documentation_en-US" xlink:label="lab_mnlk_ConversionOfClassCIntoClassAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Class C into Class A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionOfClassCIntoClassAMember" xlink:href="mnlk-20231231.xsd#mnlk_ConversionOfClassCIntoClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ConversionOfClassCIntoClassAMember" xlink:to="lab_mnlk_ConversionOfClassCIntoClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fc51e3af-3a6b-42d8-a9cf-c83748493c09_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock_fe000f88-461f-4d57-af51-0e880d82ea83_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Allocation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_30041b8d-f5d1-40bc-9a8f-8dd4cd641ef7_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurocommercial Papers</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_133546c9-b720-49ae-8b93-1b69aa81c188_periodStartLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain (loss), beginning balance</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_3706d42d-fce4-43ac-9490-dc7fb9c08b2f_periodEndLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain (loss), ending balance</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_92baf271-8525-4a0d-9f2e-b0e03f68c47a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_TradeAndOtherPayablesCurrent_0d264dce-1cf9-4762-89a5-2de305ff58f3_terseLabel_en-US" xlink:label="lab_mnlk_TradeAndOtherPayablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_mnlk_TradeAndOtherPayablesCurrent_9b000305-1859-4094-9348-280753853116_totalLabel_en-US" xlink:label="lab_mnlk_TradeAndOtherPayablesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mnlk_TradeAndOtherPayablesCurrent_label_en-US" xlink:label="lab_mnlk_TradeAndOtherPayablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade And Other Payables, Current</link:label>
    <link:label id="lab_mnlk_TradeAndOtherPayablesCurrent_documentation_en-US" xlink:label="lab_mnlk_TradeAndOtherPayablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade And Other Payables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TradeAndOtherPayablesCurrent" xlink:href="mnlk-20231231.xsd#mnlk_TradeAndOtherPayablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_TradeAndOtherPayablesCurrent" xlink:to="lab_mnlk_TradeAndOtherPayablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_26108f2c-183f-42e3-81c9-e28552f9bfe0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d3d4e3e3-bcac-4c60-8ce8-3db81f881ee6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_0349fed9-8c6f-4cc5-8c12-562c43813aec_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MoonLake AG Restricted Founder Shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0de1bbd3-ad8f-4956-870c-544056a9ca4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary_70e7ae32-c84b-4887-ac3b-e25f3a63c54b_terseLabel_en-US" xlink:label="lab_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital injection from MoonLake to MoonLake AG (Note 12)</link:label>
    <link:label id="lab_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary_label_en-US" xlink:label="lab_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase From Capital Injection In Subsidiary</link:label>
    <link:label id="lab_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary_documentation_en-US" xlink:label="lab_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase From Capital Injection In Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" xlink:href="mnlk-20231231.xsd#mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" xlink:to="lab_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_RiskAndLiquidityDisclosureTextBlock_ea210131-4b15-4e26-af03-3d2391c9f6b4_terseLabel_en-US" xlink:label="lab_mnlk_RiskAndLiquidityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Liquidity</link:label>
    <link:label id="lab_mnlk_RiskAndLiquidityDisclosureTextBlock_label_en-US" xlink:label="lab_mnlk_RiskAndLiquidityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk And Liquidity Disclosure [Text Block]</link:label>
    <link:label id="lab_mnlk_RiskAndLiquidityDisclosureTextBlock_documentation_en-US" xlink:label="lab_mnlk_RiskAndLiquidityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk And Liquidity Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RiskAndLiquidityDisclosureTextBlock" xlink:href="mnlk-20231231.xsd#mnlk_RiskAndLiquidityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_RiskAndLiquidityDisclosureTextBlock" xlink:to="lab_mnlk_RiskAndLiquidityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e90100a4-1992-4292-b5fd-71cd7cd7c5d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ab00e61d-a141-43d6-9c4f-8b09f66f946f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of the award</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_d9c08194-99a3-4077-9733-a38c6b47958c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c793177-401f-4e9f-aef8-c61e97276862_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) attributable to parent, before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_14e7ea0a-0700-486f-ba72-d3cbc7d3c592_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e822a2e8-2a8e-4f71-b995-fc6aeaa6f214_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_58bde028-2a12-452d-a3f7-467eea085ec1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion and transfer of shares between classes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c0f51ad7-5e14-4e50-8b26-f7403d44141b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f94d98a2-834b-44d4-a807-05da1a6b56db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a347f4b4-710b-4d4d-bdce-000b5d53e462_terseLabel_en-US" xlink:label="lab_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration amount</link:label>
    <link:label id="lab_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Variable Consideration Amount</link:label>
    <link:label id="lab_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="mnlk-20231231.xsd#mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_168e17ec-a661-419b-a052-9c2c88a130af_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_8b938f35-19a4-4ef5-898d-5ec0db8a71bb_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_6432816c-2cde-4cb8-82bb-133911607d13_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_AuditorInformationAbstract_label_en-US" xlink:label="lab_mnlk_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_mnlk_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_mnlk_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AuditorInformationAbstract" xlink:href="mnlk-20231231.xsd#mnlk_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_AuditorInformationAbstract" xlink:to="lab_mnlk_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1306d86a-05a6-481b-a864-46521d4f32f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_8c332744-e0b5-41b6-aae6-6da4d07e81b7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_0892aa1c-dee9-4e49-b10b-87e7fd1dd279_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation granted under the equity incentive plan ESPP, ESOP, reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b2eaf7d-083c-4027-824a-bd89b61f95aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_6ca180b2-8a5a-42f8-8017-777a53a8ff2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9d489fb2-0e45-48a0-b41f-c2b5f9829d0b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0f6aeb0c-1bc3-49ad-86aa-f904d4226576_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_AccruedSupplyAndManufacturingFeesCurrent_b9d86bdf-c237-4b3c-9b6c-9578ed98db9f_terseLabel_en-US" xlink:label="lab_mnlk_AccruedSupplyAndManufacturingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply and manufacturing services</link:label>
    <link:label id="lab_mnlk_AccruedSupplyAndManufacturingFeesCurrent_label_en-US" xlink:label="lab_mnlk_AccruedSupplyAndManufacturingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Supply And Manufacturing Fees, Current</link:label>
    <link:label id="lab_mnlk_AccruedSupplyAndManufacturingFeesCurrent_documentation_en-US" xlink:label="lab_mnlk_AccruedSupplyAndManufacturingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Supply And Manufacturing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedSupplyAndManufacturingFeesCurrent" xlink:href="mnlk-20231231.xsd#mnlk_AccruedSupplyAndManufacturingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_AccruedSupplyAndManufacturingFeesCurrent" xlink:to="lab_mnlk_AccruedSupplyAndManufacturingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6f158f2c-082c-41b1-95f3-e0e2d70c9c11_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b5145e25-6376-48ce-ab0c-8d4877a38b77_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SaleOfStockOptionToPurchaseTerm_c932df6b-3089-4871-8c0c-e86f6e8f005d_terseLabel_en-US" xlink:label="lab_mnlk_SaleOfStockOptionToPurchaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, option to purchase, term</link:label>
    <link:label id="lab_mnlk_SaleOfStockOptionToPurchaseTerm_label_en-US" xlink:label="lab_mnlk_SaleOfStockOptionToPurchaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Option To Purchase, Term</link:label>
    <link:label id="lab_mnlk_SaleOfStockOptionToPurchaseTerm_documentation_en-US" xlink:label="lab_mnlk_SaleOfStockOptionToPurchaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Option To Purchase, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockOptionToPurchaseTerm" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockOptionToPurchaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SaleOfStockOptionToPurchaseTerm" xlink:to="lab_mnlk_SaleOfStockOptionToPurchaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_2a326614-be41-4b84-b87f-b56a7104edc8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7bb0d9bd-83c8-4f90-a73d-3e81149bb29a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2ceebc26-21df-4382-a41e-44d1e7432366_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_2e240305-8f76-4318-9998-d17471118ce0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement_8884f7c7-720a-4536-beba-f318e3d60300_terseLabel_en-US" xlink:label="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emission fees and capital tax payments on share issuance</link:label>
    <link:label id="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement_label_en-US" xlink:label="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Emission Fee Reimbursement</link:label>
    <link:label id="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement_documentation_en-US" xlink:label="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Emission Fee Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" xlink:href="mnlk-20231231.xsd#mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" xlink:to="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_CambridgeOfficeMember_ee68e679-dc08-480c-a52c-1f5f9c33f502_terseLabel_en-US" xlink:label="lab_mnlk_CambridgeOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge Office</link:label>
    <link:label id="lab_mnlk_CambridgeOfficeMember_label_en-US" xlink:label="lab_mnlk_CambridgeOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge Office [Member]</link:label>
    <link:label id="lab_mnlk_CambridgeOfficeMember_documentation_en-US" xlink:label="lab_mnlk_CambridgeOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CambridgeOfficeMember" xlink:href="mnlk-20231231.xsd#mnlk_CambridgeOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_CambridgeOfficeMember" xlink:to="lab_mnlk_CambridgeOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f0729cca-055a-4edd-a3fc-ab381de1a4b6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f31c4d57-fbca-4891-9286-cce0fa9c2396_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_27397d4e-7df3-4b4f-92ab-3ae316e5ca90_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3b2056f6-27cb-4b49-bec8-47214e3693dc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0b545b2f-0c8d-4427-8f24-2585ba3d881e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_52736ca0-f083-4680-b370-0c6e7015a792_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_UnrecognizedCommitmentsAndContingencies_1f7844ee-e263-4564-8ec9-81d5d2d15f98_terseLabel_en-US" xlink:label="lab_mnlk_UnrecognizedCommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total commitments not yet recognized</link:label>
    <link:label id="lab_mnlk_UnrecognizedCommitmentsAndContingencies_label_en-US" xlink:label="lab_mnlk_UnrecognizedCommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Commitments And Contingencies</link:label>
    <link:label id="lab_mnlk_UnrecognizedCommitmentsAndContingencies_documentation_en-US" xlink:label="lab_mnlk_UnrecognizedCommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Commitments And Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_UnrecognizedCommitmentsAndContingencies" xlink:href="mnlk-20231231.xsd#mnlk_UnrecognizedCommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_UnrecognizedCommitmentsAndContingencies" xlink:to="lab_mnlk_UnrecognizedCommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ba7a1d92-d7b1-416f-a395-52e4d200c8c6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_783100c4-e559-4c9c-b220-ae7800bb1c64_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9836a2ae-f0b0-4343-ad65-da4f68111efd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1ff85101-4901-4043-b115-c1aa36031d2e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a6bfc6bc-d210-491d-a1c6-2345b4437d4a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, end balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9e51d4a7-9747-4f7e-809e-6916ccfdc4e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fe8dddae-6aa1-43f0-af22-702124e08c61_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ceb968fe-7508-482b-87f6-6faeea702d2d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a334c7ed-e4e6-4f0d-9b07-d62eeace7de2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f4421d05-899d-4cd7-a549-9c042615d65f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_173a3e43-7148-4cf0-94b0-bced44f40c90_verboseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1cc06b31-7624-4bb2-b622-29cc851d34f1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5391e483-6231-4e28-9a5c-ac17d1dc4696_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ReverseRecapitalizationAccruedExpenses_1a78ee5a-8ae8-4d0c-aaa0-cb9fc6719c62_negatedTerseLabel_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">of which accrued expenses</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationAccruedExpenses_label_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Accrued Expenses</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationAccruedExpenses_documentation_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAccruedExpenses" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ReverseRecapitalizationAccruedExpenses" xlink:to="lab_mnlk_ReverseRecapitalizationAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_dbf03362-f4a7-4336-8ca4-2132e68a16e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning PBO</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_643d61d4-17e7-44cd-ac05-81912ae6e283_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending PBO</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SaleOfStockStampDutyTax_377a7477-5527-4497-8d94-7313ae47e701_terseLabel_en-US" xlink:label="lab_mnlk_SaleOfStockStampDutyTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stamp duty tax</link:label>
    <link:label id="lab_mnlk_SaleOfStockStampDutyTax_label_en-US" xlink:label="lab_mnlk_SaleOfStockStampDutyTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Stamp Duty Tax</link:label>
    <link:label id="lab_mnlk_SaleOfStockStampDutyTax_documentation_en-US" xlink:label="lab_mnlk_SaleOfStockStampDutyTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Stamp Duty Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockStampDutyTax" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockStampDutyTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SaleOfStockStampDutyTax" xlink:to="lab_mnlk_SaleOfStockStampDutyTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_CommonStockVotesMultiplier_1cb6df7a-4a87-49ef-ae33-84ea510ab01b_terseLabel_en-US" xlink:label="lab_mnlk_CommonStockVotesMultiplier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, votes per share multiplier</link:label>
    <link:label id="lab_mnlk_CommonStockVotesMultiplier_label_en-US" xlink:label="lab_mnlk_CommonStockVotesMultiplier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Votes Multiplier</link:label>
    <link:label id="lab_mnlk_CommonStockVotesMultiplier_documentation_en-US" xlink:label="lab_mnlk_CommonStockVotesMultiplier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Votes Multiplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockVotesMultiplier" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockVotesMultiplier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_CommonStockVotesMultiplier" xlink:to="lab_mnlk_CommonStockVotesMultiplier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1149b22f-0401-4aac-8304-205155e69ad4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax_b0b0a9ab-7be5-48b4-aeb4-d2d183ae0aff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_2b844de5-ea9e-496c-b81e-c09efdc98652_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_d3b57e11-93d0-4a5e-bf32-f51cefb1c05c_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_34894155-71ff-4d48-a418-4ef7ba7f0bd2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_40b53b5d-71f5-4d51-b6aa-ac35651d6c65_negatedLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3f5fe832-63e5-4168-8871-264e2cfff5c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cccbf30-d170-4398-b21a-dcbd62b6b5f7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_dd2db0a3-5308-4f0c-9ede-919cbbc660f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_54be2c2a-e54c-4a59-80d8-fe92e74d9397_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_StockForfeitedReverseRecapitalization_73c40dab-5e24-4931-b0e9-035b24e773cb_terseLabel_en-US" xlink:label="lab_mnlk_StockForfeitedReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock forfeited (in shares)</link:label>
    <link:label id="lab_mnlk_StockForfeitedReverseRecapitalization_label_en-US" xlink:label="lab_mnlk_StockForfeitedReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Forfeited, Reverse Recapitalization</link:label>
    <link:label id="lab_mnlk_StockForfeitedReverseRecapitalization_documentation_en-US" xlink:label="lab_mnlk_StockForfeitedReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Forfeited, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockForfeitedReverseRecapitalization" xlink:href="mnlk-20231231.xsd#mnlk_StockForfeitedReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_StockForfeitedReverseRecapitalization" xlink:to="lab_mnlk_StockForfeitedReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e12a2e6f-1f47-4d2d-b63e-aa463c847bc8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DefinedBenefitPlanBondMember_65c43d99-28b9-4078-94ab-f9d919df3517_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonds</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanBondMember_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Bond [Member]</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanBondMember_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanBondMember" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanBondMember" xlink:to="lab_mnlk_DefinedBenefitPlanBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_CommonClassAPrivatePlacementMember_1536879e-524c-445f-90eb-dee0e9ee4cfe_terseLabel_en-US" xlink:label="lab_mnlk_CommonClassAPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common class A, private placement</link:label>
    <link:label id="lab_mnlk_CommonClassAPrivatePlacementMember_label_en-US" xlink:label="lab_mnlk_CommonClassAPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A, Private Placement [Member]</link:label>
    <link:label id="lab_mnlk_CommonClassAPrivatePlacementMember_documentation_en-US" xlink:label="lab_mnlk_CommonClassAPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A, Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonClassAPrivatePlacementMember" xlink:href="mnlk-20231231.xsd#mnlk_CommonClassAPrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_CommonClassAPrivatePlacementMember" xlink:to="lab_mnlk_CommonClassAPrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fd86ada8-52d5-4a4c-88c6-3d3f3e000e2f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount_1a9e526d-7498-432f-99ba-2d29ac92d0dd_terseLabel_en-US" xlink:label="lab_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining authorized repurchase amount</link:label>
    <link:label id="lab_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount_label_en-US" xlink:label="lab_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Authorized Repurchase Amount</link:label>
    <link:label id="lab_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount_documentation_en-US" xlink:label="lab_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount" xlink:to="lab_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8cb0ce0a-7d99-46f2-840a-509371c8c67c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7a271a21-1758-4935-8f20-70fe1adf1d31_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_f09320a5-73b2-4775-a565-bb2299853eff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rates changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_55a1f766-3402-4880-ab3c-e6fb0027d208_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_97346d8c-aa4e-4aa1-8a9e-b04c03f3fa5e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share attributable to controlling interest shareholders (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8c8b378f-126c-4fcd-88f0-886ba4edb3af_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f5001fa1-388d-4891-923b-9310f9ff7a1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8325cd5b-cb7b-4d9e-9881-17058f7d1816_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0c73dd8e-be36-4237-ae11-b4c60828d2aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent_9c1636d2-178f-48ed-bf9e-712cc1b8d2ce_terseLabel_en-US" xlink:label="lab_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other consulting and advisory services</link:label>
    <link:label id="lab_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent_label_en-US" xlink:label="lab_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Consulting And Advisory Fees, Current</link:label>
    <link:label id="lab_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent_documentation_en-US" xlink:label="lab_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Consulting And Advisory Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent" xlink:href="mnlk-20231231.xsd#mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent" xlink:to="lab_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_74e2cee8-7c1e-4c80-8864-66bde84eccdb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ProceedsFromReverseRecapitalization_08fd43ae-4f17-43b5-9871-2bb98b2ae23b_terseLabel_en-US" xlink:label="lab_mnlk_ProceedsFromReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Business Combination</link:label>
    <link:label id="lab_mnlk_ProceedsFromReverseRecapitalization_label_en-US" xlink:label="lab_mnlk_ProceedsFromReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Reverse Recapitalization</link:label>
    <link:label id="lab_mnlk_ProceedsFromReverseRecapitalization_documentation_en-US" xlink:label="lab_mnlk_ProceedsFromReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ProceedsFromReverseRecapitalization" xlink:href="mnlk-20231231.xsd#mnlk_ProceedsFromReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ProceedsFromReverseRecapitalization" xlink:to="lab_mnlk_ProceedsFromReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0c376118-116d-4627-be98-72bf80e4d0a7_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_412a39eb-381a-4548-be67-f83f16a556da_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments_546f1c4a-f71c-47b3-90d0-dcae7be1c8bb_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid, Net Of Adjustments</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid, Net Of Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" xlink:to="lab_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_5215c818-4ff1-4da8-a10a-46ebe7301509_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9946562b-ab8d-46c1-9bb5-4a81832ba655_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2e368562-8b09-48e4-a0cc-2fee197ab4a9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by plan participants</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassCMember_d599ebd9-bf99-43f3-8f0e-d9a5d8e8c3fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class C</link:label>
    <link:label id="lab_us-gaap_CommonClassCMember_label_en-US" xlink:label="lab_us-gaap_CommonClassCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassCMember" xlink:to="lab_us-gaap_CommonClassCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_6f83fdb5-8364-4a19-ae55-9b14fb4969e8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension liability</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_f13e77e7-d6c5-48d3-a142-2fb856b4fa3e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0a3b1dff-0f21-4134-8dde-c34d7960425b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_StockConvertedReverseRecapitalization_a6d5f8f3-42dc-48c0-bfa3-3102305440bb_terseLabel_en-US" xlink:label="lab_mnlk_StockConvertedReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Helix Class C ordinary shares to ML parties (other than the BVF shareholders) (in shares)</link:label>
    <link:label id="lab_mnlk_StockConvertedReverseRecapitalization_89b1cf5d-397a-4e65-83e0-a09430c18051_verboseLabel_en-US" xlink:label="lab_mnlk_StockConvertedReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock converted (in shares)</link:label>
    <link:label id="lab_mnlk_StockConvertedReverseRecapitalization_label_en-US" xlink:label="lab_mnlk_StockConvertedReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Converted, Reverse Recapitalization</link:label>
    <link:label id="lab_mnlk_StockConvertedReverseRecapitalization_documentation_en-US" xlink:label="lab_mnlk_StockConvertedReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Converted, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockConvertedReverseRecapitalization" xlink:href="mnlk-20231231.xsd#mnlk_StockConvertedReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_StockConvertedReverseRecapitalization" xlink:to="lab_mnlk_StockConvertedReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_74c270b2-c69a-405a-ae53-6c50c3fac19a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_13b6ad31-aab7-4f6c-bc53-7d571cd00739_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3f5aef72-84d5-4e38-bdaf-d7385b6ae328_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b00e8cc9-5c83-4478-bcf8-fe963d86b6a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_7b69af44-bd59-45cc-b677-72ec35f746ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other payables</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_09857797-53a3-4d80-854a-124a8bcfbddf_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5fbd717-b973-4285-a655-23e5cc52aa38_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_2598bc68-0dd9-4441-95b6-147080fc5e55_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_82641bc1-5209-4098-8734-51e7a4e2e3bb_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7fb5bdba-597a-47ff-a089-95ed5a1f711a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_459f9398-80e6-4d3e-8da7-4d39ede2feb2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns_4f7ec83c-3896-4f0a-9a35-2ba78cde1ac6_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on plan assets above expected return</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Return Above Expected Returns</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Return Above Expected Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" xlink:to="lab_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2516592c-7b7f-4ffc-8596-9f595eca6f61_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_f1ddff02-0c9f-4e20-b63e-5762f8a40a10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:to="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_79604b85-df8c-4566-8fa4-25421c173bda_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_bb439e6b-1515-42e2-8ede-e2199349de90_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendment</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_6b1a50a3-4e83-4f3b-b44b-d4b904be3343_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_997d8179-e3d3-4630-8c30-338db907ee6b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromParent_11703148-5d45-4302-b4f7-4c7c7ebea3aa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from contributions from parent</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromParent_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributions from Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromParent" xlink:to="lab_us-gaap_ProceedsFromContributionsFromParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent_365be669-f168-4111-aa39-f146336dd307_terseLabel_en-US" xlink:label="lab_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development services and license fees</link:label>
    <link:label id="lab_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent_label_en-US" xlink:label="lab_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Services and License Fees, Current</link:label>
    <link:label id="lab_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent_documentation_en-US" xlink:label="lab_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Services and License Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" xlink:href="mnlk-20231231.xsd#mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" xlink:to="lab_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_MoonLakeAGMember_6edb7c53-6983-461f-a19b-c30e5db5d851_terseLabel_en-US" xlink:label="lab_mnlk_MoonLakeAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MoonLake AG</link:label>
    <link:label id="lab_mnlk_MoonLakeAGMember_label_en-US" xlink:label="lab_mnlk_MoonLakeAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MoonLake AG [Member]</link:label>
    <link:label id="lab_mnlk_MoonLakeAGMember_documentation_en-US" xlink:label="lab_mnlk_MoonLakeAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MoonLake AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MoonLakeAGMember" xlink:href="mnlk-20231231.xsd#mnlk_MoonLakeAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_MoonLakeAGMember" xlink:to="lab_mnlk_MoonLakeAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_e42e9067-413e-452d-9ff3-9fa8eddc0fc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e3506718-4a6f-4fe2-8f64-92ac4d839a31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7705a941-a734-49b6-84b4-0e46dbd1f3f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_b0a198ab-d4b7-446e-bc22-3d677b5230ce_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_OperatingLeaseAreaOfLeasedSpace_f6595a48-987d-4fa2-bf67-210816c3859e_terseLabel_en-US" xlink:label="lab_mnlk_OperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square foot of leased space</link:label>
    <link:label id="lab_mnlk_OperatingLeaseAreaOfLeasedSpace_label_en-US" xlink:label="lab_mnlk_OperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Area of Leased Space</link:label>
    <link:label id="lab_mnlk_OperatingLeaseAreaOfLeasedSpace_documentation_en-US" xlink:label="lab_mnlk_OperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Area of Leased Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLeaseAreaOfLeasedSpace" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLeaseAreaOfLeasedSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_OperatingLeaseAreaOfLeasedSpace" xlink:to="lab_mnlk_OperatingLeaseAreaOfLeasedSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SupplyAndManufacturingFeesPayableCurrent_e455152f-4f13-4b14-9ca8-c4ffa8a089d9_terseLabel_en-US" xlink:label="lab_mnlk_SupplyAndManufacturingFeesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply and manufacturing fees payable</link:label>
    <link:label id="lab_mnlk_SupplyAndManufacturingFeesPayableCurrent_label_en-US" xlink:label="lab_mnlk_SupplyAndManufacturingFeesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Fees Payable, Current</link:label>
    <link:label id="lab_mnlk_SupplyAndManufacturingFeesPayableCurrent_documentation_en-US" xlink:label="lab_mnlk_SupplyAndManufacturingFeesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Fees Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SupplyAndManufacturingFeesPayableCurrent" xlink:href="mnlk-20231231.xsd#mnlk_SupplyAndManufacturingFeesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SupplyAndManufacturingFeesPayableCurrent" xlink:to="lab_mnlk_SupplyAndManufacturingFeesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_316850d7-502c-4e2a-8bb4-7f993043299a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of debt securities by level within the fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_fce7e32e-9730-4835-823b-2c56f2e8442c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_e8a8bb86-899d-4f37-8091-e5ec1526b52c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MoonLake AG common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_47f22ad4-70fa-4b3f-864a-111dd9452ed3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation granted under the equity incentive plan ESPP, ESOP, and reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cadc5ce5-b7fe-47dc-b784-cfe886ff191b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_306a994b-efbc-4d2c-b54b-fb16e5537ce8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4c0b0fde-da1f-4005-8283-9201fa407a06_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A ordinary shares upon Business Combination (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b2acce69-06c5-4fe8-8217-d8f5c2bd8f77_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus issuance of helix class A ordinary shares to BVF shareholders (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b4562102-6414-49fb-9523-7a2d221abbe7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_bd3408ee-19c7-417b-99ba-6014d0bcbb10_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_04ef45a5-b694-410a-bcf8-0627051a318b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_MLPartiesOtherThanBVFShareholdersMember_c4b29376-eab2-4494-bc8c-473013534c97_terseLabel_en-US" xlink:label="lab_mnlk_MLPartiesOtherThanBVFShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ML parties other than BVF shareholders</link:label>
    <link:label id="lab_mnlk_MLPartiesOtherThanBVFShareholdersMember_label_en-US" xlink:label="lab_mnlk_MLPartiesOtherThanBVFShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ML Parties Other Than BVF Shareholders [Member]</link:label>
    <link:label id="lab_mnlk_MLPartiesOtherThanBVFShareholdersMember_documentation_en-US" xlink:label="lab_mnlk_MLPartiesOtherThanBVFShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ML Parties Other Than BVF Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MLPartiesOtherThanBVFShareholdersMember" xlink:href="mnlk-20231231.xsd#mnlk_MLPartiesOtherThanBVFShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_MLPartiesOtherThanBVFShareholdersMember" xlink:to="lab_mnlk_MLPartiesOtherThanBVFShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_7e042f63-2d16-45cc-b628-89d7d033aca5_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_RecapitalizationExchangeRatio_a153e43c-f1bb-4b3b-8517-f031d40c8873_terseLabel_en-US" xlink:label="lab_mnlk_RecapitalizationExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_mnlk_RecapitalizationExchangeRatio_label_en-US" xlink:label="lab_mnlk_RecapitalizationExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recapitalization Exchange Ratio</link:label>
    <link:label id="lab_mnlk_RecapitalizationExchangeRatio_documentation_en-US" xlink:label="lab_mnlk_RecapitalizationExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recapitalization Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RecapitalizationExchangeRatio" xlink:href="mnlk-20231231.xsd#mnlk_RecapitalizationExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_RecapitalizationExchangeRatio" xlink:to="lab_mnlk_RecapitalizationExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ReverseRecapitalizationTransactionCosts_cecdfe50-7dc9-4f74-a9e4-671598641b32_negatedTotalLabel_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Helix transaction expense</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationTransactionCosts_label_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Transaction Costs</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationTransactionCosts_documentation_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationTransactionCosts" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ReverseRecapitalizationTransactionCosts" xlink:to="lab_mnlk_ReverseRecapitalizationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_365c9aab-5eb7-4eec-8df9-b2bbe6b11e51_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_August2023SalesAgreementMember_df09d66d-44da-410e-9a99-cd1e8a167364_terseLabel_en-US" xlink:label="lab_mnlk_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Sales Agreement</link:label>
    <link:label id="lab_mnlk_August2023SalesAgreementMember_label_en-US" xlink:label="lab_mnlk_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Sales Agreement [Member]</link:label>
    <link:label id="lab_mnlk_August2023SalesAgreementMember_documentation_en-US" xlink:label="lab_mnlk_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_August2023SalesAgreementMember" xlink:href="mnlk-20231231.xsd#mnlk_August2023SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_August2023SalesAgreementMember" xlink:to="lab_mnlk_August2023SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_7831479c-3927-4eb0-9c53-7a939515800d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d3a8e37b-b33a-4d93-8a94-47889a3ae388_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_4282ee2a-8ebe-4dc7-a83e-766d11a54166_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1e94e181-a083-449e-b77c-ab58536b0d8e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PT_3b67521d-20f3-4ee0-9bf1-578338a4cd75_terseLabel_en-US" xlink:label="lab_country_PT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portugal</link:label>
    <link:label id="lab_country_PT_label_en-US" xlink:label="lab_country_PT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PORTUGAL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PT" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_PT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PT" xlink:to="lab_country_PT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e72a8fea-a2bb-480f-a000-4f374d849c90_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_bbe8813b-7709-4c9a-b282-aee5b7616014_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2beb845a-18ce-4e85-ba7d-e1147617d71e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_85e8b563-c50b-438c-805c-1c373608b828_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DefinedBenefitPlanInfrastructureMember_4138678c-0346-446c-8bad-c9a7944ab592_terseLabel_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanInfrastructureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infrastructure</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanInfrastructureMember_label_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanInfrastructureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Infrastructure [Member]</link:label>
    <link:label id="lab_mnlk_DefinedBenefitPlanInfrastructureMember_documentation_en-US" xlink:label="lab_mnlk_DefinedBenefitPlanInfrastructureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Infrastructure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanInfrastructureMember" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanInfrastructureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DefinedBenefitPlanInfrastructureMember" xlink:to="lab_mnlk_DefinedBenefitPlanInfrastructureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_487ea37d-931c-42a0-a003-e31a557985d4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses and related employees compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock_7a48925d-8b15-481e-876b-a5724717ea44_terseLabel_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Proceeds and Ordinary Shares Issued</link:label>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock_label_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reverse Recapitalization [Table Text Block]</link:label>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock_documentation_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:to="lab_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_21848bf1-4906-4b6c-925c-c93d65ec1bb6_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b380ddaf-4125-498d-818a-34e0d52da54d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ReverseRecapitalizationAbstract_label_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization [Abstract]</link:label>
    <link:label id="lab_mnlk_ReverseRecapitalizationAbstract_documentation_en-US" xlink:label="lab_mnlk_ReverseRecapitalizationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAbstract" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract" xlink:to="lab_mnlk_ReverseRecapitalizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrentAbstract_4ef9dfc7-a5c3-40e9-9584-0bb5d3b1e3d9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses - non-current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_332ac7d3-ddb1-4be3-9124-4574333bc732_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Financing Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5f6c3d17-4b5d-4d47-a983-cd83019a5640_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_2c4e6402-f212-45fa-9818-f2e6f02a5de3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity (deficit)</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_40f9b644-c06c-44f0-9cf7-4b4b00ed1d29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a7fcf6e2-5814-424f-bf56-99ff00b339c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in months)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_a9ac03bc-67f1-42da-b1f4-731fb79cda0c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_CurrentAssetsInExcessOfCurrentLiabilities_b5b49f7a-ebc4-4b6d-b21b-0364f3f9619e_terseLabel_en-US" xlink:label="lab_mnlk_CurrentAssetsInExcessOfCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of current assets less current liabilities</link:label>
    <link:label id="lab_mnlk_CurrentAssetsInExcessOfCurrentLiabilities_label_en-US" xlink:label="lab_mnlk_CurrentAssetsInExcessOfCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets In Excess Of Current Liabilities</link:label>
    <link:label id="lab_mnlk_CurrentAssetsInExcessOfCurrentLiabilities_documentation_en-US" xlink:label="lab_mnlk_CurrentAssetsInExcessOfCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets In Excess Of Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CurrentAssetsInExcessOfCurrentLiabilities" xlink:href="mnlk-20231231.xsd#mnlk_CurrentAssetsInExcessOfCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_CurrentAssetsInExcessOfCurrentLiabilities" xlink:to="lab_mnlk_CurrentAssetsInExcessOfCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_31426ded-35c7-4d99-a4aa-ba258644ca1c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_7af7f6c0-267e-4122-bee4-fd0c9817771f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_1abaf0ce-2e8b-4cc1-b6b6-7d8187259314_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_82d2a3be-5df5-4ea6-8366-c80ad985caf9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_311bccb3-dd72-407f-aa8f-37e0959c1a0e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_989b1c6a-acaa-4247-b2a4-c7bcf2b7db04_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_80219111-601a-491a-ab85-3ae23012bd88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a0f91ecd-6e7f-456e-9dd1-fd8ea8261b66_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ClassVVotingStockMember_4101c851-37ed-4a1e-97f4-86d4c8326753_terseLabel_en-US" xlink:label="lab_mnlk_ClassVVotingStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class V Voting Stock</link:label>
    <link:label id="lab_mnlk_ClassVVotingStockMember_label_en-US" xlink:label="lab_mnlk_ClassVVotingStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class V Voting Stock [Member]</link:label>
    <link:label id="lab_mnlk_ClassVVotingStockMember_documentation_en-US" xlink:label="lab_mnlk_ClassVVotingStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class V Voting Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ClassVVotingStockMember" xlink:href="mnlk-20231231.xsd#mnlk_ClassVVotingStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ClassVVotingStockMember" xlink:to="lab_mnlk_ClassVVotingStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4fe49b8a-2d36-42c2-a323-0e5d32aacd28_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRentCurrent_12521786-d8c6-491b-85ed-e80b37031e70_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent / leases</link:label>
    <link:label id="lab_us-gaap_AccruedRentCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rent, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrent" xlink:to="lab_us-gaap_AccruedRentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAbstract_99c207b0-f74b-4f40-a7c8-b410a6eb731c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses - current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a18ffdb8-38a6-44c2-b3c6-8cba5f7cd241_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_TotalSharesRollForward_a240e18e-41ce-468f-9aa7-192a0d8f3ded_terseLabel_en-US" xlink:label="lab_mnlk_TotalSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number of Shares</link:label>
    <link:label id="lab_mnlk_TotalSharesRollForward_label_en-US" xlink:label="lab_mnlk_TotalSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares [Roll Forward]</link:label>
    <link:label id="lab_mnlk_TotalSharesRollForward_documentation_en-US" xlink:label="lab_mnlk_TotalSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TotalSharesRollForward" xlink:href="mnlk-20231231.xsd#mnlk_TotalSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_TotalSharesRollForward" xlink:to="lab_mnlk_TotalSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_d41df0cf-d3a6-4a0d-adb3-c41eba34d936_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_UnderwritingAgreementMember_bb1110ce-bb93-408d-9407-1057f5d8d475_terseLabel_en-US" xlink:label="lab_mnlk_UnderwritingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting Agreement</link:label>
    <link:label id="lab_mnlk_UnderwritingAgreementMember_label_en-US" xlink:label="lab_mnlk_UnderwritingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
    <link:label id="lab_mnlk_UnderwritingAgreementMember_documentation_en-US" xlink:label="lab_mnlk_UnderwritingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_UnderwritingAgreementMember" xlink:href="mnlk-20231231.xsd#mnlk_UnderwritingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_UnderwritingAgreementMember" xlink:to="lab_mnlk_UnderwritingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_7ba62635-b8e9-465a-813f-b54136188ad3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a6e06f0f-8018-4da7-ad3f-dca6bb3d46a1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9a53d5d0-2e13-4ce6-9ad3-18cc00a4b873_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1580e758-eb20-4696-be4a-e90780cb6733_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total weighted average number of outstanding shares, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_2806b858-9a75-49ff-92a0-e97e3cb1a9e4_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a958286d-5033-40a9-9681-46abf9f0fff1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a3a99f3a-7cd3-49fb-9244-90e6a9d54bc6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_09e01689-db59-4103-82ff-0c78ac008c85_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_79eef8d7-3dd6-43be-b305-d86b6b8eb454_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SaleOfStockAuthorizedAmount_9ae43ce5-2606-47ae-9761-2aba84074df9_terseLabel_en-US" xlink:label="lab_mnlk_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, authorized amount</link:label>
    <link:label id="lab_mnlk_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_mnlk_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:label id="lab_mnlk_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_mnlk_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockAuthorizedAmount" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SaleOfStockAuthorizedAmount" xlink:to="lab_mnlk_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees_9f5b5a26-be0b-4f86-ac00-9fe72f1177ca_terseLabel_en-US" xlink:label="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund of stamp duty fees</link:label>
    <link:label id="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees_label_en-US" xlink:label="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Stamp Duty Fees</link:label>
    <link:label id="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees_documentation_en-US" xlink:label="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Stamp Duty Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees" xlink:href="mnlk-20231231.xsd#mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees" xlink:to="lab_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_9b9c1fbd-015b-4866-ae05-0afb66771bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in CHF per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_81461e84-1641-47ed-9c3c-4d73b4d9b369_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_65a8b202-abee-44ae-bf27-0b226ab566d2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_85573c6f-63d8-4056-9a77-c68539e78adc_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_dbc4fedf-7f95-4023-943a-6514b216c6a7_negatedTerseLabel_en-US" xlink:label="lab_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease, Right Of Use Asset</link:label>
    <link:label id="lab_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease, Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="mnlk-20231231.xsd#mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_111c7233-1d92-48a5-9de6-0e631b4c4b9e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_a2c0b1c6-7aab-4655-85f3-1dc723766bc5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepayments</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_afa0b71a-ed69-4256-aa7b-a5efb75684fb_terseLabel_en-US" xlink:label="lab_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]</link:label>
    <link:label id="lab_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_label_en-US" xlink:label="lab_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]</link:label>
    <link:label id="lab_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_documentation_en-US" xlink:label="lab_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward" xlink:href="mnlk-20231231.xsd#mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward" xlink:to="lab_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_90451d18-6100-4401-a99f-7a0b8b010b1b_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Shares</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89868976-9e00-46c9-82d5-983ec68e9f39_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_a292a135-7707-41a6-903d-90b8501b51b4_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_fb41e464-ffa5-4bd8-86db-e855edaad926_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_30302e2e-4243-46b2-9184-4854c61fb29b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4f1a5071-952a-4663-8051-55748baf220d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information and Geographic Data</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SonelokimabProgramSLKProgramMember_cae3fbc1-388c-4ba0-a178-abf7b8374530_terseLabel_en-US" xlink:label="lab_mnlk_SonelokimabProgramSLKProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SLK Program</link:label>
    <link:label id="lab_mnlk_SonelokimabProgramSLKProgramMember_label_en-US" xlink:label="lab_mnlk_SonelokimabProgramSLKProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonelokimab Program ("SLK Program") [Member]</link:label>
    <link:label id="lab_mnlk_SonelokimabProgramSLKProgramMember_documentation_en-US" xlink:label="lab_mnlk_SonelokimabProgramSLKProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonelokimab Program ("SLK Program")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SonelokimabProgramSLKProgramMember" xlink:href="mnlk-20231231.xsd#mnlk_SonelokimabProgramSLKProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SonelokimabProgramSLKProgramMember" xlink:to="lab_mnlk_SonelokimabProgramSLKProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da9aff17-752e-412d-9aed-6819b943111b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8b7de6f0-cf61-4d8e-a2e3-dca3f39bc49d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e09fe5cd-6136-4b68-be8e-a583d1dda475_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowInvestingActivitiesLesseeAbstract_eb64b205-cc19-4801-8e7d-b0ef50d6c77c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from investing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowInvestingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Investing Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowInvestingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b17e365-aa38-447c-8468-d4008d1284af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carry forward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_80293f28-cf41-4824-a331-6143b4c40d0f_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_747aff38-e098-47a7-a471-d9e24a98dbec_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_97597327-c382-4026-8efb-3f09e6c9b115_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total weighted average number of outstanding shares, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_25cb6b18-a9cd-4852-a27e-0f70e5d66f3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial income (loss) on employee benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_26915d9e-d642-43f0-9688-6280e8f96ccb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ATMSharesMember_94a555f9-784f-4aec-ac05-f61155252d12_terseLabel_en-US" xlink:label="lab_mnlk_ATMSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Shares</link:label>
    <link:label id="lab_mnlk_ATMSharesMember_label_en-US" xlink:label="lab_mnlk_ATMSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Shares [Member]</link:label>
    <link:label id="lab_mnlk_ATMSharesMember_documentation_en-US" xlink:label="lab_mnlk_ATMSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ATMSharesMember" xlink:href="mnlk-20231231.xsd#mnlk_ATMSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ATMSharesMember" xlink:to="lab_mnlk_ATMSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0f3d0172-9819-407f-ab1b-f81b8d0fce40_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationLineItems_e91783dd-7e7e-449c-9217-2ae7ec3a5c55_terseLabel_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reverse Recapitalization [Line Items]</link:label>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationLineItems_label_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reverse Recapitalization [Line Items]</link:label>
    <link:label id="lab_mnlk_ScheduleOfReverseRecapitalizationLineItems_documentation_en-US" xlink:label="lab_mnlk_ScheduleOfReverseRecapitalizationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reverse Recapitalization [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems" xlink:to="lab_mnlk_ScheduleOfReverseRecapitalizationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_5baa2a70-e388-4fcc-930b-6dccb8928d69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_eeb6754a-3d2e-4625-acda-3fe818e565ef_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Of which classified within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_fd770658-219f-4d43-8335-8235d42e7975_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_CommonStockRollForward_eec564a2-a251-445c-8f9f-44bb86803ad4_terseLabel_en-US" xlink:label="lab_mnlk_CommonStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_mnlk_CommonStockRollForward_label_en-US" xlink:label="lab_mnlk_CommonStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Roll Forward]</link:label>
    <link:label id="lab_mnlk_CommonStockRollForward_documentation_en-US" xlink:label="lab_mnlk_CommonStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockRollForward" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_CommonStockRollForward" xlink:to="lab_mnlk_CommonStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_fcdff36c-9ac3-4421-b2e6-6d1a03261b66_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by plan participants</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ac54ed96-afea-4045-8624-0d788abe65a6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants of additional shares under ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_cd5181f8-6469-43f4-b934-77bd8a1441f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_SupplyAndManufacturingExpenseNoncurrent_ddab3da2-70ec-4fbc-b563-c4d1bef07c97_terseLabel_en-US" xlink:label="lab_mnlk_SupplyAndManufacturingExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply and manufacturing services</link:label>
    <link:label id="lab_mnlk_SupplyAndManufacturingExpenseNoncurrent_label_en-US" xlink:label="lab_mnlk_SupplyAndManufacturingExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Expense, Noncurrent</link:label>
    <link:label id="lab_mnlk_SupplyAndManufacturingExpenseNoncurrent_documentation_en-US" xlink:label="lab_mnlk_SupplyAndManufacturingExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SupplyAndManufacturingExpenseNoncurrent" xlink:href="mnlk-20231231.xsd#mnlk_SupplyAndManufacturingExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_SupplyAndManufacturingExpenseNoncurrent" xlink:to="lab_mnlk_SupplyAndManufacturingExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_d388a94f-05e5-445a-81cf-958685eb43d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5b56fe4e-1a4e-4df5-8739-96ef584830ad_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_9a67d7b6-41a5-4b86-a981-5a0a5be8bfac_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_5ba74d32-974f-45c6-adce-eab71c5d0135_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgages</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_78cefb37-c388-494f-85c5-ddb08fbb75e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of investments in short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlk_Dr.JorgeSantosDaSilvaMember_label_en-US" xlink:label="lab_mnlk_Dr.JorgeSantosDaSilvaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jorge Santos da Silva [Member]</link:label>
    <link:label id="lab_mnlk_Dr.JorgeSantosDaSilvaMember_documentation_en-US" xlink:label="lab_mnlk_Dr.JorgeSantosDaSilvaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jorge Santos da Silva</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_Dr.JorgeSantosDaSilvaMember" xlink:href="mnlk-20231231.xsd#mnlk_Dr.JorgeSantosDaSilvaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlk_Dr.JorgeSantosDaSilvaMember" xlink:to="lab_mnlk_Dr.JorgeSantosDaSilvaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9f41a03b-c4ed-4d7d-a9a3-7d4c5fdf48eb_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_6f7ff906-efee-41a8-95aa-db02ed81a611_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in prior year estimates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_33386aa8-dfe6-4f3f-bb53-9106a7a90a6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_66a86f70-3263-4c44-b082-88125de6c008_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>mnlk-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:25f78456-bf3c-4d7d-8669-3aa27460a960,g:c66f622e-48e1-41cd-88e8-9a7e0d2c3eaf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://moonlaketx.com/role/Cover" xlink:type="simple" xlink:href="mnlk-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_089274ad-8921-4def-b51e-738bd17a7cf8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_ece3c852-c446-4dbf-8cdf-3302a863f0bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_089274ad-8921-4def-b51e-738bd17a7cf8" xlink:to="loc_dei_DocumentInformationTable_ece3c852-c446-4dbf-8cdf-3302a863f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ece3c852-c446-4dbf-8cdf-3302a863f0bf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_615b5f9a-0543-4f9e-a6b1-5be590453fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f72a70d0-6ed6-48a7-86b6-0bcfcfb52d26" xlink:to="loc_us-gaap_ClassOfStockDomain_615b5f9a-0543-4f9e-a6b1-5be590453fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d4959eb2-c7e7-43e0-a20a-09be3e23d030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_615b5f9a-0543-4f9e-a6b1-5be590453fcd" xlink:to="loc_us-gaap_CommonClassAMember_d4959eb2-c7e7-43e0-a20a-09be3e23d030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_722129b9-b61c-42c3-81cd-9ef0f354c0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_615b5f9a-0543-4f9e-a6b1-5be590453fcd" xlink:to="loc_us-gaap_CommonClassCMember_722129b9-b61c-42c3-81cd-9ef0f354c0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ece3c852-c446-4dbf-8cdf-3302a863f0bf" xlink:to="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_320fa574-868c-4ced-a06e-1fe12a526639" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentType_320fa574-868c-4ced-a06e-1fe12a526639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c9551395-db61-486a-8dda-e33f20fcf66b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentAnnualReport_c9551395-db61-486a-8dda-e33f20fcf66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a9127f05-d2c2-4a9f-9876-230f1cf0fea0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_CurrentFiscalYearEndDate_a9127f05-d2c2-4a9f-9876-230f1cf0fea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8880d6e5-cff9-4130-999f-ceda4dbda2e0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentPeriodEndDate_8880d6e5-cff9-4130-999f-ceda4dbda2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e39fda42-aa69-4597-af6f-51d034e0d634" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentTransitionReport_e39fda42-aa69-4597-af6f-51d034e0d634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ab39ede9-e679-46c0-81ef-8d528817300f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityFileNumber_ab39ede9-e679-46c0-81ef-8d528817300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a7bb7e37-84c6-4e37-9e70-54c3faba9af5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityRegistrantName_a7bb7e37-84c6-4e37-9e70-54c3faba9af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2049e05a-5cb0-4c37-9f7d-091a1c76c6ee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2049e05a-5cb0-4c37-9f7d-091a1c76c6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_24fa03da-42e3-47bd-91e5-7f5e762a7aa6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityTaxIdentificationNumber_24fa03da-42e3-47bd-91e5-7f5e762a7aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_eab299ad-51d2-4347-b3b7-da1abfceac62" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityAddressAddressLine1_eab299ad-51d2-4347-b3b7-da1abfceac62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_45490885-f8ef-4e48-a470-8cc1be1424c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityAddressPostalZipCode_45490885-f8ef-4e48-a470-8cc1be1424c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e009f59b-497f-4cae-8578-2cb3605b3a35" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityAddressCityOrTown_e009f59b-497f-4cae-8578-2cb3605b3a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_fe68fd5f-35dd-4245-97c2-4b32ff2b31e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityAddressCountry_fe68fd5f-35dd-4245-97c2-4b32ff2b31e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_de198459-ab97-4b7b-8adb-11cb77657bba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_CityAreaCode_de198459-ab97-4b7b-8adb-11cb77657bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2c7bc242-3ea8-4c14-a330-74f4b5e1a015" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_LocalPhoneNumber_2c7bc242-3ea8-4c14-a330-74f4b5e1a015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6bc23b49-e7fc-4a63-a455-d275fc0bf1a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_Security12bTitle_6bc23b49-e7fc-4a63-a455-d275fc0bf1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c9d908f2-2846-4500-9ae0-1b4e5ef2b300" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_TradingSymbol_c9d908f2-2846-4500-9ae0-1b4e5ef2b300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_edb57af5-1f90-4ab5-bb62-43feb8b27144" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_SecurityExchangeName_edb57af5-1f90-4ab5-bb62-43feb8b27144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_20fc2a01-93a3-4f61-8152-689fc553eecb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_20fc2a01-93a3-4f61-8152-689fc553eecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_9ff8b107-bce2-47cc-b870-45f0859176bc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityVoluntaryFilers_9ff8b107-bce2-47cc-b870-45f0859176bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c15200a6-8e5e-42a7-9dbe-d72db7e618ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityCurrentReportingStatus_c15200a6-8e5e-42a7-9dbe-d72db7e618ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2b43ad70-5790-45ab-81ed-d952a63ec569" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityInteractiveDataCurrent_2b43ad70-5790-45ab-81ed-d952a63ec569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a6d9df3d-d2c7-44ff-9521-115a2f3eb546" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityFilerCategory_a6d9df3d-d2c7-44ff-9521-115a2f3eb546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_02c040ab-0ab8-446a-b892-c072efa1d9d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntitySmallBusiness_02c040ab-0ab8-446a-b892-c072efa1d9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eff582af-8407-4f58-9f97-3dce47c3387d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityEmergingGrowthCompany_eff582af-8407-4f58-9f97-3dce47c3387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_ddcd5cdd-a27c-4c45-80e6-41381ee48e8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_IcfrAuditorAttestationFlag_ddcd5cdd-a27c-4c45-80e6-41381ee48e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_6d672cfb-2783-493d-b0b2-47f082413686" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_6d672cfb-2783-493d-b0b2-47f082413686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_331e2177-d267-447a-80bb-45afbfa06cc7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityShellCompany_331e2177-d267-447a-80bb-45afbfa06cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_102412b2-9f18-4cd3-96a3-fcc64b518faa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityPublicFloat_102412b2-9f18-4cd3-96a3-fcc64b518faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_937910bc-f845-41c7-94b7-68ec0db84200" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_937910bc-f845-41c7-94b7-68ec0db84200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f7b6ef71-34e0-48ae-bda2-bf7c79d7a756" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f7b6ef71-34e0-48ae-bda2-bf7c79d7a756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_27705019-beb0-4c90-80e1-a7df44b77e7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_AmendmentFlag_27705019-beb0-4c90-80e1-a7df44b77e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4009eea6-5449-4d9e-9fcb-7ff8fa61916f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentFiscalYearFocus_4009eea6-5449-4d9e-9fcb-7ff8fa61916f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f7e18eed-7c3c-4ddb-8e6b-14ff15759204" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f7e18eed-7c3c-4ddb-8e6b-14ff15759204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_64a11978-0bc8-4dab-b8f0-64beb9aa92f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_32b50139-8bd3-471a-b6b5-692f13a8bf14" xlink:to="loc_dei_EntityCentralIndexKey_64a11978-0bc8-4dab-b8f0-64beb9aa92f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/AuditInformation" xlink:type="simple" xlink:href="mnlk-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AuditorInformationAbstract_06621205-a42d-46cc-acd4-a1f9dcf3dd76" xlink:href="mnlk-20231231.xsd#mnlk_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a5f497f7-c8b4-4cc8-9f47-26c71ff15690" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_AuditorInformationAbstract_06621205-a42d-46cc-acd4-a1f9dcf3dd76" xlink:to="loc_dei_AuditorFirmId_a5f497f7-c8b4-4cc8-9f47-26c71ff15690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_f679480d-2370-46d5-b989-6c7e9b63db8b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_AuditorInformationAbstract_06621205-a42d-46cc-acd4-a1f9dcf3dd76" xlink:to="loc_dei_AuditorName_f679480d-2370-46d5-b989-6c7e9b63db8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_43db1cc3-535c-4697-95de-05de1ae426f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_AuditorInformationAbstract_06621205-a42d-46cc-acd4-a1f9dcf3dd76" xlink:to="loc_dei_AuditorLocation_43db1cc3-535c-4697-95de-05de1ae426f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ee60aa77-fbd5-45f5-87e4-488825b7a14d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ae0f316-3299-45d2-a9c9-923dcc1e5221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee60aa77-fbd5-45f5-87e4-488825b7a14d" xlink:to="loc_us-gaap_StatementTable_4ae0f316-3299-45d2-a9c9-923dcc1e5221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a079ac24-479f-4004-bcde-ed2fc5231d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ae0f316-3299-45d2-a9c9-923dcc1e5221" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a079ac24-479f-4004-bcde-ed2fc5231d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_85d49b86-1297-4f41-b1e8-80b7878cc055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a079ac24-479f-4004-bcde-ed2fc5231d8c" xlink:to="loc_us-gaap_ClassOfStockDomain_85d49b86-1297-4f41-b1e8-80b7878cc055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9507ed40-98f1-4d7b-874f-1b09c1214d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_85d49b86-1297-4f41-b1e8-80b7878cc055" xlink:to="loc_us-gaap_CommonClassAMember_9507ed40-98f1-4d7b-874f-1b09c1214d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_e2b7c6b4-75fd-46d6-9d6c-0d3a79096630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_85d49b86-1297-4f41-b1e8-80b7878cc055" xlink:to="loc_us-gaap_CommonClassCMember_e2b7c6b4-75fd-46d6-9d6c-0d3a79096630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ae0f316-3299-45d2-a9c9-923dcc1e5221" xlink:to="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ba997bf-1f07-4bd8-9edd-1a0e3834baa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3ba997bf-1f07-4bd8-9edd-1a0e3834baa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_af46f2b6-c0e6-4d8f-af0f-28ff365890c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_af46f2b6-c0e6-4d8f-af0f-28ff365890c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ef7d3cb3-3784-4805-af72-40670843838d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ef7d3cb3-3784-4805-af72-40670843838d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_97775efe-b959-40d2-b350-eda0c5a7dac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_97775efe-b959-40d2-b350-eda0c5a7dac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a8bbdfbc-4f58-45ab-881c-d28a1758452c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f713492-fdac-4edb-bf84-3ce06b93c618" xlink:to="loc_us-gaap_AssetsCurrent_a8bbdfbc-4f58-45ab-881c-d28a1758452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e4d4c41-097f-414b-87f7-8f9063c2e99f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e4d4c41-097f-414b-87f7-8f9063c2e99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_27829250-196b-451c-98c0-bdf937b72c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_27829250-196b-451c-98c0-bdf937b72c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_24a13e45-e37b-4f16-9dc0-0ac397a78d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_24a13e45-e37b-4f16-9dc0-0ac397a78d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_f0166e5e-f693-4d4b-84c9-dce3e9a896c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8cf35b4c-ef93-4fef-985d-d1b21d7d1d2d" xlink:to="loc_us-gaap_AssetsNoncurrent_f0166e5e-f693-4d4b-84c9-dce3e9a896c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4efcc909-8201-462a-929b-c48bd7984ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_Assets_4efcc909-8201-462a-929b-c48bd7984ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TradeAndOtherPayablesCurrent_c5b7d97a-55c3-49f3-b002-be6801fdaca0" xlink:href="mnlk-20231231.xsd#mnlk_TradeAndOtherPayablesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:to="loc_mnlk_TradeAndOtherPayablesCurrent_c5b7d97a-55c3-49f3-b002-be6801fdaca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f5b169c-9480-47dd-9249-522d501f706f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f5b169c-9480-47dd-9249-522d501f706f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4fd80066-a4d6-4d70-aa4f-4ec87c905c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4fd80066-a4d6-4d70-aa4f-4ec87c905c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_34b7cff0-1000-4eed-a725-1799a9f391bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9328acde-bcea-4300-8978-231b5d8f36e2" xlink:to="loc_us-gaap_LiabilitiesCurrent_34b7cff0-1000-4eed-a725-1799a9f391bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da349f2e-2a25-4356-8a12-8c9b441567e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da349f2e-2a25-4356-8a12-8c9b441567e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0bc609bf-a390-41a0-85e7-7cf69cc7ff1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0bc609bf-a390-41a0-85e7-7cf69cc7ff1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fcd0510d-0dfb-43d0-9c2c-96a235d307e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3cb3b8a1-1a71-4523-9899-54e321df340e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_fcd0510d-0dfb-43d0-9c2c-96a235d307e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0953124b-3cff-487a-8296-1074c0ac3121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_Liabilities_0953124b-3cff-487a-8296-1074c0ac3121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4b23d642-0cc0-4061-abca-a09a11794858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4b23d642-0cc0-4061-abca-a09a11794858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a9b5e073-9c76-4ff2-ac4b-0226422892f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_CommonStockValue_a9b5e073-9c76-4ff2-ac4b-0226422892f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_07d311b1-1093-4ba6-8031-a8c90cd636be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_AdditionalPaidInCapital_07d311b1-1093-4ba6-8031-a8c90cd636be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e91fb5ff-33a3-4ba2-9cc9-8b59f44bd7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e91fb5ff-33a3-4ba2-9cc9-8b59f44bd7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_074ce07d-9344-4abd-897a-03ba1e1afaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_074ce07d-9344-4abd-897a-03ba1e1afaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_985d35d8-63d9-486f-88d6-cffc6c1275c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_StockholdersEquity_985d35d8-63d9-486f-88d6-cffc6c1275c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ecd4c4ad-b966-48f8-af53-5c3671b3dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_MinorityInterest_ecd4c4ad-b966-48f8-af53-5c3671b3dacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_79773ee4-768d-4c9b-afb7-625b1a36ce28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89c85ea8-9119-4b65-ac21-1a3baef7dc59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_79773ee4-768d-4c9b-afb7-625b1a36ce28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c7289a9-01b4-4f93-8e95-6af69f3db30b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7b758a3-8110-4152-9e51-9f35fb533ed1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c7289a9-01b4-4f93-8e95-6af69f3db30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bc1f149f-af09-4732-937c-e4f9cefa67bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_396abef4-a1de-4684-bf79-6822cb09399f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bc1f149f-af09-4732-937c-e4f9cefa67bb" xlink:to="loc_us-gaap_StatementTable_396abef4-a1de-4684-bf79-6822cb09399f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_870972b5-c978-415e-9ffa-31b307e520dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_396abef4-a1de-4684-bf79-6822cb09399f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_870972b5-c978-415e-9ffa-31b307e520dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b0581b7a-2668-418b-aa61-06aa0c33aa97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_870972b5-c978-415e-9ffa-31b307e520dd" xlink:to="loc_us-gaap_ClassOfStockDomain_b0581b7a-2668-418b-aa61-06aa0c33aa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9a9d90ea-22ef-4ddc-b8c3-3f432f897af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b0581b7a-2668-418b-aa61-06aa0c33aa97" xlink:to="loc_us-gaap_CommonClassAMember_9a9d90ea-22ef-4ddc-b8c3-3f432f897af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_c4e71266-fc3d-4d3e-ac58-8e219802ca28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b0581b7a-2668-418b-aa61-06aa0c33aa97" xlink:to="loc_us-gaap_CommonClassCMember_c4e71266-fc3d-4d3e-ac58-8e219802ca28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_396abef4-a1de-4684-bf79-6822cb09399f" xlink:to="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9bbb3524-60ac-410d-a0cb-8f8d7c2a2842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9bbb3524-60ac-410d-a0cb-8f8d7c2a2842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_865e9642-801b-4128-b52c-a2693b1c3aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_865e9642-801b-4128-b52c-a2693b1c3aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2fb5d100-a7d3-4437-a499-d2bf35b7f689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_CommonStockSharesIssued_2fb5d100-a7d3-4437-a499-d2bf35b7f689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b55575e4-3331-42a1-b8f9-10d1329bf4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8ee0e19-8af2-4e97-b043-92c65960b3cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b55575e4-3331-42a1-b8f9-10d1329bf4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_26ae637c-b0ab-4602-be17-e15faf56aa99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_803df6fe-8cc2-43cd-baec-34ac3ce90f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_26ae637c-b0ab-4602-be17-e15faf56aa99" xlink:to="loc_us-gaap_StatementTable_803df6fe-8cc2-43cd-baec-34ac3ce90f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3800b995-c0cb-4e71-bf8f-32eb9e3144a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_803df6fe-8cc2-43cd-baec-34ac3ce90f86" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3800b995-c0cb-4e71-bf8f-32eb9e3144a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ad03ee0-442a-477b-b182-0758f8a7e2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3800b995-c0cb-4e71-bf8f-32eb9e3144a8" xlink:to="loc_us-gaap_ClassOfStockDomain_9ad03ee0-442a-477b-b182-0758f8a7e2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_fc49a007-287f-4f1e-b0ca-71615ba1dea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9ad03ee0-442a-477b-b182-0758f8a7e2a3" xlink:to="loc_us-gaap_CommonClassAMember_fc49a007-287f-4f1e-b0ca-71615ba1dea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_803df6fe-8cc2-43cd-baec-34ac3ce90f86" xlink:to="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e8727a89-946a-4e39-a4da-4a2c075df93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e8727a89-946a-4e39-a4da-4a2c075df93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_19f6c031-d085-41ff-b07b-9939296f7004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_19f6c031-d085-41ff-b07b-9939296f7004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_14cb8d46-2893-45ca-9762-a0c23b2791b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6656bc6e-2119-48c3-8b12-f393a4adf190" xlink:to="loc_us-gaap_OperatingExpenses_14cb8d46-2893-45ca-9762-a0c23b2791b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_452edb57-7815-4587-91af-bff5a722eae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OperatingIncomeLoss_452edb57-7815-4587-91af-bff5a722eae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_34d6347f-7fff-49aa-abe5-e15a94493f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OtherNonoperatingIncome_34d6347f-7fff-49aa-abe5-e15a94493f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_551f78c5-0fd9-4714-98a8-1e9a443f8634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_551f78c5-0fd9-4714-98a8-1e9a443f8634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_032fe4a1-fe09-48f9-b5b2-71a2ba3fc345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_032fe4a1-fe09-48f9-b5b2-71a2ba3fc345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c8d52fe2-646a-4c53-ae50-537d93be2c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_ProfitLoss_c8d52fe2-646a-4c53-ae50-537d93be2c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1837b9ae-7f09-4f0f-ab9e-29dff9f92457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_NetIncomeLoss_1837b9ae-7f09-4f0f-ab9e-29dff9f92457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5840eb5a-62e4-4475-9e85-09d74cb7f335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5840eb5a-62e4-4475-9e85-09d74cb7f335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8b112ad7-b4c6-42e2-8102-7bda574aa634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8b112ad7-b4c6-42e2-8102-7bda574aa634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_28a31212-f5b1-483f-bbe1-34ab017b7838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_28a31212-f5b1-483f-bbe1-34ab017b7838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_75a83482-2a10-4f4a-99a2-2b4692417d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_75a83482-2a10-4f4a-99a2-2b4692417d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2879eae8-b1b5-4fcf-8189-663860ef7998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2879eae8-b1b5-4fcf-8189-663860ef7998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_97c2135e-f2c2-4cae-b74b-402d1a3682c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_97c2135e-f2c2-4cae-b74b-402d1a3682c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a8565ef2-7103-4f1b-9cd6-cc3bd96bb8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a8565ef2-7103-4f1b-9cd6-cc3bd96bb8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_841a5df3-5a81-4b79-9d86-ec55a870c838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_841a5df3-5a81-4b79-9d86-ec55a870c838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2b7940b9-f773-46f3-8334-2becd8bd45c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2b7940b9-f773-46f3-8334-2becd8bd45c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8fbd8944-3916-4074-9554-14b900d22f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8fbd8944-3916-4074-9554-14b900d22f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e563a96-ece1-4c1c-b63e-99a411481eef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a70d017-6ad2-4a54-825d-6e4a81c6fe69" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e563a96-ece1-4c1c-b63e-99a411481eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5ae2a887-3f9e-42db-96b8-0aa80b60637d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5ae2a887-3f9e-42db-96b8-0aa80b60637d" xlink:to="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3ee37c72-b7da-4f70-8e5b-a690d3006331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3ee37c72-b7da-4f70-8e5b-a690d3006331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f1c64c4f-f232-4f5f-8057-1e4fa0099f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3ee37c72-b7da-4f70-8e5b-a690d3006331" xlink:to="loc_us-gaap_EquityComponentDomain_f1c64c4f-f232-4f5f-8057-1e4fa0099f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1c64c4f-f232-4f5f-8057-1e4fa0099f1d" xlink:to="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ee8c0046-531d-4761-992b-58f74a6f3475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_PreferredStockMember_ee8c0046-531d-4761-992b-58f74a6f3475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dfe43770-a964-4d21-a756-a4977000a98e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_CommonStockMember_dfe43770-a964-4d21-a756-a4977000a98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_aa48c652-0a89-4a1e-9b24-1005c30a7fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_TreasuryStockCommonMember_aa48c652-0a89-4a1e-9b24-1005c30a7fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ca780546-3781-422a-a2ed-0d68730e3fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ca780546-3781-422a-a2ed-0d68730e3fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ea1164e3-cd74-45d4-9b01-a0b529756f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_RetainedEarningsMember_ea1164e3-cd74-45d4-9b01-a0b529756f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcf1acd6-7463-4169-86cd-e5ffacd949ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a3d8c578-f5b6-4bec-984a-8787733476b3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcf1acd6-7463-4169-86cd-e5ffacd949ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_25c57b20-ef74-46d8-af70-3f49c95752b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1c64c4f-f232-4f5f-8057-1e4fa0099f1d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_25c57b20-ef74-46d8-af70-3f49c95752b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_a0f85242-01b1-4db0-bd90-c629b7f81da9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_srt_RestatementAxis_a0f85242-01b1-4db0-bd90-c629b7f81da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5b9cb120-4df6-4bc1-9861-bb62b47e5338" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_a0f85242-01b1-4db0-bd90-c629b7f81da9" xlink:to="loc_srt_RestatementDomain_5b9cb120-4df6-4bc1-9861-bb62b47e5338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_557326b1-bafd-4623-acf8-14f97a2410db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5b9cb120-4df6-4bc1-9861-bb62b47e5338" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_557326b1-bafd-4623-acf8-14f97a2410db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_42f7637f-47ca-4671-ac0b-0ef6e8543cc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5b9cb120-4df6-4bc1-9861-bb62b47e5338" xlink:to="loc_srt_RestatementAdjustmentMember_42f7637f-47ca-4671-ac0b-0ef6e8543cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_899cc692-48b8-4268-a411-62bd14b2f629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8bd32dcb-8ca0-4bb1-b8b0-8da957632d6c" xlink:to="loc_us-gaap_ClassOfStockDomain_899cc692-48b8-4268-a411-62bd14b2f629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_32dd9614-f82a-4f08-b4f5-a18e77242d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_899cc692-48b8-4268-a411-62bd14b2f629" xlink:to="loc_us-gaap_CommonClassAMember_32dd9614-f82a-4f08-b4f5-a18e77242d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_f3dca9cf-6376-4d77-a078-b80a6e73a1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_899cc692-48b8-4268-a411-62bd14b2f629" xlink:to="loc_us-gaap_CommonClassCMember_f3dca9cf-6376-4d77-a078-b80a6e73a1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_28532529-8b7e-4c32-80d5-0ec5b348fbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_28532529-8b7e-4c32-80d5-0ec5b348fbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_3afe17a0-ea65-4182-a5ce-d02cbd26314d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_28532529-8b7e-4c32-80d5-0ec5b348fbbc" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_3afe17a0-ea65-4182-a5ce-d02cbd26314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionFollowingBusinessCombinationMember_7caa61cd-5d1a-42ea-ad10-886098b80e6f" xlink:href="mnlk-20231231.xsd#mnlk_ConversionFollowingBusinessCombinationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_3afe17a0-ea65-4182-a5ce-d02cbd26314d" xlink:to="loc_mnlk_ConversionFollowingBusinessCombinationMember_7caa61cd-5d1a-42ea-ad10-886098b80e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionOfClassCIntoClassASharesMember_76c52911-5999-4c6e-b1fe-4847c53ae27f" xlink:href="mnlk-20231231.xsd#mnlk_ConversionOfClassCIntoClassASharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_3afe17a0-ea65-4182-a5ce-d02cbd26314d" xlink:to="loc_mnlk_ConversionOfClassCIntoClassASharesMember_76c52911-5999-4c6e-b1fe-4847c53ae27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b39f5b37-56a3-4f05-aa56-cbe0411e5057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e13fb5b-2134-4678-bff9-4afb3eafe09c" xlink:to="loc_us-gaap_StatementLineItems_b39f5b37-56a3-4f05-aa56-cbe0411e5057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b39f5b37-56a3-4f05-aa56-cbe0411e5057" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_aad830ed-8746-46d8-842b-709cd2806f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_aad830ed-8746-46d8-842b-709cd2806f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f11b4ed9-9b8a-4bad-aa0f-47805ab1572c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f11b4ed9-9b8a-4bad-aa0f-47805ab1572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_199fab9e-68fa-4ada-9c32-23b17aacfc98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_199fab9e-68fa-4ada-9c32-23b17aacfc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_06aeef25-4e30-4880-a890-595b213f8bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_06aeef25-4e30-4880-a890-595b213f8bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization_e0f412de-354c-47da-90e3-92c3cf1ee2e0" xlink:href="mnlk-20231231.xsd#mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization_e0f412de-354c-47da-90e3-92c3cf1ee2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8ac99893-73be-42d8-97df-1c9ccb8a31de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8ac99893-73be-42d8-97df-1c9ccb8a31de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_cbfce7ea-e7c4-4c4b-b45b-0fe2869eae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_cbfce7ea-e7c4-4c4b-b45b-0fe2869eae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9659319a-1707-4f48-97ee-7edadad07a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9659319a-1707-4f48-97ee-7edadad07a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a821bb3b-553b-46f8-9440-d14101672282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a821bb3b-553b-46f8-9440-d14101672282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement_4cf7e36b-a3b1-4276-8bae-f93c5e945be9" xlink:href="mnlk-20231231.xsd#mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement_4cf7e36b-a3b1-4276-8bae-f93c5e945be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6609c863-f6a5-46c9-8fe2-bda90e2c4340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6609c863-f6a5-46c9-8fe2-bda90e2c4340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_de9756e3-6086-48bd-b6cb-5a2a6dd0d789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_de9756e3-6086-48bd-b6cb-5a2a6dd0d789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b6b1246-9f77-4b41-bb9c-75db893369c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_ProfitLoss_4b6b1246-9f77-4b41-bb9c-75db893369c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_61fdd95a-af1f-4ae9-9c58-bbfc32f77ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_61fdd95a-af1f-4ae9-9c58-bbfc32f77ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a6f23566-84d8-481f-a7b1-b62b56d616f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a6f23566-84d8-481f-a7b1-b62b56d616f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1e69d123-49e1-4034-a51a-1660827412fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1e69d123-49e1-4034-a51a-1660827412fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary_4110f4ee-70b6-41f3-a119-7a7bc75af419" xlink:href="mnlk-20231231.xsd#mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary_4110f4ee-70b6-41f3-a119-7a7bc75af419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees_e3f42594-b4f2-45e0-878b-f9f32f07e2e2" xlink:href="mnlk-20231231.xsd#mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees_e3f42594-b4f2-45e0-878b-f9f32f07e2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3b5df86e-f354-4d54-a0e0-36efced6674b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3b5df86e-f354-4d54-a0e0-36efced6674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ead4206e-1f02-4b3a-b9e5-156588d54c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ead4206e-1f02-4b3a-b9e5-156588d54c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4f8aae9b-2f74-413a-950b-7d406e3c4f43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4f8aae9b-2f74-413a-950b-7d406e3c4f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_67b9ef25-b700-4674-8d1e-80dc8876a441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95d95944-e235-4c45-931d-7c3021736e7b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_67b9ef25-b700-4674-8d1e-80dc8876a441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9e9241c7-f4a8-4e22-8076-97493e4ea926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9e9241c7-f4a8-4e22-8076-97493e4ea926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_db050486-1759-4908-8b25-b7403eb47678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9e9241c7-f4a8-4e22-8076-97493e4ea926" xlink:to="loc_us-gaap_ProfitLoss_db050486-1759-4908-8b25-b7403eb47678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63096e0a-6d1b-4487-aa57-619d2051b4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9e9241c7-f4a8-4e22-8076-97493e4ea926" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63096e0a-6d1b-4487-aa57-619d2051b4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f083889a-d427-43a5-86e4-8fd80c4d64a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63096e0a-6d1b-4487-aa57-619d2051b4cc" xlink:to="loc_us-gaap_Depreciation_f083889a-d427-43a5-86e4-8fd80c4d64a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_acfaae74-850b-4feb-93b9-9bd9909f8be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63096e0a-6d1b-4487-aa57-619d2051b4cc" xlink:to="loc_us-gaap_ShareBasedCompensation_acfaae74-850b-4feb-93b9-9bd9909f8be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpenseReversalOfExpenseNoncash_ac05819d-4cb2-4bd0-aad4-60ab53b33270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionExpenseReversalOfExpenseNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63096e0a-6d1b-4487-aa57-619d2051b4cc" xlink:to="loc_us-gaap_PensionExpenseReversalOfExpenseNoncash_ac05819d-4cb2-4bd0-aad4-60ab53b33270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_10e8268c-e4b1-4dbf-9d8d-8f0a74742d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63096e0a-6d1b-4487-aa57-619d2051b4cc" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_10e8268c-e4b1-4dbf-9d8d-8f0a74742d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5340eece-f648-4710-93ea-77f7c320b01f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_63096e0a-6d1b-4487-aa57-619d2051b4cc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5340eece-f648-4710-93ea-77f7c320b01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_a312511c-a4a3-4bee-9446-d175859a6680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5340eece-f648-4710-93ea-77f7c320b01f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_a312511c-a4a3-4bee-9446-d175859a6680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_562b02cc-cb44-419d-a0de-101929f3b8bf" xlink:href="mnlk-20231231.xsd#mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5340eece-f648-4710-93ea-77f7c320b01f" xlink:to="loc_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_562b02cc-cb44-419d-a0de-101929f3b8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_38477406-9b6c-4914-b561-13111ad73454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5340eece-f648-4710-93ea-77f7c320b01f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_38477406-9b6c-4914-b561-13111ad73454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_242aed95-293d-4900-9aa2-7330310de10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5340eece-f648-4710-93ea-77f7c320b01f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_242aed95-293d-4900-9aa2-7330310de10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ce076a6d-b93b-4f31-bd65-dc9e74a89f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5340eece-f648-4710-93ea-77f7c320b01f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ce076a6d-b93b-4f31-bd65-dc9e74a89f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0da44d63-b37e-4493-a9a9-fe626d0cc35f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5340eece-f648-4710-93ea-77f7c320b01f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0da44d63-b37e-4493-a9a9-fe626d0cc35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e1b4c29-afe5-4c7f-908c-233624a6f1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9e9241c7-f4a8-4e22-8076-97493e4ea926" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e1b4c29-afe5-4c7f-908c-233624a6f1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowInvestingActivitiesLesseeAbstract_cb111805-470e-4ad6-884f-925217158bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowInvestingActivitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:to="loc_us-gaap_CashFlowInvestingActivitiesLesseeAbstract_cb111805-470e-4ad6-884f-925217158bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_612991cb-2c62-4b41-a55e-647e691caae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowInvestingActivitiesLesseeAbstract_cb111805-470e-4ad6-884f-925217158bda" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_612991cb-2c62-4b41-a55e-647e691caae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_19ee115e-1ddf-42ea-b186-19093f9de378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowInvestingActivitiesLesseeAbstract_cb111805-470e-4ad6-884f-925217158bda" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_19ee115e-1ddf-42ea-b186-19093f9de378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7aedaa7f-af18-43b6-b0c6-754f58008433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowInvestingActivitiesLesseeAbstract_cb111805-470e-4ad6-884f-925217158bda" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7aedaa7f-af18-43b6-b0c6-754f58008433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b56f56b0-e482-4ae1-a006-d6fe3a5ad2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowInvestingActivitiesLesseeAbstract_cb111805-470e-4ad6-884f-925217158bda" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b56f56b0-e482-4ae1-a006-d6fe3a5ad2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:to="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_b9a6837d-59c9-426e-aa63-c83a3ae8181f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_b9a6837d-59c9-426e-aa63-c83a3ae8181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PaymentsOfStampDuty_1d9093d2-dfe0-4d35-8461-738c9ce1dfa6" xlink:href="mnlk-20231231.xsd#mnlk_PaymentsOfStampDuty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:to="loc_mnlk_PaymentsOfStampDuty_1d9093d2-dfe0-4d35-8461-738c9ce1dfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ProceedsFromReverseRecapitalization_7134bd6e-0840-4310-990f-f87c2b5ff133" xlink:href="mnlk-20231231.xsd#mnlk_ProceedsFromReverseRecapitalization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:to="loc_mnlk_ProceedsFromReverseRecapitalization_7134bd6e-0840-4310-990f-f87c2b5ff133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ProceedsFromContributionFromParValueOfCommonStock_308fd2b0-e78b-4d5d-b9be-556b1a299d00" xlink:href="mnlk-20231231.xsd#mnlk_ProceedsFromContributionFromParValueOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:to="loc_mnlk_ProceedsFromContributionFromParValueOfCommonStock_308fd2b0-e78b-4d5d-b9be-556b1a299d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_8cd8ab43-94c3-4411-b73b-48953418b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_8cd8ab43-94c3-4411-b73b-48953418b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_12094160-d194-4233-8081-976181c44171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_12094160-d194-4233-8081-976181c44171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_624d377a-9463-45ed-813c-feb774a6926b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowFinancingActivitiesLesseeAbstract_4ed51342-f27a-4812-8457-0bc8bc2f37e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_624d377a-9463-45ed-813c-feb774a6926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a8f41ce2-7e07-4ea0-a7e6-2d5c63211c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a8f41ce2-7e07-4ea0-a7e6-2d5c63211c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b19fe7fb-26bb-4b24-95c2-de36beb2212c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b19fe7fb-26bb-4b24-95c2-de36beb2212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8b2bef3-ccc5-41f4-80f1-b9603d7712cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8b2bef3-ccc5-41f4-80f1-b9603d7712cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f3b8544-5d25-4bb2-87ef-efbb57404eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f3b8544-5d25-4bb2-87ef-efbb57404eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8f4c6212-8f72-4c85-8fed-2aa029e4e83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_736e54ff-f131-4e27-a0f8-4ecf3362d875" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_8f4c6212-8f72-4c85-8fed-2aa029e4e83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_552d419c-16c3-4c60-ab07-2a92d3be1fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8f4c6212-8f72-4c85-8fed-2aa029e4e83d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_552d419c-16c3-4c60-ab07-2a92d3be1fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_13bdbd89-17d1-4ca5-a279-30fd46275379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8f4c6212-8f72-4c85-8fed-2aa029e4e83d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_13bdbd89-17d1-4ca5-a279-30fd46275379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_843a8a2d-dfc9-4116-ba9c-f89159e8d705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8f4c6212-8f72-4c85-8fed-2aa029e4e83d" xlink:to="loc_us-gaap_OperatingLeasePayments_843a8a2d-dfc9-4116-ba9c-f89159e8d705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/OverviewoftheCompany" xlink:type="simple" xlink:href="mnlk-20231231.xsd#OverviewoftheCompany"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/OverviewoftheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_608d656f-d95a-495d-a05c-31c843e85f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_97d91ee1-1269-4e51-8e70-369c40de5685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_608d656f-d95a-495d-a05c-31c843e85f5c" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_97d91ee1-1269-4e51-8e70-369c40de5685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalization" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BusinessCombinationAgreementwithHelixandRecapitalization"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAbstract_42f3c088-4f06-433d-a939-98c1038867b9" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationDisclosureTextBlock_b6f22685-10d0-47e6-bc49-2c65abaf0b82" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_42f3c088-4f06-433d-a939-98c1038867b9" xlink:to="loc_mnlk_ReverseRecapitalizationDisclosureTextBlock_b6f22685-10d0-47e6-bc49-2c65abaf0b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_435b9581-6078-447f-9513-29f507179d79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_a04eb0e9-2d20-41bd-8a37-b9535ba6c5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_435b9581-6078-447f-9513-29f507179d79" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_a04eb0e9-2d20-41bd-8a37-b9535ba6c5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/RisksandLiquidity" xlink:type="simple" xlink:href="mnlk-20231231.xsd#RisksandLiquidity"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/RisksandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_b194479f-3ab7-41d7-9153-f9aad4f54083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RiskAndLiquidityDisclosureTextBlock_f65c6ac7-0da1-404c-a41f-e905ec0e81ca" xlink:href="mnlk-20231231.xsd#mnlk_RiskAndLiquidityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_b194479f-3ab7-41d7-9153-f9aad4f54083" xlink:to="loc_mnlk_RiskAndLiquidityDisclosureTextBlock_f65c6ac7-0da1-404c-a41f-e905ec0e81ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mnlk-20231231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6610b241-011b-46f1-8450-954dc2b679ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a85c036b-2ddd-4a4e-bab4-5a5f01f54dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6610b241-011b-46f1-8450-954dc2b679ce" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a85c036b-2ddd-4a4e-bab4-5a5f01f54dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/Investments" xlink:type="simple" xlink:href="mnlk-20231231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb54a4ca-534d-41fb-9c60-f29b1717938e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_18a9bc06-d837-48d9-a6d5-d9a2bf52c835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb54a4ca-534d-41fb-9c60-f29b1717938e" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_18a9bc06-d837-48d9-a6d5-d9a2bf52c835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/PrepaidExpenses" xlink:type="simple" xlink:href="mnlk-20231231.xsd#PrepaidExpenses"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/PrepaidExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_fef1dcb2-01df-45ba-94f9-44b88636e2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_3d8e2cb5-d5e1-43cf-ba3f-91388a76f72a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_fef1dcb2-01df-45ba-94f9-44b88636e2a5" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_3d8e2cb5-d5e1-43cf-ba3f-91388a76f72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/TradeandOtherPayables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#TradeandOtherPayables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/TradeandOtherPayables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_05512fcc-1ac3-402f-a7fa-1b524b60d4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0bd698a3-5be9-41e5-84af-bef3191c9399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_05512fcc-1ac3-402f-a7fa-1b524b60d4a1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0bd698a3-5be9-41e5-84af-bef3191c9399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="mnlk-20231231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b4931e9d-f01b-4234-b433-056be30a4145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7281a0d9-5233-4cca-9ccc-6492efcaf61f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b4931e9d-f01b-4234-b433-056be30a4145" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7281a0d9-5233-4cca-9ccc-6492efcaf61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/Leases" xlink:type="simple" xlink:href="mnlk-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_15151e95-c03f-4410-9f5b-52eb36044f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_29e21c40-0ca6-462f-9c7d-00d2f8d5f3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15151e95-c03f-4410-9f5b-52eb36044f29" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_29e21c40-0ca6-462f-9c7d-00d2f8d5f3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_627b4487-c4c5-45e8-bb45-4a6efb683d73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_dfa14876-42f1-407e-9891-60160ddea130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_627b4487-c4c5-45e8-bb45-4a6efb683d73" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_dfa14876-42f1-407e-9891-60160ddea130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficit" xlink:type="simple" xlink:href="mnlk-20231231.xsd#ShareholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/ShareholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d109b83c-0a7b-4a5e-850a-8d78040528e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1de63a57-d84b-45e6-af7d-6b5c4a8c511a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d109b83c-0a7b-4a5e-850a-8d78040528e0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1de63a57-d84b-45e6-af7d-6b5c4a8c511a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/NetLossperShare" xlink:type="simple" xlink:href="mnlk-20231231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a87f317c-60f2-46e4-87d5-c960fbd04d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1653fdd3-14bd-468d-9ef7-c47a33902899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a87f317c-60f2-46e4-87d5-c960fbd04d8b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1653fdd3-14bd-468d-9ef7-c47a33902899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53b5072c-f76f-4504-bd38-4601cbda80c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f139b5b0-2286-4aa5-a921-4777fde6200f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53b5072c-f76f-4504-bd38-4601cbda80c7" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f139b5b0-2286-4aa5-a921-4777fde6200f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0e1d6b65-dc2f-4f5f-8da5-c1690ff03623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3e641511-415f-4080-a0c6-699521bbf9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0e1d6b65-dc2f-4f5f-8da5-c1690ff03623" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3e641511-415f-4080-a0c6-699521bbf9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68b5f285-c2d9-41d4-9870-b62a0fffa4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd9e8876-7f7c-49d9-88ac-62bde3a39d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68b5f285-c2d9-41d4-9870-b62a0fffa4d3" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd9e8876-7f7c-49d9-88ac-62bde3a39d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SegmentInformationandGeographicData" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SegmentInformationandGeographicData"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SegmentInformationandGeographicData" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2754fc5e-1ca7-4d75-b6d6-6d0cdabec9af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_72b9694f-bb58-4f0d-843c-f8598ea4eff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2754fc5e-1ca7-4d75-b6d6-6d0cdabec9af" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_72b9694f-bb58-4f0d-843c-f8598ea4eff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_de239a62-9793-45c9-9925-dcb3104f244f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2ce8a8fe-3e17-478a-b8bc-dacf850416f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_de239a62-9793-45c9-9925-dcb3104f244f" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_2ce8a8fe-3e17-478a-b8bc-dacf850416f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ce64f9e7-df16-4609-ab63-d81792a32b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ce64f9e7-df16-4609-ab63-d81792a32b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_83783f3c-6d16-40e9-9c80-bb8869244bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_UseOfEstimates_83783f3c-6d16-40e9-9c80-bb8869244bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_88b8c369-97d4-406c-9489-868e80a891d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_88b8c369-97d4-406c-9489-868e80a891d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_039b7b56-a2c3-4c2d-b8fd-3e5044846bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_039b7b56-a2c3-4c2d-b8fd-3e5044846bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e40a761e-6ffa-4715-be4d-aaf30ca829d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e40a761e-6ffa-4715-be4d-aaf30ca829d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_abf4582b-59ce-4081-b9aa-b044af00cefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_abf4582b-59ce-4081-b9aa-b044af00cefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_97be9d35-bf8c-46ac-b2c7-00c72ff83689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_97be9d35-bf8c-46ac-b2c7-00c72ff83689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c06358fd-6a33-48fe-abb1-bee19b7b811e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c06358fd-6a33-48fe-abb1-bee19b7b811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2f947621-6466-48ee-b4dc-0801bc7b91ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2f947621-6466-48ee-b4dc-0801bc7b91ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6af1a88a-f965-4ab1-8d7b-527ec8c7084b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6af1a88a-f965-4ab1-8d7b-527ec8c7084b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3e109e15-9070-4189-bb0c-89eaf30faefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3e109e15-9070-4189-bb0c-89eaf30faefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9b10bb76-f003-43f7-be64-4974ca865b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9b10bb76-f003-43f7-be64-4974ca865b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5e555a80-9ecf-46fd-8e60-f6e7b57bba64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5e555a80-9ecf-46fd-8e60-f6e7b57bba64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_c670422d-c54b-4c05-aff8-6084bf1ef47e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_c670422d-c54b-4c05-aff8-6084bf1ef47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_3097fe38-ddf6-4704-b3a0-c92b170c8234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_3097fe38-ddf6-4704-b3a0-c92b170c8234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_21263f4a-a004-446a-97d7-61c2584a66c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_21263f4a-a004-446a-97d7-61c2584a66c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9b7345a0-f53a-4770-b526-1554a14e790d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0741d86f-939b-4abe-8ac7-7447dcab3b5c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9b7345a0-f53a-4770-b526-1554a14e790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BusinessCombinationAgreementwithHelixandRecapitalizationTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAbstract_692cc54a-54bf-4963-9cbe-73798321dfe3" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock_8a2c605e-7f4b-45b1-b49e-eca8820f448c" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_692cc54a-54bf-4963-9cbe-73798321dfe3" xlink:to="loc_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock_8a2c605e-7f4b-45b1-b49e-eca8820f448c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_085eba98-1946-4bc2-b18a-9b69114bddab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9b167b3a-47e7-45e6-b04c-89bd73699baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_085eba98-1946-4bc2-b18a-9b69114bddab" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9b167b3a-47e7-45e6-b04c-89bd73699baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/InvestmentsTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6ef3ad32-b124-49b1-a4dd-f155cded02a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_cccf3cd9-0ff2-412d-a713-357dcb582991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6ef3ad32-b124-49b1-a4dd-f155cded02a5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_cccf3cd9-0ff2-412d-a713-357dcb582991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_fa70658f-6414-4eca-ac20-bae429f41232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6ef3ad32-b124-49b1-a4dd-f155cded02a5" xlink:to="loc_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_fa70658f-6414-4eca-ac20-bae429f41232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/PrepaidExpensesTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#PrepaidExpensesTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/PrepaidExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_961712b9-ffc7-48ca-b4f3-869a888c59c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_de34d6ce-9f0e-4447-87dd-d25779eb45e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_961712b9-ffc7-48ca-b4f3-869a888c59c1" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_de34d6ce-9f0e-4447-87dd-d25779eb45e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/TradeandOtherPayablesTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#TradeandOtherPayablesTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/TradeandOtherPayablesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b28b6dd5-7510-49f9-8cf7-f5b7a8dede64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TradeAndOtherPayablesCurrentTableTextBlock_d996ed86-6d4d-4221-8148-4e3e5db2911d" xlink:href="mnlk-20231231.xsd#mnlk_TradeAndOtherPayablesCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b28b6dd5-7510-49f9-8cf7-f5b7a8dede64" xlink:to="loc_mnlk_TradeAndOtherPayablesCurrentTableTextBlock_d996ed86-6d4d-4221-8148-4e3e5db2911d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_50ed4202-59b7-415a-94ab-56d482468ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ae833e48-1282-4064-9e29-9949be521023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_50ed4202-59b7-415a-94ab-56d482468ef9" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ae833e48-1282-4064-9e29-9949be521023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/LeasesTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_378e4ea2-0ab7-4a90-a7ca-08df82da2383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_efaa2646-c339-4ecc-952e-5bb256d1974d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_378e4ea2-0ab7-4a90-a7ca-08df82da2383" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_efaa2646-c339-4ecc-952e-5bb256d1974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_af990018-086a-4ec9-8baa-1c6a22c3b049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_378e4ea2-0ab7-4a90-a7ca-08df82da2383" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_af990018-086a-4ec9-8baa-1c6a22c3b049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0337fee9-2449-4e76-9fa9-1279f93f7f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_0f62cc91-7fb2-460c-b4e5-865362b85134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0337fee9-2449-4e76-9fa9-1279f93f7f5d" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_0f62cc91-7fb2-460c-b4e5-865362b85134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_be988cd5-3eae-4a1b-b7ab-694d3506ae62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0337fee9-2449-4e76-9fa9-1279f93f7f5d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_be988cd5-3eae-4a1b-b7ab-694d3506ae62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_68bde94a-a653-441a-86ec-d0fe1b438b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0337fee9-2449-4e76-9fa9-1279f93f7f5d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_68bde94a-a653-441a-86ec-d0fe1b438b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_c89f3226-a53b-4dc0-86ac-1192fd5d9db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0337fee9-2449-4e76-9fa9-1279f93f7f5d" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_c89f3226-a53b-4dc0-86ac-1192fd5d9db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock_52d7fed9-3b97-475b-9fb6-17e3fe8be487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0337fee9-2449-4e76-9fa9-1279f93f7f5d" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock_52d7fed9-3b97-475b-9fb6-17e3fe8be487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficitTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#ShareholdersEquityDeficitTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/ShareholdersEquityDeficitTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_036e2bdb-1cfe-4c86-97ff-5c7ef392fcee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock_4692ef10-f335-4385-80bc-c2dbf40e9b24" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_036e2bdb-1cfe-4c86-97ff-5c7ef392fcee" xlink:to="loc_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock_4692ef10-f335-4385-80bc-c2dbf40e9b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ad3f59d4-0cf3-4705-bdd3-0dd1786a3839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_788f6fb3-d77d-4d0e-831d-447dfacd0c21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ad3f59d4-0cf3-4705-bdd3-0dd1786a3839" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_788f6fb3-d77d-4d0e-831d-447dfacd0c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664e87b7-0b02-4dbb-8f79-39dc3f15febb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd577260-fa72-4346-bc41-e1cc01dc48fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664e87b7-0b02-4dbb-8f79-39dc3f15febb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd577260-fa72-4346-bc41-e1cc01dc48fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock_f63fb8c9-ddc8-4b3f-aea8-9ac805775724" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664e87b7-0b02-4dbb-8f79-39dc3f15febb" xlink:to="loc_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock_f63fb8c9-ddc8-4b3f-aea8-9ac805775724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_e9029a16-e135-4a26-8cc3-38011c5c709d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664e87b7-0b02-4dbb-8f79-39dc3f15febb" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_e9029a16-e135-4a26-8cc3-38011c5c709d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_710cd556-7cfb-40ac-98f7-29f835c848d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664e87b7-0b02-4dbb-8f79-39dc3f15febb" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_710cd556-7cfb-40ac-98f7-29f835c848d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_47f7cb52-bcfc-4c7e-ba91-e6ccab3b9165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664e87b7-0b02-4dbb-8f79-39dc3f15febb" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_47f7cb52-bcfc-4c7e-ba91-e6ccab3b9165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6e8bfb73-039c-4f0d-8026-d9cccf23eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664e87b7-0b02-4dbb-8f79-39dc3f15febb" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6e8bfb73-039c-4f0d-8026-d9cccf23eb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f797e59d-1540-42a4-a356-b69c43ba5b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_664e87b7-0b02-4dbb-8f79-39dc3f15febb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f797e59d-1540-42a4-a356-b69c43ba5b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d8964b7f-48d0-4e14-b7d1-7d03f5fbce3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1f12a9e7-0f3a-4db9-ba17-50cbd86f94d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d8964b7f-48d0-4e14-b7d1-7d03f5fbce3d" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1f12a9e7-0f3a-4db9-ba17-50cbd86f94d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ef76fc13-c7f3-4ff8-b4e3-199ea96b3ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d8964b7f-48d0-4e14-b7d1-7d03f5fbce3d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ef76fc13-c7f3-4ff8-b4e3-199ea96b3ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_226d278e-a3c7-44c8-9adf-9b22e368ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d8964b7f-48d0-4e14-b7d1-7d03f5fbce3d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_226d278e-a3c7-44c8-9adf-9b22e368ca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SegmentInformationandGeographicDataTables" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SegmentInformationandGeographicDataTables"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SegmentInformationandGeographicDataTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5de2ae69-cf63-429d-bfd8-39e1e5c66c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f0cd2b6a-1228-49ca-8768-b089fd39e743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5de2ae69-cf63-429d-bfd8-39e1e5c66c96" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f0cd2b6a-1228-49ca-8768-b089fd39e743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAbstract_2e864fd0-72a5-451c-8bf8-4e618f27235a" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_2e864fd0-72a5-451c-8bf8-4e618f27235a" xlink:to="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e4efb4b2-e5aa-45af-8bb0-edf0b0823681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e4efb4b2-e5aa-45af-8bb0-edf0b0823681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e4efb4b2-e5aa-45af-8bb0-edf0b0823681" xlink:to="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1daf355c-eeb8-4f59-b7c9-bb930b75ad12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1daf355c-eeb8-4f59-b7c9-bb930b75ad12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ClassVVotingStockMember_3d783152-cbe5-4917-909e-25bd23e2f21c" xlink:href="mnlk-20231231.xsd#mnlk_ClassVVotingStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_mnlk_ClassVVotingStockMember_3d783152-cbe5-4917-909e-25bd23e2f21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_49525f3c-c69f-476d-af32-4a332fae1d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_us-gaap_CommonClassBMember_49525f3c-c69f-476d-af32-4a332fae1d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_433c4d98-0160-4de2-ab42-1fbfe2126926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_us-gaap_CommonClassAMember_433c4d98-0160-4de2-ab42-1fbfe2126926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_7c2d4399-8145-47cc-b717-3b9418cd08d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1e7d7b53-d276-4536-b11b-1d42195a5212" xlink:to="loc_us-gaap_CommonClassCMember_7c2d4399-8145-47cc-b717-3b9418cd08d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1003dad3-ebea-423e-ae72-4dee9d28b482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1003dad3-ebea-423e-ae72-4dee9d28b482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f15a5d2-3ef2-4ad3-93a4-ec2a41628898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1003dad3-ebea-423e-ae72-4dee9d28b482" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f15a5d2-3ef2-4ad3-93a4-ec2a41628898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PIPEInvestorsMember_16a40a7f-f14d-4bde-be39-ea1a5986cb2c" xlink:href="mnlk-20231231.xsd#mnlk_PIPEInvestorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f15a5d2-3ef2-4ad3-93a4-ec2a41628898" xlink:to="loc_mnlk_PIPEInvestorsMember_16a40a7f-f14d-4bde-be39-ea1a5986cb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_6f7f5716-26a1-488a-b0fa-fc5cab969913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f15a5d2-3ef2-4ad3-93a4-ec2a41628898" xlink:to="loc_us-gaap_PrivatePlacementMember_6f7f5716-26a1-488a-b0fa-fc5cab969913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ed1bc80b-16b1-42b9-906f-e566d8800368" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:to="loc_srt_CounterpartyNameAxis_ed1bc80b-16b1-42b9-906f-e566d8800368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4591a-9ab9-410a-8c31-f7d5e5decffa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ed1bc80b-16b1-42b9-906f-e566d8800368" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4591a-9ab9-410a-8c31-f7d5e5decffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PIPEInvestorsMember_28f7a1d8-ee16-464a-ab4d-d4bb7612b0d6" xlink:href="mnlk-20231231.xsd#mnlk_PIPEInvestorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5b4591a-9ab9-410a-8c31-f7d5e5decffa" xlink:to="loc_mnlk_PIPEInvestorsMember_28f7a1d8-ee16-464a-ab4d-d4bb7612b0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_45345637-ee57-46ca-ab2f-44461b001b99" xlink:to="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationNet_cc353640-b003-4ed8-9b87-6da8d9875922" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_ReverseRecapitalizationNet_cc353640-b003-4ed8-9b87-6da8d9875922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_896d650f-3471-4010-9a77-ff7a73f03fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_896d650f-3471-4010-9a77-ff7a73f03fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e825e39f-2e76-43ea-be9a-13aee7751b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e825e39f-2e76-43ea-be9a-13aee7751b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_721936b4-723d-4e61-8498-f6fc0ecee1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_721936b4-723d-4e61-8498-f6fc0ecee1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockVotesMultiplier_aa260f56-e69c-4d32-a24c-003806e7fb33" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockVotesMultiplier"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_CommonStockVotesMultiplier_aa260f56-e69c-4d32-a24c-003806e7fb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_8ea1f268-1ca0-46ea-afc8-f336200f358a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_8ea1f268-1ca0-46ea-afc8-f336200f358a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockConversionRatio_ccc54969-be04-4524-b1f4-38dd9bef18c4" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockConversionRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_CommonStockConversionRatio_ccc54969-be04-4524-b1f4-38dd9bef18c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_0fd851a3-15ef-457c-9c00-0baeb1059ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_0fd851a3-15ef-457c-9c00-0baeb1059ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1e12558b-d68a-4a6d-99fe-2b3b15090aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1e12558b-d68a-4a6d-99fe-2b3b15090aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockConvertedReverseRecapitalization_2e9a6e5e-f4e2-4638-bc90-1c248c55da68" xlink:href="mnlk-20231231.xsd#mnlk_StockConvertedReverseRecapitalization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_StockConvertedReverseRecapitalization_2e9a6e5e-f4e2-4638-bc90-1c248c55da68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_663627ea-752e-4eac-8541-7d595106fdce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_663627ea-752e-4eac-8541-7d595106fdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_aa837057-ea9f-485a-9b55-0650f02c41a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_aa837057-ea9f-485a-9b55-0650f02c41a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f2f1c35-1478-4bed-b67e-841e6de8a938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f2f1c35-1478-4bed-b67e-841e6de8a938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_692f6336-966e-4145-8f6e-b19b9d8ed11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_692f6336-966e-4145-8f6e-b19b9d8ed11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed_1ac44499-4a1f-4d83-b29f-ac143d66ff49" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_e094a7a4-7cf9-4de1-b270-e8bff561b9cb" xlink:to="loc_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed_1ac44499-4a1f-4d83-b29f-ac143d66ff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_InvestmentsAcquiredThroughReverseRecapitalization_458a74fe-e678-42b0-a7ba-fcbd7e9f2d0b" xlink:href="mnlk-20231231.xsd#mnlk_InvestmentsAcquiredThroughReverseRecapitalization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:to="loc_mnlk_InvestmentsAcquiredThroughReverseRecapitalization_458a74fe-e678-42b0-a7ba-fcbd7e9f2d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_edcf6b49-cd06-49c4-a336-b43ca8f60873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_edcf6b49-cd06-49c4-a336-b43ca8f60873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6136b01e-a43f-4f77-bd4e-73a77bebee37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6136b01e-a43f-4f77-bd4e-73a77bebee37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationTransactionCosts_43e8817f-fc84-48ad-9f04-12698ef8b42e" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationTransactionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:to="loc_mnlk_ReverseRecapitalizationTransactionCosts_43e8817f-fc84-48ad-9f04-12698ef8b42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAccruedExpenses_fac98b9e-d204-41fb-ae14-11eb2f874cbf" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAccruedExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:to="loc_mnlk_ReverseRecapitalizationAccruedExpenses_fac98b9e-d204-41fb-ae14-11eb2f874cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees_0149bd59-9037-47ad-99a9-4ae4b7bd0ada" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:to="loc_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees_0149bd59-9037-47ad-99a9-4ae4b7bd0ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationOtherTransactionExpenses_bdae789e-2388-4ece-9ea3-fe6132017fa5" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationOtherTransactionExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:to="loc_mnlk_ReverseRecapitalizationOtherTransactionExpenses_bdae789e-2388-4ece-9ea3-fe6132017fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationNet_2230caa5-c30e-4e66-946e-25f0c1a4342d" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_da0cc315-f313-4ea8-a1d9-ab782fa2c892" xlink:to="loc_mnlk_ReverseRecapitalizationNet_2230caa5-c30e-4e66-946e-25f0c1a4342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ReverseRecapitalizationAbstract_1324f23d-1139-48d4-b8e1-d3f878698c7e" xlink:href="mnlk-20231231.xsd#mnlk_ReverseRecapitalizationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ReverseRecapitalizationAbstract_1324f23d-1139-48d4-b8e1-d3f878698c7e" xlink:to="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:to="loc_dei_LegalEntityAxis_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f4c9b682-6796-4bbd-9a32-9acae844a6b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_11bb5b99-88b1-4c84-bfb6-5a2ac3a6284a" xlink:to="loc_dei_EntityDomain_f4c9b682-6796-4bbd-9a32-9acae844a6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_HelixAcquisitionCorpMember_c9eeae02-2e77-4390-a055-27d9b16f88c9" xlink:href="mnlk-20231231.xsd#mnlk_HelixAcquisitionCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f4c9b682-6796-4bbd-9a32-9acae844a6b6" xlink:to="loc_mnlk_HelixAcquisitionCorpMember_c9eeae02-2e77-4390-a055-27d9b16f88c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b88621b5-2e03-40da-a423-36487a956416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b88621b5-2e03-40da-a423-36487a956416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b88621b5-2e03-40da-a423-36487a956416" xlink:to="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_a589dd91-72ab-4988-9188-63ceeccb7edb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:to="loc_us-gaap_PrivatePlacementMember_a589dd91-72ab-4988-9188-63ceeccb7edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_164ba37d-d542-4e68-9d16-3b01020d03ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:to="loc_us-gaap_CommonClassAMember_164ba37d-d542-4e68-9d16-3b01020d03ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonClassAPrivatePlacementMember_2affab67-6a3e-454a-8beb-24703a8cf5d8" xlink:href="mnlk-20231231.xsd#mnlk_CommonClassAPrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonClassAMember_164ba37d-d542-4e68-9d16-3b01020d03ae" xlink:to="loc_mnlk_CommonClassAPrivatePlacementMember_2affab67-6a3e-454a-8beb-24703a8cf5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonClassARedeemableMember_cb09a1b0-3c38-4623-a296-7e427c377130" xlink:href="mnlk-20231231.xsd#mnlk_CommonClassARedeemableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonClassAMember_164ba37d-d542-4e68-9d16-3b01020d03ae" xlink:to="loc_mnlk_CommonClassARedeemableMember_cb09a1b0-3c38-4623-a296-7e427c377130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_851fb1fe-6437-42af-84f7-66705294a574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:to="loc_us-gaap_CommonClassBMember_851fb1fe-6437-42af-84f7-66705294a574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_0a1b4b1f-abe5-464c-8565-e075a41fdaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ca1b651-f974-4a2d-b587-ff7c1b4c6ef7" xlink:to="loc_us-gaap_CommonClassCMember_0a1b4b1f-abe5-464c-8565-e075a41fdaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:href="mnlk-20231231.xsd#mnlk_ScheduleOfReverseRecapitalizationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationTable_8bbf9c02-11a3-4ccc-87ea-7649216d1278" xlink:to="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2ef11ec6-bc66-4803-9d1c-64b7f9339ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2ef11ec6-bc66-4803-9d1c-64b7f9339ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ed8835fc-eaec-4dfc-b781-cabfd54a7ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ed8835fc-eaec-4dfc-b781-cabfd54a7ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a1ea807c-20b8-47c6-b33a-b1ce22ee33c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a1ea807c-20b8-47c6-b33a-b1ce22ee33c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_825a35d4-41ee-4ee8-aa1c-daa67dbae659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_825a35d4-41ee-4ee8-aa1c-daa67dbae659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization_69129f80-a0ab-4898-935b-b0a277ab4776" xlink:href="mnlk-20231231.xsd#mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization_69129f80-a0ab-4898-935b-b0a277ab4776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockConvertedReverseRecapitalization_037d9a7b-2de4-4c6a-844b-c75fe5aa1441" xlink:href="mnlk-20231231.xsd#mnlk_StockConvertedReverseRecapitalization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_ScheduleOfReverseRecapitalizationLineItems_52373021-819c-412a-90a4-9d59906d4b95" xlink:to="loc_mnlk_StockConvertedReverseRecapitalization_037d9a7b-2de4-4c6a-844b-c75fe5aa1441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#BasisofPresentationandSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_914ceeb4-d78c-43f2-82ee-dd9f58859505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_914ceeb4-d78c-43f2-82ee-dd9f58859505" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a5c025a2-14a9-4127-96a6-30f920d5794d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a5c025a2-14a9-4127-96a6-30f920d5794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_770d97b5-7a6b-4de2-b114-2ca24dac016c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a5c025a2-14a9-4127-96a6-30f920d5794d" xlink:to="loc_us-gaap_ClassOfStockDomain_770d97b5-7a6b-4de2-b114-2ca24dac016c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_30d00f00-2c7b-4a88-9651-66c27525a1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_770d97b5-7a6b-4de2-b114-2ca24dac016c" xlink:to="loc_us-gaap_CommonClassAMember_30d00f00-2c7b-4a88-9651-66c27525a1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_eb0c7bb4-88d9-4efd-aa13-8d235d7c7458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_770d97b5-7a6b-4de2-b114-2ca24dac016c" xlink:to="loc_us-gaap_CommonClassCMember_eb0c7bb4-88d9-4efd-aa13-8d235d7c7458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_114ae073-c485-4b1b-9275-399c05a8af9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:to="loc_srt_RangeAxis_114ae073-c485-4b1b-9275-399c05a8af9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6426416-89bd-44fd-afa5-9360ae5b1b92" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_114ae073-c485-4b1b-9275-399c05a8af9c" xlink:to="loc_srt_RangeMember_a6426416-89bd-44fd-afa5-9360ae5b1b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ef41746-e7ee-4c96-a4e5-dce0df312516" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6426416-89bd-44fd-afa5-9360ae5b1b92" xlink:to="loc_srt_MinimumMember_8ef41746-e7ee-4c96-a4e5-dce0df312516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab9cd08f-cb24-4574-bc2f-aefe7a12921b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6426416-89bd-44fd-afa5-9360ae5b1b92" xlink:to="loc_srt_MaximumMember_ab9cd08f-cb24-4574-bc2f-aefe7a12921b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_694f0572-bd9b-4df2-a0d7-ff3ce6411498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_694f0572-bd9b-4df2-a0d7-ff3ce6411498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94b5337e-7c3b-4d31-9c36-746e3ccb491e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_694f0572-bd9b-4df2-a0d7-ff3ce6411498" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94b5337e-7c3b-4d31-9c36-746e3ccb491e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_25482f2b-1a1f-4858-956d-def88f75c4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_94b5337e-7c3b-4d31-9c36-746e3ccb491e" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_25482f2b-1a1f-4858-956d-def88f75c4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f8bb5d8-e603-48a6-af82-505ad353b4fd" xlink:to="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RecapitalizationExchangeRatio_00a7dcc9-9ce7-4cf6-8d1e-8acb8a96fadd" xlink:href="mnlk-20231231.xsd#mnlk_RecapitalizationExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_mnlk_RecapitalizationExchangeRatio_00a7dcc9-9ce7-4cf6-8d1e-8acb8a96fadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_501e8f9f-4016-4039-b6b9-bba15caae740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_501e8f9f-4016-4039-b6b9-bba15caae740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8efb3974-6547-4f4c-8d55-822489d094e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8efb3974-6547-4f4c-8d55-822489d094e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_de7e2cdd-b270-4ac9-8c84-407734d2e387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_de7e2cdd-b270-4ac9-8c84-407734d2e387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_63a0b148-8a77-47ae-bc8a-5f39e50c5332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_63a0b148-8a77-47ae-bc8a-5f39e50c5332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_8b136c04-f156-4154-a010-fa0e8b8ecb75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_8b136c04-f156-4154-a010-fa0e8b8ecb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NumberOfOperatingLeases_c4dd9b82-da29-4726-8411-e99147c87ddf" xlink:href="mnlk-20231231.xsd#mnlk_NumberOfOperatingLeases"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cd67ba0b-ce94-4438-b238-8e441d0577e1" xlink:to="loc_mnlk_NumberOfOperatingLeases_c4dd9b82-da29-4726-8411-e99147c87ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/RisksandLiquidityDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#RisksandLiquidityDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/RisksandLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_173f783d-fae7-4f1b-9bf9-15aca514b7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6212577c-ffcb-4ecb-902a-477004648ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_173f783d-fae7-4f1b-9bf9-15aca514b7ba" xlink:to="loc_us-gaap_ProfitLoss_6212577c-ffcb-4ecb-902a-477004648ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CurrentAssetsInExcessOfCurrentLiabilities_5140ca35-04af-491a-9c57-465e80217b5a" xlink:href="mnlk-20231231.xsd#mnlk_CurrentAssetsInExcessOfCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_173f783d-fae7-4f1b-9bf9-15aca514b7ba" xlink:to="loc_mnlk_CurrentAssetsInExcessOfCurrentLiabilities_5140ca35-04af-491a-9c57-465e80217b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_3d008a9d-1983-4e25-9f38-d2c2043d4445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_173f783d-fae7-4f1b-9bf9-15aca514b7ba" xlink:to="loc_us-gaap_Cash_3d008a9d-1983-4e25-9f38-d2c2043d4445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_797a8b33-11c6-496b-85b8-2eb733762f61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_797a8b33-11c6-496b-85b8-2eb733762f61" xlink:to="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ef95151-a6dd-475e-93d1-ca7f59a1f396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ef95151-a6dd-475e-93d1-ca7f59a1f396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ef77a36-98f6-40bd-8964-4ebec32ec40b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ef95151-a6dd-475e-93d1-ca7f59a1f396" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ef77a36-98f6-40bd-8964-4ebec32ec40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e9a7fdde-31df-4e7b-822f-1f2f4ca4c524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ef77a36-98f6-40bd-8964-4ebec32ec40b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e9a7fdde-31df-4e7b-822f-1f2f4ca4c524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_107c4a38-7970-49a3-9f7f-7fbcdfee55c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:to="loc_us-gaap_FinancialInstrumentAxis_107c4a38-7970-49a3-9f7f-7fbcdfee55c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75865f12-e52c-4412-bc1b-e4f0274f3a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_107c4a38-7970-49a3-9f7f-7fbcdfee55c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75865f12-e52c-4412-bc1b-e4f0274f3a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a1667d92-a48c-4102-9051-2f1cf4719899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75865f12-e52c-4412-bc1b-e4f0274f3a59" xlink:to="loc_us-gaap_CommercialPaperMember_a1667d92-a48c-4102-9051-2f1cf4719899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ad4207ac-23ad-4d6c-ac71-e34f5609a9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75865f12-e52c-4412-bc1b-e4f0274f3a59" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ad4207ac-23ad-4d6c-ac71-e34f5609a9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_949bec74-8f5b-4588-87d1-90fb0ac3d0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_fa955332-9ceb-455e-8432-f4d078d05f53" xlink:to="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_949bec74-8f5b-4588-87d1-90fb0ac3d0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b0be0ed4-b616-45ca-b37e-401796ad0ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_949bec74-8f5b-4588-87d1-90fb0ac3d0e7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b0be0ed4-b616-45ca-b37e-401796ad0ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b11d98a5-ea61-4223-9a34-82bac2c94b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_949bec74-8f5b-4588-87d1-90fb0ac3d0e7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b11d98a5-ea61-4223-9a34-82bac2c94b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1dd2da1d-e5b8-4afc-b450-05a0d23c974b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1dd2da1d-e5b8-4afc-b450-05a0d23c974b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_97e0faca-f349-4049-96f7-7a34b3f06ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:to="loc_us-gaap_FinancialInstrumentAxis_97e0faca-f349-4049-96f7-7a34b3f06ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9ac6536-6afa-4aab-8f0d-217af1d2d697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97e0faca-f349-4049-96f7-7a34b3f06ecb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9ac6536-6afa-4aab-8f0d-217af1d2d697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5be71cc9-9ccf-4d36-95bb-6c045ade8074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9ac6536-6afa-4aab-8f0d-217af1d2d697" xlink:to="loc_us-gaap_CommercialPaperMember_5be71cc9-9ccf-4d36-95bb-6c045ade8074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f44fac7b-c5eb-4e44-8964-03cb087eb53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9ac6536-6afa-4aab-8f0d-217af1d2d697" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f44fac7b-c5eb-4e44-8964-03cb087eb53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_219ce96a-2674-4c63-b784-c808b8937298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_219ce96a-2674-4c63-b784-c808b8937298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d5d90521-eeb3-47ee-a36d-1ffa03e062f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_219ce96a-2674-4c63-b784-c808b8937298" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d5d90521-eeb3-47ee-a36d-1ffa03e062f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6c9f3f79-71a4-4adc-a156-c916d45b696e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d5d90521-eeb3-47ee-a36d-1ffa03e062f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6c9f3f79-71a4-4adc-a156-c916d45b696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_095e43c0-e7cb-4c4e-93bc-e263ae18117f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d5d90521-eeb3-47ee-a36d-1ffa03e062f7" xlink:to="loc_us-gaap_DebtSecuritiesMember_095e43c0-e7cb-4c4e-93bc-e263ae18117f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9eb67b74-80f5-40e8-abd4-36992090bb85" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b5997064-68dc-4d1b-b95d-517073a3aa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b5997064-68dc-4d1b-b95d-517073a3aa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f44bf770-380c-45e5-95a6-4946a5cc0f58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f44bf770-380c-45e5-95a6-4946a5cc0f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dda2891b-47d8-4a25-8fa7-0c2ecd2400ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dda2891b-47d8-4a25-8fa7-0c2ecd2400ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_195b53f8-7682-4098-a513-f9a172395a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e490eee-46ea-4885-885e-7e48f23a2a89" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_195b53f8-7682-4098-a513-f9a172395a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/InvestmentsFVchangesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#InvestmentsFVchangesDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/InvestmentsFVchangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b8efbcc2-e0da-4110-8c36-15b68fdf5b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_74910250-dcaf-43d1-a81c-999c4a4495df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b8efbcc2-e0da-4110-8c36-15b68fdf5b17" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_74910250-dcaf-43d1-a81c-999c4a4495df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbb4e0d2-4838-4732-98ed-d22806a91825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_74910250-dcaf-43d1-a81c-999c4a4495df" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbb4e0d2-4838-4732-98ed-d22806a91825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6da9d64d-60cc-441a-a8c8-aa667a6cd80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbb4e0d2-4838-4732-98ed-d22806a91825" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6da9d64d-60cc-441a-a8c8-aa667a6cd80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fddd3401-eca4-4a67-b99c-84c958ec3e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6da9d64d-60cc-441a-a8c8-aa667a6cd80b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fddd3401-eca4-4a67-b99c-84c958ec3e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e81f1ebc-ad46-4646-b0c9-60644c8fe162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_74910250-dcaf-43d1-a81c-999c4a4495df" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e81f1ebc-ad46-4646-b0c9-60644c8fe162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:href="mnlk-20231231.xsd#mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e81f1ebc-ad46-4646-b0c9-60644c8fe162" xlink:to="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_5b10973e-6546-442e-af34-080f90739fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_5b10973e-6546-442e-af34-080f90739fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5effdcff-765b-4c4c-a289-3bb99cd56925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5effdcff-765b-4c4c-a289-3bb99cd56925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax_311272bd-3be4-418d-9795-fe95775ba8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax_311272bd-3be4-418d-9795-fe95775ba8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_dd1e1647-c639-4d1e-a1f6-18f7362a69b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward_8f3ae26e-1dc7-4868-8446-a4424234cae7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_dd1e1647-c639-4d1e-a1f6-18f7362a69b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/PrepaidExpensesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#PrepaidExpensesDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/PrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bcafd65c-1bb7-403b-9608-3a5babbf10eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAbstract_19b9948a-9f92-4517-b0e2-314c0290ed21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bcafd65c-1bb7-403b-9608-3a5babbf10eb" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAbstract_19b9948a-9f92-4517-b0e2-314c0290ed21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_4e538cda-0228-4830-85e8-ca3ad234f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_19b9948a-9f92-4517-b0e2-314c0290ed21" xlink:to="loc_us-gaap_PrepaidInsurance_4e538cda-0228-4830-85e8-ca3ad234f2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PrepaidResearchAndDevelopmentExpense_a73c0dad-6ade-489f-994d-557c4dceec22" xlink:href="mnlk-20231231.xsd#mnlk_PrepaidResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_19b9948a-9f92-4517-b0e2-314c0290ed21" xlink:to="loc_mnlk_PrepaidResearchAndDevelopmentExpense_a73c0dad-6ade-489f-994d-557c4dceec22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent_f4a045e7-f5fb-4f9c-9be4-a34e934c5edd" xlink:href="mnlk-20231231.xsd#mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_19b9948a-9f92-4517-b0e2-314c0290ed21" xlink:to="loc_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent_f4a045e7-f5fb-4f9c-9be4-a34e934c5edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_88858ea1-8506-4333-9789-a89fcf1f1f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_19b9948a-9f92-4517-b0e2-314c0290ed21" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_88858ea1-8506-4333-9789-a89fcf1f1f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_e4934d06-2e2b-4d79-b9fa-f074d5b88662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_19b9948a-9f92-4517-b0e2-314c0290ed21" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_e4934d06-2e2b-4d79-b9fa-f074d5b88662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrentAbstract_0a4b3525-7bb8-4b45-8923-e348a6d3edd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bcafd65c-1bb7-403b-9608-3a5babbf10eb" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrentAbstract_0a4b3525-7bb8-4b45-8923-e348a6d3edd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SupplyAndManufacturingExpenseNoncurrent_86999110-5551-4430-8768-6d915b14a364" xlink:href="mnlk-20231231.xsd#mnlk_SupplyAndManufacturingExpenseNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrentAbstract_0a4b3525-7bb8-4b45-8923-e348a6d3edd1" xlink:to="loc_mnlk_SupplyAndManufacturingExpenseNoncurrent_86999110-5551-4430-8768-6d915b14a364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_f93f1c32-ac28-4e3f-830c-921d0f641b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrentAbstract_0a4b3525-7bb8-4b45-8923-e348a6d3edd1" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_f93f1c32-ac28-4e3f-830c-921d0f641b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/TradeandOtherPayablesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#TradeandOtherPayablesDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/TradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_09ea621c-8c59-48c9-a619-985c01b232c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedResearchAndDevelopmentExpensesCurrent_8f3aeae8-923d-48f0-9423-bf718048f799" xlink:href="mnlk-20231231.xsd#mnlk_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_09ea621c-8c59-48c9-a619-985c01b232c6" xlink:to="loc_mnlk_AccruedResearchAndDevelopmentExpensesCurrent_8f3aeae8-923d-48f0-9423-bf718048f799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SupplyAndManufacturingFeesPayableCurrent_76fba3e6-83f3-4739-9fdb-8434d09bdc57" xlink:href="mnlk-20231231.xsd#mnlk_SupplyAndManufacturingFeesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_09ea621c-8c59-48c9-a619-985c01b232c6" xlink:to="loc_mnlk_SupplyAndManufacturingFeesPayableCurrent_76fba3e6-83f3-4739-9fdb-8434d09bdc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent_3f2e6feb-c92a-4a5e-a3b7-961f48f8dc86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_09ea621c-8c59-48c9-a619-985c01b232c6" xlink:to="loc_us-gaap_AccruedRentCurrent_3f2e6feb-c92a-4a5e-a3b7-961f48f8dc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_de578619-2de6-4906-bb13-b65a5b87a8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_09ea621c-8c59-48c9-a619-985c01b232c6" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_de578619-2de6-4906-bb13-b65a5b87a8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TradeAndOtherPayablesCurrent_6122bfc7-7482-447a-9994-bca1877ff84e" xlink:href="mnlk-20231231.xsd#mnlk_TradeAndOtherPayablesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_09ea621c-8c59-48c9-a619-985c01b232c6" xlink:to="loc_mnlk_TradeAndOtherPayablesCurrent_6122bfc7-7482-447a-9994-bca1877ff84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2a136565-f573-4e2d-a99e-e548e2e4fe3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_45f2c63e-f9ee-48b8-abb6-7dfd4d2d3a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a136565-f573-4e2d-a99e-e548e2e4fe3a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_45f2c63e-f9ee-48b8-abb6-7dfd4d2d3a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedSupplyAndManufacturingFeesCurrent_3841d45a-a49d-4079-92af-21d0adbbfd7e" xlink:href="mnlk-20231231.xsd#mnlk_AccruedSupplyAndManufacturingFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a136565-f573-4e2d-a99e-e548e2e4fe3a" xlink:to="loc_mnlk_AccruedSupplyAndManufacturingFeesCurrent_3841d45a-a49d-4079-92af-21d0adbbfd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent_811e654e-d2ae-4a79-98c6-fbedad084819" xlink:href="mnlk-20231231.xsd#mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a136565-f573-4e2d-a99e-e548e2e4fe3a" xlink:to="loc_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent_811e654e-d2ae-4a79-98c6-fbedad084819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_AccruedConsultingAndOtherFeesCurrent_fa2358e6-0cd7-4294-bcbc-01ae99272a13" xlink:href="mnlk-20231231.xsd#mnlk_AccruedConsultingAndOtherFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a136565-f573-4e2d-a99e-e548e2e4fe3a" xlink:to="loc_mnlk_AccruedConsultingAndOtherFeesCurrent_fa2358e6-0cd7-4294-bcbc-01ae99272a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_51a2aa8d-76f2-49f1-b956-a4340e9d75b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a136565-f573-4e2d-a99e-e548e2e4fe3a" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_51a2aa8d-76f2-49f1-b956-a4340e9d75b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_53b13a69-511b-4c58-9e34-d45d4bf70676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a136565-f573-4e2d-a99e-e548e2e4fe3a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_53b13a69-511b-4c58-9e34-d45d4bf70676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_13043a67-46b7-4ad2-a4cd-78de8ca76e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a136565-f573-4e2d-a99e-e548e2e4fe3a" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_13043a67-46b7-4ad2-a4cd-78de8ca76e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_64c44109-da5f-4dbd-af14-1ad2cab9cfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ab88f92f-bddb-49fb-9b44-b542c47ae4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_64c44109-da5f-4dbd-af14-1ad2cab9cfb2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ab88f92f-bddb-49fb-9b44-b542c47ae4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e531f9ee-a769-4ff1-909a-a540732e7a99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ab88f92f-bddb-49fb-9b44-b542c47ae4eb" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e531f9ee-a769-4ff1-909a-a540732e7a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e531f9ee-a769-4ff1-909a-a540732e7a99" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OfficeLeaseMember_b2b58652-f0e4-4ff2-926b-719c75c9249f" xlink:href="mnlk-20231231.xsd#mnlk_OfficeLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:to="loc_mnlk_OfficeLeaseMember_b2b58652-f0e4-4ff2-926b-719c75c9249f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PortoOfficeMember_efdd5cf9-ffbc-4ad0-ba2d-eacfc7ce5eb9" xlink:href="mnlk-20231231.xsd#mnlk_PortoOfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:to="loc_mnlk_PortoOfficeMember_efdd5cf9-ffbc-4ad0-ba2d-eacfc7ce5eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CambridgeOfficeMember_88ae4eb8-ef54-48dc-a087-110b2cc12dec" xlink:href="mnlk-20231231.xsd#mnlk_CambridgeOfficeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f1bb09ec-783c-4d2d-a398-d29e4a0bc44a" xlink:to="loc_mnlk_CambridgeOfficeMember_88ae4eb8-ef54-48dc-a087-110b2cc12dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ab88f92f-bddb-49fb-9b44-b542c47ae4eb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLeaseAreaOfLeasedSpace_09037f67-28b6-4512-843f-c9b002e69c29" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLeaseAreaOfLeasedSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_mnlk_OperatingLeaseAreaOfLeasedSpace_09037f67-28b6-4512-843f-c9b002e69c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_92074990-0e0a-430d-9db0-6703d6f130d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_92074990-0e0a-430d-9db0-6703d6f130d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions_af3266a4-593d-416a-ac8c-53961497bb73" xlink:href="mnlk-20231231.xsd#mnlk_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions_af3266a4-593d-416a-ac8c-53961497bb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6af0acd0-c0eb-4b59-9d17-3f7eb476bc24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6af0acd0-c0eb-4b59-9d17-3f7eb476bc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_ae46a244-03b2-4e75-b2f4-a781cf64c0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6dc223eb-473a-42aa-b1b1-ed72126f8daf" xlink:to="loc_us-gaap_OperatingLeaseExpense_ae46a244-03b2-4e75-b2f4-a781cf64c0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1d17c414-a8e8-4991-b027-f226b5ad0e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fe893890-3c1a-4dbc-8116-f4d6e2c70b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d17c414-a8e8-4991-b027-f226b5ad0e35" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fe893890-3c1a-4dbc-8116-f4d6e2c70b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a1e75e3c-76a4-4f73-ae93-3901959051f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d17c414-a8e8-4991-b027-f226b5ad0e35" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a1e75e3c-76a4-4f73-ae93-3901959051f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#LeasesFutureLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d1b0378a-5ff2-4b47-8cf0-37752fcfaaff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d1b0378a-5ff2-4b47-8cf0-37752fcfaaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d7aedc7-b8de-4041-b043-7626780ceb96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d7aedc7-b8de-4041-b043-7626780ceb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c298a6e9-2ff6-4665-a846-adb7b06c5d57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c298a6e9-2ff6-4665-a846-adb7b06c5d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b93376fd-48fd-442a-98be-c4e67fd4975e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b93376fd-48fd-442a-98be-c4e67fd4975e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b5f82179-6c5d-44f3-b11b-8438f1b81ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b5f82179-6c5d-44f3-b11b-8438f1b81ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_91f68080-09a8-4cde-889e-e138a223dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_91f68080-09a8-4cde-889e-e138a223dc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_155eaf76-c1ba-42f0-b5c8-6ea8a5a41a79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_155eaf76-c1ba-42f0-b5c8-6ea8a5a41a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1b8e034-6f0c-40fd-8644-9bc9554b4c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1b8e034-6f0c-40fd-8644-9bc9554b4c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cda1c7d1-2204-4dec-a2b2-0e8a4691416b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_OperatingLeaseLiability_cda1c7d1-2204-4dec-a2b2-0e8a4691416b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ebd575b1-305e-4fa5-bb12-99e2361f8f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ebd575b1-305e-4fa5-bb12-99e2361f8f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18d7fb03-0eca-41a1-915d-04a948f64bed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bf04c7bc-d0ec-4ce9-bcb4-11f282c66101" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18d7fb03-0eca-41a1-915d-04a948f64bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mnlk-20231231.xsd#LeasesFutureLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3775ba61-aae2-4331-812b-9c28f8390d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ce9a5e7d-742d-44c8-8359-871c10d0176e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3775ba61-aae2-4331-812b-9c28f8390d56" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ce9a5e7d-742d-44c8-8359-871c10d0176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6d5100be-bf8a-42da-9976-136b07c0631a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6d5100be-bf8a-42da-9976-136b07c0631a" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f1581d3c-bb24-4335-94d6-489dcae0bd52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f1581d3c-bb24-4335-94d6-489dcae0bd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_25406409-6081-4dbc-9c62-a689878e35a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_25406409-6081-4dbc-9c62-a689878e35a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6f8ae7b0-872e-4ca2-98e1-d4056fd1973a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6f8ae7b0-872e-4ca2-98e1-d4056fd1973a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_05683d8a-9179-4665-ad56-d731ba5e4787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_05683d8a-9179-4665-ad56-d731ba5e4787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_299ed545-a397-407c-ace0-0e7cc8a342dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_299ed545-a397-407c-ace0-0e7cc8a342dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments_98524b29-e53f-4948-a77f-a649cdf61355" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments_98524b29-e53f-4948-a77f-a649cdf61355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_56263268-70c6-49a0-b5bc-bc25e5e71ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_56263268-70c6-49a0-b5bc-bc25e5e71ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_9d5b186b-9761-4acb-a33f-8f6ee71e5e38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_9d5b186b-9761-4acb-a33f-8f6ee71e5e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_faf70f15-2d77-4e4c-9fa5-07d81db35aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_473188b5-2c32-4e43-85b1-372270fb9c4e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_faf70f15-2d77-4e4c-9fa5-07d81db35aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6d5100be-bf8a-42da-9976-136b07c0631a" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d52f4bbc-ac95-4bde-a94b-ac1a121e6eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d52f4bbc-ac95-4bde-a94b-ac1a121e6eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_6e72fb18-b772-4753-90de-f58341f88ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_6e72fb18-b772-4753-90de-f58341f88ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns_fd7f9da7-e4a5-4099-b600-75222391ba45" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:to="loc_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns_fd7f9da7-e4a5-4099-b600-75222391ba45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_64e82a71-6422-4fcf-8586-97ba5642fe28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_64e82a71-6422-4fcf-8586-97ba5642fe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_d1453bb8-74ca-4ae6-a228-2e47f444641a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_d1453bb8-74ca-4ae6-a228-2e47f444641a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments_778cebd4-52c9-4dae-8f37-fe0ce6e0fc8a" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:to="loc_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments_778cebd4-52c9-4dae-8f37-fe0ce6e0fc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_633c4605-9637-4bf3-bdf0-64a6c8827865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_633c4605-9637-4bf3-bdf0-64a6c8827865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9609b1ec-31e1-45bc-8333-1ec55829d281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_5f7cc98c-65c3-4872-a918-c60ad56d98b7" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9609b1ec-31e1-45bc-8333-1ec55829d281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_41778348-d26a-4cc4-9bf1-92292b7a6d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_21471ea8-3207-4c32-a882-0ae69e37a8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_41778348-d26a-4cc4-9bf1-92292b7a6d62" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_21471ea8-3207-4c32-a882-0ae69e37a8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_bd2954da-c748-4b03-a21f-d51dfccc5eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_41778348-d26a-4cc4-9bf1-92292b7a6d62" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_bd2954da-c748-4b03-a21f-d51dfccc5eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_486aba08-4845-498e-b2cc-ac3c694bf42a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_41778348-d26a-4cc4-9bf1-92292b7a6d62" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_486aba08-4845-498e-b2cc-ac3c694bf42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansChangesinPreTaxAOCIDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e063512d-cabb-418d-b51e-0983ba7b4733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_25ccb891-c783-406f-b71d-0a6641b6d382" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanAOCIRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e063512d-cabb-418d-b51e-0983ba7b4733" xlink:to="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_25ccb891-c783-406f-b71d-0a6641b6d382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2eb42c0e-d838-4fd0-b122-5c7b23dd5a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_25ccb891-c783-406f-b71d-0a6641b6d382" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2eb42c0e-d838-4fd0-b122-5c7b23dd5a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_8b32e29c-e198-491e-8159-4e275c22430e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_25ccb891-c783-406f-b71d-0a6641b6d382" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_8b32e29c-e198-491e-8159-4e275c22430e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_70336a48-9905-42b7-914a-566614a8d1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_25ccb891-c783-406f-b71d-0a6641b6d382" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_70336a48-9905-42b7-914a-566614a8d1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_5a7819ce-f756-496a-abd4-adb3e1bb065e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_25ccb891-c783-406f-b71d-0a6641b6d382" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_5a7819ce-f756-496a-abd4-adb3e1bb065e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e3d6fc39-a2f6-4d48-ad0a-33a00067025c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward_25ccb891-c783-406f-b71d-0a6641b6d382" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e3d6fc39-a2f6-4d48-ad0a-33a00067025c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9f7e26e4-40e5-45ff-87ac-f926f44aad30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8eceecc7-d1ba-42c9-874a-2359afe4a137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9f7e26e4-40e5-45ff-87ac-f926f44aad30" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8eceecc7-d1ba-42c9-874a-2359afe4a137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets_3b22c3f2-82ba-4829-929d-5779d104fa1d" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9f7e26e4-40e5-45ff-87ac-f926f44aad30" xlink:to="loc_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets_3b22c3f2-82ba-4829-929d-5779d104fa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation_0944df99-efd6-4a82-96c8-eb7f7cffb945" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9f7e26e4-40e5-45ff-87ac-f926f44aad30" xlink:to="loc_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation_0944df99-efd6-4a82-96c8-eb7f7cffb945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_1a5e4820-a240-4c6e-8dac-aa4b4f5fe285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9f7e26e4-40e5-45ff-87ac-f926f44aad30" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_1a5e4820-a240-4c6e-8dac-aa4b4f5fe285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#EmployeeBenefitPlansAllocationPercentageDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ebf31efb-ffb8-4c3d-a6d2-ff1dd8bb25d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_2c00f7ff-1442-4df6-ab07-542311600675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ebf31efb-ffb8-4c3d-a6d2-ff1dd8bb25d9" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_2c00f7ff-1442-4df6-ab07-542311600675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5d1c0273-9bca-4e32-999a-5685d6921141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_2c00f7ff-1442-4df6-ab07-542311600675" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5d1c0273-9bca-4e32-999a-5685d6921141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5d1c0273-9bca-4e32-999a-5685d6921141" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_dc590775-bbfc-48c7-b4d5-27d657c40af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_dc590775-bbfc-48c7-b4d5-27d657c40af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanBondMember_4a5f7cd8-4a7d-4445-a4f8-b35a50c82722" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanBondMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_mnlk_DefinedBenefitPlanBondMember_4a5f7cd8-4a7d-4445-a4f8-b35a50c82722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_f2889209-d54a-4669-a0e6-6a5a362251ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_f2889209-d54a-4669-a0e6-6a5a362251ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanLiquidityMember_10b16523-b46a-4037-a139-797bced42c38" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanLiquidityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_mnlk_DefinedBenefitPlanLiquidityMember_10b16523-b46a-4037-a139-797bced42c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_6019d01c-b788-4b82-a1a2-f262aa834f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_6019d01c-b788-4b82-a1a2-f262aa834f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_4ac4eae3-e2ad-47f4-ab8c-8ee76b13cf53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_us-gaap_OtherInvestmentsMember_4ac4eae3-e2ad-47f4-ab8c-8ee76b13cf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DefinedBenefitPlanInfrastructureMember_9921a914-58a8-49d1-9213-5e8e3ae0c6c3" xlink:href="mnlk-20231231.xsd#mnlk_DefinedBenefitPlanInfrastructureMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_5932fd35-51c9-421d-8022-e57aeac18f64" xlink:to="loc_mnlk_DefinedBenefitPlanInfrastructureMember_9921a914-58a8-49d1-9213-5e8e3ae0c6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems_578f13fc-a668-4e30-8b86-95def08c0a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable_2c00f7ff-1442-4df6-ab07-542311600675" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems_578f13fc-a668-4e30-8b86-95def08c0a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_8612671c-3435-461b-83f0-5e142ad0b39c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems_578f13fc-a668-4e30-8b86-95def08c0a2e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_8612671c-3435-461b-83f0-5e142ad0b39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a0f539e7-bbaa-4250-831b-f4055d431300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a0f539e7-bbaa-4250-831b-f4055d431300" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_00cb033e-61d2-4a4a-960d-c6e4c0332b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_00cb033e-61d2-4a4a-960d-c6e4c0332b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1ab5deee-9d93-46d4-a644-f5e0569a904b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_00cb033e-61d2-4a4a-960d-c6e4c0332b46" xlink:to="loc_us-gaap_EquityComponentDomain_1ab5deee-9d93-46d4-a644-f5e0569a904b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_53ff95d7-730a-40da-8663-407c5234a810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ab5deee-9d93-46d4-a644-f5e0569a904b" xlink:to="loc_us-gaap_CommonStockMember_53ff95d7-730a-40da-8663-407c5234a810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ac6749d8-201e-48cb-9691-459eb25e3066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ac6749d8-201e-48cb-9691-459eb25e3066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_99628cc1-45bb-4dec-aed9-bf0d764d28f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ac6749d8-201e-48cb-9691-459eb25e3066" xlink:to="loc_us-gaap_ClassOfStockDomain_99628cc1-45bb-4dec-aed9-bf0d764d28f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e0611f1b-4d83-496f-8290-cfe66a5c026f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_99628cc1-45bb-4dec-aed9-bf0d764d28f0" xlink:to="loc_us-gaap_CommonClassAMember_e0611f1b-4d83-496f-8290-cfe66a5c026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_cb85daf3-d928-46cf-ab7e-a4f70559d3df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_99628cc1-45bb-4dec-aed9-bf0d764d28f0" xlink:to="loc_us-gaap_CommonClassCMember_cb85daf3-d928-46cf-ab7e-a4f70559d3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_655d181f-f8c3-4395-aa3e-577a5cb4717c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_655d181f-f8c3-4395-aa3e-577a5cb4717c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_9b28a0cc-fad0-4f86-ab59-d334d5407234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_655d181f-f8c3-4395-aa3e-577a5cb4717c" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_9b28a0cc-fad0-4f86-ab59-d334d5407234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ConversionOfClassCIntoClassAMember_0aa829c5-57bf-4913-ace5-a56eadb55524" xlink:href="mnlk-20231231.xsd#mnlk_ConversionOfClassCIntoClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_9b28a0cc-fad0-4f86-ab59-d334d5407234" xlink:to="loc_mnlk_ConversionOfClassCIntoClassAMember_0aa829c5-57bf-4913-ace5-a56eadb55524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ced98458-2cd5-465d-9352-2be106c6a673" xlink:to="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:to="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a83db472-16ec-4f44-84c5-749e2fcf8410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a83db472-16ec-4f44-84c5-749e2fcf8410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5820b3f3-59b6-4970-ab4d-be0cddcb7b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_CommonStockSharesIssued_5820b3f3-59b6-4970-ab4d-be0cddcb7b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa1e9119-14f3-48f8-bda1-13d94f2db2db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa1e9119-14f3-48f8-bda1-13d94f2db2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0aba1d45-a1ad-4ed3-b847-fc56cf688207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0aba1d45-a1ad-4ed3-b847-fc56cf688207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8ba59655-f2ab-4885-9020-d9f6f4745b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8ba59655-f2ab-4885-9020-d9f6f4745b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_91871083-2106-49a3-a6b5-c943304d536d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_CommonStockRollForward_efc85acb-0e58-4452-9a27-48c67e3a216e" xlink:to="loc_us-gaap_CommonStockSharesIssued_91871083-2106-49a3-a6b5-c943304d536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:href="mnlk-20231231.xsd#mnlk_TotalSharesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:to="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SharesAuthorized_765699bf-669d-402c-a9b7-3e845377922a" xlink:href="mnlk-20231231.xsd#mnlk_SharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:to="loc_mnlk_SharesAuthorized_765699bf-669d-402c-a9b7-3e845377922a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8a330f50-7419-4081-85b3-8dbc3fc07a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:to="loc_us-gaap_SharesIssued_8a330f50-7419-4081-85b3-8dbc3fc07a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_00b98874-d9a8-46d9-90c1-8d1ad7fd7e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_00b98874-d9a8-46d9-90c1-8d1ad7fd7e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SharesAuthorized_9a9af908-63ca-4da1-bd58-fb4c0ce4f457" xlink:href="mnlk-20231231.xsd#mnlk_SharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:to="loc_mnlk_SharesAuthorized_9a9af908-63ca-4da1-bd58-fb4c0ce4f457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_00f0b61e-85d0-4070-9c5c-a50153601a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_TotalSharesRollForward_b8686c86-9c3e-4ab0-84ab-a1d841d9bdec" xlink:to="loc_us-gaap_SharesIssued_00f0b61e-85d0-4070-9c5c-a50153601a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_df4c96c9-9156-4cd2-84de-7eb24044c951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3103e558-6e74-42c7-a59c-59849f8b4295" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_df4c96c9-9156-4cd2-84de-7eb24044c951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#ShareholdersEquityDeficitNarrativeDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bce6ae88-49ce-45b7-b008-58a8437b7b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bce6ae88-49ce-45b7-b008-58a8437b7b77" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_201b24b7-50c5-4cc3-a7b0-b8434a044330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eeb7c82b-3a3e-4121-a3e7-06d206dbc2c2" xlink:to="loc_us-gaap_ClassOfStockDomain_201b24b7-50c5-4cc3-a7b0-b8434a044330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_be0f387c-4c5a-4b8e-8e5b-9beefb69c672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201b24b7-50c5-4cc3-a7b0-b8434a044330" xlink:to="loc_us-gaap_CommonClassAMember_be0f387c-4c5a-4b8e-8e5b-9beefb69c672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_ada1b22c-3994-4289-9eef-dc0af0769399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201b24b7-50c5-4cc3-a7b0-b8434a044330" xlink:to="loc_us-gaap_CommonClassCMember_ada1b22c-3994-4289-9eef-dc0af0769399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5e4f13ec-fa2a-441b-9863-4732d7b67944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5e4f13ec-fa2a-441b-9863-4732d7b67944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4f1056df-b059-4d92-9481-8759070c2034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e4f13ec-fa2a-441b-9863-4732d7b67944" xlink:to="loc_us-gaap_EquityComponentDomain_4f1056df-b059-4d92-9481-8759070c2034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b2303cba-9538-4957-acc9-49bd913bc2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4f1056df-b059-4d92-9481-8759070c2034" xlink:to="loc_us-gaap_CommonStockMember_b2303cba-9538-4957-acc9-49bd913bc2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b189b683-330d-443c-8b46-f1201dd2a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_AwardTypeAxis_b189b683-330d-443c-8b46-f1201dd2a7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e45ee91-f09b-44d5-a22d-6059f82a81e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b189b683-330d-443c-8b46-f1201dd2a7b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e45ee91-f09b-44d5-a22d-6059f82a81e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ATMSharesMember_7854d71d-5767-447c-ac84-1413cd9bd7c0" xlink:href="mnlk-20231231.xsd#mnlk_ATMSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e45ee91-f09b-44d5-a22d-6059f82a81e3" xlink:to="loc_mnlk_ATMSharesMember_7854d71d-5767-447c-ac84-1413cd9bd7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_94612f9d-feda-4b12-aa3b-7473b5735482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_PlanNameAxis_94612f9d-feda-4b12-aa3b-7473b5735482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be32170c-a08d-489a-ad82-e8ef882f7bff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_94612f9d-feda-4b12-aa3b-7473b5735482" xlink:to="loc_us-gaap_PlanNameDomain_be32170c-a08d-489a-ad82-e8ef882f7bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_May2023SalesAgreementMember_2dd1c5f4-af13-4012-97d6-2a7ee385662e" xlink:href="mnlk-20231231.xsd#mnlk_May2023SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_be32170c-a08d-489a-ad82-e8ef882f7bff" xlink:to="loc_mnlk_May2023SalesAgreementMember_2dd1c5f4-af13-4012-97d6-2a7ee385662e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_August2023SalesAgreementMember_c3c27beb-2e77-46c7-8cbe-ddefb1ddff6f" xlink:href="mnlk-20231231.xsd#mnlk_August2023SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_be32170c-a08d-489a-ad82-e8ef882f7bff" xlink:to="loc_mnlk_August2023SalesAgreementMember_c3c27beb-2e77-46c7-8cbe-ddefb1ddff6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9f27694c-7858-43d9-8258-b1a1caafaea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9f27694c-7858-43d9-8258-b1a1caafaea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9f27694c-7858-43d9-8258-b1a1caafaea7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_UnderwritingAgreementMember_4a36ce20-a385-4b9c-bffe-ad6ed3c5871a" xlink:href="mnlk-20231231.xsd#mnlk_UnderwritingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:to="loc_mnlk_UnderwritingAgreementMember_4a36ce20-a385-4b9c-bffe-ad6ed3c5871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a21dcb2f-17a3-4b77-9237-a26355305db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a21dcb2f-17a3-4b77-9237-a26355305db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_May2023SalesAgreementMember_fdeb7b5b-27d2-4ac0-8abc-f7d2bc28012b" xlink:href="mnlk-20231231.xsd#mnlk_May2023SalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6d49879-8f6a-4830-8925-e4db548eaead" xlink:to="loc_mnlk_May2023SalesAgreementMember_fdeb7b5b-27d2-4ac0-8abc-f7d2bc28012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad15a2e2-6604-4d1a-a1bd-076f79e96902" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_srt_CounterpartyNameAxis_ad15a2e2-6604-4d1a-a1bd-076f79e96902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d8829a2-78e5-436a-b829-587714995a3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ad15a2e2-6604-4d1a-a1bd-076f79e96902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d8829a2-78e5-436a-b829-587714995a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MoonLakeImmunotherapeuticsMember_e5a79015-37b0-4a02-8d7a-7f8f9ac664da" xlink:href="mnlk-20231231.xsd#mnlk_MoonLakeImmunotherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d8829a2-78e5-436a-b829-587714995a3c" xlink:to="loc_mnlk_MoonLakeImmunotherapeuticsMember_e5a79015-37b0-4a02-8d7a-7f8f9ac664da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_059f9d35-be4b-413c-9f7b-001a1e8e7275" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_dei_LegalEntityAxis_059f9d35-be4b-413c-9f7b-001a1e8e7275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b86c8f10-918d-498a-9930-368511c66382" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_059f9d35-be4b-413c-9f7b-001a1e8e7275" xlink:to="loc_dei_EntityDomain_b86c8f10-918d-498a-9930-368511c66382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MoonLakeAGMember_00b91a65-edf0-4a82-9c2d-3f09e00c9766" xlink:href="mnlk-20231231.xsd#mnlk_MoonLakeAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b86c8f10-918d-498a-9930-368511c66382" xlink:to="loc_mnlk_MoonLakeAGMember_00b91a65-edf0-4a82-9c2d-3f09e00c9766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee2bd26e-5ad7-4928-b7ce-8fb5954cf2c0" xlink:to="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1dd43b01-06d0-4519-ac9d-ed6b5faf5a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_CommonStockSharesIssued_1dd43b01-06d0-4519-ac9d-ed6b5faf5a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_161db033-b254-4b94-b8ac-39b0e60a1b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_161db033-b254-4b94-b8ac-39b0e60a1b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0203c917-5115-406d-8e9c-eccf8a03d8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0203c917-5115-406d-8e9c-eccf8a03d8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2620aa87-7104-457e-bf06-c7a4f9dbff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2620aa87-7104-457e-bf06-c7a4f9dbff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_CommonStockVotesAttachedToShares_6f6c452e-9414-44e3-b51e-43756816d7a0" xlink:href="mnlk-20231231.xsd#mnlk_CommonStockVotesAttachedToShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_CommonStockVotesAttachedToShares_6f6c452e-9414-44e3-b51e-43756816d7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8cef48f0-c2e6-4c25-88be-9d307b71510a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8cef48f0-c2e6-4c25-88be-9d307b71510a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_430b3341-3ca6-47a5-8b6b-c523750bd412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_430b3341-3ca6-47a5-8b6b-c523750bd412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockAuthorizedAmount_b763a899-7faa-4e49-a008-2dfa0f932236" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_SaleOfStockAuthorizedAmount_b763a899-7faa-4e49-a008-2dfa0f932236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount_94125efe-b744-4c11-8b7b-18b750468d09" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount_94125efe-b744-4c11-8b7b-18b750468d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4404799d-ee32-4e72-a925-fea6213ff191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4404799d-ee32-4e72-a925-fea6213ff191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e8d0872c-1767-41e0-88ad-17038ea4cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e8d0872c-1767-41e0-88ad-17038ea4cdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf60f799-798a-4e79-a8be-af5c6f39b808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf60f799-798a-4e79-a8be-af5c6f39b808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockOptionToPurchaseTerm_8532c3fc-5cb9-41bc-97ac-d1d95cbb0167" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockOptionToPurchaseTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_SaleOfStockOptionToPurchaseTerm_8532c3fc-5cb9-41bc-97ac-d1d95cbb0167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_92c4ba80-0325-43b1-b43c-70b08d9d4ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromParent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_92c4ba80-0325-43b1-b43c-70b08d9d4ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SaleOfStockStampDutyTax_5543d782-ee11-40bb-bddc-a170556b0bb3" xlink:href="mnlk-20231231.xsd#mnlk_SaleOfStockStampDutyTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_219f6623-dfbc-45d9-9593-c13a45ae6b94" xlink:to="loc_mnlk_SaleOfStockStampDutyTax_5543d782-ee11-40bb-bddc-a170556b0bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#NetLossperShareCalculationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c24d0423-46a9-4323-961a-010b5b9671a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_7749fe10-31f9-42b5-81d7-743cddefe4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c24d0423-46a9-4323-961a-010b5b9671a8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_7749fe10-31f9-42b5-81d7-743cddefe4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd06310a-b45e-4e0d-a9c0-db0c9a838a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_7749fe10-31f9-42b5-81d7-743cddefe4e7" xlink:to="loc_us-gaap_NetIncomeLoss_fd06310a-b45e-4e0d-a9c0-db0c9a838a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_61476db5-9caa-4427-b53f-8e3554c832f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c24d0423-46a9-4323-961a-010b5b9671a8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_61476db5-9caa-4427-b53f-8e3554c832f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9d5970d-3e6c-405c-91b3-c2fb5806a415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_61476db5-9caa-4427-b53f-8e3554c832f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9d5970d-3e6c-405c-91b3-c2fb5806a415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074aaec6-bc34-4b80-8931-e30765b0fded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_61476db5-9caa-4427-b53f-8e3554c832f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074aaec6-bc34-4b80-8931-e30765b0fded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_71240d2a-f81a-47dc-8500-124bd499fe23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c24d0423-46a9-4323-961a-010b5b9671a8" xlink:to="loc_us-gaap_EarningsPerShareBasic_71240d2a-f81a-47dc-8500-124bd499fe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cae06898-b635-4371-aaa4-6336add5b02c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c24d0423-46a9-4323-961a-010b5b9671a8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cae06898-b635-4371-aaa4-6336add5b02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/NetLossperShareNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#NetLossperShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/NetLossperShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e7a54857-7ed0-4ff0-9c20-2b950feee512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e7a54857-7ed0-4ff0-9c20-2b950feee512" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_52da509c-072d-41be-996d-5a632badb515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_us-gaap_StatementClassOfStockAxis_52da509c-072d-41be-996d-5a632badb515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ead7c7d-2a78-48de-a5eb-593fded5de16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_52da509c-072d-41be-996d-5a632badb515" xlink:to="loc_us-gaap_ClassOfStockDomain_9ead7c7d-2a78-48de-a5eb-593fded5de16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_a18c3743-4658-4f31-97f7-ecdfc30fb109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9ead7c7d-2a78-48de-a5eb-593fded5de16" xlink:to="loc_us-gaap_CommonClassCMember_a18c3743-4658-4f31-97f7-ecdfc30fb109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1761d347-ff04-4081-a744-03217fcc07be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9ead7c7d-2a78-48de-a5eb-593fded5de16" xlink:to="loc_us-gaap_CommonClassAMember_1761d347-ff04-4081-a744-03217fcc07be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ea58bf33-948a-49b2-864d-82c780602422" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_srt_CounterpartyNameAxis_ea58bf33-948a-49b2-864d-82c780602422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9c85d2c-d602-4a7b-b165-75f167f5e171" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ea58bf33-948a-49b2-864d-82c780602422" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9c85d2c-d602-4a7b-b165-75f167f5e171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MLPartiesOtherThanBVFShareholdersMember_41250b1d-b91f-46e8-98c3-5ab14ed1cb65" xlink:href="mnlk-20231231.xsd#mnlk_MLPartiesOtherThanBVFShareholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9c85d2c-d602-4a7b-b165-75f167f5e171" xlink:to="loc_mnlk_MLPartiesOtherThanBVFShareholdersMember_41250b1d-b91f-46e8-98c3-5ab14ed1cb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_acf0af5b-0818-4e42-9a6b-0847708da76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_acf0af5b-0818-4e42-9a6b-0847708da76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_46e7dfdc-c0f3-46af-bb2f-07b4e381aacb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_acf0af5b-0818-4e42-9a6b-0847708da76a" xlink:to="loc_us-gaap_EquityComponentDomain_46e7dfdc-c0f3-46af-bb2f-07b4e381aacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ee1b4794-52d5-4942-bcc4-c406fb1c82c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_46e7dfdc-c0f3-46af-bb2f-07b4e381aacb" xlink:to="loc_us-gaap_CommonStockMember_ee1b4794-52d5-4942-bcc4-c406fb1c82c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_srt_StatementScenarioAxis_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a3db1bf9-6d53-490b-a689-9915976d2d92" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c7d18e1a-3b16-4480-8b31-ac6f7ae76a99" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a3db1bf9-6d53-490b-a689-9915976d2d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_9e6288df-1cca-45a6-b6e8-428602f68a66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a3db1bf9-6d53-490b-a689-9915976d2d92" xlink:to="loc_srt_ProFormaMember_9e6288df-1cca-45a6-b6e8-428602f68a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_92031988-cd6b-4323-9bb1-e067a67a9505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_92031988-cd6b-4323-9bb1-e067a67a9505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cb4f7b8a-64dd-48f3-9e9b-78dfe35070cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_92031988-cd6b-4323-9bb1-e067a67a9505" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cb4f7b8a-64dd-48f3-9e9b-78dfe35070cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6fd06dfd-0c51-438e-9524-7a1414880975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cb4f7b8a-64dd-48f3-9e9b-78dfe35070cd" xlink:to="loc_us-gaap_SubsequentEventMember_6fd06dfd-0c51-438e-9524-7a1414880975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d58c9e32-3f5b-4aca-997a-360ad5ce7768" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_19402576-b577-4434-8dee-3812cfb6c024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_CommonStockSharesIssued_19402576-b577-4434-8dee-3812cfb6c024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_ef3b4995-359d-44cd-994c-ad5138651498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_ef3b4995-359d-44cd-994c-ad5138651498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockConvertedReverseRecapitalization_8890830d-8edf-475c-b5cd-eaa8f37b02b7" xlink:href="mnlk-20231231.xsd#mnlk_StockConvertedReverseRecapitalization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_mnlk_StockConvertedReverseRecapitalization_8890830d-8edf-475c-b5cd-eaa8f37b02b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b1384fc-8e5c-4e3b-a0c6-e97acf014e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b1384fc-8e5c-4e3b-a0c6-e97acf014e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d0ba618-6b1a-486d-8f86-56a11a98a9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d0ba618-6b1a-486d-8f86-56a11a98a9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_319a960a-61d9-4d00-9df4-15c81bafbde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_EarningsPerShareBasic_319a960a-61d9-4d00-9df4-15c81bafbde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_02d58422-2d0c-4bf5-8c6d-d0a1b0abd96f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_EarningsPerShareDiluted_02d58422-2d0c-4bf5-8c6d-d0a1b0abd96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_StockForfeitedReverseRecapitalization_98357419-ab2a-4853-9769-753c9f71bcca" xlink:href="mnlk-20231231.xsd#mnlk_StockForfeitedReverseRecapitalization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_mnlk_StockForfeitedReverseRecapitalization_98357419-ab2a-4853-9769-753c9f71bcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6ac3baba-f9c1-48d2-aedc-b82495272ead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38ad42cb-6f93-4f5b-ba8f-6fe8d0e8fe23" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6ac3baba-f9c1-48d2-aedc-b82495272ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2df0a6c5-566d-4eee-b7bf-08a7915399bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2df0a6c5-566d-4eee-b7bf-08a7915399bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42b91af7-147a-4132-b2a3-333a10515575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2fa5e3a0-ac5b-4be2-817c-4e6ca3f6aa7a" xlink:to="loc_us-gaap_EquityComponentDomain_42b91af7-147a-4132-b2a3-333a10515575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_da5d59a3-8301-45af-937e-f4b1dc370f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42b91af7-147a-4132-b2a3-333a10515575" xlink:to="loc_us-gaap_CommonStockMember_da5d59a3-8301-45af-937e-f4b1dc370f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6a350649-65b9-446c-a5d4-665832848c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6a350649-65b9-446c-a5d4-665832848c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_24503c92-1333-4047-b21f-b2da5cda49dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6a350649-65b9-446c-a5d4-665832848c7f" xlink:to="loc_us-gaap_ClassOfStockDomain_24503c92-1333-4047-b21f-b2da5cda49dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_6546c57c-f061-4e6f-8d46-3242eec969db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_24503c92-1333-4047-b21f-b2da5cda49dd" xlink:to="loc_us-gaap_CommonClassCMember_6546c57c-f061-4e6f-8d46-3242eec969db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ca5589e0-33cb-4735-b16e-eb53d6a9abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_24503c92-1333-4047-b21f-b2da5cda49dd" xlink:to="loc_us-gaap_CommonClassAMember_ca5589e0-33cb-4735-b16e-eb53d6a9abc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6428f820-ff89-48cf-b9b9-a8ffb79de539" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_dei_LegalEntityAxis_6428f820-ff89-48cf-b9b9-a8ffb79de539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e9208cf9-d4a8-4a2f-8ab3-4a549355350e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6428f820-ff89-48cf-b9b9-a8ffb79de539" xlink:to="loc_dei_EntityDomain_e9208cf9-d4a8-4a2f-8ab3-4a549355350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_MoonLakeAGMember_028f1a08-7d23-4342-abf1-447c8b93fef0" xlink:href="mnlk-20231231.xsd#mnlk_MoonLakeAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e9208cf9-d4a8-4a2f-8ab3-4a549355350e" xlink:to="loc_mnlk_MoonLakeAGMember_028f1a08-7d23-4342-abf1-447c8b93fef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_765a2bac-4eb4-43ec-b955-046ab2ee3d09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_AwardTypeAxis_765a2bac-4eb4-43ec-b955-046ab2ee3d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_765a2bac-4eb4-43ec-b955-046ab2ee3d09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_78d08e87-0174-498f-9c17-13902157fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:to="loc_us-gaap_RestrictedStockMember_78d08e87-0174-498f-9c17-13902157fd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0d2883c8-98a9-4fc5-a23d-f7aa1fa44f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:to="loc_us-gaap_EmployeeStockMember_0d2883c8-98a9-4fc5-a23d-f7aa1fa44f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ef65029b-f1d8-4316-b085-dee1b54f57a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a1eeef8-f4f7-484a-bf55-58d03cbe3cab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ef65029b-f1d8-4316-b085-dee1b54f57a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9bf9b688-9c43-4355-aad0-9be296d1f977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_VestingAxis_9bf9b688-9c43-4355-aad0-9be296d1f977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_9bf9b688-9c43-4355-aad0-9be296d1f977" xlink:to="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_baf88241-4985-4102-a55b-98dcf69cb4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_baf88241-4985-4102-a55b-98dcf69cb4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedPaymentArrangementTrancheFourMember_886e30e9-6d8a-47a8-b172-758ffec82f57" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:to="loc_mnlk_ShareBasedPaymentArrangementTrancheFourMember_886e30e9-6d8a-47a8-b172-758ffec82f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a6e7e01f-d1a9-4173-ad17-b01534eee247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a6e7e01f-d1a9-4173-ad17-b01534eee247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1ede1c64-035b-4737-ba84-4ee8c9b85ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_caaf4aba-8c76-41d2-a3e3-3c1c39f2bfb7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1ede1c64-035b-4737-ba84-4ee8c9b85ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5e3357ca-5912-468d-8b99-ee7c2f1979d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_PlanNameAxis_5e3357ca-5912-468d-8b99-ee7c2f1979d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fae26e7a-1db6-4559-8903-3ab3b1e757e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5e3357ca-5912-468d-8b99-ee7c2f1979d7" xlink:to="loc_us-gaap_PlanNameDomain_fae26e7a-1db6-4559-8903-3ab3b1e757e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EmployeeStockOptionPlanESOPMember_ae7e0577-4fae-4e3e-b4c6-2929505910c3" xlink:href="mnlk-20231231.xsd#mnlk_EmployeeStockOptionPlanESOPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fae26e7a-1db6-4559-8903-3ab3b1e757e1" xlink:to="loc_mnlk_EmployeeStockOptionPlanESOPMember_ae7e0577-4fae-4e3e-b4c6-2929505910c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember_72762b9d-bdf0-4b41-b11c-2aaedfd67752" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fae26e7a-1db6-4559-8903-3ab3b1e757e1" xlink:to="loc_mnlk_EquityIncentivePlanMember_72762b9d-bdf0-4b41-b11c-2aaedfd67752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_f9cc8951-5442-4895-a26f-6efabbeccd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_GranteeStatusAxis_f9cc8951-5442-4895-a26f-6efabbeccd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_df2418a0-7b62-42b0-90f6-177ab2bf7fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_f9cc8951-5442-4895-a26f-6efabbeccd7d" xlink:to="loc_us-gaap_GranteeStatusDomain_df2418a0-7b62-42b0-90f6-177ab2bf7fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6dbefe6d-bd55-4c4e-9e1c-ef6a4f242165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_df2418a0-7b62-42b0-90f6-177ab2bf7fdb" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6dbefe6d-bd55-4c4e-9e1c-ef6a4f242165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_687a4b3b-7d72-4bb9-93c1-e4acf4e8fd95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_df2418a0-7b62-42b0-90f6-177ab2bf7fdb" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_687a4b3b-7d72-4bb9-93c1-e4acf4e8fd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_993697d0-8c5b-440c-8d07-52c5ef3986cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0979181e-a19e-4652-891f-12a80310427b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0979181e-a19e-4652-891f-12a80310427b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_278b32a2-1896-4502-bae5-bbcea0a0705d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_278b32a2-1896-4502-bae5-bbcea0a0705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage_36a587a9-f96f-4391-9e66-562fa75597c9" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage_36a587a9-f96f-4391-9e66-562fa75597c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2a44fe0b-e4ad-4932-bcc4-4675a7b51020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2a44fe0b-e4ad-4932-bcc4-4675a7b51020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_NumberOfCoFounders_1e305b67-813b-4b53-8dce-3bc266be49ba" xlink:href="mnlk-20231231.xsd#mnlk_NumberOfCoFounders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_mnlk_NumberOfCoFounders_1e305b67-813b-4b53-8dce-3bc266be49ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_84939cac-1d20-424b-8ecb-18819755a34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_84939cac-1d20-424b-8ecb-18819755a34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_420e8181-6b89-462d-a4c7-528dfb8e503b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_420e8181-6b89-462d-a4c7-528dfb8e503b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SharePriceNominalValue_1c9b9ac8-05cb-4fad-bf79-cb17f390005f" xlink:href="mnlk-20231231.xsd#mnlk_SharePriceNominalValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_mnlk_SharePriceNominalValue_1c9b9ac8-05cb-4fad-bf79-cb17f390005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_006e6bc5-c28d-4ccc-a018-1d4b5cf61693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_006e6bc5-c28d-4ccc-a018-1d4b5cf61693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c99851d9-1419-4095-90ed-15a0b5a939eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c99851d9-1419-4095-90ed-15a0b5a939eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4cfe723b-c3e1-4a0d-a455-f2f460f38539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4cfe723b-c3e1-4a0d-a455-f2f460f38539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13ab32e0-38e9-4af1-9997-1a29b44ba85e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13ab32e0-38e9-4af1-9997-1a29b44ba85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ad150fff-0435-4e3a-a69e-d0bc4b148ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ad150fff-0435-4e3a-a69e-d0bc4b148ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_d7c74d81-09d8-4acb-8fed-8c52b2dea183" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_d7c74d81-09d8-4acb-8fed-8c52b2dea183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6e6d4cb2-a394-402f-87ea-fa221ce791eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e2a8d-84af-48df-89d2-9fac51962898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6e6d4cb2-a394-402f-87ea-fa221ce791eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c61a208d-906e-4535-a07b-0e2a628feb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c61a208d-906e-4535-a07b-0e2a628feb85" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e79a683-e3ef-4919-aa23-09fef024f85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:to="loc_us-gaap_AwardTypeAxis_0e79a683-e3ef-4919-aa23-09fef024f85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0e79a683-e3ef-4919-aa23-09fef024f85b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e9b7c550-1818-4b31-a9a8-c02b2ab14ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:to="loc_us-gaap_RestrictedStockMember_e9b7c550-1818-4b31-a9a8-c02b2ab14ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_38008e83-49c1-4e7c-adbf-1383a39e612d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:to="loc_us-gaap_EmployeeStockMember_38008e83-49c1-4e7c-adbf-1383a39e612d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_992e6e3d-a89e-4bcd-9bb0-3d45ab0fbbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9013578e-5d58-49d3-916f-549dc1c06420" xlink:to="loc_us-gaap_EmployeeStockOptionMember_992e6e3d-a89e-4bcd-9bb0-3d45ab0fbbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6e59b8c6-af78-4d2a-99f1-791b2f744bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:to="loc_us-gaap_PlanNameAxis_6e59b8c6-af78-4d2a-99f1-791b2f744bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2c813c9f-f693-4c2c-b72c-269e1a090829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6e59b8c6-af78-4d2a-99f1-791b2f744bab" xlink:to="loc_us-gaap_PlanNameDomain_2c813c9f-f693-4c2c-b72c-269e1a090829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember_a02212ee-b096-4725-8f8b-c556dba6321b" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2c813c9f-f693-4c2c-b72c-269e1a090829" xlink:to="loc_mnlk_EquityIncentivePlanMember_a02212ee-b096-4725-8f8b-c556dba6321b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_288f4a4d-4f54-4a68-85e6-3b41edd9ca22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_288f4a4d-4f54-4a68-85e6-3b41edd9ca22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d10f95e-8ca4-46fa-b899-a334b09c1556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_288f4a4d-4f54-4a68-85e6-3b41edd9ca22" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d10f95e-8ca4-46fa-b899-a334b09c1556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f7c67a8-6d5b-4537-ae91-31d467d4c246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d10f95e-8ca4-46fa-b899-a334b09c1556" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f7c67a8-6d5b-4537-ae91-31d467d4c246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da715845-4cb9-4eb0-ad61-94bbce80e749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d10f95e-8ca4-46fa-b899-a334b09c1556" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_da715845-4cb9-4eb0-ad61-94bbce80e749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6bcc00cf-fc39-4524-bbfe-2deada58da59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4979c2cb-1e52-4f32-a50d-568732c585e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6bcc00cf-fc39-4524-bbfe-2deada58da59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0921601e-07e7-4d5f-a37a-d61c9b81be7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6bcc00cf-fc39-4524-bbfe-2deada58da59" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0921601e-07e7-4d5f-a37a-d61c9b81be7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81cdd9e0-7d0e-4aa0-a088-11d799e02949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81cdd9e0-7d0e-4aa0-a088-11d799e02949" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:to="loc_us-gaap_AwardTypeAxis_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ccaeb5a7-3b25-48c2-8aad-d70df955c0b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_343ce9c0-e751-4695-a280-b1326b1d9579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:to="loc_us-gaap_RestrictedStockMember_343ce9c0-e751-4695-a280-b1326b1d9579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_aa4fceaf-4b08-4ac3-b7ed-7b56661b7bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:to="loc_us-gaap_EmployeeStockMember_aa4fceaf-4b08-4ac3-b7ed-7b56661b7bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e8125bee-d198-4816-a682-6ca006e61db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45e23b21-44b0-4dbc-98ee-4e513c4ed3fc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e8125bee-d198-4816-a682-6ca006e61db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8699dd4f-8ce1-4e24-a9d7-d857027032f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:to="loc_us-gaap_PlanNameAxis_8699dd4f-8ce1-4e24-a9d7-d857027032f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e6325db5-a3f8-49bd-9863-575fe596a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8699dd4f-8ce1-4e24-a9d7-d857027032f0" xlink:to="loc_us-gaap_PlanNameDomain_e6325db5-a3f8-49bd-9863-575fe596a2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EmployeeStockOptionPlanESOPMember_b1ac8d9e-56ef-4c83-9edf-1ca2c32019e4" xlink:href="mnlk-20231231.xsd#mnlk_EmployeeStockOptionPlanESOPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e6325db5-a3f8-49bd-9863-575fe596a2a7" xlink:to="loc_mnlk_EmployeeStockOptionPlanESOPMember_b1ac8d9e-56ef-4c83-9edf-1ca2c32019e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember_c666f7fb-50bc-4af0-a50d-cceab663d1ec" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e6325db5-a3f8-49bd-9863-575fe596a2a7" xlink:to="loc_mnlk_EquityIncentivePlanMember_c666f7fb-50bc-4af0-a50d-cceab663d1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36a2d506-9887-4b28-b901-36c194ac28ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc65e792-75ef-4521-9786-67caf209070d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc65e792-75ef-4521-9786-67caf209070d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue_686b260e-9620-4404-bcdd-64860b28ec09" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue_686b260e-9620-4404-bcdd-64860b28ec09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_b288fb0a-5c25-4925-ab9b-eff77109c6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_b288fb0a-5c25-4925-ab9b-eff77109c6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise_74be5528-6455-4895-a238-0f370d63a314" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise_74be5528-6455-4895-a238-0f370d63a314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares_66821004-c798-4bd8-877b-f45c28cd4a47" xlink:href="mnlk-20231231.xsd#mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares_66821004-c798-4bd8-877b-f45c28cd4a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fef0167a-e25b-4461-894a-2dffc891f56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fef0167a-e25b-4461-894a-2dffc891f56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b856e60b-6d5e-4d33-b11d-7ab51bea97c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b856e60b-6d5e-4d33-b11d-7ab51bea97c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eea1278e-15f3-43e2-bf89-72d05ea43889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eea1278e-15f3-43e2-bf89-72d05ea43889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_eb3a72f5-f983-4e54-9096-a28d30776ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_eb3a72f5-f983-4e54-9096-a28d30776ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d4a50d6-9160-4c20-b4ad-ddfc67640129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d4a50d6-9160-4c20-b4ad-ddfc67640129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a91c7eab-050e-4d3c-bd25-98200f79bc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d9d73f9-a158-40f2-a584-070006986a58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a91c7eab-050e-4d3c-bd25-98200f79bc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SharebasedCompensationAwardedandGrantedDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_381c4f2b-d0c0-412e-b3ff-311336cbacca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_381c4f2b-d0c0-412e-b3ff-311336cbacca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f63f05af-e686-4234-a09b-17040e934a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:to="loc_us-gaap_AwardTypeAxis_f63f05af-e686-4234-a09b-17040e934a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f63f05af-e686-4234-a09b-17040e934a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b5bb51e4-8b92-42a1-879f-e0437400ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:to="loc_us-gaap_RestrictedStockMember_b5bb51e4-8b92-42a1-879f-e0437400ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_af3a422c-5454-41dc-86e9-57d946da3d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:to="loc_us-gaap_EmployeeStockMember_af3a422c-5454-41dc-86e9-57d946da3d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_33bcc47f-5993-4185-9c9a-62ff39010461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c8076db-80a7-4d28-add0-21e571c3d0e0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_33bcc47f-5993-4185-9c9a-62ff39010461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0540e7c9-1557-4482-b711-f2440c6c4664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:to="loc_us-gaap_PlanNameAxis_0540e7c9-1557-4482-b711-f2440c6c4664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b884b592-34f4-4905-90d8-a24b65cf801b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0540e7c9-1557-4482-b711-f2440c6c4664" xlink:to="loc_us-gaap_PlanNameDomain_b884b592-34f4-4905-90d8-a24b65cf801b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EmployeeStockOptionPlanESOPMember_d0bb91e4-5557-47da-b5ba-136da4561186" xlink:href="mnlk-20231231.xsd#mnlk_EmployeeStockOptionPlanESOPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b884b592-34f4-4905-90d8-a24b65cf801b" xlink:to="loc_mnlk_EmployeeStockOptionPlanESOPMember_d0bb91e4-5557-47da-b5ba-136da4561186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EquityIncentivePlanMember_90bb176f-fb1f-4253-9bef-e41ffc5c7569" xlink:href="mnlk-20231231.xsd#mnlk_EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b884b592-34f4-4905-90d8-a24b65cf801b" xlink:to="loc_mnlk_EquityIncentivePlanMember_90bb176f-fb1f-4253-9bef-e41ffc5c7569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_65106ac7-f997-4b6b-97bd-5f6edc26736e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_501fd52c-1b97-4342-a076-e5d17a670ece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_501fd52c-1b97-4342-a076-e5d17a670ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd37a34b-1fb7-4ad6-8036-8f952e80c622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd37a34b-1fb7-4ad6-8036-8f952e80c622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00aaf339-c27f-4085-b548-0510f2af9645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00aaf339-c27f-4085-b548-0510f2af9645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4bf5f749-40b7-4c36-9e08-cfe521a0c0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2e46444-59d1-4165-a1a4-568842a1a34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4bf5f749-40b7-4c36-9e08-cfe521a0c0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b96e562a-70a6-4ef3-a711-7efa4768ce0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b96e562a-70a6-4ef3-a711-7efa4768ce0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38740505-4759-4c29-b798-672d24001d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38740505-4759-4c29-b798-672d24001d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b09052e6-89a0-404f-b2dd-e5c59f6f7852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b09052e6-89a0-404f-b2dd-e5c59f6f7852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_62ae3dd4-a699-4454-b8b7-b6a11442ad99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eec2a1a4-7daf-4737-a30a-caebdffbef17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_62ae3dd4-a699-4454-b8b7-b6a11442ad99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1f56cf45-694a-4fed-a447-b69c6588caf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a96c6f2e-0904-4d3c-9048-394ba89e14a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1f56cf45-694a-4fed-a447-b69c6588caf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aba9d2f8-37af-4abc-9386-4d84a3e8a858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_734447ed-ac45-460a-9440-6148f0893b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aba9d2f8-37af-4abc-9386-4d84a3e8a858" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_734447ed-ac45-460a-9440-6148f0893b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLossCarryforwardExpirationAxis_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLossCarryforwardExpirationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_734447ed-ac45-460a-9440-6148f0893b45" xlink:to="loc_mnlk_OperatingLossCarryforwardExpirationAxis_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OperatingLossCarryforwardExpirationDomain_e6055893-d505-4800-a08c-cb17c47d3985" xlink:href="mnlk-20231231.xsd#mnlk_OperatingLossCarryforwardExpirationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationAxis_2088bf49-e3f3-4ef6-ab01-9d6e09bed9b4" xlink:to="loc_mnlk_OperatingLossCarryforwardExpirationDomain_e6055893-d505-4800-a08c-cb17c47d3985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ExpirationIn2028Member_d7012986-7c19-42fc-aa74-0cdb4cac41f0" xlink:href="mnlk-20231231.xsd#mnlk_ExpirationIn2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationDomain_e6055893-d505-4800-a08c-cb17c47d3985" xlink:to="loc_mnlk_ExpirationIn2028Member_d7012986-7c19-42fc-aa74-0cdb4cac41f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ExpirationIn2029Member_1dadd828-f48a-4779-b8af-63d2c786f46d" xlink:href="mnlk-20231231.xsd#mnlk_ExpirationIn2029Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlk_OperatingLossCarryforwardExpirationDomain_e6055893-d505-4800-a08c-cb17c47d3985" xlink:to="loc_mnlk_ExpirationIn2029Member_1dadd828-f48a-4779-b8af-63d2c786f46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_734447ed-ac45-460a-9440-6148f0893b45" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97a42d7-6cf6-4130-9404-926d5285129f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97a42d7-6cf6-4130-9404-926d5285129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b056a260-44cd-4c3d-bc93-0886414a6d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b056a260-44cd-4c3d-bc93-0886414a6d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_637c6b24-62a2-4452-8bb6-c5ac81128a04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_637c6b24-62a2-4452-8bb6-c5ac81128a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_62c49856-4abc-4ccc-9cf4-b26248539bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a6341387-b1c5-4117-8ac3-b2969a93db75" xlink:to="loc_us-gaap_OperatingLossCarryforwards_62c49856-4abc-4ccc-9cf4-b26248539bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesSummaryofNetIncomeDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f478dbff-e0cc-49dc-919d-60bdf6028277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c730b703-ba8d-4f43-8e16-0e1b3a1e4b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f478dbff-e0cc-49dc-919d-60bdf6028277" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c730b703-ba8d-4f43-8e16-0e1b3a1e4b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1e3b85b7-7fec-4d2e-bdff-48c349984052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f478dbff-e0cc-49dc-919d-60bdf6028277" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1e3b85b7-7fec-4d2e-bdff-48c349984052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_721151c6-6b17-45ef-8ef7-468f8f61e0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f478dbff-e0cc-49dc-919d-60bdf6028277" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_721151c6-6b17-45ef-8ef7-468f8f61e0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesStatutoryTaxPercentDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_80c75884-dd4b-463f-ac0e-88864f46832e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_80c75884-dd4b-463f-ac0e-88864f46832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_172ca7ec-975b-4be6-adcf-4b8104bb9a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_172ca7ec-975b-4be6-adcf-4b8104bb9a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_aa71e6a2-56f9-4190-a872-427bc634a470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_aa71e6a2-56f9-4190-a872-427bc634a470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent_62ba10d3-c764-4a5f-b9ea-11ba1ce4b603" xlink:href="mnlk-20231231.xsd#mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:to="loc_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent_62ba10d3-c764-4a5f-b9ea-11ba1ce4b603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_912fa532-b7e1-49ac-bc17-d2a840774faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_912fa532-b7e1-49ac-bc17-d2a840774faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2ce30258-cc33-4058-a69c-758f98f33530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2ce30258-cc33-4058-a69c-758f98f33530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_5fd3ac1d-f77a-4dd9-bd5b-07a896d119d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_5fd3ac1d-f77a-4dd9-bd5b-07a896d119d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a10732c-4c22-40e4-abf5-38d5eb503f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c253407f-d286-47ba-b7d4-e2e3c4551d14" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a10732c-4c22-40e4-abf5-38d5eb503f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#IncomeTaxesSummaryofDeferredTaxDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_463f64b8-20d8-440d-b0a0-114b96438b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_463f64b8-20d8-440d-b0a0-114b96438b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_957c4c16-fa44-44ae-88e2-a963e1ef3d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits_957c4c16-fa44-44ae-88e2-a963e1ef3d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxAssetsLeaseLiabililties_b4eade83-d446-4c1c-8107-44ffda79cf9d" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxAssetsLeaseLiabililties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_mnlk_DeferredTaxAssetsLeaseLiabililties_b4eade83-d446-4c1c-8107-44ffda79cf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6bf8041f-4a7f-4dd7-88bd-03ddc4d29594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6bf8041f-4a7f-4dd7-88bd-03ddc4d29594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_975c1b79-b856-41e2-8d15-c4074892f0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_975c1b79-b856-41e2-8d15-c4074892f0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_bb2a9484-9231-4065-9b84-70de05b78020" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_bb2a9484-9231-4065-9b84-70de05b78020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_308d9e44-b35b-490e-9b6b-ae2e320264ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_308d9e44-b35b-490e-9b6b-ae2e320264ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_0168a3aa-20b0-4a17-b9cd-48e11614fcf4" xlink:href="mnlk-20231231.xsd#mnlk_DeferredTaxAssetsNetIncludingValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance_0168a3aa-20b0-4a17-b9cd-48e11614fcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f94a814b-e5b5-4476-af53-5a1d86d3d376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f94a814b-e5b5-4476-af53-5a1d86d3d376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_35f3e597-4b9f-4c08-a100-073cea652fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34685b85-1455-4103-b8ba-2bb69178ddd1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_35f3e597-4b9f-4c08-a100-073cea652fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7436edcc-9090-4964-a270-32b87125ec0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7436edcc-9090-4964-a270-32b87125ec0c" xlink:to="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dc5729ce-6114-488e-99b5-1d6350d9ef96" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_srt_ProductOrServiceAxis_dc5729ce-6114-488e-99b5-1d6350d9ef96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_301c6959-09b5-4940-aba7-89bde62ca45b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dc5729ce-6114-488e-99b5-1d6350d9ef96" xlink:to="loc_srt_ProductsAndServicesDomain_301c6959-09b5-4940-aba7-89bde62ca45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a402dd31-4f3e-4cc7-bae4-2937d594329e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_301c6959-09b5-4940-aba7-89bde62ca45b" xlink:to="loc_us-gaap_LicenseMember_a402dd31-4f3e-4cc7-bae4-2937d594329e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c1d2f105-22ac-45c1-87f2-2ab8ff97e733" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_srt_CounterpartyNameAxis_c1d2f105-22ac-45c1-87f2-2ab8ff97e733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b15a622-e9e3-4660-b452-8796e871d281" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c1d2f105-22ac-45c1-87f2-2ab8ff97e733" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b15a622-e9e3-4660-b452-8796e871d281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_SonelokimabProgramSLKProgramMember_e10a3e9d-8005-461b-82aa-1abe1c8a8e79" xlink:href="mnlk-20231231.xsd#mnlk_SonelokimabProgramSLKProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b15a622-e9e3-4660-b452-8796e871d281" xlink:to="loc_mnlk_SonelokimabProgramSLKProgramMember_e10a3e9d-8005-461b-82aa-1abe1c8a8e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8a00de47-3be0-4dac-aaab-824f32d8f1ff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7f3372e9-44f0-412b-96fd-3fa3a1f0b7ea" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8a00de47-3be0-4dac-aaab-824f32d8f1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_OfficeLeaseMember_dc8216b3-a47f-42e9-bcf1-76f7126f202c" xlink:href="mnlk-20231231.xsd#mnlk_OfficeLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8a00de47-3be0-4dac-aaab-824f32d8f1ff" xlink:to="loc_mnlk_OfficeLeaseMember_dc8216b3-a47f-42e9-bcf1-76f7126f202c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3d12874f-5ee3-424e-a554-9bdf22a4902c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3d12874f-5ee3-424e-a554-9bdf22a4902c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf8dc3c7-c1eb-494c-ad06-d5a68fee6472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3d12874f-5ee3-424e-a554-9bdf22a4902c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf8dc3c7-c1eb-494c-ad06-d5a68fee6472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_PrepaidExpensesNoncurrentMember_3d2c179f-ac23-442d-9cd1-8e9ae4d119ac" xlink:href="mnlk-20231231.xsd#mnlk_PrepaidExpensesNoncurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf8dc3c7-c1eb-494c-ad06-d5a68fee6472" xlink:to="loc_mnlk_PrepaidExpensesNoncurrentMember_3d2c179f-ac23-442d-9cd1-8e9ae4d119ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f870f91f-8404-4440-8091-6034f0fea0a9" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_UnrecognizedCommitmentsAndContingencies_26e255fb-9d44-4c49-afaf-c9fb8b881ad3" xlink:href="mnlk-20231231.xsd#mnlk_UnrecognizedCommitmentsAndContingencies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_mnlk_UnrecognizedCommitmentsAndContingencies_26e255fb-9d44-4c49-afaf-c9fb8b881ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount_45cac5b8-0d60-48a8-9693-f7af391551c0" xlink:href="mnlk-20231231.xsd#mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount_45cac5b8-0d60-48a8-9693-f7af391551c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_60bb47a1-c313-47d5-90a4-676babfed25c" xlink:href="mnlk-20231231.xsd#mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_60bb47a1-c313-47d5-90a4-676babfed25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dceed4d1-63cf-4f3f-8ba2-4b483ba05488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_79c7cd52-bd66-4a2a-bb95-8951b878b5f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dceed4d1-63cf-4f3f-8ba2-4b483ba05488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SegmentInformationandGeographicDataDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8e13515b-2e9e-4254-800d-6b028f20466c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_39cb7cd5-d08f-4c5d-91ee-06ac803ebb01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8e13515b-2e9e-4254-800d-6b028f20466c" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_39cb7cd5-d08f-4c5d-91ee-06ac803ebb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_37c4af07-6e9a-4426-8327-5ca95415cc1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_39cb7cd5-d08f-4c5d-91ee-06ac803ebb01" xlink:to="loc_srt_StatementGeographicalAxis_37c4af07-6e9a-4426-8327-5ca95415cc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_37c4af07-6e9a-4426-8327-5ca95415cc1c" xlink:to="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_a499f8f8-abdc-4980-a94e-98a4569a4534" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CH"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:to="loc_country_CH_a499f8f8-abdc-4980-a94e-98a4569a4534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_1f28d33c-1bde-4427-b0b2-42fa7278beb6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:to="loc_country_GB_1f28d33c-1bde-4427-b0b2-42fa7278beb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PT_35a9c95c-f99b-4384-a1a6-b121dcf817db" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_PT"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_aa8c7584-cdc8-484d-ad85-e7f59cbff126" xlink:to="loc_country_PT_35a9c95c-f99b-4384-a1a6-b121dcf817db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_508c0e46-5623-4dcc-a41b-581f470a4680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_39cb7cd5-d08f-4c5d-91ee-06ac803ebb01" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_508c0e46-5623-4dcc-a41b-581f470a4680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_0fb82d43-b287-4d2f-bde0-e8872380dbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_508c0e46-5623-4dcc-a41b-581f470a4680" xlink:to="loc_us-gaap_NoncurrentAssets_0fb82d43-b287-4d2f-bde0-e8872380dbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://moonlaketx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mnlk-20231231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_de811a56-304d-4dc7-aff9-632872e8f1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_de811a56-304d-4dc7-aff9-632872e8f1b6" xlink:to="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bb736c4d-2f8b-44c2-b918-d0bdee2a9927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bb736c4d-2f8b-44c2-b918-d0bdee2a9927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27b82232-ef1d-4457-989b-d31154c2af45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb736c4d-2f8b-44c2-b918-d0bdee2a9927" xlink:to="loc_us-gaap_EquityComponentDomain_27b82232-ef1d-4457-989b-d31154c2af45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5948555a-1e1a-43b9-b1a1-4c0cd75d2648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27b82232-ef1d-4457-989b-d31154c2af45" xlink:to="loc_us-gaap_CommonStockMember_5948555a-1e1a-43b9-b1a1-4c0cd75d2648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a79ab89e-5b0d-400d-b277-fe7a3ecb0229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a79ab89e-5b0d-400d-b277-fe7a3ecb0229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_360484ac-b74f-4175-938d-2c59c80e218b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a79ab89e-5b0d-400d-b277-fe7a3ecb0229" xlink:to="loc_us-gaap_ClassOfStockDomain_360484ac-b74f-4175-938d-2c59c80e218b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_852de4c1-a3d8-4695-aa12-e1ff666336c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_360484ac-b74f-4175-938d-2c59c80e218b" xlink:to="loc_us-gaap_CommonClassCMember_852de4c1-a3d8-4695-aa12-e1ff666336c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3060fadc-7d1b-4dc8-9be7-9fad412ad3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_360484ac-b74f-4175-938d-2c59c80e218b" xlink:to="loc_us-gaap_CommonClassAMember_3060fadc-7d1b-4dc8-9be7-9fad412ad3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7ce0bd63-2b3e-4438-a827-c740c3e2f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf74e5e2-9cf5-4c86-ac6d-3736dad9405c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7ce0bd63-2b3e-4438-a827-c740c3e2f09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ab42b5b8-e4e4-4226-b16f-ce54cab28090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7ce0bd63-2b3e-4438-a827-c740c3e2f09d" xlink:to="loc_us-gaap_SubsequentEventMember_ab42b5b8-e4e4-4226-b16f-ce54cab28090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3c9fa3f5-58a7-4053-81ac-3e50bff4315f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3c9fa3f5-58a7-4053-81ac-3e50bff4315f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ccb3e6e-c2a9-4783-af6a-ac3994605ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c9fa3f5-58a7-4053-81ac-3e50bff4315f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ccb3e6e-c2a9-4783-af6a-ac3994605ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_August2023SalesAgreementMember_c954589b-df6a-406e-ba58-abff1b623e25" xlink:href="mnlk-20231231.xsd#mnlk_August2023SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ccb3e6e-c2a9-4783-af6a-ac3994605ad2" xlink:to="loc_mnlk_August2023SalesAgreementMember_c954589b-df6a-406e-ba58-abff1b623e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bbd4b1c2-0c88-4733-839b-4a544c7717e5" xlink:to="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_78e8daea-4b6c-49e5-a89d-17a77d5516f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_78e8daea-4b6c-49e5-a89d-17a77d5516f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5a2de872-5777-4d2b-86af-a44d1af93a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5a2de872-5777-4d2b-86af-a44d1af93a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f9b76823-71bf-4f7f-a6e5-de49981a00d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f9b76823-71bf-4f7f-a6e5-de49981a00d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_847fd11e-66e7-47ef-8b35-fc57f4c01a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9ca7e98-09cb-42fa-ab7f-891c2a27c7ba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_847fd11e-66e7-47ef-8b35-fc57f4c01a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_ATMSharesMember" xlink:href="mnlk-20231231.xsd#mnlk_ATMSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_mnlk_ATMSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_Dr.KristianReichMember" xlink:href="mnlk-20231231.xsd#mnlk_Dr.KristianReichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mnlk_Dr.KristianReichMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlk_Dr.JorgeSantosDaSilvaMember" xlink:href="mnlk-20231231.xsd#mnlk_Dr.JorgeSantosDaSilvaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mnlk_Dr.JorgeSantosDaSilvaMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
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M/+7AV?%_I"T^HW14WA;R5>O)M]U(]A?Z[CVAOZ'[SZ9S?7W#YQ SE>N%73S
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MZ&!Z7S.A#%B1G97>O"X,5!%DBCN_CA+27]U0<%,S%&[_ 6$MV]?$;KAT*V(
M%G'&Z@#*(1I8_Q,F1.]@A$I6'XS'CRJH<G\_]T*X/HD8Z1\5EA4\6^W^:'S+
M]PO+'ZS#!_FI_>A>E#^UWBL,3HE$N%TZVH1J30X]PQ746$0<O4[3RA9J,-YK
M0@V.'4O/)\=^:Z,8).<JW9/:WC"LF8C1TR#NU50F!G2.SV)%_O721B%V$MW7
M:S\?TA8Q5NFPQ@X<R@'J?.DC)M0@P=3PS-R=R"&(F#&\Z1.8M3JU^YK&'KOS
MYI9WO]NTY5(9K?.+R&^D_3# VW]J.KX5!?)75>X4=A Y%D2Y[\Z<B,&P-],:
MZ9V0,1'SH+"6O][$;KCT(F)L[[44_[HA4VI,<$X0G'4_D.Z2!D>CWTIR6FQ+
MW@<1,U9]!@F(.^/. ,^Z<C,YV>'M4FP[7PY' ?#L)AZZYXS-URK/,:&:@WU
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M\>8#%10,G4'I)SUW%@R53#N%5YN8I\^P1 RF7)43/X%Y]GYH!*@#T-39=L,
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MD,-%8JG@6BKT@]F,IQ?TZVKDY'5&0R".2MK"*&V5_[!0SK/-TV21:*]_"",
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?E&$8AF&8@2+$_P,QTRPIU8@8,@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mnlk-20231231_g1.jpg
<TEXT>
begin 644 mnlk-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )$"/(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2
MB@!:*3-&10 M%5;_ %*UTNVDN+N=+>&,99W. !7GS_M*?#"/4SIS>-=+%[G'
MD^8=W\JZ:6&KUU>E3<O1-_D2Y16[/2Z*J:=JMGJUK'<V=Q'<P2#<LD9R"*M;
MANQGFN>2<7:2LQWOL+129HS2&+129I: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***3- "T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%(3BC<-V.](!:*3<*6F 44E+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 444F: %HI*6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI#TI:0]#0 G\-(WRCCDTN1Q3?O-CI0".?\=>,K#P#X3U/7M0E6&VLX6D9F.
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M*TCN*Z3LSZ+QC('RBE9O6D[XKP[]J;]H#5/@%H.D:AI>@2:])>WD=LZ1HSE
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MP?Q%\?77A+6] LK>%9$U"3:[-U'(''YUWNWT]:MQ<4F^HA12T@XI:@84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !13=W:ES[4 +12;A^-&[VH
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MX9Q0 ZBF[O7BC>* '44E+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M';.WTZU[%X^\?:'\,_#-WK_B"]CL-.M5):21@H/&<#WKX(^->A6_P9_X*#^
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M+3+>RM;6,)F., N0,$DCJ:\,_;L_9UTCXH_!O6=3L[6&PU_3(6NTO84"RNB
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#)'=/_ .OB?_T,UZX?O"M,1_&EZA'8=1116 PHHHH **** "BBB@ HHHH
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M!AU3I3K8A1=1:*QG*OJTEL?JGNY&TY!IMQ<16D+23.L<:CEV.!7R%_P3B_:
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M ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!X;^V-_R1/4O^ND?_ *,6O8]$_P"0/I__ %[Q_P#H(KQS]L;_ )(GJ7_7
M2/\ ]&+7L>B?\@?3_P#KWC_]!%=<_P"!#U?Z$KXF7*<O2FTY>E<@UL+1110,
M**** "BBB@ HHHH **** "BBB@ HHHH **** &\-Q0,BEQWHQ0 ?CFCFC:**
M $SCOFEHVCTHQ0 ?CFDXZCBEQBC]: $R&IU)2T %%%% !1110 4444 %%%%
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M(7_;O_Z":]Q6N_&_Q?DOR)AL.HHHKS^A84444P"BBB@ HHHH **** "BBB@
MHHHH **** $]?2D_&EQ1M% !UHX/%%% ";LY[48/<\TNT48H 3V-&.:7K10
MGXYIU(5!Y(YI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* $KF/B9_P D_P!>_P"O1JZ>N8^)G_)/]>_Z]&JZ?QH3V.)_99_Y([8?]?$_
M_H9KUP_>%>1_LL_\D=L/^OB?_P!#->N'[PK3$?QI>HH[#J***P*"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!,<TFVEHVCI1<!K$+SU]J7'J:7 Z]Z*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#PW]L;_DB>I?\ 72/_ -&+7L>B?\@?3_\ KWC_ /017CG[
M8W_)$]2_ZZ1_^C%KV/1/^0/I_P#U[Q_^@BNN?\"'J_T)7Q,N4Y>E-IR]*Y!K
M86BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4C4M(U
M)@>-_&[_ )'#P;_UW/\ Z$M>S5XS\;O^1O\ !O\ UW/_ *$M>S5W5OX-+Y_F
M1'XF%%%%<184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4+
M10M  W2FM_2G-TI#_2@3V/#OA+_R7#XA?]N__H)KW%:\-^$G_);_ (A?]N__
M *":]R6N_&_Q?DOR)CL.HHHKS^A84444P"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 2N8^)G_)/]>_Z]&KIZYCXF?\D_U[_KT:KI_&A/8X
MG]EG_DCMA_U\3_\ H9KUP_>%>1_LL_\ )';#_KXG_P#0S7KA^\*TQ'\:7J*.
MPZBBBL"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#*)IO_ ,CT?Z@9I_S\I_?+_P"1#^T*79_U\S]R**_#?_AY)^T9_P!%$_\
M*)IO_P CT?\ #R3]HS_HHG_E$TW_ .1Z/]0,T_Y^4_OE_P#(A_:%+L_Z^9^Y
M%%?AO_P\D_:,_P"BB?\ E$TW_P"1Z/\ AY)^T9_T43_RB:;_ /(]'^H&:?\
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M'H_X>2?M&?\ 11/_ "B:;_\ (]'^H&:?\_*?WR_^1#^T*79_U\S]R**_#?\
MX>2?M&?]%$_\HFF__(]'_#R3]HS_ **)_P"433?_ )'H_P!0,T_Y^4_OE_\
M(A_:%+L_Z^9^Y%%?AO\ \/)/VC/^BB?^433?_D>C_AY)^T9_T43_ ,HFF_\
MR/1_J!FG_/RG]\O_ )$/[0I=G_7S/W(HK\-_^'DG[1G_ $43_P HFF__ "/1
M_P /)/VC/^BB?^433?\ Y'H_U S3_GY3^^7_ ,B']H4NS_KYG[D45^&__#R3
M]HS_ **)_P"433?_ )'H_P"'DG[1G_11/_*)IO\ \CT?Z@9I_P _*?WR_P#D
M0_M"EV?]?,_<BBOPW_X>2?M&?]%$_P#*)IO_ ,CT?\/)/VC/^BB?^433?_D>
MC_4#-/\ GY3^^7_R(?VA2[/^OF?N117X;_\ #R3]HS_HHG_E$TW_ .1Z/^'D
MG[1G_11/_*)IO_R/1_J!FG_/RG]\O_D0_M"EV?\ 7S/W(HK\-_\ AY)^T9_T
M43_RB:;_ /(]'_#R3]HS_HHG_E$TW_Y'H_U S3_GY3^^7_R(?VA2[/\ KYG[
MD45^&_\ P\D_:,_Z*)_Y1--_^1Z/^'DG[1G_ $43_P HFF__ "/1_J!FG_/R
MG]\O_D0_M"EV?]?,_<BBOPW_ .'DG[1G_11/_*)IO_R/1_P\D_:,_P"BB?\
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MHFF__(]'^H&:?\_*?WR_^1#^T*79_P!?,_<BBOPW_P"'DG[1G_11/_*)IO\
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MT_\ ^1Z/]0,T_P"?E/[Y?_(A_:%+L_Z^9^Z-%?A=_P /%/VA/^B@?^473_\
MY'H_X>*?M"?]% _\HNG_ /R/1_J!FG_/RG]\O_D0_M"EV?\ 7S/W1HK\+O\
MAXI^T)_T4#_RBZ?_ /(]'_#Q3]H3_HH'_E%T_P#^1Z/]0,T_Y^4_OE_\B']H
M4NS_ *^9^Z-%?A=_P\4_:$_Z*!_Y1=/_ /D>C_AXI^T)_P!% _\ *+I__P C
MT?Z@9I_S\I_?+_Y$/[0I=G_7S/W1HK\+O^'BG[0G_10/_*+I_P#\CT?\/%/V
MA/\ HH'_ )1=/_\ D>C_ % S3_GY3^^7_P B']H4NS_KYG[HT5^%W_#Q3]H3
M_HH'_E%T_P#^1Z/^'BG[0G_10/\ RBZ?_P#(]'^H&:?\_*?WR_\ D0_M"EV?
M]?,_=&BOPN_X>*?M"?\ 10/_ "BZ?_\ (]'_  \4_:$_Z*!_Y1=/_P#D>C_4
M#-/^?E/[Y?\ R(?VA2[/^OF?NC17X7?\/%/VA/\ HH'_ )1=/_\ D>C_ (>*
M?M"?]% _\HNG_P#R/1_J!FG_ #\I_?+_ .1#^T*79_U\S]T:*_"[_AXI^T)_
MT4#_ ,HNG_\ R/1_P\4_:$_Z*!_Y1=/_ /D>C_4#-/\ GY3^^7_R(?VA2[/^
MOF?NC17X7?\ #Q3]H3_HH'_E%T__ .1Z/^'BG[0G_10/_*+I_P#\CT?Z@9I_
MS\I_?+_Y$/[0I=G_ %\S]T*1J_##_AXI^T)_T4#_ ,HNG_\ R/1_P\4_:$_Z
M*!_Y1=/_ /D>C_4#-/\ GY3^^7_R(?VA2[/^OF?K7\;O^1P\&_\ 7<_^A+7L
MU?A=_P /%/VA/^B@?^473_\ Y'H_X>*?M"?]% _\HNG_ /R/6T^!<TG",.>G
MIYR_^0)6/I7;L_Z^9^Z-%?A=_P /%/VA/^B@?^473_\ Y'H_X>*?M"?]% _\
MHNG_ /R/6/\ J!FG_/RG]\O_ )$K^T*79_U\S]T:*_"[_AXI^T)_T4#_ ,HN
MG_\ R/1_P\4_:$_Z*!_Y1=/_ /D>C_4#-/\ GY3^^7_R(?VA2[/^OF?NC17X
M7?\ #Q3]H3_HH'_E%T__ .1Z/^'BG[0G_10/_*+I_P#\CT?Z@9I_S\I_?+_Y
M$/[0I=G_ %\S]T:*_"[_ (>*?M"?]% _\HNG_P#R/1_P\4_:$_Z*!_Y1=/\
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MG]\O_D0_M"EV?]?,_=&BOPN_X>*?M"?]% _\HNG_ /R/1_P\4_:$_P"B@?\
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MK7/^?W_R$G_Q-'_"=:Y_S^_^0D_^)H_L/$_S1^]_Y![>)[[17@7_  G6N?\
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M ,A)_P#$T?V'B?YH_>_\@]O$]]HKP+_A.M<_Y_?_ "$G_P 31_PG6N?\_O\
MY"3_ .)H_L/$_P T?O?^0>WB>^T5X%_PG6N?\_O_ )"3_P")JS;_ !$U:$C>
M89Q_MQX_EBIEDN)2T:?S?^0>VB>Z45Y7I?Q)M;AE2\@:V)X\Q3N7\>X_6NLM
M[J*\A66"198VZ,IR*\JOA:V'=JL;&T9*6QT]<Q\3/^2?Z]_UZ-4M%<\7RR4B
MCA/V6?\ DCMA_P!?$_\ Z&:]</WA7/45527M)N?<2T5CHZ*YRBLQG1T5SE%
M'1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5
MSE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>Q:5J46K:?#=1?=D&<>A[BOA,RP'U27-#X'^'D=].IS*SW+=%%%>*;!1110
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M[F2CUT(]E35*]K[Z^?W_ *&'^UG;RWG_  3@_9Y@@B>>>6ZT](XHU+,[&RN
M% '))/:J,G[!GP0^"OAKPS!\>?BIJ'AOQGKJCR['2)(_(@8G&&/D2G8I*@RL
M43(;G'-=%^T5XC?P?^P/^S%KT4"W,FEZMI-\L+-M$ABM9W"D]@=N*[']H?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^Q?^"=_P 6)M,\6:CX"O)B;+4HVO+%6/W)T&74<_Q(">/[E?'5
M=I\%O%$G@WXM>$=9C(7[+J<!?/3RV<*X_P"^6:N#'X=8G#3IOMIZ]#2G+EDF
M?LC1117X\>T%%%% !1110!\/?![XU6GPE^+?QNCNO"_B;Q#]N\47#*_A_3Q<
MK%LN+C(<EUP3N&.O0UT_Q*USQ)^UI?\ A;PMHG@/Q%X9\+VVHQ:IJ.O>([$6
MQ01[TVQ*6(<X<_=8L3Q@*&)[']EWPOK7A_XE?'"ZU32+_3;;4?$LD]E->6SQ
M)<QF:X(>-F #KAE.5R.1ZU]$U]%BL53HXASIPO-):W_NKIY'-"#E&S>A\A>*
M/AS;?%#]M_6](U#4+VSTF/PU#<WMO8S-";Z)9(1]G=U(8(79&..?DP,9R+WA
MWP79_L]_M8^%/#'@ZXN[/PKXMTZZDN]'FG:6*.:*.5UD4N2<_NU'/(^;YB#@
M=EH/AK5X?VV/$FN2:5?)HDOA-+:/4FMW%L\OG6Y\L28VEL*QVYSP?2CXB>&M
M7OOVO/A1K-OI5]<:19:?J"76H16[M;P,T$P4/(!M4DD  GG(K3V[E:DY>[[+
M;I?E;7SO\Q<O6VMSUGX@2>+E\/L/!,>COKK2J$;7C*+5$Y+%O*^<G P,=R,\
M9KYZ_9MU"\T+XZ>-M(^(D=POQ4U.&.Y^V+,KV5S9(!L6!54! HQPV2=O8A@=
M^;Q7\0?@?\3O%3ZOX>\3_$/P+KET;W3+K14-]=:>Y&6MO(W#9$.0.@P >2S
M/^%GA/Q5\1OCA=?%KQ3H=UX1L[;31I&CZ-=NIN2FYB\DH"Y4;FD(!P3N'\(!
M//3@J-"HI-<LHZ-/5O1I=]]U;I<IOFDK;GN/BKPKI?C;P[?Z%K5K]MTJ^C\J
MXM_,>/>N0<;D(8=.Q%?&OP%^&OAO2_V7/B=XNMM.\KQ#+I&NZ8]YY\AS;",L
M$V%MG5%YQGCK7W!7Q]\+;;Q+X;^"?Q2^&&J^"/$=KK2V.M3VE^E@TMC>^9%A
M(XI5^](Q<X4 @A>N3MJ,#4FJ,X1E;WHNU^FM_P!+CJ)<R;\SH?V3?@#X9;X?
M^!O'M^;[4?%8A,\=]->2[8HL.D=NL>[;Y:+@@8SN&<@?*,;]E6Q\1ZE^QSJ5
MKX2U*ST?Q!-=726U_?EEB@RZ;W)4$@A-V#@X.#@XKVW]FK2;[0?@3X,T_4[*
MXTZ_M[$)-:W<312QMN;AE8 @_6OG#P?\*?'U]^P[JGAK3]+U+2?$3:A+,^F7
M,;VMQ<V^]2\85]I(9<G'\6,<YQ7;[5UYU54G_P O(VOJDKR_#\#.W*E9='^A
M2^(GPW^ GA'P#J,USX\%_P#$:VM6<:U:ZU)=W<M\(RJJR(6 7S  00&  RPZ
MUN>.O%5]XV_9K^ FL:G<27=_/XLTQ)[B;EY&07,99CW)V9)[YS5^XO7U/X=:
MEX9^'G[/VJ>%]:N+%[:XOM:TJ.VAM=T95W28DR7+@;PIQDG:<'.TT9? WB67
M]F#X'Z6OAW5_[3T[Q9:SWMB;"43VT2RW6Z22,KN1!N4[B ,,#GD5U\VD'4DV
MU+JTW;E?;9?,CO;L7/VEK[2X_CI86_Q7;6_^%4MIBFRCTY9!:/=F1=YN&B(<
MX S@98?(1C)SW7[,V@^"[/Q!KVH_#?XA2ZUX0GA14\)RO(_]G29'[U?-;S%4
M@%1E!GNS;>-7XC>+_B!\/?B5<W<_AS4/'OPUU2R$(TS1;..:ZL)E \PLFT-*
MKC=P6QSCC !X?X2> [WQ5^T6/B+I?@&\^&GA:STMK-K34(!9W&HS,67<;=>$
M4#;D>J*<MGCAYN;"<KE9*/1IQ;[<KU4O-?D:;3^9].:QJ2:/I%]?R#=':P23
ML,XR%4L>Q]*^ ?!OC[X-_%*SU#Q+\:O%FI7?BN\N9C:6&+X1:1!D>6L/D)LS
MQNST.1E<Y)_0/4+&#5+&YL[I/-MKB-H94R1N1@01D<C@GI7RU\+?$7CK]F'0
M[KP+K_P_\0>+]"L9IGT35_"MJ+OS8Y)&?9,@(*?,S')Y&<8(P3S9?*,:=3EO
MSZ6M)1=M;V;3\KHJINK[%;]G+Q)HOQ=M?B7\*KK6KKQGX+MPCZ1J-X9?M)LY
M!S$SR*K Q,$VDKP=V,J%KB8]<\>2VH_9A\YH=7%XUHVOR7 (.AB,R!1@Y#&/
M"A?[AV$#J/H?2_BA\0K7P'XM\5>(O DEHT1QX?\ #NGQRW6HS\$#[0(]P 9R
MO*@;0&R#@$^-_P##-OBV+X9S_$MIIT^-YOF\1@HOF%1AO]!5#P08R/EP<, @
M^7KZ%.K#VDY5+)-JVJ?OV^+2RM_-I:YFT[*W](U/VF_AVGA_3_@AX-\(W+Z"
ML.MK965VK$R6Y*@>;NQG?DEL_P!XYXI/CA\"].^ 7@9_B-\.[[5-)\1:'+;3
MWC3ZC-,FJ1^8J-]H5FPQ._) VKC< .1C._:4\:Z]XNT'X':]IFAWVB^*9O$,
M?DZ3J\#6LB78**(V#X^1GZ,>"K GN*W_ (E>+/&O[2'AJ#X>:;\._$G@X:C<
M1C7-6UZW\FUMH(W#E8)/^6Q9D&" ,XZ$,2'2=>,*+E+W;RY[M;<VM^_6WGY@
M^5N5OD<Q\>_C1X>\7?%+PUX6\7^(K[PQ\.7T:/5=1BL#*QU&29-T4#F%"VP
M@GJIP>AP1S5K\4OA=\*?B+X.OO@YXIOGTN^U..QUSPS+]N:U:WDPOGH)T'SH
M<L/G)W,,#;N%>Q_$KP#XG^%/Q:T/XD?#_P -_P#"0:5%HZ:#JVAVTG^D?9D8
M%'B#$DD!8QA<G]V,C#,PZ30?C)X\^(7B[2+3P]\-M5\.>'EN,ZMJGC*W-I((
M0 2L$*ODN<X#?,N>HZD3&K35&/LU>'+JN=)7UO=6;OVU[6"SYG??T.%U#PY%
M^TW^T5XRT'Q%=WTG@3P5#;VXT:"X,$=W=2C<7EV88J#&^,'/R*01D@]AX6_9
MG3PGKGB/08K]K_X1ZY8A)/#-Y=S&2UN0R\Q2?>$>U<??!.1G.T9Q==T_Q3\!
M_CAXH\::1X2U#Q?X0\71VQOK70E$MY9W,*D;_*/S."#*>" 2^"1\N=[X<WWC
MKXH?%A_&6H6.N>"O UA9?9+#P_JI,$]_.2X>XF@!^3:#@!LYPA'<URU)U%3O
M2FE345;7K97TWYN;K\]BTE?5:W_KY'C?[->D^'_A/^S_ .,?BG8Z2#XHLEU"
MR6Y:XEP\2R(8X]I)0?,J<[<\=>M<=X-USX!>*/"UKK/Q+\=ZUJ7Q&O4\Z[U7
M_B8+-9.6)$4/EH8PJ@A>C#KMVC 'J?P/\(ZM>?#7QQ\&/%/A/7M%NKI]0DAU
MR6T8Z;('*>64G!P7#-N"C*D(><G;6M\./BO\0/A%X/L/!/BOX5^)=;U;2(X]
M/L-0\.VRW%E=0( D;/*#B/"[1D@],L%.0/1G4;G5<6W)ROI))\O2S:>G=>ES
M)+1=O3J<%H7[37B.R_97\67%CJ\FN>(M&U@:'I^O2([R7%O(P,5PPD 9I-GF
M ;E!X0L"=V>\\5?LG:5X-^%.OZKHNLZQ'X]BTJ:2ZUV2]EG;4"(&$D$L3$HT
M;C*CY=R_*<DC!Z3QI\/_ !M^T!^SSK.D^+],TSP[XIO)OM6FV5O,[+;*CJT2
M3-D@N0'5B.,.#@$8'+>*/C=\2O$'PWU7PI'\)O%-OXTDT^6QN]0DMQ_9Z-L"
M23Q3)Q(>6950'G&-PKF4Y2?^S6B^=\RNMM+:Z)QW\B[?S:Z'IW[*O_)O'@7_
M +!X_P#0FKS3]NGP%H6M^&?"NMWMCYVJ+K=II@G\Z1?]&E9S(FT,%Y('.,CL
M17JO[-6DWV@_ GP9I^IV5QIU_;V(2:UNXFBEC;<W#*P!!^M<U^V!X7UWQ+\*
M[*3P]I$^N7NE:Q:ZF]C:C,LL<>[<$ !+'+#@ GKP<5PT:G)F7,I6]YZ_-FC5
MZ5O(XSXJ^&_[+\5_##X$>#)KGPIX2U,W5[J#V<TCSFWC9IVB25F++N82<DGE
MT[ J<WXU_!?3?V9_!'_"P_A?<WWAR]T6XMC?6)OIIK;48'E6)ED1RP+%GC/8
M *< '!'3?$BU\1^-+GP#\8_!OA;6(-8\.R7,=[X:UB'[%?W-FV4=!&VY=V [
M+C)82#&6 6L/XJ:_XV_:>T&T\ Z+\/O$?@_3KJXAEUW5_$L M8H8D;<4A&3Y
MWSA2"/[H^7#;E[J,JEZ5Y>XK^TNUJ[N_-WNK6W\C.26NFO0^H=(U*+6M)LM0
M@5UANX$G19  P5E# '!/.#ZU;JOI]C%I>GVUG ,0V\2PH#C[J@ =/858KY=V
MOH=04444AA7:?#?6&BO)-/=ODE!>,>C#J/R_E7%U?T&Z-EK-E,/X95S]"<']
M*X\915>A.#[?B7"7+),]IHHHK\S/2"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR2 N&.Y1DXY(X(.1[)XL\4Z9X)\-ZEKVLW2V>F:? T\\S=E Z =V)P HY)(
MY-95,/4IRC%Z\VUM;^@U),UJ*\8_9E^.&J_'+2O%6HZGIL&E1Z?J\EG:6T<;
MK*D(4,HFW,<R#."0%&1T%>SU%:C/#U'3GNAQDI*Z"BBBL2@IT>1(N.N1BFU<
MT>V-YJMI"!G?*H/TSS43DHQ<GT!'ME%%%?E1ZH4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !112JI9@HZDXH WK?_CWC_W1_*BGJNU0/08H
MH ^(?^"K7P3F^('P5T[QGIUOYVI>$9WEGVK\QLI0!*>O\++&W? W5^/U?TK:
MII=KK>F7>G7T"75E=PO!/!(,K)&P*LI]B"17X-_M>?LRZO\ LS?%*]TF:)YO
M#=[(\^C:@ 2LL!/",>SID CVSWK]NX%S>,Z+RVJ_>CK'S3W7R>OS\CP\?1:E
M[5?,\-HHHK]:/("OTB_;X_X9U_X:*U'_ (61_P +/_X2C[!:^9_PBO\ 9WV+
MR]GR;?/^?=CKGC/2OS=KW/\ ;/\ CIH/[17QSOO&?ANTU&RTN>SMK=8=5BCC
MG#1IM8D([KC/3YJ^>QV#J8K'X>:<HQC&I=Q=M6X67SL_N.FG-1IR7I^I])^(
M?^%:_P##L_X@?\*L_P"$K_X1_P#X3"W\_P#X3#[-]K^TXL]VS[/\OE[/*QGG
M._MBO9?B5X7T"/\ :,U;XE:]I=IXA/P[^$MKKFGZ-=_<GO%>Y,<AZC:FQAR#
MM9T8<J*^%/#'[0/A[1?V*O%WP@GLM3?Q+J_B5-9@NHXHS9K"JVH*NYD#A_W#
M\!".5YZX]4\9?MZ:#=?'_3O%ND^'=1U;P3>>#8_"'B/P_J_EV[7\!,IDVE'D
M QO4JQP2 Z_*&)KY"ME.-YZD:<9/WJFK>K35/2^GQ)22>GR.N-6%E?R_7\CN
M_P!DG]K'Q?\ '3Q+\1-(\>BQUJ]3P?JUSI>IQV$,$]@FU/,ME9%4^0PVG:<_
M-&O7J.8^ GQ.U7X/?\$Z/%7BGP_%:+XBM/B T>G:A=6Z3MI\LEC;1M/$K@@2
M>4\J D<"1JR/AG^T%^S9\";[QA>^!_#GQ%N[[Q%HMWI(N=>:R86*2KD1Q1QR
M#*LX3<[L6"Q@ '+9\AT?XZ:#I_[&FN_"22TU%O$=]XM77H[I8H_L8@$$,>UF
MW[]^8VX"$8(YKL_LY5JDU2PSA2E.E[K22LK\VG;75=?F3[3E2O*[LSZ*^#_C
MW]HCXB?#&X\5^ O#=IH.OZMJTMWXC^*^L75A#_:H1&2.!([B,".*-0$_<AE#
M(?NY<5T/[3GPDF^*'@/]G>_\=Z[H6L>.=8\5?\(GK'B7PI) T%U!+<E<O*L8
M#2P[,=-JNTORG->%:+^T#\)?B-\ _ 7P\^+MCXZM[CP7-="QOO!TEHR74,K[
M@)8YRJAE&$!PQPN<_.PJW\:/VMO!'B'X)_#OP=\,_#NL>"[_ ,$^(/[3T\W?
MDW$>Q/,,<S2[LM,SLLC*8]H+,-S8RV7U'%K&0E0HJFU.6JCM&TE&\^9MK:T5
M%*.UE9#]I#D:E*^G^70]!^/'[8>L_!_]HZZ^'FCZ7I=E\&_"UY!ID_A&'3('
M6[A1$6:1G8;S,<L48.N"D9/.XMZY'\.=+U[]M;]I7QQ>0^'[C4_!^F6,VD?\
M)6R+I=M>2V<9CNKAF'RK$8<Y&",D@@X(^<?$W[1WP ^(WC2T^*_BCP-XSC^)
ML0BN;K0].O;;^PM0O(<"*225_P!\BL$3<J)@8 PQW,[;_P#;>T'_ (:4^*/B
MC_A&[_7/A?\ $.SATS6- O7CM;MH5MXX?-5D+[9$_>E0KC._[RG!7!Y;B'34
M<-AW":I<LGI[TN:FY:WU;2E[S?O7W[/VD;WE*ZOIY:,]OM9-2^*7A#QMX<^/
M_P =?@[XTT:[TF:;1;RPUNR;4-+U1.8)8?+2'*?,^Y-WS8"C 9PW#Z3\7==^
M"?\ P3?^&WB'PLEC;^)&\5WEI::M=6<5S+IZL;EI'MQ(K*DC*GE[\$A'<#!;
M(\DC^*'[.?PT\(^)_P#A O!7BGQ;XOU>R:RL[OXB6^GW%II.2"9H8HPRO*.H
M9E_A X5G5N;\5?'KP_KG[&_@SX306>I)XCT7Q#-JUQ=211BT:)Q. J,'+EOW
MJ\% .#SZ]E/*YSY(^R?L_:1;BXJ*LHR3?*MD[I.^_;O+JI7=];?JNI]'>+-<
MG^-7P3_9N^+7BFWL[KQ_)X\M]"NM:@ME@FN[9)Y"HE"85B#$I''&6QC<V?3+
MKXM>+?!G[6G[6VFZ-K$EE8V'@:\\26T(BC<1ZC!86*PSC<IY4,1M/RGN#@5\
MC:)^TWX7TW]GGX2^ Y;#5VU?PEXU3Q'?3)#$;>2V625BD3>9N,F)!PRJ.#\U
M=?:?M?\ P[O/VL/BSX\UO0_$5SX"\>^&YO#LUK;) FHQ1RP6T;MM,NS/^CL.
M'X#@]MM<E3*J[=2#HW@E44596M[6,HI+T3LBE5CH^;73\F:?@SQ9J/C?_@GW
M\>_$7B6[GU?4M2\8V%W?W!=8Y)F::T+X.TJF>0,+A>,# Q7T=)XB\8>+M:T.
M]_9U\:> _&/PJM[6V\SX1-]DL[TVZ*/,AD$T;LKR%)#YDA0J2O#@$GXUTO\
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M_C5/\78?"OQ%UWQ=<:NNJ_V5K%Q9+IMM,T@9Y5*LTCF/EHXVPN0%RHP5\?\
MLJK3P5"BL,K^SU]WF?/II9R2B_[[3:6BLD;>U3G*7-U[]/ZZ'K'PZ\1:O\!O
MVAOVLO!O@K47T?PWH_A/6?%&G:?'!#Y=I?K';O$\8V8"Q^:R*GW=H4$-C->=
M_#OXA^(]8_8+^./C:\U:>;Q5+XVT[5&U,X$GVD7%FXD  P,, 0  !@   8KG
MM)_:W^';?M5_%OQSK>B^(KSP%X^\/W6@36ULD$>HPQSQVZNVTR[,_N67A^C!
MNVVN1;X\?#KPS^S7\5?A3X8MO%$\?B+7+34-&N]6@M@4@B:W9A<F.7A\Q.!L
M5@?EZ9..J&7UFX.=%\[=!MV6O+;GN^ZW:9#J+6TM/>_X![I\6/@+8_M.?M6_
M![QA:6S0>$_B=HL.N:NT4;E8&M(5^V1,58;/E$$6\,,/+GDD;H/!/QB^)/QN
M^+/Q9\7_  J\ 6NO>([J^6RTCQYJ$R1VGAW2HF A6."Y7RU=HXS(QSG<Q.SL
M?-_@Q^W!9_#']E7Q)\.;G2M0G\7+;WUCX:U>S94CLK>]*FXW2%]Z,K[Y%**<
MG:,KRU<O\ _V@/ 'A_X$^-?A'\2M*\1MX=U_4(=435/";0?;(Y8_+Q&RSD(4
MS"A[]6XS@BOJ&,C2G"I2YE3M3@GK>'-=RLFG+W>1.-[/E:=P]I"Z:=KZOUM_
MG?[SZ=^.WA_QYX@_89^(MY\8_$'AGQIXQ\/ZI87.EWVDS6\]SI\<MQ!"\4AA
MC0)G=*.=V?F'\*U^:%?6M]^T5\&=!_9N^(_PA\%^'/%NG6^O_9+JVU[5C;W-
MU=W,-RLI6Y1'1(8]L4:+Y>\C<Y(8CYODJO>R##U<-2K0J0Y4YMQ5E%6<8[)-
MI*]]+^NISXB2DXM.^G^9]7?\%(M/C\(_&OP[X&L6<:+X1\+:=I-C$3\NQ59B
M^/[S%N2<DX&2>,>Z?M\?\,Z_\-%:C_PLC_A9_P#PE'V"U\S_ (17^SOL7E[/
MDV^?\^['7/&>E>&_MZ7B?%.3X9_&K3(_^)/XR\/1V]R 9&-MJ5JS1W,+,RCA
M2556_CV,P&,$\%^V?\=-!_:*^.=]XS\-VFHV6ESV=M;K#JL4<<X:--K$A'=<
M9Z?-7DX'!U<3'!-N4>2%12:=FIW@FGZM2^XVJ347/S:MZ:GTGXA_X5K_ ,.S
M_B!_PJS_ (2O_A'_ /A,+?S_ /A,/LWVO[3BSW;/L_R^7L\K&><[^V*X[Q!\
M7/AG\2]'\+^%_P!IGP'XR\'>.O#VEQ:;!XCT.$6T\UFF6A\VVG7Y<@MR$8$N
MQ&T-A?*O#'[0/A[1?V*O%WP@GLM3?Q+J_B5-9@NHXHS9K"JVH*NYD#A_W#\!
M".5YZX[B^_:6^#OQZ\(Z'#\=O"?BC_A-=&LDTY?%O@J> 7%]"A&SSXYV";L9
MR<-DEB-H;"Q' 5J#FYTYR7M)-2B_?2<8I-;73LTUKTT8_:*5K-;+T,GXR? .
MTTCX#2^,OA/\4;SQ]\(;?6%;4=&NUELY-+OG18TFDMV(21R&$?FA%;#* &7+
M";X8WT'B[_@GY\:-&U"/[1)X.US2-9TV25 WV=KR=;:01L3E05C?(  ^;/.3
MC*^+W[1G@6'X,O\ "3X-^&=8T'PC?7D.I:QJGB*X274-2FC4*%9$+)&N4B<[
M"/F7 51G=M65Q:?"?_@G=J*3I:OK?Q7\1(ENJOB4:=I\@8R,-O.VXC9< XQ,
M#G.5KL:Q'U:G&NGS.M#DO92Y4TVY<NE^53O;IOK<CW>9N.UG?M_5['RE1117
MVIPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7U5_P3[^%\GB;XG7
M'BZYASIV@1,(G8<-=2*54?\  4+'V)6OFOPKX6U/QMXBL=$T>U>\U*]E$4,*
M#J3W/H!U)]J_6_X$_"FU^#/PSTGPW"4DNHD\V]N$!Q-<-R[<]L\#V KYO/,:
ML/AW2B_>GI\NO^1U4(<TK]$>@4445^9GJ!1110 5\Q>.M+/[0G[3%_\ #_5K
MZ]@\$>$],AO+[3;6<Q"_NI=C*)"N&V>7(!P<C:<$%B1].U\[>/\ 1?%/PC^.
MU]\3= \,W7C#0=<TQ+'5].TH WL,T>T1S*F,R#:BKA?]K.,*3Z6!=IRY7:5G
MR^NGXVO;S,JFR[&GX9^"MQ\!/&%[KGA#4I(OAY_9DTE]X9N[F24QSH'=9+=G
M#8!X!!(/+$EN //O@G\#=,_:-\#K\1OB=/?:[KFN37$EG''=36T.F1*YB00H
MC  YBW G((*Y!()/<>'[KQE\=/B=:ZQ>:/XB\$?#;2[&XM7TG6";.XUBXE4*
MWF0*V51 00Q)&5^7[[A>7^&?BGQI^S-X?E\!Z]\/_$WC#3-/EF?2-9\,VPO$
MF@=RZ)(HP8R"7SDDC( &-I/I\U?DDHS7MO=NTU>VNE^KVOUMZ,R]V^WNF3I.
MMZQX7\._M$?"K5M7N]=M/#F@W-UI-Y>2&66.TFLW<0NYY8JKQ <8^]C "BL/
MP5^S?X;\7?LLIXN\0WFIZKXACT66^TZ[^V21KIRPQGRXH8P=FW$2[B5).2>#
MC'8>'/A?XRO?!?QQ\=^)](DL?$_C/1[J&QT"W?[3/! MM(L,1*C+2$>6NT<_
M*,J"=H[CX<^'=5L?V/X-&N=,O+?6!X:NH#I\MNZW'F&.0!/+(W;B2.,9YK:I
MB/91O1E9\T;V[\OO?*^_1DJ-]UT9YA\/_@?I_P >?V?[/QIX\U/5/$'B^XL)
MFL=2DOI(_L"Q,R1+&BX0D^4K,S*S,S,22>:Y#Q]XFUGQI^QK\&-2N=2E767\
M3V]LFH2 22*T1O(8Y#TW$"-3SR<<DDDU]$_LZZ#J>A_LPZ#I6HZ==V&J1Z?<
MH]E=0-',K&24@%& 8$@CC'<5X+=?#WQ4W[(?P>T8>&=8.KV/BQ;F[T\6$OVB
MWB\^]/F21[=R+AT.X@#YAZBM*=;FK24I:1J:=DK2V\M$)Q]U>:_R+O[1OP5T
MWX ^$_#?CCP5J6JV7CNWU."SDURYOGG>\,D; M,LFY3]S&U0%(8@@C&+O[2'
MP3T;X(^![/XE>&[S55\<:3J%M+=:U<:A)++J!9U5C*K[D.3CY0 N,@@CBO2?
MVTO#6K^*OA7I-IHNE7VL72:]:3-!86[SNL8$F7*J"0HR,GIS5O\ ;0\.ZKXJ
M^ 6L:=HNF7FKZA)<VK):V%N\\K 2J20B@DX'/2L,/BJDOJ_//>34O-76C\M7
MIL5*"7-9'!?M;?%#3K7XG>#_  !XB\27OA3P;<6KZIK=WIXD:6Z0LZ10'RU+
M!2T3@XR#O!(^4&O+-?\ BA\(O@_JNA>(O@MXIO;::+4$75/#KB_:SN[1EVR-
MB=,%QA<9;OD<@"OH3X[>"/%NC?%3PE\5?!6D+XBO=*MWTS4]'\P)+<6C%B#&
M3QE3(YXYR5X89%6;#XX>/_'VM:38>$_A?K&A6YGC;4]3\:6QLXH(<_O%B0-N
MD;&-K#OU7&2*H5(1H4^17C9\RYDE?6_,FFWY?@$D^9W_ "/.O$_P_B^)W[;&
MNZ%?ZE>V6BCPY;WE_:V,K0F_C22("!W4AE0LZL<')V8X."+?AWP79_L]_M8^
M%/#'@ZXN[/PKXMTZZDN]'FG:6*.:*.5UD4N2<_NU'/(^;YB#@=EH/AK5X?VV
M/$FN2:5?)HDOA-+:/4FMW%L\OG6Y\L28VEL*QVYSP?2CXB>&M7OOVO/A1K-O
MI5]<:19:?J"76H16[M;P,T$P4/(!M4DD  GG(K/V[=J3E[OLMNE^5V^=_F/E
MZ];G(Z5X/L_VIOC;\07\7W%[=^#?"-Z-&T_08[EX8))E#+-))L*L3O3<#G/(
M&2%P>BB\(ZW^RSX;^(6L:9K#:IX$M]-^U:1I%].\D]C=*JKL#%3F(GISQA1@
M\L:(A\4_LY?%CQMJ]KX-U7QGX*\77<>HAO#L(GN[*Y.[S0T/#,&+$YSMX7D$
ML*LZ;X/\9?M 77CO5?$T.K^$?".K:.VCZ'X<U*0I(&R3]MGA5OD<,.%8$D-@
MY55)4Y/2\E["T=-/*Z2WYKWN_7H"]/>/!O!NN? +Q1X6M=9^)?CO6M2^(UZG
MG7>J_P#$P6:R<L2(H?+0QA5!"]&'7;M& /HK]C?XI7GQ$^'^KV.H:L_B"X\/
MZG)80ZQ('WWUK]Z&5RX#%B-P^8 X5=PW$USWPX^*_P 0/A%X/L/!/BOX5^)=
M;U;2(X]/L-0\.VRW%E=0( D;/*#B/"[1D@],L%.0/;?A3JGC+6_"8O\ QSI-
MAH6KW$\CQ:=8R-)Y%OQY:RL209.N2O'(X!R 9A4O3FFKJ^CYTU_VZDE96^7S
M"FM5_D>0_M^_\F]77_82M?YM6!^T7X7E\<?M3?"[P]'JUYHL6I:9>Q7%W8-M
MG\E4D>2-6_AWJA3/8,>#T/8_MN^&M7\6? NYL-#TJ^UF^.H6[BUT^W>>4J"<
MG:@)P/6CXB>&M7OOVO/A1K-OI5]<:19:?J"76H16[M;P,T$P4/(!M4DD  GG
M(J<)44*$&GJE5_\ 258)J\G\OS. \>?#/2?V;?C-\+M9\ O>:-;^)-:CT?5=
M-:[DGAN8Y'1=Q,C,<C>QY)YP1M(Y^O*\"_:<\-:OK_C/X,3Z9I5]J4-AXLMK
MF\DM+=Y5MHA)&3)(5!V* #\QP.*]]KS\74=6C1G-WE9W?7?2YK!<KDD<?XN\
M!>'KZ^OO%5SI%K<>(8-+DLX=0F3?)%$-[A4SPIW,W(&><9Q7GW[$O_)L7@S_
M +??_2V>O8O$$;S:#J4<:-)(]M(JJHR22AP /6O*_P!D'0=3\,_LZ^$M-UC3
MKO2M1@^U^;9WT#0S1[KN9EW(P!&5((R.A!J5-RP<E)_:C]UI!;WUZ/\ 0\)^
M$-Y\6+?XE?&=?AU8^%[JR/BV\-TWB!I@XD\Z7 3RW'&.N:H_M97OQKN/@_<+
MX[L/!MKH/VR L^BM<&X,F3M WN5QUSQVKVK]F/PUJ^@>,_C//J>E7VFPW_BR
MYN;.2[MWB6YB,DA$D98#>I!'S#(YH_;=\-:OXL^!=S8:'I5]K-\=0MW%KI]N
M\\I4$Y.U 3@>M>U'%1680CRQM>.O79=;F'*_9O4]:\2?$KPCX-ODLM?\5:+H
M=Y)&)DM]2U&&WD:,D@.%=@2N589Z9!]*6TD\)_$BUL=5M6T7Q3;6<_F6E["8
M;Q(9D(.Z-QN"N"%.0<@@4GB3X:^$?&5\E[K_ (5T77+R.,0I<:EIT-Q(L8)(
M0,ZDA<LQQTR3ZUY!^TEJ?B'X4_#6ST#X2^$;FWN=5GD21_#.CLXL8<#S)%6%
M=J2,64 G!^\1R,CPZ-.%:4:=-M3?5['1)N-V]C"_:.\<3?&;6&^!_@=3?ZE>
M2Q-X@U2/YH-+MTD5F5CW?(7(R/[G+,0)OB1H-EI/[2W[/FA"5QINFV=_';K,
MX)S%; 1YR,;B8T'3)P/:L+X4_%6V^#OA:+1="^!?Q(&?GNKV716,]Y+WDE;'
M)))XZ <# KO_ (]^#?$?C*S\ ?$3PCI\LOB#PM-_:2:#?#R)[B"98S- >3ME
M 0 J?]H#)P#ZZ_<3C1MRPM))MK64HVN^W3T1C\2<NNA2_;N4?\,[:K*"5DAO
M;22-E)!5O- R,>Q->S6NGZ39_P#%4WVGZ?IVK&Q'VS4Y($BECBVJSJ\I^8(-
M@)!.!L&>E?.WQ OO$W[53:!X*C\!^(_!OA^*]CO]?U'Q':?9U*1@_N(.<R;F
M/WE((PIP 36?^U3XE\6^)OB%8^#?^$.\7ZK\-[58[C5CX<TR9WU.0C>(?.V[
M?+7Y,[3UW=U&W&&'E4A3PSE9KF;UV3MY[NVWH-RLW+T+^CZI+^U5\>M!\1:5
M;W%O\.? <TLEOJ<@V?VG?':0$!YV@JC="0J\[3( .D\22)^TG\6!X6MW6Y^'
M'A"=)]<=3F+5=0P3%:@CAHXOO.,X)X(^ZU6OAS\>&;4-#\+V7P9\<>%]*9TM
M(II=%,-I:*> S= J \D_4\U?OOV,O@[J5[<7=SX/\RXN)&ED?^T[P;F8DDX$
MV!R>U.=2%&=JB<+*T+6E;75O5:[^C]$"3DM->YC_ +*/_(Q?&S_L>M0_]#-?
M0=?+'[+G[/.B>$_'GC?7KSPI>:7?Z/XDO;?P]=7;7,8%B5:-3&&;;*A1F <A
MLYSG/-?4]<.8\CQ#=-W5E^7JS2G?EU"BBBO,-0KKOASI1NM4:\9?W=NI /\
MM$8_EFN7L[.6_NH[>!"\KG %>Q:#I*:)I<-JG+*,NW]YCU->%FV*5&BZ:^*7
MY=3>E'FE?L:%%%%?"'<%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5<TV$R3[S]U.?QJK'&TC!5&2:W+: 6\(0<GJ30!+1110 5YM\?O@)X
M8_:,^'MYX4\3P,(W_>6E]"!Y]G,/NR1D_J#P1D&O2:*VHUJF'J1JTI6E'5-"
ME%25GL?@)^TM^ROXR_9C\5?V?X@MC=:/<NPT_6[=#]GN@.<9_A<#&5//UKQJ
MOZ2_%'A31O&VB7.CZ_I=IK.EW*E)K.]A66-P01R".O/7J*^"_CI_P21\/>)K
M^75/AEX@'A620LS:/JBO/:;B2?W<@.^,=L$/^%?MN3\<8>M%4LR]R7\RV?JE
MJOR]#PZV!E%WIZH_*BBOI;QM_P $YOCWX+GD \%G7K9>EUHEW%<*WT3<)/S0
M5YU<_LK_ !FM)-C_  G\:L?^F>@74@_-8R*_0J6:8&LN:G7BU_B7^9YSI5([
MQ9Y=17IG_#,/QC_Z)-XY_P#";O/_ (U1_P ,P_&/_HDWCG_PF[S_ .-5O]=P
MO_/V/WH7)/L>9T5Z9_PS#\8_^B3>.?\ PF[S_P"-4?\ #,/QC_Z)-XY_\)N\
M_P#C5'UW"_\ /V/WH.2?8\SHKTS_ (9A^,?_ $2;QS_X3=Y_\:H_X9A^,?\
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M<_\ A-WG_P :H^NX7_G['[T')/L>9T5Z9_PS#\8_^B3>.?\ PF[S_P"-4?\
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M (U1_P ,P_&/_HDWCG_PF[S_ .-4?7<+_P _8_>@Y)]CS.BO3/\ AF'XQ_\
M1)O'/_A-WG_QJC_AF'XQ_P#1)O'/_A-WG_QJCZ[A?^?L?O0<D^QYG17IG_#,
M/QC_ .B3>.?_  F[S_XU1_PS#\8_^B3>.?\ PF[S_P"-4?7<+_S]C]Z#DGV/
M,Z*],_X9A^,?_1)O'/\ X3=Y_P#&J/\ AF'XQ_\ 1)O'/_A-WG_QJCZ[A?\
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M3=Y_\:H^NX7_ )^Q^]!R3['F=%>F?\,P_&/_ *)-XY_\)N\_^-4?\,P_&/\
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M1_PS#\8_^B3>.?\ PF[S_P"-4?7<+_S]C]Z#DGV/,Z*],_X9A^,?_1)O'/\
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M/^&8?C'_ -$F\<_^$W>?_&J/KN%_Y^Q^]!R3['F=%>F?\,P_&/\ Z)-XY_\
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M<_\ A-WG_P :H^NX7_G['[T')/L>9T5Z9_PS#\8_^B3>.?\ PF[S_P"-4?\
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M[C_GG_X\/\: *U%6?[/N/^>?_CP_QH_L^X_YY_\ CP_QH K459_L^X_YY_\
MCP_QH_L^X_YY_P#CP_QH K459_L^X_YY_P#CP_QH_L^X_P">?_CP_P : *U%
M6?[/N/\ GG_X\/\ &C^S[C_GG_X\/\: *U%6?[/N/^>?_CP_QH_L^X_YY_\
MCP_QH K459_L^X_YY_\ CP_QH_L^X_YY_P#CP_QH K459_L^X_YY_P#CP_QH
M_L^X_P">?_CP_P : *U%6?[/N/\ GG_X\/\ &C^S[C_GG_X\/\: *U%6?[/N
M/^>?_CP_QH_L^X_YY_\ CP_QH K459_L^X_YY_\ CP_QH_L^X_YY_P#CP_QH
M K459_L^X_YY_P#CP_QH_L^X_P">?_CP_P : *U%6?[/N/\ GG_X\*<NESMU
M"K]30!4I\4+S,%09-:$6DJO,C[O8<5>CC6-=JJ%'M0!!:6:VRY^\YZFK-%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >2?M,?\B'8?\ 82C_ /14M>MUY)^TQ_R(
M=A_V$H__ $5+7K===3^!3]7^A"^)A1117(6%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'DGQF_Y'SX:_]A(_^C;>O6Z\D^,W
M_(^?#7_L)'_T;;UZW795_@TO1_F1'=A1117&6%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'DGP9_Y'SXE?\ 82'_ *-N*];K
MR3X,_P#(^?$K_L)#_P!&W%>MUUXK^*_1?DB(;!1117(6%%%% !1110 4444
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M "R_\"#Z]6/U\_X>_?!S_H6O'/\ X 6?_P ET?\ #W[X.?\ 0M>.?_ "S_\
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M11_J/D_\LO\ P(/KU8_7S_A[]\'/^A:\<_\ @!9__)='_#W[X.?]"UXY_P#
M"S_^2Z_(.BC_ %'R?^67_@0?7JQ^OG_#W[X.?]"UXY_\ +/_ .2Z/^'OWP<_
MZ%KQS_X 6?\ \EU^0=%'^H^3_P LO_ @^O5C]?/^'OWP<_Z%KQS_ . %G_\
M)='_  ]^^#G_ $+7CG_P L__ )+K\@Z*/]1\G_EE_P"!!]>K'Z^?\/?O@Y_T
M+7CG_P  +/\ ^2Z/^'OWP<_Z%KQS_P" %G_\EU^0=%'^H^3_ ,LO_ @^O5C]
M?/\ A[]\'/\ H6O'/_@!9_\ R71_P]^^#G_0M>.?_ "S_P#DNOR#HH_U'R?^
M67_@0?7JQ^OG_#W[X.?]"UXY_P# "S_^2Z/^'OWP<_Z%KQS_ . %G_\ )=?D
M'11_J/D_\LO_  (/KU8_7S_A[]\'/^A:\<_^ %G_ /)='_#W[X.?]"UXY_\
M "S_ /DNOR#HH_U'R?\ EE_X$'UZL?KY_P /?O@Y_P!"UXY_\ +/_P"2Z/\
MA[]\'/\ H6O'/_@!9_\ R77Y!T4?ZCY/_++_ ,"#Z]6/U\_X>_?!S_H6O'/_
M ( 6?_R71_P]^^#G_0M>.?\ P L__DNOR#HH_P!1\G_EE_X$'UZL?KY_P]^^
M#G_0M>.?_ "S_P#DNC_A[]\'/^A:\<_^ %G_ /)=?D'11_J/D_\ ++_P(/KU
M8_7S_A[]\'/^A:\<_P#@!9__ "71_P /?O@Y_P!"UXY_\ +/_P"2Z_(.BC_4
M?)_Y9?\ @0?7JQ^OG_#W[X.?]"UXY_\  "S_ /DNC_A[]\'/^A:\<_\ @!9_
M_)=?D'11_J/D_P#++_P(/KU8_7S_ (>_?!S_ *%KQS_X 6?_ ,ET?\/?O@Y_
MT+7CG_P L_\ Y+K\@Z*/]1\G_EE_X$'UZL?KY_P]^^#G_0M>.?\ P L__DNC
M_A[]\'/^A:\<_P#@!9__ "77Y!T4?ZCY/_++_P "#Z]6/U\_X>_?!S_H6O'/
M_@!9_P#R71_P]^^#G_0M>.?_   L_P#Y+K\@Z*/]1\G_ )9?^!!]>K'Z^?\
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M_@!9_P#R77Y!T4?ZCY/_ "R_\"#Z]6/U\_X>_?!S_H6O'/\ X 6?_P ET?\
M#W[X.?\ 0M>.?_ "S_\ DNOR#HH_U'R?^67_ ($'UZL?KY_P]^^#G_0M>.?_
M   L_P#Y+H_X>_?!S_H6O'/_ ( 6?_R77Y!T4?ZCY/\ RR_\"#Z]6/U\_P"'
MOWP<_P"A:\<_^ %G_P#)='_#W[X.?]"UXY_\ +/_ .2Z_(.BC_4?)_Y9?^!!
M]>K'Z^?\/?O@Y_T+7CG_ , +/_Y+H_X>_?!S_H6O'/\ X 6?_P EU^0=%'^H
M^3_RR_\  @^O5C]?/^'OWP<_Z%KQS_X 6?\ \ET?\/?O@Y_T+7CG_P  +/\
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MHHHKI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIEZ"0-L9<9#<YP6SC.0,<\KPM2-/VCMM>UU>W>Q?.KV/5J*;)(D,;R2,L<:
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M;,]MP,]T[?ET_*OD\XP22^LTUZ_YG51G]EG5T445\F=84444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2WD\J9']#4=%
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M"$S%'@D).-@)W9[K_>KR;P;X5O?'7C#0O#6F^7_:.LW\&G6WG$A/-FD6--Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[6TN$E-O,OWHY I.UQW4X(K0KYG_ &)-!_X16W^*6B_:I;[^S?%MU9_:I_\
M63>6 F]O<[<GW-?3%88JBL/6E3B[I?Y%0ES1NPHHHKD+"I+=#)/&@&2S 8_&
MHZU_"=B=0\06<>,JK^8WT7G^E959JG3E-]$-*[L>PT445^6'J!1110 4444
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MFOG?)YP._<VYLMG)R<]:YL/DE:G1G2G-.]+V:W[RLW]Y4J\7)-+K<^XO"?\
MR(_[??\ V$XO_2^_KA_A3_RC-^-G_8S:=_Z-M*^7(?B#XIMX-?@B\2ZQ'#X@
M8/K,:7\H74F#,P-R-W[X[G<Y?/+$]S4%IXR\06'AF^\.6VN:E;^'KZ59[O28
M;N1;2XD4@J\D0.QF!5<$@D;1Z5T+)ZFOOK6=.?\ X H)KY\OXD^V7;HU]]_\
MS[F\?^"]?D^,_P"Q3XI31[V3PVOASP78OJJ0,ULEPMT&,;.!A6Q(A .,[N,\
MUN3W'Q@\)_M"_M(>*_A5;:#XNM8-6%MKO@C4+>2\N;^(C$4JVR ,ZKYDOW9
M>'!5N ?A6V^,WQ L]#T_1;?QSXD@T;3I8I[+3H]7N%M[:2-Q)&\<8?:C(X#*
M5 (89'-4;7XC>+++Q5-XGM_%&M0>)9V+RZS%J$RWDC$@EFF#;R>!R3V%<O\
M8E=QY9RBTHN-FFTUSJ6JO\KIZ.S17MX[J_\ 2L?87QZ^'W@WQC^ROK/Q0U;X
M0GX&>/K'68--L]/B\VTM]85MA<QVLJ(% 5Y6^1<_N3\Q *CQ#]AC5;;1OVMO
MAC<74@CB?51;AF('SRQO$@Y(ZLZCUYXR>*\K\8_$;Q9\1)[>;Q7XHUGQ--;A
MA#)K&H37;1!L;@ID8XSM7./0>E9&DZK=Z%JMEJ5A.UM?6<R7%O,N,QR(P96&
M>X(!_"O3H9;4A@:N$J3OS\UM6U%-6LFVVTM]>YE*HG44TMCZ_P#@O8W&F_\
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M)KJ.R='SCY2P=)NO/S-ZFO2_A=_R9';_ /8JW?\ Z*EKT#0?@3X0\*_#/5O
MNB6+Z5H^JVDUK=RP/NN)/-C,;R&1PV7P>,@@8  P,5HZ#\+M*\._"U/ 5M<7
MCZ.NGR::)Y70W'ENK*3N"A=V&/.W'M6M;&4JD5&-]''[HQM?U)C!IW?F>;_L
MPPQ_\,C^'X_+7RVTV\W+M&#F68G(]\G\Z^=[K_DRCX(_]CDO_I1?U]J>!/AK
MIGP]^'=EX-TZ>[FTNT@DMTFNG5IBKLS$DJH7.7/\/I7%R?LO>%9/A?X6\!G4
M-8_LCPYJ8U6TF$T7VAY0\S[9&\K:5S._ 4'@<]<Z4\;2C5G-[.?-\K2_S0G3
M=DO+_(X_]O2-9?@[I".H=&\0V896&005EX-7/V\$5OV<=9+*"5N[0J2.A\Y1
MD?@3^=>G_%KX2Z1\9/#=MHFM7-]:VMO>Q7RO8.B.9$#  ET8;?F.>,^]2?%K
MX6Z5\9/!-UX7UJXO+73[B2.1Y+!T24%&##!96'4>E<V'Q5.G]7YOL2;?II_D
M7*+?-YGSU\?-+UR\_;"\ KI?BM/!$]WH,EMI^L2V,5VIN!)/OA$<A"EF5T S
MW8 9)Q6I\4/@#XU\4:+86?C?X^68T\:A#):&\\-6=K_I8R(O+<2J=YRP !R<
MD8->X?%#X1>%_C!H\&G>)M/^U+;2>=;7$,ABGMW[E'7D9XR.AP,C@8XKPS^R
MGX3T77[#6=7U;Q)XWO=.*FQ_X2C4S=QVI7[I1 JKQS@$$ G(&<$=%/'05.#4
MN64%;X(M];6;V\R73=WY^9R_AS_D_;Q3_P!B:G_H^VH^)W_)Z_P;_P"P;J7_
M *3SUZS9?"72+'XN7_Q%CN;XZW>Z8-*DMV=/LPB#HVX+LW;LQKSNQR>*-=^$
MND>(/BAX:\>7%S?)J^@03P6L,3H+=UE1T8NI0L2 YQAAVZU@L53YU+_IVX_/
ME:_,?*[?,\G_ &8]MK\8OCS;7CK_ &TWB%9F5L[S:L93;_4!6/3IGGJ,R_M$
M>+]!UBQ^)?@[1M(:Z\;VWA22]N]0BM8@$M<J6A:4D.3MVML .=RXR0<=Q\2/
MV=?"_P 2/$,/B%KG5O#7B6-%B.M>';PVEU(@Z*[8(;&!R1G  S@"M?X9?!KP
M[\*].U*#3%N]0O=5D\W4]4U:<W-W?O\ -@S.1@X#,,  <DXR234L10]HL3=\
MUEIYJW7MH'+*W+T/#/@3X!^)7B+X0^%+WPS\=([+1VL(ECL8_"UI<?9&"@/
M9&;<Q1LJ2>3C/>O2OV:_AI%\-])\4)!XWL_&RZEK$MW<S6%K%;Q6]U@"9-D<
MCJK9"Y4;=N ,"LVZ_8[\&QWUY)H>L^*?"6G7THFN]'T'5VM[*X;(X:,JQQUX
M!& <#'&/4_ /P^T#X8^&;?0/#>G1Z;IL)+"-269W/WG=CRS'CDGH .@ HQ6*
MA4C)4Y?$]N2*\]6M6PA!IJZV\SQ+]OW_ )-ZNO\ L)6O\VH^)W_)Z_P;_P"P
M;J7_ *3SUZS\7_A+I'QJ\&R>&M<N;ZUL7GCG,FGNB2[D)(&71ACGTHUWX2Z1
MX@^*'AKQY<7-\FKZ!!/!:PQ.@MW65'1BZE"Q(#G&&';K4T<53IT8P>Z53_R:
M*2"46Y7]#R;]K/\ Y'KX$_\ 8Y6O_HV*OH^N)^(?PETCXEZMX3U#4[F^@F\-
M:G'JMFMHZ*LDJ,K!9-R-E<J. 0?>NVKCJU8SHTH+>-[_ #=RXIJ39X9\8/C!
MK.H^)A\,OAD([WQO=)F^U)N;?0X#C,LIP1OP1A>>HX)*JW5? KX)Z=\$_"TM
ME#<RZIK6H2?:M5U:X8F2[G.<MR3A02<#KR2222:X6]_8N\.77B36M<B\;>.-
M/U#6+I[N\:PU.& 2.S,W18!P"S8'8'BNM^&7[/5C\+_$C:Q;>,O&&N2- UN;
M77-46XM\,0=VP1K\PVC!SW-=M6>'5#V5&=NKTUD_-]NR^>Y"4N:\D>.?L^?"
MOPA\0/B)\;KGQ)X=T_6Y[?Q?=QQ27L(D**9I20,].:K_ +:7P;\#>!_@?=:G
MH'A32M(U#[=;Q"YM;94D"ECD XXSBOHOX>?"72/AIJWBS4-,N;Z>;Q+J<FJW
MBW;HRQRNS,5CVHN%RQX))]Z/B_\ "72/C5X-D\-:Y<WUK8O/'.9-/=$EW(20
M,NC#'/I6JS"V,C5YWR*W?HE?07L_<:MJ9WQ'_P"%N_VY!_P@/_"%?V/]G7S?
M^$D^V?://W-NV^3\NS;LQGG.[VILWQ%U'X5_#&Z\1?%F\T.SO;9V!'A_S3#-
MG_5QQ++\S2-@\=._ !(])KS3XV? 71?CQ9:1::YJNL:=;Z;,]Q$FE311[Y"
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M2MR.-8D"J, 4 .HHHH *9-#'<0O%+&LL4BE7C< JRD8((/44^B@#\Y?VPO\
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M,/\ AS%_U6'_ ,MC_P"[*/\ AS%_U6'_ ,MC_P"[*/\ 7#(_^?\ _P"2S_\
MD0^IU_Y?Q1^9]%?IA_PYB_ZK#_Y;'_W91_PYB_ZK#_Y;'_W91_KAD?\ S_\
M_)9__(A]3K_R_BC\SZ*_3#_AS%_U6'_RV/\ [LH_X<Q?]5A_\MC_ .[*/]<,
MC_Y__P#DL_\ Y$/J=?\ E_%'YGT5^F'_  YB_P"JP_\ EL?_ '91_P .8O\
MJL/_ );'_P!V4?ZX9'_S_P#_ "6?_P B'U.O_+^*/S/HK],/^',7_58?_+8_
M^[*/^',7_58?_+8_^[*/]<,C_P"?_P#Y+/\ ^1#ZG7_E_%'YGT5^F'_#F+_J
ML/\ Y;'_ -V4?\.8O^JP_P#EL?\ W91_KAD?_/\ _P#)9_\ R(?4Z_\ +^*/
MS/HK],/^',7_ %6'_P MC_[LH_X<Q?\ 58?_ "V/_NRC_7#(_P#G_P#^2S_^
M1#ZG7_E_%'YGT5^F'_#F+_JL/_EL?_=E'_#F+_JL/_EL?_=E'^N&1_\ /_\
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M_P#_ ,EG_P#(A]3K_P OXH_,^BOTP_X<Q?\ 58?_ "V/_NRC_AS%_P!5A_\
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M^*/S/HK],/\ AS%_U6'_ ,MC_P"[*/\ AS%_U6'_ ,MC_P"[*/\ 7#(_^?\
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M?4Z_\OXH_,^BOTP_X<Q?]5A_\MC_ .[*/^',7_58?_+8_P#NRC_7#(_^?_\
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M^6Q_]V4?ZX9'_P __P#R6?\ \B'U.O\ R_BC\SZ*_3#_ (<Q?]5A_P#+8_\
MNRC_ (<Q?]5A_P#+8_\ NRC_ %PR/_G_ /\ DL__ )$/J=?^7\4?F?17Z8?\
M.8O^JP_^6Q_]V4?\.8O^JP_^6Q_]V4?ZX9'_ ,__ /R6?_R(?4Z_\OXH_,^B
MOTP_X<Q?]5A_\MC_ .[*/^',7_58?_+8_P#NRC_7#(_^?_\ Y+/_ .1#ZG7_
M )?Q1^9]%?IA_P .8O\ JL/_ );'_P!V4?\ #F+_ *K#_P"6Q_\ =E'^N&1_
M\_\ _P EG_\ (A]3K_R_BC\SZ*_3#_AS%_U6'_RV/_NRC_AS%_U6'_RV/_NR
MC_7#(_\ G_\ ^2S_ /D0^IU_Y?Q1^9]%?IA_PYB_ZK#_ .6Q_P#=E'_#F+_J
ML/\ Y;'_ -V4?ZX9'_S_ /\ R6?_ ,B'U.O_ "_BC\SZ*_3#_AS%_P!5A_\
M+8_^[*/^',7_ %6'_P MC_[LH_UPR/\ Y_\ _DL__D0^IU_Y?Q1^9]%?IA_P
MYB_ZK#_Y;'_W91_PYB_ZK#_Y;'_W91_KAD?_ #__ /)9_P#R(?4Z_P#+^*/S
M/HK],/\ AS%_U6'_ ,MC_P"[*/\ AS%_U6'_ ,MC_P"[*/\ 7#(_^?\ _P"2
MS_\ D0^IU_Y?Q1^9]%?IA_PYB_ZK#_Y;'_W91_PYB_ZK#_Y;'_W91_KAD?\
MS_\ _)9__(A]3K_R_BC\SZ*_3#_AS%_U6'_RV/\ [LH_X<Q?]5A_\MC_ .[*
M/]<,C_Y__P#DL_\ Y$/J=?\ E_%'YGT5^F'_  YB_P"JP_\ EL?_ '91_P .
M8O\ JL/_ );'_P!V4?ZX9'_S_P#_ "6?_P B'U.O_+^*/S/HK],/^',7_58?
M_+8_^[*/^',7_58?_+8_^[*/]<,C_P"?_P#Y+/\ ^1#ZG7_E_%'YGT5^F'_#
MF+_JL/\ Y;'_ -V4?\.8O^JP_P#EL?\ W91_KAD?_/\ _P#)9_\ R(?4Z_\
M+^*/S/HK],/^',7_ %6'_P MC_[LH_X<Q?\ 58?_ "V/_NRC_7#(_P#G_P#^
M2S_^1#ZG7_E_%'YGT5^F'_#F+_JL/_EL?_=E'_#F+_JL/_EL?_=E'^N&1_\
M/_\ \EG_ /(A]3K_ ,OXH_,^BOT"\9_\$H/^$1U[PUIO_"TOM?\ ;-S]G\W_
M (1[9Y/SQKG'VH[O]9TR.GO77?\ #F+_ *K#_P"6Q_\ =E6^+<EBE)U]'_=G
M_P#(B^IU_P"7\4?F?17Z8?\ #F+_ *K#_P"6Q_\ =E'_  YB_P"JP_\ EL?_
M '94?ZX9'_S_ /\ R6?_ ,B/ZG7_ )?Q1^9]%?IA_P .8O\ JL/_ );'_P!V
M4?\ #F+_ *K#_P"6Q_\ =E'^N&1_\_\ _P EG_\ (A]3K_R_BC\SZ*_3#_AS
M%_U6'_RV/_NRC_AS%_U6'_RV/_NRC_7#(_\ G_\ ^2S_ /D0^IU_Y?Q1^9]%
M?IA_PYB_ZK#_ .6Q_P#=E'_#F+_JL/\ Y;'_ -V4?ZX9'_S_ /\ R6?_ ,B'
MU.O_ "_BC\SZ*_3#_AS%_P!5A_\ +8_^[*/^',7_ %6'_P MC_[LH_UPR/\
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M_P#Y+/\ ^1#ZG7_E_%'YGT5^F'_#F+_JL/\ Y;'_ -V4?\.8O^JP_P#EL?\
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M .2S_P#D0^IU_P"7\4?F?17Z8?\ #F+_ *K#_P"6Q_\ =E'_  YB_P"JP_\
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M_J,_^2O_ -G1_:N#_G_!_P"0>RGV/,J*]-_X4M_U&?\ R5_^SH_X4M_U&?\
MR5_^SH_M7!_S_@_\@]E/L>945Z;_ ,*6_P"HS_Y*_P#V='_"EO\ J,_^2O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \D_
M:8_Y$.P_["4?_HJ6O6Z\D_:8_P"1#L/^PE'_ .BI:];KKJ?P*?J_T(7Q,***
M*Y"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \D^,W_(^?#7_L)'_P!&V]>MUY)\9O\ D?/AK_V$C_Z-MZ];KLJ_P:7H_P R
M([L****XRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH \D^#/_(^?$K_L)#_T;<5ZW7DGP9_Y'SXE?]A(?^C;BO6ZZ\5_%?HO
MR1$-@HHHKD+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "L#Q__P B'XD_[!MS_P"BFK?K \?_ /(A^)/^P;<_^BFK2G\<?43V,'X%
M_P#)*]$_[;_^CY*[VN"^!?\ R2O1/^V__H^2N]K3$?QI^K_,4?A04445SE!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117 _&[XU
M^&O@#\/M0\6^*+DQ6=LI$-O'@S74Q!VQ1CNS'UX'4\5K2I3KU(TJ2O)Z)(3:
MBKLZ_7->TWPQI5QJ>KW]MIFG6ZEYKJ[E6.-%'<L3@5\)_'K_ (*R>$_!MY+I
M7PVT;_A,KR,E7U2\=H+%2/[@ WR_^.#T)KX0_:D_:]\8_M0>)#)JD[:;X8MI
M,Z?H-NY\F+J [_WY"#]X],X&!7A-?M>3<#4:<56S)\TOY5LO5K5_+3U/$K8Z
M3=J6B[GT[XW_ ."D7Q[\:7#M'XNC\.VK=+71+**%5^CL&D_-Z\UN_P!JKXSW
MLF^3XK^-%/\ TQUZZC'Y*X%>645^B4LKP%!<M*A%?]NK_(\UU:DMY,],_P"&
MGOC'_P!%9\<_^%)>?_':/^&GOC'_ -%9\<_^%)>?_':\SHKH^I87_GU'[D+G
MGW/3/^&GOC'_ -%9\<_^%)>?_':/^&GOC'_T5GQS_P"%)>?_ !VO,Z*/J6%_
MY]1^Y!SS[GIG_#3WQC_Z*SXY_P#"DO/_ ([1_P -/?&/_HK/CG_PI+S_ ..U
MYG11]2PO_/J/W(.>?<],_P"&GOC'_P!%9\<_^%)>?_':/^&GOC'_ -%9\<_^
M%)>?_':\SHH^I87_ )]1^Y!SS[GIG_#3WQC_ .BL^.?_  I+S_X[1_PT]\8_
M^BL^.?\ PI+S_P".UYG11]2PO_/J/W(.>?<],_X:>^,?_16?'/\ X4EY_P#'
M:/\ AI[XQ_\ 16?'/_A27G_QVO,Z*/J6%_Y]1^Y!SS[GIG_#3WQC_P"BL^.?
M_"DO/_CM'_#3WQC_ .BL^.?_  I+S_X[7F=%'U+"_P#/J/W(.>?<],_X:>^,
M?_16?'/_ (4EY_\ ':/^&GOC'_T5GQS_ .%)>?\ QVO,Z*/J6%_Y]1^Y!SS[
MGIG_  T]\8_^BL^.?_"DO/\ X[1_PT]\8_\ HK/CG_PI+S_X[7F=%'U+"_\
M/J/W(.>?<],_X:>^,?\ T5GQS_X4EY_\=H_X:>^,?_16?'/_ (4EY_\ ':\S
MHH^I87_GU'[D'//N>F?\-/?&/_HK/CG_ ,*2\_\ CM'_  T]\8_^BL^.?_"D
MO/\ X[7F=%'U+"_\^H_<@YY]STS_ (:>^,?_ $5GQS_X4EY_\=H_X:>^,?\
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M_P#/J/W(.>?<],_X:>^,?_16?'/_ (4EY_\ ':/^&GOC'_T5GQS_ .%)>?\
MQVO,Z*/J6%_Y]1^Y!SS[GIG_  T]\8_^BL^.?_"DO/\ X[1_PT]\8_\ HK/C
MG_PI+S_X[7F=%'U+"_\ /J/W(.>?<],_X:>^,?\ T5GQS_X4EY_\=H_X:>^,
M?_16?'/_ (4EY_\ ':\SHH^I87_GU'[D'//N>F?\-/?&/_HK/CG_ ,*2\_\
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M9T4?4L+_ ,^H_<@YY]STS_AI[XQ_]%9\<_\ A27G_P =H_X:>^,?_16?'/\
MX4EY_P#':\SHH^I87_GU'[D'//N>F?\ #3WQC_Z*SXY_\*2\_P#CM'_#3WQC
M_P"BL^.?_"DO/_CM>9T4?4L+_P ^H_<@YY]STS_AI[XQ_P#16?'/_A27G_QV
MC_AI[XQ_]%9\<_\ A27G_P =KS.BCZEA?^?4?N0<\^YZ9_PT]\8_^BL^.?\
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M\SHH^I87_GU'[D'//N>F?\-/?&/_ **SXY_\*2\_^.T?\-/?&/\ Z*SXY_\
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M?_16?'/_ (4EY_\ ':\SHH^I87_GU'[D/GGW/3/^&GOC'_T5GQS_ .%)>?\
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M1_PT]\8_^BL^.?\ PI+S_P".UYG11]2PO_/J/W(.>?<],_X:>^,?_16?'/\
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MX:>^,?\ T5GQS_X4EY_\=KS.BCZEA?\ GU'[D'//N>F?\-/?&/\ Z*SXY_\
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MEV.BW0C[*?=;?..WW6.REC:E-^]JC^C[^T+C_GI_XZ/\*/[0N/\ GI_XZ/\
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M_P!H7'_/3_QT?X4?VA<?\]/_ !T?X56HH L_VA<?\]/_ !T?X4?VA<?\]/\
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M&!##(Y'!/2DHI[:H"'0K.'PSI4&FZ:GV:RAW>7%DOC<Q8\MD]2>]7_[0N/\
MGI_XZ/\ "JU%#;D[L"S_ &A<?\]/_'1_A1_:%Q_ST_\ '1_A5:BD!9_M"X_Y
MZ?\ CH_PH_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/\ GI_XZ/\ "JU%
M %G^T+C_ )Z?^.C_  H_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/^>G_
M (Z/\*K44 6?[0N/^>G_ (Z/\*/[0N/^>G_CH_PJM10!9_M"X_YZ?^.C_"C^
MT+C_ )Z?^.C_  JM10!9_M"X_P">G_CH_P */[0N/^>G_CH_PJM10!9_M"X_
MYZ?^.C_"C^T+C_GI_P".C_"JU% %G^T+C_GI_P".C_"C^T+C_GI_XZ/\*K44
M 6?[0N/^>G_CH_PH_M"X_P">G_CH_P *K44 6?[0N/\ GI_XZ/\ "C^T+C_G
MI_XZ/\*K44 6?[0N/^>G_CH_PH_M"X_YZ?\ CH_PJM10!9_M"X_YZ?\ CH_P
MH_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/\ GI_XZ/\ "JU% %G^T+C_
M )Z?^.C_  H_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/^>G_ (Z/\*K4
M4 6?[0N/^>G_ (Z/\*/[0N/^>G_CH_PJM10!9_M"X_YZ?^.BG+J<Z]2K?454
MHH TXM6!XD3'NM78Y%E7<C!A[5S]/CE>%@R'!H Z"BJUG>K<C!^63T]:LT %
M%%% $%]?0:;97%Y=2K;VMO&TLLLAPJ(HRS$^@ )K\*OVTOVI=4_:8^*-U.EP
M\7A#2I7M]&L5.$\L$@SL.[OC.3T& *_0O_@J9\;KCX9_ NU\+:7<_9]5\7SO
M:NRD;Q9Q@-/CN,EHUSZ,:_'"OVO@7)XQIO,ZJNW=1\DMW\]OD^YXF/K._LE\
MPHHHK]=/')+>WEO+B*"")YYY6"1Q1J69V)P% '))/:OL/P7_ ,$IOC;XM\/V
MNIW;^&_#$EPN\:?K5]*+E <XWK##(JDC!VELC." <@?*?@?Q3-X'\:^'_$=O
M$L]QH^H6^H1Q,<!VBD60*3Z$K7Z<^./$/[-W[>G_  CFN:E\2M2^'WCFWB6&
MUL[K4OLXM)LABBI,/*8EB,/$RLY5><C%?(9]C\=@Y4OJZY:;OS34'.W;W4UH
M^K.S#TX33YM^U['YV_'#X"^,?V>?&3>&_&6G"SO&C$T%Q"QDM[J,_P <3X&X
M \'N",$5Y[7W9^V=\#?C)JWQ.^$?AWQ[X^M_'NA:]?IH^A^)H-(@MOL[W$L*
M,LRQ ;B5\MUW2-N ?:>'->I?%KQ;^SC^QEXL\-?">]^#6F>-5%C'+K'B35(+
M>>[A60D"3+Q,\DA^9RJF,*"FS/ 7.CGTGAZ"C#VU6:;M3T5HNS?O6MZ;WT[7
M<L/[TKOE2[_\ _,&BOUC\.?L9^ ?AW^W+IT4/A[2M9\!>*/#-[J-IH>K6BW<
M-I<120+(%656&W$B,ISD;V7  &7?!75OV>OBE\>O&WP0LO@/H=K;Z-)?;->N
MK>&6>ZDAG"S\E/,A7S&;RPLA 0* L8PHYY\647!U*%&4XJ*FVK*R;:=[O=-6
MLK_<4L([VE))WL?DU17Z5?L<?L?^#+K5OC)XPU/PDOQ!/A/Q-?Z!X>\,W4B"
M*5[?)_>>:XC<NLL2CS?E7:S?,2-O1_M.?LM:/\0?V7?$7CB?X,Z?\$?'_A<2
M7JZ?I5W:2V]U:IM,NYK1=K@Q;BNY$99$QG86+;SXJP<,8L+RNUXIN\=Y;>[?
MF:[M*R)6%FX<Y\+_ !&_95\6?#'X(^#_ (I:IJ&C7'A_Q0\*65M9SS-=QF2)
MY5\Q6B51\L9SM=N2/K7C5?H_^TQH-UXJ_P""?7[-6BV.S[;J6I:79P>8VU?,
MDM)T7)[#+#FMWXQ:I^S[^P6?"7P[O?A#IWQ.UJZLTO-5U?5K>W>X6%I'0RJT
MD;Y<LDF(E* !5RW0UCA>(*KIJ#INI5E.HE&-E[L'NVW;_-E2PZO>]DDOQ/SS
M^$/PNU7XU?$C0_!.B7%G:ZKK$K0P3:@[I I",YWE%9@,*>BGG%6?C=\']9^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#]Z/V5?%TOCK]G+X>:S._FW$VCP13/_>DB'E.?^^D->JU
M\[_\$^%E3]C_ .'HF.6\N\(_W3>W!7],5]$5_)6:4XTL?B*<=E.2^Z3/KJ3O
M3BWV04445YAJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPU:K]=E2GM*$9V?V7LUZ;:=[]SGE%<B:Z.QYQ1117N& 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\T<F)H*O&RW1_._17N7[47[(_C']E_Q*8-7@;4?#=U(1I^O6Z'R9NIV/_<D
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M/"J&(J8F3O*22]$KZ?>VV_3303E>*CV"BBBNXS"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBI[&QN=4
MO8+.SMY+J[N)%BA@A0N\CL<!54<DDG&!2;MJQD4,,EQ,D42-)*[!41 2S$\
M =S7[%?\$]_V7[GX#_#J?7?$-LL/B[Q$J230GE[2V S'"?\ :).YAZX':O-O
MV)?^"?#>!;W3O'WQ*@5]=C FL- ;#):,<%9)O60=EZ GG)''WU7X?Q?Q+#&)
MY?@I7A]I][=%Y=WU/<P>%</WD]^@4445^4'K!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*/\ B(.*_P"?$?O8?V?'^8_GK_X9A^,?_1)O'/\ X3=Y_P#&J/\ AF'XQ_\
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MF\<_^$W>?_&J_H4HH_XB#BO^?$?O8?V?'^8_GK_X9A^,?_1)O'/_ (3=Y_\
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M_F/YZ_\ AF'XQ_\ 1)O'/_A-WG_QJC_AF'XQ_P#1)O'/_A-WG_QJOZ%**/\
MB(.*_P"?$?O8?V?'^8_GK_X9A^,?_1)O'/\ X3=Y_P#&J/\ AF'XQ_\ 1)O'
M/_A-WG_QJOZ%**/^(@XK_GQ'[V']GQ_F/YZ_^&8?C'_T2;QS_P"$W>?_ !JC
M_AF'XQ_]$F\<_P#A-WG_ ,:K^A2BC_B(.*_Y\1^]A_9\?YC^>O\ X9A^,?\
MT2;QS_X3=Y_\:H_X9A^,?_1)O'/_ (3=Y_\ &J_H4HH_XB#BO^?$?O8?V?'^
M8_GK_P"&8?C'_P!$F\<_^$W>?_&J/^&8?C'_ -$F\<_^$W>?_&J_H4HH_P"(
M@XK_ )\1^]A_9\?YC^>O_AF'XQ_]$F\<_P#A-WG_ ,:H_P"&8?C'_P!$F\<_
M^$W>?_&J_H4HH_XB#BO^?$?O8?V?'^8_GK_X9A^,?_1)O'/_ (3=Y_\ &J/^
M&8?C'_T2;QS_ .$W>?\ QJOZ%**/^(@XK_GQ'[V']GQ_F/YZ_P#AF'XQ_P#1
M)O'/_A-WG_QJC_AF'XQ_]$F\<_\ A-WG_P :K^A2BC_B(.*_Y\1^]A_9\?YC
M^>O_ (9A^,?_ $2;QS_X3=Y_\:H_X9A^,?\ T2;QS_X3=Y_\:K^A2BC_ (B#
MBO\ GQ'[V']GQ_F/YZ_^&8?C'_T2;QS_ .$W>?\ QJC_ (9A^,?_ $2;QS_X
M3=Y_\:K^A2BC_B(.*_Y\1^]A_9\?YC^=^\_9Y^*FFW%M!=_#/QA:S73;((YM
M!NT:5L@80&/YCDC@>HJY_P ,P_&/_HDWCG_PF[S_ .-5^W/QF_Y'SX:_]A(_
M^C;>O6ZVGQ]B8PA+V$=;]7W)67QNUS'\]?\ PS#\8_\ HDWCG_PF[S_XU1_P
MS#\8_P#HDWCG_P )N\_^-5_0I16/_$0<5_SXC][*_L^/\Q_/7_PS#\8_^B3>
M.?\ PF[S_P"-4?\ #,/QC_Z)-XY_\)N\_P#C5?T*44?\1!Q7_/B/WL/[/C_,
M?SU_\,P_&/\ Z)-XY_\ ";O/_C5'_#,/QC_Z)-XY_P#";O/_ (U7]"E%'_$0
M<5_SXC][#^SX_P Q_/7_ ,,P_&/_ *)-XY_\)N\_^-4?\,P_&/\ Z)-XY_\
M";O/_C5?T*44?\1!Q7_/B/WL/[/C_,?SU_\ #,/QC_Z)-XY_\)N\_P#C5'_#
M,/QC_P"B3>.?_";O/_C5?T*44?\ $0<5_P ^(_>P_L^/\Q_/7_PS#\8_^B3>
M.?\ PF[S_P"-4?\ #,/QC_Z)-XY_\)N\_P#C5?T*44?\1!Q7_/B/WL/[/C_,
M?SU_\,P_&/\ Z)-XY_\ ";O/_C5'_#,/QC_Z)-XY_P#";O/_ (U7]"E%'_$0
M<5_SXC][#^SX_P Q_/7_ ,,P_&/_ *)-XY_\)N\_^-4?\,P_&/\ Z)-XY_\
M";O/_C5?T*44?\1!Q7_/B/WL/[/C_,?SU_\ #,/QC_Z)-XY_\)N\_P#C5'_#
M,/QC_P"B3>.?_";O/_C5?T*44?\ $0<5_P ^(_>P_L^/\Q_/7_PS#\8_^B3>
M.?\ PF[S_P"-4?\ #,/QC_Z)-XY_\)N\_P#C5?T*44?\1!Q7_/B/WL/[/C_,
M?SU_\,P_&/\ Z)-XY_\ ";O/_C5'_#,/QC_Z)-XY_P#";O/_ (U7]"E%'_$0
M<5_SXC][#^SX_P Q_/7_ ,,P_&/_ *)-XY_\)N\_^-4?\,P_&/\ Z)-XY_\
M";O/_C5?T*44?\1!Q7_/B/WL/[/C_,?SU_\ #,/QC_Z)-XY_\)N\_P#C5'_#
M,/QC_P"B3>.?_";O/_C5?T*44?\ $0<5_P ^(_>P_L^/\Q_/7_PS#\8_^B3>
M.?\ PF[S_P"-4?\ #,/QC_Z)-XY_\)N\_P#C5?T*44?\1!Q7_/B/WL/[/C_,
M?SU_\,P_&/\ Z)-XY_\ ";O/_C5'_#,/QC_Z)-XY_P#";O/_ (U7]"E%'_$0
M<5_SXC][#^SX_P Q_/7_ ,,P_&/_ *)-XY_\)N\_^-4?\,P_&/\ Z)-XY_\
M";O/_C5?T*44?\1!Q7_/B/WL/[/C_,?SU_\ #,/QC_Z)-XY_\)N\_P#C5'_#
M,/QC_P"B3>.?_";O/_C5?T*44?\ $0<5_P ^(_>P_L^/\Q_/7_PS#\8_^B3>
M.?\ PF[S_P"-4?\ #,/QC_Z)-XY_\)N\_P#C5?T*44?\1!Q7_/B/WL/[/C_,
M?SU_\,P_&/\ Z)-XY_\ ";O/_C5'_#,/QC_Z)-XY_P#";O/_ (U7]"E%'_$0
M<5_SXC][#^SX_P Q_/7_ ,,P_&/_ *)-XY_\)N\_^-4?\,P_&/\ Z)-XY_\
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MT?9IO^>3_P#?)K?HH P/LTW_ #R?_ODT?9IO^>3_ /?)K?HH P/LTW_/)_\
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M:/LTW_/)_P#ODUOT4 8'V:;_ )Y/_P!\FC[--_SR?_ODUOT4 8'V:;_GD_\
MWR:/LTW_ #R?_ODUOT4 8'V:;_GD_P#WR:<MG.W2-OQXK=HH RH])=OOL%'M
MR:T(;6.W'R+SZGK4M% !1110 4444 %%%% !117C7QM_:\^%G[/_ .X\5^)H
M1JI'RZ3IZFYNS]47[GU<J#71A\/6Q514J$'*3Z)79,I1BKR=CV6BOS9\;?\
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M_?&/_H6O W_@!>?_ "71_J/G'\L?_ @^O43]?**_(/\ X>_?&/\ Z%KP-_X
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M+7@;_P  +S_Y+H_U'SC^6/\ X$'UZB?KY17Y!_\ #W[XQ_\ 0M>!O_ "\_\
MDNC_ (>_?&/_ *%KP-_X 7G_ ,ET?ZCYQ_+'_P "#Z]1/U\HK\@_^'OWQC_Z
M%KP-_P" %Y_\ET?\/?OC'_T+7@;_ , +S_Y+H_U'SC^6/_@0?7J)^OE%?D'_
M ,/?OC'_ -"UX&_\ +S_ .2Z/^'OWQC_ .A:\#?^ %Y_\ET?ZCYQ_+'_ ,"#
MZ]1/U\HK\@_^'OWQC_Z%KP-_X 7G_P ET?\ #W[XQ_\ 0M>!O_ "\_\ DNC_
M %'SC^6/_@0?7J)^OE%?D'_P]^^,?_0M>!O_   O/_DNC_A[]\8_^A:\#?\
M@!>?_)='^H^<?RQ_\"#Z]1/U\HK\@_\ A[]\8_\ H6O W_@!>?\ R71_P]^^
M,?\ T+7@;_P O/\ Y+H_U'SC^6/_ ($'UZB?KY17Y!_\/?OC'_T+7@;_ , +
MS_Y+H_X>_?&/_H6O W_@!>?_ "71_J/G'\L?_ @^O43]?**_(/\ X>_?&/\
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M?OC'_P!"UX&_\ +S_P"2Z/\ 4?./Y8_^!!]>HGZ^45^0?_#W[XQ_]"UX&_\
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M_J#?^37_ -A1_P +I_Z@W_DU_P#84?V5C/Y/Q7^8>UAW/3J*\Q_X73_U!O\
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M@W_DU_\ 84?V5C/Y/Q7^8>UAW/3J*\Q_X73_ -0;_P FO_L*/^%T_P#4&_\
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M"C_A=/\ U!O_ ":_^PH_LK&?R?BO\P]K#N>G45YC_P +I_Z@W_DU_P#84?\
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M7_V%']E8S^3\5_F'M8=STZBO,?\ A=/_ %!O_)K_ .PH_P"%T_\ 4&_\FO\
M["C^RL9_)^*_S#VL.YZ=17F/_"Z?^H-_Y-?_ &%'_"Z?^H-_Y-?_ &%']E8S
M^3\5_F'M8=STZBO,?^%T_P#4&_\ )K_["C_A=/\ U!O_ ":_^PH_LK&?R?BO
M\P]K#N>G45YC_P +I_Z@W_DU_P#84?\ "Z?^H-_Y-?\ V%']E8S^3\5_F'M8
M=STZBO,?^%T_]0;_ ,FO_L*/^%T_]0;_ ,FO_L*/[*QG\GXK_,/:P[GIU%>8
M_P#"Z?\ J#?^37_V%'_"Z?\ J#?^37_V%']E8S^3\5_F'M8=STZBO,?^%T_]
M0;_R:_\ L*/^%T_]0;_R:_\ L*/[*QG\GXK_ ##VL.YZ=17F/_"Z?^H-_P"3
M7_V%'_"Z?^H-_P"37_V%']E8S^3\5_F'M8=RE\&?^1\^)7_82'_HVXKUNO!/
M!GBS_A$=>\2ZE]E^U_VS<_:/*\S9Y/SR-C.#N_UG7 Z>]=;_ ,+I_P"H-_Y-
M?_85TXC+<74J.48::=5V7F1&I!+5GIU%>8_\+I_Z@W_DU_\ 84?\+I_Z@W_D
MU_\ 85S?V5C/Y/Q7^9?M8=STZBO,?^%T_P#4&_\ )K_["C_A=/\ U!O_ ":_
M^PH_LK&?R?BO\P]K#N>G45YC_P +I_Z@W_DU_P#84?\ "Z?^H-_Y-?\ V%']
ME8S^3\5_F'M8=STZBO,?^%T_]0;_ ,FO_L*/^%T_]0;_ ,FO_L*/[*QG\GXK
M_,/:P[GIU%>8_P#"Z?\ J#?^37_V%'_"Z?\ J#?^37_V%']E8S^3\5_F'M8=
MSTZBO,?^%T_]0;_R:_\ L*/^%T_]0;_R:_\ L*/[*QG\GXK_ ##VL.YZ=17F
M/_"Z?^H-_P"37_V%'_"Z?^H-_P"37_V%']E8S^3\5_F'M8=STZBO,?\ A=/_
M %!O_)K_ .PH_P"%T_\ 4&_\FO\ ["C^RL9_)^*_S#VL.YZ=17F/_"Z?^H-_
MY-?_ &%'_"Z?^H-_Y-?_ &%']E8S^3\5_F'M8=STZBO,?^%T_P#4&_\ )K_[
M"C_A=/\ U!O_ ":_^PH_LK&?R?BO\P]K#N>G45YC_P +I_Z@W_DU_P#84?\
M"Z?^H-_Y-?\ V%']E8S^3\5_F'M8=STZBO,?^%T_]0;_ ,FO_L*/^%T_]0;_
M ,FO_L*/[*QG\GXK_,/:P[GIU%>8_P#"Z?\ J#?^37_V%'_"Z?\ J#?^37_V
M%']E8S^3\5_F'M8=STZBO,?^%T_]0;_R:_\ L*/^%T_]0;_R:_\ L*/[*QG\
MGXK_ ##VL.YZ=17F/_"Z?^H-_P"37_V%'_"Z?^H-_P"37_V%']E8S^3\5_F'
MM8=STZBO,?\ A=/_ %!O_)K_ .PH_P"%T_\ 4&_\FO\ ["C^RL9_)^*_S#VL
M.YZ=17F/_"Z?^H-_Y-?_ &%'_"Z?^H-_Y-?_ &%']E8S^3\5_F'M8=STZBO,
M?^%T_P#4&_\ )K_["C_A=/\ U!O_ ":_^PH_LK&?R?BO\P]K#N>G45YC_P +
MI_Z@W_DU_P#84?\ "Z?^H-_Y-?\ V%']E8S^3\5_F'M8=STZBO,?^%T_]0;_
M ,FO_L*/^%T_]0;_ ,FO_L*/[*QG\GXK_,/:P[GIU%>8_P#"Z?\ J#?^37_V
M%'_"Z?\ J#?^37_V%']E8S^3\5_F'M8=STZBO,?^%T_]0;_R:_\ L*/^%T_]
M0;_R:_\ L*/[*QG\GXK_ ##VL.YZ=6!X_P#^1#\2?]@VY_\ 135R'_"Z?^H-
M_P"37_V%4/$'Q4_MS0=2TW^R_(^V6TEOYOVC=LWH5SC:,XSTS5PRO&*2;A^*
M_P Q.K"VYT'P+_Y)7HG_ &W_ /1\E=[7B?@7X@?\(5X5L=&^P?;/LV_]_P"=
MY>[=(S_=VG&-V.O:M[_A=/\ U!O_ ":_^PJZV68N564E#1M]5_F*-2"2U/3J
M*\Q_X73_ -0;_P FO_L*/^%T_P#4&_\ )K_["L?[*QG\GXK_ #*]K#N>G45Y
MC_PNG_J#?^37_P!A1_PNG_J#?^37_P!A1_96,_D_%?YA[6'<].HKS'_A=/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGY7"_P >:W[:W['WQ&_:6^-'AKXA_#74-+UCPYJ&F6D5OJ0U-8ELPIDD696
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV7@GP^UB^K1^%VU>%?$CZ&/]+%ED%MI'*C@\\#)4'@XKG7O?5Z5-))W>JO\
M:E:_?RUU^97\S?\ 6AY]\;O".N? GP7-XKT_XY>([KQ38NDC:7K6II);WSM(
MA*1VQ/RX4LVW#\#' YKK=4UK_A)/VI/@MJVU5^W^&;JZVKG WPLV!GGOWKPS
MXL+\%9_A'K%K\(_!TVOZA'$&N/$#6ET(M.C5E:1WEN /G( 4*O\ STX_NGUO
M0)%E^.G[/3HP=&\%.593D$&UZBNV4+4N::?-:HM4HNW+V7X7(OK9>7YGU=7R
M#^SW\)_LG[1GQ17_ (3+Q;-_PCMYIS9FU3<=3WQ2G%[\G[X+C"], FOKZOE[
MX>^-M*^'/[67Q2T3Q$\VF7GBRYTTZ,TD#F*[*1."%< @$F51D\9!!((Q7B8*
M4_95XT]W'_VY7_"YO4M>+9S'[/G@_P 9_&BW\5ZKJOQ2\6:=8:5XBGM+"UL-
M08'<A1W\TL"7CVNBJF<##?0^B_ _Q5KNI_&GX]6<]_>:M!I=Y9C3M/NKMS##
ME;@E(PQ(C#%5S@=AZ53_ &&_^1%\=_\ 8Y7_ /Z*MZQ/A3)J\/Q0_:C?P^ =
M>5K=M/RH8?:1#=^5P>#\^W@\5Z6(?M)XB#M9)6TM;WHF4=%%_P!;,NVOPC\=
M>*?#=UXF^)WQ6\0> ]8N)&,>FZ+JL=G8Z>@)"JY0[9"54'(8=>23FN0TGXC:
MOX__ &.?BK!KNLIXAU#1+JYTU=40#_2H5,31RY'!SN;!!/ 'UKD/AKJ'P6G\
M,K+XYT/Q!XQ^+DA=[W2;^TO;B^GG+':B*!Y84[@1N.>>><"E^',<UK^R_P#M
M!VUUI\>CWD.K3K-ID17;:-\@,0 XPI!48X^7BNWV35^=?#*-O=45O;W=VUY^
MG4B_;LSTKXN_$36?!_PM^"FCVGB!_!N@Z]:6\&J^)(8F>6T1+>%D1"/NE\O\
MW;9U W9Z?X7^&-7L_&VEZAX%^,K?$#P9\_\ :^FZ]JJZC<IE5"F.1%)4C.[:
M=F" .=QQ%XH\;ZGX'^%_PPN=1\)VOBKX<7&DVL.OC[$;NXM<VRB-Q&6VE"6&
M25. ".K+7DG]F^ ?&GQK\!WGP!L[ZVU&WU!9M:U+3K>>WL;>S##S5=9@HW%2
M1M  8$+R2*Y:</:4G&UE[UW9..[^+K%]OE8MNSOZ'W37S1\.?%NN7WQ"_:1M
MKG6=0N+?2?)_L^&6ZD9+/,5T3Y()Q'RJGY<?='I7TO7RE\+O^2E_M3?]L/\
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MWX;7M0\$3_'+QTO[0#ZK(8[\Q>&K>XBNFL&L\G9Y2VZ\OM9,D\98_P 6:M?
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M9\$_L=ZW\+O _CJZ\8^)+KQ';ZO/?7&CSV,=T FT^2KJ=D:*J#$C;F8N0,$
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MWQ?^*WPV^'G[/:_!;X4:Q=>-8-6U"/6/$'BR\LI;))I$ $<,%O)\RX**23P
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M445](<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M93V)']W^=>N !0 !@4 !0 !@"EKX7%XNIBZG//Y+L=T(*"L@HHHKB+"BBB@
MHHHH S]:\.Z5XDMOL^K:99ZI;_\ /*]MTF3GV8$5P]Q^S3\(;J0R3?"KP3,_
M]Z3P[9L?S,=>D45O3Q%:DK4YM>C:)<4]T>9_\,P_!S_HDW@;_P )NS_^-4?\
M,P_!S_HDW@;_ ,)NS_\ C5>F45M]=Q7_ #]E][%R1['F?_#,/P<_Z)-X&_\
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M#?\ A-V?_P :KTRBCZ[BO^?LOO8<D>QYG_PS#\'/^B3>!O\ PF[/_P"-4?\
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MG_1)O W_ (3=G_\ &J],HH^NXK_G[+[V')'L>9_\,P_!S_HDW@;_ ,)NS_\
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M9_\ QJO3**/KN*_Y^R^]AR1['F?_  S#\'/^B3>!O_";L_\ XU1_PS#\'/\
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M!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F44?7<5_S]E][#DCV/,_\
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MCS/_ (9A^#G_ $2;P-_X3=G_ /&J/^&8?@Y_T2;P-_X3=G_\:KTRBCZ[BO\
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ML?\ P&3_  K%\;^']+M/!>OSP:;9PS1:?<.DD<"*R,(V((('!![UUU8'C_\
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M*NJ<DZ,$GKK^A"^)A1117*6%%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mnlk-20231231_g2.jpg
<TEXT>
begin 644 mnlk-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3B"<0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM\ MQ "<;A@D2)G^)3QE=P4D"HJX6K15Y+0<:D9;'KU%%%<AH%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD9(R,_(TW_!5ZQ6^1(OAK</9%@&F?6E60+GDA/(()QSC<.>,]Z*>'JU5>$=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?/G[??_ ":5X[_[</\ TOMZ^6/^"5?_
M "4;QO\ ]@F+_P!'"OJ?]OO_ )-*\=_]N'_I?;U^5_PJ^"?C3XVZE?6'@O1O
M[9N[*(3W$?VJ"#8A;:#F5U!Y]*]K"Q4\+*+=E??[CEJ.U1-'[IU^*?[/G_)U
M7@C_ +&>#_T>*Z3_ (8$^//_ $(G_E8L/_C]<A^S+!):_M*?#N&5=LL?B"U1
MESG!$H!%;4*,*4)\L^:Z(G)R:NK'Z/?MY?&6]^#OPVT6>V\/>'O$T&J:C]EN
M+'Q+9-=VY41LX(0.HSD=\TW]@KXPW?Q=^&NMRS^&_#OA:WTS4C;6]AX9L39V
MP#1J[,8R[#<68\C%<!_P51_Y)3X._P"PT?\ T1)1_P $KO\ DE/C'_L-#_T1
M'7%R1^I\UM;_ *FUW[6Q\0?%"SU#X6_M)Z\WB2P_M>[TOQ&U]<VMXS 7\?G^
M<"S')VRH5;)YP^:_235?!_PK_;Z^$.E:A:NUG)9LJ17%JJ)>Z5(,;[=A@C:1
MV.5(VLO8U:_:Y_9&TK]HC0#J6FB'3/'-C$19W[#"7*CD03$=5_NMU4GN"0?S
M1\#^./B%^R?\4VGB@N] URQ<1WVDWZ,L5U%UV2IT=&!RK#U#*>AKK36*@I0=
MIQ,OX;:>S/V/^&?PQ\.?"'P?9^&O"VGIIVEVV6P#NDED/WI)&/+.<#)/H ,
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M/[1'AV6_\.SO;W]J%%]I5U@3VS$9S@'YD)R XX.#T.17R;_P5C_YI9_W%?\
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MX=^+]2;4[_P[J2W.ESRVL<,AT^89C1O*15.U?*.2 3YIZ@87Z KY5DD'A/\
MX*.Q)$ZL/$_@K=,K?+M9)6P1C[QQ:#KV9O2OJJG62NFNJ01[!1117.6%%%%
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M^"HVLZK8_!GP[8VH*:5?:RJWLBYY9(G:*,G.,$AFQCK&.F.?AG_FZS_N=?\
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MS:?^SK8V\98)?:_;6\N#C*B&>7GU^:-:\\_X)3:#9C1_B!K1@B:_:>ULUG*
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M2W#F1[_XMU__ (17PKK.M_8KC4?[-LIKS['9KNFG\N-G\N,=V;;@#U(KS?\
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MZ:Y!?0SW7DNH99C9A0PC(YW[MN".>0*^G+6X6[MHIT$BI*@=1+&T;@$9&58
MJ?8@$=Z4J<J;3D@34MCSO]G/XD:G\7O@KX8\7ZQ!:6VI:I#))-%8HR0J5F=!
MM#,Q'"CJ3SFJEI\<_P#C(N^^%.H:(;"3^R%UC3=5^U;Q>ID*Z>7L&PAA)C#,
M"(R>#Q7/_L/_ /)JW@#_ *]I_P#TIEKB?VFXE\)_M1?L\^,(0$EN-2N-!GDP
M&)6<+'&H'_;>;GMD&ME"+JSA;O;Y$W?*F?55%%%<AH%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\^?M]_\FE>._P#MP_\
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M3=?$9 TATE4L25)^03$S8('KM!SCT7/:O-O^"CGP8O/ _P 8G\9V]N?[!\4
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M-?6->9_'+X$Z5\;M'TY)[ZZT+Q#H]Q]KT?7]/.+FPFRI)7D95MJY7(SM!R"
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M.AXZ9UC4A'W;[)KYLFSW\S@O#MC!=_\ !2/Q1+-$))+7P6DT+'^!S);(2/\
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M600<@@X((((!!%.OO^"8.D:9JEGIEY\:+&TU*]S]ELY]&1)I\==B&[RWX"O
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MNM1;6?$NL73:EK6I8PLURPY$8P,(O.,\DDGC.T<UO9TY*76VGZFGQ25CRO\
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M?^A15]>5\M?MN>#M?\6:S\'7T30]2UE+'Q/'<7;:?:23BWC#1Y>0H#L7@\G
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MWD+0S1-O8X9& *GV(K!/]PUY_H7]L\J_X*(31:3X#^'.MHGEW^G^-;%H;R(
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MRZ].F0-L<&V16Y([03'K_#T;.*5"3E5YGYO\ EI&Q]5T445RF@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!Y/\2?@+'XX^+GP_P#B'8:R=#UK
MPM*ZR_Z,9A?6K\/ ?WB[#M:4!AG_ %ARK<"O6***IR<DD^@K!1114C"BBB@
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M@#/) KQ+]DOX1^(OA]X;\1>(O',2Q>/_ !=J4FI:NBRQR"+#.(HPR$KM 9B
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MIE%'M)]V'+'L>9_\,P_!S_HDW@;_ ,)NS_\ C5'_  S#\'/^B3>!O_";L_\
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M%EX^5NF?NDGBNSTO4H=8TNSO[?=Y%U"D\>]=K;64,,CL<&CVD^[#ECV//?\
MAF'X.?\ 1)O W_A-V?\ \:H_X9A^#G_1)O W_A-V?_QJO3**/:3[L.6/8\S_
M .&8?@Y_T2;P-_X3=G_\:H_X9A^#G_1)O W_ (3=G_\ &J],HH]I/NPY8]CS
M/_AF'X.?]$F\#?\ A-V?_P :H_X9A^#G_1)O W_A-V?_ ,:KI_ 7CW3_ (B:
M//J6FPW,$$-U):,MTJJV]" 2-K$8Y]:Z6CVD^[#ECV/,_P#AF'X.?]$F\#?^
M$W9__&J/^&8?@Y_T2;P-_P"$W9__ !JO3**/:3[L.6/8\S_X9A^#G_1)O W_
M (3=G_\ &J/^&8?@Y_T2;P-_X3=G_P#&J],HH]I/NPY8]CS/_AF'X.?]$F\#
M?^$W9_\ QJC_ (9A^#G_ $2;P-_X3=G_ /&JZ3X@_$+3OAOI-IJ.IPW4\-S=
MQV2+:(K,'<$@G<R\?*>_X5U%'M)]V'+'L>9_\,P_!S_HDW@;_P )NS_^-4?\
M,P_!S_HDW@;_ ,)NS_\ C5>F44>TGW8<L>QYG_PS#\'/^B3>!O\ PF[/_P"-
M4?\ #,/P<_Z)-X&_\)NS_P#C5=)J7Q"T[2_'VD>$98;IM2U.WDN89413"JH&
M)#'=D'Y3T!KJ*/:3[L.6/8\S_P"&8?@Y_P!$F\#?^$W9_P#QJC_AF'X.?]$F
M\#?^$W9__&J],HH]I/NPY8]CS/\ X9A^#G_1)O W_A-V?_QJC_AF'X.?]$F\
M#?\ A-V?_P :KTRBCVD^[#ECV/,_^&8?@Y_T2;P-_P"$W9__ !JC_AF'X.?]
M$F\#?^$W9_\ QJO3**/:3[L.6/8\S_X9A^#G_1)O W_A-V?_ ,:H_P"&8?@Y
M_P!$F\#?^$W9_P#QJO3**/:3[L.6/8\S_P"&8?@Y_P!$F\#?^$W9_P#QJC_A
MF'X.?]$F\#?^$W9__&J],HH]I/NPY8]CS/\ X9A^#G_1)O W_A-V?_QJC_AF
M'X.?]$F\#?\ A-V?_P :KTRBCVD^[#ECV/,_^&8?@Y_T2;P-_P"$W9__ !JC
M_AF'X.?]$F\#?^$W9_\ QJNA^)7Q'T_X7>'DUC4[2^O+9KA+?9I\2R.K,"03
MN90!\N,YZD#O71Z?>IJ6GVUW$&6*XB651(,, P!&1V/-'M)]V'+'L>=_\,P_
M!S_HDW@;_P )NS_^-4?\,P_!S_HDW@;_ ,)NS_\ C5>F44>TGW8<L>QYG_PS
M#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F44>TGW8<L>QYG
M_P ,P_!S_HDW@;_PF[/_ .-4?\,P_!S_ *)-X&_\)NS_ /C5>F44>TGW8<L>
MQYG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F44>TGW8
M<L>QYG_PS#\'/^B3>!O_  F[/_XU1_PS#\'/^B3>!O\ PF[/_P"-5Z911[2?
M=ARQ['F?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z911
M[2?=ARQ['F?_  S#\'/^B3>!O_";L_\ XU1_PS#\'/\ HDW@;_PF[/\ ^-5Z
M911[2?=ARQ['F?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^
M-5Z911[2?=ARQ['F?_#,/P<_Z)-X&_\ ";L__C5'_#,/P<_Z)-X&_P#";L__
M (U7IE<_X0\;6/C3^V_L,5Q%_9.ISZ5/]H51NEBV[F7#'*G<,$X/L*/:3[L.
M6/8Y/_AF'X.?]$F\#?\ A-V?_P :H_X9A^#G_1)O W_A-V?_ ,:KTRBCVD^[
M#ECV/,_^&8?@Y_T2;P-_X3=G_P#&J/\ AF'X.?\ 1)O W_A-V?\ \:KTRN-T
M+XI:;K_Q UGP?#8ZE!J6EQ>=--<0!('7*@%&W9.=X(R!D D4>TGW8<L>QB_\
M,P_!S_HDW@;_ ,)NS_\ C5'_  S#\'/^B3>!O_";L_\ XU7IE%'M)]V'+'L>
M9_\ #,/P<_Z)-X&_\)NS_P#C5'_#,/P<_P"B3>!O_";L_P#XU7IE%'M)]V'+
M'L>9_P##,/P<_P"B3>!O_";L_P#XU1_PS#\'/^B3>!O_  F[/_XU7IE%'M)]
MV'+'L>9_\,P_!S_HDW@;_P )NS_^-4?\,P_!S_HDW@;_ ,)NS_\ C5>F44>T
MGW8<L>QYG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F4
M4>TGW8<L>QYG_P ,P_!S_HDW@;_PF[/_ .-4?\,P_!S_ *)-X&_\)NS_ /C5
M>F44>TGW8<L>QYG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L_
M_C5>F44>TGW8<L>QYG_PS#\'/^B3>!O_  F[/_XU1_PS#\'/^B3>!O\ PF[/
M_P"-5Z911[2?=ARQ['F?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_P
MF[/_ .-5Z911[2?=ARQ['F?_  S#\'/^B3>!O_";L_\ XU1_PS#\'/\ HDW@
M;_PF[/\ ^-5Z911[2?=ARQ['F?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_H
MDW@;_P )NS_^-5Z911[2?=ARQ['F?_#,/P<_Z)-X&_\ ";L__C5'_#,/P<_Z
M)-X&_P#";L__ (U7IE%'M)]V'+'L>9_\,P_!S_HDW@;_ ,)NS_\ C5'_  S#
M\'/^B3>!O_";L_\ XU7IE%'M)]V'+'L>9_\ #,/P<_Z)-X&_\)NS_P#C5'_#
M,/P<_P"B3>!O_";L_P#XU7IE%'M)]V'+'L>9_P##,/P<_P"B3>!O_";L_P#X
MU1_PS#\'/^B3>!O_  F[/_XU7IE%'M)]V'+'L>9_\,P_!S_HDW@;_P )NS_^
M-4?\,P_!S_HDW@;_ ,)NS_\ C5>F44>TGW8<L>QYG_PS#\'/^B3>!O\ PF[/
M_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F44>TGW8<L>QYG_P ,P_!S_HDW@;_P
MF[/_ .-4?\,P_!S_ *)-X&_\)NS_ /C5>F44>TGW8<L>QYG_ ,,P_!S_ *)-
MX&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F44>TGW8<L>QYG_PS#\'/^B3
M>!O_  F[/_XU1_PS#\'/^B3>!O\ PF[/_P"-5Z911[2?=ARQ['F?_#,/P<_Z
M)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z911[2?=ARQ['F?_  S#
M\'/^B3>!O_";L_\ XU1_PS#\'/\ HDW@;_PF[/\ ^-5Z911[2?=ARQ['F?\
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M /C5>F44>TGW8<L>QYG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\
M";L__C5>F44>TGW8<L>QYG_PS#\'/^B3>!O_  F[/_XU1_PS#\'/^B3>!O\
MPF[/_P"-5Z911[2?=ARQ['F?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW
M@;_PF[/_ .-5Z911[2?=ARQ['F?_  S#\'/^B3>!O_";L_\ XU1_PS#\'/\
MHDW@;_PF[/\ ^-5Z911[2?=ARQ['F?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_
M!S_HDW@;_P )NS_^-5Z911[2?=ARQ['F?_#,/P<_Z)-X&_\ ";L__C5=QX9\
M*Z+X+T6#2/#VD6&A:3;EC#8:9;);P1[F+-MC0!1EB2<#DDFM2BI<I2T;&HI;
M(****D84444 %%%% !1110 4444 %%%% !5#7-!TSQ/I-UI6L:=::MI=TGEW
M%E?0+-#,O]UT8%6'L15^B@#S/_AF'X.?]$F\#?\ A-V?_P :H_X9A^#G_1)O
M W_A-V?_ ,:J&X_:<^&EK<2P2^)=LL;%'7[!<G!!P1_JZZWP9\2/#/Q"@EE\
M/:Q;ZEY7^LC3*2(.Q*, P'N1CKZ5I[2?=D\L>QS'_#,/P<_Z)-X&_P#";L__
M (U1_P ,P_!S_HDW@;_PF[/_ .-5Z911[2?=ARQ['F?_  S#\'/^B3>!O_";
ML_\ XU1_PS#\'/\ HDW@;_PF[/\ ^-5Z911[2?=ARQ['F?\ PS#\'/\ HDW@
M;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^-5Z911[2?=ARQ['F?_#,/P<_Z)-X
M&_\ ";L__C5'_#,/P<_Z)-X&_P#";L__ (U7IE%'M)]V'+'L>9_\,P_!S_HD
MW@;_ ,)NS_\ C5'_  S#\'/^B3>!O_";L_\ XU7IE%'M)]V'+'L>9_\ #,/P
M<_Z)-X&_\)NS_P#C5'_#,/P<_P"B3>!O_";L_P#XU7IE<QX"^(&G?$2RU.ZT
MV&Z@CT^_ETZ472*I,D84DKM8_+\PQG!Z\4>TGW8<L>QS7_#,/P<_Z)-X&_\
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M_P#&J/\ AF'X.?\ 1)O W_A-V?\ \:KTRBCVD^[#ECV/,_\ AF'X.?\ 1)O
MW_A-V?\ \:H_X9A^#G_1)O W_A-V?_QJNE^'/Q T[XG>&(M=TN&Z@M))'C"7
MB*LF5.#PK,,?C73T>TGW8<L>QYG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_
MZ)-X&_\ ";L__C5>F44>TGW8<L>QYG_PS#\'/^B3>!O_  F[/_XU1_PS#\'/
M^B3>!O\ PF[/_P"-5Z911[2?=ARQ['F?_#,/P<_Z)-X&_P#";L__ (U1_P ,
MP_!S_HDW@;_PF[/_ .-5Z911[2?=ARQ['F?_  S#\'/^B3>!O_";L_\ XU1_
MPS#\'/\ HDW@;_PF[/\ ^-5Z911[2?=ARQ['F?\ PS#\'/\ HDW@;_PF[/\
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MJ$$?CGP-?>$]/G9475([N.]MHV8X7S70 (#SZGIQ@YK@O!'A?Q5K/Q8^)O\
M97C%/">IQZGF2%](ANI)K=BQA8-(0P7;C@<<@]Q78^)?ACXZOM O[?7/B[!_
M9$T+1W7VKP[:I'Y9&#EBXQ]<C% &A\>9$FC^&LD;K)&_C+365E.00?,P0?2N
M)_:,U[Q''XX\$P1>%?.LK/7K673KO^T8U_M&;Y#Y.S&8OFRNYN.,UN?$319/
M#?@[X/Z5)J"ZJ;+Q3I,"WJQB,2HJR!3@$_P@=SGK5O\ :%_Y&+X5?]C3:_\
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MS1Q,I+@@<;2<]*7]JA-WPXL7FC>338]8M&O]H.!!N(.[T&XJ/J17KMFT$EI
MUJ8VM613$82"A3'R[<<8QC&* /G>R\=6OCS]H[P+=16UQIU[;Z==P7NG7B%)
M[68)(2C ^Q!![@CH<@>H_$7XMVG@6_L]'M=-N_$/B6^C,MMI-BN79 3EV;!V
MK\K<X/W3]:XOQ3]@_P"&L/!?D;/M_P#9=Q]IVXSCRY=F[WQNZ]L59^&(5?C_
M /$_^TT4:T1:FU8]39[,?+VQQ%GW_&@">Z^.NM^$KFW?QQX!O?#.DS2+&=3@
MOH[Z*(L2 9/+4;1GZGVZ9Z[XA?%#3_ ?AVQU-89-:EU*>*VTZTL&#O=O)RNP
MC.01SD9Z@=Q6[XL@TRY\+ZM'K6P:0;64W;2#(6(*2S=#T )Z=J\9^&_@!_B=
M^S;X1L;O4+G2]1M)6O+#4(/OV\D<THA? (R AZ9'8Y!YH [SP1\3M2U[Q)<>
M'O$7A2\\+:RD'VJ*-IA=0319 +"9%"Y!*@CWQUXJ#QI\8O[#\2'PUX>T"\\6
M^)$5))[.U8116R,/E,LI!"9RO48PV215/P-\0/$MAXT3P/XXM;+^V)+/[79:
MKIK-Y%ZBX#!D(RC\,3T'!P!\N[S7X0^%O&6MZMX[?3O',?A?54UV<:C9C18+
MIW8G*OYCD'8?G"KT&"1UH ]%LOC??Z3K-M8^.?!UYX,@NI!##J3W275F)",J
MKRH J$\^O3G !(W_ (C_ !0'@>]T;2K#2)_$/B'6'=+/3;>18RP499W<Y"*,
MCDCID]%-<3XP^%/C36/#=[9>(_B[;_V-<*L=Q]I\/VL28+#;E]XP=VW&"#G&
M*Z/QG\);[7M!\+2:;K\FG^*_#,0%CJGE_NY7\M4D$B9.%DV#/+8!(^89! -?
MX>?$6X\97&J:=JF@7GAO7--91<V5P?-3:V=KI, %<'#=/0XR*[6O._AK\1M6
MUWQ!K7A7Q1IUMIWB;2%261K%V>VNH7)VR1YY48V\,<\]N0OHE !7A.B_M1-X
MD:XT_2/!FHZMXACFF7[!9S!XUB0X$DDI4;-QXQM/;GD ^[5X9^R:=-/A7Q+]
MG$(U,:U/]KQCS2O'EY[[<;L=L[\<YH V[;XX7VB:Y8:=XZ\(W/@V._.VWU!K
MV.[M=^<!7D0 )GCKZ\X'-:OQ;^,-K\)&T.2]T^2]M=1G>*22&3#Q!5!RJ[3O
M)S@#*_6I/CU)I<?P?\5+J[QK;O8R+$)21NN,9A QU/F!"/ISQFO+/%%C<:AI
MG[/UOJ\:FX-S;--&Z'G;'$P# ]\ 9'KF@#M=8^-/B3PUX1NO$.M> GTFU66W
MCMH;C5$,T_FM@EE6,^65&,AN<G&!S6U\4/C)I_PIUCP_;ZI:/+9:HEVSW,3D
MO$845E58]IWEV=5'*@$Y)Q6%^U3_ ,DFE_Z_[7_T8*/BMIL.J_&[X00S@E%F
MU*<8_O1PQR+_ ./(* *UY\??$'AZT@U;Q)\-]2T3PW(ZH^HF[262 %PNZ2$*
M&09/<C/&,YK1U#XW:CJFI7UOX'\&W7C.TL6:.XU*.[2UMBZ@;DB=@?,(R.G7
MMD<UM_'C_DCOBW_KP?\ I5KX,V$&F_"7P?%;1B*-M*MYBH)/SR1AW//JS,?Q
MH D^&?Q'M/B5HMS=PVD^F7MG<O9WNGW7$MO,O53^?7ZCJ#7.:Y\;+B7Q->>'
M_!OA:[\8ZCI\ABOI([A;6VMW&?D,K@C=\K#!QRN.36-\-?M:_$#XT)IVT7GV
MJ%K=6QM\TPR8)SQRV,U>_97%DOP;TT6R;+M;BX%^ISO^T"0YWY[[-GX8H R?
M$?[3%WX)TN]/B;P/?Z'K$:AK2UFN0]O>$2*KJEPJ$;E5M_W2,#KR,]'\1OCE
M;?#EO"C76D37D6NP3R#[/)F2-TC1DC5-OSEVD5<Y&.O/2L[]K#^S_P#A2NJ_
M;MOG>?!]CSU\[S!T]]GF9]LUF^---35OB5\"H)" JI>3C(SS';PR#]4% &SJ
M'QG\0>&;33M1\3^"#X?TB[U".R:XDU5)I(4<$B5HTC/'&"N<@UZM//':PR33
M2+##&I=Y)&"JJ@9))/0 5D>-O"EKXY\)ZKH-X2L%] T1D R8VZJX&1DJP#8]
MJ^?[SXBZEXD^%.D_#QIA9^-;V_/AB^ (;RDB*K+*?F)93$5RPX)+X[4 >V?"
M[QY+\2/#)UMM+;2[:2XDCM5>0N9X5( EY5<;CNXYZ=:Z+6M:L?#NDW6IZE<I
M9V%K&99II.BJ/YGT Y)X%)H>BVGAS1K+2["(0V=G"L$2#LJC S[^I]:\H_:J
M1F^'.G/)&TFF1ZS:-J. <"WRP.<=!N*#\10 ZS^.'BKQ%:R:EX;^&.H:KH0!
M>*]N-0CM7F0$_,D3*2V0.,$YSBI?"O[1%KXL\?:3X4CT&\T^^N(IC>I?MY4U
ME+&A;88]IW @##9'!Z=J]9MO)^SQ?9]GV?8/+\O&W;CC&.,8KQ/Q3]@_X:P\
M%^1L^W_V7<?:=N,X\N79N]\;NO;% %WQ9^T=#X7\>ZUX27P[=:GJEJUO'916
M<NY[QY8A(05V_(J@X)RW;CKBTGQNU;0-<T^S\;>";KPG9:A.MK:ZDM_%=P>:
MQ.U9&0 1Y )ZGIG& 363X'T^"?\ :H^(]Y)&K7%O96:1,0#M#P0[L>A^4?K6
MO^U/"DGP.U^4@^9 ]K)&P)!5OM$:Y_)C^= '?>,O&6D^ ?#]SK6M7(MK*  <
M#+.QZ(H[L?3\3@ FO-XOC-XWNK'^U+;X3:E+I!PRR-J,:W+*0,$6^S>>O;/\
MZA^/:)_PG7PKDU"-7T)=8=;AI1^[$Q">3N/3J'//H?>O:: /+OAS\>+#XF>-
MK[0M.TR>V@M;+[4UQ=/LE5PZHT3Q;?E92QYW'I[UR_@7Q3=^"?!OQ:UVSTP:
MP]AXOU*>2U\_R28QY>]@VUONKENG0&K'A#[!_P -7>,OL.S=_8L?VGR\8\[=
M#GIWQMS[YK9^ T:31_$J.1%DC?QEJ2LK#((/EY!'I0!Z3H.N6?B;1+#5K"3S
M;*]A2>%\8)5AD9'8\\CL:X<_&BRANO&]Q<V31^'?"S+!+JB.S&YN,#?"B; -
MRL0IRW5E['(\VT?QY_PHOP_X_P#"-U,RSZ*&N?#R.0\LT,[$1 9.&V2,NX8Z
M%C@X(KT?P7\'[+3_ (/CPAJZM(^H0M)J4D3;7:>0[F8$$C*G: >0=@XQQ0!1
M\*_&S4]4U;1X==\$:CX>TS6MJZ=J)E%RDCL"56154&+(!(S]3@9(Z72OB,FH
M_$7Q+X7DLEMH]%MH+EKYI\B02*&.5VC:!GKN/X5PF@ZYXM^"^K>'?#/B=H/$
M/AC4+I-+TW6X-R7,,C<11SH>#G&!@\ $DG&*N^"_^3DOB)_UX6'_ *+6@"K;
M_M&7=Y9_V_;^!]3F\$"X,!UY9E+[0Q4R"WV[B@QRV< @CJ,5[/'()HT=0P5@
M&&Y2IY]0>0?8UX1<Z?XF_9JTVZN]+:'Q)\/(9O.DTZX<I>Z>KL=WE,?E=-Q4
MD'DD]!\SGW.QO8=2LK>[MG\RWN(UEC?!&Y6 (.#R.#WH GHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)'</,V,9;R1.ID)QZ1AB?H:^BOATVGMX"\/'2UC73S80F%8L8"[!Q]<]??-
M&#\._C#8^.-2NM%O=.NO#?B:T4//I&H !]IY#(>-ZX(/0'GIC!.-KOQQU!?$
MFL:7X5\&7WBR/166/4;J"X6$1N2<I&I4F1ACH.<@]N33^+#1P_&KX5R6!0:V
MUQ<1RB-09&M"@W[N/N@;\9Z?.1SFI?$W@#Q3X'\5ZMXP\ SP7HU >=J?A[4"
MVRX=>KPL#\KD= >,D]1A0 =]8>/M&O?!,?BQ[AK+16M_M+2WD9C:-1U#+USD
M8P,Y.,9R,^?6OQN\6>(+>74/#OPPU'4]$4%H[RYU".UDF4$_,D3*2V0. "2>
ME<M\<O%P^)7[/F@^(M/CDLM.N]2MWO?,C$OV= TD;[AP& E"CG ;CIFNRMOA
MW\2?L\7V?XNI]GV#R_+\-6FW;CC&&QC% '4_#OXG:;\0H;J**WN=*UBQ8)?:
M3?ILN+=L=2.ZGLW?T'2N)D_:)NKI[_4M'\$ZEK/A#3[AH+G6X)E5@%&7=("-
MSJ.3G(XQG'2KO@KX<ZOH_P 4)==U?Q_;>(]673_LEQ9)ID-K*868,C-Y;\88
M##%>G&<5B:KX=\4? )M9UWPL8==\&/(U_>Z'=NRW%IWD>"3D$8R3N[#H3\U
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M:32)>+'>A(8(U)"MYC)R[;6.P#MP2> GPM_L_P#X:,^*']F[?)\NW\S9T\[
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MS8&21CJ>"=N\^&H^(GPG\$-:ZC-HVN:78VEUIVH1<^5)Y*9#+W4X'N,#MD$
MZ'X?_$B\\5:I?Z-K?AN\\+Z]9H)VM)G\^*2$L5#I,H"MR",?EG!QW5>9_#GX
M@>(;KQ9?>"_&6GVMMXBL[-;^*\TYF-M>6^\(74-RI#$#W.[@8Q7IE !1110
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M]A):):V@?  9HE)#8Q[9[Y&0>J\;?#W_ (3+Q#X3U3[?]C_L&]-YY7D[_/R
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MI[NDCV_FO&KE2&7=M(W#(!P>.!Q0!YY^S/X#'@WX;P7<UN+;4-:?^T)H@?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;XV>#5\0:/#=69CN)+*]T^_C\NXLKF/&^&1<\,,J?HPZ'@=S7S]^QOH.I_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#Y*^"OQHT&#]K/XWZ9KEY!I-YJE_:6FFRW!*17
M/V*$PRQ*[8&]=ROMSSYC$#U]U^+_ ,<O"/P3\/7.H^(M5@BNUB+VNE1N&N[U
MSD)'%&/F.YAMW8VCJ2 ":\/_ &9/AGX6^-7P:\8S^,-#M->L?$7C+5M6"W"8
M='>14+QNN&C;$9&4V'&1WY]7^'W[*/PF^%NL)JWAOP58VFI1G=%=7,DMW)"W
M'S1F9WV-QU7!Z^IKMJ^RY_>OII]QE'FMH8_[+GPKN/#OP%MM+\8:3$UWK=S<
M:M?Z/?P*Z0F>7S%B=&SDJ A(89!R" 16?=?LHCP/>S:M\'O%=_\ #O4'.Z32
MGS>Z/<X5AA[=SE22WWU;Y>2%)KZ!HK#VT^9R[E\JM8\$DU?XE?$+P;XZ^'?C
M;P-'I6MWOAN]BM=>T2[\W2;]Y$:'8K28>!R74JC[B5#$D8P9_P!E3XI>%=6_
M9M\+W,>JV&GQ>'-)@L-86XF6$6,L,81S-NQLW%"^6X(.<GK7NE>1^*OV3?A'
MXV\72>)M:\$6-YK,LOGRS"26-)I.[21(X1R<9.Y3DY)SDU:G"2<9*WH*S3NC
M@?@3<Q_%CXT^//CA.%A\)0V@\.^&KV[S&);2!RUU<C=PL;2J=K<'!<':0V?7
M?#_CKPO\?/ASK-QX/UJ'5],NH[G3&N8U>/RY=FUE8.H92 ZGE>0P(R",]C9Z
M/8:=I<>FVEC;6NG1Q^4EG#"J0JG3:$ P![8KG?AG\)_"GP=T&XT7P?I":+ID
M]T][);I-)*&F955FS(S'HBC&<# P*F4XRUZJUO0$FCR3]BOQUH/_  SSI.C3
M7]GIVK>%([BSUNQGF1'L7BFD+O)DX"$?-O\ N\GG(.,[X3WD7Q[_ &F-=^)]
MDHN?!OA?3V\.:%>$,JW5RS[KBXC[,H#-'NS@AEXSDCT+QW^RI\*/B7XD?Q!X
MC\&6=_K$AS+=)-- 93M"YD$;J'. .6!(Q7I>C:+I_AW2[?3=)L+72].MEV06
M=G"L,,2]<*B@!1[ 5<JD/>E'=_@)1>B?0^=OV'=>TCP]\*+WX>SW-M9^)O!F
MI:A::K9R2J)0!=2,)CTW)M8+O&1\O7M5?POJ%M^T9^U7#XMTAX]3\!?#JRFL
M++4XR7@N]6N /-,+ [75(BH+?W@A&0RL/3?B1^S%\+_BWKR:UXK\(VNIZLJJ
MINUFF@DD"\*',3KOP./FSP .@%=[X:\+Z/X-T>#2="TRTTC38!B.ULH5BC7W
MP!U]^IIRJ1NYQW?X7W!1>B>R/G[]CG5M+\+M\0OAS=74%KXHT?Q5?S/8O(/-
MN+>5E>*X48&Y2OIR,#(&152YUFQ_:0_:D\-#0I8=6\%?#9);V]U&%BUO<:G,
MH6&..125<Q;5?C !# YX%>K?$S]G#X;?&'5+?4O%_A2UU?4(%5$NO,E@E*KD
MJK-&REE&X_*V1S77^#?!.@?#WP_;:)X:TBTT72K<82ULX@BYP 6;NS' RS98
MGDDFAU(W<U\3_IARO;H87QR\1?\ ")_!?QUK .)+/1+R6/J,R"%M@R.1EL#/
M;-8W[+NCOH/[.OPYM)$V/_8=K.R\\&2,28.>0?GY'8YKM_&7@_2/B!X7U'P[
MK]I]OT?4(_)N;;S7C\Q<@XW(0PY Z$5HZ;IUOH^FVEA9Q^3:6L200Q[BVU%4
M*HR22< #K6',N3E\RK:W+-%%%9E!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%>9?&_P#:0^'W[.^DV][XWUY-->ZW
M?9+**-IKFYVD!MD:@G R,L< 9ZUX)X/_ ."K7P/\4:LEE??\))X6B;@7NL:<
MAASS@'[/+*P],E<<\G&2-XT*LX\T8MHS=2$79L^R**@L;^VU2QM[VRN(KRSN
M8UF@N('#QRQL 5=6'#*0001P0:\5^/7[9WPK_9UNCI_BG76GU[R_-&AZ5%]I
MN\;0PW $+$6!&WS&7.<C@$C.,)3?+%793DHJ[9[C17RU\(?^"D7P:^,'B:TT
M"WO=4\,ZG>$1VR>(;:.!)I"P58Q(DCJ&.1@$C/3.>*^I:<Z<Z;M-6",HR5XL
M****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV3D,&!YS6'^V%K6@:%^S%\29_$D=M/I\FB7,$<%T5 EN'0K JYZ/YI0J1R"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_H>_$W_@WN/_ (NC_A=/Q"_Z'OQ-_P"#>X_^+H_L:I_.@_M*'\I^L%%?D_\
M\+I^(7_0]^)O_!O<?_%U]"?L1?$+Q3XL^*VJVFN>)=8UFT31995@U"_EG17$
M\ #!78@'#$9]SZUA6RN=&FZCDM#2GCHU)J"CN?;E%%%>(>F%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?-'[?O\ R1W1O^P]#_Z3
MW%?2]?-'[?O_ "1W1O\ L/0_^D]Q7=@?]YAZG+BOX,CX#HHHK[\^4"BBB@ H
MHHH **** "BBB@ HHHH *]E_8]_Y.+\)?]O?_I)-7C5>R_L>_P#)Q?A+_M[_
M /22:N;%?[O4]'^1M0_BP]5^9^EU%%%?G9]>%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5\;?\ !1+_ )I__P!Q#_VVK[)KXV_X*)?\
MT_\ ^XA_[;5Z>6_[W#Y_DSBQO\"7R_,^-:***^Z/EPHHHH **** "BBB@ HH
MHH *^E_V O\ DL6L_P#8!F_]*+>OFBOI?]@+_DL6L_\ 8!F_]*+>N''?[M/T
M.K"_QHGWY1117P!]6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?-'[?O_)'=&_[#T/\ Z3W%?2]?-'[?O_)'=&_[#T/_ *3W%=V!
M_P!YAZG+BOX,CX#HHHK[\^4"BBB@ HHHH **** "BBB@ HHHH *]E_8]_P"3
MB_"7_;W_ .DDU>-5[+^Q[_R<7X2_[>__ $DFKFQ7^[U/1_D;4/XL/5?F?I=1
M117YV?7A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&W_!1+_FG_\ W$/_
M &VK[)KXV_X*)?\ -/\ _N(?^VU>GEO^]P^?Y,XL;_ E\OS/C6BBBONCY<**
M** "BBB@ HHHH **** "OI?]@+_DL6L_]@&;_P!*+>OFBOI?]@+_ )+%K/\
MV 9O_2BWKAQW^[3]#JPO\:)]^4445\ ?5A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MQM_P42_YI_\ ]Q#_ -MJ^R:^-O\ @HE_S3__ +B'_MM7IY;_ +W#Y_DSBQO\
M"7R_,^-:***^Z/EPHHHH **** "BBB@ HHHH *^E_P!@+_DL6L_]@&;_ -*+
M>OFBOI?]@+_DL6L_]@&;_P!*+>N''?[M/T.K"_QHGWY1117P!]6%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-'[?O\ R1W1O^P]
M#_Z3W%?2]?-'[?O_ "1W1O\ L/0_^D]Q7=@?]YAZG+BOX,CX#HHHK[\^4"BB
MB@ HHHH **** "BBB@ HHHH *]E_8]_Y.+\)?]O?_I)-7C5>R_L>_P#)Q?A+
M_M[_ /22:N;%?[O4]'^1M0_BP]5^9^EU%%%?G9]>%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5XU7LO['O_)Q?A+_ +>__22:N;%?[O4]'^1M0_BP]5^9^EU%%%?G9]>%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5\;?\ !1+_ )I__P!Q#_VVK[)KXV_X
M*)?\T_\ ^XA_[;5Z>6_[W#Y_DSBQO\"7R_,^-:***^Z/EPHHHH **** "BBB
M@ HHHH *^E_V O\ DL6L_P#8!F_]*+>OFBOI?]@+_DL6L_\ 8!F_]*+>N''?
M[M/T.K"_QHGWY1117P!]6%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?-'[?O_)'=&_[#T/\ Z3W%?2]?-'[?O_)'=&_[#T/_ *3W
M%=V!_P!YAZG+BOX,CX#HHHK[\^4"BBB@ HHHH **** "BBB@ HHHH *]E_8]
M_P"3B_"7_;W_ .DDU>-5[+^Q[_R<7X2_[>__ $DFKFQ7^[U/1_D;4/XL/5?F
M?I=1117YV?7A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&W_!1+_FG_\
MW$/_ &VK[)KXV_X*)?\ -/\ _N(?^VU>GEO^]P^?Y,XL;_ E\OS/C6BBBONC
MY<**** "BBB@ HHHH **** "OI?]@+_DL6L_]@&;_P!*+>OFBOI?]@+_ )+%
MK/\ V 9O_2BWKAQW^[3]#JPO\:)]^4445\ ?5A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7S1^W[_P D=T;_ +#T/_I/<5]+U\T?
MM^_\D=T;_L/0_P#I/<5W8'_>8>IRXK^#(^ Z***^_/E HHHH **** "BBB@
MHHHH **** "O9?V/?^3B_"7_ &]_^DDU>-5[+^Q[_P G%^$O^WO_ -))JYL5
M_N]3T?Y&U#^+#U7YGZ74445^=GUX4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7QM_P42_YI_\ ]Q#_ -MJ^R:^-O\ @HE_S3__ +B'_MM7IY;_ +W#Y_DS
MBQO\"7R_,^-:***^Z/EPHHHH **** "BBB@ HHHH *^E_P!@+_DL6L_]@&;_
M -*+>OFBOI?]@+_DL6L_]@&;_P!*+>N''?[M/T.K"_QHGWY1117P!]6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-'[?O\ R1W1
MO^P]#_Z3W%?2]?-'[?O_ "1W1O\ L/0_^D]Q7=@?]YAZG+BOX,CX#HHHK[\^
M4"BBB@ HHHH **** "BBB@ HHHH *]E_8]_Y.+\)?]O?_I)-7C5>R_L>_P#)
MQ?A+_M[_ /22:N;%?[O4]'^1M0_BP]5^9^EU%%%?G9]>%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\;?\%$O^:?\ _<0_]MJ^R:^-O^"B7_-/_P#N(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\;?\ !1+_ )I__P!Q#_VVK[)K
MXV_X*)?\T_\ ^XA_[;5Z>6_[W#Y_DSBQO\"7R_,^-:***^Z/EPHHHH ****
M"BBB@ HHHH *^E_V O\ DL6L_P#8!F_]*+>OFBOI?]@+_DL6L_\ 8!F_]*+>
MN''?[M/T.K"_QHGWY1117P!]6%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?-'[?O_)'=&_[#T/\ Z3W%?2]?-'[?O_)'=&_[#T/_
M *3W%=V!_P!YAZG+BOX,CX#HHHK[\^4"BBB@ HHHH **** "BBB@ HHHH *]
ME_8]_P"3B_"7_;W_ .DDU>-5[+^Q[_R<7X2_[>__ $DFKFQ7^[U/1_D;4/XL
M/5?F?I=1117YV?7A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&W_!1+_F
MG_\ W$/_ &VK[)KXV_X*)?\ -/\ _N(?^VU>GEO^]P^?Y,XL;_ E\OS/C6BB
MBONCY<**** "BBB@ HHHH **** "OI?]@+_DL6L_]@&;_P!*+>OFBOI?]@+_
M )+%K/\ V 9O_2BWKAQW^[3]#JPO\:)]^4445\ ?5A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-'[?O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5\;?\%$O^:?\ _<0_]MJ^R:^-O^"B7_-/_P#N
M(?\ MM7IY;_O</G^3.+&_P "7R_,^-:***^Z/EPHHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QM
M_P %$O\ FG__ '$/_;:OLFOC;_@HE_S3_P#[B'_MM7IY;_O</G^3.+&_P)?+
M\SXUHHHK[H^7"BBB@ HHHH **** "BBB@ KZ7_8"_P"2Q:S_ -@&;_THMZ^:
M*^E_V O^2Q:S_P!@&;_THMZX<=_NT_0ZL+_&B??E%%%? 'U84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>2?M,_M'>&_P!F?X:WGB36YHYM2E1XM(TG?B6_N0N50=P@
M)!=\84'N2JG7^.WQV\*_L\?#^\\5^*[SRK>/]W:V<1!N+V<@E88E)Y8XZ]
M22 ":^7?V8_@3K_[17Q /[0WQJLYVN)I?,\(^%;P V^GV@.Z&8H0,XS\@*C)
M!E()92.JE35O:5/A7X^1E.3ORQW.R_8F^!?B6UU#7OCA\4-LGQ)\<*LRVQC
M_LVQ*H8XMI&Z-RJH"FX[42-3\P:NI_;;_:6/[/WPR6UT(?;?B!XD<Z=H.G1
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M[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHK\[/KPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^&?VA_\ E)A\ ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\;?\%$O^:?\ _<0_]MJ^R:^-O^"B7_-/_P#N(?\
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MN1.:@KL^\**HZ'?2:EHNGWDH59;BWCE8(, %E!./;FKU8EA17F'[2/QXT?\
M9Q^$FL>,]6"SRPC[/I]CO"M>WC@^5"#Z'!9B,D(CM@XQ69^R5XG^(OC3X$^'
M]>^*$-M;^)M1#W"QPV_D2?9F/[EI4!VB1E^;"@85E! 8-6GLY<GM.FQ/,N;E
M/8J***S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP#-_Z46]<.._W:?H=6%_C1/ORBBBO@#ZL**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKTCPZ'J,D;,
MDBVTC*RG!!"G!!KQG_A(]6_Z"EY_X$/_ (U[)XB_Y%_5/^O67_T UX57H89)
MIW.6LW=&C_PD>K?]!2\_\"'_ ,:/^$CU;_H*7G_@0_\ C6=179RKL879H_\
M"1ZM_P!!2\_\"'_QH_X2/5O^@I>?^!#_ .-9U%'*NP79H_\ "1ZM_P!!2\_\
M"'_QH_X2/5O^@I>?^!#_ .-9U%'*NP79H_\ "1ZM_P!!2\_\"'_QH_X2/5O^
M@I>?^!#_ .-9U%'*NP79H_\ "1ZM_P!!2\_\"'_QH_X2/5O^@I>?^!#_ .-9
MU%'*NP79H_\ "1ZM_P!!2\_\"'_QKW6OGFOH:N'$I*UCHHO<****X3I"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:/V_?^2.
MZ-_V'H?_ $GN*^EZ^:/V_?\ DCNC?]AZ'_TGN*[L#_O,/4Y<5_!D? =%%%??
MGR@4444 %%%% !1110 4444 %%%% !7LO['O_)Q?A+_M[_\ 22:O&J]E_8]_
MY.+\)?\ ;W_Z235S8K_=ZGH_R-J'\6'JOS/TNHHHK\[/KPHHHH **** "BBB
M@ HHHH K:E>?V?I]U=;/,\B)I=N<9V@G&?PKA?\ A;7_ %"O_)C_ .PKLO$7
M_(OZI_UZR_\ H!KPJNVA3C-/F1SU).+5CT/_ (6U_P!0K_R8_P#L*/\ A;7_
M %"O_)C_ .PKSRBNGV%/L8^TGW/0_P#A;7_4*_\ )C_["C_A;7_4*_\ )C_[
M"O/**/84^P>TGW/0_P#A;7_4*_\ )C_["C_A;7_4*_\ )C_["O/**/84^P>T
MGW/0_P#A;7_4*_\ )C_["C_A;7_4*_\ )C_["O/**/84^P>TGW/0_P#A;7_4
M*_\ )C_["C_A;7_4*_\ )C_["O/**/84^P>TGW/0_P#A;7_4*_\ )C_["C_A
M;7_4*_\ )C_["O/**/84^P>TGW/0_P#A;7_4*_\ )C_["O0Z^>:^AJY,13C"
MW*C>E)RO<****Y#<**** "BBB@ HHHH **** "BBB@ HHHH *^+O^"L__)K=
MK_V,5I_Z*GK[1KXN_P""L_\ R:W:_P#8Q6G_ **GKJPO\>'J8UOX<CZ[\)_\
MBKHW_7E#_P"BUK3FF2WB>65UCB12S.YP% Y))["LSPG_ ,BKHW_7E#_Z+6OE
M/_@IE\5]9\'_  >TKP-X:W'7_']Z=&18I561K?"B5%4]0_F1QD\ "3D\C.=.
MFZM1074N4N2/,SS'0X&_X*+_ +54NMW4?VGX%_#F8P6EO-$PCU>Y;)W<_>#L
MBNP/2)(U*J92:_1"OS[\&?\ !(;PO:^$K:'Q/\0/$4^OQJ9T;13%!96UPRC+
M*DB.S@%4&[<A8(.%X"W_ ($^,OB)^R7^T?H_P'\>Z[+XU\%^)8R_AG7;J1VG
MM0B,$BP2Q5,QB,Q9VH2K*0I8'NK1A6THRORK:W3KZG/!RA\:WZGWK1117EG6
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNOB+_D7]4_Z]9?\ T UX57HX7X6<M;=!11178<P4444 %%%% !1110 4444
M%?0U?/-?0U<.*^R=5'J%%%%<!TA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 5]#5\\U]#5PXK[)U4>H4445P'2%%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !-'_"P- _Y__P#R#)_\37C=%/ZM#NQ>VD>R?\+ T#_G_P#_ "#)_P#$T?\
M"P- _P"?_P#\@R?_ !->-T4?5H=V'MI'LG_"P- _Y_\ _P @R?\ Q-'_  L#
M0/\ G_\ _(,G_P 37C=%'U:'=A[:1[)_PL#0/^?_ /\ (,G_ ,31_P + T#_
M )__ /R#)_\ $UXW11]6AW8>VD>R?\+ T#_G_P#_ "#)_P#$T?\ "P- _P"?
M_P#\@R?_ !->-T4?5H=V'MI'LG_"P- _Y_\ _P @R?\ Q-'_  L#0/\ G_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^-O^"B7_-/_P#N(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\;?\ !1+_ )I__P!Q#_VVK[)KXV_X*)?\T_\ ^XA_[;5Z>6_[W#Y_
MDSBQO\"7R_,^-:***^Z/EPHHHH **** "BBB@ HHHH *^E_V O\ DL6L_P#8
M!F_]*+>OFBOI?]@+_DL6L_\ 8!F_]*+>N''?[M/T.K"_QHGWY1117P!]6%%%
M% !1110 4444 %>:>,/&&KZ7XBN[6UN_*@CV;5\I#C**3R1GJ37I=>-_$#_D
M;K__ +9_^BUKJP\5*;NC&JVHZ!_PL#7_ /G_ /\ R#'_ /$T?\+ U_\ Y_\
M_P @Q_\ Q-<[17H>SAV1R\TNYT7_  L#7_\ G_\ _(,?_P 31_PL#7_^?_\
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MEZ^2_4TE",]S\N?VI/@C\3_V8_AN/$MY^U3X[UW4KJZCLM.T:*:[ADNY6.2
MWV]B%5022%;G:,<U]T_LI^!?%'P_^!WAVQ\:Z_J_B+Q7=1_;M1N-:O9;J:&2
M0 ^0&E^951=J[>S!CWKYFT65OVU?VYKC5(YEOOA5\)62.W"R!H+W4BS8D49(
M8&1&.Y<J4MH^GF<_>U=>)J2Y(TY;[O1?)&-**YG);!1117G'2%%%% !1110
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M3_KZE_\ 0S6=7MQ^%'FO<****H04444 %%%% !1110 4444 %%%% 'LGP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\;?\%$O^:?_ /<0_P#;:OLFOC;_ (*)?\T__P"XA_[;5Z>6_P"]P^?Y,XL;
M_ E\OS/C6BBBONCY<**** "BBB@ HHHH **** "OI?\ 8"_Y+%K/_8!F_P#2
MBWKYHKZ7_8"_Y+%K/_8!F_\ 2BWKAQW^[3]#JPO\:)]^4445\ ?5A1110 44
M44 %%%% !7C?Q _Y&Z__ .V?_HM:]DKQOX@?\C=?_P#;/_T6M=>&^-^AA6^$
MYVBBBO2.,**** "BBB@ HHHH **** "O9/A__P BC8?]M/\ T8U>-U[)\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%<!TA1110 4444 %%%% !1110!X5XB_Y&#5/^OJ7_P!#-9U:/B+_ )&#5/\
MKZE_]#-9U>W'X4>:]PHHHJA!1110 4444 %%%% !1110 4444 >R?#__ )%&
MP_[:?^C&KHJYWX?_ /(HV'_;3_T8U=%7C5/C?J>C'X4%%%%9E!1110 4444
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M5ROA7QQ_PDVH26OV+[-LB,N[S=^<$#&-H]:ZJLI1<79FBDI*Z"BBBI&%%%%
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:/V_?\
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M2.,**** "BBB@ HHHH **** "O9/A_\ \BC8?]M/_1C5XW7LGP__ .11L/\
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M.!D9QG/4=.M?+?@[_@EW\!/#>DI:ZIH.I>*[OJU]J>JW$3D\YPMNT2@<^A.
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M/TNHHHK\[/KPHHHH **** "BBB@ HHHH SO$7_(OZI_UZR_^@&O"J]U\1?\
M(OZI_P!>LO\ Z :\*KT<+\+.6MN@HHHKL.8**** "BBB@ HHHH **** "BBB
M@ KZ&KYYKZ&KAQ7V3JH]0HHHK@.D**** "BBB@ HHHH **** /"O$7_(P:I_
MU]2_^AFLZM'Q%_R,&J?]?4O_ *&:SJ]N/PH\U[A1115""BBB@ HHHH ****
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M $6M=>&^-^AA6^$YVBBBO2.,**** "BBB@ HHHH **** "O9/A__ ,BC8?\
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M0 4444 %%%% !1110 5]#5\\U]#5PXK[)U4>H4445P'2%%%% !1110 4444
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M\)'JW_04O/\ P(?_ !H_X2/5O^@I>?\ @0_^-9U%'*NP79H_\)'JW_04O/\
MP(?_ !H_X2/5O^@I>?\ @0_^-9U%'*NP79H_\)'JW_04O/\ P(?_ !H_X2/5
MO^@I>?\ @0_^-9U%'*NP79H_\)'JW_04O/\ P(?_ !H_X2/5O^@I>?\ @0_^
M-9U%'*NP79ZU\-;VXOM#GDN9Y;B07+*&E<L0-J\9/UKK*XWX5_\ (OW'_7TW
M_H"5V5>15^-G=#X4%%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110
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MNOB+_D7]4_Z]9?\ T UX57HX7X6<M;=!11178<P4444 %%%% !1110 4444
M%%%% !7T-7SS7T-7#BOLG51ZA1117 =(4444 %%%% !1110 4444 >%>(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@N/^O5O_ $-*]4KR\1_$.VE\(4445S&P4444 %%%% !1110!XW\0/^1NO_\
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M_P#H;UZI7E?Q4_Y&"W_Z]5_]#>NG#_&8U?A.-HHHKU#B"BBB@ HHHH ****
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M* "BBB@ HHHH **** /5/A7_ ,B_<?\ 7TW_ * E=E7&_"O_ )%^X_Z^F_\
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MO=?$7_(OZI_UZR_^@&O"J]'"_"SEK;H****[#F"BBB@ HHHH **** "BBB@
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MZM_Z&E>J5Y>(_B';2^$****YC8**** "BBB@ HHHH \;^('_ "-U_P#]L_\
MT6M<[71?$#_D;K__ +9_^BUKG:]JG\"]#SY?$PHHHJR HHHH **** "BBB@
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M\B_JG_7K+_Z :\*KT<+\+.6MN@HHHKL.8**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"OIO\ T!*[*N-^%?\ R+]Q_P!?3?\ H"5V5>16_B,]"'PH****Q+"BBB@
MHHHH **** /GFBBBO=/,"BBB@ HHHH **** "BBB@ HHHH ^AJ***\(],***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *^:/V_?^2.Z-_V'H?\ TGN*^EZ^:/V_?^2.Z-_V'H?_ $GN*[L#_O,/4Y<5
M_!D? =%%%??GR@4444 %%%% !1110 4444 %%%% !7LO['O_ "<7X2_[>_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXV_X*)?\T_\
M^XA_[;5]DU\;?\%$O^:?_P#<0_\ ;:O3RW_>X?/\F<6-_@2^7YGQK1117W1\
MN%%%% !1110 4444 %%%% !7TO\ L!?\EBUG_L S?^E%O7S17TO^P%_R6+6?
M^P#-_P"E%O7#CO\ =I^AU87^-$^_****^ /JPHHHH **** "BBB@ KQOX@?\
MC=?_ /;/_P!%K7LE>-_$#_D;K_\ [9_^BUKKPWQOT,*WPG.T445Z1QA1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFC]OW_DCNC?\
M8>A_])[BOI>OFC]OW_DCNC?]AZ'_ -)[BN[ _P"\P]3EQ7\&1\!T445]^?*!
M1110 4444 %%%% !1110 4444 %>R_L>_P#)Q?A+_M[_ /22:O&J]E_8]_Y.
M+\)?]O?_ *235S8K_=ZGH_R-J'\6'JOS/TNHHHK\[/KPHHHH **** "BBB@
MHHHH SO$7_(OZI_UZR_^@&O"J]U\1?\ (OZI_P!>LO\ Z :\*KT<+\+.6MN@
MHHHKL.8**** "BBB@ HHHH **** "BBB@ KZ&KYYKZ&KAQ7V3JH]0HHHK@.D
M**** "BBB@ HHHH **** /"O$7_(P:I_U]2_^AFLZM'Q%_R,&J?]?4O_ *&:
MSJ]N/PH\U[A1115""BBB@ HHHH **** "BBB@ HHHH ]D^'_ /R*-A_VT_\
M1C5T5<[\/_\ D4;#_MI_Z,:NBKQJGQOU/1C\*"BBBLR@HHHH **** "BBB@
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M +#T/_I/<5]+U\T?M^_\D=T;_L/0_P#I/<5W8'_>8>IRXK^#(^ Z***^_/E
MHHHH **** "BBB@ HHHH **** "O9?V/?^3B_"7_ &]_^DDU>-5[+^Q[_P G
M%^$O^WO_ -))JYL5_N]3T?Y&U#^+#U7YGZ74445^=GUX4444 %%%% !1110
M4444 9WB+_D7]4_Z]9?_ $ UX57NOB+_ )%_5/\ KUE_] ->%5Z.%^%G+6W0
M4445V',%%%% !1110 4444 %%%% !1110 5]#5\\U]#5PXK[)U4>H4445P'2
M%%%% !1110 4444 %%%% 'A7B+_D8-4_Z^I?_0S6=6CXB_Y&#5/^OJ7_ -#-
M9U>W'X4>:]PHHHJA!1110 4444 %%%% !1110 4444 >R?#_ /Y%&P_[:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^-O^"B7_ #3_ /[B
M'_MM7V37QM_P42_YI_\ ]Q#_ -MJ]/+?][A\_P F<6-_@2^7YGQK1117W1\N
M%%%% !1110 4444 %%%% !7TO^P%_P EBUG_ + ,W_I1;U\T5]+_ + 7_)8M
M9_[ ,W_I1;UPX[_=I^AU87^-$^_****^ /JPHHHH **** "BBB@ KQOX@?\
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M117,;!1110 4444 %%%% 'C?Q _Y&Z__ .V?_HM:YVNB^('_ "-U_P#]L_\
MT6M<[7M4_@7H>?+XF%%%%60%%%% !1110 4444 %%%% 'JGPK_Y%^X_Z^F_]
M 2NRKC?A7_R+]Q_U]-_Z E=E7D5OXC/0A\*"BBBL2PHHHH **** "BBB@#YY
MHHHKW3S HHHH **** "BBB@ HHHH **** /H:BBBO"/3"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFC]OW_ )([
MHW_8>A_])[BOI>OFC]OW_DCNC?\ 8>A_])[BN[ _[S#U.7%?P9'P'1117WY\
MH%%%% !1110 4444 %%%% !1110 5[+^Q[_R<7X2_P"WO_TDFKQJO9?V/?\
MDXOPE_V]_P#I)-7-BO\ =ZGH_P C:A_%AZK\S]+J***_.SZ\**** "BBB@ H
MHHH **** ,[Q%_R+^J?]>LO_ * :\*KW7Q%_R+^J?]>LO_H!KPJO1POPLY:V
MZ"BBBNPY@HHHH **** "BBB@ HHHH **** "OH:OGFOH:N'%?9.JCU"BBBN
MZ0HHHH **** "BBB@ HHHH \*\1?\C!JG_7U+_Z&:SJT?$7_ ",&J?\ 7U+_
M .AFLZO;C\*/->X44450@HHHH **** "BBB@ HHHH **** /9/A__P BC8?]
MM/\ T8U=%7._#_\ Y%&P_P"VG_HQJZ*O&J?&_4]&/PH****S*"BBB@ HHHH
M**** "O*_BI_R,%O_P!>J_\ H;UZI7E?Q4_Y&"W_ .O5?_0WKIP_QF-7X3C:
M***]0X@HHHH **** "BBB@ HHHH **** "O5/A7_ ,B_<?\ 7TW_ * E>5UZ
MI\*_^1?N/^OIO_0$KFQ'\,VI?$=E1117EG:%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&W_  42_P":
M?_\ <0_]MJ^R:^-O^"B7_-/_ /N(?^VU>GEO^]P^?Y,XL;_ E\OS/C6BBBON
MCY<**** "BBB@ HHHH **** "OI?]@+_ )+%K/\ V 9O_2BWKYHKZ7_8"_Y+
M%K/_ & 9O_2BWKAQW^[3]#JPO\:)]^4445\ ?5A1110 4444 %%%% !7C?Q
M_P"1NO\ _MG_ .BUKV2O&_B!_P C=?\ _;/_ -%K77AOC?H85OA.=HHHKTCC
M"BBB@ HHHH **** "BBB@ KV3X?_ /(HV'_;3_T8U>-U[)\/_P#D4;#_ +:?
M^C&KDQ/P+U-Z/Q'14445YIV!1110 4444 %%%% &=XB_Y%_5/^O67_T UX57
MNOB+_D7]4_Z]9?\ T UX57HX7X6<M;=!11178<P4444 %%%% !1110 4444
M%?0U?/-?0U<.*^R=5'J%%%%<!TA1110 4444 %%%% '&_%3_ )%^W_Z^E_\
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M'O\ R<7X2_[>_P#TDFKFQ7^[U/1_D;4/XL/5?F?I=1117YV?7A1110 4444
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M\;^('_(W7_\ VS_]%K77AOC?H85OA.=HHHKTCC"BBB@ HHHH **** "BBB@
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MM;6,:F6ZN<%0WEQ+R0"PR>@SR:[[6M6@T'1[[4[HL+6R@DN9=@R=B*6; [G
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MHH **** "BBB@ HHHH *^E_V O\ DL6L_P#8!F_]*+>OFBOI?]@+_DL6L_\
M8!F_]*+>N''?[M/T.K"_QHGWY1117P!]6%%%% !1110 4444 %>-_$#_ )&Z
M_P#^V?\ Z+6O9*\;^('_ "-U_P#]L_\ T6M=>&^-^AA6^$YVBBBO2.,****
M"BBB@ HHHH **** "O9/A_\ \BC8?]M/_1C5XW7LGP__ .11L/\ MI_Z,:N3
M$_ O4WH_$=%1117FG8%%%% !1110 4444 9WB+_D7]4_Z]9?_0#7A5>Z^(O^
M1?U3_KUE_P#0#7A5>CA?A9RUMT%%%%=AS!1110 4444 %%%% !1110 5]#5\
M\U]#5PXK[)U4>H4445P'2%%%% !1110 4444 <;\5/\ D7[?_KZ7_P! >O*Z
M]4^*G_(OV_\ U]+_ .@/7E=>IA_@.*K\04445TF(4444 %%%% !1110 4444
M =E\*_\ D8+C_KU;_P!#2O5*\K^%?_(P7'_7JW_H:5ZI7EXC^(=M+X0HHHKF
M-@HHHH **** "BBB@#QOX@?\C=?_ /;/_P!%K7.UT7Q _P"1NO\ _MG_ .BU
MKG:]JG\"]#SY?$PHHHJR HHHH **** "BBB@ HHHH ]4^%?_ "+]Q_U]-_Z
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MQ?A+_M[_ /22:N;%?[O4]'^1M0_BP]5^9^EU%%%?G9]>%%%% !1110 4444
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M +6M*^Q_'OCW0/A?X0U/Q3XIU.+1]!TV,2W5[,&*Q@L%  4%F8LRJ%4$DL
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M%% !1110 4444 %%%% !1110 4444 %%%% !17SUXH_8[_X2?Q+JVL?\+O\
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M?0Z.BN<_X=^Z3_T6OXS?^%6G_P 8H_X=^Z3_ -%K^,W_ (5:?_&*W]M1_F_
MR]G/L='17.?\._=)_P"BU_&;_P *M/\ XQ1_P[]TG_HM?QF_\*M/_C%'MJ/\
MWX![.?8Z.BN<_P"'?ND_]%K^,W_A5I_\8H_X=^Z3_P!%K^,W_A5I_P#&*/;4
M?YOP#V<^QT=%<Y_P[]TG_HM?QF_\*M/_ (Q1_P ._=)_Z+7\9O\ PJT_^,4>
MVH_S?@'LY]CHZ*YS_AW[I/\ T6OXS?\ A5I_\8H_X=^Z3_T6OXS?^%6G_P 8
MH]M1_F_ /9S['1T5SG_#OW2?^BU_&;_PJT_^,4?\._=)_P"BU_&;_P *M/\
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M/^&'_P#JOWQR_P#"S_\ M-')3_G_  #FE_*='XB_Y&#5/^OJ7_T,UG5STG[
M.F32-))\;?C.\C$LS-XL4DD]23Y%-_X=^Z3_ -%K^,W_ (5:?_&*[U6HI6YO
MP.7V<^QT=%<Y_P ._=)_Z+7\9O\ PJT_^,4?\._=)_Z+7\9O_"K3_P",4_;4
M?YOP%[.?8Z.BN<_X=^Z3_P!%K^,W_A5I_P#&*/\ AW[I/_1:_C-_X5:?_&*/
M;4?YOP#V<^QT=%<Y_P ._=)_Z+7\9O\ PJT_^,4?\._=)_Z+7\9O_"K3_P",
M4>VH_P WX![.?8Z.BN<_X=^Z3_T6OXS?^%6G_P 8H_X=^Z3_ -%K^,W_ (5:
M?_&*/;4?YOP#V<^QT=%<Y_P[]TG_ *+7\9O_  JT_P#C%'_#OW2?^BU_&;_P
MJT_^,4>VH_S?@'LY]CHZ*YS_ (=^Z3_T6OXS?^%6G_QBC_AW[I/_ $6OXS?^
M%6G_ ,8H]M1_F_ /9S['T/\ #_\ Y%&P_P"VG_HQJZ*OF.W_ &%XK2%8H/CS
M\;X8EZ1Q^,0JCG/ $%2?\,/_ /5?OCE_X6?_ -IKAE&G*3?/^!TQ<DDK'TQ1
M7S/_ ,,/_P#5?OCE_P"%G_\ ::/^&'_^J_?'+_PL_P#[34\E/^?\"N:7\I],
M45\S_P###_\ U7[XY?\ A9__ &FC_AA__JOWQR_\+/\ ^TT<E/\ G_ .:7\I
M],45\S_\,/\ _5?OCE_X6?\ ]IH_X8?_ .J_?'+_ ,+/_P"TT<E/^?\  .:7
M\I],45\S_P###_\ U7[XY?\ A9__ &FC_AA__JOWQR_\+/\ ^TT<E/\ G_ .
M:7\I],5Y7\5/^1@M_P#KU7_T-Z\[_P"&'_\ JOWQR_\ "S_^TU4NOV"K&^D$
MES\<OC5<2 ;0TOBY6('IDP>]:TO94Y7<OP,Y\\E:QNT5SG_#OW2?^BU_&;_P
MJT_^,4?\._=)_P"BU_&;_P *M/\ XQ77[:C_ #?@8>SGV.CHKG/^'?ND_P#1
M:_C-_P"%6G_QBC_AW[I/_1:_C-_X5:?_ !BCVU'^;\ ]G/L='17.?\._=)_Z
M+7\9O_"K3_XQ1_P[]TG_ *+7\9O_  JT_P#C%'MJ/\WX![.?8Z.BN<_X=^Z3
M_P!%K^,W_A5I_P#&*/\ AW[I/_1:_C-_X5:?_&*/;4?YOP#V<^QT=%<Y_P .
M_=)_Z+7\9O\ PJT_^,4?\._=)_Z+7\9O_"K3_P",4>VH_P WX![.?8Z.BN<_
MX=^Z3_T6OXS?^%6G_P 8H_X=^Z3_ -%K^,W_ (5:?_&*/;4?YOP#V<^QT=>J
M?"O_ )%^X_Z^F_\ 0$KPC_AW[I/_ $6OXS?^%6G_ ,8JU:_L)V]C&8[;X[_&
MVWC)W%8O& 4$^N!![5E4J4JD>52_ TA&<7>Q]/T5\S_\,/\ _5?OCE_X6?\
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MOCE_X6?_ -IH_P"&'_\ JOWQR_\ "S_^TT<E/^?\ YI?RGTQ17S/_P ,/_\
M5?OCE_X6?_VFC_AA_P#ZK]\<O_"S_P#M-')3_G_ .:7\I],45\S_ /##_P#U
M7[XY?^%G_P#::/\ AA__ *K]\<O_  L__M-')3_G_ .:7\I],45\S_\ ##__
M %7[XY?^%G_]IH_X8?\ ^J_?'+_PL_\ [31R4_Y_P#FE_*?3%%?,_P#PP_\
M]5^^.7_A9_\ VFC_ (8?_P"J_?'+_P +/_[31R4_Y_P#FE_*?3%%?,__  P_
M_P!5^^.7_A9__::/^&'_ /JOWQR_\+/_ .TT<E/^?\ YI?RGTQ17S/\ \,/_
M /5?OCE_X6?_ -IH_P"&'_\ JOWQR_\ "S_^TT<E/^?\ YI?RGTQ17S/_P ,
M/_\ 5?OCE_X6?_VFC_AA_P#ZK]\<O_"S_P#M-')3_G_ .:7\I],45\S_ /##
M_P#U7[XY?^%G_P#::/\ AA__ *K]\<O_  L__M-')3_G_ .:7\I],45\S_\
M##__ %7[XY?^%G_]IH_X8?\ ^J_?'+_PL_\ [31R4_Y_P#FE_*?3%%?,_P#P
MP_\ ]5^^.7_A9_\ VFC_ (8?_P"J_?'+_P +/_[31R4_Y_P#FE_*?3%%?,__
M  P__P!5^^.7_A9__::/^&'_ /JOWQR_\+/_ .TT<E/^?\ YI?RGTQ17S/\
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M'MJ/\WX![.?8Z.BN<_X=^Z3_ -%K^,W_ (5:?_&*/^'?ND_]%K^,W_A5I_\
M&*/;4?YOP#V<^QT=%<Y_P[]TG_HM?QF_\*M/_C%'_#OW2?\ HM?QF_\ "K3_
M .,4>VH_S?@'LY]CHZ^AJ^5O^'?ND_\ 1:_C-_X5:?\ QBM'_AA__JOWQR_\
M+/\ ^TUSUI4JEK2_ UIJ<+Z'TQ17S/\ \,/_ /5?OCE_X6?_ -IH_P"&'_\
MJOWQR_\ "S_^TUS\E/\ G_ VYI?RGTQ17S/_ ,,/_P#5?OCE_P"%G_\ ::/^
M&'_^J_?'+_PL_P#[31R4_P"?\ YI?RGTQ17S/_PP_P#]5^^.7_A9_P#VFC_A
MA_\ ZK]\<O\ PL__ +31R4_Y_P  YI?RGTQ17S/_ ,,/_P#5?OCE_P"%G_\
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M:<TOY3Z8HKYG_P"&'_\ JOWQR_\ "S_^TT?\,/\ _5?OCE_X6?\ ]IHY*?\
M/^ <TOY3Z8HKYG_X8?\ ^J_?'+_PL_\ [31_PP__ -5^^.7_ (6?_P!IHY*?
M\_X!S2_E/IBBOF?_ (8?_P"J_?'+_P +/_[31_PP_P#]5^^.7_A9_P#VFCDI
M_P _X!S2_E.T^('_ "-U_P#]L_\ T6M<[6!<?L"Z?=S-+/\ '#XTS2MUDD\6
MJS'C'),%1_\ #OW2?^BU_&;_ ,*M/_C%=T:M*,4N;\#E=.;=['1T5SG_  []
MTG_HM?QF_P#"K3_XQ1_P[]TG_HM?QF_\*M/_ (Q5>VH_S?@+V<^QT=%<Y_P[
M]TG_ *+7\9O_  JT_P#C%'_#OW2?^BU_&;_PJT_^,4>VH_S?@'LY]CHZ*YS_
M (=^Z3_T6OXS?^%6G_QBC_AW[I/_ $6OXS?^%6G_ ,8H]M1_F_ /9S['1T5S
MG_#OW2?^BU_&;_PJT_\ C%'_  []TG_HM?QF_P#"K3_XQ1[:C_-^ >SGV.CH
MKG/^'?ND_P#1:_C-_P"%6G_QBC_AW[I/_1:_C-_X5:?_ !BCVU'^;\ ]G/L>
M[_"O_D7[C_KZ;_T!*[*OF"U_83M[&,QVWQW^-MO&3N*Q>, H)]<"#VJ?_AA_
M_JOWQR_\+/\ ^TUQ35*4G+G_  .F//%6L?3%%?,__##_ /U7[XY?^%G_ /::
M/^&'_P#JOWQR_P#"S_\ M-1R4_Y_P*YI?RGTQ17S/_PP_P#]5^^.7_A9_P#V
MFC_AA_\ ZK]\<O\ PL__ +31R4_Y_P  YI?RGTQ17S/_ ,,/_P#5?OCE_P"%
MG_\ ::/^&'_^J_?'+_PL_P#[31R4_P"?\ YI?RGTQ17S/_PP_P#]5^^.7_A9
M_P#VFC_AA_\ ZK]\<O\ PL__ +31R4_Y_P  YI?RFE17.?\ #OW2?^BU_&;_
M ,*M/_C%'_#OW2?^BU_&;_PJT_\ C%>A[:C_ #?@<GLY]CHZ*YS_ (=^Z3_T
M6OXS?^%6G_QBC_AW[I/_ $6OXS?^%6G_ ,8H]M1_F_ /9S['1T5SG_#OW2?^
MBU_&;_PJT_\ C%'_  []TG_HM?QF_P#"K3_XQ1[:C_-^ >SGV.CHKG/^'?ND
M_P#1:_C-_P"%6G_QBC_AW[I/_1:_C-_X5:?_ !BCVU'^;\ ]G/L='17.?\._
M=)_Z+7\9O_"K3_XQ1_P[]TG_ *+7\9O_  JT_P#C%'MJ/\WX![.?8Z.BN<_X
M=^Z3_P!%K^,W_A5I_P#&*/\ AW[I/_1:_C-_X5:?_&*/;4?YOP#V<^Q]4T5\
MS_\ ##__ %7[XY?^%G_]IH_X8?\ ^J_?'+_PL_\ [37G\E/^?\#KYI?RGTQ1
M7S/_ ,,/_P#5?OCE_P"%G_\ ::/^&'_^J_?'+_PL_P#[31R4_P"?\ YI?RGT
MQ17SUX7_ &._^$8\2Z3K'_"[_C)JW]GW<-W_ &?JGBSSK2Y\MP_E31^2-\;8
MVLN1D$BOH6LI**^%W*BV]T%%%%04%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445\O_MK?MM:?^RGINF:=8Z4NO^,=6C::
MVLYG,=O;P@E?.E8<MEA@(N"<-EEP,Z4Z<JLE""U)E)05Y'U!17YD^$_^"J/Q
M&\&^+M.M/C%\-;?2-%OECE633K"ZL;I(6!/G)'<2,)E.5(P5XSR<BON+XZ?%
MZY^'_P"SOXC^(WAA+:^FL]*74K!=0AD$4BMM*[TRC@%6Z94COBMJF&J4Y*,E
MOL1&K&2;70]4HKYC_8+_ &G/%/[4GP\\1:]XKL-(T^\T[5?L,2:/#+%&R>2C
MY8222$MECT(&,<5ZI^T;\2-3^$/P/\8^,M&@M+G5-&L6N;>&^1GA9@P&'"LK
M$<]F%9RI2C4]D]RE-./,MCTBBOE?]B3]K76_V@OA)XP\9^/HM#T&'0+V2.6?
M3HY8+>.W2W65Y)#+*^, L2<@8'2O'_!_[?\ \5/VA/VAI_!7P=\,>'9?"?G\
M:QKMA=2R06B8$EU-LGC"J3DHA )+(I.36OU6IS2C_+N1[6-D^Y^A%%,A$BQ(
M)65Y0HW,B[03W(&3@>V33ZY#8**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HKXI_;X_;7\<?LL^+_"NE>%-*\/ZA;ZK8RW4[:S;SRNK+)M 4QS1
M@#'J#7DFB_\ !4?XH_#SQ!ID/QC^$W]D:7?XE1[*QNM.N3!T,D4=R[+-C_>4
M'IN'6NV&#JU(*<5N82K0C+E9^F-%9WAWQ!I_BSP_I>N:1<K>Z5J=K%>VERH(
M$L,B!T< @$ JP/(SS7Q9^RC^W)X[^.G[2WB#X>:]I/AVTT73X;Z2*?3;:=+D
MF&98TW,\[KR&.<*.?2L(4934I+[.YI*:BTGU/N2BO@[]JC_@HIK?@/XO6?PW
M^#NB:9XQ\0PSFRU$WEM/<+]L+!5M85BD0EU((<Y(!.WJK5[7\7OB1\;?AA^S
M?9>(K'PQI/BWXI--;K=Z/HFDW=S:QK(3O5(HYFE;8, OOP2"< '%7]7FE%O3
MFV)]I%WMT/H:BOR^\0?\% OVL?">CW.KZY\%+/1M*M0&GOM0\*:M!!$"0 7=
MYPJC) Y/4BO=_P!@?]K/XH?M4:QXHNO%.C>&M-\+Z/!'$LVDVUQ%/)>2,"JY
MDGD!01JY/&<LG/4'2>$J4X.;M9>9,:T92Y5N?95%%%<1N%%%% !1110 4444
M %%%% !1110 4444 %%%% !117RK^WM^V#J?[*GAGPR/#5EI>I>)=;NI-D&K
M)+)#';1*/,<K&Z'):2,#+#^+@X.-*=.562A'=DRDH+F9]545\_?L3_M-7'[4
M?P@?Q%JMI8Z?XAL+Z2PU"TT\L(MP"NDBH[,RJR.!RQY1N>,#Z!I3A*G)PEN@
MC)25T%%?E%X/_P""GW[1GQ$OI[+PK\-O#OB:\@C\Z6WT?0M1NY(X\@;V6.Y)
M"Y(&3QDBNU\)_P#!6+Q/X5\366D_%OX8-HL4B*;F;3EFMKB)3G$JVUQDNI(Q
MC>.Y!.,'ME@:ZZ7^9@L139^E%%8_A#Q?HWC[PSIOB'P]J4&KZ+J,(GM;RV;*
M2(?U!!R"IP0000""*N:QK%GX?T>^U34)UM;"Q@DN;B=@2(XT4L[''.  3QZ5
MP6=['3YERBOSA_9Q_P""H7BCXK?M!:)X0\3:#X?TOPMKMY)96=Q:+-'=P2/G
M[,'9Y61RS;(R JY+Y'3:?T>K:M1G0:C-&<*D:BO$****P- HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **_+23_@IA\?]=^(>N^%_"'P^\.^)KJPNKB.
M.UTW1=0N[DPQR%-[+%<D_P!W)P!D]J]*^ /_  4VU?7/BG;^ /C!X/@\&ZI=
M7*627<"2VJVEP1C9<PSL60,Q4 Y^7(R".1WRP5:*O8YUB(-V/T!HK'\7^+]&
M\ ^&=2\0^(=2@TC1=.A,]U>7+82-!^I). %&220 "2!7Y[>-?^"JWB;Q=XJF
MT+X*_#63Q&X!$,VHVT]U/-B3!<6UN0P4KC&6SEAD<8.%*A4K? C2=2-/XC](
M:*_-/1_^"I/Q*^'/B.SL?C+\(I-&M;C[WV.TN=-ND7<"TB17182X4CY=R9)'
MS"OO[X6_%;PK\:/!MIXI\':M%K&C7)9!+&"KQR+]Z.1& 9'&1\K '!!Z$$NK
MAZE%)R6G<4*D9Z(ZZBO@OQS^WC\1/A/^V1#\+?%NA^'X?!EQJ\%O#J4-C<QW
M365QCR9@[7!1MA<!V"8)CD 4'@?>E14HRI).774J,U*Z70**^#_VBOV^/'/A
M']J&Q^$'PQT7P[JT[3V>FSW.KPS3$WLY4[5,<\:A461 V>C!\D8K[PHJ4I4U
M&4NH1FI-I= HHHK$L**** "BBB@ HHHH **** "BBB@ HHHH ***\(_;3^/&
MO_LY? ^Z\9>&K/3;[5(KZWM1#JL4DD.V1B&)$;HV>./FJX0=22C'=DRDHJ[/
M=Z*\2_8Y^-NN?M"_ ;1_&WB.TT^RU6\N+F*2'2XY(X (YF1<!W=LX49^;K7A
M&I?MR>.[/]NE/@NFD^'3X6;5H;#[6UM/]M\MX%D)W^?LW98_P8QVK6.'G*4H
M+>._R(=2*2?<^Y**^0?^"@7[7_C+]E+_ (0/_A$M,T/4?[>^W_:?[:@FEV>1
M]FV;/+ECQGSFSG/08QSGYWF_X*8?M#>#;&PU[QC\(-/M/#%XJM!=OH^HZ?'<
M!@&4QSRR.A!!R, Y!!K6G@ZM2"G&UGYDRK0BW%GZC45YO^S[\=_#O[1OPSL/
M&?ALR16\SM;W-E.RF:SN$QOBDVDC."K#U5U.!G%=7X\\8V'P]\$Z]XHU1]FG
M:-8S7]P>^R-"Y X/)Q@  DDBN5QDI<K6IMS)JZ-VBOSR_9!_X*5>*OCA\<M/
M\$>,]%\.Z7I^KQS)87.F+-#(DZ(9$1S)*ZMN5&4 !26*XZXK]#:TK49T)<LR
M(5(U%>(4445@:!1110 4444 %%%% !1110 4444 %%%% !1110 445^??Q^_
MX*6>*--^+5[\/?@OX(A\7:GIEU)9W5U=VMQ>&ZFC)61+>W@9&*JPQYA8AL'"
MXPQWI49UG:",YSC35Y'Z"45\0_LA_P#!1B3XW>.$\ >._#*^'?%TS2+;W&FQ
M2_99'0#=%)&Y9X6R&Y9BO&"0<9[?]OC]J?Q9^RSX1\*ZKX4T_1M0N-5OI;:=
M=9@EE156/<"HCEC(.?4FK>&J*HJ36K%[6/+S]#ZGHK\P]'_;Y_:W\1:5:ZGI
M7P/MM3TV[C$UO>6?A+5Y89D(R&1UG(8'U!Q7VG^R7\3?B)\6/A;+K?Q.\*?\
M(;XD749K==._LZYL<P*L923RYV9^2S#=G!Q[&G5PTZ*YI-?>*%6,W9'M-%?%
MO[2'_!3?PA\'_$UYX3\(Z-)X\\2VKM;7#PW'E6=O/P F\*QE8,2&50.5V[@<
MX\9D_P""B7[3'AVW3Q!XB^!\-OX2 \Y[EM U.T4PE2RD7+R-&!C!W;2" >!V
MJ.#K27-:U^XG7@G:Y^G%%?+G[+G_  4"\!?M'75MH$P?PIXVD7Y='O6W1W1"
M N;>4#:V#GY&VN0"0" 2/J.N:I3G2ERS5F:QDIJ\6%%%%9E!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445
MP_QJ^+VA_ GX9ZWXW\1&4Z9I<:DPVZ[I9Y'8)'&@_O,[*,G@9). ":<4Y-);
MB;LKL[BBORONO^"JWQFN8[KQ3I_PNT>/P#'="'[3+:7LPB)^[$]Z'6+S"<_\
MLQG^[7WI^S+^TAH/[3WPZ7Q1HME=Z7+%,;:\T^\4EH)1SA7P%D4C!#+]" 00
M.JKA:M&/-):&4*T)NR/7**^'?@[^W%X[^(7[:^O?!_4=)\.P^&K#5=8L8KJU
MMIUO#':-,(RSM,4W'RUW80 Y. *^XJRJ4I46E+KJ7&:FKH**^&_V4?VY/'?Q
MT_:6\0?#S7M)\.VFBZ?#?213Z;;3I<DPS+&FYGG=>0QSA1SZ52_:H_X**:WX
M#^+UG\-_@[HFF>,?$,,YLM1-Y;3W"_;"P5;6%8I$)=2"'.2 3MZJU;?5:O/[
M.VNYG[:'+S'WC17,?#5O%\G@G2I/'9TD>*Y(A)?1:)#)':PN>?+3?)(S;?NE
MMV&()  XKIZY&K.QL%%%%(84444 %%%% !1110 4444 %%%% !117F_[1OQ(
MU/X0_ _QCXRT:"TN=4T:Q:YMX;Y&>%F# 8<*RL1SV8548N345U$W97/2**_*
MCP[_ ,%0?V@M8T>\\1P_##0M8\+::^-1U'3M'U#R+?@'#W G=(S@J?F'<>M?
M;O[(?[6NA_M8>"K_ %&RT^71-?TB2.'5=*D?S%B+AC')'( -T;[' R P*,",
M;6;JJX6K17-):&,*T)NR/>J*^*?V^/VU_''[+/B_PKI7A32O#^H6^JV,MU.V
MLV\\KJRR;0%,<T8 QZ@UZQ^TY^UAI'[-OP;M/$FH""Z\4:O;8T;2/FQ<W&Q2
MS$ Y$4>]2QST*J#EA4?5ZC46E\6Q7M(W:?0]^HKY8_8A^.GQE_:*T.[\7>.-
M%\-^'_![9ATT:?87,5S?R _-(K27#J(EP5SM.YL@$;3GPGQ/^VE^UUIGB75K
M/3O@1]KT^WNYH;:X_P"$/U=_-B5R$;<LV#D '(X.:I86<IN":NO,3JQ24NY^
MCM%?EEX/_P""E7[0OB[XI:5\/T\%>#=.\27VHIIK6E]I=]#);REMK>8C70*[
M>201D8-?J;45J$Z%E/J.G4C4^$****YS4**** "BBB@ HHHH **** "BBB@
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M^\:**\=_:T^/!_9Q^!NN^,[>&VNM7B:*UTRTO QBFN9' 4,%()55WN1D9"$
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M/O@N"5W%XF_BC)8[3W&#7XF:+\;?$'P'^,WQ&UOPPR0:U?G4M*AO&SNM!+<
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M9V\Y1S@*LN&QQS.>O.-\53JU*'M*JM)/\&9T90C4Y8/1GZ$4445X1Z 4444
M%%%% !1110 4444 %%%% !1110 4444 %?BW\2!XY_X)]_MD:CXELK+[7IMY
M>7-U8R7(/D:IIT[[WA,@48D3<JL0/E= V"I&[]I*\5\5+\&OVOM)\3_#^YU#
M2?&#Z3M%V+)U>?397+HLL,N"%D!1QE2>F&!#8/;A:WLF^97B]S"M#G2L[/H4
MOV8_B-\*OC^FJ_%7P5I=K9^+M3AAL=?,J*-0@,:XCBEP?ND*-KKPX1<\Q[5^
M:_\ @L=_R37X>?\ 87N/_1(KYE\!^&_$/[$_[?&@^$].UP:N'U6STNY;3_O7
MEA>/'B*6+M)M>-]AZ,J$'[K5]-?\%CO^2:_#S_L+W'_HD5W1HJGBJ;B[Q>WW
M'/*;E1DFM49/P%_X*@?"SX6_!?P7X1U70/&%QJ6BZ7!8W$MG9VK0LZ( 2A:Y
M4D?4 ^U>G_&W]MC3?&_[$/C'XB^ ;?6=(EN+O_A';9]1AACGAE<QB23Y)'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIOCF"[@67;&W+*&/[ WU_;:78W%[>W$5G9VT;33W$[A(XHU!+.S'A5 !))X
M%?D#\5/$Z?MW?M\>';7PK!+=^&;"6UTY;Z.-\-I]O,TL]R?E!129)-N['WD!
M(S@+ 7O._P -M1XBUE;>^A]M?\%+?A/_ ,+,_9=UJ^MX/-U3PM,FMP%8]S^4
MF4N!D<A1$[N>W[H9Z9'+?\$J?C*_Q"^ -SX1O"IU'P;="U5E'+VDQ:2 MS]X
M,)TX &V-.IS7V1K&D6?B#1[[2]0@6ZL+Z"2VN(&) DC=2KJ<<X()''K7XA>&
M?'?B7]@OXT_%GPK#).;Z32[S0H+J-=KH[A9+.]4$C! *..HQ(>#Q3P\?K%"5
M'JM4*H_9U%4Z/0])\0:;+^VO_P %([FP4K<^&=-U,0S><BF,:;8$"4 =Q,ZL
M!G/-P,@ $#]@*_.'_@CW\)_L>@^-?B/=P8DO94T2PD>/!\M,2SE6/)5F:$<<
M9B/4CC]'JSQTE[14H[15B\.O=YWNPHHHKSCI"BBB@ HHHH **** "BBB@ HH
MHH _)/\ ;?\ ^4C_ (/_ .OK0O\ T<M?H5^V)_R:S\4_^Q>N_P#T6:_//]OE
MF\/_ /!0CP?J5\C0V>=%O%D; #1)<;68$G&,QN.?[IK] _VU-2M=*_91^*,U
MY/';1-HD\"O(< R2 1QK]6=U4>["O8J[4/E^AQ0_Y>'R_P#\$<?^2:_$/_L+
MV_\ Z)-?-OQ"^*6E?!7_ (*6>(?&VN6]Y=:5I&OSRSPZ>B/.P:W*#8'95)RX
MZL.,U]+_ /!'.WD7X6_$"<KB)]9A16R.66 $C_QX?G7A+>'=*\6?\%7+[2=<
MTRSUG2KKQ%<+/8ZA;I/!*!:N0'1P589 /(Z@5U*WUBM?:QD[^RIV[G.?M@?'
MNU_;N^*W@?2OAMX3UG[1:PO91B^B3[1.\LBGYDB9PD:8SN+G[S$A<<_L)X(\
M/R>$_!>@:'+<-=RZ9I]O9-<,<F4QQJA8GWVY_&H/"/PY\)_#^%X?"_AC1O#<
M3_>CTC3XK56YSR(U&>:\^_:Z^,C_  '_ &?/%GBVU*_VI% MKIZL"<W,S"-#
MP1]W<7//1#]*\NI55?DHTXV2V^9U1A[/FG)ZGYO_ !GC;]NC_@H,OA*QU"<>
M&+6;^RH[RV1F,%I;(SW,@W< M()0K$8RR<-WV?V"O$U]^R[^V1XG^$OB:\=;
M34YI=%!^=(I;R.0&UG"8/$B;@N<<3+SZ^)?L<_M8:=^R;KGB'6G\#_\ "6ZM
MJEM'9Q7!U06?V:$-O=1^XD+;V$9/('[L<&J/[2'[4D?QP^-FC?$_0?"\G@?Q
M!IZ6S.4U,W@EGMWW0S@^5&48 (O&>$7H<Y]UT9N]"WN6M?3?N>?SQ7[R_O7/
MWEHKBO@M\2+;XO\ PF\)^,[4QA=:TZ&ZDCC!"Q3%<2QC//R2!U[_ '>IZUVM
M?*R3BVF>NG=704444AA1110 4444 %%%% !1110 4444 ?CA^TYHOCK]BG]M
M*[^)VD6_F6>L:I=:UIMW<(9+:Z6X+&YM9, 8(\UUV_>"LC YP:_0/]ESXP_"
MK]IZ^N_B9X>T2TTWXAPVB:7JL5R%:_M80S,B[A]Z-NTB@;@H4_<VKV'B75OA
M#^TE-XD^%FHWVC^,+JQA$VH:7&PE>TR"@E20#"2*7QN1MR%L'&:_*?Q7X#US
M]@O]L[P]9:!KS:M'%=6MW;M;,#/<6,TI1K6X0<!V564CN"CKMR,>W&V+AR2T
MFE]Z.!WHRYEK%L^T/^"OW_)M7AK_ +&ZV_\ 2.]KRS]EW_@I5\,?@G\!?"/@
MG7-"\676JZ1!)%/-I]G:O Q::1QL+W*L1AQU4<YKU/\ X*_?\FU>&O\ L;K;
M_P!([VND_8=^ ?PQ\6?LJ_#[5]<^'/A/6=5NK69I[[4-#M9YY2+F4 N[QEF.
M !R>@%1%TUA(^T5U<;4G6?*^@_Q3^W;HGC[]D7XH?$OP#9ZWI5QH2C2X'U2W
M@2:*ZG,44<R*DLBD(UPC<G^$\'OX7_P29^ &C>(+'Q!\7->MX]4U:VU%M,TE
M;N+?]F=426:Y!;.7;S44,.5V2<_-Q]7?M)?LZZ/K/[+/Q%\%?#[PII&AW.HV
MJWL6GZ-81VBW5Q!)',B[8E4-(WDJ@)[E0>*^5/\ @DY^T%H^A:?KGPCU^[BT
MS59M0;4=(%SB/[0[(D<MN"2,R QJRKC)R_7;@*%GAJCHJVOSL.5_:QY_Z9^E
MU>4Z#^RS\+/"_P 4[CXB:5X,TVQ\43(H6X@B"10OA@TL<0^1)'#89P,G&>I8
MMZM7F7AO]I/X;>,/BMJ7PYT;Q78ZAXKT^'S9;6"3<C$$^9&D@^5Y(\9=%)*Y
MY^Z^WS(\]GR7\SKERZ7/3:***S*"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC?]L+_@G3HO
M[1>O2^,/#6K1^%O&<J(EUYT.^SO]HP&D"_,DF-HWC<"$ *Y^8?9%%:TZLZ,N
M:#LR)0C-6D?F5I/_  2Z^*WQ"\3:/+\8/BM'K.BV/[H_9-1N]0NT@&#Y<#7,
M86/)XZ$#KM;I7VU\9O@B/%?[-FO?"_P9%8Z+'-I*Z7ID5R[K;P*NT*&8*[8
M7KAB>^:];HK6IB:E1IR>VQ$:48II=3\L/!W_  3?_:>^'=C/9^%/BUI'AFSG
MD\Z6WT?Q)JEI'(^ -S+';@%L #)YP!7U1H?[./Q1O/V-?%7PO\8^+K3Q-X[U
M9+B.+6+[4[J[A"NZE%>:6/S<  \!3C/%?4]%7/%U*EF[::["C1C'8^8_V"_V
M8_%/[+?P\\1:#XKO](U"\U'5?MT3Z/-++&J>2B88R1QD-E3T!&,<UXY\<O\
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M,5!6B@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O(OVF?V9_"W[47@%?#OB)IK*ZM93<Z;JUHJF>S
MFVE<C(^:-N-\? 8 <AE5E]=HJHRE"2E%V:$TI*S/RT7_ ()<_'.PTV;PG8?%
MC2X_ D\[2S:>-0OHHI&)QYC6@0Q%R%7.6]LG )^X?V4_V7M _99^'IT+2YY-
M2U:^=;C5=5E 4W,P7&%7^&->=J\D9))))->U45TU<55K1Y9/0RA1A!W1^9'C
MS_@F[\<[SX[>,_B!X+\=>'?#4NKZWJ&HV5U:ZO?6EY##<3R.%9HK?Y6V/A@K
M$=1DBO>?V0/V<_CY\(?B5J>L?%/XG_\ ":^'Y](EM(-/_P"$@O[_ ,NY::%U
ME\NXC51A$E7<#GY\=":^OJ*J>+J3CR2M]PHT8Q=T?#?[*/[#?COX%_M+>(/B
M'KVK>';O1=0AOHXH--N9WN09IED3<KP(O 4YPQY]:ZC]N[]AN3]J"/1==\*3
MZ7I'C:Q(M9[O5))8X;FS^8A&,:.=Z.<J=O1F!/ Q]>45'UJI[15;ZH?LH\O)
MT/,/V;O#'Q"\$_"31_#WQ,U'2]9\1Z6/LB:EI=S+.+JV4 1/*TD4;>:!E3PV
M[8&+$L0/3Z**YY2YFV:I65@HHHJ1A1110 4444 %%%% !1110 4444 %>;_M
M&_#?4_B]\#_&/@W1I[2VU36;%K:WFOG9(58L#ERJLP''937I%%5&3BU)=!-7
M5C\JO#/_  33_:7\$Z5<Z9X=^*>B:#IMU()I[/3/$.IVT,K@ !F1+8!F^4<D
M9X%?3?[%W[ 6G?LPZE<^*=<UA/$?C2XA:WCEM4:.UL8F^^L8)S(S8&78# X"
MCDM]=45UU,95J1<6]S&-"$7='Q3^WQ^Q1XX_:F\7^%=5\*:KX?T^WTJQEM9U
MUFXGB=F:3<"HCAD!&/4BOICX@?![1?BQ\(;KP%XIMUNM/N[&.VD:,G,4J %)
M4/!W*ZAAZXP>"17?45BZTW&,;_#L7[.-V^Y\2?L._LD?&3]E7QIJL&K^(?"^
MK^ =70F[L;.]N3/%.@/E7$2/;A=Q^XXWC*L"2QC45XW\5/\ @G+^T#\3/C-K
M7Q'?QAX-T[7+W41?VT]KJE_'+:%"H@$;BVW*8U2,*0<C8,'BOT_HK=8RHINH
MK7?D9^QBXJ/1'YL:7^Q/^V!:ZG:37/QZ\ZWCF1Y(_P#A,=8;<H8$C!AP<CUK
M])Z**PJUI5K<UM#2%-0V"BBBL#0**** "BBB@ HHHH **** "BBB@#X.^,_[
M _CKX\?M<1?$'Q/K7AUOA_'=6JKIB33/>?8H%4^3L,&S,CARV7('F-C. *^\
M:**VJ5I5%%2V1$8*+;74^1?V]OV*M2_:FM?#.I^%+S2M,\4Z4[VTTVKRS1Q3
M6; MMS&C_,LF"!MY#O\ ,, 'IOB=^S_X\^)G[$8^$]]J.ACQRVG:?8RW_GS?
M89&MKF!]Y?RO,RT<.3^[^^V.!S7TI15+$348Q_E=T3[.-V^Y^6OA+_@G3^U+
MX!TLZ9X8^,&E^'--,AF-GI/B;5+6$R$ %]D=N!N( YQG@5Z-\$?^"5-OI7C"
M'Q3\7?%@\;W,$@D72;97:WG9=H0W$TOSR)@8\L*HX7+%<J?T$HK>6-K23UM?
MLB%AX(\-_;,^$'C3X\? ^^\$>"-1TK3+S4[N#[=-J\TD4;6J,9"JM'%(VXR)
M%Q@ KNY[&G^Q3^S/+^R[\'O^$=U*YLK_ ,1WU[)?ZG=V.YHF<@)&B,RJQ141
M>H'S,Y YKWZBN;VTO9^RZ;FO(N;GZF-XR\):7X^\)ZSX:UJW^U:1JUI+8W<.
MXJ6BD0JP!'(.#P1R#@BOD']A7]C7XD_LH^/_ !5/K>M^&]6\)ZU:+$4TZ>X^
MU&:*0F"0H\*H!L>8$;B07&"<'/VO11&M*$)06S!P4I*3W04445B6%%%% !11
M10 4444 %%%% !1110!\.^/OV'?'?BK]NJU^--IJWAV/PM%JNFWS6<US.+WR
M[>W@CD 00E-Q:)L?/C!&2.@^XJ**VJ595%%2Z*Q$8*-[=0KX3^/_ /P2YT7Q
MMXLO?%_PR\2-X!UR>0W!TWR3]B\X_>:)HR'MP>3@!QDX 4=/NRBBE6G1=X.P
M2A&:M)'YB7W_  3;_:(\=1C1_&OQKM]1\.1X\J&?6-1U ##+M_<2HJ#@9X;@
MJ![C[-_9E_9&\#?LNZ+/#X=@DU#7;Q=E]KU\ ;FX4,6" #B-!Q\J@9V@MD@&
MO;J*UJ8JK5CRMZ>1$:,(.ZW"O@S]N3_@GSXI_:.^+-GXS\%:EX?TII=.CM=2
MCUBXGC:6:-F"2+Y<,@_U913T^X..IK[SHK*C6G1ESPW+G!5%:1YY^S[\(++X
M#_!OPMX'LO+<Z7:*MU<1[L7%TQ+SRC=SAI&<@'H"!T KT.BBLY2<FY/=E)65
MD%%%%2,**** "BBB@ HHHH **** "BBB@#YT_;"_8ST#]J[0+%Y+S^P?%FDI
M(NGZLD0<,C#/D3#@M'N (YRA+$?>8-\DK_P3!^.?B:.Q\-^*OC#92^";4[HK
M<7]]?" ]<QVDBI&#DGHX]:_4&BNRGBJM*/+%Z&,J,)N[. ^!OP3\-_L^_#C3
MO!OA>&1;"US)+<3MNENIVQOFD/\ >8@<#      %?+6F_L-^.[/]NE_C0^K>
M'3X6;5IK_P"R+<S_ &WRW@:,#9Y&S=EA_'C'>ON2BLHUYQ<FG\6Y3IQE9=@K
MY%_;Z_97^(_[4]OX1TOPEK'A_3-#TEI[FZBUBXGC>:X<*J,/+ADX50_<?ZP\
M'BOKJBIIU)4IJ<=T.45-<K.'^"/PNLO@K\)_"_@G3V62#1K)8&F50HFE.6ED
MP!_'(SM_P*N<_:H^!,'[1GP3U_P:7@@U.9!<Z7=7)<1P7D>3$S%<D*<E6.&P
MKD[20!7K=%)5)*?/?7<?*K<O0^:_V%/V?_'G[-?PSU?PAXTU'0]3MVU$WVG2
M:-/-*8U=%$B/YD4>!N0,, \N^>U?2E%%%2;J2<Y;L(Q45RH****S*"BBB@ H
MHHH **** "BBB@ IDT*7$3Q2HLD3J59'&0P/!!'<4^B@#\Z_B]_P2QUBQ^(!
M\7? [QM'X/N6F>>.QO9YK4V#L3G[-<P*SJFUBH4KD 8W-GC:_9U_X)HZIX7^
M+$/Q#^,'BV'QIK-G.E];VUO--<+<78Y$MS-,H>0(P!"X&2JEC@%&^^J*[7C*
MSCRW_P S#V$+WL?.'[=W[.'B7]J#X1:1X5\*WVE:?J%GKL.IR2:Q-+'$8DM[
MB,@&..0[LS+QC& >?7Y-\/\ _!/W]K'PGH]MI&A_&NST;2K4%8+'3_%>K001
M DDA$2 *HR2>!U)K]0:*5/%5*<.16MZ!*C&3YF>!?L=_"/XH_!_P3K>G?%7Q
MI_PFVKW6H?:+2[_M6ZU#R8/+1=F^X167Y@QP!CG->8_M+_\ !-'P?\:O$E[X
MO\*ZM+X%\77<C75T\41GM+RX)+&5DW!HW9L9=#CJVPL23]ET5FL14C-U(NS9
M7LXN/*]C\QW_ .">/[3MY;QZ)=_'"&3PSCRS;MXAU1U5"I# 0&/8>K#&X9!/
MKBOH+]E?_@G3X+_9UU:#Q-JE_)XT\90\V][<0"&VLCSS##ECOYQO9B> 5"<Y
M^MJ*TGBZLX\M[+R)C1A%W"BBBN,W"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M15Y_\MZ],HH]H_+[D'*CS/\ X1_XQ_\ 0]^!O_"*O/\ Y;T?\(_\8_\ H>_
MW_A%7G_RWKTRBCVC\ON0<J/,_P#A'_C'_P!#WX&_\(J\_P#EO5S1]%^*<&J6
MLFJ^,O!][IJR W%O9^$KJWFD3/*I(VIR!"?[Q1@/0UZ!11SO^D@Y4%%%%9E!
M1110 4444 %%%% !1110 5C^*K77[S26C\-:GINDZGO4K<ZKITE]"%_B!B2>
M%B3V._CT-;%%-: >9_\ "/\ QC_Z'OP-_P"$5>?_ "WH_P"$?^,?_0]^!O\
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MS_Y;UZ911[1^7W(.5'F?_"/_ !C_ .A[\#?^$5>?_+>C_A'_ (Q_]#WX&_\
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M\_\ EO1_PC_QC_Z'OP-_X15Y_P#+>O3**/:/R^Y!RH\S_P"$?^,?_0]^!O\
MPBKS_P"6];_@_3?'5C>SMXJ\1^'=9LVCQ%%H^@3Z?(CY'S,\E[.&&,C:%!R0
M<]CUM%)S;T_1!RH****@H**** "BBB@ K'\56NOWFDM'X:U/3=)U/>I6YU73
MI+Z$+_$#$D\+$GL=_'H:V**:T \S_P"$?^,?_0]^!O\ PBKS_P"6]'_"/_&/
M_H>_ W_A%7G_ ,MZ],HJ_:/R^Y$\J/,_^$?^,?\ T/?@;_PBKS_Y;T?\(_\
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MZBOE3]I/]O32_@C\1M&\ >%O"TGQ*\97CB.YTK3[XP/:.VWR8R1#)ND?).P
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M\4V4I;W/KNN+^+/QD\&_ SPNGB+QQK<>A:.]REHEP\,LQ>9@S*BI&K,3A&/
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M5':LP SMYF&0#GG XYZ+_@K-H<'AGX*_"C1[8*+;3[Q[2(*NT!8[94&!DX&
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M<I6/UCHHHKE*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^&?!GB_^V=<DA>=;7^S+R#*(,L=TL*KQ]<UWOQ.^%WAKXR>#[KPKXOT^35=
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M?$CPY\(O!>H^+?%NH_V3X?T_R_M-YY$DWE^9(L2?)&K,<NZC@'KD\9-?D/\
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M_&'[>WP(\!^*-5\.ZWX]CM=8TNY>TO+>/2[V<13(=KIOCA92000<$X(([5]
M5^1?_!3W]GCX?_ FY^'MQX(T.32+C77U.34I9=0N;M[EHS:E&)GD<@@RR'(Q
MG=SGBOUC\17&H6?A_5)](M5OM5BM97L[5R )I@A*(264 %L#E@.>HZUU5J5.
M,(3IM^]??R)3=VF>8_%?]KCX1_!#71HOC/QK:Z3J^Q9&L8[>>ZFC5AE2ZPQN
M4R.1NQP0>XKM/AO\5O"'Q>T#^VO!GB&Q\1::'\MY;*7<8GZ[)$.&1L8.U@#@
M@]"*^#OV7?\ @G-<^*YO&'B/]H[0;Z]\0ZA<8M(9=:$C.6&Z2Z>2VE)9RQP
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M/V?9O '[!7P/UQ+.WMM9T:4S7TT!*3(-0!G^8Y&YE98D/4@CY<*#7U9^U/\
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MI3M/T;M_P12N]+:'Z.^'?#^G^$_#^F:'I-LMEI6F6L5E:6RDD10QH$1 222
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MK5K*8GYC&_VB0!&Y)3:/F^;(^;=CB:T,1&][-=.C7Z%13B?0M?FC_P %FO\
MFC__ '&/_;&OTNKYH_;-_8R_X:Z_X0__ (K#_A%/^$?^V?\ ,,^V?://\C_I
MM'MV^1[YW=L<X82I&E6C.;LE_D5)75D?2]? '[8W[6FM_$KQ1+\ /@?"VN^(
M]69]/UC5+0ADB4@B6WC?[HPN[S93P@! .<E?LKXS>!M9^)?PQU[POH'BF?P5
MJFIPK!'KEM;^?);)O4R;5WIRR!TR&!7?D'(%? W_  YE_P"JP?\ EL__ '95
MX7V$7SU9:K96;^8I7V1]A_LE_LSZ7^R_\+;?P];2B^UN\*W6L:@K,5N+G;@A
M >D:CY5X!(&2,DU[77R%^R%_P3__ .&4_B5J7BW_ (3S_A*/MFD2Z7]C_L?[
M)LWS0R^9O\^3./)QMQ_%G/&#]>USUVG4;4N:_78<=M@HHHK H**** "BBB@
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ME)4O&PZJ&7YE4YXP>F_9Y^%OB+X,_#2P\(>(/&7_  G TW,5EJ,E@UK,EO\
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M!GL/K2N2^%/PM\/?!?P#I/@_PM:-::-IL92,2-ODD8DL\CM_$[,2Q/ YP
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M_$;XC>'OA/X-U+Q3XIU*+2M%T^/S)KB7J>RHJ]6=C@!1R20!7YS>'=%\8?\
M!3_XU6WB+7K&?P_\$/#%P\=O:EMCW&=I:(./O32!4WLIQ&F #N(+_3'[8/[%
MNL_M8:[HLK?$V?POX?TRVVIH8TG[7$UR6<M<EO/C^8HR( 0=H0X/SFOG?_AS
M+_U6#_RV?_NRNG#NA3AS.=IOR;M_P12NWMH?I-I]C;Z78VUE:1+!:VT:PQ1+
MT1% "J/H *L5YG^S=\&?^&>_@OX=\ ?VQ_;_ /9'VC_B8_9?LWF^;<RS_P"K
MWOMQYNW[QSMSQG%>F5YDK*32=T:!1114@%%%% !1110 4444 %%%% 'YQ_\
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M^S[-X _8*^!^N)9V]MK.C2F:^F@)29!J ,_S'(W,K+$AZD$?+A0:^K/VI_\
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M?64=[?7EAX=&E&-;3SQ(J)YQG;?Y:R$ E!D@'BO3CC(*51M_X?NL9\CT)_\
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MZ?\ ^BGKZ<_X*(>/=5^'_P"R?XNN='\R.[U$PZ6]Q&Q!@BFD"RMT[IN3M@R
MYXP8O''[&/\ PF7[66@?&S_A,/L?]E?9_P#B1_V9O\WRD9?]?YPVYW?W#C'>
MO>/'W@31/B=X-U?PMXCLQ?Z)JD!M[FW+%2RGD$$<A@0"".00#7=.M#FI/?E2
MN9V>I^1NA?L9_#K5/V)+KXP3_$-[7Q3%;S3"V::'["+A"2M@4V^9Y[J !\XY
MD4[2O)^WO^"8OQ&USXA_LOVRZ[-/=3:%JD^CVUU<N7>6W2.*2/DCHGG&,<G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#RCXE?$SP4VJMX7U#0+OQOJ**S3:;I>G"]>WZ?>R0%/?@Y&WG'
M&>>\*>./#/@<NVA?!SQIILL@*O-#X>'FLI(.TN9"Q&0#C..*T/AWJFG_  W\
M>>-]%\1-%I5_K&KS:M8WUUM1+VW<9"+)T_=D-\I/&_@<FO5O^$ETC_H*V7_@
M0G^- $^DZA_:VE65]]FN+/[3"DWV:[C\N:+<H.QU_A89P1V(-6Z9'(DT:21N
MLD;@,K*<@@]"#Z4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTWXC:<VH*YC5;F&>VCD89^6.26-4D)(P K'<2 ,Y&>K^#/[2/PY_:#_MC_A
M/$7]O_V1Y/VW_0;FV\KS=_E_ZZ--V?*?[N<;><9%5*E4BKRBU\@NCTRBBBLA
MA1110 4444 %%%% !1110 4444 %%?G#\;/V6/CS^U7\</$LWCW5Q\._A3I\
MEP^E33W<%U;QVT>%C<6T<_\ K) BR.TC*%RV#PJ5A?\ !.OQQXO\$_M.>*?@
M_'XM/C?P38VUT$N+>5Y[2+[.Z)'/ 23Y:G<$*@["67EL*:[_ *JO9N49IM*[
M7_!(YM;6/T[HK\KOB<WCO_@H-^UMXI^&&G^)_P#A&_ GA-[J)MD;20^7!,L3
M3-&K@3R/-MV[F4!!D8(;-?X*V_CK]B+]MSPY\*KOQ5/XD\+:\\-N]O&S)!/%
M.K1PR^2Y812)(JYVDG:A7=AJKZG[OQ>]:]O^"+F\C]6:*_,;]I_Q1\1?VNOV
MO+OX$^%-;G\/^%-'5H;PQ.R1R 1*UQ/<*&!E 9_+5,D=" -S&N/;1?'/_!,?
M]H/P7:3^,)O$'PXU^1&N\0/!;SP!@EQF NRK-#YOF*5<YRFXX9EHC@^:*7-[
MS5[!SGZTT5YCX]_:6^&WPP^(FA^!?$_B5=*\4ZVL#6%B]G<.LHFF:&(F5(S&
M@,B,/F88QDX'-<S#^W)\";CQC#X8B^)6DR:I+*84=1*;0MS_ ,O6SR,''!\S
M!R,=1GC5*HU=1?W%W1[I17CWQ2_:]^#_ ,%]:_L?Q?XXL]-U7 +V<$$]W+'G
M.-ZP(Y0\'AL=O45Z-X-\;:!\0O#MKKOAG6+/7='NAF&]L)EEC;'!&0>&!X*G
MD$$$ U+A**YFM NC;HKQ#QG^VS\$/A_XJ;PYKGQ"T^WU=)!%)%;PSW*1.<</
M+%&R)C(SN88YSC!JW8?M@_![5OB!I/@K3_&]KJ/B+5?+^Q6]E;7$\4_F+N7;
M.D9BZ=?GX((.",57L:EK\K^X+H]DHHHK(84444 %%%% !1110 4444 %%%%
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MSOMGF[DV[<>;'MQUSDU<%&4DI.R[B?D?0E%?B;^V#^Q/I7[)GA[0[F;XC?\
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MVE=R,H93@@$9!'!&:4J<X:R5@NF6J***@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !17'_%[P9JOQ%^&?B/POHNO_ /"+
M:AJ]HUDNKBU^TM;H^%D*IO3YC&74,&!4L&YQ@_EM^S=\&?\ AGO_ (*<^'?
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M PQ^8&."05 8Y[ L<@BL#Q9K<7PGMOBKX:UP-;67B=+[5-%U#RF,=S-/ 1+
M2"=K*VT#.,\DXRH++OXJ66L_!7P]X%\*$Z]XKU71;?3'M;49%J# J2M*Q&%
M&X>W7@#- 'T/HFKP>(-%L-4M=QM;ZWCN8MP .QU#+G'?!%7:R?"6B?\ ",^%
M=&T??YO]GV4-IYG][RXU3/Z5K4 %%%% !7YH?&__ )2R> ?KI_\ Z*>OTOKX
M<^*G[-OQ&\2?\%#/"/Q,T[P[]H\$6!L_M.J?;K9=FR-P_P"Z:02'!(Z*:[L)
M*,92YG;W61+H?<=?$G[>W[7G_"-V-S\&OAR)];^)'B)!I]P--'F/I\<V%,8P
M"3/(K%54<H&WY!VY]^_:DU'XJV/PHN8?@YHD6L>,;Z=;022W4$!L8&1R]ROG
M.J,X*HH4GK(&P0I!_-+X:_LF_M@?"/QG<^+?#'A1;3Q+<+()-4O+_1KZ<F0Y
MD8-<2OM9LG+##$$@G!-:82E3?[R<EILF_P Q2;V1]%>)_P!F5OV:O^";OQ"T
M.Z,=WXGU&WAU'5YK<,5$GGP_NQR<K&HQN& <,V!FO3?^"7M[!=?LBZ%%%(LD
MEMJ-]%,HZHQF+@'WVNI_$4?LV>"_CM\1O!OQ*\+_ +35O]ITC5[2WLM.C']F
MAMCK<+<E39]&&8"&?D$ KT-?,$/[)O[6_P"SI<^(O"WPCU>;4O!NHSO*MUI]
M_96QDR% D*7#JT,Q554M&?X,;B *VTJQG2G-<U[WOIL+:S2-_P#81NHM6_X*
M*?';4;-OM%C.FN21W" [65]7@9#GW )'T-?IG7R?^P/^QO>_LN^&]9U'Q+=V
ME[XOUWRUG2Q9GBLX$R5B#D#<Q+98@8R !D#<?K"N/%SC.K[CNE9%15EJ?CE^
MQ[^S9X;_ &C?VI/B!;^,(Y+OPYHDUY=RV$,[PM=2M<E(T9DPP0 NQVLIRJCH
M35#]H+]F?2?AW^V[H7PR\&7E]H/A[Q5)8V^VWN7>6UMKM_)N(P[G+KM$AVL3
MD'!S7US^PC^S;\1O@S\;OBEX@\8^'?['TC6@_P!@N/MUM/YV;EG'RQ2,R_*0
M?F I/CU^S;\1O&G[>WP\^(VC>'?MG@S23IIO-2^W6R>5Y4TC2?NVD$C8# _*
MISGC->I]9_?M<_N\O?2YGRZ;'AO_  46_8T^&_P!^%'A7Q3X&L+G2+EM532+
MR*2[EN!=AX)9!,QD8[7!@(P@"GS#P,"JG[='Q$\1^+?@Y^S3X-&JFVM?$/AN
MQU/4/.D*Q7%P\-ND;RN<L50M(W/][)W$#'UO_P %'/@GXT^/7P1T/P_X%T;^
MW-7MO$4%]+;_ &J"WVPK;7*,^Z9T4_-(@P#GGIP:\^_:2_9Z\*>-/V5_A+X/
M\<^-_#OPV^(OAGP_:PZ;_P )#JUO!"TR6L$5U YW'<FZ- 7CW8*J1N'!SHUT
MU3=1W:;\V-QWL=#JO_!++X)?\*^ETN*/4[#6XX"?^$GDOY&E#A"-[Q%A"4W?
M,5"J>,;A7C?_  1E_P":P?\ <'_]OJXR;P;^UK;?"N70_%/Q&T_P_P#"*WL'
M$GB2XUBQGAFM I)CCGAW74Q92RJA(#<+D#%=U_P1IL9X['XM7C1,+6:32H4E
M[,Z"[+#Z@.G_ 'T*<U-8:ISSYMOS_K0%;F5D?I/1117A&P4444 %%%% !111
M0 4444 %,FF2WA>65UCB12S.YPJ@<DD]A3Z9-"EQ"\4J+)$ZE61QE6!X(([B
M@#YT_:&^'OA3]N;X1W'A/P=\2-#E-AJ,%]+?:3+%JB1LJ2A(Y!%*-F[<3DG^
M$\&OD/\ 9#O_ !1^QI^UY+\$_$MII.H6/B-EB&J6<""?F-Y+>59 H<HQ^5HY
M#\I)*]/GT=>_8I_:#_9G^*&N:[^SMJ:7&@ZHQ2*U2ZMEFA@)++%-'>'RY/+/
MRK)EFP<\;F%>E_LI_L7_ !#C^-US\:/CKJRZAXN@D9K&Q6:*XW2-&8_.D*#R
MT1%;$<<>-I /R[0#[2=.G2E'G3@UHNMS'5M::GU5\=OCMX5_9Y\ 7GBOQ7=^
M5;Q_N[6SB(,][,02L,2GJQQUZ  DD $U\7?L9?"_Q5^TQ\>]3_:7^(%L;+3?
M/=?#VGR!L$JOEHT9^4&*%/E#;3O<LW4$GR7]H;]FW]K;]I#XB2>*/$7@%8X8
M24TW24US3GMK"'.0BJ;C#$X!9B,L1S@ */8/A%8_MU:7X\\%67B.WBM/ UOJ
M5E#J5O F@)'%IZRH)458?G51$& $?S #Y><4HTHTJ3Y)QYGOKT[(=VWJCFOV
M:+B/3_\ @JA\4(;EO(ENI-72%'!!=C*D@ _X K-]!2_\%DKJ*[U3X1:="WFW
MR)JDAMT!+;9&M%0X[Y*.!_NUZ!^UY^Q7X_O/C);?&?X&7JV7C!SNO;&.XCMI
M/.$7E^?"[D1G>GRNC$9))^;>V.(^$O[$_P </C)\=M)^(O[0E]''#HTT4@M;
MBZ@GGNQ$QDCAC2V)BBAWLQ;D'DX4[BPTC.ESQQ',M%MUO:Q-G9QL<G_P4Q\'
MO\0_VV/ACX5CF6VDUS1]+TQ9FZ1F;4KJ,,>#P-V>AJS_ ,%"/V*?AQ\!?@KH
M'BCP-I]SIM_!J4&FWK7%[+.;Q'AD/FL')"R;HU)"!5^8X P!7M?[4W[-WQ&^
M(_[;WPA\?^'?#O\ :/A+0?['_M'4/MUM%Y'D:E-/+^[>19&VQNK?*ISG R>*
M]&_X*%_!OQA\<O@+;^'/!&D?VWK*ZS;W9MOM,-O^Z6.4,VZ5U7@LO&<\U,,1
MRNC%2TZ_\$;CN?/GPR_8/\ _$+]C^7QWXH;5-2^(FN:)/K8\07%_*SV\NUY(
ML1[]DB[0@;?EFRV"A(V^9?LI_%;Q!\-?V /CMJFC:C<6-[INH6R6-Q"Q+VSW
M300.R9.%.&!##D'GJ!7Z#?"GX?:_X:_9+T/P9J5A]F\2VWA;^S9;'SHVVW'V
M<ILWJQ0_,<9#8]Z^;?V._P!F?4OA'^SO\6/#7QUL;?P9X?U^1$FNKK5K0(D#
M1>7YGG)(R1D.RXW'[V.#25=2C/G=_>5EY7Z!R[6.)_8/_8/^&'Q<^ ]EXX\<
M64^OZAK$UU'#;Q:A+!'9I'*8E)$14^9F-F^8LNUUXKS/3O@CHO[/G_!2[P7X
M0\/7L]YI,>I6UW MT0TMN)8F;RF8?>QV) .",YZG5^&GP9_:,^#^J:SIW[.?
MQ&T'QSX.O+QV:ZT/6--NH$*A 'E@N&98I=C1[O+W$A5!) 6N!^!_AW7K?_@H
M9X.LM8\4V_C[Q,NK+<:IJVGW#7,33+ TDR"4@;Q$JE20 !L('"UUKF<JDO:7
M33T[?Y$]M#]HZ***^:.@**** "BBB@ HHHH **** "BBB@ HHHH ^%_^"I7[
M26H_#'P!I_P]T$W%IJ?BN&1[O4H93&8;-&4-&N.2922IY&%##G=Q\8_%/Q!\
M'/#_ .Q?X7\"^"/%">(O'MQXBMM=\0N--N8#N%G<1LBR2Q*&CB:1$4!N2S.
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M0?BY#)##>>'[KQ%!9WTDR1JL+P?,&278$4H^ R@$$=&\!_:LTG]H^X^&9O\
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MYM_8V^#>C_MT?'+XD>,_BA>W6LQVCP7360NC;R7+2NXC4[.1%''!LVHR[<H
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MU9=)62,X8 C<I!&<9R.YKK_^"QM]!'X$^&]FTJBYEU*[E2+NR)$@8CV!=/\
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M=2CW]PZ'Z%64_C6.(YEA4ISYGS;_ "''XM$?2%%%%>,;!1110 4444 %%%%
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M34;2:)"N5\PI;L99I=CN%,@SR064$FE"5.M[.;DERO6_K?0-5=6)_&43P_\
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M2>Y\.? W_@E3X)^&/C"Q\0^*O$<_CV2Q<2V^GS:>MK9F0$[6ECWR&0#Y2%W
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M#LQ-7W/SR\#_ /!'CPUI.OV]UXJ^(5]XCTN)P[Z?8Z8M@9<<[6D,TI"G@':
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;YYK6*21L 98H"3@>YJ)4Y05WW:^X=S1HHHK(845\N_MC?M8:C^S[KW@C3-
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MIM:T#Q-I-H;87<:/MF@FB'RHZYR,8&U>22PK:5!Q;2DFUOO^J%S'TC17S_\
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MAV_OKNQ\B,^;-&X"/O*[Q@'H& /<41@Y-KM^@7/<J*^2_&NJ?&#XD?M6>+?
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MWQG'RR1D@[9$.&5L<$ UE*HHQA&7PM?J]2K;V/$/ ?\ R?\ ?%+_ +%+2_\
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MMT \-U"%\^SG7F.>%B#M=3T/H2.A-9RFDHPG\+2_X<=MVCQ_X#_\GH_M2?\
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M.BJ']G/QSKGP)^(C?L^_$;49M1*HTW@;Q)<*Y&J6*AB;5W(P)H5 &,D8^48
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M69W+_P!G7$A!!7+':[-T^8G&X)O?%+_E(9\%/^Q=U;_T7)7T#\3OAKH'Q?\
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M/B-K'B3P+KD'BNR636/"T=NMOJVD1+F6!59F^UP^I ;#+QE5&>FY #G/B/\
M"WQ19W7BR_\  [6,]MXHLGMM5T>\_=_O"AC$\## #D,Q8,<$Y)R2-N'IG@#X
MC^//"N@^#O$EK;^$?"MA;0V]ZUK=)/=7R1*JJF5)50=N3_7H?>-#URP\2Z3:
MZII=U'>V%T@DAGB.58?T(.00>000>17D_BWXC:W\1-<U#P5\.F1)8!LU/Q,[
M'R;$'(*1X'S2G! (/!!QT+* >P6=I#86D%K;H(H(46.-!T50, ?D*FK-\-Z*
MGAOP[I>DQRO<1V%K%:K+)]YPB!0Q]SC-:5 !1110 4444 %>!>)?AEXHT?\
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M:/6[6TAFV0S74:.L32C&6$;,)% (^95SD94]A133<7= %%%%( HHHH ****
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MZ#X=CT'P[*]Q$SWLDDK23W&R.1F4+\R 2;>'4A<@D?0%%%7*;G:_06P4445
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MA%/#VAM=36_VF>\FNK^;SKBYGFD,DDLCX&6+-V Z"NPHIW=K %%%%( HHHH
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MOK;1+V2ZAG-_IK3&2&8^624)+N-K@$ +P.@]WHJU-J+CT8NMPHHHJ!A1110
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MC4$ L\:2-*@&<Y9!P">@I+SXO:1;^+9O#5O:7^HZP@@>."S2-A,DJEO,5BX
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MUA98IY;AXTBX CE;+2-*H4=<YW;1S5WX\?\ )'?%O_7@_P#2L.^4-\2/A$2
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M6&AS;#_:MQ#$(HU;H\B"4RHOJS( .^*\W?1;W5_#_CN>PLWU.?2_'8U,Z=&
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M.O/=8\-W7B3_ (6:+2UGU%[#Q/9Z@^GVLACENXXTC,D:.""K%=Q!'.5&.2*
M/5+WXK1:3IZZGJ?AKQ!IFBY&[4KBVBV1*?XY(ED,R+ZEHQCOBMG7O'6F:"=+
MBS+J%YJQ(T^SL%$LEU@ LRG(4*%8,79@H'>O+-6\1_#ZZ\.[M,O]>\1ZG>QF
M.#P_#XBU$W,KMA?+EC,Q,2Y/S,XP!D\\ Z]XL/PU^(&CZW>V,]CX8_X1R/1S
M<)NGCTUXY-ZK*_+!""%\P\95<GG( -^[^,-CI.L:;I6KZ'K.C:AJ5W':6L-U
M%"RRESC>LD<K(54E=P#;AN'RFM;4/']M#KMWHNFZ=J&OZI9HLEW;Z>L:BW#
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MN% '- &Q)?V-U\5M/MTU+5OM7]C27:6L,R_V=)%YJIO9>K29<8/3 _/*\/\
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MG/\ >"$?C7=_\+L\&WVD[UO_ +5=3#R_[$$):_=RN?*-OC=D_=R1MR1S@YH
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M#YFC/&2C+AQD$'@UV_C;QA8^ _#=UKFI+*UE;-$LGDA2PWR+&#\Q P"X)YZ
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M@-\R[2VTGH.I!X>\-:SXQ\!VGBB77]4M?%.I6PU*V^Q7T@LX"Z;H81;$B)D
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M=&9,X89&"#D<YQD"LGP+XN?7-<N=.\0:''HGC.RME\X* ZW%N2/WD,O>(O\
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M.1D5S7P]O_'GB[X3Q>*KSQ:UKJ+V\D]O;QV-N8'5"PS,-FXEMI^XR8!'4@T
M>W45Y!;^(/%?B;X6S^.8==.B3?89-0MM+@M(9K?8@)VRLZEV+A<Y5DVE\?-C
MFSXD^*]Q=-X7TW2UNM.N=:TY=6N+NWTZ747M+<A?E6.-22Y9@NYAM7J020*
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MU+1M'M+(Y\R:UU>6>1>#C"-:H#S@?>& 2><8/GGPMO/$L'_"8KI6D:3>VO\
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M-N2 3C.<<XKS;P3XBM?A6_C/PQJA%OIN@"36=.5 03I\I9]B _>*2;DSDY)
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MH72V5L-C-YDS*S*O .,A&Y.!QUJ/Q%XKTCPG:QW&K7T5DDCB.)6RSRL?X40
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M2*AD+7VDW=HF 0.'EB52>1P#GJ<<&N.U+[1\<OA?I,NF^3IL-_=0RWMO?!I
M$AFS+%\A!;YX]O!7(SRN:T=%\7:YIOCJ/POXFCL)'O;62ZT[4=.CDBCG\M@)
M(VC=F*N%96X8C'?M0!U/A[Q%I_BK2(=4TNX^U6,Q=4EV,F2KE&&& (PRD<CM
M6E7G?P?C:VF\>VY&%C\47C*.O#I%*?UD-=;X7TW5M*TOR-9U@:[>^8[?:Q:K
M;#:3E4V*2.!QGJ: #Q!XKTSPS]F6_FD$UTS+!;6UO)<3S%1EMD4:L[ #DD#
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MU43X^T%='U/5&U%4T_3+J2RO+AXW5894<(ZG(Z!B!N''?.*YG]GO_DD^E_\
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M_&WASQ-X_P# ^IZ/=V>DZ7=RS6LD#0ZA+<1L([A)'W$P(5.$P, Y)YQ7H%%
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M?.\4R1OD.0"59.""0>36-#\./%NI>+-;UW6]2TN:34/#TFD16UHLB1VSER5
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M/L[7%RY41Q-Q(1A&RVW( P.N<C%=-10!GZ!H=KX:T.PTFQ3R[2R@2")>,[5
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M5?>%]7UKQKX-\07*65I_94%]'=V\-P\OS3+&$\MC&NX#8<DA>O0TSPAX'OO
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M/>N0UWX1ZSJG@GQWHT-Y9P7>O:\NJ6LV]]L48>W;YODX?$+< $9(YZX];HH
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MW?'-=!X@\#WT?CBQ\6>');:VU!E6TU2VN<I%?6V<Y)521*F!M;'3Y3Q7<44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mnlk-20231231_g3.jpg
<TEXT>
begin 644 mnlk-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1H!\H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#S7X]_'OP_P#LZ^#[/Q)XDL]2O;&ZOTT](]+BCDE$C1R2 D/(
M@VXB;OG)''IX+_P](^%7_0O^,?\ P"M/_DFC_@J1_P F_P#A_P#[&>W_ /22
M[KYK_8N_9'\)_M(^%O%-_P"(=4UG3KO3;F.WM_[,EA6,[D+9=7C8G! Z$5ZM
M&C1]C[6J<\I2Y^6)]T?"+]LKX7_&C7(]$T36)K/6IA^YL-4@,$DW!)"')5B
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MV>0F<[<?>XS7H/[47[7>B?LSQZ5:W&CW/B#6]21YH;**7R(UB4X+O*5;&6X
M"D\$G'&?S+_97^+FC_ _XU:/XOUVVOKO3;.&XCDBTZ-'F)DA9%P'=1U89YZ5
M]K?M:?$+X)_$[X3_  [\6>.=&\6K:ZX)Y=(N]#2V2_MD4IYB2B20Q[6^7CY^
MG!'.?0JX:$*\5R^Z_P S"-1N#UU/?OV:_P!HS1_VDO!$^N:=83:1>V<_V:^T
MZ:02>2^T,"K@#>A!X.%.0>!CGUROGG]AV/X;O\'9;CX::9J]EI9U"6&ZN/$"
MQ?;KJ954[W,3%2H5U50, 8/&22?6_B-\5/"?PCT,:QXOURVT/3V?RTDGW,TC
M;2VU$4%G. 3A037G58KVCC!?(WB_=NSJZ*^1+K_@I[\);>^,$>F>*KF($#[5
M%8P",Y R<-.&XS_=[<9KVWX/_M(_#_XYPO\ \(KKL<]]&"TFFW0\FZ09(SY9
M^\/ESE<@ C.,XHE0JP5Y1T!3B]$STZBL;QGXIM/ W@_7?$E_'--8Z/83ZA<1
MVZAI6CBC:1@@) +$*<9(&>XKY]^'/_!0KX7?$;79M.2'6O#\<%K+>3:AK<-O
M#;1QQ@$Y9)W.3D  #DD#J:F-.<TY15TAN26C/INBOE#5O^"EWP@TO6&L8HO$
M.I0K,8C?VEC'Y& <>8-\JN5[_=S@=*]^^%OQ=\)_&CPV-=\(:O'JU@',4N$:
M.2&0#)21& 93]1@CD9'-.5&I35Y1L@4HO1,\U_:N_:H_X9AL?#=S_P (Q_PD
MO]L2SQ[?[0^R>3Y80YSY3[L[_;&*Z#]F3X]_\-&?#F;Q5_87_"/>7?RV/V3[
M9]ISL5&W;_+3KOZ8[=:^%/\ @H;^T)X=^+.O:?X3TBRU2VU'PCJFH65_+>Q1
MK#(X=8B8BLC$C=$WW@O!''8=I_P3W_:;\+^"]!TSX77MAJ\OB#6=;DDM[FWA
MB-JHD2,+O8R!A_JSG"'J*[WA?]F4^7WOT,?:>_:^A^B5%>0_&[]JKX>_ &:W
MM/$VI2RZK.%==+TZ(37(C.<2,I("KP>I!/8&N \ _P#!1/X0^.M:@TR6YU3P
MO),^Q+C7X(H;?.,_-(DCJ@[98@5P*C4E'F478UYHIVN?3M%,AF2XB26)UDB=
M0RNAR&!Y!![BGUB6%%?._P :_P!N3P)\!_'<_A/7])\17FHPP1SM+IMM \.U
MQD %YD.?7BH/&7[?7PL\'^++?PX)-7UO5'F2WG32K-9%M96.#&[.Z@LI.&";
ML'(Z@@;JA5:34=R.>/<^CZ*9-,EO$\LKK'$BEF=S@*!R23V%?,_CO_@HE\'?
M!.H&SM[_ %+Q3(I =]!M5DC7.?XY7C5L8'W2?O#T.(A3G4=H*XW)1W/INBOF
MSX=_\%!/A#\0M5@TXZC?^&;F<[8_[>MTAC+;@H4R([HN<YR2!@')%?2$,R7$
M22Q.LD3J&5T.0P/((/<43ISINTU8:DI;#Z*Q?&'C+0_A_P"'KO7?$>JVNC:3
M:KNENKN0(H]%'=F/0*,DG  )-?,FK?\ !3;X0Z=JLEI;VOB75+=7VB_M+")8
M7&<;@))4?'?E ?;M3A2J5/@5Q.2CNSZUHKYWU/\ ;P^%-G\.7\965]?ZU:0W
M<5G<:=8VZB]MWD#E"\<KH-I\MOF!(KJ_V?/VFO"_[25IK=QX9L-7L4TEXHYQ
MJT,498R!RNWRY'S]PYSCM3=&I&+DXZ(.:+=DSUVBJFK:M8Z#IMSJ.IWMOIVG
MVR&6>[NY5BBB0=69V("@>I-?,?BS_@I)\'O#.H2VMK+K?B,1OL,^DV*^4<#D
M@S21Y&>,CKC(R,$J%.=3X%<')1W/J>BOF[X<_P#!0+X0?$35(--.IWWAF\N&
MV1+K]NL$;-V!E1WC7/\ M,!VZD"OI&E.G.F[35AJ2EL?%/AG_@I'_P )%\7=
M*\#_ /"N_L_V[7(M%^W_ -M[MF^X$/F^7]G&<9W;=P],]Z^UJ_%#X<S);_M:
M>&)976.)/&]JS.YP% OU))/85^B7C[_@HG\(? NM3Z9%<ZIXHDA?8]QH$$4U
MOG&?ED>1%<=LJ2*]#$X:THJC'H84ZFCYF?3M>!_M1?M=Z)^S/'I5K<:/<^(-
M;U)'FALHI?(C6)3@N\I5L9;@ *3P2<<9ZOX*_M*> ?C];W'_  B6K-+?VL8E
MN=,O(FAN85+$!BIX89QED+ ;E!()Q7CG[?S?".'0_"G_  L[3/$<T\TTZ:=J
M'A<0"YA"B,R(QF8*5;*<%6Z'&._+1I_O5"I%^AI*7NWBSUC]FO\ :,T?]I+P
M1/KFG6$VD7MG/]FOM.FD$GDOM# JX WH0>#A3D'@8Y]<KYY_8=C^&[_!V6X^
M&FF:O9:6=0EANKCQ L7VZZF55.]S$Q4J%=54# &#QDDG$US_ (*&?#GP_P#$
M;4/!=QHOBA]4LM5DT>2:*UMC 9DF,18$W ;9N&<E0<=NU$Z+E4E&G'1 I6BG
M)GU#17S5\1?^"@WPB^'NLRZ8M]J'B:XAR)7T"W2:)6#%2OF/(BL>,Y4D8[UV
M_P $OVJ_AW\?II+/PSJDT>L11>?)I.HPF&Y5.,D<E7P3@[&;'&>HSFZ-2,>9
MQ=BN:-[7/7J**\$^,'[;GPL^#.K7&D:EJESK6MVS;9].T.$3R0MG!5W9EC5A
MSE2^X8Y'(S$(2J.T5<;:CN>]T5\T?#S_ (*%?"'X@:U;Z6U]J7AFYN"$B?7K
M98HF<G 4R1NZIGKEB%]\\51C_P""BGPVF\>KX231_%#Z@VI_V4LZVML8#(9?
M*#!OM&=F><XSCMVK7ZO5O;E9//'N?4M%%%<Y9\D_M'_M[?\ #/OQ.N?"'_""
M_P!O>3;0W'VS^U_LV?,7.-GD/T]<U]*_#OQ9_P )]\/_  SXG^R_8?[:TNUU
M+[+YGF>3YT2R;-V!NQNQG SCH*_+7_@H]_R<]J7_ &#;/_T77V-X?_:V^&WP
M)^!?PUT[Q%K$D^N+X3TN7^R--A,]SM-G&1NZ(A(Q@.RD@@].:].KAU[*#IQU
M9A&;YGS/0^I:*^8/ _\ P48^#OC+4A9W5YJOA9V.(Y=<LU2)SD<;XGD"]>K[
M1P>>E?3D,R7$22Q.LD3J&5T.0P/((/<5P3ISIZ35C524MA]%5M2U*ST>QGO;
M^Z@L;*!=\MQ<R"..-?5F)  ]S7S#XO\ ^"DGP>\+ZD;2TEUOQ,%)5KC1[%?*
M4CMF:2,MWY4$''7IEPISJ? K@Y*.Y]3T5X;\)_VT/A3\8-2@TO2M>;3=9N)/
M*@TW6(3;RS$XVA&R48DG 4-N..G2O3/B7\0-/^%?@36?%FK0W5QIVE0>?/%9
MJK3,N0,*&903SW(I2ISC+E:U'S)JZ/E;XU_\%&?^%/\ Q2\0>#O^%>_VO_9,
MRP_;?[:\GS<HKYV?9VV_>Q]X]*^H_%WCO_A%?A5K7C/[#]J_LW19M8^P^=L\
MSRX&E\O?M.,XQNVG&<X[5^,G[0WQ$TWXM?&;Q1XNTB"ZMM-U2X66&*]15F4"
M-%^8*S '*GH37Z+:-^TMX8_:"_9E^+EGX=L-6LI?#OA"XBNSJD,48<R65P%\
MO9(^1^Y;.<=1[X]*MA5",&H^OX'/&HVVFR+]G#]O;_AH+XG6WA#_ (07^P?.
MMIKC[9_:_P!IQY:YQL\A.OKFOK:OR#_8#\1Z7X1_:#@UC6M0MM*TNTTN\>>\
MNY1'%&NP 98\<D@#U) K[-U;_@I=\(-+UAK&*+Q#J4*S&(W]I8Q^1@''F#?*
MKE>_W<X'2HQ.&:J<M&.EBJ=3W;R9]7T5QWPM^+OA/XT>&QKOA#5X]6L YBEP
MC1R0R 9*2(P#*?J,$<C(YKL:\UIQ=F;[[!1112 \A_:!_:@\'_LWVVD2>)HM
M1O9]4=U@M-*CCDFVH!N=@\B +EE&<]3TX.&?L_?M3>#OVD%U=?#46HV-SI90
MS6FK)%',R/G#HJ2/E01@GC!(]:_-[]N3XIR?&#]HC5+:P$EQ9:&W]A64<1+B
M5XY&$C*H'):1F'&<A5Y(Q5;]B[XH3_!7]HS2$OO]'L]4E_L'44F<(L0DD4!F
M)! V2*A)XX##(!->S]2C[#F^U:YR^U?/;H?L7117EW[2?QNM?V?_ (2ZIXKE
MBBNK\,MKIMG,2%N+I\[%..P =R,@E8VP<XKR(Q<VHK=G2W979-\9OVBO GP%
MT])_%>L+#>2H)(-+M0);R==VW<L>1A<@_,Q ^4C.>*^5-:_X*N:7;WTJ:1\.
M+R^LP[".:]U9+:1E[$HL,@!/<;CCU-?*GP=^$?C;]L/XK7B3:M)+.Y^UZOKU
M_P#O1;1LQY"Y&YB<A8UP/]U02/T$\)_\$Z?@QH.E16^JZ->^);P(HDO+S49X
M2S ?,52%T !/8YQZUZLJ6&P_NU?>9SJ4ZFL=$<K\.?\ @IU\/O$US%:^*-'U
M+PA-(0/M&1>6JDG'S.@5QUZ^7C /3O\ 6WAWQ'I?B[1;36-%U"VU72[M-\%Y
M:2B2*1<D'##C@@@^A!%?$'QP_P""9&D7.CS:A\,+^:SU2%-PTC5)]\-Q@L2J
M2D91R" -V5X&2N2PZ;_@GW^SOX_^$NG:CKOBG4;G1=/U:/\ =^$W4%MX( N)
ML_ZM]H("KR01N/ 6L:M/#RA[2E*WD5&4T[21Z?\ 'O\ ;-\%?LZ^,+/PWXDT
MO7[V^NK!-0232[>"2(1M))& 2\R'=F)NV,$<^GG,'_!43X432JCZ)XN@4]9)
M+*V('Y7!/Z5\\_\ !4C_ ). \/\ _8L6_P#Z5W==Y\$?^">?@3XL?!'PUXJN
M=?\ $5AK>K6?GOY,L#6T;[R.(S%N(P.F_P#&MHT</&E&I4OJ3S3<FHGV!\'?
MVC/ 'QXAN/\ A$-<6\O+5!)<:?<1-#<Q*3C<48#<N2!N7*@D#.>*]+K\3?#%
MYK'[-?[2D,=I>&6^\-:\UC+-$-JW4*RF.0;<G"R1[AC.1NZ@C-?ME7+BJ"HM
M.+NF:4YN2U/GGXW?MQ?#_P" WCE_"FMV.NZEJD=O'<3-I-M"\<6_)5&,DJ'=
MMPW (PZ\YR!P/_#TCX5?]"_XQ_\  *T_^2:^+OCE<77QU_;"UZPMK@W3:IXC
M71;6:-E9?+21;9&4CY=NU V?3D]S7VC_ ,.M_A5_T,'C'_P-M/\ Y&KKE1P]
M&,?:WNT9\TY-\I[E\ ?VB/#G[1OA_4M8\-66J6-M877V25=5BCC<OL#Y41R.
M,88=2*P?VA_VNO!7[.OD6>K&XU?Q!<Q^;%I&G[3(J9P'D8G$:GG&<DX. <&M
M3X*_ CPM^RUX+UZVT*^U6]TZ61M2N9-4FBDD79& 0I1(P!M7O^=?E+X;TO6?
MVJ?VBK>UN;EH=1\5:JTL\^/,-O#R[E1QD1Q*<#@?(!P*RHT*56<I?814IRBD
MNK/L#2?^"KFES:K''J?PXO+332^'N+35DGF"YZB)H4!..V\?7O7V'\*?B]X6
M^-7A6+7_  IJ27]FVU9HC\LUM(5#&*5/X6&?<'L2.:^9_B__ ,$Y_AXOPKU(
M^"M/U"T\6:?9R36MPUY).;Z10&V2(<KE@I4>6J\L.O2OF;_@G3\4[OP3\?+3
MPZ]TR:+XFBDM)H6)V>>B-)#(!_>RIC!])3]1<J-&M3E.BK-$J4XR2GU/UDHH
MHKR3I"BN5^(WQ2\*?"/P^VM^+]<M=#T[<$62<EGE8_PQQJ"\C=\*"0 3T!-?
M.'_#SOX2?VE]F_L_Q3Y.[;]L^P0^5C^]CS]^/^ Y]JVA1J5%>,;DN48[L^N:
M*^<_&G[>GPK\(^$=#\26]SJ7B33=6FEMT&CP1M+;R1JC,DR2R1E#B1<=<\]J
M](^!?QRT']H+P7)XG\.VFHV5A'=R61CU2...7>BJQ.$=QC#COZ\4I4JD8\TE
MH"DF[)GHE%?+FD_\%$OAMK'Q LO"":1XF@U"ZU1-)6YN+:V6W21I1$'9OM&0
M@)R3C..W:G^./^"C'P@\%ZK)807.K>)VC(#3Z':QR0\C/#R2(&]/ESS5_5ZM
M[<K%SQ[GU!17EWP5_:4\ _'ZWN/^$2U9I;^UC$MSIEY$T-S"I8@,5/##.,LA
M8#<H)!.*]1K&491=I*S*33U045X)\8/VW/A9\&=6N-(U+5+G6M;MFVSZ=H<(
MGDA;."KNS+&K#G*E]PQR.1G'^&__  4#^$?Q&UJ+2_M]_P"&+F8?NW\00QP1
M,V<!/,61U4GK\Q ]\\5K["JX\W*[$\\;VN><?\/*/^+K?\(7_P *Z_YC7]C_
M &[^W/\ IOY7F;/L_P".W=[9[U]M5^)G_-UG_<Z_^WU?MG75C*4*7+R*UR*<
MG*]PKP_]H#]KKP=^SCK6E:7XETW7+ZXU&W:YB;2H(9$50VTAC)*A!SZ U[A7
MYJ_\%5/^2C>"/^P3+_Z.-8X6G&K549;%5).,;H]I@_X*B?"B:54?1/%T"GK)
M)96Q _*X)_2O=/@S^T?X!^/5O<GPCK(N;VU7?<:=<QM#<Q+NP'*-]Y>GS*2!
MN )!XKXO_9P_8&\$?&WX!^'_ !C?Z[X@TW7=4%SN%M) UJACNI8EQ&8MQ^6,
M9^?J3]*^:-/37?V:/VCX[6SOA)JGAK6Q;F:%FC2ZC60!E8 YV2(<,N>C$5W?
M5J%3FA3;YD8^TG&SELS]M*9-,EO$\LKK'$BEF=S@*!R23V%/KY__ &Y/BU_P
MJ?\ 9^UMH'*ZIKH.BVFQ]KJ94;S)!@$C;&'.>.2O()%>33@ZDE%=3I;Y5=G$
M2?\ !3;X3IK36 TWQ/)&+CR!?+:6WD$;MOF FXW;._W<X[=J^LK6ZAO;:*XM
MY4GMYD$D<L3!D=2,A@1P01SD5^ 0TV[.FG4/L\GV$3"#[1M.SS"I;;GUP,X^
MGK7Z[_L&_%H_%/\ 9^TJ&Z=6U3PZPT6X&\%V2-%\F0C (!C*KDYR48Y)S7I8
MO"QHQ4H?,YZ=1R=F?1=> _M&?MG>"OV>+I=)NX[CQ!XG>,2_V38,H\E3RIGD
M/$>1R  S'@[0"#7OU?B%\2-4'B;]I#7[GQU--903^)I(]7:)&9[:$7)2147)
M/R("%7)/R@5CA*$:TGS;(NI-Q6A]K>#/^"J7AO5-62W\3>"+_0+)V5?MEC?+
M?;,G!9T,<1VC@_+N.,X!/!^U/#/B;2O&6@V6M:'J%OJFDWL?FV]W;.'CD7IP
M?4$$$=000>17Q1\8O^">O@KQYX!TC6_@M+;V5XR)(AFOY9[34H7Q\_F.S[&
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MZN+'(Q-<:PL4N,\_((6'_CU?2/[/_P"UEX&_:(A>#19YM,UZ%-\VBZCM6?:
MNYXRI(=,MC(P>.57(KR+X8?\$X?AQ'\+]/@\7VFH7WBR\MHYKN_AO)(#:2L
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MQRQK(H< D!@&&<$C/<UMC**HS]Q61-*7,M=S9HIDSF.)W6-I6521&F,M[#)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&[/P?^)_P[U;X2^/];\(ZVB+J6E7!AD:,Y212 R2+WVNC*XS@X89 /%?I?\
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MT>3Q!^R7XCTN*18I;[4M0MED?HI>WB4$^PS7YR^"/"NF:U\0-/\ #_BC6_\
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MD9"HK'&<G  Y(K]3C\'9/@-^Q7X[\&/K;>(%L?#NM2)>-;_9QB2&:3:$WO@
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M$,I>5KA2?7(F'(XX(Z@UI6]["1:[_P"8H?Q&<=_P5.TU9?@OX5U D;X/$"P
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M_P"UYX3N_@/^UAJ6J:0JVHEO8/$VF, 0%9W\PG'8"=)0 #T48QT'[ 5\0?\
M!43X7R:UX!\.>.;.W>231+EK*]9.BV\^-CM[+*JJ/>;OVSP53EJ\KV>A557C
M?L==^VA\>["#]D>#4M'NU2;QU;V]O9*LV)!!*@DG.WJ0(P8VZ8,H!ZX/YY?L
MT_$[_A3_ ,</"7B>65HK"WNQ#?$'C[-*#'*2.^U6+ >JCIU&#KGCWQ!X^\/^
M#/"EQ*]W:^'XI;+38-Q)S/.7/4]22BCV11V%?0?[:_[+J? OPC\-=1TZ,36R
MZ>-'U6[BP$>_4O-YF, _O-\N.N%A //)]6G3A0C[&7VKG-*3D^==#VG_ (*C
M?%"*'P?X0\$V5Q'*VISMJ]R8\D^3&"D//0J[.YXS_JAT[]O_ ,$^_!MI\*OV
M9KWQEJ:B)]8>?5KB4$EUM( R(I!XZ)*X]I.3V'YXZ;<>(OVBOBEX1T;4+PSZ
MA>#3]!@F8G$4$:I"&.<GA078\Y)8XYQ7[%?$+P'%+\"?$O@OP_;"VA;PW<Z/
MI]LFYQ&IM6BB09))P-HY.:XL1%4:4*%]]S:'O2<S\B?&GCKQ#^U1\:H[K7]?
MT_2CJ$Y@M[C6+M+2PTRU&Y@NYCM157)ZEG8_Q,W/TO8_L:_LY1Z'Y5Y\?M.G
MUG;_ ,?<&N:;%;YXY\DEFQUX\SN.>.?D#X1^#M$^('Q TKP]X@\3IX/T^_<Q
M#6)K83Q0R8.P.-Z85FPN[. 6!/&2/M7_ (=.?]53_P#+>_\ NJNVO*%.T>?E
M^1C!.5W:Y\J>([6]_9=^-%E>^#/&^D^*7T]DO++6M#NDE@GC)(,4RQNVTG:R
MO$6/RMUPP-?J+\0OVC+/0_V6;CXL:7&J/=:3%<6%O,0^RZFVI'&PXW;)'^;'
M4(U?*=C_ ,$P=(U/5+S3+/XT6-WJ5EC[59P:,CS09Z;T%WE?Q%>G?M.?!*\^
M'O[!G_")0:H=<?PO)!</=M 83/']I.<)N;;M$W]X\(?I7)6G1K2IJ]W?72VA
MK%2BGH?"?PV\*R?M$?%*[N/&GC[2_#:7+->:GK_B"]BB9\G&V-7==[G@!00%
M4=@ #]*ZY^QM^SQ+H+1Z-\?M+MM:&2MQ?:YITUL>N 8U*,/X>=YZ'CGCYU_9
MG^!NA_M >,+GPSJ/C=/!VJM&LFG1RZ>+E;XC/F("9H]K@;2%YW#=TV\_4O\
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MF*M:/\6/JB9?"SX[_P""6/\ R6+Q9_V 3_Z40U^G%?F/_P $L?\ DL7BS_L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'QWXR_:*U#4M \%>(M<TYK"U1;S3=*GN(2P3! =$(R.XS7Z"_ C3KO1_@?\
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M%OJ>F0C,EY$N!'+&.\BC*D?Q*%QRN&^VJ*SI5949J<2I14E9GXJ:%\??C/\
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M.T3&/*K'XI^.OAC\<OB5XJU#Q'XC\!>-M3U>^D\R:XET&Z^@51Y>%4# "C@
M "KOACPA^T;X)TTZ?X=T3XHZ#8-(93:Z7::E;1%R "VQ !D@#G'85^S]%=W]
MH.UN16,?8^9^5'P9_P"&E?\ A<'@7^WO^%K?V'_;MC]O_M'^T_LWV?[0GF^;
MO^7R]F[=NXQG/%?JO117%6K>V:=K&T8\O4****YBPHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@=<^&_B'5M6NKRU^*OB
M[1;>9]R:?8VNCM# /[J&;3Y)"/\ >=C[U1_X5-XI_P"BT^.?_ +0?_E97IE%
M:<[_ *2)Y4>9_P#"IO%/_1:?'/\ X!:#_P#*RC_A4WBG_HM/CG_P"T'_ .5E
M>F44>T?E]R#E1YG_ ,*F\4_]%I\<_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\
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M@_\ RLH_X5-XI_Z+3XY_\ M!_P#E97IE%'M'Y?<@Y4>9_P#"IO%/_1:?'/\
MX!:#_P#*RC_A4WBG_HM/CG_P"T'_ .5E>F44>T?E]R#E1YG_ ,*F\4_]%I\<
M_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\ Y65Z911[1^7W(.5'F?\ PJ;Q3_T6
MGQS_ . 6@_\ RLH_X5-XI_Z+3XY_\ M!_P#E97IE%'M'Y?<@Y4>9_P#"IO%/
M_1:?'/\ X!:#_P#*RC_A4WBG_HM/CG_P"T'_ .5E>F44>T?E]R#E1YG_ ,*F
M\4_]%I\<_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\ Y65Z911[1^7W(.5'F?\
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M/^%3>*?^BT^.?_ +0?\ Y65Z911[1^7W(.5'F?\ PJ;Q3_T6GQS_ . 6@_\
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M>F44>T?E]R#E1YG_ ,*F\4_]%I\<_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\
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M@_\ RLH_X5-XI_Z+3XY_\ M!_P#E97IE%'M'Y?<@Y4>9_P#"IO%/_1:?'/\
MX!:#_P#*RC_A4WBG_HM/CG_P"T'_ .5E>F44>T?E]R#E1YG_ ,*F\4_]%I\<
M_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\ Y65Z911[1^7W(.5'F?\ PJ;Q3_T6
MGQS_ . 6@_\ RLH_X5-XI_Z+3XY_\ M!_P#E97IE%'M'Y?<@Y4>9_P#"IO%/
M_1:?'/\ X!:#_P#*RC_A4WBG_HM/CG_P"T'_ .5E>F44>T?E]R#E1YG_ ,*F
M\4_]%I\<_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\ Y65Z911[1^7W(.5'F?\
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M/^%3>*?^BT^.?_ +0?\ Y65Z911[1^7W(.5'F?\ PJ;Q3_T6GQS_ . 6@_\
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M>F44>T?E]R#E1YG_ ,*F\4_]%I\<_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\
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M@_\ RLH_X5-XI_Z+3XY_\ M!_P#E97IE%'M'Y?<@Y4>9_P#"IO%/_1:?'/\
MX!:#_P#*RC_A4WBG_HM/CG_P"T'_ .5E>F44>T?E]R#E1YG_ ,*F\4_]%I\<
M_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\ Y65Z911[1^7W(.5'F?\ PJ;Q3_T6
MGQS_ . 6@_\ RLH_X5-XI_Z+3XY_\ M!_P#E97IE%'M'Y?<@Y4>9_P#"IO%/
M_1:?'/\ X!:#_P#*RC_A4WBG_HM/CG_P"T'_ .5E>F44>T?E]R#E1YG_ ,*F
M\4_]%I\<_P#@%H/_ ,K*/^%3>*?^BT^.?_ +0?\ Y65Z911[1^7W(.5'F?\
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M0 4444 %%%% !17CG[*>O:EXB^%8N]5U"ZU.Z^W3)Y]Y.TK[0%P-S$G%>QT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'SU^TWJ7]C?$3X2W_V2ZOOLVH3R_9K*/S)I</;'
M:BY&YCV%=;-\>KN2&06/PT\<376/W<=UI7D1L<]"^XX'X&N>_:"_Y*U\&?\
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MF_QH @\<?#OQ=\-O#EQXH\,^/=?U2]TN)[J[LM>NA<6\\2KE]JD +@;CCGH
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MD&GNDE[I7B&Z^TQSQ%MK;3@;<;AP .,D'( -K]DF-%\'^*9 BB1O$5RI;')
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M)?\ T UY5^R-_P D7L?^ONX_]#KU7Q+_ ,B[JO\ UZ2_^@&O*OV1O^2+V/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^!]+\._;/[0^PJZ_:?*\K?N=G^[N./O8ZGI73T4 </X%^&?_  A?C#QEKO\
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M^&?]M?%;PWXT_M+R?['MYH/L/D;O.WI(N=^X;<>9G&T]*[BBB@#S[P3\)_\
MA#OB%XK\4?VK]L_MUP_V7[/L\CYB?O[SNZ^@J7X??"W_ (03Q;XSUO\ M/[=
M_P )'=K=>1]G\O[/M:5MN[<=_P#K>N!T]Z[RB@#A_A)\,_\ A5NBZII_]I?V
MG]MU*74/,\CR=F]479C<V<;.N1UZ5J_$3P?_ ,)]X*U7P_\ :_L'VZ(1_:/+
M\S9\P.=N1GIZBNCHH Y#1-/'PH^&5O:,+G6TT2R^;['"JS3J@))5&?&<9XW<
MXXR>*\T\+_#RQ\70'Q;\+O&EYX0L]282W.G16Z3P1SC!96A+!48<97D8Z?*1
M7O5>8:Q^SSX9OM;N-7TNZU?PKJ-PQ>:?0;YK8NQSDXP0,Y/0#J?4T <1\6?
MMCX9\"ZSKOCWQ7>>+M62UECTVWN0EO;+<.@C1X[9" 6!.2<G R<9&:].^"7A
MVZ\*_"GPSIE[$8+N*U#RPL"&C9V+E6!&0PW8([$&LOP_^S[X6T?6UUG49-2\
M5:LA#1WGB&[-TT9 P,# 4]L$@D;1C&*],H 9)&)HW1BP5@5.UBIY]".0?<5X
MROP%\3Z?8WFDZ3\3]5L]!NF;=:7-HEQ,J,<LJS%@RDY;E0.O2O::* .<\ ^
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MNVY.,XSC)QGK6M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM"]U1OM<,"P*H55<B1@6(5Y?N@D<\<BOIFN2;7L813[FB^)L****YC0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8)QOD95SD D@BER2[!=':45P?AGXO6&M^+#X6U31]6\(^)7MVN[;3=;2'-W
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M?AO'X]FUI;;PI(F]+ZXMY8F?YR@58F02%BP("A=QXP#D4O9R[!=';45Y;?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@HHHK,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$Z'XJU(0@7VKZUI\5U//,1\[*SJ3&N20JIC  ZG)/S6_@33?V,O^"@?@'2O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'A2_O8[-I@<>2)CPA/50_F#CC(([5]8USU8>SJ2AV9I"7-%,****R+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&D@N(Y7D)A^< NBQR"++ ;@N<#.!ZS16/M)<GL^E[E\JYN;J? EC^SG^T?\
MLCZIJ-M\"=6TSQYX NY6N8/#7B)T26UD:1<@%WC'W>K)*@;YR4#!2;&K_!?]
MJ?\ :R@BT+XMZGH?PM\ M,K:CI'AXK+=7JKR%!624$94??E"@L&V.5 'WG16
M_P!:GO9<W>VIG[%;7=NQA>!?!.C?#?P?H_A?P]9)IVBZ5;):VMO'_"BCJ3U9
MB<LS'EF))R2:W:**Y&VW=FX4444@"BBB@ HHHH **** "BBB@ HHHH ****
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M66-M<+XKUK1M:N&<&"31M'ETY$7'(99+JX+'/<%?H>M=%12YG:P6.&\-Z/\
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M:$$=W;[".<Y+9R.F.7:?8^*X_"4MO>ZUHUQXG*2"/4K?2)8K)6).PFU-TSD
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MBCF>H6/.OB+-XXT./5M=LO&OA/P[X6T^U:[F_MCPS<WLEO''&6ED>:/4(05
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M_B%HNF6/A+QOX;1=8@UW2X1;3S-$0=CM&5W,1C:YRRLJX/8^)?M!?$"[\4>
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MVE3##6]Y&&QR#E6ZJ<@'*D$8'->G4J48U$JD>9K1OT\CEC&;C>+LF>2_L1?
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M8#.6/5J\JT?0=3\0W+6VE:==:G<*AD:&S@:5PH(!8A03C) S[BOVZ_X*2?\
M)EOQ$_[AW_IRM:^&_P#@D#_R<KXE_P"Q1N?_ $LLJ^IHXJ^'=11MRZ6^X\BI
M1M546]S[C_X)]_%K6?B5\ --TSQ/97UCXG\,;=*N?M\#Q/<0*O\ H\XW#G,8
MV$Y)+1.3U%?3-%%?-5)*<W)*USU8IQ23"BBBLR@HHHH **** "BBB@ HHHH
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MH0@(3:1[W81Y0E06:1F*J=H C7JG'U/117-4J.I)RD:QBHJR"BBBLR@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ^$_VE_\ DMOB/_MV_P#2:*O,*]/_ &E_^2V^(_\ MV_])HJ\PK[_  W\
M"GZ+\CY.M_%EZL****Z3 **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#T_\ 9H_Y+;X<_P"WG_TFEK[LKX3_ &:/^2V^'/\
MMY_])I:^[*^2S;^.O3]6?09?_"?K_D%%%%>(>F%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?,_P#P4D_Y,M^(G_<._P#3E:U\-_\ !('_ ).5\2_]BC<_^EEE7W)_P4D_
MY,M^(G_<._\ 3E:U\-_\$@?^3E?$O_8HW/\ Z665>WA_]RJ>O^1P5/X\3]?*
M***\0[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KX;_X*_?\FU>&O^QNMO\ TCO:^Y*^&_\
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MWPY_V\_^DTM?=E?)9M_'7I^K/H,O_A/U_P @HHHKQ#TPHHHH **** "BBB@
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M_@C%_P UA_[@_P#[?5^F%:8__>)?+\D3A_X2"BBBN Z0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#\E/VZ/\ DZ?QM_VY?^D-O7@]>\?MT?\ )T_C;_MR_P#2&WKP
M>OKZ'\*'HOR/GJO\27JPHHHK8S"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_>.OP<K]XZ\7,OL?/]#TL%]KY!1117B'IA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PG^TO_R6WQ'_
M -NW_I-%7F%>G_M+_P#);?$?_;M_Z315YA7W^&_@4_1?D?)UOXLO5A111728
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
MG_LT?\EM\.?]O/\ Z32U]V5\)_LT?\EM\.?]O/\ Z32U]V5\EFW\=>GZL^@R
M_P#A/U_R"BBBO$/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F?_ (*2?\F6_$3_ +AW
M_IRM:^&_^"0/_)ROB7_L4;G_ -++*ON3_@I)_P F6_$3_N'?^G*UKX;_ ."0
M/_)ROB7_ +%&Y_\ 2RRKV\/_ +E4]?\ (X*G\>)^OE%%%>(=X4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5\-_P#!7[_DVKPU_P!C=;?^D=[7W)7PW_P5^_Y-J\-?]C=;?^D=
M[77A/X\/4PK?PV>9_P#!&+_FL/\ W!__ &^K],*_,_\ X(Q?\UA_[@__ +?5
M^F%:8_\ WB7R_)$X?^$@HHHK@.D**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _)3]N
MC_DZ?QM_VY?^D-O7@]>\?MT?\G3^-O\ MR_](;>O!Z^OH?PH>B_(^>J_Q)>K
M"BBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PG^TO\ \EM\1_\
M;M_Z315YA7I_[2__ "6WQ'_V[?\ I-%7F%??X;^!3]%^1\G6_BR]6%%%%=)@
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z
M?^S1_P EM\.?]O/_ *32U]V5\)_LT?\ );?#G_;S_P"DTM?=E?)9M_'7I^K/
MH,O_ (3]?\@HHHKQ#TPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
MDI^W1_R=/XV_[<O_ $AMZ\'KWC]NC_DZ?QM_VY?^D-O7@]?7T/X4/1?D?/5?
MXDO5A1116QF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5^\=?@Y7[QUXN9?8^?Z'I8+[7R"BBBO$/3"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /A/]I?\ Y+;XC_[=O_2:*O,*]/\
MVE_^2V^(_P#MV_\ 2:*O,*^_PW\"GZ+\CY.M_%EZL****Z3 **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T_P#9H_Y+;X<_
M[>?_ $FEK[LKX3_9H_Y+;X<_[>?_ $FEK[LKY+-OXZ]/U9]!E_\ "?K_ )!1
M117B'IA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\M?LD6J?%CXB_$_XXWP^UOJNJS>'O#DTF"(=(M6
M"@Q^@ED!9O=/<Y]T^,FN'PS\(?'.L!MAT_0KZ[W=,>7;N^?TKA_V+="7P[^R
MG\+K14$8DT."\P!CF<&8G\?,S^-=$?=I2?>R_7_(S>LTCT#XH>&M=\9> =;T
M/PUXE;P?K5_!Y$&N):_:7M,D;W1-Z?/LW!6W#:2&YQ@_BK^V5^Q__P ,D:KX
M7LO^$M_X2O\ MN&>;?\ V;]C\GRF08QYLF[._P!L8[U^Z=?ES_P64_Y&KX7_
M /7E?_\ HR&NW+ZDHU533T?^1SXF*<')[H^T_P!AW_DTOX8?]@A?_0VKM_CC
M\/\ 7?BG\,-;\*>'_%;>"KW5(Q;R:Q'9_:I(H21YBHOF1X9URN[.0&..<$<1
M^P[_ ,FE_##_ +!"_P#H;5[G7#4DXUI-=W^9T15X)/L?@U^V'^RO_P ,G^.-
M%\._\)/_ ,)3_:6G?;_M/]G_ &/R_P!Z\>S;YLF?N9SD=>E?LS^S#_R;5\)O
M^Q1TG_TCBK\XO^"PW_);_!?_ &+H_P#2F:OT=_9A_P"3:OA-_P!BCI/_ *1Q
M5Z6+G*IAJ<I;LY:,5&K)(VOC%\+])^,_PR\1>#-:B62QU:U:'<PR89.L<J_[
M2.%8>ZUY]^Q=\1M2^(GP!T7^WY&D\4Z!-/X>UGS#EQ=6KF,[CW8IY;$^K&O<
MZ^9?V7E&B_M"?M+^'% 18/$5CJ_EC@9O+3S"V/?97G1]ZE*/;7]/U.IZ33[G
MTU1117.:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5\-_\ !7[_ )-J\-?]C=;?^D=[7W)7PW_P5^_Y-J\-
M?]C=;?\ I'>UUX3^/#U,*W\-GF?_  1B_P":P_\ <'_]OJ_3"OS/_P"",7_-
M8?\ N#_^WU?IA6F/_P!XE\OR1.'_ (2"BBBN Z0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#\E/VZ/^3I_&W_ &Y?^D-O7@]>\?MT?\G3^-O^W+_TAMZ\'KZ^A_"A
MZ+\CYZK_ !)>K"BBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K]XZ_!ROWCKQ<R^Q\_P!#TL%]KY!1117B'IA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PG^TO_P EM\1_]NW_
M *315YA7I_[2_P#R6WQ'_P!NW_I-%7F%??X;^!3]%^1\G6_BR]6%%%%=)@%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z?^
MS1_R6WPY_P!O/_I-+7W97PG^S1_R6WPY_P!O/_I-+7W97R6;?QUZ?JSZ#+_X
M3]?\@HHHKQ#TPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH YCXH: WBOX9^+M$2,ROJ6D7=FL8&2QDA=
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MY.7(SC.%#'M61^R;\*+SX-? 7PSX?U;YO$,B/J&KR$[F>\G<RR[CW*E@F?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_>.OP<K]XZ\7,OL?/\
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MK>HX(([6&.&&-8H8U")'&H554#   Z "I*SJ3YWIHEL5&/+ZA1116184444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?#?_!7[_DVKPU_V-UM_Z1WM?<E?#?\ P5^_Y-J\-?\ 8W6W_I'>UUX3
M^/#U,*W\-GF?_!&+_FL/_<'_ /;ZOTPK\S_^",7_ #6'_N#_ /M]7Z85IC_]
MXE\OR1.'_A(****X#I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R4_;H_P"3I_&W
M_;E_Z0V]>#U[Q^W1_P G3^-O^W+_ -(;>O!Z^OH?PH>B_(^>J_Q)>K"BBBMC
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK]XZ_!ROWCKQ<R^Q\_T/2P7VOD%%%%>(>F%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?"?[2__);?$?\ V[?^DT5>85Z?^TO_ ,EM\1_]
MNW_I-%7F%??X;^!3]%^1\G6_BR]6%%%%=)@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!Z?^S1_R6WPY_V\_P#I-+7W97PG
M^S1_R6WPY_V\_P#I-+7W97R6;?QUZ?JSZ#+_ .$_7_(****\0],**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\E/VZ/
M^3I_&W_;E_Z0V]>#U[Q^W1_R=/XV_P"W+_TAMZ\'KZ^A_"AZ+\CYZK_$EZL*
M***V,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OWCK\'*_>.O%S+['S_0]+!?:^04445XAZ84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\)_M+_P#);?$?_;M_Z315YA7I_P"TO_R6
MWQ'_ -NW_I-%7F%??X;^!3]%^1\G6_BR]6%%%%=)@%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!Z?\ LT?\EM\.?]O/_I-+
M7W97PG^S1_R6WPY_V\_^DTM?=E?)9M_'7I^K/H,O_A/U_P @HHHKQ#TPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **YKXC?$;P]\)_!NI>*?%.I1:5HFGQ^9-<2GD]E15ZL[' "CDD@"OCJ
M3_@IIK?B)[G4O G[/_C'QAX0M]QDUU#)&H56;<Q6.WE0 !2>9!T(.,9K>G1J
M55>",Y5(PW9]U45XE^S5^UQX(_:>T^_&@?:])U[3<?;]!U552ZB' ,BA6(>/
M<2NX8((&Y5W 'USQ%XBTWPCH.H:WK-[#IVE:? ]S=7<[;4BC4$LQ/L!6<H2A
M+EDM2E)25T:-%?)GP?\ ^"EGPQ^-7Q(T/P3H>A>+;75=7E:*";4+.U2!2J,Y
MWE+EF PAZ*><5]9U52G.D[35A1E&:O%A1145U=0V-K-<W,T=O;PH9))I6"HB
M@9+,3P  ,Y-9%DM%?%7B;_@ICIVK>(+S2?A%\+_%'Q=>RD5+B\TV&2& @JQ#
M)LAED(^5@-Z)G:Q&0,GO/V??V[/"WQJ\:77@;6]#U+X=^/H7=5T'71M>7: 2
MJL54^8 23&R@X!(S@XZ98:K&/,X_UZ;F2JP;LF?3-%%%<QJ%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!\S_P#!23_DRWXB?]P[_P!.5K7PW_P2
M!_Y.5\2_]BC<_P#I995]R?\ !23_ ),M^(G_ '#O_3E:U\-_\$@?^3E?$O\
MV*-S_P"EEE7MX?\ W*IZ_P"1P5/X\3]?****\0[PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKX;_ ."OW_)M7AK_ +&ZV_\ 2.]K[DKX;_X*_?\ )M7AK_L;K;_TCO:Z\)_'
MAZF%;^&SS/\ X(Q?\UA_[@__ +?5^F%?F?\ \$8O^:P_]P?_ -OJ_3"M,?\
M[Q+Y?DB</_"04445P'2%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DI^W1_R=/XV_
M[<O_ $AMZ\'KWC]NC_DZ?QM_VY?^D-O7@]?7T/X4/1?D?/5?XDO5A1116QF%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
M\=?@Y7[QUXN9?8^?Z'I8+[7R"BBBO$/3"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /A/]I?\ Y+;XC_[=O_2:*O,*]/\ VE_^2V^(_P#M
MV_\ 2:*O,*^_PW\"GZ+\CY.M_%EZL****Z3 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#T_P#9H_Y+;X<_[>?_ $FEK[LK
MX3_9H_Y+;X<_[>?_ $FEK[LKY+-OXZ]/U9]!E_\ "?K_ )!1117B'IA1110
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MCQ/U\HHHKQ#O"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _)3
M]NC_ ).G\;?]N7_I#;UX/7O'[='_ "=/XV_[<O\ TAMZ\'KZ^A_"AZ+\CYZK
M_$EZL****V,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH YKXC?$;P]\)_!NI>*?%.I1:5HFGQ^9-<2GD]E15ZL[' "CDD@
M"OB+X5_#_6?^"@GQ5;XL?$>POM/^$.C3>7X3\*WA'E7Q!P\L@'WEW*"YP0Y(
MC#%8R#]&_M*?L@^&?VIIM('BOQ+XIT^PTM6\G3=&O((K9I"3F9TDA?=)@[0<
M\#( &3GQ#_AT#\'/^AE\<_\ @?9__(E>A1E2A!OFM)^5[>G^9S5%.4MKH^X8
M84MXDBB18XD4*J(,!0.  .PI]?%_A7_@E'\)?!_BC1]>L_$7C26\TN\AOH4G
MO;0QL\3AU# 6H)&5&<$''<5]H5R5(PC\$K_*QM%R?Q*Q\,_M#_\ *3#X _\
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MDJT\J( TI"A06(Y8@  9[#%3UYIU!1110 4444 %%%% !1110 4444 %%%%
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M_P"AE\<_^!]G_P#(E?3GP!^ ^@?LY?#N'P;X:O-2OM+BN9;H3:K+')-ND(+
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MXDL+K5?#NJ65C=-97MS:RPP72L5,,C(0K@CD8)!XYXKXJ_X)M_\ )1?VDO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% ' _$_X!_#OXS6QA\:>#]+U]MNQ;FX@VW*+Z).F)%'^ZPKQ^/\
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M;>#=<NOH\[YD8?[S&N^HKDE6G)6;T^Y&ZA%:V"BBBL2PHHHH **** "BBB@
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MJ2NE9;+Y&D(\JL]PHHHK T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#\E/VZ/\ DZ?QM_VY?^D-O7@]>\?M
MT?\ )T_C;_MR_P#2&WKP>OKZ'\*'HOR/GJO\27JPHHHK8S"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_>.OP<K]XZ\7,O
ML?/]#TL%]KY!1117B'IA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'PG^TO_R6WQ'_ -NW_I-%7F%>G_M+_P#);?$?_;M_Z315YA7W^&_@
M4_1?D?)UOXLO5A111728!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >G_LT?\EM\.?]O/\ Z32U]V5\)_LT?\EM\.?]O/\
MZ32U]V5\EFW\=>GZL^@R_P#A/U_R"BBBO$/3"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /GFBBBO=/,"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /0_A+_ ,Q7_ME_[/7H=>>?
M"7_F*_\ ;+_V>O0Z\FO_ !&=U/X$%%%%8&H4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)))K*')]N_R-)<_V3SW_ (;H^"'_ $.W_E)OO_C%'_#='P0_Z';_ ,I-]_\
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M7I_[2_\ R6WQ'_V[?^DT5>85]_AOX%/T7Y'R=;^++U84445TF 4444 %%%%
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M]?\ (****Y3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#@OC]_R0GXC_\ 8MZE_P"DLE<'^PO_ ,FL>"?^W[_TNN*] ^.U
MO+=_!#XAP01O--)X=U%$CC4LSL;:0  #J2>U</\ L2Z?=:7^S%X,M;VVFM+F
M/[;OAGC*.N;V<C(/(X(/XUU+_=WZK\F8?\O5Z?J>XT445RFX4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^2G[='_)T_C;_MR_](;>O!Z]
MX_;H_P"3I_&W_;E_Z0V]>#U]?0_A0]%^1\]5_B2]6%%%%;&84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[QU^#E?O'7BY
ME]CY_H>E@OM?(****\0],**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^$_VE_^2V^(_P#MV_\ 2:*O,*]/_:7_ .2V^(_^W;_TFBKS"OO\
M-_ I^B_(^3K?Q9>K"BBBNDP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ]/_9H_Y+;X<_[>?_2:6ONROA/]FC_DMOAS_MY_
M])I:^[*^2S;^.O3]6?09?_"?K_D%%%%>(>F%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?/-%%%>Z>8%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >A_"7_F*_\ ;+_V>O0Z\\^$
MO_,5_P"V7_L]>AUY-?\ B,[J?P(****P-0HHHH **** "BBB@ HHHH ****
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M^++U84445TF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'I_P"S1_R6WPY_V\_^DTM?=E?"?[-'_);?#G_;S_Z32U]V5\EF
MW\=>GZL^@R_^$_7_ ""BBBO$/3"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /GFBBBO=/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /0_A+_S%?^V7_L]>AUYY\)?^8K_VR_\
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M%O4O_262N#_87_Y-8\$_]OW_ *77%=2_W=^J_)F'_+U>GZGO-%%%<IN%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DI^W1_R=/XV_[<O_
M $AMZ\'KWC]NC_DZ?QM_VY?^D-O7@]?7T/X4/1?D?/5?XDO5A1116QF%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^\=?@
MY7[QUXN9?8^?Z'I8+[7R"BBBO$/3"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /A/]I?\ Y+;XC_[=O_2:*O,*]/\ VE_^2V^(_P#MV_\
M2:*O,*^_PW\"GZ+\CY.M_%EZL****Z3 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#T_P#9H_Y+;X<_[>?_ $FEK[LKX3_9
MH_Y+;X<_[>?_ $FEK[LKY+-OXZ]/U9]!E_\ "?K_ )!1117B'IA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'SS1117NGF!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H?PE_YB
MO_;+_P!GKT.O//A+_P Q7_ME_P"SUZ'7DU_XC.ZG\""BBBL#4**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX;_ ."OW_)M7AK_ +&ZV_\
M2.]K[DKX;_X*_?\ )M7AK_L;K;_TCO:Z\)_'AZF%;^&SS/\ X(Q?\UA_[@__
M +?5^F%?F?\ \$8O^:P_]P?_ -OJ_3"M,?\ [Q+Y?DB</_"04445P'2%%%%
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M_P"2V^'/^WG_ -)I:^[*^2S;^.O3]6?09?\ PGZ_Y!1117B'IA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'SS1117NGF!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H?PE_P"8
MK_VR_P#9Z]#KSSX2_P#,5_[9?^SUZ'7DU_XC.ZG\""BBBL#4**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KX;_X*_?\FU>&O^QNMO\ TCO:
M^Y*^&_\ @K]_R;5X:_[&ZV_]([VNO"?QX>IA6_AL\S_X(Q?\UA_[@_\ [?5^
MF%?F?_P1B_YK#_W!_P#V^K],*TQ_^\2^7Y(G#_PD%%%%<!TA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'R5\1_P#E(]\*_P#L6YO_ $7J5?6M?)7Q'_Y2/?"O_L6YO_1>I5]:
MUU5]H>GZLPI;R]?\@HHHKE-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ."^/W_ "0GXC_]BWJ7_I+)7!_L+_\ )K'@G_M^
M_P#2ZXKO/C]_R0GXC_\ 8MZE_P"DLE<'^PO_ ,FL>"?^W[_TNN*ZE_N[]5^3
M,/\ EZO3]3WFBBBN4W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /R4_;H_P"3I_&W_;E_Z0V]>#U[Q^W1_P G3^-O^W+_ -(;>O!Z^OH?
MPH>B_(^>J_Q)>K"BBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K]XZ_!ROWCKQ<R^Q\_T/2P7VOD%%%%>(>F%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"?[2__);?$?\ V[?^
MDT5>85Z?^TO_ ,EM\1_]NW_I-%7F%??X;^!3]%^1\G6_BR]6%%%%=)@%%%%
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M_P#;M_Z315YA7W^&_@4_1?D?)UOXLO5A111728!1110 4444 %%%% !1110
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MWM?<E?#?_!7[_DVKPU_V-UM_Z1WM=>$_CP]3"M_#9YG_ ,$8O^:P_P#<'_\
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MH **** "BBB@ HHHH _)3]NC_DZ?QM_VY?\ I#;UX/7O'[='_)T_C;_MR_\
M2&WKP>OKZ'\*'HOR/GJO\27JPHHHK8S"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *_>.OP<K]XZ\7,OL?/]#TL%]KY!111
M7B'IA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PG^TO\
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MUM_Z1WM=>$_CP]3"M_#9YG_P1B_YK#_W!_\ V^K],*_,_P#X(Q?\UA_[@_\
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M^$_V:/\ DMOAS_MY_P#2:6ONRODLV_CKT_5GT&7_ ,)^O^04445XAZ84444
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M\)_LT?\ );?#G_;S_P"DTM?=E?)9M_'7I^K/H,O_ (3]?\@HHHKQ#TPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YYHHHKW3S HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T/X
M2_\ ,5_[9?\ L]>AUYY\)?\ F*_]LO\ V>O0Z\FO_$9W4_@04445@:A1110
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M $FEK[LKY+-OXZ]/U9]!E_\ "?K_ )!1117B'IA1110 4444 %%%% !1110
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MBBB@ HHHH *_>.OP<K]XZ\7,OL?/]#TL%]KY!1117B'IA1110 4444 %%%%
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M4445@:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 4444 %%%% !7[QU^#E?O'7BYE]CY_H>E@OM?(****\0],****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^$_VE_P#DMOB/_MV_
M])HJ\PKT_P#:7_Y+;XC_ .W;_P!)HJ\PK[_#?P*?HOR/DZW\67JPHHHKI, H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /3_
M -FC_DMOAS_MY_\ 2:6ONROA/]FC_DMOAS_MY_\ 2:6ONRODLV_CKT_5GT&7
M_P )^O\ D%%%%>(>F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?/-%%%>Z>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >A_"7_F*_]LO_ &>O0Z\\^$O_ #%?^V7_ +/7H=>3
M7_B,[J?P(****P-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** (YIX[:-I)I%BC7J[L !^)JK_;FG?\
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M_P BU9_\#_\ 0VI ;=%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!XSXH^!-_K_P"U!X0^*<>J6\6GZ)I<FGR:>T;&65F6Z7<&Z ?Z
M0O\ WR:]FKAM6^,GAO1?BUHOPYN9;@>)M7M&O;6-828C&HF))?L<02<?3UKN
M:TFY.W-VT]"(J*ORA1116984444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110!^2G[='_ "=/XV_[<O\ TAMZ\'KWC]NC_DZ?QM_VY?\
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MPY_V\_\ I-+7W97R6;?QUZ?JSZ#+_P"$_7_(****\0],**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^>:***]T\P**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]#^$O_ #%?^V7_
M +/7H=>>?"7_ )BO_;+_ -GKT.O)K_Q&=U/X$%%%%8&H4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)
MXT_Y%J\_X!_Z&M>7UZAXT_Y%J\_X!_Z&M>7U2)84444Q!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>H>"_P#D6K/_ ('_
M .AM7E]>H>"_^1:L_P#@?_H;4F-&W1114E!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'R5\1_^4CWPK_[%N;_ -%ZE7UK7R5\1_\ E(]\
M*_\ L6YO_1>I5]:UU5]H>GZLPI;R]?\ (****Y3<**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@OC]_R0GXC_\ 8MZE_P"D
MLE<'^PO_ ,FL>"?^W[_TNN*[SX_?\D)^(_\ V+>I?^DLE<'^PO\ \FL>"?\
MM^_]+KBNI?[N_5?DS#_EZO3]3WFBBBN4W"BBB@ HHHH **** "BBB@ HHHH
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M_@?_ *&U)C1MT445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!\X^./AEXGU3]M_X?>-K729)O"VFZ'+:W>HAT"12E+X!2I;<>98^@_B
M^M?1U9%SXOT&S\26OAZXUO3H-?NXC-;Z5)=QK=31@,2Z1$[F7"/R!CY&]#6O
M6LY.7+?HB(Q4;VZA1116184444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '(?&+1;WQ)\(_&^DZ; UUJ-_H=]:VT"D R2O;NJ*
M"2 ,L0.?6N/_ &2?!FM?#W]GWPKX?\0V#Z9K%G]K\^UD969-]W,Z\J2.593P
M>]>KZAJ%KI-A<WU]<PV=E;1--/<W$@CCBC4$L[,>%4 $DG@ 5!H7B#2_%&E0
M:GHVI6FKZ;/N\J\L9UGADVL5;:ZD@X8$'!X((K7F?L^3I<CE7-S=2_111618
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^2G[='_)T_C;
M_MR_](;>O!Z]X_;H_P"3I_&W_;E_Z0V]>#U]?0_A0]%^1\]5_B2]6%%%%;&8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M[QU^#E?O'7BYE]CY_H>E@OM?(****\0],**** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >A_"7_F*_\
M;+_V>O0Z\\^$O_,5_P"V7_L]>AUY-?\ B,[J?P(****P-0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,3QI_P BU>?\ _\ 0UKR^O4/&G_(M7G_  #_ -#6O+ZI$L****8@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O4/!?_(M6
M?_ __0VKR^O4/!?_ "+5G_P/_P!#:DQHVZ***DH**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^2OB/_P I'OA7_P!BW-_Z+U*OK6ODKXC_
M /*1[X5_]BW-_P"B]2KZUKJK[0]/U9A2WEZ_Y!1117*;A1110 4444 %%%%
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M_%EZL****Z3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#T_P#9H_Y+;X<_[>?_ $FEK[LKX3_9H_Y+;X<_[>?_ $FEK[LK
MY+-OXZ]/U9]!E_\ "?K_ )!1117B'IA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'SS1117NGF!1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z'\)?\ F*_]LO\
MV>O0Z\\^$O\ S%?^V7_L]>AUY-?^(SNI_ @HHHK U"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q/&G
M_(M7G_ /_0UKR^O4/&G_ "+5Y_P#_P!#6O+ZI$L****8@HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O4/!?_(M6?\ P/\
M]#:O+Z]0\%_\BU9_\#_]#:DQHVZ***DH**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^2OB/_RD>^%?_8MS?^B]2KZUKY*^(_\ RD>^%?\
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M7_I#;UX/7U]#^%#T7Y'SU7^)+U84445L9A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?O'7X.5^\=>+F7V/G^AZ6"^U\@H
MHHKQ#TPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X3_:7
M_P"2V^(_^W;_ -)HJ\PKT_\ :7_Y+;XC_P"W;_TFBKS"OO\ #?P*?HOR/DZW
M\67JPHHHKI, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO4/&G_(M7G_ /_0UKR^J1+"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
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MOX%/T7Y'R=;^++U84445TF 4444 %%%% !1110 4444 %%%% !1110 4444
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M%O4O_262N#_87_Y-8\$_]OW_ *77%=2_@-^:_)F'_+U>GZGO-%%%<IN%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DI^W1_R=/XV_[<O_
M $AMZ\'KWC]NC_DZ?QM_VY?^D-O7@]?7T/X4/1?D?/5?XDO5A1116QF%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^\=?@
MY7[QUXN9?8^?Z'I8+[7R"BBBO$/3"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /A/]I?\ Y+;XC_[=O_2:*O,*]/\ VE_^2V^(_P#MV_\
M2:*O,*^_PW\"GZ+\CY.M_%EZL****Z3 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#T_P#9H_Y+;X<_[>?_ $FEK[LKX3_9
MH_Y+;X<_[>?_ $FEK[LKY+-OXZ]/U9]!E_\ "?K_ )!1117B'IA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'SS1117NGF!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H?PE_YB
MO_;+_P!GKT.O//A+_P Q7_ME_P"SUZ'7DU_XC.ZG\""BBBL#4**** "BBB@
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M^,5]344?6*G</9P['RS_ ,,!Z=_T6_XT?^%8O_QBC_A@/3O^BW_&C_PK%_\
MC%?4U%'UBIW#V<.Q\L_\,!Z=_P!%O^-'_A6+_P#&*/\ A@/3O^BW_&C_ ,*Q
M?_C%?4U%'UBIW#V<.Q\L_P## >G?]%O^-'_A6+_\8H_X8#T[_HM_QH_\*Q?_
M (Q7U-11]8J=P]G#L?+/_# >G?\ 1;_C1_X5B_\ QBC_ (8#T[_HM_QH_P#"
ML7_XQ7U-11]8J=P]G#L?+/\ PP'IW_1;_C1_X5B__&*/^& ]._Z+?\:/_"L7
M_P",5]344?6*G</9P['RS_PP'IW_ $6_XT?^%8O_ ,8H_P"& ]._Z+?\:/\
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M/_\ 5?OCE_X6?_VFOIBBCV]3N'LX]CYG_P"&'_\ JOWQR_\ "S_^TT?\,/\
M_5?OCE_X6?\ ]IKZ8HH]O4[A[./8^9_^&'_^J_?'+_PL_P#[31_PP_\ ]5^^
M.7_A9_\ VFOIBBCV]3N'LX]CYG_X8?\ ^J_?'+_PL_\ [31_PP__ -5^^.7_
M (6?_P!IKZ8HH]O4[A[./8^9_P#AA_\ ZK]\<O\ PL__ +31_P ,/_\ 5?OC
ME_X6?_VFOIBBCV]3N'LX]CYG_P"&'_\ JOWQR_\ "S_^TT?\,/\ _5?OCE_X
M6?\ ]IKZ8HH]O4[A[./8^9_^&'_^J_?'+_PL_P#[31_PP_\ ]5^^.7_A9_\
MVFOIBBCV]3N'LX]CYG_X8?\ ^J_?'+_PL_\ [31_PP__ -5^^.7_ (6?_P!I
MKZ8HH]O4[A[./8^9_P#AA_\ ZK]\<O\ PL__ +31_P ,/_\ 5?OCE_X6?_VF
MOIBBCV]3N'LX]CYG_P"&'_\ JOWQR_\ "S_^TT?\,/\ _5?OCE_X6?\ ]IKZ
M8HH]O4[A[./8^4[C_@GKH=WK]MKL_P 8_B_/KMK&8;?5I?$T37<,9W HDQM]
MZK\[\ @?.WJ:U/\ AA__ *K]\<O_  L__M-?3%%'UBKW%[.'8^9_^&'_ /JO
MWQR_\+/_ .TT?\,/_P#5?OCE_P"%G_\ ::^F**/;U.X_9Q['S/\ \,/_ /5?
MOCE_X6?_ -IH_P"&'_\ JOWQR_\ "S_^TU],44>WJ=P]G'L?,_\ PP__ -5^
M^.7_ (6?_P!IH_X8?_ZK]\<O_"S_ /M-?3%%'MZG</9Q['S/_P ,/_\ 5?OC
ME_X6?_VFC_AA_P#ZK]\<O_"S_P#M-?3%%'MZG</9Q['S/_PP_P#]5^^.7_A9
M_P#VFC_AA_\ ZK]\<O\ PL__ +37TQ11[>IW#V<>Q\S_ /##_P#U7[XY?^%G
M_P#::/\ AA__ *K]\<O_  L__M-?3%%'MZG</9Q['S/_ ,,/_P#5?OCE_P"%
MG_\ ::/^&'_^J_?'+_PL_P#[37TQ11[>IW#V<>Q\S_\ ##__ %7[XY?^%G_]
MIH_X8?\ ^J_?'+_PL_\ [37TQ11[>IW#V<>Q\S_\,/\ _5?OCE_X6?\ ]IH_
MX8?_ .J_?'+_ ,+/_P"TU],44>WJ=P]G'L?,_P#PP_\ ]5^^.7_A9_\ VFC_
M (8?_P"J_?'+_P +/_[37TQ11[>IW#V<>Q\S_P###_\ U7[XY?\ A9__ &FC
M_AA__JOWQR_\+/\ ^TU],44>WJ=P]G'L?,__  P__P!5^^.7_A9__::/^&'_
M /JOWQR_\+/_ .TU],44>WJ=P]G'L?,%]^PC;:I97%G>_'7XV7MG<1M#/;7/
MBY9(I8V&&1T: AE()!!&"#@U#HO[ >F>&]-AT[1_C9\9=(TZ'=Y5EI_BI+>"
M/+%FVQI;A5RQ).!R23WKZEHH^L5=KB]G#L?,_P#PP_\ ]5^^.7_A9_\ VFC_
M (8?_P"J_?'+_P +/_[37TQ11[>IW'[./8^9_P#AA_\ ZK]\<O\ PL__ +31
M_P ,/_\ 5?OCE_X6?_VFOIBBCV]3N'LX]CYG_P"&'_\ JOWQR_\ "S_^TT?\
M,/\ _5?OCE_X6?\ ]IKZ8HH]O4[A[./8^9_^&'_^J_?'+_PL_P#[31_PP_\
M]5^^.7_A9_\ VFOIBBCV]3N'LX]CYG_X8?\ ^J_?'+_PL_\ [31_PP__ -5^
M^.7_ (6?_P!IKZ8HH]O4[A[./8^9_P#AA_\ ZK]\<O\ PL__ +31_P ,/_\
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M=?\ F#V-/^4^*O\ AU%\,/\ H=_B+_X-K7_Y%H_X=1?##_H=_B+_ .#:U_\
MD6OM6BCZW7_F#V-/^4^*O^'47PP_Z'?XB_\ @VM?_D6C_AU%\,/^AW^(O_@V
MM?\ Y%K[5HH^MU_Y@]C3_E/BK_AU%\,/^AW^(O\ X-K7_P"1:/\ AU%\,/\
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M_M-?3%%2\36EO(I4H+9'S/\ \,/_ /5?OCE_X6?_ -IH_P"&'_\ JOWQR_\
M"S_^TU],44O;U.X_9Q['S/\ \,/_ /5?OCE_X6?_ -IH_P"&'_\ JOWQR_\
M"S_^TU],44>WJ=P]G'L?,_\ PP__ -5^^.7_ (6?_P!IH_X8?_ZK]\<O_"S_
M /M-?3%%'MZG</9Q['S/_P ,/_\ 5?OCE_X6?_VFC_AA_P#ZK]\<O_"S_P#M
M-?3%%'MZG</9Q['S/_PP_P#]5^^.7_A9_P#VFC_AA_\ ZK]\<O\ PL__ +37
MTQ11[>IW#V<>Q\S_ /##_P#U7[XY?^%G_P#::/\ AA__ *K]\<O_  L__M-?
M3%%'MZG</9Q['S/_ ,,/_P#5?OCE_P"%G_\ ::/^&'_^J_?'+_PL_P#[37TQ
M11[>IW#V<>Q\S_\ ##__ %7[XY?^%G_]IH_X8?\ ^J_?'+_PL_\ [37TQ11[
M>IW#V<>Q\S_\,/\ _5?OCE_X6?\ ]IH_X8?_ .J_?'+_ ,+/_P"TU],44>WJ
M=P]G'L?,_P#PP_\ ]5^^.7_A9_\ VFC_ (8?_P"J_?'+_P +/_[37TQ11[>I
MW#V<>Q\DZG_P3B\,ZU?27NH?%SXN7]Y)C?<77B6*21\  99K<DX  ^@%5?\
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M,/\ _5?OCE_X6?\ ]IKZ8HH]O4[A[./8^9_^&'_^J_?'+_PL_P#[31_PP_\
M]5^^.7_A9_\ VFOIBBCV]3N'LX]CYG_X8?\ ^J_?'+_PL_\ [31_PP__ -5^
M^.7_ (6?_P!IKZ8HH]O4[A[./8^9_P#AA_\ ZK]\<O\ PL__ +31_P ,/_\
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M+;?C=Y/B\)G'3.(/<U9_X8?_ .J_?'+_ ,+/_P"TU],45/UBKW#V<.Q\S_\
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M[QC?6XN5CN&86UK&S%49POS2,Q5L1@J<<DC(#>.>!_\ @I!XPT#QK:Z-\6?
ML>CVUSY9W:?9W-M<P*Y&V4PS.YD0@D_+@D8QGH>N.%JSCSI&;J13LS] :*\H
M_:2^+FH?"3X!Z]X[\.PV=]>V:6DELFH1NT+K+<PQDLJLC?=D)'(YQGTK%_8]
M^.6O?M!?">?Q/XBM-.LK^/4YK(1Z7')'%L1(V!P[N<Y<]_3BL?9RY/:=-BN9
M7Y3W&BO+?VG?BEJOP6^!WB7QGHEO9W6J:;]F\F'4$=X6\RYBB;<$96/RR$C#
M#D#Z5QO[,?[2]U\4/@/J_P 0_'C:3H,.F7MQ%<36,<D<"0QQQMN(=W8MER,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KQ?\ ; ^$FH?&CX"Z_H.CY?68?+O[*'<
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M970Y# \@@]Q3Z^=.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/+;7(P/,17@4891AAN'13VP?JRBBHJ5'4ES2W'&/*K(****S*"BBB@ HHHH
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MCZ*GZQ4YU.^J'R*UCR7]F7P1X_\ AK\,K3PQX_U'2]8N]-;R;&^TVYEF+6P
MV1R>9$A!3[H/.5P.,<^M445A*7-)R925E8****D84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !69XHCU6;PUJT>@RV\&N/:3+82W1(A2X*'RB^%;Y0^W/RGC/!Z
M5IT4P/D']C7]BW7?@%XUUOQ5XPU+2=5U2:U^R6/]FR23",.P:61FDC0ASM50
M1GAGR>:^OJ**TJ5)59<TMR8Q459'Q?>?L4^+_"_[64/Q2\#ZCH-GX?\ [474
M9=/O+BXCN LJ[;Q%"Q,N'WS;?F &\#&!6M^VI^R+XQ_:.\6>'=4\-:EH=C;Z
M=9/;2KJL\T;LQDW J(XG!&/4BOKJBM5B:BDI]5H3[.-FC\[[C]AO]H[7;6/3
M-:^+UO<Z/PK6\GB#4KA%4# Q$T04X'&,BOH?]E[]C'PY^SDTNKR7K>(_%MQ$
M86U*6$11V\9.2D,>3MSP"Q))QQM!(/T313GBJDX\KT7D"IQ3N?'G[7/[(?C[
M]I'XI:+J=GK>A:=X3TZUCM5AN9IA<KND+3R!%A*EB"H +@'8O3FOK/P_H=GX
M8T'3='T^(0V&GVT=I;Q@ !(XT"*./0 5H45C*K*<5![(I12;9X/^V%^S?+^T
M?\.;;3=+GL[/Q+IMTMQI]U?O(L(5B%F1B@8@%<'.UN44<9)'0_LO_#GQ3\(_
M@WI'A#Q;=:9?7^EO+%!<:7+))&UNSET#&1$.X%F7@8PJ]\UZO11[67L_9O8.
M57Y@HHHK(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KSCX)_'70_CUI&KZMX;L-3ATG3[Y]/6^OXXDCNY% +-"%D9
MBH#(<L%^\,<A@*/[5/C ^!/V=?'^KJ#YHTJ2TB97"%))\0(X)_NM*#COC'>H
M/V3? 4/PY_9W\#:4D8CN)M.CU"ZS&%8S7 \YPW)R5+[,^B#IT&RBO9.;WO;_
M #)O[UBAXO\ VSO@YX#\3:CX?UWQA]AU?3Y3!=6_]F7DGEN.HW)"5/X$U+X0
M_;&^#7CK5[;2](\=V+7UR_E0Q7D,]GO?LH:9$&3D #/)X&3Q7E/[,/\ R>%^
MT/\ ]?,'_H;UZY^UEX?\*:S\ ?&USXKL;6Y@L=)N9K6XF0>;!<;/W1B?JK&0
M1C@X/ .02*VE3IQDH6>MNO?RM^I"<FKGHWC+QCI'P_\ "^H^(M?N_L&CZ?'Y
MUS<^4\GEKD#.U 6/)'0&I/"?BK2_''AO3=?T2Z^VZ3J,"W%K<>6\?F1L,AMK
M@,/H0#7RKJNMZQXB_P"":<NH:[-)<:E)X<"M--R\D:S!8F8]R8U0ECR<Y/)K
MVG]E'_DVWX<?]@6W_P#0:SE248-]4[%*5V>KUB>,/&_A_P"'VBR:OXEUFQT+
M34.TW-_.L2EL$A%R?F8A3A1DG' -0_$+QM8?#?P/KGBC5"18:3:274JK]Y]H
MR%'NQP![FOFWX!?!.7X[&T^,WQAB3Q!J^K+]HT30)P3I^F6;%3$5A8<L0"PR
M6!5@QRQR)A!-.<WH-O6R.W_X;N^!7VQ+7_A/8?,9E0-_9UYY>3C&7\G:!SR2
M<#O7K/@?XB^&/B7I+:GX5UZPUZR5MCRV,ZR>6V,[7 Y1L<X8 X(K4_L'3/[)
M_LO^SK3^S-NS[%Y"^3MSG&S&W&>V*\<7]D7P?H?Q6T'QSX-FNO EU92L]_I^
MA;8K74H\<1/$041<]=JC()QAMKJ_W4EI=/[_ /(7O'9?$[XU:'\)=<\':=KM
MM?\ E^)]0&EVU];QQM;V\Y*A!,6<,H;=P55@-K9QW] KYP_X*!^&6U[]F?6K
M^ R+?:#>6FJVS1<,CK*(V8'/&U)9&R/2O=?!/B)?&'@S0->3R]FJ:?;WR^42
M4Q+&K\9[?-2E%>SC->:&G[S1M4445B4%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>,?M3_
M +0$?P%^'ZS6$8OO&&L.;/0=-$9E:>?*@ML!RRIN7('4LB_Q5<(N<E&.[$W9
M79Z!I/Q,\+Z[XVU?PAI^M6UWXDTF)9K[3XR2\"-C!)QC^)<@'(R,XS6YJVK6
M.@Z;<ZCJ=[;Z=I]LAEGN[N58HHD'5F=B H'J37CO[*OP%;X+^!Y+O7&^W^/O
M$$C:CK^IRL))7G<EC%Y@SN5"3DY(9R[?Q #SW]HJ!OC5^TU\._@]=74R^$X;
M*3Q'K]G!(56]5680PR;><;HAD';Q-D'<%QM[.,JCC%Z+KZ?UH3S-*[._TG]M
MCX):UKD>D6OCVS^V22^2IGM;F&$MNV_ZYXQ'C/?=COG%>X5R7BKX3^$?&7@.
M3P9J>@6+^&FB$,>GPPK%';@ A3$% \MES\I7&.U>'_L.^(M7T_2?'7PNUN<W
MMQ\/M7;3;6[; :2S<OY((ZX_=N03_"RC^&DXPE!RAT[A=IV9].T5\Y6?[>'P
MYU#P;I6NVMGX@N[S5)YX;/P[:V23ZG,(AEY!$DA4)P<,6&<'^Z<=3\-?VJ?"
M'Q&\:?\ "'2Z?K_@_P 7M&9HM#\5::UE<S(%+%D&64X52V"02,D @'$NC4BF
MW$?-'N>R45X3XL_;$\'>'_$.H:1I&B>*O'+Z6774[SPII!O+:P9,;UEE+*/E
M!R2NX#H3GBO0_A3\7O"_QH\+IKOA;4/MEL&\JX@E0QSVLH +12QGE6&?<'J"
M1@U,J<XKF:T#F3=CLZ*XCXK?&;PA\%=#BU/Q9JR:?'<,8[6V1&EN+J0#[D4:
M@LQY ST&X9(S7E@_;@\)6"17?B'P9\0/".A2*'37=;\.O'9,I*A6#(SL0=ZX
M(7N.Y +C2G)7B@<DMV?15%>9^"_VA/"GQ ^)NI^"=#:ZO;NQTN'5_P"THQ&U
ME/!*(RAC<.6)Q*O50.#S7IE1*+CHT.]]C*OO%6DZ;XBTO0KJ_AM]7U2*>:RM
M)&P]PL.SS=G8E1(A(ZX)., D:M?%7_!0/0=>\3?$[X$:;X7OAIGB.:[U/^SK
MLN4$=POV1D.X X^8#G!ZU[)^R_\ M$GXT:+J&C^(K5-"^(OA^5K76=%;Y7RI
M"F=%/.PMD$<[6&#P5+;RHM4U47S^\E2]YQ9Z7\1?B3X<^$_A:?Q'XKU'^RM&
M@=(Y+GR))MK.P51MC5F.21VH\:?$GPY\/? ]QXP\0:C_ &?X=MTBDEO/(DDV
MK*ZI&=B*7.6=1P.,\XYKPW_@HI_R:WKO_7[9_P#H]:/VS_\ DR#Q%_UY:5_Z
M66M.%)24+]7;\O\ ,3DU?R/H_3=2M]8TVTO[.3SK2ZB2>&3:5W(RAE." 1D$
M=:LUS?PT_P"2<^%?^P3:?^B4KI*YGH[&@4444@"BBB@ HHHH **** "BBB@
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M9%<0:?JUJEW!'=JJRJC#(#!68 _0FG*G."O)6$I)['0T445F4%%%% !1110
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M'0=!M/VD_P!KWQQ<^)5.K>$/APL&GZ;HUX ]LU[*K>;*T>"KX:.3J<_ZK/3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG^RKX^ALPQF6WMYFVDC]W'=0R2?^.*U>B?!G4K/6/A#X)O;!E:RFT2S>+:
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M\_9[\3:C=VD/]K:';_VA97VP>;'Y9RR;L9VLI8%>F2#VKL/V4?\ DVWX<?\
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M7P1\/=/NI-/7QYXBM=%O+N-L,MLSJ'4'J-S,F?50P((:L/\ X*4_\D=\'?\
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M9XK^-(=/X4%%%%<IH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1"^U,J2#M SDYSDUZ9,UYX^^(.NZ.VK7NEZ+H MDDMM.E,$MU/(GFDM,N'5
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MN =C!G(/WE.1U /4:*\/^'OBOQ#\3/%R:7J.JQVD7A-R;V32[@I_;$X=D1\
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MABN06 W$$Y)R:[_7/$.J^)OB1K>C)IVOW6BZ"MNCP:#>P6IN)I8B^Z65IHI
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M_-A><T >B5DWWB 6/B#3-)_L[4+AKY97-Y!;EK:WV#.)9.BENBCG)';BO*?
M/Q'U'P_:^(+CQ7<22?:]-;Q;91RL<P6KD@VW).W9B+"C/,A[\"3PY)XATOQ9
M\-8=7U+4#>:O!JNH:C:37#E%D9876+8> L6XJJ]%YQUH ] L_B%IU\?%(CAN
MA_PCLC1W>Y%^<B/S#Y?S<\'OCFMCP[K<'B7P_IFKVJ21VVH6L5W$LP <)(@8
M!@"1G!&<$UXAX4\,V=G<_&":.;4&>SFFCC$NI7$BL#:<F16D(D//#.&(XP>!
M6GX#\%WMY\%])U6^UW6+;5!HL4EI]AOY(8+9$BS#B)&"/E A;S V3GH#B@#V
MRN0U[XBIH_BA] MM!U;6M0CL%U%QIXM]JQ%V0?ZV5"6RAX /459^&?B2X\8?
M#_P_K-VJI=WEG'+,$^Z7Q\Q [ G)QVS7%ZU:ZS=_'Z[31=1L],G/A:'=->63
M70Q]JF^ZHECP0><G(]J .OMOB9HEQX1OO$3//;V5C))!<Q30L)HID?8T13KO
MW8  ZDBET7X@0:IK2:1>:3JNAZA-&9K>+4H%"W"* 6*/&SIE=RY5B&&1Q7$>
M!_"]MK6A^-/ /B)6DU9;H7FI:A:28%R]P?-BN8_E C=3&!LVX4Q _-G)W/!O
MB?6_#_B*#P;XN:.ZOIH9)=+UF'A=0BCQO5T_@F4%6(&003@\<@'4^-?&6F^
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MH6?Q.\2:CX.\-Z/;B[O-9U'5+S2Y;^R,*W30VQ8NZ"4K&)6C4#+' .X@9P*
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M$D.O>(M776]1M5=+*.&U^S6]IOR'9$WN2Q4A=S,3@$#J:["B@#SRR^#\%O\
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MSD:^L>#_ .UO&OASQ!]K\K^QXKN/[/Y>[SO/5!G=GY=NST.<]JZ.B@#BM/\
MAO\ 8#XW/]H[_P#A)96D_P!1C[-NA$>/O?/TSV]*U]%\+?V/X$L/#?VKSOLN
MFQZ?]J\O;NVQ"/?MSQG&<9_&MZB@#!\!^%O^$)\':1H/VK[;_9\"P?:/+\OS
M,=]N3C\S61K'@G6)/'S>*-'UFQL9GTQ-->WOM.>Y4JLKR;P5GCP<OC'/3WKM
M:* //)/A!'?:7J;7VM74WB2_F@N6UR%%A>*6#/D>7&/E"J"P(.2V]LGD8T]+
M\%:C+XBL=:\1ZO;ZQ>:= \-BMG8FTCB9QB61@9'+.P 7J% SA<G-=A10!RWP
M_P#!!\%V&H?:;W^U-5U*]EOKZ^\HQ^;(YX"H6;:JJ%4+N(&/>F>)O 2>(/%&
MD:U%=+9S6L,]E=H(B3>6LH&Z)F5E888!E.3@Y..:ZRB@#+\/^%](\)V*V>C:
M;:Z9;* /+MH@F<="Q'+'KR<GDUJ444 %<%:_#W6?#=QJ:^&?$5OIFFWT\MT;
M*\TW[2+>60@NT3"1,?-DA6# 9Z8XKO:* .-;P7>^&_ MSHOA6Y6/4;AY&?4]
M1D)E,DKDRW#,J?/+\Q(X R%' &*JWWPI@M[/PN- U!M(O?#K.;2>>+[2LBR#
M$HE4E2V_J2&4Y)((KO** .8\#>"1X/AU*:XO6U/5M4N3=WUYY8B61\!0%C!(
M10H  R3W)-0>)O <NJ>)+/Q'I&JOHVNV\/V5I6B\^"Y@W%O*EBW+D!B2"K*1
MD\],==10!YI=?"C6-;\8:!XBUKQ6;V?2+AIHK.WL!!;;2&!55\QF#<K\S,W"
MXQS72:?X*^P_$+5O%'VS?]OLH;/[+Y6-GEECNW[N<[NF!C'6NGHH YSXB>#_
M /A/O!6J^'_M?V#[=$(_M'E^9L^8'.W(ST]161%X)\3VND_V-!XR*:6%6)+A
MM.4ZC'$"!M6<.$W;05#F(GG/)YKNJ* .(OOA/I3:#H>GZ7/=:+<:$QETR^MG
MW20N00Q8-D2!\G>K?>!/3-8OC3X4>(_B%H;Z7K?C-%MOW;+'INE^1')(CA@T
MH:5R_0_*&5<[3CY>?4:* .'\:^!-9\:0ZGID_B&&#PYJ/EI+9KI^;B.,;=ZQ
MSB0 ;\'ED;&X^U3^(OA^]]X@T_7]"U,Z#K-I!]C+>1YUO<6P)80R1;EX#$D%
M64C)YZ8[&B@#C=#\!WL7BK_A(]?UMM:U.*%K>TCA@-M;6B.<OLCWL26PH+,Q
M/RCVQE^$_A#_ ,(O_P (-_Q-OM/_  C%M>6W_'ML^T^?M^;[YV;=O3YLY[5Z
M-10!SGP]\'_\('X3M=%^U_;O(EGD\_R_+W>9,\N-N3TWXZ\XS[5S-M\%K>/P
M7)H<NK3BZCU275[+4K9/*DM;AG9E8+N(; 8J0>&!/3MZ310!P%]\.];\3S6$
M/B;Q.FH:3:2QSM8Z?8&S%U)&=R-,_FN6PP5MJ[5RHXZ8U],L=;E^(&M7]]+)
M#HL5M#:Z=;1R@QS$Y>69TR<,&(0'C@'@Y!KJ** ,SQ)X=L?%N@WVCZG$9K&\
MC,4J!BIP>X(Z$'!_"N67P1XL&GC2SXYD.F [/M']GK_:1AQMV&X\S;NQ_P M
M!$&SSFN\HH \VT?X-C1_!_@O05U<RKX;U-=1$YML&XP9ODV[_E_UW7)^[TYX
MZ;QIX/\ ^$N_L+_2_LG]EZK!J?\ J]_F^7N^3J,9W=><8Z5T=% '#-\/]2T?
MQ)J.K>&->32DU*03WNGWUF;NVDFQM,J@21LC$;<X;!VC(J+PK\,;W1/'D_BO
M4O$D^MW]QIW]GRI+;K$BXE#@QA3A% &-N#DEFSDXKOJ* ,#QMX.M/'&@OIUU
M+-:NLB7%M=VSE);:=#F.5#ZJ>:Y?Q!\.?%7BSP_<Z)JOC=187$$D$CV&E"">
M8,"%\Q_-8$ XR$5-PW ]>/1Z* .&T?X:R:-K6DZC#JO[W3_#O]@H/LPY8-&P
MFY8]X_N8/7K3]-\!ZK-XHTC6_$.NPZO/I%O+#9I:V'V4%I JR2R?O'W,0H'R
MA0,G YKMJ* /.=0^$'V_P5XR\/\ ]K>7_P )%J$U_P#:/LV?L_F,AV;=_P V
M-G7(SGI71^,?!_\ PEDWAZ3[7]E_LC58M3QY>_S=B2+LZC;GS,YYZ=*Z.B@#
MSC2?A=K'AGQ#X@UC1?%"P2ZQ?/=S6=YIXGM@I "C:)$?>OS?,' ((!7Y0:WO
M#7@@Z3KE]KVI:A)K&O7B>0URR>5%! &++##&"=B#@G)9B1DFNIHH X.V^'^M
MZ'IEQHV@^)8=,T1WD,$<FGF6ZM$<Y*12^:%P&+%2Z,0& R<"EUSX3V-]X#TC
MPKIMRVFV.FW%M-$[)YS,(G#X/(Y8@Y/OT[5W=% '.)X/V?$2;Q3]KSYFE1Z9
M]D\OIMF>3?OSWWXQCMG-8.E?#O7?"=G+I?AKQ1#I^A;RUM:7FFBZELU+%F2*
M7S5RN2V/,5R!@=J]!HH X"7X1VHT/2+"#4)5GM=:M]<N[VX3S);V>-PSE^1@
MM@#(X4  # K8^(7@K_A/-#M].^V?8?*O;>\\SRO,SY4@?;C<.N,9SQZ&NGHH
M *\^TKX=Z[X3LY=+\->*(=/T+>6MK2\TT74MFI8LR12^:N5R6QYBN0,#M7H-
M% ' :I\([6\^&NK^%(-0EBGU4F6[U2X3S99IV92\KKE<D[0, @   <"N_HHH
M X?QKX$UGQI#J>F3^(88/#FH^6DMFNGYN(XQMWK'.) !OP>61L;C[5?UKP;-
M-KEEK6AWT.D:I;VS63>=:^?;S6YY6-HPZ$;7PP*L.X.0>.IHH Y#1?A^(=4U
M;5M<OAK>JZG;"RE=8?(@CMAD^3''N8A268DEF))ZU0TGP%XC\*Z=_9.@^+(8
M]&C3R[2+5=--W/:)@X5)1-&"JY^4.K8  Y KOJ* .(O?AO-J&G^&8;G7;J]N
MM(U9-7FO+M [W3A9 4 !"QKF3@*,*% P>M:GC3P?_P )=_87^E_9/[+U6#4_
M]7O\WR]WR=1C.[KSC'2NCHH Q/''_(E>(/\ L'W'_HMJ\[^%/@_Q)I_PX\.M
MHOBM+6QO-*MYA:ZEI_VLV[R0HS&)Q*A W%B%;<!NQC Q7K]% '%6_P )M&7P
M-?\ AFZDN;N+496N;V^:39<3W+,'\_<. P95(XP-JC! JAJ7P^\5ZUH;:)>^
M.,Z<\30R36^F".\F0]GE\PKTR"412<UZ)10!Y];_  G^S^#O!>@_VKN_X1R^
MMKS[1]GQ]H\K=\NW?\F=W7)QCH:V++P+#;^*O%6K7%P+J#7K>VMI+,Q[1&L2
M2*?FW?-N$GH,8[UU-% 'G-A\./$N@:+)H>C>-/LNC*OE6OVK3O/N[./)PD<W
MF@$ 84;T8@ 8[8NS?"FRAT7PCI6GW<MK:>'M2CU%3,#-)<%5D#!F)&"S2EBW
M0=ACIW-% '.>-/!__"7?V%_I?V3^R]5@U/\ U>_S?+W?)U&,[NO.,=*CT_P5
M]A^(6K>*/MF_[?90V?V7RL;/++'=OW<YW=,#&.M=/10!PMK\/]6OO$&AZEXC
MU^#65T5II+2.#3OLS/*Z[-\I\QE8JI.-JIR<^U:_Q"\'_P#">>$[K1?M?V'S
MY8)//\OS-OES)+C;D==F.O&<^U='10!QWC'PCK_B>/5+&W\1P6.C:C;_ &66
MV?3O-FB0@K(8I1(N&8,>65L8&!UST^EZ;#H^EV=A; K;VL*01@]0JJ%'Z"K5
M% 'G/A_X8ZYX/U+7+O1?%,:KJVH7-_-9ZAIWGVZ-+(&!0+*C!@,J3NVMP=H(
MYUM'^&UG;Q:Y)K-P^O:EKD7V?4+J91$'AVE!#&B_ZN, G@')))+$\UV%% 'G
MMG\/_%&DZ,FB:?XV:+2HAY<,T^G++?QQ;<!!-Y@0XXPQC)XZU0T#X(+H/AWP
M]I*:T\Z:/KQUH326^6E&)!Y1^?K^\^_SG'3FO4:* .)D^']_H_B"_P!5\,:X
MNDG4I?/OK"^M3=VLLNT+YJJ)(VC<@#)#8.%XXK)LO@_>KXBU?6]2\43ZK?ZG
MHLFD2M+:JB1[FR&C56PJ@?P=R6;=DUZ910!@Z+X6_L?P)8>&_M7G?9=-CT_[
M5Y>W=MB$>_;GC.,XS^-<W;?!^"W\&^&=(75KF#5?#J@V&L6BB-TDVE23&2P*
M,#AD.<C(R*]"HH XS_A%?%>H36*ZKXNA^PP.KS0Z1IILY;K:00KRM-(54D#(
M0+D$C.#2:EX!O;?Q=<^(_#NM+I%Y?1JE_:W=L;JUNBBA8W*"1&5U7C*L 0!D
M=<]I10!Q&B_#...37+KQ%J4OB34=9MOL5W+(A@B%MM(\F.-6.Q?F<]2<L3G/
M-4['X?\ BK2=%71+'QN8]*BS'#--IHDOHHL$+&)O,"':,88QYXKT.B@#D?A?
M\/U^&GA?^Q4OWU)!<S3B>1-K8=BV#R<D>O?K@51\5_#.Z\0>.M/\4V.OS:/?
M6%B]I"D=NLJLS.&)?<<,A7<I7 /((8$5WE% '&?\('?:UKFG:EXFUB/5%TUU
MGL["QM#:6RSC=B9U:21G< @+\P48)QDYJ%OA_J6C^)-1U;PQKR:4FI2">]T^
M^LS=VTDV-IE4"2-D8C;G#8.T9%=S10!RW@GP.?"<FIWMYJ4^M:UJDJR7E_,-
M@8*"(T2,':BJ"< <\G)/&#P/X%A\(^ [;PQ<7 U."-)HY)#'Y8D61W8C;N..
M'QU[5U-% '#^"OA79>$O!&H>&IKR;5+:_,JSRS#!,31B%(P"3PD*1H,D_=[#
M@6? 'PYM?!/@G_A'YY_[5,YE>]NI$*-=/(3N9AN./EPO7H!77T4 ><V'PX\2
MZ!HLFAZ-XT^RZ,J^5:_:M.\^[LX\G"1S>: 0!A1O1B !CMB]??"72IO VG>&
M[.YO+#^RY5NK#4$F+7$%RI8^<2>&)+OD'@AR !QCN** . OOAWK?B>:PA\3>
M)TU#2;26.=K'3[ V8NI(SN1IG\URV&"MM7:N5''3&YH_@_\ LGQKXC\0?:_-
M_MB*TC^S^7M\GR%<9W9^;=O]!C'>NCHH YC3_!7V'XA:MXH^V;_M]E#9_9?*
MQL\LL=V_=SG=TP,8ZU-XW\%VOCC28;2>XN+&XM;A+RSO;5]LMM.F=KKG@\%@
M0000Q^M=#10!YAXR^%GB;Q_X=N-%U?QK''921!"NGZ5Y!E89PTI,S;AG!*KL
M!QZ5T>D^ _[+\9QZ_P#;O-V:+#H_V?R<9\N1G\S=N[[L;<=NM=910!SG@[P?
M_P (G-XAD^U_:O[7U674\>7L\K>D:[.IW8\O.>.O2CP7X/\ ^$1_MW_2_M?]
MJ:K/J?\ J]GE>9M^3J<XV]>,YZ5T=% '!^'OA[JWA'PR=-T;Q##!='4YK]KB
MXT_S8W21V8PM'Y@./F'S*P/R^Y%:_@CP;_PB4.J2SW:W^IZK>O?WERL/E*78
M!0J*68JBJJ@ LW<YYKI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669387520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOONLAKE IMMUNOTHERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1711963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Dorfstrasse 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Zug<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">415108022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary share, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MLTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Portions of the registrant&#8217;s definitive proxy statement relating to its 2024 Annual Meeting of Shareholders, to be held on or about June 5, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001821586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,874,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,012,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846668726944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Mountain View, CA<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669496688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 451,169,337<span></span>
</td>
<td class="nump">$ 39,505,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">59,838,900<span></span>
</td>
<td class="nump">32,609,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,056,862<span></span>
</td>
<td class="nump">217,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses - current</a></td>
<td class="nump">2,102,203<span></span>
</td>
<td class="nump">4,179,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">514,167,302<span></span>
</td>
<td class="nump">76,511,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,628,480<span></span>
</td>
<td class="nump">282,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">320,865<span></span>
</td>
<td class="nump">49,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses - non-current</a></td>
<td class="nump">8,423,468<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">12,372,813<span></span>
</td>
<td class="nump">331,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">526,540,115<span></span>
</td>
<td class="nump">76,843,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TradeAndOtherPayablesCurrent', window );">Trade and other payables</a></td>
<td class="nump">1,837,684<span></span>
</td>
<td class="nump">254,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term portion of operating lease liabilities</a></td>
<td class="nump">1,197,876<span></span>
</td>
<td class="nump">153,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,930,120<span></span>
</td>
<td class="nump">7,256,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,965,680<span></span>
</td>
<td class="nump">7,665,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion operating lease liability</a></td>
<td class="nump">2,499,990<span></span>
</td>
<td class="nump">128,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension liability</a></td>
<td class="nump">583,426<span></span>
</td>
<td class="nump">282,206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">3,083,416<span></span>
</td>
<td class="nump">411,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,049,096<span></span>
</td>
<td class="nump">8,076,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">609,969,236<span></span>
</td>
<td class="nump">129,192,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(116,657,472)<span></span>
</td>
<td class="num">(80,650,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2,357,621<span></span>
</td>
<td class="nump">350,946<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">495,675,683<span></span>
</td>
<td class="nump">48,898,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">17,815,336<span></span>
</td>
<td class="nump">19,868,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">513,491,019<span></span>
</td>
<td class="nump">68,766,698<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">526,540,115<span></span>
</td>
<td class="nump">76,843,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Shares</a></td>
<td class="nump">6,047<span></span>
</td>
<td class="nump">3,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Shares</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">$ 1,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_TradeAndOtherPayablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade And Other Payables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_TradeAndOtherPayablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669308576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Apr. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,701,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846670252864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">$ (31,801,880)<span></span>
</td>
<td class="num">$ (42,048,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(22,321,216)<span></span>
</td>
<td class="num">(23,012,463)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(54,123,096)<span></span>
</td>
<td class="num">(65,061,417)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(54,123,096)<span></span>
</td>
<td class="num">(65,061,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">10,138,367<span></span>
</td>
<td class="nump">591,732<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(43,984,729)<span></span>
</td>
<td class="num">(64,469,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(94,388)<span></span>
</td>
<td class="num">(36,366)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(44,079,117)<span></span>
</td>
<td class="num">(64,506,051)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Of which: net loss attributable to controlling interests shareholders</a></td>
<td class="num">(36,007,260)<span></span>
</td>
<td class="num">(49,973,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Of which: net loss attributable to noncontrolling interests shareholders</a></td>
<td class="num">(8,071,857)<span></span>
</td>
<td class="num">(14,532,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on marketable securities and short-term investments</a></td>
<td class="nump">2,330,101<span></span>
</td>
<td class="nump">390,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax', window );">Actuarial income (loss) on employee benefit plans</a></td>
<td class="num">(336,579)<span></span>
</td>
<td class="nump">269,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">1,993,522<span></span>
</td>
<td class="nump">660,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(42,085,595)<span></span>
</td>
<td class="num">(63,845,405)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to controlling interests shareholders</a></td>
<td class="num">(34,511,723)<span></span>
</td>
<td class="num">(49,437,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">$ (7,573,872)<span></span>
</td>
<td class="num">$ (14,407,944)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares, basic (in shares)</a></td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares, diluted (in shares)</a></td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic net loss per share attributable to controlling interest shareholders (USD per share)</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Diluted net loss per share attributable to controlling interest shareholders (USD per share)</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares, basic (in shares)</a></td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares, diluted (in shares)</a></td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic net loss per share attributable to controlling interest shareholders (USD per share)</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Diluted net loss per share attributable to controlling interest shareholders (USD per share)</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846665653872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Conversion Following Business Combination</div></th>
<th class="th"><div>Conversion Of Class C Into Class A Shares</div></th>
<th class="th"><div>Common Class A</div></th>
<th class="th"><div>Common Class C</div></th>
<th class="th"><div>Previously Reported</div></th>
<th class="th"><div>Total Shareholders' Equity (Deficit)</div></th>
<th class="th">
<div>Total Shareholders' Equity (Deficit) </div>
<div>Conversion Following Business Combination</div>
</th>
<th class="th">
<div>Total Shareholders' Equity (Deficit) </div>
<div>Conversion Of Class C Into Class A Shares</div>
</th>
<th class="th">
<div>Total Shareholders' Equity (Deficit) </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Conversion Following Business Combination</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Previously Reported</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Revision of Prior Period, Adjustment</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Conversion Following Business Combination</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class A</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class A </div>
<div>Conversion Following Business Combination</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class A </div>
<div>Conversion Of Class C Into Class A Shares</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class C</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class C </div>
<div>Conversion Following Business Combination</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class C </div>
<div>Conversion Of Class C Into Class A Shares</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Previously Reported</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Revision of Prior Period, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock, Common</div></th>
<th class="th">
<div>Treasury Stock, Common </div>
<div>Conversion Following Business Combination</div>
</th>
<th class="th">
<div>Treasury Stock, Common </div>
<div>Previously Reported</div>
</th>
<th class="th">
<div>Treasury Stock, Common </div>
<div>Revision of Prior Period, Adjustment</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Conversion Following Business Combination</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Conversion Of Class C Into Class A Shares</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Income </div>
<div>Conversion Of Class C Into Class A Shares</div>
</th>
<th class="th">
<div>Accumulated Other Comprehensive Income </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Noncontrolling Interests</div></th>
<th class="th">
<div>Noncontrolling Interests </div>
<div>Conversion Of Class C Into Class A Shares</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,880,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,196<span></span>
</td>
<td class="nump">22,200,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2021</a></td>
<td class="num">$ (11,645,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,645,007)<span></span>
</td>
<td class="num">$ (11,645,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,645,007)<span></span>
</td>
<td class="nump">$ 72,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,061,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,061,984<span></span>
</td>
<td class="num">$ (53,643,615)<span></span>
</td>
<td class="num">$ (53,643,615)<span></span>
</td>
<td class="num">$ (168,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (168,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,161,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,528<span></span>
</td>
<td class="nump">11,799,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Held in Treasury, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,942,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,756)<span></span>
</td>
<td class="num">(1,885,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization', window );">Noncontrolling interests recognized on historical net assets of MoonLake AG in connection with the Business Combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,346,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,551,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,966,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,346,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,880,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="num">(12,161,331)<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
<td class="nump">18,501,284<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
<td class="nump">15,775,472<span></span>
</td>
<td class="num">(2,051,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,578<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,578<span></span>
</td>
<td class="nump">$ 3,536,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,578<span></span>
</td>
<td class="num">$ (205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,870<span></span>
</td>
<td class="nump">$ 3,520,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,536,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of Class A ordinary shares upon Business Combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,424,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of Class A Ordinary Shares upon Business Combination</a></td>
<td class="nump">134,653,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,783,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,782,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,869,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement', window );">Emission fees and capital tax payments on share issuance</a></td>
<td class="num">(56,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation granted under the equity incentive plan ESPP, ESOP, and reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation granted under the equity incentive plan ESPP, ESOP, reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan</a></td>
<td class="nump">9,658,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,352,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,348,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,305,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(64,506,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,973,249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,973,249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,532,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">660,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, end balance at Dec. 31, 2022</a></td>
<td class="nump">$ 68,766,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,898,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,192,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,650,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,868,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of Class A ordinary shares upon Business Combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,501,284<span></span>
</td>
<td class="nump">15,775,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Ordinary Shares, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Apr. 05, 2022</a></td>
<td class="nump">52,701,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,218,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,218,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,989,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,479,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,989,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation granted under the equity incentive plan ESPP, ESOP, reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan</a></td>
<td class="nump">7,106,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,907,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,907,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,198,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(44,079,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,007,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,007,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,071,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">1,993,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Ordinary Shares, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)</a></td>
<td class="nump">482,454,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,454,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,453,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary', window );">Capital injection from MoonLake to MoonLake AG (Note 12)</a></td>
<td class="num">(2,750,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,060,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,061,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,310,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees', window );">Refund of stamp duty fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, end balance at Dec. 31, 2023</a></td>
<td class="nump">$ 513,491,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495,675,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609,969,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (116,657,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,357,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,815,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Emission Fee Reimbursement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Stamp Duty Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease From Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase From Capital Injection In Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480513/718-10-30-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480843/718-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660391008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (44,079,117)<span></span>
</td>
<td class="num">$ (64,506,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">13,158<span></span>
</td>
<td class="nump">12,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">7,106,005<span></span>
</td>
<td class="nump">9,654,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionExpenseReversalOfExpenseNoncash', window );">Net periodic pension benefit cost for the qualified pension plan</a></td>
<td class="num">(85,254)<span></span>
</td>
<td class="nump">304,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">484,762<span></span>
</td>
<td class="nump">220,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(839,733)<span></span>
</td>
<td class="num">(68,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="num">(65,513)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(6,346,203)<span></span>
</td>
<td class="num">(2,730,373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Trade and other payables</a></td>
<td class="nump">1,582,712<span></span>
</td>
<td class="num">(1,314,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating leases liabilities</a></td>
<td class="num">(222,259)<span></span>
</td>
<td class="num">(152,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(326,725)<span></span>
</td>
<td class="nump">2,685,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow used in operating activities</a></td>
<td class="num">(42,778,167)<span></span>
</td>
<td class="num">(55,893,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowInvestingActivitiesLesseeAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of short-term marketable debt securities</a></td>
<td class="num">(175,732,711)<span></span>
</td>
<td class="num">(42,226,021)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of short-term marketable debt securities</a></td>
<td class="nump">150,833,021<span></span>
</td>
<td class="nump">9,901,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(284,634)<span></span>
</td>
<td class="num">(16,009)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow used in investing activities</a></td>
<td class="num">(25,184,324)<span></span>
</td>
<td class="num">(32,340,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)</a></td>
<td class="nump">482,454,426<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_PaymentsOfStampDuty', window );">Stamp duty on capital injection from MoonLake to MoonLake AG (Note 12)</a></td>
<td class="num">(2,752,918)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ProceedsFromReverseRecapitalization', window );">Proceeds from Business Combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">134,646,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ProceedsFromContributionFromParValueOfCommonStock', window );">Contribution for par value of Class V Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of loan liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Grants of additional shares under ESPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow provided by financing activities</a></td>
<td class="nump">479,701,508<span></span>
</td>
<td class="nump">119,692,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of movements in exchange rates on cash held</a></td>
<td class="num">(75,307)<span></span>
</td>
<td class="nump">8,540<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">411,663,710<span></span>
</td>
<td class="nump">31,466,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">39,505,627<span></span>
</td>
<td class="nump">8,038,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">451,169,337<span></span>
</td>
<td class="nump">39,505,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">41,713<span></span>
</td>
<td class="nump">4,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Non-cash operating lease assets obtained in exchange for lease obligations</a></td>
<td class="nump">3,637,545<span></span>
</td>
<td class="nump">435,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 422,519<span></span>
</td>
<td class="nump">$ 155,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_PaymentsOfStampDuty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Stamp Duty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_PaymentsOfStampDuty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ProceedsFromContributionFromParValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contribution From Par Value Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ProceedsFromContributionFromParValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowInvestingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowInvestingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpenseReversalOfExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpenseReversalOfExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674668912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Overview of the Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Overview of the Company</a></td>
<td class="text">Overview of the Company<div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Information</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. MoonLake Immunotherapeutics is currently a single asset company focused on the development of Sonelokimab (&#8220;SLK&#8221;), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, &#8220;MoonLake&#8221;, and the &#8220;Company&#8221; refer to the combined company following the Business Combination (as defined in Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combination Agreement with Helix and Recapitalization</span>), together with its subsidiaries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674471328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination Agreement with Helix and Recapitalization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationDisclosureTextBlock', window );">Business Combination Agreement with Helix and Recapitalization</a></td>
<td class="text">Business Combination Agreement with Helix and Recapitalization<div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022 (the &#8220;Closing Date&#8221;), MoonLake Immunotherapeutics, a Cayman Islands exempted company (formerly known as Helix Acquisition Corp.) (prior to the Closing Date, &#8220;Helix&#8221; and after the Closing Date, &#8220;MoonLake&#8221; or the &#8220;Company&#8221;) consummated the previously announced business combination (the &#8220;Closing&#8221;) pursuant to that certain Business Combination Agreement dated October 4, 2021 (the &#8220;Business Combination Agreement&#8221;), by and among Helix, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#8220;MoonLake AG&#8221;), the existing equityholders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equityholders of MoonLake AG that executed joinders to the Business Combination Agreement (collectively, the &#8220;ML Parties&#8221;), Helix Holdings LLC, a Cayman Islands limited liability company and the sponsor of Helix (the &#8220;Sponsor&#8221;), and the representative of the ML Parties (such transactions contemplated by the Business Combination Agreement collectively, the &#8220;Business Combination&#8221;). Net proceeds from the Business Combination totaled $134.7 million, which included funds held in Helix&#8217;s trust account and the completion of a concurrent PIPE investment.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Business Combination Agreement, approved by the boards of directors of each of MoonLake AG and Helix, (i) the Company changed its name from Helix Acquisition Corp. to MoonLake Immunotherapeutics, and (ii) MoonLake AG merged with and into MoonLake, with MoonLake AG as the surviving company in the Business Combination and, after giving effect to such Business Combination, MoonLake AG as a subsidiary of MoonLake. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business Combination Agreement provided for, among other things, the following transactions:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.37pt">Two business days prior to the Closing Date, the ML Parties and MoonLake AG effectuated a restructuring of MoonLake AG&#8217;s share capital to, among other things, (x) convert the Series A preferred shares of MoonLake AG, par value of CHF 0.10 per share, into an equal number of MoonLake AG Common Shares such that the ML Parties held a single class of capital share of MoonLake AG immediately prior to the Closing and (y) approve a capital increase for the issuance of 4,006,736 Class V Voting Shares of MoonLake AG, par value CHF 0.01 per share, to Helix, each Class V Voting Share due to its lower par value having ten times the voting power of a MoonLake AG Common Share (the &#8220;Restructuring&#8221;).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.6pt">At the Closing, 2,875,000 Class B ordinary shares of Helix, par value $0.0001 per share (the &#8220;Class B Ordinary Shares&#8221;), constituting all of the then-outstanding Class B Ordinary Shares, were automatically converted into Class A Ordinary Shares on a one-for-one basis.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.83pt">At the Closing, Helix amended and restated its existing memorandum and articles of association to, among other things, establish a share structure consisting of the Class A Ordinary Shares, which carry economic and voting rights, and Class C Ordinary Shares, which carry voting rights but no economic rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.37pt">On the Closing Date, Helix paid all unpaid transaction expenses and contributed $134.7 million to MoonLake AG, including $15.0 million loan repayment pursuant to a convertible loan agreement dated March 20, 2022, </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by and between MoonLake AG and Cormorant Asset Management LP (&#8220;Cormorant&#8221;), and assigned by Cormorant to Helix on March 31, 2022.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.14pt">On the Closing Date, following the Restructuring, Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P. (collectively, the &#8220;BVF Shareholders&#8221;) assigned all of their MoonLake AG Common Shares to Helix and Helix issued to the BVF Shareholders 18,501,284 Class A Ordinary Shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.37pt">On the Closing Date, following the Restructuring, Helix issued 15,775,472 Class C Ordinary Shares to the ML Parties (other than the BVF Shareholders). Please refer to Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholders&#8217; Equity (Deficit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on the exchange mechanism adopted. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on the Closing Date, Helix issued to the PIPE Investors (as defined below in the section entitled &#8220;PIPE Financing&#8221;) an aggregate of 11,700,000 Class A Ordinary Shares.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the open of trading on April 6, 2022, the Class A Ordinary Shares, formerly those of Helix, began trading on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the trading symbol &#8220;MLTX&#8221;.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PIPE Financing</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2021, concurrently with the execution of the Business Combination Agreement, and subsequently on March 31, 2022 and April 4, 2022, Helix entered into subscription agreements with certain investors (collectively, the &#8220;PIPE Investors&#8221;, which includes affiliates of the Sponsor and certain existing equityholders of MoonLake AG) pursuant to which, and on the terms and subject to the conditions of which, the PIPE Investors have collectively subscribed for 11,700,000 Class A Ordinary Shares, 11,600,000 shares of which were issued at a price of $10.00 per share for gross proceeds of $116.0 million and 100,000 shares of which were issued to placement agents of the PIPE in satisfaction of an aggregate of $1.0 million of fees owed by Helix to such placement agents.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Net Proceeds</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the elements of the net proceeds from the Business Combination:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:83.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">in thousands</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investments held in Trust Account</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">115,051</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix  prior to the Closing Date</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(80,842)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plus PIPE investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">116,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less Helix transaction expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(15,520)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(5,798)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which deferred IPO underwriting fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(4,025)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which other transaction expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(5,697)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Available Closing Date Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">134,689</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Ordinary Shares Issued</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the number of Ordinary Shares outstanding immediately following the consummation of the Business Combination:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:83.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Helix Acquisition Corp. Ordinary Shares prior to the Business Combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,805,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class A Ordinary Shares (Helix management - IPO private placement shares)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">430,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class A Ordinary Shares redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">11,500,000</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:83.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class B Ordinary Shares (Helix management - sponsor promote)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">2,875,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(8,080,645)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus issuance of Helix Class A Ordinary Shares to PIPE Investors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,700,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plus issuance of Helix Class A Ordinary Shares to BVF Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,501,284</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total MoonLake Class A Ordinary Shares Outstanding at Closing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">36,925,639</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus issuance of Helix Class C Ordinary Shares to ML Parties (other than the BVF Shareholders)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,775,472</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total MoonLake Class A and Class C Ordinary Shares Outstanding at Closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,701,111</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information about the Business Combination can be found on Form S-1/A filed with the SEC on July 26, 2022, declared effective on August 2, 2022 and to the exhibits included therein, available at www.sec.gov.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669471248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#8220;MoonLake AG&#8221;), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board ("FASB").</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to ASC 805, for financial accounting and reporting purposes, MoonLake AG was deemed the accounting acquirer and Helix was treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Accordingly, the Business Combination was treated as the equivalent of MoonLake AG issuing shares for the net assets of Helix, accompanied by a recapitalization. The net assets of Helix were stated at historical costs, with no goodwill or other intangible assets recorded, and are consolidated with MoonLake AG&#8217;s financial statements on the Closing Date. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Business Combination Agreement, the ML Parties received 33.638698 Ordinary Shares in the Company for every MoonLake AG Common Share or Series A Preferred Share (the &#8220;Exchange Ratio&#8221;). The BVF Shareholders received 18,501,284 Class A Ordinary Shares whereas the rest of the ML Parties (excluding the BVF Shareholders) received 15,775,472 Class C Ordinary Shares which can be converted into Class A Ordinary Shares at the discretion of the shareholder (refer to Note&#160;12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; Shareholders&#8217; Equity (Deficit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on the classes of ordinary shares). The number of shares, and the number of shares within the net income (loss) per share held by the ML Parties in MoonLake AG prior to the Business Combination have been adjusted by the Exchange Ratio to reflect the equivalent number of ordinary shares in the Company (identified as &#8220;the equivalent of&#8221; throughout these consolidated financial statements).</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain MoonLake AG shareholders (ML Parties other than the BVF Shareholders), did not exchange their shares in MoonLake AG for Class A Ordinary Shares in the Company and therefore continued to hold an economic interest in MoonLake AG and Class C Ordinary Shares in the Company. The Company recognized a noncontrolling interest equal to the ML Parties&#8217; (other than the BVF Shareholders) proportionate interest in the net assets of MoonLake AG.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are presented in U.S. Dollar (&#8220;$&#8221;), unless otherwise indicated. The term &#8220;Swiss franc&#8221; and &#8220;CHF&#8221; refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and &#8220;&#8364;&#8221; refers to euros.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining whether the in-process research and development expenditure (&#8220;IPR&amp;D&#8221;) has an alternative future use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining assumptions used in estimating the fair value of share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the amount of accruals in connection with the completion of clinical trial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company&#8217;s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future results of operation may be affected.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December&#160;31, 2023, the Company considers $129.4 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. As of December&#160;31, 2022, the Company considered $19.9 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities and short-term investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in &#8220;Interest and dividend income&#8221;. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the &#8220;Accumulated other comprehensive income (loss)&#8221; component of shareholders&#8217; equity (deficit) until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified as either &#8220;Cash and cash equivalents&#8221; or &#8220;Short&#8209;term marketable debt securities&#8221; according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statement of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the &#8364;100,000 Fundo de Garantia de Dep&#243;sitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the guidance included in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three levels of inputs to fair value measurements:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1, meaning the use of quoted prices for identical instruments in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3, meaning the use of unobservable inputs. Observable market data is used when available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a stand-alone basis for the purposes of allocating resources, and assessing financial performance.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of <span style="-sec-ix-hidden:f-428">three</span> to five years. As of December&#160;31, 2023, property and equipment, net relates to information technology, office equipment, and leasehold improvements.</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Contract Costs and Accruals</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Transaction</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goods or services received in a share-based payment transaction are measured using a fair value-based measure.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#8217;s common stock on the date of the grant.</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companies&#8217; volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The fair value of the common stock granted under the ESPP (as defined below) has historically been estimated by management with reference to the market-based transaction with the other Series A Preferred Shares Investors, as there was no public market for the common stock. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains or losses from foreign currency translation are included in the consolidated statement of operations in "other income, net". The Company recognized foreign currency transaction gain of $151,493 for the year ended December&#160;31, 2023 and a foreign currency transaction gain of $325,317 for the year ended December 31, 2022.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Class A Ordinary Shares</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the &#8220;In-License Agreement&#8221;) with Merck Healthcare KGaA, Darmstadt, Germany (&#8220;MHKDG&#8221;) to acquire the Sonelokimab program (the &#8220;SLK Program&#8221;) and determined that substantially all of the fair value of the gross assets acquired related to IPR&amp;D of SLK. Therefore, this transaction was accounted for as an asset acquisition.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&amp;D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension Accounting</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for pension assets and liabilities in accordance with ASC 715, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Retirement Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the recognition of the funded status of pension plans in the Company&#8217;s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of December&#160;31, 2023 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statement of operations separately from the service cost component, in &#8220;<span style="-sec-ix-hidden:f-439">other income (expenses), net</span>.&#8221; Plan assets are recorded at their fair value. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income (loss). </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake does not have any finance leases. As of December&#160;31, 2023, the Company has three operating leases related to the office spaces which are located in (i) Dorfstrasse 29, 6300, Zug, Switzerland, (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. The operating leases are recognized over a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-Use (&#8220;RoU&#8221;) assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less and that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. The FASB also issued subsequent amendments to the initial guidance, ASU 2019-04, ASU 2019-05, ASU 2019-11, and ASU 2020-03 (collectively, &#8220;Topic 326&#8221;). The Current Expected Credit Losses model requires a company to estimate credit losses expected over the life of the financial assets based on historical experience, current conditions and reasonable and supportable forecasts. The Company adopted this new guidance as of December 31, 2023 upon the loss of its &#8220;emerging growth company&#8221; status. The adoption did not have a material impact on the balances reported in the Company&#8217;s consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment reporting &#8212; Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends guidance on reportable segment disclosure requirements. It is effective for fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact. The early adoption option will not be exercised. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income taxes - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Taxes Disclosure,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which amends guidance on to enhance the transparency and decision usefulness of income tax disclosures. It is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact. The early adoption option will not be exercised. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large Accelerated Filer Status</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company is considered a &#8220;large accelerated filer&#8221; and no longer qualifies as an emerging growth company or smaller reporting company. The Company is required, pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, to include in its Annual Report on Form 10-K for the year ended December 31, 2023 an attestation report as to the effectiveness of the Company's internal control over financial reporting that is issued by its independent registered public accounting firm. In addition, beginning with the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2024, it will no longer be permitted to take advantage of the reduced reporting requirements applicable to smaller reporting companies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846671144128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_RiskAndLiquidityDisclosureTextBlock', window );">Risks and Liquidity</a></td>
<td class="text">Risks and Liquidity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern, Liquidity and Capital Resources&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a loss of $44.1 million for the year ended December&#160;31, 2023. As of December&#160;31, 2023, the Company&#8217;s current assets exceeded its current liabilities by $504.2 million. </span></div>As of December&#160;31, 2023, the Company had $451.2 million of cash and cash equivalents. Based on the Company's current operating plan, management believes that the Company has sufficient capital to fund its operations and capital expenditures until the end of 2026.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_RiskAndLiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk And Liquidity Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_RiskAndLiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846668707472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                               </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:21.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.184%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Level 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">109,608,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">109,608,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42,552,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">42,552,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certificates of deposit</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">79,626,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">79,626,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9,937,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9,937,899</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">189,235,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">189,235,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,490,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,490,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, accounts payable and accrued liabilities approximate their fair values as of December&#160;31, 2023 and December 31, 2022, due to their short-term nature. Pension plan assets fair value is determined based on Level 2 inputs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660380128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of December&#160;31, 2023 and December&#160;31, 2022 are as follows:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">107,624,341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,984,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">109,608,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Certificates of Deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">78,890,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">736,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">79,626,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">186,514,788</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2,720,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">189,235,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">128,197,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,199,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">129,396,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within short-term marketable debt securities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58,317,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,521,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">59,838,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42,265,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">287,479&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42,552,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Certificates of Deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9,834,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">103,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,937,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,099,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">390,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,490,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19,775,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">106,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19,881,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32,324,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">284,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32,609,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair values of the Company&#8217;s short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:78.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning balance, January 1, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">390,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8,751,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6,421,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ending balance, December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2,720,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company&#8217;s marketable debt securities maturities are all due within one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846765400304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses</a></td>
<td class="text">Prepaid Expenses<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:58.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prepaid expenses - current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Insurances</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,077,478</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,416,597</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Non-clinical research and clinical development services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">842,729</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,443,863</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other consulting and advisory services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">70,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">105,651</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other prepayments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">111,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">213,357</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,102,203</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">4,179,468</span></td></tr></table></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:58.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prepaid expenses - non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing services</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,423,468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">8,423,468</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#8212;</span></td></tr></table></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses - non-current relate to advance payments made to a contract manufacturing organization pursuant to a manufacturing run reservation agreement for the commercial-scale manufacturing of Sonelokimab in 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660533328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and Other Payables</a></td>
<td class="text">Trade and Other Payables<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development services</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">911,454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31,687</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing fees payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">553,459</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">65,979</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rent / leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">108,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">264,522</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">157,306</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,837,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">254,972</span></td></tr></table></div>Accrued Expenses and Other Current Liabilities<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bonuses and related employees compensation expenses</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,780,219&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,109,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,603,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development services and license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,226,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,803,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Consultant and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">853,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">218,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">367,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Legal fees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">98,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">6,930,120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">7,256,845</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846675520896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Trade and Other Payables<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development services</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">911,454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31,687</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing fees payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">553,459</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">65,979</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rent / leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">108,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">264,522</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">157,306</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,837,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">254,972</span></td></tr></table></div>Accrued Expenses and Other Current Liabilities<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bonuses and related employees compensation expenses</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,780,219&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,109,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,603,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development services and license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,226,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,803,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Consultant and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">853,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">218,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">367,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Legal fees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">98,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">6,930,120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">7,256,845</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674488096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an open-ended office lease agreement, effective November 1, 2021, to lease approximately 2,300 square feet of space on the last two floors of the building located at Dorfstrasse 29, 6300 Zug, Switzerland (the &#8220;Office Lease"). The Company estimated the effective duration of the Office Lease at inception and determined a period of 3 years, with expected expiration in November 2024. In December, 2023, the contract was extended, leading to a new estimated effective duration of the lease period of 3 years, with expected expiration in January 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2023, the Company entered into an office lease agreement, effective as of October 9, 2023, to lease approximately 3,900 square feet of office space on the fifth floor of  the building located at Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. This lease has a 3-year initial term, with two extendable periods of 3 years each. It is expected to be extended once until October 2029. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2023, the Company entered into an office lease agreement, effective as of October 16, 2023, to lease approximately 6,000 square feet of office space on the first floor of the building located at 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom. This lease has a 3-year term agreement and is set to expire in October 2026. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average discount rate for the operating leases as of December&#160;31, 2023 and December 31, 2022 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average remaining lease term (in months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum annual lease payments under these operating leases as of December&#160;31, 2023 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:70.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,343,255</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,343,255</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,029,249</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">95,794</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">95,794</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">65,923</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,973,270</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(275,404)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,697,866</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less current portion of lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,197,876)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term portion operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,499,990</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded lease expense related to its operating leases of $399,882 and $155,552 for the years ended December&#160;31, 2023 and December 31, 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674685072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates a defined benefit pension plan in Switzerland (&#8220;the Plan&#8221;) and a defined contribution pension plan in the United Kingdom and Portugal, in accordance with local regulations and practices. As of December&#160;31, 2023 the Plan covers the Company&#8217;s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in projected benefit obligations (&#8220;PBO&#8221;) and plan assets is presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Beginning PBO </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,321,969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,322,874&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Service cost </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">451,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by plan participants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / losses </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">487,991</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(374,317)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">229,902</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(204,695)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign currency exchange rates changes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">208,608</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(16,267)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plan amendment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(107,750)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Ending PBO</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,494,481</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,321,969</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Beginning fair value of plan assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,039,763&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,083,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Return on plan assets above expected return</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(115,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by the employer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by plan participants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">200,424</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">138,243</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Benefits paid </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">229,902</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(204,695)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign currency exchange rates changes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">155,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14,687)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Ending fair value of plan assets</span></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,911,056</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,039,763</span></td></tr></table></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts recorded on the consolidated balance sheets:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fair value of plan assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,911,056&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,039,763&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Present value of projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,494,481)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,321,969)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Funded status</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(583,425)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(282,206)</span></td></tr></table></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded in accumulated other comprehensive (income) / loss:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / loss - beginning of year</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(101,716)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">168,177&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / loss of current year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">444,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(268,076)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,817)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prior service (cost) / credit recognized in current year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(107,750)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">234,863</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(101,716)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to calculate the ASC 715 liabilities are summarized in the table below:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.657%"><tr><td style="width:1.0%"></td><td style="width:57.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.35%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.20%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Inflation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term expected rate of salary increase</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.30%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.30%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr></table></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service cost of $122,698 was recognized in the net periodic benefit cost for the year ended December&#160;31, 2023. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of plan assets is presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Equities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.00&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.11&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mortgages</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liquidity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Real estate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">26.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">27.17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Alternative investments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.40%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Infrastructure</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.16%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of plan assets is determined based on Level 2 inputs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As all members of the Plan are active, no future expected benefit payments are currently in payment and foreseen to occur within the next ten years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846770945648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity (Deficit)</a></td>
<td class="text">Shareholders&#8217; Equity (Deficit)<div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class C Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued and Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Balance - January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">500,000,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">38,977,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">100,000,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">13,723,511</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">600,000,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">52,701,111</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Issuance of Class A Ordinary Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">10,270,818</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">10,270,818</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Conversion of Class C Ordinary Shares into Class A Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">11,218,035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(11,218,035)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Balance - December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">500,000,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">60,466,453</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">100,000,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2,505,476</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">600,000,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">62,971,929</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Fully paid-in registered shares with a par value of $0.0001 </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, the Company had the following classes of shares:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class A Ordinary Shares</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company's Class A Ordinary Shares began trading on The Nasdaq Capital Market ("Nasdaq") under the symbol &#8220;MLTX&#8221;. As of December&#160;31, 2023, there were 60,466,453 Class A Ordinary Shares issued and outstanding. The Company is authorized to issue up to 500,000,000 Class A Ordinary Shares, par value $0.0001 per share. Holders of Class A Ordinary Shares are entitled to one vote for each share. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class C Ordinary Shares</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there were 2,505,476 Class C Ordinary Shares issued and outstanding. The Company is authorized to issue up to 100,000,000 Class C Ordinary Shares, with a par value $0.0001 per share. Each Class C Ordinary Share entitles the holders thereof to one vote per share, but carries no economic rights.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Business Combination (the "Closing"), MoonLake, MoonLake AG and each ML Party entered into a Restated and Amended Shareholders' Agreement (the &#8220;A&amp;R Shareholders' Agreement&#8221;). With the intent to approximate the rights, obligations and restrictions that an ML Party would enjoy if it were a holder of Class A Ordinary Shares, the A&amp;R Shareholders&#8217; Agreement (i) imposes certain transfer and other restrictions on the ML Parties, (ii) provides for the waiver of certain statutory rights and (iii) establishes certain mechanics whereby MoonLake and each of the ML Parties are able to effect the conversion of MoonLake AG Common Shares and Class C Ordinary Shares into a number of Class A Ordinary Shares equal to the Exchange Ratio. In 2022, pursuant to the A&amp;R Shareholders&#8217; Agreement, a ML Party submitted an exchange notice to the Company, pursuant to which the ML Party effected the conversion of 61,000 MoonLake AG Common Shares and 2,051,961 Class C Ordinary Shares into 2,051,961 Class A Ordinary Shares using the Exchange Ratio. In 2023, pursuant to the A&amp;R Shareholders&#8217; Agreement, certain ML Parties submitted exchange notices to the Company, pursuant to which such ML Parties effected, in the aggregate, the conversion of 333,486 MoonLake AG Common Shares and 11,218,035 Class C Ordinary Shares into 11,218,035 Class A Ordinary Shares using the Exchange Ratio. The foregoing description of the A&amp;R Shareholders&#8217; Agreement is not complete and is qualified in its entirety by reference to, and should be read in connection with, the full text of the A&amp;R Shareholders&#8217; Agreement filed as an exhibit on the Company's Current Report on Form 8-K filed with the SEC on April 11, 2022.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, the Company issued 10,270,818 Class A Ordinary Shares under the following: </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-Market Offering</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2023, the Company entered into a Sales Agreement (the &#8220;May 2023 Sales Agreement&#8221;) with Leerink Partners LLC (formerly known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), through which the Company could issue and sell up to $200,000,000 of its Class A Ordinary Shares (the &#8220;May 2023 ATM Shares&#8221;), through Leerink Partners  as its sales agent. The May 2023 ATM Shares to be sold under the May 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-271546), which was declared effective by the SEC on May 9, 2023, and a prospectus supplement thereto filed with the SEC on May 11, 2023.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 27, 2023, the Company reduced the maximum aggregate offering amount of its Class A Ordinary Shares that could be issued and sold under the May 2023 Sales Agreement to $0 and no longer intends to sell Class A Ordinary Shares under the May 2023 Sales Agreement unless the Company files a further prospectus supplement indicating an amount of shares proposed to be sold.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2023, the Company entered into a Sales Agreement with Leerink Partners (the &#8220;August 2023 Sales Agreement&#8221; and together with the May 2023 Sales Agreement, the &#8220;Sales Agreements&#8221;), through which the Company could issue and sell up to $350,000,000 of its Class A Ordinary Shares (the &#8220;August 2023 ATM Shares&#8221;), through Leerink Partners as its sales agent. The August 2023 ATM Shares to be sold under the August 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-274286), which was declared effective by the SEC on September 11, 2023, and a prospectus supplement thereto filed with the SEC on August 31, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company sold 544,894 Class A Ordinary Shares for gross proceeds of $15.2 million. In December 2023, the Company sold a further 525,924 Class A Ordinary Shares for gross proceeds of $31.7 million. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public Offering of Class A Ordinary Shares </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2023, the Company entered into an underwriting agreement with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein, to issue and sell 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per share (the &#8220;Offering&#8221;). In addition, the Company granted the underwriters an option for a period of 30 days to purchase up to an additional 1,200,000 Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions (the &#8220;Option&#8221;), and such Option was exercised in full by the underwriters.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Offering closed on June 30, 2023, and net proceeds from the Offering, including proceeds from the exercise in full by the underwriters of the Option, were $436.7 million, after deducting the underwriting discounts and commissions and the offering expenses in the amount of $23.3 million.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of the Offering, the Company opted to direct a substantial portion of the net proceeds to MoonLake AG. This was executed as a two-step process: (1) the Company acquired the remaining 22,756 shares of MoonLake AG common stock held in treasury through a share purchase and assignment agreement formally executed on July 09, 2023 ($38.9 million) and (2) the Company contributed additional funds to MoonLake AG&#8217;s capital reserves through a cash contribution agreement formally executed on July 10, 2023 ($275 million). A stamp duty tax of $2.8 million was levied on the aforementioned capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674681552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Business Combination, the Company has retroactively restated the weighted average number of outstanding prior to April 5, 2022 to give effect to the Exchange Ratio.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the loss per share calculations for the year ended December&#160;31, 2023 compared to the year ended December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:56.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss attributable to controlling interests shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(36,007,260)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(49,973,249)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total weighted average number of outstanding shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,122,534</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">29,361,353</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net loss per share &#8211; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(0.73)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(1.70)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of shares used to calculate the net loss per share &#8211; basic for the year ended December&#160;31, 2023 excludes 2,505,476 Class C Ordinary Shares as they do not carry economic rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that ML Parties (other than Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.) elected to convert their 74,482 MoonLake AG Common Shares into 2,505,476 Class A Ordinary Shares, the weighted average number of shares outstanding would have been 57,679,106 for the year ended December&#160;31, 2023, resulting in a net loss per share of $0.76. Upon conversion, 2,505,476 Class C Ordinary Shares would be forfeited and there would no longer be any non-controlling interests.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the Company's number of Class A Ordinary Shares outstanding would be 63,886,757 as of February&#160;29, 2024, the date the consolidated financial statements were issued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674685072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">Share-based Compensation <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 the Company had the following share-based compensation arrangements:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Restricted Founder Shares (as defined below) &#8211; created in April 2021 by MoonLake AG (no longer active and fully vested as of April 2023);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Employee Share Participation Plan (&#8220;ESPP&#8221;) &#8211; created in July 2021 by MoonLake AG;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The Employee Stock Option Plan (&#8220;ESOP&#8221;) &#8211; created in July 2021 by MoonLake AG;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">MoonLake Immunotherapeutics 2022 Equity Incentive Plan &#8211; created in April 2022 by MoonLake Immunotherapeutics. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the arrangements is to attract and retain the best available personnel and to provide participants with additional incentive to increase their efforts on behalf and in the best interest of the Company and its subsidiaries.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake AG's compensation plans are settled with Common Shares, and with a number of Class C Ordinary Shares determined by multiplying the number of Common Shares by the Exchange Ratio. The reference to &#8220;Common Shares&#8221; in this Note 14 refers to common shares in MoonLake AG. As a result of the Business Combination, the Company has adjusted the share numbers related to the Restricted Founder Shares and Common Shares (under the ESPP and ESOP) prior to the Business Combination by the Exchange Ratio. The owners of Common Shares have the right to exchange their Common Shares for a number of Class A Ordinary Shares derived using the Exchange Ratio. In the event MoonLake AG shareholders elect to exchange their Common Shares, such MoonLake AG shareholder forfeits a number of Class C Ordinary Shares equal to the number of Class A Ordinary Shares issued (refer to Note&#160;12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; Shareholders&#8217; Equity (Deficit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class C Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, the Company has recognized an increase in equity in the consolidated balance sheet, and share-based compensation expense in the consolidated statement of operations of $7.1 million. The share-based compensation expense was driven by the following share-based compensation plans and programs:</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:50.688%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Compensation Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MoonLake AG Restricted Founder Shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">1,574,300&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">4,840,608&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ESPP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">3,352,885</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">3,910,076</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ESOP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">973,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">539,713</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MoonLake Immunotherapeutics 2022 Equity Incentive Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">1,204,952</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">364,381</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">7,106,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">9,654,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which: included in research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">1,524,715&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">954,379&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which: included in general and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">5,581,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">8,700,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, 11,079 Common Shares (the equivalent of 372,683 Class C Ordinary Shares) issuable from the authorized conditional capital shares remain available for future grants under the ESPP and the ESOP by MoonLake AG.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MoonLake AG - Restricted Founder Shares  </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2021, the shareholders&#8217; agreement between the co-founders, the Series A investors and MoonLake AG imposed a reverse vesting condition on 90% of the total 110,000 Common Shares (the equivalent of 3,700,257 Class C Ordinary Shares) held by each of the three co-founders. Therefore, 99,000 Common Shares (the equivalent of 3,330,231  Class C Ordinary Shares) held by each of the co-founders were subject to these restrictions and considered unvested (the &#8220;Restricted Founder Shares&#8221;). The Restricted Founder Shares vested on the 28th of each month at a rate of 4.166% over a period of two years until April 28, 2023. In the event of a termination of the contractual relationship of the relevant co-founder before the end of the vesting period, MoonLake AG in first priority, or any third party designated by it, and the other shareholders in second priority pro rata to their shareholdings, had an option to purchase all or a pro rata portion of the leaver shares that remained unvested on the effective day of the termination at nominal value of CHF 0.10 (equivalent of $0.0001) per share.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the valuation of the Restricted Founder Shares awarded are summarized below:</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4/28/2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value of Restricted Founder Shares on the grant date (USD)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">49</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders (USD) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">336.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Purchase price (CHF)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.10</span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Restricted Founder Shares with reference to the market-based transaction with the other Series A Preferred Shares Investors (refer to Note 9 of MoonLake AG's audited consolidated financial statements for the year ended December 31, 2021, as filed by Helix Acquisition Corp. together with its revised definitive proxy soliciting materials with the SEC on March 4, 2022).</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Restricted Founder Shares at co-founder&#8217;s resignation date by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company&#8217;s fully diluted shares (1,070,196).</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Restricted Founder Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">4,440,309</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards vested for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,330,231)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,110,078</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards vested for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,110,078)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">0</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Share Participation Plan (ESPP) 2021-2025 - MoonLake AG</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP grants will vest 25% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, the awards can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#8220;Change of Control&#8221;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESPP 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">01/18/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value per share of Common Shares on the grant date ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">336.39</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Purchase price (CHF)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.10</span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value (USD 360,000,000) as defined by the Business Combination Agreement by the Company&#8217;s fully diluted shares (1,070,196). </span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESPP</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,060,561</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,177,354</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of January 1. 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,237,915</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which vested as of January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">307,794</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,237,915</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which vested as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,607,425</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, MoonLake AG had $6.2 million of total unrecognized compensation expense related to the ESPP that will be recognized over the weighted average period of 2.05 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Option Plan (ESOP) 2021-2025 - MoonLake AG</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESOP grants will vest 25% on each anniversary of the grant date. In the event of a termination of the contractual relationship between the Company and the entitled employee, options can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#8220;Change of Control&#8221;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.  </span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">ESOP 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">5/1/2022, 6/22/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">4.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price (USD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">3.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">75%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">&#8212;%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#8217;s industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:72.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">01/01/2023, 04/24/2023, 07/03/2023, 07/17/2023, 08/01/2023, 08/07/2023, 08/21/2023, 08/29/2023, 09/01/2023, 09/11/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">25.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price (USD)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">37.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;%</span></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#8217;s industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESOP</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">224,033</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">242,736</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">466,769</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">133,446</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards forfeited for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(15,137)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">585,078</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">219,223</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, MoonLake AG had $4.2 million of total unrecognized compensation expense related to the ESOP that will be recognized over the weighted average period of 2.45 years. </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MoonLake Immunotherapeutics 2022 Equity Incentive Plan</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022 (the &#8220;Effective Date&#8221;) the Company created the &#8220;MoonLake Immunotherapeutics 2022 Equity Incentive Plan&#8221; (the &#8220;Equity Incentive Plan&#8221;) to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Awards made under the Equity Incentive Plan to a person who is initially elected or appointed to the Board, and who is a non-employee director at the time of such initial election or appointment, vests and becomes exercisable in 3 equal yearly installments occurring over the three year period following the date of grant, subject to the non-employee director continuing in service on the Board through each such vesting date. Each subsequent award vests and becomes exercisable on the earlier of (i) the 12-month anniversary of the date of grant, and (ii) the next annual meeting of the Company&#8217;s stockholders following the date of grant, subject to the non-employee director continuing in service on the Board through such vesting date. Awards made to employees, officers and other service providers of the Company under the Equity Incentive Plan vest 25% on each anniversary date. In the event of a termination of the contractual relationship between the Company and the beneficiary, options can be deemed forfeited by the Company if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#8220;Change of Control&#8221;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.</span></div><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:106%">Weighted average assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">4/6/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">8.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price ($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">12.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">75%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">-</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. </span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:72.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">06/08/2023, 10/11/2023, 10/25/2023, 11/01/2023, 11/06/2023, 11/15/2023, 11/16/2023, 11/20/2023, 11/27/2023, 12/01/2023, 12/04/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">25.58</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price ($)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">37.22</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. </span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:35.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">MoonLake Immunotherapeutics 2022 Equity Incentive Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#8212;</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">180,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">180,000</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#8212;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">132,400</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">312,400</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards exercisable as of December 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">60,000</span></td></tr></table></div>As of December&#160;31, 2023, the Company had $3.3 million of total unrecognized compensation expense related to the Equity Incentive Plan that will be recognized over the weighted average period of 1.75 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674488096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate (&#8220;ETR&#8221;) was -0.3% and 0.1% for the year ended December&#160;31, 2023, and for the year ended December 31, 2022, respectively. The Company is not aware of any items that would cause the quarterly or period-to-date ETR to be significantly different from the Company's annual ETR. The difference between the income tax provision that would be derived by applying the statutory rate to the Company's loss before income taxes and the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income tax provision recorded was primarily attributable to non-deductible expense which includes the Swiss entity's recognition of taxable income associated with the sale of treasury shares from MoonLake AG to MoonLake Immunotherapeutics.. The Company continues to incur losses for the Cayman Island and Swiss entity and its ability to utilize the deferred tax asset related to the tax losses is not considered more likely than not.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's main operating affiliate, MoonLake AG, is subject to taxation in the Canton of Zug, Switzerland. For the years ended December&#160;31, 2023 and 2022, the Company did not incur any significant income tax expense or benefit, as the Company incurred tax losses and provided a full valuation allowance.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income or loss before income tax were as follows:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:41.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(43,469,946)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(62,115,251)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(514,783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,354,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(43,984,729)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(64,469,685)</span></td></tr></table></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount computed by applying the statutory income tax rate to loss before income taxes as follows:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:41.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Statutory income tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Effect of income taxed at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in prior year estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Utilization of unrecognized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Non-deductible expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(0.3)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">0.1%</span></td></tr></table></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets (liabilities) were:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:41.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,493,559</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,492,435</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Defined benefit plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">69,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">33,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">56,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net operating loss carry forward</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">6,715,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">7,210,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">11,334,793</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">11,736,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(55,862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(55,862)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax assets (net)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">11,278,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">11,736,269</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(11,278,931)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(11,736,269)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax (net)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt;text-indent:1.44pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8212;</span></td></tr></table></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company&#8217;s net deferred tax assets before valuation allowance were $11.3 million. In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of its deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on the weight of all evidence, the Company has determined that it is not more likely than not that the net deferred tax assets will be realized. A valuation allowance of $11.3 million has been recorded against the deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, MoonLake AG had net operating losses of approximately $56.6 million of which $12.6 million will expire in 2028 and $44.0 million will expire in 2029.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net operating losses will not be subject to any limitation due to change in ownership according to Swiss Income Tax Law.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no unrecognized tax benefits and does not expect that uncertain tax benefits will change significantly in the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846667699200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements as of December&#160;31, 2023 primarily in regards to the clinical and non-clinical development services with contract research organizations ("CROs"), as well as supply and logistics services with contract manufacturing organizations ("CMOs"), for the advancement of SLK. As of December&#160;31, 2023, the total committed expense under these agreements amounted to $44.2 million, of which $8.4&#160;million are recognized under Prepaid expenses - non-current and the rest remain unrecognized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's In-License Agreement with MHKDG includes contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company is obligated to make research and development and regulatory milestone payments upon the occurrence of certain events. Subject to the terms of the license, additional milestone payments of up to &#8364;299.6 million ($331.3 million using a December&#160;31, 2023 exchange rate) are potentially payable upon satisfying specific milestones related to regulatory filing acceptance, first commercial sales, and aggregate annual net sales. The milestone payments are payable in cash. Milestone payments due prior to obtaining regulatory approval will be recorded as research and development expense upon determination that a milestone payment is probable to occur. Milestone payments due after obtaining regulatory approval will be capitalized when and if incurred. The Company will use commercially reasonable efforts to cause the milestones to occur. However, if the Company reasonably determines that a technical failure or commercial failure has occurred with respect to all or a part of the SLK Program, the Company, at its sole discretion, can terminate all or part of the SLK Program. As of December&#160;31, 2023, the Company made a total of &#8364;7.5 million ($8.1 million using the then applicable exchange rate) in additional milestone payments.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on May 12, 2023, MoonLake AG entered into an agreement with Research Cooperation Technologies, Inc. (&#8220;RCT&#8221;) and MHKDG, effective as of June 1, 2023, pursuant to which the Company was granted a royalty-bearing, nonexclusive, sublicensable right and license under RCT&#8217;s patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces the Company&#8217;s sublicense for similar rights under the In-License Agreement. In the aggregate, the Company is required to pay royalties within the range of low to mid-teen percent of net sales under the aforementioned agreements with MHKDG and RCT. Royalties will be recognized in the consolidated statement of operations when net sales are recognized.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Lease </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2023, the Company committed to an open-ended lease agreement with an effective start date of January 15, 2024, for additional office space at its corporate headquarters at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the effective duration of the Office Lease at inception and determined a 3-year term, commencing at the effective start date of January 15, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674528624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information and Geographic Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information and Geographic Data</a></td>
<td class="text">Segment Information and Geographic Data<div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, net of consisting of property and equipment, and operating lease right-of-use assets by geographical area as of December&#160;31, 2023  are as follows:</span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:41.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Country</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">507,392</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">331,969</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,704,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">737,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">3,949,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">331,969</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846671423792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partial Share Conversion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2024, pursuant to the A&amp;R Shareholders&#8217; Agreement, a ML Party submitted an exchange notice to the Company, pursuant to which such ML Party effected the conversion of 44,394 MoonLake AG Common Shares and 1,493,356 Class C Ordinary Shares into 1,493,356 Class A Ordinary Shares using the Exchange Ratio. Please refer to Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholders&#8217; Equity (Deficit) &#8212; Class C Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information regarding the conversion mechanics.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market offering</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January and February 2024, the Company sold an aggregate of 914,828 Class A Ordinary shares through the August 2023 Sales Agreement for gross proceeds of $53.3 million, bringing total gross proceeds under the August 2023 Sales Agreement to $85.0 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674471328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (36,007,260)<span></span>
</td>
<td class="num">$ (49,973,249)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846661671952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=mnlk_Dr.KristianReichMember', window );">Dr. Kristian Reich [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, Dr. Kristian Reich, the Chief Scientific Officer of the Company, adopted a trading plan intended to satisfy Rule 10b5-1(c). Dr. Reich&#8217;s plan provides for the sale, subject to certain conditions, of up to 200,000 Class A Ordinary Shares held directly and indirectly by Dr. Reich. The plan terminated on February 28, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Dr. Kristian Reich<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Scientific Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">October 16, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">135 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=mnlk_Dr.JorgeSantosDaSilvaMember', window );">Dr. Jorge Santos da Silva [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On October 17, 2023, Dr. Jorge Santos da Silva, the Chief Executive Officer and a director of the Company, adopted a trading plan intended to satisfy Rule 10b5-1(c). Dr. Santos da Silva&#8217;s plan provides for the sale of up to 200,000 Class A Ordinary Shares, subject to certain conditions. The plan terminated on February 29, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Dr. Jorge Santos da Silva<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">October 17, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">135 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=mnlk_Dr.KristianReichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=mnlk_Dr.KristianReichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=mnlk_Dr.JorgeSantosDaSilvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=mnlk_Dr.JorgeSantosDaSilvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660405056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#8220;MoonLake AG&#8221;), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board ("FASB").</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to ASC 805, for financial accounting and reporting purposes, MoonLake AG was deemed the accounting acquirer and Helix was treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Accordingly, the Business Combination was treated as the equivalent of MoonLake AG issuing shares for the net assets of Helix, accompanied by a recapitalization. The net assets of Helix were stated at historical costs, with no goodwill or other intangible assets recorded, and are consolidated with MoonLake AG&#8217;s financial statements on the Closing Date. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Business Combination Agreement, the ML Parties received 33.638698 Ordinary Shares in the Company for every MoonLake AG Common Share or Series A Preferred Share (the &#8220;Exchange Ratio&#8221;). The BVF Shareholders received 18,501,284 Class A Ordinary Shares whereas the rest of the ML Parties (excluding the BVF Shareholders) received 15,775,472 Class C Ordinary Shares which can be converted into Class A Ordinary Shares at the discretion of the shareholder (refer to Note&#160;12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; Shareholders&#8217; Equity (Deficit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on the classes of ordinary shares). The number of shares, and the number of shares within the net income (loss) per share held by the ML Parties in MoonLake AG prior to the Business Combination have been adjusted by the Exchange Ratio to reflect the equivalent number of ordinary shares in the Company (identified as &#8220;the equivalent of&#8221; throughout these consolidated financial statements).</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain MoonLake AG shareholders (ML Parties other than the BVF Shareholders), did not exchange their shares in MoonLake AG for Class A Ordinary Shares in the Company and therefore continued to hold an economic interest in MoonLake AG and Class C Ordinary Shares in the Company. The Company recognized a noncontrolling interest equal to the ML Parties&#8217; (other than the BVF Shareholders) proportionate interest in the net assets of MoonLake AG.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are presented in U.S. Dollar (&#8220;$&#8221;), unless otherwise indicated. The term &#8220;Swiss franc&#8221; and &#8220;CHF&#8221; refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and &#8220;&#8364;&#8221; refers to euros.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining whether the in-process research and development expenditure (&#8220;IPR&amp;D&#8221;) has an alternative future use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining assumptions used in estimating the fair value of share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the amount of accruals in connection with the completion of clinical trial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company&#8217;s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future results of operation may be affected.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities and short-term investments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in &#8220;Interest and dividend income&#8221;. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the &#8220;Accumulated other comprehensive income (loss)&#8221; component of shareholders&#8217; equity (deficit) until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified as either &#8220;Cash and cash equivalents&#8221; or &#8220;Short&#8209;term marketable debt securities&#8221; according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statement of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the &#8364;100,000 Fundo de Garantia de Dep&#243;sitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the guidance included in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three levels of inputs to fair value measurements:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1, meaning the use of quoted prices for identical instruments in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3, meaning the use of unobservable inputs. Observable market data is used when available.</span></div>Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a stand-alone basis for the purposes of allocating resources, and assessing financial performance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of <span style="-sec-ix-hidden:f-428">three</span> to five years. As of December&#160;31, 2023, property and equipment, net relates to information technology, office equipment, and leasehold improvements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Contract Costs and Accruals</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Transaction</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goods or services received in a share-based payment transaction are measured using a fair value-based measure.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#8217;s common stock on the date of the grant.</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companies&#8217; volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The fair value of the common stock granted under the ESPP (as defined below) has historically been estimated by management with reference to the market-based transaction with the other Series A Preferred Shares Investors, as there was no public market for the common stock. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.</span></div>Gains or losses from foreign currency translation are included in the consolidated statement of operations in "other income, net".<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Class A Ordinary Shares</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.</span></div>In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the &#8220;In-License Agreement&#8221;) with Merck Healthcare KGaA, Darmstadt, Germany (&#8220;MHKDG&#8221;) to acquire the Sonelokimab program (the &#8220;SLK Program&#8221;) and determined that substantially all of the fair value of the gross assets acquired related to IPR&amp;D of SLK. Therefore, this transaction was accounted for as an asset acquisition.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. </span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&amp;D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy', window );">Pension Accounting</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for pension assets and liabilities in accordance with ASC 715, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Retirement Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the recognition of the funded status of pension plans in the Company&#8217;s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of December&#160;31, 2023 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statement of operations separately from the service cost component, in &#8220;<span style="-sec-ix-hidden:f-439">other income (expenses), net</span>.&#8221; Plan assets are recorded at their fair value. </span></div>Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake does not have any finance leases. As of December&#160;31, 2023, the Company has three operating leases related to the office spaces which are located in (i) Dorfstrasse 29, 6300, Zug, Switzerland, (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. The operating leases are recognized over a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-Use (&#8220;RoU&#8221;) assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments. </span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less and that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. The FASB also issued subsequent amendments to the initial guidance, ASU 2019-04, ASU 2019-05, ASU 2019-11, and ASU 2020-03 (collectively, &#8220;Topic 326&#8221;). The Current Expected Credit Losses model requires a company to estimate credit losses expected over the life of the financial assets based on historical experience, current conditions and reasonable and supportable forecasts. The Company adopted this new guidance as of December 31, 2023 upon the loss of its &#8220;emerging growth company&#8221; status. The adoption did not have a material impact on the balances reported in the Company&#8217;s consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment reporting &#8212; Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends guidance on reportable segment disclosure requirements. It is effective for fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact. The early adoption option will not be exercised. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income taxes - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Taxes Disclosure,</span> which amends guidance on to enhance the transparency and decision usefulness of income tax disclosures. It is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact. The early adoption option will not be exercised.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481097/715-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 80<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480576/715-80-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674528624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination Agreement with Helix and Recapitalization (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock', window );">Summary of Net Proceeds and Ordinary Shares Issued</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the elements of the net proceeds from the Business Combination:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:83.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">in thousands</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investments held in Trust Account</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">115,051</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix  prior to the Closing Date</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(80,842)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plus PIPE investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">116,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less Helix transaction expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(15,520)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(5,798)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which deferred IPO underwriting fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(4,025)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">of which other transaction expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(5,697)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Available Closing Date Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">134,689</span></td></tr></table></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the number of Ordinary Shares outstanding immediately following the consummation of the Business Combination:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:83.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Helix Acquisition Corp. Ordinary Shares prior to the Business Combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,805,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class A Ordinary Shares (Helix management - IPO private placement shares)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">430,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class A Ordinary Shares redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">11,500,000</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:83.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which Class B Ordinary Shares (Helix management - sponsor promote)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">2,875,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(8,080,645)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus issuance of Helix Class A Ordinary Shares to PIPE Investors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,700,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plus issuance of Helix Class A Ordinary Shares to BVF Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,501,284</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total MoonLake Class A Ordinary Shares Outstanding at Closing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">36,925,639</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus issuance of Helix Class C Ordinary Shares to ML Parties (other than the BVF Shareholders)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,775,472</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total MoonLake Class A and Class C Ordinary Shares Outstanding at Closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,701,111</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ScheduleOfReverseRecapitalizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ScheduleOfReverseRecapitalizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846675858288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of debt securities by level within the fair value hierarchy</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:</span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                               </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:21.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.184%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Level 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">109,608,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">109,608,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42,552,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">42,552,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certificates of deposit</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">79,626,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">79,626,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9,937,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9,937,899</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">189,235,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">189,235,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,490,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,490,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846671145408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of investments in short-term marketable debt securities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of December&#160;31, 2023 and December&#160;31, 2022 are as follows:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">107,624,341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,984,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">109,608,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Certificates of Deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">78,890,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">736,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">79,626,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">186,514,788</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2,720,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">189,235,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">128,197,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,199,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">129,396,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within short-term marketable debt securities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58,317,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,521,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">59,838,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eurocommercial Papers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42,265,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">287,479&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42,552,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Certificates of Deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9,834,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">103,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,937,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,099,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">390,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">52,490,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19,775,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">106,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19,881,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Of which classified within short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32,324,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">284,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32,609,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock', window );">Schedule of fair value changes of marketable securities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair values of the Company&#8217;s short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:78.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning balance, January 1, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">390,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8,751,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6,421,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ending balance, December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2,720,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674493584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid expenses</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:58.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prepaid expenses - current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Insurances</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,077,478</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,416,597</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Non-clinical research and clinical development services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">842,729</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,443,863</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other consulting and advisory services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">70,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">105,651</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other prepayments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">111,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">213,357</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,102,203</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">4,179,468</span></td></tr></table></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:58.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prepaid expenses - non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing services</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,423,468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">8,423,468</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846671423792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TradeAndOtherPayablesCurrentTableTextBlock', window );">Schedule of trade and other payables, current</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development services</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">911,454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31,687</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing fees payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">553,459</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">65,979</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rent / leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">108,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">264,522</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">157,306</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,837,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">254,972</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_TradeAndOtherPayablesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade And Other Payables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_TradeAndOtherPayablesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674493584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bonuses and related employees compensation expenses</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,780,219&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,109,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supply and manufacturing services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,603,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development services and license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,226,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,803,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Consultant and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">853,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">218,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">367,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Legal fees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">98,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">6,930,120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">7,256,845</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846668716224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average discount rate for the operating leases as of December&#160;31, 2023 and December 31, 2022 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average remaining lease term (in months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future minimum lease payments</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum annual lease payments under these operating leases as of December&#160;31, 2023 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:70.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,343,255</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,343,255</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,029,249</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">95,794</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">95,794</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">65,923</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,973,270</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(275,404)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,697,866</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Less current portion of lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,197,876)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term portion operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,499,990</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669257040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the changes in projected benefit obligations (&#8220;PBO&#8221;) and plan assets is presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Beginning PBO </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,321,969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,322,874&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Service cost </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">451,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by plan participants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / losses </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">487,991</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(374,317)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">229,902</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(204,695)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign currency exchange rates changes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">208,608</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(16,267)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Plan amendment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(107,750)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Ending PBO</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,494,481</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,321,969</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Beginning fair value of plan assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,039,763&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,083,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Return on plan assets above expected return</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(115,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by the employer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contributions by plan participants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">200,424</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">138,243</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Benefits paid </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">229,902</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(204,695)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign currency exchange rates changes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">155,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14,687)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Ending fair value of plan assets</span></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,911,056</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,039,763</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Defined Benefit Plans Disclosures</a></td>
<td class="text">Amounts recorded on the consolidated balance sheets:<div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fair value of plan assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,911,056&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,039,763&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Present value of projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,494,481)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,321,969)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Funded status</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(583,425)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(282,206)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded in accumulated other comprehensive (income) / loss:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / loss - beginning of year</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(101,716)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">168,177&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Actuarial (gain) / loss of current year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">444,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(268,076)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,817)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prior service (cost) / credit recognized in current year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(107,750)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">234,863</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(101,716)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Defined Benefit Plan, Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to calculate the ASC 715 liabilities are summarized in the table below:</span></div><div style="text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.657%"><tr><td style="width:1.0%"></td><td style="width:57.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.35%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.20%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Inflation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term expected rate of salary increase</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.30%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.30%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">p.a.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock', window );">Defined Benefit Plan, Plan Assets, Allocation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of plan assets is presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Equities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.00&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.11&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mortgages</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liquidity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Real estate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">26.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">27.17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Alternative investments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.40%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Infrastructure</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.16%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment allocation of defined benefit plan assets. Includes, but is not limited to, investment allocation percentage or range of percentages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846675858288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock', window );">Schedule of Stock Authorized and Issued</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class C Ordinary Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Issued and Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Balance - January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">500,000,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">38,977,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">100,000,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">13,723,511</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">600,000,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">52,701,111</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Issuance of Class A Ordinary Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">10,270,818</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">10,270,818</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Conversion of Class C Ordinary Shares into Class A Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">11,218,035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(11,218,035)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Balance - December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">500,000,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">60,466,453</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">100,000,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2,505,476</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">600,000,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">62,971,929</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span>Fully paid-in registered shares with a par value of $0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Stock Authorized And Issued Roll Forward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674522448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earnings per share, basic and diluted</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the loss per share calculations for the year ended December&#160;31, 2023 compared to the year ended December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:56.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss attributable to controlling interests shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(36,007,260)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(49,973,249)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total weighted average number of outstanding shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,122,534</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">29,361,353</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net loss per share &#8211; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(0.73)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(1.70)</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846664394576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text">The share-based compensation expense was driven by the following share-based compensation plans and programs:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:50.688%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Compensation Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MoonLake AG Restricted Founder Shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">1,574,300&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">4,840,608&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ESPP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">3,352,885</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">3,910,076</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ESOP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">973,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">539,713</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MoonLake Immunotherapeutics 2022 Equity Incentive Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">1,204,952</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">364,381</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">7,106,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">9,654,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which: included in research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">1,524,715&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">954,379&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Of which: included in general and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">5,581,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">8,700,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the valuation of the Restricted Founder Shares awarded are summarized below:</span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4/28/2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value of Restricted Founder Shares on the grant date (USD)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">49</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders (USD) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">336.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Purchase price (CHF)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.10</span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Restricted Founder Shares with reference to the market-based transaction with the other Series A Preferred Shares Investors (refer to Note 9 of MoonLake AG's audited consolidated financial statements for the year ended December 31, 2021, as filed by Helix Acquisition Corp. together with its revised definitive proxy soliciting materials with the SEC on March 4, 2022).</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Restricted Founder Shares at co-founder&#8217;s resignation date by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company&#8217;s fully diluted shares (1,070,196).</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Nonvested Restricted Stock Shares Activity</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Restricted Founder Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">4,440,309</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards vested for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,330,231)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,110,078</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards vested for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,110,078)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards unvested as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">0</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESPP 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">01/18/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value per share of Common Shares on the grant date ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">336.39</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Purchase price (CHF)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.10</span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value (USD 360,000,000) as defined by the Business Combination Agreement by the Company&#8217;s fully diluted shares (1,070,196). </span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESPP</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,060,561</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,177,354</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of January 1. 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,237,915</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which vested as of January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">307,794</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,237,915</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which vested as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,607,425</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESPP 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">01/18/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Estimated fair value per share of Common Shares on the grant date ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">336.39</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Purchase price (CHF)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.10</span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value (USD 360,000,000) as defined by the Business Combination Agreement by the Company&#8217;s fully diluted shares (1,070,196). </span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESPP</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,060,561</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,177,354</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of January 1. 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,237,915</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which vested as of January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">307,794</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,237,915</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which vested as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,607,425</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">ESOP 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">5/1/2022, 6/22/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">4.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price (USD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">3.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">75%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">&#8212;%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#8217;s industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:72.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">01/01/2023, 04/24/2023, 07/03/2023, 07/17/2023, 08/01/2023, 08/07/2023, 08/21/2023, 08/29/2023, 09/01/2023, 09/11/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">25.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price (USD)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">37.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;%</span></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#8217;s industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div style="margin-bottom:0.12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:106%">Weighted average assumptions for the awards issued during the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant date</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">4/6/2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">8.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price ($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">12.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">75%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">-</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. </span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:72.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Weighted average assumptions for the awards issued during the year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Grant dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">06/08/2023, 10/11/2023, 10/25/2023, 11/01/2023, 11/06/2023, 11/15/2023, 11/16/2023, 11/20/2023, 11/27/2023, 12/01/2023, 12/04/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Estimated fair value of the option on the grant date using Black-Scholes model ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">25.58</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price ($)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">37.22</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected term of the award on the grant date (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected volatility of the share price </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Expected dividend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected term represents the period that share-based awards are expected to be outstanding.</span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%">The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. </span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">ESOP</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">224,033</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">242,736</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">466,769</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">133,446</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards forfeited for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(15,137)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">585,078</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Of which exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">219,223</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:35.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Grants awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Program</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">MoonLake Immunotherapeutics 2022 Equity Incentive Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#8212;</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">180,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">180,000</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#8212;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Awards granted for the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">132,400</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards issued as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">312,400</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Awards exercisable as of December 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">60,000</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846670320000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income or loss before income tax were as follows:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:41.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(43,469,946)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(62,115,251)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(514,783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,354,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(43,984,729)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(64,469,685)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount computed by applying the statutory income tax rate to loss before income taxes as follows:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:41.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Statutory income tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Effect of income taxed at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in prior year estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Utilization of unrecognized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Non-deductible expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(0.3)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">0.1%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets (liabilities) were:</span></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><span><br/></span></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:41.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,493,559</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,492,435</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Defined benefit plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">69,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">33,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">56,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net operating loss carry forward</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">6,715,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">7,210,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">11,334,793</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">11,736,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(55,862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(55,862)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax assets (net)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">11,278,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">11,736,269</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(11,278,931)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(11,736,269)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total deferred tax (net)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt;text-indent:1.44pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674524032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information and Geographic Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Long-Lived Assets by Geographic Areas</a></td>
<td class="text"><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, net of consisting of property and equipment, and operating lease right-of-use assets by geographical area as of December&#160;31, 2023  are as follows:</span></div><div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:41.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Country</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">507,392</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">331,969</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,704,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">737,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">3,949,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">331,969</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846656452288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination Agreement with Helix and Recapitalization - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 04, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>SFr / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationNet', window );">Reverse recapitalization, net | $</a></td>
<td class="nump">$ 134,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of loan liability | $</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,924<span></span>
</td>
<td class="nump">544,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnlk_PIPEInvestorsMember', window );">PIPE Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issuance price per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">IPO Private Placement Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed', window );">Aggregate fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (CHF per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mnlk_ClassVVotingStockMember', window );">Class V Voting Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,006,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockVotesMultiplier', window );">Common stock, votes per share multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockConversionRatio', window );">Common stock, conversion ratio (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of Class A ordinary shares upon Business Combination (in shares)</a></td>
<td class="nump">18,501,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred Shares purchased by a director following his appointment as chairman of the board of directors (in shares)</a></td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of Class A ordinary shares upon Business Combination (in shares)</a></td>
<td class="nump">15,775,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_StockConvertedReverseRecapitalization', window );">Issuance of Helix Class C ordinary shares to ML parties (other than the BVF shareholders) (in shares)</a></td>
<td class="nump">15,775,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_CommonStockVotesMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Votes Multiplier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_CommonStockVotesMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received On Transaction, Satisfaction Of Fees Owed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ScheduleOfReverseRecapitalizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Reverse Recapitalization [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ScheduleOfReverseRecapitalizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_StockConvertedReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Converted, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_StockConvertedReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnlk_PIPEInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnlk_PIPEInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mnlk_ClassVVotingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mnlk_ClassVVotingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846670161504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination Agreement with Helix and Recapitalization - Summary of Net Proceeds (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_InvestmentsAcquiredThroughReverseRecapitalization', window );">Investments held in Trust Account</a></td>
<td class="nump">$ 115,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date</a></td>
<td class="num">(80,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Plus PIPE investment</a></td>
<td class="nump">116,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationTransactionCosts', window );">Less Helix transaction expense</a></td>
<td class="num">(15,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationAccruedExpenses', window );">of which accrued expenses</a></td>
<td class="num">(5,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees', window );">of which deferred IPO underwriting fee</a></td>
<td class="num">(4,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationOtherTransactionExpenses', window );">of which other transaction expenses</a></td>
<td class="num">(5,697)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ReverseRecapitalizationNet', window );">Available Closing Date Cash</a></td>
<td class="nump">$ 134,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_InvestmentsAcquiredThroughReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments Acquired Through Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_InvestmentsAcquiredThroughReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Deferred Initial Public Offering Underwriting Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationOtherTransactionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Other Transaction Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationOtherTransactionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ReverseRecapitalizationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ReverseRecapitalizationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846659851200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination Agreement with Helix and Recapitalization - Ordinary Shares Issued (Details) - shares<br></strong></div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Apr. 04, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">52,701,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Ordinary Shares, net of transaction costs (in shares)</a></td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Plus issuance of helix class A ordinary shares to BVF shareholders (in shares)</a></td>
<td class="nump">18,501,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization', window );">Total MoonLake class A ordinary Shares outstanding at closing (in shares)</a></td>
<td class="nump">36,925,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Plus issuance of helix class A ordinary shares to BVF shareholders (in shares)</a></td>
<td class="nump">15,775,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_StockConvertedReverseRecapitalization', window );">Issuance of Helix Class C ordinary shares to ML parties (other than the BVF shareholders) (in shares)</a></td>
<td class="nump">15,775,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlk_HelixAcquisitionCorpMember', window );">Helix Acquisition Corp.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlk_HelixAcquisitionCorpMember', window );">Helix Acquisition Corp. | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Less redemptions of class A ordinary shares of the class A ordinary shares issued by Helix prior to the closing date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,080,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlk_HelixAcquisitionCorpMember', window );">Helix Acquisition Corp. | Common class A, private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlk_HelixAcquisitionCorpMember', window );">Helix Acquisition Corp. | Common class A, redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlk_HelixAcquisitionCorpMember', window );">Helix Acquisition Corp. | Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ScheduleOfReverseRecapitalizationLineItems', window );"><strong>Schedule Of Reverse Recapitalization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ScheduleOfReverseRecapitalizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Reverse Recapitalization [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ScheduleOfReverseRecapitalizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_StockConvertedReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Converted, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_StockConvertedReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnlk_HelixAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnlk_HelixAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mnlk_CommonClassAPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mnlk_CommonClassAPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mnlk_CommonClassARedeemableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mnlk_CommonClassARedeemableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846664284592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_RecapitalizationExchangeRatio', window );">Exchange ratio</a></td>
<td class="nump">33.638698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,235,642<span></span>
</td>
<td class="nump">$ 52,490,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,493<span></span>
</td>
<td class="nump">325,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList', window );">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other income, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_NumberOfOperatingLeases', window );">Number of operating leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Of which classified within cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,396,742<span></span>
</td>
<td class="nump">$ 19,881,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of Class A ordinary shares upon Business Combination (in shares) | shares</a></td>
<td class="nump">18,501,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of Class A ordinary shares upon Business Combination (in shares) | shares</a></td>
<td class="nump">15,775,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_RecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_RecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846667702176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 44,079,117<span></span>
</td>
<td class="nump">$ 64,506,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CurrentAssetsInExcessOfCurrentLiabilities', window );">Excess of current assets less current liabilities</a></td>
<td class="nump">504,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Unrestricted cash</a></td>
<td class="nump">$ 451,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_CurrentAssetsInExcessOfCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Assets In Excess Of Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_CurrentAssetsInExcessOfCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669504992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract', window );"><strong>Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">$ 59,838,900<span></span>
</td>
<td class="nump">$ 32,609,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">189,235,642<span></span>
</td>
<td class="nump">52,490,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Eurocommercial Papers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract', window );"><strong>Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">109,608,915<span></span>
</td>
<td class="nump">42,552,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract', window );"><strong>Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">79,626,727<span></span>
</td>
<td class="nump">9,937,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract', window );"><strong>Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">189,235,642<span></span>
</td>
<td class="nump">52,490,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Eurocommercial Papers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract', window );"><strong>Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">109,608,915<span></span>
</td>
<td class="nump">42,552,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract', window );"><strong>Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">$ 79,626,727<span></span>
</td>
<td class="nump">$ 9,937,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846656921584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Fair Value and Amortized Cost of Investments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 186,514,788<span></span>
</td>
<td class="nump">$ 52,099,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">2,720,854<span></span>
</td>
<td class="nump">390,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">189,235,642<span></span>
</td>
<td class="nump">52,490,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Of which classified within cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">128,197,581<span></span>
</td>
<td class="nump">19,775,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1,199,161<span></span>
</td>
<td class="nump">106,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">129,396,742<span></span>
</td>
<td class="nump">19,881,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DebtSecuritiesMember', window );">Of which classified within short-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">58,317,207<span></span>
</td>
<td class="nump">32,324,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1,521,693<span></span>
</td>
<td class="nump">284,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">59,838,900<span></span>
</td>
<td class="nump">32,609,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Eurocommercial Papers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">107,624,341<span></span>
</td>
<td class="nump">42,265,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1,984,574<span></span>
</td>
<td class="nump">287,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">109,608,915<span></span>
</td>
<td class="nump">42,552,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">78,890,447<span></span>
</td>
<td class="nump">9,834,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">736,280<span></span>
</td>
<td class="nump">103,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 79,626,727<span></span>
</td>
<td class="nump">$ 9,937,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669263744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - FV changes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward', window );"><strong>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="num">$ (2,330,101)<span></span>
</td>
<td class="num">$ (390,753)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward', window );"><strong>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross unrealized gain (loss), beginning balance</a></td>
<td class="nump">390,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">8,751,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income</a></td>
<td class="num">(6,421,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross unrealized gain (loss), ending balance</a></td>
<td class="nump">$ 2,720,854<span></span>
</td>
<td class="nump">$ 390,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669519856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAbstract', window );"><strong>Prepaid expenses - current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurances</a></td>
<td class="nump">$ 1,077,478<span></span>
</td>
<td class="nump">$ 1,416,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_PrepaidResearchAndDevelopmentExpense', window );">Non-clinical research and clinical development services</a></td>
<td class="nump">842,729<span></span>
</td>
<td class="nump">2,443,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent', window );">Other consulting and advisory services</a></td>
<td class="nump">70,018<span></span>
</td>
<td class="nump">105,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepayments</a></td>
<td class="nump">111,978<span></span>
</td>
<td class="nump">213,357<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total</a></td>
<td class="nump">2,102,203<span></span>
</td>
<td class="nump">4,179,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrentAbstract', window );"><strong>Prepaid expenses - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SupplyAndManufacturingExpenseNoncurrent', window );">Supply and manufacturing services</a></td>
<td class="nump">8,423,468<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Total</a></td>
<td class="nump">$ 8,423,468<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Prepaid Consulting And Advisory Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_PrepaidResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_PrepaidResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SupplyAndManufacturingExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply And Manufacturing Expense, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SupplyAndManufacturingExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660452544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Payables (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development services</a></td>
<td class="nump">$ 911,454<span></span>
</td>
<td class="nump">$ 31,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SupplyAndManufacturingFeesPayableCurrent', window );">Supply and manufacturing fees payable</a></td>
<td class="nump">553,459<span></span>
</td>
<td class="nump">65,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Rent / leases</a></td>
<td class="nump">108,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">264,522<span></span>
</td>
<td class="nump">157,306<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TradeAndOtherPayablesCurrent', window );">Total</a></td>
<td class="nump">$ 1,837,684<span></span>
</td>
<td class="nump">$ 254,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SupplyAndManufacturingFeesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply And Manufacturing Fees Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SupplyAndManufacturingFeesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_TradeAndOtherPayablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade And Other Payables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_TradeAndOtherPayablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846656988512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Bonuses and related employees compensation expenses</a></td>
<td class="nump">$ 2,780,219<span></span>
</td>
<td class="nump">$ 1,109,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_AccruedSupplyAndManufacturingFeesCurrent', window );">Supply and manufacturing services</a></td>
<td class="nump">1,603,739<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent', window );">Research and development services and license fees</a></td>
<td class="nump">1,226,281<span></span>
</td>
<td class="nump">5,803,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_AccruedConsultingAndOtherFeesCurrent', window );">Consultant and other fees</a></td>
<td class="nump">853,905<span></span>
</td>
<td class="nump">218,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Tax liabilities</a></td>
<td class="nump">367,976<span></span>
</td>
<td class="nump">109,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Legal fees</a></td>
<td class="nump">98,000<span></span>
</td>
<td class="nump">15,832<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 6,930,120<span></span>
</td>
<td class="nump">$ 7,256,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_AccruedConsultingAndOtherFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Consulting And Other Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_AccruedConsultingAndOtherFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Services and License Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_AccruedSupplyAndManufacturingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Supply And Manufacturing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_AccruedSupplyAndManufacturingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846664341792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 13, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 09, 2023 </div>
<div>ft&#178; </div>
<div>period</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Lessee, operating lease, lease term extension | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399,882<span></span>
</td>
<td class="nump">$ 155,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_OfficeLeaseMember', window );">Office Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_OperatingLeaseAreaOfLeasedSpace', window );">Square foot of leased space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_PortoOfficeMember', window );">Porto Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_OperatingLeaseAreaOfLeasedSpace', window );">Square foot of leased space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_CambridgeOfficeMember', window );">Cambridge Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_OperatingLeaseAreaOfLeasedSpace', window );">Square foot of leased space</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_OperatingLeaseAreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Area of Leased Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_OperatingLeaseAreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_PortoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_PortoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_CambridgeOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_CambridgeOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846674471200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Weighted Average Lease Term And Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in months)</a></td>
<td class="text">39 months<span></span>
</td>
<td class="text">22 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669539088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,343,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,343,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,029,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">95,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">95,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">65,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,973,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(275,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">3,697,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="num">(1,197,876)<span></span>
</td>
<td class="num">$ (153,629)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion operating lease liability</a></td>
<td class="nump">$ 2,499,990<span></span>
</td>
<td class="nump">$ 128,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669571648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 122,698<span></span>
</td>
<td class="nump">$ 451,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669505712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Changes in Summary of PBO And Plan Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Beginning PBO</a></td>
<td class="nump">$ 1,321,969<span></span>
</td>
<td class="nump">$ 1,322,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">122,698<span></span>
</td>
<td class="nump">451,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">30,639<span></span>
</td>
<td class="nump">5,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Contributions by plan participants</a></td>
<td class="nump">200,424<span></span>
</td>
<td class="nump">138,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) / losses</a></td>
<td class="nump">487,991<span></span>
</td>
<td class="num">(374,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments', window );">Benefits paid</a></td>
<td class="nump">229,902<span></span>
</td>
<td class="num">(204,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign currency exchange rates changes</a></td>
<td class="nump">208,608<span></span>
</td>
<td class="num">(16,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendment</a></td>
<td class="num">(107,750)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Ending PBO</a></td>
<td class="nump">2,494,481<span></span>
</td>
<td class="nump">1,321,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning fair value of plan assets</a></td>
<td class="nump">1,039,763<span></span>
</td>
<td class="nump">1,083,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">36,523<span></span>
</td>
<td class="nump">15,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns', window );">Return on plan assets above expected return</a></td>
<td class="nump">48,938<span></span>
</td>
<td class="num">(115,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by the employer</a></td>
<td class="nump">200,424<span></span>
</td>
<td class="nump">138,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Contributions by plan participants</a></td>
<td class="nump">200,424<span></span>
</td>
<td class="nump">138,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments', window );">Benefits paid</a></td>
<td class="nump">229,902<span></span>
</td>
<td class="num">(204,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency exchange rates changes</a></td>
<td class="nump">155,082<span></span>
</td>
<td class="num">(14,687)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending fair value of plan assets</a></td>
<td class="nump">$ 1,911,056<span></span>
</td>
<td class="nump">$ 1,039,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Obligation, Benefits Paid, Net Of Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Plan Assets, Benefits Paid, Net Of Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Plan Assets, Increase (Decrease) for Return Above Expected Returns</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846670206240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Benefit Plans - Amounts Recorded on the Balance Sheet (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Fair value of plan assets</a></td>
<td class="nump">$ 1,911,056<span></span>
</td>
<td class="nump">$ 1,039,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Present value of projected benefit obligation</a></td>
<td class="num">(2,494,481)<span></span>
</td>
<td class="num">(1,321,969)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Funded status</a></td>
<td class="num">$ (583,425)<span></span>
</td>
<td class="num">$ (282,206)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669280464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Changes in Pre-Tax AOCI (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward', window );"><strong>Defined Benefit Plan, AOCI Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Actuarial (gain) / loss - beginning of year</a></td>
<td class="num">$ (101,716)<span></span>
</td>
<td class="nump">$ 168,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Actuarial (gain) / loss of current year</a></td>
<td class="nump">444,329<span></span>
</td>
<td class="num">(268,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) / credit recognized in current year</a></td>
<td class="num">(107,750)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Total</a></td>
<td class="nump">$ 234,863<span></span>
</td>
<td class="num">$ (101,716)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DefinedBenefitPlanAOCIRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, AOCI Rollforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DefinedBenefitPlanAOCIRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660493664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Benefit Plans - Assumptions used to calculate liabilities (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation', window );">Inflation</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Long-term expected rate of salary increase</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Expected return on plan assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Inflation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846664039984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Benefit Plans - Allocation Percentage (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember', window );">Equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems', window );"><strong>Defined Benefit Plan, Plan Assets, Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Defined benefit plan, plan assets, actual allocation, percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.11%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanBondMember', window );">Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems', window );"><strong>Defined Benefit Plan, Plan Assets, Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Defined benefit plan, plan assets, actual allocation, percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">28.89%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems', window );"><strong>Defined Benefit Plan, Plan Assets, Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Defined benefit plan, plan assets, actual allocation, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.86%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanLiquidityMember', window );">Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems', window );"><strong>Defined Benefit Plan, Plan Assets, Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Defined benefit plan, plan assets, actual allocation, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.41%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember', window );">Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems', window );"><strong>Defined Benefit Plan, Plan Assets, Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Defined benefit plan, plan assets, actual allocation, percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">27.17%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember', window );">Alternative investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems', window );"><strong>Defined Benefit Plan, Plan Assets, Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Defined benefit plan, plan assets, actual allocation, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanInfrastructureMember', window );">Infrastructure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems', window );"><strong>Defined Benefit Plan, Plan Assets, Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Defined benefit plan, plan assets, actual allocation, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.16%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanLiquidityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanLiquidityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanInfrastructureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mnlk_DefinedBenefitPlanInfrastructureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660037376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Deficit) - Schedule of Stock Authorized and Issued (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TotalSharesRollForward', window );"><strong>Total Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SharesAuthorized', window );">Authorized, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,701,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SharesAuthorized', window );">Authorized, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,971,929<span></span>
</td>
<td class="nump">52,701,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockRollForward', window );"><strong>Common Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares under the ATM facility (in shares)</a></td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TotalSharesRollForward', window );"><strong>Total Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares under the ATM facility (in shares)</a></td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (CHF/USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockRollForward', window );"><strong>Common Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TotalSharesRollForward', window );"><strong>Total Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (CHF/USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockRollForward', window );"><strong>Common Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares under the ATM facility (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,486<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TotalSharesRollForward', window );"><strong>Total Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares under the ATM facility (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockRollForward', window );"><strong>Common Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares under the ATM facility (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,218,035<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TotalSharesRollForward', window );"><strong>Total Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares under the ATM facility (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (CHF/USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Common Class A | Conversion Of Class C into Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockRollForward', window );"><strong>Common Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,218,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockRollForward', window );"><strong>Common Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,218,035)<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_TotalSharesRollForward', window );"><strong>Total Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (CHF/USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Common Class C | Conversion Of Class C into Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockRollForward', window );"><strong>Common Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,218,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_CommonStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_CommonStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares, Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_TotalSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_TotalSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mnlk_ConversionOfClassCIntoClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=mnlk_ConversionOfClassCIntoClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660948768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Deficit) - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 10, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 27, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 04, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 11, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,701,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,924<span></span>
</td>
<td class="nump">544,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SaleOfStockStampDutyTax', window );">Stamp duty tax | $</a></td>
<td class="num">$ (2,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlk_MoonLakeAGMember', window );">MoonLake AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mnlk_MoonLakeImmunotherapeuticsMember', window );">MoonLake Immunotherapeutics | MoonLake AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="nump">38,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Proceeds from contributions from parent | $</a></td>
<td class="nump">$ 275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnlk_UnderwritingAgreementMember', window );">Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 436,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issuance price per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnlk_UnderwritingAgreementMember', window );">Underwriting Agreement | MoonLake Immunotherapeutics | MoonLake AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">22,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SaleOfStockOptionToPurchaseTerm', window );">Sale of stock, option to purchase, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mnlk_ATMSharesMember', window );">ATM Shares | May 2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount', window );">Sale of stock, remaining authorized repurchase amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mnlk_ATMSharesMember', window );">ATM Shares | August 2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,161,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,486<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockVotesAttachedToShares', window );">Common shares, votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,218,035<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C | MoonLake AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_CommonStockVotesAttachedToShares', window );">Common shares, votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,218,035)<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_CommonStockVotesAttachedToShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Votes Attached To Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_CommonStockVotesAttachedToShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SaleOfStockOptionToPurchaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Option To Purchase, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SaleOfStockOptionToPurchaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Authorized Repurchase Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SaleOfStockStampDutyTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Stamp Duty Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SaleOfStockStampDutyTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from parent as a source of financing that is recorded as additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnlk_MoonLakeAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnlk_MoonLakeAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mnlk_MoonLakeImmunotherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mnlk_MoonLakeImmunotherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnlk_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnlk_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mnlk_ATMSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mnlk_ATMSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_May2023SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_May2023SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_August2023SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_August2023SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669262272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Calculation of Net Loss per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to controlling interests shareholders</a></td>
<td class="num">$ (36,007,260)<span></span>
</td>
<td class="num">$ (49,973,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total weighted average number of outstanding shares, basic (in shares)</a></td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total weighted average number of outstanding shares, diluted (in shares)</a></td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in USD per share)</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in USD per share)</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669804400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares, basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares, diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="nump">52,701,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ProFormaMember', window );">Pro forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares, basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,679,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares, diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,679,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,161,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mnlk_MLPartiesOtherThanBVFShareholdersMember', window );">ML parties other than BVF shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">MoonLake AG common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_StockConvertedReverseRecapitalization', window );">Stock converted (in shares)</a></td>
<td class="nump">15,775,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C | ML parties other than BVF shareholders | Pro forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_StockForfeitedReverseRecapitalization', window );">Stock forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares, basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares, diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,122,534<span></span>
</td>
<td class="nump">29,361,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Pro forma | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,886,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | ML parties other than BVF shareholders | Pro forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_StockConvertedReverseRecapitalization', window );">Stock converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_StockConvertedReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Converted, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_StockConvertedReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_StockForfeitedReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Forfeited, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_StockForfeitedReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mnlk_MLPartiesOtherThanBVFShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mnlk_MLPartiesOtherThanBVFShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846665247152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>co-founder </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2021 </div>
<div>SFr / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,106,005<span></span>
</td>
<td class="nump">$ 9,654,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">52,701,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_NumberOfCoFounders', window );">Number of co-founders | co-founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember', window );">Employee Stock Option Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember', window );">Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,204,952<span></span>
</td>
<td class="nump">364,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-Based Payment Arrangement, Tranche Three | Equity Incentive Plan | Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=mnlk_ShareBasedPaymentArrangementTrancheFourMember', window );">Share-Based Payment Arrangement, Tranche Four | Equity Incentive Plan | Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Payment Arrangement, Tranche Two | Equity Incentive Plan | Share-Based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Payment Arrangement, Tranche Two | Equity Incentive Plan | Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-Based Payment Arrangement, Tranche One | Equity Incentive Plan | Share-Based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments', window );">Share-based compensation arrangement by share-based payment award, number of vesting installments | installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-Based Payment Arrangement, Tranche One | Equity Incentive Plan | Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">MoonLake AG Restricted Founder Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,574,300<span></span>
</td>
<td class="nump">4,840,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,352,885<span></span>
</td>
<td class="nump">3,910,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized share-based compensation expense, non-option awards | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Employee Stock Option Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Share-Based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Share-Based Payment Arrangement, Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">ESOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 973,868<span></span>
</td>
<td class="nump">$ 539,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">ESOP | Share-Based Payment Arrangement, Tranche Three | Employee Stock Option Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">ESOP | Share-Based Payment Arrangement, Tranche Four | Employee Stock Option Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">ESOP | Share-Based Payment Arrangement, Tranche Two | Employee Stock Option Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">ESOP | Share-Based Payment Arrangement, Tranche One | Employee Stock Option Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlk_MoonLakeAGMember', window );">MoonLake AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage', window );">Reverse vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlk_MoonLakeAGMember', window );">MoonLake AG | MoonLake AG Restricted Founder Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.166%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_SharePriceNominalValue', window );">Nominal value (CHF per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C | MoonLake AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C | MoonLake AG | MoonLake AG Restricted Founder Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,330,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,330,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,161,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,505,476<span></span>
</td>
<td class="nump">13,723,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,466,453<span></span>
</td>
<td class="nump">38,977,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_NumberOfCoFounders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Co-Founders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_NumberOfCoFounders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Vesting Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_SharePriceNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price, Nominal Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_SharePriceNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=mnlk_ShareBasedPaymentArrangementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=mnlk_ShareBasedPaymentArrangementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnlk_MoonLakeAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnlk_MoonLakeAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846660507600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Share-based Compensation Expense By Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 7,106,005<span></span>
</td>
<td class="nump">$ 9,654,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,524,715<span></span>
</td>
<td class="nump">954,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5,581,290<span></span>
</td>
<td class="nump">8,700,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember', window );">Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,204,952<span></span>
</td>
<td class="nump">364,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">MoonLake AG Restricted Founder Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,574,300<span></span>
</td>
<td class="nump">4,840,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3,352,885<span></span>
</td>
<td class="nump">3,910,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">ESOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 973,868<span></span>
</td>
<td class="nump">$ 539,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846657224096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise', window );">Enterprise value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares', window );">Fully diluted shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,070,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember', window );">Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated fair value of the option on the grant date using Black-Scholes model (in dollars per share)</a></td>
<td class="nump">$ 25.58<span></span>
</td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 37.22<span></span>
</td>
<td class="nump">$ 12.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of the award</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of the share price</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">MoonLake AG Restricted Founder Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated fair value per share of Restricted Founder Shares on the grant date (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue', window );">Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders of MoonLake AG (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Purchase price (in CHF per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated fair value per share of Restricted Founder Shares on the grant date (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Purchase price (in CHF per share) | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">ESOP | Employee Stock Option Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated fair value of the option on the grant date using Black-Scholes model (in dollars per share)</a></td>
<td class="nump">$ 25.5<span></span>
</td>
<td class="nump">4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 37.1<span></span>
</td>
<td class="nump">$ 3.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of the award</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of the share price</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Founder Resignation Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Denominator, Fully Diluted Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Numerator, Enterprise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846664323280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Awarded and Granted (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember', window );">Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding beginning balance (in shares)</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Awards granted (in shares)</a></td>
<td class="nump">132,400<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding ending balance (in shares)</a></td>
<td class="nump">312,400<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Awards exercisable (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">MoonLake AG Restricted Founder Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,110,078<span></span>
</td>
<td class="nump">4,440,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards vested (in shares)</a></td>
<td class="num">(1,110,078)<span></span>
</td>
<td class="num">(3,330,231)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding, ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,110,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,237,915<span></span>
</td>
<td class="nump">1,060,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,177,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards vested (in shares)</a></td>
<td class="num">(1,607,425)<span></span>
</td>
<td class="num">(307,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding, ending balance (in shares)</a></td>
<td class="nump">2,237,915<span></span>
</td>
<td class="nump">2,237,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">ESOP | Employee Stock Option Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding beginning balance (in shares)</a></td>
<td class="nump">466,769<span></span>
</td>
<td class="nump">224,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Awards granted (in shares)</a></td>
<td class="nump">133,446<span></span>
</td>
<td class="nump">242,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Awards forfeited (in shares)</a></td>
<td class="num">(15,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding ending balance (in shares)</a></td>
<td class="nump">585,078<span></span>
</td>
<td class="nump">466,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Awards exercisable (in shares)</a></td>
<td class="nump">219,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669558288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">$ 11,334,793<span></span>
</td>
<td class="nump">$ 11,736,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">11,278,931<span></span>
</td>
<td class="nump">$ 11,736,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">56,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_OperatingLossCarryforwardExpirationAxis=mnlk_ExpirationIn2028Member', window );">Expiration in 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_OperatingLossCarryforwardExpirationAxis=mnlk_ExpirationIn2029Member', window );">Expiration in 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 44,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_OperatingLossCarryforwardExpirationAxis=mnlk_ExpirationIn2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_OperatingLossCarryforwardExpirationAxis=mnlk_ExpirationIn2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_OperatingLossCarryforwardExpirationAxis=mnlk_ExpirationIn2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_OperatingLossCarryforwardExpirationAxis=mnlk_ExpirationIn2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669471120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Switzerland</a></td>
<td class="num">$ (43,469,946)<span></span>
</td>
<td class="num">$ (62,115,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(514,783)<span></span>
</td>
<td class="num">(2,354,434)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) attributable to parent, before tax</a></td>
<td class="num">$ (43,984,729)<span></span>
</td>
<td class="num">$ (64,469,685)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846664310176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Statutory Tax Percent (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effect of income taxed at different rates</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Change in prior year estimates</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent', window );">Utilization of unrecognized losses</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expense</a></td>
<td class="num">(12.30%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Utilization Of Unrealized Loss Not Recognized In Prior Year, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846656984512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Tax (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 4,493,559<span></span>
</td>
<td class="nump">$ 4,492,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits', window );">Defined benefit plan</a></td>
<td class="nump">69,173<span></span>
</td>
<td class="nump">33,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DeferredTaxAssetsLeaseLiabililties', window );">Lease liabilities</a></td>
<td class="nump">56,527<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">6,715,534<span></span>
</td>
<td class="nump">7,210,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">11,334,793<span></span>
</td>
<td class="nump">11,736,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(55,862)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(55,862)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance', window );">Total deferred tax assets (net)</a></td>
<td class="nump">11,278,931<span></span>
</td>
<td class="nump">11,736,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(11,278,931)<span></span>
</td>
<td class="num">(11,736,269)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax (net)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DeferredTaxAssetsLeaseLiabililties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabililties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DeferredTaxAssetsLeaseLiabililties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DeferredTaxAssetsNetIncludingValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, Including Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DeferredTaxAssetsNetIncludingValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669771792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 12, 2023</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_UnrecognizedCommitmentsAndContingencies', window );">Total commitments not yet recognized</a></td>
<td class="nump">$ 44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mnlk_PrepaidExpensesNoncurrentMember', window );">Prepaid Expenses, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_UnrecognizedCommitmentsAndContingencies', window );">Total commitments not yet recognized</a></td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_OfficeLeaseMember', window );">Office Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License | SLK Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount', window );">Revenue remaining performance obligation additional variable consideration amount</a></td>
<td class="nump">$ 331.3<span></span>
</td>
<td class="nump">&#8364; 299.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amount</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">&#8364; 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Remaining Performance Obligation Additional Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Remaining Performance Obligation Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlk_UnrecognizedCommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Commitments And Contingencies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlk_UnrecognizedCommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mnlk_PrepaidExpensesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mnlk_PrepaidExpensesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mnlk_SonelokimabProgramSLKProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mnlk_SonelokimabProgramSLKProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846659963520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information and Geographic Data (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 3,949,345<span></span>
</td>
<td class="nump">$ 331,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">507,392<span></span>
</td>
<td class="nump">331,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">2,704,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PT', window );">Portugal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 737,398<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139846669719904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Oct. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,924<span></span>
</td>
<td class="nump">544,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.7<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | August 2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,270,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,486<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="nump">44,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Common Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,218,035)<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Common Class C | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="nump">1,493,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,218,035<span></span>
</td>
<td class="nump">2,051,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Common Class A | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion and transfer of shares between classes (in shares)</a></td>
<td class="nump">1,493,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnlk_August2023SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnlk_August2023SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M\-C^/_]CF(EK(<^J -#HE5&N$J_0NISYOLH*8%@-10G<K!R%9%B;4)Y\54K
MN1,QZH=!,/49)MQ+8S>WDVDL*DT)AYU$JF(,R[<%4%$GWLB[3#R14Z'MA)_&
M)3[!'O1SN9,F\CM*3AAP101'$HZ)-Q_-%E.[WVWX0:!65V-D,SD(<;;!.D^\
MP!H""IFV!&Q>+[ $2BW(V/C3,KWN2"N\'E_H#RYWD\L!*U@*^I/DNDB\SQ[*
MX8@KJI]$_0W:?":6EPFJW!/5S=[(G)A52@O6BDW,"&_>^+6]ARM!&-P1A*T@
M=+Z;@YS+%=8XC:6HD;2[#<T.7*I.;<P1;C_*7DNS2HQ.I_,J)QJM>?-YS3W%
MOC98N^AG+6+1(,([B%&(MH+K0J&O/(?\?X!O_'2FPHNI1=A+7$$V1-%H@,(@
MC'IX49=DY'A17Y)"7J>)?LT/2DOS4_R^E7'#&]_FV4*9J1)GD'BF$A3(%_#2
MCQ]&T^!+C]MQYW;<1^_</A#)T'IURUX_H/?.)IV+R;M</&(&MRSTJQ?X#!)]
M)Y2^H>?] &TVNQY/T\[3]%V>-B*[^Z_V$[:BXMJT*F3+>X"6\UNN_*MR8B!/
MKFDHE%EM4UG=;->7YDTY_MO>-+4MEB?"%:)P--)@^,E<FVP:11-H4;KB/ AM
M2MT-"]-;0=H-9OTHA+X$]H"N6Z=_ 5!+ P04    " "K0%U8,N&!OYX&  !8
M'P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*V9:6_;.!"&_XK@+HHN
MT-0\=)!M8B!ULFB!;AO4Z>YG1:9CH3I<B<[Q[W<H.];!P_;6^9!(SG#\#L69
M9TB=/Y;5SWHIA/2>\JRH+T9+*5?OQ^,Z68H\KM^5*U' ?Q9EE<<2;JO[<;VJ
M1#QO!N79F" 4CO,X+4:3\^:SFVIR7JYEEA;BIO+J=9['U?-'D96/%R,\>OG@
M>WJ_E.J#\>1\%=^+F9 _5C<5W(UW7N9I+HHZ+0NO$HN+T25^/Z5,#6@L_DG%
M8]VY]E0H=V7Y4]U\GE^,D%(D,I%(Y2*&/P]B*K),>0(=O[9.1[OO5 .[UR_>
M_VJ"AV#NXEI,R^S?="Z7%R,V\N9B$:\S^;U\_"2V 07*7U)F=?/;>]S8!FCD
M)>M:EOEV,"C(TV+S-W[:3D1G /8M \AV #ET -T.H$V@&V5-6%>QC"?G5?GH
M5<H:O*F+9FZ:T1!-6JC'.),5_#>%<7(R_?9U]NW+YZO+V^LK[^/EE\NOTVMO
M]NGZ^G;FG7D_9E?>FS_^/!]+^"HU8)QLW7[<N"46MU<B>>=1_-8CB%##\.GA
MPTE_^!@"W$5)=E&2QA^U1;FN*E%(+ZYK(6M3.)OQOGF\RJ7W]2I.Q,4(DJ46
MU8,835Z_PB'Z8 KN1,YZH=)=J-3E?3*-ZZ47%W,O41?BUSI]B#.(W1CUQE70
MN%()_S#Q XQ#3FET/G[HAJ1;4AZ@("2M84^NOY/K.^7.EF4ESZ2H<EC5U4\A
MX[M,0![>2:\6R;I*92J,TC=NPXZ@@#/*.$(#Y;HA)2'B&#&S\F"G/' J_R:7
MHH)*E@B881!M5!EH7XYATEA(!B)U.X(C3+A98KB3&#HEWE1B%:=S3SQ!U:]%
M#1F=;#+!I#4T:(#T0W2@5;?S<<3]T#*?T4YLY!1[6\HX>]'GR-1(?_#8QV%$
MT7!2=<LHA.5-*3$K93NES%E-OI;%V7Z=[)05Y43.>N'R7;C<O=!7HHIE6MQ[
MF0!@>I4BXUFY.%O#C3U^KN==2)C/AOFIVQ%&@HY93S1&+=C0GL4/O4XEGYMB
MJ.K@"KH/^=8KA''U;[WUZP1B83"0:[#S.=0=B]P.A_&QN5JTZ\RH&&M*F$]H
M-Q&WDG5#V^RV0,5.B&VSM3@H$[:N>E60T(@P/"PM!DM*,0]ML]M"$;NIN)'K
MD$CUJD+"P$<8:PM -XU"YE.*L$5ERT+L']2F9&E\EV96]&$G4H\M+:?RUH^Y
MI2AV8_2VBN>BR=&R >HJ?K;2%!MPRJB:_>$S,O T\'ED*?RX!2IV$[73KJS@
M2FU$RH57#BKDON>G$Q1C'K$H'(9A, R@BMK2H44M=K/V,DFJM>@4FW;^DP/7
MH Y7:!L1)L/R;C","+1 ?F )HJ4P=E)OT##LT\LT&9R'H$/3JQM&(50"/[3H
M;3&*^<%MPSZU3B(?G>$G\M;?>K4@)FX0?RF+^T'*6/+EV;@STX%+? X_PR=G
M,,2$\<!2EDF+9K('S=M3"[=,';(!HSX9YK3!#OH=@BS+BW2VN,<2><\B(P;8
M(I",-<FZH8\!C):M'VFI3 ZA\CZ9.F\Q13Y'7-.I6S($R=O9P?2%MF F[EWJ
MM,SS5*K^<5,JD[)0RU<4B4WT_X"J9SQ*^'U'_9A;,)/ 6:ZNH66&[OG-7"S2
M))7&0R#B9/O1QR8G\M8/N&4[<;/]<CY/57F"):DZ\;.T\))XE<(2-8:NLSE$
M@!1.J+8N#1@G'',"ORPKLR4YV4OR=;[.8@DTWSXIHUJ=PF<8 ]<B/QINFTVV
M#(4!(MC2/Y&6V<3-[*[<;;]1YO TEZK$/@@O+>!>&"/0N4QH$(4$#^7KAC1
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MCSNO/=4[Y[_CZCXM:MA4+F 8>A?!^&KS&G=S(\M5\R;TKI2RS)O+I8B!Y,H
M_K\H2_ERHUZN[EZF3_X#4$L#!!0    ( *M 75AAA5BS?P,  ( 3   8
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MM8'0\='D]F9Z>WWECA\\%UR,K\<W$P],+SWO80I.[A#%,?<Q#V8H_ J^@<]
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MC.:8R@!1OR"$OQ;D%DFQZ3;Z#U!+ P04    " "K0%U8Y?2W4?(%  "=&0
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M"=7*"1.6TS-9*V>I)Q&CXU91K89J=51KH%H3U5JHUD:U#JIU]]KQ$6S;4I<
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MIFBN[>BN[AAJ"8ZV,D6U JH54:V$:N6D";-SN8QEVCFU"$>[E:):#=7JJ-9
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MULGE8HN*/Z.+LOG:1=D\WT6YZ07:TM\F'X:/M^V\L6T]DS.,C%JJHQV/4:V
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M^WYP^.5#Z'_W-U]W8WSZ/U!+ P04    " "K0%U82(X'&0X(  "%(   &
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MD.D68EVR;(^2"A)*XV5[4;(40O2?YLC0^/RSE/DG]HWK8?]P??G[*X;9FHW
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M%H#?MQ(:YN9&/^#P/P^6_P)02P,$%     @ JT!=6/W.@!>N P  Y@<  !@
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MT+L0AQ4]Q.CX .UO+47;3]C!\+0O_P902P,$%     @ JT!=6)N4[LB;"P
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M6YV<5P$B9R@\[B#?P?Q?N(;J@[X?TFK\/A-V(Y"6NXT;G==YW;*)(53[A1<
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MO_IBU<J]59\I:U7N/BX%ATOI 'Z?*^1C^$(,ZO]F<?D_4$L#!!0    ( *M
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M$CCO'NPA +V[EO;^$)&]P ZXMVDP)QLM1[^C.E:V>N$B)ZH_VI:T02)/*?C
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M5J4\C+N2!QL:4RDU_XC(,I2IG0CJKRIS98<RWBA1]/A!,<'CI$T*8BX3[L^
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M4)>P*)7->NO0YE+U'M.^.86:Z4S]<!ZOP6P/J:M]X16X""J7ZNA#FZ-[/ (
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M%Q2U4Z#S0BE[%)R#_DW>_ ]02P,$%     @ JT!=6.=X\?^0!   ,0L  !D
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M<E+N5A]_A).?S//56MGP2XYS;9)$I)ZLT_T)C KZ;IB?\O&4PS- R5X!B!-
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MYLX[3YP>0[?;:8>],PQ;_%B!\06XO]?:G2?^@.7SM_D+4$L#!!0    ( *M
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MPP;&!^#^5FMWFO@$\U.Y^@902P,$%     @ JT!=6.@&8W=3!0  /PT  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULM5=1;]LV$/XK!S<K$D"Q9<FR
MK30QX*0;UJU=@[1=L0U[H*633$P2-9**X_[ZW5&R8S>)FS[LQ:8HWL?O[KL[
M4N<KI?\Q2T0+=V51F8O>TMKZ;# PR1)+8?JJQHK>9$J7PM*CS@>FUBA29U06
M@\#WQX-2R*HW.W=SUWIVKAI;R JO-9BF+(5>7V*A5A>]86\S<2/SI>6)P>R\
M%CE^0/NIOM;T--BBI++$RDA5@<;LHC<?GEV.>+U;\+O$E=D9 WNR4.H??GB3
M7O1\)H0%)I81!/W=XA46!0,1C7\[S-YV2S;<'6_0?W*^DR\+8?!*%9]E:I<7
MO6D/4LQ$4]@;M?H9.W\BQDM48=POK-JU0UJ<-,:JLC,F!J6LVG]QU\5AQV#J
M/V$0= :!X]UNY%B^%E;,SK5:@>;5A,8#YZJS)G*R8E$^6$UO)=G9V5LDE\SY
MP!(6SPR2SNZRM0N>L!L&\$Y5=FG@QRK%=!]@0"2V3((-D\O@(.)K3/H0#CT(
M_" \@!=N/0L=7GC0,_AKOC!6D_A_/^9D"S%Z'((+XLS4(L&+'F6\07V+O=G+
M%\.Q_^H P=&6X.@0^H'0/\<.WE0P;W+*$ X8A<TN$:Y468MJ#5A9U)B"K*P"
M40'7\"FR4*"R3"8(!8. R#4BE9CU +,,787 ;^H6RP5J:+5@:+597]=:W4DJ
M!BS6$'BA[U,=-4(C9-Q!5 8N7D#UQGP*0?3L2D%6**4-O^?I12.+5%8Y%"HA
MJ!2$A==*9RR4H6V"V(,Q8__9Y!Y\6$G[!74AJA2.V?SEBVD0^*_>MYZX</1.
M^O!Q-P#&.I:IV^_>M[31PG6#CLDN!K.058)UVRYHMQ0IC%1TS!!JU%)Q_""$
M-0IM/"I5NP2\JPF<EM! =NBRNH\BA7#49[4HP=U,F^&M8 G5$"<GK(0A .LT
M\CC:+CZL'E34VN[]>=J75J+OI/F+J$B^-5.:].%]!>\3JYAVO$OSR;SZ9C()
M)_I#T,<S*O3BAQG5;;*76)G,R">758>2ZJ81\(X\Q *N'><48?X%4[Q5,!W[
M'HR&D7\:AI$'UTI;U?XUN2@XG:3I2"[)"P'A*<>3?)=6B@(X-;K8<H:WXHE%
ML9' [&@ *)(E)0$EF+E7@O@L<*LZN4;^-965Q39>%*QX3Y5A^'_(,AQ_0Y>Q
MYS]7%TT5_TU=X@AN,"=.0(V-X#RXN@Q@./], U$NM$QS].ADR;GH/?A$(2?#
M7PDE5>73TK D]_ZZ$J:%ANA:U>8]<L[O1'?<MHV5.[R9VRUJNHO0=8,O-(ZU
MVZ9%)KP'*U-I$D6J =44^4]^L]/4<+G&-O:F"_BF!6S/.8?Y]6Q NVBG4:8*
MNC69LT<,'QI]?I83QQ2 TIW<)Q#&\)C=ODNC?@P_@-^?TB_'*FML0^RH+<JR
MX:!0 RDVS4>L.?*&TCA%%PGS/;'XRND_6%.J#3;=6STO'3WNK'!$QU0X"KT@
MBG@BVG\<TR/5D!>,8M?B*/.\23SB\70S)J?H.IM1=& <>3$1^:CL0Y>H-TT(
M=^+3:6$,R+)N;%MS9$Y)?QQ,(F_DCT[VS LI%K*0EGO;.)YXT_&XM4\:K3E)
M:VHX71/_VN)XZ W99#(^@;>JRD^=@%N#_;#NV!W1R3R*8R^._;U#46.B-'>:
MUH#[4&4X30K1M2-)?CZ0BY@=A00WG08N78^&4>1%4;!-]J[%N2;VS SW:%=3
MM\VH6/<?NTT-=BZU)>K<7=TI;BQ]>[_=SFZ_#N;MI?A^>?MI\4[H7%;<,C(R
M]?N3J >ZO:ZW#U;5[HJ\4)8NW&ZXI",8-2^@]YE2=O/ &VR_F6;_ 5!+ P04
M    " "K0%U8M*IA,Y &  #=#P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6RM5VMOX[82_2L#MRD<0)7ULB5O'D"RN\5=W%TT2-K>#Q?]0$NTS582
M59)*XOWU/20EQ]D\VBWZQ:8DSN'PS)D9\O1.JM_UEG-#]TW=ZK/)UICNS6RF
MRRUOF YEQUM\64O5,(-'M9GI3G%6.:.FGB51M)@U3+23\U/W[DJ=G\K>U*+E
M5XITWS1,[2YY+>_.)O%D?'$M-EMC7\S.3SNVX3?<_-Q=*3S-]BB5:'BKA6Q)
M\?79Y")^<YG9^6["+X+?Z8,QV9VLI/S=/GRHSB:1=8C7O#06@>'OEK_E=6V!
MX,8? ^9DOZ0U/!R/Z#^XO6,O*Z;Y6UG_3U1F>S8I)E3Q->MK<RWO_L.'_<PM
M7BEK[7[ISL]-L6+9:R.;P1C/C6C]/[L?>#@P**(7#)+!('%^^X6<E^^88>>G
M2MZ1LK.!9@=NJ\X:SHG6!N7&*'P5L#/G[YNNECO.Z9*W?"T,7=6LU:<S VP[
M8U8..)<>)WD!)T[HDVS-5M/[MN+58X 9G-I[EHR>72:O(K[C94AI'% 2)>DK
M>.E^IZG#2U_ N^9&* X]F7&OFOY_L=)&01F_/K=CCY<]CV>SY8WN6,G/)D@'
MS=4MGYQ_]TV\B$Y>\3;;>YN]AOX5<?DG./33EM-;V72LW1$27#'#-3$K9]A7
MM!HF=T/V=3 BT=+-G3"?N<)31=/OOBF2)#HQ@+*@[C$^.2;[\0&JA"J46/4N
M![_$L[8_M\)@WG]%NZEDXZROI#+]AM6!G</*4JJ*M25':I@MU;)D->K!IJ^9
M!=7.I+-1%"77(5UHDFN"?'BSXFHO(1H=A4NW7&GW/'!@?8_S$TU\H$M_N5NW
M]&K4S> ZO[5JPF(59V8;4"4T6XE:F%T !T>Y!205&:Z0O<YA:^#7L5_A[U@1
M[0<+6VY9N_$N=$K^AOIU$!*YJL5FV/@8@JO+'Q^Q[^AE6G/KJB8GS]:#H B_
M>8:;+]\DT,M&M"V"0D"G;RD.TB0.EHOE,$Z"(L_H!K('ZZ!4&XKQ<K$L*)O'
M093/Z0/6Q-+&?TVC8)$N:1Y$\P5X?U"%IM7.N]PQA1@*1 2.HZT$69)1G!9!
MDJ5T49J>*8'83S=H-L<T@Q2P1TU9D0?+94S3-,^"-,Z/'Q*\8Z*B)%D&RRBA
M:1)E<'!^3"CH*-=00J\4;\L=\7M/.OE,&".01$6PB J:QHL@60#8Z8<A;I4K
M)-,XRH-\'AV34U!R8JO? V=)D"VS("OB1_Q]'?MK)A3=LKKG5AZ'D;684;H,
M\D7JQT4:1'%&[^\[+QE(L%>06_O(+%T$<ZP9S_&7T/6S<]@**0)2'@-E1;!,
M+1FP+7*P\22*+BE\"JDG ?P',?^WXAC/(;L"EC$,"W@^A.EU<I=Q[,1Z2/1%
M(WOKJ>*V*H$;Z4L!RIR6M:B82S-6NWKEVK+^>_GVPU>[<N73^L#HE6(!TD8Q
M'H.&48R@L+?]FK1AIK=K3>>049: 7(R3(@F2:''\=-N^,/>-+<*6!7"@0$*#
M6K.U11[RF8H6+_B8J'^/AA>RG+['GL:4P%9WG"GK8!S%01XOK+/QH@CB/'\1
M 59>)L9;9QF*1;+$)F$8Y7Z3T.)GS]>8T."JL"7E2@F4<3W4NZDM:1:Z5+P"
MT9:732L^>V8>K?.T1OPD#;Q#>4BSH'#)^[ /VY@1][[I?)KT&I!&$GI>Z;AV
M:KNX>4MY/*=:^'XC;/=6?&@DHQMVIF&KFG]-W7\G=&EC[3*(XC"='U$7LI"2
M,(F&X5]5F# :9Z9A,0X_M&O?L &Z?WDP_"C;S?>V31[4'>L"XJ:13VB/T!/N
M'9K#E33:>[4?/NI%L/IV[$=W3'\1(,M,R^WY!E&M1+E/&&>[MOT:,USXN$N/
M)\R%/E*U/8V,3?W?:+OO_^A].-,,+-*1_8]C_%_*ML+;Q+]-BK!8XO\3%+MA
MML2-T\-B@;^/ C@0Y@X,>X,PLRC7',KC-MG!XL+%*<G#.#^BBQK<VP,*,E>T
MMYAC.]P8S#3,\(L0*H8#<X\4@]H&/1]1%,:+(T?(RP45A%3<GX)<A=2^=G[$
M&:JF!$MVO?&'-Y!*C:-%CR<BWW:QI+_$!=1*6O?.B;U8]F=6MO.>V_E#)M8[
M=YCR7]P1"3%&='AK<TNBD"EWPMM+X][@Q-8Z!>CPN>/\[.#*U7"U<1=+-!R;
M.O[VM7^[O[M>^"O;PW1_\?W$%"J;IIJO81J%^7Q"RE\F_8.1G;O K:3!== -
MM[A_<V4GX/M:2C,^V 7V-_KS/P%02P,$%     @ JT!=6#NZ,(S7"@  XR
M !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULK5I9<]LX$OXK*(TK8U?1
MLDB=3FQ7R4XRDYE<%6=GMFIK'R 2DK F 08 +7M__78W>.FTD^S#Q"((]/'U
M#<[%2IL[NQ3"L8<L5?:RLW0N?WEV9N.ER+CMZEPH>#/7)N,.'LWBS.9&\(0.
M9>E9U.N-SC(N5>?J@M8^FZL+7;A4*O'9,%MD&3>/UR+5J\M.V*D6OLC%TN'"
MV=5%SA?B5KA_Y)\-/)W55!*9"66E5LR(^65G&KZ\'N!^VO"7%"O;^LU0DYG6
M=_CP+KGL]% @D8K8(04.?^[%C4A3) 1B?"MI=FJ6>+#]NZ+^EG0'76;<BAN=
M_BT3M[SL3#HL$7->I.Z+7OTN2GV&2"_6J:5_V<KO[0/'N+!.9^5A>,ZD\G_Y
M0XE#Z\"DM^= 5!Z(2&[/B*1\S1V_NC!ZQ0SN!FKX@U2ETR"<5&B46V?@K81S
M[NIVR8U8ZC01QK[X91*%XU?LS;="ND=V_%K,92S=R<69 TZX_RPNJ5Y[JM$>
MJF'$/FCEEI:]48E(U@F<@8BUG%$EYW5TD.)K$7=9/PQ8U(OZ!^CU:[W[1*^_
MAUZIX[^F,^L,N,:_=RGI20QVD\!P>6ES'HO+#L2#%>9>=*Y>_!*.>J\."#BH
M!1P<HO[#AOEYJNPFY=:R*?MD$JD@4AF=LNPXK-[=['SW53N>LH]%-A.&Z7GU
M:EJXI3;ROR)A[ZPMX,]S5KA*V*?"60<_I%JP:YYR%0MVRO[@JD#.I3.P8:\7
M]/Q_K#\)SL?C8 0_P]9RV _&43\8AB$;M9:'43#NA4$(R\B5Z(/<^_0GP*)7
M0#F(QKU@$D[JI<V_K2TW6MT#VIB":MK;^$GE]-.,PR *)T&O/ZR7CINUDRTI
M&LP@? 29I;\+M5$O&(Q&P6#87T,M"H:]83 8C]9 &T4 <1B<1^=D]+=%FCZR
MG,OD5&*:7DCKA $#6B_[2KHEX[#!L'N>%@3P4:\+E$(VM?BT)5O W%( ;EG.
MU2-;\H2>YSJ%"H*N$"-,@LYZ)B_W(O=)L6EN9,I&1#I:(_VKW7MN)A9<,<@,
MY'M@NJ]P[".W"?_&;G@NT=$_<','5?.XX]<[)ZR 9&>(@WW,9I#+T1!1[]6'
M]U__23_#5]V#2AO!5OA/RR#[))1-F.@F3+HD: 6=M(PW@04.1H=8D>/OM@/L
M81*TS%;9+ >9"?4N^]WGD4,A _\PH9QTJ1= *\'NM4-K&B9XO*QH[8N+YZ#5
M^.G>Z/I9L,(ML+:8!-NNO@.S-ZCS;@H54)8\J$S27D^ H U>32]@L\*QF!LC
MX9C23,1:Z4Q"*<!NQ(*W.:(6I]J2)\_I\;J )X$RZ&P&(E"#=(QO.C=^9^<D
M@!*NU7M^)YI?;/H;@4B6^_">?>8&*@?(31%/.8RS+P( =B7<4VC@H -@[<+S
M*YLNC!#PQGFF99A,7_ L?_5EW]XR@DZZ[&\$&@\"1R2";//<Z <);9J@-U[_
M@.E9*A>DGR5YP%#.R-@ON"5WL-IHLM)%"MJI_VCPASF3SCL8+ZUQP--]8MFE
M055F6SK+$R:S7&,.BX5QT#ICJE%V#BS(1]'HZZ*"?9!!*:E$AL<2Z(#6]S(!
M0AA0N&/%H<LE22O2:(W":1#5@T(LX#"<1DL!0- ^-I)D(EYR)6-(W>AZL\?&
M^K7I2S=JI*% !U(";2'F<^BYO=^M%;^V&X'G9;!:Y0F@?+ T<J;JOF)?LA'?
M"DC+L!DYOWE -1:"?4'K=]D[51: O#!8ZEVU\5DV"T" VDML,<ND\Q[.1,5'
M:2=C45$ML\HZN]52QLLV<H\E5B+9@=8HI'1S&+0HZ VA&(_"P_!M;ML&KZ#\
ML!^Y_@\C5SE6RUL:!#?@L\_ SQ9-\D%B%80!DSY(^ *80]"+8 >J_7X_&$Q&
M3\#:ZK0.XKJU[WN _4I=#8BJ<0<$<6QD[DHYGY].)&9^J * 6"J<CU)8PV"0
M<TEY&3*9I?)B!/@<A#2,OA#;BOPUH!-V2;EO!JD39GL\ [BI<G;&RN;!G$.[
MQYQX<-\GXUQB \"MCYBEG$%J+5-:JQDKC,'-7T2N#;W'P9M-3O\LSZ^JO'_[
MY@9?^]8N]#U!U*TFF4_@$ 8@M7B>]C\*J,F^$#W1;9:=0KM_WV?7NMFK.].7
M4&Y/8>6T; TK0; -_< ?*TDW6&Z4SUN.+<#N"HE$J'O?V%251H_0>X%<[RA
M%/80[]_?L&.\P!$&>O4[I5<*;7'[US6[%7%A),41[#IAQR6G31H5!Q3=Z&*Q
M;"6S2I&8/,BW3>12 GS%]T]'4:N!TG/RQ[UCYBZ%IU\_E.^W)=G2%W1#!I9
MX@L R ?;#FHH'/B\!<=M670?S@%V!9265E6TM%I+(K*9)!OWABJ;SLL)R?B6
MBQHELG+E[+>G?7;\%KR=?80, <GJ-!J'P\$(U/6 KT"Y1, (A"[C4Q\4?(SI
M5F"@_.>5KZ%H'!L%F\/F K-O#IF"V%)W"9+NCJ^VSW;1B?\HH 6-QKN\&,0I
MXK*.91PZL2)K$C&8O(P$GNE"N:=<@!JS>!_$3]N)7*Y')Z I3C4D7>.;Q80L
M3I[Y=&#O)5^H%+OGMOZ((#@;)$A#W=MNO"4,'C'8'I%0+3#*81D.85N8M+R2
M<)\6B\*Z/2GKB?RQ.R6L]=V>^H'$0D@ZO1"D6NTF^\.D17WCW4]GDO[PAS))
M6\G_2S+937!W/CF \(^GE++*_D1B&423[TPLMR)WOGPVM>S'\\N&6U.K6?G4
MNH\3#L/!()B<#_::&T>@!8A!<10+D=#=P5$X[$8LDVD*P!"+N@78PZ<)XF$T
M#,ZC[^;8#[OCAN/G D:LN&D&#DPPAU/L>J K[U\KK-Z83M8#?KNVDYU^*Q;@
MP4LALZVW/IT907?9"OP'K&^K+J]FA1&A>.83O1%2!<U521VIDZ<NEAC.W>#7
M!$Q=&Z";\Q>P1T.\.&FN.=8"N<*QN0X D_(DD>CXZX M8*BN9JLU#0 \[3MM
MM"!'3E(G-![T6,(?*8PA[*!?M]45$&^XP)0)??_3*B+?W4K6Y6/-AHFT,58$
M/X- 0Y\!L#3^KP% DC>9BV#'F<B_H$ 6#\+$TOKFGWKV,H[;,/@\5OLEWA'!
M 5WZ8+_7#G %[6SMXW.C,Z)6G<71*TZ+Q"NXN:L2YI LE:-Y'0)_[W(TZ(^:
M2 )!YK 5DA1T&JX:JIX)(!6P9:L1$0^Y4);F.#\TUK7X"#)1OPG?M_6]LQ\F
M:<IJ#6D-!FW7 _?R93R!F2M&;X>9%R\>G03OP?FF16(-7#C3FDW11C#,E3:-
M"U>.4<RM]*EU(O<'K7U)M_%M$7@,XY IW=\(_$*+6D11,!Z.JHYCXU8F]I.P
M=3J^8U!6R'\<3(2V,(]UC>1E6-810B4 D%XHRD!-+J*OQOB!H!:>W L6>F5_
MRHZ/^I/N>87WB;^=BDXV^@'EC)QY[9L@G!=J"["Z*L;E-7WY:<ZVI(^Y738T
MZ>/P,R0.>[7$T7A8"]R%V ?#9CE+"A@^'7_P3M2=5%O(>JFXEYX8>1O._<@/
M7L-J)>N:3-MM$6#M/W[XN1Z?4),Y^&<9;G-(02JF>H#EVZ=W,*$VU(IHX&#0
M'T&=3!I3CL<40^DC'E/<%494CDFWDISN +J[OFF>M3X\PW"YH,_KEE$,^F_0
M]6K]!7_J/UPWV_WG?QB9%U(A3G,XVNN.AQU_7UD].)W39^R9=DYG]',I. B.
M&^#]7&M7/2"#^O]KN/H?4$L#!!0    ( *M 75C^&=+4BP0  ,8*   9
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M)_47[^5\4>(7_3>OEGPN;D3Y\_(ZAT_]ADHL4Y$54F4L%[/7)V?>B_,0Q].
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M-(UZ,H+8F'$),:$6%G)9OX?OQ K<Q-(CV"GNG":>Q?7(VM8T@\ZN969L)G-
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MJI0>%P(P?(X#X/U,J;+^@ LT/SA_\U]02P,$%     @ JT!=6!$2V]KB!P
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M<<<2-SDHZX#V7$JS$VR"[K]A]@M02P,$%     @ JT!=6#M).-9R P  M <
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M$Z0M,/L;(?0AL ?T\SC_#5!+ P04    " "K0%U8(&6^OAD%  "0&@  &0
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M<@_?8]T:GC+_B<P.\E\4^2^,XWZ'<U@P$F4S6@)?5-T^JWK :/O6'C#7>)_
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MPNU8*C5XIA,V@>\ [DZ!*V[!WD"2:FI^(*^X^ G+323L*=7.534FR1(\'UI
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MJ>Z0OB/'I*B4]3AW9%N@9PP+\P#38IXB*9(/_3%[.6G,21"".E%WD%(AIB>
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M5%]O6Y;8^.55R??GOIP;YZ:ZQ!9#O?-^%@"K!,Q9O297TN$BAX 0+-DM1DB
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M6Z[4_]X:M+Y$!(XY67;2GN/,W3BBX&]?]< OOA.\!8.!3991X$CF,<P.PW$
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M'MOH+HR]2@B-VF!,*CL(@14<1[$Z )QV8:=5IA2BXS144QL3IC#F.A^?4OW
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M^ #\OC*F<1]P 7^W_^O_!5!+ P04    " "K0%U8N5F"9DX$  "G"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6RU5EMOXC@4_BM6=K4J4K:YD #M
M A(P,YI*[1:UW=F'U3Z8Y$"L)G;&=J"=7S_'=F!H"ZCS,"\0V^=\YSM7>[@1
M\E$5 )H\5257(Z_0NKX, I454%%U+FK@>+(4LJ(:EW(5J%H"S:U2509Q&/:"
MBC+NC8=V;R['0]'HDG&82Z*:JJ+R>0JEV(R\R-MNW+%5H<U&,![6= 7WH/^I
MYQ)7P0XE9Q5PQ00G$I8C;Q)=3A,C;P6^,-BHO6]B/%D(\6@65_G("PTA*"'3
M!H'BWQIF4)8&"&E\;3&]G4FCN/^]1?]D?4=?%E3!3)3_LEP7(V_@D1R6M"GU
MG=A\AM:?U.!EHE3VEVR<;#_V2-8H+:I6&1E4C+M_^M3&84]A$!Y1B%N%V/)V
MABS+#U33\5"*#9%&&M',AW75:B,YQDU2[K7$4X9Z>CQM%.XH16:B6C!.;:@F
M*PF D==(1A?D,Y3LB5">DSO(:,TT+=DW)WGV0!<EJ,XPT$C&0 99:WCJ#,='
M#$<QN1%<%XI\Y#GD+P$"]&+G2KQU91J?1/P V3GI1CZ)P[A[ J^["TW7XG6/
MX-W!&J2"MT[_-UDH+;&>_C_DM@--#H.:'KM4-<U@Y&$3*9!K\,9__!;UPK].
M4$YVE)-3Z.-[UUI$+,G?V-!S*3* 7-G<W<H<\XN']P5%R^1*J>9UW)T'IVT\
M%$"6HL1N9GQ%M,E_V]+L&\)J/,:>,]6C# ^SYLBEWG)92E'9W4.E=TD8QT/1
M**2,'/D:E'98!92Y.7V0V!5DDF6BP0+]G411ZH=I1*X-5$950;0@F<#<X=#(
MH:H-[H[*K*0H-GD3#6:C01;/;;77D@EID)R24,99[# @9X/0'R1QA\S+1I'Y
MU?PCLMK21#8]/PQ#Q\9!8:EP1=T0@B><IEA39T@ZC<..H;4I6%;@>,JD8=!*
M*'*6^OV+P9X$SAJ0Z!*YFM^2!IM&;B33AM<2$#'QPSC=$Q?(7!XR;J%[%_T.
MF:PI*VT"7W@X,T'$P'83OS>X(.](.&^J!1I#VZ_CBO> TIA+H\JJ"G*&%LKG
M?4#4SS!#!M'2;#-UN#Q<2"?9UX8I9L5G0M;G;^R^R-_!(1<E_B!,;;)NMS$[
M5AUGSFQ%.5Y4-L]_VBR@E;6)6%UB1]M]914Z).F&[X,V-8KWK EJ%/EI>%!M
M^BY&JL8PHM?8:I70T"&Q/^BG/\KQ%[6#'V)'])*T[0BC2GD&QH13/F8$X6S[
MN"X74ID(]-L(_#S6],LGMRI$B<V!: .,9^3'@X0\")S?>.$(?DT?C[M]NU>M
M5.\<[?;\BQA[IGMQFM;L$*V;:S*G4C.3M+8G"\I=7;YBW"$X%OJ8LJ0?'Z-L
M1ODQ:T?HIS%&-?*C*#ITQ01[CX<*Y,H^D7"2FO'JWA&[W=TK;.(>'S_$W1/N
MALH5P^(J88FJX7D_]8ATSR*WT**V3Y&%T/BPL9\%OB1!&@$\7PJLVW9A#.S>
MIN/O4$L#!!0    ( *M 75@<2 +#$P,  /$&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;(55VV[C-A#]E8%:M%U C63ZJM0VD,LNND #!)MT^[#8
M!TH:6T1X44DJWOQ]AY2C=1*O^R)QR)DSYU SH^7.V ?7('KXIJ1VJZ3QOCW/
M,E<UJ+@[,RUJ.MD8J[@GTVXSUUKD=0Q2,F-Y/LL4%SI9+^/>K5TO3>>ET'AK
MP75*<?MTB=+L5LDH>=[X)+:-#QO9>MGR+=ZA_[N]M61E THM%&HGC :+FU5R
M,3J_G 3_Z/!9X,X=K"$H*8UY",;'>I7D@1!*K'Q X/1ZQ"N4,@ 1C7_WF,F0
M,@0>KI_1/T3MI*7D#J^,_$?4OEDEBP1JW/!.^D]F]R?N]4P#7F6DBT_8];ZS
M(H&J<]ZH?3 Q4$+W;_YM?P\' 8O\!P%L'\ B[SY19'G-/5\OK=F!#=Z$%A91
M:HPF<D*'CW+G+9T*BO/K#UQ8^,QEAW"#W'46Z<:]@]_N>2G1O5MFGK($WZS:
M(U[VB.P'B",&-T;[QL%[76/]$B C>@-']LSQDIU$O,;J#,:C%%C.QB?PQH/F
M<<0;_[_F:^$J:8)L!U\N2N<ME<G78Z)[R,EQR- ZYZ[E%:X2Z@V']A&3]2\_
MC6;Y'R<(3P;"DU/HZSMJQ;J3"&9#%5=Z<%AU5GA!K,LGD/B(H6Y\(S3X!F$3
M!#Y&@8U RVW5/!W3=#+K<4WW =Y(ZF6AM^!#D4 \#44C=#\E8KN5- (BFRNC
M6JZ??G7@&F/][QZMHA*V#]B'OU:D^CJL@?M#)0&3Q@"YV9":6E$XX+JFK+6H
MN,>8K+^+$_<0SG:-J)I#;E!)[IS8A/2O M7WKC@'JD14)=JA&M_L,/@K,F!P
M;SR7KZSWG36540IM)<B\Y2U:!S_#*"_26;Y(B]'TC35AZ73*PL9+XPJM)\9!
MN>L+HS5.>)A3,)NE<S8_7!9I,9ZGBZ(X6/6<*-^B2-EXFLXF[(U%R29%GD[S
M^4OC6%5G!V.()&[CL'50F4[[?B(-N\,\O^C'V'?W_F=PP^U6:$>?<T.A^=E\
MFH#M!VQO>-/&H58:3R,R+AOZ)Z$-#G2^,<8_&R'!\)=;_P=02P,$%     @
MJT!=6$F])\:;!   R@L  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
MM5;;CMLV$/T50BF"!&#7$G7?M0WL+6F*!EEDT_:AZ ,MCRQV)=$A*3ONUW=(
MV;(W\;J+%'VQ>)DY<^;"\8S74CWH"L"0+TW=ZHE7&;,\'XUT44'#]9E<0HLW
MI50--[A5BY%>*N!SI]34(^;[R:CAHO6F8W=VIZ9CV9E:M'"GB.Z:AJO-%=1R
M/?$";W?P42PJ8P]&T_&2+^ >S*_+.X6[T8 R%PVT6LB6*"@GWF5P?A5;>2?P
MFX"U/E@3Z\E,R@>[>3>?>+XE!#44QB)P_*S@&NK: B&-SUM,;S!I%0_7._0W
MSG?T9<8U7,OZ=S$WU<3+/#*'DG>U^2C7/\'6'T>PD+5VOV3=RR:Q1XI.&]EL
ME9%!(]K^R[]LXW"@D/E/*+"M G.\>T..Y0TW?#I6<DV4E48TNW"N.FTD)UJ;
ME'NC\%:@GIF^:U>@#4;9:/+J$Y_5H%^/1P:1[?VHV*)<]2CL"92 D?>R-94F
MM^T<YH\!1DAIX,5VO*[82<0;*,Y(&%#"?!:>P L'/T.'%_Z[GY3<P,P0WL[)
M[>=.F VYAZ)3P@C0Y(_+F38*:^7/8U'H;43';=CW<ZZ7O(")AP]$@UJ!-WWY
M(DC\BQ,>1(,'T2GTZ3V^QWE7 Y$E$0=9$RW1E53F1P.JP=)0#V!L'K$VT4L]
MN';,GY,6C_OSJ0)2<J'(BM<=N"CR!LV+OV%."JG-]_(CLPW>_B75[FQ#S&:)
M%K1%Q'J 9@9JJ EG^>M31KAR&J6LL=WH\R-ZEX_9OE52:]*UV-%J=[K 3J:_
M/:YQCR3?[%V_[90L9-. *@2OR1U?@M+D!Q+X*4U81,,HL#N:9Q&-TPC7+U]D
M+& 73B:GB9_1/(C)-2"?4A3<P-;5I=3"D#2C6>[3*$I)&B:49?X D*(V2VC*
M4O))&C2.B%E"XR"B:9;ACN&=3[/X*ZM93ED8TR1BY$-)UI4H*E+47&NTCSZN
MA:DP7077E0NO6P"^$738Y3)@&0WRE,99@(X%>4Z#)!@,!"RG88ZT3L,_KQKB
MC(9!2IF?HJ68!33)P\%2G-,LQ.CY_I$2^-\3'#'*DIBBNS;264JC-'\49Q2(
M8V83_&1RK0,1)C'&4@@IP_+8J><T#U/,?#ZD%J%\#'7JLAEB2:1Q^,@>"D1X
M'&.LOB^M")ZB0REFU<=*8]D^IT@T"S"M^7]/:<AHB.\BSD*,&G[1^9V9T$8+
MJPDC=J)5QD.KC)_=*@]Z55'Q=M&GX8#EZ0YYTM")#NGZCV@7I#?B;FVH3;7G
M@8';LW.T[.VU;):\W;C(I!?Z>;&EATG!_O<+K* FC)2BY:VK7KP%^]]G"T!!
M(1>MJWIA!Z.B:[H:*W1.)#)0^&X:)%S9T6L%*()[."=7L!!M:WV:\1I1@9*?
M>=OA*$=VO75?GA^>!"(SP%D2+(DM97P<.*!IDJ$FEAI6,3[ASD9K+X/<2B6;
M9Y(EKQ(:8<]@?O+:CB2/2'_[EW#8+X^5W^A@OL)NL'!3I$;+2+(?M8;385"]
M[.>SO7@_Y;[G:F';3PTEJOIG*1:8ZB?'?F/DTDUK,VEP]G/+"H=M4%8 [TLI
MS6YC#0SC^_0?4$L#!!0    ( *M 75C>%23A" ,  (@&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;)55WV_;-A#^5PYJ4&P &TF4;"FI;2 _6JP/
M78.FVQZ&/=#2V28JD1I)Q<G^^ATI64U7Q\!>I./Q[KOO/E*GQ5Z;KW:'Z."Q
M;91=1COGNLLXMM4.6V'/=8>*=C;:M,+1TFQCVQD4=4AJFY@GR3QNA531:A%\
M=V:UT+UKI,([ [9O6V&>KK'1^V641@?'9[G=.>^(5XM.;/$>W6_=G:%5/*'4
MLD5EI59@<+.,KM++Z]S'AX#?)>[M,QM\)VNMO_K%AWH9)9X0-E@YCR#H]8 W
MV#0>B&C\/6)&4TF?^-P^H+\/O5,O:V'Q1C=_R-KMEE$908T;T3?NL][_@F,_
M,X]7Z<:&)^R'V**(H.JMT^V83 Q:J8:W>!QU>)90)B\D\#&!!]Y#H<#R5CBQ
M6AB]!^.C"<T;H=603>2D\H=R[PSM2LISJSN#G9 UO'ND8[9HX:<O8MV@_7D1
M.X+W07$U0ET/4/P%J)3#1ZW<SL([56/]/4!,O"9R_$#NFI]$O,7J'+*4 4]X
M=@(OFYK- E[V(MX&C<$:;K1UEL&-Z*03C?P':P:C$@R$JN&3VZ&!*VO16;B5
MMFJT[0W"GU=KZPQ=I;^.Z3-4SX]7]Y_7I>U$A<N(OA^+Y@&CU>M7Z3QY>Z*W
M?.HM/X6^NJ?/M>X;!+TYM (X'NHQKJ?1_HL ;^@RDG3* 1T*MFM2YW P/W@X
M?%"DEE 5)9Y!RI*B8'E1!CM/YVQV4<"O6KVIJ*RL1 ->#F&J7=!^\M;X0$.C
M:WU5+Y?T>&7.6<$O@+,\SU@YS\:SJC35;)Q4VP BZ@=IM7GZEE@D+$E+2),9
MF\_2,:OS?3[Y"A;2-&47Q)*G&<MF!7S1=#>(,V=IPAE/,K)SEA87+)^7/VA,
M"BG?TO]0Z;[ONN8IT&V%ZC=TK7KC&Y@XGT')<IZ%@F?P^E7)4_YV(G9D[]A%
MBI]-AQ;--LQ 2X+UR@V#8O).8_9JF"[?PH<9_5&8K506&MQ0:G)>S"(PP]P;
M%DYW8=:LM:/)%<P=_2K0^ #:WVCM#@M?8/KYK/X%4$L#!!0    ( *M 75A>
MW SSIP(  *,%   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;'U4VVZ;
M0!#]E1&IHE9"X6+P);&1[*15^Q#5BM/VH>K#&@:# KMT=XF3O^_L@JE;.7YA
M;W/.G+/+S'POY),J$#6\U!57"Z?0NKGV/)466#-U)1KD=)(+63--2[GS5".1
M91945U[H^V.O9B5WDKG=6\MD+EI=E1S7$E1;UTR^KK 2^X43.(>-AW)7:+/A
M)?.&[7"#^ENSEK3R!I:LK)&K4G"0F"^<97"]BDR\#?A>XEX=S<$XV0KQ9!9?
MLH7C&T%88:H- Z/A&6^QJ@P1R?C=<SI#2@,\GA_8/UGOY&7+%-Z*ZD>9Z6+A
M3!W(,&=MI1_$_C/V?F+#EXI*V2_LN]AH[$#:*BWJ'DP*ZI)W(WOI[^$(,/7?
M (0](+2ZNT16Y1W3+)E+L0=IHHG-3*Q5BR9Q)3>/LM&23DO"Z>11L@R!\0R^
MZ@(EK-DKVU:HX/VC'3_,/4UI3+"7]I2KCC)\@S((X5YP72CXR#/,_B7P2-\@
M,CR(7(5G&>\PO8)1X$+HAZ,S?*/!],CRC=[@&TP:W\LTE2VK%/Q<;I66])O\
M.N6Y8XQ.,YK2N58-2W'A4&THE,_H))<7P=B_.:,W&O1&Y]B3#95BUE8((@<]
M/)BP#];T7ESZ6Z1$KD^)/T]/UXOUEK@.5PS_[X3P0*:83 N;.<-GJN:&:E.#
M\5JF=)?O8!8$;A1'-"/8>#J!3=LTU:N%U(RW.=UM*TN^@QP)T"N'.!X1; ;C
MV)U-9I2)6#VHD&I-0>!/W3":P>7%- S"F_XO/9B&<!RY,<D+XHD[\L?P*#2K
M2$#@3D<3TF#$A'%$Q.&I=_"."J=&N;/M04$J6JZ[&AIVAPZT[ KO;WC7ONZ9
MW)5<D>Z<H/[5)'9 =BVA6VC1V#+<"DU%;:<%=5&4)H#.<R'T86$2#'TY^0-0
M2P,$%     @ JT!=6 1=M/,# P  2P8  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL?55M;]LX#/XKA#<,.\"H;3EQG"X)T'0[[( -5[3=]N%P'Q2;
MB87)DB?)3?OOCY(3-S>T^1+KA<_#AZ3(+/;:_+0-HH/'5BJ[C!KGNLLDL56#
M+;<7ND-%-UMM6NYH:W:)[0SR.H!:F; T+9*6"Q6M%N'LQJP6NG=2*+PQ8/NV
MY>9IC5+OEU$6'0]NQ:YQ_B!9+3J^PSMTW[H;0[MD9*E%B\H*K<#@=AE=99?K
MB;</!M\%[NW)&GPD&ZU_^LU?]3)*O2"46#G/P.GS@-<HI2<B&;\.G-'HT@-/
MUT?V/T/L%,N&6[S6\H>H7;.,R@AJW/)>NEN]_XR'>*:>K]+2AE_8#[;3>015
M;YUN#V!2T HU?/GC(0\G@#)]!< . !9T#XZ"RH_<\=7"Z#T8;TUL?A%"#6@2
M)Y0ORITS="L(YU97565ZK.'3(Y79H@6N:OC;-6C@NC<&E8,O@F^$%$[0[?M[
MOI%H_U@DCIQ[BJ0Z.%H/CM@KCC(&7[5RC85/JL;Z_P0)J1ZELZ/T-3O+^!&K
M"\BS&%C*\C-\^9B*//#EK_#=\*<07$A!R N7%OZYVEAGZ/'\^U+, ^/D94;?
M4)>VXQ4N(^H8B^8!H]6[-UF1?CBC=S+JG9QC7]U1@]:]1-!;>MQ#&?&TC#J4
ML3J443Z7\:5(SONB7&.[(;9CON'W$P9KK?JC:X.2.Z^G[:1^0CJM=.NE\="+
MH\RWP.)9F<8LF],ZB[-T'L_R"=SU72>? E7+5;^E_/=&J!WX)(J*D%E<I#G9
MSN'=FY)E[ /<4H:YJ9J JO&!!D[7^LA'C+^0M"+7L,5 PE@1LS*#:5P2W21G
M<*V5I9;F!'Q.8K NIWD\3Z? LC).60;W_/$TJY 7LW@^*\ '4;("ON".RP$Z
M)T2:0D9NR,6]=G3Q%HIXGJ=QQE):SV(V+>)R,GWI920G#=ZBV84QYG/:*S?T
M^G@Z3LJK84 \FP]C]BLW.Z$L2-P2-+V832,PP^@:-DYW85QLM*/A$Y8-37LT
MWH#NMUJ[X\8[&/\_5O\!4$L#!!0    ( *M 75B"(8\).0,  .@'   9
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M:[4#[:T=FA="JL';D1/2'\K2:K<KG)^=+BNNL5)UB=J\?C5B='@-;[ZUPOZ
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M5NYA0NT-W/Y:*?NX\ 'ZIV[Z$U!+ P04    " "K0%U8F<VK(?@"  !\!@
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M,,33*BPK_CR@]0Y\OC2&MH9/,'QPYK\!4$L#!!0    ( *M 75CP#K-G'0D
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M//C7P?X;/UZ=I[/5K-ZF[OX:NR>M49O6:.>FM4XQAKDWH?U2<6>"W:#3Q-I
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M;+Z3<%W?LCWO:V\D7-^U(B_<0:5'_#"THC#YHJL%Q_,LWV_UP)HIXX_XWX;
M<KQH?^/-1+5A01 '^#\;[:4$,W2#U;_U+L-)+'=%P?=3\X4?).R2S+]=O#SN
M3BG&2[6->AZ<_7!8OL8XG7;7\G<TSH/!G=E]QMG-$G.KN GUH\YW7063,_QZ
M30'=U65E/O%JG[9?R)V:[\+6T\WG=6^IG''H[#F;PE+=.@; @OC%FOE1B05^
M)381524*',X9!8K6$^#]5(AJ]4,K:+\;//DO4$L#!!0    ( *M 75BKMWA
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M-I%).:,LN"A.>OT-FJ:#TF)0&H&BV9JTJ;H?O<#$#YJ_@])B4!J!HMEJM;4
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MU.I%BTUYK[@46HN\?$PI2:@T#:!^)81^?3$=U'?9TW\ 4$L#!!0    ( *M
M75B<_(KMJ@(  $L'   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;*U5
M76_3,!3]*U9 :)-@^6B2P4@CK>T02 Q-FPH/B <WN6VL.79GW[;;O\=VTM!U
M6?D0?6CLFWN.S[F.K[.-5+>Z D!R7W.AAUZ%N#SS?5U44%-](I<@S)NY5#5%
M,U4+7R\5T-*!:NY'09#Z-67"RS,7NU)Y)E?(F8 K1?2JKJEZ& &7FZ$7>MO
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M--?,)54+)NS&S@UE<')J3*JF=3<3E$O7_68232]UP\K<=J!L@GD_EQ*W$[M
M=W_F/P%02P,$%     @ JT!=6,6]!93) P  3Q0  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&ULS5A=;Z-&%/TK(UI562D;&#!?J8W4V+MMI*P4)=WM
M0]6',;ZV1P&&S@SV5NJ/[PPF8&),;2TK^24&?,_AG#MWK),9;QE_$6L B;ZF
M228FQEK*_-8T1;R&E(@;ED.FOEDRGA*I;OG*%#D'LBA!:6+:EN69*:&9$8W+
M9X\\&K-")C2#1XY$D::$_W,'"=M.#&R\/GBBJ[74#\QHG),5/(/\G#]R=6?6
M+ N:0B8HRQ"'Y<3X!=].<:@!9<47"ENQ=XVTE3EC+_KF?C$Q+*T($HBEIB#J
M8P-32!+-I'3\79$:]3LU</_ZE?UC:5Z9F1,!4Y;\01=R/3$" RU@28I$/K'M
M;U 9<C5?S!)1_D7;JM8R4%P(R=(*K!2D--M]DJ]5(_8 >'0$8%< ^U2 4P&<
MTNA.66EK1B2)QIQM$=?5BDU?E+TIT<H-S?0R/DNNOJ4*)Z./A'+TA20%H$]
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MC:\H^.[T:G<C65X> ,V9E"PM+]= %L!U@?I^R9A\O=%G2O498O0?4$L#!!0
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M*1*1YUPF*<O0/=MPV5]":YS1N_%,T=I'P4:Q ;_^8=#:%(P^#9XI6KL@35L
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M&S:@PX*D71^*/=#RL4V4$C62LI-OOT-*%AQ+-OJP%YN7<_G]#V^:'Z3ZIG<
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M06LB\G)M8$Y$@:L"VG1V/J^5YXS%8> =/EO]!8<&VFOS].3ER02?BDR8A\Y
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M3]_R94H:]\MV36R_[[%L8U"5+9@J*$75?/ECVX<#0#@X 8A:0/02T#L!B%M
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MOJ+BU9>%ZD2RO'PY7S.I7O7+PQW!,>&%@;J^84R>3HH)FN\[\W\!4$L#!!0
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M+2Z,PEV./)-]+BHA'P'(-92PYH;,!"LU.2-7A:Q+H\D<<JE6L")8<[-%'$-
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MQ:ORYJ@W<9;%R_+A0OASD10%\O=OXSA[?%(TL+V#[^0_4$L#!!0    ( *M
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ML[(Z\'IQFZ?I8IT8K6F!5D=1S48U!]5<5/-0S4>U -5"5(M03:":1+68TM1
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M#)05P/.YE.9Q80VT ][X'U!+ P04    " "K0%U89O3]8[\(  !67@  &0
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M"*;I>+W7\=JHXT.:D/)&N4TH8]6AUQ 2%B!A# GC()@FIFVIVTKK(FXIZF:
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M/W].DOS]31%@_RCYV?\!4$L#!!0    ( *M 75C+Q,M'U!   ./S   9
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MA+IJE"90FD1I"J5IBF;'S+CJQ#U+^I?L2U:4V</W5NPH2ZAW;FB=0C*UZXA
MVY0H3:$TO>O]L+O8>.+$[8FKL\>B.F^L5YXK7S;_>OGMJERER\NZTU_,-K_N
MOSQ"%7)#:R\"Z/N/5X83:*L2I2F4IG>_(W;/&SN<N.UP>R'V/[TG+\ON;F5P
M_Z/F%Z5)E*90FJ9H=I:,^4T.;7X3U/RB-('2)$I3*$U3-#MFQOPF;O/[_&*%
M2N&&UCXU3Z<]M0J=F8S2%$K3.]\0J]\GQO9.]OY>/L?XTPT9VKD-S0^M\=9H
M[,>=]8@%VJY$:0JE:8IFQ\!(V,G>ZTUL^7I&-V!P!-R'$VS]LD>!'H=$:0JE
M:8IF1\((TXE;F/Z<+V;+=.Y]2>>WF??B[.^J3L=]"?B^OD&D"N^XJ0B]@4%5
M*DH3*$VB-(72=$.;6J=:?TO5,")UXA:IS6CA;)Z6I7?6V_NH2T5I J5)E*90
MFJ9H=DR,2YT<VJ5.4)>*T@1*DRA-H31-T>R8&9<Z<;O49U^[N/F#4X1.ZVUH
M[8%_$(VB<?>[.V3/AGZ8!&'D^YV/T*$'J"F:W?G&LDX&6=:;M-B,6'X[%_:(
MY3OW> 6UK2A--+3$OF :C?QN!O;;3J%'IRF:G0!C6R=NVVH/1FSAVMO1J%9%
M:0*E292F4)JF:'9HC%:='%JK3E"MBM($2I,H3:$T3='LF!FM.OG&6M7-'YRB
MQQ8Q3$:C($JZX@T5JRA-H32]QUMB]?W4J-6I6ZVZZM)S;@NZFQT:"90F4)I$
M:0JE:8IFA\L(V^FA9\U.4>&+T@1*DRA-H31-T>R8&0D\=4O@9]<O-W]PBH+'
M)^LP' 5AYP)'H,U*E*90FM[C+;'[WDC>Z0#)^[:W<U')B]($2I,H3:$T3='L
MF!C).SVTY)VBDA>E"90F49I":9JBV3$SDG?ZC26OFS\X1:CDG3YVM_%H',?C
MJ+/\F>S9,IQ,DR3NSHU1Z!%JBF;WOK&\T_^3Y76W,S@%^_E6L>=V<L_M%/HJ
M-$6S^];XV^E>_G;]P='>+D-]+4H3*$VB-(72-$6S0V)\[?30OG:*^EJ4)E":
M1&D*I6F*9L?,^-KI %_KS<KR-OTXSW8.+5!)B]+$]+'?]/U1,NU6'E31HC1-
MT:Q,^",C<NO'WW3LN:.!H0EA<8+%21:G-C@KP8$?^V'7^FBLY4Y2_%92W!-7
MVV.9:BRZ>Y[<#N#P9*">E<5)%J=8G,9PG?0$K?0<>G'>S1%@<4.GY;(XR>(4
MB],8KA.WL!6WO03OP,'.#NKP"*':=X.S[^<&\:0K4MAV%8O3&*X3CG$K'$Z?
M1XQY4&W+XL0&MWM>9=^66R96LL>H,5PG!%$K!(.DZ].UVXZ&AH<!U:\;W$X_
MQ[:K6)S&<)V\Q*V\[*5I>X>_O7<0=P"'YP*==LOB)(M3+$YCN$YZDE9ZDH,/
M?U&7S.($BY,L3K$XC>$Z<9NTXN;^QC=@A(,J8Q8G-K@];BKV;;KEKB)[D!K#
M=5(P;:5@T S=YPQQ4 O,XL0&M\<0!S7!+$YCN/N\')?76;82Z2H]/5EDQ55V
MELWGI7>1WRXK?"UN'I[UBNQ3':?7;X.CXT?/"_^U].OGCPWF].0FO<I^2HNK
MV;+TYMFG"CEZ52\V5<RNKA]^6.4W56*/O(_Y:I4OU@^OL_0R*^H-JM]_RO/5
MYH>Z@;N\^+P^[-/_ 5!+ P04    " "K0%U82M_L9#P$   >%P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V-RYX;6S%6%UOHS@4_2L6.UK-2#L%F^]N$BE?
M,U-IJHD:S>[#:A]<<!)4P!GC-.V_7QLHA(18F\I27A(P]Q[N/3YQCNY@3]E3
ML2&$@Y<LS8NAL>%\>VN:1;0A&2YNZ);DXLF*L@QS<<O69K%E!,=E4I::R+(\
M,\-);HP&Y=J"C09TQ],D)PL&BEV68?8Z(2G=#PUHO"T\).L-EPOF:+#%:[(D
M_.=VP<2=V:#$24;R(J$Y8&0U-,;P=HJ03"@C_DK(OCBX!K*51TJ?Y,U=/#0L
M61%)2<0E!!9?SV1*TE0BB3I^U:!&\TZ9>'C]AOZE;%XT\X@+,J7IWTG,-T,C
M,$!,5GB7\@>Z_T;JAER)%]&T*#_!OHZU#!#M"DZS.EE4D"5Y]8U?:B(.$J!W
M)@'5">@XP3F38-<)=MEH55G9U@QS/!HPN@=,1@LT>5%R4V:+;I)<;N.2,_$T
M$7E\M-Q@1CY+(F(PI9E01X%+?C^#LX_F+_*:@,DK6*0X!Q]GA.,D+3Z)I)_+
M&?CXX=/ Y*(X^0HSJ@N95(6@,X5 !.YISC<%F.<QB;L INBJ:0V]M39!2L09
MB6Z #?\ R$)V3T'3_Y^.%.78#=-VB6<KF9Z<TCEF#.=K(GX;'#R^@L.X!7XM
ME\=[S&+PSW<!">XXR8I_^PBNWN_TOU^>![?%%D=D:(@??$'8,S%&O_\&/>O/
M/G(T@76H<AJJ'!5Z1Y31(56D4EY?\Q6B6R+*L^MYY$/+LRQW8#X?]G4:%WJN
MX_M!$]<IV6U*=I4E/P@2,(LV .<QF)%G<3YNRZV;GR]9B7CI?FD"ZS3O-<U[
M5Y:VIY,J36 =JOR&*E^[M"M$[T"RT$6.#X^E?1H7NH[MA_W*#IJ* V7%7TE.
M&$Y+88]C\1>4%)QA^>>KTK82\](-TP36:3]LV@^OK.U0)U6:P#I40:LU$Y9V
M==>0A[)UW0"BT#J2=T]@X%N6'9X1.#SP0%!9]OS7+N&OX"Z/Q*Y)84M;TUNK
M$N?2O=*%UNT:M5VC*RN[+D 779K0NG2U]@TJ+<_[M&V?'MW(<D(7'6O[--#V
M'#N 9Z3=.BFHME+WE.;?\1,!XZ] >!3.DHB+!K[0G7#9K-K;HK=T)>[%>Z<)
MK<M":\Z@>VVI:S5SNM"Z=+5V#BHMT/ND[O6X%-^QK9-C_#30"1QAU<\X<-A:
M*ZCV5O/E8M%;FC+MXKW1A-9MLG5C,+BVE+5Z-UUH7;I:]P:5CN=]4@Y/#V/;
M14%P;+C[ D-H6;[7+V74&BFD-E+SY8]>*:O3+MT;76C=)EO;A>"5I8RT^C5=
M:%VZ6K^&E ;G75*N(3OC#M\.O.!(R3UQKAWZT#X2LGDP:<P(6Y<#V$*4L\MY
M-9EK5ILA[[@<;1ZM3^#MM!K5MC#5Y/@>LW62%R E*P%IW?BB*%8-8ZL;3K?E
M//.1<DZS\G)#L' S,D \7U'*WV[D"YJ1^.@_4$L#!!0    ( *M 75A7! 'L
M_08  / X   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;,6;;V^;.!S'
MWXJ5FTZ==$W Y$_;:R,U 6Z3-BUJM+L'IWM P4E0 >>,TZ[27OS90 %38D+U
M.W6J%B#VQP[?G_]]#==/E#VD.T(X^A%'27HSV'&^OQJ-4G]'8B\=TCU)Q#<;
MRF*/BU.V':5[1KP@RQ1'(VP8TU'LA<E@?IU=6['Y-3WP*$S(BJ'T$,<>>UZ0
MB#[=#,S!RX6[<+OC\L)H?KWWMF1-^/?]BHFS44D)PI@D:4@3Q,CF9G!K7KF6
M(3-D*?X,R5-:.T;RI]Q3^B!//@<W T/6B$3$YQ+AB8]'LB11)$FB'O\6T$%9
MILQ8/WZAN]F/%S_FWDO)DD9_A0'?W0PN!B@@&^\0\3OZ](D4/V@B>3Z-TNQ_
M]%2D-0;(/Z2<QD5F48,X3/)/[T=Q(VH9\.1(!EQDP*=FL(H,5B/#^%B5QD6&
M<;.$V9$,DR+#Y-0,TR+#-+OW^<W*[K3M<6]^S>@38C*UH,F#3*XLM[C!82(C
M:\V9^#84^?A\O?,8.9?:!&A)8Q&PJ9=)?HYN4Q%N>WF2HC.;<"^,TH_7(RY*
ME7E'?E'"(B\!'RG!Q.@K3?@N14X2D$ %C$1URSKCESHOL)9H$W^(+/,WA UL
MH0]HA%+Y*]*6NBU/)V$]R3Z=9*+O:QN=??A8(QX'.WVJN':9KI)NGTH>9RFJ
M6&4D61G<TD;2XG4DW3+F)5LBNB..[I]1/=W*>\XNWSYY+$!_?Q%(])F3./VG
M+<[R\L?MY<LN^"K=>SZY&8@^-B7LD0SFO_YB3HW?VP(#$F9#PAQ(F L$4R)B
M7$;$6$>?.PDG;,_"E*!'+SH0]!-]:--52^FK*R3,SF&3#";'Z,>Y-37R?]>C
MQ[IHD,6Z0#!%M$DIVD0KFGN(HF<4A-&!BP9:=%YG85(<?A0B'NU^%EIT7R4A
M878.F]:4-(V985Y.&SI"%NH"P10=IZ6.4WWC^_<0\F?T.?%%!RLF;V@5>4F;
M9EI,7\T@838DS(&$N4 P1=A9*>SLG<?9&61$0,)L2)@#"7.!8$I$7)01<:%O
MZBD/Q1I+Z+SQ0E:,M72#^$Y\9!-X)/[DV59$"$>!2(L.:9ALT2+R_(?SM;^C
MD>CF8QJ0*.OL QI%'DO1GK"\NV^=^.?5NJAUJG@RG%RH7>KR=:J+(9ZHB6SM
M+^RK+"3,!8(IREZ6RE[JE?U!F"_G3V(6Y9,>RER^NN?6;(AQ0YG7J4S\6AIM
M%?M* PES@6"*-*91K9R-#G'VQ)>M3LQRXY?VYLD>MG61K(=-T3,1LK;UH&_.
M:>MS]I4.E.9"T53Q:K:'>9IXCS02PV<DYTJ%A%FKREM<JY"%H8)KS<88SAJM
M9GE:,EM?S=X20=)<*)HJ$:XDPEJ)[L+TX7S#"$&A7$B2E",F1JY637#;S3;&
M34W:DUE-3;3UZJT)),V%HJF:5!Z/J34,JF83A(]A0)+@N"16R[UNZM&=QM97
MJ+<8H.8*%$T5H[)73+V_\I72Y(OW0-#M'^A.- _18TEI7'I( C$[6!]=INNY
M?6?XH#0;E.: TEPHFJIWY<R8DW=>^9F@!@XHS0:E.: T%XJF!D9E]9@=7D_;
M K!<(,AYS='NH65E>/HJ0U^MWN$":AX5M+IW.[YLF'V@);I0-#4(*EO(U'H,
M1UV 3NG%8;A-\IXD"P"1B2:E@^#3\TV>+Y67ZH-.CT@!]91 :79!4Q;+UG1H
MO8H64,,(BJ9&2V49F7K/:'5@_LY3G(7E)[>F(OK9M=FXT!?16U1(F@U*<T!I
M;D$SQ\HRQ"S#396T\HK,#K-HO5JUR@3IN2Q!:38HS0&EN5 T]1F'RE["QCO/
M]C"DH;,$I=F@- >4YD+1U,"HK"O<85V]TVQ/7ZW>X6*>-.K:H*4ZH#07BJ8&
M0F608;U!!C&&ZXOH+2HDS0:E.07MZ*A;2/I_^&NX\M=PA[^V_K82JCGQ/J+/
MA* UI_X#^I9OXLD=?'0FD[2W3]#GHT!I-BC- :6Y4#15\LK%P^/W'N=![3Y0
MF@U*<T!I+A1-#8S*[L/Z)['>;5N_J)=9]T[DQG[#O7])5G^H:CS$9G, !_7M
M0&DN%$U5N/+M<(=O]];M_8*K*&3-FH/9LDBFS+&&TW%3(-#GK$!I+A1-%:CR
MU'"'I]9KB[\#IMGB?W-.6Y^SMWB@%A<4316OLKAPQV-1;][B+\!=6_RG);/U
MU>PM$:@5!453):HL*ZRWK'IL\1>DKBW^(\F:6_SZ>O76!-1W@J*I;W%4OI-U
MXF--G5O\!4B[Q7]"&EM?H=ZO3X!Z/5"T7(Q1[46MF+!M]DI=BGQZ2'C^_E-Y
MM7QM[S9[6:UQ?6%>V?G+=Q4F?Q?PJ\>V89*BB&P$4G9' \3RU^OR$T[WV>M@
M]Y1S&F>'.^(%A,D$XOL-I?SE1!90ON0X_P]02P,$%     @ JT!=6"/),*;]
M!   0!D  !D   !X;"]W;W)K<VAE971S+W-H965T-CDN>&ULW5E1;Z,X$/XK
M%B>=NM*V8)M TDLBM6EW;Z7K-FIU=P^G>W"(DZ "SMI.TTKWX\\F%$(P%+2L
M=+H^- 9FQM]\>(8/,]XS_B0VE$KP$D>)F%@;*;>7MBV"#8V)N&!;FJ@K*\9C
M(M4A7]MBRRE9IDYQ9"/'\>R8A(DU':?GYGPZ9CL9A0F=<R!V<4SXZS6-V'YB
M0>OMQ$.XWDA]PIZ.MV1-'ZG\?3OGZLC.HRS#F"8B9 G@=#6QKN#E#'G:(;7X
M(Z1[<30&.I4%8T_ZX,MR8CD:$8UH('4(HGZ>Z8Q&D8ZD<'S+@EKYG-KQ>/P6
M_5.:O$IF002=L>C/<"DW$VMH@25=D5TD']C^5YHE--#Q A:)]#_89[:.!8*=
MD"S.G!6".$P.O^0E(^+( 7HU#BAS0*<.;HT#SAQPFN@!69K6#9%D.N9L#[BV
M5M'T(.4F]5;9A(F^C8^2JZNA\I/3QPWA]%P3L00S%JO5(4C*[SFXVA.^5*=)
ML@2?.4FD&I_=4$G"2'Q0UX5V%6-;*A@ZF!UD4UX?ID0U4T($[E@B-P+<)BI^
M.8"M\.=)H+<DKE%CQ!L:7  ,/P+D(&P -&OOCAK@X)Q3G,9S:^+=?MN%\A5\
M20*:Z$4*YA%)3#PUAM$%?"FV)* 32U6HH/R96M.??X*>\XLIQYZ"E3)V\XS=
M-#IN7$77U55TQ=7"65-5]Q(L7L&QW9R\IJ?39?81W&^U@U"#G112K;DP68._
M'E@4 56OVN9O$X5NGQ3V%*Q$X2"G<-"X:%(:!&!'V2_H.DR2=$34"@HH. N3
MK.P^F,@XS."E,^C^_3R%0T?]C>WGXS2K9H5%";N78_?:8%^_-8EFE%X5)49N
M!:7!K)Q,":J?0_6[TDPSMMMQ[%=@86A 7S5K0C_,T0_;H*<OE >A((OH7;C#
M"@[/L"*J5C5 1SG042/0.\:2W\@3!5>?P0,5DH>!7AF?V$ZU?'[H \9'1V/8
MKO7<4[ 2 ] IGJS.CVZ*^9-$,;C3%P2XEQM%H-R0I&B97UGRK$BFRN/K+EZH
MZVR5<=RBA69I],1Y7]'*I!_)&=BQOC]V[Z/9'*7JA=!Q_.%)W1@,7==UL#,R
MEP]$11ZH31Z'V_HN7E2!<5X#V&"),5:R"=8@+D0/;%8])N:[M=9L G,;RO!7
M34X3+<,O% QL?+I/;Q_G<R.H7A5&7]'*218: P[^'RVI42MU)KVG:&72"W$$
M6ZFC[VQ)53F$$/9'<'!:(0;=Y'C.P*LK\$(YP5;2J:7*@U4%5"EF@TB"OH\'
M;@W40B;!5CJI9?>LJI]S=?-]%U6X-5ABQ_='=8 +N02;]5(/S7/4=H&\;UA^
M"2\$#VI\MJL6>C\'_X#;>!NQ5TK!HV3!4]82TG=@<*9-C/";0W>M^+ZBE8DH
M1 B"_]'78=2HCCK3V%.T,HV%!D*M--!WO1*CJN!Q/<_W1B=58;!#ZK4.XYJB
M*&01:B6+6G9-9- W&+NN=PJW:H=<Y&.O!FXA@U"S#,K@KAA?T; -8-?0/ <0
M^Z> ?X3P087P09UW5[JU5U3=-!D,!U6!;; [66_E# H5@5JIB ZO_L@@&> (
M(7P*N7'BKK?&/MJ+CBE?IUOT @3JS5\>=G3SL_EG@*MT\_OD_#6\G!TV\XLP
MAV\+=X2K+B! 1%<JI'/A*\[Y8;O^<"#9-MWQ7C I69P.-Y0L*=<&ZOJ*,?EV
MH"?(/YI,_P502P,$%     @ JT!=6#B<5KQ6 P  I@T  !D   !X;"]W;W)K
M<VAE971S+W-H965T-S N>&ULM5=K;]HP%/TK5O90*W7D!0$ZB%2@TRJU6]6N
MVX=I']SD E&3.+/-H_]^?H1 :(A&E?*!Q([O\3DGU\[U8$7H$YL#<+1.XI0-
MC3GGV;EILF ."68MDD$JGDP)33 733HS648!ARHHB4W'LCPSP5%J^ /5=TO]
M 5GP.$KAEB*V2!),GT<0D]70L(U-QUTTFW/98?J##,_@'OA#=DM%RRQ0PBB!
ME$4D112F0^/"/A_;K@Q0(WY&L&([]TA*>23D23:NPJ%A24800\ E!!:7)8PA
MCB62X/$W!S6*.67@[OT&_8L2+\0\8@9C$O^*0CX?&CT#A3#%BYC?D=57R 5U
M)%Y 8J;^T4J/;7<,%"P8)TD>+!@D4:JO>)T;L1-@>P<"G#S V0]H'PAP\P#E
MG*F9*5D3S+$_H&2%J!PMT.2-\D9%"S51*E_C/:?B:23BN'^5!B0!] .O@:%/
MZ!NF%$MCT<D$.(YB=BIZ'^XGZ.3]Z<#D8D899P8Y^DBC.P?0;0?=D)3/&;I,
M0PC+ *:@6O!U-GQ'3BWB!((6<NTSY%B.6T%H_/_A3@T=M[#/57CN ;SO&4B_
MTAFZ)HRAL;#O6:RM%:8A0[^OQ6ATQ2%A?ZJ\T]#M:FBY?L]9A@,8&F*!,J!+
M,/R/[VS/^ERENR&PD@OMPH5V';I_.9V"6HXHTNG$\1H)7Z!*=3W4B=5RK0]5
MJ3;6@;;.9+D]+7VK95GVP%Q6<.\4W#NU$TY@"I1"J#ACQH"S,S2CXFU6D==8
MG1T*MNVZ[6[?+5AHLE4#NZ[G>/UJNEY!USN>[A+'"ZQWQ5CLRS@-*IW7R%Z)
MD]/M]5U[C[QW)/EN0;Y;2WZ[6F*Y6H+=U5)%N/N"<,?S+/G;(UP[[2N3OU>(
MZM4G_SJ+J'8_2N6^TJN24HMQ[%IO"*PDMU_([;_=CM=OTH6&P$HNV-;VNVDU
MFLLY7&GU.97)7#_Q:X7M% 3V<?G<KY13"W+LJVP*K2S9V4IVWBZG<^RFG&@(
MK>S$MIRQ:^N$X[/:??&I:+>MRJQNM$ Q=RK>!.A,'00$7[)(N2XFB][BL'&A
M2NR]_I$\A*A*>@NC3S WF,ZBE*$8I@+2:G6%2*H/!;K!2:;JZD?"196N;N?B
M( 54#A#/IX3P34-.4!S-_']02P,$%     @ JT!=6(5#=U:X @  "P<  !D
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MOJ44<D(-R1EV*;O-K7#M4]Y.?19U>M%+W]F8UL XV?;B]S%H? Q:)YL65"P
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MI@->7PJA'QIF4[#>9@Y_ %!+ P04    " "K0%U8!P%X+_8"  #)#   &0
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MU+\&<!V@[J\9DW<3W<U6?R_!/U!+ P04    " "K0%U8_S ED@\'  #>30
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MKJKF79?LM*B^LD/"K!(V+6!Y3^EI.6&31?YH>#H45$<QTYPO6L4XLFD.$B9
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M- ZE.5":0-&:JT'4OH<QQF9= ^I[0&D6E&9#:1Q*<Z T@:(U-5C['L9K;V"
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MBMT2J&U3EBXZ+-6MYL7YIPSGGV%\^!=02P,$%     @ JT!=6'-\>"Q1 @
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M()\_*" HY@_*$)3G#[J'H/OY@QX@Z&'^H+1$&9<$21.L";1.R'4B\#HAV(E
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M(FN%(FN%(FN%(FOUE;+>.;?_S_'3L^QM.[SDL^DOONL_4$L! A0#%     @
MJT!=6 =!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "K0%U8S]@6$^\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " "K0%U8Y?2W4?(%  "=&0  &
M    @('U'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MJT!=6#!>O)KF&P  6*D! !@              ("!'20  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( *M 75A(C@<9#@@  (4@   8
M          " @3E   !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " "K0%U8_<Z %ZX#  #F!P  &               @(%]2   >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ JT!=6)N4[LB;"P  <B$
M !@              ("!84P  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( *M 75AG(^4<2"   *IC   9              " @3)8  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ JT!=6,F'/Y^$
M @  L@4  !D              ("!L7@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " "K0%U8EIO:X%@#  "?!P  &0
M@(%L>P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *M
M75CG>/'_D 0  #$+   9              " @?M^  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ JT!=6)?H3]5) P  80<  !D
M         ("!PH,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " "K0%U8%."AOBP#   *!P  &0              @(%"AP  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( *M 75@G2S[)/0,  #8'
M   9              " @:6*  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ JT!=6.@&8W=3!0  /PT  !D              ("!&8X
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "K0%U8M*IA
M,Y &  #=#P  &0              @(&CDP  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( *M 75@[NC",UPH  .,@   9
M  " @6J:  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MJT!=6/X9TM2+!   Q@H  !D              ("!>*4  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " "K0%U8ADR">_H/  !\/@  &0
M            @($ZJ@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( *M 75@1$MO:X@<  .03   9              " @6NZ  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ JT!=6)8"L^>-!P
M-1(  !D              ("!A,(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " "K0%U8OOE%SK@"   G!@  &0              @(%(
MR@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *M 75@[
M23C6<@,  +0'   9              " @3?-  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ JT!=6,TU\V=# @  FP4  !D
M     ("!X-   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *M 75A)O2?&FP0  ,H+   9              "
M@3+_  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ JT!=
M6-X5).$( P  B 8  !D              ("!! 0! 'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " "K0%U87MP,\Z<"  "C!0  &0
M        @(%#!P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( *M 75@$7;3S P,  $L&   9              " @2$* 0!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ JT!=6((ACPDY P  Z <
M !D              ("!6PT! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " "K0%U860W2+_X%  #<#P  &0              @('+$ $
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *M 75@U_<CR
M_0(  /8&   9              " @0 7 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ JT!=6)G-JR'X @  ? 8  !D
M ("!-!H! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "K
M0%U8\ ZS9QT)  !#*   &0              @(%C'0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *M 75BKMWA H@0  %8+   9
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M970T-"YX;6Q02P$"% ,4    " "K0%U8*AU]YHP%  #7'@  &0
M    @('G0@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M *M 75B<_(KMJ@(  $L'   9              " @:I( 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ JT!=6,6]!93) P  3Q0  !D
M             ("!BTL! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " "K0%U86:%!+S0%  #<&0  &0              @(&+3P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( *M 75B_J:"07P,
M *@+   9              " @?94 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ JT!=6$(=IO@% P  W@D  !D              ("!
MC%@! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "K0%U8
MF>OMQKP"  "+!P  &0              @('(6P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( *M 75A'"K>]+0,  " )   9
M      " @;M> 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ JT!=6(8^G;+;!   #B@  !D              ("!'V(! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "K0%U8].0IU%$"    !@
M&0              @($Q9P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( *M 75BY->ME.P,  *0,   9              " @;EI 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ JT!=6!/\'K)9
M @  H 4  !D              ("!*VT! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " "K0%U8LLO**K $  #K$0  &0
M@(&[;P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( *M
M75A6VP="G (  (@&   9              " @:)T 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ JT!=6!3K'50: P  D0@  !D
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M=#8S+GAM;%!+ 0(4 Q0    ( *M 75B9/A,G) ,  .P)   9
M  " @6Z< 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @
MJT!=6&;T_6._"   5EX  !D              ("!R9\! 'AL+W=O<FMS:&5E
M=',O<VAE970V-2YX;6Q02P$"% ,4    " "K0%U8R\3+1]00  #C\P  &0
M            @(&_J $ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4
M Q0    ( *M 75A*W^QD/ 0  !X7   9              " @<JY 0!X;"]W
M;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ JT!=6%<$ >S]!@
M\#@  !D              ("!/;X! 'AL+W=O<FMS:&5E=',O<VAE970V."YX
M;6Q02P$"% ,4    " "K0%U8(\DPIOT$  ! &0  &0              @(%Q
MQ0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( *M 75@X
MG%:\5@,  *8-   9              " @:7* 0!X;"]W;W)K<VAE971S+W-H
M965T-S N>&UL4$L! A0#%     @ JT!=6(5#=U:X @  "P<  !D
M     ("!,LX! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *M 75C_,"62#P<  -Y-   9              "
M@9O? 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ JT!=
M6"8<%Z." P  PQ@   T              ( !X>8! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "K0%U8EXJ[',     3 @  "P              @ &.Z@$
M7W)E;',O+G)E;'-02P$"% ,4    " "K0%U8T(M+&ND%   *,@  #P
M        @ %WZP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ JT!=6'-\
M>"Q1 @  ^RP  !H              ( !C?$! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ JT!=6,X5S%\/ @  ZBL  !,
M     ( !%O0! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %0 5  #%P
&5O8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>228</ContextCount>
  <ElementCount>362</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Overview of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/OverviewoftheCompany</Role>
      <ShortName>Overview of the Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Business Combination Agreement with Helix and Recapitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalization</Role>
      <ShortName>Business Combination Agreement with Helix and Recapitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/RisksandLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/PrepaidExpenses</Role>
      <ShortName>Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/TradeandOtherPayables</Role>
      <ShortName>Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Shareholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/ShareholdersEquityDeficit</Role>
      <ShortName>Shareholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Segment Information and Geographic Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SegmentInformationandGeographicData</Role>
      <ShortName>Segment Information and Geographic Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Business Combination Agreement with Helix and Recapitalization (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationTables</Role>
      <ShortName>Business Combination Agreement with Helix and Recapitalization (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalization</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/Investments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/PrepaidExpensesTables</Role>
      <ShortName>Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/PrepaidExpenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Trade and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/TradeandOtherPayablesTables</Role>
      <ShortName>Trade and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/TradeandOtherPayables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/EmployeeBenefitPlansTables</Role>
      <ShortName>Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Shareholders??? Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/ShareholdersEquityDeficitTables</Role>
      <ShortName>Shareholders??? Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/ShareholdersEquityDeficit</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/NetLossperShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/SharebasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Segment Information and Geographic Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SegmentInformationandGeographicDataTables</Role>
      <ShortName>Segment Information and Geographic Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/SegmentInformationandGeographicData</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails</Role>
      <ShortName>Business Combination Agreement with Helix and Recapitalization - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Summary of Net Proceeds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails</Role>
      <ShortName>Business Combination Agreement with Helix and Recapitalization - Summary of Net Proceeds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Ordinary Shares Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails</Role>
      <ShortName>Business Combination Agreement with Helix and Recapitalization - Ordinary Shares Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Risks and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/RisksandLiquidityDetails</Role>
      <ShortName>Risks and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/RisksandLiquidity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Investments - Schedule of Fair Value and Amortized Cost of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Fair Value and Amortized Cost of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Investments - FV changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/InvestmentsFVchangesDetails</Role>
      <ShortName>Investments - FV changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/PrepaidExpensesDetails</Role>
      <ShortName>Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/PrepaidExpensesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/TradeandOtherPayablesDetails</Role>
      <ShortName>Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/TradeandOtherPayablesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Leases - Schedule of Weighted Average Lease Term And Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Schedule of Weighted Average Lease Term And Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Leases - Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Employee Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Employee Benefit Plans - Changes in Summary of PBO And Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails</Role>
      <ShortName>Employee Benefit Plans - Changes in Summary of PBO And Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Employee Benefit Plans - Amounts Recorded on the Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails</Role>
      <ShortName>Employee Benefit Plans - Amounts Recorded on the Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Employee Benefit Plans - Changes in Pre-Tax AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails</Role>
      <ShortName>Employee Benefit Plans - Changes in Pre-Tax AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Employee Benefit Plans - Assumptions used to calculate liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails</Role>
      <ShortName>Employee Benefit Plans - Assumptions used to calculate liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Employee Benefit Plans - Allocation Percentage (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails</Role>
      <ShortName>Employee Benefit Plans - Allocation Percentage (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Shareholders??? Equity (Deficit) - Schedule of Stock Authorized and Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails</Role>
      <ShortName>Shareholders??? Equity (Deficit) - Schedule of Stock Authorized and Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Shareholders??? Equity (Deficit) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails</Role>
      <ShortName>Shareholders??? Equity (Deficit) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Net Loss per Share - Calculation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails</Role>
      <ShortName>Net Loss per Share - Calculation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Net Loss per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/NetLossperShareNarrativeDetails</Role>
      <ShortName>Net Loss per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Share-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Share-based Compensation - Share-based Compensation Expense By Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails</Role>
      <ShortName>Share-based Compensation - Share-based Compensation Expense By Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Share-based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails</Role>
      <ShortName>Share-based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Share-based Compensation - Awarded and Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails</Role>
      <ShortName>Share-based Compensation - Awarded and Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Income Taxes - Summary of Net Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails</Role>
      <ShortName>Income Taxes - Summary of Net Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Income Taxes - Statutory Tax Percent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails</Role>
      <ShortName>Income Taxes - Statutory Tax Percent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Income Taxes - Summary of Deferred Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/CommitmentandContingencies</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Segment Information and Geographic Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails</Role>
      <ShortName>Segment Information and Geographic Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/SegmentInformationandGeographicDataTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="mnlk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://moonlaketx.com/role/SubsequentEvents</ParentRole>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="mnlk-20231231.htm">mnlk-20231231.htm</File>
    <File>mnlk-20231231.xsd</File>
    <File>mnlk-20231231_cal.xml</File>
    <File>mnlk-20231231_def.xml</File>
    <File>mnlk-20231231_lab.xml</File>
    <File>mnlk-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mnlk-20231231_g1.jpg</File>
    <File>mnlk-20231231_g2.jpg</File>
    <File>mnlk-20231231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="761">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="17">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mnlk-20231231.htm": {
   "nsprefix": "mnlk",
   "nsuri": "http://moonlaketx.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "mnlk-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "mnlk-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mnlk-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mnlk-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mnlk-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mnlk-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 297,
   "keyCustom": 65,
   "axisStandard": 23,
   "axisCustom": 1,
   "memberStandard": 43,
   "memberCustom": 30,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/ecd/2023": 2,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 228,
   "entityCount": 1,
   "segmentCount": 74,
   "elementCount": 635,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 761,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 17
   },
   "report": {
    "R1": {
     "role": "http://moonlaketx.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://moonlaketx.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-101",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://moonlaketx.com/role/OverviewoftheCompany",
     "longName": "0000008 - Disclosure - Overview of the Company",
     "shortName": "Overview of the Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalization",
     "longName": "0000009 - Disclosure - Business Combination Agreement with Helix and Recapitalization",
     "shortName": "Business Combination Agreement with Helix and Recapitalization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:ReverseRecapitalizationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:ReverseRecapitalizationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "longName": "0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://moonlaketx.com/role/RisksandLiquidity",
     "longName": "0000011 - Disclosure - Risks and Liquidity",
     "shortName": "Risks and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:RiskAndLiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:RiskAndLiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://moonlaketx.com/role/FairValueMeasurements",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://moonlaketx.com/role/Investments",
     "longName": "0000013 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://moonlaketx.com/role/PrepaidExpenses",
     "longName": "0000014 - Disclosure - Prepaid Expenses",
     "shortName": "Prepaid Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://moonlaketx.com/role/TradeandOtherPayables",
     "longName": "0000015 - Disclosure - Trade and Other Payables",
     "shortName": "Trade and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "0000016 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://moonlaketx.com/role/Leases",
     "longName": "0000017 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://moonlaketx.com/role/EmployeeBenefitPlans",
     "longName": "0000018 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://moonlaketx.com/role/ShareholdersEquityDeficit",
     "longName": "0000019 - Disclosure - Shareholders\u2019 Equity (Deficit)",
     "shortName": "Shareholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://moonlaketx.com/role/NetLossperShare",
     "longName": "0000020 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://moonlaketx.com/role/SharebasedCompensation",
     "longName": "0000021 - Disclosure - Share-based Compensation",
     "shortName": "Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://moonlaketx.com/role/IncomeTaxes",
     "longName": "0000022 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://moonlaketx.com/role/CommitmentandContingencies",
     "longName": "0000023 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://moonlaketx.com/role/SegmentInformationandGeographicData",
     "longName": "0000024 - Disclosure - Segment Information and Geographic Data",
     "shortName": "Segment Information and Geographic Data",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://moonlaketx.com/role/SubsequentEvents",
     "longName": "0000025 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationTables",
     "longName": "9954472 - Disclosure - Business Combination Agreement with Helix and Recapitalization (Tables)",
     "shortName": "Business Combination Agreement with Helix and Recapitalization (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:ScheduleOfReverseRecapitalizationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:ScheduleOfReverseRecapitalizationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://moonlaketx.com/role/FairValueMeasurementsTables",
     "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://moonlaketx.com/role/InvestmentsTables",
     "longName": "9954474 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://moonlaketx.com/role/PrepaidExpensesTables",
     "longName": "9954475 - Disclosure - Prepaid Expenses (Tables)",
     "shortName": "Prepaid Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://moonlaketx.com/role/TradeandOtherPayablesTables",
     "longName": "9954476 - Disclosure - Trade and Other Payables (Tables)",
     "shortName": "Trade and Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:TradeAndOtherPayablesCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:TradeAndOtherPayablesCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9954477 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://moonlaketx.com/role/LeasesTables",
     "longName": "9954478 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://moonlaketx.com/role/EmployeeBenefitPlansTables",
     "longName": "9954479 - Disclosure - Employee Benefit Plans (Tables)",
     "shortName": "Employee Benefit Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://moonlaketx.com/role/ShareholdersEquityDeficitTables",
     "longName": "9954480 - Disclosure - Shareholders\u2019 Equity (Deficit) (Tables)",
     "shortName": "Shareholders\u2019 Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://moonlaketx.com/role/NetLossperShareTables",
     "longName": "9954481 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://moonlaketx.com/role/SharebasedCompensationTables",
     "longName": "9954482 - Disclosure - Share-based Compensation (Tables)",
     "shortName": "Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://moonlaketx.com/role/IncomeTaxesTables",
     "longName": "9954483 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://moonlaketx.com/role/SegmentInformationandGeographicDataTables",
     "longName": "9954484 - Disclosure - Segment Information and Geographic Data (Tables)",
     "shortName": "Segment Information and Geographic Data (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
     "longName": "9954485 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Narrative (Details)",
     "shortName": "Business Combination Agreement with Helix and Recapitalization - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-85",
      "name": "mnlk:ReverseRecapitalizationNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlk:ScheduleOfReverseRecapitalizationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "us-gaap:RepaymentsOfShortTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails",
     "longName": "9954486 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Summary of Net Proceeds (Details)",
     "shortName": "Business Combination Agreement with Helix and Recapitalization - Summary of Net Proceeds (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-85",
      "name": "mnlk:InvestmentsAcquiredThroughReverseRecapitalization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlk:ScheduleOfReverseRecapitalizationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "mnlk:InvestmentsAcquiredThroughReverseRecapitalization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlk:ScheduleOfReverseRecapitalizationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
     "longName": "9954487 - Disclosure - Business Combination Agreement with Helix and Recapitalization - Ordinary Shares Issued (Details)",
     "shortName": "Business Combination Agreement with Helix and Recapitalization - Ordinary Shares Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-101",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-90",
      "name": "mnlk:StockIssuedDuringPeriodSharesReverseRecapitalization",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
     "longName": "9954488 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-101",
      "name": "mnlk:RecapitalizationExchangeRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "mnlk:RecapitalizationExchangeRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://moonlaketx.com/role/RisksandLiquidityDetails",
     "longName": "9954489 - Disclosure - Risks and Liquidity (Details)",
     "shortName": "Risks and Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "mnlk:CurrentAssetsInExcessOfCurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://moonlaketx.com/role/FairValueMeasurementsDetails",
     "longName": "9954490 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails",
     "longName": "9954491 - Disclosure - Investments - Schedule of Fair Value and Amortized Cost of Investments (Details)",
     "shortName": "Investments - Schedule of Fair Value and Amortized Cost of Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://moonlaketx.com/role/InvestmentsFVchangesDetails",
     "longName": "9954492 - Disclosure - Investments - FV changes (Details)",
     "shortName": "Investments - FV changes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://moonlaketx.com/role/PrepaidExpensesDetails",
     "longName": "9954493 - Disclosure - Prepaid Expenses (Details)",
     "shortName": "Prepaid Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://moonlaketx.com/role/TradeandOtherPayablesDetails",
     "longName": "9954494 - Disclosure - Trade and Other Payables (Details)",
     "shortName": "Trade and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "mnlk:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "mnlk:TradeAndOtherPayablesCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "mnlk:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "mnlk:TradeAndOtherPayablesCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9954495 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://moonlaketx.com/role/LeasesNarrativeDetails",
     "longName": "9954496 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-124",
      "name": "mnlk:LesseeOperatingLeaseNumberOfRenewalOptions",
      "unitRef": "period",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-124",
      "name": "mnlk:LesseeOperatingLeaseNumberOfRenewalOptions",
      "unitRef": "period",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://moonlaketx.com/role/LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails",
     "longName": "9954497 - Disclosure - Leases - Schedule of Weighted Average Lease Term And Discount Rate (Details)",
     "shortName": "Leases - Schedule of Weighted Average Lease Term And Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails",
     "longName": "9954498 - Disclosure - Leases - Future Lease Payments (Details)",
     "shortName": "Leases - Future Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails",
     "longName": "9954499 - Disclosure - Employee Benefit Plans - Narrative (Details)",
     "shortName": "Employee Benefit Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails",
     "longName": "9954500 - Disclosure - Employee Benefit Plans - Changes in Summary of PBO And Plan Assets (Details)",
     "shortName": "Employee Benefit Plans - Changes in Summary of PBO And Plan Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails",
     "longName": "9954501 - Disclosure - Employee Benefit Plans - Amounts Recorded on the Balance Sheet (Details)",
     "shortName": "Employee Benefit Plans - Amounts Recorded on the Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails",
     "longName": "9954502 - Disclosure - Employee Benefit Plans - Changes in Pre-Tax AOCI (Details)",
     "shortName": "Employee Benefit Plans - Changes in Pre-Tax AOCI (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails",
     "longName": "9954503 - Disclosure - Employee Benefit Plans - Assumptions used to calculate liabilities (Details)",
     "shortName": "Employee Benefit Plans - Assumptions used to calculate liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails",
     "longName": "9954504 - Disclosure - Employee Benefit Plans - Allocation Percentage (Details)",
     "shortName": "Employee Benefit Plans - Allocation Percentage (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DefinedBenefitPlanPlanAssetsAllocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DefinedBenefitPlanPlanAssetsAllocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
     "longName": "9954505 - Disclosure - Shareholders\u2019 Equity (Deficit) - Schedule of Stock Authorized and Issued (Details)",
     "shortName": "Shareholders\u2019 Equity (Deficit) - Schedule of Stock Authorized and Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "mnlk:SharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "mnlk:SharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
     "longName": "9954506 - Disclosure - Shareholders\u2019 Equity (Deficit) - Narrative (Details)",
     "shortName": "Shareholders\u2019 Equity (Deficit) - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-101",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-156",
      "name": "mnlk:SaleOfStockStampDutyTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails",
     "longName": "9954507 - Disclosure - Net Loss per Share - Calculation of Net Loss per Share (Details)",
     "shortName": "Net Loss per Share - Calculation of Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
     "longName": "9954508 - Disclosure - Net Loss per Share - Narrative (Details)",
     "shortName": "Net Loss per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
     "longName": "9954509 - Disclosure - Share-based Compensation - Narrative (Details)",
     "shortName": "Share-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "mnlk:NumberOfCoFounders",
      "unitRef": "co-founder",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails",
     "longName": "9954510 - Disclosure - Share-based Compensation - Share-based Compensation Expense By Plan (Details)",
     "shortName": "Share-based Compensation - Share-based Compensation Expense By Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-170",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
     "longName": "9954511 - Disclosure - Share-based Compensation - Assumptions (Details)",
     "shortName": "Share-based Compensation - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-183",
      "name": "mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "mnlk:ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "mnlk:ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
     "longName": "9954512 - Disclosure - Share-based Compensation - Awarded and Granted (Details)",
     "shortName": "Share-based Compensation - Awarded and Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-211",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-213",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954513 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails",
     "longName": "9954514 - Disclosure - Income Taxes - Summary of Net Income (Details)",
     "shortName": "Income Taxes - Summary of Net Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails",
     "longName": "9954515 - Disclosure - Income Taxes - Statutory Tax Percent (Details)",
     "shortName": "Income Taxes - Statutory Tax Percent (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails",
     "longName": "9954516 - Disclosure - Income Taxes - Summary of Deferred Tax (Details)",
     "shortName": "Income Taxes - Summary of Deferred Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
     "longName": "9954517 - Disclosure - Commitment and Contingencies (Details)",
     "shortName": "Commitment and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "mnlk:UnrecognizedCommitmentsAndContingencies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "mnlk:UnrecognizedCommitmentsAndContingencies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails",
     "longName": "9954518 - Disclosure - Segment Information and Geographic Data (Details)",
     "shortName": "Segment Information and Geographic Data (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://moonlaketx.com/role/SubsequentEventsDetails",
     "longName": "9954519 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-228",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "mnlk_ATMSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ATMSharesMember",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Shares",
        "label": "ATM Shares [Member]",
        "documentation": "ATM Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities",
      "http://moonlaketx.com/role/TradeandOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade and Other Payables",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails": {
       "parentTag": "mnlk_TradeAndOtherPayablesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "mnlk_AccruedConsultingAndOtherFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "AccruedConsultingAndOtherFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consultant and other fees",
        "label": "Accrued Consulting And Other Fees, Current",
        "documentation": "Accrued Consulting And Other Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax liabilities",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r145"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal fees",
        "label": "Accrued Professional Fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_AccruedRentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails": {
       "parentTag": "mnlk_TradeAndOtherPayablesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent / leases",
        "label": "Accrued Rent, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r717"
     ]
    },
    "mnlk_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails": {
       "parentTag": "mnlk_TradeAndOtherPayablesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development services",
        "label": "Accrued Research And Development Expenses, Current",
        "documentation": "Accrued Research And Development Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development services and license fees",
        "label": "Accrued Research And Development Services and License Fees, Current",
        "documentation": "Accrued Research And Development Services and License Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_AccruedSupplyAndManufacturingFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "AccruedSupplyAndManufacturingFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply and manufacturing services",
        "label": "Accrued Supply And Manufacturing Fees, Current",
        "documentation": "Accrued Supply And Manufacturing Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r110",
      "r176",
      "r562",
      "r591",
      "r595"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14",
      "r34",
      "r474",
      "r477",
      "r512",
      "r586",
      "r587",
      "r864",
      "r865",
      "r866",
      "r871",
      "r872",
      "r873"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r743",
      "r972"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r609",
      "r871",
      "r872",
      "r873",
      "r946",
      "r974"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emission fees and capital tax payments on share issuance",
        "label": "Adjustments to Additional Paid In Capital, Emission Fee Reimbursement",
        "documentation": "Adjustments to Additional Paid In Capital, Emission Fee Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStampDutyFees",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refund of stamp duty fees",
        "label": "Adjustments To Additional Paid In Capital, Stamp Duty Fees",
        "documentation": "Adjustments To Additional Paid In Capital, Stamp Duty Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r779",
      "r789",
      "r815"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r782",
      "r792",
      "r818"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r783",
      "r793",
      "r810",
      "r819",
      "r823",
      "r831"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r440"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r172",
      "r204",
      "r245",
      "r255",
      "r258",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r467",
      "r471",
      "r489",
      "r558",
      "r649",
      "r743",
      "r756",
      "r907",
      "r908",
      "r958"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r178",
      "r204",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r467",
      "r471",
      "r489",
      "r743",
      "r907",
      "r908",
      "r958"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r467",
      "r471",
      "r489",
      "r907",
      "r908",
      "r958"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://moonlaketx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r775"
     ]
    },
    "mnlk_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://moonlaketx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r775"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://moonlaketx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r775"
     ]
    },
    "mnlk_August2023SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "August2023SalesAgreementMember",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 Sales Agreement",
        "label": "August 2023 Sales Agreement [Member]",
        "documentation": "August 2023 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r311",
      "r557"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt securities, available-for-sale",
        "terseLabel": "Fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r311",
      "r549",
      "r878"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term marketable debt securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r311"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Significant Accounting Policies",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "country_CH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CH",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Switzerland",
        "label": "SWITZERLAND"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_CambridgeOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "CambridgeOfficeMember",
     "presentation": [
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cambridge Office",
        "label": "Cambridge Office [Member]",
        "documentation": "Cambridge Office"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/RisksandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrestricted cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r560",
      "r620",
      "r643",
      "r743",
      "r756",
      "r859"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r171",
      "r714"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which classified within cash and cash equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r118",
      "r202"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r118"
     ]
    },
    "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowFinancingActivitiesLesseeAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from financing activities",
        "label": "Cash Flow, Financing Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowInvestingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowInvestingActivitiesLesseeAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from investing activities",
        "label": "Cash Flow, Investing Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from operating activities",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of Deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/Cover",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r173",
      "r174",
      "r175",
      "r204",
      "r228",
      "r229",
      "r231",
      "r233",
      "r239",
      "r240",
      "r301",
      "r325",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r339",
      "r340",
      "r343",
      "r346",
      "r353",
      "r489",
      "r601",
      "r602",
      "r603",
      "r604",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r621",
      "r635",
      "r659",
      "r677",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r838",
      "r868",
      "r876"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r239",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r351",
      "r353",
      "r601",
      "r602",
      "r603",
      "r604",
      "r730",
      "r838",
      "r868"
     ]
    },
    "mnlk_ClassVVotingStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ClassVVotingStockMember",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class V Voting Stock",
        "label": "Class V Voting Stock [Member]",
        "documentation": "Class V Voting Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eurocommercial Papers",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r90",
      "r559",
      "r634"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r319",
      "r320",
      "r699",
      "r904"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/Cover",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class A",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "mnlk_CommonClassAPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "CommonClassAPrivatePlacementMember",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common class A, private placement",
        "label": "Common Class A, Private Placement [Member]",
        "documentation": "Common Class A, Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_CommonClassARedeemableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "CommonClassARedeemableMember",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common class A, redeemable",
        "label": "Common Class A, Redeemable [Member]",
        "documentation": "Common Class A, Redeemable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class B Ordinary Shares",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_CommonClassCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassCMember",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/Cover",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class C",
        "label": "Common Class C [Member]",
        "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_CommonStockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "CommonStockConversionRatio",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, conversion ratio (in shares)",
        "label": "Common Stock, Conversion Ratio",
        "documentation": "Common Stock, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r747",
      "r748",
      "r750",
      "r751",
      "r752",
      "r753",
      "r871",
      "r872",
      "r946",
      "r971",
      "r974"
     ]
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MoonLake AG common shares (in shares)",
        "label": "Common Stock, Other Shares, Outstanding",
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares, par value (USD per share)",
        "verboseLabel": "Common stock, par value (CHF/USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "mnlk_CommonStockRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "CommonStockRollForward",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares",
        "label": "Common Stock [Roll Forward]",
        "documentation": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares, shares authorized (in shares)",
        "periodStartLabel": "Authorized, beginning balance (in shares)",
        "periodEndLabel": "Authorized, ending balance (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r635"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares, shares issued (in shares)",
        "periodStartLabel": "Issued, beginning balance (in shares)",
        "periodEndLabel": "Issued, ending balance (in shares)",
        "verboseLabel": "Common shares, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares, shares outstanding (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "netLabel": "Shares outstanding (in shares)",
        "verboseLabel": "Number of shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r104",
      "r635",
      "r655",
      "r974",
      "r975"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r561",
      "r743"
     ]
    },
    "mnlk_CommonStockVotesAttachedToShares": {
     "xbrltype": "integerItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "CommonStockVotesAttachedToShares",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares, votes per share",
        "label": "Common Stock, Votes Attached To Shares",
        "documentation": "Common Stock, Votes Attached To Shares"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_CommonStockVotesMultiplier": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "CommonStockVotesMultiplier",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, votes per share multiplier",
        "label": "Common Stock, Votes Multiplier",
        "documentation": "Common Stock, Votes Multiplier"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r134"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to controlling interests shareholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r185",
      "r187",
      "r195",
      "r553",
      "r576"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82",
      "r85",
      "r185",
      "r187",
      "r194",
      "r552",
      "r575"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r139",
      "r185",
      "r187",
      "r193",
      "r551",
      "r574"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r158"
     ]
    },
    "mnlk_ConversionFollowingBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ConversionFollowingBusinessCombinationMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Following Business Combination",
        "label": "Conversion Following Business Combination [Member]",
        "documentation": "Conversion Following Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ConversionOfClassCIntoClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ConversionOfClassCIntoClassAMember",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Of Class C into Class A",
        "label": "Conversion Of Class C into Class A [Member]",
        "documentation": "Conversion Of Class C into Class A"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ConversionOfClassCIntoClassASharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ConversionOfClassCIntoClassASharesMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Of Class C Into Class A Shares",
        "label": "Conversion Of Class C Into Class A Shares [Member]",
        "documentation": "Conversion Of Class C Into Class A Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion Description [Axis]",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Name [Domain]",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares converted",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r334",
      "r341",
      "r513",
      "r718",
      "r720"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_CurrentAssetsInExcessOfCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "CurrentAssetsInExcessOfCurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/RisksandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess of current assets less current liabilities",
        "label": "Current Assets In Excess Of Current Liabilities",
        "documentation": "Current Assets In Excess Of Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Gross unrealized gain (loss), beginning balance",
        "periodEndLabel": "Gross unrealized gain (loss), ending balance",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r885"
     ]
    },
    "mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward",
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of investments in short-term marketable debt securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r895"
     ]
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which classified within short-term marketable debt securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r748",
      "r976"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid expenses",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "mnlk_DeferredTaxAssetsNetIncludingValuationAllowance",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r146",
      "r451"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "mnlk_DeferredTaxAssetsNetIncludingValuationAllowance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails",
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, gross",
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "mnlk_DeferredTaxAssetsLeaseLiabililties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiabililties",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets, Lease Liabililties",
        "documentation": "Deferred Tax Assets, Lease Liabililties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax (net)",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "mnlk_DeferredTaxAssetsNetIncludingValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DeferredTaxAssetsNetIncludingValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets (net)",
        "label": "Deferred Tax Assets, Net, Including Valuation Allowance",
        "documentation": "Deferred Tax Assets, Net, Including Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r944"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plan",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails",
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, valuation allowance",
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "mnlk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right-of-Use Assets",
        "documentation": "Deferred Tax Liabilities, Operating Lease Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension liability",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r100",
      "r132"
     ]
    },
    "mnlk_DefinedBenefitPlanAOCIRollforwardRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanAOCIRollforwardRollForward",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, AOCI Rollforward [Roll Forward]",
        "label": "Defined Benefit Plan, AOCI Rollforward [Roll Forward]",
        "documentation": "Defined Benefit Plan, AOCI Rollforward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Actuarial (gain) / loss - beginning of year",
        "negatedPeriodEndLabel": "Total",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r383"
     ]
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Actuarial (gain) / losses",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Funded status",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of plan assets",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r355",
      "r356",
      "r369",
      "r648",
      "r735",
      "r967"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Expected return on plan assets",
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Expected return on plan assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term expected rate of salary increase",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "mnlk_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAssumptionsusedtocalculateliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inflation",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Inflation",
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Inflation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning PBO",
        "periodEndLabel": "Ending PBO",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "mnlk_DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid, Net Of Adjustments",
        "documentation": "Defined Benefit Plan, Benefit Obligation, Benefits Paid, Net Of Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions by plan participants",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "mnlk_DefinedBenefitPlanBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanBondMember",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonds",
        "label": "Defined Benefit Plan, Bond [Member]",
        "documentation": "Defined Benefit Plan, Bond"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "documentation": "Information by defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r387",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions by the employer",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r372",
      "r392",
      "r733",
      "r734",
      "r735",
      "r736"
     ]
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equities",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r381",
      "r391",
      "r735",
      "r736"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning fair value of plan assets",
        "periodEndLabel": "Ending fair value of plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r371",
      "r372",
      "r373",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency exchange rates changes",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "mnlk_DefinedBenefitPlanInfrastructureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanInfrastructureMember",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Infrastructure",
        "label": "Defined Benefit Plan, Infrastructure [Member]",
        "documentation": "Defined Benefit Plan, Infrastructure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanInterestCost",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest cost",
        "label": "Defined Benefit Plan, Interest Cost",
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r360",
      "r380",
      "r390",
      "r735",
      "r736"
     ]
    },
    "mnlk_DefinedBenefitPlanLiquidityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanLiquidityMember",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity",
        "label": "Defined Benefit Plan, Liquidity [Member]",
        "documentation": "Defined Benefit Plan, Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r388"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAmendments",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan amendment",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsAllocationLineItems",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Allocation [Line Items]",
        "label": "Defined Benefit Plan, Plan Assets, Allocation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r735"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsAllocationTable",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Allocation [Table]",
        "label": "Defined Benefit Plan, Plan Assets, Allocation [Table]",
        "documentation": "Disclosure of information about investment allocation of defined benefit plan assets. Includes, but is not limited to, investment allocation percentage or range of percentages."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r735"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsAllocationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsAllocationTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Allocation",
        "label": "Defined Benefit Plan, Plan Assets, Allocation [Table Text Block]",
        "documentation": "Tabular disclosure of investment allocation of defined benefit plan assets. Includes, but is not limited to, investment allocation percentage or range of percentages."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "mnlk_DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid, Net Of Adjustments",
        "documentation": "Defined Benefit Plan, Plan Assets, Benefits Paid, Net Of Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions by plan participants",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency exchange rates changes",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "mnlk_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Return on plan assets above expected return",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Return Above Expected Returns",
        "documentation": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Return Above Expected Returns"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanRealEstateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanRealEstateMember",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate",
        "label": "Defined Benefit Plan, Real Estate [Member]",
        "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r735"
     ]
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanServiceCost",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinSummaryofPBOAndPlanAssetsDetails",
      "http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service cost",
        "label": "Defined Benefit Plan, Service Cost",
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r379",
      "r389",
      "r735",
      "r736"
     ]
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plan, plan assets, actual allocation, percentage",
        "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage",
        "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r398",
      "r429",
      "r430",
      "r432",
      "r738"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r775"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r775",
      "r811"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "mnlk_Dr.JorgeSantosDaSilvaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "Dr.JorgeSantosDaSilvaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Jorge Santos da Silva [Member]",
        "documentation": "Dr. Jorge Santos da Silva"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_Dr.KristianReichMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "Dr.KristianReichMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Kristian Reich [Member]",
        "documentation": "Dr. Kristian Reich"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share attributable to controlling interest shareholders (USD per share)",
        "verboseLabel": "Net loss per share - basic (in USD per share)",
        "negatedTerseLabel": "Net loss per share - basic (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r214",
      "r215",
      "r217",
      "r218",
      "r220",
      "r226",
      "r228",
      "r231",
      "r232",
      "r233",
      "r237",
      "r483",
      "r484",
      "r554",
      "r577",
      "r721"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share attributable to controlling interest shareholders (USD per share)",
        "verboseLabel": "Net loss per share - diluted (in USD per share)",
        "negatedTerseLabel": "Net loss per share - diluted (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r214",
      "r215",
      "r217",
      "r218",
      "r220",
      "r228",
      "r231",
      "r232",
      "r233",
      "r237",
      "r483",
      "r484",
      "r554",
      "r577",
      "r721"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Class A Ordinary Shares",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r234",
      "r235",
      "r236"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of movements in exchange rates on cash held",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails",
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate",
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r447",
      "r462"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r945"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of income taxed at different rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r942"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r945"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expense",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r945"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in prior year estimates",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r945"
     ]
    },
    "mnlk_EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesStatutoryTaxPercentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Utilization of unrecognized losses",
        "label": "Effective Income Tax Rate Reconciliation, Utilization Of Unrealized Loss Not Recognized In Prior Year, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Utilization Of Unrealized Loss Not Recognized In Prior Year, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonuses and related employees compensation expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized share-based compensation expense, non-option awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESOP",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_EmployeeStockOptionPlanESOPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "EmployeeStockOptionPlanESOPMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option Plan (ESOP)",
        "label": "Employee Stock Option Plan (ESOP) [Member]",
        "documentation": "Employee Stock Option Plan (ESOP)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity (deficit)",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r166",
      "r189",
      "r190",
      "r191",
      "r209",
      "r210",
      "r211",
      "r213",
      "r221",
      "r223",
      "r238",
      "r302",
      "r305",
      "r354",
      "r433",
      "r434",
      "r435",
      "r457",
      "r458",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r482",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r512",
      "r586",
      "r587",
      "r588",
      "r609",
      "r677"
     ]
    },
    "mnlk_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plan",
        "label": "Equity Incentive Plan [Member]",
        "documentation": "Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r779",
      "r789",
      "r815"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r776",
      "r786",
      "r812"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "mnlk_ExpirationIn2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ExpirationIn2028Member",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration in 2028",
        "label": "Expiration in 2028 [Member]",
        "documentation": "Expiration in 2028"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ExpirationIn2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ExpirationIn2029Member",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration in 2029",
        "label": "Expiration in 2029 [Member]",
        "documentation": "Expiration in 2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of debt securities by level within the fair value hierarchy",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r141"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails",
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r486",
      "r520",
      "r521",
      "r522",
      "r728",
      "r729",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails",
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r372",
      "r377",
      "r486",
      "r521",
      "r728",
      "r729",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]",
        "label": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]",
        "label": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]",
        "documentation": "Disclosure of information about the gain (loss) of assets and liabilities measured at fair value on a recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails",
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r520",
      "r521",
      "r522",
      "r728",
      "r729",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r337",
      "r351",
      "r479",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r573",
      "r726",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction gain (loss)",
        "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r754",
      "r949",
      "r950",
      "r973"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r793",
      "r819"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r793",
      "r819"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r793",
      "r819"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r793",
      "r819"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r793",
      "r819"
     ]
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r661"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Axis]",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Domain]",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "mnlk_HelixAcquisitionCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "HelixAcquisitionCorpMember",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Helix Acquisition Corp.",
        "label": "Helix Acquisition Corp. [Member]",
        "documentation": "Helix Acquisition Corp."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r775"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Switzerland",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r461"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) attributable to parent, before tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r112",
      "r150",
      "r245",
      "r254",
      "r257",
      "r260",
      "r555",
      "r568",
      "r723"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesSummaryofNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r461"
     ]
    },
    "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax",
        "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax",
        "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r866"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r662"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r662"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r443",
      "r448",
      "r449",
      "r455",
      "r459",
      "r463",
      "r464",
      "r465",
      "r606"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r163",
      "r222",
      "r223",
      "r246",
      "r446",
      "r460",
      "r578"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r444",
      "r445",
      "r449",
      "r450",
      "r454",
      "r456",
      "r600"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r867"
     ]
    },
    "mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets",
        "label": "Increase (Decrease) in Operating Lease, Right Of Use Asset",
        "documentation": "Increase (Decrease) in Operating Lease, Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r783",
      "r793",
      "r810",
      "r819",
      "r823",
      "r831"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r835"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r835"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r835"
     ]
    },
    "mnlk_InvestmentsAcquiredThroughReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "InvestmentsAcquiredThroughReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails": {
       "parentTag": "mnlk_ReverseRecapitalizationNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments held in Trust Account",
        "label": "Investments Acquired Through Reverse Recapitalization",
        "documentation": "Investments Acquired Through Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r152",
      "r153",
      "r165",
      "r267",
      "r270",
      "r487",
      "r488"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "mnlk_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "presentation": [
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, lease term extension",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r204",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r468",
      "r471",
      "r472",
      "r489",
      "r633",
      "r722",
      "r756",
      "r907",
      "r958",
      "r959"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r149",
      "r565",
      "r743",
      "r869",
      "r899",
      "r948"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r170",
      "r204",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r468",
      "r471",
      "r472",
      "r489",
      "r743",
      "r907",
      "r958",
      "r959"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r95",
      "r96",
      "r97",
      "r99",
      "r204",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r468",
      "r471",
      "r472",
      "r489",
      "r907",
      "r958",
      "r959"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets by Geographic Areas",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "mnlk_MLPartiesOtherThanBVFShareholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "MLPartiesOtherThanBVFShareholdersMember",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ML parties other than BVF shareholders",
        "label": "ML Parties Other Than BVF Shareholders [Member]",
        "documentation": "ML Parties Other Than BVF Shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities and short-term investments",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r393",
      "r547",
      "r585",
      "r625",
      "r626",
      "r682",
      "r684",
      "r686",
      "r687",
      "r689",
      "r710",
      "r711",
      "r725",
      "r730",
      "r737",
      "r745",
      "r909",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965"
     ]
    },
    "mnlk_May2023SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "May2023SalesAgreementMember",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2023 Sales Agreement",
        "label": "May 2023 Sales Agreement [Member]",
        "documentation": "May 2023 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r393",
      "r547",
      "r585",
      "r625",
      "r626",
      "r682",
      "r684",
      "r686",
      "r687",
      "r689",
      "r710",
      "r711",
      "r725",
      "r730",
      "r737",
      "r745",
      "r909",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r148",
      "r204",
      "r301",
      "r325",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r489",
      "r564",
      "r637"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "mnlk_MoonLakeAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "MoonLakeAGMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MoonLake AG",
        "label": "MoonLake AG [Member]",
        "documentation": "MoonLake AG"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_MoonLakeImmunotherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "MoonLakeImmunotherapeuticsMember",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MoonLake Immunotherapeutics",
        "label": "MoonLake Immunotherapeutics [Member]",
        "documentation": "MoonLake Immunotherapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MortgageBackedSecuritiesMember",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgages",
        "label": "Collateralized Mortgage-Backed Securities [Member]",
        "documentation": "Securities collateralized by mortgage loans."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r880",
      "r887",
      "r892",
      "r893",
      "r894",
      "r970"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Of which: net loss attributable to controlling interests shareholders",
        "verboseLabel": "Net loss attributable to controlling interests shareholders",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r120",
      "r151",
      "r168",
      "r183",
      "r186",
      "r191",
      "r204",
      "r212",
      "r214",
      "r215",
      "r217",
      "r218",
      "r222",
      "r223",
      "r230",
      "r245",
      "r254",
      "r257",
      "r260",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r484",
      "r489",
      "r571",
      "r658",
      "r675",
      "r676",
      "r723",
      "r754",
      "r907"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which: net loss attributable to noncontrolling interests shareholders",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r140",
      "r183",
      "r186",
      "r222",
      "r223",
      "r570",
      "r866"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r793",
      "r810",
      "r819"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "mnlk_NoncontrollingInterestDecreaseFromReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "NoncontrollingInterestDecreaseFromReverseRecapitalization",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Noncontrolling interests recognized on historical net assets of MoonLake AG in connection with the Business Combination",
        "label": "Noncontrolling Interest, Decrease From Reverse Recapitalization",
        "documentation": "Noncontrolling Interest, Decrease From Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital injection from MoonLake to MoonLake AG (Note 12)",
        "label": "Noncontrolling Interest, Increase From Capital Injection In Subsidiary",
        "documentation": "Noncontrolling Interest, Increase From Capital Injection In Subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r354",
      "r871",
      "r872",
      "r873",
      "r974"
     ]
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived assets",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Restricted Stock Shares Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "mnlk_NumberOfCoFounders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "NumberOfCoFounders",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of co-founders",
        "label": "Number Of Co-Founders",
        "documentation": "Number Of Co-Founders"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_NumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "NumberOfOperatingLeases",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating leases",
        "label": "Number Of Operating Leases",
        "documentation": "Number Of Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_OfficeLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "OfficeLeaseMember",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Lease",
        "label": "Office Lease [Member]",
        "documentation": "Office Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r254",
      "r257",
      "r260",
      "r723"
     ]
    },
    "mnlk_OperatingLeaseAreaOfLeasedSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "OperatingLeaseAreaOfLeasedSpace",
     "presentation": [
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square foot of leased space",
        "label": "Operating Lease, Area of Leased Space",
        "documentation": "Operating Lease, Area of Leased Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term portion of operating lease liabilities",
        "negatedTerseLabel": "Less current portion of lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term portion operating lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r506"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://moonlaketx.com/role/LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r742"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://moonlaketx.com/role/LeasesScheduleofWeightedAverageLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in months)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r742"
     ]
    },
    "mnlk_OperatingLossCarryforwardExpirationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "OperatingLossCarryforwardExpirationAxis",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforward Expiration [Axis]",
        "label": "Operating Loss Carryforward Expiration [Axis]",
        "documentation": "Operating Loss Carryforward Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_OperatingLossCarryforwardExpirationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "OperatingLossCarryforwardExpirationDomain",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforward Expiration [Domain]",
        "label": "Operating Loss Carryforward Expiration [Domain]",
        "documentation": "Operating Loss Carryforward Expiration [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/OverviewoftheCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overview of the Company",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r138",
      "r596",
      "r597"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior service (cost) / credit recognized in current year",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r110",
      "r382"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial income (loss) on employee benefit plans",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax",
        "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r110",
      "r382"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized gain on marketable securities and short-term investments",
        "negatedTerseLabel": "Other comprehensive income before reclassifications",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income",
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r22",
      "r184",
      "r187",
      "r192",
      "r491",
      "r492",
      "r497",
      "r550",
      "r572",
      "r864",
      "r865"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Actuarial (gain) / loss of current year",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r110",
      "r133"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r110",
      "r182"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansChangesinPreTaxAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r110",
      "r182",
      "r382"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvestmentsMember",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alternative investments",
        "label": "Other Investments [Member]",
        "documentation": "Primary financial statement caption encompassing other investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash items",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "mnlk_OtherPrepaidConsultingAndAdvisoryFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "OtherPrepaidConsultingAndAdvisoryFeesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/PrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other consulting and advisory services",
        "label": "Other Prepaid Consulting And Advisory Fees, Current",
        "documentation": "Other Prepaid Consulting And Advisory Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/PrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepayments",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r902"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r781",
      "r791",
      "r817"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r784",
      "r794",
      "r820"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r784",
      "r794",
      "r820"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_PIPEInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "PIPEInvestorsMember",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Investors",
        "label": "PIPE Investors [Member]",
        "documentation": "PIPE Investors"
       }
      }
     },
     "auth_ref": []
    },
    "country_PT": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "PT",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portugal",
        "label": "PORTUGAL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholders' Equity (Deficit)",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails": {
       "parentTag": "mnlk_ReverseRecapitalizationNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "mnlk_PaymentsOfStampDuty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "PaymentsOfStampDuty",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Stamp duty on capital injection from MoonLake to MoonLake AG (Note 12)",
        "label": "Payments Of Stamp Duty",
        "documentation": "Payments Of Stamp Duty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of short-term marketable debt securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r198",
      "r268"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAmountsRecordedontheBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Present value of projected benefit obligation",
        "label": "Liability, Defined Benefit Plan",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r356",
      "r369",
      "r968"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementPlansPensionsPolicy",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Accounting",
        "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r16",
      "r69"
     ]
    },
    "us-gaap_PensionExpenseReversalOfExpenseNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionExpenseReversalOfExpenseNoncash",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net periodic pension benefit cost for the qualified pension plan",
        "label": "Pension Expense (Reversal of Expense), Noncash",
        "documentation": "Amount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanAssetCategoriesDomain",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansAllocationPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "documentation": "Defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r387",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "mnlk_PortoOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "PortoOfficeMember",
     "presentation": [
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Porto Office",
        "label": "Porto Office [Member]",
        "documentation": "Porto Office"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r747",
      "r750",
      "r751",
      "r752",
      "r753",
      "r971",
      "r974"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (CHF per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r339"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Preferred stock, beginning balance (in shares)",
        "periodEndLabel": "Preferred stock, ending balance (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r635",
      "r655",
      "r974",
      "r975"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://moonlaketx.com/role/PrepaidExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses - current",
        "totalLabel": "Total",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r315",
      "r316",
      "r715"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrentAbstract",
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses - current",
        "label": "Prepaid Expense, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://moonlaketx.com/role/PrepaidExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses - non-current",
        "totalLabel": "Total",
        "label": "Prepaid Expense, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrentAbstract",
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses - non-current",
        "label": "Prepaid Expense, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_PrepaidExpensesNoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "PrepaidExpensesNoncurrentMember",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses, Noncurrent",
        "label": "Prepaid Expenses, Noncurrent [Member]",
        "documentation": "Prepaid Expenses, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/PrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurances",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r727",
      "r902"
     ]
    },
    "mnlk_PrepaidResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "PrepaidResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/PrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-clinical research and clinical development services",
        "label": "Prepaid Research And Development Expense",
        "documentation": "Prepaid Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO Private Placement Shares",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProFormaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProFormaMember",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma",
        "label": "Pro Forma [Member]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r839",
      "r840"
     ]
    },
    "mnlk_ProceedsFromContributionFromParValueOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ProceedsFromContributionFromParValueOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution for par value of Class V Shares",
        "label": "Proceeds From Contribution From Par Value Of Common Stock",
        "documentation": "Proceeds From Contribution From Par Value Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributionsFromParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributionsFromParent",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from contributions from parent",
        "label": "Proceeds from Contributions from Parent",
        "documentation": "The cash inflow from parent as a source of financing that is recorded as additional paid in capital."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails": {
       "parentTag": "mnlk_ReverseRecapitalizationNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plus PIPE investment",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants of additional shares under ESPP",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r19"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of short-term marketable debt securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r879"
     ]
    },
    "mnlk_ProceedsFromReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ProceedsFromReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Business Combination",
        "label": "Proceeds From Reverse Recapitalization",
        "documentation": "Proceeds From Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r548",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r712",
      "r731",
      "r744",
      "r847",
      "r905",
      "r906",
      "r911",
      "r969"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r548",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r712",
      "r731",
      "r744",
      "r847",
      "r905",
      "r906",
      "r911",
      "r969"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/RisksandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r183",
      "r186",
      "r200",
      "r204",
      "r212",
      "r222",
      "r223",
      "r245",
      "r254",
      "r257",
      "r260",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r466",
      "r469",
      "r470",
      "r484",
      "r489",
      "r555",
      "r569",
      "r608",
      "r658",
      "r675",
      "r676",
      "r723",
      "r740",
      "r741",
      "r755",
      "r866",
      "r907"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r556",
      "r567",
      "r743"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r159",
      "r162",
      "r566"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r370",
      "r393",
      "r424",
      "r425",
      "r426",
      "r523",
      "r547",
      "r585",
      "r625",
      "r626",
      "r682",
      "r684",
      "r686",
      "r687",
      "r689",
      "r710",
      "r711",
      "r725",
      "r730",
      "r737",
      "r745",
      "r748",
      "r903",
      "r909",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r370",
      "r393",
      "r424",
      "r425",
      "r426",
      "r523",
      "r547",
      "r585",
      "r625",
      "r626",
      "r682",
      "r684",
      "r686",
      "r687",
      "r689",
      "r710",
      "r711",
      "r725",
      "r730",
      "r737",
      "r745",
      "r748",
      "r903",
      "r909",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
      "http://moonlaketx.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984"
     ]
    },
    "mnlk_RecapitalizationExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "RecapitalizationExchangeRatio",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio",
        "label": "Recapitalization Exchange Ratio",
        "documentation": "Recapitalization Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r776",
      "r786",
      "r812"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of loan liability",
        "terseLabel": "Repayments of loan liability",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r334",
      "r341",
      "r513",
      "r719",
      "r720"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r442",
      "r966"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Contract Costs and Accruals",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period, Adjustment",
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r220",
      "r221",
      "r237",
      "r482",
      "r483",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r850",
      "r851"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Axis]",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r237",
      "r303",
      "r304",
      "r458",
      "r481",
      "r482",
      "r483",
      "r484",
      "r499",
      "r511",
      "r512",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r777",
      "r787",
      "r813"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r778",
      "r788",
      "r814"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r785",
      "r795",
      "r821"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Domain]",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r237",
      "r303",
      "r304",
      "r458",
      "r481",
      "r482",
      "r483",
      "r484",
      "r499",
      "r511",
      "r512",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MoonLake AG Restricted Founder Shares",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r128",
      "r563",
      "r590",
      "r595",
      "r605",
      "r636",
      "r743"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r209",
      "r210",
      "r211",
      "r213",
      "r221",
      "r223",
      "r302",
      "r305",
      "r433",
      "r434",
      "r435",
      "r457",
      "r458",
      "r473",
      "r475",
      "r476",
      "r478",
      "r482",
      "r586",
      "r588",
      "r609",
      "r974"
     ]
    },
    "mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue remaining performance obligation additional variable consideration amount",
        "label": "Revenue Remaining Performance Obligation Additional Variable Consideration Amount",
        "documentation": "Revenue Remaining Performance Obligation Additional Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration amount",
        "label": "Revenue Remaining Performance Obligation Variable Consideration Amount",
        "documentation": "Revenue Remaining Performance Obligation Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ReverseRecapitalizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ReverseRecapitalizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization [Abstract]",
        "documentation": "Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ReverseRecapitalizationAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ReverseRecapitalizationAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails": {
       "parentTag": "mnlk_ReverseRecapitalizationTransactionCosts",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "of which accrued expenses",
        "label": "Reverse Recapitalization, Accrued Expenses",
        "documentation": "Reverse Recapitalization, Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails": {
       "parentTag": "mnlk_ReverseRecapitalizationTransactionCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "of which deferred IPO underwriting fee",
        "label": "Reverse Recapitalization, Deferred Initial Public Offering Underwriting Fees",
        "documentation": "Reverse Recapitalization, Deferred Initial Public Offering Underwriting Fees"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ReverseRecapitalizationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ReverseRecapitalizationDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination Agreement with Helix and Recapitalization",
        "label": "Reverse Recapitalization Disclosure [Text Block]",
        "documentation": "Reverse Recapitalization Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ReverseRecapitalizationNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ReverseRecapitalizationNet",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse recapitalization, net",
        "totalLabel": "Available Closing Date Cash",
        "label": "Reverse Recapitalization, Net",
        "documentation": "Reverse Recapitalization, Net"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ReverseRecapitalizationOtherTransactionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ReverseRecapitalizationOtherTransactionExpenses",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails": {
       "parentTag": "mnlk_ReverseRecapitalizationTransactionCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "of which other transaction expenses",
        "label": "Reverse Recapitalization, Other Transaction Expenses",
        "documentation": "Reverse Recapitalization, Other Transaction Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ReverseRecapitalizationTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ReverseRecapitalizationTransactionCosts",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails": {
       "parentTag": "mnlk_ReverseRecapitalizationNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationSummaryofNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Less Helix transaction expense",
        "label": "Reverse Recapitalization, Transaction Costs",
        "documentation": "Reverse Recapitalization, Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease assets obtained in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r742"
     ]
    },
    "mnlk_RiskAndLiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "RiskAndLiquidityDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/RisksandLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Liquidity",
        "label": "Risk And Liquidity Disclosure [Text Block]",
        "documentation": "Risk And Liquidity Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "mnlk_SaleOfStockAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SaleOfStockAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, authorized amount",
        "label": "Sale Of Stock, Authorized Amount",
        "documentation": "Sale Of Stock, Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate fees",
        "label": "Sale Of Stock, Consideration Received On Transaction, Satisfaction Of Fees Owed",
        "documentation": "Sale Of Stock, Consideration Received On Transaction, Satisfaction Of Fees Owed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_SaleOfStockOptionToPurchaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SaleOfStockOptionToPurchaseTerm",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, option to purchase, term",
        "label": "Sale of Stock, Option To Purchase, Term",
        "documentation": "Sale of Stock, Option To Purchase, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance price per share (USD per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SaleOfStockRemainingAuthorizedRepurchaseAmount",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, remaining authorized repurchase amount",
        "label": "Sale Of Stock, Remaining Authorized Repurchase Amount",
        "documentation": "Sale Of Stock, Remaining Authorized Repurchase Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_SaleOfStockStampDutyTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SaleOfStockStampDutyTax",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stamp duty tax",
        "label": "Sale Of Stock, Stamp Duty Tax",
        "documentation": "Sale Of Stock, Stamp Duty Tax"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported",
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r223",
      "r237",
      "r458",
      "r481",
      "r482",
      "r483",
      "r499",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r845",
      "r848",
      "r849",
      "r850",
      "r874",
      "r900",
      "r901",
      "r947",
      "r956",
      "r957"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r394",
      "r839",
      "r875"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued expenses and other current liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Assumptions",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsFVchangesDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282"
     ]
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r914"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)",
        "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/EmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of earnings per share, basic and diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Share Activity",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r111"
     ]
    },
    "mnlk_ScheduleOfReverseRecapitalizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ScheduleOfReverseRecapitalizationLineItems",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Reverse Recapitalization [Line Items]",
        "label": "Schedule Of Reverse Recapitalization [Line Items]",
        "documentation": "Schedule Of Reverse Recapitalization [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ScheduleOfReverseRecapitalizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ScheduleOfReverseRecapitalizationTable",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Reverse Recapitalization [Table]",
        "label": "Schedule Of Reverse Recapitalization [Table]",
        "documentation": "Schedule Of Reverse Recapitalization [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ScheduleOfReverseRecapitalizationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ScheduleOfReverseRecapitalizationTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Proceeds and Ordinary Shares Issued",
        "label": "Schedule Of Reverse Recapitalization [Table Text Block]",
        "documentation": "Schedule Of Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Option, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "mnlk_ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions [Table Text Block]",
        "documentation": "Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Authorized and Issued",
        "label": "Schedule Of Stock Authorized And Issued Roll Forward [Table Text Block]",
        "documentation": "Schedule Of Stock Authorized And Issued Roll Forward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r126",
      "r127",
      "r128",
      "r173",
      "r174",
      "r175",
      "r239",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r351",
      "r353",
      "r601",
      "r602",
      "r603",
      "r604",
      "r730",
      "r838",
      "r868"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r622",
      "r623",
      "r624",
      "r683",
      "r685",
      "r688",
      "r690",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r713",
      "r732",
      "r748",
      "r911",
      "r969"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicData"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information and Geographic Data",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r264",
      "r724"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Shares",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r910"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders of MoonLake AG (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Founder Resignation Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Founder Resignation Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value per share of Restricted Founder Shares on the grant date (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards outstanding, beginning balance (in shares)",
        "periodEndLabel": "Awards outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Awards vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fully diluted shares (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Denominator, Fully Diluted Shares",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Denominator, Fully Diluted Shares"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise",
     "crdr": "debit",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Numerator, Enterprise",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Estimated Grant Date Fair Value Calculation, Numerator, Enterprise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility of the share price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issuable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of vesting installments",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Vesting Installments",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Vesting Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Awards forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of the option on the grant date using Black-Scholes model (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards outstanding beginning balance (in shares)",
        "periodEndLabel": "Awards outstanding ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (in CHF per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails",
      "http://moonlaketx.com/role/SharebasedCompensationAwardedandGrantedDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationSharebasedCompensationExpenseByPlanDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Three",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Transaction",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r402",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r436",
      "r437",
      "r438",
      "r439"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Employee",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Nonemployee",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "mnlk_ShareBasedPaymentArrangementTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "ShareBasedPaymentArrangementTrancheFourMember",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Four",
        "label": "Share-Based Payment Arrangement, Tranche Four [Member]",
        "documentation": "Share-Based Payment Arrangement, Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_SharePriceNominalValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SharePriceNominalValue",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal value (CHF per share)",
        "label": "Share Price, Nominal Value",
        "documentation": "Share Price, Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term of the award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "mnlk_SharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SharesAuthorized",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Authorized, beginning balance (in shares)",
        "periodEndLabel": "Authorized, ending balance (in shares)",
        "label": "Shares, Authorized",
        "documentation": "Shares, Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Shares issued, beginning balance (in shares)",
        "periodEndLabel": "Shares issued, ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "mnlk_SonelokimabProgramSLKProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SonelokimabProgramSLKProgramMember",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SLK Program",
        "label": "Sonelokimab Program (\"SLK Program\") [Member]",
        "documentation": "Sonelokimab Program (\"SLK Program\")"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/Cover",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r173",
      "r174",
      "r175",
      "r204",
      "r228",
      "r229",
      "r231",
      "r233",
      "r239",
      "r240",
      "r301",
      "r325",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r339",
      "r340",
      "r343",
      "r346",
      "r353",
      "r489",
      "r601",
      "r602",
      "r603",
      "r604",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r621",
      "r635",
      "r659",
      "r677",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r838",
      "r868",
      "r876"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r166",
      "r189",
      "r190",
      "r191",
      "r209",
      "r210",
      "r211",
      "r213",
      "r221",
      "r223",
      "r238",
      "r302",
      "r305",
      "r354",
      "r433",
      "r434",
      "r435",
      "r457",
      "r458",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r482",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r512",
      "r586",
      "r587",
      "r588",
      "r609",
      "r677"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://moonlaketx.com/role/SegmentInformationandGeographicDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r622",
      "r623",
      "r624",
      "r683",
      "r685",
      "r688",
      "r690",
      "r698",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r713",
      "r732",
      "r748",
      "r911",
      "r969"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r238",
      "r548",
      "r599",
      "r621",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r656",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r677",
      "r749"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r394",
      "r839",
      "r840",
      "r875"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r238",
      "r548",
      "r599",
      "r621",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r656",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r677",
      "r749"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r780",
      "r790",
      "r816"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_StockConvertedReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "StockConvertedReverseRecapitalization",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Helix Class C ordinary shares to ML parties (other than the BVF shareholders) (in shares)",
        "verboseLabel": "Stock converted (in shares)",
        "label": "Stock Converted, Reverse Recapitalization",
        "documentation": "Stock Converted, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_StockForfeitedReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "StockForfeitedReverseRecapitalization",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock forfeited (in shares)",
        "label": "Stock Forfeited, Reverse Recapitalization",
        "documentation": "Stock Forfeited, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation granted under the equity incentive plan ESPP, ESOP, reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r75"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A ordinary shares upon Business Combination (in shares)",
        "verboseLabel": "Plus issuance of helix class A ordinary shares to BVF shareholders (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion and transfer of shares between classes (in shares)",
        "verboseLabel": "Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r30",
      "r58",
      "r128",
      "r336"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Class A Ordinary Shares, net of transaction costs (in shares)",
        "terseLabel": "Preferred Shares purchased by a director following his appointment as chairman of the board of directors (in shares)",
        "netLabel": "Issuance of shares under the ATM facility (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r103",
      "r104",
      "r128",
      "r601",
      "r677",
      "r692"
     ]
    },
    "mnlk_StockIssuedDuringPeriodSharesReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total MoonLake class A ordinary Shares outstanding at closing (in shares)",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation granted under the equity incentive plan ESPP, ESOP, and reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r103",
      "r104",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A Ordinary Shares upon Business Combination",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A Ordinary Shares, net of transaction costs (Note 12)",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r103",
      "r104",
      "r128",
      "r609",
      "r677",
      "r692",
      "r755"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationOrdinarySharesIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less redemptions of class A ordinary shares of the class A ordinary shares issued by Helix prior to the closing date (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r103",
      "r104",
      "r128",
      "r604",
      "r677",
      "r694"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r107",
      "r108",
      "r122",
      "r637",
      "r655",
      "r678",
      "r679",
      "r743",
      "r756",
      "r869",
      "r899",
      "r948",
      "r974"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Equity, beginning balance",
        "periodEndLabel": "Equity, end balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r83",
      "r166",
      "r167",
      "r190",
      "r209",
      "r210",
      "r211",
      "r213",
      "r221",
      "r302",
      "r305",
      "r354",
      "r433",
      "r434",
      "r435",
      "r457",
      "r458",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r482",
      "r491",
      "r493",
      "r497",
      "r512",
      "r587",
      "r588",
      "r607",
      "r637",
      "r655",
      "r678",
      "r679",
      "r696",
      "r755",
      "r869",
      "r899",
      "r948",
      "r974"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 Equity (Deficit)",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r203",
      "r338",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r354",
      "r480",
      "r680",
      "r681",
      "r697"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r515"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r515"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r515"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r515"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r515"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r516"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://moonlaketx.com/role/BusinessCombinationAgreementwithHelixandRecapitalizationNarrativeDetails",
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails",
      "http://moonlaketx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_SupplyAndManufacturingExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SupplyAndManufacturingExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://moonlaketx.com/role/PrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply and manufacturing services",
        "label": "Supply And Manufacturing Expense, Noncurrent",
        "documentation": "Supply And Manufacturing Expense, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_SupplyAndManufacturingFeesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "SupplyAndManufacturingFeesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails": {
       "parentTag": "mnlk_TradeAndOtherPayablesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply and manufacturing fees payable",
        "label": "Supply And Manufacturing Fees Payable, Current",
        "documentation": "Supply And Manufacturing Fees Payable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "mnlk_TotalSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "TotalSharesRollForward",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitScheduleofStockAuthorizedandIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Number of Shares",
        "label": "Total Shares [Roll Forward]",
        "documentation": "Total Shares"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_TradeAndOtherPayablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "TradeAndOtherPayablesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://moonlaketx.com/role/TradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "totalLabel": "Total",
        "label": "Trade And Other Payables, Current",
        "documentation": "Trade And Other Payables, Current"
       }
      }
     },
     "auth_ref": []
    },
    "mnlk_TradeAndOtherPayablesCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "TradeAndOtherPayablesCurrentTableTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/TradeandOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of trade and other payables, current",
        "label": "Trade And Other Payables, Current [Table Text Block]",
        "documentation": "Trade And Other Payables, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of fair value changes of marketable securities",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://moonlaketx.com/role/FairValueMeasurementsDetails",
      "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r337",
      "r351",
      "r479",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r573",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock, Common",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Held in Treasury, beginning balance (in shares)",
        "negatedPeriodEndLabel": "Held in Treasury, ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "mnlk_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://moonlaketx.com/role/ShareholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting Agreement",
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "mnlk_UnrecognizedCommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://moonlaketx.com/20231231",
     "localname": "UnrecognizedCommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total commitments not yet recognized",
        "label": "Unrecognized Commitments And Contingencies",
        "documentation": "Unrecognized Commitments And Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r156",
      "r157",
      "r160",
      "r161"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://moonlaketx.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares, diluted (in shares)",
        "verboseLabel": "Total weighted average number of outstanding shares, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r233"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://moonlaketx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails",
      "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares, basic (in shares)",
        "verboseLabel": "Total weighted average number of outstanding shares, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r233"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481097/715-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "80",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "b",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "30",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.18)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0001821586-24-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001821586-24-000008-xbrl.zip
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MAT2G*V6;-%"%6JT*DZE9H4?(DVD%$2/XH!_5%HY/\LH5,(:;Q$[OVPX]/VJ
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M"\0Q;O(*9$ZA;')N+?HSB1*Z3,L/%+/W K$G"-,1]*]0L(&@*F5'P)51&-3
M.84Z S%MZEV>*$.E^)U_<8=UZAL-F@J*99%%K';XOX:TI#C'._FIM<;E')-(
MCD*<CR04:E>T\H9]C)2M;&M*Z>W8 .X$M(Y68B2YE'.$DW"G%>"B49<K,&[2
MS4''A,:#9>U^=C^CZC^28L!>)J2+';) !-R.,,A@")$S[P7RD"]AFQ).0(MA
M8Q&C5;(J5,7R?WQV#!@ >:-CPU,Z*L29-3/"8)3R_)8"@N\9CY9!>@,:+ET
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M&(Z8U*6:VHYLB7UC854@[6H$8CXVFZ^M0JK"(KJ>M1NM-"7DJOE<&5;:\$\
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M/O;6)\J=@V!H#NENI&G&U%\S$4;70]9G,/&EQN<[EQI3'A\]NQBY\!@505"
M8%B@]2NJSP^S??[IHR]?P)]H^%R\KX#],#PM?T<7+_S/LBF+K_X/4$L#!!0
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MQ?7$.YRHUSFCY+^+^W(-+H#7)WTN+83>3S=FDYWW90ZT"[<.^_WAQX+M_TW
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M)JAA$ 5NA,8K)MH(%A8"R.JB:("3X4)0@>;"YMZDQD^UT.C&K'$AWJ*SS7:
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M28,MHW,2CUYHD7NI#*ZKH=&&RF<M,LT?._E#FWCI]G&:(*Y)HV2H429NQ*5
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MW6LW23.6JTDJ:2%('O=(QD56' [@8!]@F V'F>S'PU$!H\.X/X+#\>7K_5[
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MNNK>WU6[(:I^ ))(H:LQ-)*8+1 N$JD*J:CA4I!X3Q2DH$ DE<DB%&RX-@>
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M721)F6;PH^*Y*$%/--O$1U^_VAL,>H=NNX]/][+CP@/AZ?3IB-LX)O[T#]\
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M]K[F)\?"C_\I@DQ^&IM_?H$WBM@=C+_*:QD4^8^YZ20<96E"=[07E2][[(?
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MI:>CO'Z5<IR.:21M-!^,I/S6IR&I=%Z ^7V#3Z,H_"I^R,[GIVJ/F"Q_$&4
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M __W:5N;345I-%H1$KH2MR?*!\O9G44ANK?V<6^WWMIIM4",WDD4]QQ$Q?@
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M T0GS0+#$.D;X[0]WA&7N@_%&" (:"7\P!4\"XH2:PXLB("'&4$17A[X\KK
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MFSQ-Y94CU%;)2$;5E_\^0*B$*J57X>@Q/2*._XU\(<B=TE1QA6ZN6*;Z3RK
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MJD^ILR&KC!,!AC[Y,.-Y8K/@XJ2:6=0!)U3 :>VKV'^<NI_!BTUW0!P&('_
M:XK*G]"#TK"?H>GW+QS0,;!3/.;P4B;2>,1^.7T[&K\4J-!5192=F*(Z3.NG
M&(T:E\S]24'9YH:=:R=75_5O%R=K[QK.)VI 1[INWDHM\0%7F.-M:<N\?;Q3
M)6YIW8LB/4FJ0EY1WOH40:7T+MZR]0K3/4XX[3U;QU49T^MK(SBS[]1+T\B
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M41]IJYEM"_^3.PR=]?;F+^]FGE>SRD;N8=9[2+A4,-#-Y##[&]._IDK>U'=
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M]<W,V[P5#0\]Y[W-<]Z-GDKMQ& #H';$LQ8 _ZO'U?^3.VW &N  3S2\)F:
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MW0&))%3I7%2C<*:K'&)(>5R;["MOZ_%^2 Y&C@EQ''%LM;%DIR+/-<+\&1Q
MDZK NCU0/4N,ZWD* ZK<4)/+G2&GV4Y,$WBRX%^H?.'7)=;[-I2AS'XHJSPM
MU;EL&1<)FK^MBM>-9AT>5G5U-2<6/O:84A/.L.N!C$,*\Q/-<VISEQJLVO98
M<1=4DLNY6=3QA9/7"" <BZ?L2QK?:Q[$^EY#O$3Z.%63*H0\<Z0(GG9S%%@(
M9DEXND7#]&*M6,T$.X#SKR%]F1^S_.Q130\]C*O&&3'P/U@8QR< 21[75.0
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M][1-#M8!,.@7PG6ZI-26Q-IP"5AI16G;<B D";^K$\;EA(K53)&G.M?P^55
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M7H>XV+'1J0XH';M*8M F #P>_OZKL\>H9T)<)GM["DXEM:L-H?HQM94J#7B
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MT:[4924XWV;"N* Q,XY'%8T4AB[>ARS'5?27[K8#?AB"^N(LKWEI[ZBHP7$
M&,>_C!L>X%\0P29N& 'IF6*P\>-!^1R 3")ER<AQPN(*^SC;X8Y1AOMP?3&<
M+P'!<Z='81SQ3K.&=,Z$/T)MY213M2GQT6IEKO+A=HM+<388GTP:68@O0!,4
M[4S1<@4QAOB[[=AF80REF5*T;(CXV//+Y204\=8#RF,E0BQR4L&$#=2O3@HX
M#M6RD^;6$']$E_@OP7J]WG7;L)ZEL$RGW"9Z %-KA/!,K/H\&6N!C<T'V,)T
MNBB^#(!S/$YBASS-V! @NEZ2-$=\?YHC[QL 8A1_CY9+2PJ%;<C$J(-)E3'[
M5B,O/IQQ+4,<E*!>%=?QT+CP4FF8L5#BQ0ZJ6]IOR92J8"&/<=_U6&N2&<_U
M;QR[!#/.R<XEHK*2JM!H7FA(:D+;,U?(0GDV2GEC/S*VF=((N4\>5.,62-J^
MT8@F8S=U=^"@>(A<?ZX;#\J#3O[A_82^!].I@B<;$,W ]. RYCS>B.M5!T*?
MX41L./?J%H@\2"[3A9/-&C/D4$JT7P/.+$[AZ4W(1"H-:-&-[F6,JM"%E)-,
ME[K*'+2RZ.-E*KZ"NY.8C[#4-2V=\:P4JLH; I8F@4QESK%% KXRTRR<>CB%
M)WFP_:2D&N'3)VG+YGYA>U9QAX SP-\M:$C#*T(3*0'"$R6CVA#S<N[Q6?]S
M/3OK+\E*?$,A]^.OTO;$[J.N,K80QKJDEEIY$#4=/Z1/&O(F8'&*PQ;#C_]&
MT'-NGIE+ZSWE2.A4?+J$9=:%I\\RQS7K&%54PJNEW0L3[MP<H="T(PCO5&*>
M<;A$_>W$P7OA"AN =08HA) E#N39%W5@;*Q;YQJ@43265#=54\7Q8VC4F91L
MW[@W92L2_=H*-I^-R,'7Z3L.2ME&6;*<8.)<JO%T7F(1.'JF-TY*"LI.HO)/
M,!4CK6>^*75I(';A1KHX*%6C9@E?$FZ9/B. 2#X7NN^J^*S+W=1(XT3*WHO8
M4^4%1B_H)'4DV.^"4 7.A3A@.&:'WSHC4X/RI0YU$FAP1^7SP1#QJIX]LYA.
MHY?G3Y\9T["+EFD!]!*4.VVRZ2=/'#*I'650]YK%^^37/["ORD$>Q>T162$%
M%]<H+! MF&US&3BD3\+17+6@_:2U,86YS=F]LD*6B*3HQ4KUU==C87'ZS"[I
MA-&_A&'+/+:LPB>C-GA_\^*>__1T..YNXQD_*U?)AJTG\6 ')WGC'P9<JBRW
MB8(.;(_.(9V*70AO>9CHB*6]00\!)D& T/ >^EOFL8M/?[?/H0\L^GQ7-ET9
M[U1(!]:K@,[J15!*V;B3K'GW3@_,K3B",VK$6<+%/:=M!W)L,1YGYY;Z<+R+
MM+# EJ,I%5J;VM[6Q1&DS4QG;]@FF9[G=3Q)V2,V+9E'?[$[???R_+G=R\CI
MA2:5UOO%18N.IXSIGK,ES/(I]V>7P.E?TCM=Q7<&7R6F')M [GMA"V&N#@$8
M@)@7DMN\,#;<@%*3$3ZQTZ.U93.^??+3B<A&_!UUGT?^3B<Q!0?T_(K47(C&
MO[&P&V,V= G?[:W[GAN5@1%Y)D#;T-%C1QQLCIS4\28K<<("(D3;FR"!R'C2
MS&RGF4TDM3.*LKJ$2%.8BZ9<M]Q91"KK=M0K>1&S5KI4C=$:QZ=<Y_]>>K$O
MMOD4>6D.Y[E?F9QGR0<D$WQ/RT3/X?&KZ4OKOQ'8YT*LB7SI0C.@[ ?P=T(Z
M3^W)56!96,XG1Y3RIY>4(3,W"N'RRC&^.^#0DL3 J0>6\)WQVN6F8@Y+ALK7
MCKEOGDWPQ+1>I'9<Q)$J%<8^81>W^P+R#FAF(]).VL47M')<FUKV1&0A"!\8
M#251 8+'WC5? ?[-/U#;%;YX%1)H:J;@ 7J7(^Q JX]/'AUA!T?8P6<]8$?8
MP><'._C4?DHBVDF(NHG3QI/(BVN *->=TO\.WU.J$TRKS@6?>I1"T'-L(&[J
M />C&I;FF\9G>:Z9K$GE.J%34:DS3P%<N(70 F1Y!9:_<,(1&0FF^=;GJ+"\
MDX)(US6+,E=48+$&@1*L6&17*T_A'17=VQXEI,X#H%WTD!''R[VY-YPR</R&
MR &9HP(<AB.8F<] Q. 3.U=]NZS879G6=CH8YY@G%%<Z,C+H7&CBZ! OQM8C
M9^]O1)"8J1$SSB5<&BM\ZX;R>T))S*=DO_NX3@GSTFM-(R7MI6KAF-/'.X 8
MKYB:-CY*J+L!DGFD\N9CN=N>=UTL@P/?N PP/_3C)_K(BL-@B=3:)4'?YXE/
M9T^YQ 9>Z<=/3NBJ2A"/OE)+BM"X6U,-^@60>L+"5"0%_L10#BC4IF4^$0RD
M0JF8N,Z1X9KE25<T(%5JXN']P6NA3G!T)I)(R![4GP"EH1^8>/609.\PD3U$
M!5C5?[+O04KM658 *U=0*9+C4%8<3QK' ]]I?B-EK*PIN!N=%8;AGIUM>1K1
M0=.31"\GSN,_*>---4G,G]FO);4V+C4S,KBP9D?<VJ.T,&J(9/#FG" NEB5%
MO:3\46Z55FMS5;3K@OF'>$&2$6.\%G^"H5WR.5(^N+G'%NQLZL0&KS$M"#D
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M)_YI3?+ABTD)%-DSG)#U..R7^TW#'B)>[Y4(MQO"=M+6($264-P"O[JJ2)H
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MQF6#53*WY.#*RGG#'7#EAE. I;HL]I2:9_N^C:](3$UF&N*P/F/!FKL.#/S
M@M@Y+:;B,@CO<KF^(& .+:X[/0H'W_GU-#T%<Z\P&+$1P^@&I_6#PUA3,_V#
MEJ%) F0'7;L)RBOCVC"5@>IT]AKJ8GII_C;3M O3T%RXR>=**#?7 PFJ2["Q
M8THT1W1_#8I4E"_&L& ME4@!:JXU0E\;]#9HJESOM,9*@]9)$:"XS(O\37L9
MXYA_^B0W@@LU"]G \SC4NWEBA-'7FWR=T]E3\SI3"E?)EA O74NKNE:81I*
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MM<0V<0KX^H[('S(B&:B!4&*%,!_DQBV8$$WPQCL^^3S6N@OA+?9"=E9RO_&
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M("C+*"NC&,/O:>T/BP%=OUX+/^O$^VN(K*;S%]#Y49M&<J7IB.L"9/S@:IT
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M4?T[!#IQY<"7<'P^Q=">U4X%&FO8(*R;FO.S"33#OJ/G$J+?]%4<*W2C&-*
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MG'3#'I^=SEY1[]7W!6K[OX]K_=EDOO[?='@3-0\UHN_2$0ZT.D3OEN /O-#
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MA*J=T%$1(=/SFB.K!3A:W\^0W.#:5?F6X2<P*2EXHYU?(<M7F?PP769'UTF
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MA<"I6@9<JA*!6!Y=;W%QHFI,W==QVF@=9[+4UI6$JR!?+12A6XEQ6-43D/%
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MYB)[C=QD*M;YTMD$!G$: S"?-1<4/-#%)K)B@BSJPN17A]2^^GTB-6?-80;
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M;)AP:Y47A/EK0CC;3B'0I('94:Z8@D\RT RFH0&2"[O/#EM'P1>W\Q<>X2@
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M\)MW$>/,,?"!$#BL/AO8J[RCHTCL1U)7L86:'8Y03P@-0VA\?D)HG! :]WK
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MEF3]#=]TX,>;V@,>0@KX[H@!9JMM]QG7!*J-JT=-P>QU%6H=#="/'G4GEO#
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MPD!/QK+4#%;^H_90R-Y10>O$>\5D/!4U.ET._#SA$=X2J.I%!,A=YE=R&$%
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MQY\KULWZW.,W@RL<=E AB T".[,;>K&JRG61H!S3AS?Y9CM;*$!T;T3+(NW
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M6WCI7$\L;A+0 UXYLD@;B*E)PQCIU"*400HZ7?$G-(D6E3_[^(0F.:%)[O6
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MT4(1HD-^"7I$I7QT?D^PPQ3!RUEVU!$:!'RI!W20>'+0=6_GC<2"F1F-S%&
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MYH"8 -BMN/.<4$.4_FI"V%HX_O'T22C</M#@>H2:'E\SOCX_][-G:\J&7:Y
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MT&-O9S6%4C#&CB-#/ XW##L(?PQ^90=O"L+4^0'(S)N/K+6N(W1[Q$5/+>S
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ML],3UB%DGBI"YIKAM@^.XYY] 0JNM.#UD<*!C(JNG(XFCN>)9Z6P'I'8SDS
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MR"Y!:WZAJ4LJ4/7XLG 3A+4S2'S1F+#AYJ5<9#65,,58^/AB*O6)8.U71;?
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MX30E2/ BF[J>CS%6(J"J=I7-^9FI[ ] ;<2$'GYLUMC60P&;!<.34:WF2;>
M[("(S1,LUN :CM-QLDJ_!7_V_JL7!K^:9!Y7"]QJG^&^66RWKJXY7^[M26I/
M9<Y1(2.*L 0]S ^FW<&V]'F<)+AL[]Y]#)[]I/_\Z;D%*0_V^T?PJCW_1%B0
M,D=EN:N@S6_Q1[4H1OD5''%;Q8][#U4X\ZL0[8!M"D!I,>S01-8E?UTO< ]A
M,2-XW7%,P$%'DXM")+!'$4V6.>QG>L\9+ SR%R#P>E5[HO#WS/*H1@2]R."Y
M5 ?#BUQG<$729L$8XFOX430S6+<SHUE,JP5"M[%?@BW<)M&'HE&(2/P'+;(T
MFR2-9S8;\+E'P3 FR.8 0P6U'Y]'"2Z3#-MH)^CT#"&-8+,)D1'F"$QJB+M+
MQ"E^$K%%@FE)DT=F!5A9J=^;+:H!HZ-D7($124M GD2&'$S6G(6MCWLQ %$1
MD[6BM>YXK=14L3%,"\,V88Z563+.1Q&DWZ@KG6:2$Q:0K&CH-U5HEXI7-HAI
M=T1@<2_/P+WAWX#X87829A8F$4X<4VMJ2GRE>9Y52TZ7R,NU+*T0+@NI6T!N
M.Z=S0UC&*1Y=_'5!C% 5X?@C*ZE^_UQ33<LBR[%G*!Q3< QRNDTO_5B<UB5:
M88C+Q?8.]";):U+WS.-:^49>)^BVZ2K)O#?\%'W[O#S]R1]#47OS!WTS>U ;
MOE>94!8L.DE8+4VV1!KI+$^F%_%4*@$O_/H%:?$8D4%#23DB63@GP0='F4T/
M]@W72Q]PCYR1[\5. ,D!],<L?QOER";63V=_M"RT%H?]'TO6YB0<W([2#_8S
M4L?69 [U2%\@CP[N<7;&T)5LG'\D? VU,(,HWXQ9BEBQ D=,!?*]:K8;?RP2
M6I&7CA]*WXDT9&PBFHJV2D)<&P3YMN0JM07"X2C/$BVQBDOJPLN2$E>)=Q)M
M?3T5&[;5XY1$_0'S7KZ/5AA@'5#) ,\E>?C!1\P%!H,Q6X!D#[.(4EN.]0N8
M@1@ ,GMEMD>GU 2_?PZ>X1*_?_OI5.Y^]KZ_?W*P]_OG/; LGC^W15;_ITH-
MQ7?I]=@ZLB)EQ9D;ZKFXW,-Q6]]6G%WD:<O)E.7R6702:*-3_=+*,O3AN'_W
M)=-G3S*]5"/WDUK!5E;%GU]^LN+JZ(!JV+Q2K(WC'8Q@QLW7]7$79QQQHR/)
M72@=8:<[^S2G.-&)$--S8W@5$QP@@HFC 1X=./L]C^I1-#7@*=X!QCWZ4K:,
MX6JK2!_ML"N$6ZE]-9UCV_9>'Z_!0UB"O6RV)_N(:7(B";A8XFBBK'Z395QQ
M_RJOYL&I5P8&LD"7Y,TK7R>X F$[]3,0J>,(7"9;7]S^RM>]OWK!ZPHK3^'$
MO4?61BQL"4Z1 -$9UJ_?>^^CF\<PL]H8"T6$F(\5K&&\$',;=I?V_!"N@PRM
M72H6C&"?<IVD>K]X#<_/$*^=Y]'".VBR J_,Q"QDWUUZ3-=6-N).%*!1^5">
M?OKM0_U0?OQ\VCB5?^).NVRGW\3)/%V W,("G)?(JCNGK?/)-VRLE^.=QH-]
M5A84!.7R*![<YL,G%KWW[8IJB?.BU#9U>!GN\AXM 'IF5"^H+A2QBZY/-U@,
MWI2SAB_IN-/Z^+$,[Q#K +Q9"7A:_%81M(++))J8<699"7A:]=,(0K9$4$\J
M]<%+8_(]]  -CJ"@NDARA[A&RM.-R+TA;8UK1;K*I(AD<:;QR6 ;\ _Z+J0R
M,6P#$/&!*ECWXRGW+>';[8#50\6/34R)I95C] [4SRDS1 MY+I3.<4SV@25$
MEL=BX6>62P/FH_W]F]?:HCD/1[WC)P-'.-Q=8JO=R;EVJ?\N];\#L[JSJ?_V
M*,BO59QP,HPU89Z-83PN\$SD3XP-+:6-2E0:L7\4[:KF,?7%X0B(>T CFO_N
MCX;=0&7\:#>H"=8(>K,-1EH-S2?X%UL'2B30\J3F$YPQIY$+YYUR1,995OK\
MIU[$^G>CJ&8I(4>:W(S8Q">8/V6.'[*HSR6(X@@9@B)*7.#%(JS=/L+'"5)9
MF@O(L_%&S9J[4*G>:.^I<TV 24_A&>[$I_<12)H1TKJ[/3>I%E-'! &FX"OF
M#Y6OD!ZZ_O9)#1'J9Y3XMIM(C>P+?U^7T5=3BSX3*<C:Y@>K,.4R_#B=5'5F
M9;PN+=2A9(@'MB+,B F+G!AE2,*O2V'OB+7(!"3DGWGO:$FN88B'<Q5+XDRI
M+V,2P:$X([NTQ(@9#]Q(2&MM1#3CLZ3";#DL5DM[*B:"R?A/7AM/^#A A$(N
M,#[6*DK$3Q/T![:EXKR\;@7/0>0]&B5/_DAS&8PZLEPPJ.I=&(&FP<^C@WYO
MH!%56XE C@K^!>L&.,<!N^)736#ZJ!RW+00T<]'"'6.^2;<K?&BX]F@.-V/O
MS#VBYEE0(1<EG%S'.(\;G;N[",G_SP?]?F]?/R&TU1)UH3&KI!>+&V_MO&FE
M!/T0/#)J'^E73> +$]JW)&'(:SU\\IOL W+E+TN)7-C=]?Y/D#1O%XLJS;Q(
M,BSA7VF\!)&<P4R_FT8A=RX[RY)DM8<-6K&MQ1C;M5!/'HP&@)A4@BZ!0&EC
MP03$!_Y0D[,.Y91$%[3W+2%2Z7IC-/B.ZKUU.)!$_$DQ49T([JZ=B\GK'4LQ
M^:Q!,QY[W[\EM79KY".[ACO]9-!Z!XEDI_ ^<*(']]DU\Y8#NV]>G?Y@F/;]
MZ3W&79^.,&T_(%([]@'3C-<DW]HIC7 *(CH)#D(7/+?Q1MIEOZK ?9DMQG$J
M*0<$Y9@9$CPQ@O*Y!ETCHF?]N3\<]8ZLI9(RVQ\U@)/DJP8G5:]3>%52;:"3
MO+07I3V\"/^P/D;#ZY#I.M0'4H=DS/.,FZ%.""T'0_JY?^ LJA LK,-]WSS!
M=_\\['N?DA/^@\$T3^(07!--?PI6X9G9D^I^/1V[^G&7'0[8D&R+]WU;G,):
M%(\@--5G](N#4\M025DD!1S*CFY>9',U)+_?&9REK]3J!1O?!^_>O0R>(;3?
MY""[&9^"F*'_^M4O5H6KGML$4/,9+C6G/?^L(\SP:08>,'8$-%"U)/M\L+^/
MY*%$(+J]QK[].T^_O)??KP]@[3,1U4_S$LTM:J[E21((*C(8M3,<-TVM*ZBV
MK8;I4SF!2@_QFT1SPV23S 1C)TE56VU@\?*?]X;!LS?8!OW/K!<,A\.]P5'_
M8'1HV],14M%,$DI,<8M$5.=24DP-@%G$G82>:"/L(\F4BHU:H?@C*(PT7F_V
M$>;'Z)Z\)[_F_DXE*@<^EH,CG4IJYYVF4C)AITL%4(O&"KE-$#@:HND6T;=X
M42'7[!P+3$ICE8KXL)<="*\VH6737;YSZ0#NTQUI%F!?+Y-[H5PZIIO>?86G
M5RDQ4F*?*=S%D8L-MVY #:()L-'.@' L6 O2'<[[TH?W:#Q5<PS)#Z^A'=H%
MOB]+Y:';U,8UA?KPX+N$NC^0-;G.\+E:0=MVJ>P]N/&[[U45[>-KUQ9;)O4N
M%<9H<'Q-A>$B-LX&^7Z]T=BP3ZO:X(U0O%"$FSG<K6/ACK#73907OQ_N'^V'
MQ_WC+8*?=RU-=&-ODV/=XGB,#GLGZE5<RD/ZI" 51QVDHH-4=)"*!S&K/PBI
M>,#*Y',U+LP_*S';U_2(5!>(7LA<,)F=OQ&:;*1=G!E^TA^%QX,6+5.L:YDM
MYLPFA7,P[ U=9,LA"0E%V+C^2G83F98@5O<O5V,/= -<,_;UD>"CSN>$6=]D
M,>SJ%W^/Z[WF\T@Q_T7.);W1);X/!KOPM/Q6S<&VAS<N&D&N0,IS<R,P7K)]
M+&C9O@P?EG*Q'AK!,<%T&Q[1L76$-G*8EFA;\U+: , RQ_8M=(SV>W S-GVE
M8UESF'3E78%4L['/'#E_)=Y0&S=,&E<U<2)&>M90RYK]8 J6#94E"@&=^'7U
MX'8_'%S^982H;OTVB@W4AJ7T)^CX*QQZL8B))J3N*'Z@D3<*TK#.D7]!CH[Y
MAL 5Z6F-95;JY_C3\+1"65_\ !5V:&# !N4^AON^LX<)%"N<+9N%WNL7HZU?
MI1._;=[U*/%ZA0Q!_WDT/'29#Q@(VMG@L&)J7C'H5]PL2JMB]YR%<PC*WX67
M?AYX>NK)0S;>6"(B:=^(62^O!-MM >R[M50<*!%Y8FT%&"E(GX* ,4K_NCMK
M6PKN>9]EZ3O$Q9W^)H6N<FHGE45SE!<9Z$2SU/KD7X)G_>>4&)\0^$9IBQ92
M$#T8A$<'AVJ_P(N]E]#^H+A)-OD:G)F$! /6>155OK+&3B1BUHH^X0>"U:K7
MW ?$A(357';,=);@!_L2< ^>_3P\=EXW5[@^&SSWI2A"CZ0$@SJ-Q^-*)M4;
MNZ7@<I2MTL;+#9M@4_815&]ZA:'V]^U0!T<'=J0[=PY^D+%F^, 8:]J2X(^R
MZ'4;*B M*JS]E5/N%2@Y6(Q%9TT\L( ?/.44"=-]M4,+O+#LE%ZF1:4C&DR_
M9GAL?X(S2,8,\@(M U+I=Y/$WX)3%%D<&X.[\V7/E;;B[]V]]MRO0^1 %!#Q
MR$6,@#029 J (Y3$Z5>LR)H;M#P+$%^S\KG/Y&&#LQZL5W^M8OHE3!P+[697
M2\])$R#SR]]?[XV&P][^R;!W,#QTK#=UR:61=N.0G@RB\%C6?4'MN,D4JDT-
M=1%TN22:#BF&V[X8U@;8^B[:'U8J8N4[776U-SR;8)&D@#-J"8?W[\C=B/VL
M-&\#)-@GV CX&;B6+Z,5G)_@;8%37%C<HC;#]AB:Y'.HNI@[[](3;>>TAKNB
M"^J&$CPC&]E#Q3#A'G;WUG[%EW]U&&S\ZK8;G6ORL78L+W^-OTRP6^>Z@;DD
M%AXBGT\_]"\6[PW4^GE\3J:N3*'8?JTOIK:M;''.^2Y.D% B%*>M[:[Z(,=F
M$B$F#_,U%J@J( .W"-(;69:,:&R8O28M9GR\XKSV6&G4XI)-?L( /LE\0ZJ)
M.0/VX30>#H\/3XZWBI&K).->ZV,_X:?6/,RVQ+<5UY[)USYE*-OIR0RY1@>:
MG8=-<M*WA=8_YEI)X >F&+]LVJU4"CTAYT<*;H0 DCL[PAYC0U'*5GK!7R*[
MP<Q>F/*,/7UY IGS//GX7*(^8 O<VPYJ<6LVUA&V^?R@N5'0I^LU?#J94+^$
MN4J+C5_4>+.K 6A*;8RQ$,4);UMMI8 N!M')%;YTG/!0A7,K6IL<Z=8,OTNS
M8)YE4ZH10 DK!6+@T,SCL5+5L9_"74',M.?QVG(+^JWB+<JU_WS]B[9LXJ>8
MD3N^"<[UH\,'P+G>I?%V?,*Z--X.IO'N&GOOZ,T]:?\=K+(W$\PX>6#!C$]<
MJ/O8DG7;+3>O./X[:I[?,FC.+RC3PE8T=JA4-Z]5!#D2>/0)6DI>0S1I4O@Z
MX;1UX4%;XA/G4_"P<ZZGE'[E:^76]>Y3ZX.GHN@8_E)BA;1TBH)/^CV[0.M4
M&ZVU-/DFNR]CELL+:6QE7T\^F(R! 71@ZR5W4\A[SQW CP</[,!_L%6TKR7M
M\J!=M&MFY3_Y):%>/>-=3L;N",)/FPID;48.(P=Q40KQ%HR "LVS@HBEJ)"<
M/5SN:*=/L^6U=39>$&%[*,(L=3=6-]:9 =ASXO+P=AH$2\Q -'Z;/H"'&+E1
M*LQ6.B/\LG&]EIC_2>=[B9F5O^#:7"9,]OK'][: Y/ ?OKB_WKXO:M/5'_6H
M2!>#EMG*F+UF89^_'T AP8["GXVSM*)?CD&AS.(2^WQ@\&"/>=<Q1 !W2SS
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M+1?RFTO#I5-CL\K(<LT*9W*Z[K7B4:$W,=,F%'E,K5!\S4M#)4UOTCQ+$NV
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M=FJU@Y4MZ/M)2R_09PXQB/23;;",9804/DR++(FY(@)45>G ;E9WDB&/';5
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M.,M^[?D$BZC^#J(=#.S^='LD#DMZQ?C?C<L6-GM%N8UEA+8[+TQ,9ECD,+%
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M ."F$P0>N.:1R;4*]K+!&(A@M-)T'L8N)K[/2EMGW#4 MB6XUAG[MB.I+ W
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M=HCVW]5[_\5R0=@Z?8#Y"8[E5'7K3&U\LCY3'U,U/@T^L]]E'*IN#;QQ2/7
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MCH&N&*!Z=T8Z=A\#TO=\.J;I*QW6@.^"V[%*<R_2BT^&?ZO]*8--8BJU\VB
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ME^W0?B$NP3P8ZDEK,+)=.PA]FK$Z+E6YZ5$FI*\\L8Z=JQ+.%2!]G1F>V%0
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MW2SUQIRC/.(U+E9!9XR+Y=JJW-2W&VA05I"HRKL$>05YJ_NNTXJ'H]LD]0@
M;3055 JM]Q.TMT0\-&<D9NIV[V.&AMZNG3=TN=UJR$UM<>B*B*%7(VBS7Z9I
MX,K;AMPPV[+96AQFL(/X3CZ7H*SHN)]H]D;Q';/>V&%X9[]1W%,M#;Z)[8PH
M_7ZZ]D;IE</.*YT8-SQ9[SR_^IVX9)A_(4!#K9VW&[+>6ARP59I%$$=[P*O#
M.T6=,"Y(-V7=7)>S.ZT<^AT)CS![7F"BM&3%ZKL;_)2%&(E=&V6I9=^?R_K@
M>X [FV2*&SJXGPU9:;9E=6VFN !K4["_8/_BO>\M^+]!/6E#,64E91GO#BN*
M]3(H8'K!3%-_6/YZ*+V]V/V7KYB[ILI9LA+A#2GTI-29^3.[1HY+G^\NGG;X
M0<:;LLDN5!Q8@YO70S4,:F$K2E/6S#VT' JFV!/P;\<5)NZ_D=M-7=8:ZT+O
MA?I>1XK][I*5*:<._^GU,*<BRAM(\DYR)LW:>0L<'55N&7MP= 1C[ 3C=\(9
MK=JY"CZ KLFME)4Q6;)I;5$LO=W3'V4U]*F7.V,$=^+Z!.[DWV0@/5NV*P$H
MC"S_)^$C34E_XD\W900OGA^>@12/P'AX!5&FD[&%Q5"Q'$O!1=)+-LAV7BW;
M02ZZ]OPN0'HWYJ7.X%\3QCN;;IEML!7#NB*KZR;<BZ+J0Q15'X G#-P\W%;D
MIK%F5:JH8ZU.'6OYE6BG'TXL'W=%\#+63^A[?T9%2D9CQ_L@1.JQQ+,$=')/
M45V>4DE"QB;2)2!Y"7SBD@&O5'A ?@$\_!T^C-6*8*7] D8:15+?#H"6EP"?
M[O,#/)<WV!@X50!.W92-9LGJ6RO*+WO0I0=A$QSN8[;E5GL[_7ID93"L9[2?
M/".N"4X0Z(]DFL AW::-Q1/W9LOMMBX;VIHVQ')6)1\S-VSN,6W,#E@X82JR
MV5BS0_VTVLYFJ'Q*Y8LY%S4?<?'6YBNKCZER*YN;D@)*$2#MHX_*,-CXWI8A
M&^UU?50%."=">H3T%)D:/;3XX)@I76XU#+FA9&Q#/-T"FD730!1/;F;EIVR
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M;/R:_#Z 25//#:TAZ\;B<'#!'F4(TF_$&]1GW(HUZ![-5F/K>J<=<(48,"$
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M?C:E=JV""%ZCH+9I$?:&W.VOF,V;,<9U$?]^4\C[G5QW)(4BBV%^7D^UUDB
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MU%B1ZWAQJ\9\JQR@!,].N9%DA5!"(.$FG6*3Q,,-S^>E%I21E$E9X*O*5 Z
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MZVNQURR:%\C?-5Y[0Z8\GXX%^X.'HZCVP#84494-_/C)^"Q=V,X$08J L:@
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M>VIOVT,RFZ]WYS2^&SXJX;10E(/R47LI'QW1:;$#'CYV[BQ#RZD'Y<[.R=E
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M-Q>)SLE9J]N3![UTP61M[[X#/EJKRZ,$/L*95<V!W%>KPD<?S)Z]8<^:N=R
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M4!W3.N&YBUO==]D12!6-4$I:6^+RME4EC:7KY-FL&/FG,3C584DR#RV19LW
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MD,B8.HVQ.9(EG45I:Z817B&==L9*&<<K+$C35Q[6!;A,SM(QK14C:%>K!BL
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M>*6)L))9S>2J86Q_,"8T,PT[2TEI#F*U[XTL&,'\95 I@G42D:):5M]K!Z7
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M*X_2&2=^_^.?-__ ^(6^G,*O>XRY!(Z!5<%1F@;A%NJ*\0;-,S'6H/PX>==
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M13JW3A,305H[H?!_Q^9T!?_W[LSUR_\'4$L#!!0    ( *Q 75CWCN2JO!4
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M[<FMQ:;Z\WU[H8IOP4T<%#2O\#3G614S-L_TCJ9!7YPCQ\XPF#C4&DSA(0R
MY,G2PE*8_3"O;'A!PA[=H2P31D/9IS !4<HC,&;VUK4+.1T+?=EU1+QLI5 ^
MG\H.BJWT^)51,OVJ6GLJ^_#_'IN1$:S7'N_@$76>L?(@2SY)%3($:>=Q[5J*
M@09K>L\+F.((JQF32H"9<"(?/9_PEN]CL8&-/45QEIKP,#ZH0=@3M@Y+'(U;
MW9 E?E)/_)Z,:U&'2LU^]^EJ49F*-(]88X@M[DJ^]_R'5=:G[X*9Z[&_@_,6
MA0YR%7-HL0><+OKABK2[OOY)*'AO>7YU=8[58P_$#YC;FGC/1*S5E@QNB4>%
M)Z/W):&JQ0L9MU2LC_9\%[&NN%C1G46-UH<\-M]RD-".@4KW)*\2$32EYRUM
M[=)^>T2]A]EG^]=/2_%>P41& DIZ[_G%2=&)"E7B4Y]!5=VW../6]J*LB/K.
ME&33M]Z@Y$8)"[Q%[F4ALJ.14\IH?MC9IYOOV6EQ$3OD8-IWITZQ-[1?(958
MMHKVN>@A%PGW>^(/IHF$?*F-LYAA99VG1+@IS(*.O6$481*_FZP3ILJF.Y"?
M'!.5"5#*4H*HR-8IK-/5(:UH&'+;>;@39^47#MWTK0K]C23)819RFUATCAVM
MUXG3;[#!B*!XNP]^;A@>U[WL*I^R:GZBQOUK>:W?.N,Q])COA06HBE,9Z895
M"%.L"X[ 4VQCQI;1?7;K@%%'\LHMOM5G4(EA=X>7I@6IA23_)B"V7FENAE&;
M?#^NBDVA]SS:S$I.NVU_O>\6WG!6<!&0(9_*6C1%Z[[.@09]^DI,XT212MFJ
M*#7U6R<]LF]SB\>L/.T?]KCO_H-887!?7"9-;0J#QO"2.'VVE9T#\:U_K:]Z
MMP.NVU5B3.>=8E><X5&2O;6-U"$3?T2L@,DS?JUG3&5WP(836VK+LH*Y_'5F
M&P1RO@Y>?P6UB2U)ZWK>/8IX:WTEK_,P7=FT:*L:OM8+F9H43&CRJ4J11.')
MD1%AS^ ]<'EFW1+I:8.#IZ585C5*V\;S":/VC.@X7CF-JV"WEZY!CF//41&R
M*.['CE,<Q3N,L#<_BA*5P<8%&^NKW!3NN(JL"N-#ZVZV]2FJ@UW_IBFBJLM%
M1B7X=B1_3W%Q0[Z5-:3'GK@[*JP(4QM?>:W?VHX*N[0NERQ>&C<:_E'G8>0O
MWW P5^;XRT__ E!+ P04    " "L0%U8,][4$CHB   "2@$ %0   &UN;&LM
M,C R,S$R,S%?8V%L+GAM;.5]67-3RY+N^_D57.[KS4W-PXZS3X>9SB&"#02&
M[KY/BAJRL.Z6);<D,_2O[RS)-K+PH*&6O.!&$("%6.NKRJ]RJ,K*_/N_?3T=
M/?J,T]EP,O[C,?^-/7Z$XS3)P_&G/QY__/ 2W.-_^\??_O;W_P7PGT_?OW[T
M?)+.3W$\?_1LBF&.^=&7X?SDT?P$'_W'9/K7\'-X]&X4YF4R/07XQ^*_/9N<
M?9L./YW,'PDFU.77+O]U^KO0Q3JE#<0B$ZAL,SAC/,@0A%6&!6_8__GT>S*F
M&"$0E$,.BB?ZFD,'/EAD622)H2P>.AJ.__J]_A;##!_1\,:SQ8]_/#Z9S\]^
M?_+DRY<OOWV-T]%OD^FG)X(Q^>3RVX\OOO[UA^]_D8MO<^_]D\6_7GUU-KSI
MB_18_N0__WQ]G$[P-,!P/)N'<:HOF U_GRT^?#U)8;Z8]7MQ/;KU&_4GN/P:
MU(^ "Y#\MZ^S_/@??WOT:#D=T\D(WV-Y5/_\^/[5U2M/)Y/Q*/R%\Z^_I<GI
MD_K/3YZ]?7/\]O6KYT<?7CQ_>O3ZZ,VS%\?_>O'BPS&!7SQL_NT,_W@\&YZ>
MC?#RLY,IEC\>GXY'?Q$((;E80OC?MS_LR7=T*8S2^6@Q&:_IYXM'5C M@.+7
M.8XS+J?C\I6C2;KVI5$5QF1Z^3]'(>)H\>G@? :?0C@;O!Z&.!P-YT.<#4HP
M(B6%P! M*"$18N(,DLZ66ZL#$_'ZS-1AS&@<"^F5,(L+$5X\^TF=LB<XFL\N
M/UE,XF(";WC]<NJ:C.39^71*BWD@4O2*.P<A$8-4HJ7D)/TM1"F,-AF3]=T-
MZ +%]7&MD.)HFAY-IAFGI* >/_J"59E<Z*HEI#!-U]CRXSJY^,:3V?GIZ>*9
M,)SCZ>7_+]/):1MISR=-YWHI4@+?4.9O)N-T 85T;2I6*. ^D.K5I#J<IN$%
MG3QR%E.(MCNQ?P>RB>3%SROY'6>\"^$?C?/Q?)+^.IF,:%9G+_[K?#C_-D!6
M$+%4Z^L=*"P<8LP).%JRL3$ZR;$['MR(J>&8!S([[9GT8$LB_P$M#4\Z#<P%
M+Z4NC'MV*'7=&[6V/Q/N8/Q64]Z,Y\\FIZ?#>?5.Z^B>3<9S\F+)FUTL9>N2
MI-4,.C$:F/<9O+8,6&9<19$LN9&-.7 'G)XJO/:<:"629ASY<7ROQFET7N.=
M=Y/I0@3S^708S^<ACO##I.IN0DTS2D_\]&H\QRG.Y@-OE$'F.0CR=$%9ZTF/
M)[+DP6CI! 4E*C>F4QODFS!/_@K,>P!!]XVDV;AD% ] ;HPF3Y-'"%QS0!1!
MB!A<U.XG(&F+^1L((SAW2H%BDERYD!D$E@U$BNA=D)%G+SJ?BSZY @_ L?N7
MZ%9B:K;<_AR.)]/%!%P,2B160@@:+.D8TCLQ0G210S&*#)3(4H?6<=$ZACYY
M"#V@REXB:D:4H]D,Y[.!(;7/*8 C3P6)J>@MQ(P%A+-H;#$F<MV8'LLWM\&_
M$HX2=I,<F57N/5E9$P-X+BR4+)QS,0<:9R<CV2[V/Y1.W$&^ZT3=:XH;$_5R
MQZE(PS0:#EZPZDLQ1>Y+CN CD\E[P[(RG4AYBXV]0^FR9B+>97([WLXK&4U4
M*8-$7\AX!@[.< 1=4$B7%$NYPVWIVY;T]J-[CF4XQOP4Q_27^3L<U\.I=Z,P
MOGG8QBK-@I)@K#.@!$/R&0KY#-8I84U))K7>O-X.89]4W/[,65\.'4JKV7IY
M>X;34+<>7F.8X26P;RNP;):II"C *$&PM-$08E' 5&'*91M1M-XCO!=4G_1F
M>]ZTE4ECT[F"(G"EF"T>4*L,B@M!7#4(10J+.4H>DCJHC[0O_=]7NKPM'V>X
M>,\@%')0G-/@-=( I2%7.C)&L#@Z&WW2)71*_35 ?5*7>['A;L;O(X9F;'\W
MG1"H^;>JK^='XUS#N[.Z7?N&$ E4-I6<P&9&B&Q4$ LR*!IC,#01'%L;UKOP
M]$D=-N5%,R$TI 6>A6%^\?6,S#FN#E-X)ZUF8*0@OSEJ3RI9"9"!='7R3&59
MFE/B9BQ]VLEN3(<&D]]1*,F35,;8"*X4!*52 F]Y'6$@)F9A=6RM$NX()7<8
MS><P'-5=JI>3Z7$8X3'2Y"Z\FN<8Y]]_NARO5Y%G$AB-ET5:?86!SYR<5Y50
MYQ2+2ZVWT+>$V#]KN0M7?HBQ.Y13NZAB?H+3]YAP^+E"G9&ZOMH5"#QYBF8@
M,D\CUD&"L]P1,H\^*E2:MW8:;T?3/\/9@B*-9K\CFWD))19FM6(.I%,6E"%#
M$)!)0%F*49@*UZUW6&\$TC]KV8(#^\]YN^23,#NI*0[T1_7?/I/2JDD/\V=A
M.OU&/O^_A]$Y#K*Q4@I!J)CS!$U;@J81<K!&,RF\*JWMYT; -J&'^NGHT5XF
M7>S@7HXT"^.]B!J0G#E0-%[27UQ!8JQHK9Q$VSH.OR\)=P<'*Z7I.>;KJ1T+
M57TML1+1('-A>1ZB(I(G:^@WFUS*O$B9FB^#C8#UR9G:DR$_>%3-!;/W6JC7
M!08?IB'C)91WX=O"EE\..$4KJLVFM1CJ#B %5#YC .<("1J;T*[MROYX!>'>
MM_3)/6HD]+8SV_4V_)7;9ICU3DO2\BA >6<AII!!1XIWHW12B^9.\YV(^N0T
M-58'#4718=K;0#@?I2'?+3,L9/.C!(\TQ)C(,+-B2E#IP&E;N^4E3\:+YRX]
M#J]MX)D"DN"])BU+JC9&6T]1LD*KK5"R]:[".H8^6;H]Y7Y3SO'.T]V,S.]Q
M'NJYZ(LP'=,RFY']/3^M<XRYGIBFX7P@C741C:/U&R,H2>LKH%!@M?3*&<N"
M;IU$?#^J/EG#QL1H+))V6ZPY#^MLA-$["F9?C9^%L^$\C 99*IHVP2GTD8YL
M-&GZ6*(!5"&@YR4+U=Q+OAE*GPQA8U*TF/QV3/C.R(771JKL;(HG-:?B,[X:
MI\DIOI[,ZE;7V_(A?!U(C=FA9^ EZKJ]10Z<]Z8F14H?(GERMOGV]'80^[2Q
MT)HY'0IKC5%_?[(^?:_IY_WO=Q]_H-__?/'FP_';EV_?O7A_].$5_>O1F^?/
MWO[Y[OV+?[UX<_SJWU^\?GN\]^7O+=[4]F;XKD-L=&U\(V8(F3$I:X!%BL.4
M-A%\\!),8(E<_.)L\V6\_=IM._;;#WB.\O\[G\TOCK^7\Y,$DTY;#Y)G2ZN4
M4:"3'0/-G#3"",]E)Z<I#;#WR<]NSL4;CV0.+?"VQWDWH%]+<!R%<9VMC^-P
M6B\__#?F?Y)7N1CB=#@CO_(YC6O\Z1U.AY/\?43*E(*&/$F,'!3+Y%B(I,%)
M(8+FI5C=/+^PP_'T*4IX,%H?G!C-J$YO_SY'M-J<3"8C:%'S2DH)X)G)H+D*
M/)24LVE]\' -0(,D-IK_Q5"**K*6T0"9-,5O0@GRYXH&(8J+(F#"YKF,W]_>
M)UV_NX1OR$[;97:[X>I&%\UT=H4S'4#'8D"%PB!D1RZWM\HIJ8/7K3<-MP:Y
MI0*%GX0LW0JK&:>^8]SQ)B,WLMA [HE!TMGT6W!(%L4)0LN"QB(;$VP_Q$U<
M(WKTY/+48 EGH)S46GI!X;/-)#S,$#S+9,%*BAR1V^8%A&Z!TB?=>T!VW>BJ
M["FH]L=]*\K%\IA$/;.RK"[R'"T$,AU@K U&"<T):%=G?+=Y' _KOCXD6_84
M4*=,*;J8* I1-EE),6!!\-E8\%Y%XWDVSK6VXO<R98^17>2HD7GU7!L=.*"P
MY$1%[R$*"G"-#<F@*2';SL9U"6)+;=FM][&O\&]E]4Y3WK(:U7K >!7T87(^
M5Q@BD7>EE"P0+2KP,@IDN<C$6E<CN0-.AR/=2:4Q),D'K:!H<CN5#Q$<J1WP
MANN@3!#(#S@[7559.I0WTHJ'-QRS/YC4#[%(-RL/Y6LAR%2U$Z<)S#2!3C@$
M*Z0II*6X;.[.[ FY5X'G W"SN5C;.T%7=HN\+>:]2""R)QB8.?A ZX(IY9PM
M2@;?_%SH;E=A^U']$\?TQ-'1.!_ET^%X.)O7YW_&B^</<E3">R,@R!1K?K>"
MD**$8AR3&#%(T=H=N@=2GY3W?IQ87Q8M9=$P46J&])B:J/\</^-HLKCZ>@G)
M:J6"Y!)R+(M"HH'"D:R 82#/L-""#*UKU]P)J$^18UMRM)/#(:SS3BY&S-H9
M3FH=%[5':BZ&0XHJDK7<*8\NV)_*L>PH':&0F8W*)HB:,5#!%/":*\BD&C13
MR0C6R:Y>@U2B'CC5G3-SFU/WG63:LKK$Y=%1C)$;+0WHY&MAQR3 Y;KA;ZU#
M3#*6YK6IMCN8.Y32[A-S=I1/%_QPDBN=; %F%+TU9@<A2 ]*IL"<UA0%'HH?
MNQXGD00OK.5%1L @6NE2D@BI'I4JQ6A2':O9Q+P$DW.RL76"]RU0>K7AMZ/8
MU]G;8M;[<J(8?"I%E@PN5/=*&@H]"ZUG[\CE#MH:U=SDMCQ1?%B5VI1/!Q%A
MM^F]SU^\.7[Q_+8DV&='Q_]Z^?KM?^R:TKOITYND\>XTE$:IN_7:^-K5<8J1
MB EICOGB:OGU#U:^N<SR(B)-Z_VZY[C\\XI8+[ZFDS#^A._#'%^4@FD^<$H4
MED4&)NK^IPV)U):7($U$J:*0VK5.<CWL"!LD E4(M-H_#TFZ3[]]G"&]_RH*
M/DKSX>?E-6:M<I&.XN!04J@^C(3H@@''I"N6%J1IGE"].;I>Q3']Y?@-J45=
MB+]EGMI-^%Z-/]/\7<<GF/=HA0%,M5I1) ,5,1M@Y)P(*4WAJ745M<W1]<FR
M__STW%?\7=/SY7 <QNDZ/FY<$L(HD#I*F@89(-:\/*F#RCH))USK/=?-T?7I
M*N+/3\]]Q=^,GLLAOBVKPWX[WFN"KZ;R^7!V-IF%T3^GD_.SNKT]G*5%)ZIS
MS!?F8S*>#:)WV8FZ&$LM!H0U;M1*03':8XF1N=*:]@\_ZC[=S_R)EM/#"VXK
MNG9M16YRPFSV1F4GH>1 5HY9 P%)H5!DGK7E:)EK7?EN5Q]\^WEXCF=33,.%
M* :%:8Y%DP&W48!R,D/T6-N4!9VC4C'[UN[<ZOO[%$]TQ(\?>P[L./TM]_O6
M%,WU6H2#[.NA*PU*L:! )6LA,%\@Q!J$F* 06]]$N@]3KU)_#L24IG+JD#VW
MEV?[7JEII4Z;]UE[AAY\K&T)0VV@@9J#]!J=Y"7ET/HD>U_,?7+<'XQ\'8JY
MW:G<LH7+Q0)YCY]Q2MY(]76N"I+3W VR+#Y66)8FA=2NMA ->5-8E$615<BJ
M]9'%9LCZY-(>B&@=B*Q=5;>3,,6GQ/Y<C[X)SM)JUSX_3A.A3<W$7USQ]UK7
MY@96%5ES/K%UYNS-2#:AB_ZUZ-) )%WD #!F@T?!0-?,0Q45A\B+!YY-E,+;
MJ&USC;)5CHCYM6BPX]1WZP5-SFLPOZQ6.K#":#1"$:Q8SU0EC4X5#5ESSQG/
MB3X^A)NS"FH3HMA?BRAM!=6V8,N%;5L>WE\Z]3%;6V(6@":YFNT6P;E(<(HH
MG)2;1M_Z@O:M8#;AB_O%HJXVDNE0T:PWCQB@* RK:Y1831?QT8 O(4$F+XD4
M84Q:M#XQOA_5)M3QOQAU&LNJ39'R&T#=V<N-/.EL:Z(\XZ%VIQ8&7+V>'06B
MT$FZ7-82_VZI6[[EBS?:"F2_"&,ZETR7^N?F\MN#DK.2QGH06F:"QTD]HM4@
M)4\N)A\8MKX-M3&XC<CUBVTT=R.YASC4MR$%[1-I24F_J>@S>",\Y-I@19&3
MEF+K!.M=#_6W5,[T_(289R^)),]J8F9-U20&U9_?A>FB!OC;LE(5?$!3(9.E
MR#8'62]#) E>Z !*H//9JN2"WD@];_WJG^"L9E_R7%//W<JFX1W$L_"M7G>;
MO2W')Y/I_ -.3VNGN4&2I@X]@BV>@W+((91@P21?3(XI\MPZ*_-6,#_#^4TK
M]K253!LO<)7,RSU6)+=T62]\^-_+/306 H4RPD$V6H"JVV>.S QXK;)06+0(
M;FO5<LO+?H(3E<Z428OY;[F'>07LU6QV3D/&2M<PQ=G',<F!W BB\/!S;<=S
M\^;KHGKH50K(0A6^/5LF>@0AE<^Z!LJ)-*+E H)"3WZK8LG42]F\@S;,W0WH
M)SB?::W%^D.01IKPNTZ>A].SY^?D &MNI+,U[R+F0O-3)-0K,:"4,C&[D'$]
M=+E-\_WX\"W/:'YJR]=D@CM5;:_&-+HP>G<>1\/TMA2L98T'R@?K=&: -8="
ML5JRB]M4^]?SQ$)2G+?O=+HAN)_@<.<0*F=_P3W$;0ENBPNUBH42,M6*A!*B
MR34V8-8YFHK$6M^BW?6VQ [KZV*A?Y@<I?\Z'T[Q[L[7 RY(2EQJ<-;7XKQ&
MD=>+Y.2$+"*GZ*CXUDG*6T+LU57CCFCVPV+K4(J=J/(_P_P"SR(=;HE^T2IW
M-"*C<SM\TDD\8A8)BBVIU@!/$-FB@0ZY(,;4.ONM&QDT =ZG:TV'8N7!!=Z.
MJ^L+BL9RAM/YM^H&SPEW39Q?%"@:**=IS3@+MI8W4<'26A*U>&!AQEBM>&G>
M-71S=%N&Z+^F,FPCNP[OS#\]GPW'.)M1O!7)#5O(Y],4L6+\,IR?_ M'PZ^A
MWMVXOMMP7"=^^FU2:&8O%]OSVF1P-+N.>K/+]5W V/\6?N>3L^=U_46\=,MV
M$+UZ8'*0WM6L-L.P7O.AP#AA 2YCH%]HQ7JMW5OBTMO?T<W^T;OI\'.8(ZV:
MM)CL@4W2T+K7P#@:6I2.@T]&@#*.QZ)3+,W+R6R&K ^G&BUIL-GVS5[R:6XI
MR7"_Q[/S:3H)L[4C%:-0:<LS,(FU3S2-/^3D(,::EE4<#['U_:3[4?7B,*-3
MTK053*M$EFKKE\[?TCCG#R?3R?FGD]LVU*5QMEB^(+4E4M?^ H%%X*B<X30C
M/*J-U.?6K^[#\487!#F (-J0Y18D'Z9A/ NI_O799#:?#:)S3M::<]F(ZL6)
MFOJ0586GE4N%*"[WL;#K+]SR .'G41V=S?IA^: -<\@-@RPD,54[#3%Q"9X7
MZ8/PH6"'?&@SJ$72X<J+KDKL1I\Y-R177JII+]F T]*!9,I[)642?#-]N.6+
M^^YC[<6"319 $XETNA">8\'IM(;4-VRS+X[YOM0]E?&GEUBS6#4!3U;4XLRF
MQMD<HJ@M(&7.Y ED'=EF24@MT/1A=^Q!V=6=[#JEW,5]TJNUH'1B2;!,,U*+
M0@2*0YRJM7X%V8>8D^)BL\3CS=[7=Q>M<]KL,_\=;FBM>)?'Z03S^0@GY648
M+A/NPC@?7;:HK=,R*2O?WV/_JL%;]]^N:CWT1L4DUS?8ZS'02@OL54Q/PVPX
M&R0F@I)6UASU6L-.& H+)=9Z_IF[:$2)K<]9ML6X[];%/>]+Z?RT$@#S/Z>3
MV>SC>(IUW2W;*C_%,IG6XK^#6%*R*",P43L[FVPA6"& S+ZA7T8Q;)W8W 1X
MK\Y).Z7G^L[(X>7>;+?M[G/=E5.S(J-U*3I0W!*ZG"09F@I6.^5ETH7%UDE[
MFV+K@Z_7"]XU$5YGU-IT5=3[V]]7A1;)VUK*K.X^@(K)0U1!0M8E^I@$IM3Z
M-+0)\#YXDKT@9?=B[]#OO%Y;:1]?\I8G[>\?;@*QD<]W_57U.O0YA9CUH$AF
MEY 7X$$5"AJ9([GQ"#9[[41QI%[:9W3?C&6OH/3X_.QL].UHG/\,X_-"<=;Y
M]'LWJM7QEJ*UJ9W=G?#U!IZMN<D>A!<417-FDMXL*MWPA7W8*VM*@FNA:!>S
MWC#);'6XSRZ@,!V4#LR -#I26%S;,K@40!>AN+;24O3=*>&?[<?V:W4-;AEB
M\<XR$J+-U6>(*8)G.4#)T@MK#=>Y]2'K[6CZNP!V8<2-U27VET*K2V$+''=W
MSQ-6J\R2HM$65;V$VM8V&G(H"Q85K46Q60[*)F_KDW_?3OC=3'9KO?=J/#N?
MUO20@31*<)<C%$2D&((<PYC(+2-7S.D2D-GFU:37,?3)IVZO!?::\39K?U41
M/9L0D-$BC;*V5_T\G$VFW^IAP>58=7+H-84&-:\#E# :O$NV&GWOM166X;U>
M\=9O[=-=N\:ZH+/)[S ^^C -N>Y!+[$O:V?M$R7=^;S]8Z7-X;;(X5R\[6CM
M;9<"S"4%(5'5XKRDU$5=W%HEX!1Y)TQ6E_5&Z[>LGKO>LI<RN#@*NM,V70TG
M.L-9JH5"C*P)@MQ#,%Q L2)K:VR0)FPTG&W>V@>OL*VDKRF$S@30;HOO>M6\
M9>/6"T!":%UB31E52'J0APP!O8.DO6": /'0NF3='7#ZX$-V0Y76LFA)CB5]
MQ_-+'"B=$MJ5VMNU)A<P"YZ\'. \E:Q$5 %;%Z7[$44?O,C.J;#/S+?Q)6_>
MU:D^S,50KQRF6#PR0J6YL43.5 B:(H:6(J04T<CU[DQ;;:;]^,8^^) =FHU.
M)KY#'W(MY>32/;M N5(]?@^_<NMW[.]K[C>L5ED:MY;G7ZW*KUTP)6H-,@<*
M)F3Q0'8A0<Q%QAQK<ECSC(--@.W=@XNH,?F&Q,3%@=/*DR^7 +=HE)<<G#4T
M<G2NCMS5+O*68FQ&RZQU4Y-[0?7!J^V./S\TGFHJHS:FZV+4UX+PQ:!7(W"#
MR9F<+8C%71<FR.'&C"!#))$+&1 W.P/:Y&U]<%^[YT0WD]^4$S<'8\<X_3Q,
MBXEX37^2OE\%6R@0\QD=:%4MN34&@N.)L)L44*&5V6[#E!TP],'G/2Q_NA94
M4U;=[K)=0E/)8_"NWJSC#I37-!WDT9/79AQ7C@"N=Q>YFT/WOK$/3O)A&=-6
M"*W#Z-K; F>U*4X8K6 BN"LGY#EXR[V4D'*IE8\\@F.VU')+W&9>HC+-D_0V
MA]>GQC3=.S9=R:TUL9;M##Z$K]]Y[BRW03(/10A9JUA(\%$Y0&V,Y,JP+%KW
MK;D53)\JG1V,-'O*I,-@?5$D?/;RG)0C+OY^>2M\C^#\WF?N'XQO![M1\/V:
MUCWB+?75KP"<XT!RZ2C$J5MR-?.[MO"EV$:"-C7K,DATS2O^;(IM7R6SZ7O>
MT)Q_^(*CS_CG9#P_J1>;@A.<!R@AB[IAJ<$7\LH<+\5GG[7TK:^+[(JU3P%[
M)YQ;UU('$6HS.[<IVO]+\<('HA(.&!/6Z"(A%R0-7FK"#4H'D5NRQ39+;)[J
MLC7(/NT(](ITNXGQ8=CV93*0,2;, <'D:$#IHA=ECD%;X=$AA1?-NXYN";%/
M>P?]8]J6(GP0GKT<?L:!2,4[@1)*=+60/.?@>3#@$QHLB9Q+V[K8UK88^[3G
MT#NF;2W$AZ':Y'PZD%HZJ;D%IC6"(F2D<XV#H*01EF8EK[>C.2S5"&.?]B+Z
M1[5MA7APJAV5.4ZO5D7 I+B3",[06E"*5D7(/@"3)N8DF<#2.JUD)Z!]VLOH
M%>EV%V>[WJNWM$&3QO(06;7KTM1B/!8"BPQBY ZYB"7JUG'H1NWJFHUP91N2
MYM='\E8@FKKDG:8E'\BE0=0,BZ1P+;9>1_>"ZE-PW8(C/]S]:2J5KI?#Y6ZD
M+%HF<GO!U9U-,@ZL=B5R)%^MK5$R<-:ZK>/=B/H4#A^0)KO(XP%WAP=K?3?:
M[ _34[O?(5Z'?N@]XF22YLEXP.K^*QXT!.\9A.!QD;])8<"ON$?\<9R'LT5F
M<\VE2_35H]/ZTZ"(PGP)'J3##,JR D$X!(%*^F!0*MWZK',GH'TR8)VP;2NG
MKXDX.W?ZO.79&F:!LZQ 4=P#GLD,#!FJ'&W0S0] ]^A1W+MMWGW8TT(D'5JX
MRW3%ISC&,IPOFM@M&3Q[CZD*)->C#GP:1O4.Y_$)XGR/H]%]7K>_36PVV$;&
M\CFA&&->@;."YM.X5I%Y-5X%,S RA&R=!W*/B(FJEE)URD%TM8JQ=E8DT7@A
M;PUR7R5VPPMK9_A:I[W^</'Y;"6B8 Y96EPMJ 6<E3"U0CM'B"DP*;Q36K3N
M;+<UR#Z9S6YYMZX!NY5GNP(!.*Y935?75R:S^13GP^FB=<2/8YC]F-E]/0>*
MP'*5R>SK4 O/"IXAR)(A9LEB]HS4?O-F(&V'T(L.$ _#V8<D0Z=E9Z_RL%:[
M_RP_WJNP[ ;/;5$Z=EOXC0SU\@VUHEOM,/.,G(3A^)Q\N@OG;C*^J/2V O#%
MU_DTT"(9C@GF*Z+V0L'1_Z21T&L^O:*(88JS^2 DY4MAO-YQ#J!"U!"9C8!9
M)Q>"44ZUWI#M<#C[:N$=H)$=(0U4.XO[:+VI7995J/WF$WA=FRXSSPO%7U;P
MUD'.[FC[Y [TA=WK2OA 7&CF0>R ]SG]938?I@%67:J9!+(/M7F,J]!K.115
M4B8OR&75^N+>'G#[%,7_0NS=B0T'<A?F87Y.]/]&/[W#:5JX04W\A=L?W-9A
MV'  C3R&%Z5@[=;Y7;SOPQQO8L% .,6%=O5PPV<2ME+@I2L@B\W*.S0AM'8
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MDK"UIX"QR FH0@@ND^6(DO/HL'CS$ '3&LP^98_W2+'N(\P'<0->C$.:+PS
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MTT'7>TSG4U(O(>.'X7R$ TM05-2!H2N):;"*=GI3#].=*8G3I,!W8O3FB$?
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MAJ$P$+2FK4BUOE7< .7IL]Y Q#TLZY<ZN%<>A3&B.)\,XZ7F:CFA6?#@F<
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M9M>(ZGT$VT-ULLO;LO=0O=%+PU-PKC)DQ3!BK6JCD $Z6;410Y8^ZO8!\IO
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M"L,#!VB=4?L(ZXH>4FGZX:9A/=&E,"Z7.MK--M44E^08633(BD9)>YSR+*;
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MHM?? S0\ZL"Q9K-:!*:]-XS^C[5W@B^T#4KPS4O&[@*P>US:U57WYH#+LZ"
MT;I87U1>#*V\M31KI"59V1 D#SQ&WSZ([%Y8A[H,[T]?;L=_M>7BT=QL;_"B
M@T->@';THG2@N="78(MCCM;KJ JWF)I? CVN8]KFC&]Y$KN+Y!_[N=8V<_GW
M2>R.!UP[*4B?!US[L/O8-;8$2-8HRRP4VB, (IG /#,I'!219;:A=<#>X]?4
M/4]B'XVB[D+JP4YB340GENF:J=0T7\N"B9'5<&\#&3WOI<_6L9W$[L3M5B>Q
MNQ!SX)/8HC6]4"ZR9.K-+VJ]C!7@*D7N'4:CH+7.'.U);"?-:432(8OU2!$2
M!@M,6K<HPZ]J&R'-DN<^^J"<//IB/7W;]$UDWT-XQ1W5)K9!]J,7[=F)O>T+
MM.PC^L,6[<DF!VZD8(A1,5TKQX&RF8E2@"OD5C9OT_Y4BO;TI!.[2/S017ML
M"D45%Y@34)MDYL2@IB6F(&S6)MI@FW>.?"I%>W;B;9>B/;L(O0=K]/J.N6IO
M&@QJE3A#E\C"2;I&.<?$4%H%*+P0KC16A'4XCD8!.@OY !?Z-TRGJ]=#BTO%
M030A.$YVKO6Y=JD4D<5@,C/"<:=  9C6U>IWQ7AXA3G<!46O?/5Q>W\WWI3.
MS\Y'Y%[EOTPGL]EOX^E%L8AZ>?T+ELF4S/6OU=>*Q3G.E.<T"8.&?'6P3 =M
M"7\B$[ZU3],$^ ^LB3TP>_CE;^,D:ES%Y21R!ND#O5G:95_;BI,8"SC&D\24
MI>8<#[PF;@?\W^K9DMD>'/JM*W:)8*)1Q3-GO62:!\_ ",5* .&D"K7T^P/%
MV?U(2M:$GXT%L_H)B7KYMV5UR4:Q3K<>US*(Z6ZL#Q*=A%X4@62P0]:T;5GZ
M$GD*S)+-I9,O*)H'(3ZZZ"2G@^#2<)83%*9K)BQXD5@((6G0FNS-?AW%)Q2=
MM(N^[!.=M L7CR8Z:;NLZQ2C1IYI_?2J-KFOJ9$>,\M2>FXA""];!\$][KH;
MS?5AO](:N_#RX&4/M@'[[](:+1GO5/]@'[H>7,=LAI"MSK2HIT7R#] [E\CD
M VL=V)3]OTMK/+QJ[<+2@4MKE)RSTEPP3(O; .M8I/6:>9V"\9@4JM8&U5,N
MK;$+D3N4UMB%A=:-%.[>VN\^75L4W9V,1O3AWV&:![XH0&F1B9P<O5?6TQ1T
M;0RFI99*)[A9G7!#)<^&H![[J< ^9OJ#$M?[I>#N4[D\1C-1\. 4UH+R)$TM
MD4%1FG'/2^!.A0*M4XN;@3^<ICZL_NSD:_9%?@_[[.G\$ZXKP5Q!;EX)3O)_
MGR\/G=[@_+0LYH&EY%0*<]8L;FII<9 ^,!7KKI"-#<W=SU;8?U =?A#J>[@&
MN&L>[S#5LM;+*-5*Z7?T+XF4D]-GKVB"?Z>989[\/CXME_/\/CLEA'0R9IH.
MDITC?&;!!<,*!N.<B61,M;Z^ZG=&_U;WAU:3'II^M-N0<A9DOFG'DE6AAD30
MAB2*9<(7IZP$&V+KE(S&UDC#FZ!ET?HW,*TU[+]@ATN@#4_J?/^S#<)&5S^O
M<39#7 SX'&=I.OQ\ ?;"*[ Y2:EJN+]3P+0$8%%$<A"SDT+:XC.T]LOO@=3U
MK5K_^.71,43O2Y"%Q9QIRJ%$1F^&9M%HF6K[%HVMC['N@'.HZYR6.G!SA6XE
M[8>^N%FTOZ8EZL6L=CLY&><K*]ASI/TG#9=!DY>3/"VKQE*+8SXT2I10HR>=
MI36XE%IT)  #H\DED.A@NP)E][0'[P3RH:YUFFG)Y"'8:NC";0O\#9SA)>*+
M4\%M,.]RT=- T];A/.P]SX%584<%;,;C8]'!(F+D 1-S7M7@6YD9J.!9E@$U
M\)BTWBHLZTGIWH9[H">H>KO0UU#E%D[E:2%7;;D)7%Q'1!EK44')"J_^5RF2
M!6DC<R(D9U*0M!ML=8Q_Z]&'\Y</1\>DF2Q;7^V\G4SGDR6D50WWDK-));!2
M8JK)/YQ%H-DAI))<0H,Q;,7LK4<?.[/=9-GZG7T&9W$ZS!_Q&B+O%U:99U@,
MZ5I-PP#N'1."1YF2D/EF=/@&=M<^_M@9[B[3A@>RR]7D6K^_DRG":5E\F]]_
MAH0#'KARQ3HF?:SU,H6L=?L+2R%R+M&&)+=[F^\9Z/!7J'VXQLU%VL-%Z'+>
MUT%^P.G9:7E&?O6RDJ;D3H? &4=.4U<\LY C9]9QE6T1](O68<#WHSH.#>F)
MA=:+_SIXJQ:A[W",O\/H="&-V0"*DM:"9B:HS+2P9,,FGYA1P0H=7(Q.;;5"
M;#_F<:A"GX+NX=YN'=(+A%5Q!Q8*AT062N)5#M$$4E?AF"H.HW8VIN8=E.Z!
M=!QJTH?\>[C1N@[LQ=?/Y$'C@ P;"U+70D)1UH9.AD59-#F]7J1B=>+-BW&L
M!7)<JM!=UK<50#>_C'MQ]GDT^89XI?_X[&0TNBA!\!:G"<=S^-CEEF[7(3I?
MWW6:4Z-[O=MMW>O_EQ7,+[%<:IIQGHR%0DZ%M9[T0G'FHZ\%XD@&W"<.LG4)
ME!TA=K]-WV:XY9V#3)S>@U*8T)K>DEPL@\@=,YJ42EC.K6M??'IK>(>Z%^Q3
MAVX'W_7#SD/?&VZ>WR_?OL_P&<SQXV1:XR3JJ:_)(G'I% LQ096CK+E+P(SU
M)ML@A="M6XCL ._A4K]ZTI![-;$-4ST$>JZ!=7'XM VPGG*^-H)ZF/RNWNB<
M],G%894E*%FR,LR(%,C*%)EY+FLC)P<(27BR"Y^VDMR3J/4(=&0'"GK0C=L"
MJ/7:YM]NU>[*R03NJM,0:9_7/CD6=39,NFR-2YI#<U=M6VR']]X:T7GO_M.
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MB]+H>HRKR?:#FNP8.5I.?D#_]:VOX#E*-=A7WH>H<7VE<!B77*4@'*.UC=P
M4E;F,22&*14/7&7?_"+^490Z/Z F["GM/KHA;E%"2UI9>RPXYD0]%S .:Z<H
MRY(#3=9++$5@?PKQV N8-5*,)M)OF'%TLQ#SWR9STMOY'*I?^6&RU..!+39I
M(Y$%+0B<1EK03.T4J)RQ7EAR\K>+B;]OI*?,=GM1]A .W;% MD]8M">;-DFL
M9?:D8=['VD!8<1>=,()#XS7BJ90T[V_Y."!G/<=^G5?1T0]7S.57XRMWF0.M
M>%1*"Z82$%8'A#7:R&H#:6=XS%HT+V*V [ZCT*:^^&AX*;@L2'LECNF[(75R
M5@^U!]%9!3X$Y@H TZC)Q^+<,YD+\!*4E&J[XX<[!GG*9#<58,,SW9NXWF$5
M3(TW^@[PRD7&$BIME-)@(7O(:=HQDQ"D@RXR05\-U]9G'G;E>HMQCXG^UF*^
MK1&^X39!V]AL2$]=I"N^PX3#+YA/KZ]+FFL7ZJ$**DGJZR2#&NU2$*P4BHSE
MT+K8\DX G[+R],_(;?4)G3._EMFK*PG4O0S&"9]-9O/9 $EWO9.)B46JJ4!.
M%A!D^I$KCZ!3+JV/.N["<PS*T4S>:TZ].A^!7M'<M]-ANG2R4[&\N+KKU<-]
M4E+:]:HI#,4D6U2(GOO^EHUK6(Y!"9K(>8T"=&S9<HEJ&;+Z8?+V8JO[@-.S
M@3=*UCX5S*082#MIVL%!8EGD0+^*7-@M.R;</=!39KBY(->PW/E0\^UTDA#S
M["4)@G:H^708SRO,Q2_>DAY6JT8F'<%SQI6LP2Y1L%CK73@>N<\AZU):]_#;
M M935HV^I+]&0[J=:EY1W_=S./O\_'S^[0-\'1BC578UQQ+)QM4\1A9S3@QH
M>S+&1OJ%VO7]OSK 4R:WF>#6L*F;-]EX@_/7D]GL\\6VTZ*UQGV/[-Q08R?,
MC=IHG(SGPSP<G==Q+@\&7WQ-HW-Z^/(%/OM\/E^8]Z?E!4RKKSA;;>>7*J7(
MBM,R168+*9(NAC0 ?*$?J\F'OJ!L78*I%?9VS3HZ(EK&YF7C4ZB>DJI"U)!J
MK(D#IBR';!(Z9YM;HDUG<*B6( ^BNYN[B!R<_,??>,3(#(:'Q+B3N9J!2+.Q
MF1FP2D;(T8B[0FV/K/'(X15DZUXENQ!UF"X5VR#Z87N5[$37_>TJ]I'U8;0@
M(&277*YU9SS3/B,#@Y&1L5KHG3$9A7VB[._=JZ0Q^;N(N-]>)=_[+ B?E-.T
M$]M:E: HP8(KCF'*)2E>HKAYJW.L#2QVXF:+!A8["+;?7B6K[BG"69%5;:->
M:FA3[1<+]8Z)U])')27N8C^!98^N+4TCJO<1;.,DS+69A0C&QZ)4+;(.M2RZ
M9-[JS+Q,SG/+I9;'FY[]8(9?$SH:9^]OGXVX#<@?.*-[)P[W2M;=AX 'R^B&
MD+S),K%,P.C]<.3$"VN8,T585PP*M]6]_^/6DETSNOM7DEWDWCSW[/5;0D-K
MZ6E-.?[P"<:__.WEU;[$JQ)%0AH>168QB$+6#WH6R!0BDSD*C5FD:&^<0VQ*
M2=MNP,>:W[T35Y.>!=V#A7EWAQ](A4/=/,D:\C6P3;( MOZHG>,^@[/M(Y0?
M=8NTQW,BU9FP'EJMK&\<M VH'[VKVD[$;=5+:Q^I'ZZKFD672TXL\5*=:R@L
MU@)HY&1I5%X I-:1!$^EJUI[3=A%V ?IJH8HHG9!,R.S(1.+IAA3TBQI;DL4
MB4RMYF>4C[:KVB[DW-M5;1?)-K0FJDWU7:O?)QS#=#A9:'-R67@4M+>1V<2T
M]ISYJ 2#9(L#)%W>KK7N/3[&VL%_8&NA#2$-4^86@"YP_#:>?<8T+$/,%R_!
M-J :GEML!'+X<XH&)$WZDG#C@XG-X$#E*&()S&9#:V#@D8&MO:*#,,'9+'-H
M<=1Y8-KO.'@X%.N["+8QVV^GDY>3Z1E<;$P!K?0^%R82K5_:@&6Q^KI:>G*L
MB_5PL\3-7A1?'_6PAPJ-:)@TD6$?1P7G<8;_/*]VZQ?Z\KT!7I!<B> ]2YG,
M5*VD8B%&P9!;!_2_8'CSD)7U4'[@#;\E27WD+=^&M;K%VP)87ZTJ-H%ZN X5
MG:F[7QTZR+VGWC;K ::HBXL>F-6Y-O,A[RA@B,S1"HC*U([3S;M1'%8AMFA"
M<3A]V$7<_>O!Q8YG2^:6O&/&DQ$T58\L&*F9 Z&%]IZ'_]O>ES6YD>1HON]_
MP8S?Q\N:9>FHJ9G:DDS2UM@^I<$O%:U3I);,5)?ZUP^<AY07DQ&D1Y!Y/'2:
M2IV*@ .?.P /X,.#Q*,-,' TDOHVAGK8_'MH>4R"/:^8T):"'%VG;BFIP*6<
M03HN8@DF,J$:&_]D"/9.HE"[A6&&Q<ORV]I=HKA<9*C<RR"UKR.98Z( 2D6@
MZ(E+9S17OG4_P$ZA7C#4P%BMOX9O^O$KT4]E<:CD/_E#COAU<HD7DW\M57/N
MG&>N#O=VF9(O974DY).8&4D+E9U;A(X]KEU>]\R ,I =!J#]^^\\^?P7B7=&
MTN'G?)/OYQJB?\'%))ZK0.A5)9*P)*?*DG)^%@WDVM5;&%?9MQZ7VTO 9P:S
MX8TXP.?T+<*^KDK,Z>Y12JL/:+@#$W@=6U1Y,8LSH URCMZASZW]7D\17U#7
MW) #\!K>5L)J,U#2B=XP2CQX\J 28^!34<!U=#Q@"2FWICN^5Y!GBJ'#C3+
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M]FVX: TH7OLV9)8@(X_2%Q'*;;*#QV#@'4G,,/;MH\KQ4N7E045G&9UWG\B
M>>V  A;GA.(UVM4D+"-A-9U?WJ58C(]!Q4[#0 [/@>\7</SHX0!C=LML&UBB
M8?*Q:@V\X]=^NKVUJ&]G5_.UI,Z9+%FNO)9U5(I%!X%; 5:[4G)T@L*63I\
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M!2$X[P&E5'0V1DX'XN,'R(Z(X4CXZ*'Z8:XU,SWP+\J.7^=O^6+V=<EKM2J
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M38O?UG1D_YWK"("<SK[E.7[.R__S-5[FMSB9KRBU2S0Z6R_ Z@IJ37&OM\Z
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M-U2WOUG0T&,UL>M17@DUT)T4'0=+1:6]7V093O< E,)LWRJ[Z93KT^4D@\^
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MLA@SC59E(O7"V* Z(QJ[K V,59@\TT^OG!"UI\UY^(1!Z$"?JE?-B]\"WRQ
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M/J62E*G&.N4=WK3'+SYXJ5H2G\I7$>5%<\,6,/UAN_8<]W!I3KX.>6)UKS6
M L066J#W,HUYHU<MM:@1HA>#GDETN7V%;>H:4B^K^GA*>KV-@$DR6\':!FJ/
M=Z!&V__;,GKZ UEIJ/8\',-1B7ZYJQQI;N"XK#]^3]'V(NTT*V&H7VZ+@7AZ
MG.90<O3^/,).EYA0BT:)*+RP7V1/9W^4T6D/B[&@>N46R_7?&2#39SB8:60P
M1/H_X<8AGB-6*RA =T)-2K7MG!<QDLQ" 0J6*,!U,[S#1CZ1!P;Y_I)XZYJ.
M.GO3G9\#[]\A&AR,R(:9#0VKY2)">B6J)?,M?O1]6^,WMV=B#5(.(Y35*Z'7
M87,HEN99<68+'']V5IGHP_@Q+VZR\2Z4R-XH@/TL:[ JB)"R*%N+.WSJKT10
MQHKH=>]6O3NR^Y787G 4;M"+-NZP;T_191KV9<H8*\UQ<FO+@4S)3D1N#FOB
M1W$0*MITQ?;-GA$[47;L_*0MO7:SYG<!U55)_#-"SUPT"#[%?Q);^F%69_4>
M[2S7]P-WF5.LL9W)^=Z(M1@7-]PV?KX"EQ+L@$^2*]*ZU"O:TGUM+&XS#'WH
MK5DP#A\W$^+G?<!1<^&-O;T@[=6'ZYCM?'[S8'(OWL1@,7ATK</0-1@S,.QO
MD-ZLPB'M4+KJ^XTQ.(,7PQ]?^#VFQ2)96*:J%+SU?DYS31YG6F=)\WZ6DWC)
M<6S=88)C=O:8\R.N;UV<W4P'V63&(5SZ7<(Z]L0\(0P!,>@K> ^5WJZ(N>W?
M=+ -$XAL6S9H)+F [NJ)C8P\]FC)>ZI]<Q^-1Y)RU43\'Q%&Y!LA+WK'S=4?
M:NMZ9'.<6#HS']50O=J(+A9IE1QAF$UXGT7 ;VS?[D5=>?< ;7-?/^43R)?$
M08 >BA!N3$]%ET1SV[?<^#25X)/YKIY)L4M5::AN"JL/Y;]+[IXJAH94,TSW
MD_O198]*[1_LH[VY%M0#KMQ]V3B;N7O1/?&KP5[&(*9_*8]1?1MFM&O: !<J
MP7F%NI,>MJO'3FZQQ=]4I#M[&FQ3CGI>RQ(WL]D8P'#MPQ[&T3F5 DS6?2.R
M> [LYWMP]<>&Y![P]=24T.CH;H9Y/$3U?_SK\Y9_I#?B;.( BZ[+LI[SFT'R
M&\8U;Z\&J>@H@9/4CF2* ER3V]"QY,,FDG5"FR0/O:B.KNL7-@17)J O[+.R
MA!JHLR_M7*(&S/W?2KE2T=_=OJ&B(--94Z=5=+&8Z8WX3P28:65/P93^J>+!
MKVP/JQA;U ->#R]%_7S:!HYU)IQ*!QV\^@GUC]:L!24[V+@_D',?B;2UDYE'
MT*],E7A%50LZS3JQ4@,@/5.;.RU6\=[S]17P,F;8%-^)\PJO=O6A>K *OT:%
MLPQ;49"0R%FGQWN?$2.<^$6"#Q:!]^JN5BS0/=N_]DOFK"F=XL.K[(N0(G@A
MPAXTEKO90N8K=&3A'ZA>/E- PWLX5Q- ED8.GGL5 CZ1>FPJ0;NC>SI;=%0E
MMN+'5/%0"^8,P1:_TD.4RO1.U/_:;>-W#W_JUB^:Y[P>^2VB?\G F41SI.*Y
MY<#6E10@1?A:U1:J#3:VQ6>SBI\N*^WF?CA@JW/G8TSHL>]A\G#V'G]/4J@:
MV%\5*[[9Q*@F!(.M#"[CWW_+W\BD\6X;^P%NRWLS(W7[<JZ'L:(V4_M8T9V!
M)V]V("8=+)F5$;9J _NAAT;P7@1[K:3_TQK"76SQ^+#Y<I=5>7GQ^%<9NN>Q
MRNZH-,1T,I*O!$'ME8Z0,;/<\+[/]K?N)[@-# E)!&#!/;5*CF:F=:#CEMY3
M5[&R9J55@O$QG\7[+=0TGIK7>'/=I #6<YD:^6H^^9R..[8W:FZZ"6X/4?N;
M=0@N%&]/F+.>QKQ,+/.-+YG'7<6N//[>5OV,R785ACK57J11$'JQ[J0C3D<7
MUTOELF3P_6>B7FN(H,Y+2RY;?O.CABHE$$, -?K>)#+?ZO+KAZ-7XI<C3%.;
MV03U;HM\2U?4G"P=DF[L;"MN:Q:7TE6K/;/^KY[SGZZ(?H7<@NYN'NSX+J^^
M);RC $(4P)(*+#3RLG&IJE$B^+MSTQM("@!CI0 _;&J>D&8L-0^I34$;'Q6K
MKLXB2,>'"@2JP;<T<9DKIX8]V SN'/\M%*.154C,Z=2U=#."OP1U(L<.Y[RB
M5.@.-0@B6MB]5W(L@KH5Y<$V9:5OTVXRZE_C.QCZT14NV)$Y4OVB.)(GUF]G
M$Q9/ ;"&WQ&-AMX,*?"AHS+D+=,5>,@43N3K0\7+J"U406>.47900[E&9ZM1
MTGOGI^)?N$54O(Y^I0 SX!Y$<6TS*>>QI-*^VOV)?=-F--8 ,6K>K$93V:TF
M0."46AV=>YLR?4+_C!77O ?J,I8*7[UF2S,_JJ,FB=#:4MRE5TOTCCG>SE6Z
M5B%MRSH@'D)N>U+"I)6'SZ->4X@.><0YSL=%B9'W];L<X>J@H:/VAN<1M:Y)
M1!^"Z1PH3,EKO6*& K!X3UG6^JU>:A2O=E.JO_3@<GYABA:=(LJ6BHL_>V??
MPU* E\3CL@$N^KT)NH'!'QHU4-O\Y:OWY!1\^II[&UK2_%?VSLNA.(6C>T]K
M=%_;ARI^FJD.FAE56-2T/FS/CMDML+J6I$G0R=;>JM)S%QW)$%D4GZ>K4JM
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MU%^+5$@![#JM9C0#2]ZIJ,ZL\XUA*H/?\3U3$'F*7RRWGX^_$)9S/:/BMGS
M):.""J.;),D^?VC&JK2*)R=^3_I<XR5G1O9(G*-!96\MCW?"2HM)T 8SMU"8
ML<+%NB?J<'?O,?PY N90;?D+ 5-OJ5R#.T)*X7=2S8XACOOQE^R&/B-?<J
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MF,U W2<D\'=?TY(3%_3\".(E3% [D-"_#;F3_GG(O?ZW(3>U5YJ]]*^>]Q!
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M+(FH$A\R>^OXO.6MA.Y'0(?M \!K4S4=A$_%)O&.9V@X(H?VRESWCZ]JY'*
MD':4#3PS"!EC9J[+&<V%@JA.\TL/*/WS335SNK/154II3_<+A-UK5K$;_M1%
M<G4X9>@XE4[FT[7^IJ:#_O Z4R9-^WN<)/SWJ,'_T^M;I7H2%HT[3U0O58Q-
M9 $V-K[WSJ783[K% 2@/S@#O/AM*0V>=5-B9;W25Q)[.[-P66;-#.L(1P*7*
MO*O9]T^_@P+SY;E1:_&^"OV: QQ:C]O-ROC. &\92=7MY?Z,*67ISXM%5N+(
MZ?DKD._7[2KA\^?/_#?RNB#N:!25O<1&433M&6JG_2]U@DY]8IB-''2!"*S=
M/> )0LO_AKC,!"N/2AUBK)3$3C?%Q_>MVM?B5D'J;_13QIR&OT)'\N?R:^$?
MH(KG-S]8@;EX#Q3 7H3'!^<V@>:&#R@=C50=G=VN?QH'?1R$!UTZ[/CJ)G?O
MI3W^\\L#2XQ<!0_0Y[S>N"2$A]E&2]BA* -U(7<YLB4I/5?+E7_BS68#"J0M
ME&8%4O4.M)IQRE;(N<D5Y'=H74$=@5V 86#@S.XL4^(ZD8T(C-E31FONY'L<
MM+[+;^X]G&N!+0[T:O#OQTTK;XX4E?:0QQ#4,.C#G_5INYSFNCX&YG;"0N.P
M1LJ][YY0WQ3B7&E5ZT)+@^_KEIJ4''>UX2!TO7['&8!D!N.#&"[)XWQQZ)W@
M*&"]SC 1I@FY.I0O'X;K^Y+<&NJ.E*9WRJHL5=U36FA-,SSV&7.HGE]@4R^(
MD_:_']?R#36+]K8+;R@,/\TL&?83#%9=-#(F@N,!^Z^<G#W$<((Y+]J<[Y%H
MOI/(?< KAZ-T)!2Z6X<?'Q,-AY@$;AYN5J).!#RN9JGAYC.L%/IK*+\!9J,C
M%QJ57QEKB'0'6;7MX)KM43,S(/2+91[99(&"%A:)<S>WDMRKMH.1RM110GCQ
MI)\-V)HLY:F#9N)DDT>]W<>B^$:F^335MJ23JYZ;&]?#"QO*X,UDN'+)O)$5
MHR0\D,1$EI?H\:4#Q_0AI0C?<_'KF+4/JG_79N2_J3XQ#40X=+ TU];]T+.(
M\ ^6-.L+FO=3R[)Y!)VNJYVK" X32Y^#&G+Q-K6(=I;"O[<:DX4W^$NZ0+!>
M9P:D[":0$]0*])I!-7PYS9;+A%VL35M[_&/P]^]RFA<FBS2])C3'&85,"84)
M3]XX=^Y,&"M1)@SA/_W??_N/] [*[7\QKVS]E2)$T@PGQ/GR,6G?1YO$=%)Y
M)[7,@R8J%(VXRFE7]>BMW,$S8A&<=?YWK4;&(8H8Z='HT,7&L&7G\_+)@W+4
MYXJ)@M5^3\/A:^[NGY:*R,E^R\$]3ZM+*FC*$\_*CMJ=2JOUF9ES)>TT!LFG
MH]9%=#FM#?]GK8]0'P3^$8R)PCB&O.'=G#+A [E7VE8=\PW1X-J&2+R7A6_R
MJU7V+]6QDC$!\XJ? 7#&>'HJ7PEV%?WV/\)[&%&R=B4/T(<L,AL<$M_BF[FF
M<V>[)0L3K<GVI+R0S\DT"P6L'<]H\4 Y(1/&)E*MO4_<_Z^...^OU'YAOC]0
M/I)[KP@W56X3S4S_X9O]L.BC9(-,ZY:LJ4]* :VOU20KU>GI $_9>=-YGP[?
M_K07XECF/WM+]7<ZRE!\(:/1L"#]%C+/_?<GZV9(^&G&"@F(,>;I10H1,M((
M'!@J_ U1Y83XB=E-,_W)XN,Q;E""I4T$[VGOB-KH'8++4@Z:E2*[!.?VS"HE
M2+R'6#Z3DT48+%WY+)<9'W_+3!.7*MZGWG7A\D9'8&%RE[79FW6"2D:B5Z-=
ME4A:W<V)3[Z!-6M/S75#+_WOB:O^__:_84_LZJJZ]>Y\H7W7[D PGS''-W:E
M@ENPUE'U-LL'+,027R9YT'?=>=,?#OF=!?YF\6FS+%X[T)&D2&V/@CB*P;_[
M_Z>E=+%0^2VDVEBKP,W1K@7^/D<";YZRO?:]SFX7L;U77UQ6_"C.;ZM15;UC
M3Y#G- A>E:Q&0N##J-Q)+4O&1F1GLB+U:KB;K/,@636;F)M0M;H>NC.";HO>
M'F\3CKLU6%3,V]'&C;Y=:X+1?0WC@2J!?9=&8YR?S,A-+A@PSGK^R)WA27V&
M>VB>2B,J$(M2'-BT;'=O_\ ?TS/ZGI\M7MD^S-L(=W?>-WK8YF&!YH<7#CXO
MH%O,!S/:&E;YUJ6EY*"V.10U] SPL2G].#0O7C=$]=<9(-ZNO;N='6(X<:3I
MS7L=/]VND^XVG=)<UYVTQ6\\,OM*<@6@77I:@I3U.@-<A'(;8QU94;U;QW*8
M"/U2O3WN&3&.]X'JR]/P+81V<]=IB6^WPU!F]K=M)7,G/\+<,B?P(D6 M;0Y
M8%L#<30?"LW^WDLV[NE:!^0( FC4^QQ8CZ(T_M/,P(C[A(IKT1:..V[I1O,B
ME2"2X\\)IDE:HICL=L:0\L8?'JH6X8TFB9\E/9DR]#N>_Z.A2RIGU?\&<2 M
M^.+/ !W-<H4%?X$? F%7A[FJ(Y\S_)4K2@\6511ICKAB"KV[+)94$ED!+IT]
M\,CRK%(];%PM$]RVS\O7A9#:^73$(8H$8(PL]-:&D[#&I3;_C#O;PGRISS)4
M6>_JYCP.Y<CY^/J2@02O9CZ/CHKW"5OR87X,DO8/*'"/UXL[,5QTBX,7)_.,
M+BI$97]6"DPGZ,(G(WF2[N3*Y9;E\\^J%NU\;=VJ:>?0^MV&,W]KX!+Z0Y9(
M)/261ZALZ<P_\4PX.,@SL3(- /0?N";'NVN>EF2P%)FRDR=#,/FRE,^R94>L
M>],0ZI9/:ZHU/'MW@SY( B"YD@I8F;:\?71K\$[H 0CDNZ$L-NPEW0MT<T[B
MA_?)2O?8)95\[RC6+]G:MT79ZPM4EETV&Q2?[U-@7OK(^?(-U\X15^DHF_E$
MWH9?ZG\Z/PIJ)&^-K1C\W$Z) SF,X1+7*CPO\Z&E(@]'E3E2$QSR[^HWG%>C
M8_.MJ/\#S:K_Z_:D/.-989G:5Y9M&.E?\ND8I;2D'&>F?4GR*ULL;*G"F6Z-
M]!9O;4+(R_5=]W*ZFKN:[T7I'32C*X'C:WL7\*K6RT>P1ZCOF=Y5FYFA@8<,
M@:[!3!U:[,R5*3^D!L-CQ:R7T+@0LL+6&:!.M4=Z0=PCSY=EL?]@ Q5!5_F#
MH_/.SN;'R\31T-.6MP'@D?@AK_90C;YA[9F![8-]+:UP[F*<]6\\2K*@W4XK
M CXN/[=,Y9NA\DN;GP&B4LX 3$ J>_(/N^-\?-P9P#T\?FAV'W1 #?^[G:<X
MWJ[J/7\&>'4&2,IBPW$11LB]4('ZR5?U33NXJFDA*\GE'"5/Q(?+NS]'3;.0
M84*197%]F+6<0M[>XGE'A ^WLR;PYV:),K^_4W[987XL#&-W!NBJHUZ#=5:>
M =Z?4_5SL/98EO*?\SE&:Z_'C@:-UE&03J/2?.N:Y!=MF>?I[_#R?_;]L<=:
MM16CP.\IFB0C[VK/$V7T?![!::7O^I;*]U[!2$0NKW\!DA/?AZ/%X'B(4H3@
M3H8=A"I!#HY].OVL.4ER.*NSPHNQY0MMS&D7_DJ2==[/(U,^Z&(6RTS?J69/
MLVE,H)!]AVH>2W*GL"B>"E^=0U#H!E^BS%=H!28K!-EIX8.\6<>,LR:J>46>
MO::+916A]5/:\B7=GU)#(4D_IZ+2*>W._;MG@)?YJ+Z>,X"0EA&!PX"P43,-
MM^@X08QDEO4]9^;X*SYY()N>\O28626W!*CD/5.ZIG,!8C(%98-U:&A98O/9
M>CR0-^I)$6.;J*BI9A,4I-9F3F^BN_HR>XBIU 7]"WJ5R=&P>IZ=6;PXN9<'
M28]?[[9OV;OJT1AJT#23-1 5]ZCI:H^@/W.%FO'(CHW,,X#_[+Z0R/+WR!)J
M;]9>IZ&L,C=!Z%^\M5/2YHODG1<T='=P;NAVJ(O/A:OOU*M'=U;MBJ9D%*-N
MF60VCS\:I*""9BQGUDSK5Q_MM]3IQ)& RVB4*%:B2R"9B\34%93%VE[A-;Y
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MR9U-'WNHIEM_8/O=3D0%%7CLS^1_]:U<-X@E:A_.#/VC(SP&>P'G@5S+&[*
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M8#IV-AE#'\#!WCL8[9M1E.JO;8( ]LT_U&Y3M;'?S1R_!6,0ZQ?VI@]TD@D
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M%$!WT9_U*C>%4 !9E4<_W'0KESV,"^ =-TG6%$".]D(6Z?HVB#@*_+/B_S<
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M\JM,\\Z>Y9%/K%?NM1ND;XT\K]BH]ZU!,OMZ6#Y8\HC?"K#3 S\(0 //!7#
M;N*38GUP6=V^MA&*M\K-FY'/JT9R6I*UXZ1/QTLV/.6&VLR>PO0H:-M @2>5
M$H/G;Y?.%,2=L"P)\3VMSP&#SJY2,[75VD!9CQA3PXF+DN? 'RZJW>-$9]J_
M2>+B*$EX'%6WLN^YB="3-UAV>;CI-8+K%QDD 8_D2.KXE<[2$U9V" JI>(%/
M?..FY9DWJ\6:5RD,F=9,&81':ZR\^Q(5L04!/07'[J-Y&FO ]+5G[+DU0LS6
M)J]#8AXGOND7L!&P,7T2:B$9G\<U5F =E#/B,!9E7K>CY=_X:W4Z4<<-+7I
MCM@,X":QX5%=VZR@4-(53+2*V=AS 5UG%C^V*:J@E]Y7KG)2V?1'X4>P=>2;
MY*]P9O*I*9-IXFZ[L3QK_D8HAWCS3Z=G]H"93WT7&DLOQ;.\TS#J]DIWP$.A
MHR;>^HK;=C.6I'IV@?)O$$:)G-;^XUR0[1R R$BX0E1:.+YP[X@QTO, PJX_
MHCSI*IC)-V8/W'>^$NW66[BD-SS4'(9!;9CC2[&HD*=XP1 2K2<\Q^(&5'RY
MJ:Z664C 237U@2VG07^02%",\YO2>UA!98UBV:-O8@;U\,]#3U[F]R?.'O()
MJOIM;VSCKE0@'4&T,-D3@I769.<D81-$ 6@V2TXIE'3=H)*7K-3O/??BU459
M :YUD!WCI."3,= K1AZ8-/'6_.K6JSL?7JW$M"M46==%;WR,FUQI2(CJX[?V
MV]&A>68H.G6!3G<T7\0O<SAU/3F),'M,-EJ[IN:D.-#2C$HL0B!:F<BH5#'D
M%V!T K$#\[(4R\@)-=*:>C&^-_-R?"-5<="<^JJA^>*NE[+)1@Q81V/*RAI#
M 4PD+]A&[#'2._J" L4]Q40Z'U;9CTOO)WVMB KIZ%6<;O\ ]'V<>\U8[NGY
M4.?@]P6%>JJJZ"T]S55_J<W9.9<9SE4;OTR@JE]45B5C#T>S)WOP%&8Y^[A)
MK+A%H_,'!]V5.K:CNPE]'*_HV%'\,:HN0-96!F+//#R")@SFFCWP<9W^],RU
MYO@>(6A*BDII]]<R6C5.JIT\KXI^DXUK/B4>)=WZ#@1][:G66&=)7KDNR]SH
MG-:@DV7RJ03ZC %NPW<:2+_=VB%P%:-OWF2R=3Z1#C2(UA-Z!6RJ]H)V.X[!
MY]-!U:"@ "GH %8\%B_3/NQP^Z>>>8GIM,7TY(#CK?@GB9;//2!?/IXUS^8M
M1779FHA*<Q7<>&+P9-.3+<W8:_L@52UJZ1JWV3$J7 @!&44^CXWA @;&1FXK
M\ZP-_HQD^OZU0+!!8^),0WGBUWZ W*N/Z%,S45QXX5]"SXN>&W@(WS!7?YF1
MU=NO]S[@VM.<")&\U_^W+YS]7S3.#)+/DES&R#30;GIS[23-FH-S6INR]5M;
M_+THWC-T+C/J/U*/P3A@3 T\G(]EF*22;2DVF^'#X?EL_]V^&N\'OG.(KM3#
M'@(5<90".!<;G8]3RU>>D;!\A6975/>B <!;90]#$$DHR9_C>7B6\19>TCCI
M3$6(CG$_ :0JE!-!FM]K_[LM(HP\XTC'[3<!G.-2O$!]O/-D+:_RLI;6!WBU
MT]Q DK3P>L/SRYA 3JK8AQ,XX.8UW##6JJP1'-9L:N]3U IK,LU-0FMJ<+:+
M%N5_EVM?G >J6&D=W;"O2PWKTHU%.M2&KMA&Y$^MJ &=;!N^2\K^! D7']G;
M'S)D^>"6:KBU-,A7U1'HOL(VZXM'!E\N,"=:\&8Z] 2Y]U[V=#BD">Z0IP ,
M'UJ,S:Y-@1TANW(-2P-?_3F=\>P=XP'*C;@G9J$4 +/9)/U]1^#U>W6G^[/W
M$R=\/.>E?58MK\%"L-'N7?(2F\CRGOE-ICFS,42S%'U.VJJ9@OD#R?N;BEWW
M%%BNWY2[-D*7?N9G)H XO) !6J ",2A?_YFJ5%!<;-:RG% ,]5^4KC\?&)G-
M=.L5AH? ?T8DE+I!>-[B::'VW(Q^[2AI;R/24*IZRQM^*4 )>@:C-"V=*8P7
MJTCQ$?:)="@6V(7TGHI0*^MG@ K0S2_(RD[C)#IUZ4F/!HV-<-W5CF43";69
M,ZUV4YSHGRZ]$RN. !=UUHYU+IJ37B10?C^B58@8>FCGY)FR.>:W3OPV6'>%
MSI[G%+^D\#L7=<53/X3.?*, ;$1*)3A)9L3\!<2%*=4"J(Q1_"Q'&6FB$^'R
M>BLQ^]&'#F9^V(3@5P';=%"I?A*?X;-O6_FEDRWB21D2,YL_Y%+C'QU&5)$4
ML.7\76.25G:IB76EMCPHIW&V>%K^71;,^YOS"^@T+&(3151WI@ P7&04>6:'
M A@$U<)05=N]%(#I$FFBV]<=?"U@0%D OQ(<<)HX#I[$3,+D\LW6QL?"P[\M
M.%RB)[Y[<25XR>F-C(ZZ5 B/1%VN</A:JM&O!OUDT7CE@0KG+\!+,"6\>L=
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MSCUD=OS[^!X,!<!DS[70*:/1"-DS/DO#\R[*=23 ,[?,T=<[K$R@==1YTV-
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M4L>,!7 LG.MO<\@=<SHP'%D9Q->K?]!^\[A4^&76L=0YN6YU_*?X0G1W.PA
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M<*W-.;"_^&%ERE1/HO;,R4DJ(ABX1&@P(!,B>]@:SEY9$-:UB><@ETA..21
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M_C.C3UU?;CPIO7:W_8K[IH$:BT[:E>:=>%U\LO"U.+-X H, H8@$6/+",I$
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M<\-E5JS6,D.QB]__T2O@1!]J54^W&_QZ*Y)366_>R?Q6(4-S.E(FY.RW'\R
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MG(%D(67K(G*#"TW%I^\D7M8XV\EB8\3A?$,J=0EL\P-@,W?.#3RQN9#8 >>
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M^_NG^.0]9(?LF'0+-:Z+XX/1B[6><VX9:(VY$_D0V)9E PGP"U5BH$7(]@5
M?$]%";)')J6ROY;:"#F+"MV;T$]J_92ES,[^$-X2AB>B;6GR"%!AL'TQ2-V@
M6ES'3+;7G8#=%+T9,^6$$ZAEKC &N_G./B[&J?EVR.>]1]A98\'HE5%<FT.1
M26YQCMFYLZ^WIQ'=O#%LU%8O&JO"K>1D?D"?$F*)8E"67P;FF.  )]<9]B0#
MW(,+'R6NJ;Z\=Q&MOI'$2^',.>_!LC5'!7.(8L:&+29&$?DAJRVF>>%08,EK
MQM=-UW7IFD5@5NL[;/042Y^?4J<$B#CQIU:AZNK.8VWG^SE\^T@ 5B=E %1G
M3!PJ"[8#%V$S?OB*#CWY.?"C][;-S?BW.8_!K3;5S/>V_;(/D#R?GZ>)R%45
MQ3'GO!H"JWFJX."5BW;*!:=:>3H><8HD !S8L%2D3(^_14CQ9<=:MF5<O:UD
MW#XKBG'\VC0(9;?R.H6RCM;HE\T\_J)>TNK'XN)G)J+>B4"OHA#-$E-G9"3H
M(+Q(CPPJHM!#!YGVL!<"U0(YN?;+S JJVU(G(=<,?9GGZ?OWMR>Y2(!S5W%J
M$3*Z'Q",KIN>2^@$Q'R]D-@NW^0#78Z?>U/?C10L*/.CA_C]!!VLR"6=OPO$
MS&@,Z,! O6'$NL>E\ BG<I3CTQDZ>@8LLA-]*O2R6=4KX:"+'93SN,0SM5##
M4%,?FR'B[#2PC!"=BI^Q.*XY,#3DJR!6UK['W<5?_T64[%J$!=4EI-Q,PMPJ
MYFM SVRU/W6KJZ0[9F5L,:=8N5%UL7>M4_>:H_)E9[!X6NMW7:9FQ<?ZZMGZ
M1>$7:3]Y4G*/'*@UDP#L594XV&ME/O3.9J&/64<[Q$1O;[2:+9RK%'EF6;WC
MTZU(52G1/H2= V2+/$#UAWYZX"_W$@,J^!@V\!2D"< 7SB&-"@\G]-,'/]C:
M'H%ZO1SSO(_O+K-T)J]M>;8QZX%0?O^<!4O_'<6K8ZL2[;2YF-=.KB$AK^04
M9Q2GQ4>S.W9RLJUO9Q/4?BIIT:ZV&@>QAF^.N(<;@)>>OEP:-C8XTCTR0X>G
MGR.D-7&_+L]+=#X? >;K! 9IL/4XDP ^=^'ZV8;/AD6^&>KY?7E^1LNR<SQT
ML-4HS0XL,#>[XP.U^AEG?"\S5/2L_S]CD=P_2^+H6\^,QA2MHT_&:&&!GK?/
M? ^K-/0Y+Y3W^W^RSZ8V$F19/=X6MQ6W.M+]ZI0J":>VX?WEK^++1)P@ <I6
M"G'2>/VZRF?<EM0;,4KM$= L(2N^V O<?4GM"N&7+>L/5TD SB9JK.V1']8;
MAI)@FF(7=SJ_=C/S1_+@<V43*\$L!IW@K_!B5,.1B8!HLNE00HQEP;Z:@( _
MG$-\ +\[ %K&Z?EV$F\1$O&:ST?F'=60'OJ7\S9'UZ!)=6E1A"X 9_[FL+5Q
MT-A! @>3&KNFS)J&IL2KJ.0X&ZIN_OQ\E.5E<ZQ:ZZEJ_:MH#8^<V8?>M#HT
M$>FR%[_Z78N.9V^FXMK,P<Y@ DRPAQB@*6;NHWC1FT,?LZY]U)"5:[6E"#7*
MHF!G2_G9<&KI4GJ::%!F\4#N1L&V=Y<,3/#5V.RGVK1:KZOIK!C5POF,R^MU
M1X$^-Y.*[(9R>HNGJ1B80]]1]U.M07@#HBT?]9)'0@ FQ5[:H6KV'-;YQ:(=
MXWT2@"8>'C3B9A,]$I_+R":\\N+C3'ET,Z4US^=O)6]4J>C#[ W7\V7RNJN3
M]\:_#<<ILWJSM< G"]L1%US3O!^]KH"Q8VTM:F4G$P(6-B]_,[6P8 S>IJ-A
M6(&&[9]?\M/1S+^$=R;D0<TPLQVJ@VZBVCQ(T)6!,0(5^4?Y'=,W4I?NQZG4
MEF'E*&.8&9GI>S-X,V.ZT075HRPR_7-]HXCBBJ8C!CMED-F:EUI'5!3H&N%K
M@V'N)I&W?.@-7.QVC>OGK,&%&+D>/>FR<BH/A?+K7907J<XVWH%-'2_(C+7I
M7L;.^D@@V01;O=Z8&L%1N#1EC8K"<5[];WPARV(Z[(@H2FFZYPM-]IFY)DX7
M71<UGPZ%&VBX:^>2 ,P9G;Z#=K.K@Z,D0'5>>,6,H/FO@XSS6(9[Z-SJ/ N[
MR>#@VX[L6UL[E&NE#3U6<9HVU#F&#7T4LERW^K%41RT8XP HQ8OY1DLDB $;
M@FJ422,3_:MV/&#<^<6$2]]=;=C[*=-IN"2I/@R8D #6\T_-?6)&\O8MP(V'
M<\XXNUV7612A @]C:(=?@*JS3EZI0U=F)\A+!"^4OW8-H^:F>I\52CVC&5'&
ME#;1J9=6P/P4ZXT#89$_Y'6JO_9G0VS;N5E&*FED-* *"\72VZ.WS&OYNA@3
MZ(+3>Z>4WND&#QCM]3!G_5P7-9&(<8375NTV91Z5SZ[FXVT(65!M3);V@*M#
M-ST;DIMMH+HR. @O874D+L_.%>();>PQZ=/M:5T4O"+6%GOT'-M* ISQE8<8
MM =[FSR;_KR;J<KK4U%@%7?I3!]+]YF GW#HU;U)46-_) 'T3(7C@49NHP=N
MMZ9VN;??1S??;?>J _![Q[8N'!OPPWWR)CQ[(Z',8HT)I+HWH9L#DDQ@B_H9
M33/)UMWG'.<D;]S]5$^5@_;[9K+.OIV@>,IR(_P8T<!_$_P0@97 =+=EG(%J
M.Q=AC3;..73;EC>6-OGIVGE3N$6^[J<#\N[ZNTQC%\G 2(0V,!5AC1^BH_Q]
M.=9-)^X7PEJ8LF"VW;"K,8_T:ST$%$M/5!4BPW]@E9@+GDM6%A0<"N>)RQQ,
M$K8'<6?S^6H-?ATQ? !6RH8W78+8/D$7W3F5#5-D\R4Z=@3B#9]+5!S%27W_
M=/UZ_/LGOD84BI_4*9T@BT?]F(S0AC,^\\4,#]!Y2!C=AG:::D?S59.AMB-5
MZJ2P>DE>VGN\(F=3PP/F79]JB3?WP:OB^7N]\;@IAY,=H-WM6B<?"=Q%$L 6
MJH@)JL=DM?[J:6)'LV:(_9+ZQ+K_-.WQG:I029.D@$X20()F.>@E&[QO\G_F
MB\ <19&@&[D".GLQ6@.BZ\=54P=#]^^"1)3(4TC)XI\CZO\ADM[>OOJTT;^O
M;U:KL#Z$5>AYX(6&R(XSAFI\,<[O->KMVU7HI,P?1S^*X"MIUKO$V*,+.#,]
MMF6,9YH[LJS%,J W?#Q:[W0SA#4\RN?[E0X:'*?KH"%SO-C:X!(J^WWP>"*1
M!CU[KG&HP0<C<L['75+@^R\.NH3PMT8:C=9<B5\$4Z,[Y@RQ,#:,V*V09:PP
MB,?NN%IE>>90J8>;!7D<._=%3X7EY/[F[[>@_O\C^@4)SPND=._?.^O?"I#2
M=C0Q(Z1?8IA53 YM[^@ZF4O<4A+9_I?O'6TW9WF&% VSI^V\^C(<"^S&:/4=
MS#H3U*>YV]3;H,*852*-- IX95:K 'IG%(:B;X@.4TZ$1"B%,1%:+F(1&,S:
M.9]C%:\)7X>(GZO]'[XM+@^<YOT?[+UW5%/=MC<<1$5!09H(*$%!0*I*4UI$
MI8F =.DB'02D!PB)BO02!0%!(-([2)<:(!0!Z3W4! 3I"<T *5^>>]]S[CGG
M>>\[SKUC?-]]OW'\8XVQ-^P]U_S-N=::O[FS]MP9,8^>%)9(07G \^2S#?CM
M5C_&<H(JB-FT3+.$Y>!&0G-XARUQN'%\^\"0,& GT*W$!AZ"DVX-NF4#4S+8
M2:>'K'PTX7B\4=&CV\<3:_T<22,_IXC[% #J)O&/_<U:BPBBP#:(, ;$?0?]
ML;\Y'DSE,F<;!LC25H,Y[$,4 #,=.P6@Q/>K E:Y2.S:G:  SJ'P<'*$;"P,
M]^F/+<L&L'^4!;O_0?<_;OQ"'H#O @>LB)),G: C_KD_MFF[[5( ,;I_$F5(
MHM=5(SZ\;$PDP.=0QTJ@[S!%V)\44_N3)..]&RI _ 4/JUTL*)!I@T !W/JG
M,;+!VI4[8 /AI W0;X"_ ?X&^!O@;X"_ ?X&^!O@ORC ?G+>L0+18,AU/$@-
M@X@6O6H_R5\_Z+:H-RD(J+))I>TJ+T+\N?]:4%47,=P7>, "IP!4-"UKS33A
MY;?R.(_/K$/+<B+( S'H95 ZDF /C(;M:31Z40!O9ZDW<V61.<,6@206]S]>
MDI/UIP ZBX[8,LLI@/#@2 H P7P\936%)]L<KE, H=9_O+/W\%,7B* U!\,7
M@C ?H7^\+"B 'R"S^B&(SLB,1T+_<>,DS*'K$+Y2]J<.\O\LBAPBE$6^QBA"
MAJAM6Y,0P/^"JG!"^)VR0SRP*>P  OM(#J#^[Q_4@O])4ME/O4@0EA>+7&F'
M'@!_X_N-[S>^?S%\:<<#4RO8W$\>KJ?F4:!+IGW>T[RQKJ<WN8R^7;IG<QBK
MOA 06??GN'+LA?]$5AL(11ZP@(YDYIK<:A# YS9G-"?5S/:#NDT@;A/_?,!@
MA_\E0O7\:T2VWP!_ _P-\/\M@(;E&>3.^<L*RC=C)S .$5B;N6.=0!7B,EKD
MUTYD!#@XJK;AONP^=?5C6G98W$:!"/P40#L%P-)]>>[FJ!0%<'KJAU];V.;$
MTZT3G1 D$=I,)# =\Q"52.F;-NY,CEI^):[M]7/9F2ZU=SA;6\[<^?G*9]OJ
M@:[5]60/ ;L4M;AJS0>'-IF'^S"9_IZGS@;5D:,MQU+SN]T4P':\VE0N!9"N
M0P% 4N8SF\W7[IK)K[L^PBXS:(:7YE:[QG<QA#E^XK=N.<[CQ06=-_OK?>;
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M1 $P0?^@S/<G7B-Q)ZC!*NXG!:"["_\!)Y\$6F9"FW6MWL%PO_ZHL",&YJ8
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ME!!-UNF ?0Q\ZJ<H%[D+)%B ]JD^[BXCM\'_]GBCV&$'*D)$H5%UJZ/&'RF
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M<.[LC.&F:[WOWH[ QJ9XLRQ$I3G,-'2E:T[H:YC9I3&;)),Z.R3/TRC6-Q1
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MJ^G"^,NROP+LAE'VTA?--$]K3G$$50B=%G"M>\X=U[=N(=BAPPD>!H:"*K/
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M]?$ZB]X4 'V5%9NSY47<2D@505PZQJ@SJ#YMMYN+S3 )> .]ID%;BO7:>36
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M)IZ-$F$4P,GC$>*#8G"2)4*WPBPBQP;Z76(W7\$Y2;["SM#<]23.(,#8 ==
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M@^4,ZL-T]\O)Q9/GWGATJ#+GB#^591 !^<Y*ZP3.^S3_4/UE')#>NLC$W+%
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M'4B6*4+:WMNQXLT7$EQBBL\OB+Y7$::I5^,]OW-+H?+EK%DJ-;^PLG!_10$
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M"Y'IQLT=Y%+/D'KO#ZF!9M#!".X^!-#"O MF%S@MJ"Q%N?EP&ND.PO)=*]'
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MW]>[3._,FBS;<8L^[HV&./K#UZ$' [F\K=DY6:59@5Q]J#I.1)K5ND#9NN<
M!2//8: 9*-S]-Q_;\7\45KUD,42O2N2Z,.&9+G[M<F>UZ"GILH 60Y/),;"R
M^INX3O7>,H\960[\*SNKDM*'A9W/+; Q$ZC'U$8D*ZIQBB[1N"HZJY9PO,N*
M\@,HRA+/^KY9B7*J/C[7!0ZB 4[FA]X^S>20/WB3P^GR>PX;]_4@60/36=)S
M[>&53LRV,U6[C&=+3*A1D\-4^6_>(_WOH$^$FY'T\DC;,ZBF*?;E7<7+HR3S
MC96 T0W+83.NZR<->$Y>!]4\V9 <-,WOTX2I%*?;TI=Z0@.0N1=$QS<.W?'P
MWI_.0#B$Z7.X$^D8DL#4=IB('R-J;\,59MZR'=7:NF87,F^BOY0 :)[GSUGS
M6. C^DLZ*7R\ ?\YF=UY4;=[;V4;M]DJ$[.+5:]H93WMZR3#[#AR;[(KF_1X
M\J$7PSEE@TL)N'?*RN-M]  A[>^E!L;FM7EFJJ+E.F:,L@:,$IE57?^WMPG^
MTV$,CTC CD1?@A6]VC[605W90B:#^-K0-B3(=&+.<NPG"V%(&KJ:QSH_$*.!
M2?(;BQ"S^:1K:175G^Z7[7/?0!/AYB\,O8K HHK/OR4;^)X.3/Q:1"A,?HXU
MIH0R'G2SLWUK4]_#^K6;[VO$K#4]7+5V;F>+3,H1C$H7,926&Z6Z(<Y2U BL
M3;U<4%_75CZ+?:VBQ^./*MZZQX^]^FFG'H4;485^!ZT?(5\F,1$3OV<6$1 I
MU5NCP**5\MCY"0@[*^/!B+@J_\7 *ST(:XK_X01H3;E'L@^4&@DMZ&UA94W0
M50AB"#B]>/0V0Y> 3YS/=]/-,24>ZY*3GWV3<P>W2="L ^ ,_.")P')-^WTX
M3-/!N5YP""[S2<<F?SDE59."1 SO3^"2$)\;V,QV=C_KZBXON1WG,+CS]^;3
M?RU@)' #]1QA(3O5)^*GE+95_5,.R'(Y6G7+38Y#(% _$$760#9>K/68?3,]
M2!4%'Y86K2A^D+6661G#2$9#4I0GN:6"K#!O6V+!!:%7,]8$2J/[7'IR^]]J
M.XC,LX8BZ2B6A-6VT[ZNC?NVT,EZ/K,TR>/%]IN=I";T2L Q:.6O5^AKX^^H
MW1B6 HIR#JQF\$,+-B.WQ'FB]P6X^$6,*FN!)_0$XH3O%1PPG+N9RM0W.W!I
MUS7UL=AB%7*S2W@^[J/U50#C9A[>163&OZJ+R&$JQ3F0MXW,5%]3Y#38S<C?
MVHQC-U]6$7J;6VOV:E*J1&5GU&"<,*^]:N7G9Z>!>DK<E96_(MPLPLQFV;LN
M2P.<$XP\",NB ?H,1][Y)C:I(*.GCZ[(E4CLB<=%0@E";;7=7#8[YI=C]1]N
M;HT.>^ZE%6T?<(XZ3S%[P2[>&,X]>.\Z]AYX=1]->EQUX7W"Y$V!HM*[*GFY
M= C.G?O._855N9V+DL]>S$IDQOSXU[I5_E7QQ%&#;6CG [3$[+:M^,&3T(<(
M^WW3;)+]M&5&\K+[IZMUE48O0Z,&#U2I"HL//1AY[#9U-XM_],O/BZ23D'BJ
MY8T9*6V#J)Q42E_+A)UZ-'""ZK4:=!QP)/C:D6L :T9SDH65] ?ICVI4O:*)
MDQ*29S-C)*.^_/NQ4\= YOB-I!D]UY(5K%U&KBL-H(:&]3]:' OF;/Z!Z &=
M=,F6T\?G-5X![6;CU]. W>U6\9JN8#;SA#+ELB6L6*MZW\(OH6=ZT%+B+QTK
MAAK0'SK/C;W[HI,G?ND\]_[2>?Y@  GTX:0!0':[14^UB_X7K]$><8=N$Z$!
MIVX3U7JIO)&XQ0-VUV/(:27[_R9JK_Q+U+YABJ0_1@,0/O_LE-C?D*0BNC9M
M.H3:W_Q)25K@EY(TSI5R?HT&^$-*^L\,6[W1!%JV(GO' M>414:W0:3'P%#4
M3YU?DF%A$R@:@"_K+PWG#4ADK5:B]\@R=9&B 4+VOW2G\1[4:*5@##ZMY#^$
MM?_<K+\=QW_\_B]S<;;=-,#T:\0I9-]YO!+UC#>2XA3W5W;1=S+C"F<PBVOU
M1('X-3_47SG(X*\,&R^_,MCY84HY2)EL3E"/N_(_\!#H+^S6R<5HU,30 *AB
M\NCOP/P.S._ _ [,[\#\#LS_DX$!VY.O4L0&<MBQ<&F\96G0G)H&L/1F_$"\
MH+\41WU5M+_*'RLTTN]_X@DQ+AM86U^32MEHAK&WA2YQ'#%9RJSBATTD<QAH
MGE5+)+ZF >)/-5.;#GVTE.L\O-H!<HS;.[T&6A,#4F.2ZURJ5Y!'47D')Z%G
M&&-FAIERQN5EN^L3)&SV!TM-+\*<GEWA;U91%7A[O@45\(@&8 23-'^Z[M/]
MTCV50X8[&9@'.*&ZJ00S;[G#0'+W89;8;&F H XJ![)))@OY_5P[#7 DD2)I
M&(/ ?MP&U5ZJX47BGRU-_3SY2YGTUQ>"_ONK.',UA7[S?O/^/^8)*1/LP64#
M<$?\/I.> \RF>I 1+" ;9F;:'633 +S<J 8TLCHLBB?K8VF :\^ E!-@//HJ
MJ8<&$%ELAI(9@ ?\KE85EL9.@\3[4U=61[K#DL92_IR>164+Y*<&<X%(S*AI
M\U>F,N6YE-Y-Z:ZB_YQGL/X9>87<])OVF_:;]K])FT4QE)(M]=I0IZUKRB-6
M^"VOB;+U\'A%PSO:3K-M/3_2\)-SF0;X\P*Q'1<*VM* Z]( 7U[2 'T5G*M>
M0S%Y!L;>B6->6[>N2_[/"LI3\J\G\];:/WW%^\W[S?M7Y+42,)$_:\#'5[<;
M/XPURYL'-F?'-\1\;5(\&T)/)[0S8D(?1P/,W22('X2Z('\:&0\4&+T-Z$7,
M.$)LDTA7LD:=4"R> 7GC_,XU;]36M\&,->7GW>1N=^".D$R=_[RL%$)P4$I"
MW1GJ^&$3OR=95R#+Z71QH#1C$_TZ,RG^/Z]!)G\L/T^Z#4HYMZ]T</02$L\+
M:HK[BSY>^T]- --OUF_6?R$K'[)$Y(*]O@1[KU'4E$<)M\C,&4SKZPA_::#)
M^;KI[_@?[C\;6$4//H#F;GXY?)B_0NY?--^IWIZ*G60;4G.<UM,3/'\\8T%U
M\$U2]OV]6T^//@7G,?Z\N)*>F$6744T-DXD.YS"PR#G\N';\'P A'4(:5;LW
M D-D!^TK3M:YU.[.F(9Y@=E(Z$:EX=.7RK%VFV\]>\X5MFZ?4P9D^&HM+UN%
M6QJ+OKWHJ([>>UEAH\EA>L'F'_3:B3X!SDL#Q&_/F!Z$15)C*]$0M#K)>5K0
MJ#E#DE"V0V'B+/\8L&A>_+6@#MYQ]S;]"T'__9'WIB;G=8TAX(JYJ!>-_[#5
M/1 "':Z,M05%9*DZ;,_T(3N),^L:@9"FU*'8XLBJJN)4GE<OY7KX 7+^3YV6
M:_05Q8NZX4PT0()I)G(<>0 4\RGKH$A^EX'+X-1E[@S:GIZ\OK 7E<_#TE]S
M2EOP9&%Q:>'@YY["S6T.[^N:'";'_Q&Q_XW?^'L I(W]&U!+ P04    " "L
M0%U8ON4>*FXV P D300 %    &UN;&LM,C R,S$R,S%?9S(N:G!G[+MG5)-1
M]R\8!*4H57H+2I6J=!"(B'01$2$(*"(HO:,$# E%BE0! 04ATD1JI(,@D=Y[
M[X3>22@QD)#<O/^9N?/E?K@SL];,6K/NR7.^Y#E)]G[.WK^RU@EYFKP,8#'2
M,]0#4%%1 ?Y27@#R'$ '0'WITG\NRJ"A7)?I+E^FH;G,0$M[A>X:P[5K5QFN
M7F5D8F-A9&)ENGJ5A9.%]3H[!P?'-68N;DYV;C9V#O;_? D5->4S-)?I+U^F
M9V>\RLC^?WF0_P)8Z6A6Z-NIJ6X"+K%24;-2D=L!0 " ZC+5?PW _SZH+E%B
MO$)+1\]PE;*@A@5PB8J:^A(-]7^BIMP-IMP'T+!>9KMQ1_O*=3-[VIL^[/*A
M23ETPO<K6CB>C&!$%%[YAM$S<')Q\_"*BHE+W))45%)64553UWF@JZ=O8&AD
M_M3"$FSUS-K!\?4;)V<75S__M^\"((%!X1\B(J.B/\8DIWQ.34O_\C4C-R^_
MX$?ASZ+BRJKJFMJZ^H;?K6WM'9U=W3V]HV/C$Y-3TS.SZ)75M?6-S:WM'>S1
M\<DI[A_^[/P_>5$!J*G^C_$_S(N5DM<E&AIJ&MK_Y$5U*> _"UAI+M^X<X5-
MVXS6WN?Z3?E0.O;[23D5+?3""D\P'*]\1Q@X1131HMC_I/9?F?W/)1;V?RNS
M_Y[8_YG7+. :-15E\ZA9 2# A7ENC 3@?\W_-?]?GTUUN"Q\03&1$R^P8L>S
ME88+L/Z1B?,2$] 60'O);TAD>NM9@J0_Q-U>8RZ H/; A.>0+EP"UBFZ&L6V
M_5L@OCG+,?V.<BK-2..=%)=KCJDMW">7ZN)Y>C-_UCY0$Y4UWRV60 Z91J P
MCX>B%U7P$^@E.COG9JY8D_&W7T[.7M?5-#Q+4TZWES1IH:K8H</E9O%,F'1]
M-S)2;CCGTH56$8)@PXN*>'JT':-*>&[D[/-7[Z,+)WY\,,$]B2Y@-0M]/O3G
M"R<-; OCUP9_"9_EZ[03;!)?L5]EJ4NW5FIG;2O1=_\ETYUD^_D&X/[VK^O5
M3"*V"1M_/ERDUV[Q[V9^/L^-P=O@?E^@WII&O;B-PNBW3<O JQ5Q1S6,KD<@
M17T5FBX&)T]PGD+XX#)7_,0Q&1 .6LY#\&C<+1'MK"B:AA3W^9ZE!4RRM!R%
M']- .!@J! :7Z?@%M6>Y):L2Y6],Q+P#63LCU?'7L6-MJ&K:4'NL>-2L02TJ
M*=#!)U0F?_F2644+MU D/\M[_M!Q_%@7+W,;DNFYVZ+HA,Q)\,UQ9N6=9;2V
M. "@)I(2 A"9XHO[W& ]/KDSI2*!'%B* V+,+^!F3?65>)_<N6W>=\H_"DLZ
M-I^S,2]:M06Z)(5&+BUACNA R]\1 O9-SQ"=MX>X/3H73<3Z]?3_^=YD3,1S
M!N_^5F48!;_3DZTV(U#K0JDQ3B2&4('U_=HLK().3*>X9'S95N^Z\"9??DB:
MNP/-9Q&,]Y_+P>A<MPSX1\7WFF"CIJC'8UXWGY4=E,UK^.9=BWRB'K->HN?_
M_$>\L*A,[#AXO8NH*;R"O+A*8B(#_DJA2(9ESZE)#'FK)>_S/;Q:2(+C,G70
MD>U]S9*D+JJL=<#IYI7?L#R;"L%9VNU4CDV[2S!U2  N!".M)8(A&').'<E)
M>]X6K?X&,%)6%:9A:0MC=OBD97]1BO(T%2#2XCL"T)K4AIC]C2S&_.NEOU.K
M#Y4W;3\9/0P7_ ;6D'B4OZ!8H]N07Q[<I0NSA;>-:DF2 <.HY4/BI48R8"T#
MA-X&<L"W[# !)*KG9,"1B?_%_0I$;>AYHJXOD$[#K 2RA';Z0-0IMVYY7>(Z
MZ\@UQ8GK[>-5C 8R\'P)#5,525IL5KC(!RWG:"GAP=C,]A=LF,%8]&Z6G&&R
M*LWYY^M]BLF!KJ-L#E_9 ?U/KSFM;Y;3*JE?+Q&G.X@75>)X%_SO?Q@6P0:G
MB5]'PH;MZ#>QH.@RQ5TI_*E:Z8<@6U]]SG:#:?Z[#8.V_TY6RLLY"[B/C>WU
M\AWW$GUR8Z0^#4ODQ@ DD'V'<7:U 9T@!B(<:QIY@N(.3M>MG'I=65=#ZJ\*
M_E3:>/_ V5CP;K+I']CW*5UKMMS<]?'H 2,<@T1N0Q^#!#*!#%C.L0,V!6)4
M2"Q _'VEI3W3?=-]YEIXSMQ\8+/=3"V\++XB\<ZY@]JF*D>9I&?UN'"CV)-U
ML-/T9W HK!W.KF&*?;_L+BB$]2R\*"NIS?&AJB=H/";&@)WG>(NQ*;/-RF1
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MKA]G_R&ZP:$+ZTG[;5/LCS7"(O<B)9XXZ$PPE'5#?(9S:I@4XL=PX5@F5/X
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M_!V\\G*W*VB]F7:K^0:^AF ""5\U.0C_B7=H=<LKC\^=<V.YR#[: \KT=VH
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MZX:^%O:_1(7K-5,_?8>]07!I*&#KNBO@02^P94V6/-Q[9?;2Z%G36=7'((G
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M=9WV]<(6!FN+K4F,#U>,4TJVT2I>RP&Y3(G577-4'5O"GK^N)!\!^<CT?T!
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MU@ 8A)_"]>)!JS#F<X#[Z'JAA,65YM1QG6:CX7=,"FE2=/-0%/*.<1!G_SD
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M5_VBD^>>TCE\41Z6J!,C&.RG31K>^M0F](WXBW*+5=#!&<P)N:V:(AV<_(^
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MMP PW3?V<_CJ)UZ;1>E07;<+7J$SC@Z(['ID Y-HQ.YMZ-'];&B7!.)7-GZ
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MVU(^Q,CNOMH@9K/$TQRTR2[Y^9)N,S_]D;/-K+"R,_4T9EL_VHX+7LE92>)
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M>;"?=&!JAQ<T>6!0]G1[NY&7_%%*EP\[K@]]R+11R,&5KT6;IYP#P6^P,N?
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M??/56G(M0I+9HM*XC7V=?\Y<B=8BE)<X3J/D\?U7N0(LS&'&G-_"[JO2ZJH
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MHS'-6R1!*B05R&'B_V7YO^JU[HBA;CO>%8M?-;_=DHL-.?WF.YSSC<B^UD>
MVD>$S1MOP,'#4]"_<_29WD/O9R+8S#MF[5:E1+5+35@TW_L_+Y0&U@Y;_8=>
M_VFQ(LK\GXQ+YJ"B.P7DNE-J/U7OW+7_EJK<*&D@X!!&-T\M^L4\]C CRX<O
M_^_(DQO,0A1OBA^$+C*&FXPB&@)&-=B%DSX5\3Q?1A5W<$2Z_/HG3EC_0,D6
M]A6B-^9Z#GQB'@I$5(QGC5?7-6U]K_/CIJC7N2:YFW9 \H[<3[VT[_^/]9-_
M7N1YZ(,_5B)#O.29$W-O_$1IN;)]*RDLDCSAON0NS(C\NZY$EJ-KPTL@I @[
M9=/FVH;ZZLH7GEQ5$?(Y]-=CKA)'K*Y& %J:""$:8X_^#B]?F"4MRM@4OI[C
MKDZMPL1%3L3)+D?SIY!U_#L4YW_FR?DO[/_"_B_L_QW8C4Q9L92HL;;?$S45
M67@YU/?0(F-Z8;.MACNP)K2]7DG-(Z7^A+<4E)RQBXV%][PUFK_V-5ZFU=71
MT56A!?X/0K2RQ'X.K'IC-<^!-VL$QZDL_./XC@JLT+.+=)JWNZ$NW'R<EL7O
M)M+I77<D3#'OG)&PKEA=&FVYPD$-$1F3(/,=,?<L/J7IJD_RDFQ5?4#BX,V\
M_6MIIA91$^])-] 2A!#M1DP-U:58],@P&3B18;AHB;27GY;*B^% 5LQ)G]Y+
MTF-JX@:XISA+I^6G1-+,N6EG:EG3(BPEGDXAW</E'X %OR*6@IFC\K[=%6!;
M&_S*5AQ_EW==/5GC@W\K2?QHD>\D?3RTO:@R:HX>0V53\VUODG.+G$,TF&^,
MZ">$G?)2=4DS&UX#)V]FB6W(M)R6;Q'JT$]U0T:\J8C0(7V&.EAQ2T5?8\G_
M5EL_"@NGO^J3L_2]/]P-KB=7L+MP1OIXN4D*]\B&(!VW/=5A2EP_<<PB8R(8
MCU.Y%4!'";N:,'QI(%@.&"3U=2Q8+@N1;8Y&/S1Q-T"?U7XZMA@C]#J^2WDG
M6?G%,)!+*A'_QJ^#;JO;\;FBA29C"9ZR9+"PV:Z[WF5P>A5IXY_Y(/ T!=AN
MLD5[C;7+EI0&V>4N8@.[&*BN!L?GEAXQ9T@UQEPJ?;#!M*D.K-?W#T5EW$)5
M2YXL"F.=\S=E^4-.4H)*=MV_ 4IML;H/E#2(U^&FHA[YS=>$+[C=5_1+&[YS
M@&9I[\6MW*$O'U 0/['!A48OQX#FB9W9I!G%JM*6:OG,<D]M3'0ULN\0Y0Y>
MZ)ZWE$'2$J66> RIH2Y"80TML+;R/9+UNB,FB"18M7L@N_YM'["O7B83@I2*
M@,GICU>7!1DE+(8VBLQKYZM=[HQ-N[E#I ?G#&SC6@J#G^5QVD;?P-+QE^X5
MR\N[ICK>69G+02E=B[W^9:@/[?=R3_'>LI>!VCEP[6 %>D:WA*\I@6(+@1U?
M#LBC,=_;ULZO#',FW6LJ&86JYSH/]^WN,)V^>[I 00EA7_9?]^+8DU,,^YZD
M-8QG\"[R"!7D5GX#=OG&'42FRQ\OZI=L'D'E/W\H-@*1N3 6%KI"7U^ZW2P5
MV,6<-AD[:VH,S^NR0<>\^&9)5=\V2\;T*D9-7I]T-_G[W!Q6NW.J@)'!@'EU
MBSN]+\NDZ!?+EW.@-1)P(5!ANYP+L+WRO"M0\GFLIED&C4*QZ*O<GU)WB7C?
MY0/\ "\CO,]SB&XCL_K]CQ5IO./RE]NHLG0+RS*C_CR3<\"JNV56#!+2.Q/1
M=63A+L7ZOF$H,KQV1:K=^HIRY-M'Y!32]Y,YHNX+S3(05(6"S##BL^? IJT2
M>RJ"[=G+2?'G]5/BBE@UV!6W&^:8ZH;9+)1[%K#JMJ>'S>Z<=0^$*'J7V(R%
MVX$&I/IY1+W\ +9>;D NCD^_R1R3*%Q2YK_T#,"Z0E3L7:G/ <=GY$2^. =C
MA9;'0.(<TB#"-5RLT.K"%<=\"U=314PNW$ERV*W>47Q9\^8#DM<Q/MY38H@6
MYAF/(TSRB"N+^CHL3O&&!MC5TB6(!Y9N&0_1N[?9P87BG!JA0\1#+Q)EAZGQ
M633X0@$$AZ+=W#F@(,56?W*(\66Q(B['^J,#.,AV;EK)JL:ZKF32/,D 8RQ"
MY]9XKM[@6OY(ROX1F?D$"6T_G&B2RG_ $06YX8-0 +D]-]&3JSNPRWXO;28Q
M#/@=;7LY!J8L-U$AH'2VBO0@GG/ PJ-+GK< 7K"N;J8>O*U1,ET1%*BN?'DN
MBI0U<-[ ?,4L&"3;/"RT=SP47@Y]IW5=S1531C&;XVO(*/,6R?$J0N=*"#R9
MVHK W,M2'-L243VI_RSFP9'P@U^EO)B(J28UCBAY&A)3NJ/BXN,=0Y>=ECW&
M*9PJ..943N1+\X?2=63$Y$:G%KWV#:S<,B&!)ZNAH!+]-/[28O%;D?OW>VB7
M:?"<[C)_'%5J97;*V$P'G1ZS/0>^E@#NPMAM'Y;66E,N=.)G^7L8G0&%LMFX
MW<+]:U]<&.^$ I1ZEQW=+GI<>?,BP_1GZEC# M/-#\HJKI)?:6GZF=HHRNGX
M'^B1_3'E0C )U]>P-[?OEB J5EB@>P)++A0/$^%R#F:*(3!O%<!3,>#B[2Q"
MK!Z_ISKH4Q0F<DK,[W3-_#"GG8S/KJRFI#+- MSM-SO\'M#M_&=^M)W?)%Z/
MIO'(ZYH\!ZKG:6:Q_(N+<UO4<[,OSP';1P';T]H\@NZQ'Q?. ?FAGR*F;<CH
M,'THY2\[09/'W2LFX&>=;BD"&7=2##$1W63+?C^S:NM:9;H<?Y?ATVLBSX&W
M5=#-4VO&NV?%-[=[FK#>!.[=!5'64S\H+%#(#(&_>TGS((J=#[608N/+A7V3
MOY7"/L*=E#C[T4#O41IDZ*:.0>#@BLCIE $2'#;)SH0U=D;Z"'!-%5/=CJ,+
M PM84-Y7.ZE)SZ&7(7E'Q[D\9<=M+0YF_52INES$1QY J:.6"TF2,[[07A"B
M&:T=/S!BCF;YGC+=*KED4W-7C3A* V]%O"!_'2WW$HW)I<68WJR#H=+:E>GK
M/3T^C0;UZ-5@EX*1)#'"VGF@D.>_3"3$3=CAVI\"Z7*H6NL8&5]<D]X;+=4A
M_0F]#+HG%=PDY)RUV4"W$091EBQQ%7LY4Q[)^:FGD-W0>$WIJ6/F4P=A[:^&
M>)?&D>,Y+2FX+TT]2F]1,<'.Y\ZLB5'5\LV2^P!MVMD5&;ATW]EGH[:F6RM$
MX-6S)EN#2SM6[.^E9QJ;1=+<< M')F9[).*!*._.I3E*9F6,*D[&,1X3X;LJ
M1!J'4V,+W12U(BY$AT2(MURR8F#NKG#$>$L[@'3K5YW;OPFA111::/RNEDF&
M(Z4B]XNA,(%F&AN]+5+R2LELYOG*&&&5YH&-L@_G@"R"<'_&9C8II)GTSL )
M1CMY%>Z<_VJV>.?RG#)#H@G'M:>/TCB4MTS#_SSK;_Y2##=EF\(S0%>L[+D#
M^K4UF#&+",E7QJ*7C*2>H/ .<I@!)R\&>.13@@_USC,43UX.UMDH]G;%Q,=^
M!\/,3_WMX?7$U,+:.@^8:,^!2WB^N#E==/FDO#EXI:I,J<8H1W)2=U;^ U6\
MP%K]M2ZV$"5MDO6*W6-M6M\A<_71XX)E-*\_=X/F=1/-=<TY8)JL4NC6B$.K
M76_K-NAY%GGT;(OQU)366#%I<*W5R'9B94>13[/(AA;L''!=,W<Z5A1!1GMA
MEB[O,*_7YOR ?Y)7. ?()E ),89G,,%#/W+0+\!)@Q%S4B9^5J2X^FBX95?!
M&I]39IUUS6@29HY8X-EY-EZJ-]@^*<8_IC'R'"JV2<J-XNO[8_]P46?BX3:(
M!6N>O]U '3"R.+\$MSGB'!I@?9)3Q^E8G?8K]ZR0QKTCG"%%*EXK^F6U[5G6
M\H.ZP,9A^_N@'(/2F6IJ(Z7)[Y*P=\^H/@8$B1SNP1F[1<* T\5^N'ZS_%EV
MTW57.EAWNC<XSZ3-.\_TEL;>^ZNW[K;B;C[8)]MT(LW'JV!KK9>-<0KL4UJ-
M:,I0<+;HG+4D7]([DK69<K>ROOGEL['C4J$NQ=?G0' YRBRV:N\<F''GL)Z+
M0/8GO3^ V._,T5DB/KW G@-H19P6K>TCHU1]!:V,GY ?%9V&)WBK2]YE40U+
M'TOMEN#L1#]0@_'BX4SCR\U1O^^&4Q/%]^M66V[[-%B68H/0RMHHCI /KA+!
M6C8FCSU*JG<TKU"<@'GYRB-6J095O?SG]0_".<<$(4)%:B4?F!_ /B]4!]YZ
M>TU32GGXDI=;&1,6O$R*3<=)8E6[#W3J1X]9-(P..W0"#^9Z64<_F0$1?B'?
MU<QC/+,HCMHX:& "WIU)[.QHAB A>8'B' Z;,,DO)@_$#8'R9%K!!_?)3N"F
M]RF9(6\)'>A;J*F0ZNM#]-A8.NZ,P8F/NL9<E)_[[Y'P./U0%9[A?J%(#%%"
M"X1$TK02I&&5A.FXH3TWH]*4@573;\O"[[CNXD442$D!2&/3%((RJ,FB9'M1
MSD<.+H(U>Z'EYI@_$TE_/<^-]S[!/,:-(^W^+T9NURQ*E4KL$C1G1W(2)(-R
MW0CD;(A1IL@YT7!]S\UUO^P^D*\-^B'32G*12#^= [2D_@<N=O<[U#,[0;<F
MV4:'M&ICS?EI+=+G5V]'1*EOQ8]H.8*$L<^06N8=[C6F7-A&\%FD0Q$;?!:B
M:$O]NGPN:5'8W:Z;3*:;+QN=V6Z\Y_T 59UBW\*3N=)"WGDYJF"-L&]P.,%-
MS?.47BM0OH:(:YV)A-@,L=%I',WTRB;%K2#+U /\:LQ092"A[>B9K:5M3NME
M!X<%!0I1/EB9'-86S:(_!7E0XF'0Q>Q:D[YB=TO/D+EK9J_TJY-;+[NG;F23
MR)!"_?7-SX#!Q\T6&(U';*GX&5=;2E3)"N-ZLF^;I;#')+<TM<8]W2I')(NV
MO2> @WE8[J:XC"',J,_2'DJ(E&ACFLP'^.!)&3C'1K:J%M9U/\F]9FDSJY2U
MX'1D&=D\5E+NJ&9)QW9Z?\]]@\CT$<#CL;,S2"I1A 8C;Y2UJPZO_AA;_0$;
MM_3(B6,21E_6<2JJ/N"5)N8[+@ I:.3"4= NS:(F6WN,*/]#/=6=B/<W1<9/
M_<E^.W?;]LOKFCOF6V=6'3>7,:<&.G\84]WTG&-]0DR\!+SS6O>3,S%':H?*
M2R!8RF[NF%[RX9FPJ(V:98G4)1\[+0DPU!=;2V#LL7=R]!^P@^A@>_/P]R;E
M%<&%1O(U1M],JN8[5YM4:?5?O,2DK\U,J-TGDN&E"\(]/P=Z>9((+7O07Z^S
M5VI2*8K0C0@2L0#=]^-YC(1?#O#;%^2UY^XEV 9\Z::'U^@-X\[,&\<"-!U.
MLMG;/'MWXH!7@ENWKC%=T782ZQ9+&1D'2=G(?L_U 2]#KRQX#(YVI<A%/I:K
MAM4(9MFKI_L?D?5L3=6H2=2BD03U@W#H3MLYD&N$%7MS)165U(8V5KT=65WD
M&1:@/<3]9OYH^R<<G745Q(17J\8F?)M?Z+ &)7M;.F'<&WRFJ.=^_GA.\/'-
MSI<8M,UD$;R#EM@(P;,@;%L8MV4AP7Q;7'7&QK;N3*?DI60+A^5M<+XH+7.(
M!,X(KX0=3G$;\<3D&RT8LT#&R+_PRCM-#YB>)73%X5G&5"H_-!J'^_OFR1&&
MN666,G"2OHQ9Y)E4A#$&WZNC!]JA3930KSM4^;::AJ7*<XM4MXL*7]VGJG]1
M>S8J+'M!(_"JV#4[U%K3W2FC1U.QMN7:G#CYY#@I]9$X":T6&;=8 QG&G:''
M@V?%BE47K=+C[1;[N0U/E$^T N1 V.5D9MUR3B(5J24A 0XUNY05XU>8%!\1
M<<36)$HY<1GXL,W!A'^ 2-62TT4K!E"&_ K_\5".IR[^A49.$"OU':M1,3@C
M7UJ@:8D\>K:#>TR]O(,YR9/[=6'A%0WN7X"^6F33/5MDYM7MAAL(OLN_;E#%
MD'^9*ZQC8KK?*JE0M($;^M20% JBW5*D9'YCB32>.T*$+Y.![]V^7]GG^];P
MB8I31X F$@9X6[8?L&NBN3IXC>T$JANM!;FC)DP?KGL\][NS9L 2M2^S-=D@
M8&M4@=J/=RW8-KAG^<:6*=$Z9[-0,?D7<9P';0I[N#5B@+E?L_R3LJ7EM39J
MBKYL8A A;[(I&U.H"@Z1=>YET?BN5CPKF>WG('#8NL%V924030OL*$:QWT?3
M%:<D!1,8MYE+/Q)YE-E+D.V9OB/!]]+<$XB1;I,9O&]VC3!"W\R/QL0CU'^Q
M#(!^K]R+W#:K39#X7/'5+E@ASX&37%*--,_F.!7,NXOVR;2<P5 *]7<OU"$9
MD8QE-&CM:45$L3S#Z@<<%&,"GW5#2A^NS30NL31@N@ 3M.4>&V40WKO$0P,B
M=Z%<8@F8[;.^T[XW//'6K<MN^+"LY;1:>]F548C]1/4-9^TJ=&V ?1.O1?[3
MFIJ&N*4N=]*4SCU#)H!J]9)71G(WD43\L@_HZCE@$_WI)$ZUQ!%L\3Y6!-BC
M))&KV/35_3W9LJ=]30,E9_8Y<%T)4ZG:&O.B>81YX]#\=)C4!RG$9 TB0IT-
MPDI>A=O>!5C)JRHVP^0J?N&? CQ-BT(1BU(-%83Q&JQ6@68.JVC/;(2M4Y]2
M&SU.*N-'%7Z;(]HJ$Y4.X8O7B31[:/)F$I'+T4AS,^,I<BS?>>CKR47'02F(
M=4:O=*Q81I95"\@]R9B];BP$D^@:VTUX)9O]"&UW:JC)[LZ><=R/9>B2\KV*
M G>5N T]8>Z8]FC1R] T4^SE$5D[>#UGO%]JG*=D _\(NICK-TR00N6["V?A
M'+.0)O/!!0HO]^YYW'J-+[%JO!KZO@S5NTB\10'?'ZUU4HQ:+N#U-+#4$)OZ
MJ'RBF/OH0]D;#03D=<*;V-CIHYY=VQ!%9OZO#>@?70/Q:HBEZZ)M@OE1/^WM
MA:7:0\MO]'7>ZW>UV'62GU-#;^#OME!>=!7M4L]$A[X%UZ,.92CYAP<['UUY
MRO(NHC%8EEY:^O8/CC8HZ6[U.1"(;&=NJ([.?SAJH_=HSB0O9O\]";5HGA5I
MC!N%2!>@BRKK'M!^/E'MX;I$8@-B'Y,H*<JSX=%UBI.[].+="YVW/2019T^O
MJ&^YE'WJO6B*T$)!JY7&5K^,K02-3O-Z8M2_1AE8S5[QVE<,<DBAJ%]9"OA=
M&P(16W$+[ 0QC@O&:XZYUDG=^2DJ1:4FRT[AZ!_82A+G&-:XW'(J(_0I\QCQ
MYASX-NEW?XXPDN2>")W#$$C'UU%*=<)LGN_U<,ITHM=]&L/(G69:.:.RZ7;1
M/3R1;,J77S/:Z^5EZGB23D]]?+5%X#E+J9XK^B'P%<W;T?/^*&>LE#5W/Z,4
M[OX9ON8R_SS&D_L7AUBF<\6/$+W*VL8:J.CBBD2B5!M+@A_G\J&TPN8EK_^;
MCV+^&T7>&//L'(BE,3D'RH^7#J.*;$DU4C%9J&34;]7? 8:FZ:Z[[:)D&.'H
M@;F1SC2V^2/&4K5EH3:S*Y"'J$58 390%>=SN",E?-5W0AS*.:W4+LWV$G-@
MBEL^!T)\65 DU%V(L]M+6M1I/>B P05IP<X*5I?!N\29_[#K%J1J:&.D1%([
M;%A0\$.J3L7$'1?KDK73;)VO@??WY'I[@'>47B.HZ$C8@A%<9QRB@7B/BDH&
M W51MD6K*1HTUN\%F$O-9TEO17EVRTXE01ZAZL;L0:2;[@8C.U2S-KH=F+*[
M]P=C/V'8&J,O/Z?(4_">,L#IL4Q@I0I3E0: %,H:$EPWI8B[.7HN\P-F )#D
MB/P]%<8XL!P=\CLI5+RB3C#7TYD]G7SZK=2C=Z1>!+5\SK<US1R0U[7H1)A[
MEHV7RD:PO.:'#,<QH>XGL2BI;BQ1L/8Q$Q/<]NM9"(Z^ R=FB0'/('%"22>0
MDNSW"C4KWS)Q7#BOJ4$< V;J\Z):<M4>NQGZP]! [12K#BD;FAA) J*:Y!QV
MB;R]TP7B299?VNVGJ>U[0LVLUD9&H7 5#DKN/@>"UHH\P#H!BJQ89ER[%V0W
MOR''W7%Q3O6G0[-M%A'1QO@O)*E$FP=7.^'^I"\_1(O0AP[ST'X6_>QG3'/L
MC?%XXPKSZU=B@J_7LE+(D-:5PCM;R"&N/EEF<SN9#*\)/2GT43M[IFPP=7RE
ML%-7-ZB>,8NB=@7>90P-:N88A;E7FZB.XG3"!M*TUXJM-G<M>O3G@:?I1Y/U
MQF91IO>F7,:*-Q7))02T.]9"H_8UL5]37G:#7 *MWP]Z=#\XWHFR1;8$JR:A
MH(A%?W??AB:='3?)]WOF5*'95(^SD )XZ7WGR>:0*/%@\2CQET@ENA>J '$6
M\:B?](#8B@&>AX,"'B;/EMO<(O^%RMKYE9KMK3><!FK."0^S!98XR5VO-$5C
MWJ$90I&$N:KP=I!]@O,*2X&0J^*>=-*N'FVTBZ^^E$;M]2,A4G>8NV+5SWNV
MMNA+BYSZC) W^7#FU?1"^28*F^C=QG/@]D%$RZ[UCW-@^'86I>5%KQ^$CEMJ
M^SW1$O(KG>?"-[SI\B.YTVF,V;N'(#(ECUV/U65S4*BI$.I93\A*4M?+TF&U
M4C8=T)V59S8/1&)D]]I(N7#]>TI4'JE("IAY]G8BNQA*9>/C7AG_^S V#3 U
M9EJ]IXU:+5+I(=P_8]426+]@Z);A.!^^9=*0 _MU8V]-6]O0[\F#=%3O8ZHX
M7A-)S.#5<:1XOG. ZJ)>?\"18B $]^0(\S?'!VGF2W1'S?FU0S@:ZV]#H*?/
M%_:8WE#.SG%3GM18SBE4*;$G@-$=G1EWHFR7R/!2XQ(+5*J;Q]>+-G<AZ,$G
M5MN:Y '2O5NM@WS%6&_TXWYXW.*TIKEK%C8 ?F5';=S@W68>RSNS@UL]IR'Y
MQR2'7FH=%USMF;6D]G?\JT_6 Y<D:F,1X2^B^^Y+VA'5L3CZ;VFC#CK8[(=6
M$E-+=Y9N9J&O%)A;WO;QL]:9_3EY4/] CD-.^2@NYQU5MQ6Q$"(7\_4[-A/)
M-ICP'?IAFVI[\TT%[F';!JL4RUP0DI=WM#[3'W0';0111K?S!LKWE,%:7644
M8;<Y9CY6V3/"#RKB^Y#2)Z5+RTGXST+A'!AFL[/+A2VMVJ?L! 'HM&=+VF>B
M,8@2M@N,8+-9ZOC]-/Z/=#C$],7:C1><P"YMS4'"J?C0<\@QPUT/>UR"53#5
M9H* 6E#'1:I/#&(6U3S!ZZR[&MPJG=Z?NCVYN")8QZ$DNK>QZ6@3(?/GD^<
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MFX #68%NCR'C^I\VCI<LGOR,T,2XW. &USDP7GT8Y< 2E5S:-X=8ZLRLZL)
MPPLP/H']AW@)ZUI[Z6X6QB[ ]<),O-8M-[\VA/%YI_.]K'B=-*OU^T-=[0=7
MKH:,@:5AEU(>[5F>[:V#8P&.-MG$*L0-$"*K?G(Y^86?;I*+7^1@=GQ:E$B:
M2U'S-:QST>8Y0'MGRA7*,><1K6^BN)M$K_%=V?9>T!=1,4]P-R.YB&F:)5UH
M(=:]BP-(-9R"\+^9@C >2ISMA[CMUM*GKWIPKU)%Q#>6;VH/*+$OF'O29UN
MW8G>!WA,ONR_]?!%L.ISOP=MFZHV7ME?;>D)MX=_[>F/N<^ 2Y -(3\9[:*^
M)G%5M-%Y^4F#PS-I;V.UOVZEI&$>8J[_4.5C$I/Z?$O?P)QWX<,R[Q/RC1(G
MC"(+7GO%VSD?:X;(R"O<_$*>E%0[8BA?%+&O/BV)GF+1&&*O*[PHC6+6:*QE
MVUY15OQC,YJ9U$[[2(K>IE9/CHZ,X]W$1>V9%1QHJ&J7W2PILM&Q6Z1;1(GU
M(FN&R5IV&GO7+0<CGTSL&O<WCX*3++H:<5$[:8@684JZ+F/"L%<4;$7 N8/
M@=*:K"VQ-CB1K'R8U$L.>O*4RL+:Y&&!<\O5H85MYR?C*8I8FST.G)!UFI6>
M8/%K$H1HMPB/-"G(5&Q0\J(PZRM:+DC<G@3=W0:B):'TIDKSSI_F'#8(LRG
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M%5IF2RP.8@N@B BBV^O"-12W<&)W4A1?71Q3R+A3?U.2[=VJ'W/QKBZQ!$/
M#;_-YLWSF/1SG/(7NDUE?/BU_0>7FXKM/+<3>-SZ2SZYC-3<%@.AS@ /TL>
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M,HI^V.WC@_$'MY NE>+D8_*?>)NWLB]8#14LF)YO;^^2L MKX.3:;/P!8C0
MC,QR(J2MH;S ,AG4FN+N+,S]Q+/#&BK(:-UM;%U)L0R_T$^.]EFIVKR[YCN]
M44^PH>E\:V,Z\P1TF61U8^7MJZ ;7F<"K'\>B^</24CNFS-\%*\TP0PLBX3:
M/[&UX&3I] L7>A@I1MU>4'_*.[CISE.L78N%OL: SWC.S'A[K@[[/5V$#X^V
MJZ_7^J@*&<1,.C/NK? HV7+(0W_[/)#RB)@T?%UTROK.\=AH:C#GEL$3%CJV
ME?\O1*THQJ[9& C+6O&4F95*Y$_.:\PMFH1?O1IC<>NIL\7GK?5>F8&:%Y00
M/&C@/TFA#![2.?#>=CFEUSN:*J./4-(=NYZD[6V^L<F#REY?^D)LS7P?4=Q"
MX7$9Z2>IG]0_+#)4<<AOFKQ,PR-351*3ZMWK:^J@!6+[A691IYQSUZ,HR\$R
M_6U&[Q0Q8N*PW.B$S9WC<8Z8!:XMYCOQH/\XY^BU62J/;2ZQJ#8!%I0'0<YD
MW([MC><KCL:Q 2&GL(D6!?7W/9[UM #481X2BO=G0L>K.?=R9H6:))V)DJTI
M87D@B:B+K2NQB*$(H1$(=:W.O+W-(%$8)V#X<X]=J#UG:DS+VXI6J,!5YJ2V
M7MLIGRV?HOSYT:8:,)7^ZUP#N <*B"12>16\8#1S8'77XE)A>0K+_&GS28RO
MCI6JW5MT?IMXL?XB[GD>G@PJAT,MH_K$.\87GYZM4(G=JGNEGB@0X$]1>LPH
M[XK[I'X"%+]_6+]3BY#^T6%-.6*[;I0ZY_:F_1^Z(A#KW-5FUF*&3_U*T2 M
M_3J+17E?Z@<OV6W]J(5R]KWRM7D+*H*:  PH[XY;EE>!D->H\8SR+L4"P9*
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M)+= 8][F 3KSG*4HYCL%Y]LL9<XP,E51^Y5]/R\4MITH<6))>\,]SSBG<+A
MW<:/PU(8)XZ/_]A,DE>GQPH$0^N%O:MI'DL7[!'>E9</-I_]]N2)[+N8]\X7
M#7(4?^35BF/K(<'%0!A&($K5MA X:"D_>MA865/G<K+TU94L%"][WGO,R<^T
M 0:B0[\4\%+8CF) W $3M7$7(\WUI =SYO[*IP]"'SJT:!9#'C59Z2D*(]Q,
M,D_GB'X]UO+<4V8.!O.WMTS;F6-[:^9K^FB\%[2:9U84!NC0KKH,<@_$&"1L
M<)6O/6C.KU_?S8GBZ#BN@3$(%]ND0$];MGHM%9^<?QQUJ5*@B7?1+IH0><2^
MM2;.\[C(SNEM4XQ@.5U38/PKM1 MW:S!R&DF=;LXHNEQ.H7+Z7"V.<$PX7G'
M[? TI52:G96)EUWTCV^ZE.M_&&-[(R,>,QU[C\JB%] AW.A:0+&_L&3 0=]L
MJPMX;W4REY]AWYEWMJXNDZSH#9HWEOC*$QS8V$O7[+0,?U8GM^Y/-4(2@6B#
M*V!^^5-KR6=J1%3<$S$5 :[^Q@^?G=+CZ5,+@EG&*L)?&@2<-S]7\<#<$6=Q
M^-+UIV1&J54#B6\IO ^>[=3%4.TY+(I*@<1Q>"XKHZ,AI9(5S1:.!MC>D'G"
M-A^P?,SX$WA]^RF_H@Z_^\[3\,SIP,K8PS:JKQ!&N'W4]GGO(\@)[U^-"DBF
MVF<C9)#C]^+*6OW)U\"-KO?.@H;1G<JYJWU*-$QN>,T@,(\%[!90Z/[EKD$K
M]QZ^O.B72YA!F;KQ6<:=G(M1UJ!Y;TY6=&G*(9P7;9<?SB!\M'Y@)-[2HK=8
M2R]B"7X30.W9;J9TL6>CL+!B]YO%Y/LM?SF8[S= 7^1#UO@JQXPT+JT CK&8
M3[W@7/7AE%<W44!*&+3T8^/U*?' .8$)%6,T$.PP1]%#)VH!1XSD/85D'8J?
M@SODON&*.X>Y3B]DJ'&YC\8FR)@7,EY]FG0!]@2HPZFOWDH^4P .<6_2.^Y)
M_'QC4F-%V*](8ZN.U@?LF+M@83UGVRU4E(4\ZUZ9:3\6H1IVSJ>!:EC7>'IS
MM)">91GOY#C;V^CE;#T)L\U_,2$0LL^SR7 3?FX-VUX]J:>?NWFW:Q%4_Q)Y
MA<E5;X.)2I&MT;]WED>:I C 6TR/$*'6V+*9J$*#]+[G*2FSR_;WY=\>1G'G
M<26 \IZ^TE5L]<T:%*XUD"@J;HE\G-I[(K!#",^V.[O!0S/HWR=OMM3DX\5_
M8?CZ&1.M#E%IU]4.0='P=M5%Z[1FSNR-Q8G1F_O+.C_WC+2>_8_V _S_ ZCF
MR* *D=H)YHVZA0<LSRMK8QE.9UJ,NTFVV#=8'\>WSW)N6U0T@B,LN8% ;)?V
M4*G:[1']UXZ<]]>FGXB/57\9B356%#/.9+I!(Z7#._J)-!Y978[ HINMODW\
MBBVM\>)<I4^V@S8SM&DH8:KA?*0?\-/JPMY!?FXM_'1E5</.G+4'[*/7)K@>
M?4IV80SGBEAK.>?GB)K"ZQG4'#/N+WNJDD&8Y!AW] 3U@FDSBLI;><FC4O4R
MA@?.ZGC4&G%N8NSXPY-FJK=\!3O7V"[8!*E]A&;"=(_3X//6WAD6CB1V2(L!
MPW:,(*D/.U.'U]>:D*G462KG/%!:KD'1$-6QH\U^O [^'#\WW,49MZZ.WSSO
ML_],R7I+[_K/$>?L@O0,S:4M&$6+,\+)H(<5"QPD-N3QURI4^(1_*O8!/@#@
M*7*<Z)F>">%'^LVWC^Y/IDMTO>H/#?GU-K=++^D^D2EKDUIT+;(5%Q:T)QW.
M+U#YDZB3/>G(?;?Q@7#A@/--XZ"<L2#9T\N?'%4(!.K(%1_132.<YV@SF%E*
M53S]26LN\*L5"W]N7VU;0B<"+Z7FJIQ@NO6BYH?_QX#UGI?>7D^P!AMH+*7;
MS@82-8K&5P;[6'TMTG:6G(L"($J-[9U?=*8>E^?*@ES>BNO/)V],8@?G-O>2
M9\YB$].2_==+-F-WGMS+[[W9(7Y-3"7V9ES:M4^,3K";@.8\<^2 /0I3R*YF
ML>>8[O.L3R+NO2WG+[&N2K[\Q)=Y#3\4<RC&E7L2QZ!VE*9%,(0\ @0QHPU]
M NL?+V&78_(A#J/)]^.6)LN6BGYD607=, DOWPJ&"MEPKY-!]LA896@S.'2W
M_H,?&QD4Y3&FWC%?*-NI(=FZWSVF:RGT($G+SD1"<0[D)1N\FB:"[4U<D#QU
MH#4J1_![H%>'Z*PLK;J!^U'GP_\Y0&/MC]M! P O@C11$GA0H)?O;=U8KNR?
MU7YIS31^6;?O^)ILB0\<RVC$U=3_:]I?[6;OUK0!DNB!;9O$>P!W">J6+_+.
MC7FKM)@,K(^>/;?*,+5US>!GLO&[Z+.]\G.^?K2XA(5?H216HD)R"WK"Q#>F
M9U%"3E__L<GSH2VF$Q*W"S]PN$EA<@+\$U>49R)R@ 2=VH$R<T6/,_([(J&8
MD7GJ]BM7&TUH<U'R6(6-?"QR'AU.*;=:\-Q'!K7'C]-4/ECJ!S.<8UIY4] D
M*]-XXRH=->@MI#1Z8\UR'<<A#J';;8]6/S]%Y#I.(/&L<6_F3$!551;.J+22
MA.DGHY)3W]0$"L@\3)&[J(.U>TL'ONM-6/@55"\ DX'S63J6FRI+)&U>#ZRH
MU';2PL<7:_3U;F@K$FJ3&FAB\?C.V?LE:0-;IXL*I03MOP39,/.&-S,6Y 2=
M%F+Q7:[-;$)_!S<QG_1.(+S6Q4HAF;XP+<;;)<T+JN?QQOX(FS;F5LMZ 3]'
M"!-'-#WS[U9G1<YM-XIOGP6V=.7\O)[45./ X:)5SX*FEU6*+SH;?SW9F1;]
MR-75X/R\FH#I\7=5![L%",NI8D I8Y8+IO;YVR_S%-$KTE+&L=:=G[2;AUUB
M6DF!P <LLEF L_1DOZJYE7Q.5D&&M2/??NMW%:808O+=.0^J[U2-:^*=Z/E
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M0WOPN#)F3/.PO]VJ!Z4H4I&6?WUI_C/ AJL@LNJ3',B@XQ8P?J*^ Q6#GLN
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M@X#)7\VU?Q>P_4F-0?1'_[62O)["9ZS67#'H8,$Y9;&,>N+AC7]WQ01E>XR
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M?A$_&\XOY)9CK^Q^HW;&VLKL522=T\=DZIKOS&9'4O4B "4D- >XY#9H]('
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MIF /!M>L]?),(R=K_U4F'4#5 8R'EX<WO<3&$#9L/QVUP1!"CF"$-%V@AUI
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M]?MJTQT+#6#?3GS?"H]^9!31'&^VBTZWBTZWBTZWBT[_SQ2=KGP'>]=N82M
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M%24G"CX5? Z0-I*0;S\]>U7XBZ;K*5UN$L21%V**0UP!*$!/$^]8:O)Q($*
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MO^$)I=>1+4T,N/Y%:NE$&CJ9WR=$/\/U^OS"HEQ"#/+,(KQW#)>'90BU3)J
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M74O&Q/SWK:Z&(PN?!=PI<4$-4+<T/61?6!O#MI&6V*\^&R.CL)O\ \]B39=
M+R:$9272O[:K_:+=<T%J@%[!JT??X.219Y8]W:"Y@&9I#3FW@5=.II=_Q;Q4
MRY3D)0>@P)D@@/0VT7%HYX^P?8KY>7&K9;)[;E+WA_,-J5X4.U"1 >XX:OF)
M+7^@E(I.!%<D02H6)L*X/)I_":2T"QK]#(F\57%G]U_=CS@H9I0#M@A$/G)
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M&B6 ;VUW!]&ZJI B"87YV^NE97D-#0:;:I?%;'6+HP.312[=XT@[$%>09[\
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MA%'?%\#@UD=)/*19-?5_4!,^S:3 AN'D[@12'#4R)?1)E,-B1LY0D8)0K^X
MR%]!I.4ZOZ/)[AL3-OF1@!@1$["[R8#[Q/?;:@F45Q@-K O^:J.2*Z$8^BR=
MNH"7=MN$IQV.:D:XQW4;YR\G,#HY?Q7D7[FFF(HSPJAA52!IZ+:)-FF<6D-+
MNNNY>DUJC6L\BQ5VFVO#F80_ZY=G/X S#%+EV8'5)UQ=1<7CI)#-JAA?1^,1
MA/_(U"FYL/OSK7[%N-;;AO*@G;1"IF/X7C/QKK%.$/G\=5TF527&!E\IN3#B
M[U_,!;%**\[CV[@E:L6J'D-FGLZST;IP4_'+IQU#LT1XB/+Y^.O/7B-;<<2;
MMY( 8D_ISJ+^-1JN^&8A82<3V"@W+=&_M[PEN7_%C _ WQP'/GLFOY**UL?<
M%L1]].C6QX;#MP>GVR7;'3WFF(=6V_<C'-;T!(G;];53YSFA".W7]*Q>U"LY
MV<PP9J!%B,4\S2VZ'/ZRD5H35-".--0_DUQ^FW5Z[0(PD52F'F [RD)IA7 A
M*"8]A$X^;;9>;5])!!ZY^8'1$C87@*TBX4CBYJ^',HS5TH:=ZW?/ZYJ+0M4*
ME]4+EQ9NS<V\'!>^0A-\+*E8+H43P2&OO&Q':L>=R3178%G+B?+=F.D;4:A:
MPVZ[6 IV9#!\S7%>GZD=T5!:K@ZA4G<#N(_?(>?SB8YL9'VF'=?@RC?RZ]"O
M8;&MHL)^$40, R)FVIE!#EF7=^;R1KP_SWT]MYD<5SF-+_OI'#\;P5^M45G-
M,""B#YWIN0 @3<3?IL 95&0P@BNGX4_=AC*4>R?F'G"(%]F\-[>WP_U1R?K#
MG9R@0C&@3%MR 7@2<U7\%;Q2++0$$J90.BXJN]L]]^I)?C++LN([J6!L,%L'
MSZ;"G!?Y>D47?"Z*0.<Q%W*\IA\!%0=&^MZN$*NE.&DXA U12PVS&8<YK]^T
M-[NARC:8O9BT:2TC/%-L>!577U_,Y.#J&=V4F>V[:A6'$03MUZXZIIDTMR*K
MREH2705DHQ?-'V::##A/7E^RBF#E61SV3#_X"1OJDK1^D-"]R_\P.^G[SSO*
M(;2>X+?M=9K[^06$Z7/]<#H"4.Y-;0R]OZ6HNF]%;7B(.O=3/>#L&H$_)O3Y
MFALU=!:8MXS4%X\^PCGB/_I0BA\P![EU[?D(3Y_5RR64_&Q^SI_PO<;B6?H7
M[YW+]BZ3/MFF.:?)T9_IXY2SN>+RMW(B4;$K?]4:"S5$C*DWLI#MA*N^19!F
MD["--;TQ7QOV<X2PC.G'7%TJC1NDDB$_.)\&'QK YN&U&G'89VXP$N1A5SO%
M[KCM]I$UQ9L].OQGA 6N<EV344]P\+*.W_--;.[SAX=](T!]% N.*5)4RJ2R
M;O)DOC50+0SQ[8@IF2U7UO15;NXE-JT=BAY8(49S-3P4!JRN?X.[F8UQSU"N
M<^?3"YNLVGPYL5[4/RK_JP*6[_S(N&#-WZLDJ"^#W:MHDV/;^Z?'/&DW^_+>
M !&ISI"'KU=;/[BEF ;XO2YH>Q/J#]_:FR'1W@J3OQEMST_.VL%&1,(.D0N
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MG0LVL0_JI?[(_DGQ]7H#FU!^+(D&=B=R'S+X3;G^ B!%:T>UU/<-6.^WMXH
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MZIR'0P>J@R%_=?96X9#-'%-^/K<(O5WF/"?:V2@U4+I-OW-K-_92J9_I^L/
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M]0O/]TX#=GMMK9^\-2V5X&[YT&*46G$,Z8'-*F+0VT3!5(E$DG[C^<V>QY5
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M:O/N$]-M*.Q=L@K:@/RQ5?[)T][5V6<=SR.TNVL_+U1^[1?- 6@<6%_9,/O
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MB>[FWSG:-2XF8J!TCEG@R!317R6O/]55L-ZTNUD,"+N)J;SIB58O;5P/^/O
M5.]*T/_0*,W1DZLP!A+T,WN$DT5Y36G(9M)8+<R7*)C\T6^QM',>=-^^[#H%
MCFM6=%F!T;OD"K2> 1)E;'H"00A%8H.MXUP"2?Y+J7=@4"?!Y%\:F9\D2Q'&
M@NH$F_(+!V:U.W2EQ<0?E/3U"W^GB33K6[VIO<78@:I>[P3SP1].@OC_YDH8
M[_$X)6KYOG6LJH?(?'*M_)J6SU9AOA1N^^N4E^!)80C W85$Y#(0%C [;F 9
M.#5>#E]R N@Y+B?+ZK@G@2=N*RCF0MP0EN0,BJ@+B(-<W,R  SY+A\A9XZ[\
MLH$:SG#PI?Z9;Z!-N4W^*B]1OR+*_Q9M>O\Q)T6@^333<QO1#7]$+FSEAU_!
M78S_1!CHDBEP;NS8K:BU!FVN#JJ&+75R!/FRWC0L\US.VPE8V@N#\C5?P]8]
M&?<>R&/UR]M&VC94A'!7)^ZHRKD"WP])_NC\)$$_;\NC9=&+XAF OZ%&KM\)
M4IW)0Q<6(B,$!Q52;,2X1EM(Q;^OSC]YMQZW8_[W5@9^\0SP[AW\_!F@GHZ2
MZ_ M@I<[)GU7Y@R0=))Y:JT'_T8THBQF0=N!4;.J05HR&">0F-]/7)>OAGD>
M_'F @6OK/;LHNP61U0]!YS^>1V#+"T@BR)+-7)[Q<BW= IV/6V8=HHWC,N6(
MW^G#_ONDG2C^X+BD^N$WANT@^+?[; ]31C.\.GL$94=)--0XK LAU)IH,NK5
MY-O8U)C$+A*O;]01,AC(J2.:!! -MH%BR_%]!##N>W<RP:$]5XXR,RT:OFX)
MW1[H4XA2Z/7Z48P[&O)%<;1R^[FL2(3N-DLMDT$F%K<:_18#E)JRYN^:AGY9
MBQZ-8BK^/:SP$<]Y@B)*$R3T".[_@F6<101<TY[\X;-3,K3=R66MN?49?=**
M9Y7\IK]HUM_\NQ_N>KJ1^J%]F2I98%.Y__^2[O]FQ__O$*]% Z78^M^Y("@K
MOI+F9G=\]V^F)O -W.9?X$>Z,*E4"NY%2)A</'BDGS*F4E6?]_;[!>E[IC]T
M4M1?:I[R;E)$X8;8]0ZY"YL@&9Q;/CD50P8/$$W6DT47H9G"77FBSH,>N_E!
M;U=QJ="D,P#VX<A59S [RIGERM/9B(8Q..>7N:<I*?8BYO*9=I+NH>L+T@X\
M$LYX_@"ZG63<.H4#0I! M[=EN&>? 3A:&FUDSP!9L K]T7E6[0MM<7GW@H<]
MK6-I2XW0R^@#4M3Z/%'SOW_]T,+]WX S0BB^!JL+5Z?NGCU!M;.2?FIYR"L/
M_/,A]_ ;NU2>];TF;QI0:*$O^C+2B849\6]V2F<>^Y:KP (IRS#VWFC8HE5C
M6/O<JEE-[5<Z::*A:<(?G9Y'PAN+64T>CO#9S<!,/;^Z_SX$@L:MS&+#<NP;
MY3S7J802L8@^KT6W'&_1V8A.M*V94FK*J&ZN2S1NR=%3$"C+7@E_EZ1#1[L4
MHFGQB_.$FVIWVN1<$)#$T$ (<%^*9S817K$.O&]R]ZDW8W9=@^/0-WUQ?_X0
MIDK^. =?]664M51QB^2;(H9Q5$L@*3K6U^F]C0JN)Q2+[CAN%<&I%%&]Z,PV
M4>^H7UCMN+&GH6UW.'_3>3T2KE=(:-*MG/*ROHU^/%9NRV%I\\Q0-.:1]J4?
M2]-K:!(GXPH=29HENI6-P%.X6?O6OK!F@CMK\NAPZT*SJB+3+3'?2VPO(_33
M$G8*[K6,H72HIJJJ0PC CG0B^+!=/T8^.:4;N;IJ,0N\N@1R4CVO(SWW/GDA
M7N\N:/C=J^.,5:7=;>\)4SV/=__+\QEKO+ =.>R<!:'%'=LXUU4,]W<;+B\P
M<G#G8T\^B>/2C]/O$K?\8YO$(" UOG6@BJ_U(8C\>[*68+ORERUE^AF7C*^T
MW_R,;V4.@-F(:PU43^>CR;O9.1;OI-:RO;-Y[T-B(T(1,9K'? 9P^'V8J85<
M5O[%;:Y0FD04Z&[/'IA9>Z[+ET3W/B<G$&,M%T,E$[[M")HF7&[%-YGR"%=7
M<[SE48S1K; @W7 ]:<]Z+]H#:%H>]C'+56<H*]AQ"TG_^[O5,S_C.P=VX79]
M\:N0ZI%K=.<@[X2NKGZ([1<]MP"W)1R16\X M.78.^=/+A85F[A@OD=EG@'@
M Z^VC8[4+1V-0"F ^Y9TWY[O7?*@.)0?_34 E1 AYN3R5H%G\(M3"+D-B[>1
MT5H"A</IXT9%3YK-FN.5'F!$ZO<K:>YEJM, EE+DK1/;P;&SJKUY$1JJ"<U@
MUT"' N=6WV3F0E[1K3\049D&TP6#(3ZV""VV\4+X"QQ'VSKF7_L^L[;"G7B)
M/.-QY1L^-^B\IXI@[A$CFD'O;AQ*!;=Q3E &\@2U5(F:5-ZD3N)9'F&;%V(3
M_Y*N(OAJ!K:+K):-T0'2KB8// _GL6W[FBX(&FI\V^HB9\R2;0VI^UM.2WX'
M=ASA1(PM\C7@5#YAT1361"9@2L=IX/,%(\02)LZ=G M>**-7X&I_$<1\M;QE
MF@DCZ>&>_J<H$))'>D$,@--C@3'*4.8MA';"]).Q79NQ_45M6;S[E3Z?1E@"
MUT,=6GZ.$/H=Z"V+52CIRC'>CX#$BJ]C=GI#E-258N.]C]25;]A/R+HM_LE7
M*;R:N>I!K]#G(?]A?CV&;(OC[/GD@"$_#!2>A-4\*;4/T+008OA"?_>:V#N
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M>K\V69O#S[+"T-.7]^>#F"2T.$I*--+*84R$?>S5.YR=Y.M3@#M3I+TBEK\
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M4]E\>^K=I?=' 3XB3(3;AWOQZZ!%%)!NMXN&:)3M76DL5]FF>GS9)\[D/JU
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M"8<3+6>UBYZ;SI\+_-TRF78DJB_]\0&E3,T:W_C+?$J4BWU G0]9 U_,. $
M- -QC&T@A6_XG3!*F'_A<[EA-^"L](YFIWE,RGO[E^J';26R3-1!%&<5BBAQ
MIAQ_=ZVCQ2Q$AN7732OL9(_?%B<7=5W_5R(BX=%"@?*& 1>EU,K(P 4)$0'9
M7(P<0.$>RLX,T[)RQ7 \2'#K!, F7? C=[QEY'(YZ?'8=46T)DM%7K*&'G-
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M#)*C1,"?)0+(P40VJ@(Q5J@(N8E^4^F"AA4\3+M<,'L[AY?\N;1?PK3UY0-
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M'>=0O1#I:\B'%5$I#;PZ8(;1'[U(?[>SF+H?_'B9,ZGV8V(>#7Z9J#V'/X5
M.R(G@ *!KT3F?W%OF?*G9MQG>KB VHU@>U8?G9V4V_Q>RE?\Z(@M<MWD'54Y
M0>3#4^./OQ$J)X#+/9@1((T-N)?_8WF=-TB:B%A< /RTL((BNAJ D3(>W@1S
M7[>[ F8(>KIO>JTU9^D2']HHP_I)/L&]<-PXE6',2K>^=HSLD*VWYS+V,XUC
M6# $-BTJ]='IN4(-V[GEUP.NE@_??'GW\^TG;/:>/[:>=(Z8WI;1$P]2<PZ^
M/.;;;SIN/RFK%(N]>6%65_3-Q[/\>FO,]5Y\9B)@B6XV)VP(/F>+$$9Y0^6&
M=N_?CS5"03A!B"#N'.Y:_>507P9PPZ7'<K8S(F+NKKJ/*9]. &Z(:.K%6J(;
MIM3B*>ZQUYT7^_//5:[:A[-QKR0+SMT+.U7S/?G^J(XNT')KX5M/N++LC,+"
M8G[S5L$T:DQ:>>;S(\E-@9G!#O%-@<">6M&H6><7KR>V&T8*OF-%\\8VIKNG
MFI,FB$[6WVCJ0WK,UZ-:E_()^-K8OVZXK[ !>MWHBYS7C3A^\@$E-=>31C4G
M $KNBF2[BGSABY=Z\7]W &/_G ,HJ::\/90-1WTKB&FY0'1YU F2F2B]6E?G
M_.F)0?$,2V"H4MQGR3SGU^5\3&<!'TU=9T;N:V[LZ[O-@'(G;=@_HFC2X-MN
M!RH><<87P@LEM <]VSP^=A5@^MR<QE"9H/S 0<C"NM<F,V*NSF0Y6:H/;@><
M0>@3JTEZT,:EA9A=623LTE)$0U/]&';'EA>Y%KIHI8URH8=5]/K+\ )NB?@&
M1P:W(LYJ6N"," %5N.%X)>2VF_M-G4V_:M*]1TN70AXUB#FL75+,V$/\:\4B
MC\OO'S:?  SAPJNS=];@,0L,!^PS<.HY*5RB 4X\JT-OPN,@=KPRV464I# ,
M)51T5BCR.$@) -\C#M\(AE@B_J4Z$2'L_TTU'H869KNO7QG%M:BV+<,C@!?(
MBI_)UA%Z3YMPE*FHSY4MR?;QICQAOUB2MYGR@:?>G69:GSK7=U^Z?][S.07Q
M/D.!YC=0TZI+1NV0UQF(!!B?F__2ST<Z@7J#Q;;?O;F)R3[A(5SEDB> IH54
MM4Y[MS61#? _%HN<IA0K(="@Y:4/*.+O9:F;(/3\IO(H669*!>(\?E7LC$E$
M[POQ*/MK^FQ:[2'[CB@M\']=66(7]<O\<0'(:1#5^V='>?3"0VUH]S_N*#-F
M$8>[0*S$$,;H8-ZV93<V(/=S2]_)K&-K_Q_]01Z_;K76U[ )8DT7$M1V&)5_
MN^+I%A%Q-'K+@'!K7EYNM"KEZ>'7W&_R-/2V3VKDIM=TL J\M<J;FJRBILXH
M$G'L3>BD1)&],49Q%Q%\(.;GG.;0MM,&_@Z$) ^IN;]"N)QM4/[IMPI[28^7
MQ33039L]!'5*[@G@N:P0,1B.%K!R96=VT?J0&X/I'Y2TDA9\:)DH;0\#.+C?
M#CFJ"4>ZLBW=5UVS+GW^9SN9S^9@O&#YTJO1?>JYKL5F)V^MIT77$-)5*1(V
M&#>-%_!H1^9#3#.$>HX"]P!N'RX97$O5'I^7B'#&[/2FI6MEXA3$* =2KO_2
MYM)BVD)Y(E:1=)](TDI9KBF@?%K" NF&&IJJTNXP<^]SS4O=?JRWQ*'8,O\Z
MN>MV1H&DL<]F?7Y?R93-J043NWA*CK5SBQHE46:WP]+*B@CNB'"Y:IRM<C=\
M?R>W$ OQH(F"NTCL]@G #B+8I50LF&Z\@6LO(,Y!;JWJDAEXJ=QFA#E*G!LM
MOG<C7]V NI0>("]"':\EWCT/^S9G]3:[]%-#8ET^[XH$_4O!I#T:C,6HT^"J
MZVBQ-\'7-E$.N"^?Y))D#PUU1IW?EID-2+AW6^1/[USH5?S.\([+Y?;CK4#U
M^JM]AZC2 U:3B6BRP_D.&O_!<7=[X^)\G9[P/EG<]+?_VV93 WQFBGKV"+?5
M@R@_AB([+T[Q!"M-*6U]NCWV*('PV(#%@T-2)T^$Y4K:?(G7P*G6,\UKA I*
MAG*I*T%CM.4B3&E4P+QA-+\\9O[GSK.0++7*%IT &S-1<D]6'J99D1! #$(2
M>0@6N)XWROWLY="88>U _6WR^LJ,!'OX?-R#0\&PF"'S6..FJXXK"[VPALU@
M[S]5CB< 1PA+\"B/D"0"<WK!%22(&TY.XQ=O3A/PRUI13S/ZV5#Q5CAQ)ZE1
M1'TV9B.8@:Q104&@%K\B<"%$=PQ\^RKIL7.*^G7A]+NN75$?R6V\.:$S0ZU&
MFE,_4#A#X,P"AIWV9K*)A(6>>2"U+?-Q?67R2/"LA_<OR>O90T^3\*']4Y>>
M)Y(5:?:,&#!,ED80=>$8FO_Z88>=7#A@(*D>(Q0':?9LCS(<_''R4/Z<R?.N
M_I^K?E,&T;K:V?L%;>SA:>!:=BP"KW"$4<GU#<K;</-5\I.W#E#0=/6Z7!OR
MDFTZ2?%3GF#XRHZ=&6HQ%UZ.Z$"\!C'^@#U=--_Q,6V>,+N7J9.\L7/%P5DT
M95 G*4.KJB/T[!/8R-%+FAS2)-,UU5#RD)IPDBKY$6Z JM[<G($YZKA(O5)I
M>%NC?66(2]4M66>;C9B_WAG**RC[.G@ZPZB[]^ 3W4/BUK*4!I*S:9<[,5RD
MOC8PUMQO=<=6X\'E>/.H<0X#T'W/FMHO<YOM#S[E>D12&3<-1C1R#QL)=B>
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MREMJ)JZ[[;XHN])861?O&(%A9!<L_\9@8_ZR3XN>L^U,5:JZCJ21HU3*B*W
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MJIVZ$6AOK:F#Q,@%YJI$II^S-J"D0E?^VIA1%Y\/O J*F8\3U%/']TKCN-X
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MZ8K6=A-AINBW+<3U&,O[E/2& 79#&?XJ>SW'(ZXFG<OK&KQ8*[ [OER!'V*
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M8.BR08N+K'#8,T!52HU)MY2E7O4^OWO3^;OUEF"*WT-E6HLWL^E&=3-,#P[
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M7B#?_#Q^.:#H7:4]Y*M>%,NPL]"D::+B.(?6='JO4CC#'#KC78)E0IRVP.&
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M >IZ7\M&V'6Y><&MPC4>'FMT.$MD,CJS%<.*[!K,@\6!R3<*)#RFTIL5Y@2
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M;_5;8]^G?->Y"\J UYQYG]TR%.VB_TG1)B S*X3YO1CNKM:/)M=!+*HG^[&
MW(<6;S=_<0'*FLKCWUM;!J$NR5<Y[%Z8)%>&QGDJ_3XJFYH4C>/\HO4PTUU8
M[SG-]\\B;N^MQ''+IOCO,&R(O6S, 4YV'7(823YP45@.Q]^=/$)L^7R<DSFH
M.:41L K,$\RZ'I'T^B.G=+;J\!@@_%,N2OS>;#>HRL,J>/'5'(_C5M>DU0QT
MA>^EO_#OKB:_:,:IPFZ^P'#O8W1.@6?(IK$G.B'3Z>J6DI' .N.<XZA\M#J+
M8\ Z@W7?A4D!HHY=_W&%N]J-QUW6,W4^,D^A<>R@'EHI^<IHAP=!C]/4R'86
M?4I]J]UGV]"98:VYYB+(X>;:S4?<)C3?O@G7 ,)"TL @/A"K!JL[Q\=:;<_J
M%2?>^<=SLN8B2SZ_)<Q$R0"/:&A?#JKY&=:&EH5R(HYRR[E/C4:HD)LE:_>2
MW'T^=KRW%Z.Q=G;HI59_NRGA]=ZU!1Q)!(BZP"%X\![P0N^4X;!,&=CLDRN2
MP'^(D_<3N4,$T/&^G0.=C=S /2.W\@7:>BA='.5"W*HP(1:M4V7=ST1_ZWYM
M6]3.HTY=H;T_M IOR/A6J0;LIV, WD)"BQY3P1">(_AK01*EKX>DCQ=:/_]Q
M"PFR\-]KI\@T 2B.X6R(@,QB-R+ N;:*"/A08VZ#DXP"XC3;I[M-B0":D$0O
M',A;,ZV*+YG7B_F3B_?&DPH[BOXP%94A!;+#3L</G;4%WJ'U]G:TKT%902Q)
M#\:1C87:[%_3>9X1V&:C!#TX\]):_!46O"G'>D:NO]:;O -]$)P "PD^I0Z6
M&Q(Y5?R)4YIM,64)Y=2=;JGR;=@+48+_2GYLXO\\N*@K(R9MH4X]CY]JNQ_&
MA4"I7P_GR]JM"A#V.9?W9+;Z_KM,::JK57[QA:;^+11]YW2NN6FIAZT"&ANB
M7Z'WUGMA<"AUA;=<Q24E!9$UX"@SU<U;KA]2T?W"6&[)KH_"^'H;JU*P+H_$
MR,VO0U/BY'D( M.^<AM/;H)"0LL@RBU>80K0,.<:E&/(_3/WU?>BZP,WRMKH
MZ=:WF]=8.2)Y!QWI4$8/EU?=U>X[ZH"]G>5Z.L=X*MY_V*Q\HUY/2Y9X&$TF
MG@B5MPV57-E&4<<'C8G)9C_.M%G/$/>?GZ_C&RUNR.G+_G8_I5#JYWXO5 -L
MCER%(8<LIIH]=T[WD].;U"%N41?J@7\VU+?\>A^]N&%RT(CZH=_YDUHH#"4Y
MA_7?-Y@,K#'M#VE-N;*/O7GU=\UR=+!&X[<$7O*C.)$G?E8G$.!N^,>X\H ;
M'9-.1CK2>.A'LCBC)WU*Z''*NU7,WPU4-)">29@(Q(HZ_$ M-P[\,(PCL6)I
M;<7^4_%GM:\<Y7Q-W<ER!D/N7BJ4(1R\D&L:(=7ZJ !X>:*WAC3EX,=-WI D
M%^XTWD%#"ZLT,2^?\_N4#6W;7-)C !_E <^@J<<S1 !<8,XT?E/@T<Q <Y19
M<M&:@J-;(2MY\+U(&DU)" ?XP01./.R#[3##KW*9SD;%>/03SQOYSU+6^?N.
M:=FB5;Z(O*;R2,?)C%.MN:O/$@&'UO>99+',MVWQR[7@4M_4!5"(B/<PW_JO
M]G0ZC.-9;Y0(YF;9WC!PZ>! T?M[3?>=N_VWJ8XL[7STB_<DR&%$0&S38]\*
MPT].NVJM^37P>SSV/\NR5JC&;W(53'RY/%"_)G'_O7,+6'WC6="A+?9ND3%T
M(LA.9>/=P2E[BOS@^:4[SU9FY@2C+=.8J*DZ0,P2OHN\O2(O[N[,E3T)5'\-
ML6TB I19B0#_.L+*STNA$1M!\2D*S;"?&NIUGDJ]PB+'WA2"M_JRN&4EX[(H
M^!MR-=)PUD:>*'*=#F3/7(( TM9]]O' ]N*;LIS:HBA5ULIV#>]!$SWYC*+K
M&&J4>I\C/\:\V+US;#-*H+VM-8S-@RM._97,V*\[VUO@S%#JX"T?E;$',]V:
M5:&50([0WB&C0L0/8[=[TUXGK2G5G2D<CW7JK<@OZ:J::8L_XMHTHRYQ!-O&
M&$_>M^Y&KO9XEJA5I=XU$)JOU-/1<+XO*=LE2 ZEM.K$[,*QFK)]RI-V'J)@
M7=_K:.:A2]VUPTTLWO3^!T_,/CQQ4Q6DG_%E!3]#9J_%',=^1$[['M6(WIE8
MOSV7GW2X(**R A0O6*</F&ROBY?DV5@W%+S2J56FWW8$_\"(&!_BT8\[Q@55
MKH[7Z<V*#=<I8,^M0@\W<]BOL3=6W:!,2:KYX[T:JAY6"]-'Z:.3G'A7I,Q^
M&N?%YV*-71XL:JOGW E)?4'^7IF;>R#LS<\=92U1S!!GXH++S\TB8[MWO"'#
M^3;1K=;90JT%*PV%,[<7QVU0<]$$08R.T5S1@*UQ3[7?KNWFI$BFJ910<*O[
MFU>YO \X15A^^3,]8D2#DJWFP@UGO<":M7MJC'0,)JNKTBDOUCO[)VG?16RY
MJ/(E%?4[<6IHPMMQF@J-XQ'>=?*B*6B6\Q%ARN6J%R%7^F/-R,X3?JC-T#&E
M0EG2=>*,D@>F@FA^ZHM%3]3WQ%G:-U]E*%YRIPRA7/3[6@?ZJ2$>4K+G1*-P
MZ+SV'7(H;?5;7>RK4N6$D8)Y)I.H?]F%@.JE%YIVAIA$!G3;TX]..XN?7H9
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M\C$>80Z1!.QKR&Y(.;&95BS2V=7(WY\JL#@VA3Y@U6V_DOI;7DH*\/Q[/Y_
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M4KY@W)7&$_VXV$[D2V_N(T?%O9TO27(REZO@@S6%"4X30$HL4U*?U7JJ4AI
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M(]='W!SQSQB9.J4,-TRS'$S\X[!3_4A3Z=X5GFN#?'_TO_53?;RS?P1D43]
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M.*';$CGFJ.T21^#%D;%ADD8W=;8M5*<T)\TZ?2P!-69 GUDGJ^S@)PZGRJI
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M(JN?^ZO)9$&E'GK? C?3WIUWXWB5Y#3NWVPX+<1KG]!CN)WH*8@VY\Q,*IJ
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M4;,^)R:TV6WR^^@C0"5<_57*V:K_:>)?;6C 05RM'*]C+RWB[QU0W\!8)M.
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M'R')!O"=@.')=,I#*=NM3]\U490N8_FE6!0$PBG7L(_-1"Z^T?/.\L);4)!
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MEL,'=VBD0P/<R)MKWQ7=*956.N)ZC+8-YIGWQ\[FT$).[\NQ)$8!<TW(L_
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M5&,;"J=6=4B.80IZRCF;QCE;\Q[BH[E_21J-=DOZ+P1K=_YZ0"P3!4(QE94
MKB,PFA?P1?H76?MW@LJ1AR"8OR4K457$LW*V;&#-RQ=C(U;<N0NR_& OU49@
MY>Y25;7AS\9EZN?W3CBOWSV/I]SYBE7!:"QR)W5P<4#M&/_G\+QT8;\%R=:O
M$>#Q4.]WP;BVGSHF(:.SL)AK)HS*0&KC<7X6B[KG,CJZHB3.H)@J&XN_C"2"
M6-R*SGR:P2KY]T/ ;;_!W^/CAIF\@0M<0F)8_.K05#18>);_GD=:#;^0XIHJ
MIO3N8^AP-AICW1H:;3BT\Q$ 6ZJI %=:1/5"91(+@S[8:M00JI4V<C-#ZYA
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MM>H/7 +I+[A>O1_=L=>K!C\"5&9\\D^R4X-$BZY]VE^;/!')P?:#@Q$[YPK
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MW'0;?JFAG_WR-P(["8)SYGF#V9PHJ".JOZ5:.=]0Z.R:0RI*UW[S3/\F*DU
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M[:D_Q[@PZ\GP<F-U(YT1>\^JC5ZX]6]+DCK__WD"V<2:X-[8&5:V:*9%U\A
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MS+<+5DU_KI$^K1NVA%YJ)1VSC[WXV8ZYXF*%Y"(7@OUAE-:XY F82OE??!*
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M'!)MK*I!@&;%9DUKT^U2/M]T<-H+T#(Y5=_$[Z2.#8.7EJ6QRITW>'1(4.I
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ME<H%S10!?#J;./L&YL?2_S[YR43^>#R T",8XIAV(+F_:]5<JB2HA$JI$<?
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MNQO_-7[(C=ZJ(9_3-^[:T;@>_,CRINXYCY$3:FO*YO^M,L#N\"_O0-7(C&C
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MV1,/$B!D4^6!?:@@0T(CL1;[ZE*]"&L;^NKG:C-F\0@CB]9T\[>S3>ED12M
M CQ=IXZ:[)%M1*\G*'9'8<_W>Y6H,HU;7QF\]A%)?V'\-2[XB>_W7K[SL*]
MM*59#+M1Q;E8TH>'"X:W:N.!6;V@4N@_>6=  F2^(-<P0M)5$N <'.*XUPO$
MB<%?:MV"LJ(7$^N"2 !6&^_P9G@A\?XGI2:_KE1A.5]ARC(28*@EA4_#4Z_4
M>-],<24W 4O3NXY4^ (4N-Y&1HJ.@_WXN"6;@^<IJZ**G(3JBOF+E79!7X<*
MD2M[B<<=>!/TX.[G"R7BS)MASU#7'O1"UX+\! NR]4%-F=KEE?Q;Z;^O3>K]
M_I"\B,H*V*JX*:7:6>9IZFO\< ^>LM[*1:X*+];48/3>P>J_2ZOT_?@')DJ6
M[V(&$:+FR1E%JZV,7X29NO8$GX'0QVDQD&,9W# ) *@%G=WHD<;]\ _"+&+[
M%FNDZAAGO0J%':\N>"S90IO2?=+?IN7XSC'"3<T"(61/]-<2.6'?>K>!>,8F
M$F#'ZR"+3_/:,'(-Q?W7U.1/X0\T#38>O8?BW208VZ#GLRN=?1X'80W!5HFJ
M*SU?SLSY4N5B^0UJ@$@@M@,-/CS8L=T?V@9CJ+]&/;73@S>-5.;3I"<,>(4-
M!9@R4?36FKU"7-*0NI *E7%J^5;?;+^J;LMKT9YIF2LAXIC^XNY;@R^\8,0>
MY&T/[\P)'%F.36QM;F_W" )R>M7>^KO]51G]Y[>E?SJ?T3-5H" ?_5@*O96[
M1.1KRW+QDH[&0T8Q(GU[Z435L$ Y>NO/K(E,7%O3?$;8J[V*A*([IK?]@$XG
M6& ?/&GM*FY^TZ:9!*#W,H2Y+5M[I(TK-<7H7"LUVWP,?Q;!IE;_GBA#KHYJ
M1 &9OFX#G*39G)2&;?G2J%)MOY.A6D_Z'9^,ZV,_7F4)V-7?4C^N?X_8* !Q
M_,:S8_[,]M<_'_V(RY60NA&3L+3W4?'-",UI0YELI"C(/*!8KUG--+'Q7J6I
MO%&DV8*1^,>NS!+Q.O"6RJ ,/508?>$=15;:SS5O/]/-"+#]X8R7&_K0E;).
M3P=@_\8.487U3Q+98)Z1>1>@02U3%.+I!966-:@[#10%VE##UA;IE>J&#NVT
MZ]UN/,B5W /Q1*W!Z?'"F_S, ]FGZCD)BJMVGC[?/-!Z,\NC/,7R]S-&N742
MN/@#I[R.TU["^)J 2(;>@%!X?TMN2M;KD #;:R<&VZF./ZL&-OF'9+<1]1RE
M1B7.$Z(?)&X<OO_Y%CR>:X;G,-YL^8RY--Y'5Q*:RWCWP-)$U-=7JC9[5<3S
MGO92S_2;%_F9R=NM7K!4T$8QD%:#JVKT,?5D[59P\HO9G\&?1YF%-30R!/W,
M<C3F"4ZUJ+'!*8&].7(JAG(22C4H,>=KVT16*=M21'.R<6"9T[UO*WVE\5<L
MT?VJX]<?J8B+L">>\ R9OW4LJ1DST7Q@[D2'B<:NX&S1[M9M,TI2%GMV"ZB\
MI^?!<;2%!O:J-W]__5S-%%!Z>B5 C7L8YT=."I0X?0RO79+Q120)$"OM!NR$
ML>CPL2JX4V@,IL\;'OQET?P[Z'UXL^UO0"?[%"]R+Q_6/P;:.H#U<9&A<T!T
MAGPG"U;B"@E01@2_;SPD 5)7UY:.(#[@+7?\JCMA$G$1"6D)FD\NI7?H2EP4
MRL^O?U;/3/@ \JZGB9I47\@JQ>68+,K4*?$&MR<T55Q/Y]3QN4X.;!JM%XMM
MX-UZ/.=#HI'**] ANPPQ52GU:K[7O'GVH&5FLF^:9S21/@']T=,*> _SG#Y\
M5#3K,^6?-K'C^N<XA0M]',WV?/<H.K5!VL\''#E4$,BK$\CV^TM RFE.^=>2
MEVV7M+=Z9,C<XI$?%=0'1T.6H=?6#WH$9X-6'SC\OCIS9Z'"N2-;=,!-:OA'
MLOO>OME,C\?LK",A%^2!0ST]>IU;'MO\V=<M)E>Q(\6%(NN%VI(0G_Q>,:OC
MNG71PUR.Y5T]K1G_QNROA*8R$WG[@3]C!WP&I>]7-L3Y,LP>F]7#_ZG\) BZ
MD@1P1_E\".@HZV!*\OR,[7AOWC5ZF4+XZ>/)T)UZP70G$U7U#'-'T^PSJZ4!
MP_\0PJ:YLS:,*@-_]*0U7D);LM>T>5O.7N2E+-\FK)!1=CZVL,^[[%$G]<,0
MM:LM$C#0FSZ7'$OU3)MO![S!,NL[F1O$W#B*996-1O&:3LE6^K2??)G4*FP^
M/[JXC+<#<?P;STW><NMY#?5^W3;>WF"#:>A[VB^"U\;J3 /,4PTGPFVZ;GD,
M&@$5"@OTQ=PBN9PH+_2BEM;H"872.8:=J=L# F*A X@EY2O%HP_'WN]HZ*>/
M !0$F+[1*AW-XV(PPI8"-P@E2A=P?A.EM^RX7(.3X 3N0B1K@(6N[BA(Z!)G
M@-D8M?/K(IX9Z++0OLF@1V3MQA3N9D[LB8FM%-YD(XEP:70)C,I6&8]L%*,N
MN.+/7QS]Y[?J)(4&L%E#8<M'<LB.,;NY:/_J>5EF!##/+^3IYG9Z^+-(;2K6
M.1;M'? @\!IBH["''K/WXGF*WT93"Q:<G"#$7?^C<-8B!O/W+'7J\XNSV/6W
M?^2^I14CW&1>R$9-PJ]LHY'[F5ZGC9.+K:U7#)(F7:TDV=C_?*"GJ68QW =(
MUH!N9DD!'\5IHH3C<=T7$5 03@K#;HUV:RW&91]8SD+AZCY:"ZN;?O(<6<$Y
M!3;X!D! \9NHYF/IN&J=+48NLWFIA7NMW:VINTIO 9N..H [(NXTGY7.&/X%
MY2@2=T1< 1V_6D/8:O' 1M70]817/J!C(_/X8OKG1>*_^]@",LV*=D% V%.9
M2U&3'6MYQ;A7F@\?SAU=]X[V+A[DJ/>[)BAIO&OT;B7$9RAJVYW//1L'(6.)
M"A>&\1Y&@EX_3^$=P"*S*R42N?U\?!8XKW/W/&G\3$D?3FF[S@UZ!*?"WUOH
MTM]VC!C4DNY>J!/.('/Y6FNE[W 1KX_+KQ\4W9E\IKZ7BU/!DA5[9@F./&A(
M ^QG@F2XI;AER4[]\_BWY=RBT_#&^0&H$VYTT^_E&FOF@)-DSX74.W\.V8&B
MO?8WQP:SPOY#9A\ &7?JUA#"B(TB&)MTE]^%KE>N>3JB$:K"$1[4%/&2-S%!
M%,KTNI/SI$_&-#J307]Y[D<$SUR.4/L13QR>,\(T[8&$,]E96\/"[ [>#!QM
M4R#!F#BB)L2 .$4"-.>\1'C$.S%>#6N:".=85TZJ0-EB7W06RI?$W6^1EPW]
M 1;J2MJ,P[/';0[ &(YQ&A#/"DAHPQ^D6MW19E<&I:<D8(+/@.FK=/"/^81>
MD/0S+;:W!R1 @Q^*6TA',:DR%&(%^$1-O=JCW<L'S>CK3]/?.*W[H<_L:*38
MY#&<^ZPQ>QCEB$+UY+EKKJY@[)#V0S,3&I-LJM-ZMN_3   ZD>-!J".&F9S6
M-IF9#L!7G3C1S:>)J")1K76E;Y\3K6FXDSF")5-CLLQ:PW/(*@9C?KS^BLC]
MK2DO>3FT86\J(G[]DKV-%=!7_<W4+2DX]EGX8BJQ#_1Y+S9*/C30 E.>^BC/
M?,:Y(X)!ZJ;:SDM75RL9R2X798IG')),5HWIB4,I/.:EJ&J?[Y5&I@Z?-4\W
MAO$<T5\0;$&=CKP#X:[#+X]^YST%<X$E--.?;DB:O!8WXVN@/LCF<S](Q+\A
MM(-<"0K8<(QU4MAF.IE+TO8TL\=OMP5*M+0EI_Q"<".MLG)"0+"9'C+%>N6#
M=YPC7L=++#1)>1%]C,W1)^@E?__K&0_]5-WO' ;8Q-E^,OSU$J\([I_%>C7S
MQ]'U^-KZ1H;H<H#?^7* 4_&>A)H>7CQ-N[*6\(+ MOW2+LSY5WK8Z9U'K&TN
MM\*HG".D ].'3,*&7Y, &R7K-'CC*FWWY\B].&OK[]+-WAQ_++=3AKA%!-F'
M_%^N4^:N*=X<#13O9)WZMR5C$@#CQ(>0J]OP)B(>;XL%HF0.(R1DM(;WPIR"
M>PLZL2TKYQL$R;ZHZ_\6?K6X\:J8U.+-Y0F5 ;M\K*M"6&FOCU33&*8F$=/>
M9C%F-:Q:!6O90XENPB]#97K00:C46NGR+0(]^%/VVK5D.1I>_=S[+^- J];5
ML0+0:8O4K4#KX,<7"L15.'H:Q,9,-F"3ELRR85<MUB(;+^Q1H&<5RXTCIIT=
M>ZU&YQV(:S 78 H2^(4YR7U0ZWK3G(SBW_()SQ^_TH=%.E>*:)A^ROTI/+E@
MV)CB0(;N]9YS)=P2SN7E?]+'>'?M=@S#S>%;WD)Q@#?7+G/W"FM.^"1_K)A:
ML;XWDR._&.B6Z#+IG+#J[&EKF<[C+'4H?V?T5*C'&^=]$075P!5@>(W1CH5I
M6SYBUG-B$1[K5DVOQ(O3K?*<407OV, >9U$8[F$1_Z'\W;S$[A2'C)5SI\3$
M_7U>24]?:5$#J4T=D8RQ7G..*]DB: #?SF(\E);PN8OFXFYH\8-O&K>9:ITK
MD/9Y;W*;Y.Y)"U_A3(X0"?#/$F%A8EZDEWV;F6$GV&'Z]=1(,A-7B9$TQ('(
MJL8&$]O6RN89;B?\-3NQ5M(WW=GJP=</&9/%&>J+\*A_T5\> _-D!(,;T$-)
M6PQRI7V9#JM>V=^&:=<&A"ZGNM].71!D4=7;2_3*SW>8F69X[S3<,NT 'I1)
M+F3"R7P<K@KMMX\V:'W7T,M[Z<^*?')6JA)U'E_ Y<MZ!B/UA2YD3!?B11WO
MV*<H#)HQH>'>]M<T:MA//[FOOR3^#OUE1:]T4W)(A49\.)B,XK#U/B"2\LLZ
M7]-I&SJUE?,0<^/L4%3 <8ZAK4*&>^=*:K%P^I32SZS\CULH43?%HRIZR3&B
M+'$6P=1SV:!E[>9B-K_YM(N)]()RX8^L!(J6BC/]*P$#3*JC7[3DRLFH-(MB
M6UNA+9O5L'KT3FRR[?.+^MF=@K1?=D,QMM5#T@/M@QY+)ZNA1RC#B[MD\:.$
M!\WBS0@O20 Z(/+$X'B]@=!XV!FB>ROO-,PO/\QF")14SW>Z=@F7OIF6R,/C
M+<"Y@%+JUDR=E:K>*1J]%J3JHO'\$7/X&>Q_LN];<$W"ZD$NG=&TCT#1A01Q
M=AT]FRO074$"]"F1,\0ZUO%K,!&R3)S?_6VQ-/7VW9#ZH\4.\+^-,:.T,U9H
M& GP6!)&X)@_@@!AWNO_JEM905GH:R_UPO((7A.LIH!J:3;M$"!,9R1/ARWX
M9'+AN%;2G/"WW(2=.R+10K,C\8_,"UA36<J%KKT75P\_>CW^F'#SZYE/I1?V
MFRY5!N:B8NS^CW>4F2]?R&70 <Y1 6/2S-GVN3<**R1WX4G 5O+L0%X[:<SA
MQ2KLO#MZBLKEAP.5TZB[/HG$:,O]#GN3[; 9JRJ8^N'E<22J<]5VZ@I8?FE4
MY&F2/^U#D7O)- _VQ]/G?"U4=U@'H907IE&]:]0X;W3FD(!&PR+^8<5!RTO?
MQDK'Y5&^!D-UR<:8ES9[$0*TNQW/,*42=N6.\7D9X(3CN"_ 9?9>>)-[0A C
M<W^X6Z=SB+,G=@EHU1JK.N9G^45"(?_'\(/;?YT.(._(\V8,/+OE=(L$^$1'
M LS$>Q]O)5NISE1M\[_*SR\.#J-!T5V8AZI@ V>EUB'9WJ@G&.[#XPB66HT/
M+GY/W[!IKOAJAB&OO9+<%2?GS9JK;F?F1.[)EK"S,D>?^R^<\\7>4.P1JL[T
M[7KF0%Y32/_O*^]X!WF^O5K=]5EW:Y9J4?HU.?+B4%Z_._)D2P9W8ZHO8HIR
MHO0GVLLNJB=[,OM\9W'J5HJ*99@S"6 -%KS$RG[35/99?_-T_^:<E6OPU[!R
MY95@S;P-=Q3%)EF)]9M4X9Y@<B."TE#(H#Y46T/(:K/#<\'#I[(B?,"[-*7@
M[9Q#F6V?A[V(IM;76Y\*,I;!64W+WQ7^3#!4;I  '9M\$16'!O7?D=N##RS%
M7!N5RK6"@CG,=?US8SC,[U#_?ZP#^<F!;0':6<>#2 !G300QPW'Q"XP.YI$6
MOTZ-\GM. E >3)3H5'QM,*/_OKS"[4+IM3V1,K*Q?:D'3TY.);!1! Y&'(J
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M$L#;CP9Y=]EZ?5#NRQ5G#Z38<C+3B]3Y"_ZM(W;;4)D^9$]WQ3C?576?FIQ
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M%Y0&H!*/8NA3V6.LN[>Y5%=5CT&1U1M'R_U8N0Z,YD(QYO87[%1@94-"4($
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ME! WUCY;K%'I.-)?&)/2(@A\=>5U@O.[JO!-]X4Q-Y 12605@G:*+@'KS9>
M!9,)B_R7RDJ9-=MNN*ON,4ZG]4?!;9#HVJ7*)30YOMEFRG38"(]7,,EXUL!B
MOCA[,+?9_7O.\@WP%<OQ@_[K>)W_X:[%IE__[?A#MH$BOP*;N5=54\N=DJH8
M5.-CDW-["VG#4_="VDYXU0,@!%;4K YHIK5C\O#/E$P72LQLUF'W)KO?PXJU
MPX"3,O_Q0F,FW?:%$XF[&G3W-\MG%$Y31R\!KR\![^#*XWPB)_Q,.UR9][8M
M;($J/8PU]LF9?[6[/?IN@^-F^/PPMLN7 )*E?>L6"YXZ.QJ2J.Y:FI.[\.B>
M>,=9:?) T!]0XO$N!+ LFOF"H'*1!5/'&J]H1C6]7,EWT=CLG-+FG4SA8A'_
M*6L?FVA[(+.\KO01NO;BXK_;H+ 7W[V#R1;*.R&,,[..I[/52U]L2S6YNKM7
M?E* Z0AJ/Z\HKFM?APJ4F^@O% VF5NXX\/L72"0,EP-P5(]PMBNJH$XX]]CJ
MF'<,ZPRK](EP8\7.GYZDGB1=;UE#B.R<Z][!=4SK7!A1U[+G$G""IB)^ZK+9
MMN' NP?W%4,O <3F'))K_%QL >I*^'$'0@-4)N6:9 #Z7F$=+D+TB9\>0PK9
M_I)HEJ*"I,RZ4$-X .)"A&08Q8IY";X.FLO7__:?3E\42+10P.3JQHX;D7SR
MDRCG(""KVZ)%=UOQPD>&WQP?WY_ W!_5*("<W&8S'E]D$,3JWUL@8MSR0#/I
M&OO-3=L>OY$,**0+/[+_;S.F<$4_H=7%+69JZNQL[)E0BL,D3,W]2_3D_8Y<
M*7+?J^-1[O>419/XN.D+\+/IZO!;1<J!%?/'2[@[0^UBY3=@!LD]9ZFX88)<
MPP,^LUJALP1.@Q_ZG'$0?Y6/SX)DZ."Y4_<Q2RN3D1A$>X!#>).R\ZFUE'["
MJZL"37$3^9Z ^3U/[1/52+8Q,/!6;>WW]>$ZS40SD=SH#=GK(KDA_Z<%T/B_
MS2?<?22?(H[_ZS34[=%XDUH0_X><++1WHZ*DO5E7]6B::,C'G,K8XWX&BS82
MVA''@%PDQ[C%O<!*1?JXT0]X!)-W\I7:2A1KY<I<,[P5&Q(8C9>,WCD]F,9S
M<QX&SK<_2V>MBT*EL&ME/:U\T/L"*A"/0JA[IO-_!E6!"2SE78L<4P=R;I'R
MD<@6WKJ4 FLE12;7O7?M,]4?F"6UR5TM 78>R1M*;AV(66,492:<(^TI[MV=
MI"[PGL5XFN^IZ/WV6YX5RY[.IS+1QWGQW_,<A?9>;!5OP24)&A<?B2(P$/;^
MUC!.TPI[-Y[:+@FO/NKJ*N'7<-5.FXW:)1\M/,YU\938-0Y:^70)J 2V^UP4
M7P*HP3/PSK5:Q&90I%O:^JKOQ9+DO(,*N,30W+3K:66"S/3W,</FA'[(M/'R
M04*3(/XI-/#Y%(P)I<JA&[V(M6L:]\Z(@1I4-X93+@ XA<B&C&W62>I"!A>,
M2N![TT*F3XMS V-9YJQL9'?SIW6\7]'^1(L+&M<^>#!DQ85_%>W9]=0DQ?+M
M;5V10\2]X'9EPLURJ/"RQ"0")<%B..PV9U'WR6(G-<GRJ4$/-5U%VP,A/H_I
MJ73B-.0GL!!+@YR-C&_AY?:7<]Y@=N*BW;^)?Y*_\BU"X^9C/AHQ%QYINN2J
MBS'UUQ4L<6!3Y<IZE@0Q$)<XC :OC1/6#V+1&07><4SW&V@8THDG6/+$%7YH
M>?Q1>E]ZMEGGU.?B/?P.+KG'-/LFUFXV+61/0A(^<GMG?F_BCKLG++>T_L8:
M$=O@(*#P]$(]M\$^/D-7_;8G&]M$)G^/Q)U-0QP+EOS96&F95+DP9O&KBXO+
M]:HQ74&+WN_1B@ZOM,B+A,ZG-@_V:#"1/7"ZB]RJ"QT(!ORA2E7QK61BN9R$
M:"#T,6L;*:%]>_<AA>-@.:7]+$7CFO7?/ / 'A#V^J3S$@"7NKAX5[@NXUE]
M_(-<H\&]5R]8R?J$L.\@7_@K^-L1'_A8+@J;.'_LPBFQDG$%<Q>U@\WCLC$?
M;B;X?-IIS!H6Z;]'+IST\ #RX]CP:6/!-36)#H,-QU.@\'\W%I'J2#-!%@(H
MC( I%..BT&527#ZC;V\W2%\U\TUE*IK+Y'$HH_,C&252^3@O7L/1^!3B8IZ,
M>W.?3I;=9F\HR$\=_23=0?[6G?X:5::OW/$%JQ)ZY/E;GNPSZ;_AV%_+#&@V
MS.JJ7OGJP)4C2ZS)Q)\X(:# \.#?V5O0"!WOOR$&K/XOGT')>>\IB@V%\5?Y
MH2U7E3EA+_-V1G1<0QG04HR.N]_4G-DUM/0E%#R]WIO:_DV_<,JM-9L1:I[P
M&4^P:\QL[2!)FU/^ZT2^+3[F,1K5[.0WJ?UBM+(E5VT>R;A;QTB3AUC&BWW/
MC3Z:<UG(0'P&U4YU\//B^D^CQ^4DR-MM;DW);ORL5F\:\R[:ORG.0D'U1%"P
M;@ >2J >*SL.?G<)8!"70K^N;*G&[&=1=I4B7RN^3'3),]4TDBFA%@CKO=68
M+O:MP,\HT[&Z(O/E[[E]4GM!*^(?;$.J$D+&-!KKB7\F]O+Q&AE%'PA#-P?)
MQ20UUE[<TP@(5_T9+.>3,!.Y>M9VP/SG7#X2)52?X)Y@BH$E/[O]+&6^E&HP
M)Q0.OCZM\KU\^H?H=U2ANN=^N*B3WN9J5MK>"EX-YC:)CJ_^"OVV$]0MA6;@
MT)9]Q/0NR6)Y?RXV:-@KEA;5JM=*ZO.A8S JG*WM2D8Y(P0:C6;X(GYV7_GQ
M-0'XSJ*\<']4(-EXJFWL<D *JVF77N5Z]4>-])CZPQYT%IZ[%DV=FBV(61]G
MYY/Z67O/WX]?7&$X[L_W/U=-.EFJ$VX(\2%A@K88M]-8G$[1P+>M;'[L1J1L
MX5GIRICG"T\]Q=3IST,+_%W#]-/E,Q:BV[;">BIQUM>?CV<-]00SP;M!-W(P
MNCVQ)UE4QLWC^VZ"4=[?7R7AC3+</<>T*O9%\]ZLU]^.O-+R\[]-<@*I3$..
M(?S"44VD,O79=Q6?I9PHN5TM$VY>R\8LLA ;N_I-/:A"7>ESWT38^]05KJ>2
M6W\+3SLN$MZVOHF3X7702.<5ZSZ':3QPO7TC^E12*\)(D8('#?=(HA8(;25O
M;0N>%5Y>6*LY!T:NJC[P_Z-R0-.G$B5(6T:88VDG#_7XJ [O,336X5 R7'/:
M\OR6OP\'0=U.'^.PV%_(*T<6(]6!?K[J"##V[0%+;L6@UJ>_Y;%)CXIZ8"R0
M[\'D<-:$T%;:8P1UG"<>>:=+2Z$6N;:)LWV&D)0>,6!Y-W]2=AZ=/ETT:57^
MA.G;UZ*_3)BSY4BDL]1L3*=%:4^(BN'5-(;8TK+\EC2->C-FIH 2.TGC-P^;
M]H5O;+1:;^5^:_:S_C91\N#Q1T+H)2"<%\M/Y(+@C8ELEX#HX%^@%4F\_EQP
MA2L,(89N;!K 2]>Z*?^*]8*0)&S[LQ9^7%Y/NE2(<2>0>X+PY'2*(TYI6YYY
MX4:8N+(.]3AZD/[^U-66Z=SJ5!FC3 >W]XC7)1-GP!>D*?'#/;;!Z+=9EH*0
M%G?R<I9JJCU$JB<DA&H^?8UGY+8-<==26:THCR+>A#'BX@+QAM TDUH,5;3P
MZ 8V96#<;^3-E 1YAYOY^W<=+B+@K+95GJG=9M:OT9^$[\YY-#CF-U+"G\#'
M$11 06C8:3AVHZ  1][%E9KE5=0GQ.$;(/>GXFD^PQ=K@PB^9=('V;+Y&CO[
M^L3BW3=-%9<^V)"/$$6@8F:8LF:WTSCAYR'M,F7D4@+%10(A.^WF>O2<:N6_
M2<E9^IG0A7C?,'^6S3_FVF22WWE7/CTU5,<*O>FZQ?HW>IH'39N#K5L#;]6B
M53%7^T\_X&Q]5C93N25>47$HO?XJ'OB>A;Z'Y[U'RMN L-#GUPFU:8]Q8W@A
MW \4].:4BJ!7Z\NFVMCFE.78_<&]&]\,,Y<WR>K)[S2Z6TW"DL![?W[,GN<5
MC\ IB:/\?')B$@Q(:=P07F&0LDS%UL,WM6;>Z\[,H#[_@I'^TR.I]T3NP(19
MF@Z+.QGNZ=E+S+-SG7[7$9+/+5/XWG1KZ>;Y^K=M-#0'GY;AUK%.W?H,^J@%
ML''T-I?"K]&WJ-HD.U=.RSULL4QB.Y5 J*871(_8?@FH*/S0)(CJUX_B4QZ;
MTPHTR]Q6TFV_M::U]7Q U@X6(GC/1.B>JY9UGNK1]ZT.O8(TN]CGS]/7@<3<
M:+$-O:,CJM-SW./55D[XB$5$00Y4#&FQD3G)_KTVW35%%7D[]$7(UGL[/\XR
M/ORI-@Z-2= ?:3)9T=%UB?A:.+>@DLV;9"9'<_=VC-?<P)7$>]ZW/Z$IO/LH
M4OC+QL$%/-ZK;!0IB6&Y&:Z;J[[O\)($;]P4JG>PE&2/&-7]E-]FF&$]AZYK
M*"IG;5!.>\*W;)-'6TD-ZO72S)G612:13W/E F@<]-U*^[14Q]!G=NI^"F Y
M^+K(#1-TWXXVL%3=WI)-J3_-[KGC]QT8'F\![PMP0-_^.CL_9_4M$76A*&_N
MQ'SE%;2O+\) <2Y)2\!>>_\:U5%7"SEQF*1W?&+Z73C4L-E?I(%6:39L@5&"
M7_0%#FJ$!99Y^#X#0J#E,]?OCG0-?O*7\&;^CRC48;(7D<1[,'NLJ#4T1K\%
M,Q"[QW=@@;WA!N*AO_F:N1>W13_232/%=AZ%25AQC<$XK!!35B2N45=6/),=
MI62VTM*S 0O0_N+O?>%]I9%+5.R5 T0SE^?N][?PI\2I8 KB+6C:Z4?L8&$^
ME 9Y7I;AX1M'MYZ:X"$KDW!'.L7G$76O8-ALJV:+B*/";.3>%&I!<O(W:M,(
MT0'V'3'O9%$9?3KI6LR5PREN%L+ZW]-2?HL4??!A98%0:_#4'H'N!;^ O <J
M8]S0;(4[%J1UWZ3^=;O_I7><?Y&C\5S'C6\ R:VK^B_3+YAQ]?8>1;"[V(*"
M?.8%Z_DWM16/*41LM'ESW'_\4!1* I"7.9?D?JOVLW!RH7CYNP1N0>Q 4,&"
M5OAGC3MGOS4N)S!M-;PU/8NYO9&7/V_9$5XZ+R*Y!>@3H ](OWB:&VVRJW2X
MX=3YWI\M0E<D0C@QC$U=_-%=VYX<GN0]L4,.)(0*+@X?1E2QGM<T+D/8'7T7
M;TT:Z 8&Y>F[\:9\=8^IGY'_'LV8EP1?W@D@MHR8/&K\ZIM:8ARI6O9\U#M#
ME>IIY9CL[IN]8[R(T>SL+-MLHD8T&Y/F"P @2-2YV,S-I:"V+DJX]@NMI[IH
MA*;1O>=A[10>848C5M\BUWB"*>!B_QWOK+HY3I!>3F!SFFSAG8Q-]9N%)WN)
M@U._#E[%C8=6/GGZDX[P+/^D?+*QV)*! ^IKZ=RO7^T8D%44[VS9RP62X62A
M3=)8EEDW"RTAXQ1X9R$+-GG[N/3UY/=!QK7_=/FL/O': :J5S)DCH*=SCI-@
MN.*8V1005+/MMM=]3<28,T53W;Z?[[U#ZN&%\.E/W"ZF2^.CBGVIN0K-3TMG
MTVVO6Y(!P?G=?Z1C&=3:4*VOOY=]7D5(29@5,6X[0QOY8^)LL:VG/Z<$[O>@
MI#AE^C\E/;>OJ'+4^AMYY88:P'NNX_SZQ;6+N%8[19"#F/*"K=DDWR4 >5Y:
MV>[C["@8%+U OG^=BL_V^&_OZ@9-^^V6]-Q?I3$I6H?JYO2RX]:+)825_TP9
M011;'@]_\,:/R(V!MZ)H;A"4*1A\"K:3YY&5-!G?1,Q90]ID,GTZ&2S.ATY]
M,)R-%RDPB14I-D>6.?_SQS-+C@WA]?%/: >ODSS7 \6U '#UB+D^X[J>++KB
M*7MRFM<A!Y'5K:MUIO4TE#B,*0]3T4%1$Y1_^-=8A,>G>,AR3/9\_*8U7'YP
MRS.>E5"0%1"-/SO]B!/C1YM@9"8D2C=&"!J)WPH*) MX/JHV=6G@7FL8]-?[
MW?R-\:UYT'XV*[KSJL"PV_>7M3J7T]VR6()Q#)&#8R\.U5]_2]>V';R_Y.#_
MA[M4\C0)3)F2^P4JQ-38VFP]2N#'IIUV8"NM=?D*498+C9;/6XS94O+MTLBA
MACQ.GLA;\?ZS=/"A$6L09+>WOO$2 -EPV N /!YL 1!NC &O$.Z-$H0+E:VT
MJ8\.7.= VPK/J+X(\'?DA[ %BGY75!0^FB(IG5B8+N:L)STR6H4N=W&'R-2:
M>/ DX*VN>(,=(D#=7BWQAJ+]BWO%[?AZM_%SL?C4.][?-IO/Y%+D;MMB-2$7
M.2W2A.>8'1R_(5:RNGS:P7F[HH/+_^?,G-@M_Z25BL[D4*J"H-I+ ,7%Q2<?
MMW#G8!+S3P>%05K"]M)]LY2(IX/,,XEK5/N-: ,J$X,9_!I#U5;ICU7%Y17J
MPV_/'&<6&L-9#6W\*[ @DK*D=0*QJSSV6FTE:Z)"LFCDXC6S)F\WV9.9H+S"
MP;/W'G^D)^M5'.H-D"))^UG-=B/=E0&.)[C(O+E&UJ0E';R5K]M'[?YN6"[0
M=M"CKWSFJ=AP85RF8._$2&S1G?V$[@-N8A>"785[)8O?K DS65#L9%$R>C F
M&V,NM5EM8G)S\TT8I;C9LMW%6'*VV($43CCXO=P!!8&R88R@GNND1(=W!C/'
M6!N-ZC@^O;%"5O. BB)L4)GK'!Z=7E<_&2GTGT)N -T"\A%(RL:>I&R<3>I(
MRD9@= 6;4CV>-KHU)7;ED91);/AO%VJ.+.3_K6Q,?78;T/*EK[[2/SX41'&T
M,WR8:JWFB/*Q# 9 <X,DW3BM%C2#V.,\AU7NG'S6XKDS&NX_3R\] "_&70+:
MSL'(5LI=/HZI6XY5I48+I9O4#WVH\NX*K'P*:5M>?F=-R6J*?%HNF?I3X[K"
M$4B0* [O +$1F7>3%W!>>HW8UPFT7ZK'CZ4S<JB%7-]I)UH"UK[;GVVR63Z^
MR&Y],Y20GO(M"\4=S,[-]HFC"9LU@'2?(^N^^)4U\.YF=Y?0>@7![,(_MP'>
M:C1; %\+9)LG.&/<]E:QPJ39X9)]@&AK$:D;.SY@?!A7)!GE*0!=K3=X3?>+
MC)K[5Z9M,_RWH;H7&*FB7E8CR6@P+79T0+QN@NGO!BICS\+V5>165+V0\AC'
M)$WQ!M,,N5&-;J-'%7%:5#S+4UNWV5B=&NYO:GDFR%2L("KX(WT@UXA_@+2C
MU<TR1QH3$L2Y37,G]@.*D?WFK#3/![0D/]:[QA@X53^B[J#HU==?KVUN]I>?
M>%U:(:[Z(.)<(0S&NU+J9Y-@VJ# E;=U;E>K];.S.B]NAA6]<!-,7KX?I(0*
M;I<GDCNUTA- J& V7-[#IA$Y]".?,?3+"0D+F@^DTO:]OG-#/+X_\^3P.1Y!
MJG#BSPG^5XDDMWL/W!.,,6)X-UN+;"7'>2&!7"-E)Z5>&HW._BZR<QK9*!W'
MD/Z79*^IMS)?+&OUQ'N=WF9+$8W_-#[UJ(#/_C4,\M_2&B48M=(0+#%C*.'W
MU0O*6I39@Q)>S^IK(YR=P^WJWEF/BY"UN.2$/AO4\._I:^5MM7?CAP\ E;BR
MP_@*OV^9'I4.?D%)*,DOD5&D,'_B;TSTF KQ2!Q_AZ=4]]'D%'GNI:/9<-][
M3-L7Q*:BC?5:E4+?JP%RM8S[(+AH?!GHOQ3.W.T'N.]_S)E_N'#4HL6Y60J/
M@W>V_O+-PP,)*N/\2-%$:*%UJF*Y"RK%3@>Z2GLKQA-CYN:I)63_DX$3I#6B
M_M:XB,'AQF%.'!#LNS_T.V'.:WD(R< .'UN\/^&M?P679CZZ#^Q:6]P^5T=B
M^FI^4[J4?7B^\BF,U$Q]R\>"(VM^F4.I.DW/F+0ID4KV5:1>F^+]DCDTGT^-
M*I9K2Z3DQY3/RQMRF)0;GC7X+]G"$3H)=#LC3^*$RAUE?@CTO3(( >P['^:=
M/L$)8UDZ(561[ZI5(6TVPJ-5<X&UCN52WH$?7G[PEZ']50FXJL63?7(^H<[J
M0?_)GK7VVN,OA=-B*,C<T:GF!/".+A62@6*Z^A+P00+%?I[]A?I/6J(DA6>W
M<F^>J"96Q,JSSJWF>\FV20IG$;)(7=L<$9W.T;,4>PF@.HXBT-FB>+TZ4W<_
MTR=[N+('>M575OR-VGCDQXX/UW.>!KU:FJ%"MBCAH@IP_=U<JH,9*[J2/BTF
MX[EVR49?M*5_%--^HB=79@J]NNC'##+:*IM9S8@QB,O8>?5]M[A^C20RIMHL
MI6:Y5WPV(]:_B)]H95IOIU5*/E&X3FT]3;'WXFF-8OO@M2NMHBB2%^S""T(K
M][62S3 F^-J91:^KNSK-^2GM]F^^V5RC<#TX@%1_,I65UHNUXFJ0]/Z;-1E+
ML,$L=1[$0$A#1WH$J@1$U 9Y]]9:K!]K*"MK)0BD7F=BI4-JA&7[%I5/E(>
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ML;_YSNCYOG$[C\=#/H2ZUR6 P4>GU*L-R#E>7G!TX";;[QRU/LL!2V#^Q0,
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MQFB0\QMP5^/"5T"L!)Z1-6QD),&E=/>CXWZ2S;;-S0;\,R^DI;/+ VZ/.G?
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M-FY-*]J 9E8#*@:,WPJ"(.I&:L8O@QV#29XO7X7$YH<JB.9X^7W7S[OIFU)
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MXE-@CA:#H(VW64TZ[UD/$NEVLZB@-NV$5WCDD^-T,+S=R$]70ACQNC _Z#6
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MN_S19<0UH+)]]2N.]#)\W0=H ;0[@F[M^OG,-Q\L-Y?72?5Z7 -J/ODF(3J
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M[5[[U8B)[HA4*K+WRBQUI29B(,T@[6&9*PLFG7!7O-19?=+^5YB=Z:.L+]>
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M/>I!!C:H=V?A-:. W;, \DE8+93^A0W7MI=D%#W3P0W<Y_4F #XQ4$!.^\,
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M"T4=ZHQOM-;'/X_KO*=:9$ *RKO+]?[&8Y4%*O*?V*K9%TV1/4]GHG\XD!^
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M#)W<G(N=U\3H=?I_N)*3T9P0=QMQ_%EF_*-\@..#3"Z<-DO8@A]PVS_ZXEW
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MB5@F,T8C5"Q#^$-(W31$W-W_L3/JP=NI>]I4YM6Q.B:P_Z*:X;]#U)FA7'H
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M>+JLZU"=X<3]NSH<3P"!+=F2-X+A:\>'"] V$ZCI%%QSGML8WA8KI(*WE3#
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M-_HIYN'@)7["![L&M8,@^%+;X-^ [29Y:-K >&(C!^+P\C=D&70Z#;%I@6*
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M;'79!'71W]Q<,<C7@TK>TG(F%J$J8D^[J%ME^>ANR9Q5>E#&$VT_2P(HG4A
MR%2I[IJ&A3>.1KNTW^L\%K]SL=R8XV1&6LO(/5.J^.O*+!T+]@)Y@13MR/M)
M\@:1*&E[@ST2\&#N'9)9+:X3D>.DH>!.]>P?K;PM*($IAOB [!$/ZU';<S9_
MXV[GX+-S7N3A?Q+138S3UQU'_.,MYB:3D,.V3.0>)S,TZLS.YL_8P,:?(T_(
M1"_G Y.(.XTL/M2@!#HL*K3Z:JF\\41C8HHPY,'SF<.+JX0RSJ2PQ.F(&IS!
M;<8O:XP6?%S=J3E-Q/,^PPA*'Y9)N604CN*^RC8Z-Y<-F:E#7.&EGC,<*3#Q
MM#W@ ]LQFQ\W(J<8BU6M+.LE_ C\,DNCEX6B=FQ+=V-F$!]"DST2\-U!4 H?
M"(&G4 5.!4*5?]S>21@<\<+O6CTTCJJXEB=EI>0*5]N"SZK.XW5DO>&V(.$N
M'!,,0G%"35>=67J>(<R+3,<8[]?SC]FZ6:X%4#5-C6Z@\^/1PI!I\5+T1L$*
M@S7B>7]Q&-\XXTG,2$&2/4)&JAN[/8^Z\RPGX%E?]+OSV>M3A*,6JJT&#PAM
MAV&R-#@47CRFR4\//)\+1LO!5_5LKVL77J3GZ>ZF7JMP399FB*C>V1[S&<.!
MY+73:(>%8W3]/BW;I??(#SU+K38/B:0O&=VW#G46:BI*7+ZC.XJ)D#C^K+")
MR$W\.60")GS)K\E#YKF+?HX<R;5\2EQ.6P[X..)HTFHDT6#W&D5/O*)?A0J7
MA:2MU):K.C^O]CC(3:7+G-#3#2&O:Q]1\';*P;1:0]XC!3W1GQ_V.?MP/S),
M=.;08/UPEFUF7K,Y,J5P+ETD8&R(,+3'[-[L[+AL+;0 .4H<2E7#*63Z5HNZ
M/9E!ZX9?H8^WLG<7B%?J'Y,D 8H5D"MJ5&9F;!3VLKH] XEHP1>]5T0UA\D0
MW?'IOX#>_DM__Z?K;ZE?H_UA:%C]H261^B1.N_JRE]+7ZC[BZ<4^=Y\SV#PT
MMS:.BO[R*^^Y\4]EM73WPJ_IM4 5B;V(;_2!<&NKHM<8%".8J?:U=Z R24*Q
MTE?HZ9N8#TF\ ;O*?D6<6%& 30I'#SK1UW;OLWF1B>EK/)P08A+ ING/,5^$
MB%U;(EJ**4BIV*2NLYJJN$4+O#4+81),.76<XA6P>FD'!P^ 3[^#G_2"8"(@
M)H4XE@B^RMZ-\]4!_%5%UPH;T/U7SWYZ&\M62\75Z/W9*);G!($1U=;4XP!G
M+/B/O*< +GYU"HW@]'+ !C4:'JP90$Z#)A-YN6MY\R&VO#I;HN:/V!S@'E/.
M0Y\(WB;YN?TSQ\J%?"ZKAX7%[A=V5PM[^8!P[$4Y+H(KQM".GM;$I?3;5FKT
M':$K$IR*N=HL#NLN=?ESK6S,4W=$C>Y&-ZSP/OP<^V/VJJPOO;T)S\$]G^;J
M(X=?YG^LRQHYJZA,G/M6ZYHVGJLI^\"A1W[;6? >U2M6AOI3B0?R\1ECS\HM
M,A"6D!A+*^I;ISS#;!74LT65^0$ZY<Z[95(L0D-?AL0F\/+JARAYJ TWPX]M
M.W_BT:T7\KQNJV&&II;7E%?S/M2Q56N\,0I2>''UK&)WJTGMP55B=[G:ZA@V
M7@4;EWP^F4!?9)W@_TQKTO@JQ^Q"4NH1+1=MKBW]29;#."\Y]-2H3,,4VQ4Q
MH4.;!NGB<L/1>B^MC 3QYS%MY^C8F)F.BGZ"\L.Y!PP>IFF+/>1X02#CL1E+
MQ]Q/C?J^_Q\1R#W$KVQ<7E?[QV\1V-$3YQX-$2*I$<TA^WL_#=WU]^6#KC]Q
M!,XH%G6$ &&'!21FAE>:?AD#S>Y:R#;;.]S_(%?2Q'N^0GSTNT+7?:$LT7C!
MLCJW[D83GD.D_#D;*!V!)K<;O1%0?JJIN]'G<M_XR9U+N"TKO-TP8,_K-_3]
MG/(VK!X16,T.JJ"%1$Z!*O=*>YQL;OF7EL(JA]E<S=K+FB\WQ(P/0/S@U$XP
M7RBMDPCE,X9C7WO7!GFNU"#M1?0O>L'/E.@=VO^@7A.Z'WMF]SP6N;SZOGE-
MKB[TYT *8R8<:R'?2H.+[>ALI -?9S>ZFA=,6;EJ&CY\G7_Z*IW_U6.,]+)^
M1G "8W-S,A\8<" /^FG@=(.=[1B7&=Q2,),R54_PAF6:YZV>U5*T- 0<?S\C
MV7YF,DO]15B>MXBIIT)WB_=;&(?/#QCV47?0U'&"*AR==T:E M=5]GB->6AX
MG9%&,IVUXZD#:R'%&Y?/@._U-S?W568<P!(U?WF1L)J78LWA3_N>!MW7^G#>
MXKNS8'[^K."WA9?C-]M""<3#(/+,)R9,ALRL/3(!IZ8K+/JV01YVDUAW9UOW
MX_VKS4[1O)K2WYIR(J)/77O'R55I$Q3 K:^5BU\:>*OYJ#Q<>D<.@J8G,%?4
M3$K@F#-B9B T)B#'FF/PDWZ%39.1QD33#(>W-VP2?6]_Y62\V0IQ_7O;A,6B
ML-HB(UOHC;HJ:&TR#S;PM24Z24FK/'EPON^!=N"HEC8=YVW* 0OA\"\4IXY0
MA7M'D G>&HXR"Z,VO(7>Z<KAC6D_IBNNKLH3*&)'VU]P5W*1@<$,P(=S[V1<
MB!"Q8-^.C>EMZ$O<FY!:]IP*E57)=).H]TBNR!EOMDQ?*NDU-NKF.:X5P53(
M&4UURX3BX IQHOK8X1<QMFTYZ2'U'[+:IQR,N"[N0Z^9OS;D?O+ SXK5O*VD
ME^8TQ9'O()S '(;W)P'^NC7[=G43W!M/,Y%/-K0VT^J5GD9L-KVLB;K6?/N$
M8,2*L2N!<0/O#J$AGH+7.6:/%?E<P(7F-9BV4G+)PIO+9S)@\_$\V95F!5E:
MYSFOY\A-UN.CG=UYOHWO5V DZF&T7@;8V(U +\,TPQ4#L>'ZL7&1B>><TE?G
M."T#-4^LVBRH4;KE-,"_01IH.=!3D<4?"'>PI2;O]<%'C0E^?O(?Y>6-Y7$'
MOI0\;_9=@&!B0;[(#']=$LN,:[VQ:VT"X=:JF(I+L,K7ZV/M@U(QT(:(0,@#
MIXME6?TJXX@Z$I"3JJ^4/;XF@#QY&"'/:\,M"\H[H9C*X&QN4(WOV*:2#O=H
MS'  H^=Z>).*J^W ^D B!LW/\N-+^P=CLHFKJ_\K-FC]CJ+=N_2')&K5S!^I
MD;<W/?I.CX]2MS:1]V_;>PM^2SOK;G#YT)$O;F7QPWO$H'3? ]BOQP__NY\3
MP8R&8=\N3VTSD1E5#1E@V*%HG@'4XB5W,@&A)XJ-[>B.+^#;"]:+= /@=4HY
M\!^:6R3@*(3PC&Q'43HDX%/Z O$8%.PAWR?W;=4S[W_?W@UO[5WZYQ7<*PIN
MN@1>C]+#XR)0['D2T!0%WMNQVZ<V@4_?(0$1$&WO^K$KS>4])LPDX"1W'@FX
MI=)-. ''I1(9Y0R)OO$(\#0)F%$:@+W\Z]G^F6=[NRA/@]UM5+')L6-?-+ ,
M%UZ=E!+^/)0[4WU/WR_0G#'G."^YG=@)*RA=Y:5/;@8+]=*PP!NV$O6NRKR.
MB_@$+PW]MF^G[B&IORB>.GGJQ"RW3?)+=:^\91LV*:$D9N9F$#J]\<J'>UES
M69X9"PTDB'U1.5D:O:'4:[O&YQ8FQ"3"?E0K]E'XC""]M>_NM%U]A$I#4(,N
M@IX@[(RA3'H1F2<>]GQ7T>)<;K*5ZE@M$-BE>%RMPIL$("OS'DZ&SE5:8)&U
M,(:TXIC&9/H?7AI\GRQ*O2T?^*[6<7#XLC&7^+U.=*[)(BL#8[='Q-,;X%T4
MFK4'A68:F2,!IG#+1CQ7Q>[:IOAJT\9'UI5N P,],6E!H3BL71WJN)=4]++:
M21!Z"UL9;ZJ#WK85I;ESU6B-SDQ[G/+A];Z+A6O5QPABA3A&T'<*O1!P;BAN
M82TL6RG%4/A'8LF,P+N+:P=E$XD+B3WKN[0/YT-G*TVQ034(!I'/53A=WTH9
MC$T+S^:3[X,WOER9C92-*3"XRWM%69+3/*'TBY<T-B,/+5 IY(F.8-^J/YUF
MWYPR;H63BQ8\K7&7SP5(.P5(UC1R;[SLQR+^,>OK$S;$/P<-<]U8#+'VV(LA
M&:"=X=625+-4@X@;QJSF^A>N#$X:,N9_BO16NJWPV$OH,,*'EL"$>^[#CW7U
M?=R[L_C9[4)5 GY^[;,NJQEKLNZ)!@M7 =KB#XZ!C[VIW8(?U7=%EL*QLEU6
MFN^R+^'E,D)].6AL;,(^!MMB0CVC\V2_O+J1)J"N%ZGW"F!;O?9H*,'Y]W<7
M=1XH"50=9L.?<M!$/H=H#JZ_EYC8^ER@XS\S9"^YC<RPF4>.Q:M6_2!P3).
M4 /CP@F8EQ3N>'6Q_2DS$6$_B. :RW)NKMKCP'(!.,.579A'09*:_[Y.I1^^
M!+L1):M[( <B[X,6PMO<$M\/^/%>"2\^77Y!.?:=W%+\342Y_O6M4^&1CG[+
M['1EIAA;QGJ]WOS4ZCZ1Z<CEP>4S[^+XU5NF]T_?RMEY9X[FN](HUI'K<][+
M%80>:(-*Z"IB)NXA"6B\#HI*F1J^&Y UY/Y\Q.4E3\>%N7:NV<=KDK(X?5AA
M4!UJU+"9FZH:!4IX8E3L3BE]:3W>MD@44!7E<;D0DO@^ 2-;&M?C-?90D=*M
MYE#]L*+ZK%OJC,3J1#YH6#L*PS=5.3I;\>H@GH72ML6D2DT)"88+\,<8E1+.
M!$U'1?@<)= /R4)GJE@.:'3+<$R[.,/#;)J('V+%V4+K 1-*G1SA9Y*E'83&
M]:;PKD)*"0?P&DFYH WAO(HDI54H&A)J0@U>$T?@/+PU9QHMM9.UO0UUC._;
M%;X+/[>EHTPY'K3G:M_-.53HMM(T*E$/IUKA%L#1+EN-7HE]OJNKRPBG%EBD
MTGGR,CLU[@G0>B$=!P_;M@- 2TT<?;"SP(T(EH?^W<[N#L/W?OBDQ;QB,H^^
M"40?]Q'T&4649!0?J+N]7QJU1]P#/3,?&-0_, LJLW^+_QC.R<(CH_OFU;1Y
MW-/IU-MN;9$ZWY:=M+Y\:9I0(IB"23,BH(#K&E^:E0==$E]5;N1S)V-Q12/]
MT?#*PHZ1)@Q3Q?2V>JH+)=Q4E@.-H/?I(@''5XO>IQG"Z,!'RI8)Z.^'X_?,
M$YZ.-Q\/=I6=-A^JGRH8:HH:4<,;86\?!WT3HB*<!;26]^L7I2-7L3[=+/O0
M=D9$8\LXW%^D;XJ18)Q&[)_Z!FN@B0H8#7/SE5.Y7UE8Y%0<=S;9_$&18'1*
MR?S!JQDVTTZ[T!</;_0;/2X:[HJ(=GBQ:3FK&XZL=#^P]>EA']@-*O*L<C0<
MO!BM(B?'*5!<%/Y$[*GK"'OV6NME%D>/K\PK/D<.\ZKEB$THQL?8T@;=@6)5
MT:$VE6YZT!=6]+UDXA6^]'CDU<^^L2[A,\>X4G\>"!&/XI;EPMIAXD,NRYI]
M&5MT(9[[%DIC;("KN\544"9O%*G(8"0E\SZ \BJ]AB:\5E->RNWZ#%4C_:EA
M-YE'I4,Q-[_%"55I-@ZJ6)GHZ# T7XCFI6:)/FE4?:1%;%EE,F?'_<YXR<*%
M7NX!E4FH<:4(1H6>%;2\-[2=Y=.385WR<LJ@,]PN4(LN(LKYL8UF)1*O@\U(
MGX:/-*.[0G+FG(6,&8?5.#C??W@C$:>6_6*L&2+"J9NR,CH7%.BD<FBF71[9
M_."KKTI.3E8DH\!;%9F81>!BM8E&4>(3C]8E%Z^E TF!;V2@L%JAL0\[UE^D
MDDZSZ[7T7#]#<F><TF8I>R\'S]YGY]Q-"=9CXK*>XTNG&"IOV>>-U9^K;WR<
MV5:DN"]82#$NB4RW,2 !#3;%\>.YJE!_L@Q?N/'/Y_*1_(>I\F(V\&,$'HLL
M-SOT9!5.1+^B_/3%F,]C79-&ILKN%G&2%B=2YP"&..'F(\%?&CLW\QI&0ROD
MGH3N3>'O'.:NPZWO>3T1D646\;63E7"F31N,F?KX@6U<N4R/U4R@S>R<[\G6
MM=#]"XEH00?[.$SXN]@?&C VMRW\/"XJO/J<#3?5(4*>$U[7T'\C?C.?<,?]
M9>H#_2.U6H++N65"05:/))]?8K7NZ(6_H ^%4WEII/[,Y,/K:>"4SSQR44_#
M&A(X/N29OIE^A;9X?YJ%%[W[F)%I.G1Q/T_%'5^-LD>41.T4[!YG:GFJ$ARM
MEV0>TB]:SAE(]>;6^J6=EN=,NMW0HMVUUYE>1_JW8=2+R=SEN(4&8T?B+2)G
M7]J16 ? /?A4&YWALQ.NSU]HT0[,2)" 8JHUVVE#*8(J9N/5Z!TW^<D[P@T>
MQETK+;;QCE*/2T5+;F?)=-QRZ[JJX-1,+Y4NS(RO*.Y(U[SF(K^:\IW^-8I#
M5N+@EI=D7Z4%VCW-AB:W6;ARI<10?X@#_0;NKLP9[GOBW!L%UQW_%,R>R7Q(
M1KYOJ$ 6ZU\:Y;^:1H'(]B@PKR<__MU9682?A,\+D8#G*+S'MO16MS]JBTR+
M2V '<AY<[F(D(+AK&7Z4W-&O8O]'-NL@ORSA1TL0SF:>QUQU7#5NG*D57%?F
M>:P=&_3R%@\NATF=J@5*[Z4,7569,0=M9H2RQM#<!4Z=9,K"-%&]N%WJH%^T
MD@EU.JJLS#K#ULTVLC/K<#DX/YR+U5PTT5=.P=RMOG:?/XH@ ?_D%J52,GC#
M9K%#]ZSK/2XNM4V>+SS'3I\X%[J7,(7>;8*.R'FA@BRJA0DBP>MJ)Y=+Y4T*
MTC/<591;QBY;2_,XUE!?CY-3BRLI+4)1D8!CS08>3O+?4BIA:.B:.W8,T[&@
MZJ<GSXY[H#IG!)HUY.!I%4]>%4W6\K>3)0%'K/&A=>KON-)RK=/2LV6G9G9K
MO"GP$:"KA)^7BGN6WI+#>*/3T][T2*E2167U4\$KD>Y[-O/0/X:U80X:!GT-
MVAEEID(7^!XRND;+DZEKT$T")PGX'-\,!2&6)* E=GNA!O)JGVIU#KL.H02M
MMS2K>S%E<8NJV>V<,2_>^-:\[V'AM-\<2M-0>*!@$!;G4'ZBS]\8$Q6.>F8'
M7F1Y1;SA]FVE892N /I:S'/!W2YZL.>%L.6[UP>U9V>'&V9+!NL9'Q[A?7>8
M#)]^SWT4%,$D01OV\86N,U6.:H["V<8&Z<7A#I:71-[&/W6>X4A\Y3Z65.'3
MA60!"PY,O,1!5<D^RT'Z$*]'0NXZDZS8WD.41O(#3OY8-AEZ2)-.<20/@^2!
M9$D/79) M4O4TVB%"+8)WPOA<6:OJ+*0;XCGW>+@8S9-W=BAVM)'R#HY[B7#
M)NY+1=X%RY'^HDN#^?)8WJ.;%.%FG&;>[5%!4ZPDP.;X)O'"65 96_VHC,"?
M;K27T/3E _K* L5SC:_+8=V\5[M8O:^35Q/58C* G0A\C>Z\,J;4DVO&8#@R
M^NFN J0C.2TQ6IDWVII%F,O.W8>&>&(G*_..TL.^M:(D^<&FMA-KS]>>Z)WS
MY1M]V_1),#NR!J!"ZPBDE*GZ_I]ZF3P0/OT1OJD!MQ(YX(#BBR>\<S J-'FZ
M]>7IL1%]^B;CH^VG6.XW/A 5/9U_8O;Q&[>%4#"'>+*4!/"QX*-)0$$A>1",
MAX903#X7EJ GY;E7B%>'>)]M5W$/Y%N,GK3D"5#8?2J8.A'@@GFQ4E3:MZG(
MA I"?L!U$\Y0-9MP8:&O"7>P848)$#HOI=Z=@\S*GHTTO;FR)PP22EV\0G//
MSRO7*,BQLB^365(Z@JGRDB667A?TV%+*!<<:=,7CRI\&F=\MM1%(OG0W/-15
M8/0[IT58]JM;O&Z[?E"+*$824'N[6(!XC:#7/U0G?7P5;OEC&TY?RS*:W&K^
M)(]WE?ZVWM'ECO'$"VNT=LWPKR;( ]Z'*!;Y$RLB&%J5>GNY@:8@S$=6N[3D
MTU0?9HOL/].6^KCX>Z<%O'S(49!M,I6LN5OAA,H*6%C=T^S;WI:?!*G0$[ Z
M* 7A2(K->G>>U2AM;-ZT3Y;@S= 6-8<TVVXORRK7V'D24(AJZKR.]P,5/KF-
M/5 K_+CH8CSJX-/IE*AZ]AZ';\G+X=G'N$3=--T8F2QYVZZ6T;;FFF1!'.5'
M+ >1VMD=LQ'LJI(!6C96<ZO(T>A6Q9\==,AUP7U]RL^0OVAQ+/$(_E4S$(<L
M)#CC#.M@M%X0D5!9!:3>TNB%^H7T_IC\D?[710K=789"K\JZT# FPK/!2C4R
MU0; 6@S$CYL^H5D1-)M>:>D.]E(6^S:N)CP:K_XUYW%4$I_"J.)T9&/;U]O5
MY\BB5AYD=2/+?C0GKC18F*# ;7*I6*OT>^%3-L$\QH;<(S(.KMQ']A[:FX2C
M[]_G'C7*;U?=7EIT5'QD-!ZZN/23]99?S"0!)^P:$&?AED9+W,PXB>#9RA^K
MZX_LUA77NJISMGC=.9_R^-K#;'7;X 5!:T<P,$:;Y$N@&(Y?K:#7YX(;&^/5
M<N?2D>GJ O7@0E[KSTRT/0Q%%[ZIL6E12.Y_*[.7G1PHX['6F=6A_FDRM_\Z
M:^&_Z%D+>_.A DBGK=^>G#N@"@FX!CNP(%O4T.>A9"\^$O >>?B-!(RL_%AI
M11(471^!I\G=??WE_V3TNX:@!E)A-V;$"H*:DNE[=_!C!2]>G!MS"%N,R>#5
M(*Y0XT 28#;%Y$8EA$V=@8?)<CRI;$ZSN=:<-]Q([+ 2IQ;!J'GL>X2.BF4R
MFV\?]- Q>!1YM140!Y/IY0W:L4,8VLQ;-W*<,R80#I1FS;W?8>'P$DNRSFVN
M%T\^!P9@+>^R*W0N+^'&K:H%J)PZHLX95S_ZNO?$,?I:<Y5WUG^T/UOUI&*>
M7IV] 0'%(QA21Z?Q/&P:L3:',\,GQ!C!@J!4VY;LT+?XYGZ"2I'2@GLRC%!P
M>V03D?G <RBS"%Z<&4X?UTL0 [VM?G0R3ECKFHU3!.-VD GP_WEOI';(W&?M
M.@8=F+Q_;]6]2\J(JZT'W&!J\S LE 1P$/1GA,[.J_(H1LHQ-L'PYO<<C.&G
M/8>^>EW].9;3G5^#:GWH>[<IQPKR;:<G'%86MZK-38E;[!M?\I5U$F,_]JTK
M+C,8_-P<TO"G#DKX7])P!'AQBO .-JI";.H^S',U(0$'YEXR T0AGXYJ.6R3
M'V??"HN+LG!QY3&J#^@$J<K/B(T]"_LI%Z$\T!:K5 L[X2S"" -5%(BM%3BN
MJ;%B9?D!V:EG'Z^,X7B^/C3W8:%(3J1>S\E.?V$].2@/>_W.])G#]7GHL!H^
M$!O5@'@M?QH[*YU7'!]:*9$Q]JQT7[C?5RCV&8.IKI99G YUYLL9WJQ:UOQ,
M?.%A6B4?E@6M%CS77YRC@!/N#!_<UXF,%II0>XE[R[99^);U<GIB^)'E^WY=
M7B_)\.SI=1[<P!@B&:SCI -?YQN_&=*MAGQ7<7RYQUN1FOK9,=GPA9ICLLUU
MM!KAS*/IS+HJ#R[8@80ZSG:<9U<%8S53%L#A<F=/F9WGZJ+$4;G"3ALOF?@B
MVWW#'9[=+(<1CP0(5@UQ9(K ?QA-$$_F(0$AMHU3HV(A*>4PH=6O+7,Q[OQ1
M$]EE7=<JJ#)L<@Z3R)2?/HBL7><S,3+T5.)I\=(\(N_+8[\&K3%<9]9/J1=7
MCUT<TS.W4+09G0^X<L$M72&:7S,W4I25^P3/=Z0T^.A BB )0K)L7(E4V#QD
MT/I./+T[K^B]@Z^-ON=<3-F/-L^JYO1%4EZ+O:>U\&ZH$B^LJ#&G,0+A]6DE
M2I$A\BEYAF?XZU#!KNWH@TY/0^+PCV+5A[<XV?TU;P0X7I*Y4W[#0M'=_L*9
MJMN([P3EF2@Z4.*.MZ7QT(U#GOOWPILV\7,7PBPA5Y^\5.+)_+*3SS_3O-HW
M#1F5N1/T$)?Q%I]E6XA7O3]"R*DP>F/8'D/E5V1Q[]R^)66U-_G/IZ-1Q[8/
MU8W5O#$3#T_%X#GR[C,'Q?1=JXEJ/A@H2E<L7/AHM=,[RR?I6:"KR+]JE]>-
M.\"W@HVX"I50)ZQ&@1KM4E_G"S.68QQF;V,2 TKHM#:/+2554A]4%\AR3"=1
MH!>";)T@IQ;Q!F>CK*_1QOH+,=DD*]=P%LC&R9+I98RA<[=!2I90NL6W/?;;
MLMG=+\DRE>+FGS&7O_9 _?^]!TK>G3Q@$[(UOSLS/XADNMNA2QR!K^XL.B\@
M_K\Z>].&!# D]1./D?OZV/J?.8/RO^.+>13^8!*NO88$4,X4VK':X)8H5]]2
MNS-VK85OE? ^H:**!J:'*$@ ;0_V#C'(CI V!<>%;JF%)T-Z"1ID7GP"M,BP
MD;;-0&9TH\MDQV06S[J9CY:'79E]?*L>4%0Z1@&[0P+J7O\\W_?N3!T,Y"DF
M 3/.P^C[#%%RZP/;!=V=FJJ;8W?\2$#@(GB>!-PI)6K:H<!&%]0IZ#,1P,L"
M5?4-ZX(Z+'"T8.R4]H[$T 8_/-)1\$5V7XL$8#_YL,)[)+'QQ!-K<'#"%H2A
MN_T)9^QEB5S8ZK!/JM+^<:HB:H$C:>H.%$P:;Y.;"N,+2LN3B+!9(^_TPQ4]
M)(X'$Q3HPP!Z.W>?M8:/&!@^+*F#%[9+;+ RLCRW[NQ1DVQFGH=@)R#'H(LN
M)*!-=9<$L"+-<?P!-]38K##UL)[M0X<&R7<&RSI9]J=?GJ MKF5CDSU((--A
M],V?1Y2DV*-%" RC) !7KH[7V>U#Q?J:]!+7(NF)'*G308=T4WO*U>0!8>XG
M2!YFR'-X&>(HGOF<P?'C\[]\%6OU6Y6X2ER[=VHL+4(WA^YZLHT:D8F^GGZ?
MG_NG>/MY4C)''HR6((R%^3E3P#^YW;GU8R.4-6+P8\8=NTNW;PF5,7%RTLD%
M2'ER>&9-S1%OFPSN#U?,J+&108K>ZQH< SEMXNVG5*#M&8:X-#M,<YS*^FAS
M',4KCZ$W)*#>R>LT"?@\1@(N24P1GE0A#7YL;S!:.2Z5ER!LLJV&@,N#KE]S
M?[0<.4:I>(S[IFSD0 O\[^;YZM_Z_%9S 55A]G=3;.?&@L\'=7%"C3KR'-BI
M4'B1<\X$"; L)G:7A_FTC"KN)?-I!"C*)D\65Y$ :BITT/_#WGN'-=EMZ<-1
M4$2:2!,$HH""(B * E(B(B @(" @-2I(BX" ]!($ >G2I0N(2(WT3J2+-*7W
M$IHT22@AD/9[///-S/OJF7/TS,QWG9GQCYWK2I3]K+V?M=:][K7W7IO(%$D-
MGXD8)H/"!XDTLPQ/943R&G._3!U%?XW*E:_]6%?<]\K/:O><WMB*;UCNJ9E-
M:A;;3Q7!P-!O(&#>AA($^:(1'%1^H#Q5 UYJ7>-<EI"@LV:YB0I7J[6]K=+D
M]_@ /^=1#!1G%^D'WI:&+YS%DT%A^E4K'-Y%A?>=S+QMZ1;BNM1IL<.,P;SQ
M5R@O74ICO\EWS.W4,,L/\@THC!++2(IJZ6LC@-7.UL@=@7\""$=L\@9)5)\
MP3\D<&&4ZM]\&;,,D^O/M9$0'1UK)":ZI9F77+QATGV$XL*UCE.TF[!",BB
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MXZ8&6,L&4;BJ,.>H3V\:V]188IO.TD)<A2Q 1HMT'O\.AGX'0_\K@Z%YQ'-
M_Z,V N!8(<#<,G?.[P\UZ.("LJ:!;X=H<69OE1\^QA[#N9A'+S\P.RZ1\!8-
M/4&U:'IYPF-X4'<0:N7A4] 4O_G_'>B-G?B5DW<S#1!X!S4ND@QZ,)5-!KTN
MT:?"TP#J6.#&3YI&;M>@ZBGFRNLJX91RIQLI[<7ZW%RU;D2(7^AI&[L&HLCE
M+P=X;;%PNG,VJ<N4MKR^(JEO$5*Q$>CV\>HBUO$2 Z\?PYR)&G%R']'Q$MXY
MN+R?-@=8RKFJWZN%OU<+?[G]>"RX8?ZOGB!&4!/</%[JD4[*]'YOMWOI/U14
MZ@>3,"()\\' +]3 S!A3W?Q/92.A_ 3%NE3(3&8Z3>&0.^LD0>JRF'Q/DU>]
M<O15%W"<]WW#'LX0.9MY)>/A;UZWY,(O%5 J8IH;B&1X/_V\*.S#ZFRW8ESL
MC)^0>>/A*NB(#\H(,>K:J-W-VRWH72G"R\I/O.(P,%277HM-<^%-GEZ0'0H1
M* C]F:G^74WAO[>: L52DD!F?7_7KYJ + ,0-;?"UQ-(O:9!INX !7V Q'8"
M[ 6A@#B+Q+!/:LX D8C>X8S_Z@MV_@=4&)%3_09BY[AQ^@"434SOBV@C"F%_
M#5EK\M<9- =?:D^9(K^IG&/RKQSOX61KW]@[#0'4;,UH +D=KSKS;8OLGG@D
M):!XNZ0$8WUW#)YT4[,%CF?=$2&>B:Z"C$!)ZF:-$"S@NK*'60:0D]-YA,0@
M0KUI>NZ&V,\^_W>5@/_^*@$'MKH!^%Q>_-6=M]Q!?S)$F3\O@<5 <6%?<]#?
M%)SB'[EA\V]3D?\!!32.E:<P.";04=H^]K?Y>)N-(NW Z@3)6=RK>ZZ7$Q?8
MC,7@'&8];2VP#/137XY/&"];7Z9Q?TWMHU#RA%\T![(6J;IO49;"*>23]Z^0
M6?I+D/DHJN!SR=7\K(,%!9>.R,HSCWNZ%=Z_FQ%\.MB#SX9%V<>OFB'<,'4J
M%&W?GA0>T!+O.I1TB-A:WW)!%Q4E-/_0F3>#\B!#N4-Z\71PN?T)GQY3QL&=
M;J4YW4%AN=$E4Y,/YM'JE3%Y"Y'\1_/D?/52(F/2>UJ</"=R2H&)2_PI1CB?
M\P-#W8W\?HU[9QL2P "@F:P^+OH;FNFU_4S?_^[ ZYQQ4L ':A%JMK3/'4^S
M[N7WT_4$&9[]<-U?/>2'.P$WT-/O<[X@>>=7X:Q_*=JX?/&7L V"M?K6XVPO
MWAWHT1KV]2-.\X>?]BZ,XU;[=RP_ =;5Y(/\E9AA"P@!:MR?_B+T4640_K2$
MW2OW1QH[/TSBE<XE' %&^_[OGE']U?9/?J,?50<4@,$%WNFCW\ PF0Q27-'=
M*?2*PX!)VK)H!*FU&KEMF@TU'-;USEC>+SUJU/F7&I8_E\CYMTC)#P<X,CY^
M%(08ZI% BNXP!J^) )ZM>"8=[P-,R6K(AMS?(; U"?C:'6C,13(H(;]_YW<N
MZ7<NZ7]S+HEGJ8F#;BE8R$O!(=.Z?Q4;=<)VQT"(%_;6[/33&['A'ZM<9SB]
MUE=@I@VNF,I6.(LUN*+25^:0=9Z[*=.@F(J]B!@0MK1,/<H0N6E_\0VF2Q1]
M@B$AAQ]R0R\F+ NV<T-)5;_R&O#6+OT,</QK.[H?F [+OVL\,FVDX/[0B4E!
MMKSEP<V%\*>T83F!VM24W$?$#P?,$D6:]N]P6(2_&;/F>'2R+E_Z!.L1LXG6
M9!L!T,-@?HIHE0*&T+'UW0 2$V[8H)\??R4[QRJA,KYT37]S(8+JB6W!$<E[
M]$=.S449)ZQES14ZH?3?@VG<8EH2IL>N#FZ,-7QV7E!F)2;H*"'/GW_;E!E!
M96_8'V^<0A16OK2XL.(QR:QE$/\S.N"C^@,9=ON^IC$4JH"[#9C=UB \^"]F
M]\CBE]0,WP[UC\.WFPH_Q,K!,Y;O-0S_PN:M_PT7]E+U MS(,^?EKQJH![@)
MNA<".$018EH]?=W6'PFS.AQUN2;]/0!"!737_ZMK)O\(S(CJOX+@JTUP;NXW
M+,C WLO?%_+VL?R!-)>UDT%U:@M[/(^!<.?;Y!WH^\]XK[\"SG\5Q)WUQ[C3
M\R]FU]7_9<_@@L2O!'*2(I'3F]=] $T;J<R%+U^(:_QN>:=H:VZ7\"(=((98
MH17HOMJ9Q_!W2$)2NQ]\'4\&J14)YL)KD;I[EQGV/.HA.E-6/RO [ZS5[ZS5
M_[2LE127VJQR@#,\F$,_TFX;*=&:9%)J,+H"MHKS>OO\!<MF\YJ,.O\9E;T:
MM.BP?I!;Z5Q\_2O2D"D-#FIOG2/WM-#Z.'3"N(,S<-G\3NTI7JJC;%>6!ZD7
MJI<C'0KYV06=7/H_/2_;N/?+>,U]ZE.!E]:K%<,K.51C3R:5QM2DWTJ4N$?=
MS.9R/4?Y4(6=DC&-[C9:Y.D32& #2S%Z.G -7EIF)/1M(\66>8+%'H?27FIB
MA,'(IN>^+CQXZFP-&MH,974+;)-\6-_W)+06QUM%V=:G2%,3"/*[\R_UEIP@
MI:XMW3IS#(UP>AS2P*]O7'O Y_-BZX.(%X@$IPMJ99=%P1?,I/BC?>)R+E1+
MU4 Q/*M)DYJW?G9POS>._P4??V\<_V$9\)_^_DJ&Z&^!VT?E!I9OH"I!"AW(
M7S7<$T1!"*\]9Z'$4"?XEWK5AO*B/+Q"_XX%<V7"7U8"C=_,_@J=/_2W$]=3
M7L!L1#,! 41K/?"J5,R+&+!LP/S<16L2D?!EYU9GD5W7%>19()X1T<]9\>S^
M60%^Y[]^Y[_^1^:_#A1X,:.QU9C0Z[@$Q]VL%D/QY+OCYU4S)]J:[KF>G8@)
M#5KBK<QVW9F;.HO#.,R206-F3="CP\H1,&^G6][RY9>E&*AUJVTS9:L@F#6I
M#_BIP37QUP-QU;767VZX.R_\<J;[(P8:N"[S<-;;[!KR$@V77@_LI#_-(0?.
MMUH5T?3T)V90)0UL!(D^'T8<VRUT6N P0_8RR3YZV)$J9C>ZKC :1+7HLM[/
M D.!0\#O22",Q/.^2;MIY7[A\D.5%F-G1&_T'>*G8A\/FZMW(H- ) $U3/KL
ME8 Y]K+MONR!.L*8\KDXL\VE:)&Z:SU>==L;AH;&"<OPEDA7 *-_.F'P&Z-_
M8_2/S5BB;>,Y1V_3="#'<# !,DNSP6V#E=.,FB6*55753,LX5$Q&?9@^7RO5
MQ'UL>T7N#AD4". Q0)V50N?2\5^!"8O;J;_*]!;!@LN2NA-FD@C ^P;>P:>[
M9FE=&9VN@BYZFKN\K[Z05DG_9LM&2?-"VPMCI3N/]*1++Z6]?"\^,\4'^)Q4
MW%9CPM6'R.=("\0Q-P];#?O246%$GKHU-O'2X9&N>,&JA82<6R'X8>6JNKK/
M:Y8#%X8UD/%'IE#=%DQ'^,[3M'&".,]]F #U7 ZI/%IEK62O,7[)/4-7,EW0
MIQ%2O!$,-P=DUH#/\@R5%9KAX6MRRMC[";L^RF,2=E.APSW&9K)TWC!%+_NY
MWG$X"OF,X( 28M @)L@\1-%!;@W872@L]]2OW41D1NC=2+TR\FYL5H'V,NW%
M^9W,05$=Q]5-A5VK5N&@46;]IH1I].V-4$.3\-;UC;7D.35I::LQZZ_\2>N\
M(>*4I:5<D*.O#JK(@ 0G(>:0,2,=8JX,7:Y;T5(C%!VT_'B2&-$=\59$?5R@
M*XC[SL.#T5D9'?Q]L>B=<^UI:IIW&/.II7DGOV2&+/[#VW]^K^/_7L?_/[:.
MOV=).LJ.*=7"6:/MIIM,V9BZYQ!@8T AK:]@0VZ1C%@,ID3+%IY'\8".-1:Q
M)'P=BEVNB;EMHA(;^V"^5P1WM0-OZ3-FN-2RIULDQ^TE 1EMX+9M[JRII;V9
M>I-"</?-$M_A9V!5_%A=,Q:&XS?#RQ+8T--^A93:)@:-BS826@="D]OWWL1(
MWRGY>D;_\0=%18A+O5P90DM#+Z+SAKID5:'K?4665)3(,6L2$YJ46V2S*_@P
MVSJ^9&IRXAV?(JV5R80O]:GS,>][67JLO(( WL2 B\Q=C2<QX0[-'MZ2,<(<
M7#B^9$VU-G3P%NMCI>NU@BG^38UGO4FO<2;H516<"GKW&MHGZ*1R]A=LOBTK
M2DV*L[2R5M1";@TVKSD":=Y/;]<,X98E9M<9P/@<5_4O69NRE5<=:.@P?R98
MPN7+>>CFC>?R%Q*D XV')^)&H;O66B82.V30T^( B'M-).*;<W#X)>?P)Z6
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MO_YGYQ.WV/1<!6.C&%:.2)X./'+JF#QH2+1\^$IK[;A".#&=#+)BH/'I,ST
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MFFJ*ZJ8TP<NSR!99,*K2;WN#^8N(6)(Z&90X7X9Y.;$6E?4(89_(4597+02
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M,;LV-[*73CH!)^7OMHL0+I!!>'7P#[T*8'>D@THCS1;A?^Y$#-X,H.N@#PX
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M(];6,3I8I[I!,20C3 X\Z 7V:G <&S$UEJD8YJ7H4G1COA][/W#VL^8C<+Y
M9F:VLK9QWX1#Y/F2?V#GP-\@0)U(*\W1C>;T,DN_X>O#AD;2R=9TK8$Y-GD6
MY0G67.U=0>$=;6OT\D>;!ZSRPE+ 8JY,*OF7MY["9U*FV2]L+WN)6V($;VE2
MJ8O&&S%ZNW-J3$HDWPN\U')H96H4U=!$3();RK)A[=&7K?:]-M[:)!24KGC$
M^A]VOSYS"#H;[CY6EZ;"%V-:J_CD3LM /K>![)%P20"V0 1#HC_I@EO^7,YS
M@N<LA,7J*F,]TK-6,&# ;OWK#*WH;I;O^B-SK\*I>E[L8V*:CS1!"I=J6^B&
M1T$)9[BYU*RS8C1)4\C:25YAQKKJK#N2LEM18PT5F2G%NF>XE>T:U_I<Y61P
M!G@N7.][,JA\J!BC@=?YE(TF+N;DF;;;VCM<-GE6?>EEH\X1XTA1IRV,OQ^L
MC%@",9_%*W_AL!T*/A.1/B<DWO+8=+J#1^%,,5^=AM9=M,:"M,817M^VALC,
MG%46J8&-/#!/>>098J(7XQP9%(BD+901G2,JJPT);P]M/K(O&T^T$'H$&N5,
M,[\IKUG#(&5,+]I;J*5X_YR32D=L7)Q?B$#NB5\X/?P?-CW+$-Y!"_10(;>_
M4!W'W-BMBN.3QT^K^05]% FPCY6;(.2$H3WT4IG?[U%AQ8FASM.^IN)#!-TY
M.C6506>50I\.,V(R7\R1YG?6YA;18J=[!F\KN5EV+#8T9(;T9:OH)HA5GA75
MTE-NW4TOU@PEB. -%#!J[_<C_"UGR:!UQ8&'_1O"PKQ5-.?7ZQ1IF(3!7N,^
M]PZC19\:3E?DK(7.@<>D6].X!F7$<ZU<KNP[QXRKUA1L*:VUJ;]_&\%/:380
MLK\2,OC YMRY'4.FM3F+R!Y\Y(@]-F+8UJQ?'!$ZM'L5<G1HT\U?NTKQ]D51
MIAO,,PYA(?M@K"DQS$L*+R564Y=0B(*P3MRX;ZMZ]X;6>)N&J@*WQ@2:YKA*
M^TGY4T0F12E4GH8,0G'^:(I.-69IW0E_&H?'1N&R,U=</*8"<MPT-<HC!N]7
M)]UWK'TM)/.4]7CV\_,@X0,C@$\O($ R1G%F\OU/O.5.TP6FVW)EU]T#'9?\
MQ!,A"V+)4#0[7Y)RA_M#-G.RI3]I!%KJA2R#-R?;2JBE]?2VU-CV35COZF_P
M-+$\-X@*.7R*I;%G:('9(5I9 2]"D,)H-D'\/92?R1@YOX%"E^TOW#:V=NS@
ML[7K,:%@9Z2?,4AX&G9^M]NCGMG3P!-B@:77]?E+H8&?J9?P#[>ZN9GT=A.&
MN:&H_)6ID^\&9ON>X)?ZA_9)DM'2U<P'NX\8L(?X?G!L]$&WG_;-PM_!O<<Q
M89TQI*)7>UFJT7UG]8]HJV .2O+C"P4D-\)<WT+,IP\HH)>PKN@KL5'/OY[M
MSQH0+CVA=]F80:K9T?%.0]?^J>5/CS+K8Y*GL&30)?N-NQDH,FA<&@CZ".IO
M<7 33-"(L[><SJ%!)/;A?)I11);C]3LDRH&&8\3B!CJW5?V*ONU(KI'RG<Z]
MVZWNM%C/Z9+ Q&/F\Z#+'3/F&%,=_$4RJ&/6YQ,9M+-%10K<64TO3P@BG"L@
M',"4]X:LV=K=*^ZSLRBO2J1*/M36.WDB/:_XA9*DI S%BYN%V1HIYAF6A36[
MFY4KUQUMEK+<.MNN*@/1&\V*',_P5U)CUC)F;UA"3J=CH>A:S\"A2+XGAU^C
MTT/*D)QN]NK#VVJ(BN6K830.,(>%.A_S1Y=.PGR;OUP3WRS*+USEY@$").O.
MM[!2%8=<E=GWA6(3=5$%C0\L9#O";\?+I,QOPL;@#\%[5Z:#P-A#E630)YB4
MMI:_MTZQJKYE_A!_F(P]8'Q!8Q>2D,'.R5PTZ@IE$],]Q><>'6=T]+$XK<%L
MGO*83@%#TS8$IB,P%+EEW>&[:WTEVD0U?S?=ZH/6UW:09])>Y0Q;HY2/]$G-
ML.D3#S2/V>R7$+-N?.*G7-Y_F,PBRA(0=.':A4MW6>ZU7W \>TQ=JOO+E9T2
M:3C.;N,I])$:%*=Y?XL]C@)N:>KN+MD&[1BCDHE^+#U<@ .C1 +ESBP+Y>+T
M3=\-%\15R%1<+D@S,I,VIM<J[CE!X2>H@Z>Z1>H@=9)ZRDA=XZ5KIM?WI)U2
M'K5-6%8(MK-A%=$^01@C>4ROOT4-^LQ@;,'NOD] A:")JHP#4XO\#>.=L:Q3
M*?<K:I"3*M9/2&30)EN="Y2I0=P*3NW<2V4]MEY.!B6@O*]9NPP/8=J&L%O1
M&92M*9<")QMU[UVI<)C^)+C$@!, !QJ9$A-W\G&TH=ZOI@QM*KK9:"-*GH\^
M[3VI;7"2MZ]^N%&.Y_^Q]]W1<+[1NB-:0A"]MVA)M.C1B6@178Q.HH[!Z+V%
MZ)T@>K3H1'1&[T1THAN]FU$F@S&NW[GKWG7ON6?==<X]Y\_[Q_OO]\V:]]W/
M?I[][F\_YC3>0G+S*:,+Y2#DW]%M,EVR@9H!/_^98LJC39&=\#SH9,-_GI4!
M8P-G[@#U.$%8@<R5<Z0QIS1@8H<+1F$E:]#N2,@2UN@+)Y-/,S_Y$>][^%RU
MXX_4%TQS/Q6AW\$[VC8=S7OH AL<O3;4.3DR;S1CD^%LECC9EJAT%H;8V$V1
ME@K[.0GB++?2 Z_&:\\\AW##DY-M@X(H?'W;CP\^':A[GQY5P"D["%%,:NTN
M'6N;IT]4%N,[RT9Z5,V\.&+-+'YOO];04+'E6^L#G*\MOL!#S=ZH^TNBI#T\
M!%$:],^EE&L6NEG?M[^W>=++N>K2RIKHB1"57Z:F]WLU4AAK%E-3<IDO-<9=
MUSD5Y)@08C37PI0$WER2;53E3_[N9_SU V\;Y'HW5CGV[TK\5;]?F*O9"Y0F
MC)G6FU@3S]X7-P8%*G@R6-)+T,_8# @3P,4>M1X? =(<FS'?$*-B@-,7>8S^
M?'.[8DW,) V>TXY.2UA%=:X8%;9J6<\M<C1/(0KTJD?+-4(#YIF3<7%,>9Z:
M=PR#[VK!G5*K%Q=0(2?G>KG>#FA)L%7*@=O#<#-Y,A4]+OS'!K;X-R6,FKWF
MBR4]S*3_>+(\=&\-[%R_ U#7V]C5RU*"JJS=!'%Y#/$,-2C5+!)5A@'!+GQQ
M*M^7E<>8=G]JFY%OC"^1=Z\R(XCSBT!T7-%0UVM#CYE3J>=%]*-@O'<00VN>
MPFU\]NIU"?)<[@D,!=H,WCF00/B]#>:H<)S6#:V(Y%!@0/X,)E3DL4W]D.?L
M&Z)$]*[L-W=&%7:&F&5=07-"]!HME!4.5(C11=A49OI[/;9L:'P#<N(KPCY1
MI OYY8,MC0=+%C(SD'4B>63 #@QDA=OVD3S<TWGF/N_120SU?%=4JO\X]DA^
MM9G5+W[KP>9;5V T/GN3[:0>, /%C_P,+^DCB6K-"W$7;6UOJYV"S=Z?SD+2
MAB_PMVS/+)VWH_HJ9N76S\TRM)\U[TV<!L16G%*")""1]>T$!QCZ '.]:)_*
M*G8'Z9[>NK&%/ZEDK&S5CUYUL=O/]_]3KL0W0XCUG7ZB@X2=AF=LB%=?RAX=
M_MS&\2)$*BDT8R=\)7;VG?\9.'K_2E749,$!G6QDE>YK5 SLRFC><-)XV[^,
MP%91ZH@W45G2P *NUWA6,"NB[8\YTVO?I?(U[S./DF&X/T,@M/)&N_(-M]*G
M*7$^_RC.Q=_=>HYQAO&JC*6(DKX\XGMM*3T8*R5?>@>P17FN/$TV'G^J*EI9
M74;[)]ID.T<9._8\'MP;M%Z0=P;V/;T-7+@#[%T6(L?O "DL".I;'Y#YM2%8
M@^++%_[9I;,[@("X2!#;WJV83M.<\)+:C;C4H5IILK?5(M!5,%PW!(L6QZ-"
M9 PM? =(=H.9W^ L!NU]J4YNR8T?^*1(H?.?J#]''QS0<]]O/(<*+TR!/7FD
M6YOB<1H[',"P-8&'G]#!Y@V!02*R3!#Z-9""_==VQYA)E^3'\=WOY;14I7_C
M X08<-G=7_X?17+@0"!YO.:2[>9%[O/V3T4H^76_\%"5<(,ZXAIO@0Q&XW"S
MN+^!IVE%#\;,W_I[(F[\>5&2]UF;HD^E9=I]WZKQE>[-F6A_XK+E+ZMQ,Z'N
M?5.RXI%-DOHAG?8U!:X-VV-)>.<ZIK(5&.-O"OYN;ZT@DNT\YB9L$1NR3R#^
M+N3A2FQHO_L:<> +;\V-G7"/A(?@M,6=W)IM:**3?EQC^.)>ER##$^<NNK.U
M/Z<PRO20#JI],YY.S6-F>M3/60]'H%';[?9,GAWAL\@VHFZYYZG[4/)QRMT\
M)G=)R$(G,@3E@U#HF7/9;X5$>5#"3Z-XCB>4<;O2Z3G83BJ"*]&6O ^Y*FQN
M<\15I^-.40)NPM5(F:X"Z/A@7CU7F P=6GE"BK&F839GKM;:+3 SY>'<R"H-
M6[+JX^K?M($&2S2ZPY2[V,@SN'RMJ3&&5).1A"#]F;_F;<C:0B'.F=5:KK-L
MA%0\_JL187M5TZ<MR0<!7(H^>7&R=N-8*+:N3.48IX:$IOW6J?"I#],?02<B
M#X">?PJ8!5@\5H)+L"*Y*'][TR.;X0DQ4%LP3%I7&2$6C);W]5PP].Y5$^7U
M_(/O8.M&M!R+QY(L1\M.\/;+8JO\K[;<-45!4/(J5QK08$.1Y_<NEMQ6LA\!
MW!&,G('C2#0AS<,JT0J(%[?OC0S\J8OO<^>7(C)"T6W=Z5K9_+X!LKR>\$7C
MW"M%;]Z(XQ(X<E=M?O6,UTUAOE[M.>0$*E0)&IC6$5#*S_HHB6/3+?O,'Z;*
M@I5YF1>Q*EJ+2EK/(>^7L (^ 5TWE)MV,RZ6CY3VLKS4MR"9R'0M><4];/!6
M]<A=6%O1YM\SI>C_.CUF)XA2%J09?@? N326%AH(Y$Q0GN%GO7DGVC/G%R%P
MP@V-+'3\EMCE-.#9*!1JVO09_;X8M=GKZ]198!K0I#IC81QCG,"[><[V(7')
M!(_Y-5:-S&U%Y];2OXQSI[J7=_*%2.W[Z'=$N=P!+(R#;O&:7!)^ZAJO]IF>
M&UQ 2+T3U.#Q,5Z58*.PQM3B1<ZK4[YMTGZZ+:PT*5<5[)E$[L'ZM26W]?"J
M"N7OW8@'PWSL%ODGCM4LGVT9;9)%8HE]TS;SWHZ@AN$1?7ET@3+>,KTFT\7-
M*.G"19';+5X/LEZ_TNT>MC[Z7Q[:V[?;2Z,)&^*7:^3^O/"\6*FG&)I9*>GO
MRW:Y:O*4^?4)UJU)L7VB&Z(,3X X3Q[NJRMEZ^S,=JQ@K_HQ2@EQ]*GR:/Q\
M<T!K2JR /<3REW)'EEP6M!9V!\"_M)Z"&F\<F@KIOJ"MW P'9Q3B6%&K:(]8
M/5$ZLF+BWDU8V-V8*X:/(W50-3SI0+K/3#@S-1=C5!@;,FHL/>/\E;/$GQ+9
MQ ]^8/EB'P;5KO5P\^/Z\TY!#0/S%F7$$-;E!XO5#5XWHV4R$U3:I)[T(<&Z
MW-/>7+DOMI6$3W;+-7IV7!L2=%!N"-V>(&IAH4IO!9/&>>'+(-ZM4-=ZQWK1
M>26LQ/70<, \T)P9[3-Q_$^G\R(A;+>?A-!P\/M^!\<,L+>#O:Y)GH'Z@8G#
MEX36Z@=UB-AZEMRJ/ ?$^#''^NG]\2!+Z>YXFG:HWBS!#9ZR3RX@?%8UNZ5>
MN?3W*JR0Y47^L#4V^T:!7J/[Y3M[TW&]@@Y'S:7!;E)CA;(#)DK$7!+,I^B-
M.?GJWN-6EU4L'7:@#4MH4AA[?##"+ 9!CXR!W_,&DKWKXFWT(C1SZVD L_JD
MA9B7;S(E,1V%645]:$MT#5MVX@M3NJBBS>:K=+=INQH:E-N-/DIA S\VXG-U
M_>D3;^Y^,LZ; *[^3)?:W"V+9+:KKV341/6)*A9RKUXA5;^K>><:FEI&4=1)
M9N-B)ZL>O>!X)+^H BKY<<V]NS2^9-Z=;M30G_ 9*KG)'_5@(5K38_V6M(8E
M+OP5GZ'0WPCNI--ICMWC8?C(?-?U>&2:NI%Q'.U&@O8$W>CPS'%LLH_].YV?
MS[$BA_59G !G<E72<9K;7)G2X]]*RZ\#SNR- AJVY-.X(]/>$[^4LW@XWBGR
M\<=_:,;LO[V@-YN= Z;,Z\J]IIK]1FTA'YG44VL0IJ:"*0P*A_4I>^6##7H?
MMV;T-YP6ZRHC^B7>#T95^TM37NB 11LG5S5M6O@9^'Z5COVQ*K3PV"CWWAS$
M,*) L"N/<0HP52MG*CV.&+5FO= 3%45&PTA\@F\IH?W^CC?8!ZLOYC$2_N:S
M4@XUS%$U54=.U9N)NZ,D+85R@I[E ]JO=U\ =*?:&/'EZV^+[@#@-0835*I&
M%8PD@A O[_O>?+!TG=E(U<[(Y'H%K#"E;/RZ\J+K(!7W40-7 =#&W@NH?/\;
M;RL[R/WU$#A&S.%0:\> BG<NE)5STXO0$AR8U-ZT2T]*V'"-2<W3V^\8O'U9
M^@Z:@SDW@T+OZ-\K)^X!K^\)@TH(C.+GBQ_=BX/;W-G^"P-R;"DHMALUSL(;
M]@7T.X2)EUC*/M4X<1F20SG3*UR3_Q?@9_4N/4.(GG7\JWZ;_3+ES#P_@XKZ
MH_$"NYJ\2Y(E8#<W7Q*H8"_W!2*\IA3D>5T[Y2_VG7 I2^5[G)5B-O<Q<+$K
M];'+X="X,;P$^06NW'\H_5%=%+FIVCYI>>ZA+F82<>0E^CQ$387FF."E:W<D
MS59L;&^QSHMCD@Q'MYF]FNQ36:<\[*6KID8,/:*Q&.9=?);7[^E+V)C63,OU
MRX8H6/PF8_!5C1>\*;H^C][;L]=TH@8V*QR#^CPW[WG\)4GSX*$X#L.3?R:^
M%;]P"X&F?E*5CC/B'I7A#9S*?8@2*S7>EVB?72W>D/QRSGM!1+=07?/=1 "'
MI8MVT:4Y%N/QR^X.T @)63/Y.075+?"N@S6,G4<>K0T8"2TH.O<' U[QE L&
MGE-JAR8_+W]/=Y\?&UM.]8!Y_FRHI?Q_/JC[G'5#-JUUGP4_!^FEJ+;>^+M\
MO]*MX!QTJ,E_)3.[)T(6$U/'>/J/ Q#;?UD3U+^>YO;/?6^\^9CMS<N#I#?]
M.H?:=>':R8(%ZJ@[0$>2IDSJ175ZB4+AOJ<GU7J,GX'.P^[!E?<$$@ )XMGS
M3C2%D'* +M(0P3Z4-18VEC,G_EMF(BD9</B)*U @9;%]M]MW$975W4K\(X7P
M\PP/2YMANA.#*ETCK"G>+?=5=480GDS-!:N_ RH4UMD3A#+J;.@<]):%"2(@
MH9A!'_*K7(I9F9[S$QN:+T>.79:?ECC;-Y:0W'#KX^UZ#!^".A;#INSX8HRH
M)J9A@6]=R>18DH*%Q<F)6'Y9?H@=B/^OZS&7VV"CRDWV@N,"=.1G7:!M#.:/
M5G'G41OBP;,DRRCAL?+(EQ3X<@#&,#O,B.R98R>Q[!$AY [P;99DB0VC'K'!
M?!L:A"P )F+&.QO3NVNPT61P_4]5J,$CH\:<XEZ(!^0VW8\K_6DUP8G*V[Q2
M=IU8#@FF@X[.;TMO?7-S;EQ!?WWSCBHV]QQZ:=-65VT656Z7O;2&N3"OJLRB
MX+8Z=7,R3U"<R.[4RN^3/*N\WP#40QHO)4BG&6NC\]>9HP.Q;@N@SRL3B.U)
M45FO)2\.43OUF106"/3DSY%H PHG9X$Q;^((KK@[P(>_+9.R,.99&58T ZBH
M>?JDOHCLP$@&N3RIRHPU[28P/O+HXX+.VYD!/BVDIBJ7R^IX5O[E+>5Y#5IL
MMSOA9R=:LX'D6'B97A4ST':C9:'R3#F]SKE[?&RQ B6[B=_?&=M)=F&<\!@E
M:(Z+%FQ(5 L*VFC323?*YJ%_0'-&L&51AA/L64<FHS3^1^_MF?XEL^">9U[#
MC(#ZC1!:T3!O5+YHJ&N+Y.L3/;<#.>8X\]OT[>8LI#O*85[^<Z%<G7:+9TX(
MQZ/![Q/0OX<F><>S&P^E9&]X4;/?G=FAT?3/]&)/?3CEY*[Y=NX P7_WS;+@
M00I9O;*/_,D+EY79@72!$98@=M<01B-)]]</69ZX2N,"T<UFG=\"ZJH+HKF_
M_OC/M.#4?))A0(O.RSJ.QTCL]J\H]+4F?$;S%Z^(IL NIS1&NQGL!1$JAS?0
M*$)(]P>V1M$CRK\K_D!XT 9.4"TCL@5^N"$2ALQ9;YSA:I_P-R4J2EE2IP^[
MG0EY>50I8ZZ;QK)ND3M"5#J:LG$KD:$Q#_PS@7A_!TB0_7BO=NPD?N=OJEMN
M:/820;1,!:_7S!/'2T'5-YG/V;XTC7<YP"F.EX(-#3UV=.\/+.[3SR.//T)P
M;7C1/GGMLE[S)TV:)WEONU Y&S4H)W7=7B8B.%..A\LZ(9&.-- 4H9%OAT2>
M)*7+XV!UV=K@HKK$E[*)!MK6%FUAI]'"G<PHL4W^$.&KRUMPS\A<:W@8%I[Q
M(3YO^P=Z^K_!DA=;(2\%7WH=E11E@M'5FM\')R_/\HY&UAQO*SOM#BN A-:,
MVY_)WI30%S_XT(8=&I+LZG/5/@:RSVLJ"8%<>#7"/5-J4'D#9VP\3-3J+[Q/
MR$S"M 46WP/9R?2:F-# ]S?L:+99#*V_[(P'/\4=8&A[HUW)U,M 0]:%I^0I
M0XA;4[+/S>]>K@<M,Z8O7'?U._+B1EM3]*7\,(]"X>?OICK(P4PO;Z1<P;Z-
M^1SYK6R\C/5OLRQI]]/Y!AD#W]U.QI&@GHM&=,+N )]$VOE$FA#O9+B::FMG
MM!O5R$8?'VF]/#)[-8[&/S0VAZOG78GZ06X(3>\ (H48 NH[ /LN[/0V0<(+
M$]52'6][.7J5= ?@&R_TIU^_Y;I_8IA[#;&=?I1ET7[CH2.$P/,]H^I)WU::
M5+*J5.95YWKL_C?,<AXC6M9JS?9'6_WTI7(#-FO)RYYQ3LW71K!AP/K)?M?@
M[/LS8,_XE<K@ .0&L!"T%T.W77SZ(OWXNF"[.,*?:(HW4#APII,2[;6A@EEQ
M65_1Q9"N/)@RS^3FB"I2Y7@O?O7G^[I;=])O<=-.H*E1KY\C;WN?JC1TR#+Y
MN9Z@1%)($=-#MEBZ*]M^"<W((&O96#,VU*?"O?F.9RCPYB/]3?/IBZ&^=%_K
M/:[;IZ]0J_&F,99MC(/;)A?(.T 35V^ +U5H3Q(J8D"&9?3%GH12E.N\(5:+
MXQ I<'OK9)UA,S3NQ>OW=%\H9]-'T6%4A87+9W> A4[80!:\!GF JONV-\E.
MIS*9?+*X*A 69I.\JDO#F&JX('?QH&.F)NH.8#VY*3F^I+:1>@>(_]98CWB\
MR$!F8K#XNXXC>FA"F.HF/42'Y5M2H@H7E[BL@]X&Y'?U:0$Z0M-R.V&Q$*-A
MB;2] _QH+$17<6LB<U$D5:O@.5GJ#MJA1EDR*4ER26,>K'G@)[WPL)G'T"S!
MB@/B51F=EKP&973VX-'X/8PZ*E\9 6<N-9RR0<.>05F4+5G*/7> >J_!./I[
MB78D60'VQ),T-2)<HO$PY?(1-%CV.4RUD)/4>*0_\'#H@(9$Z[;N#K U)*5X
M!S S F+2C.93 E?-?U;=&(+OE8'4(^3G&_M"5-:;!GSK$=;'?*G493KYV9:S
M*,GS0]G&('0&?F3GX>C;.\#4J-&*JUDZY_*:9Q_XU+SV)(](=BL;!<1TB^9=
M<W 754-@)>B4/()[[<@Y?0=X4^R>NC/JZ=1XG]V+_D,^!?^;9P%WX-(JSSQ4
M9944Q0W#?W*8*Y$S=[+=ZQ@R(F,B2I%3=2Y$N<7#][#7IJ.L)C/(O@8/E26/
M& P.%$0IJ*3W>6&(?39FW.V"YI8-W\963UY>?1$.!0A<=0\.@0M)('8U9Y=[
M;S#D=(/(9PC93U#:D@5OZDW;F/H 8_5HS3KCL6=T:N(V#@&IK^3ZXW<X%=)X
M0[RK=0?,Z2^9X]=^=/:U7+8+@SJX)[9-^8&-89KIN\HNA+3D*<'R6[8A54LX
MUV_6FCI[C8^E+>!'1KN1:./G @HP<, +=^CYU0-QFN_]5S^**D3%W$7,D0&W
MF9>$_,&!0A-HSS+K#1+F<0^_<D*A<\.KO0<LQRW$.X-L/$HJE+-CSZI]1_5F
MVZXR%J2?^O%WBU-!0F4>N%N[.S[H3OVR]<2QL!L/RH\AX!!VA)=T-T8?I#?)
M\-4:6R82O(R'9'L!W(<P\,O*O,]!S(6WZ?X"CO#I3>F&DU"^D(%I=00[E> R
MZ#JUVK#@V20K:PBZ>2GOBU.O4]^UXUSMC9F_*]PVJ@!^4OS-GP?^KJIL8>T@
M;>=10\QFG4T?9%U9S@L0N!DB[TS%ICY=<<S<T]#ITC3&]+XE[D;/7_8'JO#&
MVI\"OEKQV(O.<:RX;_ZE:L[/P4?)-@KQSCW2G7$!22[?%U9 /T'GB_(BGY-H
MF.94>M],IBYJY=.\4*89$#!_B3:\ Z2@4?1W (L<W3N :C7XP'>D/H]79/OZ
M9V&;S+-[^NB.PIMB1FF@%3E^?-GWA6*8I]C37N],K1C_3GO5+?O,)O61M&:-
MT>$=8+TPF@?SX,_ARP1^O2F/0\DV^OR_ZU\@]!$U9A%LGP8?I&,>[?\#JQO4
M][":@(EJO,=9]3L Y[C;?3R"-7=F)Y:\&P+W$JX\#6Z;I+1]*KWYN\SPIOCO
M=3@JK&9A7XQZ,KF2ES'=-5Y0C#I!*F!B1)XH^B])6.<CM  <TO,#Y=?3:@^Z
M]G?XK2JYG9J1$96L<"Y.'XF3$@Q@(#BOB6?&=<((^U/"+R08#_9E7DY@ABOV
MC!((MTW?!(?9=+,:^+I;Q+HUX2?#.X\KF$-AIOR;$>$>_!%,;%K60H.6O -Y
M4F]R8N.8OW;= 1XQQ,9#4TU\K"7>"E^;[544<]>![S'/LA!UCO1#B!9Z@4B0
MC1&0VWSK@!\^M5>V/%FU.97%G\PR6)#5O?^J^@,EN<>OJW)_*Q3'AI]L>*MH
MJ11/FJ-+!:I-OP',_9Q7;CS%@4/K7.HS5D]<?G@@$KC'O. T9RR[, J#NO$-
M.N)-R0F2C$R&ZPZ6LF"$=VF50G1.KQ_4Y4P>Z&DKNOP_N\7]SZ'(VC? H.'&
M?VPD?O .8D*5CPKO]VP)OHGI:KP#7!,Q-WBALR!]03</EH/VA /_-VX]KXEN
MOL)\#JB;/=QE7HS9;"PL7C'R?XYRX5\*?.:=0'6(#.@#B9[(@*,8-2PM2IRE
M4@$M-(2MG<=)-T9+_E@3;)/NXE754F[E7"=4YCG"J 1F4*J<N.RRCCA+[NM$
M_R:D*VKE1LK_R52-"*/RAJ1WS&#KI! XD+5Y2@0_&41S8K=I$_KTY?+Y*&GS
M'8"@^DOIL/)B<]-"D.FC+ZE73IY!M#*/#= DMZ'^QC!3"57^:K:&Z ,,XJ?1
MP7XUJY!:_.@@]L_282[V6RRXAF+6^GAP#JTIO=P/:VMQ''H[N'RUL2HJ#'Z(
M;$0%;)(0HVS-4]Y/?Z]WE+GV=K1M\@L29V#CSXY)%DV62$C/;=A<>XB15;[A
M0WU<@I4,^(%7\$QQX[YG;:CP6#=/7W*;U+W1+GBM@'OETB3[;"5\Y5/93&B,
MV9E7DZF"2MN%2.=Z@:[2&H$_O5UUF9_;QB%EHSB@\.'.U: S_KN$4Q*C;8RH
MO]2T#$=0MP*& ;0X"_7*M*X))]=*F]-._=HOO:E4*4%Y+DI6$H*%'VHL\1\!
M'FKE?O.SI%.\^_P3QX5):*NR6!$9G>5")5_.CS&K'5X3YVSDD-THSU9N=$[S
MYX/]L@S#=53^6)2AN;<T49R:GPO,/[>F1Y^RW2A5N?E>FS;,Q+47U$9R5S[/
M:^YPKQ/ KAG-:Q5 FOK7W@%P%N[CPO;^4/UH6#LWV@VUCYW/O%4+(J.])[U8
M.5*RL+RPU>>?.L8J0#+"=3?2Z[0";,K<S4M#+%\MV9\$GDAF[V%6Z$X*/6#F
M./[2TR=%T_.#N4\;)B%\FPZ"2T*E'OBER[\R+K6Z0NA^W(-5L>R9LC_C'< R
M+ ^3L@*LP$SG_0L^R(8P$E^ZY]'8>=7:7U,5]EP!M1G^5W@P$*'4T#D9]G)2
M90I;S\.U6R-&\Y=X^\G5QFA.';&J?(P6 2264[LQ;[C%IDFE)(.W95'/(WH9
MF8$H29+8_J*7X%;%"X&L>CGV3%J-7OI&P2[&SU:(T/B&/]Y!R!UX8ZA=*Z0_
M0%(/!=E84C0XK7*Z6-AI]'')F9!ZNU5(\M7I+ZT#G@S7C;._"8*Y_S1T:AQV
M2F*?2=W;QEUJ=*X_7X49Y*P0MW@:O4A%OT#-,9KS+94-%6C[.L=@+C8OX Y0
MU2^NV%\4L *3O:)TAUR?1=P!%*O ^D$1CM:U<$R&H\11)KU!H<?0*XM@TJ03
M[M?-3#NP_]S%TK,'W!6E#E7%S<VI+$UACY/5N''?: D:I'0!W%+,F?S%ZYIO
MZV3$^?OB]+D_HPS7;\)C>HT"9A2IM5II5ER]:;5&JD*\7T3[OI+51\UW^RKW
MR1+:,S',5VVU35[BD)HL];OPMB1AXRUUB.H#UJVPAX;$<:(102@+S>"UBZ=!
MV_?RZEYES:O3]CQ:J5]+1U/8LJ^T,90<7=X!N')NY/_E<^]/^K)602MH]]NB
MCY T^0V#Y?SU8YOF%RY[?DR76W< ;%D;\_![3-)&@'O_!M*?NR<0#EN*)D&0
MAZDW0J3-.3WJXT/XN[QFQ9LKS":WF7< .T?@1D=.X1HJI2N0MREZND^TU<',
M8R[+^=-KDW*LEL*>[/5-OJO!DWX/S=2FA^U&YOD$UV++U]__SYL5-!*E?3..
MXKP#]"U,;S?F(I$J;/O; V9/J!GQ6>"O=MK--X#'+K:(A.Z_&!(45]%!K@B"
MK\5^3M.S4<AX<=]EI)@]V9#]/=:7EX-PZT_++O5':!.4+00.01+-H^D=91?3
MWTY*M?")'I/]FHI([3JB4W;%UWJX=5E:0JW^;%1I$8W/-59^Y-%9F]>;(P1;
M.SI=/_VQI, X5_>!N-;/A4:R)-F[+[A6=D7I_:!\(U07F8GR*$&U(>=0AL6$
M[&?^RA:3ARX# ZQ!CD[' JHN?\/_R%VROG<+%K@8/#J]3R)W /@HIC].Z)YW
M/*VA0]T3:JXKN!BF6Z($DV(R5<)U7,+7:#'?FIY_2;+ <L._X/\5,U8W>N9)
ME"40U[P?ZQ)]Q8TD00B;T:/H$60DN6#SQ]XQ.J)(B^Q!AUKEI]\LYWG8MY)]
M=AL"O,R9@[JE'3^TP\?[8_PBD_U\H+HN#$EO\Y-FON&J2#U1IA%)E85I8!35
M-I1VCYC741[C6*MHLSGD0: PHNIR;'8,7>@FS^ V^B2:)V&E^GVS[K3%7CG^
M9* @W"GA7BX0K>U)7'Z6B,_P(U?D$6)QL")M<26FL66-8#GCWD[ \<[2NXUP
MNF3&\ZYY.]M0$^9F-NP&6R,#P;/2?A@:U-:WR,=:A#N.B-M8AM _6K9G;L2+
MVQP3W=1$21:#F9] 59WCB.H;%QWFYJB2DWJ7QR4*"DI[+7/ZRA%M;&\3LP_$
M!YT2KA=[8E0-L[G0Y&[_3)@R[\DCJX<(_<;\1KQIS+7]"VV>%4)M=/35)-XC
M7[918 EH?2V*S+Z)=,TLJ,?0A:A_BX>6*X<M8<QZG8&L*_13SNSEMFTT1CA"
M$_:/'='S;_\5S87_UEW;B+\^7"J(K(/.N[!GBD*W C2]J,R>L<00^UEIEWG%
ML6KBXM3,[X9^U3L=0\'TJ<B[27%&6-I-GK](%:_0D9T'T>="^!UQSI6F[?7\
MQ=MLII?2C='3><O.E W-VHJ47__79G62]#L ^/3182<-U 5>!^O/_52^XOUQ
M4]_4V&PVOQ'R4P%'/CCN>[?<]N,U;J;O4G@\N 'RBI1%)6.43'W%-G_^\9R3
M_R^;>?(__)N8G[C? :+7'LF\,$--=\]=1_0%X8%58LI02IO:3QU%W]"0&_K$
MRNFH\M+%JPX(U ]2[AX;;L3IX/Z$SW<E1*8SL21>@9A:2OCR/E8J"3H99GB&
M#[(#E#04 V@5(<=/IW;B%AAJ"J4DD1"4R 8)[H$9/V(^?K>A!7$'B'5*WCB3
M5#IGG3Z>^$BOLAR;$WS,3O;P#:!Q;.Q$6-OPMP8DX[]WEI;^EW26_EN;W^7O
MC JJ0JO *0>R8#44!TPDB,>"52OAQ9;."/[LX WQ$ :H>C*MAK)2]R+6F2PA
M9B*/RI_P8Z,L10<1*D:O4P]$K0N7(CT0>$>(+O]H*.LIQ\[\-:6>P6*G(ZN@
M,>Y-X2B'NYK1BM!69R1=>M\=8'%)]3XVA-3@?!7PZ2ZO:=;9RS7R)$B0\",6
M3IHJ)4/#QEWV5!:+1)*Q2ZZ("TG9QW823@DE?:P_IH\+ZYMB 0^4Z7"T![\]
MJ']6+)$]K,C-3B#ZCS7=T+_'?O$_O*JQ-R-Z;R$;RL'5PFM$WB5:\*#(#ZE.
M1R+<]!%1_EOXI+^>;&\X)(ZX2H@23Y $*>I9;9R$M9P[1=R\\[X#]/CZ@NX
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M6Z7-]X?-?FO&<1FZCE=TDV&9JT'CKYM3H.C[FO"V9")*12,JA^X B!NRGCM
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M0LN)J%OJ_Z#SS+<71L;)S'HX68;LNNZ^K+V!^9)_&J\QFJNAF/6'E'F+'FY
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MG :?W7R.1C@J=L]<:7]3T('K3,- <7G$O1>OJ[AR/9K<3=9H3DMN)Z7'*E5
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M^@4>UK. #;HP*%SF%_+/<7-0U,^NELY3F;H7P/>A&(3;0;R=C#\CWI]N==X
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M'/K%PQL:2A6ASINK>S?UU<G>ZL^K)8 I-X%N@S.:<"VAKZI[W],3;21J E/
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MD]"!L<\=Z 92UR#$KF.63=[5V=RF_"YWR#0CH1-2/7?!%E CS_Q6?I4I??
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M<UKB9?K/NF9#%#/L!WX"J<<#B 26>QD4>M!U,..^AQFB1+MHB''W<S,&+07
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M!9?3\'2;1"O(C&S7CD$!ORL1+=5@ZE1_4/66TRU.5KVE4Z%V]9;N!X?Y8-)
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MXPN(B'*?DYA![H1Q0N+ =WPM.AOM'F>W)&<K2&7;*95F(F\DK\[HM[]E.R5
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MEGLXI/.YF2@E^RZE:7A)"1/\]2S56*B.;+ V@%:"GZCT7$NO-L<M^2V6=1B
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M6&"?D\ - YAP/X"(^C$DPG$@=BC#B1L[,4Y,C-1^\W.S1.K,-!-@*Y^9\3F
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M#J?%&*4C@$:/4]KU.)-8I2,(]..5CE\=(6:I(<8HWJ_YM9#S_;\XSC]*H[G
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M/@J%%SC2K25:5MBPWSE;VU)I44W<3.D!GAM%KLQX]TQ'0N-*8AQ\1S:8E=!
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M,ZK*"2T\["5Q@D/H) %7]X@$Q@$5,(HP)2((7$RICN4_U\'L;'<C(]@(6=7
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M;E>*'3A]X77/]?1+")).D=SEQ$F40.30 !*!I;L41'X2,NQ28I2[.$"&N9G
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MH-CQ:-\=^W_*^?P_%LN_%K])NEHNI#"D(8:P32J*6!C#(,H8Q H+2$2:P"3
M2!F/ 1&K^@>=/4W-(M2;3",M_*<1%VSE!97 KCOT<PC;;LX]X#;.OKP'9#UV
MY!UP7+ 9/]?RR/OP#@6/M^!=+_0]?&G0XV491AG)8A@KB2$.,PD)2I%&,0H"
M_=<@($[WR)J-3\T '!T6KOX7N/W7QGSA'PP%+\_7YXN6=T-I>](Q35I&:D?
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M(4,TAJ$B4I(P2QBV"J1U]#,UHUI+:@J8'8AZ98J7.7!!M" ;I[&*S#)&LHA
MK!*]JM$(024SE65A0E*"9VNSMQX/V5UO YX:;\L"'I3H*.N!^<&U?6'QB-;
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M,Z:S/8U]QM2E\HDSILY7+KX\_D"+^Z(LBRI*D[6EJYK%*DT%XP0R%&H3HG@
MF4 (*BY#1!), ^E4',JBS^F9DH.KY,^TJ%P@\.'WWSZ"9UE4O^I_^? L^%F
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M[O4)S;X='8^6L;JV/,A1?1<2OHJ:G.MFW!(F'<H>%2SI>KXG.^>&K>2_-MI
MW;[H/S[G"UFR+<U205)!8P:1"CC$219#FH@4<AGH[:X@,N-. >AS'4UMQ=W+
M"4I!+Z /.XNMG6'P@=C AJ$?6.Z4D!U(^.)Q/-?-N.2+'<H>,29V/>]F&,K@
M0_$ZN_G'+$G33* (063L ,Z42>H+4R@Q#A6F F$N;4S OLG)3?:_\O7_R$+_
MFV523@.=]DG<3^>AI^M_WGW[/[=?/U]_^7CYY#S6L"5SIGZXFH7U7_83L-'4
M*%/M6/3MI#KQFW[KZJ^T^*<L+W'^9KCKRJC=PW*>\]=9BH. T4#"D' *,8HX
MS"C1<PLE-.8RXAA1EY7U?%=3FVY[2<%J)VH9XUY]UYMRJ&5X OGB1:[69?:R
MVW+; KG=@NL'R('G< /#O917H)(3_%G_=Y S@6Y\/"W$+1V-NA1W*_QV,;9X
MHV\E'9-W4I;,J&HYA7I_'L4X@RDAL=Z?IREDG"J81BQ1@4K""#.WPCF''4S-
M=M0I356]$-=Z.&^PLS,'ER RL!'8@E&5N:F9=N]6JXW?&C>G]?=6TN9-\R-7
ML#FMW''!FC//]9O&O\B%+.C<'.J)IWR1&Q_>7%JL#]MG$94H(AA#$IG:Q8A2
MF'&&8"Q0EJI8Q0D2#I<++;NU^K+'OVM82UUN$.B!W&[SOPMT.W/@ \-QK$,3
MMT-9MTD=_HR$)2J>;$97;Z.:$$O5WUH4V]=ZQO/X=RDV<WFO/DJ5+Z3X67>G
M\K5)A*O8(E:F7/7CPC LW2W.,948>NUO9ANSS\&)11@B_7](,X$AIBC0/ZD4
MQFG*14A1PMW2I0:3=&H[EZVBAA&Y5A74NH(RY;/6%NS5-1SXYYF5:L9\QV#D
M8!^&931S"L,]='QEH)$&?Y8J#^/5#3XPOJ*S@\DY;GAW:+B/XL.#=_@.118<
MSUB]]#4A0W/O@XA_B"-<KT!/@7#_?0Z'O<+HE5K?PVWPLES7ZF:^7,EORU\7
MS[G)9GVSI[!ET.IN:FJ[P4ID4,IL%O]O^5/%D_/EX:Z1UKVZ M_L+XC:PMIN
M+0= =& [: OF(!LH1[CZT7%9M#\>*Y>]L@?D7 ZO]71ZY:,Q3E_E\[(P=-]5
MQ+WZ<__Q$Y2Q* XC&$I)S'&V=F4YTPZLQ(B&:1IA876<[=3KU,Q/+;3V+]2R
M>"KMO*,?:86UI4_H&\&A_;L:O)W XYR[.<'DR]NRZG-<S\D%AB,OR.GEGG=H
M2H;R.@5^QH,@IEB;&QE$$F(F&"0H)3!22#!)A<"I<BD_?]"ZDUD9K0#]EL>)
MEJ(ZWH@Y ,_.?O2&9.AM22G7U?:^I,>[+*<4]G5;Y:#M<>^CG%+KZ,;)R8=Z
M4BT4=<V!\F"OOA% &=+_FB*8A F#V*2]ZCU"! GC(0X05H*X42Z<Z&1JVX&=
MC-59LB/SPBD4[6;NI=@,/('?P#( ^WX; +Z8&4YU,2Y#0XN21TP-;<_VXN>^
M6XC\)1<;.G?GY3YZ=VH3U_!,-X1THN$^!L8B+G A)D.ON(=P^&?;/JM\7Y;M
MXP;'9-<^J\X;5NWSS_6];O+\/"\CB71^0U??/\V7?S5<T5U8/Y.)C!G'D+,,
M01S0#+*8(>VP(QPEBM"8./')6O8[M5G>$+MX!6)/^K!4@&LU@-)Z@'ROR+^[
MWE"Q&PY+=]X_R$,[] V)@1$9&)F;P9%!3DD<@?)VO<6NUY%ONSA!<7SYQ>WU
MGLFW=<OWS]+DZBP>K_E:FT63W/M9:K=D?^53<890+%.8)"B#F"0$$B(3F$51
MEA"F4$("IZQ<VYZG9KEN=M:IK BPW,H/Z$X!QR1>ZS&P,U:#(#NPN=I9J"NP
M$QOLY;X"E>2#V"QGO'RE"5OW.V[^L"L<1XG%S@WTKEKZ)NGC]E^;?/VZOY^P
M)=;@*&5"8IBE(C-UAPFDVF;!6 D5,A9PG#CE]]EV/#7+54KI;)ZL8;:S3D.
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MA*(HH%8)]QW]3&V9JD0%6UE!)2RHI;6S@UW0MJ] '@$;>&WIB96U#;)$HJ6
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M$8<X"%-(0DPA$R1C"5)93)UJO#KV/S53O6, _K!5X"=MC$%3A_^U-9A_&CU
MK8@C89[K,-D9RP'!']A0#H![G_OF?=#S=X?<J?>Q[X7W@>;$7>]>S;B90LG%
M[(O^UL3M#\DW9D=SKU3.=0^?%OL(N85-LVIH:A:L%!CL) 9;D:_TC%FN]=;/
MLKZ='8KM=LD[@ -;H6[L[ B6K4V/$T MQY.ZG=K&<+$W+7:MCV)(G!3=F@VW
MERY@^3PH>[+?A]\^/<^7KU+6F> )IX@$+(2$QA3B4!%( I3"-$UI'%&B5"B<
M63NMNIZ:C>GT7[;B]R#EM!L+2^=Q$(3'\!EMP!T@9=\=,)]TEG8=CT]/Z03(
M2;I)MQ;<<Q\_UH=AG_(5I_/*Q_RD_VTURP0FF=)&*Y XAIC0 #*,%.0ABU5&
MPDP$5IE0K;U,S3YM!065I%N6BU)6^ZS'\Z"V6Q]O4 T=K>^#DE.^8R<*O;(=
MS[<Z6JYCIV+-3,?NAWNF:,G52LJ:)VOQ^-EX5)]SRO*Y=J-J8[/ZN)%?]%;I
MVU]R_B)_72[6WU>S0"54LH!#Q'@$<48%) FE4&4!%C@,DSA-G)*U>@HR-;.A
MOS+LF)75=PCL]B]C #NPD:E4N ([)4"IQ178Z7%E*".9U'N=7%R!_Y*T /<+
MCQ'O2T'TE;/55XQQL[<N!.LHC^O2]OID='%>;*3X;?/\/'^]7HA?Z6*C*%^7
M\?=/4JYN-H4A*)VQ3)"$";,9BE*(6<1AQA+]1YP2*3(B6&9U*\2IUZD9O4K@
M\J3PJ2DR6,GB13O;EALF-^3;S=]@> YLZVJ100VI*25U(#4P8E^!6O A<'7)
MPAL W[%R\OS@[)BNYXA7>_*>;6,CIO(YZG>8V.?ZLJ_#S;KC[9*2RY7N_=ZD
M-^S7G/WO9HE",5$AAP'1?V#$D#;V*H(RD*%( YYQY$0S=:E 4UL,MC-+_C#G
MT74"29DM G@U@F"^E_[2(T_'P>M[!CK<D+S/H>AVD!I"E^-4JM3<:%N,E(=#
MTG[P#G9JZBC..Q^C]@.O^URU9[ON!ZT/+\]OKAY9'JP>O3@U6ZB]$_"R.F L
MV!>XN *E\/9'J<<X=1^=7@31P+;I!#I#7+=JA:'7@>AQ:Z,=@)Y5I'G@>?ZA
M8:.$)O#R27\>,Q8C',LPADF4FDL37$)J@H5$8)*F-"(L38>(#FX%F)H=T%]/
M.DQ4< >YWVA@'R"G& 4T.HP?!GR+WLCAOUWWDPS[O06G;[COJ!WWC<>W0EP7
MQ=U"?,O7<VF[ZSA\:VJFIA3*?D_Q!H+N#45_[0>V#]\**HQ5.,AST'+F+[G8
MT#EH!\9I-W$:@UY;B3=-C;:/.*U"<Q-QYHD>P?3?Z*ZV\GU9\O+;\D&/^G<]
ML4W-RQG/HE"HA,$H()G>+:0($JYW"Y(D*I%$!4%LE11ET]G4IJL1M^3@-@)?
M@64I<ED K1;ZJBQ3[!#H[4+;(F[N$<.!)_T6OM\J^"IIP;<E>-C!UUK<UQT^
MA_"X1QA'BHI?"J=;.-P2G]8H>%<;XP6_+;4YB'G;OM//;3O<0]U6\=A92*,P
M21"&3)K"\8SHGTBJ((L3FJ( 2\&)BV]VLI>IF=E2MFU(VLT3.XVBG;MU,38#
MF\\C7^JV R%GEZD5 4]^T>D^1G5^6M5\Z^&T/WQI#OK!!=F4L4!D3$ 2<0*Q
MR@)(TTC 2!*$<,98F#E=S3O=S=1F^]G+TKT,P!EH[2S Y8 -O8/J2A4W=3'I
MZKM_T] .C?>D\'>\#-RJZ/ED;X]7>G533\OJIEQ]^R'D4C(>)C!$0D$<D1!2
MC*2I](!DBJ,P2IP2.(]ZF)I1J 2LMK9N!N $>#+$013$D"@3WXX0@9GN'PJ4
MXA0A1+@,W$H4703?6%6'*@!+/H)+$;2SGA>A,K#A;'Y/ URC.:NZ)\-XW/ZH
M-O&L>F_-X?D'^Z1UBO_>K-9E!/G;\EJ(W)A6.C<'!G>+&_J<K^G\]BE?F9([
MGZ3\*O,GMM&FR;PQ(X1@E?(4IF% (8ZC1+M0C$*EI[^,1*(-0F"?ZGF!)%.S
MK%LY@9)U&@FO%"@IKI[KD#U8UA7'@'YZ8TY[7;(7+QDXBXC76,,QL$UJJ&%B
MB'M%RC,Q<+< M2[F!F ]:%H=<*#/6,/BDF@ZTO",E7PZZ# YYJ1Z@+8]3_62
M#D;,7?6 PV$^JX\&W<\T]R=>US_RE>V9YN%;4UM@]M+]N_W)YAL@ND\V^V,P
ML%5O'&+^:43SE!-U6M]>IYAOFAKM%/.T"LU3S#-/]-@[WM G5N3BL2:0J/T8
M*1,BDS2#@@<$8A)P2..00Z1BE?$H4G%@7^+L9!=3FXP[(6MJ$X?MPFD(+;9G
M%P,SM"_X!I-N?] 6'(=-TL4@C;3[L?Z W#8RK>JW[E!.OSG>UJ-5\H,]1?N3
M[IP/-_GZU7#AWRR%G*D@#3/.#=.UX::1HJR?KNT9BP@2$E',K"*";QN>G $S
M!'!&.&"DL^=R. "KW6A= L'0ILI.>R>.AE.J]J)E.&AH-":&4^(WR1=._KYO
M<3GM">CA7#TL5WK__W_RYVKJ18AC$:=0,3W_,,D0S$*20,YEH&C&PRBSGGKG
MNYG:1*S+I=6B7H%*6*"E=9R9+<AVSU,_> T\:_M"U:.T7!L2%U26.]GLR(7E
MVE0[KBO7^K3;]%\5Z]E#L10;OKXO?JLNQ9=>:9A&62JPA*E0$<0,*SWQ*8,1
ME1%*9,QI9A53/M?!U*9\+6,9)*[%[/)I[8!LG^<^X!EXAO= QGIR=ZG?=J2D
MWVT<)^F_[2?WV69'F=9=2FTG=.=S_4[4;VEABM.N'F11GHCN+^5%+ SB1"4P
M3#DS<SJ#3)KLFS1$6$9)%@GN<K)^MJ>I3>XO<@T^+U<K\+RM'N!V2GP>TO;9
M[16HH1?R6D9SZ['"R#,=K#48GLZ1S_<SZGERI[IOSY6[7^C-+[%\DK^MZ;J,
MY'\V Y4O%Q^7IIKU+& QCEFH8,")@!@;JGP58AC&)&8T$H0@JWM(5KU-S3Y4
MPH*=M& K+OBS$MB= +\%:CN;X0W P<\ >F/7AY^A&Q-_Y LM?8W-K-"M]@G:
M!(N7>N;T\N]2;,P-@2_+A:G5(T5IJJ[Y.G_1#LH;,H!8.Q,)IP%4 =&^1$("
MR*(TT*8FD6F 8IIF5D<1_;J?FK'92F^NL^SDKU?<K0:.><!NPV%G?X8#>6"#
M9(/OH-5S^R'G*ZW8K?-QTXU[ 7.4AMROE1X'J[\O"LF7CXO\?\J4YZ>\2IJX
M7NB_+<PU";G@AKL)J91@+"648:+M6YQ@2"3/($$B%J% AHO:^JC5LM.I6;6J
MA"3?"PP6RS5XU8[77AV',T=;Z-MMV5" #FS!FA*#AL@E&>"!T ,@ZG"N.P"R
M(YWT>D#8[0S8$:K64V';ML8[)W;4[N#DV/7=2^L'5.P<ANB>T90BD850I Q!
MC!(%:93%, XE%AH#3KCUV=:9/J9FI=^RXM=4-!=4#MC#V7V@Y0&D@2UO#WPN
MJ!EPA("'B@'[-M^I7L"14N>K!1P_ZGYX]9M\- W^(I>/!7W^GNMFZS!+2B*D
M)S&&,HXSB'G&(0O# %*9DB!@#/$$VYY@G>UE:A.\*:%C\*H=S>YC+"\8#3R_
MW>!Q.L;J5/^"LZSS;8]VH-6I7O-4J_OA"TIV'Q14O%OP^<:P*STL"[-EO%ZO
MBYQMUJ4/^'^[>[?FN'$E7?1]_PK$?NH5(<SA!23!\[ C9-GN\1G;4LCJGMC1
M#Q6XVIQ5*FJ156YK?OT&2-:]B@6@0(K[/+1;MD@@\P.12 "97Y8Z0U@Y$4I'
MU>CW3PLU ]5^<9;C."41$5 &-( H1C$D/$T@)TBF. Q#(?ELJ3<TAN=17L2R
M,B4;X8;>T;4UNQT*9E\_3*&4. D#Y9KE^H] #1,-PP2RD) X#>*01V+VTE2<
M^;8DU7*J@W4HXH!W>(T^-X"*[\5"7R(!2N;F"6V>QX^D5+*4,LBC4$VS/.20
MJ$471C%**$)QQA'IQN_#@D][]-8"#C]V0NU WW+4#$^'1Q^'H:^_._@W:H!.
M#["KB$Z*VU<%K'7Q7,7>&[8^"]M?+]3XM>Z] 7ET#NVW=7\$R)J@ZU[JTY.*
M,.7MB"14EC:#>88RB&0F( YR =,\3!F3G"&17$MYO-_EU#9%:X+><D,J-1<;
M D-]3<0ZP:]G0C[ WLR8^D5T8$-YENWXJ0/S[A*87MB-3^,S()_Q08=OSF!\
M&@ 3SN(S;]J?O7PI%L7SZKE+"),"<\[5KBHE1+GKL0P@D5$$LR *(R0"S%*C
M\C-'+4_-G'3"F9^J[.-T^23%6?N!IWXGET=.F;/:7G%8LM_>: <D)]78/10Y
M_8#;LO^?HOC^8RGX[4\UL;^+KRO=YKUL&9#N5\MZ21;:$;FE=;L0,4'S%$L!
MLZ3)!HXHQ)E,82J)$$1-46Y7WMU6@*G-X?=B43X7"_U9VBWZULB;N0!#XCFP
M55B+#CK902M\P];;B ]VY+\![XOY2C_]UUH5CY$WKBAZ<ANLNQ_5B7 %Y]"E
M<&['S=0]5-IM7[X^J(]N>;O@>JOUHD^7OXKEC,0Q8IG@4""1JKU-P&%.@PSR
M-%)FC8F,"ZO(PK[.IF;"UK(VB3EB+>@-6 C+?4POPF;FRQ=N YNJM9@WH!&T
M0>[#%KFO/<A9VR(32#S9G=ZN1K4Q)DH?VA.C=ZZ-4S[-7;K#;UZ?"9:5"$4A
MUX2:><XA8CR#)$$YS%F HC1,>)H8E5'V)]+4[-!%GMY6FYNK@YN=Q]#P2'O4
MD1G8TED/RD@1T=="ZSU*VEF@-XJ<OA; \]'45[=L3PEW^S>I^(=?%7NH"F9<
MYFK_K:F9PP^_1,6*6H!&.G-6N ,L^FW6=3 ,;'L:P8 A#E;$<*=5=B*&.VAJ
M-&*XTRKL$L.=><*17IW4/V9A%I-8H!AF(<+*AY$!S!$-(&6"(R11P');4G#5
MK,T7-PX/N XE5GO.@NGS!5T:P)(+7&-EYBO8ZC_PC+OKT]6>X'M'.5^<WKK)
M<6F\=Y0X8N[>_9UC!2-=;5JODY7XH9;*XJ=H\RTURX#:M]S+)_)K%C(6I#0.
M899&"")*(TC3*(*:S PG(8^1#&WBS$PZM5H.1X@B:^NVLUVA0=%(;5GLR 3P
M),Y#@7 ,TTBACD2$84X2!@D+,QYRAE(SMJK! !_!_Q@5<#-KZ1O&@:UIB^">
MO*#+<O]-B_R/YJ1(GV\KN3T6I+) R5=]*I,NQRU790'"4?4JFW<=TD$?Q4\]
M?Q]%5T2@^.]FAW3+6+42O*M"5,]"DF$A$@(Q$<K;XIIXEY  ,II+EF9ASM)H
MMA#?B?)2G@R30LVZ-II#>3N'C@08;CZIB?+WCX+] *05=UWLRB9[T1#[?GOD
M&\IQS%$G,#B46)_=M'A^& Q/BV10_[B.E OJ 5^[7% [I'I300V;&B\3U$ZW
MO410RU==,T@Z/I1[J7<!'^?EW[7E57U?$Q,R&UM"'AV3I^OD-9(.<N]N HFW
M..2>KD:.+KZL]'',L,$[;E_V>R&+A>#OQ$+]L-27:=V/]W1>?&\-.*<RB.,T
M@E+' R/U(\2,(!B%<2123,)4Y/89-08]V\R+\=)EWFW29![>W=OMCDS03E',
MTY C&&9"H8T85QM1?9,8YF%$1*JVI[%M_LL@6(^0W++@@\%L9K4] S>P\>ZD
M!9V,3;C"S>9O6Y']F7 +?#Q9<I,>1S7H%A <VG6;5QVOR9Z>OW]9O!3OBYIM
M;[9M;LQ.-3"UPZOVZNBI>-;6XLO7AT] BSLOZY4I96L_7H:W:M="-<H%VVF4
M/).V&D'B?@%WLM5Q[^+Z%#NZENM]V.%(Z1MI;M[U';MR>)Y?WJ_T[?JO69QE
M)$-9!I,DTJY#GD',<P2S.(R)0)FF331F%#O3R=3F?B,;X$HX79W3XBSC'(@&
MAT$>H!EZ&Z<D!/>RK>9[ UJ0M)B]A\_F(%F<\'@ :Z0C'3?0[$YQ+J#1>VQS
M[MWQSFDN2+]W,'/I69>2==O:R7^62U%_6<V7Q<N\$-4L9#3E,B,0$:Q,7RXD
M)"*.(4:")&% :!!2\[IU9_N9FO7KBG;7[1?[4PO;L-6WA8F?-W+;U&T[#[*!
M:?0#W<#6<;?4^0UHY 1?/&-E4^C."V9C5;MSP\ZR]MU%1/H+X)U_?<0J>!=U
MV"^%=_EQ9P+_2N?OOA?M_S\M]O-Z/Q>$%O-B^3H+0Y332)/Y(\V<0PB#. Z0
M C@)DT2D.>%&U&?6/4_-JM[O9_S78-Y):LR=:@^^V7G4() .;&W7,H/?UE+_
M Q2+0R8 L!'=*_&_'5K^B@ 8]CMV00 [.$X4![!LP'^8W*-@<U+7A2S:R@3;
MLN0?E<*W]W>?/I;5?U;%4O#R[X5R0 5;5<W,W80?T8 &)"<49E0D$&&*E*^H
M_M"DVUAME ,BI46HQ3A23S1*X_:Y7&D&Y&JCH.! ?WHZ;&.E'% M""A'B"[S
M\&&8V> )C//;1;3]UNKZCZ8PU@TXU!=L%6Z_ JTRD&4%&J6AUKI)\=[H/7Y4
MG+\Q&B&>SH.PDXG$\P>\30R?QUZ=4]%EL=2BS"**$>)JT1$D%Q#E*8,4AP*R
M(!>2LQRG2603VKUMVLJ%'B& 6T_JN9++.J=\#16/:9*),(1YS .U&4D$I#*.
MH$Q")B0-69!851UTA&JD,H-7014CG".U0X-9*"5$'&%(4(@A$C*C)),!Y9%=
MHHX;6..DZUP-%PIHHCXNKN%2[A]/0DA30B!A<9(F(4]9FJS=OT'@VO?2I@Z7
MF5/D]L4,[,!HW0]"\"= U'D,E3]"AW7#8],W'"AT@JSA\(EKJE&J-5G4#Z3@
MFFHDEHD46*T,::QW<V&*(<99"*,4B8A)*1-F1>9RW,74%HPF+/-%R=8XUNT^
M2E]^.AQ.'8)I? IU!43#'S=I/!KI@!;/,T/+>>6]EI#<Z^ -ZD:>4O!TL<B3
M3[I-;]6"_KB5N?A9<,'?O?Y1"_YI\;%8D 73Y% ME8 N.)4PQI1#&$ >9IJ-
M/\>01B&!G%&>1C2EB<QL7&GSKJ?H:NNT92#GY=_@I5, T%<@U\(#LI'>SD18
M#(B9Z1@&YA'\B,;H/NR ^YN67%G??X"-\.#V,LS6]L8>,4]VR*+C4>V3/2"'
M=LNAA6MXMC^W9^8UJXJ&$>5SL1"?EN)9;7)YQ&E 8IC$FE]3!@SF@@N8ASFC
ME*5I( -[DNVS_4W-D5F30G=4T#LB@[^TT*"1VK**]B7,S>R41R0'-D[7@NC(
MJWT1&J^DVN=[>P-&[8NJGZ;3OOR:(UG+^?*'VP#?G;+:B*I]442@2!#3!VLY
MQ ''4(H\$AGB>9QG-C;'KONIF:"M] VMHT.95,=A,#-#PX$[L%7:K8YZ!.QP
M@>?7X>:+ML:N\W$);IR .:+"<6O%)=1=!T1]+"LI] 7-F63?618S%'!"82(T
M94X>AY &(H=!G- (B4S]WCSZTZC+J=FQ1FA]'M1*#7XK%FT0:/T/FW!O([3[
M3=<P& YLKEKX-@+KB^W3Z?W>P;2)I/<-ZEAQ]5>#:QEC;X-3?\2]44LCQM_;
M:+8?C6_UIILC^BB61.<S?B"53H^NN\HE(HQ()%()0ZDK2:DM+Z1I+" A*(T9
M1AEEV,;A/-W-U SR[4[XD\[S9(4EO_H9-,W\QNLQ&MC@K@4$:PD]EH<Q \&3
MLW>FDU&=NGY%#YVW"T\[.&DG\IC+!>\^V#1A*.9Y#B-,<XB"#,,<*5=-YCP/
M<R[C)#3:;U[L:6H60$MF0Z[4BZ*!S^4+FX%G_AF2 B7J91-@"9J%;^4+O)%<
MJO,@>O*A3/#H=9UZ&QC/8S+18\]1,GK!.7?Q3H<BWCY4Q4_E&*C&64/KTWVN
M81*G.,L%3")],H<2"?- 4,B%4)M9(1"31FSGAOU-S5YVF65-M":XO0$OK=3@
M92VV=6)>+]H&%M4OAB.<N"GX[M;P=0*#C<0NYM4 1^M$1U]XCIOP>!Y7KSF/
M)N 8Y#[V-C-V#J2)3B=R(8U>N[;"SX?GEWGY*L0W4?TLF#A=S>)VWHR=^NE>
MJCUS^7U1_+?@#PT+UEU9+^N=PC\<IX03K&PX3R BRI!CS%(8\UC&(@@"$3D6
M_O$LZ=2L_\72,QV5(V^O$];G%OHXJ<U!<JT/Y/L+,-N@3V)<ASY4O79(1ZHN
M-- (>"\ZY%O.-ZI%-!#<YTL4#=6A R4;_Z^G\FNY>!#E5U'J[C\N[&G9^AJ9
MFEG?R0=L8^OAPX=[\%7]MPL^^%B6RT6YM&%KZX6RWPA[17%@(VH)X!!$;B9(
MN9&Y];8\'J&;B8)[I&Y&+UQ'[/8HGDFASV=O5\L?9:6-T:-X45_5#V6YVN5Q
M%I)<)%'*889R#%$<29CGE,"(1SEA><0#;E2>VZ'OJ=F9AKNKE&LFI&JM 2 ;
M%=0_KG4 Q,)E=!D9DRORP? >VJW;ITG;" ^VTH.M^%;>N0O4;E1TGB%_&X:Z
M*Z%W9JZS ,^4T,ZDR3?AN;/0]1S]G4T3CG'F6WZBVP5O.OU1SM7[M2Z+O'R=
M848#)@(",WT3AU(908S47Y,@C[.0899FS"9;YE*'5LO#"#DR3[J/71JG3?ES
MV\+"%Z$VV__[!'!@>__Y +4/_:C9QY,;0N$KH/Q2=^-&E!LJ?Q12;OJ>FT&Y
M_4F*N3Y[^5A6VI*]%W2Y)<90-JM::C.F-\9J)UW4LXQ$64BB$(99@G4$9@*Q
MC *8!5*$A,N0QU9%"VT%F)K!V4@(6-F3/.X'?#.3,R2D@\<,T.4>9]!&%RC+
M"FIMFC/##O*[/LBM[9,K;I[LE77WH]HO5W .[9ES._:'< ]"5+]7Y>JE<0J:
MT\#6=#XN%[?/2]-CN O-3&V#K,4%C;R@=89V)%9[AN6J6EAMU4R0O'P*YQ'$
M@4V0!_RL3MT,D7$Z=[O4]F@G;X9*[IZ]F;[BJQR6LD>B^+ZX6U656+#7#[_4
MKFWQ73R2I;AK?JJ/:PM)M:N* I+ +*811%F60)*D":0TBM1WEL3"B6#2BW!&
M4VI\'LE.$\ Z58#H= $5T133[5\L4_+\C*:9=S7>X$RKEM0-6 _=6E'P5)%%
M/6_O)7XGQ:(C7QJRZM056 ]6E\I%IC>N7'4%C)=K6UW3N&.8S^F;WFT(PKO7
M[2-=A$)3L.<C*:H_R7PE;NMZ]=QD:]>/1?W/CY40:T(P+?<L24@HLS2%,0J4
MI<<X@(3&#(I4TB"(,AX%5KDM@TL\-;=4RPBE$A(4G92-P;<,YAE\G,W6@$F-
MWM"W0#O!/7LWT3OJ:IJ<DT% 6F>U<"BM0:,VV-'[!FC-@59]0[X''ON^"?O0
MG['&R5<(T.#RCAL*-!;\1R%!HW7LMEZM,[(>1+66HV"S/(M1RC'3"9-"E^4(
M(=;TP31 +(AE+$EBE!;0V\O4UH7WQ7RE4R<7'7WI3E4C<D#8N<O6N5E$ZNW&
ML :__?'M_;8!PX3X_D'!#-,XPQ*&4<H@DFJ+C;$,U!\I5</$:4RD'>?NU<,R
M+OWNSH! 0+6L#>> ?Z1E$@2A5!]]C#%7+E8>PCR**<SC,)"YE!D)B<-FVAWN
M\3?'HV-NYNY<_<4.[*)L4HN5@*T?HC:P6D9_GD0O!)Y6_]-]C+IB]ZIYN,KV
M/^Q8$6:OSLQC\?W'\E[^4>OU6"QG.(X2QA,*&<TH1%PMCCG&^BXR2+#,>(C#
MU&:%[.UM:BOE0;$J4&EQ82GA2L>Y:8DM3\WZL38S#=X0'-A$'!2ATGN/#KT_
MZF97XI,YV @47S5%>OL:MR2(B=I'%3V,7G)TLTWR ;Z6BY_*D12\V0#4S6W#
M[N_U3>37<OF_Q7*;+="$8=RWVX-9P+*8<ZS\=!&G$$5Q!HFN9T$12P,<81X1
M8N6VCR'UU(S;'XMJ(V=3/VISS"#:W*$;4+:26[H]HWP"AF[4U 9VQ).CDVEA
M&UW7!T6M#C=-7(?Z[1*\*H=XJ^?%#$![MV[,(?'E)HXB\[ANYYC#<.3&CMJY
M8Y@>8_K#5\OD0SDO-/WB+:V7%6&F?MKY!B9D,+9"@K64X*^UG!XS0B^#X2ND
MZWQ'XP9O753X*$SK\AL.:4]-^;:'2NB:)G=J5NC2QXOOMPM^RW\6=5F]?A2B
M;N\-E[.<A6F<\DCM[K"$" L.J50[OBR,& NI\JN8.4N*3<]3\XWNNZ*::ZF;
MX&S2R0WJUFS9$%!9#4._?1D4W*'WA VNG=Q@*SA0DH.UZ$#+?M/%/-AD-UF!
M;)';-!38(V4V^03=+J_)!;C>K":K!L?+:7+1<R^CR:D!^_#<-G]!W[:UMW.;
M&[?WA91"AXX(AZ1YNU:G9NI;Z<%&_)W[<K!5X,8AC=X2[7ZK/RS00]\66&(\
M0*:]&W9.(<"678T6$>P&P6Z L&,+CA%FVRS/K^K;NI=-[*.NMJ7Z*W7:YRS3
M90B%P#!CH8"(X>:2&,$TI5Q@)!CC1MSTYEU.S7JM<_-;'O"_6B$MJ_H8 &VV
MX_4+W]!'97;(V0="&8/A*Y+I<H?CAB(9 W 42V3^IL..^*$JE<W@M2Y1?JYR
M0( E1S%1-D6&&40Q36#>%#ZE-,<T(B**S8M>&'0X-;.R%AGH807O5G6Q$'6M
M@Q%IL; MUF "N,&6US., YN7#8):7!\E+TQ0M-C3>D9SI*WLE:C:[5XM(.K=
MM)JT,]Y>U4*KO2VJS7L..].JTF?[MPLR?ZV+VGX/>N;]J1E6)6>Y$.6J/@CL
M[N2VV%R> \Q@&^D!JZ$WC/TP#;$_O "*VT[P7*/C[?DNJ+6WN[OTK+>\SW7(
M][W4?VWB3G101YRE88AA&*8<HC3*(!6YVMM%5.) (!Z0;/;2D$9^6Y)J:;:E
M,^S=YML_E&&X:?!.?"\6#0F5U/D</YM\#K5G>5%/.<6?F8X%"B,2YX+"&(<$
MH@1A-19I!B6.99B2)$DYZ<;BPX*_\4BL)1C0'"WX&PR"V:9[ %@'-NZGTU_U
MGVU48.T_Z,02I.'R5D_V^M:9J7U0&.2>]K[NI>31MMWN'^L'4O"O8GDOMQRN
M]2Q!J0P9(E!F(8,HHS', QY SHC(J @9IN:[=E<IIN9QKF4%^F[IJNH_AJ-@
ML)4? ]NW-V(;Y+4J-T!GFMQ+L*/.&*-Q59TF_Z/RIC6</(W.M=6>[%"UK 1E
MV/A;5HFRT_]"!2G+QGQM87:25?_0<8MDSG1!2N4E'A$MZ*K-VIMI20VB,&%8
M;7*0E"%$NIH)"0/E8J>"BBP.PB3(;6ZLO$DVM65K+9L#98&_T7+UP$<8@S=9
MWG;T G\T[ 1;S3:/[O+7;$;1+\F =\0'<_A=Y7KC+<&5<%[>-%S;@?T)\U/%
M;ZOJ_:IJ/2'#<^7]MZ9F)'?Y0-8RFA\A'R!R^>#8'8R!K=5319H#&BL\K(Z'
M3ZON="A\T-1H1\&G5=@] #[SA-U<XZ*8?5@LB^7K+>=JD.L[]>-]]53^O9CE
M.4J3-**04,TWD+(0YI3J6F[*)8HC2M(D,9F9/7U,;8JV8H).SAN@)54X BVK
MV53M [1_SGJ":>B['A>$C">O 08]LUB]W<YB]<-V%O>U.<IT-E!J/:]-'G4H
MMJ53LIZ>OW]9O!1WBYI7_..<?#>NLG7R[:G-W$9*\%0\ZY7ER]>'3TWH?*$
M$H;G:#U(75YLKP=IX'G;AP_X2POKJTA6+Q)NU;%.-SE>6:Q>E?;J8?4_Z>L\
M8WN,<J<IGS0'E/;-W[TVOR35LF#%"UDL9Y&(4ZS6<(AID.L4,01)P!B,I!!A
MGA&*R)4'&*:B3,U>[$FKZ?F:"\*7K<!77Q,:#Y+KN<40T+_].?S1P#2_W5%G
MR(,)6T@'.XDP%N2-CQYL ;M\UF#=HIM1W:FL?;>NWY[DN: \UUFTREC&,H98
M!@+RG"0<"\QB:<53<MS%](S@3D7W.SN#=P) ,T-V'2P#&ZA]1,!?K8 >$PW.
M:^_)EISH8%0;<5[!P[G?\Z071TDH_[9L[,E.C:BO2HLNISC5\5&<)A#'*8*(
MA#DD(DE@3D,D*<K37%A15MMU/S5;T,F[*0UG60W.$GLGG\<CH@.;D;5\KS?@
MR.7I<&Y=GZWT@[DUAJ@-X\I<ZOPMW1=#8"ZX+*:M7%W/<F?VR# 6628RR%.6
MJ&T=CR$)4:2V=53M]BB2)!:.12P=#=1HE2L7Y0)V NY6L70N76EMD_YO,3U-
M=;@AS,L85F0"QL+*)OB<^OH,^'T7>-6D4A9Z _0H7LIJ.0M(3$,N)0QD%$(4
MQ@ABS@5D,>)9G@8H2HR")OLZF9IGLI83; 4%K:3F5S)G ;U\)^,#IJ&/5>P1
MLKJ2N02!TYW,V49'NY2YI-;NK<S%9]VO91XJP9?5\\+I5F;OY:G-W+U+!RVI
M4+T^:^_)_DIF'R7S&QEG@,:\D-G#9I#KF),P7'4;L]_BZ)<Q)Q4Z=1=S^D&'
M3(>&XN!.\UQ62UVX_G16-TEY(K&,(8HX4[XY"R!5_CB,0P5BD" 46*0U&'4Y
MM5G_J:Y71(VC3KOZ=S$O?FV.TQ34Q8)H3C[-(5KKFB5?/K>7+NIOOY4-]=GR
M!UFH/P1X]^?'O>HE_VAJ/+2O&A9WL!@WG-.0R83#.,\(1"+5YT(B@"3(41RP
M$ =):%;'9)B1&Z>H2<NOPM9R#XIXOPT?!L6!C7H+WT;@&Q]4$F9@6F2.> =U
MI#21Z\&URP6QPJDW\<.LI?&R/*PTVTOIL'O3->[WJ?&$VGAB'=EO%?Y[\/+4
M5L<=\<![XVR)\]A<]H2OAF5@HWDJ'M@8)8>XX#-(7!$>?-CBR%'"9Q0Z#A8^
M]Z#;V?2G!:MT39+WHOW_IT5'BET_D%==DVZ6(19E 8T@2W/E4P4)T3=L,4Q9
M$NC;=!;F5C?J%WN<W&17G[9HZ*A;W_:E%=/RN/HRT&9'UU[A&]@HK&4%OZVE
M_0=0ONA:8-!)[.]8VQ@<3T?<E_L;];C;6/W#HV_S%Z\)U&G\CJ;R1'V[6OXH
M*UT_8A;&-"4\#B$A-(-(I@Q2INQ+QI,L9#P(LM@JO+&GKZE9EBY0I=V;W:PW
MU&0CK_W.S03P6"9$R"R"&/%$;9)C#"DG$O(LQHD:"Q%'V)[UQQ/LXS'];.6[
M 73#^D/)O#GV& 1Y&@0",Y;#A.$8(I0IY)G$4(H\C3E.%?C8EN/'*^[#\_KL
MHBY:CI]!(3=;5#V!./!RVIF+1LR;M@1H#;:2^HYOZX7#:Z#;Z9[>(.*M5^73
MH6_]KUQ5"&F]^#:E"M9%-#*JW'")D++920Y1PM1RF689S"+!XD1F*"56!-P]
M?4UMN;R_POWN@]3,1G@":N@;J0/?^@8T@GHL,V*!A]\"4R=[>HL*4WTJGRDQ
MU?N*HY'X28JY;O-C66GZ[F^"K:HF>N6]H,OMWV9!CI,LRS.8Q$1Y'5Q3]B>(
MP#!"!"O_@W)N6=S=M.OI78UH^4"]$? &D+4J4)85K$G/;O2Z49") CH+,TCS
M3-\KX@3JW&L8Q4+9\"0B)+8*5!YB#,8PXA\WC(X# 6UHS0> ;V#3WGR[WW:^
MW=N];_=;W[=K;]TM\?%EZDV['=?N6X)QM C8ON\>;/AIH;Z%Y^9T^*DY58R2
M7!GY%,. <^4O(A3"7.WR88BR  >2)<*< .)<)U.S,9M0NAU!P5^-J(:%6GHA
M[;<POH :VIJX8.04<'@.A*L"#H\:'3W@\)Q:IP(.SS[K2O3RL*+S@GV<EV0Y
MPU&*0LI"F$0Z/URY>Q!G,8))*#*"1"1BLV"EDZU/;6IWU"6MA* 1T9;391>[
MRU/Y*D0&GL,V8#C0MYQ0^@KBEMW61J9L.:'(,5G+J8?\[,SV%WFU(UP]:^8U
MP7^ORKK^8U$)'76A_DJ*Q3NA+(5X(K]FF:0)Y93 I(EERZ2$),"Y6KT%3T@H
MLS"TNG?U(M74S$$C*UAMA 7?E;2V1T->ALMMVS'X(+S]GN0&[*@%V@';*@:T
M9OH"1NL&E'+#;6&NPGJ@_8V;3&^Z^;D*QDL[H^L:OY8V3Y_45:\SE.0RC[4;
M%8@4(AX+B#G)]$^YX"*2@D9NG'EM!U,SHD=T<*V8KEQY'8JFKI4[-N-X5\:P
M7$&0MZ^[!W:\KL$WHL;;5^<\+][!<YX+5QP&M2@3\RB6JVIQ2\N?XL.O%\&:
M\%?]3_4,R4PP'#,8XUQ->AD0F),X@1$E&69<A(2E7BI96(DU-5/1B@7*Q6XM
M'D"TY$!THH.J><A3J06[4>PW.F\W-H.[81<IN4[%XJGU$W0CVB@(UAIV_^JK
M7(;=&'JJGS'86$ZGH(;?,?579,,)>N>J&W:]3:,,AQ-"QG4YW%IW2'Z>S[NX
M_YVP_[HC$C/-@>YI8VJKGY(5G$ATL*@AVHM8_^+E$ZR!EZ-S.'FD8C-%PRT[
MNJ_A\9*D#=3;RY4V>=YIDM_R_WHJ=:%2ZZE]\.84)_1.S2*=R[Q;_=9J7A^"
M9#2;K\!GA#G< XW_J7P&"M<)?-C<F-/VC"H'D_7<4^XD)+INRV?E%7Q:BN=+
M>Z&S[TWI&]REU]!"SLMZI8.>_]+2@D9<SQ0;)Z&XBF)CO\71*39.*G2*8N/T
M@_8?X_UJ62])$]K_*)CR-ZO7IL;U\])TW3C?PM36C_U2Z?T5=&V NCQU_6 T
M\/S=$1*LI00VF%E-X<N0.,WCGF9'F\R75=N=T09/.Z?QO53BAV;+_"G4)K-\
M%DW9QR?RZW;9TGSKNYRG4O/G:>+O<JY:^_YIH>:BJ)>S* G3)(\8S&@F=3U&
M!G&2IS"729X(1E*9AI:I?M?(,T5KLE$'S/5%*=E10[M@BSU%0-%I8GGC?>TX
M]ING-QB=@>W8_L"TJH#?/JL!^D=;QK:4^NKZ!MP>#->^9F"MFM=,+1\8^\OF
MNDJ:L3.^?$!W(BO,2[-N%GI3&?Z+(-I5YO>+1WV=7NDRCZ0N:GUQKC]<)=E\
MQ07_M/A *IWY6K>QK3+D7,H@@@'+E8D640!I&@N89&DD,4$!"0,;$WVM0%.S
MT4WZ0J/0#5BK!!JFSDXIT&AUT\2U=#8"K'73Y =K[>SBD;V-KYGI'G/4!K;=
MXPV8M?'VA;(GZWVU.*.:;U_@'=IO;^TZQHYRWA#3DKDNJOYI<=>2<LT:7FB*
M$\@E9A E:0JQ) A&"8I"%F8QY7;1H*?[F9JYW8H)7I2<4,W'CJ;,,L;S#*QF
MYM #6$.?E&UQTB)JNW5W 2?[>,I^%'Q%2)[I9=R8QWY5CZ(8+SSNM63@LUCP
MYDA^1BF*<Y%2&"9A E$D(H@%%U!$ZGN)4<Y%;N6K7>IP:L:AB84@:_&\E/K;
M@FMF&7Q"-K").!U/LO[;MOC[^;"2-O;D(MZ^2O@=@3ALH;YM=U,HQW>DO&'1
MO>/WO.22;F^54AJ2)-!$ D)S&,F80HH0A1S17'DH(HY1?$4^J=,UU-OEE)K<
M0]GAVV]W?*(VM+UQ!NS:+-,C-'QEFGX>]QK/5+T+&:?'S[OY(]]6M!;_6JG&
M/_S41314*[>_BGJ6YQG'899#$7-E$=(X@)BI/^(8<V43,J%<%!LWY$P_4S,(
M6S%!(R?0@H*_M*B6ASKG@#5S03S -; E<$+*VHNX@(,GY^%<+Z/Z#!=4/705
M+CWN9@X>JI()P>N/2KR]*K_Z'QY(PZP5AED0APC#A".U0XF#2#D+,H.(92P3
M5)"86)U:&/0Y-3.Q%AGH801LKS!V\T\OI)>7RQE[,^OA&=&!+<D^F'?'8#[T
M@VEM5"S@\61@3'H<U=A80'!H>&Q>=4C^NF6L6NDX]EJH%W_<+OA[\5/,RQ?M
M 'T3U<^"B5K]ZV?U_T4M/@I1KRG_XC2A(DUS*,,40Q2&FGXXUG]5_DN<<AX'
MF7&VE[L<4S-6:Q4:MG.^50+4G1;-+^:M'D *4Q;&:X>KWY:-. A#'^.V2H#-
M."B!P8X>X-ON.'2J *W+98)'KP-BD:,USL",E)0UY #9Y5]=#VMOPM45S8^7
M874]!GLI51Z:<UC%OI1JBT[^*6Y_[Q('4L%IIAGPTUR?L*6AA"3,*51[:I%P
MFG"<&$7)G6Q]:BO.6CYP^[N%Y3K"S&"!N :)@<W^#@B7\RH,T+"PSM>@,I+-
M-?E$[&SG.:5[+>+12^/9N7/R[EFOLP_Y*@S4<!<_"B:*GPT!]TR@2.1!FND2
MU@*B).(PES)6?Q L.&>!9-%L(;YK_I:G:PH$'?9L])'F[4=ZU/]P'VK+3UYM
MY;RV0M 1XF9[>D\ OFF-H!;+1P,L/10).@?/8%6"CCI\XS)!YP"X7"?H[)N.
M=PRZD,([U3+?31-I4Y0JLF _Q),:%-&M<R).E/D)U0:>I#J?0 = R!3!/"(,
M<1SG)+;*)[#J?6J>5",\;*37Y/_-;F0G$?@&="J 1@?+&PJK83&\MQ@*[*%O
M,ZQP]I@G>Q5POJX_K/H>]U+$!9:CJQ*G1IP]K/)9\]<]E/."O3Z)7\MW2J%_
MSK(L2$B.0D@TC2_*:0HQH@@& J6<\E#&TJI4P+F.IF;!NL0:):B#ZW0:2F.'
MZ6J AG>3.FQN0"LE^*O[OQ87-/)Z-#*7(/'G&IWN9FR'J%?9$VY0__/N,5<?
MB\6WY?/R0U65U5U9J<V$-D ?Y^3[C 8DS#%I0JW4G@NE E(613#F:9;1)(H#
M9E1EV:R[J1F'33B1$ED9XH+,P;>EVMDU_];(#[8*@+^T"@XA63WP]YL2_Z .
M;%"\XND4L749IJOBMGJ:'SUZZ[*JIV*X#-YR.&^^?Q&5\FH6WS_K'=RMVL?=
MR^9'_DU_*C.9)GE"$(8YSKC:5)$(4IEF, H#'*8LQDEN9&9,.IN:D?GVKY7R
M_X LRR:G=]Y("IJG+<YC+R%L<%CM$;>![<A&4M#(=P.TL!J\5ESPS3-X%F?;
M'D$<Z:C[.C#M#L$-T>D]$[_4QGA'Y(;:[)V8F[[C8&2_K5Y>YJ^W"_Z%+%:2
ML.5*YP_J&\.N$.#Z(EV@) F32)]>A3%$-$0P9P1#AJ0D6!=\X$;5KZUZG9S9
M;>1NKLR?=R5O(DS6!3\M;(@Q^@:6> A,ASZA:N'4H0E[0C=Q"-O"H/8!(\:X
M6ACI(? =R5I[PMG.;-OBU6N_C1L;SY#;ZK=GT:U?MJ<W^[2H"_7DEFGSLP7A
MWOF7)V0^.B'/,+A^]LV\=QD3)]JNGF9'H^VZK-HN;9?!TU>2PK3LT">(#=2,
M^5HNJCV>@X;-8'N2&H<I3@*>P22(F":&(1!3BF F\SP.4!SEN54HOP^A)N?'
ML!^"K^9">^Q\O](PH*]J._E3C<[?Q?)'L0#+'VJ?N:F%"WX4RA>MV _#JBM>
MA];LD'SL 1O8RNWRPK0:G:&'T5[IKEHM7TS'!C/,X;M/J'V3PUPCTML0Q'@
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M1-0NB40)3A%B)+3?()WL:FJFO75JJZVH#CN8TYA:["ZN1FH4SW]'2AU*LAR
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MH^0>8;)C5Z;D -^0VUV,I(B:<>F!(CA2B^6!9A0U&"\*E\'%PE7KF/9Z]'Y
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M1C3-##  -+V?SV@ZRQ_O)Z&V'LPUX_Q6%QW%:2-AG?""ME?N37T'2=[4N\2
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MR:52X"57O4EC(%^;4J6>U+[R$&>;6]^Z/RY5ORE10QPU-L  (+4Q@]652^W
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M[@0PJRE[#!9%\XK6YW/C<)!Y'[]Q.$370T#+_</PDI0/C%D0KG(*%X[D?%,
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M83V/K5NRWQ.BWPN);O!SFJ9/1DRSUQ#7\[AYUSA26F".VH)UG+"OG07/ RV
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MOV(DQ5P?C>)TL4X,C6$^.2.AF$"*-<F#JXTJ8PZ4((JDI&K=).((,7ONLS,
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MD49.XW6!3F%..N<#4(IN0<F@P1FDV+9DQY+*1H76+38VQ^_7IPX+&;-&9AH
MQ'94+894*$.OF5/-RU7!2)E9K.__L_?,%Q>Q^9G?\=6EG;F]0<.N@>D& ,#W
MM=)G-GWU1YT!KM_(ALEYN?S&I=II5DP[4@JH%.O)9&:DJ*S L!"UC%(*V[S(
M;R_)^F5N&#1 .S#M  "[JE*[4O9*LY?S&7&&3AB7 -6ZATL!GUTFU\^"5;8^
MA6U]?[=3F'[I'@8-RS8&',Y+_/NGKM>:N[PUOU:;EHHA)H1B% 7GEC/:&S"
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MS5G'$'YR"P_1VY(6*')9_G@_"=,ES;B^U?BVXMFS 7,(%+.$PFF/DM% 9,F
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MP.LD(->&8!B%X*)U_?K3SK#?3*'38_R!PF0 N]A)VAE%%T7$(B&EI"O[NJ+
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M7BDLQHM9V?3)M#8_CC]/QV6<ZMNX-;?2J@?>9)QJF<<Q#NF(85KXHE-GURC
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M>([M']3 >^PA82,/<CW2C:DW3A0,9U$H#HQ7]G93>"V\9;0]J9Q$--8G;.Q
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M%R3#>%F_&J%BP1J.8$H)E(!P#1%5AA"*9"DXX7/K#C(/B--OU\*N7%,C]0\
M2=NHU+8'?2$6I9V(H'W">MM86] %RFYI@83"6*()-,;5WL+UVSBP(Y1U8YH!
M8.[NX>OV27D;T6=)RZ>X1$E&2!!%Y55DR8I2G#2N=>WF7H+UV^RO(ZRU-\D
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MP+#L/H##1)IK?=!'V1_].1\G^FJ5'ZXTLSA+R_'W^^4GZ)GP@1M:U34?#,*
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MYR^[DG^E7;"J(*"ID8J(#(*-]1E S!9]$9GM5Z)X\- #9FLZQ-:WO&&W^A]
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M=I?C!)T8A9$"N*H/X[BPX W-1K+B!<O:>M4<1R=5O'57LM3*W'M7NAVB^P&
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MTNT V8^?PNJ(EF\:(J12N[<8\#I&J"5".F1T;)#AKS_S4?E!N-CKJ/P0(?6
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M/B:O-47V:;^2C5:(VT7H7O!SEPZ_)F+J9W+JCE5.4@X\V<Q!"*9 9:SSE*,
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MN4?_=EMY;X1+:=U..X+*2'$NL0IB8=D:E84KS=7-#U1T8J).$^]#G7,:KWM
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M+)&\N5(>=GK;Y7\\^9[Q9PRVP$1#7G9@.7Z_CLMIGH;%M[J:^S=UO@AKO$I
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M?1%^EI821G-F0K+D'/J:R&@B>!LSZ&(P)V&L-*W'(/^GI<2AF!VNI<0AXN_
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M1 +4K^6_U_SYM8 '2 ?QH <!URV;P "^[:G%DU:?2]?(\_D[GXQ>;EUT@[C
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MZ__ZC_\#4$L! A0#%     @ K$!=6(%[&L/U'P  99<  !(
M ( !     &UL='@M97AH:6)I=#0Q+FAT;5!+ 0(4 Q0    ( *Q 75A$N. I
MD@<  -PG   <              "  24@  !M;'1X7S(P,C-Q-'AE>#,Q,61A
M<VEL=F$N:'1M4$L! A0#%     @ K$!=6"^<O]V"!P  :"<  !\
M     ( !\2<  &UL='A?,C R,W$T>&5X,S$R8F]D96YS=&5D="YH=&U02P$"
M% ,4    " "L0%U8 _^-$XX$  #6$@  '               @ &P+P  ;6QT
M>%\R,#(S<31X97@S,C%D87-I;'9A+FAT;5!+ 0(4 Q0    ( *Q 75BL3)T>
ME 0  )02   ?              "  7@T  !M;'1X7S(P,C-Q-'AE>#,R,F)O
M9&5N<W1E9'0N:'1M4$L! A0#%     @ K$!=6!1J^"H? @  QP<  !X
M         ( !23D  &UL='A?97@R,3%S=6)S:61I87)I97-L:7-T+FAT;5!+
M 0(4 Q0    ( *Q 75@,S!AP8P,  &,*   >              "  :0[  !M
M;'1X7V5X,C,Q8V]N<V5N=&]F:6YD97!E;BYH=&U02P$"% ,4    " "L0%U8
MYG*J$N(/  #E7@  '0              @ %#/P  ;6QT>%]E>#DW,2UC;&%W
M8F%C:W!O;&EC>2YH=&U02P$"% ,4    " "L0%U8ZW+A*UD* P!"N1P $0
M            @ %@3P  ;6YL:RTR,#(S,3(S,2YH=&U02P$"% ,4    " "L
M0%U8]X[DJKP5  #<\P  $0              @ 'H60, ;6YL:RTR,#(S,3(S
M,2YX<V102P$"% ,4    " "L0%U8,][4$CHB   "2@$ %0
M@ '3;P, ;6YL:RTR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ K$!=6$F"
MY^.D<P  EQ\% !4              ( !0)(# &UN;&LM,C R,S$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( *Q 75@,:90T&F@! ,)" @ 4              "
M 1<&! !M;FQK+3(P,C,Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( *Q 75B^Y1XJ
M;C8# "1-!  4              "  6-N!0!M;FQK+3(P,C,Q,C,Q7V<R+FIP
M9U!+ 0(4 Q0    ( *Q 75AP+^)_NKX! -6% @ 4              "  0.E
M" !M;FQK+3(P,C,Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( *Q 75AS?0@T:1X!
M +H1#  5              "  >]C"@!M;FQK+3(P,C,Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    " "L0%U8J/1^OTRX  "E>@@ %0              @ &+@@L
K;6YL:RTR,#(S,3(S,5]P<F4N>&UL4$L%!@     1 !$ H00   H[#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>mnlk-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mnlk="http://moonlaketx.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mnlk-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.KristianReichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.KristianReichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.KristianReichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.JorgeSantosDaSilvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.JorgeSantosDaSilvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mnlk:Dr.JorgeSantosDaSilvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionFollowingBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassASharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mnlk:ClassVVotingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-05</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:PIPEInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:PIPEInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-04</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-04</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mnlk:CommonClassAPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-04</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mnlk:CommonClassARedeemableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-04</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-04</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:HelixAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-04-04</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <instant>2022-04-05</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:PortoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:PortoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:CambridgeOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:CambridgeOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-13</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanLiquidityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanLiquidityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanInfrastructureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mnlk:DefinedBenefitPlanInfrastructureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlk:ConversionOfClassCIntoClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlk:ATMSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:May2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-11</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlk:ATMSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:May2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-27</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlk:ATMSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:August2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-27</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MoonLakeImmunotherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-09</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MoonLakeImmunotherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-09</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MLPartiesOtherThanBVFShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MLPartiesOtherThanBVFShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:MLPartiesOtherThanBVFShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlk:MoonLakeAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-28</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">mnlk:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">mnlk:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EmployeeStockOptionPlanESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">mnlk:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlk:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mnlk:OperatingLossCarryforwardExpirationAxis">mnlk:ExpirationIn2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mnlk:OperatingLossCarryforwardExpirationAxis">mnlk:ExpirationIn2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mnlk:PrepaidExpensesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mnlk:SonelokimabProgramSLKProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mnlk:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlk:August2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="chfPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CHF</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lease">
        <measure>mnlk:lease</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="period">
        <measure>mnlk:period</measure>
    </unit>
    <unit id="vote">
        <measure>mnlk:vote</measure>
    </unit>
    <unit id="co-founder">
        <measure>mnlk:co-founder</measure>
    </unit>
    <unit id="installment">
        <measure>mnlk:installment</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0001821586</dei:EntityCentralIndexKey>
    <ecd:TrdArrDuration contextRef="c-6" id="f-52">P135D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-9" id="f-53">P135D</ecd:TrdArrDuration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-104" id="f-428">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList contextRef="c-1" id="f-439">http://fasb.org/us-gaap/2023#OtherNonoperatingIncome</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39630</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">MOONLAKE IMMUNOTHERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">98-1711963</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">Dorfstrasse 29</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">6300</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Zug</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-13">CH</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-1" id="f-14">41</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">415108022</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Class A ordinary share, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">MLTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-7" id="f-29" unitRef="usd">1120000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">62874637</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-31" unitRef="shares">1012120</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Portions of the registrant&#x2019;s definitive proxy statement relating to its 2024 Annual Meeting of Shareholders, to be held on or about June 5, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-5" id="f-37">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16, 2023, Dr. Kristian Reich, the Chief Scientific Officer of the Company, adopted a trading plan intended to satisfy Rule 10b5-1(c). Dr. Reich&#x2019;s plan provides for the sale, subject to certain conditions, of up to 200,000 Class A Ordinary Shares held directly and indirectly by Dr. Reich. The plan terminated on February 28, 2024.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-6" id="f-38">October 16, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-6" id="f-39">Dr. Kristian Reich</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-6" id="f-40">Chief Scientific Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-41">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-7" decimals="INF" id="f-42" unitRef="shares">200000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-8" id="f-43">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On October 17, 2023, Dr. Jorge Santos da Silva, the Chief Executive Officer and a director of the Company, adopted a trading plan intended to satisfy Rule 10b5-1(c). Dr. Santos da Silva&#x2019;s plan provides for the sale of up to 200,000 Class A Ordinary Shares, subject to certain conditions. The plan terminated on February 29, 2024.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-9" id="f-44">October 17, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-9" id="f-45">Dr. Jorge Santos da Silva</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-9" id="f-46">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-9" id="f-47">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-10" decimals="INF" id="f-48" unitRef="shares">200000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-11" id="f-49">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-11" id="f-50">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-11" id="f-51">false</ecd:Rule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-54">23</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-55">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-56">Mountain View, CA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-12" decimals="0" id="f-57" unitRef="usd">451169337</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-13" decimals="0" id="f-58" unitRef="usd">39505627</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-12" decimals="0" id="f-59" unitRef="usd">59838900</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-13" decimals="0" id="f-60" unitRef="usd">32609108</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-12" decimals="0" id="f-61" unitRef="usd">1056862</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-13" decimals="0" id="f-62" unitRef="usd">217129</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-12" decimals="0" id="f-63" unitRef="usd">2102203</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-13" decimals="0" id="f-64" unitRef="usd">4179468</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c-12" decimals="0" id="f-65" unitRef="usd">514167302</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-13" decimals="0" id="f-66" unitRef="usd">76511332</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-12" decimals="0" id="f-67" unitRef="usd">3628480</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-13" decimals="0" id="f-68" unitRef="usd">282580</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-12" decimals="0" id="f-69" unitRef="usd">320865</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-13" decimals="0" id="f-70" unitRef="usd">49389</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c-12" decimals="0" id="f-71" unitRef="usd">8423468</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c-13" decimals="0" id="f-72" unitRef="usd">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-12" decimals="0" id="f-73" unitRef="usd">12372813</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-13" decimals="0" id="f-74" unitRef="usd">331969</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-12" decimals="0" id="f-75" unitRef="usd">526540115</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-13" decimals="0" id="f-76" unitRef="usd">76843301</us-gaap:Assets>
    <mnlk:TradeAndOtherPayablesCurrent contextRef="c-12" decimals="0" id="f-77" unitRef="usd">1837684</mnlk:TradeAndOtherPayablesCurrent>
    <mnlk:TradeAndOtherPayablesCurrent contextRef="c-13" decimals="0" id="f-78" unitRef="usd">254972</mnlk:TradeAndOtherPayablesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-12" decimals="0" id="f-79" unitRef="usd">1197876</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-13" decimals="0" id="f-80" unitRef="usd">153629</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-12" decimals="0" id="f-81" unitRef="usd">6930120</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-13" decimals="0" id="f-82" unitRef="usd">7256845</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent contextRef="c-12" decimals="0" id="f-83" unitRef="usd">9965680</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-13" decimals="0" id="f-84" unitRef="usd">7665446</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-12" decimals="0" id="f-85" unitRef="usd">2499990</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-13" decimals="0" id="f-86" unitRef="usd">128951</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent contextRef="c-12" decimals="0" id="f-87" unitRef="usd">583426</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent contextRef="c-13" decimals="0" id="f-88" unitRef="usd">282206</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-12" decimals="0" id="f-89" unitRef="usd">3083416</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-13" decimals="0" id="f-90" unitRef="usd">411157</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-12" decimals="0" id="f-91" unitRef="usd">13049096</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-13" decimals="0" id="f-92" unitRef="usd">8076603</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-12" id="f-93" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-13" id="f-94" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-14"
      decimals="4"
      id="f-95"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-15"
      decimals="4"
      id="f-96"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-15" decimals="0" id="f-97" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-14" decimals="0" id="f-98" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-15" decimals="0" id="f-99" unitRef="shares">60466453</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-15" decimals="0" id="f-100" unitRef="shares">60466453</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-14" decimals="0" id="f-101" unitRef="shares">38977600</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="0" id="f-102" unitRef="shares">38977600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-15" decimals="0" id="f-103" unitRef="usd">6047</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-14" decimals="0" id="f-104" unitRef="usd">3898</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-16"
      decimals="4"
      id="f-105"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-17"
      decimals="4"
      id="f-106"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-17" decimals="0" id="f-107" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-16" decimals="0" id="f-108" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-16" decimals="0" id="f-109" unitRef="shares">2505476</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-16" decimals="0" id="f-110" unitRef="shares">2505476</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-17" decimals="0" id="f-111" unitRef="shares">13723511</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-17" decimals="0" id="f-112" unitRef="shares">13723511</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-16" decimals="0" id="f-113" unitRef="usd">251</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-17" decimals="0" id="f-114" unitRef="usd">1373</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-12" decimals="0" id="f-115" unitRef="usd">609969236</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-13" decimals="0" id="f-116" unitRef="usd">129192291</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-12" decimals="0" id="f-117" unitRef="usd">-116657472</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-13" decimals="0" id="f-118" unitRef="usd">-80650212</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="0" id="f-119" unitRef="usd">2357621</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="0" id="f-120" unitRef="usd">350946</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="0" id="f-121" unitRef="usd">495675683</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="0" id="f-122" unitRef="usd">48898296</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-12" decimals="0" id="f-123" unitRef="usd">17815336</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-13" decimals="0" id="f-124" unitRef="usd">19868402</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="0" id="f-125" unitRef="usd">513491019</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="0" id="f-126" unitRef="usd">68766698</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-12" decimals="0" id="f-127" unitRef="usd">526540115</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-13" decimals="0" id="f-128" unitRef="usd">76843301</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-129" unitRef="usd">31801880</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-18" decimals="0" id="f-130" unitRef="usd">42048954</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-131" unitRef="usd">22321216</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-18" decimals="0" id="f-132" unitRef="usd">23012463</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="0" id="f-133" unitRef="usd">54123096</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-18" decimals="0" id="f-134" unitRef="usd">65061417</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-135" unitRef="usd">-54123096</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-18" decimals="0" id="f-136" unitRef="usd">-65061417</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome contextRef="c-1" decimals="0" id="f-137" unitRef="usd">10138367</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="c-18" decimals="0" id="f-138" unitRef="usd">591732</us-gaap:OtherNonoperatingIncome>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-139" unitRef="usd">-43984729</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="0" id="f-140" unitRef="usd">-64469685</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-141" unitRef="usd">94388</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-18" decimals="0" id="f-142" unitRef="usd">36366</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="0" id="f-143" unitRef="usd">-44079117</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="0" id="f-144" unitRef="usd">-64506051</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-145" unitRef="usd">-36007260</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="0" id="f-146" unitRef="usd">-49973249</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-147" unitRef="usd">-8071857</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-18" decimals="0" id="f-148" unitRef="usd">-14532802</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-149" unitRef="usd">2330101</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-18" decimals="0" id="f-150" unitRef="usd">390753</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-151" unitRef="usd">-336579</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax contextRef="c-18" decimals="0" id="f-152" unitRef="usd">269893</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="0" id="f-153" unitRef="usd">1993522</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="0" id="f-154" unitRef="usd">660646</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-155" unitRef="usd">-42085595</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="0" id="f-156" unitRef="usd">-63845405</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="0" id="f-157" unitRef="usd">-34511723</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-18" decimals="0" id="f-158" unitRef="usd">-49437461</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-159" unitRef="usd">-7573872</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-18" decimals="0" id="f-160" unitRef="usd">-14407944</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-19" decimals="0" id="f-161" unitRef="shares">49122534</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-19" decimals="0" id="f-162" unitRef="shares">49122534</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-20" decimals="0" id="f-163" unitRef="shares">29361353</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-20" decimals="0" id="f-164" unitRef="shares">29361353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-19"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-19"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-20"
      decimals="2"
      id="f-167"
      unitRef="usdPerShare">-1.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-20"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">-1.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-21" decimals="0" id="f-169" unitRef="shares">680196</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="0" id="f-170" unitRef="usd">72466</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-22" decimals="0" id="f-171" unitRef="shares">361528</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="0" id="f-172" unitRef="usd">38537</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-23" decimals="0" id="f-173" unitRef="shares">57756</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="0" id="f-174" unitRef="usd">-6202</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="0" id="f-175" unitRef="usd">42061984</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="0" id="f-176" unitRef="usd">-53643615</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="0" id="f-177" unitRef="usd">-168177</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="0" id="f-178" unitRef="usd">-11645007</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="0" id="f-179" unitRef="usd">-11645007</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-29" decimals="0" id="f-180" unitRef="shares">22200712</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="0" id="f-181" unitRef="shares">11799803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-31" decimals="0" id="f-182" unitRef="shares">1885081</us-gaap:TreasuryStockCommonShares>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-32" decimals="0" id="f-183" unitRef="shares">22880908</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="0" id="f-184" unitRef="usd">72466</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-33" decimals="0" id="f-185" unitRef="shares">12161331</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="0" id="f-186" unitRef="usd">38537</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-34" decimals="0" id="f-187" unitRef="shares">1942837</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="0" id="f-188" unitRef="usd">-6202</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="0" id="f-189" unitRef="usd">42061984</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="0" id="f-190" unitRef="usd">-53643615</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="0" id="f-191" unitRef="usd">-168177</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="0" id="f-192" unitRef="usd">-11645007</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="0" id="f-193" unitRef="usd">-11645007</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-40" decimals="0" id="f-194" unitRef="usd">23939</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-41" decimals="0" id="f-195" unitRef="usd">12730</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-42" decimals="0" id="f-196" unitRef="usd">-797</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-43" decimals="0" id="f-197" unitRef="usd">14551870</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-44" decimals="0" id="f-198" unitRef="usd">-22966652</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-45" decimals="0" id="f-199" unitRef="usd">32404</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-46" decimals="0" id="f-200" unitRef="usd">-8346506</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-47" decimals="0" id="f-201" unitRef="usd">8346506</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization contextRef="c-18" decimals="0" id="f-202" unitRef="usd">0</mnlk:NoncontrollingInterestDecreaseFromReverseRecapitalization>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-48" decimals="0" id="f-203" unitRef="shares">-22880908</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-48" decimals="0" id="f-204" unitRef="usd">-48527</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-49" decimals="0" id="f-205" unitRef="shares">-12161331</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-49" decimals="0" id="f-206" unitRef="usd">-25807</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-50" decimals="0" id="f-207" unitRef="shares">765483</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-50" decimals="0" id="f-208" unitRef="usd">1614</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-51" decimals="0" id="f-209" unitRef="shares">18501284</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-51" decimals="0" id="f-210" unitRef="usd">1850</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-52" decimals="0" id="f-211" unitRef="shares">15775472</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-52" decimals="0" id="f-212" unitRef="usd">1578</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-53" decimals="0" id="f-213" unitRef="usd">70870</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-54" decimals="0" id="f-214" unitRef="usd">1578</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-55" decimals="0" id="f-215" unitRef="usd">1578</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-56" decimals="0" id="f-216" unitRef="shares">18424355</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-56" decimals="0" id="f-217" unitRef="usd">1843</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-43" decimals="0" id="f-218" unitRef="usd">90782093</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-46" decimals="0" id="f-219" unitRef="usd">90783936</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-47" decimals="0" id="f-220" unitRef="usd">43869268</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-18" decimals="0" id="f-221" unitRef="usd">134653204</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-57" decimals="0" id="f-222" unitRef="shares">2051961</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-57" decimals="0" id="f-223" unitRef="usd">205</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-58" decimals="0" id="f-224" unitRef="shares">-2051961</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-58" decimals="0" id="f-225" unitRef="usd">-205</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-59" decimals="0" id="f-226" unitRef="usd">3520306</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-60" decimals="0" id="f-227" unitRef="usd">15739</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-61" decimals="0" id="f-228" unitRef="usd">3536045</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-62" decimals="0" id="f-229" unitRef="usd">-3536045</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-63" decimals="0" id="f-230" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement contextRef="c-43" decimals="0" id="f-231" unitRef="usd">-40078</mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement>
    <mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement contextRef="c-46" decimals="0" id="f-232" unitRef="usd">-40078</mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement>
    <mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement contextRef="c-47" decimals="0" id="f-233" unitRef="usd">-16162</mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement>
    <mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement contextRef="c-18" decimals="0" id="f-234" unitRef="usd">-56240</mnlk:AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-42" decimals="0" id="f-235" unitRef="shares">1177354</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-42" decimals="0" id="f-236" unitRef="usd">3791</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-43" decimals="0" id="f-237" unitRef="usd">7348986</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-46" decimals="0" id="f-238" unitRef="usd">7352777</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-47" decimals="0" id="f-239" unitRef="usd">2305791</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-18" decimals="0" id="f-240" unitRef="usd">9658568</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:ProfitLoss contextRef="c-44" decimals="0" id="f-241" unitRef="usd">-49973249</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-46" decimals="0" id="f-242" unitRef="usd">-49973249</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-47" decimals="0" id="f-243" unitRef="usd">-14532802</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="0" id="f-244" unitRef="usd">-64506051</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-45" decimals="0" id="f-245" unitRef="usd">535788</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-46" decimals="0" id="f-246" unitRef="usd">535788</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-47" decimals="0" id="f-247" unitRef="usd">124858</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="0" id="f-248" unitRef="usd">660646</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-64" decimals="0" id="f-249" unitRef="shares">38977600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="0" id="f-250" unitRef="usd">3898</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-65" decimals="0" id="f-251" unitRef="shares">13723511</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="0" id="f-252" unitRef="usd">1373</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="0" id="f-253" unitRef="usd">129192291</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="0" id="f-254" unitRef="usd">-80650212</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="0" id="f-255" unitRef="usd">350946</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="0" id="f-256" unitRef="usd">48898296</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-70" decimals="0" id="f-257" unitRef="usd">19868402</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="0" id="f-258" unitRef="usd">68766698</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-64" decimals="0" id="f-259" unitRef="shares">38977600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="0" id="f-260" unitRef="usd">3898</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-65" decimals="0" id="f-261" unitRef="shares">13723511</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="0" id="f-262" unitRef="usd">1373</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="0" id="f-263" unitRef="usd">129192291</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="0" id="f-264" unitRef="usd">-80650212</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="0" id="f-265" unitRef="usd">350946</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="0" id="f-266" unitRef="usd">48898296</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-70" decimals="0" id="f-267" unitRef="usd">19868402</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="0" id="f-268" unitRef="usd">68766698</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-71" decimals="0" id="f-269" unitRef="shares">10270818</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-71" decimals="0" id="f-270" unitRef="usd">1027</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-72" decimals="0" id="f-271" unitRef="usd">482453399</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-73" decimals="0" id="f-272" unitRef="usd">482454426</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="0" id="f-273" unitRef="usd">482454426</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary contextRef="c-72" decimals="0" id="f-274" unitRef="usd">-60061761</mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary>
    <mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary contextRef="c-74" decimals="0" id="f-275" unitRef="usd">1135</mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary>
    <mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary contextRef="c-73" decimals="0" id="f-276" unitRef="usd">-60060626</mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary>
    <mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary contextRef="c-75" decimals="0" id="f-277" unitRef="usd">57310111</mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary>
    <mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary contextRef="c-1" decimals="0" id="f-278" unitRef="usd">-2750515</mnlk:NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-71" decimals="0" id="f-279" unitRef="shares">11218035</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-71" decimals="0" id="f-280" unitRef="usd">1122</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-76" decimals="0" id="f-281" unitRef="shares">-11218035</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-76" decimals="0" id="f-282" unitRef="usd">-1122</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-72" decimals="0" id="f-283" unitRef="usd">52479045</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-74" decimals="0" id="f-284" unitRef="usd">510003</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-73" decimals="0" id="f-285" unitRef="usd">52989048</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-75" decimals="0" id="f-286" unitRef="usd">-52989048</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="0" id="f-287" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-72" decimals="0" id="f-288" unitRef="usd">5907406</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-73" decimals="0" id="f-289" unitRef="usd">5907406</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-75" decimals="0" id="f-290" unitRef="usd">1198599</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c-1" decimals="0" id="f-291" unitRef="usd">7106005</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees contextRef="c-72" decimals="0" id="f-292" unitRef="usd">-1144</mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees>
    <mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees contextRef="c-73" decimals="0" id="f-293" unitRef="usd">-1144</mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees>
    <mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees contextRef="c-75" decimals="0" id="f-294" unitRef="usd">1144</mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees>
    <mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees contextRef="c-1" decimals="0" id="f-295" unitRef="usd">0</mnlk:AdjustmentsToAdditionalPaidInCapitalStampDutyFees>
    <us-gaap:ProfitLoss contextRef="c-77" decimals="0" id="f-296" unitRef="usd">-36007260</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-73" decimals="0" id="f-297" unitRef="usd">-36007260</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-75" decimals="0" id="f-298" unitRef="usd">-8071857</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="0" id="f-299" unitRef="usd">-44079117</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-74" decimals="0" id="f-300" unitRef="usd">1495537</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-73" decimals="0" id="f-301" unitRef="usd">1495537</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-75" decimals="0" id="f-302" unitRef="usd">497985</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="0" id="f-303" unitRef="usd">1993522</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-78" decimals="0" id="f-304" unitRef="shares">60466453</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="0" id="f-305" unitRef="usd">6047</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-79" decimals="0" id="f-306" unitRef="shares">2505476</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="0" id="f-307" unitRef="usd">251</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-80" decimals="0" id="f-308" unitRef="usd">609969236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-81" decimals="0" id="f-309" unitRef="usd">-116657472</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-82" decimals="0" id="f-310" unitRef="usd">2357621</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-83" decimals="0" id="f-311" unitRef="usd">495675683</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-84" decimals="0" id="f-312" unitRef="usd">17815336</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="0" id="f-313" unitRef="usd">513491019</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="0" id="f-314" unitRef="usd">-44079117</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="0" id="f-315" unitRef="usd">-64506051</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="0" id="f-316" unitRef="usd">13158</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-18" decimals="0" id="f-317" unitRef="usd">12358</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-318" unitRef="usd">7106005</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-18" decimals="0" id="f-319" unitRef="usd">9654778</us-gaap:ShareBasedCompensation>
    <us-gaap:PensionExpenseReversalOfExpenseNoncash contextRef="c-1" decimals="0" id="f-320" unitRef="usd">-85254</us-gaap:PensionExpenseReversalOfExpenseNoncash>
    <us-gaap:PensionExpenseReversalOfExpenseNoncash contextRef="c-18" decimals="0" id="f-321" unitRef="usd">304031</us-gaap:PensionExpenseReversalOfExpenseNoncash>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="0" id="f-322" unitRef="usd">-484762</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-18" decimals="0" id="f-323" unitRef="usd">-220880</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="0" id="f-324" unitRef="usd">839733</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-18" decimals="0" id="f-325" unitRef="usd">68355</us-gaap:IncreaseDecreaseInOtherReceivables>
    <mnlk:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-1" decimals="0" id="f-326" unitRef="usd">65513</mnlk:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <mnlk:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-18" decimals="0" id="f-327" unitRef="usd">0</mnlk:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="0" id="f-328" unitRef="usd">6346203</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-18" decimals="0" id="f-329" unitRef="usd">2730373</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="0" id="f-330" unitRef="usd">1582712</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-18" decimals="0" id="f-331" unitRef="usd">-1314318</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="0" id="f-332" unitRef="usd">-222259</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-18" decimals="0" id="f-333" unitRef="usd">-152425</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="0" id="f-334" unitRef="usd">-326725</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-18" decimals="0" id="f-335" unitRef="usd">2685576</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-336" unitRef="usd">-42778167</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-18" decimals="0" id="f-337" unitRef="usd">-55893900</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="0" id="f-338" unitRef="usd">175732711</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-18" decimals="0" id="f-339" unitRef="usd">42226021</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="0" id="f-340" unitRef="usd">150833021</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-18" decimals="0" id="f-341" unitRef="usd">9901437</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-342" unitRef="usd">284634</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-18" decimals="0" id="f-343" unitRef="usd">16009</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-344" unitRef="usd">-25184324</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-18" decimals="0" id="f-345" unitRef="usd">-32340593</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-1" decimals="0" id="f-346" unitRef="usd">482454426</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-18" decimals="0" id="f-347" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <mnlk:PaymentsOfStampDuty contextRef="c-1" decimals="0" id="f-348" unitRef="usd">2752918</mnlk:PaymentsOfStampDuty>
    <mnlk:PaymentsOfStampDuty contextRef="c-18" decimals="0" id="f-349" unitRef="usd">0</mnlk:PaymentsOfStampDuty>
    <mnlk:ProceedsFromReverseRecapitalization contextRef="c-1" decimals="0" id="f-350" unitRef="usd">0</mnlk:ProceedsFromReverseRecapitalization>
    <mnlk:ProceedsFromReverseRecapitalization contextRef="c-18" decimals="0" id="f-351" unitRef="usd">134646009</mnlk:ProceedsFromReverseRecapitalization>
    <mnlk:ProceedsFromContributionFromParValueOfCommonStock contextRef="c-1" decimals="0" id="f-352" unitRef="usd">0</mnlk:ProceedsFromContributionFromParValueOfCommonStock>
    <mnlk:ProceedsFromContributionFromParValueOfCommonStock contextRef="c-18" decimals="0" id="f-353" unitRef="usd">42935</mnlk:ProceedsFromContributionFromParValueOfCommonStock>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-1" decimals="0" id="f-354" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-18" decimals="0" id="f-355" unitRef="usd">15000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="0" id="f-356" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-18" decimals="0" id="f-357" unitRef="usd">3791</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-358" unitRef="usd">479701508</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-18" decimals="0" id="f-359" unitRef="usd">119692735</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="0" id="f-360" unitRef="usd">-75307</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-18" decimals="0" id="f-361" unitRef="usd">8540</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-362" unitRef="usd">411663710</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-18" decimals="0" id="f-363" unitRef="usd">31466782</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="0" id="f-364" unitRef="usd">39505627</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-39" decimals="0" id="f-365" unitRef="usd">8038845</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="0" id="f-366" unitRef="usd">451169337</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="0" id="f-367" unitRef="usd">39505627</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="0" id="f-368" unitRef="usd">41713</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-18" decimals="0" id="f-369" unitRef="usd">4312</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="0" id="f-370" unitRef="usd">3637545</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-18" decimals="0" id="f-371" unitRef="usd">435005</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="0" id="f-372" unitRef="usd">422519</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-18" decimals="0" id="f-373" unitRef="usd">155552</us-gaap:OperatingLeasePayments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-374">Overview of the Company&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Corporate Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. MoonLake Immunotherapeutics is currently a single asset company focused on the development of Sonelokimab (&#x201c;SLK&#x201d;), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless the context otherwise requires, &#x201c;MoonLake&#x201d;, and the &#x201c;Company&#x201d; refer to the combined company following the Business Combination (as defined in Note 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combination Agreement with Helix and Recapitalization&lt;/span&gt;), together with its subsidiaries.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <mnlk:ReverseRecapitalizationDisclosureTextBlock contextRef="c-1" id="f-375">Business Combination Agreement with Helix and Recapitalization&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2022 (the &#x201c;Closing Date&#x201d;), MoonLake Immunotherapeutics, a Cayman Islands exempted company (formerly known as Helix Acquisition Corp.) (prior to the Closing Date, &#x201c;Helix&#x201d; and after the Closing Date, &#x201c;MoonLake&#x201d; or the &#x201c;Company&#x201d;) consummated the previously announced business combination (the &#x201c;Closing&#x201d;) pursuant to that certain Business Combination Agreement dated October 4, 2021 (the &#x201c;Business Combination Agreement&#x201d;), by and among Helix, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#x201c;MoonLake AG&#x201d;), the existing equityholders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equityholders of MoonLake AG that executed joinders to the Business Combination Agreement (collectively, the &#x201c;ML Parties&#x201d;), Helix Holdings LLC, a Cayman Islands limited liability company and the sponsor of Helix (the &#x201c;Sponsor&#x201d;), and the representative of the ML Parties (such transactions contemplated by the Business Combination Agreement collectively, the &#x201c;Business Combination&#x201d;). Net proceeds from the Business Combination totaled $134.7 million, which included funds held in Helix&#x2019;s trust account and the completion of a concurrent PIPE investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Business Combination Agreement, approved by the boards of directors of each of MoonLake AG and Helix, (i) the Company changed its name from Helix Acquisition Corp. to MoonLake Immunotherapeutics, and (ii) MoonLake AG merged with and into MoonLake, with MoonLake AG as the surviving company in the Business Combination and, after giving effect to such Business Combination, MoonLake AG as a subsidiary of MoonLake. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Business Combination Agreement provided for, among other things, the following transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.37pt"&gt;Two business days prior to the Closing Date, the ML Parties and MoonLake AG effectuated a restructuring of MoonLake AG&#x2019;s share capital to, among other things, (x) convert the Series A preferred shares of MoonLake AG, par value of CHF 0.10 per share, into an equal number of MoonLake AG Common Shares such that the ML Parties held a single class of capital share of MoonLake AG immediately prior to the Closing and (y) approve a capital increase for the issuance of 4,006,736 Class V Voting Shares of MoonLake AG, par value CHF 0.01 per share, to Helix, each Class V Voting Share due to its lower par value having ten times the voting power of a MoonLake AG Common Share (the &#x201c;Restructuring&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.6pt"&gt;At the Closing, 2,875,000 Class B ordinary shares of Helix, par value $0.0001 per share (the &#x201c;Class B Ordinary Shares&#x201d;), constituting all of the then-outstanding Class B Ordinary Shares, were automatically converted into Class A Ordinary Shares on a one-for-one basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.83pt"&gt;At the Closing, Helix amended and restated its existing memorandum and articles of association to, among other things, establish a share structure consisting of the Class A Ordinary Shares, which carry economic and voting rights, and Class C Ordinary Shares, which carry voting rights but no economic rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.37pt"&gt;On the Closing Date, Helix paid all unpaid transaction expenses and contributed $134.7 million to MoonLake AG, including $15.0 million loan repayment pursuant to a convertible loan agreement dated March 20, 2022, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;by and between MoonLake AG and Cormorant Asset Management LP (&#x201c;Cormorant&#x201d;), and assigned by Cormorant to Helix on March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.14pt"&gt;On the Closing Date, following the Restructuring, Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P. (collectively, the &#x201c;BVF Shareholders&#x201d;) assigned all of their MoonLake AG Common Shares to Helix and Helix issued to the BVF Shareholders 18,501,284 Class A Ordinary Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-17.64pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vi.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.37pt"&gt;On the Closing Date, following the Restructuring, Helix issued 15,775,472 Class C Ordinary Shares to the ML Parties (other than the BVF Shareholders). Please refer to Note 12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional details on the exchange mechanism adopted. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on the Closing Date, Helix issued to the PIPE Investors (as defined below in the section entitled &#x201c;PIPE Financing&#x201d;) an aggregate of 11,700,000 Class A Ordinary Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the open of trading on April 6, 2022, the Class A Ordinary Shares, formerly those of Helix, began trading on The Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) under the trading symbol &#x201c;MLTX&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PIPE Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 4, 2021, concurrently with the execution of the Business Combination Agreement, and subsequently on March 31, 2022 and April 4, 2022, Helix entered into subscription agreements with certain investors (collectively, the &#x201c;PIPE Investors&#x201d;, which includes affiliates of the Sponsor and certain existing equityholders of MoonLake AG) pursuant to which, and on the terms and subject to the conditions of which, the PIPE Investors have collectively subscribed for 11,700,000 Class A Ordinary Shares, 11,600,000 shares of which were issued at a price of $10.00 per share for gross proceeds of $116.0 million and 100,000 shares of which were issued to placement agents of the PIPE in satisfaction of an aggregate of $1.0 million of fees owed by Helix to such placement agents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Net Proceeds&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the elements of the net proceeds from the Business Combination:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;in thousands&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Investments held in Trust Account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;115,051&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix  prior to the Closing Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(80,842)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Plus PIPE investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;116,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Less Helix transaction expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(15,520)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;of which accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;(5,798)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;of which deferred IPO underwriting fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;(4,025)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;of which other transaction expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;(5,697)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Available Closing Date Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;134,689&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Ordinary Shares Issued&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the number of Ordinary Shares outstanding immediately following the consummation of the Business Combination:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Helix Acquisition Corp. Ordinary Shares prior to the Business Combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;14,805,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which Class A Ordinary Shares (Helix management - IPO private placement shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;430,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which Class A Ordinary Shares redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;11,500,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which Class B Ordinary Shares (Helix management - sponsor promote)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;2,875,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Less redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(8,080,645)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Plus issuance of Helix Class A Ordinary Shares to PIPE Investors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;11,700,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Plus issuance of Helix Class A Ordinary Shares to BVF Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;18,501,284&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total MoonLake Class A Ordinary Shares Outstanding at Closing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;36,925,639&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Plus issuance of Helix Class C Ordinary Shares to ML Parties (other than the BVF Shareholders)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;15,775,472&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total MoonLake Class A and Class C Ordinary Shares Outstanding at Closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,701,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further information about the Business Combination can be found on Form S-1/A filed with the SEC on July 26, 2022, declared effective on August 2, 2022 and to the exhibits included therein, available at www.sec.gov.&lt;/span&gt;&lt;/div&gt;</mnlk:ReverseRecapitalizationDisclosureTextBlock>
    <mnlk:ReverseRecapitalizationNet contextRef="c-85" decimals="-5" id="f-376" unitRef="usd">134700000</mnlk:ReverseRecapitalizationNet>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-86"
      decimals="INF"
      id="f-377"
      unitRef="chfPerShare">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-87"
      decimals="INF"
      id="f-378"
      unitRef="shares">4006736</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-87"
      decimals="INF"
      id="f-379"
      unitRef="chfPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <mnlk:CommonStockVotesMultiplier contextRef="c-87" decimals="2" id="f-380" unitRef="number">10</mnlk:CommonStockVotesMultiplier>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-88"
      decimals="INF"
      id="f-381"
      unitRef="shares">2875000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-89"
      decimals="INF"
      id="f-382"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <mnlk:CommonStockConversionRatio
      contextRef="c-89"
      decimals="INF"
      id="f-383"
      unitRef="number">1</mnlk:CommonStockConversionRatio>
    <mnlk:ReverseRecapitalizationNet contextRef="c-85" decimals="-5" id="f-384" unitRef="usd">134700000</mnlk:ReverseRecapitalizationNet>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-85" decimals="-5" id="f-385" unitRef="usd">15000000.0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-90"
      decimals="INF"
      id="f-386"
      unitRef="shares">18501284</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <mnlk:StockConvertedReverseRecapitalization
      contextRef="c-91"
      decimals="INF"
      id="f-387"
      unitRef="shares">15775472</mnlk:StockConvertedReverseRecapitalization>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-90"
      decimals="INF"
      id="f-388"
      unitRef="shares">11700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-92"
      decimals="INF"
      id="f-389"
      unitRef="shares">11700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-93"
      decimals="INF"
      id="f-390"
      unitRef="shares">11600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-94"
      decimals="2"
      id="f-391"
      unitRef="usdPerShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-93" decimals="-5" id="f-392" unitRef="usd">116000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-95"
      decimals="INF"
      id="f-393"
      unitRef="shares">100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <mnlk:SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed contextRef="c-95" decimals="-5" id="f-394" unitRef="usd">1000000.0</mnlk:SaleOfStockConsiderationReceivedOnTransactionSatisfactionOfFeesOwed>
    <mnlk:ScheduleOfReverseRecapitalizationTableTextBlock contextRef="c-1" id="f-395">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the elements of the net proceeds from the Business Combination:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;in thousands&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Investments held in Trust Account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;115,051&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix  prior to the Closing Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(80,842)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Plus PIPE investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;116,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Less Helix transaction expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(15,520)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;of which accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;(5,798)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;of which deferred IPO underwriting fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;(4,025)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;of which other transaction expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 2.5pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;(5,697)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Available Closing Date Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;134,689&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the number of Ordinary Shares outstanding immediately following the consummation of the Business Combination:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Helix Acquisition Corp. Ordinary Shares prior to the Business Combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;14,805,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which Class A Ordinary Shares (Helix management - IPO private placement shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;430,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which Class A Ordinary Shares redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;11,500,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:11pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which Class B Ordinary Shares (Helix management - sponsor promote)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;2,875,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Less redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(8,080,645)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Plus issuance of Helix Class A Ordinary Shares to PIPE Investors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;11,700,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Plus issuance of Helix Class A Ordinary Shares to BVF Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;18,501,284&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total MoonLake Class A Ordinary Shares Outstanding at Closing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;36,925,639&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Plus issuance of Helix Class C Ordinary Shares to ML Parties (other than the BVF Shareholders)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;15,775,472&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total MoonLake Class A and Class C Ordinary Shares Outstanding at Closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,701,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mnlk:ScheduleOfReverseRecapitalizationTableTextBlock>
    <mnlk:InvestmentsAcquiredThroughReverseRecapitalization contextRef="c-85" decimals="-3" id="f-396" unitRef="usd">115051000</mnlk:InvestmentsAcquiredThroughReverseRecapitalization>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-85" decimals="-3" id="f-397" unitRef="usd">80842000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-85" decimals="-3" id="f-398" unitRef="usd">116000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <mnlk:ReverseRecapitalizationTransactionCosts contextRef="c-85" decimals="-3" id="f-399" unitRef="usd">15520000</mnlk:ReverseRecapitalizationTransactionCosts>
    <mnlk:ReverseRecapitalizationAccruedExpenses contextRef="c-85" decimals="-3" id="f-400" unitRef="usd">5798000</mnlk:ReverseRecapitalizationAccruedExpenses>
    <mnlk:ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees contextRef="c-85" decimals="-3" id="f-401" unitRef="usd">4025000</mnlk:ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees>
    <mnlk:ReverseRecapitalizationOtherTransactionExpenses contextRef="c-85" decimals="-3" id="f-402" unitRef="usd">5697000</mnlk:ReverseRecapitalizationOtherTransactionExpenses>
    <mnlk:ReverseRecapitalizationNet contextRef="c-85" decimals="-3" id="f-403" unitRef="usd">134689000</mnlk:ReverseRecapitalizationNet>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-96"
      decimals="INF"
      id="f-404"
      unitRef="shares">14805000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-97"
      decimals="INF"
      id="f-405"
      unitRef="shares">430000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-98"
      decimals="INF"
      id="f-406"
      unitRef="shares">11500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-99"
      decimals="INF"
      id="f-407"
      unitRef="shares">2875000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-100"
      decimals="INF"
      id="f-408"
      unitRef="shares">8080645</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-90"
      decimals="INF"
      id="f-409"
      unitRef="shares">11700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-90"
      decimals="INF"
      id="f-410"
      unitRef="shares">18501284</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <mnlk:StockIssuedDuringPeriodSharesReverseRecapitalization
      contextRef="c-90"
      decimals="INF"
      id="f-411"
      unitRef="shares">36925639</mnlk:StockIssuedDuringPeriodSharesReverseRecapitalization>
    <mnlk:StockConvertedReverseRecapitalization
      contextRef="c-91"
      decimals="INF"
      id="f-412"
      unitRef="shares">15775472</mnlk:StockConvertedReverseRecapitalization>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-101"
      decimals="INF"
      id="f-413"
      unitRef="shares">52701111</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-414">Basis of Presentation and Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#x201c;MoonLake AG&#x201d;), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to ASC 805, for financial accounting and reporting purposes, MoonLake AG was deemed the accounting acquirer and Helix was treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Accordingly, the Business Combination was treated as the equivalent of MoonLake AG issuing shares for the net assets of Helix, accompanied by a recapitalization. The net assets of Helix were stated at historical costs, with no goodwill or other intangible assets recorded, and are consolidated with MoonLake AG&#x2019;s financial statements on the Closing Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Business Combination Agreement, the ML Parties received 33.638698 Ordinary Shares in the Company for every MoonLake AG Common Share or Series A Preferred Share (the &#x201c;Exchange Ratio&#x201d;). The BVF Shareholders received 18,501,284 Class A Ordinary Shares whereas the rest of the ML Parties (excluding the BVF Shareholders) received 15,775,472 Class C Ordinary Shares which can be converted into Class A Ordinary Shares at the discretion of the shareholder (refer to Note&#160;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; Shareholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details on the classes of ordinary shares). The number of shares, and the number of shares within the net income (loss) per share held by the ML Parties in MoonLake AG prior to the Business Combination have been adjusted by the Exchange Ratio to reflect the equivalent number of ordinary shares in the Company (identified as &#x201c;the equivalent of&#x201d; throughout these consolidated financial statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain MoonLake AG shareholders (ML Parties other than the BVF Shareholders), did not exchange their shares in MoonLake AG for Class A Ordinary Shares in the Company and therefore continued to hold an economic interest in MoonLake AG and Class C Ordinary Shares in the Company. The Company recognized a noncontrolling interest equal to the ML Parties&#x2019; (other than the BVF Shareholders) proportionate interest in the net assets of MoonLake AG.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All amounts are presented in U.S. Dollar (&#x201c;$&#x201d;), unless otherwise indicated. The term &#x201c;Swiss franc&#x201d; and &#x201c;CHF&#x201d; refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and &#x201c;&#x20ac;&#x201d; refers to euros.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;determining whether the in-process research and development expenditure (&#x201c;IPR&amp;amp;D&#x201d;) has an alternative future use;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;determining assumptions used in estimating the fair value of share-based compensation;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;estimating the recoverability of the deferred tax asset; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;estimating the amount of accruals in connection with the completion of clinical trial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company&#x2019;s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company&#x2019;s estimates and the actual results, the Company&#x2019;s future results of operation may be affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December&#160;31, 2023, the Company considers $129.4 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. As of December&#160;31, 2022, the Company considered $19.9 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable securities and short-term investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in &#x201c;Interest and dividend income&#x201d;. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the &#x201c;Accumulated other comprehensive income (loss)&#x201d; component of shareholders&#x2019; equity (deficit) until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable debt securities are classified as either &#x201c;Cash and cash equivalents&#x201d; or &#x201c;Short&#x2011;term marketable debt securities&#x201d; according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statement of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the &#x20ac;100,000 Fundo de Garantia de Dep&#xf3;sitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the guidance included in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are three levels of inputs to fair value measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1, meaning the use of quoted prices for identical instruments in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3, meaning the use of unobservable inputs. Observable market data is used when available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a stand-alone basis for the purposes of allocating resources, and assessing financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of &lt;span style="-sec-ix-hidden:f-428"&gt;three&lt;/span&gt; to five years. As of December&#160;31, 2023, property and equipment, net relates to information technology, office equipment, and leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Contract Costs and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goods or services received in a share-based payment transaction are measured using a fair value-based measure.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#x2019;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#x2019;s common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companies&#x2019; volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;The fair value of the common stock granted under the ESPP (as defined below) has historically been estimated by management with reference to the market-based transaction with the other Series A Preferred Shares Investors, as there was no public market for the common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains or losses from foreign currency translation are included in the consolidated statement of operations in "other income, net". The Company recognized foreign currency transaction gain of $151,493 for the year ended December&#160;31, 2023 and a foreign currency transaction gain of $325,317 for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Class A Ordinary Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the &#x201c;In-License Agreement&#x201d;) with Merck Healthcare KGaA, Darmstadt, Germany (&#x201c;MHKDG&#x201d;) to acquire the Sonelokimab program (the &#x201c;SLK Program&#x201d;) and determined that substantially all of the fair value of the gross assets acquired related to IPR&amp;amp;D of SLK. Therefore, this transaction was accounted for as an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&amp;amp;D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pension Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for pension assets and liabilities in accordance with ASC 715, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Retirement Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires the recognition of the funded status of pension plans in the Company&#x2019;s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of December&#160;31, 2023 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statement of operations separately from the service cost component, in &#x201c;&lt;span style="-sec-ix-hidden:f-439"&gt;other income (expenses), net&lt;/span&gt;.&#x201d; Plan assets are recorded at their fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MoonLake does not have any finance leases. As of December&#160;31, 2023, the Company has three operating leases related to the office spaces which are located in (i) Dorfstrasse 29, 6300, Zug, Switzerland, (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. The operating leases are recognized over a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-Use (&#x201c;RoU&#x201d;) assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less and that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. The FASB also issued subsequent amendments to the initial guidance, ASU 2019-04, ASU 2019-05, ASU 2019-11, and ASU 2020-03 (collectively, &#x201c;Topic 326&#x201d;). The Current Expected Credit Losses model requires a company to estimate credit losses expected over the life of the financial assets based on historical experience, current conditions and reasonable and supportable forecasts. The Company adopted this new guidance as of December 31, 2023 upon the loss of its &#x201c;emerging growth company&#x201d; status. The adoption did not have a material impact on the balances reported in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment reporting &#x2014; Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends guidance on reportable segment disclosure requirements. It is effective for fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact. The early adoption option will not be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income taxes - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Taxes Disclosure,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which amends guidance on to enhance the transparency and decision usefulness of income tax disclosures. It is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact. The early adoption option will not be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Large Accelerated Filer Status&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company is considered a &#x201c;large accelerated filer&#x201d; and no longer qualifies as an emerging growth company or smaller reporting company. The Company is required, pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, to include in its Annual Report on Form 10-K for the year ended December 31, 2023 an attestation report as to the effectiveness of the Company's internal control over financial reporting that is issued by its independent registered public accounting firm. In addition, beginning with the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2024, it will no longer be permitted to take advantage of the reduced reporting requirements applicable to smaller reporting companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-415">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (&#x201c;MoonLake AG&#x201d;), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to ASC 805, for financial accounting and reporting purposes, MoonLake AG was deemed the accounting acquirer and Helix was treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Accordingly, the Business Combination was treated as the equivalent of MoonLake AG issuing shares for the net assets of Helix, accompanied by a recapitalization. The net assets of Helix were stated at historical costs, with no goodwill or other intangible assets recorded, and are consolidated with MoonLake AG&#x2019;s financial statements on the Closing Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Business Combination Agreement, the ML Parties received 33.638698 Ordinary Shares in the Company for every MoonLake AG Common Share or Series A Preferred Share (the &#x201c;Exchange Ratio&#x201d;). The BVF Shareholders received 18,501,284 Class A Ordinary Shares whereas the rest of the ML Parties (excluding the BVF Shareholders) received 15,775,472 Class C Ordinary Shares which can be converted into Class A Ordinary Shares at the discretion of the shareholder (refer to Note&#160;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; Shareholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details on the classes of ordinary shares). The number of shares, and the number of shares within the net income (loss) per share held by the ML Parties in MoonLake AG prior to the Business Combination have been adjusted by the Exchange Ratio to reflect the equivalent number of ordinary shares in the Company (identified as &#x201c;the equivalent of&#x201d; throughout these consolidated financial statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain MoonLake AG shareholders (ML Parties other than the BVF Shareholders), did not exchange their shares in MoonLake AG for Class A Ordinary Shares in the Company and therefore continued to hold an economic interest in MoonLake AG and Class C Ordinary Shares in the Company. The Company recognized a noncontrolling interest equal to the ML Parties&#x2019; (other than the BVF Shareholders) proportionate interest in the net assets of MoonLake AG.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All amounts are presented in U.S. Dollar (&#x201c;$&#x201d;), unless otherwise indicated. The term &#x201c;Swiss franc&#x201d; and &#x201c;CHF&#x201d; refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and &#x201c;&#x20ac;&#x201d; refers to euros.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <mnlk:RecapitalizationExchangeRatio
      contextRef="c-101"
      decimals="INF"
      id="f-416"
      unitRef="number">33.638698</mnlk:RecapitalizationExchangeRatio>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-90"
      decimals="INF"
      id="f-417"
      unitRef="shares">18501284</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-91"
      decimals="INF"
      id="f-418"
      unitRef="shares">15775472</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-419">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;determining whether the in-process research and development expenditure (&#x201c;IPR&amp;amp;D&#x201d;) has an alternative future use;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;determining assumptions used in estimating the fair value of share-based compensation;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;estimating the recoverability of the deferred tax asset; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;estimating the amount of accruals in connection with the completion of clinical trial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company&#x2019;s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company&#x2019;s estimates and the actual results, the Company&#x2019;s future results of operation may be affected.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-420">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-102" decimals="-5" id="f-421" unitRef="usd">129400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-103" decimals="-5" id="f-422" unitRef="usd">19900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-423">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in &#x201c;Interest and dividend income&#x201d;. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the &#x201c;Accumulated other comprehensive income (loss)&#x201d; component of shareholders&#x2019; equity (deficit) until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable debt securities are classified as either &#x201c;Cash and cash equivalents&#x201d; or &#x201c;Short&#x2011;term marketable debt securities&#x201d; according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statement of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-424">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the &#x20ac;100,000 Fundo de Garantia de Dep&#xf3;sitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-425">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the guidance included in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are three levels of inputs to fair value measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1, meaning the use of quoted prices for identical instruments in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3, meaning the use of unobservable inputs. Observable market data is used when available.&lt;/span&gt;&lt;/div&gt;Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-426">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a stand-alone basis for the purposes of allocating resources, and assessing financial performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-427">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of &lt;span style="-sec-ix-hidden:f-428"&gt;three&lt;/span&gt; to five years. As of December&#160;31, 2023, property and equipment, net relates to information technology, office equipment, and leasehold improvements.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-105" id="f-429">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-430">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-431">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goods or services received in a share-based payment transaction are measured using a fair value-based measure.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#x2019;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#x2019;s common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companies&#x2019; volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;The fair value of the common stock granted under the ESPP (as defined below) has historically been estimated by management with reference to the market-based transaction with the other Series A Preferred Shares Investors, as there was no public market for the common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-432">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.&lt;/span&gt;&lt;/div&gt;Gains or losses from foreign currency translation are included in the consolidated statement of operations in "other income, net".</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="c-1" decimals="0" id="f-433" unitRef="usd">151493</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="c-18" decimals="0" id="f-434" unitRef="usd">325317</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-435">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-436">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-437">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the &#x201c;In-License Agreement&#x201d;) with Merck Healthcare KGaA, Darmstadt, Germany (&#x201c;MHKDG&#x201d;) to acquire the Sonelokimab program (the &#x201c;SLK Program&#x201d;) and determined that substantially all of the fair value of the gross assets acquired related to IPR&amp;amp;D of SLK. Therefore, this transaction was accounted for as an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&amp;amp;D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy contextRef="c-1" id="f-438">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for pension assets and liabilities in accordance with ASC 715, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Retirement Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires the recognition of the funded status of pension plans in the Company&#x2019;s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of December&#160;31, 2023 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statement of operations separately from the service cost component, in &#x201c;&lt;span style="-sec-ix-hidden:f-439"&gt;other income (expenses), net&lt;/span&gt;.&#x201d; Plan assets are recorded at their fair value. &lt;/span&gt;&lt;/div&gt;Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income (loss).</us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-440">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MoonLake does not have any finance leases. As of December&#160;31, 2023, the Company has three operating leases related to the office spaces which are located in (i) Dorfstrasse 29, 6300, Zug, Switzerland, (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. The operating leases are recognized over a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-Use (&#x201c;RoU&#x201d;) assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less and that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <mnlk:NumberOfOperatingLeases contextRef="c-1" decimals="INF" id="f-441" unitRef="lease">3</mnlk:NumberOfOperatingLeases>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-442">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. The FASB also issued subsequent amendments to the initial guidance, ASU 2019-04, ASU 2019-05, ASU 2019-11, and ASU 2020-03 (collectively, &#x201c;Topic 326&#x201d;). The Current Expected Credit Losses model requires a company to estimate credit losses expected over the life of the financial assets based on historical experience, current conditions and reasonable and supportable forecasts. The Company adopted this new guidance as of December 31, 2023 upon the loss of its &#x201c;emerging growth company&#x201d; status. The adoption did not have a material impact on the balances reported in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment reporting &#x2014; Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends guidance on reportable segment disclosure requirements. It is effective for fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact. The early adoption option will not be exercised. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income taxes - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Taxes Disclosure,&lt;/span&gt; which amends guidance on to enhance the transparency and decision usefulness of income tax disclosures. It is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact. The early adoption option will not be exercised.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <mnlk:RiskAndLiquidityDisclosureTextBlock contextRef="c-1" id="f-443">Risks and Liquidity&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern, Liquidity and Capital Resources&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a loss of $44.1 million for the year ended December&#160;31, 2023. As of December&#160;31, 2023, the Company&#x2019;s current assets exceeded its current liabilities by $504.2 million. &lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2023, the Company had $451.2 million of cash and cash equivalents. Based on the Company's current operating plan, management believes that the Company has sufficient capital to fund its operations and capital expenditures until the end of 2026.</mnlk:RiskAndLiquidityDisclosureTextBlock>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-444" unitRef="usd">-44100000</us-gaap:ProfitLoss>
    <mnlk:CurrentAssetsInExcessOfCurrentLiabilities contextRef="c-12" decimals="-5" id="f-445" unitRef="usd">504200000</mnlk:CurrentAssetsInExcessOfCurrentLiabilities>
    <us-gaap:Cash contextRef="c-12" decimals="-5" id="f-446" unitRef="usd">451200000</us-gaap:Cash>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-447">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;                                                                               &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Eurocommercial Papers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;109,608,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;109,608,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;42,552,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;42,552,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;79,626,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;79,626,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;9,937,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;9,937,899&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;189,235,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;189,235,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,490,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,490,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, accounts payable and accrued liabilities approximate their fair values as of December&#160;31, 2023 and December 31, 2022, due to their short-term nature. Pension plan assets fair value is determined based on Level 2 inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-448">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;                                                                               &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Eurocommercial Papers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;109,608,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;109,608,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;42,552,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;42,552,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;79,626,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;79,626,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;9,937,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;9,937,899&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;189,235,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;189,235,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,490,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,490,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-106" decimals="0" id="f-449" unitRef="usd">109608915</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-107" decimals="0" id="f-450" unitRef="usd">109608915</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-108" decimals="0" id="f-451" unitRef="usd">42552608</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-109" decimals="0" id="f-452" unitRef="usd">42552608</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-110" decimals="0" id="f-453" unitRef="usd">79626727</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-111" decimals="0" id="f-454" unitRef="usd">79626727</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-112" decimals="0" id="f-455" unitRef="usd">9937899</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-113" decimals="0" id="f-456" unitRef="usd">9937899</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-114" decimals="0" id="f-457" unitRef="usd">189235642</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-12" decimals="0" id="f-458" unitRef="usd">189235642</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-115" decimals="0" id="f-459" unitRef="usd">52490507</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-13" decimals="0" id="f-460" unitRef="usd">52490507</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-461">Investments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of December&#160;31, 2023 and December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Eurocommercial Papers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;107,624,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,984,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;109,608,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;78,890,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;736,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;79,626,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;186,514,788&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2,720,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;189,235,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Of which classified within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;128,197,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,199,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;129,396,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Of which classified within short-term marketable debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;58,317,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,521,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;59,838,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Eurocommercial Papers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;42,265,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;287,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;42,552,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;9,834,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;103,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9,937,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,099,754&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;390,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,490,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Of which classified within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;19,775,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;106,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;19,881,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Of which classified within short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;32,324,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;284,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;32,609,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair values of the Company&#x2019;s short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning balance, January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;390,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;8,751,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Amounts reclassified from accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(6,421,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Ending balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2,720,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company&#x2019;s marketable debt securities maturities are all due within one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-462">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of December&#160;31, 2023 and December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Eurocommercial Papers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;107,624,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,984,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;109,608,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;78,890,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;736,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;79,626,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;186,514,788&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2,720,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;189,235,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Of which classified within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;128,197,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,199,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;129,396,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Of which classified within short-term marketable debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;58,317,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;1,521,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;59,838,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Eurocommercial Papers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;42,265,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;287,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;42,552,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;9,834,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;103,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9,937,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,099,754&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;390,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;52,490,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Of which classified within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;19,775,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;106,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;19,881,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Of which classified within short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;32,324,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;284,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;32,609,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-107" decimals="0" id="f-463" unitRef="usd">107624341</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-107" decimals="0" id="f-464" unitRef="usd">1984574</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-107" decimals="0" id="f-465" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-107" decimals="0" id="f-466" unitRef="usd">109608915</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-111" decimals="0" id="f-467" unitRef="usd">78890447</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-111" decimals="0" id="f-468" unitRef="usd">736280</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-111" decimals="0" id="f-469" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="0" id="f-470" unitRef="usd">79626727</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-12" decimals="0" id="f-471" unitRef="usd">186514788</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-12" decimals="0" id="f-472" unitRef="usd">2720854</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-12" decimals="0" id="f-473" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-12" decimals="0" id="f-474" unitRef="usd">189235642</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-102" decimals="0" id="f-475" unitRef="usd">128197581</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-102" decimals="0" id="f-476" unitRef="usd">1199161</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-102" decimals="0" id="f-477" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-102" decimals="0" id="f-478" unitRef="usd">129396742</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-116" decimals="0" id="f-479" unitRef="usd">58317207</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-116" decimals="0" id="f-480" unitRef="usd">1521693</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-116" decimals="0" id="f-481" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-116" decimals="0" id="f-482" unitRef="usd">59838900</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-109" decimals="0" id="f-483" unitRef="usd">42265129</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-109" decimals="0" id="f-484" unitRef="usd">287479</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-109" decimals="0" id="f-485" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="0" id="f-486" unitRef="usd">42552608</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-113" decimals="0" id="f-487" unitRef="usd">9834625</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-113" decimals="0" id="f-488" unitRef="usd">103274</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-113" decimals="0" id="f-489" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="0" id="f-490" unitRef="usd">9937899</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-13" decimals="0" id="f-491" unitRef="usd">52099754</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-13" decimals="0" id="f-492" unitRef="usd">390753</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-13" decimals="0" id="f-493" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-13" decimals="0" id="f-494" unitRef="usd">52490507</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-103" decimals="0" id="f-495" unitRef="usd">19775171</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-103" decimals="0" id="f-496" unitRef="usd">106228</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-103" decimals="0" id="f-497" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-103" decimals="0" id="f-498" unitRef="usd">19881399</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-117" decimals="0" id="f-499" unitRef="usd">32324583</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-117" decimals="0" id="f-500" unitRef="usd">284525</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-117" decimals="0" id="f-501" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-117" decimals="0" id="f-502" unitRef="usd">32609108</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock contextRef="c-1" id="f-503">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair values of the Company&#x2019;s short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning balance, January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;390,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;8,751,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Amounts reclassified from accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(6,421,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Ending balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;2,720,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-115" decimals="0" id="f-504" unitRef="usd">390753</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-118" decimals="0" id="f-505" unitRef="usd">-8751307</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax contextRef="c-118" decimals="0" id="f-506" unitRef="usd">6421206</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-114" decimals="0" id="f-507" unitRef="usd">2720854</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c-1" id="f-508">Prepaid Expenses&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Prepaid expenses - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Insurances&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,077,478&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,416,597&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Non-clinical research and clinical development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;842,729&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,443,863&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Other consulting and advisory services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;70,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;105,651&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Other prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;111,978&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;213,357&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,102,203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;4,179,468&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Prepaid expenses - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Supply and manufacturing services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8,423,468&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;8,423,468&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses - non-current relate to advance payments made to a contract manufacturing organization pursuant to a manufacturing run reservation agreement for the commercial-scale manufacturing of Sonelokimab in 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-509">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.495%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Prepaid expenses - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Insurances&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,077,478&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,416,597&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Non-clinical research and clinical development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;842,729&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,443,863&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Other consulting and advisory services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;70,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;105,651&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Other prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;111,978&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;213,357&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,102,203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;4,179,468&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Prepaid expenses - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Supply and manufacturing services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8,423,468&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;8,423,468&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c-12" decimals="0" id="f-510" unitRef="usd">1077478</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-13" decimals="0" id="f-511" unitRef="usd">1416597</us-gaap:PrepaidInsurance>
    <mnlk:PrepaidResearchAndDevelopmentExpense contextRef="c-12" decimals="0" id="f-512" unitRef="usd">842729</mnlk:PrepaidResearchAndDevelopmentExpense>
    <mnlk:PrepaidResearchAndDevelopmentExpense contextRef="c-13" decimals="0" id="f-513" unitRef="usd">2443863</mnlk:PrepaidResearchAndDevelopmentExpense>
    <mnlk:OtherPrepaidConsultingAndAdvisoryFeesCurrent contextRef="c-12" decimals="0" id="f-514" unitRef="usd">70018</mnlk:OtherPrepaidConsultingAndAdvisoryFeesCurrent>
    <mnlk:OtherPrepaidConsultingAndAdvisoryFeesCurrent contextRef="c-13" decimals="0" id="f-515" unitRef="usd">105651</mnlk:OtherPrepaidConsultingAndAdvisoryFeesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-12" decimals="0" id="f-516" unitRef="usd">111978</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-13" decimals="0" id="f-517" unitRef="usd">213357</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-12" decimals="0" id="f-518" unitRef="usd">2102203</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-13" decimals="0" id="f-519" unitRef="usd">4179468</us-gaap:PrepaidExpenseCurrent>
    <mnlk:SupplyAndManufacturingExpenseNoncurrent contextRef="c-12" decimals="0" id="f-520" unitRef="usd">8423468</mnlk:SupplyAndManufacturingExpenseNoncurrent>
    <mnlk:SupplyAndManufacturingExpenseNoncurrent contextRef="c-13" decimals="0" id="f-521" unitRef="usd">0</mnlk:SupplyAndManufacturingExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c-12" decimals="0" id="f-522" unitRef="usd">8423468</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c-13" decimals="0" id="f-523" unitRef="usd">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-524">Trade and Other Payables&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Research and development services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;911,454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;31,687&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Supply and manufacturing fees payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;553,459&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;65,979&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Rent / leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;108,249&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;264,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;157,306&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,837,684&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;254,972&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Accrued Expenses and Other Current Liabilities&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Bonuses and related employees compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,780,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,109,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Supply and manufacturing services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,603,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Research and development services and license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,226,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,803,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Consultant and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;853,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;218,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;367,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;109,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;98,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;15,832&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;6,930,120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;7,256,845&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <mnlk:TradeAndOtherPayablesCurrentTableTextBlock contextRef="c-1" id="f-525">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Research and development services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;911,454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;31,687&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Supply and manufacturing fees payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;553,459&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;65,979&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Rent / leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;108,249&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;264,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;157,306&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,837,684&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;254,972&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mnlk:TradeAndOtherPayablesCurrentTableTextBlock>
    <mnlk:AccruedResearchAndDevelopmentExpensesCurrent contextRef="c-12" decimals="0" id="f-526" unitRef="usd">911454</mnlk:AccruedResearchAndDevelopmentExpensesCurrent>
    <mnlk:AccruedResearchAndDevelopmentExpensesCurrent contextRef="c-13" decimals="0" id="f-527" unitRef="usd">31687</mnlk:AccruedResearchAndDevelopmentExpensesCurrent>
    <mnlk:SupplyAndManufacturingFeesPayableCurrent contextRef="c-12" decimals="0" id="f-528" unitRef="usd">553459</mnlk:SupplyAndManufacturingFeesPayableCurrent>
    <mnlk:SupplyAndManufacturingFeesPayableCurrent contextRef="c-13" decimals="0" id="f-529" unitRef="usd">65979</mnlk:SupplyAndManufacturingFeesPayableCurrent>
    <us-gaap:AccruedRentCurrent contextRef="c-12" decimals="0" id="f-530" unitRef="usd">108249</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent contextRef="c-13" decimals="0" id="f-531" unitRef="usd">0</us-gaap:AccruedRentCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-12" decimals="0" id="f-532" unitRef="usd">264522</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-13" decimals="0" id="f-533" unitRef="usd">157306</us-gaap:AccountsPayableOtherCurrent>
    <mnlk:TradeAndOtherPayablesCurrent contextRef="c-12" decimals="0" id="f-534" unitRef="usd">1837684</mnlk:TradeAndOtherPayablesCurrent>
    <mnlk:TradeAndOtherPayablesCurrent contextRef="c-13" decimals="0" id="f-535" unitRef="usd">254972</mnlk:TradeAndOtherPayablesCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-536">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Bonuses and related employees compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,780,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,109,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Supply and manufacturing services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,603,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Research and development services and license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,226,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,803,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Consultant and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;853,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;218,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;367,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;109,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;98,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;15,832&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;6,930,120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;7,256,845&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-12" decimals="0" id="f-537" unitRef="usd">2780219</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-13" decimals="0" id="f-538" unitRef="usd">1109734</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mnlk:AccruedSupplyAndManufacturingFeesCurrent contextRef="c-12" decimals="0" id="f-539" unitRef="usd">1603739</mnlk:AccruedSupplyAndManufacturingFeesCurrent>
    <mnlk:AccruedSupplyAndManufacturingFeesCurrent contextRef="c-13" decimals="0" id="f-540" unitRef="usd">0</mnlk:AccruedSupplyAndManufacturingFeesCurrent>
    <mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent contextRef="c-12" decimals="0" id="f-541" unitRef="usd">1226281</mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent>
    <mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent contextRef="c-13" decimals="0" id="f-542" unitRef="usd">5803432</mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent>
    <mnlk:AccruedConsultingAndOtherFeesCurrent contextRef="c-12" decimals="0" id="f-543" unitRef="usd">853905</mnlk:AccruedConsultingAndOtherFeesCurrent>
    <mnlk:AccruedConsultingAndOtherFeesCurrent contextRef="c-13" decimals="0" id="f-544" unitRef="usd">218021</mnlk:AccruedConsultingAndOtherFeesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-12" decimals="0" id="f-545" unitRef="usd">367976</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-13" decimals="0" id="f-546" unitRef="usd">109826</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="c-12" decimals="0" id="f-547" unitRef="usd">98000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="c-13" decimals="0" id="f-548" unitRef="usd">15832</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-12" decimals="0" id="f-549" unitRef="usd">6930120</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-13" decimals="0" id="f-550" unitRef="usd">7256845</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-551">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company entered into an open-ended office lease agreement, effective November 1, 2021, to lease approximately 2,300 square feet of space on the last two floors of the building located at Dorfstrasse 29, 6300 Zug, Switzerland (the &#x201c;Office Lease"). The Company estimated the effective duration of the Office Lease at inception and determined a period of 3 years, with expected expiration in November 2024. In December, 2023, the contract was extended, leading to a new estimated effective duration of the lease period of 3 years, with expected expiration in January 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 9, 2023, the Company entered into an office lease agreement, effective as of October 9, 2023, to lease approximately 3,900 square feet of office space on the fifth floor of  the building located at Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. This lease has a 3-year initial term, with two extendable periods of 3 years each. It is expected to be extended once until October 2029. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 13, 2023, the Company entered into an office lease agreement, effective as of October 16, 2023, to lease approximately 6,000 square feet of office space on the first floor of the building located at 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom. This lease has a 3-year term agreement and is set to expire in October 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and weighted average discount rate for the operating leases as of December&#160;31, 2023 and December 31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Weighted average remaining lease term (in months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future minimum annual lease payments under these operating leases as of December&#160;31, 2023 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.906%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.272%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,343,255&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,343,255&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,029,249&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;95,794&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;95,794&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;65,923&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3,973,270&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(275,404)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3,697,866&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Less current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(1,197,876)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Long-term portion operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,499,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded lease expense related to its operating leases of $399,882 and $155,552 for the years ended December&#160;31, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <mnlk:OperatingLeaseAreaOfLeasedSpace contextRef="c-119" decimals="0" id="f-552" unitRef="sqft">2300</mnlk:OperatingLeaseAreaOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-120" id="f-553">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-121" id="f-554">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mnlk:OperatingLeaseAreaOfLeasedSpace contextRef="c-122" decimals="-2" id="f-555" unitRef="sqft">3900</mnlk:OperatingLeaseAreaOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-123" id="f-556">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mnlk:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="c-124"
      decimals="INF"
      id="f-557"
      unitRef="period">2</mnlk:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-123" id="f-558">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mnlk:OperatingLeaseAreaOfLeasedSpace contextRef="c-125" decimals="0" id="f-559" unitRef="sqft">6000</mnlk:OperatingLeaseAreaOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-126" id="f-560">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-561">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and weighted average discount rate for the operating leases as of December&#160;31, 2023 and December 31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Weighted average remaining lease term (in months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-12" id="f-562">P39M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-13" id="f-563">P22M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-12" decimals="3" id="f-564" unitRef="number">0.049</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-13" decimals="3" id="f-565" unitRef="number">0.008</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-566">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future minimum annual lease payments under these operating leases as of December&#160;31, 2023 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.906%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.272%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,343,255&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,343,255&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,029,249&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;95,794&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;95,794&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;65,923&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3,973,270&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(275,404)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3,697,866&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Less current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(1,197,876)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Long-term portion operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,499,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-12" decimals="0" id="f-567" unitRef="usd">1343255</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-12" decimals="0" id="f-568" unitRef="usd">1343255</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-12" decimals="0" id="f-569" unitRef="usd">1029249</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-12" decimals="0" id="f-570" unitRef="usd">95794</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-12" decimals="0" id="f-571" unitRef="usd">95794</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-12" decimals="0" id="f-572" unitRef="usd">65923</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-12" decimals="0" id="f-573" unitRef="usd">3973270</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-12" decimals="0" id="f-574" unitRef="usd">275404</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-12" decimals="0" id="f-575" unitRef="usd">3697866</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-12" decimals="0" id="f-576" unitRef="usd">1197876</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-12" decimals="0" id="f-577" unitRef="usd">2499990</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="0" id="f-578" unitRef="usd">399882</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-18" decimals="0" id="f-579" unitRef="usd">155552</us-gaap:OperatingLeaseExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-580">Employee Benefit Plans &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates a defined benefit pension plan in Switzerland (&#x201c;the Plan&#x201d;) and a defined contribution pension plan in the United Kingdom and Portugal, in accordance with local regulations and practices. As of December&#160;31, 2023 the Plan covers the Company&#x2019;s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the changes in projected benefit obligations (&#x201c;PBO&#x201d;) and plan assets is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Beginning PBO &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,321,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,322,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;122,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;451,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;30,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Contributions by plan participants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;200,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;138,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Actuarial (gain) / losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;487,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(374,317)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;229,902&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(204,695)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Foreign currency exchange rates changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;208,608&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(16,267)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Plan amendment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(107,750)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Ending PBO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,494,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,321,969&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Beginning fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,039,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,083,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Return on plan assets above expected return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;48,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(115,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Contributions by the employer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;200,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;138,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Contributions by plan participants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;200,424&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;138,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Benefits paid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;229,902&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(204,695)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Foreign currency exchange rates changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;155,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(14,687)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Ending fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,911,056&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,039,763&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Amounts recorded on the consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,911,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,039,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Present value of projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(2,494,481)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(1,321,969)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(583,425)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(282,206)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded in accumulated other comprehensive (income) / loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Actuarial (gain) / loss - beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(101,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;168,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Actuarial (gain) / loss of current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;444,329&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(268,076)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(1,817)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Prior service (cost) / credit recognized in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(107,750)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;234,863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(101,716)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to calculate the ASC 715 liabilities are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.657%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Inflation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Long-term expected rate of salary increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service cost of $122,698 was recognized in the net periodic benefit cost for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of plan assets is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;32.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Mortgages&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;26.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;27.17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Alternative investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.40%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Infrastructure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;0.16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of plan assets is determined based on Level 2 inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As all members of the Plan are active, no future expected benefit payments are currently in payment and foreseen to occur within the next ten years.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock contextRef="c-1" id="f-581">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the changes in projected benefit obligations (&#x201c;PBO&#x201d;) and plan assets is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Beginning PBO &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,321,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,322,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;122,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;451,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;30,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Contributions by plan participants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;200,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;138,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Actuarial (gain) / losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;487,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(374,317)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;229,902&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(204,695)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Foreign currency exchange rates changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;208,608&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(16,267)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Plan amendment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(107,750)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Ending PBO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,494,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,321,969&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Beginning fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,039,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,083,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Return on plan assets above expected return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;48,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(115,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Contributions by the employer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;200,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;138,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Contributions by plan participants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;200,424&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;138,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Benefits paid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;229,902&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(204,695)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Foreign currency exchange rates changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;155,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(14,687)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Ending fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,911,056&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,039,763&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-13" decimals="0" id="f-582" unitRef="usd">1321969</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-39" decimals="0" id="f-583" unitRef="usd">1322874</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-1" decimals="0" id="f-584" unitRef="usd">122698</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-18" decimals="0" id="f-585" unitRef="usd">451075</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-1" decimals="0" id="f-586" unitRef="usd">30639</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-18" decimals="0" id="f-587" unitRef="usd">5056</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-1" decimals="0" id="f-588" unitRef="usd">200424</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-18" decimals="0" id="f-589" unitRef="usd">138243</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-1" decimals="0" id="f-590" unitRef="usd">-487991</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-18" decimals="0" id="f-591" unitRef="usd">374317</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <mnlk:DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments contextRef="c-1" decimals="0" id="f-592" unitRef="usd">229902</mnlk:DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments>
    <mnlk:DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments contextRef="c-18" decimals="0" id="f-593" unitRef="usd">-204695</mnlk:DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-1" decimals="0" id="f-594" unitRef="usd">-208608</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-18" decimals="0" id="f-595" unitRef="usd">16267</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanPlanAmendments contextRef="c-1" decimals="0" id="f-596" unitRef="usd">-107750</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments contextRef="c-18" decimals="0" id="f-597" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-12" decimals="0" id="f-598" unitRef="usd">2494481</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-13" decimals="0" id="f-599" unitRef="usd">1321969</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-13" decimals="0" id="f-600" unitRef="usd">1039763</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-39" decimals="0" id="f-601" unitRef="usd">1083014</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-1" decimals="0" id="f-602" unitRef="usd">36523</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-18" decimals="0" id="f-603" unitRef="usd">15522</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <mnlk:DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns contextRef="c-1" decimals="0" id="f-604" unitRef="usd">48938</mnlk:DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns>
    <mnlk:DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns contextRef="c-18" decimals="0" id="f-605" unitRef="usd">-115877</mnlk:DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-1" decimals="0" id="f-606" unitRef="usd">200424</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-18" decimals="0" id="f-607" unitRef="usd">138243</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-1" decimals="0" id="f-608" unitRef="usd">200424</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-18" decimals="0" id="f-609" unitRef="usd">138243</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <mnlk:DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments contextRef="c-1" decimals="0" id="f-610" unitRef="usd">229902</mnlk:DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments>
    <mnlk:DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments contextRef="c-18" decimals="0" id="f-611" unitRef="usd">-204695</mnlk:DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="0" id="f-612" unitRef="usd">155082</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-18" decimals="0" id="f-613" unitRef="usd">-14687</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-12" decimals="0" id="f-614" unitRef="usd">1911056</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-13" decimals="0" id="f-615" unitRef="usd">1039763</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock contextRef="c-1" id="f-616">Amounts recorded on the consolidated balance sheets:&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,911,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,039,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Present value of projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(2,494,481)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(1,321,969)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(583,425)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(282,206)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-12" decimals="0" id="f-617" unitRef="usd">1911056</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-13" decimals="0" id="f-618" unitRef="usd">1039763</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent contextRef="c-12" decimals="0" id="f-619" unitRef="usd">2494481</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent contextRef="c-13" decimals="0" id="f-620" unitRef="usd">1321969</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-12" decimals="0" id="f-621" unitRef="usd">-583425</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-13" decimals="0" id="f-622" unitRef="usd">-282206</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-623">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded in accumulated other comprehensive (income) / loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Actuarial (gain) / loss - beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(101,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;168,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Actuarial (gain) / loss of current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;444,329&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(268,076)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(1,817)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Prior service (cost) / credit recognized in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(107,750)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;234,863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(101,716)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-13" decimals="0" id="f-624" unitRef="usd">101716</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-39" decimals="0" id="f-625" unitRef="usd">-168177</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-1" decimals="0" id="f-626" unitRef="usd">-444329</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-18" decimals="0" id="f-627" unitRef="usd">268076</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax contextRef="c-1" decimals="0" id="f-628" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax contextRef="c-18" decimals="0" id="f-629" unitRef="usd">-1817</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c-1" decimals="0" id="f-630" unitRef="usd">-107750</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c-18" decimals="0" id="f-631" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-12" decimals="0" id="f-632" unitRef="usd">-234863</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-13" decimals="0" id="f-633" unitRef="usd">101716</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="c-1" id="f-634">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to calculate the ASC 715 liabilities are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.657%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Inflation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Long-term expected rate of salary increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;p.a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate contextRef="c-12" decimals="4" id="f-635" unitRef="number">0.0135</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate contextRef="c-13" decimals="4" id="f-636" unitRef="number">0.0220</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets contextRef="c-12" decimals="4" id="f-637" unitRef="number">0.0300</mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets>
    <mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets contextRef="c-13" decimals="4" id="f-638" unitRef="number">0.0380</mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets>
    <mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation contextRef="c-12" decimals="4" id="f-639" unitRef="number">0.0180</mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation>
    <mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation contextRef="c-13" decimals="4" id="f-640" unitRef="number">0.0180</mnlk:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease contextRef="c-12" decimals="4" id="f-641" unitRef="number">0.0230</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease contextRef="c-13" decimals="4" id="f-642" unitRef="number">0.0230</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-1" decimals="0" id="f-643" unitRef="usd">122698</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanPlanAssetsAllocationTableTextBlock contextRef="c-1" id="f-644">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of plan assets is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;32.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Mortgages&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;26.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;27.17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Alternative investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.40%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Infrastructure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;0.16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DefinedBenefitPlanPlanAssetsAllocationTableTextBlock>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-127" decimals="4" id="f-645" unitRef="number">0.3400</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-128" decimals="4" id="f-646" unitRef="number">0.3411</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-129" decimals="4" id="f-647" unitRef="number">0.3200</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-130" decimals="4" id="f-648" unitRef="number">0.2889</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-131" decimals="4" id="f-649" unitRef="number">0.0400</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-132" decimals="4" id="f-650" unitRef="number">0.0386</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-133" decimals="4" id="f-651" unitRef="number">0.0100</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-134" decimals="4" id="f-652" unitRef="number">0.0241</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-135" decimals="4" id="f-653" unitRef="number">0.2600</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-136" decimals="4" id="f-654" unitRef="number">0.2717</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-137" decimals="4" id="f-655" unitRef="number">0.0300</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-138" decimals="4" id="f-656" unitRef="number">0.0340</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-139" decimals="4" id="f-657" unitRef="number">0</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-140" decimals="4" id="f-658" unitRef="number">0.0016</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-659">Shareholders&#x2019; Equity (Deficit)&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class A Ordinary Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class C Ordinary Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Issued and Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Balance - January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;38,977,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;100,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;13,723,511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;600,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;52,701,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;Issuance of Class A Ordinary Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;10,270,818&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;10,270,818&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;Conversion of Class C Ordinary Shares into Class A Ordinary Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;11,218,035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;(11,218,035)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Balance - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;60,466,453&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;100,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2,505,476&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;600,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;62,971,929&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18.01pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fully paid-in registered shares with a par value of $0.0001 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2023, the Company had the following classes of shares:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Class A Ordinary Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2022, the Company's Class A Ordinary Shares began trading on The Nasdaq Capital Market ("Nasdaq") under the symbol &#x201c;MLTX&#x201d;. As of December&#160;31, 2023, there were 60,466,453 Class A Ordinary Shares issued and outstanding. The Company is authorized to issue up to 500,000,000 Class A Ordinary Shares, par value $0.0001 per share. Holders of Class A Ordinary Shares are entitled to one vote for each share. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Class C Ordinary Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there were 2,505,476 Class C Ordinary Shares issued and outstanding. The Company is authorized to issue up to 100,000,000 Class C Ordinary Shares, with a par value $0.0001 per share. Each Class C Ordinary Share entitles the holders thereof to one vote per share, but carries no economic rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing of the Business Combination (the "Closing"), MoonLake, MoonLake AG and each ML Party entered into a Restated and Amended Shareholders' Agreement (the &#x201c;A&amp;amp;R Shareholders' Agreement&#x201d;). With the intent to approximate the rights, obligations and restrictions that an ML Party would enjoy if it were a holder of Class A Ordinary Shares, the A&amp;amp;R Shareholders&#x2019; Agreement (i) imposes certain transfer and other restrictions on the ML Parties, (ii) provides for the waiver of certain statutory rights and (iii) establishes certain mechanics whereby MoonLake and each of the ML Parties are able to effect the conversion of MoonLake AG Common Shares and Class C Ordinary Shares into a number of Class A Ordinary Shares equal to the Exchange Ratio. In 2022, pursuant to the A&amp;amp;R Shareholders&#x2019; Agreement, a ML Party submitted an exchange notice to the Company, pursuant to which the ML Party effected the conversion of 61,000 MoonLake AG Common Shares and 2,051,961 Class C Ordinary Shares into 2,051,961 Class A Ordinary Shares using the Exchange Ratio. In 2023, pursuant to the A&amp;amp;R Shareholders&#x2019; Agreement, certain ML Parties submitted exchange notices to the Company, pursuant to which such ML Parties effected, in the aggregate, the conversion of 333,486 MoonLake AG Common Shares and 11,218,035 Class C Ordinary Shares into 11,218,035 Class A Ordinary Shares using the Exchange Ratio. The foregoing description of the A&amp;amp;R Shareholders&#x2019; Agreement is not complete and is qualified in its entirety by reference to, and should be read in connection with, the full text of the A&amp;amp;R Shareholders&#x2019; Agreement filed as an exhibit on the Company's Current Report on Form 8-K filed with the SEC on April 11, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, the Company issued 10,270,818 Class A Ordinary Shares under the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;At-the-Market Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 11, 2023, the Company entered into a Sales Agreement (the &#x201c;May 2023 Sales Agreement&#x201d;) with Leerink Partners LLC (formerly known as SVB Securities LLC) (&#x201c;Leerink Partners&#x201d;), through which the Company could issue and sell up to $200,000,000 of its Class A Ordinary Shares (the &#x201c;May 2023 ATM Shares&#x201d;), through Leerink Partners  as its sales agent. The May 2023 ATM Shares to be sold under the May 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-271546), which was declared effective by the SEC on May 9, 2023, and a prospectus supplement thereto filed with the SEC on May 11, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 27, 2023, the Company reduced the maximum aggregate offering amount of its Class A Ordinary Shares that could be issued and sold under the May 2023 Sales Agreement to $0 and no longer intends to sell Class A Ordinary Shares under the May 2023 Sales Agreement unless the Company files a further prospectus supplement indicating an amount of shares proposed to be sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 31, 2023, the Company entered into a Sales Agreement with Leerink Partners (the &#x201c;August 2023 Sales Agreement&#x201d; and together with the May 2023 Sales Agreement, the &#x201c;Sales Agreements&#x201d;), through which the Company could issue and sell up to $350,000,000 of its Class A Ordinary Shares (the &#x201c;August 2023 ATM Shares&#x201d;), through Leerink Partners as its sales agent. The August 2023 ATM Shares to be sold under the August 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-274286), which was declared effective by the SEC on September 11, 2023, and a prospectus supplement thereto filed with the SEC on August 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company sold 544,894 Class A Ordinary Shares for gross proceeds of $15.2 million. In December 2023, the Company sold a further 525,924 Class A Ordinary Shares for gross proceeds of $31.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Public Offering of Class A Ordinary Shares &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;27, 2023, the Company entered into an underwriting agreement with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein, to issue and sell 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per share (the &#x201c;Offering&#x201d;). In addition, the Company granted the underwriters an option for a period of 30 days to purchase up to an additional 1,200,000 Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions (the &#x201c;Option&#x201d;), and such Option was exercised in full by the underwriters.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Offering closed on June 30, 2023, and net proceeds from the Offering, including proceeds from the exercise in full by the underwriters of the Option, were $436.7 million, after deducting the underwriting discounts and commissions and the offering expenses in the amount of $23.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the completion of the Offering, the Company opted to direct a substantial portion of the net proceeds to MoonLake AG. This was executed as a two-step process: (1) the Company acquired the remaining 22,756 shares of MoonLake AG common stock held in treasury through a share purchase and assignment agreement formally executed on July 09, 2023 ($38.9 million) and (2) the Company contributed additional funds to MoonLake AG&#x2019;s capital reserves through a cash contribution agreement formally executed on July 10, 2023 ($275 million). A stamp duty tax of $2.8 million was levied on the aforementioned capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock contextRef="c-1" id="f-660">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class A Ordinary Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class C Ordinary Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Issued and Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Balance - January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;38,977,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;100,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;13,723,511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;600,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;52,701,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;Issuance of Class A Ordinary Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;10,270,818&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;10,270,818&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;Conversion of Class C Ordinary Shares into Class A Ordinary Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;11,218,035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;(11,218,035)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Balance - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;60,466,453&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;100,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2,505,476&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;600,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;62,971,929&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;Fully paid-in registered shares with a par value of $0.0001</mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-64" decimals="0" id="f-661" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-64" decimals="0" id="f-662" unitRef="shares">38977600</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-65" decimals="0" id="f-663" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-65" decimals="0" id="f-664" unitRef="shares">13723511</us-gaap:CommonStockSharesIssued>
    <mnlk:SharesAuthorized contextRef="c-13" decimals="0" id="f-665" unitRef="shares">600000000</mnlk:SharesAuthorized>
    <us-gaap:SharesIssued contextRef="c-13" decimals="0" id="f-666" unitRef="shares">52701111</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-71" decimals="0" id="f-667" unitRef="shares">10270818</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-141" decimals="0" id="f-668" unitRef="shares">10270818</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-142" decimals="0" id="f-669" unitRef="shares">11218035</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-143" decimals="0" id="f-670" unitRef="shares">-11218035</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-78" decimals="0" id="f-671" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-78" decimals="0" id="f-672" unitRef="shares">60466453</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-79" decimals="0" id="f-673" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-79" decimals="0" id="f-674" unitRef="shares">2505476</us-gaap:CommonStockSharesIssued>
    <mnlk:SharesAuthorized contextRef="c-12" decimals="0" id="f-675" unitRef="shares">600000000</mnlk:SharesAuthorized>
    <us-gaap:SharesIssued contextRef="c-12" decimals="0" id="f-676" unitRef="shares">62971929</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-78"
      decimals="4"
      id="f-677"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-79"
      decimals="4"
      id="f-678"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-78" decimals="0" id="f-679" unitRef="shares">60466453</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-78" decimals="0" id="f-680" unitRef="shares">60466453</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-78" decimals="0" id="f-681" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-78"
      decimals="4"
      id="f-682"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <mnlk:CommonStockVotesAttachedToShares contextRef="c-78" decimals="0" id="f-683" unitRef="vote">1</mnlk:CommonStockVotesAttachedToShares>
    <us-gaap:CommonStockSharesIssued contextRef="c-79" decimals="0" id="f-684" unitRef="shares">2505476</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-79" decimals="0" id="f-685" unitRef="shares">2505476</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-79" decimals="0" id="f-686" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-79"
      decimals="4"
      id="f-687"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <mnlk:CommonStockVotesAttachedToShares contextRef="c-79" decimals="0" id="f-688" unitRef="vote">1</mnlk:CommonStockVotesAttachedToShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-41" decimals="0" id="f-689" unitRef="shares">61000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-144" decimals="0" id="f-690" unitRef="shares">2051961</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-56" decimals="0" id="f-691" unitRef="shares">2051961</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-141" decimals="0" id="f-692" unitRef="shares">333486</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-76" decimals="0" id="f-693" unitRef="shares">-11218035</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-71" decimals="0" id="f-694" unitRef="shares">11218035</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-19" decimals="0" id="f-695" unitRef="shares">10270818</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <mnlk:SaleOfStockAuthorizedAmount contextRef="c-145" decimals="INF" id="f-696" unitRef="usd">200000000</mnlk:SaleOfStockAuthorizedAmount>
    <mnlk:SaleOfStockRemainingAuthorizedRepurchaseAmount contextRef="c-146" decimals="INF" id="f-697" unitRef="usd">0</mnlk:SaleOfStockRemainingAuthorizedRepurchaseAmount>
    <mnlk:SaleOfStockAuthorizedAmount contextRef="c-147" decimals="INF" id="f-698" unitRef="usd">350000000</mnlk:SaleOfStockAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-148"
      decimals="INF"
      id="f-699"
      unitRef="shares">544894</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-148" decimals="-5" id="f-700" unitRef="usd">15200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-149"
      decimals="INF"
      id="f-701"
      unitRef="shares">525924</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-149" decimals="-5" id="f-702" unitRef="usd">31700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-150"
      decimals="INF"
      id="f-703"
      unitRef="shares">8000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-151"
      decimals="0"
      id="f-704"
      unitRef="usdPerShare">50.00</us-gaap:SaleOfStockPricePerShare>
    <mnlk:SaleOfStockOptionToPurchaseTerm contextRef="c-152" id="f-705">P30D</mnlk:SaleOfStockOptionToPurchaseTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-152"
      decimals="INF"
      id="f-706"
      unitRef="shares">1200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-153" decimals="-5" id="f-707" unitRef="usd">436700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-153" decimals="-5" id="f-708" unitRef="usd">23300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-154"
      decimals="INF"
      id="f-709"
      unitRef="shares">22756</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-155" decimals="-5" id="f-710" unitRef="usd">38900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromContributionsFromParent contextRef="c-155" decimals="-6" id="f-711" unitRef="usd">275000000</us-gaap:ProceedsFromContributionsFromParent>
    <mnlk:SaleOfStockStampDutyTax contextRef="c-156" decimals="-5" id="f-712" unitRef="usd">-2800000</mnlk:SaleOfStockStampDutyTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-714">Net Loss per Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Business Combination, the Company has retroactively restated the weighted average number of outstanding prior to April 5, 2022 to give effect to the Exchange Ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the loss per share calculations for the year ended December&#160;31, 2023 compared to the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.08pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Net loss attributable to controlling interests shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(36,007,260)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(49,973,249)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Total weighted average number of outstanding shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;49,122,534&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;29,361,353&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Net loss per share &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(0.73)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(1.70)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average number of shares used to calculate the net loss per share &#x2013; basic for the year ended December&#160;31, 2023 excludes 2,505,476 Class C Ordinary Shares as they do not carry economic rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event that ML Parties (other than Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.) elected to convert their 74,482 MoonLake AG Common Shares into 2,505,476 Class A Ordinary Shares, the weighted average number of shares outstanding would have been 57,679,106 for the year ended December&#160;31, 2023, resulting in a net loss per share of $0.76. Upon conversion, 2,505,476 Class C Ordinary Shares would be forfeited and there would no longer be any non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, the Company's number of Class A Ordinary Shares outstanding would be 63,886,757 as of February&#160;29, 2024, the date the consolidated financial statements were issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-713">Net Loss per Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Business Combination, the Company has retroactively restated the weighted average number of outstanding prior to April 5, 2022 to give effect to the Exchange Ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the loss per share calculations for the year ended December&#160;31, 2023 compared to the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.08pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Net loss attributable to controlling interests shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(36,007,260)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(49,973,249)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Total weighted average number of outstanding shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;49,122,534&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;29,361,353&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Net loss per share &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(0.73)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(1.70)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average number of shares used to calculate the net loss per share &#x2013; basic for the year ended December&#160;31, 2023 excludes 2,505,476 Class C Ordinary Shares as they do not carry economic rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event that ML Parties (other than Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.) elected to convert their 74,482 MoonLake AG Common Shares into 2,505,476 Class A Ordinary Shares, the weighted average number of shares outstanding would have been 57,679,106 for the year ended December&#160;31, 2023, resulting in a net loss per share of $0.76. Upon conversion, 2,505,476 Class C Ordinary Shares would be forfeited and there would no longer be any non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, the Company's number of Class A Ordinary Shares outstanding would be 63,886,757 as of February&#160;29, 2024, the date the consolidated financial statements were issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-716">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the loss per share calculations for the year ended December&#160;31, 2023 compared to the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.08pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Net loss attributable to controlling interests shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(36,007,260)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(49,973,249)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Total weighted average number of outstanding shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;49,122,534&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;29,361,353&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Net loss per share &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(0.73)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(1.70)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-715">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the loss per share calculations for the year ended December&#160;31, 2023 compared to the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.273%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.08pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Net loss attributable to controlling interests shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(36,007,260)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(49,973,249)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Total weighted average number of outstanding shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;49,122,534&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;29,361,353&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Net loss per share &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(0.73)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;(1.70)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-717" unitRef="usd">-36007260</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="0" id="f-718" unitRef="usd">-49973249</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-719" unitRef="shares">49122534</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-720" unitRef="shares">49122534</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-721" unitRef="shares">49122534</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-722" unitRef="shares">49122534</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-18" decimals="0" id="f-723" unitRef="shares">29361353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-18" decimals="0" id="f-724" unitRef="shares">29361353</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-18" decimals="0" id="f-725" unitRef="shares">29361353</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-18" decimals="0" id="f-726" unitRef="shares">29361353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-728"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-729"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-730"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-18"
      decimals="2"
      id="f-731"
      unitRef="usdPerShare">-1.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-18"
      decimals="2"
      id="f-732"
      unitRef="usdPerShare">-1.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-18"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">-1.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-18"
      decimals="2"
      id="f-734"
      unitRef="usdPerShare">-1.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-79" decimals="0" id="f-735" unitRef="shares">2505476</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-79" decimals="0" id="f-736" unitRef="shares">2505476</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c-157" decimals="0" id="f-737" unitRef="shares">74482</us-gaap:CommonStockOtherSharesOutstanding>
    <mnlk:StockConvertedReverseRecapitalization contextRef="c-158" decimals="0" id="f-738" unitRef="shares">2505476</mnlk:StockConvertedReverseRecapitalization>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-159" decimals="0" id="f-739" unitRef="shares">57679106</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-159" decimals="0" id="f-740" unitRef="shares">57679106</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-159"
      decimals="2"
      id="f-741"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-159"
      decimals="2"
      id="f-742"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareDiluted>
    <mnlk:StockForfeitedReverseRecapitalization
      contextRef="c-160"
      decimals="INF"
      id="f-743"
      unitRef="shares">2505476</mnlk:StockForfeitedReverseRecapitalization>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-161" decimals="0" id="f-744" unitRef="shares">63886757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-745">Share-based Compensation &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 the Company had the following share-based compensation arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Restricted Founder Shares (as defined below) &#x2013; created in April 2021 by MoonLake AG (no longer active and fully vested as of April 2023);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The Employee Share Participation Plan (&#x201c;ESPP&#x201d;) &#x2013; created in July 2021 by MoonLake AG;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The Employee Stock Option Plan (&#x201c;ESOP&#x201d;) &#x2013; created in July 2021 by MoonLake AG;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;MoonLake Immunotherapeutics 2022 Equity Incentive Plan &#x2013; created in April 2022 by MoonLake Immunotherapeutics. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purpose of the arrangements is to attract and retain the best available personnel and to provide participants with additional incentive to increase their efforts on behalf and in the best interest of the Company and its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MoonLake AG's compensation plans are settled with Common Shares, and with a number of Class C Ordinary Shares determined by multiplying the number of Common Shares by the Exchange Ratio. The reference to &#x201c;Common Shares&#x201d; in this Note 14 refers to common shares in MoonLake AG. As a result of the Business Combination, the Company has adjusted the share numbers related to the Restricted Founder Shares and Common Shares (under the ESPP and ESOP) prior to the Business Combination by the Exchange Ratio. The owners of Common Shares have the right to exchange their Common Shares for a number of Class A Ordinary Shares derived using the Exchange Ratio. In the event MoonLake AG shareholders elect to exchange their Common Shares, such MoonLake AG shareholder forfeits a number of Class C Ordinary Shares equal to the number of Class A Ordinary Shares issued (refer to Note&#160;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; Shareholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Class C Ordinary Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, the Company has recognized an increase in equity in the consolidated balance sheet, and share-based compensation expense in the consolidated statement of operations of $7.1 million. The share-based compensation expense was driven by the following share-based compensation plans and programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Compensation Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;MoonLake AG Restricted Founder Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;1,574,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;4,840,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;3,352,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;3,910,076&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;ESOP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;973,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;539,713&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;MoonLake Immunotherapeutics 2022 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;1,204,952&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;364,381&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;7,106,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;9,654,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which: included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;1,524,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;954,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which: included in general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;5,581,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;8,700,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, 11,079 Common Shares (the equivalent of 372,683 Class C Ordinary Shares) issuable from the authorized conditional capital shares remain available for future grants under the ESPP and the ESOP by MoonLake AG.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MoonLake AG - Restricted Founder Shares  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 28, 2021, the shareholders&#x2019; agreement between the co-founders, the Series A investors and MoonLake AG imposed a reverse vesting condition on 90% of the total 110,000 Common Shares (the equivalent of 3,700,257 Class C Ordinary Shares) held by each of the three co-founders. Therefore, 99,000 Common Shares (the equivalent of 3,330,231  Class C Ordinary Shares) held by each of the co-founders were subject to these restrictions and considered unvested (the &#x201c;Restricted Founder Shares&#x201d;). The Restricted Founder Shares vested on the 28th of each month at a rate of 4.166% over a period of two years until April 28, 2023. In the event of a termination of the contractual relationship of the relevant co-founder before the end of the vesting period, MoonLake AG in first priority, or any third party designated by it, and the other shareholders in second priority pro rata to their shareholdings, had an option to purchase all or a pro rata portion of the leaver shares that remained unvested on the effective day of the termination at nominal value of CHF 0.10 (equivalent of $0.0001) per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the valuation of the Restricted Founder Shares awarded are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4/28/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"&gt;Estimated fair value of Restricted Founder Shares on the grant date (USD)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"&gt;Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders (USD) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;336.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Purchase price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%"&gt;MoonLake AG estimated the fair value of the Restricted Founder Shares with reference to the market-based transaction with the other Series A Preferred Shares Investors (refer to Note 9 of MoonLake AG's audited consolidated financial statements for the year ended December 31, 2021, as filed by Helix Acquisition Corp. together with its revised definitive proxy soliciting materials with the SEC on March 4, 2022).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%"&gt;MoonLake AG estimated the fair value of the Restricted Founder Shares at co-founder&#x2019;s resignation date by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company&#x2019;s fully diluted shares (1,070,196).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Restricted Founder Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards unvested as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;4,440,309&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards vested for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(3,330,231)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards unvested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,110,078&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards vested for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(1,110,078)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards unvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Share Participation Plan (ESPP) 2021-2025 - MoonLake AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP grants will vest 25% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, the awards can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#x201c;Change of Control&#x201d;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;ESPP 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Assumptions for the awards issued during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;01/18/2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:2.75pt;padding-right:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"&gt;Estimated fair value per share of Common Shares on the grant date ($)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;336.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Purchase price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%"&gt;MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value (USD 360,000,000) as defined by the Business Combination Agreement by the Company&#x2019;s fully diluted shares (1,070,196). &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,060,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Additional awards granted for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,177,354&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of January 1. 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,237,915&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Of which vested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;307,794&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,237,915&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Of which vested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,607,425&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, MoonLake AG had $6.2 million of total unrecognized compensation expense related to the ESPP that will be recognized over the weighted average period of 2.05 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Option Plan (ESOP) 2021-2025 - MoonLake AG&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESOP grants will vest 25% on each anniversary of the grant date. In the event of a termination of the contractual relationship between the Company and the entitled employee, options can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#x201c;Change of Control&#x201d;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;ESOP 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Weighted average assumptions for the awards issued during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Grant dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;5/1/2022, 6/22/2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Estimated fair value of the option on the grant date using Black-Scholes model ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;4.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Exercise price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;3.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected term of the award on the grant date (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected volatility of the share price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;The expected term represents the period that share-based awards are expected to be outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#x2019;s industry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Weighted average assumptions for the awards issued during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Grant dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;01/01/2023, 04/24/2023, 07/03/2023, 07/17/2023, 08/01/2023, 08/07/2023, 08/21/2023, 08/29/2023, 09/01/2023, 09/11/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Estimated fair value of the option on the grant date using Black-Scholes model ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;25.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Exercise price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;37.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected term of the award on the grant date (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected volatility of the share price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"&gt;The expected term represents the period that share-based awards are expected to be outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"&gt;The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#x2019;s industry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"&gt;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.183%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.360%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;ESOP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;224,033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Additional awards granted for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;242,736&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;466,769&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;133,446&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards forfeited for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;585,078&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Of which exercisable as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;219,223&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2023, MoonLake AG had $4.2 million of total unrecognized compensation expense related to the ESOP that will be recognized over the weighted average period of 2.45 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MoonLake Immunotherapeutics 2022 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2022 (the &#x201c;Effective Date&#x201d;) the Company created the &#x201c;MoonLake Immunotherapeutics 2022 Equity Incentive Plan&#x201d; (the &#x201c;Equity Incentive Plan&#x201d;) to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Awards made under the Equity Incentive Plan to a person who is initially elected or appointed to the Board, and who is a non-employee director at the time of such initial election or appointment, vests and becomes exercisable in 3 equal yearly installments occurring over the three year period following the date of grant, subject to the non-employee director continuing in service on the Board through each such vesting date. Each subsequent award vests and becomes exercisable on the earlier of (i) the 12-month anniversary of the date of grant, and (ii) the next annual meeting of the Company&#x2019;s stockholders following the date of grant, subject to the non-employee director continuing in service on the Board through such vesting date. Awards made to employees, officers and other service providers of the Company under the Equity Incentive Plan vest 25% on each anniversary date. In the event of a termination of the contractual relationship between the Company and the beneficiary, options can be deemed forfeited by the Company if certain conditions are met. Awards feature an accelerated vesting condition linked to a &#x201c;Change of Control&#x201d;, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:106%"&gt;Weighted average assumptions for the awards issued during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;4/6/2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Estimated fair value of the option on the grant date using Black-Scholes model ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;8.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;12.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected term of the award on the grant date (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected volatility of the share price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt;The expected term represents the period that share-based awards are expected to be outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt;The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt; The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Weighted average assumptions for the awards issued during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Grant dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;06/08/2023, 10/11/2023, 10/25/2023, 11/01/2023, 11/06/2023, 11/15/2023, 11/16/2023, 11/20/2023, 11/27/2023, 12/01/2023, 12/04/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Estimated fair value of the option on the grant date using Black-Scholes model ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;25.58&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Exercise price ($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;37.22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected term of the award on the grant date (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected volatility of the share price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt;The expected term represents the period that share-based awards are expected to be outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt;The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt; The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;MoonLake Immunotherapeutics 2022 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;132,400&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;312,400&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards exercisable as of December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of December&#160;31, 2023, the Company had $3.3 million of total unrecognized compensation expense related to the Equity Incentive Plan that will be recognized over the weighted average period of 1.75 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-746" unitRef="usd">7100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-747">The share-based compensation expense was driven by the following share-based compensation plans and programs:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Compensation Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;MoonLake AG Restricted Founder Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;1,574,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;4,840,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;3,352,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;3,910,076&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;ESOP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;973,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;539,713&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;MoonLake Immunotherapeutics 2022 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%"&gt;1,204,952&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;364,381&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;7,106,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;9,654,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which: included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;1,524,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;954,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Of which: included in general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;5,581,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;8,700,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-162" decimals="0" id="f-748" unitRef="usd">1574300</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-163" decimals="0" id="f-749" unitRef="usd">4840608</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-164" decimals="0" id="f-750" unitRef="usd">3352885</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-165" decimals="0" id="f-751" unitRef="usd">3910076</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-166" decimals="0" id="f-752" unitRef="usd">973868</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-167" decimals="0" id="f-753" unitRef="usd">539713</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-168" decimals="0" id="f-754" unitRef="usd">1204952</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-169" decimals="0" id="f-755" unitRef="usd">364381</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="0" id="f-756" unitRef="usd">7106005</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-18" decimals="0" id="f-757" unitRef="usd">9654778</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-170" decimals="0" id="f-758" unitRef="usd">1524715</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-171" decimals="0" id="f-759" unitRef="usd">954379</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-172" decimals="0" id="f-760" unitRef="usd">5581290</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-173" decimals="0" id="f-761" unitRef="usd">8700399</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-174"
      decimals="INF"
      id="f-762"
      unitRef="shares">11079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-79"
      decimals="INF"
      id="f-763"
      unitRef="shares">372683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage contextRef="c-175" decimals="2" id="f-764" unitRef="number">0.90</mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-175"
      decimals="INF"
      id="f-765"
      unitRef="shares">110000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-176"
      decimals="INF"
      id="f-766"
      unitRef="shares">3700257</us-gaap:CommonStockSharesOutstanding>
    <mnlk:NumberOfCoFounders
      contextRef="c-12"
      decimals="INF"
      id="f-767"
      unitRef="co-founder">3</mnlk:NumberOfCoFounders>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-177"
      decimals="INF"
      id="f-768"
      unitRef="shares">99000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-178"
      decimals="INF"
      id="f-769"
      unitRef="shares">3330231</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-179" decimals="5" id="f-770" unitRef="number">0.04166</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-179" id="f-771">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mnlk:SharePriceNominalValue
      contextRef="c-177"
      decimals="2"
      id="f-772"
      unitRef="chfPerShare">0.10</mnlk:SharePriceNominalValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-180"
      decimals="4"
      id="f-773"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <mnlk:ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-774">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the valuation of the Restricted Founder Shares awarded are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4/28/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"&gt;Estimated fair value of Restricted Founder Shares on the grant date (USD)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"&gt;Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders (USD) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;336.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Purchase price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%"&gt;MoonLake AG estimated the fair value of the Restricted Founder Shares with reference to the market-based transaction with the other Series A Preferred Shares Investors (refer to Note 9 of MoonLake AG's audited consolidated financial statements for the year ended December 31, 2021, as filed by Helix Acquisition Corp. together with its revised definitive proxy soliciting materials with the SEC on March 4, 2022).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%"&gt;MoonLake AG estimated the fair value of the Restricted Founder Shares at co-founder&#x2019;s resignation date by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company&#x2019;s fully diluted shares (1,070,196).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mnlk:ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-181"
      decimals="2"
      id="f-775"
      unitRef="usdPerShare">49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue
      contextRef="c-181"
      decimals="2"
      id="f-776"
      unitRef="usdPerShare">336.39</mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFounderResignationDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="c-182"
      decimals="2"
      id="f-777"
      unitRef="chfPerShare">0.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise contextRef="c-183" decimals="0" id="f-778" unitRef="usd">360000000</mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise>
    <mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares contextRef="c-183" decimals="0" id="f-779" unitRef="shares">1070196</mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-780">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Restricted Founder Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards unvested as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;4,440,309&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards vested for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(3,330,231)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards unvested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,110,078&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards vested for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(1,110,078)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards unvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-182"
      decimals="INF"
      id="f-781"
      unitRef="shares">4440309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-163" decimals="0" id="f-782" unitRef="shares">3330231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-184" decimals="0" id="f-783" unitRef="shares">1110078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-162" decimals="0" id="f-784" unitRef="shares">1110078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-185" decimals="0" id="f-785" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-186" decimals="2" id="f-786" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-187" decimals="2" id="f-787" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-188" decimals="2" id="f-788" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-189" decimals="2" id="f-789" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="c-1" id="f-791">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;ESPP 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Assumptions for the awards issued during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;01/18/2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:2.75pt;padding-right:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"&gt;Estimated fair value per share of Common Shares on the grant date ($)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;336.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Purchase price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%"&gt;MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value (USD 360,000,000) as defined by the Business Combination Agreement by the Company&#x2019;s fully diluted shares (1,070,196). &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,060,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Additional awards granted for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,177,354&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of January 1. 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,237,915&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Of which vested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;307,794&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,237,915&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Of which vested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,607,425&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c-1" id="f-790">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;ESPP 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Assumptions for the awards issued during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;01/18/2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:2.75pt;padding-right:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"&gt;Estimated fair value per share of Common Shares on the grant date ($)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:123%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;336.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Purchase price (CHF)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:2.77pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:125%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%"&gt;MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value (USD 360,000,000) as defined by the Business Combination Agreement by the Company&#x2019;s fully diluted shares (1,070,196). &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,060,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Additional awards granted for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,177,354&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of January 1. 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,237,915&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Of which vested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;307,794&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2,237,915&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Of which vested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;1,607,425&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-165"
      decimals="2"
      id="f-792"
      unitRef="usdPerShare">336.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="c-190"
      decimals="2"
      id="f-793"
      unitRef="chfPerShare">0.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise contextRef="c-183" decimals="0" id="f-794" unitRef="usd">360000000</mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise>
    <mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares contextRef="c-183" decimals="0" id="f-795" unitRef="shares">1070196</mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-191" decimals="0" id="f-796" unitRef="shares">1060561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-165" decimals="0" id="f-797" unitRef="shares">1177354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-190" decimals="0" id="f-798" unitRef="shares">2237915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-165" decimals="0" id="f-799" unitRef="shares">307794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-164" decimals="0" id="f-800" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-192" decimals="0" id="f-801" unitRef="shares">2237915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-164" decimals="0" id="f-802" unitRef="shares">1607425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-192" decimals="-5" id="f-803" unitRef="usd">6200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-164" id="f-804">P2Y18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-193" decimals="2" id="f-805" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-194" decimals="2" id="f-806" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-195" decimals="2" id="f-807" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-196" decimals="2" id="f-808" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-809">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;ESOP 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Weighted average assumptions for the awards issued during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Grant dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;5/1/2022, 6/22/2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Estimated fair value of the option on the grant date using Black-Scholes model ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;4.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Exercise price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;3.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected term of the award on the grant date (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected volatility of the share price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;The expected term represents the period that share-based awards are expected to be outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#x2019;s industry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Weighted average assumptions for the awards issued during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Grant dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;01/01/2023, 04/24/2023, 07/03/2023, 07/17/2023, 08/01/2023, 08/07/2023, 08/21/2023, 08/29/2023, 09/01/2023, 09/11/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Estimated fair value of the option on the grant date using Black-Scholes model ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;25.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Exercise price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;37.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected term of the award on the grant date (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected volatility of the share price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"&gt;The expected term represents the period that share-based awards are expected to be outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"&gt;The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company&#x2019;s industry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"&gt;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:106%"&gt;Weighted average assumptions for the awards issued during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;4/6/2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Estimated fair value of the option on the grant date using Black-Scholes model ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;8.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;12.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected term of the award on the grant date (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected volatility of the share price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt;The expected term represents the period that share-based awards are expected to be outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt;The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt; The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Weighted average assumptions for the awards issued during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Grant dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;06/08/2023, 10/11/2023, 10/25/2023, 11/01/2023, 11/06/2023, 11/15/2023, 11/16/2023, 11/20/2023, 11/27/2023, 12/01/2023, 12/04/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Estimated fair value of the option on the grant date using Black-Scholes model ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;25.58&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Exercise price ($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;37.22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected term of the award on the grant date (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected volatility of the share price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:106%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt;The expected term represents the period that share-based awards are expected to be outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt;The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.08pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:106%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:106%"&gt; The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-197"
      decimals="2"
      id="f-810"
      unitRef="usdPerShare">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-198"
      decimals="2"
      id="f-811"
      unitRef="usdPerShare">3.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-197" id="f-812">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-197" decimals="2" id="f-813" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-197" decimals="2" id="f-814" unitRef="number">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-197" decimals="2" id="f-815" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-199"
      decimals="2"
      id="f-816"
      unitRef="usdPerShare">25.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-200"
      decimals="2"
      id="f-817"
      unitRef="usdPerShare">37.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-199" id="f-818">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-199" decimals="2" id="f-819" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-199" decimals="2" id="f-820" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-199" decimals="2" id="f-821" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-822">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.183%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.360%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;ESOP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;224,033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Additional awards granted for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;242,736&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;466,769&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;133,446&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards forfeited for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;585,078&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Of which exercisable as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;219,223&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Grants awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;MoonLake Immunotherapeutics 2022 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;180,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Awards granted for the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;132,400&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards issued as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;312,400&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Awards exercisable as of December 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-201" decimals="0" id="f-823" unitRef="shares">224033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-197" decimals="0" id="f-824" unitRef="shares">242736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-198" decimals="0" id="f-825" unitRef="shares">466769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-199" decimals="0" id="f-826" unitRef="shares">133446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-199" decimals="0" id="f-827" unitRef="shares">15137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-200" decimals="0" id="f-828" unitRef="shares">585078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-200" decimals="0" id="f-829" unitRef="shares">219223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-202" decimals="-5" id="f-830" unitRef="usd">4200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-203" id="f-831">P2Y5M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-204" id="f-832">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments
      contextRef="c-205"
      decimals="INF"
      id="f-833"
      unitRef="installment">3</mnlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-205" id="f-834">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-206" id="f-835">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-207" decimals="2" id="f-836" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-208" decimals="2" id="f-837" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-209" decimals="2" id="f-838" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-210" decimals="2" id="f-839" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-840"
      unitRef="usdPerShare">8.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-211"
      decimals="2"
      id="f-841"
      unitRef="usdPerShare">12.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-169" id="f-842">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-169" decimals="2" id="f-843" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-169" decimals="2" id="f-844" unitRef="number">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-169" decimals="2" id="f-845" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-168"
      decimals="2"
      id="f-846"
      unitRef="usdPerShare">25.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-212"
      decimals="2"
      id="f-847"
      unitRef="usdPerShare">37.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-168" id="f-848">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-168" decimals="2" id="f-849" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-168" decimals="3" id="f-850" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-168" decimals="2" id="f-851" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-213" decimals="0" id="f-852" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-169" decimals="0" id="f-853" unitRef="shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-211" decimals="0" id="f-854" unitRef="shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-211" decimals="0" id="f-855" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-168" decimals="0" id="f-856" unitRef="shares">132400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-212" decimals="0" id="f-857" unitRef="shares">312400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-212" decimals="0" id="f-858" unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-212" decimals="-5" id="f-859" unitRef="usd">3300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-168" id="f-860">P1Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-861">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's effective tax rate (&#x201c;ETR&#x201d;) was -0.3% and 0.1% for the year ended December&#160;31, 2023, and for the year ended December 31, 2022, respectively. The Company is not aware of any items that would cause the quarterly or period-to-date ETR to be significantly different from the Company's annual ETR. The difference between the income tax provision that would be derived by applying the statutory rate to the Company's loss before income taxes and the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;income tax provision recorded was primarily attributable to non-deductible expense which includes the Swiss entity's recognition of taxable income associated with the sale of treasury shares from MoonLake AG to MoonLake Immunotherapeutics.. The Company continues to incur losses for the Cayman Island and Swiss entity and its ability to utilize the deferred tax asset related to the tax losses is not considered more likely than not.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's main operating affiliate, MoonLake AG, is subject to taxation in the Canton of Zug, Switzerland. For the years ended December&#160;31, 2023 and 2022, the Company did not incur any significant income tax expense or benefit, as the Company incurred tax losses and provided a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income or loss before income tax were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(43,469,946)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(62,115,251)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(514,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(2,354,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;(43,984,729)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;(64,469,685)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes differs from the amount computed by applying the statutory income tax rate to loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;11.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;11.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Effect of income taxed at different rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Change in prior year estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Utilization of unrecognized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Non-deductible expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;(0.3)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets (liabilities) were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4,493,559&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4,492,435&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Defined benefit plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;69,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;33,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;56,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Net operating loss carry forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;6,715,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;7,210,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;11,334,793&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;11,736,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(55,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;(55,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total deferred tax assets (net)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;11,278,931&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;11,736,269&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(11,278,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(11,736,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total deferred tax (net)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt;text-indent:1.44pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company&#x2019;s net deferred tax assets before valuation allowance were $11.3 million. In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of its deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on the weight of all evidence, the Company has determined that it is not more likely than not that the net deferred tax assets will be realized. A valuation allowance of $11.3 million has been recorded against the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, MoonLake AG had net operating losses of approximately $56.6 million of which $12.6 million will expire in 2028 and $44.0 million will expire in 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net operating losses will not be subject to any limitation due to change in ownership according to Swiss Income Tax Law.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no unrecognized tax benefits and does not expect that uncertain tax benefits will change significantly in the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-862" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-18" decimals="3" id="f-863" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-864">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income or loss before income tax were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(43,469,946)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(62,115,251)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(514,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(2,354,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;(43,984,729)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;(64,469,685)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="0" id="f-865" unitRef="usd">-43469946</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-18" decimals="0" id="f-866" unitRef="usd">-62115251</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="0" id="f-867" unitRef="usd">-514783</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-18" decimals="0" id="f-868" unitRef="usd">-2354434</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="0" id="f-869" unitRef="usd">-43984729</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-18" decimals="0" id="f-870" unitRef="usd">-64469685</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-871">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes differs from the amount computed by applying the statutory income tax rate to loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;11.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;11.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Effect of income taxed at different rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Change in prior year estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Utilization of unrecognized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Non-deductible expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;(0.3)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-872" unitRef="number">0.118</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-18" decimals="3" id="f-873" unitRef="number">0.119</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="3" id="f-874" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-18" decimals="3" id="f-875" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c-1" decimals="3" id="f-876" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c-18" decimals="3" id="f-877" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <mnlk:EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent contextRef="c-1" decimals="3" id="f-878" unitRef="number">0.006</mnlk:EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent>
    <mnlk:EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent contextRef="c-18" decimals="3" id="f-879" unitRef="number">0</mnlk:EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-880" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-18" decimals="3" id="f-881" unitRef="number">-0.100</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-882" unitRef="number">-0.123</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-18" decimals="3" id="f-883" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="c-1" decimals="3" id="f-884" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="c-18" decimals="3" id="f-885" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-886" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-18" decimals="3" id="f-887" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-888">&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets (liabilities) were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4,493,559&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;4,492,435&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Defined benefit plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;69,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;33,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;56,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Net operating loss carry forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;6,715,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;7,210,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;11,334,793&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;11,736,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(55,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;(55,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total deferred tax assets (net)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;11,278,931&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;11,736,269&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(11,278,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;(11,736,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:1.44pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Total deferred tax (net)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt;text-indent:1.44pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-12" decimals="0" id="f-889" unitRef="usd">4493559</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-13" decimals="0" id="f-890" unitRef="usd">4492435</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits contextRef="c-12" decimals="0" id="f-891" unitRef="usd">69173</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits contextRef="c-13" decimals="0" id="f-892" unitRef="usd">33451</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits>
    <mnlk:DeferredTaxAssetsLeaseLiabililties contextRef="c-12" decimals="0" id="f-893" unitRef="usd">56527</mnlk:DeferredTaxAssetsLeaseLiabililties>
    <mnlk:DeferredTaxAssetsLeaseLiabililties contextRef="c-13" decimals="0" id="f-894" unitRef="usd">0</mnlk:DeferredTaxAssetsLeaseLiabililties>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-12" decimals="0" id="f-895" unitRef="usd">6715534</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-13" decimals="0" id="f-896" unitRef="usd">7210383</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-12" decimals="0" id="f-897" unitRef="usd">11334793</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-13" decimals="0" id="f-898" unitRef="usd">11736269</us-gaap:DeferredTaxAssetsGross>
    <mnlk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets contextRef="c-12" decimals="0" id="f-899" unitRef="usd">55862</mnlk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <mnlk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets contextRef="c-13" decimals="0" id="f-900" unitRef="usd">0</mnlk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-12" decimals="0" id="f-901" unitRef="usd">55862</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-13" decimals="0" id="f-902" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <mnlk:DeferredTaxAssetsNetIncludingValuationAllowance contextRef="c-12" decimals="0" id="f-903" unitRef="usd">11278931</mnlk:DeferredTaxAssetsNetIncludingValuationAllowance>
    <mnlk:DeferredTaxAssetsNetIncludingValuationAllowance contextRef="c-13" decimals="0" id="f-904" unitRef="usd">11736269</mnlk:DeferredTaxAssetsNetIncludingValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="0" id="f-905" unitRef="usd">11278931</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="0" id="f-906" unitRef="usd">11736269</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-12" decimals="0" id="f-907" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-13" decimals="0" id="f-908" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-12" decimals="-5" id="f-909" unitRef="usd">11300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-5" id="f-910" unitRef="usd">11300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-12" decimals="0" id="f-911" unitRef="usd">56600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-214" decimals="0" id="f-912" unitRef="usd">12600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-215" decimals="0" id="f-913" unitRef="usd">44000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-914">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into agreements as of December&#160;31, 2023 primarily in regards to the clinical and non-clinical development services with contract research organizations ("CROs"), as well as supply and logistics services with contract manufacturing organizations ("CMOs"), for the advancement of SLK. As of December&#160;31, 2023, the total committed expense under these agreements amounted to $44.2 million, of which $8.4&#160;million are recognized under Prepaid expenses - non-current and the rest remain unrecognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's In-License Agreement with MHKDG includes contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company is obligated to make research and development and regulatory milestone payments upon the occurrence of certain events. Subject to the terms of the license, additional milestone payments of up to &#x20ac;299.6 million ($331.3 million using a December&#160;31, 2023 exchange rate) are potentially payable upon satisfying specific milestones related to regulatory filing acceptance, first commercial sales, and aggregate annual net sales. The milestone payments are payable in cash. Milestone payments due prior to obtaining regulatory approval will be recorded as research and development expense upon determination that a milestone payment is probable to occur. Milestone payments due after obtaining regulatory approval will be capitalized when and if incurred. The Company will use commercially reasonable efforts to cause the milestones to occur. However, if the Company reasonably determines that a technical failure or commercial failure has occurred with respect to all or a part of the SLK Program, the Company, at its sole discretion, can terminate all or part of the SLK Program. As of December&#160;31, 2023, the Company made a total of &#x20ac;7.5 million ($8.1 million using the then applicable exchange rate) in additional milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, on May 12, 2023, MoonLake AG entered into an agreement with Research Cooperation Technologies, Inc. (&#x201c;RCT&#x201d;) and MHKDG, effective as of June 1, 2023, pursuant to which the Company was granted a royalty-bearing, nonexclusive, sublicensable right and license under RCT&#x2019;s patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces the Company&#x2019;s sublicense for similar rights under the In-License Agreement. In the aggregate, the Company is required to pay royalties within the range of low to mid-teen percent of net sales under the aforementioned agreements with MHKDG and RCT. Royalties will be recognized in the consolidated statement of operations when net sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Office Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 12, 2023, the Company committed to an open-ended lease agreement with an effective start date of January 15, 2024, for additional office space at its corporate headquarters at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the effective duration of the Office Lease at inception and determined a 3-year term, commencing at the effective start date of January 15, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mnlk:UnrecognizedCommitmentsAndContingencies contextRef="c-12" decimals="-5" id="f-915" unitRef="usd">44200000</mnlk:UnrecognizedCommitmentsAndContingencies>
    <mnlk:UnrecognizedCommitmentsAndContingencies contextRef="c-216" decimals="-5" id="f-916" unitRef="usd">8400000</mnlk:UnrecognizedCommitmentsAndContingencies>
    <mnlk:RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount contextRef="c-217" decimals="-5" id="f-917" unitRef="eur">299600000</mnlk:RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount>
    <mnlk:RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount contextRef="c-217" decimals="-5" id="f-918" unitRef="usd">331300000</mnlk:RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount>
    <mnlk:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-217" decimals="-5" id="f-919" unitRef="eur">7500000</mnlk:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <mnlk:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-217" decimals="-5" id="f-920" unitRef="usd">8100000</mnlk:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-218" id="f-921">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-922">Segment Information and Geographic Data&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, net of consisting of property and equipment, and operating lease right-of-use assets by geographical area as of December&#160;31, 2023  are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;507,392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;331,969&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,704,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Portugal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;737,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;3,949,345&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;331,969&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c-1" id="f-923">&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, net of consisting of property and equipment, and operating lease right-of-use assets by geographical area as of December&#160;31, 2023  are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;507,392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;331,969&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,704,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Portugal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;737,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:0.25pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;3,949,345&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 2.5pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;331,969&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c-219" decimals="0" id="f-924" unitRef="usd">507392</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-220" decimals="0" id="f-925" unitRef="usd">331969</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-221" decimals="0" id="f-926" unitRef="usd">2704555</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-222" decimals="0" id="f-927" unitRef="usd">0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-223" decimals="0" id="f-928" unitRef="usd">737398</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-224" decimals="0" id="f-929" unitRef="usd">0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-12" decimals="0" id="f-930" unitRef="usd">3949345</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-13" decimals="0" id="f-931" unitRef="usd">331969</us-gaap:NoncurrentAssets>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-932">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Partial Share Conversion&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2024, pursuant to the A&amp;amp;R Shareholders&#x2019; Agreement, a ML Party submitted an exchange notice to the Company, pursuant to which such ML Party effected the conversion of 44,394 MoonLake AG Common Shares and 1,493,356 Class C Ordinary Shares into 1,493,356 Class A Ordinary Shares using the Exchange Ratio. Please refer to Note 12 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholders&#x2019; Equity (Deficit) &#x2014; Class C Ordinary Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information regarding the conversion mechanics.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January and February 2024, the Company sold an aggregate of 914,828 Class A Ordinary shares through the August 2023 Sales Agreement for gross proceeds of $53.3 million, bringing total gross proceeds under the August 2023 Sales Agreement to $85.0 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-225" decimals="0" id="f-933" unitRef="shares">44394</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-226" decimals="0" id="f-934" unitRef="shares">1493356</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-227" decimals="0" id="f-935" unitRef="shares">1493356</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-228"
      decimals="INF"
      id="f-936"
      unitRef="shares">914828</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-228" decimals="-5" id="f-937" unitRef="usd">53300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-228" decimals="-5" id="f-938" unitRef="usd">85000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
